primaryid,caseid,drug_seq,role_cod,drugname,prod_ai,val_vbm,route,dose_vbm,cum_dose_chr,cum_dose_unit,dechal,rechal,lot_num,exp_dt,nda_num,dose_amt,dose_unit,dose_form,dose_freq,year_x,quarter_x,pt,drug_rec_act,year_y,quarter_y,caseversion,i_f_code,event_dt,mfr_dt,init_fda_dt,fda_dt,rept_cod,auth_num,mfr_num,mfr_sndr,lit_ref,age,age_cod,age_grp,sex,e_sub,wt,wt_cod,rept_dt,to_mfr,occp_cod,reporter_country,occr_country,year,quarter,age_group
1545908810,15459088,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Diabetic ketoacidosis,,2023,Q1,10,F,20180704.0,20230101.0,20181003,20230104,EXP,,PHHY2018GB113319,NOVARTIS,,57.0,YR,,F,Y,,,20230104,,MD,GB,GB,2023,Q1,Adult
1545908810,15459088,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Lower respiratory tract infection,,2023,Q1,10,F,20180704.0,20230101.0,20181003,20230104,EXP,,PHHY2018GB113319,NOVARTIS,,57.0,YR,,F,Y,,,20230104,,MD,GB,GB,2023,Q1,Adult
1545908810,15459088,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Pneumonia,,2023,Q1,10,F,20180704.0,20230101.0,20181003,20230104,EXP,,PHHY2018GB113319,NOVARTIS,,57.0,YR,,F,Y,,,20230104,,MD,GB,GB,2023,Q1,Adult
1545908810,15459088,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Sepsis,,2023,Q1,10,F,20180704.0,20230101.0,20181003,20230104,EXP,,PHHY2018GB113319,NOVARTIS,,57.0,YR,,F,Y,,,20230104,,MD,GB,GB,2023,Q1,Adult
1545908810,15459088,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Pneumonia,,2023,Q1,10,F,20180704.0,20230101.0,20181003,20230104,EXP,,PHHY2018GB113319,NOVARTIS,,57.0,YR,,F,Y,,,20230104,,MD,GB,GB,2023,Q1,Adult
166163478,16616347,63,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2023,Q1,Sepsis,,2023,Q1,8,F,20180704.0,20230201.0,20190723,20230207,EXP,,GB-MYLANLABS-2019M1068313,MYLAN,,57.0,YR,,F,Y,,,20230207,,MD,GB,GB,2023,Q1,Adult
166163478,16616347,63,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2023,Q1,Pneumonia,,2023,Q1,8,F,20180704.0,20230201.0,20190723,20230207,EXP,,GB-MYLANLABS-2019M1068313,MYLAN,,57.0,YR,,F,Y,,,20230207,,MD,GB,GB,2023,Q1,Adult
166163478,16616347,63,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2023,Q1,Lower respiratory tract infection,,2023,Q1,8,F,20180704.0,20230201.0,20190723,20230207,EXP,,GB-MYLANLABS-2019M1068313,MYLAN,,57.0,YR,,F,Y,,,20230207,,MD,GB,GB,2023,Q1,Adult
166163478,16616347,63,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2023,Q1,Diabetic ketoacidosis,,2023,Q1,8,F,20180704.0,20230201.0,20190723,20230207,EXP,,GB-MYLANLABS-2019M1068313,MYLAN,,57.0,YR,,F,Y,,,20230207,,MD,GB,GB,2023,Q1,Adult
174538062,17453806,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q1,Polydipsia,,2023,Q1,2,F,,20230109.0,20200224,20230109,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2020-12-009172",BOEHRINGER INGELHEIM,,81.0,YR,E,M,Y,,,20230109,,MD,DE,DE,2023,Q1,Elderly
174538062,17453806,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q1,Polyuria,,2023,Q1,2,F,,20230109.0,20200224,20230109,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2020-12-009172",BOEHRINGER INGELHEIM,,81.0,YR,E,M,Y,,,20230109,,MD,DE,DE,2023,Q1,Elderly
174538062,17453806,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q1,General physical health deterioration,,2023,Q1,2,F,,20230109.0,20200224,20230109,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2020-12-009172",BOEHRINGER INGELHEIM,,81.0,YR,E,M,Y,,,20230109,,MD,DE,DE,2023,Q1,Elderly
174538062,17453806,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q1,Hyperglycaemia,,2023,Q1,2,F,,20230109.0,20200224,20230109,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2020-12-009172",BOEHRINGER INGELHEIM,,81.0,YR,E,M,Y,,,20230109,,MD,DE,DE,2023,Q1,Elderly
183905685,18390568,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 plus 0 plus 0,,,U,,,,,10.0,MG,,,2023,Q1,Rash,,2023,Q1,5,F,20190930.0,20230216.0,20201015,20230217,EXP,,NVSC2020PT273340,NOVARTIS,"Lima F, Vidal H. 319 pustulose generalizada exantematica aguda-um caso de iatrogenia a quinolonas [Acute exanthematic generalized pustulosis- a case of iatrogenic to quinolones]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2020;27:335",72.0,YR,,M,Y,100.0,KG,20230217,,HP,PT,PT,2023,Q1,Elderly
183905685,18390568,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 plus 0 plus 0,,,U,,,,,10.0,MG,,,2023,Q1,Rash pruritic,,2023,Q1,5,F,20190930.0,20230216.0,20201015,20230217,EXP,,NVSC2020PT273340,NOVARTIS,"Lima F, Vidal H. 319 pustulose generalizada exantematica aguda-um caso de iatrogenia a quinolonas [Acute exanthematic generalized pustulosis- a case of iatrogenic to quinolones]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2020;27:335",72.0,YR,,M,Y,100.0,KG,20230217,,HP,PT,PT,2023,Q1,Elderly
183905685,18390568,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 plus 0 plus 0,,,U,,,,,10.0,MG,,,2023,Q1,Pyrexia,,2023,Q1,5,F,20190930.0,20230216.0,20201015,20230217,EXP,,NVSC2020PT273340,NOVARTIS,"Lima F, Vidal H. 319 pustulose generalizada exantematica aguda-um caso de iatrogenia a quinolonas [Acute exanthematic generalized pustulosis- a case of iatrogenic to quinolones]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2020;27:335",72.0,YR,,M,Y,100.0,KG,20230217,,HP,PT,PT,2023,Q1,Elderly
183905685,18390568,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 plus 0 plus 0,,,U,,,,,10.0,MG,,,2023,Q1,Pustule,,2023,Q1,5,F,20190930.0,20230216.0,20201015,20230217,EXP,,NVSC2020PT273340,NOVARTIS,"Lima F, Vidal H. 319 pustulose generalizada exantematica aguda-um caso de iatrogenia a quinolonas [Acute exanthematic generalized pustulosis- a case of iatrogenic to quinolones]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2020;27:335",72.0,YR,,M,Y,100.0,KG,20230217,,HP,PT,PT,2023,Q1,Elderly
183905685,18390568,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 plus 0 plus 0,,,U,,,,,10.0,MG,,,2023,Q1,Acute generalised exanthematous pustulosis,,2023,Q1,5,F,20190930.0,20230216.0,20201015,20230217,EXP,,NVSC2020PT273340,NOVARTIS,"Lima F, Vidal H. 319 pustulose generalizada exantematica aguda-um caso de iatrogenia a quinolonas [Acute exanthematic generalized pustulosis- a case of iatrogenic to quinolones]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2020;27:335",72.0,YR,,M,Y,100.0,KG,20230217,,HP,PT,PT,2023,Q1,Elderly
1848217513,18482175,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q1,Cataract,,2023,Q1,13,F,20201019.0,20230323.0,20201110,20230329,EXP,,JP-ABBVIE-20K-087-3639069-00,ABBVIE,,61.0,YR,,F,Y,,,20230329,,MD,JP,JP,2023,Q1,Adult
1848217513,18482175,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q1,Angina pectoris,,2023,Q1,13,F,20201019.0,20230323.0,20201110,20230329,EXP,,JP-ABBVIE-20K-087-3639069-00,ABBVIE,,61.0,YR,,F,Y,,,20230329,,MD,JP,JP,2023,Q1,Adult
1848217513,18482175,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q1,Rash pruritic,,2023,Q1,13,F,20201019.0,20230323.0,20201110,20230329,EXP,,JP-ABBVIE-20K-087-3639069-00,ABBVIE,,61.0,YR,,F,Y,,,20230329,,MD,JP,JP,2023,Q1,Adult
1848217513,18482175,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q1,Eczema asteatotic,,2023,Q1,13,F,20201019.0,20230323.0,20201110,20230329,EXP,,JP-ABBVIE-20K-087-3639069-00,ABBVIE,,61.0,YR,,F,Y,,,20230329,,MD,JP,JP,2023,Q1,Adult
1848217513,18482175,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q1,Arthralgia,,2023,Q1,13,F,20201019.0,20230323.0,20201110,20230329,EXP,,JP-ABBVIE-20K-087-3639069-00,ABBVIE,,61.0,YR,,F,Y,,,20230329,,MD,JP,JP,2023,Q1,Adult
1858639418,18586394,61,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2023,Q1,Troponin increased,,2023,Q1,18,F,20201101.0,20230104.0,20201207,20230111,EXP,,CA-SA-2020SA349303,SANOFI AVENTIS,,75.0,YR,E,M,Y,,,20230111,,MD,CA,CA,2023,Q1,Elderly
1858639418,18586394,61,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2023,Q1,Adrenal insufficiency,,2023,Q1,18,F,20201101.0,20230104.0,20201207,20230111,EXP,,CA-SA-2020SA349303,SANOFI AVENTIS,,75.0,YR,E,M,Y,,,20230111,,MD,CA,CA,2023,Q1,Elderly
1858639418,18586394,61,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2023,Q1,Hypotension,,2023,Q1,18,F,20201101.0,20230104.0,20201207,20230111,EXP,,CA-SA-2020SA349303,SANOFI AVENTIS,,75.0,YR,E,M,Y,,,20230111,,MD,CA,CA,2023,Q1,Elderly
1858639418,18586394,61,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2023,Q1,Hypotension,,2023,Q1,18,F,20201101.0,20230104.0,20201207,20230111,EXP,,CA-SA-2020SA349303,SANOFI AVENTIS,,75.0,YR,E,M,Y,,,20230111,,MD,CA,CA,2023,Q1,Elderly
1858639418,18586394,61,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2023,Q1,Hypotension,,2023,Q1,18,F,20201101.0,20230104.0,20201207,20230111,EXP,,CA-SA-2020SA349303,SANOFI AVENTIS,,75.0,YR,E,M,Y,,,20230111,,MD,CA,CA,2023,Q1,Elderly
1858639418,18586394,61,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2023,Q1,Hyperthyroidism,,2023,Q1,18,F,20201101.0,20230104.0,20201207,20230111,EXP,,CA-SA-2020SA349303,SANOFI AVENTIS,,75.0,YR,E,M,Y,,,20230111,,MD,CA,CA,2023,Q1,Elderly
1858639418,18586394,62,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,Tablet,,2023,Q1,Troponin increased,,2023,Q1,18,F,20201101.0,20230104.0,20201207,20230111,EXP,,CA-SA-2020SA349303,SANOFI AVENTIS,,75.0,YR,E,M,Y,,,20230111,,MD,CA,CA,2023,Q1,Elderly
1858639418,18586394,62,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,Tablet,,2023,Q1,Adrenal insufficiency,,2023,Q1,18,F,20201101.0,20230104.0,20201207,20230111,EXP,,CA-SA-2020SA349303,SANOFI AVENTIS,,75.0,YR,E,M,Y,,,20230111,,MD,CA,CA,2023,Q1,Elderly
1858639418,18586394,62,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,Tablet,,2023,Q1,Hypotension,,2023,Q1,18,F,20201101.0,20230104.0,20201207,20230111,EXP,,CA-SA-2020SA349303,SANOFI AVENTIS,,75.0,YR,E,M,Y,,,20230111,,MD,CA,CA,2023,Q1,Elderly
1858639418,18586394,62,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,Tablet,,2023,Q1,Hypotension,,2023,Q1,18,F,20201101.0,20230104.0,20201207,20230111,EXP,,CA-SA-2020SA349303,SANOFI AVENTIS,,75.0,YR,E,M,Y,,,20230111,,MD,CA,CA,2023,Q1,Elderly
1858639418,18586394,62,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,Tablet,,2023,Q1,Hypotension,,2023,Q1,18,F,20201101.0,20230104.0,20201207,20230111,EXP,,CA-SA-2020SA349303,SANOFI AVENTIS,,75.0,YR,E,M,Y,,,20230111,,MD,CA,CA,2023,Q1,Elderly
1858639418,18586394,62,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,Tablet,,2023,Q1,Hyperthyroidism,,2023,Q1,18,F,20201101.0,20230104.0,20201207,20230111,EXP,,CA-SA-2020SA349303,SANOFI AVENTIS,,75.0,YR,E,M,Y,,,20230111,,MD,CA,CA,2023,Q1,Elderly
1909998712,19099987,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2023,Q1,Eye operation,,2023,Q1,12,F,20201201.0,20230103.0,20210407,20230112,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR005112,AEGERION,,21.0,YR,,F,Y,61.224,KG,20230112,,CN,US,US,2023,Q1,Youth
1909998712,19099987,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2023,Q1,Non-cardiac chest pain,,2023,Q1,12,F,20201201.0,20230103.0,20210407,20230112,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR005112,AEGERION,,21.0,YR,,F,Y,61.224,KG,20230112,,CN,US,US,2023,Q1,Youth
1909998712,19099987,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2023,Q1,Hypertriglyceridaemia,,2023,Q1,12,F,20201201.0,20230103.0,20210407,20230112,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR005112,AEGERION,,21.0,YR,,F,Y,61.224,KG,20230112,,CN,US,US,2023,Q1,Youth
1909998712,19099987,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2023,Q1,Injection site reaction,,2023,Q1,12,F,20201201.0,20230103.0,20210407,20230112,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR005112,AEGERION,,21.0,YR,,F,Y,61.224,KG,20230112,,CN,US,US,2023,Q1,Youth
1909998712,19099987,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2023,Q1,Seizure,,2023,Q1,12,F,20201201.0,20230103.0,20210407,20230112,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR005112,AEGERION,,21.0,YR,,F,Y,61.224,KG,20230112,,CN,US,US,2023,Q1,Youth
1909998712,19099987,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2023,Q1,Hyperkeratosis,,2023,Q1,12,F,20201201.0,20230103.0,20210407,20230112,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR005112,AEGERION,,21.0,YR,,F,Y,61.224,KG,20230112,,CN,US,US,2023,Q1,Youth
1909998712,19099987,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2023,Q1,Injection site irritation,,2023,Q1,12,F,20201201.0,20230103.0,20210407,20230112,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR005112,AEGERION,,21.0,YR,,F,Y,61.224,KG,20230112,,CN,US,US,2023,Q1,Youth
1909998712,19099987,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2023,Q1,Injection site pruritus,,2023,Q1,12,F,20201201.0,20230103.0,20210407,20230112,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR005112,AEGERION,,21.0,YR,,F,Y,61.224,KG,20230112,,CN,US,US,2023,Q1,Youth
1909998712,19099987,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2023,Q1,Product dose omission issue,,2023,Q1,12,F,20201201.0,20230103.0,20210407,20230112,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR005112,AEGERION,,21.0,YR,,F,Y,61.224,KG,20230112,,CN,US,US,2023,Q1,Youth
1909998712,19099987,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2023,Q1,Off label use,,2023,Q1,12,F,20201201.0,20230103.0,20210407,20230112,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR005112,AEGERION,,21.0,YR,,F,Y,61.224,KG,20230112,,CN,US,US,2023,Q1,Youth
1909998712,19099987,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2023,Q1,Blood glucose increased,,2023,Q1,12,F,20201201.0,20230103.0,20210407,20230112,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR005112,AEGERION,,21.0,YR,,F,Y,61.224,KG,20230112,,CN,US,US,2023,Q1,Youth
1909998712,19099987,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2023,Q1,Dyspnoea,,2023,Q1,12,F,20201201.0,20230103.0,20210407,20230112,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR005112,AEGERION,,21.0,YR,,F,Y,61.224,KG,20230112,,CN,US,US,2023,Q1,Youth
1909998712,19099987,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2023,Q1,Back pain,,2023,Q1,12,F,20201201.0,20230103.0,20210407,20230112,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR005112,AEGERION,,21.0,YR,,F,Y,61.224,KG,20230112,,CN,US,US,2023,Q1,Youth
1909998712,19099987,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2023,Q1,Blood test abnormal,,2023,Q1,12,F,20201201.0,20230103.0,20210407,20230112,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR005112,AEGERION,,21.0,YR,,F,Y,61.224,KG,20230112,,CN,US,US,2023,Q1,Youth
1909998712,19099987,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2023,Q1,Thrombosis,,2023,Q1,12,F,20201201.0,20230103.0,20210407,20230112,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR005112,AEGERION,,21.0,YR,,F,Y,61.224,KG,20230112,,CN,US,US,2023,Q1,Youth
1909998712,19099987,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2023,Q1,Drug ineffective,,2023,Q1,12,F,20201201.0,20230103.0,20210407,20230112,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR005112,AEGERION,,21.0,YR,,F,Y,61.224,KG,20230112,,CN,US,US,2023,Q1,Youth
1909998712,19099987,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2023,Q1,Diabetic retinopathy,,2023,Q1,12,F,20201201.0,20230103.0,20210407,20230112,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR005112,AEGERION,,21.0,YR,,F,Y,61.224,KG,20230112,,CN,US,US,2023,Q1,Youth
1909998712,19099987,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2023,Q1,Psychogenic seizure,,2023,Q1,12,F,20201201.0,20230103.0,20210407,20230112,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR005112,AEGERION,,21.0,YR,,F,Y,61.224,KG,20230112,,CN,US,US,2023,Q1,Youth
1909998712,19099987,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2023,Q1,Blood magnesium decreased,,2023,Q1,12,F,20201201.0,20230103.0,20210407,20230112,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR005112,AEGERION,,21.0,YR,,F,Y,61.224,KG,20230112,,CN,US,US,2023,Q1,Youth
1909998712,19099987,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2023,Q1,Chlamydial infection,,2023,Q1,12,F,20201201.0,20230103.0,20210407,20230112,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR005112,AEGERION,,21.0,YR,,F,Y,61.224,KG,20230112,,CN,US,US,2023,Q1,Youth
191553879,19155387,61,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2023,Q1,Troponin increased,,2023,Q1,9,F,20201101.0,20230104.0,20210419,20230110,EXP,,CA-BAUSCH-BL-2021-012331,BAUSCH AND LOMB,,75.0,YR,,M,Y,,,20230110,,MD,CA,CA,2023,Q1,Elderly
191553879,19155387,61,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2023,Q1,Hypotension,,2023,Q1,9,F,20201101.0,20230104.0,20210419,20230110,EXP,,CA-BAUSCH-BL-2021-012331,BAUSCH AND LOMB,,75.0,YR,,M,Y,,,20230110,,MD,CA,CA,2023,Q1,Elderly
191553879,19155387,61,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2023,Q1,Hypotension,,2023,Q1,9,F,20201101.0,20230104.0,20210419,20230110,EXP,,CA-BAUSCH-BL-2021-012331,BAUSCH AND LOMB,,75.0,YR,,M,Y,,,20230110,,MD,CA,CA,2023,Q1,Elderly
191553879,19155387,61,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2023,Q1,Adrenal insufficiency,,2023,Q1,9,F,20201101.0,20230104.0,20210419,20230110,EXP,,CA-BAUSCH-BL-2021-012331,BAUSCH AND LOMB,,75.0,YR,,M,Y,,,20230110,,MD,CA,CA,2023,Q1,Elderly
191553879,19155387,61,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2023,Q1,Hyperthyroidism,,2023,Q1,9,F,20201101.0,20230104.0,20210419,20230110,EXP,,CA-BAUSCH-BL-2021-012331,BAUSCH AND LOMB,,75.0,YR,,M,Y,,,20230110,,MD,CA,CA,2023,Q1,Elderly
192764568,19276456,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,N,,,,,,Tablet,,2023,Q1,Troponin increased,,2023,Q1,8,F,20201101.0,20230203.0,20210519,20230213,EXP,,CA-ANIPHARMA-2021-CA-000632,ANI,,75.0,YR,,M,Y,,,20230213,,MD,CA,CA,2023,Q1,Elderly
192764568,19276456,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,N,,,,,,Tablet,,2023,Q1,Hyperthyroidism,,2023,Q1,8,F,20201101.0,20230203.0,20210519,20230213,EXP,,CA-ANIPHARMA-2021-CA-000632,ANI,,75.0,YR,,M,Y,,,20230213,,MD,CA,CA,2023,Q1,Elderly
192764568,19276456,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,N,,,,,,Tablet,,2023,Q1,Hypotension,,2023,Q1,8,F,20201101.0,20230203.0,20210519,20230213,EXP,,CA-ANIPHARMA-2021-CA-000632,ANI,,75.0,YR,,M,Y,,,20230213,,MD,CA,CA,2023,Q1,Elderly
192764568,19276456,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,N,,,,,,Tablet,,2023,Q1,Adrenal insufficiency,,2023,Q1,8,F,20201101.0,20230203.0,20210519,20230213,EXP,,CA-ANIPHARMA-2021-CA-000632,ANI,,75.0,YR,,M,Y,,,20230213,,MD,CA,CA,2023,Q1,Elderly
1977202813,19772028,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2023,Q1,Abdominal pain upper,,2023,Q1,13,F,20211024.0,20230315.0,20210831,20230321,EXP,,CA-TAKEDA-2018MPI014438,TAKEDA,,67.0,YR,,F,Y,,,20230321,,CN,CA,CA,2023,Q1,Elderly
1977202813,19772028,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2023,Q1,Off label use,,2023,Q1,13,F,20211024.0,20230315.0,20210831,20230321,EXP,,CA-TAKEDA-2018MPI014438,TAKEDA,,67.0,YR,,F,Y,,,20230321,,CN,CA,CA,2023,Q1,Elderly
1977202813,19772028,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2023,Q1,Clostridium difficile colitis,,2023,Q1,13,F,20211024.0,20230315.0,20210831,20230321,EXP,,CA-TAKEDA-2018MPI014438,TAKEDA,,67.0,YR,,F,Y,,,20230321,,CN,CA,CA,2023,Q1,Elderly
1977202813,19772028,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2023,Q1,Blood pressure increased,,2023,Q1,13,F,20211024.0,20230315.0,20210831,20230321,EXP,,CA-TAKEDA-2018MPI014438,TAKEDA,,67.0,YR,,F,Y,,,20230321,,CN,CA,CA,2023,Q1,Elderly
1977202813,19772028,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2023,Q1,Fall,,2023,Q1,13,F,20211024.0,20230315.0,20210831,20230321,EXP,,CA-TAKEDA-2018MPI014438,TAKEDA,,67.0,YR,,F,Y,,,20230321,,CN,CA,CA,2023,Q1,Elderly
1977202813,19772028,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2023,Q1,Cardiomegaly,,2023,Q1,13,F,20211024.0,20230315.0,20210831,20230321,EXP,,CA-TAKEDA-2018MPI014438,TAKEDA,,67.0,YR,,F,Y,,,20230321,,CN,CA,CA,2023,Q1,Elderly
1977202813,19772028,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2023,Q1,Cataract,,2023,Q1,13,F,20211024.0,20230315.0,20210831,20230321,EXP,,CA-TAKEDA-2018MPI014438,TAKEDA,,67.0,YR,,F,Y,,,20230321,,CN,CA,CA,2023,Q1,Elderly
1977202813,19772028,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2023,Q1,Constipation,,2023,Q1,13,F,20211024.0,20230315.0,20210831,20230321,EXP,,CA-TAKEDA-2018MPI014438,TAKEDA,,67.0,YR,,F,Y,,,20230321,,CN,CA,CA,2023,Q1,Elderly
1977202813,19772028,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2023,Q1,Neoplasm skin,,2023,Q1,13,F,20211024.0,20230315.0,20210831,20230321,EXP,,CA-TAKEDA-2018MPI014438,TAKEDA,,67.0,YR,,F,Y,,,20230321,,CN,CA,CA,2023,Q1,Elderly
1977202813,19772028,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2023,Q1,Product use issue,,2023,Q1,13,F,20211024.0,20230315.0,20210831,20230321,EXP,,CA-TAKEDA-2018MPI014438,TAKEDA,,67.0,YR,,F,Y,,,20230321,,CN,CA,CA,2023,Q1,Elderly
1977202813,19772028,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2023,Q1,Haemorrhoids,,2023,Q1,13,F,20211024.0,20230315.0,20210831,20230321,EXP,,CA-TAKEDA-2018MPI014438,TAKEDA,,67.0,YR,,F,Y,,,20230321,,CN,CA,CA,2023,Q1,Elderly
1977202813,19772028,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2023,Q1,Vulvovaginal mycotic infection,,2023,Q1,13,F,20211024.0,20230315.0,20210831,20230321,EXP,,CA-TAKEDA-2018MPI014438,TAKEDA,,67.0,YR,,F,Y,,,20230321,,CN,CA,CA,2023,Q1,Elderly
1977202813,19772028,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2023,Q1,Haemorrhoidal haemorrhage,,2023,Q1,13,F,20211024.0,20230315.0,20210831,20230321,EXP,,CA-TAKEDA-2018MPI014438,TAKEDA,,67.0,YR,,F,Y,,,20230321,,CN,CA,CA,2023,Q1,Elderly
1977202813,19772028,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2023,Q1,Chest discomfort,,2023,Q1,13,F,20211024.0,20230315.0,20210831,20230321,EXP,,CA-TAKEDA-2018MPI014438,TAKEDA,,67.0,YR,,F,Y,,,20230321,,CN,CA,CA,2023,Q1,Elderly
1977202813,19772028,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2023,Q1,Chest pain,,2023,Q1,13,F,20211024.0,20230315.0,20210831,20230321,EXP,,CA-TAKEDA-2018MPI014438,TAKEDA,,67.0,YR,,F,Y,,,20230321,,CN,CA,CA,2023,Q1,Elderly
1977202813,19772028,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2023,Q1,Drug ineffective,,2023,Q1,13,F,20211024.0,20230315.0,20210831,20230321,EXP,,CA-TAKEDA-2018MPI014438,TAKEDA,,67.0,YR,,F,Y,,,20230321,,CN,CA,CA,2023,Q1,Elderly
1977202813,19772028,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2023,Q1,COVID-19 immunisation,,2023,Q1,13,F,20211024.0,20230315.0,20210831,20230321,EXP,,CA-TAKEDA-2018MPI014438,TAKEDA,,67.0,YR,,F,Y,,,20230321,,CN,CA,CA,2023,Q1,Elderly
1977202813,19772028,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2023,Q1,Hypoaesthesia,,2023,Q1,13,F,20211024.0,20230315.0,20210831,20230321,EXP,,CA-TAKEDA-2018MPI014438,TAKEDA,,67.0,YR,,F,Y,,,20230321,,CN,CA,CA,2023,Q1,Elderly
1977202813,19772028,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2023,Q1,Pain in extremity,,2023,Q1,13,F,20211024.0,20230315.0,20210831,20230321,EXP,,CA-TAKEDA-2018MPI014438,TAKEDA,,67.0,YR,,F,Y,,,20230321,,CN,CA,CA,2023,Q1,Elderly
1977202813,19772028,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2023,Q1,COVID-19,,2023,Q1,13,F,20211024.0,20230315.0,20210831,20230321,EXP,,CA-TAKEDA-2018MPI014438,TAKEDA,,67.0,YR,,F,Y,,,20230321,,CN,CA,CA,2023,Q1,Elderly
1977202813,19772028,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2023,Q1,Cardiac failure,,2023,Q1,13,F,20211024.0,20230315.0,20210831,20230321,EXP,,CA-TAKEDA-2018MPI014438,TAKEDA,,67.0,YR,,F,Y,,,20230321,,CN,CA,CA,2023,Q1,Elderly
1977202813,19772028,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2023,Q1,Neuropathy peripheral,,2023,Q1,13,F,20211024.0,20230315.0,20210831,20230321,EXP,,CA-TAKEDA-2018MPI014438,TAKEDA,,67.0,YR,,F,Y,,,20230321,,CN,CA,CA,2023,Q1,Elderly
1977202813,19772028,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2023,Q1,Pneumonia,,2023,Q1,13,F,20211024.0,20230315.0,20210831,20230321,EXP,,CA-TAKEDA-2018MPI014438,TAKEDA,,67.0,YR,,F,Y,,,20230321,,CN,CA,CA,2023,Q1,Elderly
1977202813,19772028,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2023,Q1,Transient ischaemic attack,,2023,Q1,13,F,20211024.0,20230315.0,20210831,20230321,EXP,,CA-TAKEDA-2018MPI014438,TAKEDA,,67.0,YR,,F,Y,,,20230321,,CN,CA,CA,2023,Q1,Elderly
1977202813,19772028,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2023,Q1,Dyspnoea,,2023,Q1,13,F,20211024.0,20230315.0,20210831,20230321,EXP,,CA-TAKEDA-2018MPI014438,TAKEDA,,67.0,YR,,F,Y,,,20230321,,CN,CA,CA,2023,Q1,Elderly
199541933,19954193,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram (1-1-1-0, tablets)",,,,,,,,10.0,MG,Tablet,,2023,Q1,Micturition disorder,,2023,Q1,3,F,,20230131.0,20211013,20230207,EXP,,DE-MYLANLABS-2021M1071377,MYLAN,,82.0,YR,,M,Y,,,20230207,,MD,DE,DE,2023,Q1,Elderly
199541933,19954193,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram (1-1-1-0, tablets)",,,,,,,,10.0,MG,Tablet,,2023,Q1,Dehydration,,2023,Q1,3,F,,20230131.0,20211013,20230207,EXP,,DE-MYLANLABS-2021M1071377,MYLAN,,82.0,YR,,M,Y,,,20230207,,MD,DE,DE,2023,Q1,Elderly
199541933,19954193,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram (1-1-1-0, tablets)",,,,,,,,10.0,MG,Tablet,,2023,Q1,Faecaloma,,2023,Q1,3,F,,20230131.0,20211013,20230207,EXP,,DE-MYLANLABS-2021M1071377,MYLAN,,82.0,YR,,M,Y,,,20230207,,MD,DE,DE,2023,Q1,Elderly
199541933,19954193,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram (1-1-1-0, tablets)",,,,,,,,10.0,MG,Tablet,,2023,Q1,Constipation,,2023,Q1,3,F,,20230131.0,20211013,20230207,EXP,,DE-MYLANLABS-2021M1071377,MYLAN,,82.0,YR,,M,Y,,,20230207,,MD,DE,DE,2023,Q1,Elderly
199541933,19954193,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram (1-1-1-0, tablets)",,,,,,,,10.0,MG,Tablet,,2023,Q1,Flatulence,,2023,Q1,3,F,,20230131.0,20211013,20230207,EXP,,DE-MYLANLABS-2021M1071377,MYLAN,,82.0,YR,,M,Y,,,20230207,,MD,DE,DE,2023,Q1,Elderly
199541933,19954193,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram (1-1-1-0, tablets)",,,,,,,,10.0,MG,Tablet,,2023,Q1,Haematuria,,2023,Q1,3,F,,20230131.0,20211013,20230207,EXP,,DE-MYLANLABS-2021M1071377,MYLAN,,82.0,YR,,M,Y,,,20230207,,MD,DE,DE,2023,Q1,Elderly
199541933,19954193,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram (1-1-1-0, tablets)",,,,,,,,10.0,MG,Tablet,,2023,Q1,Abdominal pain,,2023,Q1,3,F,,20230131.0,20211013,20230207,EXP,,DE-MYLANLABS-2021M1071377,MYLAN,,82.0,YR,,M,Y,,,20230207,,MD,DE,DE,2023,Q1,Elderly
2004410426,20044104,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,1.0,MG,Tablet,,2023,Q1,Pancreatitis acute,,2023,Q1,26,F,20211024.0,20230215.0,20211108,20230221,EXP,,RU-ASTELLAS-2021US042176,ASTELLAS,,70.0,YR,,F,Y,,,20230221,,CN,RU,RU,2023,Q1,Elderly
2004410426,20044104,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,1.0,MG,Tablet,,2023,Q1,Gastrooesophageal reflux disease,,2023,Q1,26,F,20211024.0,20230215.0,20211108,20230221,EXP,,RU-ASTELLAS-2021US042176,ASTELLAS,,70.0,YR,,F,Y,,,20230221,,CN,RU,RU,2023,Q1,Elderly
200638997,20063899,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 every 1 Days,,,U,,,,,10.0,MG,Tablet,,2023,Q1,Nasal congestion,,2023,Q1,7,F,,20221226.0,20211112,20230105,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,E,F,Y,101.0,KG,20230105,,CN,CA,CA,2023,Q1,Elderly
200638997,20063899,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 every 1 Days,,,U,,,,,10.0,MG,Tablet,,2023,Q1,Intentional product use issue,,2023,Q1,7,F,,20221226.0,20211112,20230105,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,E,F,Y,101.0,KG,20230105,,CN,CA,CA,2023,Q1,Elderly
200638997,20063899,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 every 1 Days,,,U,,,,,10.0,MG,Tablet,,2023,Q1,Bronchiectasis,,2023,Q1,7,F,,20221226.0,20211112,20230105,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,E,F,Y,101.0,KG,20230105,,CN,CA,CA,2023,Q1,Elderly
200638997,20063899,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 every 1 Days,,,U,,,,,10.0,MG,Tablet,,2023,Q1,Wheezing,,2023,Q1,7,F,,20221226.0,20211112,20230105,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,E,F,Y,101.0,KG,20230105,,CN,CA,CA,2023,Q1,Elderly
200638997,20063899,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 every 1 Days,,,U,,,,,10.0,MG,Tablet,,2023,Q1,Malignant mediastinal neoplasm,,2023,Q1,7,F,,20221226.0,20211112,20230105,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,E,F,Y,101.0,KG,20230105,,CN,CA,CA,2023,Q1,Elderly
200638997,20063899,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 every 1 Days,,,U,,,,,10.0,MG,Tablet,,2023,Q1,Blood immunoglobulin E increased,,2023,Q1,7,F,,20221226.0,20211112,20230105,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,E,F,Y,101.0,KG,20230105,,CN,CA,CA,2023,Q1,Elderly
200638997,20063899,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 every 1 Days,,,U,,,,,10.0,MG,Tablet,,2023,Q1,Rhinorrhoea,,2023,Q1,7,F,,20221226.0,20211112,20230105,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,E,F,Y,101.0,KG,20230105,,CN,CA,CA,2023,Q1,Elderly
200638997,20063899,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 every 1 Days,,,U,,,,,10.0,MG,Tablet,,2023,Q1,Dyspnoea,,2023,Q1,7,F,,20221226.0,20211112,20230105,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,E,F,Y,101.0,KG,20230105,,CN,CA,CA,2023,Q1,Elderly
200638997,20063899,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 every 1 Days,,,U,,,,,10.0,MG,Tablet,,2023,Q1,Full blood count abnormal,,2023,Q1,7,F,,20221226.0,20211112,20230105,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,E,F,Y,101.0,KG,20230105,,CN,CA,CA,2023,Q1,Elderly
200638997,20063899,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 every 1 Days,,,U,,,,,10.0,MG,Tablet,,2023,Q1,Cough,,2023,Q1,7,F,,20221226.0,20211112,20230105,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,E,F,Y,101.0,KG,20230105,,CN,CA,CA,2023,Q1,Elderly
200638997,20063899,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 every 1 Days,,,U,,,,,10.0,MG,Tablet,,2023,Q1,Asthma,,2023,Q1,7,F,,20221226.0,20211112,20230105,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,E,F,Y,101.0,KG,20230105,,CN,CA,CA,2023,Q1,Elderly
203039047,20303904,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Drug Dose First Administered is 10 TABLET ;Ongoing: Yes,,,,,,,,,,Tablet,QD,2023,Q1,Uveitis,,2023,Q1,7,F,20211225.0,20230105.0,20220106,20230106,EXP,,US-ROCHE-2992171,ROCHE,,58.0,YR,,M,Y,94.0,KG,20230106,,MD,US,,2023,Q1,Adult
2033327533,20333275,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,Tablets,,2023,Q1,Aspartate aminotransferase increased,Aspartate aminotransferase increased,2023,Q1,33,F,20220105.0,20230315.0,20220113,20230322,PER,,BR-Eisai Medical Research-EC-2022-106612,EISAI,,64.0,YR,A,F,Y,63.7,KG,20230322,,MD,BR,,2023,Q1,Adult
2033327533,20333275,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,Tablets,,2023,Q1,Adrenal insufficiency,,2023,Q1,33,F,20220105.0,20230315.0,20220113,20230322,PER,,BR-Eisai Medical Research-EC-2022-106612,EISAI,,64.0,YR,A,F,Y,63.7,KG,20230322,,MD,BR,,2023,Q1,Adult
2033327533,20333275,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,Tablets,,2023,Q1,Alanine aminotransferase increased,,2023,Q1,33,F,20220105.0,20230315.0,20220113,20230322,PER,,BR-Eisai Medical Research-EC-2022-106612,EISAI,,64.0,YR,A,F,Y,63.7,KG,20230322,,MD,BR,,2023,Q1,Adult
2033327533,20333275,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,Tablets,,2023,Q1,Anaemia,,2023,Q1,33,F,20220105.0,20230315.0,20220113,20230322,PER,,BR-Eisai Medical Research-EC-2022-106612,EISAI,,64.0,YR,A,F,Y,63.7,KG,20230322,,MD,BR,,2023,Q1,Adult
203737966,20373796,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 Days,,,U,,,,,20.0,MG,Tablet,,2023,Q1,Adrenal insufficiency,,2023,Q1,6,F,,20230130.0,20220125,20230207,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,E,M,Y,,,20230207,,MD,CA,CA,2023,Q1,Elderly
203737966,20373796,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 Days,,,U,,,,,20.0,MG,Tablet,,2023,Q1,Hyperthyroidism,,2023,Q1,6,F,,20230130.0,20220125,20230207,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,E,M,Y,,,20230207,,MD,CA,CA,2023,Q1,Elderly
203737966,20373796,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 Days,,,U,,,,,20.0,MG,Tablet,,2023,Q1,Troponin increased,,2023,Q1,6,F,,20230130.0,20220125,20230207,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,E,M,Y,,,20230207,,MD,CA,CA,2023,Q1,Elderly
203737966,20373796,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 Days,,,U,,,,,20.0,MG,Tablet,,2023,Q1,Hypotension,,2023,Q1,6,F,,20230130.0,20220125,20230207,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,E,M,Y,,,20230207,,MD,CA,CA,2023,Q1,Elderly
203737966,20373796,15,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,Film-coated tablet,,2023,Q1,Adrenal insufficiency,,2023,Q1,6,F,,20230130.0,20220125,20230207,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,E,M,Y,,,20230207,,MD,CA,CA,2023,Q1,Elderly
203737966,20373796,15,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,Film-coated tablet,,2023,Q1,Hyperthyroidism,,2023,Q1,6,F,,20230130.0,20220125,20230207,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,E,M,Y,,,20230207,,MD,CA,CA,2023,Q1,Elderly
203737966,20373796,15,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,Film-coated tablet,,2023,Q1,Troponin increased,,2023,Q1,6,F,,20230130.0,20220125,20230207,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,E,M,Y,,,20230207,,MD,CA,CA,2023,Q1,Elderly
203737966,20373796,15,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,Film-coated tablet,,2023,Q1,Hypotension,,2023,Q1,6,F,,20230130.0,20220125,20230207,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,E,M,Y,,,20230207,,MD,CA,CA,2023,Q1,Elderly
203737966,20373796,30,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 Days,,,U,,,,,20.0,MG,Film-coated tablet,,2023,Q1,Adrenal insufficiency,,2023,Q1,6,F,,20230130.0,20220125,20230207,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,E,M,Y,,,20230207,,MD,CA,CA,2023,Q1,Elderly
203737966,20373796,30,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 Days,,,U,,,,,20.0,MG,Film-coated tablet,,2023,Q1,Hyperthyroidism,,2023,Q1,6,F,,20230130.0,20220125,20230207,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,E,M,Y,,,20230207,,MD,CA,CA,2023,Q1,Elderly
203737966,20373796,30,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 Days,,,U,,,,,20.0,MG,Film-coated tablet,,2023,Q1,Troponin increased,,2023,Q1,6,F,,20230130.0,20220125,20230207,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,E,M,Y,,,20230207,,MD,CA,CA,2023,Q1,Elderly
203737966,20373796,30,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 Days,,,U,,,,,20.0,MG,Film-coated tablet,,2023,Q1,Hypotension,,2023,Q1,6,F,,20230130.0,20220125,20230207,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,E,M,Y,,,20230207,,MD,CA,CA,2023,Q1,Elderly
203737966,20373796,31,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 Days,,,U,,,,,200.0,MG,,,2023,Q1,Adrenal insufficiency,,2023,Q1,6,F,,20230130.0,20220125,20230207,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,E,M,Y,,,20230207,,MD,CA,CA,2023,Q1,Elderly
203737966,20373796,31,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 Days,,,U,,,,,200.0,MG,,,2023,Q1,Hyperthyroidism,,2023,Q1,6,F,,20230130.0,20220125,20230207,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,E,M,Y,,,20230207,,MD,CA,CA,2023,Q1,Elderly
203737966,20373796,31,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 Days,,,U,,,,,200.0,MG,,,2023,Q1,Troponin increased,,2023,Q1,6,F,,20230130.0,20220125,20230207,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,E,M,Y,,,20230207,,MD,CA,CA,2023,Q1,Elderly
203737966,20373796,31,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 Days,,,U,,,,,200.0,MG,,,2023,Q1,Hypotension,,2023,Q1,6,F,,20230130.0,20220125,20230207,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,E,M,Y,,,20230207,,MD,CA,CA,2023,Q1,Elderly
203737966,20373796,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 days,,,U,,,,,20.0,MG,Tablet,,2023,Q1,Adrenal insufficiency,,2023,Q1,6,F,,20230130.0,20220125,20230207,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,E,M,Y,,,20230207,,MD,CA,CA,2023,Q1,Elderly
203737966,20373796,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 days,,,U,,,,,20.0,MG,Tablet,,2023,Q1,Hyperthyroidism,,2023,Q1,6,F,,20230130.0,20220125,20230207,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,E,M,Y,,,20230207,,MD,CA,CA,2023,Q1,Elderly
203737966,20373796,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 days,,,U,,,,,20.0,MG,Tablet,,2023,Q1,Troponin increased,,2023,Q1,6,F,,20230130.0,20220125,20230207,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,E,M,Y,,,20230207,,MD,CA,CA,2023,Q1,Elderly
203737966,20373796,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 days,,,U,,,,,20.0,MG,Tablet,,2023,Q1,Hypotension,,2023,Q1,6,F,,20230130.0,20220125,20230207,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,E,M,Y,,,20230207,,MD,CA,CA,2023,Q1,Elderly
203737966,20373796,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2023,Q1,Adrenal insufficiency,,2023,Q1,6,F,,20230130.0,20220125,20230207,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,E,M,Y,,,20230207,,MD,CA,CA,2023,Q1,Elderly
203737966,20373796,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2023,Q1,Hyperthyroidism,,2023,Q1,6,F,,20230130.0,20220125,20230207,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,E,M,Y,,,20230207,,MD,CA,CA,2023,Q1,Elderly
203737966,20373796,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2023,Q1,Troponin increased,,2023,Q1,6,F,,20230130.0,20220125,20230207,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,E,M,Y,,,20230207,,MD,CA,CA,2023,Q1,Elderly
203737966,20373796,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2023,Q1,Hypotension,,2023,Q1,6,F,,20230130.0,20220125,20230207,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,E,M,Y,,,20230207,,MD,CA,CA,2023,Q1,Elderly
2037504419,20375044,5,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2023,Q1,Weight decreased,Weight decreased,2023,Q1,19,F,20211125.0,20230203.0,20220125,20230210,PER,,CH-Eisai Medical Research-EC-2022-107259,EISAI,,79.0,YR,E,M,Y,80.1,KG,20230210,,MD,CH,,2023,Q1,Elderly
203821444,20382144,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Hypertension,,2023,Q1,4,F,20210930.0,20230301.0,20220127,20230310,EXP,,CA-BAUSCH-BL-2021-034002,BAUSCH AND LOMB,,55.0,YR,,M,Y,,,20230310,,CN,CA,CA,2023,Q1,Adult
203821444,20382144,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Anxiety,,2023,Q1,4,F,20210930.0,20230301.0,20220127,20230310,EXP,,CA-BAUSCH-BL-2021-034002,BAUSCH AND LOMB,,55.0,YR,,M,Y,,,20230310,,CN,CA,CA,2023,Q1,Adult
203821444,20382144,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Product dose omission issue,,2023,Q1,4,F,20210930.0,20230301.0,20220127,20230310,EXP,,CA-BAUSCH-BL-2021-034002,BAUSCH AND LOMB,,55.0,YR,,M,Y,,,20230310,,CN,CA,CA,2023,Q1,Adult
203821444,20382144,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Fatigue,,2023,Q1,4,F,20210930.0,20230301.0,20220127,20230310,EXP,,CA-BAUSCH-BL-2021-034002,BAUSCH AND LOMB,,55.0,YR,,M,Y,,,20230310,,CN,CA,CA,2023,Q1,Adult
204680082,20468008,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd (every 1 day)",,,,,Unknown,,,10.0,MG,,QD,2023,Q1,Muscle spasms,,2023,Q1,2,F,,20230209.0,20220214,20230210,EXP,,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2021-06524,ALKEM,,42.0,YR,,F,Y,,,20230210,,CN,DE,DE,2023,Q1,Adult
204680082,20468008,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd (every 1 day)",,,,,Unknown,,,10.0,MG,,QD,2023,Q1,COVID-19,,2023,Q1,2,F,,20230209.0,20220214,20230210,EXP,,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2021-06524,ALKEM,,42.0,YR,,F,Y,,,20230210,,CN,DE,DE,2023,Q1,Adult
204680082,20468008,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd (every 1 day)",,,,,Unknown,,,10.0,MG,,QD,2023,Q1,Toothache,,2023,Q1,2,F,,20230209.0,20220214,20230210,EXP,,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2021-06524,ALKEM,,42.0,YR,,F,Y,,,20230210,,CN,DE,DE,2023,Q1,Adult
204680082,20468008,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd (every 1 day)",,,,,Unknown,,,10.0,MG,,QD,2023,Q1,Feeling cold,,2023,Q1,2,F,,20230209.0,20220214,20230210,EXP,,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2021-06524,ALKEM,,42.0,YR,,F,Y,,,20230210,,CN,DE,DE,2023,Q1,Adult
204680082,20468008,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd (every 1 day)",,,,,Unknown,,,10.0,MG,,QD,2023,Q1,Arthritis,,2023,Q1,2,F,,20230209.0,20220214,20230210,EXP,,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2021-06524,ALKEM,,42.0,YR,,F,Y,,,20230210,,CN,DE,DE,2023,Q1,Adult
204680082,20468008,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd (every 1 day)",,,,,Unknown,,,10.0,MG,,QD,2023,Q1,Diarrhoea,,2023,Q1,2,F,,20230209.0,20220214,20230210,EXP,,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2021-06524,ALKEM,,42.0,YR,,F,Y,,,20230210,,CN,DE,DE,2023,Q1,Adult
204680082,20468008,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd (every 1 day)",,,,,Unknown,,,10.0,MG,,QD,2023,Q1,Noninfective gingivitis,,2023,Q1,2,F,,20230209.0,20220214,20230210,EXP,,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2021-06524,ALKEM,,42.0,YR,,F,Y,,,20230210,,CN,DE,DE,2023,Q1,Adult
204680082,20468008,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd (every 1 day)",,,,,Unknown,,,10.0,MG,,QD,2023,Q1,Fatigue,,2023,Q1,2,F,,20230209.0,20220214,20230210,EXP,,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2021-06524,ALKEM,,42.0,YR,,F,Y,,,20230210,,CN,DE,DE,2023,Q1,Adult
204680082,20468008,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd (every 1 day)",,,,,Unknown,,,10.0,MG,,QD,2023,Q1,Nausea,,2023,Q1,2,F,,20230209.0,20220214,20230210,EXP,,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2021-06524,ALKEM,,42.0,YR,,F,Y,,,20230210,,CN,DE,DE,2023,Q1,Adult
204680082,20468008,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd (every 1 day)",,,,,Unknown,,,10.0,MG,,QD,2023,Q1,Hypotension,,2023,Q1,2,F,,20230209.0,20220214,20230210,EXP,,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2021-06524,ALKEM,,42.0,YR,,F,Y,,,20230210,,CN,DE,DE,2023,Q1,Adult
204680082,20468008,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd (every 1 day)",,,,,Unknown,,,10.0,MG,,QD,2023,Q1,Pain in extremity,,2023,Q1,2,F,,20230209.0,20220214,20230210,EXP,,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2021-06524,ALKEM,,42.0,YR,,F,Y,,,20230210,,CN,DE,DE,2023,Q1,Adult
204680082,20468008,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd (every 1 day)",,,,,Unknown,,,10.0,MG,,QD,2023,Q1,Vulvovaginal mycotic infection,,2023,Q1,2,F,,20230209.0,20220214,20230210,EXP,,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2021-06524,ALKEM,,42.0,YR,,F,Y,,,20230210,,CN,DE,DE,2023,Q1,Adult
204680082,20468008,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd (every 1 day)",,,,,Unknown,,,10.0,MG,,QD,2023,Q1,Fatigue,,2023,Q1,2,F,,20230209.0,20220214,20230210,EXP,,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2021-06524,ALKEM,,42.0,YR,,F,Y,,,20230210,,CN,DE,DE,2023,Q1,Adult
204680082,20468008,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd (every 1 day)",,,,,Unknown,,,10.0,MG,,QD,2023,Q1,Off label use,,2023,Q1,2,F,,20230209.0,20220214,20230210,EXP,,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2021-06524,ALKEM,,42.0,YR,,F,Y,,,20230210,,CN,DE,DE,2023,Q1,Adult
204680082,20468008,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd (every 1 day)",,,,,Unknown,,,10.0,MG,,QD,2023,Q1,Eye pain,,2023,Q1,2,F,,20230209.0,20220214,20230210,EXP,,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2021-06524,ALKEM,,42.0,YR,,F,Y,,,20230210,,CN,DE,DE,2023,Q1,Adult
204680082,20468008,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd (every 1 day)",,,,,Unknown,,,10.0,MG,,QD,2023,Q1,Vomiting,,2023,Q1,2,F,,20230209.0,20220214,20230210,EXP,,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2021-06524,ALKEM,,42.0,YR,,F,Y,,,20230210,,CN,DE,DE,2023,Q1,Adult
204680082,20468008,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd (every 1 day)",,,,,Unknown,,,10.0,MG,,QD,2023,Q1,Visual impairment,,2023,Q1,2,F,,20230209.0,20220214,20230210,EXP,,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2021-06524,ALKEM,,42.0,YR,,F,Y,,,20230210,,CN,DE,DE,2023,Q1,Adult
204680082,20468008,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd (every 1 day)",,,,,Unknown,,,10.0,MG,,QD,2023,Q1,Hypertension,,2023,Q1,2,F,,20230209.0,20220214,20230210,EXP,,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2021-06524,ALKEM,,42.0,YR,,F,Y,,,20230210,,CN,DE,DE,2023,Q1,Adult
205685202,20568520,22,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, 1 every 1 day",,,U,,,,,10.0,MG,,QD,2023,Q1,Therapy cessation,,2023,Q1,2,F,,20230206.0,20220308,20230210,EXP,,CA-ORGANON-1905CAN010892,ORGANON,,80.0,YR,,M,Y,,,20230210,,MD,CA,CA,2023,Q1,Elderly
205685202,20568520,22,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, 1 every 1 day",,,U,,,,,10.0,MG,,QD,2023,Q1,Asthma,,2023,Q1,2,F,,20230206.0,20220308,20230210,EXP,,CA-ORGANON-1905CAN010892,ORGANON,,80.0,YR,,M,Y,,,20230210,,MD,CA,CA,2023,Q1,Elderly
205685202,20568520,22,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, 1 every 1 day",,,U,,,,,10.0,MG,,QD,2023,Q1,Respiratory symptom,,2023,Q1,2,F,,20230206.0,20220308,20230210,EXP,,CA-ORGANON-1905CAN010892,ORGANON,,80.0,YR,,M,Y,,,20230210,,MD,CA,CA,2023,Q1,Elderly
205685202,20568520,22,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, 1 every 1 day",,,U,,,,,10.0,MG,,QD,2023,Q1,Pneumonia,,2023,Q1,2,F,,20230206.0,20220308,20230210,EXP,,CA-ORGANON-1905CAN010892,ORGANON,,80.0,YR,,M,Y,,,20230210,,MD,CA,CA,2023,Q1,Elderly
205685202,20568520,22,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, 1 every 1 day",,,U,,,,,10.0,MG,,QD,2023,Q1,Bronchial hyperreactivity,,2023,Q1,2,F,,20230206.0,20220308,20230210,EXP,,CA-ORGANON-1905CAN010892,ORGANON,,80.0,YR,,M,Y,,,20230210,,MD,CA,CA,2023,Q1,Elderly
205685202,20568520,22,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, 1 every 1 day",,,U,,,,,10.0,MG,,QD,2023,Q1,Cough,,2023,Q1,2,F,,20230206.0,20220308,20230210,EXP,,CA-ORGANON-1905CAN010892,ORGANON,,80.0,YR,,M,Y,,,20230210,,MD,CA,CA,2023,Q1,Elderly
205685202,20568520,22,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, 1 every 1 day",,,U,,,,,10.0,MG,,QD,2023,Q1,Lung disorder,,2023,Q1,2,F,,20230206.0,20220308,20230210,EXP,,CA-ORGANON-1905CAN010892,ORGANON,,80.0,YR,,M,Y,,,20230210,,MD,CA,CA,2023,Q1,Elderly
205685202,20568520,22,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, 1 every 1 day",,,U,,,,,10.0,MG,,QD,2023,Q1,Sputum discoloured,,2023,Q1,2,F,,20230206.0,20220308,20230210,EXP,,CA-ORGANON-1905CAN010892,ORGANON,,80.0,YR,,M,Y,,,20230210,,MD,CA,CA,2023,Q1,Elderly
205685202,20568520,22,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, 1 every 1 day",,,U,,,,,10.0,MG,,QD,2023,Q1,Loss of personal independence in daily activities,,2023,Q1,2,F,,20230206.0,20220308,20230210,EXP,,CA-ORGANON-1905CAN010892,ORGANON,,80.0,YR,,M,Y,,,20230210,,MD,CA,CA,2023,Q1,Elderly
205685202,20568520,22,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, 1 every 1 day",,,U,,,,,10.0,MG,,QD,2023,Q1,Dyspnoea,,2023,Q1,2,F,,20230206.0,20220308,20230210,EXP,,CA-ORGANON-1905CAN010892,ORGANON,,80.0,YR,,M,Y,,,20230210,,MD,CA,CA,2023,Q1,Elderly
205685202,20568520,22,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, 1 every 1 day",,,U,,,,,10.0,MG,,QD,2023,Q1,Full blood count abnormal,,2023,Q1,2,F,,20230206.0,20220308,20230210,EXP,,CA-ORGANON-1905CAN010892,ORGANON,,80.0,YR,,M,Y,,,20230210,,MD,CA,CA,2023,Q1,Elderly
205685202,20568520,22,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, 1 every 1 day",,,U,,,,,10.0,MG,,QD,2023,Q1,Rales,,2023,Q1,2,F,,20230206.0,20220308,20230210,EXP,,CA-ORGANON-1905CAN010892,ORGANON,,80.0,YR,,M,Y,,,20230210,,MD,CA,CA,2023,Q1,Elderly
205685202,20568520,22,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, 1 every 1 day",,,U,,,,,10.0,MG,,QD,2023,Q1,Productive cough,,2023,Q1,2,F,,20230206.0,20220308,20230210,EXP,,CA-ORGANON-1905CAN010892,ORGANON,,80.0,YR,,M,Y,,,20230210,,MD,CA,CA,2023,Q1,Elderly
205685202,20568520,22,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, 1 every 1 day",,,U,,,,,10.0,MG,,QD,2023,Q1,Condition aggravated,,2023,Q1,2,F,,20230206.0,20220308,20230210,EXP,,CA-ORGANON-1905CAN010892,ORGANON,,80.0,YR,,M,Y,,,20230210,,MD,CA,CA,2023,Q1,Elderly
205685202,20568520,22,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, 1 every 1 day",,,U,,,,,10.0,MG,,QD,2023,Q1,Obstructive airways disorder,,2023,Q1,2,F,,20230206.0,20220308,20230210,EXP,,CA-ORGANON-1905CAN010892,ORGANON,,80.0,YR,,M,Y,,,20230210,,MD,CA,CA,2023,Q1,Elderly
205685202,20568520,22,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, 1 every 1 day",,,U,,,,,10.0,MG,,QD,2023,Q1,Therapeutic product effect incomplete,,2023,Q1,2,F,,20230206.0,20220308,20230210,EXP,,CA-ORGANON-1905CAN010892,ORGANON,,80.0,YR,,M,Y,,,20230210,,MD,CA,CA,2023,Q1,Elderly
205685202,20568520,22,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, 1 every 1 day",,,U,,,,,10.0,MG,,QD,2023,Q1,Pulmonary function test abnormal,,2023,Q1,2,F,,20230206.0,20220308,20230210,EXP,,CA-ORGANON-1905CAN010892,ORGANON,,80.0,YR,,M,Y,,,20230210,,MD,CA,CA,2023,Q1,Elderly
205685202,20568520,22,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, 1 every 1 day",,,U,,,,,10.0,MG,,QD,2023,Q1,Aspiration,,2023,Q1,2,F,,20230206.0,20220308,20230210,EXP,,CA-ORGANON-1905CAN010892,ORGANON,,80.0,YR,,M,Y,,,20230210,,MD,CA,CA,2023,Q1,Elderly
205685202,20568520,22,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, 1 every 1 day",,,U,,,,,10.0,MG,,QD,2023,Q1,Hospitalisation,,2023,Q1,2,F,,20230206.0,20220308,20230210,EXP,,CA-ORGANON-1905CAN010892,ORGANON,,80.0,YR,,M,Y,,,20230210,,MD,CA,CA,2023,Q1,Elderly
205685202,20568520,22,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, 1 every 1 day",,,U,,,,,10.0,MG,,QD,2023,Q1,Pneumonitis,,2023,Q1,2,F,,20230206.0,20220308,20230210,EXP,,CA-ORGANON-1905CAN010892,ORGANON,,80.0,YR,,M,Y,,,20230210,,MD,CA,CA,2023,Q1,Elderly
205685202,20568520,22,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, 1 every 1 day",,,U,,,,,10.0,MG,,QD,2023,Q1,Wheezing,,2023,Q1,2,F,,20230206.0,20220308,20230210,EXP,,CA-ORGANON-1905CAN010892,ORGANON,,80.0,YR,,M,Y,,,20230210,,MD,CA,CA,2023,Q1,Elderly
205685202,20568520,22,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, 1 every 1 day",,,U,,,,,10.0,MG,,QD,2023,Q1,Wrong technique in product usage process,,2023,Q1,2,F,,20230206.0,20220308,20230210,EXP,,CA-ORGANON-1905CAN010892,ORGANON,,80.0,YR,,M,Y,,,20230210,,MD,CA,CA,2023,Q1,Elderly
205685202,20568520,22,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, 1 every 1 day",,,U,,,,,10.0,MG,,QD,2023,Q1,Drug ineffective,,2023,Q1,2,F,,20230206.0,20220308,20230210,EXP,,CA-ORGANON-1905CAN010892,ORGANON,,80.0,YR,,M,Y,,,20230210,,MD,CA,CA,2023,Q1,Elderly
205685202,20568520,22,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, 1 every 1 day",,,U,,,,,10.0,MG,,QD,2023,Q1,Sleep disorder due to a general medical condition,,2023,Q1,2,F,,20230206.0,20220308,20230210,EXP,,CA-ORGANON-1905CAN010892,ORGANON,,80.0,YR,,M,Y,,,20230210,,MD,CA,CA,2023,Q1,Elderly
205685202,20568520,22,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, 1 every 1 day",,,U,,,,,10.0,MG,,QD,2023,Q1,Left ventricular dysfunction,,2023,Q1,2,F,,20230206.0,20220308,20230210,EXP,,CA-ORGANON-1905CAN010892,ORGANON,,80.0,YR,,M,Y,,,20230210,,MD,CA,CA,2023,Q1,Elderly
206293966,20629396,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,Y,U,,,,25.0,MG,,QD,2023,Q1,Dehydration,,2023,Q1,6,F,,20230130.0,20220323,20230207,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230207,,MD,PT,PT,2023,Q1,Elderly
206293966,20629396,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,Y,U,,,,25.0,MG,,QD,2023,Q1,Nausea,,2023,Q1,6,F,,20230130.0,20220323,20230207,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230207,,MD,PT,PT,2023,Q1,Elderly
206293966,20629396,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,Y,U,,,,25.0,MG,,QD,2023,Q1,Breast cancer,,2023,Q1,6,F,,20230130.0,20220323,20230207,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230207,,MD,PT,PT,2023,Q1,Elderly
206293966,20629396,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,Y,U,,,,25.0,MG,,QD,2023,Q1,Dysphagia,,2023,Q1,6,F,,20230130.0,20220323,20230207,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230207,,MD,PT,PT,2023,Q1,Elderly
206293966,20629396,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,Y,U,,,,25.0,MG,,QD,2023,Q1,Dry skin,,2023,Q1,6,F,,20230130.0,20220323,20230207,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230207,,MD,PT,PT,2023,Q1,Elderly
206293966,20629396,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,Y,U,,,,25.0,MG,,QD,2023,Q1,Vomiting,,2023,Q1,6,F,,20230130.0,20220323,20230207,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230207,,MD,PT,PT,2023,Q1,Elderly
206293966,20629396,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,Y,U,,,,25.0,MG,,QD,2023,Q1,Acetonaemia,,2023,Q1,6,F,,20230130.0,20220323,20230207,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230207,,MD,PT,PT,2023,Q1,Elderly
206293966,20629396,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,Y,U,,,,25.0,MG,,QD,2023,Q1,Diabetic ketoacidosis,,2023,Q1,6,F,,20230130.0,20220323,20230207,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230207,,MD,PT,PT,2023,Q1,Elderly
206293966,20629396,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,Y,U,,,,25.0,MG,,QD,2023,Q1,Oliguria,,2023,Q1,6,F,,20230130.0,20220323,20230207,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230207,,MD,PT,PT,2023,Q1,Elderly
206293966,20629396,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,Y,U,,,,25.0,MG,,QD,2023,Q1,Ketoacidosis,,2023,Q1,6,F,,20230130.0,20220323,20230207,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230207,,MD,PT,PT,2023,Q1,Elderly
206293966,20629396,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,Y,U,,,,25.0,MG,,QD,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,6,F,,20230130.0,20220323,20230207,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230207,,MD,PT,PT,2023,Q1,Elderly
206293966,20629396,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,Y,U,,,,25.0,MG,,QD,2023,Q1,Blood lactic acid increased,,2023,Q1,6,F,,20230130.0,20220323,20230207,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230207,,MD,PT,PT,2023,Q1,Elderly
206293966,20629396,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,Y,U,,,,25.0,MG,,QD,2023,Q1,Decreased appetite,,2023,Q1,6,F,,20230130.0,20220323,20230207,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230207,,MD,PT,PT,2023,Q1,Elderly
206293966,20629396,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,Y,U,,,,25.0,MG,,QD,2023,Q1,Drug interaction,,2023,Q1,6,F,,20230130.0,20220323,20230207,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230207,,MD,PT,PT,2023,Q1,Elderly
206293966,20629396,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,Y,U,,,,25.0,MG,,QD,2023,Q1,Normochromic normocytic anaemia,,2023,Q1,6,F,,20230130.0,20220323,20230207,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230207,,MD,PT,PT,2023,Q1,Elderly
206293966,20629396,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,Y,U,,,,25.0,MG,,QD,2023,Q1,Pallor,,2023,Q1,6,F,,20230130.0,20220323,20230207,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230207,,MD,PT,PT,2023,Q1,Elderly
206293966,20629396,6,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 milligram,,,Y,U,,,,25.0,MG,,,2023,Q1,Dehydration,,2023,Q1,6,F,,20230130.0,20220323,20230207,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230207,,MD,PT,PT,2023,Q1,Elderly
206293966,20629396,6,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 milligram,,,Y,U,,,,25.0,MG,,,2023,Q1,Nausea,,2023,Q1,6,F,,20230130.0,20220323,20230207,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230207,,MD,PT,PT,2023,Q1,Elderly
206293966,20629396,6,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 milligram,,,Y,U,,,,25.0,MG,,,2023,Q1,Breast cancer,,2023,Q1,6,F,,20230130.0,20220323,20230207,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230207,,MD,PT,PT,2023,Q1,Elderly
206293966,20629396,6,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 milligram,,,Y,U,,,,25.0,MG,,,2023,Q1,Dysphagia,,2023,Q1,6,F,,20230130.0,20220323,20230207,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230207,,MD,PT,PT,2023,Q1,Elderly
206293966,20629396,6,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 milligram,,,Y,U,,,,25.0,MG,,,2023,Q1,Dry skin,,2023,Q1,6,F,,20230130.0,20220323,20230207,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230207,,MD,PT,PT,2023,Q1,Elderly
206293966,20629396,6,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 milligram,,,Y,U,,,,25.0,MG,,,2023,Q1,Vomiting,,2023,Q1,6,F,,20230130.0,20220323,20230207,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230207,,MD,PT,PT,2023,Q1,Elderly
206293966,20629396,6,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 milligram,,,Y,U,,,,25.0,MG,,,2023,Q1,Acetonaemia,,2023,Q1,6,F,,20230130.0,20220323,20230207,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230207,,MD,PT,PT,2023,Q1,Elderly
206293966,20629396,6,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 milligram,,,Y,U,,,,25.0,MG,,,2023,Q1,Diabetic ketoacidosis,,2023,Q1,6,F,,20230130.0,20220323,20230207,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230207,,MD,PT,PT,2023,Q1,Elderly
206293966,20629396,6,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 milligram,,,Y,U,,,,25.0,MG,,,2023,Q1,Oliguria,,2023,Q1,6,F,,20230130.0,20220323,20230207,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230207,,MD,PT,PT,2023,Q1,Elderly
206293966,20629396,6,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 milligram,,,Y,U,,,,25.0,MG,,,2023,Q1,Ketoacidosis,,2023,Q1,6,F,,20230130.0,20220323,20230207,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230207,,MD,PT,PT,2023,Q1,Elderly
206293966,20629396,6,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 milligram,,,Y,U,,,,25.0,MG,,,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,6,F,,20230130.0,20220323,20230207,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230207,,MD,PT,PT,2023,Q1,Elderly
206293966,20629396,6,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 milligram,,,Y,U,,,,25.0,MG,,,2023,Q1,Blood lactic acid increased,,2023,Q1,6,F,,20230130.0,20220323,20230207,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230207,,MD,PT,PT,2023,Q1,Elderly
206293966,20629396,6,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 milligram,,,Y,U,,,,25.0,MG,,,2023,Q1,Decreased appetite,,2023,Q1,6,F,,20230130.0,20220323,20230207,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230207,,MD,PT,PT,2023,Q1,Elderly
206293966,20629396,6,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 milligram,,,Y,U,,,,25.0,MG,,,2023,Q1,Drug interaction,,2023,Q1,6,F,,20230130.0,20220323,20230207,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230207,,MD,PT,PT,2023,Q1,Elderly
206293966,20629396,6,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 milligram,,,Y,U,,,,25.0,MG,,,2023,Q1,Normochromic normocytic anaemia,,2023,Q1,6,F,,20230130.0,20220323,20230207,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230207,,MD,PT,PT,2023,Q1,Elderly
206293966,20629396,6,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 milligram,,,Y,U,,,,25.0,MG,,,2023,Q1,Pallor,,2023,Q1,6,F,,20230130.0,20220323,20230207,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230207,,MD,PT,PT,2023,Q1,Elderly
206310522,20631052,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q1,Rash pruritic,,2023,Q1,2,F,20190930.0,20230214.0,20220324,20230222,EXP,,PT-AUROBINDO-AUR-APL-2020-050071,AUROBINDO,"Lima F, Vidal H, Calado D, Costa P, Rocha M, Dias L. IM-181 319 Pustulose generalizada exantem?tica aguda - um caso de iatrogenia a quinolonas. .. Revista da Sociedade Portuguesa de Medicina Interna: Livro de Resumos ? Edi??o E. 2020;27:335",72.0,YR,,M,Y,,,20230222,,MD,PT,PT,2023,Q1,Elderly
206310522,20631052,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q1,Pustule,,2023,Q1,2,F,20190930.0,20230214.0,20220324,20230222,EXP,,PT-AUROBINDO-AUR-APL-2020-050071,AUROBINDO,"Lima F, Vidal H, Calado D, Costa P, Rocha M, Dias L. IM-181 319 Pustulose generalizada exantem?tica aguda - um caso de iatrogenia a quinolonas. .. Revista da Sociedade Portuguesa de Medicina Interna: Livro de Resumos ? Edi??o E. 2020;27:335",72.0,YR,,M,Y,,,20230222,,MD,PT,PT,2023,Q1,Elderly
206310522,20631052,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q1,Pyrexia,,2023,Q1,2,F,20190930.0,20230214.0,20220324,20230222,EXP,,PT-AUROBINDO-AUR-APL-2020-050071,AUROBINDO,"Lima F, Vidal H, Calado D, Costa P, Rocha M, Dias L. IM-181 319 Pustulose generalizada exantem?tica aguda - um caso de iatrogenia a quinolonas. .. Revista da Sociedade Portuguesa de Medicina Interna: Livro de Resumos ? Edi??o E. 2020;27:335",72.0,YR,,M,Y,,,20230222,,MD,PT,PT,2023,Q1,Elderly
206310522,20631052,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q1,Acute generalised exanthematous pustulosis,,2023,Q1,2,F,20190930.0,20230214.0,20220324,20230222,EXP,,PT-AUROBINDO-AUR-APL-2020-050071,AUROBINDO,"Lima F, Vidal H, Calado D, Costa P, Rocha M, Dias L. IM-181 319 Pustulose generalizada exantem?tica aguda - um caso de iatrogenia a quinolonas. .. Revista da Sociedade Portuguesa de Medicina Interna: Livro de Resumos ? Edi??o E. 2020;27:335",72.0,YR,,M,Y,,,20230222,,MD,PT,PT,2023,Q1,Elderly
206310522,20631052,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q1,Rash,,2023,Q1,2,F,20190930.0,20230214.0,20220324,20230222,EXP,,PT-AUROBINDO-AUR-APL-2020-050071,AUROBINDO,"Lima F, Vidal H, Calado D, Costa P, Rocha M, Dias L. IM-181 319 Pustulose generalizada exantem?tica aguda - um caso de iatrogenia a quinolonas. .. Revista da Sociedade Portuguesa de Medicina Interna: Livro de Resumos ? Edi??o E. 2020;27:335",72.0,YR,,M,Y,,,20230222,,MD,PT,PT,2023,Q1,Elderly
206466258,20646625,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,Y,,,,,25.0,MG,,QD,2023,Q1,Dehydration,,2023,Q1,8,F,,20230104.0,20220329,20230116,EXP,,PT-AUROBINDO-AUR-APL-2022-009438,AUROBINDO,"Rodrigues S,Esteves VL.. Cetoacidose euglicemica em doente idoso sob empagliflozina e metformina (Clinical Cases euglycemic ketoacidosis in elderly patient on empagliflozin and metformin). Revista Portuguesa de Diabetes (Portuguese Journal of diabetes). 2022;17(1):69-74",82.0,YR,,F,Y,,,20230116,,MD,PT,PT,2023,Q1,Elderly
206466258,20646625,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,Y,,,,,25.0,MG,,QD,2023,Q1,Ketoacidosis,,2023,Q1,8,F,,20230104.0,20220329,20230116,EXP,,PT-AUROBINDO-AUR-APL-2022-009438,AUROBINDO,"Rodrigues S,Esteves VL.. Cetoacidose euglicemica em doente idoso sob empagliflozina e metformina (Clinical Cases euglycemic ketoacidosis in elderly patient on empagliflozin and metformin). Revista Portuguesa de Diabetes (Portuguese Journal of diabetes). 2022;17(1):69-74",82.0,YR,,F,Y,,,20230116,,MD,PT,PT,2023,Q1,Elderly
206466258,20646625,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,Y,,,,,25.0,MG,,QD,2023,Q1,Oliguria,,2023,Q1,8,F,,20230104.0,20220329,20230116,EXP,,PT-AUROBINDO-AUR-APL-2022-009438,AUROBINDO,"Rodrigues S,Esteves VL.. Cetoacidose euglicemica em doente idoso sob empagliflozina e metformina (Clinical Cases euglycemic ketoacidosis in elderly patient on empagliflozin and metformin). Revista Portuguesa de Diabetes (Portuguese Journal of diabetes). 2022;17(1):69-74",82.0,YR,,F,Y,,,20230116,,MD,PT,PT,2023,Q1,Elderly
206466258,20646625,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,Y,,,,,25.0,MG,,QD,2023,Q1,Normochromic normocytic anaemia,,2023,Q1,8,F,,20230104.0,20220329,20230116,EXP,,PT-AUROBINDO-AUR-APL-2022-009438,AUROBINDO,"Rodrigues S,Esteves VL.. Cetoacidose euglicemica em doente idoso sob empagliflozina e metformina (Clinical Cases euglycemic ketoacidosis in elderly patient on empagliflozin and metformin). Revista Portuguesa de Diabetes (Portuguese Journal of diabetes). 2022;17(1):69-74",82.0,YR,,F,Y,,,20230116,,MD,PT,PT,2023,Q1,Elderly
206466258,20646625,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,Y,,,,,25.0,MG,,QD,2023,Q1,Blood lactic acid increased,,2023,Q1,8,F,,20230104.0,20220329,20230116,EXP,,PT-AUROBINDO-AUR-APL-2022-009438,AUROBINDO,"Rodrigues S,Esteves VL.. Cetoacidose euglicemica em doente idoso sob empagliflozina e metformina (Clinical Cases euglycemic ketoacidosis in elderly patient on empagliflozin and metformin). Revista Portuguesa de Diabetes (Portuguese Journal of diabetes). 2022;17(1):69-74",82.0,YR,,F,Y,,,20230116,,MD,PT,PT,2023,Q1,Elderly
206466258,20646625,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,Y,,,,,25.0,MG,,QD,2023,Q1,Decreased appetite,,2023,Q1,8,F,,20230104.0,20220329,20230116,EXP,,PT-AUROBINDO-AUR-APL-2022-009438,AUROBINDO,"Rodrigues S,Esteves VL.. Cetoacidose euglicemica em doente idoso sob empagliflozina e metformina (Clinical Cases euglycemic ketoacidosis in elderly patient on empagliflozin and metformin). Revista Portuguesa de Diabetes (Portuguese Journal of diabetes). 2022;17(1):69-74",82.0,YR,,F,Y,,,20230116,,MD,PT,PT,2023,Q1,Elderly
206466258,20646625,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,Y,,,,,25.0,MG,,QD,2023,Q1,Acetonaemia,,2023,Q1,8,F,,20230104.0,20220329,20230116,EXP,,PT-AUROBINDO-AUR-APL-2022-009438,AUROBINDO,"Rodrigues S,Esteves VL.. Cetoacidose euglicemica em doente idoso sob empagliflozina e metformina (Clinical Cases euglycemic ketoacidosis in elderly patient on empagliflozin and metformin). Revista Portuguesa de Diabetes (Portuguese Journal of diabetes). 2022;17(1):69-74",82.0,YR,,F,Y,,,20230116,,MD,PT,PT,2023,Q1,Elderly
206466258,20646625,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,Y,,,,,25.0,MG,,QD,2023,Q1,Breast cancer,,2023,Q1,8,F,,20230104.0,20220329,20230116,EXP,,PT-AUROBINDO-AUR-APL-2022-009438,AUROBINDO,"Rodrigues S,Esteves VL.. Cetoacidose euglicemica em doente idoso sob empagliflozina e metformina (Clinical Cases euglycemic ketoacidosis in elderly patient on empagliflozin and metformin). Revista Portuguesa de Diabetes (Portuguese Journal of diabetes). 2022;17(1):69-74",82.0,YR,,F,Y,,,20230116,,MD,PT,PT,2023,Q1,Elderly
206466258,20646625,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,Y,,,,,25.0,MG,,QD,2023,Q1,Nausea,,2023,Q1,8,F,,20230104.0,20220329,20230116,EXP,,PT-AUROBINDO-AUR-APL-2022-009438,AUROBINDO,"Rodrigues S,Esteves VL.. Cetoacidose euglicemica em doente idoso sob empagliflozina e metformina (Clinical Cases euglycemic ketoacidosis in elderly patient on empagliflozin and metformin). Revista Portuguesa de Diabetes (Portuguese Journal of diabetes). 2022;17(1):69-74",82.0,YR,,F,Y,,,20230116,,MD,PT,PT,2023,Q1,Elderly
206466258,20646625,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,Y,,,,,25.0,MG,,QD,2023,Q1,Diabetic ketoacidosis,,2023,Q1,8,F,,20230104.0,20220329,20230116,EXP,,PT-AUROBINDO-AUR-APL-2022-009438,AUROBINDO,"Rodrigues S,Esteves VL.. Cetoacidose euglicemica em doente idoso sob empagliflozina e metformina (Clinical Cases euglycemic ketoacidosis in elderly patient on empagliflozin and metformin). Revista Portuguesa de Diabetes (Portuguese Journal of diabetes). 2022;17(1):69-74",82.0,YR,,F,Y,,,20230116,,MD,PT,PT,2023,Q1,Elderly
206466258,20646625,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,Y,,,,,25.0,MG,,QD,2023,Q1,Drug interaction,,2023,Q1,8,F,,20230104.0,20220329,20230116,EXP,,PT-AUROBINDO-AUR-APL-2022-009438,AUROBINDO,"Rodrigues S,Esteves VL.. Cetoacidose euglicemica em doente idoso sob empagliflozina e metformina (Clinical Cases euglycemic ketoacidosis in elderly patient on empagliflozin and metformin). Revista Portuguesa de Diabetes (Portuguese Journal of diabetes). 2022;17(1):69-74",82.0,YR,,F,Y,,,20230116,,MD,PT,PT,2023,Q1,Elderly
206466258,20646625,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,Y,,,,,25.0,MG,,QD,2023,Q1,Pallor,,2023,Q1,8,F,,20230104.0,20220329,20230116,EXP,,PT-AUROBINDO-AUR-APL-2022-009438,AUROBINDO,"Rodrigues S,Esteves VL.. Cetoacidose euglicemica em doente idoso sob empagliflozina e metformina (Clinical Cases euglycemic ketoacidosis in elderly patient on empagliflozin and metformin). Revista Portuguesa de Diabetes (Portuguese Journal of diabetes). 2022;17(1):69-74",82.0,YR,,F,Y,,,20230116,,MD,PT,PT,2023,Q1,Elderly
206466258,20646625,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,Y,,,,,25.0,MG,,QD,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,8,F,,20230104.0,20220329,20230116,EXP,,PT-AUROBINDO-AUR-APL-2022-009438,AUROBINDO,"Rodrigues S,Esteves VL.. Cetoacidose euglicemica em doente idoso sob empagliflozina e metformina (Clinical Cases euglycemic ketoacidosis in elderly patient on empagliflozin and metformin). Revista Portuguesa de Diabetes (Portuguese Journal of diabetes). 2022;17(1):69-74",82.0,YR,,F,Y,,,20230116,,MD,PT,PT,2023,Q1,Elderly
206466258,20646625,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,Y,,,,,25.0,MG,,QD,2023,Q1,Dysphagia,,2023,Q1,8,F,,20230104.0,20220329,20230116,EXP,,PT-AUROBINDO-AUR-APL-2022-009438,AUROBINDO,"Rodrigues S,Esteves VL.. Cetoacidose euglicemica em doente idoso sob empagliflozina e metformina (Clinical Cases euglycemic ketoacidosis in elderly patient on empagliflozin and metformin). Revista Portuguesa de Diabetes (Portuguese Journal of diabetes). 2022;17(1):69-74",82.0,YR,,F,Y,,,20230116,,MD,PT,PT,2023,Q1,Elderly
206466258,20646625,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,Y,,,,,25.0,MG,,QD,2023,Q1,Dry skin,,2023,Q1,8,F,,20230104.0,20220329,20230116,EXP,,PT-AUROBINDO-AUR-APL-2022-009438,AUROBINDO,"Rodrigues S,Esteves VL.. Cetoacidose euglicemica em doente idoso sob empagliflozina e metformina (Clinical Cases euglycemic ketoacidosis in elderly patient on empagliflozin and metformin). Revista Portuguesa de Diabetes (Portuguese Journal of diabetes). 2022;17(1):69-74",82.0,YR,,F,Y,,,20230116,,MD,PT,PT,2023,Q1,Elderly
206466258,20646625,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,Y,,,,,25.0,MG,,QD,2023,Q1,Vomiting,,2023,Q1,8,F,,20230104.0,20220329,20230116,EXP,,PT-AUROBINDO-AUR-APL-2022-009438,AUROBINDO,"Rodrigues S,Esteves VL.. Cetoacidose euglicemica em doente idoso sob empagliflozina e metformina (Clinical Cases euglycemic ketoacidosis in elderly patient on empagliflozin and metformin). Revista Portuguesa de Diabetes (Portuguese Journal of diabetes). 2022;17(1):69-74",82.0,YR,,F,Y,,,20230116,,MD,PT,PT,2023,Q1,Elderly
206473478,20647347,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, QD",,,Y,,,,,25.0,MG,,QD,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,8,F,,20230104.0,20220329,20230106,EXP,,NVSC2022PT069983,NOVARTIS,"Rodrigues S, Esteves VL. Cetoacidose euglicemia em doente idoso sob empagliflozina E metformina [Euglycemic ketoacidosis in an elderly patient on empagliflozin and metformin]. REVISTA PORTUGUESA DE DIABETES [PORTUGUESE JOURNAL OF DIABETES]. 2022;17(1):69-74",82.0,YR,,F,Y,,,20230106,,HP,PT,PT,2023,Q1,Elderly
206920783,20692078,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2023,Q1,Cough,,2023,Q1,3,F,,20230321.0,20220409,20230329,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-08060,SAMSUNG BIOEPIS,,49.0,YR,A,M,Y,118.0,KG,20230329,,HP,CA,CA,2023,Q1,Adult
206920783,20692078,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2023,Q1,COVID-19,,2023,Q1,3,F,,20230321.0,20220409,20230329,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-08060,SAMSUNG BIOEPIS,,49.0,YR,A,M,Y,118.0,KG,20230329,,HP,CA,CA,2023,Q1,Adult
206920783,20692078,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2023,Q1,Rectal haemorrhage,,2023,Q1,3,F,,20230321.0,20220409,20230329,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-08060,SAMSUNG BIOEPIS,,49.0,YR,A,M,Y,118.0,KG,20230329,,HP,CA,CA,2023,Q1,Adult
206920783,20692078,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2023,Q1,Therapeutic response shortened,,2023,Q1,3,F,,20230321.0,20220409,20230329,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-08060,SAMSUNG BIOEPIS,,49.0,YR,A,M,Y,118.0,KG,20230329,,HP,CA,CA,2023,Q1,Adult
206920783,20692078,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2023,Q1,Condition aggravated,,2023,Q1,3,F,,20230321.0,20220409,20230329,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-08060,SAMSUNG BIOEPIS,,49.0,YR,A,M,Y,118.0,KG,20230329,,HP,CA,CA,2023,Q1,Adult
206920783,20692078,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2023,Q1,Arthralgia,,2023,Q1,3,F,,20230321.0,20220409,20230329,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-08060,SAMSUNG BIOEPIS,,49.0,YR,A,M,Y,118.0,KG,20230329,,HP,CA,CA,2023,Q1,Adult
206920783,20692078,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2023,Q1,Gouty arthritis,,2023,Q1,3,F,,20230321.0,20220409,20230329,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-08060,SAMSUNG BIOEPIS,,49.0,YR,A,M,Y,118.0,KG,20230329,,HP,CA,CA,2023,Q1,Adult
206920783,20692078,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2023,Q1,Mobility decreased,,2023,Q1,3,F,,20230321.0,20220409,20230329,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-08060,SAMSUNG BIOEPIS,,49.0,YR,A,M,Y,118.0,KG,20230329,,HP,CA,CA,2023,Q1,Adult
206920783,20692078,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2023,Q1,Nasal congestion,,2023,Q1,3,F,,20230321.0,20220409,20230329,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-08060,SAMSUNG BIOEPIS,,49.0,YR,A,M,Y,118.0,KG,20230329,,HP,CA,CA,2023,Q1,Adult
206920783,20692078,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2023,Q1,Anal fissure,,2023,Q1,3,F,,20230321.0,20220409,20230329,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-08060,SAMSUNG BIOEPIS,,49.0,YR,A,M,Y,118.0,KG,20230329,,HP,CA,CA,2023,Q1,Adult
206996513,20699651,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q1,Pain in extremity,,2023,Q1,3,F,,20221228.0,20220412,20230107,EXP,CA-MHPD-E2B_03840580,CA-Accord-260293,ACCORD,,60.0,YR,A,M,Y,,,20230107,,HP,CA,CA,2023,Q1,Adult
206996513,20699651,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q1,Musculoskeletal stiffness,,2023,Q1,3,F,,20221228.0,20220412,20230107,EXP,CA-MHPD-E2B_03840580,CA-Accord-260293,ACCORD,,60.0,YR,A,M,Y,,,20230107,,HP,CA,CA,2023,Q1,Adult
206996513,20699651,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q1,Joint effusion,,2023,Q1,3,F,,20221228.0,20220412,20230107,EXP,CA-MHPD-E2B_03840580,CA-Accord-260293,ACCORD,,60.0,YR,A,M,Y,,,20230107,,HP,CA,CA,2023,Q1,Adult
206996513,20699651,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q1,Pain,,2023,Q1,3,F,,20221228.0,20220412,20230107,EXP,CA-MHPD-E2B_03840580,CA-Accord-260293,ACCORD,,60.0,YR,A,M,Y,,,20230107,,HP,CA,CA,2023,Q1,Adult
206996513,20699651,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q1,Enthesopathy,,2023,Q1,3,F,,20221228.0,20220412,20230107,EXP,CA-MHPD-E2B_03840580,CA-Accord-260293,ACCORD,,60.0,YR,A,M,Y,,,20230107,,HP,CA,CA,2023,Q1,Adult
206996513,20699651,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q1,Mobility decreased,,2023,Q1,3,F,,20221228.0,20220412,20230107,EXP,CA-MHPD-E2B_03840580,CA-Accord-260293,ACCORD,,60.0,YR,A,M,Y,,,20230107,,HP,CA,CA,2023,Q1,Adult
206996513,20699651,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q1,Arthralgia,,2023,Q1,3,F,,20221228.0,20220412,20230107,EXP,CA-MHPD-E2B_03840580,CA-Accord-260293,ACCORD,,60.0,YR,A,M,Y,,,20230107,,HP,CA,CA,2023,Q1,Adult
206996513,20699651,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q1,Paraesthesia,,2023,Q1,3,F,,20221228.0,20220412,20230107,EXP,CA-MHPD-E2B_03840580,CA-Accord-260293,ACCORD,,60.0,YR,A,M,Y,,,20230107,,HP,CA,CA,2023,Q1,Adult
206996513,20699651,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q1,Spinal pain,,2023,Q1,3,F,,20221228.0,20220412,20230107,EXP,CA-MHPD-E2B_03840580,CA-Accord-260293,ACCORD,,60.0,YR,A,M,Y,,,20230107,,HP,CA,CA,2023,Q1,Adult
206996513,20699651,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q1,Weight increased,,2023,Q1,3,F,,20221228.0,20220412,20230107,EXP,CA-MHPD-E2B_03840580,CA-Accord-260293,ACCORD,,60.0,YR,A,M,Y,,,20230107,,HP,CA,CA,2023,Q1,Adult
206996513,20699651,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q1,Psoriasis,,2023,Q1,3,F,,20221228.0,20220412,20230107,EXP,CA-MHPD-E2B_03840580,CA-Accord-260293,ACCORD,,60.0,YR,A,M,Y,,,20230107,,HP,CA,CA,2023,Q1,Adult
206996513,20699651,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q1,Joint swelling,,2023,Q1,3,F,,20221228.0,20220412,20230107,EXP,CA-MHPD-E2B_03840580,CA-Accord-260293,ACCORD,,60.0,YR,A,M,Y,,,20230107,,HP,CA,CA,2023,Q1,Adult
206996513,20699651,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q1,Arthropathy,,2023,Q1,3,F,,20221228.0,20220412,20230107,EXP,CA-MHPD-E2B_03840580,CA-Accord-260293,ACCORD,,60.0,YR,A,M,Y,,,20230107,,HP,CA,CA,2023,Q1,Adult
206996513,20699651,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q1,Joint range of motion decreased,,2023,Q1,3,F,,20221228.0,20220412,20230107,EXP,CA-MHPD-E2B_03840580,CA-Accord-260293,ACCORD,,60.0,YR,A,M,Y,,,20230107,,HP,CA,CA,2023,Q1,Adult
206996513,20699651,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q1,Abdominal discomfort,,2023,Q1,3,F,,20221228.0,20220412,20230107,EXP,CA-MHPD-E2B_03840580,CA-Accord-260293,ACCORD,,60.0,YR,A,M,Y,,,20230107,,HP,CA,CA,2023,Q1,Adult
206996513,20699651,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q1,Psoriatic arthropathy,,2023,Q1,3,F,,20221228.0,20220412,20230107,EXP,CA-MHPD-E2B_03840580,CA-Accord-260293,ACCORD,,60.0,YR,A,M,Y,,,20230107,,HP,CA,CA,2023,Q1,Adult
206996513,20699651,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q1,Synovitis,,2023,Q1,3,F,,20221228.0,20220412,20230107,EXP,CA-MHPD-E2B_03840580,CA-Accord-260293,ACCORD,,60.0,YR,A,M,Y,,,20230107,,HP,CA,CA,2023,Q1,Adult
207078917,20707891,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,Y,U,Unknown,,206073.0,,,Tablet,,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,7,F,20220412.0,20230322.0,20220414,20230325,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-165275",BOEHRINGER INGELHEIM,,57.0,YR,A,M,Y,70.0,KG,20230325,,MD,JP,JP,2023,Q1,Adult
207078917,20707891,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,Y,U,Unknown,,206073.0,,,Tablet,,2023,Q1,Appendicitis,,2023,Q1,7,F,20220412.0,20230322.0,20220414,20230325,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-165275",BOEHRINGER INGELHEIM,,57.0,YR,A,M,Y,70.0,KG,20230325,,MD,JP,JP,2023,Q1,Adult
2077195210,20771952,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2023,Q1,Vitreous haemorrhage,,2023,Q1,10,F,20220418.0,20230119.0,20220501,20230120,EXP,,NVSC2022CN095120,NOVARTIS,,22.0,YR,,F,Y,,,20230120,,MD,CN,CN,2023,Q1,Youth
207954406,20795440,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,QD,2023,Q1,Ocular vasculitis,,2023,Q1,6,F,20220427.0,20230105.0,20220506,20230110,EXP,,US-ROCHE-3087474,ROCHE,,76.0,YR,,F,Y,70.9,KG,20230110,,MD,US,,2023,Q1,Elderly
208119686,20811968,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q1,Flatulence,,2023,Q1,6,F,20230208.0,20230227.0,20220511,20230313,EXP,,"CA-TOLMAR, INC.-21CA032087",TOLMAR,,60.0,YR,,M,Y,,,20230313,,CN,CA,CA,2023,Q1,Adult
208119686,20811968,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q1,Injection site mass,,2023,Q1,6,F,20230208.0,20230227.0,20220511,20230313,EXP,,"CA-TOLMAR, INC.-21CA032087",TOLMAR,,60.0,YR,,M,Y,,,20230313,,CN,CA,CA,2023,Q1,Adult
208119686,20811968,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q1,Pain,,2023,Q1,6,F,20230208.0,20230227.0,20220511,20230313,EXP,,"CA-TOLMAR, INC.-21CA032087",TOLMAR,,60.0,YR,,M,Y,,,20230313,,CN,CA,CA,2023,Q1,Adult
208119686,20811968,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q1,Fatigue,,2023,Q1,6,F,20230208.0,20230227.0,20220511,20230313,EXP,,"CA-TOLMAR, INC.-21CA032087",TOLMAR,,60.0,YR,,M,Y,,,20230313,,CN,CA,CA,2023,Q1,Adult
208119686,20811968,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q1,Chills,,2023,Q1,6,F,20230208.0,20230227.0,20220511,20230313,EXP,,"CA-TOLMAR, INC.-21CA032087",TOLMAR,,60.0,YR,,M,Y,,,20230313,,CN,CA,CA,2023,Q1,Adult
208119686,20811968,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q1,Libido decreased,,2023,Q1,6,F,20230208.0,20230227.0,20220511,20230313,EXP,,"CA-TOLMAR, INC.-21CA032087",TOLMAR,,60.0,YR,,M,Y,,,20230313,,CN,CA,CA,2023,Q1,Adult
208119686,20811968,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q1,Hot flush,,2023,Q1,6,F,20230208.0,20230227.0,20220511,20230313,EXP,,"CA-TOLMAR, INC.-21CA032087",TOLMAR,,60.0,YR,,M,Y,,,20230313,,CN,CA,CA,2023,Q1,Adult
208119686,20811968,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q1,Injection site pain,,2023,Q1,6,F,20230208.0,20230227.0,20220511,20230313,EXP,,"CA-TOLMAR, INC.-21CA032087",TOLMAR,,60.0,YR,,M,Y,,,20230313,,CN,CA,CA,2023,Q1,Adult
208119686,20811968,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q1,Pollakiuria,,2023,Q1,6,F,20230208.0,20230227.0,20220511,20230313,EXP,,"CA-TOLMAR, INC.-21CA032087",TOLMAR,,60.0,YR,,M,Y,,,20230313,,CN,CA,CA,2023,Q1,Adult
208119686,20811968,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q1,Asthenia,,2023,Q1,6,F,20230208.0,20230227.0,20220511,20230313,EXP,,"CA-TOLMAR, INC.-21CA032087",TOLMAR,,60.0,YR,,M,Y,,,20230313,,CN,CA,CA,2023,Q1,Adult
208119686,20811968,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q1,Diarrhoea,,2023,Q1,6,F,20230208.0,20230227.0,20220511,20230313,EXP,,"CA-TOLMAR, INC.-21CA032087",TOLMAR,,60.0,YR,,M,Y,,,20230313,,CN,CA,CA,2023,Q1,Adult
208119686,20811968,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q1,Vomiting,,2023,Q1,6,F,20230208.0,20230227.0,20220511,20230313,EXP,,"CA-TOLMAR, INC.-21CA032087",TOLMAR,,60.0,YR,,M,Y,,,20230313,,CN,CA,CA,2023,Q1,Adult
208119686,20811968,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q1,Incontinence,,2023,Q1,6,F,20230208.0,20230227.0,20220511,20230313,EXP,,"CA-TOLMAR, INC.-21CA032087",TOLMAR,,60.0,YR,,M,Y,,,20230313,,CN,CA,CA,2023,Q1,Adult
208119686,20811968,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q1,Nausea,,2023,Q1,6,F,20230208.0,20230227.0,20220511,20230313,EXP,,"CA-TOLMAR, INC.-21CA032087",TOLMAR,,60.0,YR,,M,Y,,,20230313,,CN,CA,CA,2023,Q1,Adult
208119686,20811968,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q1,Diabetes mellitus,,2023,Q1,6,F,20230208.0,20230227.0,20220511,20230313,EXP,,"CA-TOLMAR, INC.-21CA032087",TOLMAR,,60.0,YR,,M,Y,,,20230313,,CN,CA,CA,2023,Q1,Adult
208119686,20811968,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q1,Rash,,2023,Q1,6,F,20230208.0,20230227.0,20220511,20230313,EXP,,"CA-TOLMAR, INC.-21CA032087",TOLMAR,,60.0,YR,,M,Y,,,20230313,,CN,CA,CA,2023,Q1,Adult
208119686,20811968,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q1,Urticaria,,2023,Q1,6,F,20230208.0,20230227.0,20220511,20230313,EXP,,"CA-TOLMAR, INC.-21CA032087",TOLMAR,,60.0,YR,,M,Y,,,20230313,,CN,CA,CA,2023,Q1,Adult
208930057,20893005,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,,QD,2023,Q1,Cardiac failure congestive,,2023,Q1,7,F,20220329.0,20230307.0,20220531,20230308,EXP,,US-ROCHE-3071236,ROCHE,,61.0,YR,,M,Y,150.57,KG,20230308,,MD,US,,2023,Q1,Adult
209904393,20990439,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,Y,U,Unknown,,206073.0,,,Tablet,,2023,Q1,Long QT syndrome,,2023,Q1,3,F,,20230322.0,20220622,20230324,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-177653",BOEHRINGER INGELHEIM,,58.0,YR,A,M,Y,,,20230324,,MD,JP,JP,2023,Q1,Adult
209904393,20990439,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,Y,U,Unknown,,206073.0,,,Tablet,,2023,Q1,Cardiac arrest,,2023,Q1,3,F,,20230322.0,20220622,20230324,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-177653",BOEHRINGER INGELHEIM,,58.0,YR,A,M,Y,,,20230324,,MD,JP,JP,2023,Q1,Adult
209904393,20990439,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,Y,U,Unknown,,206073.0,,,Tablet,,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,3,F,,20230322.0,20220622,20230324,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-177653",BOEHRINGER INGELHEIM,,58.0,YR,A,M,Y,,,20230324,,MD,JP,JP,2023,Q1,Adult
209979297,20997929,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"12.5 mg, qd",,,,,,,,12.5,MG,,QD,2023,Q1,Photosensitivity reaction,,2023,Q1,7,F,20220501.0,20230321.0,20220623,20230328,EXP,,US-UNITED THERAPEUTICS-UNT-2022-011002,UNITED THERAPEUTICS,,48.0,YR,,F,Y,98.866,KG,20230327,,CN,US,US,2023,Q1,Adult
209979297,20997929,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"12.5 mg, qd",,,,,,,,12.5,MG,,QD,2023,Q1,Systemic lupus erythematosus,,2023,Q1,7,F,20220501.0,20230321.0,20220623,20230328,EXP,,US-UNITED THERAPEUTICS-UNT-2022-011002,UNITED THERAPEUTICS,,48.0,YR,,F,Y,98.866,KG,20230327,,CN,US,US,2023,Q1,Adult
209979297,20997929,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"12.5 mg, qd",,,,,,,,12.5,MG,,QD,2023,Q1,Fatigue,,2023,Q1,7,F,20220501.0,20230321.0,20220623,20230328,EXP,,US-UNITED THERAPEUTICS-UNT-2022-011002,UNITED THERAPEUTICS,,48.0,YR,,F,Y,98.866,KG,20230327,,CN,US,US,2023,Q1,Adult
209979297,20997929,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"12.5 mg, qd",,,,,,,,12.5,MG,,QD,2023,Q1,Inappropriate schedule of product administration,,2023,Q1,7,F,20220501.0,20230321.0,20220623,20230328,EXP,,US-UNITED THERAPEUTICS-UNT-2022-011002,UNITED THERAPEUTICS,,48.0,YR,,F,Y,98.866,KG,20230327,,CN,US,US,2023,Q1,Adult
209979297,20997929,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"12.5 mg, qd",,,,,,,,12.5,MG,,QD,2023,Q1,Headache,,2023,Q1,7,F,20220501.0,20230321.0,20220623,20230328,EXP,,US-UNITED THERAPEUTICS-UNT-2022-011002,UNITED THERAPEUTICS,,48.0,YR,,F,Y,98.866,KG,20230327,,CN,US,US,2023,Q1,Adult
209979297,20997929,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"12.5 mg, qd",,,,,,,,12.5,MG,,QD,2023,Q1,Epistaxis,,2023,Q1,7,F,20220501.0,20230321.0,20220623,20230328,EXP,,US-UNITED THERAPEUTICS-UNT-2022-011002,UNITED THERAPEUTICS,,48.0,YR,,F,Y,98.866,KG,20230327,,CN,US,US,2023,Q1,Adult
209979297,20997929,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"12.5 mg, qd",,,,,,,,12.5,MG,,QD,2023,Q1,Mood altered,,2023,Q1,7,F,20220501.0,20230321.0,20220623,20230328,EXP,,US-UNITED THERAPEUTICS-UNT-2022-011002,UNITED THERAPEUTICS,,48.0,YR,,F,Y,98.866,KG,20230327,,CN,US,US,2023,Q1,Adult
209979297,20997929,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"12.5 mg, qd",,,,,,,,12.5,MG,,QD,2023,Q1,Wrong technique in product usage process,,2023,Q1,7,F,20220501.0,20230321.0,20220623,20230328,EXP,,US-UNITED THERAPEUTICS-UNT-2022-011002,UNITED THERAPEUTICS,,48.0,YR,,F,Y,98.866,KG,20230327,,CN,US,US,2023,Q1,Adult
209979297,20997929,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"12.5 mg, qd",,,,,,,,12.5,MG,,QD,2023,Q1,Cough,,2023,Q1,7,F,20220501.0,20230321.0,20220623,20230328,EXP,,US-UNITED THERAPEUTICS-UNT-2022-011002,UNITED THERAPEUTICS,,48.0,YR,,F,Y,98.866,KG,20230327,,CN,US,US,2023,Q1,Adult
210789936,21078993,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,Tablets,,2023,Q1,Thyroiditis,,2023,Q1,6,F,20220701.0,20230220.0,20220713,20230301,EXP,,JP-Eisai Medical Research-EC-2022-118611,EISAI,,44.0,YR,A,F,Y,85.0,KG,20230301,,MD,JP,JP,2023,Q1,Adult
210789936,21078993,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,Tablets,,2023,Q1,Thyrotoxic crisis,,2023,Q1,6,F,20220701.0,20230220.0,20220713,20230301,EXP,,JP-Eisai Medical Research-EC-2022-118611,EISAI,,44.0,YR,A,F,Y,85.0,KG,20230301,,MD,JP,JP,2023,Q1,Adult
210974255,21097425,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,once a day in the morning,,,,,,,,10.0,MG,,QD,2023,Q1,Coronary artery disease,,2023,Q1,5,F,20220531.0,20230317.0,20220719,20230323,EXP,,US-ROCHE-3127711,ROCHE,,71.0,YR,,F,Y,87.3,KG,20230323,,MD,US,,2023,Q1,Elderly
210974255,21097425,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,once a day in the morning,,,,,,,,10.0,MG,,QD,2023,Q1,Acute coronary syndrome,,2023,Q1,5,F,20220531.0,20230317.0,20220719,20230323,EXP,,US-ROCHE-3127711,ROCHE,,71.0,YR,,F,Y,87.3,KG,20230323,,MD,US,,2023,Q1,Elderly
210974255,21097425,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,once a day in the morning,,,,,,,,10.0,MG,,QD,2023,Q1,Ischaemic cardiomyopathy,,2023,Q1,5,F,20220531.0,20230317.0,20220719,20230323,EXP,,US-ROCHE-3127711,ROCHE,,71.0,YR,,F,Y,87.3,KG,20230323,,MD,US,,2023,Q1,Elderly
211206763,21120676,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, Once Daily (qd)",,,U,,,,,25.0,MG,,QD,2023,Q1,Seizure,,2023,Q1,3,F,20220601.0,20230126.0,20220722,20230127,EXP,,US-UCBSA-2022031861,UCB,,41.0,YR,,F,Y,74.83,KG,20230127,,CN,US,US,2023,Q1,Adult
211206763,21120676,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, Once Daily (qd)",,,U,,,,,25.0,MG,,QD,2023,Q1,Product availability issue,,2023,Q1,3,F,20220601.0,20230126.0,20220722,20230127,EXP,,US-UCBSA-2022031861,UCB,,41.0,YR,,F,Y,74.83,KG,20230127,,CN,US,US,2023,Q1,Adult
211206763,21120676,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, Once Daily (qd)",,,U,,,,,25.0,MG,,QD,2023,Q1,Cognitive disorder,,2023,Q1,3,F,20220601.0,20230126.0,20220722,20230127,EXP,,US-UCBSA-2022031861,UCB,,41.0,YR,,F,Y,74.83,KG,20230127,,CN,US,US,2023,Q1,Adult
211206763,21120676,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, Once Daily (qd)",,,U,,,,,25.0,MG,,QD,2023,Q1,Therapy interrupted,,2023,Q1,3,F,20220601.0,20230126.0,20220722,20230127,EXP,,US-UCBSA-2022031861,UCB,,41.0,YR,,F,Y,74.83,KG,20230127,,CN,US,US,2023,Q1,Adult
211206763,21120676,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, Once Daily (qd)",,,U,,,,,25.0,MG,,QD,2023,Q1,Depression,,2023,Q1,3,F,20220601.0,20230126.0,20220722,20230127,EXP,,US-UCBSA-2022031861,UCB,,41.0,YR,,F,Y,74.83,KG,20230127,,CN,US,US,2023,Q1,Adult
211656032,21165603,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,5/1000 mg,,,,,,,,,,,Q12H,2023,Q1,Klebsiella infection,,2023,Q1,2,F,20220626.0,20230221.0,20220803,20230302,EXP,,ES-EMD Serono-9339931,EMD SERONO INC,,55.0,YR,A,M,Y,,,20230302,,MD,ES,,2023,Q1,Adult
211656032,21165603,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,5/1000 mg,,,,,,,,,,,Q12H,2023,Q1,Urinary tract infection bacterial,,2023,Q1,2,F,20220626.0,20230221.0,20220803,20230302,EXP,,ES-EMD Serono-9339931,EMD SERONO INC,,55.0,YR,A,M,Y,,,20230302,,MD,ES,,2023,Q1,Adult
211882333,21188233,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q1,Type 2 diabetes mellitus,,2023,Q1,3,F,,20230216.0,20220809,20230217,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-185417",BOEHRINGER INGELHEIM,,66.0,YR,E,F,Y,85.0,KG,20230217,,HP,CA,CA,2023,Q1,Elderly
211882333,21188233,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q1,Blood pressure diastolic abnormal,,2023,Q1,3,F,,20230216.0,20220809,20230217,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-185417",BOEHRINGER INGELHEIM,,66.0,YR,E,F,Y,85.0,KG,20230217,,HP,CA,CA,2023,Q1,Elderly
211882333,21188233,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q1,Blood pressure fluctuation,,2023,Q1,3,F,,20230216.0,20220809,20230217,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-185417",BOEHRINGER INGELHEIM,,66.0,YR,E,F,Y,85.0,KG,20230217,,HP,CA,CA,2023,Q1,Elderly
211882333,21188233,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q1,Drug interaction,,2023,Q1,3,F,,20230216.0,20220809,20230217,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-185417",BOEHRINGER INGELHEIM,,66.0,YR,E,F,Y,85.0,KG,20230217,,HP,CA,CA,2023,Q1,Elderly
211882333,21188233,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q1,Aortic arteriosclerosis,,2023,Q1,3,F,,20230216.0,20220809,20230217,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-185417",BOEHRINGER INGELHEIM,,66.0,YR,E,F,Y,85.0,KG,20230217,,HP,CA,CA,2023,Q1,Elderly
211882333,21188233,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q1,Weight decreased,,2023,Q1,3,F,,20230216.0,20220809,20230217,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-185417",BOEHRINGER INGELHEIM,,66.0,YR,E,F,Y,85.0,KG,20230217,,HP,CA,CA,2023,Q1,Elderly
211882333,21188233,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q1,Blood pressure increased,,2023,Q1,3,F,,20230216.0,20220809,20230217,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-185417",BOEHRINGER INGELHEIM,,66.0,YR,E,F,Y,85.0,KG,20230217,,HP,CA,CA,2023,Q1,Elderly
211882333,21188233,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q1,Blood pressure diastolic decreased,,2023,Q1,3,F,,20230216.0,20220809,20230217,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-185417",BOEHRINGER INGELHEIM,,66.0,YR,E,F,Y,85.0,KG,20230217,,HP,CA,CA,2023,Q1,Elderly
211882333,21188233,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q1,Diabetic ketoacidosis,,2023,Q1,3,F,,20230216.0,20220809,20230217,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-185417",BOEHRINGER INGELHEIM,,66.0,YR,E,F,Y,85.0,KG,20230217,,HP,CA,CA,2023,Q1,Elderly
211882333,21188233,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q1,Weight increased,,2023,Q1,3,F,,20230216.0,20220809,20230217,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-185417",BOEHRINGER INGELHEIM,,66.0,YR,E,F,Y,85.0,KG,20230217,,HP,CA,CA,2023,Q1,Elderly
211882333,21188233,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q1,Blood glucose increased,,2023,Q1,3,F,,20230216.0,20220809,20230217,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-185417",BOEHRINGER INGELHEIM,,66.0,YR,E,F,Y,85.0,KG,20230217,,HP,CA,CA,2023,Q1,Elderly
211882333,21188233,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q1,Blood pressure systolic increased,,2023,Q1,3,F,,20230216.0,20220809,20230217,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-185417",BOEHRINGER INGELHEIM,,66.0,YR,E,F,Y,85.0,KG,20230217,,HP,CA,CA,2023,Q1,Elderly
211972482,21197248,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, 1x/day",,,U,,,,,10.0,MG,,QD,2023,Q1,Blood pressure increased,,2023,Q1,2,F,,20230302.0,20220810,20230309,EXP,,CA-PFIZER INC-202201041435,PFIZER,,66.0,YR,,F,Y,89.0,KG,20230309,,HP,CA,CA,2023,Q1,Elderly
211972482,21197248,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, 1x/day",,,U,,,,,10.0,MG,,QD,2023,Q1,Blood pressure systolic increased,,2023,Q1,2,F,,20230302.0,20220810,20230309,EXP,,CA-PFIZER INC-202201041435,PFIZER,,66.0,YR,,F,Y,89.0,KG,20230309,,HP,CA,CA,2023,Q1,Elderly
211972482,21197248,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, 1x/day",,,U,,,,,10.0,MG,,QD,2023,Q1,Blood pressure diastolic abnormal,,2023,Q1,2,F,,20230302.0,20220810,20230309,EXP,,CA-PFIZER INC-202201041435,PFIZER,,66.0,YR,,F,Y,89.0,KG,20230309,,HP,CA,CA,2023,Q1,Elderly
211972482,21197248,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, 1x/day",,,U,,,,,10.0,MG,,QD,2023,Q1,Weight decreased,,2023,Q1,2,F,,20230302.0,20220810,20230309,EXP,,CA-PFIZER INC-202201041435,PFIZER,,66.0,YR,,F,Y,89.0,KG,20230309,,HP,CA,CA,2023,Q1,Elderly
211972482,21197248,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, 1x/day",,,U,,,,,10.0,MG,,QD,2023,Q1,Blood glucose increased,,2023,Q1,2,F,,20230302.0,20220810,20230309,EXP,,CA-PFIZER INC-202201041435,PFIZER,,66.0,YR,,F,Y,89.0,KG,20230309,,HP,CA,CA,2023,Q1,Elderly
211972482,21197248,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, 1x/day",,,U,,,,,10.0,MG,,QD,2023,Q1,Aortic arteriosclerosis,,2023,Q1,2,F,,20230302.0,20220810,20230309,EXP,,CA-PFIZER INC-202201041435,PFIZER,,66.0,YR,,F,Y,89.0,KG,20230309,,HP,CA,CA,2023,Q1,Elderly
211972482,21197248,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, 1x/day",,,U,,,,,10.0,MG,,QD,2023,Q1,Blood pressure diastolic decreased,,2023,Q1,2,F,,20230302.0,20220810,20230309,EXP,,CA-PFIZER INC-202201041435,PFIZER,,66.0,YR,,F,Y,89.0,KG,20230309,,HP,CA,CA,2023,Q1,Elderly
211972482,21197248,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, 1x/day",,,U,,,,,10.0,MG,,QD,2023,Q1,Type 2 diabetes mellitus,,2023,Q1,2,F,,20230302.0,20220810,20230309,EXP,,CA-PFIZER INC-202201041435,PFIZER,,66.0,YR,,F,Y,89.0,KG,20230309,,HP,CA,CA,2023,Q1,Elderly
211972482,21197248,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, 1x/day",,,U,,,,,10.0,MG,,QD,2023,Q1,Weight increased,,2023,Q1,2,F,,20230302.0,20220810,20230309,EXP,,CA-PFIZER INC-202201041435,PFIZER,,66.0,YR,,F,Y,89.0,KG,20230309,,HP,CA,CA,2023,Q1,Elderly
211972482,21197248,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, 1x/day",,,U,,,,,10.0,MG,,QD,2023,Q1,Blood pressure fluctuation,,2023,Q1,2,F,,20230302.0,20220810,20230309,EXP,,CA-PFIZER INC-202201041435,PFIZER,,66.0,YR,,F,Y,89.0,KG,20230309,,HP,CA,CA,2023,Q1,Elderly
212095453,21209545,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q1,Body mass index increased,,2023,Q1,3,F,,20230303.0,20220813,20230316,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230316,,MD,TH,TH,2023,Q1,Elderly
212095453,21209545,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q1,Blood pressure systolic increased,,2023,Q1,3,F,,20230303.0,20220813,20230316,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230316,,MD,TH,TH,2023,Q1,Elderly
212095453,21209545,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q1,Glycosylated haemoglobin increased,,2023,Q1,3,F,,20230303.0,20220813,20230316,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230316,,MD,TH,TH,2023,Q1,Elderly
212095453,21209545,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q1,Haemolysis,,2023,Q1,3,F,,20230303.0,20220813,20230316,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230316,,MD,TH,TH,2023,Q1,Elderly
212095453,21209545,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q1,Blood potassium increased,,2023,Q1,3,F,,20230303.0,20220813,20230316,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230316,,MD,TH,TH,2023,Q1,Elderly
212095453,21209545,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q1,Blood glucose increased,,2023,Q1,3,F,,20230303.0,20220813,20230316,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230316,,MD,TH,TH,2023,Q1,Elderly
212095453,21209545,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q1,Blood pressure diastolic decreased,,2023,Q1,3,F,,20230303.0,20220813,20230316,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230316,,MD,TH,TH,2023,Q1,Elderly
212095453,21209545,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q1,Weight increased,,2023,Q1,3,F,,20230303.0,20220813,20230316,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230316,,MD,TH,TH,2023,Q1,Elderly
212095453,21209545,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q1,Creatinine renal clearance decreased,,2023,Q1,3,F,,20230303.0,20220813,20230316,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230316,,MD,TH,TH,2023,Q1,Elderly
212095453,21209545,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q1,Blood creatinine increased,,2023,Q1,3,F,,20230303.0,20220813,20230316,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230316,,MD,TH,TH,2023,Q1,Elderly
212095453,21209545,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q1,Body mass index increased,,2023,Q1,3,F,,20230303.0,20220813,20230316,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230316,,MD,TH,TH,2023,Q1,Elderly
212095453,21209545,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q1,Blood pressure systolic increased,,2023,Q1,3,F,,20230303.0,20220813,20230316,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230316,,MD,TH,TH,2023,Q1,Elderly
212095453,21209545,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q1,Glycosylated haemoglobin increased,,2023,Q1,3,F,,20230303.0,20220813,20230316,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230316,,MD,TH,TH,2023,Q1,Elderly
212095453,21209545,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q1,Haemolysis,,2023,Q1,3,F,,20230303.0,20220813,20230316,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230316,,MD,TH,TH,2023,Q1,Elderly
212095453,21209545,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q1,Blood potassium increased,,2023,Q1,3,F,,20230303.0,20220813,20230316,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230316,,MD,TH,TH,2023,Q1,Elderly
212095453,21209545,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q1,Blood glucose increased,,2023,Q1,3,F,,20230303.0,20220813,20230316,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230316,,MD,TH,TH,2023,Q1,Elderly
212095453,21209545,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q1,Blood pressure diastolic decreased,,2023,Q1,3,F,,20230303.0,20220813,20230316,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230316,,MD,TH,TH,2023,Q1,Elderly
212095453,21209545,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q1,Weight increased,,2023,Q1,3,F,,20230303.0,20220813,20230316,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230316,,MD,TH,TH,2023,Q1,Elderly
212095453,21209545,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q1,Creatinine renal clearance decreased,,2023,Q1,3,F,,20230303.0,20220813,20230316,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230316,,MD,TH,TH,2023,Q1,Elderly
212095453,21209545,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q1,Blood creatinine increased,,2023,Q1,3,F,,20230303.0,20220813,20230316,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230316,,MD,TH,TH,2023,Q1,Elderly
212095453,21209545,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q1,Body mass index increased,,2023,Q1,3,F,,20230303.0,20220813,20230316,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230316,,MD,TH,TH,2023,Q1,Elderly
212095453,21209545,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q1,Blood pressure systolic increased,,2023,Q1,3,F,,20230303.0,20220813,20230316,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230316,,MD,TH,TH,2023,Q1,Elderly
212095453,21209545,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q1,Glycosylated haemoglobin increased,,2023,Q1,3,F,,20230303.0,20220813,20230316,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230316,,MD,TH,TH,2023,Q1,Elderly
212095453,21209545,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q1,Haemolysis,,2023,Q1,3,F,,20230303.0,20220813,20230316,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230316,,MD,TH,TH,2023,Q1,Elderly
212095453,21209545,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q1,Blood potassium increased,,2023,Q1,3,F,,20230303.0,20220813,20230316,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230316,,MD,TH,TH,2023,Q1,Elderly
212095453,21209545,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q1,Blood glucose increased,,2023,Q1,3,F,,20230303.0,20220813,20230316,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230316,,MD,TH,TH,2023,Q1,Elderly
212095453,21209545,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q1,Blood pressure diastolic decreased,,2023,Q1,3,F,,20230303.0,20220813,20230316,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230316,,MD,TH,TH,2023,Q1,Elderly
212095453,21209545,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q1,Weight increased,,2023,Q1,3,F,,20230303.0,20220813,20230316,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230316,,MD,TH,TH,2023,Q1,Elderly
212095453,21209545,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q1,Creatinine renal clearance decreased,,2023,Q1,3,F,,20230303.0,20220813,20230316,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230316,,MD,TH,TH,2023,Q1,Elderly
212095453,21209545,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q1,Blood creatinine increased,,2023,Q1,3,F,,20230303.0,20220813,20230316,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230316,,MD,TH,TH,2023,Q1,Elderly
212095453,21209545,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q1,Body mass index increased,,2023,Q1,3,F,,20230303.0,20220813,20230316,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230316,,MD,TH,TH,2023,Q1,Elderly
212095453,21209545,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q1,Blood pressure systolic increased,,2023,Q1,3,F,,20230303.0,20220813,20230316,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230316,,MD,TH,TH,2023,Q1,Elderly
212095453,21209545,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q1,Glycosylated haemoglobin increased,,2023,Q1,3,F,,20230303.0,20220813,20230316,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230316,,MD,TH,TH,2023,Q1,Elderly
212095453,21209545,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q1,Haemolysis,,2023,Q1,3,F,,20230303.0,20220813,20230316,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230316,,MD,TH,TH,2023,Q1,Elderly
212095453,21209545,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q1,Blood potassium increased,,2023,Q1,3,F,,20230303.0,20220813,20230316,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230316,,MD,TH,TH,2023,Q1,Elderly
212095453,21209545,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q1,Blood glucose increased,,2023,Q1,3,F,,20230303.0,20220813,20230316,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230316,,MD,TH,TH,2023,Q1,Elderly
212095453,21209545,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q1,Blood pressure diastolic decreased,,2023,Q1,3,F,,20230303.0,20220813,20230316,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230316,,MD,TH,TH,2023,Q1,Elderly
212095453,21209545,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q1,Weight increased,,2023,Q1,3,F,,20230303.0,20220813,20230316,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230316,,MD,TH,TH,2023,Q1,Elderly
212095453,21209545,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q1,Creatinine renal clearance decreased,,2023,Q1,3,F,,20230303.0,20220813,20230316,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230316,,MD,TH,TH,2023,Q1,Elderly
212095453,21209545,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q1,Blood creatinine increased,,2023,Q1,3,F,,20230303.0,20220813,20230316,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230316,,MD,TH,TH,2023,Q1,Elderly
212095453,21209545,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q1,Body mass index increased,,2023,Q1,3,F,,20230303.0,20220813,20230316,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230316,,MD,TH,TH,2023,Q1,Elderly
212095453,21209545,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q1,Blood pressure systolic increased,,2023,Q1,3,F,,20230303.0,20220813,20230316,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230316,,MD,TH,TH,2023,Q1,Elderly
212095453,21209545,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q1,Glycosylated haemoglobin increased,,2023,Q1,3,F,,20230303.0,20220813,20230316,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230316,,MD,TH,TH,2023,Q1,Elderly
212095453,21209545,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q1,Haemolysis,,2023,Q1,3,F,,20230303.0,20220813,20230316,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230316,,MD,TH,TH,2023,Q1,Elderly
212095453,21209545,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q1,Blood potassium increased,,2023,Q1,3,F,,20230303.0,20220813,20230316,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230316,,MD,TH,TH,2023,Q1,Elderly
212095453,21209545,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q1,Blood glucose increased,,2023,Q1,3,F,,20230303.0,20220813,20230316,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230316,,MD,TH,TH,2023,Q1,Elderly
212095453,21209545,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q1,Blood pressure diastolic decreased,,2023,Q1,3,F,,20230303.0,20220813,20230316,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230316,,MD,TH,TH,2023,Q1,Elderly
212095453,21209545,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q1,Weight increased,,2023,Q1,3,F,,20230303.0,20220813,20230316,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230316,,MD,TH,TH,2023,Q1,Elderly
212095453,21209545,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q1,Creatinine renal clearance decreased,,2023,Q1,3,F,,20230303.0,20220813,20230316,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230316,,MD,TH,TH,2023,Q1,Elderly
212095453,21209545,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q1,Blood creatinine increased,,2023,Q1,3,F,,20230303.0,20220813,20230316,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230316,,MD,TH,TH,2023,Q1,Elderly
212341683,21234168,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Chronic kidney disease,,2023,Q1,3,F,20131014.0,20230223.0,20220819,20230321,EXP,,US-AstraZeneca-2022A287268,ASTRAZENECA,,24466.0,DY,,M,Y,82.6,KG,20230321,,LW,US,,2023,Q1,Elderly
212341683,21234168,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Nephrogenic anaemia,,2023,Q1,3,F,20131014.0,20230223.0,20220819,20230321,EXP,,US-AstraZeneca-2022A287268,ASTRAZENECA,,24466.0,DY,,M,Y,82.6,KG,20230321,,LW,US,,2023,Q1,Elderly
212341683,21234168,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Renal failure,,2023,Q1,3,F,20131014.0,20230223.0,20220819,20230321,EXP,,US-AstraZeneca-2022A287268,ASTRAZENECA,,24466.0,DY,,M,Y,82.6,KG,20230321,,LW,US,,2023,Q1,Elderly
212341683,21234168,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Acute kidney injury,,2023,Q1,3,F,20131014.0,20230223.0,20220819,20230321,EXP,,US-AstraZeneca-2022A287268,ASTRAZENECA,,24466.0,DY,,M,Y,82.6,KG,20230321,,LW,US,,2023,Q1,Elderly
212341683,21234168,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Rebound acid hypersecretion,,2023,Q1,3,F,20131014.0,20230223.0,20220819,20230321,EXP,,US-AstraZeneca-2022A287268,ASTRAZENECA,,24466.0,DY,,M,Y,82.6,KG,20230321,,LW,US,,2023,Q1,Elderly
213838963,21383896,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"30 Milligram Daily; 10 mg, 1-1-1-0,",,,,,,,,10.0,MG,,TID,2023,Q1,Faecaloma,,2023,Q1,3,F,,20230118.0,20220928,20230130,EXP,,DE-TEVA-2022-DE-2076006,TEVA,,82.0,YR,E,M,Y,,,20230128,,MD,DE,DE,2023,Q1,Elderly
213838963,21383896,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"30 Milligram Daily; 10 mg, 1-1-1-0,",,,,,,,,10.0,MG,,TID,2023,Q1,Haematuria,,2023,Q1,3,F,,20230118.0,20220928,20230130,EXP,,DE-TEVA-2022-DE-2076006,TEVA,,82.0,YR,E,M,Y,,,20230128,,MD,DE,DE,2023,Q1,Elderly
213838963,21383896,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"30 Milligram Daily; 10 mg, 1-1-1-0,",,,,,,,,10.0,MG,,TID,2023,Q1,Flatulence,,2023,Q1,3,F,,20230118.0,20220928,20230130,EXP,,DE-TEVA-2022-DE-2076006,TEVA,,82.0,YR,E,M,Y,,,20230128,,MD,DE,DE,2023,Q1,Elderly
213838963,21383896,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"30 Milligram Daily; 10 mg, 1-1-1-0,",,,,,,,,10.0,MG,,TID,2023,Q1,Micturition disorder,,2023,Q1,3,F,,20230118.0,20220928,20230130,EXP,,DE-TEVA-2022-DE-2076006,TEVA,,82.0,YR,E,M,Y,,,20230128,,MD,DE,DE,2023,Q1,Elderly
213838963,21383896,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"30 Milligram Daily; 10 mg, 1-1-1-0,",,,,,,,,10.0,MG,,TID,2023,Q1,Abdominal pain,,2023,Q1,3,F,,20230118.0,20220928,20230130,EXP,,DE-TEVA-2022-DE-2076006,TEVA,,82.0,YR,E,M,Y,,,20230128,,MD,DE,DE,2023,Q1,Elderly
213838963,21383896,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"30 Milligram Daily; 10 mg, 1-1-1-0,",,,,,,,,10.0,MG,,TID,2023,Q1,Constipation,,2023,Q1,3,F,,20230118.0,20220928,20230130,EXP,,DE-TEVA-2022-DE-2076006,TEVA,,82.0,YR,E,M,Y,,,20230128,,MD,DE,DE,2023,Q1,Elderly
213838963,21383896,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"30 Milligram Daily; 10 mg, 1-1-1-0,",,,,,,,,10.0,MG,,TID,2023,Q1,Dehydration,,2023,Q1,3,F,,20230118.0,20220928,20230130,EXP,,DE-TEVA-2022-DE-2076006,TEVA,,82.0,YR,E,M,Y,,,20230128,,MD,DE,DE,2023,Q1,Elderly
214156754,21415675,57,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2023,Q1,Hypotension,,2023,Q1,4,F,,20230206.0,20221006,20230213,EXP,,NVSC2022CA221484,NOVARTIS,,75.0,YR,,M,Y,,,20230213,,HP,CA,CA,2023,Q1,Elderly
214156754,21415675,57,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2023,Q1,Hypotension,,2023,Q1,4,F,,20230206.0,20221006,20230213,EXP,,NVSC2022CA221484,NOVARTIS,,75.0,YR,,M,Y,,,20230213,,HP,CA,CA,2023,Q1,Elderly
214156754,21415675,57,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2023,Q1,Hyperthyroidism,,2023,Q1,4,F,,20230206.0,20221006,20230213,EXP,,NVSC2022CA221484,NOVARTIS,,75.0,YR,,M,Y,,,20230213,,HP,CA,CA,2023,Q1,Elderly
214156754,21415675,57,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2023,Q1,Adrenal insufficiency,,2023,Q1,4,F,,20230206.0,20221006,20230213,EXP,,NVSC2022CA221484,NOVARTIS,,75.0,YR,,M,Y,,,20230213,,HP,CA,CA,2023,Q1,Elderly
214156754,21415675,57,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2023,Q1,Troponin increased,,2023,Q1,4,F,,20230206.0,20221006,20230213,EXP,,NVSC2022CA221484,NOVARTIS,,75.0,YR,,M,Y,,,20230213,,HP,CA,CA,2023,Q1,Elderly
215014604,21501460,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,,,,,,10.0,MG,Tablet,QD,2023,Q1,Acute kidney injury,,2023,Q1,4,F,20220901.0,20230220.0,20221025,20230302,EXP,,JP-NOVOPROD-970464,NOVO NORDISK,,51.0,YR,,F,Y,80.9,KG,20230301,,MD,JP,JP,2023,Q1,Adult
215014604,21501460,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,,,,,,10.0,MG,Tablet,QD,2023,Q1,Dehydration,,2023,Q1,4,F,20220901.0,20230220.0,20221025,20230302,EXP,,JP-NOVOPROD-970464,NOVO NORDISK,,51.0,YR,,F,Y,80.9,KG,20230301,,MD,JP,JP,2023,Q1,Adult
215014604,21501460,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,,,,,,10.0,MG,Tablet,QD,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,4,F,20220901.0,20230220.0,20221025,20230302,EXP,,JP-NOVOPROD-970464,NOVO NORDISK,,51.0,YR,,F,Y,80.9,KG,20230301,,MD,JP,JP,2023,Q1,Adult
215014604,21501460,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,,,,,,10.0,MG,Tablet,QD,2023,Q1,Diarrhoea,,2023,Q1,4,F,20220901.0,20230220.0,20221025,20230302,EXP,,JP-NOVOPROD-970464,NOVO NORDISK,,51.0,YR,,F,Y,80.9,KG,20230301,,MD,JP,JP,2023,Q1,Adult
215907853,21590785,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, daily",,,U,,,,,25.0,MG,,QD,2023,Q1,Dry mouth,,2023,Q1,3,F,20220930.0,20230106.0,20221114,20230117,EXP,,ID-ELI_LILLY_AND_COMPANY-ID202210005173,ELI LILLY AND CO,,43.0,YR,,F,Y,66.0,KG,20230117,,CN,ID,ID,2023,Q1,Adult
215907853,21590785,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, daily",,,U,,,,,25.0,MG,,QD,2023,Q1,Chills,,2023,Q1,3,F,20220930.0,20230106.0,20221114,20230117,EXP,,ID-ELI_LILLY_AND_COMPANY-ID202210005173,ELI LILLY AND CO,,43.0,YR,,F,Y,66.0,KG,20230117,,CN,ID,ID,2023,Q1,Adult
215907853,21590785,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, daily",,,U,,,,,25.0,MG,,QD,2023,Q1,Musculoskeletal stiffness,,2023,Q1,3,F,20220930.0,20230106.0,20221114,20230117,EXP,,ID-ELI_LILLY_AND_COMPANY-ID202210005173,ELI LILLY AND CO,,43.0,YR,,F,Y,66.0,KG,20230117,,CN,ID,ID,2023,Q1,Adult
215907853,21590785,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, daily",,,U,,,,,25.0,MG,,QD,2023,Q1,Product dose omission issue,,2023,Q1,3,F,20220930.0,20230106.0,20221114,20230117,EXP,,ID-ELI_LILLY_AND_COMPANY-ID202210005173,ELI LILLY AND CO,,43.0,YR,,F,Y,66.0,KG,20230117,,CN,ID,ID,2023,Q1,Adult
215907853,21590785,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, daily",,,U,,,,,25.0,MG,,QD,2023,Q1,Pain in extremity,,2023,Q1,3,F,20220930.0,20230106.0,20221114,20230117,EXP,,ID-ELI_LILLY_AND_COMPANY-ID202210005173,ELI LILLY AND CO,,43.0,YR,,F,Y,66.0,KG,20230117,,CN,ID,ID,2023,Q1,Adult
215907853,21590785,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, daily",,,U,,,,,25.0,MG,,QD,2023,Q1,White blood cell count increased,,2023,Q1,3,F,20220930.0,20230106.0,20221114,20230117,EXP,,ID-ELI_LILLY_AND_COMPANY-ID202210005173,ELI LILLY AND CO,,43.0,YR,,F,Y,66.0,KG,20230117,,CN,ID,ID,2023,Q1,Adult
215907853,21590785,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, daily",,,U,,,,,25.0,MG,,QD,2023,Q1,Mobility decreased,,2023,Q1,3,F,20220930.0,20230106.0,20221114,20230117,EXP,,ID-ELI_LILLY_AND_COMPANY-ID202210005173,ELI LILLY AND CO,,43.0,YR,,F,Y,66.0,KG,20230117,,CN,ID,ID,2023,Q1,Adult
215907853,21590785,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, daily",,,U,,,,,25.0,MG,,QD,2023,Q1,Haemoglobin decreased,,2023,Q1,3,F,20220930.0,20230106.0,20221114,20230117,EXP,,ID-ELI_LILLY_AND_COMPANY-ID202210005173,ELI LILLY AND CO,,43.0,YR,,F,Y,66.0,KG,20230117,,CN,ID,ID,2023,Q1,Adult
215907853,21590785,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, daily",,,U,,,,,25.0,MG,,QD,2023,Q1,Vomiting,,2023,Q1,3,F,20220930.0,20230106.0,20221114,20230117,EXP,,ID-ELI_LILLY_AND_COMPANY-ID202210005173,ELI LILLY AND CO,,43.0,YR,,F,Y,66.0,KG,20230117,,CN,ID,ID,2023,Q1,Adult
215907853,21590785,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, daily",,,U,,,,,25.0,MG,,QD,2023,Q1,Appetite disorder,,2023,Q1,3,F,20220930.0,20230106.0,20221114,20230117,EXP,,ID-ELI_LILLY_AND_COMPANY-ID202210005173,ELI LILLY AND CO,,43.0,YR,,F,Y,66.0,KG,20230117,,CN,ID,ID,2023,Q1,Adult
215907853,21590785,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, daily",,,U,,,,,25.0,MG,,QD,2023,Q1,Blood glucose increased,,2023,Q1,3,F,20220930.0,20230106.0,20221114,20230117,EXP,,ID-ELI_LILLY_AND_COMPANY-ID202210005173,ELI LILLY AND CO,,43.0,YR,,F,Y,66.0,KG,20230117,,CN,ID,ID,2023,Q1,Adult
215907853,21590785,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, daily",,,U,,,,,25.0,MG,,QD,2023,Q1,Ovarian cyst,,2023,Q1,3,F,20220930.0,20230106.0,20221114,20230117,EXP,,ID-ELI_LILLY_AND_COMPANY-ID202210005173,ELI LILLY AND CO,,43.0,YR,,F,Y,66.0,KG,20230117,,CN,ID,ID,2023,Q1,Adult
215907853,21590785,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, daily",,,U,,,,,25.0,MG,,QD,2023,Q1,Abdominal distension,,2023,Q1,3,F,20220930.0,20230106.0,20221114,20230117,EXP,,ID-ELI_LILLY_AND_COMPANY-ID202210005173,ELI LILLY AND CO,,43.0,YR,,F,Y,66.0,KG,20230117,,CN,ID,ID,2023,Q1,Adult
215907853,21590785,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, daily",,,U,,,,,25.0,MG,,QD,2023,Q1,Product dose omission issue,,2023,Q1,3,F,20220930.0,20230106.0,20221114,20230117,EXP,,ID-ELI_LILLY_AND_COMPANY-ID202210005173,ELI LILLY AND CO,,43.0,YR,,F,Y,66.0,KG,20230117,,CN,ID,ID,2023,Q1,Adult
215907853,21590785,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, daily",,,U,,,,,25.0,MG,,QD,2023,Q1,Blood glucose increased,,2023,Q1,3,F,20220930.0,20230106.0,20221114,20230117,EXP,,ID-ELI_LILLY_AND_COMPANY-ID202210005173,ELI LILLY AND CO,,43.0,YR,,F,Y,66.0,KG,20230117,,CN,ID,ID,2023,Q1,Adult
215907853,21590785,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, daily",,,U,,,,,25.0,MG,,QD,2023,Q1,Pollakiuria,,2023,Q1,3,F,20220930.0,20230106.0,20221114,20230117,EXP,,ID-ELI_LILLY_AND_COMPANY-ID202210005173,ELI LILLY AND CO,,43.0,YR,,F,Y,66.0,KG,20230117,,CN,ID,ID,2023,Q1,Adult
215907853,21590785,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, daily",,,U,,,,,25.0,MG,,QD,2023,Q1,Nausea,,2023,Q1,3,F,20220930.0,20230106.0,20221114,20230117,EXP,,ID-ELI_LILLY_AND_COMPANY-ID202210005173,ELI LILLY AND CO,,43.0,YR,,F,Y,66.0,KG,20230117,,CN,ID,ID,2023,Q1,Adult
215907853,21590785,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, daily",,,U,,,,,25.0,MG,,QD,2023,Q1,Dysgeusia,,2023,Q1,3,F,20220930.0,20230106.0,20221114,20230117,EXP,,ID-ELI_LILLY_AND_COMPANY-ID202210005173,ELI LILLY AND CO,,43.0,YR,,F,Y,66.0,KG,20230117,,CN,ID,ID,2023,Q1,Adult
215907853,21590785,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, daily",,,U,,,,,25.0,MG,,QD,2023,Q1,Thirst,,2023,Q1,3,F,20220930.0,20230106.0,20221114,20230117,EXP,,ID-ELI_LILLY_AND_COMPANY-ID202210005173,ELI LILLY AND CO,,43.0,YR,,F,Y,66.0,KG,20230117,,CN,ID,ID,2023,Q1,Adult
215907853,21590785,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, daily",,,U,,,,,25.0,MG,,QD,2023,Q1,Dizziness,,2023,Q1,3,F,20220930.0,20230106.0,20221114,20230117,EXP,,ID-ELI_LILLY_AND_COMPANY-ID202210005173,ELI LILLY AND CO,,43.0,YR,,F,Y,66.0,KG,20230117,,CN,ID,ID,2023,Q1,Adult
216052233,21605223,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,Tablet,QD,2023,Q1,Pulmonary embolism,,2023,Q1,3,F,20211117.0,20230215.0,20221116,20230217,EXP,,RU-JNJFOC-20211156015,JOHNSON AND JOHNSON,,69.0,YR,E,F,Y,88.0,KG,20230217,,MD,RU,RU,2023,Q1,Elderly
216052233,21605223,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Pulmonary embolism,,2023,Q1,3,F,20211117.0,20230215.0,20221116,20230217,EXP,,RU-JNJFOC-20211156015,JOHNSON AND JOHNSON,,69.0,YR,E,F,Y,88.0,KG,20230217,,MD,RU,RU,2023,Q1,Elderly
216153612,21615361,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Dose unknown,,,,,,,,,,,,2023,Q1,Cardiac arrest,,2023,Q1,2,F,20221110.0,20230123.0,20221118,20230126,EXP,,JP-AstraZeneca-2022A381586,ASTRAZENECA,,79.0,YR,,F,Y,43.0,KG,20230126,,PH,JP,,2023,Q1,Elderly
216153612,21615361,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Dose unknown,,,,,,,,,,,,2023,Q1,Respiratory disorder,,2023,Q1,2,F,20221110.0,20230123.0,20221118,20230126,EXP,,JP-AstraZeneca-2022A381586,ASTRAZENECA,,79.0,YR,,F,Y,43.0,KG,20230126,,PH,JP,,2023,Q1,Elderly
216153612,21615361,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Dose unknown,,,,,,,,,,,,2023,Q1,Thrombosis,,2023,Q1,2,F,20221110.0,20230123.0,20221118,20230126,EXP,,JP-AstraZeneca-2022A381586,ASTRAZENECA,,79.0,YR,,F,Y,43.0,KG,20230126,,PH,JP,,2023,Q1,Elderly
216153612,21615361,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Dose unknown,,,,,,,,,,,,2023,Q1,Blood pressure decreased,,2023,Q1,2,F,20221110.0,20230123.0,20221118,20230126,EXP,,JP-AstraZeneca-2022A381586,ASTRAZENECA,,79.0,YR,,F,Y,43.0,KG,20230126,,PH,JP,,2023,Q1,Elderly
216215652,21621565,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,,2023,Q1,Infection,,2023,Q1,2,F,20221103.0,20230227.0,20221121,20230228,EXP,,DE-Eisai Medical Research-EC-2022-128366,EISAI,,73.0,YR,E,M,Y,125.3,KG,20230228,,MD,DE,,2023,Q1,Elderly
216215652,21621565,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,,2023,Q1,Malignant neoplasm progression,,2023,Q1,2,F,20221103.0,20230227.0,20221121,20230228,EXP,,DE-Eisai Medical Research-EC-2022-128366,EISAI,,73.0,YR,E,M,Y,125.3,KG,20230228,,MD,DE,,2023,Q1,Elderly
216369845,21636984,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Sepsis,,2023,Q1,5,F,20221117.0,20230203.0,20221124,20230208,EXP,,NZ-ROCHE-3222704,ROCHE,,49.0,YR,,F,Y,95.3,KG,20230209,,MD,NZ,,2023,Q1,Adult
216401704,21640170,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q1,Platelet count decreased,,2023,Q1,4,F,20220101.0,20230208.0,20221124,20230213,EXP,,CA-PFIZER INC-PV202200076163,PFIZER,,51.0,YR,,M,Y,100.0,KG,20230213,,MD,CA,CA,2023,Q1,Adult
216401704,21640170,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q1,Haemoglobin decreased,,2023,Q1,4,F,20220101.0,20230208.0,20221124,20230213,EXP,,CA-PFIZER INC-PV202200076163,PFIZER,,51.0,YR,,M,Y,100.0,KG,20230213,,MD,CA,CA,2023,Q1,Adult
216401704,21640170,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q1,Metastatic malignant melanoma,,2023,Q1,4,F,20220101.0,20230208.0,20221124,20230213,EXP,,CA-PFIZER INC-PV202200076163,PFIZER,,51.0,YR,,M,Y,100.0,KG,20230213,,MD,CA,CA,2023,Q1,Adult
216401704,21640170,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q1,White blood cell count decreased,,2023,Q1,4,F,20220101.0,20230208.0,20221124,20230213,EXP,,CA-PFIZER INC-PV202200076163,PFIZER,,51.0,YR,,M,Y,100.0,KG,20230213,,MD,CA,CA,2023,Q1,Adult
216401704,21640170,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q1,Off label use,,2023,Q1,4,F,20220101.0,20230208.0,20221124,20230213,EXP,,CA-PFIZER INC-PV202200076163,PFIZER,,51.0,YR,,M,Y,100.0,KG,20230213,,MD,CA,CA,2023,Q1,Adult
216401704,21640170,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q1,Blood immunoglobulin M increased,,2023,Q1,4,F,20220101.0,20230208.0,20221124,20230213,EXP,,CA-PFIZER INC-PV202200076163,PFIZER,,51.0,YR,,M,Y,100.0,KG,20230213,,MD,CA,CA,2023,Q1,Adult
216664645,21666464,17,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q1,Tenosynovitis stenosans,,2023,Q1,5,F,20220101.0,20230302.0,20221201,20230309,EXP,,CH-ABBVIE-22K-151-4499914-00,ABBVIE,,88.0,YR,,M,Y,70.0,KG,20230309,,MD,CH,CH,2023,Q1,Elderly
216664645,21666464,17,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q1,Thrombocytopenia,,2023,Q1,5,F,20220101.0,20230302.0,20221201,20230309,EXP,,CH-ABBVIE-22K-151-4499914-00,ABBVIE,,88.0,YR,,M,Y,70.0,KG,20230309,,MD,CH,CH,2023,Q1,Elderly
216664645,21666464,17,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q1,COVID-19,,2023,Q1,5,F,20220101.0,20230302.0,20221201,20230309,EXP,,CH-ABBVIE-22K-151-4499914-00,ABBVIE,,88.0,YR,,M,Y,70.0,KG,20230309,,MD,CH,CH,2023,Q1,Elderly
216664645,21666464,17,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q1,Muscle spasms,,2023,Q1,5,F,20220101.0,20230302.0,20221201,20230309,EXP,,CH-ABBVIE-22K-151-4499914-00,ABBVIE,,88.0,YR,,M,Y,70.0,KG,20230309,,MD,CH,CH,2023,Q1,Elderly
216664645,21666464,17,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q1,Diarrhoea,,2023,Q1,5,F,20220101.0,20230302.0,20221201,20230309,EXP,,CH-ABBVIE-22K-151-4499914-00,ABBVIE,,88.0,YR,,M,Y,70.0,KG,20230309,,MD,CH,CH,2023,Q1,Elderly
216664645,21666464,17,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q1,COVID-19,,2023,Q1,5,F,20220101.0,20230302.0,20221201,20230309,EXP,,CH-ABBVIE-22K-151-4499914-00,ABBVIE,,88.0,YR,,M,Y,70.0,KG,20230309,,MD,CH,CH,2023,Q1,Elderly
216664645,21666464,17,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q1,Diarrhoea,,2023,Q1,5,F,20220101.0,20230302.0,20221201,20230309,EXP,,CH-ABBVIE-22K-151-4499914-00,ABBVIE,,88.0,YR,,M,Y,70.0,KG,20230309,,MD,CH,CH,2023,Q1,Elderly
216664645,21666464,17,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q1,COVID-19,,2023,Q1,5,F,20220101.0,20230302.0,20221201,20230309,EXP,,CH-ABBVIE-22K-151-4499914-00,ABBVIE,,88.0,YR,,M,Y,70.0,KG,20230309,,MD,CH,CH,2023,Q1,Elderly
216664645,21666464,17,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q1,Neutropenia,,2023,Q1,5,F,20220101.0,20230302.0,20221201,20230309,EXP,,CH-ABBVIE-22K-151-4499914-00,ABBVIE,,88.0,YR,,M,Y,70.0,KG,20230309,,MD,CH,CH,2023,Q1,Elderly
2168291710,21682917,15,C,EMPAGLIFLOZIN;METFORMIN HYDROCHLORIDE,,1,,,,,,,,,,1012.5,MG,Tablets,,2023,Q1,Urinary tract infection,,2023,Q1,10,F,20221114.0,20230116.0,20221205,20230123,PER,,CO-Eisai Medical Research-EC-2022-129009,EISAI,,80.0,YR,E,F,Y,50.8,KG,20230123,,MD,CO,,2023,Q1,Elderly
2168291710,21682917,15,C,EMPAGLIFLOZIN;METFORMIN HYDROCHLORIDE,,1,,,,,,,,,,1012.5,MG,Tablets,,2023,Q1,Colitis,,2023,Q1,10,F,20221114.0,20230116.0,20221205,20230123,PER,,CO-Eisai Medical Research-EC-2022-129009,EISAI,,80.0,YR,E,F,Y,50.8,KG,20230123,,MD,CO,,2023,Q1,Elderly
217023152,21702315,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,Y,,Unknown,,206073.0,,,Tablet,,2023,Q1,SARS-CoV-2 test positive,,2023,Q1,2,F,20221031.0,20230207.0,20221208,20230208,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-207157",BOEHRINGER INGELHEIM,,65.0,YR,E,M,Y,74.6,KG,20230208,,PH,JP,JP,2023,Q1,Elderly
217023152,21702315,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,Y,,Unknown,,206073.0,,,Tablet,,2023,Q1,Pneumonia aspiration,,2023,Q1,2,F,20221031.0,20230207.0,20221208,20230208,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-207157",BOEHRINGER INGELHEIM,,65.0,YR,E,M,Y,74.6,KG,20230208,,PH,JP,JP,2023,Q1,Elderly
217023152,21702315,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,Y,,Unknown,,206073.0,,,Tablet,,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,2,F,20221031.0,20230207.0,20221208,20230208,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-207157",BOEHRINGER INGELHEIM,,65.0,YR,E,M,Y,74.6,KG,20230208,,PH,JP,JP,2023,Q1,Elderly
217023152,21702315,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,Y,,Unknown,,206073.0,,,Tablet,,2023,Q1,Myasthenia gravis,,2023,Q1,2,F,20221031.0,20230207.0,20221208,20230208,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-207157",BOEHRINGER INGELHEIM,,65.0,YR,E,M,Y,74.6,KG,20230208,,PH,JP,JP,2023,Q1,Elderly
217051102,21705110,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Off label use,,2023,Q1,2,F,20220930.0,20230203.0,20221209,20230209,EXP,,FR-JNJFOC-20221211708,JOHNSON AND JOHNSON,,74.0,YR,E,F,Y,86.4,KG,20230209,,MD,FR,FR,2023,Q1,Elderly
217051102,21705110,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Cardiac failure,,2023,Q1,2,F,20220930.0,20230203.0,20221209,20230209,EXP,,FR-JNJFOC-20221211708,JOHNSON AND JOHNSON,,74.0,YR,E,F,Y,86.4,KG,20230209,,MD,FR,FR,2023,Q1,Elderly
217051102,21705110,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,COVID-19,,2023,Q1,2,F,20220930.0,20230203.0,20221209,20230209,EXP,,FR-JNJFOC-20221211708,JOHNSON AND JOHNSON,,74.0,YR,E,F,Y,86.4,KG,20230209,,MD,FR,FR,2023,Q1,Elderly
217224806,21722480,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,Capsule,,2023,Q1,Confusional state,,2023,Q1,6,F,20221203.0,20230125.0,20221213,20230201,EXP,,US-Eisai Medical Research-EC-2022-129790,EISAI,,62.0,YR,A,M,Y,74.66,KG,20230201,,MD,US,,2023,Q1,Adult
217235854,21723585,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, daily",,,,,,,,10.0,MG,,,2023,Q1,Hypersensitivity,,2023,Q1,4,F,20221108.0,20230311.0,20221213,20230320,EXP,,DE-PFIZER INC-202201337373,PFIZER,,66.0,YR,,M,Y,105.0,KG,20230320,,HP,DE,DE,2023,Q1,Elderly
217235854,21723585,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, daily",,,,,,,,10.0,MG,,,2023,Q1,Hypersensitivity,,2023,Q1,4,F,20221108.0,20230311.0,20221213,20230320,EXP,,DE-PFIZER INC-202201337373,PFIZER,,66.0,YR,,M,Y,105.0,KG,20230320,,HP,DE,DE,2023,Q1,Elderly
217236094,21723609,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD daily",,,U,,,,,10.0,MG,,QD,2023,Q1,Neutropenia,,2023,Q1,4,F,20221121.0,20230220.0,20221213,20230225,EXP,,NVSC2022DE285738,NOVARTIS,,90.0,YR,,M,Y,87.0,KG,20230225,,MD,DE,DE,2023,Q1,Elderly
217357092,21735709,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,,,,,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,2,F,,20221226.0,20221215,20230105,EXP,,US-TEVA-2022-US-2834617,TEVA,,70.0,YR,E,F,Y,,,20230104,,HP,US,US,2023,Q1,Elderly
217358525,21735852,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q1,Urosepsis,,2023,Q1,5,F,20221210.0,20230314.0,20221215,20230315,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-207570",BOEHRINGER INGELHEIM,,67.0,YR,E,M,Y,73.1,KG,20230315,,MD,AU,AU,2023,Q1,Elderly
217363972,21736397,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Off label use,,2023,Q1,2,F,20220930.0,20230212.0,20221215,20230214,EXP,,FR-BAUSCHBL-2022BNL002790,BAUSCH AND LOMB,,74.0,YR,,F,Y,86.4,KG,20230214,,MD,FR,FR,2023,Q1,Elderly
217363972,21736397,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Cardiac failure,,2023,Q1,2,F,20220930.0,20230212.0,20221215,20230214,EXP,,FR-BAUSCHBL-2022BNL002790,BAUSCH AND LOMB,,74.0,YR,,F,Y,86.4,KG,20230214,,MD,FR,FR,2023,Q1,Elderly
217363972,21736397,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,COVID-19,,2023,Q1,2,F,20220930.0,20230212.0,20221215,20230214,EXP,,FR-BAUSCHBL-2022BNL002790,BAUSCH AND LOMB,,74.0,YR,,F,Y,86.4,KG,20230214,,MD,FR,FR,2023,Q1,Elderly
217438913,21743891,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,COVID-19,,2023,Q1,3,F,20220930.0,20230213.0,20221217,20230222,EXP,,NVSC2022FR288561,NOVARTIS,,74.0,YR,,F,Y,86.4,KG,20230222,,MD,FR,FR,2023,Q1,Elderly
217438913,21743891,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Cardiac failure,,2023,Q1,3,F,20220930.0,20230213.0,20221217,20230222,EXP,,NVSC2022FR288561,NOVARTIS,,74.0,YR,,F,Y,86.4,KG,20230222,,MD,FR,FR,2023,Q1,Elderly
217438913,21743891,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Off label use,,2023,Q1,3,F,20220930.0,20230213.0,20221217,20230222,EXP,,NVSC2022FR288561,NOVARTIS,,74.0,YR,,F,Y,86.4,KG,20230222,,MD,FR,FR,2023,Q1,Elderly
217457666,21745766,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, QD (in afternoon)",,,U,,,,,,,Tablet,QD,2023,Q1,Back pain,,2023,Q1,6,F,20221201.0,20230322.0,20221219,20230330,EXP,,NVSC2022AR189231,NOVARTIS,,68.0,YR,,M,Y,,,20230330,,CN,AR,AR,2023,Q1,Elderly
217457666,21745766,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, QD (in afternoon)",,,U,,,,,,,Tablet,QD,2023,Q1,Arterial occlusive disease,,2023,Q1,6,F,20221201.0,20230322.0,20221219,20230330,EXP,,NVSC2022AR189231,NOVARTIS,,68.0,YR,,M,Y,,,20230330,,CN,AR,AR,2023,Q1,Elderly
217457666,21745766,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, QD (in afternoon)",,,U,,,,,,,Tablet,QD,2023,Q1,Procedural pain,,2023,Q1,6,F,20221201.0,20230322.0,20221219,20230330,EXP,,NVSC2022AR189231,NOVARTIS,,68.0,YR,,M,Y,,,20230330,,CN,AR,AR,2023,Q1,Elderly
217457666,21745766,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, QD (in afternoon)",,,U,,,,,,,Tablet,QD,2023,Q1,Cardiac failure,,2023,Q1,6,F,20221201.0,20230322.0,20221219,20230330,EXP,,NVSC2022AR189231,NOVARTIS,,68.0,YR,,M,Y,,,20230330,,CN,AR,AR,2023,Q1,Elderly
217457666,21745766,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, QD (in afternoon)",,,U,,,,,,,Tablet,QD,2023,Q1,Dyspnoea,,2023,Q1,6,F,20221201.0,20230322.0,20221219,20230330,EXP,,NVSC2022AR189231,NOVARTIS,,68.0,YR,,M,Y,,,20230330,,CN,AR,AR,2023,Q1,Elderly
217457666,21745766,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, QD (in afternoon)",,,U,,,,,,,Tablet,QD,2023,Q1,Blood glucose increased,,2023,Q1,6,F,20221201.0,20230322.0,20221219,20230330,EXP,,NVSC2022AR189231,NOVARTIS,,68.0,YR,,M,Y,,,20230330,,CN,AR,AR,2023,Q1,Elderly
217457666,21745766,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, QD (in afternoon)",,,U,,,,,,,Tablet,QD,2023,Q1,Skin depigmentation,,2023,Q1,6,F,20221201.0,20230322.0,20221219,20230330,EXP,,NVSC2022AR189231,NOVARTIS,,68.0,YR,,M,Y,,,20230330,,CN,AR,AR,2023,Q1,Elderly
217736534,21773653,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,Unknown,,2023,Q1,Thrombocytopenia,,2023,Q1,4,F,20221220.0,20230104.0,20221223,20230110,EXP,,AU-BRISTOL-MYERS SQUIBB COMPANY-2022-157624,BRISTOL MYERS SQUIBB,,68.0,YR,E,M,Y,94.0,KG,20230110,,MD,AU,AU,2023,Q1,Elderly
217802232,21780223,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10mg/day,,,,,Unknown,,204629.0,10.0,MG,Film-coated tablet,QD,2023,Q1,Cardiac failure,,2023,Q1,2,F,20180730.0,20230103.0,20221227,20230112,EXP,,"ES-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-209703",BOEHRINGER INGELHEIM,,64.0,YR,A,F,Y,54.0,KG,20230112,,MD,ES,ES,2023,Q1,Adult
217802232,21780223,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10mg/day,,,,,Unknown,,204629.0,10.0,MG,Film-coated tablet,QD,2023,Q1,Left ventricular dysfunction,,2023,Q1,2,F,20180730.0,20230103.0,20221227,20230112,EXP,,"ES-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-209703",BOEHRINGER INGELHEIM,,64.0,YR,A,F,Y,54.0,KG,20230112,,MD,ES,ES,2023,Q1,Adult
217802232,21780223,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10mg/day,,,,,Unknown,,204629.0,10.0,MG,Film-coated tablet,QD,2023,Q1,Prosthetic cardiac valve regurgitation,,2023,Q1,2,F,20180730.0,20230103.0,20221227,20230112,EXP,,"ES-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-209703",BOEHRINGER INGELHEIM,,64.0,YR,A,F,Y,54.0,KG,20230112,,MD,ES,ES,2023,Q1,Adult
217802232,21780223,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10mg/day,,,,,Unknown,,204629.0,10.0,MG,Film-coated tablet,QD,2023,Q1,Mitral valve stenosis,,2023,Q1,2,F,20180730.0,20230103.0,20221227,20230112,EXP,,"ES-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-209703",BOEHRINGER INGELHEIM,,64.0,YR,A,F,Y,54.0,KG,20230112,,MD,ES,ES,2023,Q1,Adult
217802232,21780223,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10mg/day,,,,,Unknown,,204629.0,10.0,MG,Film-coated tablet,QD,2023,Q1,Right ventricular dilatation,,2023,Q1,2,F,20180730.0,20230103.0,20221227,20230112,EXP,,"ES-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-209703",BOEHRINGER INGELHEIM,,64.0,YR,A,F,Y,54.0,KG,20230112,,MD,ES,ES,2023,Q1,Adult
217802232,21780223,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25mg/day,,,,,Unknown,,204629.0,25.0,MG,Film-coated tablet,QD,2023,Q1,Cardiac failure,,2023,Q1,2,F,20180730.0,20230103.0,20221227,20230112,EXP,,"ES-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-209703",BOEHRINGER INGELHEIM,,64.0,YR,A,F,Y,54.0,KG,20230112,,MD,ES,ES,2023,Q1,Adult
217802232,21780223,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25mg/day,,,,,Unknown,,204629.0,25.0,MG,Film-coated tablet,QD,2023,Q1,Left ventricular dysfunction,,2023,Q1,2,F,20180730.0,20230103.0,20221227,20230112,EXP,,"ES-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-209703",BOEHRINGER INGELHEIM,,64.0,YR,A,F,Y,54.0,KG,20230112,,MD,ES,ES,2023,Q1,Adult
217802232,21780223,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25mg/day,,,,,Unknown,,204629.0,25.0,MG,Film-coated tablet,QD,2023,Q1,Prosthetic cardiac valve regurgitation,,2023,Q1,2,F,20180730.0,20230103.0,20221227,20230112,EXP,,"ES-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-209703",BOEHRINGER INGELHEIM,,64.0,YR,A,F,Y,54.0,KG,20230112,,MD,ES,ES,2023,Q1,Adult
217802232,21780223,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25mg/day,,,,,Unknown,,204629.0,25.0,MG,Film-coated tablet,QD,2023,Q1,Mitral valve stenosis,,2023,Q1,2,F,20180730.0,20230103.0,20221227,20230112,EXP,,"ES-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-209703",BOEHRINGER INGELHEIM,,64.0,YR,A,F,Y,54.0,KG,20230112,,MD,ES,ES,2023,Q1,Adult
217802232,21780223,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25mg/day,,,,,Unknown,,204629.0,25.0,MG,Film-coated tablet,QD,2023,Q1,Right ventricular dilatation,,2023,Q1,2,F,20180730.0,20230103.0,20221227,20230112,EXP,,"ES-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-209703",BOEHRINGER INGELHEIM,,64.0,YR,A,F,Y,54.0,KG,20230112,,MD,ES,ES,2023,Q1,Adult
217857533,21785753,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,Film-coated tablet,,2023,Q1,Ejection fraction decreased,,2023,Q1,3,F,20221128.0,20230110.0,20221227,20230112,EXP,,"ES-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-209881",BOEHRINGER INGELHEIM,,54.0,YR,A,M,Y,70.0,KG,20230112,,HP,ES,ES,2023,Q1,Adult
217857533,21785753,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,Film-coated tablet,,2023,Q1,Pyrexia,,2023,Q1,3,F,20221128.0,20230110.0,20221227,20230112,EXP,,"ES-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-209881",BOEHRINGER INGELHEIM,,54.0,YR,A,M,Y,70.0,KG,20230112,,HP,ES,ES,2023,Q1,Adult
217857533,21785753,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Asked But Unknown,,204629.0,10.0,MG,Film-coated tablet,QD,2023,Q1,Ejection fraction decreased,,2023,Q1,3,F,20221128.0,20230110.0,20221227,20230112,EXP,,"ES-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-209881",BOEHRINGER INGELHEIM,,54.0,YR,A,M,Y,70.0,KG,20230112,,HP,ES,ES,2023,Q1,Adult
217857533,21785753,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Asked But Unknown,,204629.0,10.0,MG,Film-coated tablet,QD,2023,Q1,Pyrexia,,2023,Q1,3,F,20221128.0,20230110.0,20221227,20230112,EXP,,"ES-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-209881",BOEHRINGER INGELHEIM,,54.0,YR,A,M,Y,70.0,KG,20230112,,HP,ES,ES,2023,Q1,Adult
217886164,21788616,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"12.5 mg, BID",,,,,,,,12.5,MG,,BID,2023,Q1,Pyrexia,,2023,Q1,4,F,20221113.0,20230123.0,20221228,20230130,EXP,,NVSC2022GR297132,NOVARTIS,,83.0,YR,,M,Y,104.0,KG,20230130,,MD,GR,GR,2023,Q1,Elderly
217886164,21788616,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"12.5 mg, BID",,,,,,,,12.5,MG,,BID,2023,Q1,Productive cough,,2023,Q1,4,F,20221113.0,20230123.0,20221228,20230130,EXP,,NVSC2022GR297132,NOVARTIS,,83.0,YR,,M,Y,104.0,KG,20230130,,MD,GR,GR,2023,Q1,Elderly
217886164,21788616,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"12.5 mg, BID",,,,,,,,12.5,MG,,BID,2023,Q1,Dyspnoea,,2023,Q1,4,F,20221113.0,20230123.0,20221228,20230130,EXP,,NVSC2022GR297132,NOVARTIS,,83.0,YR,,M,Y,104.0,KG,20230130,,MD,GR,GR,2023,Q1,Elderly
217886164,21788616,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"12.5 mg, BID",,,,,,,,12.5,MG,,BID,2023,Q1,Pneumonia staphylococcal,,2023,Q1,4,F,20221113.0,20230123.0,20221228,20230130,EXP,,NVSC2022GR297132,NOVARTIS,,83.0,YR,,M,Y,104.0,KG,20230130,,MD,GR,GR,2023,Q1,Elderly
217886164,21788616,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"12.5 mg, BID",,,,,,,,12.5,MG,,BID,2023,Q1,Off label use,,2023,Q1,4,F,20221113.0,20230123.0,20221228,20230130,EXP,,NVSC2022GR297132,NOVARTIS,,83.0,YR,,M,Y,104.0,KG,20230130,,MD,GR,GR,2023,Q1,Elderly
217886164,21788616,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Pyrexia,,2023,Q1,4,F,20221113.0,20230123.0,20221228,20230130,EXP,,NVSC2022GR297132,NOVARTIS,,83.0,YR,,M,Y,104.0,KG,20230130,,MD,GR,GR,2023,Q1,Elderly
217886164,21788616,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Productive cough,,2023,Q1,4,F,20221113.0,20230123.0,20221228,20230130,EXP,,NVSC2022GR297132,NOVARTIS,,83.0,YR,,M,Y,104.0,KG,20230130,,MD,GR,GR,2023,Q1,Elderly
217886164,21788616,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Dyspnoea,,2023,Q1,4,F,20221113.0,20230123.0,20221228,20230130,EXP,,NVSC2022GR297132,NOVARTIS,,83.0,YR,,M,Y,104.0,KG,20230130,,MD,GR,GR,2023,Q1,Elderly
217886164,21788616,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Pneumonia staphylococcal,,2023,Q1,4,F,20221113.0,20230123.0,20221228,20230130,EXP,,NVSC2022GR297132,NOVARTIS,,83.0,YR,,M,Y,104.0,KG,20230130,,MD,GR,GR,2023,Q1,Elderly
217886164,21788616,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Off label use,,2023,Q1,4,F,20221113.0,20230123.0,20221228,20230130,EXP,,NVSC2022GR297132,NOVARTIS,,83.0,YR,,M,Y,104.0,KG,20230130,,MD,GR,GR,2023,Q1,Elderly
218122471,21812247,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2023,Q1,Hypernatraemia,,2023,Q1,1,I,,20221226.0,20230103,20230103,EXP,,AU-MYLANLABS-2022M1141437,MYLAN,"Reimann F, Whyte I. Chronic lithium toxicity. Aust-Prescr 2022;45(3):93-94.",66.0,YR,,M,Y,,,20230103,,HP,AU,AU,2023,Q1,Elderly
218122471,21812247,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2023,Q1,Acute kidney injury,,2023,Q1,1,I,,20221226.0,20230103,20230103,EXP,,AU-MYLANLABS-2022M1141437,MYLAN,"Reimann F, Whyte I. Chronic lithium toxicity. Aust-Prescr 2022;45(3):93-94.",66.0,YR,,M,Y,,,20230103,,HP,AU,AU,2023,Q1,Elderly
218122471,21812247,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2023,Q1,Hypovolaemia,,2023,Q1,1,I,,20221226.0,20230103,20230103,EXP,,AU-MYLANLABS-2022M1141437,MYLAN,"Reimann F, Whyte I. Chronic lithium toxicity. Aust-Prescr 2022;45(3):93-94.",66.0,YR,,M,Y,,,20230103,,HP,AU,AU,2023,Q1,Elderly
218122471,21812247,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2023,Q1,Metabolic acidosis,,2023,Q1,1,I,,20221226.0,20230103,20230103,EXP,,AU-MYLANLABS-2022M1141437,MYLAN,"Reimann F, Whyte I. Chronic lithium toxicity. Aust-Prescr 2022;45(3):93-94.",66.0,YR,,M,Y,,,20230103,,HP,AU,AU,2023,Q1,Elderly
218122471,21812247,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2023,Q1,Ileus,,2023,Q1,1,I,,20221226.0,20230103,20230103,EXP,,AU-MYLANLABS-2022M1141437,MYLAN,"Reimann F, Whyte I. Chronic lithium toxicity. Aust-Prescr 2022;45(3):93-94.",66.0,YR,,M,Y,,,20230103,,HP,AU,AU,2023,Q1,Elderly
218122471,21812247,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2023,Q1,Toxicity to various agents,,2023,Q1,1,I,,20221226.0,20230103,20230103,EXP,,AU-MYLANLABS-2022M1141437,MYLAN,"Reimann F, Whyte I. Chronic lithium toxicity. Aust-Prescr 2022;45(3):93-94.",66.0,YR,,M,Y,,,20230103,,HP,AU,AU,2023,Q1,Elderly
218122471,21812247,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2023,Q1,Neurotoxicity,,2023,Q1,1,I,,20221226.0,20230103,20230103,EXP,,AU-MYLANLABS-2022M1141437,MYLAN,"Reimann F, Whyte I. Chronic lithium toxicity. Aust-Prescr 2022;45(3):93-94.",66.0,YR,,M,Y,,,20230103,,HP,AU,AU,2023,Q1,Elderly
218122471,21812247,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2023,Q1,Drug interaction,,2023,Q1,1,I,,20221226.0,20230103,20230103,EXP,,AU-MYLANLABS-2022M1141437,MYLAN,"Reimann F, Whyte I. Chronic lithium toxicity. Aust-Prescr 2022;45(3):93-94.",66.0,YR,,M,Y,,,20230103,,HP,AU,AU,2023,Q1,Elderly
218122471,21812247,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2023,Q1,Nephrogenic diabetes insipidus,,2023,Q1,1,I,,20221226.0,20230103,20230103,EXP,,AU-MYLANLABS-2022M1141437,MYLAN,"Reimann F, Whyte I. Chronic lithium toxicity. Aust-Prescr 2022;45(3):93-94.",66.0,YR,,M,Y,,,20230103,,HP,AU,AU,2023,Q1,Elderly
218123455,21812345,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,LAST ADMINISTRATION DATE BEFORE THE EVENT: 23 DEC 2022,,,Y,U,Unknown,,102145.0,10.0,MG,,,2023,Q1,Lacunar infarction,,2023,Q1,5,F,20221223.0,20230123.0,20230103,20230125,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-210026",BOEHRINGER INGELHEIM,,63.0,YR,A,M,Y,71.8,KG,20230125,,MD,JP,JP,2023,Q1,Adult
218138462,21813846,29,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q1,Diabetic ketoacidosis,,2023,Q1,2,F,20180704.0,20230101.0,20230104,20230113,EXP,,GB-AUROBINDO-AUR-APL-2022-056667,AUROBINDO,,57.0,YR,,F,Y,,,20230113,,MD,GB,GB,2023,Q1,Adult
218138462,21813846,29,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q1,Lower respiratory tract infection,,2023,Q1,2,F,20180704.0,20230101.0,20230104,20230113,EXP,,GB-AUROBINDO-AUR-APL-2022-056667,AUROBINDO,,57.0,YR,,F,Y,,,20230113,,MD,GB,GB,2023,Q1,Adult
218138462,21813846,29,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q1,Pneumonia,,2023,Q1,2,F,20180704.0,20230101.0,20230104,20230113,EXP,,GB-AUROBINDO-AUR-APL-2022-056667,AUROBINDO,,57.0,YR,,F,Y,,,20230113,,MD,GB,GB,2023,Q1,Adult
218138462,21813846,29,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q1,Sepsis,,2023,Q1,2,F,20180704.0,20230101.0,20230104,20230113,EXP,,GB-AUROBINDO-AUR-APL-2022-056667,AUROBINDO,,57.0,YR,,F,Y,,,20230113,,MD,GB,GB,2023,Q1,Adult
218151012,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Hernia repair,,2023,Q1,2,F,20220601.0,20230209.0,20230104,20230217,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230218,,CN,US,US,2023,Q1,Adult
218151012,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Large intestinal polypectomy,,2023,Q1,2,F,20220601.0,20230209.0,20230104,20230217,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230218,,CN,US,US,2023,Q1,Adult
218151012,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Oedema peripheral,,2023,Q1,2,F,20220601.0,20230209.0,20230104,20230217,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230218,,CN,US,US,2023,Q1,Adult
218151012,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Oesophageal variceal ligation,,2023,Q1,2,F,20220601.0,20230209.0,20230104,20230217,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230218,,CN,US,US,2023,Q1,Adult
218151012,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Gastrointestinal wall thickening,,2023,Q1,2,F,20220601.0,20230209.0,20230104,20230217,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230218,,CN,US,US,2023,Q1,Adult
218151012,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Vasodilatation,,2023,Q1,2,F,20220601.0,20230209.0,20230104,20230217,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230218,,CN,US,US,2023,Q1,Adult
218151012,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Vertebral wedging,,2023,Q1,2,F,20220601.0,20230209.0,20230104,20230217,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230218,,CN,US,US,2023,Q1,Adult
218151012,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Ileus,,2023,Q1,2,F,20220601.0,20230209.0,20230104,20230217,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230218,,CN,US,US,2023,Q1,Adult
218151012,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Red blood cell transfusion,,2023,Q1,2,F,20220601.0,20230209.0,20230104,20230217,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230218,,CN,US,US,2023,Q1,Adult
218151012,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Portal hypertensive gastropathy,,2023,Q1,2,F,20220601.0,20230209.0,20230104,20230217,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230218,,CN,US,US,2023,Q1,Adult
218151012,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Pulmonary oedema,,2023,Q1,2,F,20220601.0,20230209.0,20230104,20230217,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230218,,CN,US,US,2023,Q1,Adult
218151012,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Ascites,,2023,Q1,2,F,20220601.0,20230209.0,20230104,20230217,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230218,,CN,US,US,2023,Q1,Adult
218151012,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Urticaria,,2023,Q1,2,F,20220601.0,20230209.0,20230104,20230217,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230218,,CN,US,US,2023,Q1,Adult
218151012,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Generalised oedema,,2023,Q1,2,F,20220601.0,20230209.0,20230104,20230217,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230218,,CN,US,US,2023,Q1,Adult
218151012,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Vertebral foraminal stenosis,,2023,Q1,2,F,20220601.0,20230209.0,20230104,20230217,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230218,,CN,US,US,2023,Q1,Adult
218151012,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Haemorrhoids,,2023,Q1,2,F,20220601.0,20230209.0,20230104,20230217,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230218,,CN,US,US,2023,Q1,Adult
218151012,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Portal shunt procedure,,2023,Q1,2,F,20220601.0,20230209.0,20230104,20230217,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230218,,CN,US,US,2023,Q1,Adult
218151012,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Splenomegaly,,2023,Q1,2,F,20220601.0,20230209.0,20230104,20230217,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230218,,CN,US,US,2023,Q1,Adult
218151012,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Blood loss anaemia,,2023,Q1,2,F,20220601.0,20230209.0,20230104,20230217,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230218,,CN,US,US,2023,Q1,Adult
218151012,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Liver function test increased,,2023,Q1,2,F,20220601.0,20230209.0,20230104,20230217,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230218,,CN,US,US,2023,Q1,Adult
218151012,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Diarrhoea,,2023,Q1,2,F,20220601.0,20230209.0,20230104,20230217,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230218,,CN,US,US,2023,Q1,Adult
218151012,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Large intestine polyp,,2023,Q1,2,F,20220601.0,20230209.0,20230104,20230217,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230218,,CN,US,US,2023,Q1,Adult
218151012,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Dry skin,,2023,Q1,2,F,20220601.0,20230209.0,20230104,20230217,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230218,,CN,US,US,2023,Q1,Adult
218151012,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Off label use,,2023,Q1,2,F,20220601.0,20230209.0,20230104,20230217,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230218,,CN,US,US,2023,Q1,Adult
218151012,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Portal hypertension,,2023,Q1,2,F,20220601.0,20230209.0,20230104,20230217,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230218,,CN,US,US,2023,Q1,Adult
218151012,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Pleural effusion,,2023,Q1,2,F,20220601.0,20230209.0,20230104,20230217,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230218,,CN,US,US,2023,Q1,Adult
218151012,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Peripancreatic fluid collection,,2023,Q1,2,F,20220601.0,20230209.0,20230104,20230217,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230218,,CN,US,US,2023,Q1,Adult
218151012,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Oesophageal varices haemorrhage,,2023,Q1,2,F,20220601.0,20230209.0,20230104,20230217,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230218,,CN,US,US,2023,Q1,Adult
218151012,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Road traffic accident,,2023,Q1,2,F,20220601.0,20230209.0,20230104,20230217,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230218,,CN,US,US,2023,Q1,Adult
218175621,21817562,2,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,,,,,,,,Tablet,QD,2023,Q1,Rash rubelliform,,2023,Q1,1,I,20221011.0,20221227.0,20230104,20230104,EXP,,JP-AstraZeneca-2022A382564,ASTRAZENECA,,26539.0,DY,,F,Y,38.0,KG,20230104,,MD,JP,,2023,Q1,Elderly
218175621,21817562,2,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,,,,,,,,Tablet,QD,2023,Q1,Toxic skin eruption,,2023,Q1,1,I,20221011.0,20221227.0,20230104,20230104,EXP,,JP-AstraZeneca-2022A382564,ASTRAZENECA,,26539.0,DY,,F,Y,38.0,KG,20230104,,MD,JP,,2023,Q1,Elderly
218175621,21817562,2,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,,,,,,,,Tablet,QD,2023,Q1,Drug eruption,,2023,Q1,1,I,20221011.0,20221227.0,20230104,20230104,EXP,,JP-AstraZeneca-2022A382564,ASTRAZENECA,,26539.0,DY,,F,Y,38.0,KG,20230104,,MD,JP,,2023,Q1,Elderly
218191361,21819136,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,,U,,,,5.0,MG,,QD,2023,Q1,Drug ineffective,,2023,Q1,1,I,,20221227.0,20230104,20230104,EXP,,CA-MYLANLABS-2022M1141429,MYLAN,"Yau K, Poon S, Auguste BL. Drug eruption associated with empagliflozin. CMAJ 2022;194(48):E1651-E1652.",61.0,YR,,M,Y,,,20230104,,MD,CA,CA,2023,Q1,Adult
218191361,21819136,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,U,,,,10.0,MG,,QD,2023,Q1,Drug ineffective,,2023,Q1,1,I,,20221227.0,20230104,20230104,EXP,,CA-MYLANLABS-2022M1141429,MYLAN,"Yau K, Poon S, Auguste BL. Drug eruption associated with empagliflozin. CMAJ 2022;194(48):E1651-E1652.",61.0,YR,,M,Y,,,20230104,,MD,CA,CA,2023,Q1,Adult
218198221,21819822,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2023,Q1,Pancreatitis acute,,2023,Q1,1,I,,20230103.0,20230104,20230104,EXP,,"SA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-210820",BOEHRINGER INGELHEIM,Alqurashe K. Acute Pancreatitis as a Rare Side Effect of Using Empagliflozin. Endocrine Practice. 2022;28(12)doi:10.1016/j.eprac.2022.10.027.,56.0,YR,A,F,Y,,,20230105,,HP,SA,SA,2023,Q1,Adult
218198221,21819822,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2023,Q1,Pancreatitis acute,,2023,Q1,1,I,,20230103.0,20230104,20230104,EXP,,"SA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-210820",BOEHRINGER INGELHEIM,Alqurashe K. Acute Pancreatitis as a Rare Side Effect of Using Empagliflozin. Endocrine Practice. 2022;28(12)doi:10.1016/j.eprac.2022.10.027.,56.0,YR,A,F,Y,,,20230105,,HP,SA,SA,2023,Q1,Adult
218212221,21821222,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 milligram per day,,,D,,,,,25.0,MG,,,2023,Q1,Drug ineffective for unapproved indication,,2023,Q1,1,I,,20220802.0,20230105,20230105,PER,,US-STRIDES ARCOLAB LIMITED-2022SP009978,STRIDES,"Mishra R, Elshimy G, Kannan L, Raj R.. Sodium-glucose cotransporter 2 inhibitor-associated severe epididymo-orchitis.. BMJ-Case-Rep. 2022;15(7)",6.0,DEC,,M,Y,,,20230105,,MD,US,US,2023,Q1,Child
218221311,21822131,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Injection site urticaria,,2023,Q1,1,I,20221204.0,20221207.0,20230105,20230105,PER,,US-ELI_LILLY_AND_COMPANY-US202212006104,ELI LILLY AND CO,,62.0,YR,,F,Y,,,20230105,,CN,US,US,2023,Q1,Adult
218221311,21822131,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Incorrect dose administered,,2023,Q1,1,I,20221204.0,20221207.0,20230105,20230105,PER,,US-ELI_LILLY_AND_COMPANY-US202212006104,ELI LILLY AND CO,,62.0,YR,,F,Y,,,20230105,,CN,US,US,2023,Q1,Adult
218223741,21822374,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,,2023,Q1,Psychotic disorder,,2023,Q1,1,I,20220413.0,20221227.0,20230105,20230105,EXP,AT-BASGAGES-2022-111925,AT-Accord-294410,ACCORD,,72.0,YR,E,M,Y,,,20230105,,MD,AT,AT,2023,Q1,Elderly
218247051,21824705,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,,,,,2023,Q1,Pyelonephritis,,2023,Q1,1,I,,20230104.0,20230105,20230105,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-210919",BOEHRINGER INGELHEIM,,61.0,YR,A,M,Y,,,20230105,,HP,SG,SG,2023,Q1,Adult
218247051,21824705,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,,,,,2023,Q1,Septic shock,,2023,Q1,1,I,,20230104.0,20230105,20230105,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-210919",BOEHRINGER INGELHEIM,,61.0,YR,A,M,Y,,,20230105,,HP,SG,SG,2023,Q1,Adult
218265821,21826582,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,Oral,One 25-5 tablet daily,,,U,,Unknown,,212614.0,25.0,MG,Tablet,QD,2023,Q1,Hypoacusis,,2023,Q1,1,I,20230101.0,20230104.0,20230106,20230106,PER,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-211325",BOEHRINGER INGELHEIM,,76.0,YR,E,F,Y,,,20230106,,CN,US,US,2023,Q1,Elderly
218270741,21827074,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Nephrogenic diabetes insipidus,,2023,Q1,1,I,,20221226.0,20230106,20230106,EXP,,AU-LUPIN PHARMACEUTICALS INC.-2022-14954,LUPIN,"Reimann F, Whyte I. Chronic lithium toxicity. Australian Prescriber. 2022;45:93-94",66.0,YR,,M,Y,,,20230106,,HP,AU,AU,2023,Q1,Elderly
218270741,21827074,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Pneumonia,,2023,Q1,1,I,,20221226.0,20230106,20230106,EXP,,AU-LUPIN PHARMACEUTICALS INC.-2022-14954,LUPIN,"Reimann F, Whyte I. Chronic lithium toxicity. Australian Prescriber. 2022;45:93-94",66.0,YR,,M,Y,,,20230106,,HP,AU,AU,2023,Q1,Elderly
218270741,21827074,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Hypovolaemia,,2023,Q1,1,I,,20221226.0,20230106,20230106,EXP,,AU-LUPIN PHARMACEUTICALS INC.-2022-14954,LUPIN,"Reimann F, Whyte I. Chronic lithium toxicity. Australian Prescriber. 2022;45:93-94",66.0,YR,,M,Y,,,20230106,,HP,AU,AU,2023,Q1,Elderly
218270741,21827074,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Ileus,,2023,Q1,1,I,,20221226.0,20230106,20230106,EXP,,AU-LUPIN PHARMACEUTICALS INC.-2022-14954,LUPIN,"Reimann F, Whyte I. Chronic lithium toxicity. Australian Prescriber. 2022;45:93-94",66.0,YR,,M,Y,,,20230106,,HP,AU,AU,2023,Q1,Elderly
218270741,21827074,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Toxicity to various agents,,2023,Q1,1,I,,20221226.0,20230106,20230106,EXP,,AU-LUPIN PHARMACEUTICALS INC.-2022-14954,LUPIN,"Reimann F, Whyte I. Chronic lithium toxicity. Australian Prescriber. 2022;45:93-94",66.0,YR,,M,Y,,,20230106,,HP,AU,AU,2023,Q1,Elderly
218270741,21827074,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Acute kidney injury,,2023,Q1,1,I,,20221226.0,20230106,20230106,EXP,,AU-LUPIN PHARMACEUTICALS INC.-2022-14954,LUPIN,"Reimann F, Whyte I. Chronic lithium toxicity. Australian Prescriber. 2022;45:93-94",66.0,YR,,M,Y,,,20230106,,HP,AU,AU,2023,Q1,Elderly
218270741,21827074,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Diarrhoea,,2023,Q1,1,I,,20221226.0,20230106,20230106,EXP,,AU-LUPIN PHARMACEUTICALS INC.-2022-14954,LUPIN,"Reimann F, Whyte I. Chronic lithium toxicity. Australian Prescriber. 2022;45:93-94",66.0,YR,,M,Y,,,20230106,,HP,AU,AU,2023,Q1,Elderly
218270741,21827074,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Hypernatraemia,,2023,Q1,1,I,,20221226.0,20230106,20230106,EXP,,AU-LUPIN PHARMACEUTICALS INC.-2022-14954,LUPIN,"Reimann F, Whyte I. Chronic lithium toxicity. Australian Prescriber. 2022;45:93-94",66.0,YR,,M,Y,,,20230106,,HP,AU,AU,2023,Q1,Elderly
218301611,21830161,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,25.0,MG,,,2023,Q1,Gastroenteritis,,2023,Q1,1,I,20220101.0,20221227.0,20230106,20230106,EXP,DE-BFARM-22010061,DE-Accord-294428,ACCORD,,56.0,YR,A,M,Y,,,20230106,,MD,DE,DE,2023,Q1,Adult
218301611,21830161,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,25.0,MG,,,2023,Q1,Ketoacidosis,,2023,Q1,1,I,20220101.0,20221227.0,20230106,20230106,EXP,DE-BFARM-22010061,DE-Accord-294428,ACCORD,,56.0,YR,A,M,Y,,,20230106,,MD,DE,DE,2023,Q1,Adult
218301611,21830161,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,25.0,MG,,,2023,Q1,Acute kidney injury,,2023,Q1,1,I,20220101.0,20221227.0,20230106,20230106,EXP,DE-BFARM-22010061,DE-Accord-294428,ACCORD,,56.0,YR,A,M,Y,,,20230106,,MD,DE,DE,2023,Q1,Adult
218309031,21830903,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Hypotension,,2023,Q1,1,I,20221201.0,20230104.0,20230106,20230106,EXP,,GB-MYLANLABS-2023M1000939,MYLAN,,62.0,YR,,M,Y,90.0,KG,20230106,,PH,GB,GB,2023,Q1,Adult
218316001,21831600,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,Unknown,,2023,Q1,Death,,2023,Q1,1,I,,20230105.0,20230106,20230106,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-2023-002621,BRISTOL MYERS SQUIBB,,52.0,YR,A,F,Y,,,20230106,,HP,US,US,2023,Q1,Adult
218320141,21832014,4,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,U,,,,,,,Tablet,,2023,Q1,Weight decreased,,2023,Q1,1,I,20220101.0,20221231.0,20230106,20230106,EXP,,NVSC2022PK302425,NOVARTIS,,56.0,YR,,M,Y,,,20230106,,CN,PK,PK,2023,Q1,Adult
218320141,21832014,4,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,U,,,,,,,Tablet,,2023,Q1,Blood pressure increased,,2023,Q1,1,I,20220101.0,20221231.0,20230106,20230106,EXP,,NVSC2022PK302425,NOVARTIS,,56.0,YR,,M,Y,,,20230106,,CN,PK,PK,2023,Q1,Adult
218320141,21832014,4,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,U,,,,,,,Tablet,,2023,Q1,Hyperglycaemia,,2023,Q1,1,I,20220101.0,20221231.0,20230106,20230106,EXP,,NVSC2022PK302425,NOVARTIS,,56.0,YR,,M,Y,,,20230106,,CN,PK,PK,2023,Q1,Adult
218320141,21832014,4,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,U,,,,,,,Tablet,,2023,Q1,Fatigue,,2023,Q1,1,I,20220101.0,20221231.0,20230106,20230106,EXP,,NVSC2022PK302425,NOVARTIS,,56.0,YR,,M,Y,,,20230106,,CN,PK,PK,2023,Q1,Adult
218320141,21832014,4,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,U,,,,,,,Tablet,,2023,Q1,Dizziness,,2023,Q1,1,I,20220101.0,20221231.0,20230106,20230106,EXP,,NVSC2022PK302425,NOVARTIS,,56.0,YR,,M,Y,,,20230106,,CN,PK,PK,2023,Q1,Adult
218320141,21832014,4,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,U,,,,,,,Tablet,,2023,Q1,Tension,,2023,Q1,1,I,20220101.0,20221231.0,20230106,20230106,EXP,,NVSC2022PK302425,NOVARTIS,,56.0,YR,,M,Y,,,20230106,,CN,PK,PK,2023,Q1,Adult
218320141,21832014,4,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,U,,,,,,,Tablet,,2023,Q1,Hypoaesthesia,,2023,Q1,1,I,20220101.0,20221231.0,20230106,20230106,EXP,,NVSC2022PK302425,NOVARTIS,,56.0,YR,,M,Y,,,20230106,,CN,PK,PK,2023,Q1,Adult
218320141,21832014,4,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,U,,,,,,,Tablet,,2023,Q1,Diabetes mellitus inadequate control,,2023,Q1,1,I,20220101.0,20221231.0,20230106,20230106,EXP,,NVSC2022PK302425,NOVARTIS,,56.0,YR,,M,Y,,,20230106,,CN,PK,PK,2023,Q1,Adult
218331281,21833128,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5+ 850 mg,,,Y,U,Unknown,,204629.0,,,Tablet,Q12H,2023,Q1,Asthenia,,2023,Q1,1,I,20220910.0,20221129.0,20230106,20230106,EXP,,"CO-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-204464",BOEHRINGER INGELHEIM,,62.0,YR,A,F,Y,75.0,KG,20230106,,CN,CO,CO,2023,Q1,Adult
218331281,21833128,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5+ 850 mg,,,Y,U,Unknown,,204629.0,,,Tablet,Q12H,2023,Q1,Headache,,2023,Q1,1,I,20220910.0,20221129.0,20230106,20230106,EXP,,"CO-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-204464",BOEHRINGER INGELHEIM,,62.0,YR,A,F,Y,75.0,KG,20230106,,CN,CO,CO,2023,Q1,Adult
218331281,21833128,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5+ 850 mg,,,Y,U,Unknown,,204629.0,,,Tablet,Q12H,2023,Q1,Dizziness,,2023,Q1,1,I,20220910.0,20221129.0,20230106,20230106,EXP,,"CO-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-204464",BOEHRINGER INGELHEIM,,62.0,YR,A,F,Y,75.0,KG,20230106,,CN,CO,CO,2023,Q1,Adult
218335511,21833551,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q1,Hypotension,,2023,Q1,1,I,,20221225.0,20230107,20230107,EXP,,GB-Accord-294807,ACCORD,"Rashid A, Movio G, Lee GC. Nicorandil and ranolazine overdose management. BMJ Case Rep. 2022 Dec 23;15(12):e245834.",7.0,DEC,E,M,Y,,,20230107,,HP,GB,GB,2023,Q1,Child
218335511,21833551,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q1,Cardiac arrest,,2023,Q1,1,I,,20221225.0,20230107,20230107,EXP,,GB-Accord-294807,ACCORD,"Rashid A, Movio G, Lee GC. Nicorandil and ranolazine overdose management. BMJ Case Rep. 2022 Dec 23;15(12):e245834.",7.0,DEC,E,M,Y,,,20230107,,HP,GB,GB,2023,Q1,Child
218335511,21833551,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q1,Intentional overdose,,2023,Q1,1,I,,20221225.0,20230107,20230107,EXP,,GB-Accord-294807,ACCORD,"Rashid A, Movio G, Lee GC. Nicorandil and ranolazine overdose management. BMJ Case Rep. 2022 Dec 23;15(12):e245834.",7.0,DEC,E,M,Y,,,20230107,,HP,GB,GB,2023,Q1,Child
218335511,21833551,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q1,Dizziness,,2023,Q1,1,I,,20221225.0,20230107,20230107,EXP,,GB-Accord-294807,ACCORD,"Rashid A, Movio G, Lee GC. Nicorandil and ranolazine overdose management. BMJ Case Rep. 2022 Dec 23;15(12):e245834.",7.0,DEC,E,M,Y,,,20230107,,HP,GB,GB,2023,Q1,Child
218335511,21833551,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q1,Ventricular fibrillation,,2023,Q1,1,I,,20221225.0,20230107,20230107,EXP,,GB-Accord-294807,ACCORD,"Rashid A, Movio G, Lee GC. Nicorandil and ranolazine overdose management. BMJ Case Rep. 2022 Dec 23;15(12):e245834.",7.0,DEC,E,M,Y,,,20230107,,HP,GB,GB,2023,Q1,Child
218335511,21833551,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q1,Shock,,2023,Q1,1,I,,20221225.0,20230107,20230107,EXP,,GB-Accord-294807,ACCORD,"Rashid A, Movio G, Lee GC. Nicorandil and ranolazine overdose management. BMJ Case Rep. 2022 Dec 23;15(12):e245834.",7.0,DEC,E,M,Y,,,20230107,,HP,GB,GB,2023,Q1,Child
218335511,21833551,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q1,Toxicity to various agents,,2023,Q1,1,I,,20221225.0,20230107,20230107,EXP,,GB-Accord-294807,ACCORD,"Rashid A, Movio G, Lee GC. Nicorandil and ranolazine overdose management. BMJ Case Rep. 2022 Dec 23;15(12):e245834.",7.0,DEC,E,M,Y,,,20230107,,HP,GB,GB,2023,Q1,Child
218335511,21833551,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q1,Suicidal ideation,,2023,Q1,1,I,,20221225.0,20230107,20230107,EXP,,GB-Accord-294807,ACCORD,"Rashid A, Movio G, Lee GC. Nicorandil and ranolazine overdose management. BMJ Case Rep. 2022 Dec 23;15(12):e245834.",7.0,DEC,E,M,Y,,,20230107,,HP,GB,GB,2023,Q1,Child
218335521,21833552,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q1,Dizziness,,2023,Q1,1,I,,20221225.0,20230107,20230107,EXP,,GB-MankindUS-000046,MANKIND PHARMA,"Rashid A, Movio G, Lee GC. Nicorandil and ranolazine overdose management. BMJ Case Rep. 2022 Dec 23;15(12):e245834.",7.0,DEC,E,M,Y,,,20230107,,HP,GB,GB,2023,Q1,Child
218335521,21833552,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q1,Intentional overdose,,2023,Q1,1,I,,20221225.0,20230107,20230107,EXP,,GB-MankindUS-000046,MANKIND PHARMA,"Rashid A, Movio G, Lee GC. Nicorandil and ranolazine overdose management. BMJ Case Rep. 2022 Dec 23;15(12):e245834.",7.0,DEC,E,M,Y,,,20230107,,HP,GB,GB,2023,Q1,Child
218335521,21833552,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q1,Shock,,2023,Q1,1,I,,20221225.0,20230107,20230107,EXP,,GB-MankindUS-000046,MANKIND PHARMA,"Rashid A, Movio G, Lee GC. Nicorandil and ranolazine overdose management. BMJ Case Rep. 2022 Dec 23;15(12):e245834.",7.0,DEC,E,M,Y,,,20230107,,HP,GB,GB,2023,Q1,Child
218335521,21833552,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q1,Toxicity to various agents,,2023,Q1,1,I,,20221225.0,20230107,20230107,EXP,,GB-MankindUS-000046,MANKIND PHARMA,"Rashid A, Movio G, Lee GC. Nicorandil and ranolazine overdose management. BMJ Case Rep. 2022 Dec 23;15(12):e245834.",7.0,DEC,E,M,Y,,,20230107,,HP,GB,GB,2023,Q1,Child
218335521,21833552,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q1,Ventricular fibrillation,,2023,Q1,1,I,,20221225.0,20230107,20230107,EXP,,GB-MankindUS-000046,MANKIND PHARMA,"Rashid A, Movio G, Lee GC. Nicorandil and ranolazine overdose management. BMJ Case Rep. 2022 Dec 23;15(12):e245834.",7.0,DEC,E,M,Y,,,20230107,,HP,GB,GB,2023,Q1,Child
218335521,21833552,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q1,Suicidal ideation,,2023,Q1,1,I,,20221225.0,20230107,20230107,EXP,,GB-MankindUS-000046,MANKIND PHARMA,"Rashid A, Movio G, Lee GC. Nicorandil and ranolazine overdose management. BMJ Case Rep. 2022 Dec 23;15(12):e245834.",7.0,DEC,E,M,Y,,,20230107,,HP,GB,GB,2023,Q1,Child
218335521,21833552,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q1,Cardiac arrest,,2023,Q1,1,I,,20221225.0,20230107,20230107,EXP,,GB-MankindUS-000046,MANKIND PHARMA,"Rashid A, Movio G, Lee GC. Nicorandil and ranolazine overdose management. BMJ Case Rep. 2022 Dec 23;15(12):e245834.",7.0,DEC,E,M,Y,,,20230107,,HP,GB,GB,2023,Q1,Child
218335521,21833552,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q1,Hypotension,,2023,Q1,1,I,,20221225.0,20230107,20230107,EXP,,GB-MankindUS-000046,MANKIND PHARMA,"Rashid A, Movio G, Lee GC. Nicorandil and ranolazine overdose management. BMJ Case Rep. 2022 Dec 23;15(12):e245834.",7.0,DEC,E,M,Y,,,20230107,,HP,GB,GB,2023,Q1,Child
218358801,21835880,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2023,Q1,Gait disturbance,,2023,Q1,1,I,,20221226.0,20230109,20230109,EXP,,AU-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-371972,RANBAXY,"Reimann F, Whyte I. Chronic lithium toxicity. Aust Prescr. 2022;45(3):93-94",66.0,YR,,M,Y,,,20230109,,HP,AU,AU,2023,Q1,Elderly
218358801,21835880,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2023,Q1,Metabolic acidosis,,2023,Q1,1,I,,20221226.0,20230109,20230109,EXP,,AU-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-371972,RANBAXY,"Reimann F, Whyte I. Chronic lithium toxicity. Aust Prescr. 2022;45(3):93-94",66.0,YR,,M,Y,,,20230109,,HP,AU,AU,2023,Q1,Elderly
218358801,21835880,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2023,Q1,Muscle twitching,,2023,Q1,1,I,,20221226.0,20230109,20230109,EXP,,AU-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-371972,RANBAXY,"Reimann F, Whyte I. Chronic lithium toxicity. Aust Prescr. 2022;45(3):93-94",66.0,YR,,M,Y,,,20230109,,HP,AU,AU,2023,Q1,Elderly
218358801,21835880,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2023,Q1,Tremor,,2023,Q1,1,I,,20221226.0,20230109,20230109,EXP,,AU-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-371972,RANBAXY,"Reimann F, Whyte I. Chronic lithium toxicity. Aust Prescr. 2022;45(3):93-94",66.0,YR,,M,Y,,,20230109,,HP,AU,AU,2023,Q1,Elderly
218358801,21835880,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2023,Q1,Hypovolaemia,,2023,Q1,1,I,,20221226.0,20230109,20230109,EXP,,AU-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-371972,RANBAXY,"Reimann F, Whyte I. Chronic lithium toxicity. Aust Prescr. 2022;45(3):93-94",66.0,YR,,M,Y,,,20230109,,HP,AU,AU,2023,Q1,Elderly
218358801,21835880,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2023,Q1,Acute kidney injury,,2023,Q1,1,I,,20221226.0,20230109,20230109,EXP,,AU-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-371972,RANBAXY,"Reimann F, Whyte I. Chronic lithium toxicity. Aust Prescr. 2022;45(3):93-94",66.0,YR,,M,Y,,,20230109,,HP,AU,AU,2023,Q1,Elderly
218358801,21835880,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2023,Q1,Myoclonus,,2023,Q1,1,I,,20221226.0,20230109,20230109,EXP,,AU-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-371972,RANBAXY,"Reimann F, Whyte I. Chronic lithium toxicity. Aust Prescr. 2022;45(3):93-94",66.0,YR,,M,Y,,,20230109,,HP,AU,AU,2023,Q1,Elderly
218358801,21835880,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2023,Q1,Neurotoxicity,,2023,Q1,1,I,,20221226.0,20230109,20230109,EXP,,AU-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-371972,RANBAXY,"Reimann F, Whyte I. Chronic lithium toxicity. Aust Prescr. 2022;45(3):93-94",66.0,YR,,M,Y,,,20230109,,HP,AU,AU,2023,Q1,Elderly
218358801,21835880,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2023,Q1,Diarrhoea,,2023,Q1,1,I,,20221226.0,20230109,20230109,EXP,,AU-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-371972,RANBAXY,"Reimann F, Whyte I. Chronic lithium toxicity. Aust Prescr. 2022;45(3):93-94",66.0,YR,,M,Y,,,20230109,,HP,AU,AU,2023,Q1,Elderly
218358801,21835880,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2023,Q1,Confusional state,,2023,Q1,1,I,,20221226.0,20230109,20230109,EXP,,AU-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-371972,RANBAXY,"Reimann F, Whyte I. Chronic lithium toxicity. Aust Prescr. 2022;45(3):93-94",66.0,YR,,M,Y,,,20230109,,HP,AU,AU,2023,Q1,Elderly
218358801,21835880,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2023,Q1,Hyperreflexia,,2023,Q1,1,I,,20221226.0,20230109,20230109,EXP,,AU-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-371972,RANBAXY,"Reimann F, Whyte I. Chronic lithium toxicity. Aust Prescr. 2022;45(3):93-94",66.0,YR,,M,Y,,,20230109,,HP,AU,AU,2023,Q1,Elderly
218358801,21835880,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2023,Q1,Toxicity to various agents,,2023,Q1,1,I,,20221226.0,20230109,20230109,EXP,,AU-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-371972,RANBAXY,"Reimann F, Whyte I. Chronic lithium toxicity. Aust Prescr. 2022;45(3):93-94",66.0,YR,,M,Y,,,20230109,,HP,AU,AU,2023,Q1,Elderly
218364061,21836406,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q1,Cardiac arrest,,2023,Q1,1,I,,20221229.0,20230109,20230109,EXP,,GB-SCIEGENP-2023SCLIT00004,SCIEGEN,"Rashid A, et al..Nicorandil and ranolazine overdose management.BMJ Case Rep.2022;15:1-4",7.0,DEC,,M,Y,,,20230109,,MD,GB,GB,2023,Q1,Child
218364061,21836406,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q1,Intentional overdose,,2023,Q1,1,I,,20221229.0,20230109,20230109,EXP,,GB-SCIEGENP-2023SCLIT00004,SCIEGEN,"Rashid A, et al..Nicorandil and ranolazine overdose management.BMJ Case Rep.2022;15:1-4",7.0,DEC,,M,Y,,,20230109,,MD,GB,GB,2023,Q1,Child
218378721,21837872,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,U,,,,,25.0,MG,UNK,QD,2023,Q1,Diabetes mellitus inadequate control,,2023,Q1,1,I,,20230103.0,20230109,20230109,EXP,,LB-TAKEDA-2023TUS001948,TAKEDA,"Saliby R, Nakhoul. General characteristics of a Lebanese cluster of patients with Berardinelli-Seip syndrome. Endocrine Practice. 28(12):S49",27.0,YR,,F,Y,,,20230109,,HP,LB,LB,2023,Q1,Young Adult
218380771,21838077,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Haemodialysis,,2023,Q1,1,I,20221206.0,,20230107,20230107,DIR,643825,,FDA-CTU,,81.0,YR,,F,N,96.3,KG,20230107,N,MD,US,,2023,Q1,Elderly
218380771,21838077,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Hypotension,,2023,Q1,1,I,20221206.0,,20230107,20230107,DIR,643825,,FDA-CTU,,81.0,YR,,F,N,96.3,KG,20230107,N,MD,US,,2023,Q1,Elderly
218380771,21838077,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Lethargy,,2023,Q1,1,I,20221206.0,,20230107,20230107,DIR,643825,,FDA-CTU,,81.0,YR,,F,N,96.3,KG,20230107,N,MD,US,,2023,Q1,Elderly
218380771,21838077,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Cold sweat,,2023,Q1,1,I,20221206.0,,20230107,20230107,DIR,643825,,FDA-CTU,,81.0,YR,,F,N,96.3,KG,20230107,N,MD,US,,2023,Q1,Elderly
218380771,21838077,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Blood creatinine increased,,2023,Q1,1,I,20221206.0,,20230107,20230107,DIR,643825,,FDA-CTU,,81.0,YR,,F,N,96.3,KG,20230107,N,MD,US,,2023,Q1,Elderly
218380771,21838077,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Blood lactic acid increased,,2023,Q1,1,I,20221206.0,,20230107,20230107,DIR,643825,,FDA-CTU,,81.0,YR,,F,N,96.3,KG,20230107,N,MD,US,,2023,Q1,Elderly
218389921,21838992,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Frequency : Daily;?,,,,,,,,10.0,MG,,QD,2023,Q1,Escherichia bacteraemia,,2023,Q1,1,I,20221020.0,,20230108,20230108,DIR,FDA-CDER-CTU-2023-2074,,FDA-CTU,,84.0,YR,,M,N,,,20230102,N,PH,US,,2023,Q1,Elderly
218389921,21838992,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Frequency : Daily;?,,,,,,,,10.0,MG,,QD,2023,Q1,Ejection fraction decreased,,2023,Q1,1,I,20221020.0,,20230108,20230108,DIR,FDA-CDER-CTU-2023-2074,,FDA-CTU,,84.0,YR,,M,N,,,20230102,N,PH,US,,2023,Q1,Elderly
218389921,21838992,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Frequency : Daily;?,,,,,,,,10.0,MG,,QD,2023,Q1,Confusional state,,2023,Q1,1,I,20221020.0,,20230108,20230108,DIR,FDA-CDER-CTU-2023-2074,,FDA-CTU,,84.0,YR,,M,N,,,20230102,N,PH,US,,2023,Q1,Elderly
218389921,21838992,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Frequency : Daily;?,,,,,,,,10.0,MG,,QD,2023,Q1,Enterobacter bacteraemia,,2023,Q1,1,I,20221020.0,,20230108,20230108,DIR,FDA-CDER-CTU-2023-2074,,FDA-CTU,,84.0,YR,,M,N,,,20230102,N,PH,US,,2023,Q1,Elderly
218389921,21838992,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Frequency : Daily;?,,,,,,,,10.0,MG,,QD,2023,Q1,Toxic encephalopathy,,2023,Q1,1,I,20221020.0,,20230108,20230108,DIR,FDA-CDER-CTU-2023-2074,,FDA-CTU,,84.0,YR,,M,N,,,20230102,N,PH,US,,2023,Q1,Elderly
218389921,21838992,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Frequency : Daily;?,,,,,,,,10.0,MG,,QD,2023,Q1,Acute kidney injury,,2023,Q1,1,I,20221020.0,,20230108,20230108,DIR,FDA-CDER-CTU-2023-2074,,FDA-CTU,,84.0,YR,,M,N,,,20230102,N,PH,US,,2023,Q1,Elderly
218389921,21838992,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Frequency : Daily;?,,,,,,,,10.0,MG,,QD,2023,Q1,Pyrexia,,2023,Q1,1,I,20221020.0,,20230108,20230108,DIR,FDA-CDER-CTU-2023-2074,,FDA-CTU,,84.0,YR,,M,N,,,20230102,N,PH,US,,2023,Q1,Elderly
218389921,21838992,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Frequency : Daily;?,,,,,,,,10.0,MG,,QD,2023,Q1,Tremor,,2023,Q1,1,I,20221020.0,,20230108,20230108,DIR,FDA-CDER-CTU-2023-2074,,FDA-CTU,,84.0,YR,,M,N,,,20230102,N,PH,US,,2023,Q1,Elderly
218389921,21838992,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Frequency : Daily;?,,,,,,,,10.0,MG,,QD,2023,Q1,Urinary tract infection,,2023,Q1,1,I,20221020.0,,20230108,20230108,DIR,FDA-CDER-CTU-2023-2074,,FDA-CTU,,84.0,YR,,M,N,,,20230102,N,PH,US,,2023,Q1,Elderly
218389921,21838992,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Frequency : Daily;?,,,,,,,,10.0,MG,,QD,2023,Q1,Syncope,,2023,Q1,1,I,20221020.0,,20230108,20230108,DIR,FDA-CDER-CTU-2023-2074,,FDA-CTU,,84.0,YR,,M,N,,,20230102,N,PH,US,,2023,Q1,Elderly
218389931,21838993,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,Frequency : Daily;?,,,D,D,,,,25.0,MG,,QD,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,1,I,20221101.0,,20230108,20230108,DIR,FDA-CDER-CTU-2023-2099,,FDA-CTU,,52.0,YR,,F,N,,,20221202,N,PH,US,,2023,Q1,Adult
218389941,21838994,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,12.5,MG,,QD,2023,Q1,Skin ulcer,,2023,Q1,1,I,20220929.0,,20230108,20230108,DIR,FDA-CDER-CTU-2023-2105,,FDA-CTU,,54.0,YR,,M,N,106.0,KG,20221119,N,PH,US,,2023,Q1,Adult
218389941,21838994,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,12.5,MG,,QD,2023,Q1,Infection,,2023,Q1,1,I,20220929.0,,20230108,20230108,DIR,FDA-CDER-CTU-2023-2105,,FDA-CTU,,54.0,YR,,M,N,106.0,KG,20221119,N,PH,US,,2023,Q1,Adult
218389941,21838994,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,12.5,MG,,QD,2023,Q1,Amputation,,2023,Q1,1,I,20220929.0,,20230108,20230108,DIR,FDA-CDER-CTU-2023-2105,,FDA-CTU,,54.0,YR,,M,N,106.0,KG,20221119,N,PH,US,,2023,Q1,Adult
218389941,21838994,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,12.5,MG,,QD,2023,Q1,Pain in extremity,,2023,Q1,1,I,20220929.0,,20230108,20230108,DIR,FDA-CDER-CTU-2023-2105,,FDA-CTU,,54.0,YR,,M,N,106.0,KG,20221119,N,PH,US,,2023,Q1,Adult
218389951,21838995,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,12.5,MG,,QD,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,1,I,20221111.0,,20230108,20230108,DIR,FDA-CDER-CTU-2023-2082,,FDA-CTU,,70.0,YR,,M,N,85.0,KG,20221227,N,PH,US,,2023,Q1,Elderly
218390421,21839042,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,N,D,,,,,,,QD,2023,Q1,Anion gap abnormal,,2023,Q1,1,I,20220915.0,,20230108,20230108,DIR,FDA-CDER-CTU-2023-2104,,FDA-CTU,,63.0,YR,,M,N,13.0,KG,20221119,N,PH,US,,2023,Q1,Adult
218390421,21839042,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,N,D,,,,,,,QD,2023,Q1,Blood lactic acid increased,,2023,Q1,1,I,20220915.0,,20230108,20230108,DIR,FDA-CDER-CTU-2023-2104,,FDA-CTU,,63.0,YR,,M,N,13.0,KG,20221119,N,PH,US,,2023,Q1,Adult
218390421,21839042,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,N,D,,,,,,,QD,2023,Q1,Drug level abnormal,,2023,Q1,1,I,20220915.0,,20230108,20230108,DIR,FDA-CDER-CTU-2023-2104,,FDA-CTU,,63.0,YR,,M,N,13.0,KG,20221119,N,PH,US,,2023,Q1,Adult
218390421,21839042,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,N,D,,,,,,,QD,2023,Q1,Urine ketone body absent,,2023,Q1,1,I,20220915.0,,20230108,20230108,DIR,FDA-CDER-CTU-2023-2104,,FDA-CTU,,63.0,YR,,M,N,13.0,KG,20221119,N,PH,US,,2023,Q1,Adult
218390421,21839042,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,N,D,,,,,,,QD,2023,Q1,Refusal of treatment by patient,,2023,Q1,1,I,20220915.0,,20230108,20230108,DIR,FDA-CDER-CTU-2023-2104,,FDA-CTU,,63.0,YR,,M,N,13.0,KG,20221119,N,PH,US,,2023,Q1,Adult
218392441,21839244,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,D,,,,,,,,2023,Q1,Appendicitis,,2023,Q1,1,I,20221013.0,,20230107,20230107,DIR,FDA-CDER-CTU-2023-2022,,FDA-CTU,,47.0,YR,,F,N,73.0,KG,20221128,N,PH,US,,2023,Q1,Adult
218392441,21839244,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,D,,,,,,,,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,1,I,20221013.0,,20230107,20230107,DIR,FDA-CDER-CTU-2023-2022,,FDA-CTU,,47.0,YR,,F,N,73.0,KG,20221128,N,PH,US,,2023,Q1,Adult
218392451,21839245,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,D,,,,25.0,MG,,QD,2023,Q1,Burning sensation,,2023,Q1,1,I,20201116.0,,20230107,20230107,DIR,FDA-CDER-CTU-2023-2052,,FDA-CTU,,49.0,YR,,M,N,128.0,KG,20201125,N,PH,US,,2023,Q1,Adult
218392451,21839245,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,D,,,,25.0,MG,,QD,2023,Q1,Candida infection,,2023,Q1,1,I,20201116.0,,20230107,20230107,DIR,FDA-CDER-CTU-2023-2052,,FDA-CTU,,49.0,YR,,M,N,128.0,KG,20201125,N,PH,US,,2023,Q1,Adult
218392451,21839245,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,D,,,,25.0,MG,,QD,2023,Q1,Penile dermatitis,,2023,Q1,1,I,20201116.0,,20230107,20230107,DIR,FDA-CDER-CTU-2023-2052,,FDA-CTU,,49.0,YR,,M,N,128.0,KG,20201125,N,PH,US,,2023,Q1,Adult
218397481,21839748,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,Unknown,,204629.0,,,,,2023,Q1,Adverse drug reaction,,2023,Q1,1,I,20230108.0,20230109.0,20230109,20230109,EXP,GB-MHRA-TPP21160616C7050794YC1673195848246,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-211625",BOEHRINGER INGELHEIM,,43.0,YR,A,M,Y,83.0,KG,20230110,,HP,GB,GB,2023,Q1,Adult
218397481,21839748,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one daily,,,,,,,,,,,QD,2023,Q1,Adverse drug reaction,,2023,Q1,1,I,20230108.0,20230109.0,20230109,20230109,EXP,GB-MHRA-TPP21160616C7050794YC1673195848246,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-211625",BOEHRINGER INGELHEIM,,43.0,YR,A,M,Y,83.0,KG,20230110,,HP,GB,GB,2023,Q1,Adult
218406811,21840681,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2023,Q1,Cardiac arrest,,2023,Q1,1,I,,20221226.0,20230110,20230110,EXP,,GB-ALKEM LABORATORIES LIMITED-GB-ALKEM-2022-15039,ALKEM,"Rashid A, Movio G, Lee GC.. Nicorandil and ranolazine overdose management. BMJ Case Rep.. 2022;15:e245834",7.0,DEC,,M,Y,,,20230110,,HP,GB,GB,2023,Q1,Child
218406811,21840681,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2023,Q1,Suicidal ideation,,2023,Q1,1,I,,20221226.0,20230110,20230110,EXP,,GB-ALKEM LABORATORIES LIMITED-GB-ALKEM-2022-15039,ALKEM,"Rashid A, Movio G, Lee GC.. Nicorandil and ranolazine overdose management. BMJ Case Rep.. 2022;15:e245834",7.0,DEC,,M,Y,,,20230110,,HP,GB,GB,2023,Q1,Child
218406811,21840681,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2023,Q1,Overdose,,2023,Q1,1,I,,20221226.0,20230110,20230110,EXP,,GB-ALKEM LABORATORIES LIMITED-GB-ALKEM-2022-15039,ALKEM,"Rashid A, Movio G, Lee GC.. Nicorandil and ranolazine overdose management. BMJ Case Rep.. 2022;15:e245834",7.0,DEC,,M,Y,,,20230110,,HP,GB,GB,2023,Q1,Child
218406811,21840681,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2023,Q1,Hypotension,,2023,Q1,1,I,,20221226.0,20230110,20230110,EXP,,GB-ALKEM LABORATORIES LIMITED-GB-ALKEM-2022-15039,ALKEM,"Rashid A, Movio G, Lee GC.. Nicorandil and ranolazine overdose management. BMJ Case Rep.. 2022;15:e245834",7.0,DEC,,M,Y,,,20230110,,HP,GB,GB,2023,Q1,Child
218406811,21840681,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2023,Q1,Ventricular fibrillation,,2023,Q1,1,I,,20221226.0,20230110,20230110,EXP,,GB-ALKEM LABORATORIES LIMITED-GB-ALKEM-2022-15039,ALKEM,"Rashid A, Movio G, Lee GC.. Nicorandil and ranolazine overdose management. BMJ Case Rep.. 2022;15:e245834",7.0,DEC,,M,Y,,,20230110,,HP,GB,GB,2023,Q1,Child
218413551,21841355,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,E23835,20250201.0,,12.5,MG,,QD,2023,Q1,Urinary incontinence,,2023,Q1,1,I,20221027.0,,20230107,20230107,DIR,FDA-CDER-CTU-2023-2018,,FDA-CTU,,76.0,YR,,M,N,88.45,KG,20221215,N,PH,US,,2023,Q1,Elderly
218415382,21841538,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, QD",,,U,,,,,,,,QD,2023,Q1,Lip swelling,,2023,Q1,2,F,,20230126.0,20230110,20230201,EXP,GB-MHRA-TPP3802735C5197357YC1673007917180,NVSC2023GB003764,NOVARTIS,,80.0,YR,,M,Y,92.0,KG,20230201,,MD,GB,GB,2023,Q1,Elderly
218417881,21841788,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,Y,,,,,25.0,MG,,QD,2023,Q1,Decreased appetite,,2023,Q1,1,I,,20221228.0,20230110,20230110,EXP,,PT-AUROBINDO-AUR-APL-2022-057781,AUROBINDO,"Rodrigues S, Esteves VL.. Euglycemic ketoacidosis in an elderly patient on empagliflozin and metformin. Revista Portuguesa de Diabetes. 2022;17(Suppl 1):74",82.0,YR,,F,Y,,,20230110,,MD,PT,PT,2023,Q1,Elderly
218417881,21841788,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,Y,,,,,25.0,MG,,QD,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,1,I,,20221228.0,20230110,20230110,EXP,,PT-AUROBINDO-AUR-APL-2022-057781,AUROBINDO,"Rodrigues S, Esteves VL.. Euglycemic ketoacidosis in an elderly patient on empagliflozin and metformin. Revista Portuguesa de Diabetes. 2022;17(Suppl 1):74",82.0,YR,,F,Y,,,20230110,,MD,PT,PT,2023,Q1,Elderly
218435241,21843524,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,D,,,,,,,,2023,Q1,Limb amputation,,2023,Q1,1,I,20221214.0,,20230109,20230109,DIR,643908,,FDA-CTU,,59.0,YR,,M,N,,,20230109,N,PH,US,,2023,Q1,Adult
218435241,21843524,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,D,,,,,,,,2023,Q1,Wound,,2023,Q1,1,I,20221214.0,,20230109,20230109,DIR,643908,,FDA-CTU,,59.0,YR,,M,N,,,20230109,N,PH,US,,2023,Q1,Adult
218435241,21843524,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,D,,,,,,,,2023,Q1,Diabetes mellitus inadequate control,,2023,Q1,1,I,20221214.0,,20230109,20230109,DIR,643908,,FDA-CTU,,59.0,YR,,M,N,,,20230109,N,PH,US,,2023,Q1,Adult
218435241,21843524,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,D,,,,,,,,2023,Q1,Diabetic foot,,2023,Q1,1,I,20221214.0,,20230109,20230109,DIR,643908,,FDA-CTU,,59.0,YR,,M,N,,,20230109,N,PH,US,,2023,Q1,Adult
218435241,21843524,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,D,,,,,,,,2023,Q1,Peroneal nerve palsy,,2023,Q1,1,I,20221214.0,,20230109,20230109,DIR,643908,,FDA-CTU,,59.0,YR,,M,N,,,20230109,N,PH,US,,2023,Q1,Adult
218435241,21843524,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,D,,,,,,,,2023,Q1,Gas gangrene,,2023,Q1,1,I,20221214.0,,20230109,20230109,DIR,643908,,FDA-CTU,,59.0,YR,,M,N,,,20230109,N,PH,US,,2023,Q1,Adult
218435241,21843524,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,D,,,,,,,,2023,Q1,Sepsis,,2023,Q1,1,I,20221214.0,,20230109,20230109,DIR,643908,,FDA-CTU,,59.0,YR,,M,N,,,20230109,N,PH,US,,2023,Q1,Adult
218453191,21845319,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q1,Dizziness,,2023,Q1,1,I,20220825.0,20230110.0,20230110,20230110,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-211756",BOEHRINGER INGELHEIM,,68.0,YR,E,F,Y,,,20230111,,HP,SG,SG,2023,Q1,Elderly
218469461,21846946,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,12.5,MG,,QD,2023,Q1,Colitis,,2023,Q1,1,I,20221004.0,,20230110,20230110,DIR,FDA-CDER-CTU-2023-2485,,FDA-CTU,,42.0,YR,,M,N,79.0,KG,20221215,N,PH,US,,2023,Q1,Adult
218469461,21846946,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,12.5,MG,,QD,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,1,I,20221004.0,,20230110,20230110,DIR,FDA-CDER-CTU-2023-2485,,FDA-CTU,,42.0,YR,,M,N,79.0,KG,20221215,N,PH,US,,2023,Q1,Adult
218469491,21846949,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : 3 times a day;?,,,D,D,,,,12.5,MG,,TID,2023,Q1,Pyrexia,,2023,Q1,1,I,20220901.0,,20230110,20230110,DIR,FDA-CDER-CTU-2023-2491,,FDA-CTU,,43.0,YR,,,N,93.0,KG,20221215,N,HP,US,,2023,Q1,Adult
218469491,21846949,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : 3 times a day;?,,,D,D,,,,12.5,MG,,TID,2023,Q1,Abdominal discomfort,,2023,Q1,1,I,20220901.0,,20230110,20230110,DIR,FDA-CDER-CTU-2023-2491,,FDA-CTU,,43.0,YR,,,N,93.0,KG,20221215,N,HP,US,,2023,Q1,Adult
218476391,21847639,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,,,,,12.5,MG,,QD,2023,Q1,Anal incontinence,,2023,Q1,1,I,20210902.0,,20230110,20230110,DIR,FDA-CDER-CTU-2023-2505,,FDA-CTU,,72.0,YR,,M,N,,,20220530,N,PH,US,,2023,Q1,Elderly
218476391,21847639,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,,,,,12.5,MG,,QD,2023,Q1,Urinary incontinence,,2023,Q1,1,I,20210902.0,,20230110,20230110,DIR,FDA-CDER-CTU-2023-2505,,FDA-CTU,,72.0,YR,,M,N,,,20220530,N,PH,US,,2023,Q1,Elderly
218476391,21847639,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,,,,,12.5,MG,,QD,2023,Q1,Sepsis,,2023,Q1,1,I,20210902.0,,20230110,20230110,DIR,FDA-CDER-CTU-2023-2505,,FDA-CTU,,72.0,YR,,M,N,,,20220530,N,PH,US,,2023,Q1,Elderly
218476391,21847639,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,,,,,12.5,MG,,QD,2023,Q1,Urinary tract infection,,2023,Q1,1,I,20210902.0,,20230110,20230110,DIR,FDA-CDER-CTU-2023-2505,,FDA-CTU,,72.0,YR,,M,N,,,20220530,N,PH,US,,2023,Q1,Elderly
218476391,21847639,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,,,,,12.5,MG,,QD,2023,Q1,Dizziness,,2023,Q1,1,I,20210902.0,,20230110,20230110,DIR,FDA-CDER-CTU-2023-2505,,FDA-CTU,,72.0,YR,,M,N,,,20220530,N,PH,US,,2023,Q1,Elderly
218476391,21847639,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,,,,,12.5,MG,,QD,2023,Q1,Chills,,2023,Q1,1,I,20210902.0,,20230110,20230110,DIR,FDA-CDER-CTU-2023-2505,,FDA-CTU,,72.0,YR,,M,N,,,20220530,N,PH,US,,2023,Q1,Elderly
218476391,21847639,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,,,,,12.5,MG,,QD,2023,Q1,Staphylococcal bacteraemia,,2023,Q1,1,I,20210902.0,,20230110,20230110,DIR,FDA-CDER-CTU-2023-2505,,FDA-CTU,,72.0,YR,,M,N,,,20220530,N,PH,US,,2023,Q1,Elderly
218476391,21847639,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,,,,,12.5,MG,,QD,2023,Q1,Asthenia,,2023,Q1,1,I,20210902.0,,20230110,20230110,DIR,FDA-CDER-CTU-2023-2505,,FDA-CTU,,72.0,YR,,M,N,,,20220530,N,PH,US,,2023,Q1,Elderly
218542092,21854209,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 Milligram Daily; Once a day,,,Y,,,,,5.0,MG,,QD,2023,Q1,Drug ineffective,,2023,Q1,2,F,,20230118.0,20230112,20230123,EXP,,CA-TEVA-2023-CA-2843171,TEVA,,61.0,YR,A,M,Y,,,20230123,,MD,CA,CA,2023,Q1,Adult
218542092,21854209,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 Milligram Daily; Once a day,,,Y,,,,,5.0,MG,,QD,2023,Q1,Drug eruption,,2023,Q1,2,F,,20230118.0,20230112,20230123,EXP,,CA-TEVA-2023-CA-2843171,TEVA,,61.0,YR,A,M,Y,,,20230123,,MD,CA,CA,2023,Q1,Adult
218542092,21854209,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 Milligram Daily; Once a day,,,Y,,,,,10.0,MG,,QD,2023,Q1,Drug ineffective,,2023,Q1,2,F,,20230118.0,20230112,20230123,EXP,,CA-TEVA-2023-CA-2843171,TEVA,,61.0,YR,A,M,Y,,,20230123,,MD,CA,CA,2023,Q1,Adult
218542092,21854209,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 Milligram Daily; Once a day,,,Y,,,,,10.0,MG,,QD,2023,Q1,Drug eruption,,2023,Q1,2,F,,20230118.0,20230112,20230123,EXP,,CA-TEVA-2023-CA-2843171,TEVA,,61.0,YR,A,M,Y,,,20230123,,MD,CA,CA,2023,Q1,Adult
218548111,21854811,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,Y,D62117,20240531.0,,25.0,MG,Tablet,QD,2023,Q1,Diarrhoea,,2023,Q1,1,I,20220516.0,,20230112,20230112,DIR,FDA-CDER-CTU-2023-3272,,FDA-CTU,,64.0,YR,,M,N,70.76,KG,20221215,N,PH,US,,2023,Q1,Adult
218548111,21854811,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,Y,D62117,20240531.0,,25.0,MG,Tablet,QD,2023,Q1,Diabetic ketoacidosis,,2023,Q1,1,I,20220516.0,,20230112,20230112,DIR,FDA-CDER-CTU-2023-3272,,FDA-CTU,,64.0,YR,,M,N,70.76,KG,20221215,N,PH,US,,2023,Q1,Adult
218548111,21854811,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,Y,D62117,20240531.0,,25.0,MG,Tablet,QD,2023,Q1,Sepsis,,2023,Q1,1,I,20220516.0,,20230112,20230112,DIR,FDA-CDER-CTU-2023-3272,,FDA-CTU,,64.0,YR,,M,N,70.76,KG,20221215,N,PH,US,,2023,Q1,Adult
218548722,21854872,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,,2023,Q1,Nasopharyngitis,,2023,Q1,2,F,20221201.0,20230112.0,20230112,20230119,PER,,US-Calliditas-2022CAL00663,CALLIDITAS THERAPEUTICS,,33.0,YR,A,M,Y,,,20230120,,CN,US,US,2023,Q1,Young Adult
218567991,21856799,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,850/12.5mg,,,U,,Unknown,,206111.0,,,,QD,2023,Q1,End stage renal disease,,2023,Q1,1,I,,20230111.0,20230113,20230113,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-212321",BOEHRINGER INGELHEIM,,69.0,YR,E,M,Y,,,20230113,,MD,IL,IL,2023,Q1,Elderly
218567991,21856799,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,850/12.5mg,,,U,,Unknown,,206111.0,,,,QD,2023,Q1,Dialysis,,2023,Q1,1,I,,20230111.0,20230113,20230113,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-212321",BOEHRINGER INGELHEIM,,69.0,YR,E,M,Y,,,20230113,,MD,IL,IL,2023,Q1,Elderly
218587042,21858704,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,take one daily,,,,,,,,,,,QD,2023,Q1,Lip swelling,,2023,Q1,2,F,20230106.0,20230126.0,20230113,20230207,EXP,GB-MHRA-TPP3802735C5197357YC1673007917180,GB-MICRO LABS LIMITED-ML2023-00174,MICRO LABS,,80.0,YR,E,M,Y,92.0,KG,20230207,,MD,GB,GB,2023,Q1,Elderly
218592131,21859213,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 days,,,,,,,,,,Tablet,,2023,Q1,Musculoskeletal stiffness,,2023,Q1,1,I,,20230104.0,20230113,20230113,EXP,CA-MHPD-E2B_05859762,CA-Accord-295284,ACCORD,,68.0,YR,E,M,Y,,,20230113,,HP,CA,CA,2023,Q1,Elderly
218592131,21859213,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 days,,,,,,,,,,Tablet,,2023,Q1,Weight decreased,,2023,Q1,1,I,,20230104.0,20230113,20230113,EXP,CA-MHPD-E2B_05859762,CA-Accord-295284,ACCORD,,68.0,YR,E,M,Y,,,20230113,,HP,CA,CA,2023,Q1,Elderly
218592131,21859213,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 days,,,,,,,,,,Tablet,,2023,Q1,Inflammation,,2023,Q1,1,I,,20230104.0,20230113,20230113,EXP,CA-MHPD-E2B_05859762,CA-Accord-295284,ACCORD,,68.0,YR,E,M,Y,,,20230113,,HP,CA,CA,2023,Q1,Elderly
218592131,21859213,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 days,,,,,,,,,,Tablet,,2023,Q1,Pain,,2023,Q1,1,I,,20230104.0,20230113,20230113,EXP,CA-MHPD-E2B_05859762,CA-Accord-295284,ACCORD,,68.0,YR,E,M,Y,,,20230113,,HP,CA,CA,2023,Q1,Elderly
218592131,21859213,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 days,,,,,,,,,,Tablet,,2023,Q1,Renal impairment,,2023,Q1,1,I,,20230104.0,20230113,20230113,EXP,CA-MHPD-E2B_05859762,CA-Accord-295284,ACCORD,,68.0,YR,E,M,Y,,,20230113,,HP,CA,CA,2023,Q1,Elderly
218592131,21859213,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 days,,,,,,,,,,Tablet,,2023,Q1,Sacroiliitis,,2023,Q1,1,I,,20230104.0,20230113,20230113,EXP,CA-MHPD-E2B_05859762,CA-Accord-295284,ACCORD,,68.0,YR,E,M,Y,,,20230113,,HP,CA,CA,2023,Q1,Elderly
218592131,21859213,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 days,,,,,,,,,,Tablet,,2023,Q1,Glomerular filtration rate decreased,,2023,Q1,1,I,,20230104.0,20230113,20230113,EXP,CA-MHPD-E2B_05859762,CA-Accord-295284,ACCORD,,68.0,YR,E,M,Y,,,20230113,,HP,CA,CA,2023,Q1,Elderly
218592131,21859213,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 days,,,,,,,,,,Tablet,,2023,Q1,C-reactive protein increased,,2023,Q1,1,I,,20230104.0,20230113,20230113,EXP,CA-MHPD-E2B_05859762,CA-Accord-295284,ACCORD,,68.0,YR,E,M,Y,,,20230113,,HP,CA,CA,2023,Q1,Elderly
218592131,21859213,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 days,,,,,,,,,,Tablet,,2023,Q1,Spinal pain,,2023,Q1,1,I,,20230104.0,20230113,20230113,EXP,CA-MHPD-E2B_05859762,CA-Accord-295284,ACCORD,,68.0,YR,E,M,Y,,,20230113,,HP,CA,CA,2023,Q1,Elderly
218622833,21862283,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Vulvovaginal mycotic infection,,2023,Q1,3,F,,20230313.0,20230114,20230320,EXP,,NVSC2023CA005723,NOVARTIS,,67.0,YR,,F,Y,,,20230320,,PH,CA,CA,2023,Q1,Elderly
218622833,21862283,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Blood pressure increased,,2023,Q1,3,F,,20230313.0,20230114,20230320,EXP,,NVSC2023CA005723,NOVARTIS,,67.0,YR,,F,Y,,,20230320,,PH,CA,CA,2023,Q1,Elderly
218622833,21862283,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Chest discomfort,,2023,Q1,3,F,,20230313.0,20230114,20230320,EXP,,NVSC2023CA005723,NOVARTIS,,67.0,YR,,F,Y,,,20230320,,PH,CA,CA,2023,Q1,Elderly
218622833,21862283,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Cardiac failure,,2023,Q1,3,F,,20230313.0,20230114,20230320,EXP,,NVSC2023CA005723,NOVARTIS,,67.0,YR,,F,Y,,,20230320,,PH,CA,CA,2023,Q1,Elderly
218622833,21862283,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Dyspnoea,,2023,Q1,3,F,,20230313.0,20230114,20230320,EXP,,NVSC2023CA005723,NOVARTIS,,67.0,YR,,F,Y,,,20230320,,PH,CA,CA,2023,Q1,Elderly
218622833,21862283,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Off label use,,2023,Q1,3,F,,20230313.0,20230114,20230320,EXP,,NVSC2023CA005723,NOVARTIS,,67.0,YR,,F,Y,,,20230320,,PH,CA,CA,2023,Q1,Elderly
218622833,21862283,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Pneumonia,,2023,Q1,3,F,,20230313.0,20230114,20230320,EXP,,NVSC2023CA005723,NOVARTIS,,67.0,YR,,F,Y,,,20230320,,PH,CA,CA,2023,Q1,Elderly
218622833,21862283,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Drug ineffective,,2023,Q1,3,F,,20230313.0,20230114,20230320,EXP,,NVSC2023CA005723,NOVARTIS,,67.0,YR,,F,Y,,,20230320,,PH,CA,CA,2023,Q1,Elderly
218622833,21862283,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Neoplasm skin,,2023,Q1,3,F,,20230313.0,20230114,20230320,EXP,,NVSC2023CA005723,NOVARTIS,,67.0,YR,,F,Y,,,20230320,,PH,CA,CA,2023,Q1,Elderly
218622833,21862283,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Fall,,2023,Q1,3,F,,20230313.0,20230114,20230320,EXP,,NVSC2023CA005723,NOVARTIS,,67.0,YR,,F,Y,,,20230320,,PH,CA,CA,2023,Q1,Elderly
218622833,21862283,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Haemorrhoids,,2023,Q1,3,F,,20230313.0,20230114,20230320,EXP,,NVSC2023CA005723,NOVARTIS,,67.0,YR,,F,Y,,,20230320,,PH,CA,CA,2023,Q1,Elderly
218622833,21862283,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Constipation,,2023,Q1,3,F,,20230313.0,20230114,20230320,EXP,,NVSC2023CA005723,NOVARTIS,,67.0,YR,,F,Y,,,20230320,,PH,CA,CA,2023,Q1,Elderly
218622833,21862283,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Abdominal pain upper,,2023,Q1,3,F,,20230313.0,20230114,20230320,EXP,,NVSC2023CA005723,NOVARTIS,,67.0,YR,,F,Y,,,20230320,,PH,CA,CA,2023,Q1,Elderly
218622833,21862283,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Neuropathy peripheral,,2023,Q1,3,F,,20230313.0,20230114,20230320,EXP,,NVSC2023CA005723,NOVARTIS,,67.0,YR,,F,Y,,,20230320,,PH,CA,CA,2023,Q1,Elderly
218622833,21862283,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Product use issue,,2023,Q1,3,F,,20230313.0,20230114,20230320,EXP,,NVSC2023CA005723,NOVARTIS,,67.0,YR,,F,Y,,,20230320,,PH,CA,CA,2023,Q1,Elderly
218622833,21862283,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Clostridium difficile colitis,,2023,Q1,3,F,,20230313.0,20230114,20230320,EXP,,NVSC2023CA005723,NOVARTIS,,67.0,YR,,F,Y,,,20230320,,PH,CA,CA,2023,Q1,Elderly
218622833,21862283,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Haemorrhoidal haemorrhage,,2023,Q1,3,F,,20230313.0,20230114,20230320,EXP,,NVSC2023CA005723,NOVARTIS,,67.0,YR,,F,Y,,,20230320,,PH,CA,CA,2023,Q1,Elderly
218622833,21862283,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,COVID-19,,2023,Q1,3,F,,20230313.0,20230114,20230320,EXP,,NVSC2023CA005723,NOVARTIS,,67.0,YR,,F,Y,,,20230320,,PH,CA,CA,2023,Q1,Elderly
218622833,21862283,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Cataract,,2023,Q1,3,F,,20230313.0,20230114,20230320,EXP,,NVSC2023CA005723,NOVARTIS,,67.0,YR,,F,Y,,,20230320,,PH,CA,CA,2023,Q1,Elderly
218622833,21862283,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Transient ischaemic attack,,2023,Q1,3,F,,20230313.0,20230114,20230320,EXP,,NVSC2023CA005723,NOVARTIS,,67.0,YR,,F,Y,,,20230320,,PH,CA,CA,2023,Q1,Elderly
218653541,21865354,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Hypotension,,2023,Q1,1,I,20221201.0,20230104.0,20230116,20230116,EXP,,GB-AUROBINDO-AUR-APL-2023-000771,AUROBINDO,,62.0,YR,,M,Y,90.0,KG,20230116,,PH,GB,GB,2023,Q1,Adult
218656491,21865649,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2023,Q1,Medication error,,2023,Q1,1,I,20221120.0,20230115.0,20230116,20230116,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-212863",BOEHRINGER INGELHEIM,,88.0,YR,E,M,Y,,,20230116,,HP,GB,GB,2023,Q1,Elderly
218656491,21865649,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2023,Q1,Diabetic ketoacidosis,,2023,Q1,1,I,20221120.0,20230115.0,20230116,20230116,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-212863",BOEHRINGER INGELHEIM,,88.0,YR,E,M,Y,,,20230116,,HP,GB,GB,2023,Q1,Elderly
218664602,21866460,5,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2023,Q1,Platelet count decreased,,2023,Q1,2,F,20221025.0,20230207.0,20230116,20230213,EXP,,JP-009507513-2301JPN001281J,MERCK,,80.0,YR,,M,Y,74.0,KG,20230213,,PH,JP,JP,2023,Q1,Elderly
218667541,21866754,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,Unknown,,206111.0,,,,,2023,Q1,Injection site pain,,2023,Q1,1,I,,20230113.0,20230116,20230116,PER,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-212788",BOEHRINGER INGELHEIM,,83.0,YR,E,M,Y,,,20230116,,CN,US,US,2023,Q1,Elderly
218667541,21866754,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,Unknown,,206111.0,,,,,2023,Q1,Weight decreased,,2023,Q1,1,I,,20230113.0,20230116,20230116,PER,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-212788",BOEHRINGER INGELHEIM,,83.0,YR,E,M,Y,,,20230116,,CN,US,US,2023,Q1,Elderly
218686151,21868615,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Electrocardiogram QT prolonged,,2023,Q1,1,I,,20230104.0,20230117,20230117,EXP,,GB-Ajanta Pharma USA Inc.-2136766,AJANTA PHARMA,"Rashid A, Movio G, Lee GC. Nicorandil and Ranolazine overdose management. British Medical Journal Case Report. 2022; 15 (12). DOI: 10.1136/bcr-2021-245834.",7.0,DEC,,M,Y,,,20230117,,HP,GB,GB,2023,Q1,Child
218686151,21868615,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Hypotension,,2023,Q1,1,I,,20230104.0,20230117,20230117,EXP,,GB-Ajanta Pharma USA Inc.-2136766,AJANTA PHARMA,"Rashid A, Movio G, Lee GC. Nicorandil and Ranolazine overdose management. British Medical Journal Case Report. 2022; 15 (12). DOI: 10.1136/bcr-2021-245834.",7.0,DEC,,M,Y,,,20230117,,HP,GB,GB,2023,Q1,Child
218686151,21868615,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Suicide attempt,,2023,Q1,1,I,,20230104.0,20230117,20230117,EXP,,GB-Ajanta Pharma USA Inc.-2136766,AJANTA PHARMA,"Rashid A, Movio G, Lee GC. Nicorandil and Ranolazine overdose management. British Medical Journal Case Report. 2022; 15 (12). DOI: 10.1136/bcr-2021-245834.",7.0,DEC,,M,Y,,,20230117,,HP,GB,GB,2023,Q1,Child
218686151,21868615,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Cardiac arrest,,2023,Q1,1,I,,20230104.0,20230117,20230117,EXP,,GB-Ajanta Pharma USA Inc.-2136766,AJANTA PHARMA,"Rashid A, Movio G, Lee GC. Nicorandil and Ranolazine overdose management. British Medical Journal Case Report. 2022; 15 (12). DOI: 10.1136/bcr-2021-245834.",7.0,DEC,,M,Y,,,20230117,,HP,GB,GB,2023,Q1,Child
218686151,21868615,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Intentional overdose,,2023,Q1,1,I,,20230104.0,20230117,20230117,EXP,,GB-Ajanta Pharma USA Inc.-2136766,AJANTA PHARMA,"Rashid A, Movio G, Lee GC. Nicorandil and Ranolazine overdose management. British Medical Journal Case Report. 2022; 15 (12). DOI: 10.1136/bcr-2021-245834.",7.0,DEC,,M,Y,,,20230117,,HP,GB,GB,2023,Q1,Child
218720741,21872074,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,U,U,,,,25.0,MG,,QD,2023,Q1,Diabetic metabolic decompensation,,2023,Q1,1,I,,20230109.0,20230117,20230117,EXP,,SK-MYLANLABS-2023M1002694,MYLAN,Martinka E. et al. The status of SGLT2 inhibitors in the current EASD/ADA 2022 therapeutic recommendations for the treatment of type 2 diabetes mellitus and their use in practice: case reports and commentary. Forum diabetologicum. 2022;11(3):165-170,65.0,YR,,F,Y,,,20230117,,MD,SK,SK,2023,Q1,Elderly
218721301,21872130,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,D,,,,25.0,MG,Tablet,,2023,Q1,Drug screen positive,,2023,Q1,1,I,20221225.0,,20230113,20230113,DIR,FDA-CDER-CTU-2023-3631,,FDA-CTU,,66.0,YR,,F,N,,,20230110,N,PH,US,,2023,Q1,Elderly
218721301,21872130,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,D,,,,25.0,MG,Tablet,,2023,Q1,Respiratory failure,,2023,Q1,1,I,20221225.0,,20230113,20230113,DIR,FDA-CDER-CTU-2023-3631,,FDA-CTU,,66.0,YR,,F,N,,,20230110,N,PH,US,,2023,Q1,Elderly
218721301,21872130,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,D,,,,25.0,MG,Tablet,,2023,Q1,Diabetic ketoacidosis,,2023,Q1,1,I,20221225.0,,20230113,20230113,DIR,FDA-CDER-CTU-2023-3631,,FDA-CTU,,66.0,YR,,F,N,,,20230110,N,PH,US,,2023,Q1,Elderly
218721301,21872130,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,D,,,,25.0,MG,Tablet,,2023,Q1,Substance use,,2023,Q1,1,I,20221225.0,,20230113,20230113,DIR,FDA-CDER-CTU-2023-3631,,FDA-CTU,,66.0,YR,,F,N,,,20230110,N,PH,US,,2023,Q1,Elderly
218721591,21872159,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Urinary tract infection,,2023,Q1,1,I,20221230.0,,20230113,20230113,DIR,FDA-CDER-CTU-2023-4132,,FDA-CTU,,75.0,YR,,F,N,168.0,LBS,20230113,N,,US,,2023,Q1,Elderly
218721591,21872159,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Fungal infection,,2023,Q1,1,I,20221230.0,,20230113,20230113,DIR,FDA-CDER-CTU-2023-4132,,FDA-CTU,,75.0,YR,,F,N,168.0,LBS,20230113,N,,US,,2023,Q1,Elderly
218721591,21872159,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Pneumonia,,2023,Q1,1,I,20221230.0,,20230113,20230113,DIR,FDA-CDER-CTU-2023-4132,,FDA-CTU,,75.0,YR,,F,N,168.0,LBS,20230113,N,,US,,2023,Q1,Elderly
218721591,21872159,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Intra-abdominal fluid collection,,2023,Q1,1,I,20221230.0,,20230113,20230113,DIR,FDA-CDER-CTU-2023-4132,,FDA-CTU,,75.0,YR,,F,N,168.0,LBS,20230113,N,,US,,2023,Q1,Elderly
218733081,21873308,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"12 milligram, q12h",,,Y,,,,,12.0,MG,,,2023,Q1,Hepatic encephalopathy,,2023,Q1,1,I,20220709.0,20230113.0,20230117,20230117,EXP,ES-AEMPS-1311091,ES-TAKEDA-2023TUS004924,TAKEDA,,75.0,YR,,M,Y,,,20230117,,HP,ES,ES,2023,Q1,Elderly
218733081,21873308,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"12 milligram, q12h",,,Y,,,,,12.0,MG,,,2023,Q1,Hepatocellular injury,,2023,Q1,1,I,20220709.0,20230113.0,20230117,20230117,EXP,ES-AEMPS-1311091,ES-TAKEDA-2023TUS004924,TAKEDA,,75.0,YR,,M,Y,,,20230117,,HP,ES,ES,2023,Q1,Elderly
218770981,21877098,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,in the morning,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Orthopnoea,,2023,Q1,1,I,20210101.0,20230112.0,20230118,20230118,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-212409",BOEHRINGER INGELHEIM,,75.0,YR,E,F,Y,,,20230118,,MD,SI,SI,2023,Q1,Elderly
218770981,21877098,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,in the morning,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Atrial fibrillation,,2023,Q1,1,I,20210101.0,20230112.0,20230118,20230118,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-212409",BOEHRINGER INGELHEIM,,75.0,YR,E,F,Y,,,20230118,,MD,SI,SI,2023,Q1,Elderly
218770981,21877098,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,in the morning,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Hypertension,,2023,Q1,1,I,20210101.0,20230112.0,20230118,20230118,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-212409",BOEHRINGER INGELHEIM,,75.0,YR,E,F,Y,,,20230118,,MD,SI,SI,2023,Q1,Elderly
218770981,21877098,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,in the morning,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Dyspnoea,,2023,Q1,1,I,20210101.0,20230112.0,20230118,20230118,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-212409",BOEHRINGER INGELHEIM,,75.0,YR,E,F,Y,,,20230118,,MD,SI,SI,2023,Q1,Elderly
218770981,21877098,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,in the morning,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Cardiac failure,,2023,Q1,1,I,20210101.0,20230112.0,20230118,20230118,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-212409",BOEHRINGER INGELHEIM,,75.0,YR,E,F,Y,,,20230118,,MD,SI,SI,2023,Q1,Elderly
218770981,21877098,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,in the morning,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Angina pectoris,,2023,Q1,1,I,20210101.0,20230112.0,20230118,20230118,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-212409",BOEHRINGER INGELHEIM,,75.0,YR,E,F,Y,,,20230118,,MD,SI,SI,2023,Q1,Elderly
218770981,21877098,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,in the morning,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Atrial fibrillation,,2023,Q1,1,I,20210101.0,20230112.0,20230118,20230118,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-212409",BOEHRINGER INGELHEIM,,75.0,YR,E,F,Y,,,20230118,,MD,SI,SI,2023,Q1,Elderly
218770981,21877098,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,in the morning,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Dyspnoea,,2023,Q1,1,I,20210101.0,20230112.0,20230118,20230118,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-212409",BOEHRINGER INGELHEIM,,75.0,YR,E,F,Y,,,20230118,,MD,SI,SI,2023,Q1,Elderly
218770981,21877098,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,in the morning,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Tachycardia induced cardiomyopathy,,2023,Q1,1,I,20210101.0,20230112.0,20230118,20230118,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-212409",BOEHRINGER INGELHEIM,,75.0,YR,E,F,Y,,,20230118,,MD,SI,SI,2023,Q1,Elderly
218773271,21877327,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,unknown,,204629.0,,,Tablet,QD,2023,Q1,Urinary tract infection,,2023,Q1,1,I,20220914.0,20230115.0,20230118,20230118,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-212855",BOEHRINGER INGELHEIM,,58.0,YR,A,F,Y,,,20230118,,CN,GB,GB,2023,Q1,Adult
218773271,21877327,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,unknown,,204629.0,,,Tablet,QD,2023,Q1,Medication error,,2023,Q1,1,I,20220914.0,20230115.0,20230118,20230118,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-212855",BOEHRINGER INGELHEIM,,58.0,YR,A,F,Y,,,20230118,,CN,GB,GB,2023,Q1,Adult
218773271,21877327,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,unknown,,204629.0,,,Tablet,QD,2023,Q1,Dyspnoea,,2023,Q1,1,I,20220914.0,20230115.0,20230118,20230118,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-212855",BOEHRINGER INGELHEIM,,58.0,YR,A,F,Y,,,20230118,,CN,GB,GB,2023,Q1,Adult
218773271,21877327,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,unknown,,204629.0,,,Tablet,QD,2023,Q1,Fatigue,,2023,Q1,1,I,20220914.0,20230115.0,20230118,20230118,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-212855",BOEHRINGER INGELHEIM,,58.0,YR,A,F,Y,,,20230118,,CN,GB,GB,2023,Q1,Adult
218773271,21877327,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,unknown,,204629.0,,,Tablet,QD,2023,Q1,Thirst,,2023,Q1,1,I,20220914.0,20230115.0,20230118,20230118,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-212855",BOEHRINGER INGELHEIM,,58.0,YR,A,F,Y,,,20230118,,CN,GB,GB,2023,Q1,Adult
218773271,21877327,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,unknown,,204629.0,,,Tablet,QD,2023,Q1,Bladder pain,,2023,Q1,1,I,20220914.0,20230115.0,20230118,20230118,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-212855",BOEHRINGER INGELHEIM,,58.0,YR,A,F,Y,,,20230118,,CN,GB,GB,2023,Q1,Adult
218773271,21877327,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,unknown,,204629.0,,,Tablet,QD,2023,Q1,Blood glucose decreased,,2023,Q1,1,I,20220914.0,20230115.0,20230118,20230118,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-212855",BOEHRINGER INGELHEIM,,58.0,YR,A,F,Y,,,20230118,,CN,GB,GB,2023,Q1,Adult
218773271,21877327,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,unknown,,204629.0,,,Tablet,QD,2023,Q1,Abdominal discomfort,,2023,Q1,1,I,20220914.0,20230115.0,20230118,20230118,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-212855",BOEHRINGER INGELHEIM,,58.0,YR,A,F,Y,,,20230118,,CN,GB,GB,2023,Q1,Adult
218773271,21877327,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,unknown,,204629.0,,,Tablet,QD,2023,Q1,Muscle fatigue,,2023,Q1,1,I,20220914.0,20230115.0,20230118,20230118,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-212855",BOEHRINGER INGELHEIM,,58.0,YR,A,F,Y,,,20230118,,CN,GB,GB,2023,Q1,Adult
218778901,21877890,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,25.0,MG,,QD,2023,Q1,Scrotal ulcer,,2023,Q1,1,I,20220621.0,,20230117,20230117,DIR,FDA-CDER-CTU-2023-4389,,FDA-CTU,,64.0,YR,,M,N,101.6,KG,20221021,N,PH,US,,2023,Q1,Adult
218778901,21877890,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,25.0,MG,,QD,2023,Q1,Fungal infection,,2023,Q1,1,I,20220621.0,,20230117,20230117,DIR,FDA-CDER-CTU-2023-4389,,FDA-CTU,,64.0,YR,,M,N,101.6,KG,20221021,N,PH,US,,2023,Q1,Adult
218778901,21877890,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,25.0,MG,,QD,2023,Q1,Enterococcal infection,,2023,Q1,1,I,20220621.0,,20230117,20230117,DIR,FDA-CDER-CTU-2023-4389,,FDA-CTU,,64.0,YR,,M,N,101.6,KG,20221021,N,PH,US,,2023,Q1,Adult
218778901,21877890,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,25.0,MG,,QD,2023,Q1,Scrotal cellulitis,,2023,Q1,1,I,20220621.0,,20230117,20230117,DIR,FDA-CDER-CTU-2023-4389,,FDA-CTU,,64.0,YR,,M,N,101.6,KG,20221021,N,PH,US,,2023,Q1,Adult
218780011,21878001,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,12.5,MG,,QD,2023,Q1,Cystitis,,2023,Q1,1,I,20220811.0,,20230117,20230117,DIR,FDA-CDER-CTU-2023-4393,,FDA-CTU,,63.0,YR,,M,N,93.0,KG,20221021,N,PH,US,,2023,Q1,Adult
218780011,21878001,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,12.5,MG,,QD,2023,Q1,Urosepsis,,2023,Q1,1,I,20220811.0,,20230117,20230117,DIR,FDA-CDER-CTU-2023-4393,,FDA-CTU,,63.0,YR,,M,N,93.0,KG,20221021,N,PH,US,,2023,Q1,Adult
218780011,21878001,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,12.5,MG,,QD,2023,Q1,Sepsis,,2023,Q1,1,I,20220811.0,,20230117,20230117,DIR,FDA-CDER-CTU-2023-4393,,FDA-CTU,,63.0,YR,,M,N,93.0,KG,20221021,N,PH,US,,2023,Q1,Adult
218781301,21878130,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q1,Rhonchi,,2023,Q1,1,I,20221223.0,20230117.0,20230118,20230118,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-213269",BOEHRINGER INGELHEIM,,71.0,YR,E,F,Y,,,20230118,,HP,SG,SG,2023,Q1,Elderly
218781381,21878138,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q1,Dizziness,,2023,Q1,1,I,20221101.0,20230117.0,20230118,20230118,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-213264",BOEHRINGER INGELHEIM,,71.0,YR,E,F,Y,,,20230118,,HP,SG,SG,2023,Q1,Elderly
218781381,21878138,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q1,Lethargy,,2023,Q1,1,I,20221101.0,20230117.0,20230118,20230118,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-213264",BOEHRINGER INGELHEIM,,71.0,YR,E,F,Y,,,20230118,,HP,SG,SG,2023,Q1,Elderly
218785631,21878563,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,12.5,MG,,QD,2023,Q1,Acidosis,,2023,Q1,1,I,20220909.0,,20230117,20230117,DIR,FDA-CDER-CTU-2023-4385,,FDA-CTU,,39.0,YR,,M,N,90.0,KG,20221119,N,PH,US,,2023,Q1,Adult
218785631,21878563,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,12.5,MG,,QD,2023,Q1,Glycosylated haemoglobin increased,,2023,Q1,1,I,20220909.0,,20230117,20230117,DIR,FDA-CDER-CTU-2023-4385,,FDA-CTU,,39.0,YR,,M,N,90.0,KG,20221119,N,PH,US,,2023,Q1,Adult
218785631,21878563,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,12.5,MG,,QD,2023,Q1,Therapy cessation,,2023,Q1,1,I,20220909.0,,20230117,20230117,DIR,FDA-CDER-CTU-2023-4385,,FDA-CTU,,39.0,YR,,M,N,90.0,KG,20221119,N,PH,US,,2023,Q1,Adult
218786811,21878681,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,12.5,MG,,QD,2023,Q1,Dizziness,,2023,Q1,1,I,20221222.0,,20230117,20230117,DIR,FDA-CDER-CTU-2023-4375,,FDA-CTU,,84.0,YR,,M,N,,,20230103,N,PH,US,,2023,Q1,Elderly
218786811,21878681,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,12.5,MG,,QD,2023,Q1,Dyspnoea,,2023,Q1,1,I,20221222.0,,20230117,20230117,DIR,FDA-CDER-CTU-2023-4375,,FDA-CTU,,84.0,YR,,M,N,,,20230103,N,PH,US,,2023,Q1,Elderly
218792131,21879213,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,D,,,,12.5,MG,,QD,2023,Q1,Gastroenteritis,,2023,Q1,1,I,20220504.0,,20230117,20230117,DIR,FDA-CDER-CTU-2023-4397,,FDA-CTU,,67.0,YR,,M,N,122.0,KG,20220918,N,PH,US,,2023,Q1,Elderly
218792131,21879213,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,D,,,,12.5,MG,,QD,2023,Q1,Urinary tract infection,,2023,Q1,1,I,20220504.0,,20230117,20230117,DIR,FDA-CDER-CTU-2023-4397,,FDA-CTU,,67.0,YR,,M,N,122.0,KG,20220918,N,PH,US,,2023,Q1,Elderly
218792131,21879213,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,D,,,,12.5,MG,,QD,2023,Q1,Blood ketone body increased,,2023,Q1,1,I,20220504.0,,20230117,20230117,DIR,FDA-CDER-CTU-2023-4397,,FDA-CTU,,67.0,YR,,M,N,122.0,KG,20220918,N,PH,US,,2023,Q1,Elderly
218792131,21879213,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,D,,,,12.5,MG,,QD,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,1,I,20220504.0,,20230117,20230117,DIR,FDA-CDER-CTU-2023-4397,,FDA-CTU,,67.0,YR,,M,N,122.0,KG,20220918,N,PH,US,,2023,Q1,Elderly
218792131,21879213,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,D,,,,12.5,MG,,QD,2023,Q1,Metabolic acidosis,,2023,Q1,1,I,20220504.0,,20230117,20230117,DIR,FDA-CDER-CTU-2023-4397,,FDA-CTU,,67.0,YR,,M,N,122.0,KG,20220918,N,PH,US,,2023,Q1,Elderly
218793031,21879303,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,Y,,,,,25.0,MG,,QD,2023,Q1,Pallor,,2023,Q1,1,I,,20230109.0,20230118,20230118,EXP,PT-EMA-DD-20230103-225467-111642,PT-EMD Serono-E2B_90090321,EMD SERONO INC,"Rodrigues S, Esteves L. Euglycemic ketoacidosis in an elderly patient on empagliflozin and metformin. REVISTA PORTUGUESA DE DIABETES. 2022;17(1):69-74.",82.0,YR,E,F,Y,,,20230118,,MD,PT,PT,2023,Q1,Elderly
218793031,21879303,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,Y,,,,,25.0,MG,,QD,2023,Q1,Diabetic ketoacidosis,,2023,Q1,1,I,,20230109.0,20230118,20230118,EXP,PT-EMA-DD-20230103-225467-111642,PT-EMD Serono-E2B_90090321,EMD SERONO INC,"Rodrigues S, Esteves L. Euglycemic ketoacidosis in an elderly patient on empagliflozin and metformin. REVISTA PORTUGUESA DE DIABETES. 2022;17(1):69-74.",82.0,YR,E,F,Y,,,20230118,,MD,PT,PT,2023,Q1,Elderly
218793031,21879303,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,Y,,,,,25.0,MG,,QD,2023,Q1,Acetonaemia,,2023,Q1,1,I,,20230109.0,20230118,20230118,EXP,PT-EMA-DD-20230103-225467-111642,PT-EMD Serono-E2B_90090321,EMD SERONO INC,"Rodrigues S, Esteves L. Euglycemic ketoacidosis in an elderly patient on empagliflozin and metformin. REVISTA PORTUGUESA DE DIABETES. 2022;17(1):69-74.",82.0,YR,E,F,Y,,,20230118,,MD,PT,PT,2023,Q1,Elderly
218793031,21879303,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,Y,,,,,25.0,MG,,QD,2023,Q1,Blood lactic acid increased,,2023,Q1,1,I,,20230109.0,20230118,20230118,EXP,PT-EMA-DD-20230103-225467-111642,PT-EMD Serono-E2B_90090321,EMD SERONO INC,"Rodrigues S, Esteves L. Euglycemic ketoacidosis in an elderly patient on empagliflozin and metformin. REVISTA PORTUGUESA DE DIABETES. 2022;17(1):69-74.",82.0,YR,E,F,Y,,,20230118,,MD,PT,PT,2023,Q1,Elderly
218793031,21879303,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,Y,,,,,25.0,MG,,QD,2023,Q1,Dehydration,,2023,Q1,1,I,,20230109.0,20230118,20230118,EXP,PT-EMA-DD-20230103-225467-111642,PT-EMD Serono-E2B_90090321,EMD SERONO INC,"Rodrigues S, Esteves L. Euglycemic ketoacidosis in an elderly patient on empagliflozin and metformin. REVISTA PORTUGUESA DE DIABETES. 2022;17(1):69-74.",82.0,YR,E,F,Y,,,20230118,,MD,PT,PT,2023,Q1,Elderly
218793031,21879303,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,Y,,,,,25.0,MG,,QD,2023,Q1,Drug interaction,,2023,Q1,1,I,,20230109.0,20230118,20230118,EXP,PT-EMA-DD-20230103-225467-111642,PT-EMD Serono-E2B_90090321,EMD SERONO INC,"Rodrigues S, Esteves L. Euglycemic ketoacidosis in an elderly patient on empagliflozin and metformin. REVISTA PORTUGUESA DE DIABETES. 2022;17(1):69-74.",82.0,YR,E,F,Y,,,20230118,,MD,PT,PT,2023,Q1,Elderly
218793031,21879303,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,Y,,,,,25.0,MG,,QD,2023,Q1,Decreased appetite,,2023,Q1,1,I,,20230109.0,20230118,20230118,EXP,PT-EMA-DD-20230103-225467-111642,PT-EMD Serono-E2B_90090321,EMD SERONO INC,"Rodrigues S, Esteves L. Euglycemic ketoacidosis in an elderly patient on empagliflozin and metformin. REVISTA PORTUGUESA DE DIABETES. 2022;17(1):69-74.",82.0,YR,E,F,Y,,,20230118,,MD,PT,PT,2023,Q1,Elderly
218793031,21879303,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,Y,,,,,25.0,MG,,QD,2023,Q1,Dysphagia,,2023,Q1,1,I,,20230109.0,20230118,20230118,EXP,PT-EMA-DD-20230103-225467-111642,PT-EMD Serono-E2B_90090321,EMD SERONO INC,"Rodrigues S, Esteves L. Euglycemic ketoacidosis in an elderly patient on empagliflozin and metformin. REVISTA PORTUGUESA DE DIABETES. 2022;17(1):69-74.",82.0,YR,E,F,Y,,,20230118,,MD,PT,PT,2023,Q1,Elderly
218793031,21879303,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,Y,,,,,25.0,MG,,QD,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,1,I,,20230109.0,20230118,20230118,EXP,PT-EMA-DD-20230103-225467-111642,PT-EMD Serono-E2B_90090321,EMD SERONO INC,"Rodrigues S, Esteves L. Euglycemic ketoacidosis in an elderly patient on empagliflozin and metformin. REVISTA PORTUGUESA DE DIABETES. 2022;17(1):69-74.",82.0,YR,E,F,Y,,,20230118,,MD,PT,PT,2023,Q1,Elderly
218793031,21879303,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,Y,,,,,25.0,MG,,QD,2023,Q1,Vomiting,,2023,Q1,1,I,,20230109.0,20230118,20230118,EXP,PT-EMA-DD-20230103-225467-111642,PT-EMD Serono-E2B_90090321,EMD SERONO INC,"Rodrigues S, Esteves L. Euglycemic ketoacidosis in an elderly patient on empagliflozin and metformin. REVISTA PORTUGUESA DE DIABETES. 2022;17(1):69-74.",82.0,YR,E,F,Y,,,20230118,,MD,PT,PT,2023,Q1,Elderly
218793031,21879303,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,Y,,,,,25.0,MG,,QD,2023,Q1,Oliguria,,2023,Q1,1,I,,20230109.0,20230118,20230118,EXP,PT-EMA-DD-20230103-225467-111642,PT-EMD Serono-E2B_90090321,EMD SERONO INC,"Rodrigues S, Esteves L. Euglycemic ketoacidosis in an elderly patient on empagliflozin and metformin. REVISTA PORTUGUESA DE DIABETES. 2022;17(1):69-74.",82.0,YR,E,F,Y,,,20230118,,MD,PT,PT,2023,Q1,Elderly
218793031,21879303,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,Y,,,,,25.0,MG,,QD,2023,Q1,Nausea,,2023,Q1,1,I,,20230109.0,20230118,20230118,EXP,PT-EMA-DD-20230103-225467-111642,PT-EMD Serono-E2B_90090321,EMD SERONO INC,"Rodrigues S, Esteves L. Euglycemic ketoacidosis in an elderly patient on empagliflozin and metformin. REVISTA PORTUGUESA DE DIABETES. 2022;17(1):69-74.",82.0,YR,E,F,Y,,,20230118,,MD,PT,PT,2023,Q1,Elderly
218793031,21879303,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,Y,,,,,25.0,MG,,QD,2023,Q1,Breast cancer,,2023,Q1,1,I,,20230109.0,20230118,20230118,EXP,PT-EMA-DD-20230103-225467-111642,PT-EMD Serono-E2B_90090321,EMD SERONO INC,"Rodrigues S, Esteves L. Euglycemic ketoacidosis in an elderly patient on empagliflozin and metformin. REVISTA PORTUGUESA DE DIABETES. 2022;17(1):69-74.",82.0,YR,E,F,Y,,,20230118,,MD,PT,PT,2023,Q1,Elderly
218793031,21879303,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,Y,,,,,25.0,MG,,QD,2023,Q1,Dry skin,,2023,Q1,1,I,,20230109.0,20230118,20230118,EXP,PT-EMA-DD-20230103-225467-111642,PT-EMD Serono-E2B_90090321,EMD SERONO INC,"Rodrigues S, Esteves L. Euglycemic ketoacidosis in an elderly patient on empagliflozin and metformin. REVISTA PORTUGUESA DE DIABETES. 2022;17(1):69-74.",82.0,YR,E,F,Y,,,20230118,,MD,PT,PT,2023,Q1,Elderly
218812691,21881269,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,D,,,,,,,,,2023,Q1,Death,,2023,Q1,1,I,20221224.0,20230114.0,20230118,20230118,EXP,,NVSC2023HR008746,NOVARTIS,,64.0,YR,,F,Y,62.0,KG,20230119,,MD,HR,HR,2023,Q1,Adult
218836151,21883615,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,,,,,2023,Q1,Contusion,,2023,Q1,1,I,20220919.0,,20230118,20230118,DIR,FDA-CDER-CTU-2023-5004,,FDA-CTU,,75.0,YR,,M,N,110.68,KG,20221119,N,PH,US,,2023,Q1,Elderly
218836161,21883616,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,12.5 MG BID PO,,,Y,,,,,12.5,MG,,BID,2023,Q1,Weight decreased,,2023,Q1,1,I,20230113.0,,20230118,20230118,DIR,FDA-CDER-CTU-2023-5006,,FDA-CTU,,69.0,YR,,F,N,,,20230116,N,HP,US,,2023,Q1,Elderly
218836161,21883616,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,12.5 MG BID PO,,,Y,,,,,12.5,MG,,BID,2023,Q1,Cough,,2023,Q1,1,I,20230113.0,,20230118,20230118,DIR,FDA-CDER-CTU-2023-5006,,FDA-CTU,,69.0,YR,,F,N,,,20230116,N,HP,US,,2023,Q1,Elderly
218836161,21883616,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,12.5 MG BID PO,,,Y,,,,,12.5,MG,,BID,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,1,I,20230113.0,,20230118,20230118,DIR,FDA-CDER-CTU-2023-5006,,FDA-CTU,,69.0,YR,,F,N,,,20230116,N,HP,US,,2023,Q1,Elderly
218857961,21885796,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,SARS-CoV-2 test positive,,2023,Q1,1,I,20221219.0,,20230118,20230118,DIR,FDA-CDER-CTU-2023-5049,,FDA-CTU,,44.0,YR,,F,N,,,20230118,Y,PH,US,,2023,Q1,Adult
218857961,21885796,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Dyspnoea,,2023,Q1,1,I,20221219.0,,20230118,20230118,DIR,FDA-CDER-CTU-2023-5049,,FDA-CTU,,44.0,YR,,F,N,,,20230118,Y,PH,US,,2023,Q1,Adult
218857961,21885796,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Cough,,2023,Q1,1,I,20221219.0,,20230118,20230118,DIR,FDA-CDER-CTU-2023-5049,,FDA-CTU,,44.0,YR,,F,N,,,20230118,Y,PH,US,,2023,Q1,Adult
218857961,21885796,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Bronchitis,,2023,Q1,1,I,20221219.0,,20230118,20230118,DIR,FDA-CDER-CTU-2023-5049,,FDA-CTU,,44.0,YR,,F,N,,,20230118,Y,PH,US,,2023,Q1,Adult
218857961,21885796,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Pyrexia,,2023,Q1,1,I,20221219.0,,20230118,20230118,DIR,FDA-CDER-CTU-2023-5049,,FDA-CTU,,44.0,YR,,F,N,,,20230118,Y,PH,US,,2023,Q1,Adult
218857961,21885796,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Wheezing,,2023,Q1,1,I,20221219.0,,20230118,20230118,DIR,FDA-CDER-CTU-2023-5049,,FDA-CTU,,44.0,YR,,F,N,,,20230118,Y,PH,US,,2023,Q1,Adult
218866741,21886674,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,1000/12.5 mg in the morning,,,U,,Unknown,,206111.0,,,,QD,2023,Q1,Dyspnoea exertional,,2023,Q1,1,I,20190101.0,20230116.0,20230119,20230119,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-212878",BOEHRINGER INGELHEIM,,64.0,YR,A,F,Y,,,20230119,,MD,SI,SI,2023,Q1,Adult
218866741,21886674,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,1000/12.5 mg in the morning,,,U,,Unknown,,206111.0,,,,QD,2023,Q1,Off label use,,2023,Q1,1,I,20190101.0,20230116.0,20230119,20230119,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-212878",BOEHRINGER INGELHEIM,,64.0,YR,A,F,Y,,,20230119,,MD,SI,SI,2023,Q1,Adult
218866741,21886674,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,1000/12.5 mg in the morning,,,U,,Unknown,,206111.0,,,,QD,2023,Q1,Glomerular filtration rate decreased,,2023,Q1,1,I,20190101.0,20230116.0,20230119,20230119,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-212878",BOEHRINGER INGELHEIM,,64.0,YR,A,F,Y,,,20230119,,MD,SI,SI,2023,Q1,Adult
218866741,21886674,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,1000/12.5 mg in the morning,,,U,,Unknown,,206111.0,,,,QD,2023,Q1,Chronic kidney disease,,2023,Q1,1,I,20190101.0,20230116.0,20230119,20230119,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-212878",BOEHRINGER INGELHEIM,,64.0,YR,A,F,Y,,,20230119,,MD,SI,SI,2023,Q1,Adult
218866741,21886674,2,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,,,206111.0,,,,,2023,Q1,Dyspnoea exertional,,2023,Q1,1,I,20190101.0,20230116.0,20230119,20230119,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-212878",BOEHRINGER INGELHEIM,,64.0,YR,A,F,Y,,,20230119,,MD,SI,SI,2023,Q1,Adult
218866741,21886674,2,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,,,206111.0,,,,,2023,Q1,Off label use,,2023,Q1,1,I,20190101.0,20230116.0,20230119,20230119,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-212878",BOEHRINGER INGELHEIM,,64.0,YR,A,F,Y,,,20230119,,MD,SI,SI,2023,Q1,Adult
218866741,21886674,2,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,,,206111.0,,,,,2023,Q1,Glomerular filtration rate decreased,,2023,Q1,1,I,20190101.0,20230116.0,20230119,20230119,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-212878",BOEHRINGER INGELHEIM,,64.0,YR,A,F,Y,,,20230119,,MD,SI,SI,2023,Q1,Adult
218866741,21886674,2,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,,,206111.0,,,,,2023,Q1,Chronic kidney disease,,2023,Q1,1,I,20190101.0,20230116.0,20230119,20230119,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-212878",BOEHRINGER INGELHEIM,,64.0,YR,A,F,Y,,,20230119,,MD,SI,SI,2023,Q1,Adult
218873001,21887300,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,Oral,1 10-5mg QAM,,,U,,Unknown,,212614.0,,,Tablet,QD,2023,Q1,Spinal operation,,2023,Q1,1,I,20230101.0,20230119.0,20230119,20230119,PER,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-213810",BOEHRINGER INGELHEIM,,69.0,YR,E,M,Y,,,20230120,,CN,US,US,2023,Q1,Elderly
218897811,21889781,6,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 mg, qd",,,Y,,,,,25.0,MG,,,2023,Q1,Blood lactic acid increased,,2023,Q1,1,I,,20230108.0,20230120,20230120,EXP,PT-EMA-DD-20230103-225467-111642,PT-Accord-296309,ACCORD,"Rodrigues S, Esteves VL. Euglycemic ketoacidosis in an elderly patient on empagliflozin and metformin Euglycemic ketoacidosis in an elderly patient on?empagliflozin and metformin.. Portuguese Journal of Diabetes. 2022, 17(1):69-74",82.0,YR,E,F,Y,,,20230120,,MD,PT,PT,2023,Q1,Elderly
218897811,21889781,6,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 mg, qd",,,Y,,,,,25.0,MG,,,2023,Q1,Dry skin,,2023,Q1,1,I,,20230108.0,20230120,20230120,EXP,PT-EMA-DD-20230103-225467-111642,PT-Accord-296309,ACCORD,"Rodrigues S, Esteves VL. Euglycemic ketoacidosis in an elderly patient on empagliflozin and metformin Euglycemic ketoacidosis in an elderly patient on?empagliflozin and metformin.. Portuguese Journal of Diabetes. 2022, 17(1):69-74",82.0,YR,E,F,Y,,,20230120,,MD,PT,PT,2023,Q1,Elderly
218897811,21889781,6,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 mg, qd",,,Y,,,,,25.0,MG,,,2023,Q1,Nausea,,2023,Q1,1,I,,20230108.0,20230120,20230120,EXP,PT-EMA-DD-20230103-225467-111642,PT-Accord-296309,ACCORD,"Rodrigues S, Esteves VL. Euglycemic ketoacidosis in an elderly patient on empagliflozin and metformin Euglycemic ketoacidosis in an elderly patient on?empagliflozin and metformin.. Portuguese Journal of Diabetes. 2022, 17(1):69-74",82.0,YR,E,F,Y,,,20230120,,MD,PT,PT,2023,Q1,Elderly
218897811,21889781,6,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 mg, qd",,,Y,,,,,25.0,MG,,,2023,Q1,Dysphagia,,2023,Q1,1,I,,20230108.0,20230120,20230120,EXP,PT-EMA-DD-20230103-225467-111642,PT-Accord-296309,ACCORD,"Rodrigues S, Esteves VL. Euglycemic ketoacidosis in an elderly patient on empagliflozin and metformin Euglycemic ketoacidosis in an elderly patient on?empagliflozin and metformin.. Portuguese Journal of Diabetes. 2022, 17(1):69-74",82.0,YR,E,F,Y,,,20230120,,MD,PT,PT,2023,Q1,Elderly
218897811,21889781,6,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 mg, qd",,,Y,,,,,25.0,MG,,,2023,Q1,Drug interaction,,2023,Q1,1,I,,20230108.0,20230120,20230120,EXP,PT-EMA-DD-20230103-225467-111642,PT-Accord-296309,ACCORD,"Rodrigues S, Esteves VL. Euglycemic ketoacidosis in an elderly patient on empagliflozin and metformin Euglycemic ketoacidosis in an elderly patient on?empagliflozin and metformin.. Portuguese Journal of Diabetes. 2022, 17(1):69-74",82.0,YR,E,F,Y,,,20230120,,MD,PT,PT,2023,Q1,Elderly
218897811,21889781,6,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 mg, qd",,,Y,,,,,25.0,MG,,,2023,Q1,Pallor,,2023,Q1,1,I,,20230108.0,20230120,20230120,EXP,PT-EMA-DD-20230103-225467-111642,PT-Accord-296309,ACCORD,"Rodrigues S, Esteves VL. Euglycemic ketoacidosis in an elderly patient on empagliflozin and metformin Euglycemic ketoacidosis in an elderly patient on?empagliflozin and metformin.. Portuguese Journal of Diabetes. 2022, 17(1):69-74",82.0,YR,E,F,Y,,,20230120,,MD,PT,PT,2023,Q1,Elderly
218897811,21889781,6,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 mg, qd",,,Y,,,,,25.0,MG,,,2023,Q1,Breast cancer,,2023,Q1,1,I,,20230108.0,20230120,20230120,EXP,PT-EMA-DD-20230103-225467-111642,PT-Accord-296309,ACCORD,"Rodrigues S, Esteves VL. Euglycemic ketoacidosis in an elderly patient on empagliflozin and metformin Euglycemic ketoacidosis in an elderly patient on?empagliflozin and metformin.. Portuguese Journal of Diabetes. 2022, 17(1):69-74",82.0,YR,E,F,Y,,,20230120,,MD,PT,PT,2023,Q1,Elderly
218897811,21889781,6,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 mg, qd",,,Y,,,,,25.0,MG,,,2023,Q1,Oliguria,,2023,Q1,1,I,,20230108.0,20230120,20230120,EXP,PT-EMA-DD-20230103-225467-111642,PT-Accord-296309,ACCORD,"Rodrigues S, Esteves VL. Euglycemic ketoacidosis in an elderly patient on empagliflozin and metformin Euglycemic ketoacidosis in an elderly patient on?empagliflozin and metformin.. Portuguese Journal of Diabetes. 2022, 17(1):69-74",82.0,YR,E,F,Y,,,20230120,,MD,PT,PT,2023,Q1,Elderly
218897811,21889781,6,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 mg, qd",,,Y,,,,,25.0,MG,,,2023,Q1,Dehydration,,2023,Q1,1,I,,20230108.0,20230120,20230120,EXP,PT-EMA-DD-20230103-225467-111642,PT-Accord-296309,ACCORD,"Rodrigues S, Esteves VL. Euglycemic ketoacidosis in an elderly patient on empagliflozin and metformin Euglycemic ketoacidosis in an elderly patient on?empagliflozin and metformin.. Portuguese Journal of Diabetes. 2022, 17(1):69-74",82.0,YR,E,F,Y,,,20230120,,MD,PT,PT,2023,Q1,Elderly
218897811,21889781,6,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 mg, qd",,,Y,,,,,25.0,MG,,,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,1,I,,20230108.0,20230120,20230120,EXP,PT-EMA-DD-20230103-225467-111642,PT-Accord-296309,ACCORD,"Rodrigues S, Esteves VL. Euglycemic ketoacidosis in an elderly patient on empagliflozin and metformin Euglycemic ketoacidosis in an elderly patient on?empagliflozin and metformin.. Portuguese Journal of Diabetes. 2022, 17(1):69-74",82.0,YR,E,F,Y,,,20230120,,MD,PT,PT,2023,Q1,Elderly
218897811,21889781,6,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 mg, qd",,,Y,,,,,25.0,MG,,,2023,Q1,Vomiting,,2023,Q1,1,I,,20230108.0,20230120,20230120,EXP,PT-EMA-DD-20230103-225467-111642,PT-Accord-296309,ACCORD,"Rodrigues S, Esteves VL. Euglycemic ketoacidosis in an elderly patient on empagliflozin and metformin Euglycemic ketoacidosis in an elderly patient on?empagliflozin and metformin.. Portuguese Journal of Diabetes. 2022, 17(1):69-74",82.0,YR,E,F,Y,,,20230120,,MD,PT,PT,2023,Q1,Elderly
218897811,21889781,6,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 mg, qd",,,Y,,,,,25.0,MG,,,2023,Q1,Decreased appetite,,2023,Q1,1,I,,20230108.0,20230120,20230120,EXP,PT-EMA-DD-20230103-225467-111642,PT-Accord-296309,ACCORD,"Rodrigues S, Esteves VL. Euglycemic ketoacidosis in an elderly patient on empagliflozin and metformin Euglycemic ketoacidosis in an elderly patient on?empagliflozin and metformin.. Portuguese Journal of Diabetes. 2022, 17(1):69-74",82.0,YR,E,F,Y,,,20230120,,MD,PT,PT,2023,Q1,Elderly
218897811,21889781,6,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 mg, qd",,,Y,,,,,25.0,MG,,,2023,Q1,Acetonaemia,,2023,Q1,1,I,,20230108.0,20230120,20230120,EXP,PT-EMA-DD-20230103-225467-111642,PT-Accord-296309,ACCORD,"Rodrigues S, Esteves VL. Euglycemic ketoacidosis in an elderly patient on empagliflozin and metformin Euglycemic ketoacidosis in an elderly patient on?empagliflozin and metformin.. Portuguese Journal of Diabetes. 2022, 17(1):69-74",82.0,YR,E,F,Y,,,20230120,,MD,PT,PT,2023,Q1,Elderly
218897811,21889781,6,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 mg, qd",,,Y,,,,,25.0,MG,,,2023,Q1,Diabetic ketoacidosis,,2023,Q1,1,I,,20230108.0,20230120,20230120,EXP,PT-EMA-DD-20230103-225467-111642,PT-Accord-296309,ACCORD,"Rodrigues S, Esteves VL. Euglycemic ketoacidosis in an elderly patient on empagliflozin and metformin Euglycemic ketoacidosis in an elderly patient on?empagliflozin and metformin.. Portuguese Journal of Diabetes. 2022, 17(1):69-74",82.0,YR,E,F,Y,,,20230120,,MD,PT,PT,2023,Q1,Elderly
218933052,21893305,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0, Tablet",,,U,,,,,,,Tablet,,2023,Q1,General physical health deterioration,,2023,Q1,2,F,,20230111.0,20230121,20230124,EXP,DE-BFARM-20001496,DE-Accord-296960,ACCORD,,81.0,YR,E,M,Y,,,20230124,,MD,DE,DE,2023,Q1,Elderly
218933052,21893305,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0, Tablet",,,U,,,,,,,Tablet,,2023,Q1,Polydipsia,,2023,Q1,2,F,,20230111.0,20230121,20230124,EXP,DE-BFARM-20001496,DE-Accord-296960,ACCORD,,81.0,YR,E,M,Y,,,20230124,,MD,DE,DE,2023,Q1,Elderly
218933052,21893305,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0, Tablet",,,U,,,,,,,Tablet,,2023,Q1,Hyperglycaemia,,2023,Q1,2,F,,20230111.0,20230121,20230124,EXP,DE-BFARM-20001496,DE-Accord-296960,ACCORD,,81.0,YR,E,M,Y,,,20230124,,MD,DE,DE,2023,Q1,Elderly
218933052,21893305,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0, Tablet",,,U,,,,,,,Tablet,,2023,Q1,Polyuria,,2023,Q1,2,F,,20230111.0,20230121,20230124,EXP,DE-BFARM-20001496,DE-Accord-296960,ACCORD,,81.0,YR,E,M,Y,,,20230124,,MD,DE,DE,2023,Q1,Elderly
218944892,21894489,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2023,Q1,Renal failure,,2023,Q1,2,F,,20230221.0,20230121,20230228,EXP,,"SE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-213072",BOEHRINGER INGELHEIM,"Lodin K, Rosenborg S, Hemmingsson P. Fanconis syndrom ? en ovanlig biverkan av tenofovirdisoproxil. L?kartidningen. 2023 Jan 12;12022097-",7.0,DEC,E,F,Y,,,20230228,,MD,SE,SE,2023,Q1,Child
218944892,21894489,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2023,Q1,Osteoporosis,,2023,Q1,2,F,,20230221.0,20230121,20230228,EXP,,"SE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-213072",BOEHRINGER INGELHEIM,"Lodin K, Rosenborg S, Hemmingsson P. Fanconis syndrom ? en ovanlig biverkan av tenofovirdisoproxil. L?kartidningen. 2023 Jan 12;12022097-",7.0,DEC,E,F,Y,,,20230228,,MD,SE,SE,2023,Q1,Child
218944892,21894489,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2023,Q1,Fanconi syndrome acquired,,2023,Q1,2,F,,20230221.0,20230121,20230228,EXP,,"SE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-213072",BOEHRINGER INGELHEIM,"Lodin K, Rosenborg S, Hemmingsson P. Fanconis syndrom ? en ovanlig biverkan av tenofovirdisoproxil. L?kartidningen. 2023 Jan 12;12022097-",7.0,DEC,E,F,Y,,,20230228,,MD,SE,SE,2023,Q1,Child
218962041,21896204,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q1,Death,,2023,Q1,1,I,20210101.0,20230109.0,20230123,20230123,EXP,,US-APOTEX-2023AP002052,APOTEX,"Gummin DD, Mowry JB, Beuhler MC, Spyker DA, Rivers LJ, Feldman R, Brown K, Pham Nathaniel PT, Bronstein AC, Weber JA. 2021 Annual Report of the National Poison Data System (NPDS) from America^s Poison Centers: 39th Annual Report. Clinical Toxicology. 2022;60:12:1381-1643",72.0,YR,,M,Y,,,20230123,,MD,US,US,2023,Q1,Elderly
218962041,21896204,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2023,Q1,Death,,2023,Q1,1,I,20210101.0,20230109.0,20230123,20230123,EXP,,US-APOTEX-2023AP002052,APOTEX,"Gummin DD, Mowry JB, Beuhler MC, Spyker DA, Rivers LJ, Feldman R, Brown K, Pham Nathaniel PT, Bronstein AC, Weber JA. 2021 Annual Report of the National Poison Data System (NPDS) from America^s Poison Centers: 39th Annual Report. Clinical Toxicology. 2022;60:12:1381-1643",72.0,YR,,M,Y,,,20230123,,MD,US,US,2023,Q1,Elderly
218971371,21897137,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,5.0,MG,Tablet,QD,2023,Q1,Tremor,,2023,Q1,1,I,20230104.0,20230117.0,20230123,20230123,EXP,GB-MHRA-WEBRADR-20230115103550,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-213116",BOEHRINGER INGELHEIM,,44.0,YR,A,F,Y,76.0,KG,20230123,,PH,GB,GB,2023,Q1,Adult
218971371,21897137,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,5.0,MG,Tablet,QD,2023,Q1,Cluster headache,,2023,Q1,1,I,20230104.0,20230117.0,20230123,20230123,EXP,GB-MHRA-WEBRADR-20230115103550,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-213116",BOEHRINGER INGELHEIM,,44.0,YR,A,F,Y,76.0,KG,20230123,,PH,GB,GB,2023,Q1,Adult
218971371,21897137,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,5.0,MG,Tablet,QD,2023,Q1,Confusional state,,2023,Q1,1,I,20230104.0,20230117.0,20230123,20230123,EXP,GB-MHRA-WEBRADR-20230115103550,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-213116",BOEHRINGER INGELHEIM,,44.0,YR,A,F,Y,76.0,KG,20230123,,PH,GB,GB,2023,Q1,Adult
218971371,21897137,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,5.0,MG,Tablet,QD,2023,Q1,Diarrhoea,,2023,Q1,1,I,20230104.0,20230117.0,20230123,20230123,EXP,GB-MHRA-WEBRADR-20230115103550,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-213116",BOEHRINGER INGELHEIM,,44.0,YR,A,F,Y,76.0,KG,20230123,,PH,GB,GB,2023,Q1,Adult
218971371,21897137,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,5.0,MG,Tablet,QD,2023,Q1,Anxiety,,2023,Q1,1,I,20230104.0,20230117.0,20230123,20230123,EXP,GB-MHRA-WEBRADR-20230115103550,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-213116",BOEHRINGER INGELHEIM,,44.0,YR,A,F,Y,76.0,KG,20230123,,PH,GB,GB,2023,Q1,Adult
218971371,21897137,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,5.0,MG,Tablet,QD,2023,Q1,Amnesia,,2023,Q1,1,I,20230104.0,20230117.0,20230123,20230123,EXP,GB-MHRA-WEBRADR-20230115103550,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-213116",BOEHRINGER INGELHEIM,,44.0,YR,A,F,Y,76.0,KG,20230123,,PH,GB,GB,2023,Q1,Adult
218974793,21897479,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q1,Osteoporosis,,2023,Q1,3,F,20210101.0,20230306.0,20230123,20230310,EXP,,SE-MYLANLABS-2023M1006197,MYLAN,"Lodin K, Rosenborg S, Hemmingsson P.. Fanconi syndrome ? a rare side effect of tenofovir disoproxil. The Medical Journal. 2023;120:226097",7.0,DEC,,F,Y,,,20230310,,MD,SE,SE,2023,Q1,Child
218974793,21897479,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q1,Spinal pain,,2023,Q1,3,F,20210101.0,20230306.0,20230123,20230310,EXP,,SE-MYLANLABS-2023M1006197,MYLAN,"Lodin K, Rosenborg S, Hemmingsson P.. Fanconi syndrome ? a rare side effect of tenofovir disoproxil. The Medical Journal. 2023;120:226097",7.0,DEC,,F,Y,,,20230310,,MD,SE,SE,2023,Q1,Child
218974793,21897479,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q1,Pain in extremity,,2023,Q1,3,F,20210101.0,20230306.0,20230123,20230310,EXP,,SE-MYLANLABS-2023M1006197,MYLAN,"Lodin K, Rosenborg S, Hemmingsson P.. Fanconi syndrome ? a rare side effect of tenofovir disoproxil. The Medical Journal. 2023;120:226097",7.0,DEC,,F,Y,,,20230310,,MD,SE,SE,2023,Q1,Child
218974793,21897479,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q1,Fanconi syndrome,,2023,Q1,3,F,20210101.0,20230306.0,20230123,20230310,EXP,,SE-MYLANLABS-2023M1006197,MYLAN,"Lodin K, Rosenborg S, Hemmingsson P.. Fanconi syndrome ? a rare side effect of tenofovir disoproxil. The Medical Journal. 2023;120:226097",7.0,DEC,,F,Y,,,20230310,,MD,SE,SE,2023,Q1,Child
218974793,21897479,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q1,Gait disturbance,,2023,Q1,3,F,20210101.0,20230306.0,20230123,20230310,EXP,,SE-MYLANLABS-2023M1006197,MYLAN,"Lodin K, Rosenborg S, Hemmingsson P.. Fanconi syndrome ? a rare side effect of tenofovir disoproxil. The Medical Journal. 2023;120:226097",7.0,DEC,,F,Y,,,20230310,,MD,SE,SE,2023,Q1,Child
218974793,21897479,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q1,Chest pain,,2023,Q1,3,F,20210101.0,20230306.0,20230123,20230310,EXP,,SE-MYLANLABS-2023M1006197,MYLAN,"Lodin K, Rosenborg S, Hemmingsson P.. Fanconi syndrome ? a rare side effect of tenofovir disoproxil. The Medical Journal. 2023;120:226097",7.0,DEC,,F,Y,,,20230310,,MD,SE,SE,2023,Q1,Child
219014641,21901464,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2023,Q1,Intentional product use issue,,2023,Q1,1,I,,20230109.0,20230123,20230123,EXP,,US-APOTEX-2023AP002037,APOTEX,"Gummin DD, Mowry JB, Beuhler MC, Spyker DA, Rivers LJ, Feldman R, Brown K, Pham Nathaniel PT, Bronstein AC, Weber JA. 2021 Annual Report of the National Poison Data System (NPDS) from America^s Poison Centers: 39th Annual Report. Clinical Toxicology. 2022;60:12:1381-1643",57.0,YR,,M,Y,,,20230123,,MD,US,US,2023,Q1,Adult
219014641,21901464,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Parenteral,UNK,,,D,,,,,,,,,2023,Q1,Intentional product use issue,,2023,Q1,1,I,,20230109.0,20230123,20230123,EXP,,US-APOTEX-2023AP002037,APOTEX,"Gummin DD, Mowry JB, Beuhler MC, Spyker DA, Rivers LJ, Feldman R, Brown K, Pham Nathaniel PT, Bronstein AC, Weber JA. 2021 Annual Report of the National Poison Data System (NPDS) from America^s Poison Centers: 39th Annual Report. Clinical Toxicology. 2022;60:12:1381-1643",57.0,YR,,M,Y,,,20230123,,MD,US,US,2023,Q1,Adult
219043281,21904328,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MG EVERY DAY PO?,,,Y,D,E0627,,,25.0,MG,,QD,2023,Q1,Vomiting,,2023,Q1,1,I,20230106.0,,20230124,20230124,DIR,FDA-CDER-CTU-2023-6421,,FDA-CTU,,55.0,YR,,M,N,113.0,KG,20230120,N,HP,US,,2023,Q1,Adult
219043281,21904328,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MG EVERY DAY PO?,,,Y,D,E0627,,,25.0,MG,,QD,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,1,I,20230106.0,,20230124,20230124,DIR,FDA-CDER-CTU-2023-6421,,FDA-CTU,,55.0,YR,,M,N,113.0,KG,20230120,N,HP,US,,2023,Q1,Adult
219043281,21904328,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MG EVERY DAY PO?,,,Y,D,E0627,,,25.0,MG,,QD,2023,Q1,Hypoglycaemia,,2023,Q1,1,I,20230106.0,,20230124,20230124,DIR,FDA-CDER-CTU-2023-6421,,FDA-CTU,,55.0,YR,,M,N,113.0,KG,20230120,N,HP,US,,2023,Q1,Adult
219043281,21904328,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MG EVERY DAY PO?,,,Y,D,E0627,,,25.0,MG,,QD,2023,Q1,Nausea,,2023,Q1,1,I,20230106.0,,20230124,20230124,DIR,FDA-CDER-CTU-2023-6421,,FDA-CTU,,55.0,YR,,M,N,113.0,KG,20230120,N,HP,US,,2023,Q1,Adult
219043471,21904347,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG EVERY DAY PO,,,D,,,,,12.5,MG,,QD,2023,Q1,Blood glucose increased,,2023,Q1,1,I,20221208.0,,20230124,20230124,DIR,FDA-CDER-CTU-2023-6425,,FDA-CTU,,66.0,YR,,M,N,74.0,KG,20230119,N,HP,US,,2023,Q1,Elderly
219043471,21904347,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG EVERY DAY PO,,,D,,,,,12.5,MG,,QD,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,1,I,20221208.0,,20230124,20230124,DIR,FDA-CDER-CTU-2023-6425,,FDA-CTU,,66.0,YR,,M,N,74.0,KG,20230119,N,HP,US,,2023,Q1,Elderly
219043471,21904347,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG EVERY DAY PO,,,D,,,,,12.5,MG,,QD,2023,Q1,Fatigue,,2023,Q1,1,I,20221208.0,,20230124,20230124,DIR,FDA-CDER-CTU-2023-6425,,FDA-CTU,,66.0,YR,,M,N,74.0,KG,20230119,N,HP,US,,2023,Q1,Elderly
219043471,21904347,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG EVERY DAY PO,,,D,,,,,12.5,MG,,QD,2023,Q1,Anion gap increased,,2023,Q1,1,I,20221208.0,,20230124,20230124,DIR,FDA-CDER-CTU-2023-6425,,FDA-CTU,,66.0,YR,,M,N,74.0,KG,20230119,N,HP,US,,2023,Q1,Elderly
219043471,21904347,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG EVERY DAY PO,,,D,,,,,12.5,MG,,QD,2023,Q1,Malaise,,2023,Q1,1,I,20221208.0,,20230124,20230124,DIR,FDA-CDER-CTU-2023-6425,,FDA-CTU,,66.0,YR,,M,N,74.0,KG,20230119,N,HP,US,,2023,Q1,Elderly
219043471,21904347,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG EVERY DAY PO,,,D,,,,,12.5,MG,,QD,2023,Q1,Fall,,2023,Q1,1,I,20221208.0,,20230124,20230124,DIR,FDA-CDER-CTU-2023-6425,,FDA-CTU,,66.0,YR,,M,N,74.0,KG,20230119,N,HP,US,,2023,Q1,Elderly
219043471,21904347,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG EVERY DAY PO,,,D,,,,,12.5,MG,,QD,2023,Q1,Cellulitis,,2023,Q1,1,I,20221208.0,,20230124,20230124,DIR,FDA-CDER-CTU-2023-6425,,FDA-CTU,,66.0,YR,,M,N,74.0,KG,20230119,N,HP,US,,2023,Q1,Elderly
219043471,21904347,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG EVERY DAY PO,,,D,,,,,12.5,MG,,QD,2023,Q1,White blood cell count increased,,2023,Q1,1,I,20221208.0,,20230124,20230124,DIR,FDA-CDER-CTU-2023-6425,,FDA-CTU,,66.0,YR,,M,N,74.0,KG,20230119,N,HP,US,,2023,Q1,Elderly
219069661,21906966,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q1,Death,,2023,Q1,1,I,,20230117.0,20230125,20230125,EXP,,US-GLENMARK PHARMACEUTICALS-2023GMK078123,GLENMARK,"Gummin DD, Mowry JB, Beuhler MC, Spyker DA, Rivers LJ, Feldman R, Brown K, Pham Nathaniel PT, Bronstein AC, Weber JA.. 2021 Annual Report of the National Poison Data System (NPDS) from America?s Poison Centers: 39th Annual Report.. Clinical Toxicology.. 2022;60 (12):1381-1643",72.0,YR,,M,Y,,,20230125,,MD,US,US,2023,Q1,Elderly
219069661,21906966,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Death,,2023,Q1,1,I,,20230117.0,20230125,20230125,EXP,,US-GLENMARK PHARMACEUTICALS-2023GMK078123,GLENMARK,"Gummin DD, Mowry JB, Beuhler MC, Spyker DA, Rivers LJ, Feldman R, Brown K, Pham Nathaniel PT, Bronstein AC, Weber JA.. 2021 Annual Report of the National Poison Data System (NPDS) from America?s Poison Centers: 39th Annual Report.. Clinical Toxicology.. 2022;60 (12):1381-1643",72.0,YR,,M,Y,,,20230125,,MD,US,US,2023,Q1,Elderly
219088021,21908802,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,12.5,MG,,QD,2023,Q1,Pruritus genital,,2023,Q1,1,I,20220411.0,,20230124,20230124,DIR,FDA-CDER-CTU-2023-6466,,FDA-CTU,,72.0,YR,,M,N,86.0,KG,20220615,N,PH,US,,2023,Q1,Elderly
219089311,21908931,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Therapeutic product effect incomplete,,2023,Q1,1,I,,20230111.0,20230125,20230125,EXP,,SA-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-374874,RANBAXY,Altowayan WM. Empagliflozin induced euglycemic diabetic ketoacidosis. A case reports. Ann Med Surgery. 2022;84:104879,75.0,YR,,F,Y,,,20230125,,HP,SA,SA,2023,Q1,Elderly
219089311,21908931,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,1,I,,20230111.0,20230125,20230125,EXP,,SA-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-374874,RANBAXY,Altowayan WM. Empagliflozin induced euglycemic diabetic ketoacidosis. A case reports. Ann Med Surgery. 2022;84:104879,75.0,YR,,F,Y,,,20230125,,HP,SA,SA,2023,Q1,Elderly
219109561,21910956,4,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK UNK, unknown",,,,,,,,,,,,2023,Q1,Weight decreased,,2023,Q1,1,I,20220501.0,20230116.0,20230125,20230125,EXP,,CZ-ELI_LILLY_AND_COMPANY-CZ202301007906,ELI LILLY AND CO,"Mikulecka V..We meant well, and it almost turned out a little differently A common cause of the manifestation of the ^frailty^syndrome with a good ending. / Mysleli jsme to dobre, a malem to dopadlo trochu jinak. Bezna pricina manifestace syndromu ^frailty^ s dobrym.KAZUISTIKY V DIABETOLOGII 2022;20(4):20-23.",77.0,YR,,F,Y,,,20230125,,HP,CZ,CZ,2023,Q1,Elderly
219109561,21910956,4,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK UNK, unknown",,,,,,,,,,,,2023,Q1,Glycosylated haemoglobin decreased,,2023,Q1,1,I,20220501.0,20230116.0,20230125,20230125,EXP,,CZ-ELI_LILLY_AND_COMPANY-CZ202301007906,ELI LILLY AND CO,"Mikulecka V..We meant well, and it almost turned out a little differently A common cause of the manifestation of the ^frailty^syndrome with a good ending. / Mysleli jsme to dobre, a malem to dopadlo trochu jinak. Bezna pricina manifestace syndromu ^frailty^ s dobrym.KAZUISTIKY V DIABETOLOGII 2022;20(4):20-23.",77.0,YR,,F,Y,,,20230125,,HP,CZ,CZ,2023,Q1,Elderly
219109561,21910956,4,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK UNK, unknown",,,,,,,,,,,,2023,Q1,Asthenia,,2023,Q1,1,I,20220501.0,20230116.0,20230125,20230125,EXP,,CZ-ELI_LILLY_AND_COMPANY-CZ202301007906,ELI LILLY AND CO,"Mikulecka V..We meant well, and it almost turned out a little differently A common cause of the manifestation of the ^frailty^syndrome with a good ending. / Mysleli jsme to dobre, a malem to dopadlo trochu jinak. Bezna pricina manifestace syndromu ^frailty^ s dobrym.KAZUISTIKY V DIABETOLOGII 2022;20(4):20-23.",77.0,YR,,F,Y,,,20230125,,HP,CZ,CZ,2023,Q1,Elderly
219109561,21910956,4,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK UNK, unknown",,,,,,,,,,,,2023,Q1,Decreased appetite,,2023,Q1,1,I,20220501.0,20230116.0,20230125,20230125,EXP,,CZ-ELI_LILLY_AND_COMPANY-CZ202301007906,ELI LILLY AND CO,"Mikulecka V..We meant well, and it almost turned out a little differently A common cause of the manifestation of the ^frailty^syndrome with a good ending. / Mysleli jsme to dobre, a malem to dopadlo trochu jinak. Bezna pricina manifestace syndromu ^frailty^ s dobrym.KAZUISTIKY V DIABETOLOGII 2022;20(4):20-23.",77.0,YR,,F,Y,,,20230125,,HP,CZ,CZ,2023,Q1,Elderly
219146251,21914625,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,204629.0,,,,,2023,Q1,Stress,,2023,Q1,1,I,,20230119.0,20230126,20230126,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-213723",BOEHRINGER INGELHEIM,"Figaro R, Chang A, Shah V, Cordeiro K, Song N, Shenkman D. A POST-SURGICAL CASE OF EUGLYCEMIC DIABETIC KETOACIDOSIS INDUCED BY EMPAGLIFLOZIN. Critical Care Medicine. 2023;5191-doi:10.1097/01.cc m.0000906596.40556.99.",67.0,YR,E,M,Y,,,20230126,,HP,US,US,2023,Q1,Elderly
219146251,21914625,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,204629.0,,,,,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,1,I,,20230119.0,20230126,20230126,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-213723",BOEHRINGER INGELHEIM,"Figaro R, Chang A, Shah V, Cordeiro K, Song N, Shenkman D. A POST-SURGICAL CASE OF EUGLYCEMIC DIABETIC KETOACIDOSIS INDUCED BY EMPAGLIFLOZIN. Critical Care Medicine. 2023;5191-doi:10.1097/01.cc m.0000906596.40556.99.",67.0,YR,E,M,Y,,,20230126,,HP,US,US,2023,Q1,Elderly
219146251,21914625,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,204629.0,,,,,2023,Q1,Ileus,,2023,Q1,1,I,,20230119.0,20230126,20230126,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-213723",BOEHRINGER INGELHEIM,"Figaro R, Chang A, Shah V, Cordeiro K, Song N, Shenkman D. A POST-SURGICAL CASE OF EUGLYCEMIC DIABETIC KETOACIDOSIS INDUCED BY EMPAGLIFLOZIN. Critical Care Medicine. 2023;5191-doi:10.1097/01.cc m.0000906596.40556.99.",67.0,YR,E,M,Y,,,20230126,,HP,US,US,2023,Q1,Elderly
219169331,21916933,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q1,Diarrhoea,,2023,Q1,1,I,20221116.0,20230126.0,20230126,20230126,EXP,GB-MHRA-TPP59375269C8843027YC1674481817380,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-214911",BOEHRINGER INGELHEIM,,48.0,YR,A,M,Y,97.0,KG,20230126,,MD,GB,GB,2023,Q1,Adult
219175961,21917596,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q1,Death,,2023,Q1,1,I,,20230117.0,20230127,20230127,EXP,,CL-NOVOPROD-1013692,NOVO NORDISK,,34.0,YR,,F,Y,,,20230127,,MD,CL,CL,2023,Q1,Young Adult
219181262,21918126,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Diabetic ketosis,,2023,Q1,2,F,,20230123.0,20230127,20230130,EXP,,JP-009507513-2301JPN009130,MERCK,,66.0,YR,,F,Y,,,20230130,,MD,JP,JP,2023,Q1,Elderly
219181262,21918126,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Diabetic ketosis,,2023,Q1,2,F,,20230123.0,20230127,20230130,EXP,,JP-009507513-2301JPN009130,MERCK,,66.0,YR,,F,Y,,,20230130,,MD,JP,JP,2023,Q1,Elderly
219192061,21919206,13,C,"EMPAGLIFLOZIN, METFORMIN",,2,,,,,,,,,,,,,,2023,Q1,Withdrawal syndrome,,2023,Q1,1,I,20221201.0,20230115.0,20230127,20230127,EXP,,US-Accord-297371,ACCORD,,67.0,YR,E,M,Y,97.98,KG,20230127,,CN,US,US,2023,Q1,Elderly
219192061,21919206,13,C,"EMPAGLIFLOZIN, METFORMIN",,2,,,,,,,,,,,,,,2023,Q1,Retching,,2023,Q1,1,I,20221201.0,20230115.0,20230127,20230127,EXP,,US-Accord-297371,ACCORD,,67.0,YR,E,M,Y,97.98,KG,20230127,,CN,US,US,2023,Q1,Elderly
219192061,21919206,13,C,"EMPAGLIFLOZIN, METFORMIN",,2,,,,,,,,,,,,,,2023,Q1,Fatigue,,2023,Q1,1,I,20221201.0,20230115.0,20230127,20230127,EXP,,US-Accord-297371,ACCORD,,67.0,YR,E,M,Y,97.98,KG,20230127,,CN,US,US,2023,Q1,Elderly
219192061,21919206,13,C,"EMPAGLIFLOZIN, METFORMIN",,2,,,,,,,,,,,,,,2023,Q1,Eating disorder symptom,,2023,Q1,1,I,20221201.0,20230115.0,20230127,20230127,EXP,,US-Accord-297371,ACCORD,,67.0,YR,E,M,Y,97.98,KG,20230127,,CN,US,US,2023,Q1,Elderly
219192061,21919206,13,C,"EMPAGLIFLOZIN, METFORMIN",,2,,,,,,,,,,,,,,2023,Q1,Blood glucose decreased,,2023,Q1,1,I,20221201.0,20230115.0,20230127,20230127,EXP,,US-Accord-297371,ACCORD,,67.0,YR,E,M,Y,97.98,KG,20230127,,CN,US,US,2023,Q1,Elderly
219192061,21919206,13,C,"EMPAGLIFLOZIN, METFORMIN",,2,,,,,,,,,,,,,,2023,Q1,Blood glucose increased,,2023,Q1,1,I,20221201.0,20230115.0,20230127,20230127,EXP,,US-Accord-297371,ACCORD,,67.0,YR,E,M,Y,97.98,KG,20230127,,CN,US,US,2023,Q1,Elderly
219192061,21919206,13,C,"EMPAGLIFLOZIN, METFORMIN",,2,,,,,,,,,,,,,,2023,Q1,Nausea,,2023,Q1,1,I,20221201.0,20230115.0,20230127,20230127,EXP,,US-Accord-297371,ACCORD,,67.0,YR,E,M,Y,97.98,KG,20230127,,CN,US,US,2023,Q1,Elderly
219192061,21919206,13,C,"EMPAGLIFLOZIN, METFORMIN",,2,,,,,,,,,,,,,,2023,Q1,Vomiting,,2023,Q1,1,I,20221201.0,20230115.0,20230127,20230127,EXP,,US-Accord-297371,ACCORD,,67.0,YR,E,M,Y,97.98,KG,20230127,,CN,US,US,2023,Q1,Elderly
219192061,21919206,13,C,"EMPAGLIFLOZIN, METFORMIN",,2,,,,,,,,,,,,,,2023,Q1,Feeling abnormal,,2023,Q1,1,I,20221201.0,20230115.0,20230127,20230127,EXP,,US-Accord-297371,ACCORD,,67.0,YR,E,M,Y,97.98,KG,20230127,,CN,US,US,2023,Q1,Elderly
219192061,21919206,13,C,"EMPAGLIFLOZIN, METFORMIN",,2,,,,,,,,,,,,,,2023,Q1,Pain,,2023,Q1,1,I,20221201.0,20230115.0,20230127,20230127,EXP,,US-Accord-297371,ACCORD,,67.0,YR,E,M,Y,97.98,KG,20230127,,CN,US,US,2023,Q1,Elderly
219192061,21919206,13,C,"EMPAGLIFLOZIN, METFORMIN",,2,,,,,,,,,,,,,,2023,Q1,Drug interaction,,2023,Q1,1,I,20221201.0,20230115.0,20230127,20230127,EXP,,US-Accord-297371,ACCORD,,67.0,YR,E,M,Y,97.98,KG,20230127,,CN,US,US,2023,Q1,Elderly
219192851,21919285,2,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1 dosage form, bid (12.5/1,000 mg, two daily doses)",,,U,U,,,,,,,BID,2023,Q1,Coronary artery disease,,2023,Q1,1,I,,20220131.0,20230127,20230127,EXP,,ES-MYLANLABS-2023M1008631,MYLAN,,56.0,YR,,M,Y,93.0,KG,20230127,,MD,ES,ES,2023,Q1,Adult
219192851,21919285,2,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1 dosage form, bid (12.5/1,000 mg, two daily doses)",,,U,U,,,,,,,BID,2023,Q1,Acute myocardial infarction,,2023,Q1,1,I,,20220131.0,20230127,20230127,EXP,,ES-MYLANLABS-2023M1008631,MYLAN,,56.0,YR,,M,Y,93.0,KG,20230127,,MD,ES,ES,2023,Q1,Adult
219192851,21919285,4,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1 dosage form, bid (5 mg/1,000 mg, 1-0-1)",,,,,,,,,,,BID,2023,Q1,Coronary artery disease,,2023,Q1,1,I,,20220131.0,20230127,20230127,EXP,,ES-MYLANLABS-2023M1008631,MYLAN,,56.0,YR,,M,Y,93.0,KG,20230127,,MD,ES,ES,2023,Q1,Adult
219192851,21919285,4,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1 dosage form, bid (5 mg/1,000 mg, 1-0-1)",,,,,,,,,,,BID,2023,Q1,Acute myocardial infarction,,2023,Q1,1,I,,20220131.0,20230127,20230127,EXP,,ES-MYLANLABS-2023M1008631,MYLAN,,56.0,YR,,M,Y,93.0,KG,20230127,,MD,ES,ES,2023,Q1,Adult
219205861,21920586,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10mg/24h?Coated tablet,,,Y,U,Unknown,,,10.0,MG,Coated tablet,,2023,Q1,Urinary tract infection bacterial,,2023,Q1,1,I,20220911.0,20230123.0,20230127,20230127,EXP,,ES-FreseniusKabi-FK202300971,FRESENIUS KABI,,47.0,YR,A,M,Y,122.0,KG,20230127,,MD,ES,ES,2023,Q1,Adult
219205861,21920586,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10mg/24h?Coated tablet,,,Y,U,Unknown,,,10.0,MG,Coated tablet,,2023,Q1,Hypotension,,2023,Q1,1,I,20220911.0,20230123.0,20230127,20230127,EXP,,ES-FreseniusKabi-FK202300971,FRESENIUS KABI,,47.0,YR,A,M,Y,122.0,KG,20230127,,MD,ES,ES,2023,Q1,Adult
219205861,21920586,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10mg/24h?Coated tablet,,,Y,U,Unknown,,,10.0,MG,Coated tablet,,2023,Q1,Urinary tract infection bacterial,,2023,Q1,1,I,20220911.0,20230123.0,20230127,20230127,EXP,,ES-FreseniusKabi-FK202300971,FRESENIUS KABI,,47.0,YR,A,M,Y,122.0,KG,20230127,,MD,ES,ES,2023,Q1,Adult
219205861,21920586,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10mg/24h?Coated tablet,,,Y,U,Unknown,,,10.0,MG,Coated tablet,,2023,Q1,Hypotension,,2023,Q1,1,I,20220911.0,20230123.0,20230127,20230127,EXP,,ES-FreseniusKabi-FK202300971,FRESENIUS KABI,,47.0,YR,A,M,Y,122.0,KG,20230127,,MD,ES,ES,2023,Q1,Adult
219209546,21920954,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,Tablet,,2023,Q1,Liver function test increased,,2023,Q1,6,F,20221103.0,20230319.0,20230127,20230331,EXP,,IL-PFIZER INC-PV202200115137,PFIZER,,64.0,YR,,M,Y,67.0,KG,20230331,,HP,IL,IL,2023,Q1,Adult
219209553,21920955,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"12.5 mg, every morning (OM)",3037.5,MG,,,,,,12.5,MG,,QD,2023,Q1,Escherichia bacteraemia,,2023,Q1,3,F,20221203.0,20230209.0,20230127,20230214,EXP,,SG-PFIZER INC-PV202200118054,PFIZER,,65.0,YR,,F,Y,66.1,KG,20230214,,HP,SG,SG,2023,Q1,Elderly
219209553,21920955,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"12.5 mg, every morning (OM)",3037.5,MG,,,,,,12.5,MG,,QD,2023,Q1,Febrile neutropenia,,2023,Q1,3,F,20221203.0,20230209.0,20230127,20230214,EXP,,SG-PFIZER INC-PV202200118054,PFIZER,,65.0,YR,,F,Y,66.1,KG,20230214,,HP,SG,SG,2023,Q1,Elderly
219209553,21920955,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"12.5 mg, every morning (OM)",3037.5,MG,,,,,,12.5,MG,,QD,2023,Q1,Pneumonia,,2023,Q1,3,F,20221203.0,20230209.0,20230127,20230214,EXP,,SG-PFIZER INC-PV202200118054,PFIZER,,65.0,YR,,F,Y,66.1,KG,20230214,,HP,SG,SG,2023,Q1,Elderly
219209553,21920955,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"12.5 mg, every morning (OM)",3037.5,MG,,,,,,12.5,MG,,QD,2023,Q1,Myocardial infarction,,2023,Q1,3,F,20221203.0,20230209.0,20230127,20230214,EXP,,SG-PFIZER INC-PV202200118054,PFIZER,,65.0,YR,,F,Y,66.1,KG,20230214,,HP,SG,SG,2023,Q1,Elderly
219209553,21920955,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"12.5 mg, every morning (OM)",3037.5,MG,,,,,,12.5,MG,,QD,2023,Q1,Electrocardiogram QT prolonged,,2023,Q1,3,F,20221203.0,20230209.0,20230127,20230214,EXP,,SG-PFIZER INC-PV202200118054,PFIZER,,65.0,YR,,F,Y,66.1,KG,20230214,,HP,SG,SG,2023,Q1,Elderly
219218621,21921862,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Drug ineffective,,2023,Q1,1,I,,20230119.0,20230127,20230127,EXP,,PL-B.Braun Medical Inc.-2137202,B BRAUN,"Dzialach L, Sobolewska J, Respondek W, Wojciechowska-Luzniak A, Witek P.?Cushing^s syndrome: a combined treatment with etomidate and osilodrostat in severe life-threatening hypercortisolemia?Hormones 2022;21(4):735-742.",32.0,YR,,F,Y,,,20230127,,,PL,PL,2023,Q1,Young Adult
219222961,21922296,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, Q24H (10mg/24h)",22.5,MG,Y,,,,,10.0,MG,Coated tablet,,2023,Q1,Urinary tract infection bacterial,,2023,Q1,1,I,20220911.0,20230123.0,20230128,20230128,EXP,,NVSC2023ES014645,NOVARTIS,,47.0,YR,,M,Y,122.0,KG,20230128,,MD,ES,ES,2023,Q1,Adult
219222961,21922296,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, Q24H (10mg/24h)",22.5,MG,Y,,,,,10.0,MG,Coated tablet,,2023,Q1,Hypotension,,2023,Q1,1,I,20220911.0,20230123.0,20230128,20230128,EXP,,NVSC2023ES014645,NOVARTIS,,47.0,YR,,M,Y,122.0,KG,20230128,,MD,ES,ES,2023,Q1,Adult
219222961,21922296,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, Q24H (10mg/24h)",22.5,MG,Y,,,,,10.0,MG,Coated tablet,,2023,Q1,Urinary tract infection bacterial,,2023,Q1,1,I,20220911.0,20230123.0,20230128,20230128,EXP,,NVSC2023ES014645,NOVARTIS,,47.0,YR,,M,Y,122.0,KG,20230128,,MD,ES,ES,2023,Q1,Adult
219222961,21922296,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, Q24H (10mg/24h)",22.5,MG,Y,,,,,10.0,MG,Coated tablet,,2023,Q1,Hypotension,,2023,Q1,1,I,20220911.0,20230123.0,20230128,20230128,EXP,,NVSC2023ES014645,NOVARTIS,,47.0,YR,,M,Y,122.0,KG,20230128,,MD,ES,ES,2023,Q1,Adult
219230502,21923050,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2023,Q1,Nephrogenic diabetes insipidus,,2023,Q1,2,F,,20230123.0,20230129,20230201,EXP,,AU-DEXPHARM-20230148,DEXCEL,"Reimann F, Whyte I. Medicinal mishap: Chronic lithium toxicity. Australian Prescriber. 2022;45(3):93+#8211;4.",66.0,YR,E,M,Y,,,20230131,,HP,AU,AU,2023,Q1,Elderly
219230502,21923050,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2023,Q1,Acute kidney injury,,2023,Q1,2,F,,20230123.0,20230129,20230201,EXP,,AU-DEXPHARM-20230148,DEXCEL,"Reimann F, Whyte I. Medicinal mishap: Chronic lithium toxicity. Australian Prescriber. 2022;45(3):93+#8211;4.",66.0,YR,E,M,Y,,,20230131,,HP,AU,AU,2023,Q1,Elderly
219230502,21923050,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2023,Q1,Neurotoxicity,,2023,Q1,2,F,,20230123.0,20230129,20230201,EXP,,AU-DEXPHARM-20230148,DEXCEL,"Reimann F, Whyte I. Medicinal mishap: Chronic lithium toxicity. Australian Prescriber. 2022;45(3):93+#8211;4.",66.0,YR,E,M,Y,,,20230131,,HP,AU,AU,2023,Q1,Elderly
219230502,21923050,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2023,Q1,Toxicity to various agents,,2023,Q1,2,F,,20230123.0,20230129,20230201,EXP,,AU-DEXPHARM-20230148,DEXCEL,"Reimann F, Whyte I. Medicinal mishap: Chronic lithium toxicity. Australian Prescriber. 2022;45(3):93+#8211;4.",66.0,YR,E,M,Y,,,20230131,,HP,AU,AU,2023,Q1,Elderly
219230502,21923050,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2023,Q1,Hypovolaemia,,2023,Q1,2,F,,20230123.0,20230129,20230201,EXP,,AU-DEXPHARM-20230148,DEXCEL,"Reimann F, Whyte I. Medicinal mishap: Chronic lithium toxicity. Australian Prescriber. 2022;45(3):93+#8211;4.",66.0,YR,E,M,Y,,,20230131,,HP,AU,AU,2023,Q1,Elderly
219230771,21923077,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q1,Death,,2023,Q1,1,I,,20230117.0,20230129,20230129,EXP,,US-GLENMARK PHARMACEUTICALS-2023GMK078108,GLENMARK,"Gummin DD, Mowry JB, Beuhler MC, Spyker DA, Rivers LJ, Feldman R, Brown K, Pham Nathaniel PT, Bronstein AC, Weber JA.. 2021 Annual Report of the National Poison Data System (NPDS) from America?s Poison Centers: 39th Annual Report.. Clinical Toxicology.. 2022;60 (12):1381-1643",57.0,YR,,M,Y,,,20230129,,MD,US,US,2023,Q1,Adult
219230771,21923077,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Parenteral,UNK,,,U,,,,,,,,,2023,Q1,Death,,2023,Q1,1,I,,20230117.0,20230129,20230129,EXP,,US-GLENMARK PHARMACEUTICALS-2023GMK078108,GLENMARK,"Gummin DD, Mowry JB, Beuhler MC, Spyker DA, Rivers LJ, Feldman R, Brown K, Pham Nathaniel PT, Bronstein AC, Weber JA.. 2021 Annual Report of the National Poison Data System (NPDS) from America?s Poison Centers: 39th Annual Report.. Clinical Toxicology.. 2022;60 (12):1381-1643",57.0,YR,,M,Y,,,20230129,,MD,US,US,2023,Q1,Adult
219239361,21923936,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,,,,,,,,,,2023,Q1,Drug-induced liver injury,,2023,Q1,1,I,,20230116.0,20230130,20230130,EXP,,JP-NOVOPROD-1015557,NOVO NORDISK,"Sasaki N, et al.. A case of a patient with type 2 diabetes mellitus who developed hypoglycaemia due to anti-insulin antibody during symptomatic treatment of localized insulin allergy. Journal of the Japan Diabetes Society (e-journal). 2022;65(10):544-551",68.0,YR,,M,Y,48.3,KG,20230130,,MD,JP,JP,2023,Q1,Elderly
219239793,21923979,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q1,Pancreatic disorder,,2023,Q1,3,F,20220101.0,20230209.0,20230130,20230228,EXP,,US-NOVOPROD-1016004,NOVO NORDISK,,58.0,YR,,M,Y,87.5,KG,20230220,,CN,US,US,2023,Q1,Adult
219239793,21923979,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q1,Hiccups,,2023,Q1,3,F,20220101.0,20230209.0,20230130,20230228,EXP,,US-NOVOPROD-1016004,NOVO NORDISK,,58.0,YR,,M,Y,87.5,KG,20230220,,CN,US,US,2023,Q1,Adult
219239793,21923979,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q1,Feeling abnormal,,2023,Q1,3,F,20220101.0,20230209.0,20230130,20230228,EXP,,US-NOVOPROD-1016004,NOVO NORDISK,,58.0,YR,,M,Y,87.5,KG,20230220,,CN,US,US,2023,Q1,Adult
219239793,21923979,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q1,Dry skin,,2023,Q1,3,F,20220101.0,20230209.0,20230130,20230228,EXP,,US-NOVOPROD-1016004,NOVO NORDISK,,58.0,YR,,M,Y,87.5,KG,20230220,,CN,US,US,2023,Q1,Adult
219239793,21923979,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q1,Condition aggravated,,2023,Q1,3,F,20220101.0,20230209.0,20230130,20230228,EXP,,US-NOVOPROD-1016004,NOVO NORDISK,,58.0,YR,,M,Y,87.5,KG,20230220,,CN,US,US,2023,Q1,Adult
219239793,21923979,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q1,Gallbladder disorder,,2023,Q1,3,F,20220101.0,20230209.0,20230130,20230228,EXP,,US-NOVOPROD-1016004,NOVO NORDISK,,58.0,YR,,M,Y,87.5,KG,20230220,,CN,US,US,2023,Q1,Adult
219239793,21923979,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q1,Pain,,2023,Q1,3,F,20220101.0,20230209.0,20230130,20230228,EXP,,US-NOVOPROD-1016004,NOVO NORDISK,,58.0,YR,,M,Y,87.5,KG,20230220,,CN,US,US,2023,Q1,Adult
219239793,21923979,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q1,Hallucination,,2023,Q1,3,F,20220101.0,20230209.0,20230130,20230228,EXP,,US-NOVOPROD-1016004,NOVO NORDISK,,58.0,YR,,M,Y,87.5,KG,20230220,,CN,US,US,2023,Q1,Adult
219239793,21923979,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q1,Weight decreased,,2023,Q1,3,F,20220101.0,20230209.0,20230130,20230228,EXP,,US-NOVOPROD-1016004,NOVO NORDISK,,58.0,YR,,M,Y,87.5,KG,20230220,,CN,US,US,2023,Q1,Adult
219239793,21923979,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q1,Vomiting,,2023,Q1,3,F,20220101.0,20230209.0,20230130,20230228,EXP,,US-NOVOPROD-1016004,NOVO NORDISK,,58.0,YR,,M,Y,87.5,KG,20230220,,CN,US,US,2023,Q1,Adult
219239793,21923979,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q1,Neuropathy peripheral,,2023,Q1,3,F,20220101.0,20230209.0,20230130,20230228,EXP,,US-NOVOPROD-1016004,NOVO NORDISK,,58.0,YR,,M,Y,87.5,KG,20230220,,CN,US,US,2023,Q1,Adult
219239793,21923979,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q1,Infection,,2023,Q1,3,F,20220101.0,20230209.0,20230130,20230228,EXP,,US-NOVOPROD-1016004,NOVO NORDISK,,58.0,YR,,M,Y,87.5,KG,20230220,,CN,US,US,2023,Q1,Adult
219239793,21923979,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q1,Headache,,2023,Q1,3,F,20220101.0,20230209.0,20230130,20230228,EXP,,US-NOVOPROD-1016004,NOVO NORDISK,,58.0,YR,,M,Y,87.5,KG,20230220,,CN,US,US,2023,Q1,Adult
219239793,21923979,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q1,Near death experience,,2023,Q1,3,F,20220101.0,20230209.0,20230130,20230228,EXP,,US-NOVOPROD-1016004,NOVO NORDISK,,58.0,YR,,M,Y,87.5,KG,20230220,,CN,US,US,2023,Q1,Adult
219239793,21923979,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q1,Therapeutic response shortened,,2023,Q1,3,F,20220101.0,20230209.0,20230130,20230228,EXP,,US-NOVOPROD-1016004,NOVO NORDISK,,58.0,YR,,M,Y,87.5,KG,20230220,,CN,US,US,2023,Q1,Adult
219239793,21923979,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q1,Dizziness,,2023,Q1,3,F,20220101.0,20230209.0,20230130,20230228,EXP,,US-NOVOPROD-1016004,NOVO NORDISK,,58.0,YR,,M,Y,87.5,KG,20230220,,CN,US,US,2023,Q1,Adult
219239793,21923979,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q1,Dehydration,,2023,Q1,3,F,20220101.0,20230209.0,20230130,20230228,EXP,,US-NOVOPROD-1016004,NOVO NORDISK,,58.0,YR,,M,Y,87.5,KG,20230220,,CN,US,US,2023,Q1,Adult
219239793,21923979,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q1,Dermatitis atopic,,2023,Q1,3,F,20220101.0,20230209.0,20230130,20230228,EXP,,US-NOVOPROD-1016004,NOVO NORDISK,,58.0,YR,,M,Y,87.5,KG,20230220,,CN,US,US,2023,Q1,Adult
219241462,21924146,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,Tablet,QD,2023,Q1,Atrial fibrillation,,2023,Q1,2,F,,20230221.0,20230130,20230304,EXP,,SE-AUROBINDO-AUR-APL-2023-003464,AUROBINDO,"Hoskuldsdottir G, Thorleifsson S J, Ravn-Fischer A, Eliasson B.. SGLT2-h?mmare kan beh?va s?ttas ut vid allvarliga sjukdomstillst?nd - Risk f?r ketoacidos hos personer med diabetes och insulinbrist. L?kartidningen. 2023;120:22113",64.0,YR,,,Y,,,20230304,,MD,SE,SE,2023,Q1,Adult
219241462,21924146,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,Tablet,QD,2023,Q1,Chest pain,,2023,Q1,2,F,,20230221.0,20230130,20230304,EXP,,SE-AUROBINDO-AUR-APL-2023-003464,AUROBINDO,"Hoskuldsdottir G, Thorleifsson S J, Ravn-Fischer A, Eliasson B.. SGLT2-h?mmare kan beh?va s?ttas ut vid allvarliga sjukdomstillst?nd - Risk f?r ketoacidos hos personer med diabetes och insulinbrist. L?kartidningen. 2023;120:22113",64.0,YR,,,Y,,,20230304,,MD,SE,SE,2023,Q1,Adult
219241462,21924146,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,Tablet,QD,2023,Q1,Coronary artery occlusion,,2023,Q1,2,F,,20230221.0,20230130,20230304,EXP,,SE-AUROBINDO-AUR-APL-2023-003464,AUROBINDO,"Hoskuldsdottir G, Thorleifsson S J, Ravn-Fischer A, Eliasson B.. SGLT2-h?mmare kan beh?va s?ttas ut vid allvarliga sjukdomstillst?nd - Risk f?r ketoacidos hos personer med diabetes och insulinbrist. L?kartidningen. 2023;120:22113",64.0,YR,,,Y,,,20230304,,MD,SE,SE,2023,Q1,Adult
219241761,21924176,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day (10mg od)",,,U,,,,,10.0,MG,,QD,2023,Q1,Angioedema,,2023,Q1,1,I,20230102.0,20230119.0,20230130,20230130,EXP,,GB-AUROBINDO-AUR-APL-2023-003542,AUROBINDO,,60.0,YR,,M,Y,,,20230130,,MD,GB,GB,2023,Q1,Adult
219244011,21924401,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q1,Skin irritation,,2023,Q1,1,I,,20230127.0,20230130,20230130,EXP,GB-MHRA-TPP42580829C7331928YC1674553918547,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215181",BOEHRINGER INGELHEIM,,79.0,YR,E,M,Y,90.0,KG,20230130,,MD,GB,GB,2023,Q1,Elderly
219244011,21924401,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q1,Pollakiuria,,2023,Q1,1,I,,20230127.0,20230130,20230130,EXP,GB-MHRA-TPP42580829C7331928YC1674553918547,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215181",BOEHRINGER INGELHEIM,,79.0,YR,E,M,Y,90.0,KG,20230130,,MD,GB,GB,2023,Q1,Elderly
219251851,21925185,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day(10mg/24h)",22.5,MG,Y,,,,,10.0,MG,Coated tablet,QD,2023,Q1,Hypotension,,2023,Q1,1,I,20220911.0,20230119.0,20230130,20230130,EXP,,ES-AUROBINDO-AUR-APL-2023-003602,AUROBINDO,,47.0,YR,,M,Y,122.0,KG,20230130,,MD,ES,ES,2023,Q1,Adult
219251851,21925185,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day(10mg/24h)",22.5,MG,Y,,,,,10.0,MG,Coated tablet,QD,2023,Q1,Urinary tract infection bacterial,,2023,Q1,1,I,20220911.0,20230119.0,20230130,20230130,EXP,,ES-AUROBINDO-AUR-APL-2023-003602,AUROBINDO,,47.0,YR,,M,Y,122.0,KG,20230130,,MD,ES,ES,2023,Q1,Adult
219251851,21925185,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day(10mg/24h)",22.5,MG,Y,,,,,10.0,MG,Coated tablet,QD,2023,Q1,Hypotension,,2023,Q1,1,I,20220911.0,20230119.0,20230130,20230130,EXP,,ES-AUROBINDO-AUR-APL-2023-003602,AUROBINDO,,47.0,YR,,M,Y,122.0,KG,20230130,,MD,ES,ES,2023,Q1,Adult
219251851,21925185,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day(10mg/24h)",22.5,MG,Y,,,,,10.0,MG,Coated tablet,QD,2023,Q1,Urinary tract infection bacterial,,2023,Q1,1,I,20220911.0,20230119.0,20230130,20230130,EXP,,ES-AUROBINDO-AUR-APL-2023-003602,AUROBINDO,,47.0,YR,,M,Y,122.0,KG,20230130,,MD,ES,ES,2023,Q1,Adult
219281931,21928193,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q1,Lactic acidosis,,2023,Q1,1,I,,20230123.0,20230130,20230130,EXP,,US-BAUSCH-BL-2023-001345,BAUSCH AND LOMB,"Gronbeck K, Kruse D. Metformin-associated lactic acidosis with euglycemic diabetic ketoacidosis. Critical Care Medicine. 2023 JAN 01;51 (1):92. doi:10.1097/01.ccm.0000906600.16628.88",65.0,YR,,F,Y,,,20230130,,HP,US,US,2023,Q1,Elderly
219281931,21928193,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,1,I,,20230123.0,20230130,20230130,EXP,,US-BAUSCH-BL-2023-001345,BAUSCH AND LOMB,"Gronbeck K, Kruse D. Metformin-associated lactic acidosis with euglycemic diabetic ketoacidosis. Critical Care Medicine. 2023 JAN 01;51 (1):92. doi:10.1097/01.ccm.0000906600.16628.88",65.0,YR,,F,Y,,,20230130,,HP,US,US,2023,Q1,Elderly
219283632,21928363,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,,,Unknown,,206111.0,,,,,2023,Q1,Perineal abscess,,2023,Q1,2,F,,20230204.0,20230130,20230206,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215373",BOEHRINGER INGELHEIM,,63.0,YR,A,F,Y,,,20230206,,HP,AU,AU,2023,Q1,Adult
219283632,21928363,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,,,Unknown,,206111.0,,,,,2023,Q1,Fournier's gangrene,,2023,Q1,2,F,,20230204.0,20230130,20230206,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215373",BOEHRINGER INGELHEIM,,63.0,YR,A,F,Y,,,20230206,,HP,AU,AU,2023,Q1,Adult
219293171,21929317,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,Y,,Unknown,,206111.0,12.5,MG,,,2023,Q1,Vascular graft,,2023,Q1,1,I,,20230131.0,20230131,20230131,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215646",BOEHRINGER INGELHEIM,,76.0,YR,E,M,Y,,,20230131,,MD,AU,AU,2023,Q1,Elderly
219293171,21929317,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,Y,,Unknown,,206111.0,12.5,MG,,,2023,Q1,Balanoposthitis,,2023,Q1,1,I,,20230131.0,20230131,20230131,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215646",BOEHRINGER INGELHEIM,,76.0,YR,E,M,Y,,,20230131,,MD,AU,AU,2023,Q1,Elderly
219303641,21930364,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,10.0,MG,,,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,1,I,20221225.0,20230131.0,20230131,20230131,EXP,ES-AEMPS-1321151,"ES-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215683",BOEHRINGER INGELHEIM,,74.0,YR,E,M,Y,,,20230131,,MD,ES,ES,2023,Q1,Elderly
219303641,21930364,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,10.0,MG,,,2023,Q1,Lactic acidosis,,2023,Q1,1,I,20221225.0,20230131.0,20230131,20230131,EXP,ES-AEMPS-1321151,"ES-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215683",BOEHRINGER INGELHEIM,,74.0,YR,E,M,Y,,,20230131,,MD,ES,ES,2023,Q1,Elderly
219308172,21930817,9,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,UNK,,,,,,,,,,Tablet,,2023,Q1,Hyperglycaemic hyperosmolar nonketotic syndrome,,2023,Q1,2,F,20221215.0,20230327.0,20230131,20230331,EXP,,JP-ABBVIE-4288457,ABBVIE,,74.0,YR,,M,Y,60.0,KG,20230331,,PH,JP,JP,2023,Q1,Elderly
219311231,21931123,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,0.5 TAB EVERY DAY PO?,,,Y,N,E34056,20231111.0,,,,,QD,2023,Q1,Palpitations,,2023,Q1,1,I,20221129.0,,20230130,20230130,DIR,FDA-CDER-CTU-2023-8066,,FDA-CTU,,70.0,YR,,M,N,156.49,KG,20230118,N,HP,US,,2023,Q1,Elderly
219311231,21931123,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,0.5 TAB EVERY DAY PO?,,,Y,N,E34056,20231111.0,,,,,QD,2023,Q1,Respiratory depression,,2023,Q1,1,I,20221129.0,,20230130,20230130,DIR,FDA-CDER-CTU-2023-8066,,FDA-CTU,,70.0,YR,,M,N,156.49,KG,20230118,N,HP,US,,2023,Q1,Elderly
219317831,21931783,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q1,Lactic acidosis,,2023,Q1,1,I,,20230124.0,20230131,20230131,EXP,,US-EMD Serono-9379950,EMD SERONO INC,"Gronbeck K, Kruse D. METFORMIN-ASSOCIATED LACTIC ACIDOSIS WITH EUGLYCEMIC DIABETIC KETOACIDOSIS.. Critical Care Medicine. 2023 JAN 01;51(1):92.",65.0,YR,E,F,Y,,,20230131,,HP,US,,2023,Q1,Elderly
219317831,21931783,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q1,Sepsis,,2023,Q1,1,I,,20230124.0,20230131,20230131,EXP,,US-EMD Serono-9379950,EMD SERONO INC,"Gronbeck K, Kruse D. METFORMIN-ASSOCIATED LACTIC ACIDOSIS WITH EUGLYCEMIC DIABETIC KETOACIDOSIS.. Critical Care Medicine. 2023 JAN 01;51(1):92.",65.0,YR,E,F,Y,,,20230131,,HP,US,,2023,Q1,Elderly
219317831,21931783,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,1,I,,20230124.0,20230131,20230131,EXP,,US-EMD Serono-9379950,EMD SERONO INC,"Gronbeck K, Kruse D. METFORMIN-ASSOCIATED LACTIC ACIDOSIS WITH EUGLYCEMIC DIABETIC KETOACIDOSIS.. Critical Care Medicine. 2023 JAN 01;51(1):92.",65.0,YR,E,F,Y,,,20230131,,HP,US,,2023,Q1,Elderly
219329952,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q1,Rash,,2023,Q1,2,F,,20230222.0,20230131,20230303,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,59.0,YR,,F,Y,,,20230303,,CN,CA,CA,2023,Q1,Adult
219329952,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q1,Sepsis,,2023,Q1,2,F,,20230222.0,20230131,20230303,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,59.0,YR,,F,Y,,,20230303,,CN,CA,CA,2023,Q1,Adult
219329952,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q1,Joint effusion,,2023,Q1,2,F,,20230222.0,20230131,20230303,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,59.0,YR,,F,Y,,,20230303,,CN,CA,CA,2023,Q1,Adult
219329952,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q1,Antinuclear antibody positive,,2023,Q1,2,F,,20230222.0,20230131,20230303,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,59.0,YR,,F,Y,,,20230303,,CN,CA,CA,2023,Q1,Adult
219329952,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q1,Pain in extremity,,2023,Q1,2,F,,20230222.0,20230131,20230303,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,59.0,YR,,F,Y,,,20230303,,CN,CA,CA,2023,Q1,Adult
219329952,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q1,Pain,,2023,Q1,2,F,,20230222.0,20230131,20230303,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,59.0,YR,,F,Y,,,20230303,,CN,CA,CA,2023,Q1,Adult
219329952,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q1,Allergic sinusitis,,2023,Q1,2,F,,20230222.0,20230131,20230303,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,59.0,YR,,F,Y,,,20230303,,CN,CA,CA,2023,Q1,Adult
219329952,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q1,Incorrect dose administered,,2023,Q1,2,F,,20230222.0,20230131,20230303,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,59.0,YR,,F,Y,,,20230303,,CN,CA,CA,2023,Q1,Adult
219329952,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q1,Arthralgia,,2023,Q1,2,F,,20230222.0,20230131,20230303,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,59.0,YR,,F,Y,,,20230303,,CN,CA,CA,2023,Q1,Adult
219329952,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q1,Psoriasis,,2023,Q1,2,F,,20230222.0,20230131,20230303,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,59.0,YR,,F,Y,,,20230303,,CN,CA,CA,2023,Q1,Adult
219329952,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q1,C-reactive protein increased,,2023,Q1,2,F,,20230222.0,20230131,20230303,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,59.0,YR,,F,Y,,,20230303,,CN,CA,CA,2023,Q1,Adult
219329952,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q1,Arthropathy,,2023,Q1,2,F,,20230222.0,20230131,20230303,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,59.0,YR,,F,Y,,,20230303,,CN,CA,CA,2023,Q1,Adult
219329952,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q1,Tendonitis,,2023,Q1,2,F,,20230222.0,20230131,20230303,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,59.0,YR,,F,Y,,,20230303,,CN,CA,CA,2023,Q1,Adult
219329952,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q1,Blood uric acid increased,,2023,Q1,2,F,,20230222.0,20230131,20230303,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,59.0,YR,,F,Y,,,20230303,,CN,CA,CA,2023,Q1,Adult
219329952,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q1,Alanine aminotransferase increased,,2023,Q1,2,F,,20230222.0,20230131,20230303,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,59.0,YR,,F,Y,,,20230303,,CN,CA,CA,2023,Q1,Adult
219329952,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q1,Hepatic enzyme increased,,2023,Q1,2,F,,20230222.0,20230131,20230303,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,59.0,YR,,F,Y,,,20230303,,CN,CA,CA,2023,Q1,Adult
219329952,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q1,Injection site warmth,,2023,Q1,2,F,,20230222.0,20230131,20230303,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,59.0,YR,,F,Y,,,20230303,,CN,CA,CA,2023,Q1,Adult
219329952,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q1,Renal disorder,,2023,Q1,2,F,,20230222.0,20230131,20230303,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,59.0,YR,,F,Y,,,20230303,,CN,CA,CA,2023,Q1,Adult
219329952,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q1,Arthritis,,2023,Q1,2,F,,20230222.0,20230131,20230303,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,59.0,YR,,F,Y,,,20230303,,CN,CA,CA,2023,Q1,Adult
219329952,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q1,Joint swelling,,2023,Q1,2,F,,20230222.0,20230131,20230303,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,59.0,YR,,F,Y,,,20230303,,CN,CA,CA,2023,Q1,Adult
219329952,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q1,Synovitis,,2023,Q1,2,F,,20230222.0,20230131,20230303,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,59.0,YR,,F,Y,,,20230303,,CN,CA,CA,2023,Q1,Adult
219329952,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q1,Synovial disorder,,2023,Q1,2,F,,20230222.0,20230131,20230303,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,59.0,YR,,F,Y,,,20230303,,CN,CA,CA,2023,Q1,Adult
219329952,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q1,Urinary tract infection,,2023,Q1,2,F,,20230222.0,20230131,20230303,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,59.0,YR,,F,Y,,,20230303,,CN,CA,CA,2023,Q1,Adult
219329952,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q1,Osteoarthritis,,2023,Q1,2,F,,20230222.0,20230131,20230303,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,59.0,YR,,F,Y,,,20230303,,CN,CA,CA,2023,Q1,Adult
219329952,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q1,Drug ineffective,,2023,Q1,2,F,,20230222.0,20230131,20230303,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,59.0,YR,,F,Y,,,20230303,,CN,CA,CA,2023,Q1,Adult
219329952,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q1,Injection site pain,,2023,Q1,2,F,,20230222.0,20230131,20230303,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,59.0,YR,,F,Y,,,20230303,,CN,CA,CA,2023,Q1,Adult
219329952,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q1,Nephrolithiasis,,2023,Q1,2,F,,20230222.0,20230131,20230303,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,59.0,YR,,F,Y,,,20230303,,CN,CA,CA,2023,Q1,Adult
219329952,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q1,Blood iron decreased,,2023,Q1,2,F,,20230222.0,20230131,20230303,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,59.0,YR,,F,Y,,,20230303,,CN,CA,CA,2023,Q1,Adult
219329952,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q1,Condition aggravated,,2023,Q1,2,F,,20230222.0,20230131,20230303,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,59.0,YR,,F,Y,,,20230303,,CN,CA,CA,2023,Q1,Adult
219329952,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q1,Oedema,,2023,Q1,2,F,,20230222.0,20230131,20230303,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,59.0,YR,,F,Y,,,20230303,,CN,CA,CA,2023,Q1,Adult
219329952,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q1,Vitamin B12 decreased,,2023,Q1,2,F,,20230222.0,20230131,20230303,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,59.0,YR,,F,Y,,,20230303,,CN,CA,CA,2023,Q1,Adult
219329952,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q1,Pyrexia,,2023,Q1,2,F,,20230222.0,20230131,20230303,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,59.0,YR,,F,Y,,,20230303,,CN,CA,CA,2023,Q1,Adult
219329952,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q1,Cyst,,2023,Q1,2,F,,20230222.0,20230131,20230303,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,59.0,YR,,F,Y,,,20230303,,CN,CA,CA,2023,Q1,Adult
219340972,21934097,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, Q24H (cada 24 h)",1980.0,MG,Y,,,,,10.0,MG,,,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,2,F,20221225.0,20230130.0,20230201,20230201,EXP,ES-AEMPS-1321151,NVSC2023ES021152,NOVARTIS,,74.0,YR,,M,Y,,,20230201,,MD,ES,ES,2023,Q1,Elderly
219340972,21934097,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, Q24H (cada 24 h)",1980.0,MG,Y,,,,,10.0,MG,,,2023,Q1,Lactic acidosis,,2023,Q1,2,F,20221225.0,20230130.0,20230201,20230201,EXP,ES-AEMPS-1321151,NVSC2023ES021152,NOVARTIS,,74.0,YR,,M,Y,,,20230201,,MD,ES,ES,2023,Q1,Elderly
219348081,21934808,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q1,Hypokalaemia,,2023,Q1,1,I,,20230119.0,20230201,20230201,EXP,,FR-AUROBINDO-AUR-APL-2023-004963,AUROBINDO,Richard H. CEPRIM: clinical case 3. Landmarks in geriatrics. n?210:259-262,91.0,YR,,M,Y,,,20230201,,HP,FR,FR,2023,Q1,Elderly
219363561,21936356,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : At bedtime;?,,,N,D,,,,25.0,MG,,HS,2023,Q1,Diabetic foot infection,,2023,Q1,1,I,20221227.0,,20230131,20230131,DIR,646685,,FDA-CTU,,60.0,YR,,M,N,114.3,KG,20230131,N,PH,US,,2023,Q1,Adult
219363561,21936356,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Diabetic foot infection,,2023,Q1,1,I,20221227.0,,20230131,20230131,DIR,646685,,FDA-CTU,,60.0,YR,,M,N,114.3,KG,20230131,N,PH,US,,2023,Q1,Adult
219364351,21936435,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q1,Acidosis,,2023,Q1,1,I,20221001.0,20230130.0,20230201,20230201,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215718",BOEHRINGER INGELHEIM,,75.0,YR,E,M,Y,,,20230201,,MD,DE,DE,2023,Q1,Elderly
219364351,21936435,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q1,Femoral neck fracture,,2023,Q1,1,I,20221001.0,20230130.0,20230201,20230201,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215718",BOEHRINGER INGELHEIM,,75.0,YR,E,M,Y,,,20230201,,MD,DE,DE,2023,Q1,Elderly
219364351,21936435,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q1,Post procedural complication,,2023,Q1,1,I,20221001.0,20230130.0,20230201,20230201,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215718",BOEHRINGER INGELHEIM,,75.0,YR,E,M,Y,,,20230201,,MD,DE,DE,2023,Q1,Elderly
219366631,21936663,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Eye infection,,2023,Q1,1,I,,20230127.0,20230201,20230201,EXP,,CA-PFIZER INC-202300041387,PFIZER,,71.0,YR,,F,Y,,,20230201,,HP,CA,CA,2023,Q1,Elderly
219366631,21936663,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Viral infection,,2023,Q1,1,I,,20230127.0,20230201,20230201,EXP,,CA-PFIZER INC-202300041387,PFIZER,,71.0,YR,,F,Y,,,20230201,,HP,CA,CA,2023,Q1,Elderly
219366631,21936663,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Corneal infection,,2023,Q1,1,I,,20230127.0,20230201,20230201,EXP,,CA-PFIZER INC-202300041387,PFIZER,,71.0,YR,,F,Y,,,20230201,,HP,CA,CA,2023,Q1,Elderly
219366631,21936663,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Aphthous ulcer,,2023,Q1,1,I,,20230127.0,20230201,20230201,EXP,,CA-PFIZER INC-202300041387,PFIZER,,71.0,YR,,F,Y,,,20230201,,HP,CA,CA,2023,Q1,Elderly
219367381,21936738,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Unknown,,,,,,,,,,,,2023,Q1,Unresponsive to stimuli,,2023,Q1,1,I,,20230118.0,20230201,20230201,EXP,,US-Unichem Pharmaceuticals (USA) Inc-UCM202301-000125,UNICHEM,,65.0,YR,E,F,Y,,,20230201,,HP,US,,2023,Q1,Elderly
219367381,21936738,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Unknown,,,,,,,,,,,,2023,Q1,Hypotension,,2023,Q1,1,I,,20230118.0,20230201,20230201,EXP,,US-Unichem Pharmaceuticals (USA) Inc-UCM202301-000125,UNICHEM,,65.0,YR,E,F,Y,,,20230201,,HP,US,,2023,Q1,Elderly
219367381,21936738,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Unknown,,,,,,,,,,,,2023,Q1,Renal failure,,2023,Q1,1,I,,20230118.0,20230201,20230201,EXP,,US-Unichem Pharmaceuticals (USA) Inc-UCM202301-000125,UNICHEM,,65.0,YR,E,F,Y,,,20230201,,HP,US,,2023,Q1,Elderly
219367381,21936738,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Unknown,,,,,,,,,,,,2023,Q1,Lactic acidosis,,2023,Q1,1,I,,20230118.0,20230201,20230201,EXP,,US-Unichem Pharmaceuticals (USA) Inc-UCM202301-000125,UNICHEM,,65.0,YR,E,F,Y,,,20230201,,HP,US,,2023,Q1,Elderly
219367381,21936738,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Unknown,,,,,,,,,,,,2023,Q1,Mental impairment,,2023,Q1,1,I,,20230118.0,20230201,20230201,EXP,,US-Unichem Pharmaceuticals (USA) Inc-UCM202301-000125,UNICHEM,,65.0,YR,E,F,Y,,,20230201,,HP,US,,2023,Q1,Elderly
219367381,21936738,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Unknown,,,,,,,,,,,,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,1,I,,20230118.0,20230201,20230201,EXP,,US-Unichem Pharmaceuticals (USA) Inc-UCM202301-000125,UNICHEM,,65.0,YR,E,F,Y,,,20230201,,HP,US,,2023,Q1,Elderly
219367381,21936738,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Unknown,,,,,,,,,,,,2023,Q1,Bacterial sepsis,,2023,Q1,1,I,,20230118.0,20230201,20230201,EXP,,US-Unichem Pharmaceuticals (USA) Inc-UCM202301-000125,UNICHEM,,65.0,YR,E,F,Y,,,20230201,,HP,US,,2023,Q1,Elderly
219368551,21936855,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2023,Q1,Death,,2023,Q1,1,I,20210101.0,20230127.0,20230201,20230201,EXP,,US-PFIZER INC-202300041874,PFIZER,"Gummin, D.. 2021 Annual Report of the National Poison Data System (NPDS) from America^s Poison Centers: 39th Annual Report. Clinical Toxicology. 2022;60 (12):1381-1643",57.0,YR,,M,Y,,,20230201,,MD,US,US,2023,Q1,Adult
219368551,21936855,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Parenteral,UNK,,,D,,,,,,,,,2023,Q1,Death,,2023,Q1,1,I,20210101.0,20230127.0,20230201,20230201,EXP,,US-PFIZER INC-202300041874,PFIZER,"Gummin, D.. 2021 Annual Report of the National Poison Data System (NPDS) from America^s Poison Centers: 39th Annual Report. Clinical Toxicology. 2022;60 (12):1381-1643",57.0,YR,,M,Y,,,20230201,,MD,US,US,2023,Q1,Adult
219385741,21938574,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Lactic acidosis,,2023,Q1,1,I,,20230123.0,20230201,20230201,EXP,,US-PRINSTON PHARMACEUTICAL INC.-2023PRN00029,PRINSTON PHARMACEUTICAL,"Gronbeck K, Kruse D.. Metformin-Associated Lactic Acidosis With Euglycemic Diabetic Ketoacidosis.. Crit Care Med.. 2023;51:(1):92",65.0,YR,,F,Y,,,20230201,,HP,US,US,2023,Q1,Elderly
219385741,21938574,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,1,I,,20230123.0,20230201,20230201,EXP,,US-PRINSTON PHARMACEUTICAL INC.-2023PRN00029,PRINSTON PHARMACEUTICAL,"Gronbeck K, Kruse D.. Metformin-Associated Lactic Acidosis With Euglycemic Diabetic Ketoacidosis.. Crit Care Med.. 2023;51:(1):92",65.0,YR,,F,Y,,,20230201,,HP,US,US,2023,Q1,Elderly
219432671,21943267,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,Unknown,,212614.0,,,,,2023,Q1,Type 2 diabetes mellitus,,2023,Q1,1,I,20230201.0,20230201.0,20230202,20230202,PER,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-216271",BOEHRINGER INGELHEIM,,56.0,YR,A,M,Y,,,20230202,,CN,US,US,2023,Q1,Adult
219432671,21943267,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,Unknown,,212614.0,,,,,2023,Q1,Drug hypersensitivity,,2023,Q1,1,I,20230201.0,20230201.0,20230202,20230202,PER,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-216271",BOEHRINGER INGELHEIM,,56.0,YR,A,M,Y,,,20230202,,CN,US,US,2023,Q1,Adult
219483231,21948323,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q1,Pruritus genital,,2023,Q1,1,I,20220101.0,20230202.0,20230203,20230203,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-216229",BOEHRINGER INGELHEIM,,65.0,YR,E,M,Y,,,20230203,,HP,SG,SG,2023,Q1,Elderly
219516422,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Arthropathy,,2023,Q1,2,F,,20230303.0,20230203,20230307,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20230308,,HP,CA,CA,2023,Q1,Adult
219516422,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,C-reactive protein increased,,2023,Q1,2,F,,20230303.0,20230203,20230307,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20230308,,HP,CA,CA,2023,Q1,Adult
219516422,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Pain in extremity,,2023,Q1,2,F,,20230303.0,20230203,20230307,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20230308,,HP,CA,CA,2023,Q1,Adult
219516422,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Condition aggravated,,2023,Q1,2,F,,20230303.0,20230203,20230307,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20230308,,HP,CA,CA,2023,Q1,Adult
219516422,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Tendonitis,,2023,Q1,2,F,,20230303.0,20230203,20230307,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20230308,,HP,CA,CA,2023,Q1,Adult
219516422,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Osteoarthritis,,2023,Q1,2,F,,20230303.0,20230203,20230307,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20230308,,HP,CA,CA,2023,Q1,Adult
219516422,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Injection site warmth,,2023,Q1,2,F,,20230303.0,20230203,20230307,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20230308,,HP,CA,CA,2023,Q1,Adult
219516422,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Hepatic enzyme increased,,2023,Q1,2,F,,20230303.0,20230203,20230307,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20230308,,HP,CA,CA,2023,Q1,Adult
219516422,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Synovial disorder,,2023,Q1,2,F,,20230303.0,20230203,20230307,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20230308,,HP,CA,CA,2023,Q1,Adult
219516422,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Oedema,,2023,Q1,2,F,,20230303.0,20230203,20230307,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20230308,,HP,CA,CA,2023,Q1,Adult
219516422,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Incorrect dose administered,,2023,Q1,2,F,,20230303.0,20230203,20230307,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20230308,,HP,CA,CA,2023,Q1,Adult
219516422,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Rash,,2023,Q1,2,F,,20230303.0,20230203,20230307,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20230308,,HP,CA,CA,2023,Q1,Adult
219516422,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Cyst,,2023,Q1,2,F,,20230303.0,20230203,20230307,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20230308,,HP,CA,CA,2023,Q1,Adult
219516422,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Alanine aminotransferase increased,,2023,Q1,2,F,,20230303.0,20230203,20230307,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20230308,,HP,CA,CA,2023,Q1,Adult
219516422,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Synovitis,,2023,Q1,2,F,,20230303.0,20230203,20230307,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20230308,,HP,CA,CA,2023,Q1,Adult
219516422,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Nephrolithiasis,,2023,Q1,2,F,,20230303.0,20230203,20230307,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20230308,,HP,CA,CA,2023,Q1,Adult
219516422,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Injection site pain,,2023,Q1,2,F,,20230303.0,20230203,20230307,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20230308,,HP,CA,CA,2023,Q1,Adult
219516422,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Arthralgia,,2023,Q1,2,F,,20230303.0,20230203,20230307,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20230308,,HP,CA,CA,2023,Q1,Adult
219516422,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Drug ineffective,,2023,Q1,2,F,,20230303.0,20230203,20230307,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20230308,,HP,CA,CA,2023,Q1,Adult
219516422,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Psoriasis,,2023,Q1,2,F,,20230303.0,20230203,20230307,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20230308,,HP,CA,CA,2023,Q1,Adult
219516422,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Renal disorder,,2023,Q1,2,F,,20230303.0,20230203,20230307,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20230308,,HP,CA,CA,2023,Q1,Adult
219516422,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Blood uric acid increased,,2023,Q1,2,F,,20230303.0,20230203,20230307,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20230308,,HP,CA,CA,2023,Q1,Adult
219516422,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Joint swelling,,2023,Q1,2,F,,20230303.0,20230203,20230307,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20230308,,HP,CA,CA,2023,Q1,Adult
219516422,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Arthritis,,2023,Q1,2,F,,20230303.0,20230203,20230307,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20230308,,HP,CA,CA,2023,Q1,Adult
219516422,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Pain,,2023,Q1,2,F,,20230303.0,20230203,20230307,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20230308,,HP,CA,CA,2023,Q1,Adult
219516422,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Antinuclear antibody positive,,2023,Q1,2,F,,20230303.0,20230203,20230307,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20230308,,HP,CA,CA,2023,Q1,Adult
219516422,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Sepsis,,2023,Q1,2,F,,20230303.0,20230203,20230307,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20230308,,HP,CA,CA,2023,Q1,Adult
219516422,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Blood iron decreased,,2023,Q1,2,F,,20230303.0,20230203,20230307,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20230308,,HP,CA,CA,2023,Q1,Adult
219516422,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Pyrexia,,2023,Q1,2,F,,20230303.0,20230203,20230307,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20230308,,HP,CA,CA,2023,Q1,Adult
219516422,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Vitamin B12 decreased,,2023,Q1,2,F,,20230303.0,20230203,20230307,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20230308,,HP,CA,CA,2023,Q1,Adult
219516422,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Urinary tract infection,,2023,Q1,2,F,,20230303.0,20230203,20230307,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20230308,,HP,CA,CA,2023,Q1,Adult
219516422,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Allergic sinusitis,,2023,Q1,2,F,,20230303.0,20230203,20230307,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20230308,,HP,CA,CA,2023,Q1,Adult
219516422,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Joint effusion,,2023,Q1,2,F,,20230303.0,20230203,20230307,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20230308,,HP,CA,CA,2023,Q1,Adult
219528791,21952879,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",1980.0,MG,Y,,,,,10.0,MG,,QD,2023,Q1,Lactic acidosis,,2023,Q1,1,I,20221225.0,20230127.0,20230204,20230204,EXP,,ES-AUROBINDO-AUR-APL-2023-004565,AUROBINDO,,74.0,YR,,M,Y,,,20230204,,MD,ES,ES,2023,Q1,Elderly
219528791,21952879,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",1980.0,MG,Y,,,,,10.0,MG,,QD,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,1,I,20221225.0,20230127.0,20230204,20230204,EXP,,ES-AUROBINDO-AUR-APL-2023-004565,AUROBINDO,,74.0,YR,,M,Y,,,20230204,,MD,ES,ES,2023,Q1,Elderly
219531161,21953116,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,Tablet,QD,2023,Q1,Coronary artery occlusion,,2023,Q1,1,I,,20230123.0,20230204,20230204,EXP,,SE-AUROBINDO-AUR-APL-2023-004022,AUROBINDO,"Hoskuldsdottir G, Thorleifsson S J, Ravn-Fischer A, Eliasson B.. SGLT2-h?mmare kan beh?va s?ttas ut vid allvarliga sjukdomstillst?nd Risk f?r ketoacidos hos personer med diabetes och insulinbrist.. L?kartidningen. 2023;120:22113",64.0,YR,,,Y,,,20230204,,HP,SE,SE,2023,Q1,Adult
219531161,21953116,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,Tablet,QD,2023,Q1,Chest pain,,2023,Q1,1,I,,20230123.0,20230204,20230204,EXP,,SE-AUROBINDO-AUR-APL-2023-004022,AUROBINDO,"Hoskuldsdottir G, Thorleifsson S J, Ravn-Fischer A, Eliasson B.. SGLT2-h?mmare kan beh?va s?ttas ut vid allvarliga sjukdomstillst?nd Risk f?r ketoacidos hos personer med diabetes och insulinbrist.. L?kartidningen. 2023;120:22113",64.0,YR,,,Y,,,20230204,,HP,SE,SE,2023,Q1,Adult
219531161,21953116,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,Tablet,QD,2023,Q1,Atrial fibrillation,,2023,Q1,1,I,,20230123.0,20230204,20230204,EXP,,SE-AUROBINDO-AUR-APL-2023-004022,AUROBINDO,"Hoskuldsdottir G, Thorleifsson S J, Ravn-Fischer A, Eliasson B.. SGLT2-h?mmare kan beh?va s?ttas ut vid allvarliga sjukdomstillst?nd Risk f?r ketoacidos hos personer med diabetes och insulinbrist.. L?kartidningen. 2023;120:22113",64.0,YR,,,Y,,,20230204,,HP,SE,SE,2023,Q1,Adult
219544911,21954491,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Pseudomonas infection,,2023,Q1,1,I,,20230125.0,20230205,20230205,EXP,,US-AUROBINDO-AUR-APL-2023-004129,AUROBINDO,"Gronbeck K, Kruse D.. METFORMIN-ASSOCIATED LACTIC ACIDOSIS WITH EUGLYCEMIC DIABETIC KETOACIDOSIS.. Critical Care Medicine.. 2023;51(1)Supplement:92",65.0,YR,,F,Y,,,20230205,,MD,US,US,2023,Q1,Elderly
219544911,21954491,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Lactic acidosis,,2023,Q1,1,I,,20230125.0,20230205,20230205,EXP,,US-AUROBINDO-AUR-APL-2023-004129,AUROBINDO,"Gronbeck K, Kruse D.. METFORMIN-ASSOCIATED LACTIC ACIDOSIS WITH EUGLYCEMIC DIABETIC KETOACIDOSIS.. Critical Care Medicine.. 2023;51(1)Supplement:92",65.0,YR,,F,Y,,,20230205,,MD,US,US,2023,Q1,Elderly
219544911,21954491,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,1,I,,20230125.0,20230205,20230205,EXP,,US-AUROBINDO-AUR-APL-2023-004129,AUROBINDO,"Gronbeck K, Kruse D.. METFORMIN-ASSOCIATED LACTIC ACIDOSIS WITH EUGLYCEMIC DIABETIC KETOACIDOSIS.. Critical Care Medicine.. 2023;51(1)Supplement:92",65.0,YR,,F,Y,,,20230205,,MD,US,US,2023,Q1,Elderly
219544911,21954491,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Sepsis,,2023,Q1,1,I,,20230125.0,20230205,20230205,EXP,,US-AUROBINDO-AUR-APL-2023-004129,AUROBINDO,"Gronbeck K, Kruse D.. METFORMIN-ASSOCIATED LACTIC ACIDOSIS WITH EUGLYCEMIC DIABETIC KETOACIDOSIS.. Critical Care Medicine.. 2023;51(1)Supplement:92",65.0,YR,,F,Y,,,20230205,,MD,US,US,2023,Q1,Elderly
219544911,21954491,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Acute kidney injury,,2023,Q1,1,I,,20230125.0,20230205,20230205,EXP,,US-AUROBINDO-AUR-APL-2023-004129,AUROBINDO,"Gronbeck K, Kruse D.. METFORMIN-ASSOCIATED LACTIC ACIDOSIS WITH EUGLYCEMIC DIABETIC KETOACIDOSIS.. Critical Care Medicine.. 2023;51(1)Supplement:92",65.0,YR,,F,Y,,,20230205,,MD,US,US,2023,Q1,Elderly
219545351,21954535,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, Daily",,,U,,,,,,,,QD,2023,Q1,Lip swelling,,2023,Q1,1,I,20230106.0,20230126.0,20230205,20230205,EXP,,GB-AUROBINDO-AUR-APL-2023-001538,AUROBINDO,,80.0,YR,,M,Y,92.0,KG,20230205,,MD,GB,GB,2023,Q1,Elderly
219547951,21954795,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q1,Coma,,2023,Q1,1,I,,20230202.0,20230205,20230205,EXP,,NVSC2023US024498,NOVARTIS,"Spyres MB, Aldy K, Farrugia LA, Kang AM, Love JS, Campleman SL et al.. The toxicology investigators consortium 2020 annual Report. JOURNAL OF MEDICAL TOXICOLOGY. 2021;17:333-62",15.0,YR,,M,Y,,,20230206,,HP,US,US,2023,Q1,Youth
219547951,21954795,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q1,Depression,,2023,Q1,1,I,,20230202.0,20230205,20230205,EXP,,NVSC2023US024498,NOVARTIS,"Spyres MB, Aldy K, Farrugia LA, Kang AM, Love JS, Campleman SL et al.. The toxicology investigators consortium 2020 annual Report. JOURNAL OF MEDICAL TOXICOLOGY. 2021;17:333-62",15.0,YR,,M,Y,,,20230206,,HP,US,US,2023,Q1,Youth
219547951,21954795,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q1,Toxicity to various agents,,2023,Q1,1,I,,20230202.0,20230205,20230205,EXP,,NVSC2023US024498,NOVARTIS,"Spyres MB, Aldy K, Farrugia LA, Kang AM, Love JS, Campleman SL et al.. The toxicology investigators consortium 2020 annual Report. JOURNAL OF MEDICAL TOXICOLOGY. 2021;17:333-62",15.0,YR,,M,Y,,,20230206,,HP,US,US,2023,Q1,Youth
219547951,21954795,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q1,Hypotension,,2023,Q1,1,I,,20230202.0,20230205,20230205,EXP,,NVSC2023US024498,NOVARTIS,"Spyres MB, Aldy K, Farrugia LA, Kang AM, Love JS, Campleman SL et al.. The toxicology investigators consortium 2020 annual Report. JOURNAL OF MEDICAL TOXICOLOGY. 2021;17:333-62",15.0,YR,,M,Y,,,20230206,,HP,US,US,2023,Q1,Youth
219547951,21954795,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q1,Respiratory depression,,2023,Q1,1,I,,20230202.0,20230205,20230205,EXP,,NVSC2023US024498,NOVARTIS,"Spyres MB, Aldy K, Farrugia LA, Kang AM, Love JS, Campleman SL et al.. The toxicology investigators consortium 2020 annual Report. JOURNAL OF MEDICAL TOXICOLOGY. 2021;17:333-62",15.0,YR,,M,Y,,,20230206,,HP,US,US,2023,Q1,Youth
219547951,21954795,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q1,Anion gap,,2023,Q1,1,I,,20230202.0,20230205,20230205,EXP,,NVSC2023US024498,NOVARTIS,"Spyres MB, Aldy K, Farrugia LA, Kang AM, Love JS, Campleman SL et al.. The toxicology investigators consortium 2020 annual Report. JOURNAL OF MEDICAL TOXICOLOGY. 2021;17:333-62",15.0,YR,,M,Y,,,20230206,,HP,US,US,2023,Q1,Youth
219547951,21954795,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q1,Metabolic acidosis,,2023,Q1,1,I,,20230202.0,20230205,20230205,EXP,,NVSC2023US024498,NOVARTIS,"Spyres MB, Aldy K, Farrugia LA, Kang AM, Love JS, Campleman SL et al.. The toxicology investigators consortium 2020 annual Report. JOURNAL OF MEDICAL TOXICOLOGY. 2021;17:333-62",15.0,YR,,M,Y,,,20230206,,HP,US,US,2023,Q1,Youth
219555842,21955584,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Blood iron decreased,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Pain in extremity,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Synovitis,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Injection site warmth,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Condition aggravated,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Sepsis,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Synovial disorder,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Urinary tract infection,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Arthralgia,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Blood uric acid increased,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Oedema,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Cyst,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Osteoarthritis,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Nephrolithiasis,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Arthropathy,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Injection site pain,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Tendonitis,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,C-reactive protein increased,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Pain,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Joint swelling,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Alanine aminotransferase increased,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Arthritis,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Drug ineffective,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Renal disorder,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Antinuclear antibody positive,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Rash,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Allergic sinusitis,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Incorrect dose administered,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Joint effusion,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Psoriasis,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Hepatic enzyme increased,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Pyrexia,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Vitamin B12 decreased,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Blood iron decreased,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Pain in extremity,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Synovitis,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Injection site warmth,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Condition aggravated,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Sepsis,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Synovial disorder,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Urinary tract infection,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Arthralgia,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Blood uric acid increased,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Oedema,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Cyst,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Osteoarthritis,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Nephrolithiasis,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Arthropathy,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Injection site pain,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Tendonitis,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,C-reactive protein increased,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Pain,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Joint swelling,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Alanine aminotransferase increased,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Arthritis,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Drug ineffective,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Renal disorder,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Antinuclear antibody positive,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Rash,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Allergic sinusitis,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Incorrect dose administered,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Joint effusion,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Psoriasis,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Hepatic enzyme increased,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Pyrexia,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Vitamin B12 decreased,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Blood iron decreased,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Pain in extremity,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Synovitis,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Injection site warmth,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Condition aggravated,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Sepsis,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Synovial disorder,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Urinary tract infection,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Arthralgia,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Blood uric acid increased,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Oedema,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Cyst,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Osteoarthritis,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Nephrolithiasis,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Arthropathy,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Injection site pain,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Tendonitis,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,C-reactive protein increased,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Pain,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Joint swelling,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Alanine aminotransferase increased,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Arthritis,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Drug ineffective,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Renal disorder,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Antinuclear antibody positive,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Rash,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Allergic sinusitis,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Incorrect dose administered,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Joint effusion,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Psoriasis,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Hepatic enzyme increased,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Pyrexia,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219555842,21955584,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q1,Vitamin B12 decreased,,2023,Q1,2,F,,20230216.0,20230206,20230223,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-215649",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,,,20230223,,CN,CA,CA,2023,Q1,Adult
219558271,21955827,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,QD,2023,Q1,Drug ineffective,,2023,Q1,1,I,,20230131.0,20230206,20230206,EXP,,GR-EMD Serono-9381698,EMD SERONO INC,,62.0,YR,A,M,Y,,,20230206,,HP,GR,,2023,Q1,Adult
219558271,21955827,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,QD,2023,Q1,Glycosylated haemoglobin increased,,2023,Q1,1,I,,20230131.0,20230206,20230206,EXP,,GR-EMD Serono-9381698,EMD SERONO INC,,62.0,YR,A,M,Y,,,20230206,,HP,GR,,2023,Q1,Adult
219558271,21955827,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,QD,2023,Q1,Renal impairment,,2023,Q1,1,I,,20230131.0,20230206,20230206,EXP,,GR-EMD Serono-9381698,EMD SERONO INC,,62.0,YR,A,M,Y,,,20230206,,HP,GR,,2023,Q1,Adult
219558271,21955827,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,QD,2023,Q1,Gastroenteritis viral,,2023,Q1,1,I,,20230131.0,20230206,20230206,EXP,,GR-EMD Serono-9381698,EMD SERONO INC,,62.0,YR,A,M,Y,,,20230206,,HP,GR,,2023,Q1,Adult
219570573,21957057,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,3,F,,20230217.0,20230206,20230221,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-216027",BOEHRINGER INGELHEIM,"Tsigkriki L, Siarkos M, Ntantoy E, Mourvetidis P, Mavrogianni A, Askalidou T, et al. Euglycemic diabetic ketoacidosis related to SGLT2 intake, after acute myocardial infarction.. International congress of Cardiology, 20-22 October 2022. 2022 Oct;",57.0,YR,A,M,Y,,,20230221,,MD,GR,GR,2023,Q1,Adult
219570573,21957057,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Post procedural complication,,2023,Q1,3,F,,20230217.0,20230206,20230221,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-216027",BOEHRINGER INGELHEIM,"Tsigkriki L, Siarkos M, Ntantoy E, Mourvetidis P, Mavrogianni A, Askalidou T, et al. Euglycemic diabetic ketoacidosis related to SGLT2 intake, after acute myocardial infarction.. International congress of Cardiology, 20-22 October 2022. 2022 Oct;",57.0,YR,A,M,Y,,,20230221,,MD,GR,GR,2023,Q1,Adult
219570573,21957057,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Acute myocardial infarction,,2023,Q1,3,F,,20230217.0,20230206,20230221,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-216027",BOEHRINGER INGELHEIM,"Tsigkriki L, Siarkos M, Ntantoy E, Mourvetidis P, Mavrogianni A, Askalidou T, et al. Euglycemic diabetic ketoacidosis related to SGLT2 intake, after acute myocardial infarction.. International congress of Cardiology, 20-22 October 2022. 2022 Oct;",57.0,YR,A,M,Y,,,20230221,,MD,GR,GR,2023,Q1,Adult
219570573,21957057,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Atrioventricular block,,2023,Q1,3,F,,20230217.0,20230206,20230221,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-216027",BOEHRINGER INGELHEIM,"Tsigkriki L, Siarkos M, Ntantoy E, Mourvetidis P, Mavrogianni A, Askalidou T, et al. Euglycemic diabetic ketoacidosis related to SGLT2 intake, after acute myocardial infarction.. International congress of Cardiology, 20-22 October 2022. 2022 Oct;",57.0,YR,A,M,Y,,,20230221,,MD,GR,GR,2023,Q1,Adult
219571971,21957197,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Not known,,,U,,Unknown,,204629.0,,,Tablet,,2023,Q1,Metabolic acidosis,,2023,Q1,1,I,20230130.0,20230206.0,20230206,20230206,EXP,IT-MINISAL02-907955,"IT-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-216867",BOEHRINGER INGELHEIM,,62.0,YR,A,F,Y,,,20230206,,MD,IT,IT,2023,Q1,Adult
219573201,21957320,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q1,Crying,,2023,Q1,1,I,,20230128.0,20230206,20230206,EXP,CA-MHPD-E2B_05922551,CA-Accord-298848,ACCORD,,62.0,YR,A,F,Y,,,20230206,,HP,CA,CA,2023,Q1,Adult
219573201,21957320,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q1,Pain in extremity,,2023,Q1,1,I,,20230128.0,20230206,20230206,EXP,CA-MHPD-E2B_05922551,CA-Accord-298848,ACCORD,,62.0,YR,A,F,Y,,,20230206,,HP,CA,CA,2023,Q1,Adult
219579431,21957943,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tablet",,,U,U,,,,,,Tablet,,2023,Q1,Polydipsia,,2023,Q1,1,I,,20230131.0,20230206,20230206,EXP,,DE-MYLANLABS-2023M1011542,MYLAN,,81.0,YR,,M,Y,,,20230206,,MD,DE,DE,2023,Q1,Elderly
219579431,21957943,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tablet",,,U,U,,,,,,Tablet,,2023,Q1,Polyuria,,2023,Q1,1,I,,20230131.0,20230206,20230206,EXP,,DE-MYLANLABS-2023M1011542,MYLAN,,81.0,YR,,M,Y,,,20230206,,MD,DE,DE,2023,Q1,Elderly
219579431,21957943,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tablet",,,U,U,,,,,,Tablet,,2023,Q1,General physical health deterioration,,2023,Q1,1,I,,20230131.0,20230206,20230206,EXP,,DE-MYLANLABS-2023M1011542,MYLAN,,81.0,YR,,M,Y,,,20230206,,MD,DE,DE,2023,Q1,Elderly
219579431,21957943,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tablet",,,U,U,,,,,,Tablet,,2023,Q1,Hyperglycaemia,,2023,Q1,1,I,,20230131.0,20230206,20230206,EXP,,DE-MYLANLABS-2023M1011542,MYLAN,,81.0,YR,,M,Y,,,20230206,,MD,DE,DE,2023,Q1,Elderly
219583061,21958306,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Lactic acidosis,,2023,Q1,1,I,,20230123.0,20230206,20230206,EXP,,US-BEXIMCO-2023BEX00005,BEXIMCO PHARMACEUTICALS,"Gronbeck K, Kruse D.. Metformin-Associated Lactic Acidosis With Euglycemic Diabetic Ketoacidosis.. Crit Care Med.. 2023;51(1):92",65.0,YR,,F,Y,,,20230201,,HP,US,US,2023,Q1,Elderly
219583061,21958306,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,1,I,,20230123.0,20230206,20230206,EXP,,US-BEXIMCO-2023BEX00005,BEXIMCO PHARMACEUTICALS,"Gronbeck K, Kruse D.. Metformin-Associated Lactic Acidosis With Euglycemic Diabetic Ketoacidosis.. Crit Care Med.. 2023;51(1):92",65.0,YR,,F,Y,,,20230201,,HP,US,US,2023,Q1,Elderly
219591921,21959192,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q1,Liver injury,,2023,Q1,1,I,20221224.0,20230203.0,20230206,20230206,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-212022",BOEHRINGER INGELHEIM,,74.0,YR,E,F,Y,,,20230206,,MD,PL,PL,2023,Q1,Elderly
219596071,21959607,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,"25/5 mg, 1 tablet everyday",,,U,,106706,,206073.0,,,Tablet,QD,2023,Q1,Pathologic myopia,,2023,Q1,1,I,20080101.0,20230130.0,20230206,20230206,EXP,,"MX-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-216400",BOEHRINGER INGELHEIM,,66.0,YR,E,M,Y,69.0,KG,20230206,,CN,MX,MX,2023,Q1,Elderly
219596071,21959607,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,"25/5 mg, 1 tablet everyday",,,U,,106706,,206073.0,,,Tablet,QD,2023,Q1,Intraocular pressure test abnormal,,2023,Q1,1,I,20080101.0,20230130.0,20230206,20230206,EXP,,"MX-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-216400",BOEHRINGER INGELHEIM,,66.0,YR,E,M,Y,69.0,KG,20230206,,CN,MX,MX,2023,Q1,Elderly
219596071,21959607,2,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,U,,,,206073.0,,,,,2023,Q1,Pathologic myopia,,2023,Q1,1,I,20080101.0,20230130.0,20230206,20230206,EXP,,"MX-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-216400",BOEHRINGER INGELHEIM,,66.0,YR,E,M,Y,69.0,KG,20230206,,CN,MX,MX,2023,Q1,Elderly
219596071,21959607,2,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,U,,,,206073.0,,,,,2023,Q1,Intraocular pressure test abnormal,,2023,Q1,1,I,20080101.0,20230130.0,20230206,20230206,EXP,,"MX-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-216400",BOEHRINGER INGELHEIM,,66.0,YR,E,M,Y,69.0,KG,20230206,,CN,MX,MX,2023,Q1,Elderly
219598462,21959846,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,,,,,,10.0,MG,,,2023,Q1,Brain stem stroke,,2023,Q1,2,F,20190101.0,20230223.0,20230206,20230228,EXP,,HR-JNJFOC-20230213418,JOHNSON AND JOHNSON,,78.0,YR,E,M,Y,93.0,KG,20230228,,MD,HR,HR,2023,Q1,Elderly
219598462,21959846,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,,,,,,10.0,MG,,,2023,Q1,Hemiparesis,,2023,Q1,2,F,20190101.0,20230223.0,20230206,20230228,EXP,,HR-JNJFOC-20230213418,JOHNSON AND JOHNSON,,78.0,YR,E,M,Y,93.0,KG,20230228,,MD,HR,HR,2023,Q1,Elderly
219607021,21960702,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,1,I,,20230123.0,20230207,20230207,EXP,,US-Ajanta Pharma USA Inc.-2137585,AJANTA PHARMA,"Gronbeck K, Kruse D. METFORMIN-ASSOCIATED LACTIC ACIDOSIS WITH EUGLYCEMIC DIABETIC KETOACIDOSIS. Critical Care Medicine. 2023; 51:(1)92. DOI:10.1097/01.ccm.0000906600.16628.88",65.0,YR,,F,Y,,,20230207,,HP,US,US,2023,Q1,Elderly
219607021,21960702,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Lactic acidosis,,2023,Q1,1,I,,20230123.0,20230207,20230207,EXP,,US-Ajanta Pharma USA Inc.-2137585,AJANTA PHARMA,"Gronbeck K, Kruse D. METFORMIN-ASSOCIATED LACTIC ACIDOSIS WITH EUGLYCEMIC DIABETIC KETOACIDOSIS. Critical Care Medicine. 2023; 51:(1)92. DOI:10.1097/01.ccm.0000906600.16628.88",65.0,YR,,F,Y,,,20230207,,HP,US,US,2023,Q1,Elderly
219616011,21961601,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,UNKNOWN,,,,,,,2023,Q1,Pseudomonas infection,,2023,Q1,1,I,,20230125.0,20230207,20230207,EXP,,US-drreddys-SPO/USA/23/0160680,DR REDDYS,"Gronbeck K, Kruse D. METFORMIN-ASSOCIATED LACTIC ACIDOSIS WITH EUGLYCEMIC DIABETIC KETOACIDOSIS. Indian J Crit Care Med. 2023;51(1) 92:UNK-UNK. doi:10.1097/01.ccm.0000906600.16628.88.",65.0,YR,E,F,Y,,,20230207,,MD,US,US,2023,Q1,Elderly
219616011,21961601,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,UNKNOWN,,,,,,,2023,Q1,Sepsis,,2023,Q1,1,I,,20230125.0,20230207,20230207,EXP,,US-drreddys-SPO/USA/23/0160680,DR REDDYS,"Gronbeck K, Kruse D. METFORMIN-ASSOCIATED LACTIC ACIDOSIS WITH EUGLYCEMIC DIABETIC KETOACIDOSIS. Indian J Crit Care Med. 2023;51(1) 92:UNK-UNK. doi:10.1097/01.ccm.0000906600.16628.88.",65.0,YR,E,F,Y,,,20230207,,MD,US,US,2023,Q1,Elderly
219616011,21961601,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,UNKNOWN,,,,,,,2023,Q1,Acute kidney injury,,2023,Q1,1,I,,20230125.0,20230207,20230207,EXP,,US-drreddys-SPO/USA/23/0160680,DR REDDYS,"Gronbeck K, Kruse D. METFORMIN-ASSOCIATED LACTIC ACIDOSIS WITH EUGLYCEMIC DIABETIC KETOACIDOSIS. Indian J Crit Care Med. 2023;51(1) 92:UNK-UNK. doi:10.1097/01.ccm.0000906600.16628.88.",65.0,YR,E,F,Y,,,20230207,,MD,US,US,2023,Q1,Elderly
219616011,21961601,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,UNKNOWN,,,,,,,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,1,I,,20230125.0,20230207,20230207,EXP,,US-drreddys-SPO/USA/23/0160680,DR REDDYS,"Gronbeck K, Kruse D. METFORMIN-ASSOCIATED LACTIC ACIDOSIS WITH EUGLYCEMIC DIABETIC KETOACIDOSIS. Indian J Crit Care Med. 2023;51(1) 92:UNK-UNK. doi:10.1097/01.ccm.0000906600.16628.88.",65.0,YR,E,F,Y,,,20230207,,MD,US,US,2023,Q1,Elderly
219616011,21961601,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,UNKNOWN,,,,,,,2023,Q1,Lactic acidosis,,2023,Q1,1,I,,20230125.0,20230207,20230207,EXP,,US-drreddys-SPO/USA/23/0160680,DR REDDYS,"Gronbeck K, Kruse D. METFORMIN-ASSOCIATED LACTIC ACIDOSIS WITH EUGLYCEMIC DIABETIC KETOACIDOSIS. Indian J Crit Care Med. 2023;51(1) 92:UNK-UNK. doi:10.1097/01.ccm.0000906600.16628.88.",65.0,YR,E,F,Y,,,20230207,,MD,US,US,2023,Q1,Elderly
219626311,21962631,3,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1 dosage form, bid",,,U,,UNKNOWN,,,,,,BID,2023,Q1,Coronary artery disease,,2023,Q1,1,I,,20230202.0,20230207,20230207,EXP,,ES-TAKEDA-2023TUS011951,TAKEDA,,56.0,YR,,M,Y,93.0,KG,20230207,,HP,ES,ES,2023,Q1,Adult
219626311,21962631,3,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1 dosage form, bid",,,U,,UNKNOWN,,,,,,BID,2023,Q1,Acute myocardial infarction,,2023,Q1,1,I,,20230202.0,20230207,20230207,EXP,,ES-TAKEDA-2023TUS011951,TAKEDA,,56.0,YR,,M,Y,93.0,KG,20230207,,HP,ES,ES,2023,Q1,Adult
219626311,21962631,5,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,"2 dosage form, qd",,,,,UNKNOWN,,,,,,QD,2023,Q1,Coronary artery disease,,2023,Q1,1,I,,20230202.0,20230207,20230207,EXP,,ES-TAKEDA-2023TUS011951,TAKEDA,,56.0,YR,,M,Y,93.0,KG,20230207,,HP,ES,ES,2023,Q1,Adult
219626311,21962631,5,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,"2 dosage form, qd",,,,,UNKNOWN,,,,,,QD,2023,Q1,Acute myocardial infarction,,2023,Q1,1,I,,20230202.0,20230207,20230207,EXP,,ES-TAKEDA-2023TUS011951,TAKEDA,,56.0,YR,,M,Y,93.0,KG,20230207,,HP,ES,ES,2023,Q1,Adult
219627164,21962716,44,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,U,,,,10.0,MG,,,2023,Q1,Motor dysfunction,,2023,Q1,4,F,,20230313.0,20230207,20230320,EXP,,ES-MYLANLABS-2023M1012550,MYLAN,"Bugallo-Carrera C, Facal D, Dominguez-Lenogue C, Alvarez-Vidal V, Gandoy-Crego M, Caamano-Ponte J.. Neuropsychiatric Symptoms after Liver Transplantation in a 65-Year-Old Male Patient. BRAIN SCIENCES. 2022;12(1721):1-10",65.0,YR,,M,Y,,,20230320,,HP,ES,ES,2023,Q1,Elderly
219627164,21962716,44,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,U,,,,10.0,MG,,,2023,Q1,Affective disorder,,2023,Q1,4,F,,20230313.0,20230207,20230320,EXP,,ES-MYLANLABS-2023M1012550,MYLAN,"Bugallo-Carrera C, Facal D, Dominguez-Lenogue C, Alvarez-Vidal V, Gandoy-Crego M, Caamano-Ponte J.. Neuropsychiatric Symptoms after Liver Transplantation in a 65-Year-Old Male Patient. BRAIN SCIENCES. 2022;12(1721):1-10",65.0,YR,,M,Y,,,20230320,,HP,ES,ES,2023,Q1,Elderly
219627164,21962716,44,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,U,,,,10.0,MG,,,2023,Q1,Delusion of replacement,,2023,Q1,4,F,,20230313.0,20230207,20230320,EXP,,ES-MYLANLABS-2023M1012550,MYLAN,"Bugallo-Carrera C, Facal D, Dominguez-Lenogue C, Alvarez-Vidal V, Gandoy-Crego M, Caamano-Ponte J.. Neuropsychiatric Symptoms after Liver Transplantation in a 65-Year-Old Male Patient. BRAIN SCIENCES. 2022;12(1721):1-10",65.0,YR,,M,Y,,,20230320,,HP,ES,ES,2023,Q1,Elderly
219627164,21962716,44,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,U,,,,10.0,MG,,,2023,Q1,Jealous delusion,,2023,Q1,4,F,,20230313.0,20230207,20230320,EXP,,ES-MYLANLABS-2023M1012550,MYLAN,"Bugallo-Carrera C, Facal D, Dominguez-Lenogue C, Alvarez-Vidal V, Gandoy-Crego M, Caamano-Ponte J.. Neuropsychiatric Symptoms after Liver Transplantation in a 65-Year-Old Male Patient. BRAIN SCIENCES. 2022;12(1721):1-10",65.0,YR,,M,Y,,,20230320,,HP,ES,ES,2023,Q1,Elderly
219627164,21962716,44,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,U,,,,10.0,MG,,,2023,Q1,Pulmonary embolism,,2023,Q1,4,F,,20230313.0,20230207,20230320,EXP,,ES-MYLANLABS-2023M1012550,MYLAN,"Bugallo-Carrera C, Facal D, Dominguez-Lenogue C, Alvarez-Vidal V, Gandoy-Crego M, Caamano-Ponte J.. Neuropsychiatric Symptoms after Liver Transplantation in a 65-Year-Old Male Patient. BRAIN SCIENCES. 2022;12(1721):1-10",65.0,YR,,M,Y,,,20230320,,HP,ES,ES,2023,Q1,Elderly
219627164,21962716,44,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,U,,,,10.0,MG,,,2023,Q1,Confusional state,,2023,Q1,4,F,,20230313.0,20230207,20230320,EXP,,ES-MYLANLABS-2023M1012550,MYLAN,"Bugallo-Carrera C, Facal D, Dominguez-Lenogue C, Alvarez-Vidal V, Gandoy-Crego M, Caamano-Ponte J.. Neuropsychiatric Symptoms after Liver Transplantation in a 65-Year-Old Male Patient. BRAIN SCIENCES. 2022;12(1721):1-10",65.0,YR,,M,Y,,,20230320,,HP,ES,ES,2023,Q1,Elderly
219627164,21962716,44,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,U,,,,10.0,MG,,,2023,Q1,Hallucination,,2023,Q1,4,F,,20230313.0,20230207,20230320,EXP,,ES-MYLANLABS-2023M1012550,MYLAN,"Bugallo-Carrera C, Facal D, Dominguez-Lenogue C, Alvarez-Vidal V, Gandoy-Crego M, Caamano-Ponte J.. Neuropsychiatric Symptoms after Liver Transplantation in a 65-Year-Old Male Patient. BRAIN SCIENCES. 2022;12(1721):1-10",65.0,YR,,M,Y,,,20230320,,HP,ES,ES,2023,Q1,Elderly
219627164,21962716,44,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,U,,,,10.0,MG,,,2023,Q1,Irritability,,2023,Q1,4,F,,20230313.0,20230207,20230320,EXP,,ES-MYLANLABS-2023M1012550,MYLAN,"Bugallo-Carrera C, Facal D, Dominguez-Lenogue C, Alvarez-Vidal V, Gandoy-Crego M, Caamano-Ponte J.. Neuropsychiatric Symptoms after Liver Transplantation in a 65-Year-Old Male Patient. BRAIN SCIENCES. 2022;12(1721):1-10",65.0,YR,,M,Y,,,20230320,,HP,ES,ES,2023,Q1,Elderly
219627164,21962716,44,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,U,,,,10.0,MG,,,2023,Q1,Intrusive thoughts,,2023,Q1,4,F,,20230313.0,20230207,20230320,EXP,,ES-MYLANLABS-2023M1012550,MYLAN,"Bugallo-Carrera C, Facal D, Dominguez-Lenogue C, Alvarez-Vidal V, Gandoy-Crego M, Caamano-Ponte J.. Neuropsychiatric Symptoms after Liver Transplantation in a 65-Year-Old Male Patient. BRAIN SCIENCES. 2022;12(1721):1-10",65.0,YR,,M,Y,,,20230320,,HP,ES,ES,2023,Q1,Elderly
219627164,21962716,44,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,U,,,,10.0,MG,,,2023,Q1,Agitation,,2023,Q1,4,F,,20230313.0,20230207,20230320,EXP,,ES-MYLANLABS-2023M1012550,MYLAN,"Bugallo-Carrera C, Facal D, Dominguez-Lenogue C, Alvarez-Vidal V, Gandoy-Crego M, Caamano-Ponte J.. Neuropsychiatric Symptoms after Liver Transplantation in a 65-Year-Old Male Patient. BRAIN SCIENCES. 2022;12(1721):1-10",65.0,YR,,M,Y,,,20230320,,HP,ES,ES,2023,Q1,Elderly
219627164,21962716,44,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,U,,,,10.0,MG,,,2023,Q1,Atrial fibrillation,,2023,Q1,4,F,,20230313.0,20230207,20230320,EXP,,ES-MYLANLABS-2023M1012550,MYLAN,"Bugallo-Carrera C, Facal D, Dominguez-Lenogue C, Alvarez-Vidal V, Gandoy-Crego M, Caamano-Ponte J.. Neuropsychiatric Symptoms after Liver Transplantation in a 65-Year-Old Male Patient. BRAIN SCIENCES. 2022;12(1721):1-10",65.0,YR,,M,Y,,,20230320,,HP,ES,ES,2023,Q1,Elderly
219627164,21962716,44,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,U,,,,10.0,MG,,,2023,Q1,Anxiety,,2023,Q1,4,F,,20230313.0,20230207,20230320,EXP,,ES-MYLANLABS-2023M1012550,MYLAN,"Bugallo-Carrera C, Facal D, Dominguez-Lenogue C, Alvarez-Vidal V, Gandoy-Crego M, Caamano-Ponte J.. Neuropsychiatric Symptoms after Liver Transplantation in a 65-Year-Old Male Patient. BRAIN SCIENCES. 2022;12(1721):1-10",65.0,YR,,M,Y,,,20230320,,HP,ES,ES,2023,Q1,Elderly
219627164,21962716,44,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,U,,,,10.0,MG,,,2023,Q1,Neuropsychiatric symptoms,,2023,Q1,4,F,,20230313.0,20230207,20230320,EXP,,ES-MYLANLABS-2023M1012550,MYLAN,"Bugallo-Carrera C, Facal D, Dominguez-Lenogue C, Alvarez-Vidal V, Gandoy-Crego M, Caamano-Ponte J.. Neuropsychiatric Symptoms after Liver Transplantation in a 65-Year-Old Male Patient. BRAIN SCIENCES. 2022;12(1721):1-10",65.0,YR,,M,Y,,,20230320,,HP,ES,ES,2023,Q1,Elderly
219627164,21962716,44,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,U,,,,10.0,MG,,,2023,Q1,Cardiac failure congestive,,2023,Q1,4,F,,20230313.0,20230207,20230320,EXP,,ES-MYLANLABS-2023M1012550,MYLAN,"Bugallo-Carrera C, Facal D, Dominguez-Lenogue C, Alvarez-Vidal V, Gandoy-Crego M, Caamano-Ponte J.. Neuropsychiatric Symptoms after Liver Transplantation in a 65-Year-Old Male Patient. BRAIN SCIENCES. 2022;12(1721):1-10",65.0,YR,,M,Y,,,20230320,,HP,ES,ES,2023,Q1,Elderly
219627164,21962716,44,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,U,,,,10.0,MG,,,2023,Q1,Obsessive thoughts,,2023,Q1,4,F,,20230313.0,20230207,20230320,EXP,,ES-MYLANLABS-2023M1012550,MYLAN,"Bugallo-Carrera C, Facal D, Dominguez-Lenogue C, Alvarez-Vidal V, Gandoy-Crego M, Caamano-Ponte J.. Neuropsychiatric Symptoms after Liver Transplantation in a 65-Year-Old Male Patient. BRAIN SCIENCES. 2022;12(1721):1-10",65.0,YR,,M,Y,,,20230320,,HP,ES,ES,2023,Q1,Elderly
219627164,21962716,44,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,U,,,,10.0,MG,,,2023,Q1,Delusion,,2023,Q1,4,F,,20230313.0,20230207,20230320,EXP,,ES-MYLANLABS-2023M1012550,MYLAN,"Bugallo-Carrera C, Facal D, Dominguez-Lenogue C, Alvarez-Vidal V, Gandoy-Crego M, Caamano-Ponte J.. Neuropsychiatric Symptoms after Liver Transplantation in a 65-Year-Old Male Patient. BRAIN SCIENCES. 2022;12(1721):1-10",65.0,YR,,M,Y,,,20230320,,HP,ES,ES,2023,Q1,Elderly
219627164,21962716,44,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,U,,,,10.0,MG,,,2023,Q1,Insomnia,,2023,Q1,4,F,,20230313.0,20230207,20230320,EXP,,ES-MYLANLABS-2023M1012550,MYLAN,"Bugallo-Carrera C, Facal D, Dominguez-Lenogue C, Alvarez-Vidal V, Gandoy-Crego M, Caamano-Ponte J.. Neuropsychiatric Symptoms after Liver Transplantation in a 65-Year-Old Male Patient. BRAIN SCIENCES. 2022;12(1721):1-10",65.0,YR,,M,Y,,,20230320,,HP,ES,ES,2023,Q1,Elderly
219627164,21962716,44,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,U,,,,10.0,MG,,,2023,Q1,Depression,,2023,Q1,4,F,,20230313.0,20230207,20230320,EXP,,ES-MYLANLABS-2023M1012550,MYLAN,"Bugallo-Carrera C, Facal D, Dominguez-Lenogue C, Alvarez-Vidal V, Gandoy-Crego M, Caamano-Ponte J.. Neuropsychiatric Symptoms after Liver Transplantation in a 65-Year-Old Male Patient. BRAIN SCIENCES. 2022;12(1721):1-10",65.0,YR,,M,Y,,,20230320,,HP,ES,ES,2023,Q1,Elderly
219634841,21963484,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2023,Q1,Starvation ketoacidosis,,2023,Q1,1,I,20210531.0,,20230207,20230207,DIR,FDA-CDER-CTU-2023-10595,,FDA-CTU,,65.0,YR,,M,N,,,20211107,N,HP,US,,2023,Q1,Elderly
219634841,21963484,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2023,Q1,Hypoglycaemia,,2023,Q1,1,I,20210531.0,,20230207,20230207,DIR,FDA-CDER-CTU-2023-10595,,FDA-CTU,,65.0,YR,,M,N,,,20211107,N,HP,US,,2023,Q1,Elderly
219634841,21963484,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2023,Q1,Wrong product administered,,2023,Q1,1,I,20210531.0,,20230207,20230207,DIR,FDA-CDER-CTU-2023-10595,,FDA-CTU,,65.0,YR,,M,N,,,20211107,N,HP,US,,2023,Q1,Elderly
219634841,21963484,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2023,Q1,Pancreatitis,,2023,Q1,1,I,20210531.0,,20230207,20230207,DIR,FDA-CDER-CTU-2023-10595,,FDA-CTU,,65.0,YR,,M,N,,,20211107,N,HP,US,,2023,Q1,Elderly
219634841,21963484,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2023,Q1,Duplicate therapy error,,2023,Q1,1,I,20210531.0,,20230207,20230207,DIR,FDA-CDER-CTU-2023-10595,,FDA-CTU,,65.0,YR,,M,N,,,20211107,N,HP,US,,2023,Q1,Elderly
219634861,21963486,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,Tablet,,2023,Q1,Abdominal pain,,2023,Q1,1,I,20210125.0,,20230207,20230207,DIR,FDA-CDER-CTU-2023-10597,,FDA-CTU,,59.0,YR,,M,N,,,20211107,N,HP,US,,2023,Q1,Adult
219644781,21964478,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,Unknown,,204629.0,25.0,MG,,QD,2023,Q1,Gangrene,,2023,Q1,1,I,20230203.0,20230207.0,20230207,20230207,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-217232",BOEHRINGER INGELHEIM,,69.0,YR,E,M,Y,,,20230207,,HP,GB,GB,2023,Q1,Elderly
219644781,21964478,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,Unknown,,204629.0,25.0,MG,,QD,2023,Q1,Ketoacidosis,,2023,Q1,1,I,20230203.0,20230207.0,20230207,20230207,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-217232",BOEHRINGER INGELHEIM,,69.0,YR,E,M,Y,,,20230207,,HP,GB,GB,2023,Q1,Elderly
219645311,21964531,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,Unknown,,204629.0,,,,,2023,Q1,Rash,,2023,Q1,1,I,20230206.0,20230207.0,20230207,20230207,EXP,GB-MHRA-TPP30363833C1657801YC1675704855706,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-217249",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,110.0,KG,20230207,,MD,GB,GB,2023,Q1,Elderly
219645311,21964531,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,Unknown,,204629.0,,,,,2023,Q1,Burning sensation,,2023,Q1,1,I,20230206.0,20230207.0,20230207,20230207,EXP,GB-MHRA-TPP30363833C1657801YC1675704855706,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-217249",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,110.0,KG,20230207,,MD,GB,GB,2023,Q1,Elderly
219659461,21965946,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,,,,,2023,Q1,Lactic acidosis,,2023,Q1,1,I,20221225.0,20230131.0,20230208,20230208,EXP,ES-AEMPS-1321151,ES-EMD Serono-E2B_90090678,EMD SERONO INC,,74.0,YR,E,M,Y,,,20230208,,MD,ES,ES,2023,Q1,Elderly
219659461,21965946,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,,,,,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,1,I,20221225.0,20230131.0,20230208,20230208,EXP,ES-AEMPS-1321151,ES-EMD Serono-E2B_90090678,EMD SERONO INC,,74.0,YR,E,M,Y,,,20230208,,MD,ES,ES,2023,Q1,Elderly
219662201,21966220,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2023,Q1,Injection site reaction,,2023,Q1,1,I,,20220622.0,20230208,20230208,EXP,,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2022-06612,ALKEM,,74.0,YR,,M,Y,,,20230208,,MD,DE,DE,2023,Q1,Elderly
219662201,21966220,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2023,Q1,Weight increased,,2023,Q1,1,I,,20220622.0,20230208,20230208,EXP,,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2022-06612,ALKEM,,74.0,YR,,M,Y,,,20230208,,MD,DE,DE,2023,Q1,Elderly
219663221,21966322,3,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, Once a Day (((1 dosage form, bid (12.5/1,000 mg, two daily doses))",,,U,,,,,,,,QD,2023,Q1,Acute myocardial infarction,,2023,Q1,1,I,,20230131.0,20230208,20230208,EXP,,ES-AUROBINDO-AUR-APL-2023-005026,AUROBINDO,,56.0,YR,,M,Y,93.0,KG,20230208,,MD,ES,ES,2023,Q1,Adult
219663221,21966322,3,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, Once a Day (((1 dosage form, bid (12.5/1,000 mg, two daily doses))",,,U,,,,,,,,QD,2023,Q1,Coronary artery disease,,2023,Q1,1,I,,20230131.0,20230208,20230208,EXP,,ES-AUROBINDO-AUR-APL-2023-005026,AUROBINDO,,56.0,YR,,M,Y,93.0,KG,20230208,,MD,ES,ES,2023,Q1,Adult
219663221,21966322,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, Once a Day (1 dosage form, bid (5 mg/1,000 mg, 1-0-1))",,,U,,,,,,,,QD,2023,Q1,Acute myocardial infarction,,2023,Q1,1,I,,20230131.0,20230208,20230208,EXP,,ES-AUROBINDO-AUR-APL-2023-005026,AUROBINDO,,56.0,YR,,M,Y,93.0,KG,20230208,,MD,ES,ES,2023,Q1,Adult
219663221,21966322,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, Once a Day (1 dosage form, bid (5 mg/1,000 mg, 1-0-1))",,,U,,,,,,,,QD,2023,Q1,Coronary artery disease,,2023,Q1,1,I,,20230131.0,20230208,20230208,EXP,,ES-AUROBINDO-AUR-APL-2023-005026,AUROBINDO,,56.0,YR,,M,Y,93.0,KG,20230208,,MD,ES,ES,2023,Q1,Adult
219665881,21966588,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,every 1 Days,,,,,,,,,,Tablet,,2023,Q1,Eczema,,2023,Q1,1,I,,20230130.0,20230208,20230208,EXP,CA-MHPD-E2B_05951158,CA-Accord-299421,ACCORD,,79.0,YR,E,F,Y,90.0,KG,20230208,,HP,CA,CA,2023,Q1,Elderly
219665881,21966588,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,every 1 Days,,,,,,,,,,Tablet,,2023,Q1,Device issue,,2023,Q1,1,I,,20230130.0,20230208,20230208,EXP,CA-MHPD-E2B_05951158,CA-Accord-299421,ACCORD,,79.0,YR,E,F,Y,90.0,KG,20230208,,HP,CA,CA,2023,Q1,Elderly
219665881,21966588,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,every 1 Days,,,,,,,,,,Tablet,,2023,Q1,Meralgia paraesthetica,,2023,Q1,1,I,,20230130.0,20230208,20230208,EXP,CA-MHPD-E2B_05951158,CA-Accord-299421,ACCORD,,79.0,YR,E,F,Y,90.0,KG,20230208,,HP,CA,CA,2023,Q1,Elderly
219665881,21966588,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,every 1 Days,,,,,,,,,,Tablet,,2023,Q1,Immunosuppression,,2023,Q1,1,I,,20230130.0,20230208,20230208,EXP,CA-MHPD-E2B_05951158,CA-Accord-299421,ACCORD,,79.0,YR,E,F,Y,90.0,KG,20230208,,HP,CA,CA,2023,Q1,Elderly
219665881,21966588,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,every 1 Days,,,,,,,,,,Tablet,,2023,Q1,Diabetes mellitus,,2023,Q1,1,I,,20230130.0,20230208,20230208,EXP,CA-MHPD-E2B_05951158,CA-Accord-299421,ACCORD,,79.0,YR,E,F,Y,90.0,KG,20230208,,HP,CA,CA,2023,Q1,Elderly
219665881,21966588,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,every 1 Days,,,,,,,,,,Tablet,,2023,Q1,Therapy cessation,,2023,Q1,1,I,,20230130.0,20230208,20230208,EXP,CA-MHPD-E2B_05951158,CA-Accord-299421,ACCORD,,79.0,YR,E,F,Y,90.0,KG,20230208,,HP,CA,CA,2023,Q1,Elderly
219665881,21966588,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,every 1 Days,,,,,,,,,,Tablet,,2023,Q1,Diarrhoea,,2023,Q1,1,I,,20230130.0,20230208,20230208,EXP,CA-MHPD-E2B_05951158,CA-Accord-299421,ACCORD,,79.0,YR,E,F,Y,90.0,KG,20230208,,HP,CA,CA,2023,Q1,Elderly
219665881,21966588,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,every 1 Days,,,,,,,,,,Tablet,,2023,Q1,Fall,,2023,Q1,1,I,,20230130.0,20230208,20230208,EXP,CA-MHPD-E2B_05951158,CA-Accord-299421,ACCORD,,79.0,YR,E,F,Y,90.0,KG,20230208,,HP,CA,CA,2023,Q1,Elderly
219665881,21966588,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,every 1 Days,,,,,,,,,,Tablet,,2023,Q1,Contusion,,2023,Q1,1,I,,20230130.0,20230208,20230208,EXP,CA-MHPD-E2B_05951158,CA-Accord-299421,ACCORD,,79.0,YR,E,F,Y,90.0,KG,20230208,,HP,CA,CA,2023,Q1,Elderly
219665881,21966588,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,every 1 Days,,,,,,,,,,Tablet,,2023,Q1,Psoriasis,,2023,Q1,1,I,,20230130.0,20230208,20230208,EXP,CA-MHPD-E2B_05951158,CA-Accord-299421,ACCORD,,79.0,YR,E,F,Y,90.0,KG,20230208,,HP,CA,CA,2023,Q1,Elderly
219665881,21966588,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,every 1 Days,,,,,,,,,,Tablet,,2023,Q1,Joint injury,,2023,Q1,1,I,,20230130.0,20230208,20230208,EXP,CA-MHPD-E2B_05951158,CA-Accord-299421,ACCORD,,79.0,YR,E,F,Y,90.0,KG,20230208,,HP,CA,CA,2023,Q1,Elderly
219665881,21966588,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,every 1 Days,,,,,,,,,,Tablet,,2023,Q1,Skin haemorrhage,,2023,Q1,1,I,,20230130.0,20230208,20230208,EXP,CA-MHPD-E2B_05951158,CA-Accord-299421,ACCORD,,79.0,YR,E,F,Y,90.0,KG,20230208,,HP,CA,CA,2023,Q1,Elderly
219665881,21966588,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,every 1 Days,,,,,,,,,,Tablet,,2023,Q1,Gait disturbance,,2023,Q1,1,I,,20230130.0,20230208,20230208,EXP,CA-MHPD-E2B_05951158,CA-Accord-299421,ACCORD,,79.0,YR,E,F,Y,90.0,KG,20230208,,HP,CA,CA,2023,Q1,Elderly
219665881,21966588,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,every 1 Days,,,,,,,,,,Tablet,,2023,Q1,Limb injury,,2023,Q1,1,I,,20230130.0,20230208,20230208,EXP,CA-MHPD-E2B_05951158,CA-Accord-299421,ACCORD,,79.0,YR,E,F,Y,90.0,KG,20230208,,HP,CA,CA,2023,Q1,Elderly
219665881,21966588,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,every 1 Days,,,,,,,,,,Tablet,,2023,Q1,Lumbar spinal stenosis,,2023,Q1,1,I,,20230130.0,20230208,20230208,EXP,CA-MHPD-E2B_05951158,CA-Accord-299421,ACCORD,,79.0,YR,E,F,Y,90.0,KG,20230208,,HP,CA,CA,2023,Q1,Elderly
219665881,21966588,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,every 1 Days,,,,,,,,,,Tablet,,2023,Q1,Stomatitis,,2023,Q1,1,I,,20230130.0,20230208,20230208,EXP,CA-MHPD-E2B_05951158,CA-Accord-299421,ACCORD,,79.0,YR,E,F,Y,90.0,KG,20230208,,HP,CA,CA,2023,Q1,Elderly
219665881,21966588,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,every 1 Days,,,,,,,,,,Tablet,,2023,Q1,Intentional dose omission,,2023,Q1,1,I,,20230130.0,20230208,20230208,EXP,CA-MHPD-E2B_05951158,CA-Accord-299421,ACCORD,,79.0,YR,E,F,Y,90.0,KG,20230208,,HP,CA,CA,2023,Q1,Elderly
219665881,21966588,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,every 1 Days,,,,,,,,,,Tablet,,2023,Q1,Product physical consistency issue,,2023,Q1,1,I,,20230130.0,20230208,20230208,EXP,CA-MHPD-E2B_05951158,CA-Accord-299421,ACCORD,,79.0,YR,E,F,Y,90.0,KG,20230208,,HP,CA,CA,2023,Q1,Elderly
219665881,21966588,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,every 1 Days,,,,,,,,,,Tablet,,2023,Q1,Injection site pain,,2023,Q1,1,I,,20230130.0,20230208,20230208,EXP,CA-MHPD-E2B_05951158,CA-Accord-299421,ACCORD,,79.0,YR,E,F,Y,90.0,KG,20230208,,HP,CA,CA,2023,Q1,Elderly
219666481,21966648,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,Unknown,,206111.0,,,,,2023,Q1,Haematuria,,2023,Q1,1,I,,20230207.0,20230208,20230208,EXP,,"HK-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-217147",BOEHRINGER INGELHEIM,,85.0,YR,E,,Y,,,20230208,,MD,HK,HK,2023,Q1,Elderly
219701431,21970143,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,U,,Unknown,,206073.0,,,Tablet,,2023,Q1,Ketosis,,2023,Q1,1,I,20221102.0,20230208.0,20230209,20230209,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-217679",BOEHRINGER INGELHEIM,,71.0,YR,E,M,Y,54.0,KG,20230209,,PH,JP,JP,2023,Q1,Elderly
219701431,21970143,2,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,U,,Unknown,,206073.0,,,Tablet,,2023,Q1,Ketosis,,2023,Q1,1,I,20221102.0,20230208.0,20230209,20230209,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-217679",BOEHRINGER INGELHEIM,,71.0,YR,E,M,Y,54.0,KG,20230209,,PH,JP,JP,2023,Q1,Elderly
219711671,21971167,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 TABLET ONCE DAILY,,,,,,,,,,,,2023,Q1,Hypotension,,2023,Q1,1,I,20230130.0,20230202.0,20230209,20230209,EXP,,GB-AstraZeneca-2023A028534,ASTRAZENECA,,73.0,YR,,F,Y,65.8,KG,20230209,,MD,GB,,2023,Q1,Elderly
219711671,21971167,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 TABLET ONCE DAILY,,,,,,,,,,,,2023,Q1,Heart rate increased,,2023,Q1,1,I,20230130.0,20230202.0,20230209,20230209,EXP,,GB-AstraZeneca-2023A028534,ASTRAZENECA,,73.0,YR,,F,Y,65.8,KG,20230209,,MD,GB,,2023,Q1,Elderly
219715251,21971525,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Lactic acidosis,,2023,Q1,1,I,,20230203.0,20230209,20230209,EXP,,NVSC2023US025747,NOVARTIS,"Gronbeck K, Kruse D. Metformin-associated lactic acidosis with euglycemic diabetic ketoacidosis. CRITICAL CARE MEDICINE. 2023;51(1):92",65.0,YR,,F,Y,,,20230209,,HP,US,US,2023,Q1,Elderly
219715251,21971525,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,1,I,,20230203.0,20230209,20230209,EXP,,NVSC2023US025747,NOVARTIS,"Gronbeck K, Kruse D. Metformin-associated lactic acidosis with euglycemic diabetic ketoacidosis. CRITICAL CARE MEDICINE. 2023;51(1):92",65.0,YR,,F,Y,,,20230209,,HP,US,US,2023,Q1,Elderly
219719732,21971973,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,,,,U,,Unknown,,206073.0,,,Tablet,,2023,Q1,Pyrexia,,2023,Q1,2,F,,20230217.0,20230209,20230220,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-217667",BOEHRINGER INGELHEIM,,84.0,YR,E,M,Y,,,20230220,,MD,JP,JP,2023,Q1,Elderly
219719732,21971973,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,,,,U,,Unknown,,206073.0,,,Tablet,,2023,Q1,Abdominal pain lower,,2023,Q1,2,F,,20230217.0,20230209,20230220,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-217667",BOEHRINGER INGELHEIM,,84.0,YR,E,M,Y,,,20230220,,MD,JP,JP,2023,Q1,Elderly
219719732,21971973,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,,,,U,,Unknown,,206073.0,,,Tablet,,2023,Q1,Chills,,2023,Q1,2,F,,20230217.0,20230209,20230220,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-217667",BOEHRINGER INGELHEIM,,84.0,YR,E,M,Y,,,20230220,,MD,JP,JP,2023,Q1,Elderly
219723491,21972349,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q1,Septic shock,,2023,Q1,1,I,,20230209.0,20230209,20230209,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-217693",BOEHRINGER INGELHEIM,,67.0,YR,E,F,Y,,,20230209,,CN,AU,AU,2023,Q1,Elderly
219723491,21972349,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q1,Anal abscess,,2023,Q1,1,I,,20230209.0,20230209,20230209,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-217693",BOEHRINGER INGELHEIM,,67.0,YR,E,F,Y,,,20230209,,CN,AU,AU,2023,Q1,Elderly
219723491,21972349,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q1,Fournier's gangrene,,2023,Q1,1,I,,20230209.0,20230209,20230209,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-217693",BOEHRINGER INGELHEIM,,67.0,YR,E,F,Y,,,20230209,,CN,AU,AU,2023,Q1,Elderly
219759111,21975911,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q1,Metabolic acidosis,,2023,Q1,1,I,,20230131.0,20230210,20230210,EXP,,US-APOTEX-2023AP002834,APOTEX,"Spyres MB, Aldy K, Farrugia LA, Kang AM, Love JS, Campleman SL, et al. The Toxicology Investigators Consortium 2020 Annual Report. Journal of Medical Toxicology. 2021;17(4):333-362",15.0,YR,,M,Y,,,20230210,,HP,US,US,2023,Q1,Youth
219759111,21975911,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q1,Toxicity to various agents,,2023,Q1,1,I,,20230131.0,20230210,20230210,EXP,,US-APOTEX-2023AP002834,APOTEX,"Spyres MB, Aldy K, Farrugia LA, Kang AM, Love JS, Campleman SL, et al. The Toxicology Investigators Consortium 2020 Annual Report. Journal of Medical Toxicology. 2021;17(4):333-362",15.0,YR,,M,Y,,,20230210,,HP,US,US,2023,Q1,Youth
219759111,21975911,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q1,Respiratory depression,,2023,Q1,1,I,,20230131.0,20230210,20230210,EXP,,US-APOTEX-2023AP002834,APOTEX,"Spyres MB, Aldy K, Farrugia LA, Kang AM, Love JS, Campleman SL, et al. The Toxicology Investigators Consortium 2020 Annual Report. Journal of Medical Toxicology. 2021;17(4):333-362",15.0,YR,,M,Y,,,20230210,,HP,US,US,2023,Q1,Youth
219759111,21975911,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q1,Depressed level of consciousness,,2023,Q1,1,I,,20230131.0,20230210,20230210,EXP,,US-APOTEX-2023AP002834,APOTEX,"Spyres MB, Aldy K, Farrugia LA, Kang AM, Love JS, Campleman SL, et al. The Toxicology Investigators Consortium 2020 Annual Report. Journal of Medical Toxicology. 2021;17(4):333-362",15.0,YR,,M,Y,,,20230210,,HP,US,US,2023,Q1,Youth
219759111,21975911,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q1,Coma,,2023,Q1,1,I,,20230131.0,20230210,20230210,EXP,,US-APOTEX-2023AP002834,APOTEX,"Spyres MB, Aldy K, Farrugia LA, Kang AM, Love JS, Campleman SL, et al. The Toxicology Investigators Consortium 2020 Annual Report. Journal of Medical Toxicology. 2021;17(4):333-362",15.0,YR,,M,Y,,,20230210,,HP,US,US,2023,Q1,Youth
219759111,21975911,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q1,Anion gap abnormal,,2023,Q1,1,I,,20230131.0,20230210,20230210,EXP,,US-APOTEX-2023AP002834,APOTEX,"Spyres MB, Aldy K, Farrugia LA, Kang AM, Love JS, Campleman SL, et al. The Toxicology Investigators Consortium 2020 Annual Report. Journal of Medical Toxicology. 2021;17(4):333-362",15.0,YR,,M,Y,,,20230210,,HP,US,US,2023,Q1,Youth
219759111,21975911,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q1,Hypotension,,2023,Q1,1,I,,20230131.0,20230210,20230210,EXP,,US-APOTEX-2023AP002834,APOTEX,"Spyres MB, Aldy K, Farrugia LA, Kang AM, Love JS, Campleman SL, et al. The Toxicology Investigators Consortium 2020 Annual Report. Journal of Medical Toxicology. 2021;17(4):333-362",15.0,YR,,M,Y,,,20230210,,HP,US,US,2023,Q1,Youth
219777567,21977756,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,Tablets,,2023,Q1,Coronary artery disease,,2023,Q1,7,F,20230131.0,20230322.0,20230210,20230329,PER,,CN-Eisai Medical Research-EC-2023-133815,EISAI,,69.0,YR,E,F,Y,63.0,KG,20230329,,MD,CN,,2023,Q1,Elderly
219779111,21977911,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,1,I,,20230202.0,20230210,20230210,EXP,,US-MYLANLABS-2023M1013926,MYLAN,"Gronbeck K, Kruse D. METFORMIN-ASSOCIATED LACTIC ACIDOSIS WITH EUGLYCEMIC DIABETIC KETOACIDOSIS. Crit-Care-Med 2023;51 (Suppl.)(1):92 abstr. 216.",65.0,YR,,F,Y,,,20230210,,HP,US,US,2023,Q1,Elderly
219779111,21977911,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2023,Q1,Lactic acidosis,,2023,Q1,1,I,,20230202.0,20230210,20230210,EXP,,US-MYLANLABS-2023M1013926,MYLAN,"Gronbeck K, Kruse D. METFORMIN-ASSOCIATED LACTIC ACIDOSIS WITH EUGLYCEMIC DIABETIC KETOACIDOSIS. Crit-Care-Med 2023;51 (Suppl.)(1):92 abstr. 216.",65.0,YR,,F,Y,,,20230210,,HP,US,US,2023,Q1,Elderly
219779111,21977911,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2023,Q1,Renal failure,,2023,Q1,1,I,,20230202.0,20230210,20230210,EXP,,US-MYLANLABS-2023M1013926,MYLAN,"Gronbeck K, Kruse D. METFORMIN-ASSOCIATED LACTIC ACIDOSIS WITH EUGLYCEMIC DIABETIC KETOACIDOSIS. Crit-Care-Med 2023;51 (Suppl.)(1):92 abstr. 216.",65.0,YR,,F,Y,,,20230210,,HP,US,US,2023,Q1,Elderly
219784981,21978498,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"12.5 mg, BID",,,,,,,,12.5,MG,Tablet,BID,2023,Q1,Gastrointestinal haemorrhage,,2023,Q1,1,I,20220922.0,20221115.0,20230210,20230210,EXP,,US-BAYER-2023A016386,BAYER,,58.0,YR,A,M,Y,134.26,KG,20230210,,MD,US,US,2023,Q1,Adult
219800141,21980014,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,,,,,,2023,Q1,Death,,2023,Q1,1,I,,20230202.0,20230210,20230210,EXP,,US-BAUSCH-BL-2023-002244,BAUSCH AND LOMB,"Gummin D, Mowry J, Beuhler M, Spyker D, Rivers L, Feldman R, Brown K, Pham N, Bronstein A, Weber J. 2021 Annual Report of the National Poison Data System (NPDS) from America^s Poison Centers: 39th Annual Report. Clinical Toxicology. 2023 JAN 05;60 (12):1381-1643. doi:10.1080/15563650.2022.2132768",72.0,YR,,M,Y,,,20230210,,MD,US,US,2023,Q1,Elderly
219800471,21980047,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Ingestion,,,D,,,,,,,,,2023,Q1,Death,,2023,Q1,1,I,,20230202.0,20230210,20230210,EXP,,US-BAUSCH-BL-2023-002228,BAUSCH AND LOMB,"Gummin D, Mowry J, Beuhler M, Spyker D, Rivers L, Feldman R, Brown K, Pham N, Bronstein A, Weber J. 2021 Annual Report of the National Poison Data System (NPDS) from America^s Poison Centers: 39th Annual Report. Clinical Toxicology. 2023 JAN 05;60 (12):1381-1643. doi:10.1080/15563650.2022.2132768",57.0,YR,,M,Y,,,20230210,,MD,US,US,2023,Q1,Adult
219800471,21980047,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Parenteral,,,,D,,,,,,,,,2023,Q1,Death,,2023,Q1,1,I,,20230202.0,20230210,20230210,EXP,,US-BAUSCH-BL-2023-002228,BAUSCH AND LOMB,"Gummin D, Mowry J, Beuhler M, Spyker D, Rivers L, Feldman R, Brown K, Pham N, Bronstein A, Weber J. 2021 Annual Report of the National Poison Data System (NPDS) from America^s Poison Centers: 39th Annual Report. Clinical Toxicology. 2023 JAN 05;60 (12):1381-1643. doi:10.1080/15563650.2022.2132768",57.0,YR,,M,Y,,,20230210,,MD,US,US,2023,Q1,Adult
219836511,21983651,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5mg/1000mg,,,U,,Unknown,,208658.0,,,,QD,2023,Q1,Foot amputation,,2023,Q1,1,I,,20230210.0,20230213,20230213,EXP,,"PH-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-218361",BOEHRINGER INGELHEIM,,6.0,DEC,A,F,Y,,,20230213,,MD,PH,PH,2023,Q1,Child
219842101,21984210,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,strength- 12.5mg/1000mg,,,U,,Unknown,,206111.0,,,,,2023,Q1,Foot amputation,,2023,Q1,1,I,,20230210.0,20230213,20230213,EXP,,"PH-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-218358",BOEHRINGER INGELHEIM,,6.0,DEC,A,F,Y,,,20230213,,MD,PH,PH,2023,Q1,Child
219842211,21984221,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,strength- 12.5mg/1000mg,,,U,,Unknown,,206111.0,,,,,2023,Q1,Foot amputation,,2023,Q1,1,I,,20230210.0,20230213,20230213,EXP,,"PH-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-218360",BOEHRINGER INGELHEIM,,6.0,DEC,A,F,Y,,,20230213,,MD,PH,PH,2023,Q1,Child
219851552,21985155,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,Tablet,QD,2023,Q1,Atrial fibrillation,,2023,Q1,2,F,20210101.0,20230208.0,20230213,20230214,EXP,,SE-MYLANLABS-2023M1013314,MYLAN,"H?skuldsd?ttir Gudrun, Sigurdur James Thorleifsson, Annica Ravn-Fischer, Bj?rn Eliasson. SGLT2 inhibitors may need to be discontinued in severe disease states- Risk of ketoacidosis in people with diabetes and insulin deficiency. The medical journal. 2023;120:22113",64.0,YR,,,Y,,,20230214,,MD,SE,SE,2023,Q1,Adult
219851552,21985155,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,Tablet,QD,2023,Q1,Chest pain,,2023,Q1,2,F,20210101.0,20230208.0,20230213,20230214,EXP,,SE-MYLANLABS-2023M1013314,MYLAN,"H?skuldsd?ttir Gudrun, Sigurdur James Thorleifsson, Annica Ravn-Fischer, Bj?rn Eliasson. SGLT2 inhibitors may need to be discontinued in severe disease states- Risk of ketoacidosis in people with diabetes and insulin deficiency. The medical journal. 2023;120:22113",64.0,YR,,,Y,,,20230214,,MD,SE,SE,2023,Q1,Adult
219851552,21985155,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,Tablet,QD,2023,Q1,Ketoacidosis,,2023,Q1,2,F,20210101.0,20230208.0,20230213,20230214,EXP,,SE-MYLANLABS-2023M1013314,MYLAN,"H?skuldsd?ttir Gudrun, Sigurdur James Thorleifsson, Annica Ravn-Fischer, Bj?rn Eliasson. SGLT2 inhibitors may need to be discontinued in severe disease states- Risk of ketoacidosis in people with diabetes and insulin deficiency. The medical journal. 2023;120:22113",64.0,YR,,,Y,,,20230214,,MD,SE,SE,2023,Q1,Adult
219851552,21985155,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,Tablet,QD,2023,Q1,Coronary artery occlusion,,2023,Q1,2,F,20210101.0,20230208.0,20230213,20230214,EXP,,SE-MYLANLABS-2023M1013314,MYLAN,"H?skuldsd?ttir Gudrun, Sigurdur James Thorleifsson, Annica Ravn-Fischer, Bj?rn Eliasson. SGLT2 inhibitors may need to be discontinued in severe disease states- Risk of ketoacidosis in people with diabetes and insulin deficiency. The medical journal. 2023;120:22113",64.0,YR,,,Y,,,20230214,,MD,SE,SE,2023,Q1,Adult
219852901,21985290,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Renal failure,,2023,Q1,1,I,,20230202.0,20230213,20230213,EXP,,US-LUPIN PHARMACEUTICALS INC.-2023-00938,LUPIN,"Gronbeck K, Kruse D. Metformin-associated lactic acidosis with euglycemic diabetic ketoacidosis. Critical Care Medicine. 2023;51(1):92",65.0,YR,,F,Y,,,20230213,,HP,US,US,2023,Q1,Elderly
219852901,21985290,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,1,I,,20230202.0,20230213,20230213,EXP,,US-LUPIN PHARMACEUTICALS INC.-2023-00938,LUPIN,"Gronbeck K, Kruse D. Metformin-associated lactic acidosis with euglycemic diabetic ketoacidosis. Critical Care Medicine. 2023;51(1):92",65.0,YR,,F,Y,,,20230213,,HP,US,US,2023,Q1,Elderly
219852901,21985290,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Lactic acidosis,,2023,Q1,1,I,,20230202.0,20230213,20230213,EXP,,US-LUPIN PHARMACEUTICALS INC.-2023-00938,LUPIN,"Gronbeck K, Kruse D. Metformin-associated lactic acidosis with euglycemic diabetic ketoacidosis. Critical Care Medicine. 2023;51(1):92",65.0,YR,,F,Y,,,20230213,,HP,US,US,2023,Q1,Elderly
219861101,21986110,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,,10.0,MG,,QD,2023,Q1,Arthralgia,,2023,Q1,1,I,,20230206.0,20230213,20230213,EXP,,CA-FreseniusKabi-FK202301511,FRESENIUS KABI,,59.0,YR,A,F,Y,,,20230213,,HP,CA,CA,2023,Q1,Adult
219861101,21986110,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,,10.0,MG,,QD,2023,Q1,Antinuclear antibody positive,,2023,Q1,1,I,,20230206.0,20230213,20230213,EXP,,CA-FreseniusKabi-FK202301511,FRESENIUS KABI,,59.0,YR,A,F,Y,,,20230213,,HP,CA,CA,2023,Q1,Adult
219861101,21986110,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,,10.0,MG,,QD,2023,Q1,Allergic sinusitis,,2023,Q1,1,I,,20230206.0,20230213,20230213,EXP,,CA-FreseniusKabi-FK202301511,FRESENIUS KABI,,59.0,YR,A,F,Y,,,20230213,,HP,CA,CA,2023,Q1,Adult
219861101,21986110,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,,10.0,MG,,QD,2023,Q1,Alanine aminotransferase increased,,2023,Q1,1,I,,20230206.0,20230213,20230213,EXP,,CA-FreseniusKabi-FK202301511,FRESENIUS KABI,,59.0,YR,A,F,Y,,,20230213,,HP,CA,CA,2023,Q1,Adult
219862482,21986248,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Kidney infection,,2023,Q1,2,F,20220601.0,20230315.0,20230213,20230321,EXP,,CO-ELI_LILLY_AND_COMPANY-CO202212012135,ELI LILLY AND CO,,63.0,YR,,F,Y,,,20230321,,CN,CO,CO,2023,Q1,Adult
219862482,21986248,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Hypersensitivity,,2023,Q1,2,F,20220601.0,20230315.0,20230213,20230321,EXP,,CO-ELI_LILLY_AND_COMPANY-CO202212012135,ELI LILLY AND CO,,63.0,YR,,F,Y,,,20230321,,CN,CO,CO,2023,Q1,Adult
219862482,21986248,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Influenza,,2023,Q1,2,F,20220601.0,20230315.0,20230213,20230321,EXP,,CO-ELI_LILLY_AND_COMPANY-CO202212012135,ELI LILLY AND CO,,63.0,YR,,F,Y,,,20230321,,CN,CO,CO,2023,Q1,Adult
219862482,21986248,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Blood pressure decreased,,2023,Q1,2,F,20220601.0,20230315.0,20230213,20230321,EXP,,CO-ELI_LILLY_AND_COMPANY-CO202212012135,ELI LILLY AND CO,,63.0,YR,,F,Y,,,20230321,,CN,CO,CO,2023,Q1,Adult
219862482,21986248,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Influenza,,2023,Q1,2,F,20220601.0,20230315.0,20230213,20230321,EXP,,CO-ELI_LILLY_AND_COMPANY-CO202212012135,ELI LILLY AND CO,,63.0,YR,,F,Y,,,20230321,,CN,CO,CO,2023,Q1,Adult
219862482,21986248,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Oropharyngeal pain,,2023,Q1,2,F,20220601.0,20230315.0,20230213,20230321,EXP,,CO-ELI_LILLY_AND_COMPANY-CO202212012135,ELI LILLY AND CO,,63.0,YR,,F,Y,,,20230321,,CN,CO,CO,2023,Q1,Adult
219862482,21986248,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,General physical health deterioration,,2023,Q1,2,F,20220601.0,20230315.0,20230213,20230321,EXP,,CO-ELI_LILLY_AND_COMPANY-CO202212012135,ELI LILLY AND CO,,63.0,YR,,F,Y,,,20230321,,CN,CO,CO,2023,Q1,Adult
219862482,21986248,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Fat tissue increased,,2023,Q1,2,F,20220601.0,20230315.0,20230213,20230321,EXP,,CO-ELI_LILLY_AND_COMPANY-CO202212012135,ELI LILLY AND CO,,63.0,YR,,F,Y,,,20230321,,CN,CO,CO,2023,Q1,Adult
219862482,21986248,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Weight decreased,,2023,Q1,2,F,20220601.0,20230315.0,20230213,20230321,EXP,,CO-ELI_LILLY_AND_COMPANY-CO202212012135,ELI LILLY AND CO,,63.0,YR,,F,Y,,,20230321,,CN,CO,CO,2023,Q1,Adult
219862482,21986248,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Lung disorder,,2023,Q1,2,F,20220601.0,20230315.0,20230213,20230321,EXP,,CO-ELI_LILLY_AND_COMPANY-CO202212012135,ELI LILLY AND CO,,63.0,YR,,F,Y,,,20230321,,CN,CO,CO,2023,Q1,Adult
219862482,21986248,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Dehydration,,2023,Q1,2,F,20220601.0,20230315.0,20230213,20230321,EXP,,CO-ELI_LILLY_AND_COMPANY-CO202212012135,ELI LILLY AND CO,,63.0,YR,,F,Y,,,20230321,,CN,CO,CO,2023,Q1,Adult
219862482,21986248,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Blood glucose increased,,2023,Q1,2,F,20220601.0,20230315.0,20230213,20230321,EXP,,CO-ELI_LILLY_AND_COMPANY-CO202212012135,ELI LILLY AND CO,,63.0,YR,,F,Y,,,20230321,,CN,CO,CO,2023,Q1,Adult
219862482,21986248,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Ulcer,,2023,Q1,2,F,20220601.0,20230315.0,20230213,20230321,EXP,,CO-ELI_LILLY_AND_COMPANY-CO202212012135,ELI LILLY AND CO,,63.0,YR,,F,Y,,,20230321,,CN,CO,CO,2023,Q1,Adult
219865241,21986524,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,20230130.0,99.0,,,Tablet,QD,2023,Q1,Paraesthesia oral,,2023,Q1,1,I,20230202.0,,20230212,20230212,DIR,648287,,FDA-CTU,,66.0,YR,,M,N,75.6,KG,20230212,N,CN,US,,2023,Q1,Elderly
219865241,21986524,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,20230130.0,99.0,,,Tablet,QD,2023,Q1,Dizziness,,2023,Q1,1,I,20230202.0,,20230212,20230212,DIR,648287,,FDA-CTU,,66.0,YR,,M,N,75.6,KG,20230212,N,CN,US,,2023,Q1,Elderly
219866631,21986663,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Post procedural complication,,2023,Q1,1,I,,20230206.0,20230213,20230213,EXP,,"PT-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-216952",BOEHRINGER INGELHEIM,"Fustiga J, Fernandes M, Damaso F, Duarte JA, Rodrigues C. Postop Complication With Euglycemic Diabetic Ketoacidosis in a Patient Receiving Empagliflozin. Cureus. 2022 Dec 31;14:12doi:10.7759/cureus.33161.",77.0,YR,E,F,Y,,,20230213,,HP,PT,PT,2023,Q1,Elderly
219866631,21986663,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,1,I,,20230206.0,20230213,20230213,EXP,,"PT-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-216952",BOEHRINGER INGELHEIM,"Fustiga J, Fernandes M, Damaso F, Duarte JA, Rodrigues C. Postop Complication With Euglycemic Diabetic Ketoacidosis in a Patient Receiving Empagliflozin. Cureus. 2022 Dec 31;14:12doi:10.7759/cureus.33161.",77.0,YR,E,F,Y,,,20230213,,HP,PT,PT,2023,Q1,Elderly
219870601,21987060,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (after breakfast)",,,U,,,,,10.0,MG,Tablet,QD,2023,Q1,Diarrhoea,,2023,Q1,1,I,,20230208.0,20230213,20230213,EXP,,NVSJ2023JP002902,NOVARTIS,Kita K.. Gastrointestinal Symptoms ^Not For^ -Do Not Overlook Other Potential Diseases [Chapter 5] ...... of Patients Who Visit the Hospital with Diarrhea? Drug-induced Diarrhea. Internal Medicine. 2023;131:114-119,72.0,YR,,M,Y,64.5,KG,20230214,,HP,JP,JP,2023,Q1,Elderly
219887921,21988792,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Lactic acidosis,,2023,Q1,1,I,,20230202.0,20230214,20230214,EXP,,US-APOTEX-2023AP002786,APOTEX,"Gronbeck K, Kruse D.. Metformin-associated lactic acidosis with euglycemic diabetic ketoacidosis. Critical Care Medicine. 2023;51 (1):92",65.0,YR,,F,Y,,,20230214,,HP,US,US,2023,Q1,Elderly
219887921,21988792,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,1,I,,20230202.0,20230214,20230214,EXP,,US-APOTEX-2023AP002786,APOTEX,"Gronbeck K, Kruse D.. Metformin-associated lactic acidosis with euglycemic diabetic ketoacidosis. Critical Care Medicine. 2023;51 (1):92",65.0,YR,,F,Y,,,20230214,,HP,US,US,2023,Q1,Elderly
219894301,21989430,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",30.0,MG,Y,,E13459,,,10.0,MG,Tablet,QD,2023,Q1,Rash,,2023,Q1,1,I,20221211.0,20230204.0,20230214,20230214,EXP,,NVSC2023CN027343,NOVARTIS,,67.0,YR,,M,Y,60.0,KG,20230214,,HP,CN,CN,2023,Q1,Elderly
219894301,21989430,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",30.0,MG,Y,,E13459,,,10.0,MG,Tablet,QD,2023,Q1,Product use issue,,2023,Q1,1,I,20221211.0,20230204.0,20230214,20230214,EXP,,NVSC2023CN027343,NOVARTIS,,67.0,YR,,M,Y,60.0,KG,20230214,,HP,CN,CN,2023,Q1,Elderly
219894301,21989430,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",30.0,MG,Y,,E13459,,,10.0,MG,Tablet,QD,2023,Q1,Dermatitis allergic,,2023,Q1,1,I,20221211.0,20230204.0,20230214,20230214,EXP,,NVSC2023CN027343,NOVARTIS,,67.0,YR,,M,Y,60.0,KG,20230214,,HP,CN,CN,2023,Q1,Elderly
219902401,21990240,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"EMPAGLIFLOZINA (9048A), 10mg every 24h",,,Y,,UNKNOWN,,,,,,,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,1,I,20221225.0,20230205.0,20230214,20230214,EXP,ES-AEMPS-1321151,ES-TEVA-2023-ES-2854475,TEVA,,74.0,YR,E,M,Y,,,20230214,,MD,ES,ES,2023,Q1,Elderly
219902401,21990240,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"EMPAGLIFLOZINA (9048A), 10mg every 24h",,,Y,,UNKNOWN,,,,,,,2023,Q1,Lactic acidosis,,2023,Q1,1,I,20221225.0,20230205.0,20230214,20230214,EXP,ES-AEMPS-1321151,ES-TEVA-2023-ES-2854475,TEVA,,74.0,YR,E,M,Y,,,20230214,,MD,ES,ES,2023,Q1,Elderly
219922811,21992281,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q1,Depressed level of consciousness,,2023,Q1,1,I,,20230131.0,20230215,20230215,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-378431,RANBAXY,"Spyres MB, Aldy K, Farrugia LA, Kang AM, Love JS, Campleman SL, et al. The Toxicology Investigators Consortium 2020 Annual Report. J Med Toxicol. 2021;17(4):333-362",15.0,YR,,M,Y,,,20230215,,HP,US,US,2023,Q1,Youth
219922811,21992281,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q1,Respiratory depression,,2023,Q1,1,I,,20230131.0,20230215,20230215,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-378431,RANBAXY,"Spyres MB, Aldy K, Farrugia LA, Kang AM, Love JS, Campleman SL, et al. The Toxicology Investigators Consortium 2020 Annual Report. J Med Toxicol. 2021;17(4):333-362",15.0,YR,,M,Y,,,20230215,,HP,US,US,2023,Q1,Youth
219922811,21992281,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q1,Hypotension,,2023,Q1,1,I,,20230131.0,20230215,20230215,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-378431,RANBAXY,"Spyres MB, Aldy K, Farrugia LA, Kang AM, Love JS, Campleman SL, et al. The Toxicology Investigators Consortium 2020 Annual Report. J Med Toxicol. 2021;17(4):333-362",15.0,YR,,M,Y,,,20230215,,HP,US,US,2023,Q1,Youth
219922811,21992281,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q1,Toxicity to various agents,,2023,Q1,1,I,,20230131.0,20230215,20230215,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-378431,RANBAXY,"Spyres MB, Aldy K, Farrugia LA, Kang AM, Love JS, Campleman SL, et al. The Toxicology Investigators Consortium 2020 Annual Report. J Med Toxicol. 2021;17(4):333-362",15.0,YR,,M,Y,,,20230215,,HP,US,US,2023,Q1,Youth
219922811,21992281,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q1,Coma,,2023,Q1,1,I,,20230131.0,20230215,20230215,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-378431,RANBAXY,"Spyres MB, Aldy K, Farrugia LA, Kang AM, Love JS, Campleman SL, et al. The Toxicology Investigators Consortium 2020 Annual Report. J Med Toxicol. 2021;17(4):333-362",15.0,YR,,M,Y,,,20230215,,HP,US,US,2023,Q1,Youth
219922811,21992281,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q1,Metabolic acidosis,,2023,Q1,1,I,,20230131.0,20230215,20230215,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-378431,RANBAXY,"Spyres MB, Aldy K, Farrugia LA, Kang AM, Love JS, Campleman SL, et al. The Toxicology Investigators Consortium 2020 Annual Report. J Med Toxicol. 2021;17(4):333-362",15.0,YR,,M,Y,,,20230215,,HP,US,US,2023,Q1,Youth
219922811,21992281,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q1,Anion gap,,2023,Q1,1,I,,20230131.0,20230215,20230215,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-378431,RANBAXY,"Spyres MB, Aldy K, Farrugia LA, Kang AM, Love JS, Campleman SL, et al. The Toxicology Investigators Consortium 2020 Annual Report. J Med Toxicol. 2021;17(4):333-362",15.0,YR,,M,Y,,,20230215,,HP,US,US,2023,Q1,Youth
219926871,21992687,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,1,I,20221201.0,20230214.0,20230215,20230215,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-218918",BOEHRINGER INGELHEIM,,4.0,DEC,A,F,Y,,,20230215,,MD,AU,AU,2023,Q1,Child
219926871,21992687,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q1,Gastric disorder,,2023,Q1,1,I,20221201.0,20230214.0,20230215,20230215,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-218918",BOEHRINGER INGELHEIM,,4.0,DEC,A,F,Y,,,20230215,,MD,AU,AU,2023,Q1,Child
219927481,21992748,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q1,Illness,,2023,Q1,1,I,20221201.0,20230214.0,20230215,20230215,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-218920",BOEHRINGER INGELHEIM,,6.0,DEC,A,F,Y,,,20230215,,MD,AU,AU,2023,Q1,Child
219937301,21993730,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10mg,,,U,,,,,,,,,2023,Q1,Sinonasal obstruction,,2023,Q1,1,I,,20230210.0,20230215,20230215,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-218155",BOEHRINGER INGELHEIM,,74.0,YR,E,F,Y,,,20230215,,MD,SI,SI,2023,Q1,Elderly
219937301,21993730,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10mg,,,U,,,,,,,,,2023,Q1,Coronary artery disease,,2023,Q1,1,I,,20230210.0,20230215,20230215,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-218155",BOEHRINGER INGELHEIM,,74.0,YR,E,F,Y,,,20230215,,MD,SI,SI,2023,Q1,Elderly
219937301,21993730,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10mg,,,U,,,,,,,,,2023,Q1,Cardiac failure,,2023,Q1,1,I,,20230210.0,20230215,20230215,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-218155",BOEHRINGER INGELHEIM,,74.0,YR,E,F,Y,,,20230215,,MD,SI,SI,2023,Q1,Elderly
219937301,21993730,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10mg,,,U,,,,,,,,,2023,Q1,Pulmonary oedema,,2023,Q1,1,I,,20230210.0,20230215,20230215,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-218155",BOEHRINGER INGELHEIM,,74.0,YR,E,F,Y,,,20230215,,MD,SI,SI,2023,Q1,Elderly
219937301,21993730,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10mg,,,U,,,,,,,,,2023,Q1,N-terminal prohormone brain natriuretic peptide increased,,2023,Q1,1,I,,20230210.0,20230215,20230215,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-218155",BOEHRINGER INGELHEIM,,74.0,YR,E,F,Y,,,20230215,,MD,SI,SI,2023,Q1,Elderly
219937301,21993730,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10mg,,,U,,,,,,,,,2023,Q1,Troponin increased,,2023,Q1,1,I,,20230210.0,20230215,20230215,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-218155",BOEHRINGER INGELHEIM,,74.0,YR,E,F,Y,,,20230215,,MD,SI,SI,2023,Q1,Elderly
219937301,21993730,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10mg,,,U,,,,,,,,,2023,Q1,Aortic stenosis,,2023,Q1,1,I,,20230210.0,20230215,20230215,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-218155",BOEHRINGER INGELHEIM,,74.0,YR,E,F,Y,,,20230215,,MD,SI,SI,2023,Q1,Elderly
219937301,21993730,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10mg,,,U,,,,,,,,,2023,Q1,Glomerular filtration rate decreased,,2023,Q1,1,I,,20230210.0,20230215,20230215,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-218155",BOEHRINGER INGELHEIM,,74.0,YR,E,F,Y,,,20230215,,MD,SI,SI,2023,Q1,Elderly
219953621,21995362,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q1,Depressed level of consciousness,,2023,Q1,1,I,,20230211.0,20230215,20230215,EXP,,UA-SA-2023SA049604,SANOFI AVENTIS,"Tseluyko V, Mishchuk N, Ivanitska L.. Hyponatremia in patients with decompensated heart failure. Ukrainian Cardiology Journal No. 5-6. 2022;29:59-70",56.0,YR,A,F,Y,67.0,KG,20230215,,HP,UA,UA,2023,Q1,Adult
219953621,21995362,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q1,Nausea,,2023,Q1,1,I,,20230211.0,20230215,20230215,EXP,,UA-SA-2023SA049604,SANOFI AVENTIS,"Tseluyko V, Mishchuk N, Ivanitska L.. Hyponatremia in patients with decompensated heart failure. Ukrainian Cardiology Journal No. 5-6. 2022;29:59-70",56.0,YR,A,F,Y,67.0,KG,20230215,,HP,UA,UA,2023,Q1,Adult
219953621,21995362,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q1,Sluggishness,,2023,Q1,1,I,,20230211.0,20230215,20230215,EXP,,UA-SA-2023SA049604,SANOFI AVENTIS,"Tseluyko V, Mishchuk N, Ivanitska L.. Hyponatremia in patients with decompensated heart failure. Ukrainian Cardiology Journal No. 5-6. 2022;29:59-70",56.0,YR,A,F,Y,67.0,KG,20230215,,HP,UA,UA,2023,Q1,Adult
219953621,21995362,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q1,Head injury,,2023,Q1,1,I,,20230211.0,20230215,20230215,EXP,,UA-SA-2023SA049604,SANOFI AVENTIS,"Tseluyko V, Mishchuk N, Ivanitska L.. Hyponatremia in patients with decompensated heart failure. Ukrainian Cardiology Journal No. 5-6. 2022;29:59-70",56.0,YR,A,F,Y,67.0,KG,20230215,,HP,UA,UA,2023,Q1,Adult
219953621,21995362,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q1,Jaundice,,2023,Q1,1,I,,20230211.0,20230215,20230215,EXP,,UA-SA-2023SA049604,SANOFI AVENTIS,"Tseluyko V, Mishchuk N, Ivanitska L.. Hyponatremia in patients with decompensated heart failure. Ukrainian Cardiology Journal No. 5-6. 2022;29:59-70",56.0,YR,A,F,Y,67.0,KG,20230215,,HP,UA,UA,2023,Q1,Adult
219953621,21995362,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q1,Hypotension,,2023,Q1,1,I,,20230211.0,20230215,20230215,EXP,,UA-SA-2023SA049604,SANOFI AVENTIS,"Tseluyko V, Mishchuk N, Ivanitska L.. Hyponatremia in patients with decompensated heart failure. Ukrainian Cardiology Journal No. 5-6. 2022;29:59-70",56.0,YR,A,F,Y,67.0,KG,20230215,,HP,UA,UA,2023,Q1,Adult
219953621,21995362,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q1,Lethargy,,2023,Q1,1,I,,20230211.0,20230215,20230215,EXP,,UA-SA-2023SA049604,SANOFI AVENTIS,"Tseluyko V, Mishchuk N, Ivanitska L.. Hyponatremia in patients with decompensated heart failure. Ukrainian Cardiology Journal No. 5-6. 2022;29:59-70",56.0,YR,A,F,Y,67.0,KG,20230215,,HP,UA,UA,2023,Q1,Adult
219953621,21995362,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q1,Fall,,2023,Q1,1,I,,20230211.0,20230215,20230215,EXP,,UA-SA-2023SA049604,SANOFI AVENTIS,"Tseluyko V, Mishchuk N, Ivanitska L.. Hyponatremia in patients with decompensated heart failure. Ukrainian Cardiology Journal No. 5-6. 2022;29:59-70",56.0,YR,A,F,Y,67.0,KG,20230215,,HP,UA,UA,2023,Q1,Adult
219953621,21995362,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q1,Asthenia,,2023,Q1,1,I,,20230211.0,20230215,20230215,EXP,,UA-SA-2023SA049604,SANOFI AVENTIS,"Tseluyko V, Mishchuk N, Ivanitska L.. Hyponatremia in patients with decompensated heart failure. Ukrainian Cardiology Journal No. 5-6. 2022;29:59-70",56.0,YR,A,F,Y,67.0,KG,20230215,,HP,UA,UA,2023,Q1,Adult
219953621,21995362,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q1,Hypoosmolar state,,2023,Q1,1,I,,20230211.0,20230215,20230215,EXP,,UA-SA-2023SA049604,SANOFI AVENTIS,"Tseluyko V, Mishchuk N, Ivanitska L.. Hyponatremia in patients with decompensated heart failure. Ukrainian Cardiology Journal No. 5-6. 2022;29:59-70",56.0,YR,A,F,Y,67.0,KG,20230215,,HP,UA,UA,2023,Q1,Adult
219953621,21995362,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q1,Hyponatraemia,,2023,Q1,1,I,,20230211.0,20230215,20230215,EXP,,UA-SA-2023SA049604,SANOFI AVENTIS,"Tseluyko V, Mishchuk N, Ivanitska L.. Hyponatremia in patients with decompensated heart failure. Ukrainian Cardiology Journal No. 5-6. 2022;29:59-70",56.0,YR,A,F,Y,67.0,KG,20230215,,HP,UA,UA,2023,Q1,Adult
219953621,21995362,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q1,Haematoma,,2023,Q1,1,I,,20230211.0,20230215,20230215,EXP,,UA-SA-2023SA049604,SANOFI AVENTIS,"Tseluyko V, Mishchuk N, Ivanitska L.. Hyponatremia in patients with decompensated heart failure. Ukrainian Cardiology Journal No. 5-6. 2022;29:59-70",56.0,YR,A,F,Y,67.0,KG,20230215,,HP,UA,UA,2023,Q1,Adult
219953621,21995362,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q1,Hypovolaemia,,2023,Q1,1,I,,20230211.0,20230215,20230215,EXP,,UA-SA-2023SA049604,SANOFI AVENTIS,"Tseluyko V, Mishchuk N, Ivanitska L.. Hyponatremia in patients with decompensated heart failure. Ukrainian Cardiology Journal No. 5-6. 2022;29:59-70",56.0,YR,A,F,Y,67.0,KG,20230215,,HP,UA,UA,2023,Q1,Adult
219953621,21995362,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q1,Dry skin,,2023,Q1,1,I,,20230211.0,20230215,20230215,EXP,,UA-SA-2023SA049604,SANOFI AVENTIS,"Tseluyko V, Mishchuk N, Ivanitska L.. Hyponatremia in patients with decompensated heart failure. Ukrainian Cardiology Journal No. 5-6. 2022;29:59-70",56.0,YR,A,F,Y,67.0,KG,20230215,,HP,UA,UA,2023,Q1,Adult
219953621,21995362,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q1,Balance disorder,,2023,Q1,1,I,,20230211.0,20230215,20230215,EXP,,UA-SA-2023SA049604,SANOFI AVENTIS,"Tseluyko V, Mishchuk N, Ivanitska L.. Hyponatremia in patients with decompensated heart failure. Ukrainian Cardiology Journal No. 5-6. 2022;29:59-70",56.0,YR,A,F,Y,67.0,KG,20230215,,HP,UA,UA,2023,Q1,Adult
219953621,21995362,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q1,Decreased appetite,,2023,Q1,1,I,,20230211.0,20230215,20230215,EXP,,UA-SA-2023SA049604,SANOFI AVENTIS,"Tseluyko V, Mishchuk N, Ivanitska L.. Hyponatremia in patients with decompensated heart failure. Ukrainian Cardiology Journal No. 5-6. 2022;29:59-70",56.0,YR,A,F,Y,67.0,KG,20230215,,HP,UA,UA,2023,Q1,Adult
219953621,21995362,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,Y,,,,,10.0,MG,,QD,2023,Q1,Depressed level of consciousness,,2023,Q1,1,I,,20230211.0,20230215,20230215,EXP,,UA-SA-2023SA049604,SANOFI AVENTIS,"Tseluyko V, Mishchuk N, Ivanitska L.. Hyponatremia in patients with decompensated heart failure. Ukrainian Cardiology Journal No. 5-6. 2022;29:59-70",56.0,YR,A,F,Y,67.0,KG,20230215,,HP,UA,UA,2023,Q1,Adult
219953621,21995362,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,Y,,,,,10.0,MG,,QD,2023,Q1,Nausea,,2023,Q1,1,I,,20230211.0,20230215,20230215,EXP,,UA-SA-2023SA049604,SANOFI AVENTIS,"Tseluyko V, Mishchuk N, Ivanitska L.. Hyponatremia in patients with decompensated heart failure. Ukrainian Cardiology Journal No. 5-6. 2022;29:59-70",56.0,YR,A,F,Y,67.0,KG,20230215,,HP,UA,UA,2023,Q1,Adult
219953621,21995362,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,Y,,,,,10.0,MG,,QD,2023,Q1,Sluggishness,,2023,Q1,1,I,,20230211.0,20230215,20230215,EXP,,UA-SA-2023SA049604,SANOFI AVENTIS,"Tseluyko V, Mishchuk N, Ivanitska L.. Hyponatremia in patients with decompensated heart failure. Ukrainian Cardiology Journal No. 5-6. 2022;29:59-70",56.0,YR,A,F,Y,67.0,KG,20230215,,HP,UA,UA,2023,Q1,Adult
219953621,21995362,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,Y,,,,,10.0,MG,,QD,2023,Q1,Head injury,,2023,Q1,1,I,,20230211.0,20230215,20230215,EXP,,UA-SA-2023SA049604,SANOFI AVENTIS,"Tseluyko V, Mishchuk N, Ivanitska L.. Hyponatremia in patients with decompensated heart failure. Ukrainian Cardiology Journal No. 5-6. 2022;29:59-70",56.0,YR,A,F,Y,67.0,KG,20230215,,HP,UA,UA,2023,Q1,Adult
219953621,21995362,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,Y,,,,,10.0,MG,,QD,2023,Q1,Jaundice,,2023,Q1,1,I,,20230211.0,20230215,20230215,EXP,,UA-SA-2023SA049604,SANOFI AVENTIS,"Tseluyko V, Mishchuk N, Ivanitska L.. Hyponatremia in patients with decompensated heart failure. Ukrainian Cardiology Journal No. 5-6. 2022;29:59-70",56.0,YR,A,F,Y,67.0,KG,20230215,,HP,UA,UA,2023,Q1,Adult
219953621,21995362,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,Y,,,,,10.0,MG,,QD,2023,Q1,Hypotension,,2023,Q1,1,I,,20230211.0,20230215,20230215,EXP,,UA-SA-2023SA049604,SANOFI AVENTIS,"Tseluyko V, Mishchuk N, Ivanitska L.. Hyponatremia in patients with decompensated heart failure. Ukrainian Cardiology Journal No. 5-6. 2022;29:59-70",56.0,YR,A,F,Y,67.0,KG,20230215,,HP,UA,UA,2023,Q1,Adult
219953621,21995362,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,Y,,,,,10.0,MG,,QD,2023,Q1,Lethargy,,2023,Q1,1,I,,20230211.0,20230215,20230215,EXP,,UA-SA-2023SA049604,SANOFI AVENTIS,"Tseluyko V, Mishchuk N, Ivanitska L.. Hyponatremia in patients with decompensated heart failure. Ukrainian Cardiology Journal No. 5-6. 2022;29:59-70",56.0,YR,A,F,Y,67.0,KG,20230215,,HP,UA,UA,2023,Q1,Adult
219953621,21995362,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,Y,,,,,10.0,MG,,QD,2023,Q1,Fall,,2023,Q1,1,I,,20230211.0,20230215,20230215,EXP,,UA-SA-2023SA049604,SANOFI AVENTIS,"Tseluyko V, Mishchuk N, Ivanitska L.. Hyponatremia in patients with decompensated heart failure. Ukrainian Cardiology Journal No. 5-6. 2022;29:59-70",56.0,YR,A,F,Y,67.0,KG,20230215,,HP,UA,UA,2023,Q1,Adult
219953621,21995362,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,Y,,,,,10.0,MG,,QD,2023,Q1,Asthenia,,2023,Q1,1,I,,20230211.0,20230215,20230215,EXP,,UA-SA-2023SA049604,SANOFI AVENTIS,"Tseluyko V, Mishchuk N, Ivanitska L.. Hyponatremia in patients with decompensated heart failure. Ukrainian Cardiology Journal No. 5-6. 2022;29:59-70",56.0,YR,A,F,Y,67.0,KG,20230215,,HP,UA,UA,2023,Q1,Adult
219953621,21995362,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,Y,,,,,10.0,MG,,QD,2023,Q1,Hypoosmolar state,,2023,Q1,1,I,,20230211.0,20230215,20230215,EXP,,UA-SA-2023SA049604,SANOFI AVENTIS,"Tseluyko V, Mishchuk N, Ivanitska L.. Hyponatremia in patients with decompensated heart failure. Ukrainian Cardiology Journal No. 5-6. 2022;29:59-70",56.0,YR,A,F,Y,67.0,KG,20230215,,HP,UA,UA,2023,Q1,Adult
219953621,21995362,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,Y,,,,,10.0,MG,,QD,2023,Q1,Hyponatraemia,,2023,Q1,1,I,,20230211.0,20230215,20230215,EXP,,UA-SA-2023SA049604,SANOFI AVENTIS,"Tseluyko V, Mishchuk N, Ivanitska L.. Hyponatremia in patients with decompensated heart failure. Ukrainian Cardiology Journal No. 5-6. 2022;29:59-70",56.0,YR,A,F,Y,67.0,KG,20230215,,HP,UA,UA,2023,Q1,Adult
219953621,21995362,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,Y,,,,,10.0,MG,,QD,2023,Q1,Haematoma,,2023,Q1,1,I,,20230211.0,20230215,20230215,EXP,,UA-SA-2023SA049604,SANOFI AVENTIS,"Tseluyko V, Mishchuk N, Ivanitska L.. Hyponatremia in patients with decompensated heart failure. Ukrainian Cardiology Journal No. 5-6. 2022;29:59-70",56.0,YR,A,F,Y,67.0,KG,20230215,,HP,UA,UA,2023,Q1,Adult
219953621,21995362,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,Y,,,,,10.0,MG,,QD,2023,Q1,Hypovolaemia,,2023,Q1,1,I,,20230211.0,20230215,20230215,EXP,,UA-SA-2023SA049604,SANOFI AVENTIS,"Tseluyko V, Mishchuk N, Ivanitska L.. Hyponatremia in patients with decompensated heart failure. Ukrainian Cardiology Journal No. 5-6. 2022;29:59-70",56.0,YR,A,F,Y,67.0,KG,20230215,,HP,UA,UA,2023,Q1,Adult
219953621,21995362,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,Y,,,,,10.0,MG,,QD,2023,Q1,Dry skin,,2023,Q1,1,I,,20230211.0,20230215,20230215,EXP,,UA-SA-2023SA049604,SANOFI AVENTIS,"Tseluyko V, Mishchuk N, Ivanitska L.. Hyponatremia in patients with decompensated heart failure. Ukrainian Cardiology Journal No. 5-6. 2022;29:59-70",56.0,YR,A,F,Y,67.0,KG,20230215,,HP,UA,UA,2023,Q1,Adult
219953621,21995362,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,Y,,,,,10.0,MG,,QD,2023,Q1,Balance disorder,,2023,Q1,1,I,,20230211.0,20230215,20230215,EXP,,UA-SA-2023SA049604,SANOFI AVENTIS,"Tseluyko V, Mishchuk N, Ivanitska L.. Hyponatremia in patients with decompensated heart failure. Ukrainian Cardiology Journal No. 5-6. 2022;29:59-70",56.0,YR,A,F,Y,67.0,KG,20230215,,HP,UA,UA,2023,Q1,Adult
219953621,21995362,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,Y,,,,,10.0,MG,,QD,2023,Q1,Decreased appetite,,2023,Q1,1,I,,20230211.0,20230215,20230215,EXP,,UA-SA-2023SA049604,SANOFI AVENTIS,"Tseluyko V, Mishchuk N, Ivanitska L.. Hyponatremia in patients with decompensated heart failure. Ukrainian Cardiology Journal No. 5-6. 2022;29:59-70",56.0,YR,A,F,Y,67.0,KG,20230215,,HP,UA,UA,2023,Q1,Adult
219955131,21995513,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q1,Metabolic acidosis,,2023,Q1,1,I,,20230131.0,20230215,20230215,EXP,,US-TARO PHARMACEUTICALS USA INC.-2023TAR00151,TARO,"Spyres MB, Aldy K, Farrugia LA, Kang AM, Love JS, Campleman SL, et al. The Toxicology Investigators Consortium 2020 Annual Report. J Med Toxicol. 2021;17 (4):333-362",15.0,YR,,M,Y,,,20230215,,HP,US,US,2023,Q1,Youth
219955131,21995513,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q1,Depressed level of consciousness,,2023,Q1,1,I,,20230131.0,20230215,20230215,EXP,,US-TARO PHARMACEUTICALS USA INC.-2023TAR00151,TARO,"Spyres MB, Aldy K, Farrugia LA, Kang AM, Love JS, Campleman SL, et al. The Toxicology Investigators Consortium 2020 Annual Report. J Med Toxicol. 2021;17 (4):333-362",15.0,YR,,M,Y,,,20230215,,HP,US,US,2023,Q1,Youth
219955131,21995513,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q1,Exposure to toxic agent,,2023,Q1,1,I,,20230131.0,20230215,20230215,EXP,,US-TARO PHARMACEUTICALS USA INC.-2023TAR00151,TARO,"Spyres MB, Aldy K, Farrugia LA, Kang AM, Love JS, Campleman SL, et al. The Toxicology Investigators Consortium 2020 Annual Report. J Med Toxicol. 2021;17 (4):333-362",15.0,YR,,M,Y,,,20230215,,HP,US,US,2023,Q1,Youth
219955131,21995513,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q1,Hypotension,,2023,Q1,1,I,,20230131.0,20230215,20230215,EXP,,US-TARO PHARMACEUTICALS USA INC.-2023TAR00151,TARO,"Spyres MB, Aldy K, Farrugia LA, Kang AM, Love JS, Campleman SL, et al. The Toxicology Investigators Consortium 2020 Annual Report. J Med Toxicol. 2021;17 (4):333-362",15.0,YR,,M,Y,,,20230215,,HP,US,US,2023,Q1,Youth
219955131,21995513,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q1,Anion gap,,2023,Q1,1,I,,20230131.0,20230215,20230215,EXP,,US-TARO PHARMACEUTICALS USA INC.-2023TAR00151,TARO,"Spyres MB, Aldy K, Farrugia LA, Kang AM, Love JS, Campleman SL, et al. The Toxicology Investigators Consortium 2020 Annual Report. J Med Toxicol. 2021;17 (4):333-362",15.0,YR,,M,Y,,,20230215,,HP,US,US,2023,Q1,Youth
219955131,21995513,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q1,Coma,,2023,Q1,1,I,,20230131.0,20230215,20230215,EXP,,US-TARO PHARMACEUTICALS USA INC.-2023TAR00151,TARO,"Spyres MB, Aldy K, Farrugia LA, Kang AM, Love JS, Campleman SL, et al. The Toxicology Investigators Consortium 2020 Annual Report. J Med Toxicol. 2021;17 (4):333-362",15.0,YR,,M,Y,,,20230215,,HP,US,US,2023,Q1,Youth
219955131,21995513,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q1,Respiratory depression,,2023,Q1,1,I,,20230131.0,20230215,20230215,EXP,,US-TARO PHARMACEUTICALS USA INC.-2023TAR00151,TARO,"Spyres MB, Aldy K, Farrugia LA, Kang AM, Love JS, Campleman SL, et al. The Toxicology Investigators Consortium 2020 Annual Report. J Med Toxicol. 2021;17 (4):333-362",15.0,YR,,M,Y,,,20230215,,HP,US,US,2023,Q1,Youth
219959719,21995971,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,Tablets,,2023,Q1,Urinary tract infection,,2023,Q1,9,F,20221221.0,20230323.0,20230215,20230330,PER,,CO-Eisai Medical Research-EC-2023-134172,EISAI,,76.0,YR,E,F,Y,57.2,KG,20230330,,MD,CO,,2023,Q1,Elderly
219959719,21995971,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,Tablets,,2023,Q1,Malignant neoplasm progression,,2023,Q1,9,F,20221221.0,20230323.0,20230215,20230330,PER,,CO-Eisai Medical Research-EC-2023-134172,EISAI,,76.0,YR,E,F,Y,57.2,KG,20230330,,MD,CO,,2023,Q1,Elderly
219959719,21995971,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,Tablets,,2023,Q1,Oedema,,2023,Q1,9,F,20221221.0,20230323.0,20230215,20230330,PER,,CO-Eisai Medical Research-EC-2023-134172,EISAI,,76.0,YR,E,F,Y,57.2,KG,20230330,,MD,CO,,2023,Q1,Elderly
219959971,21995997,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,in the morning; ;,,,Y,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q1,Fournier's gangrene,,2023,Q1,1,I,20230111.0,20230215.0,20230215,20230215,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219070",BOEHRINGER INGELHEIM,,56.0,YR,A,M,Y,122.0,KG,20230215,,PH,GB,GB,2023,Q1,Adult
219967413,21996741,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,The dose prescribed of empagliflozin/ metformin was 12.5 mg + 1000 mg,,,Y,U,E42391,,206111.0,,,Tablet,Q12H,2023,Q1,Delirium,,2023,Q1,3,F,20230131.0,20230227.0,20230215,20230302,EXP,,"CO-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219121",BOEHRINGER INGELHEIM,,86.0,YR,E,M,Y,55.0,KG,20230302,,CN,CO,CO,2023,Q1,Elderly
219967413,21996741,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,The dose prescribed of empagliflozin/ metformin was 12.5 mg + 1000 mg,,,Y,U,E42391,,206111.0,,,Tablet,Q12H,2023,Q1,Fluid retention,,2023,Q1,3,F,20230131.0,20230227.0,20230215,20230302,EXP,,"CO-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219121",BOEHRINGER INGELHEIM,,86.0,YR,E,M,Y,55.0,KG,20230302,,CN,CO,CO,2023,Q1,Elderly
219967413,21996741,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,The dose prescribed of empagliflozin/ metformin was 12.5 mg + 1000 mg,,,Y,U,E42391,,206111.0,,,Tablet,Q12H,2023,Q1,Pollakiuria,,2023,Q1,3,F,20230131.0,20230227.0,20230215,20230302,EXP,,"CO-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219121",BOEHRINGER INGELHEIM,,86.0,YR,E,M,Y,55.0,KG,20230302,,CN,CO,CO,2023,Q1,Elderly
219967413,21996741,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,The dose prescribed of empagliflozin/ metformin was 12.5 mg + 1000 mg,,,Y,U,E42391,,206111.0,,,Tablet,Q12H,2023,Q1,Resuscitation,,2023,Q1,3,F,20230131.0,20230227.0,20230215,20230302,EXP,,"CO-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219121",BOEHRINGER INGELHEIM,,86.0,YR,E,M,Y,55.0,KG,20230302,,CN,CO,CO,2023,Q1,Elderly
219967413,21996741,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,The dose prescribed of empagliflozin/ metformin was 12.5 mg + 1000 mg,,,Y,U,E42391,,206111.0,,,Tablet,Q12H,2023,Q1,Tachycardia,,2023,Q1,3,F,20230131.0,20230227.0,20230215,20230302,EXP,,"CO-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219121",BOEHRINGER INGELHEIM,,86.0,YR,E,M,Y,55.0,KG,20230302,,CN,CO,CO,2023,Q1,Elderly
219967413,21996741,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,The dose prescribed of empagliflozin/ metformin was 12.5 mg + 1000 mg,,,Y,U,E42391,,206111.0,,,Tablet,Q12H,2023,Q1,Diabetic ketoacidosis,,2023,Q1,3,F,20230131.0,20230227.0,20230215,20230302,EXP,,"CO-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219121",BOEHRINGER INGELHEIM,,86.0,YR,E,M,Y,55.0,KG,20230302,,CN,CO,CO,2023,Q1,Elderly
219975642,21997564,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,Tablet,QD,2023,Q1,Erysipelas,,2023,Q1,2,F,20220520.0,20230314.0,20230216,20230321,EXP,,FI-JNJFOC-20230229306,JOHNSON AND JOHNSON,,60.0,YR,,F,Y,,,20230321,,MD,FI,FI,2023,Q1,Adult
220011221,22001122,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q1,Skin erosion,,2023,Q1,1,I,20221215.0,20230216.0,20230216,20230216,EXP,GB-MHRA-INPF1A811BF-173F-4E9C-8667-46C3289E196E,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219391",BOEHRINGER INGELHEIM,,54.0,YR,A,F,Y,110.0,KG,20230216,,MD,GB,GB,2023,Q1,Adult
220011221,22001122,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q1,Vulvovaginal candidiasis,,2023,Q1,1,I,20221215.0,20230216.0,20230216,20230216,EXP,GB-MHRA-INPF1A811BF-173F-4E9C-8667-46C3289E196E,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219391",BOEHRINGER INGELHEIM,,54.0,YR,A,F,Y,110.0,KG,20230216,,MD,GB,GB,2023,Q1,Adult
220011221,22001122,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q1,Rash,,2023,Q1,1,I,20221215.0,20230216.0,20230216,20230216,EXP,GB-MHRA-INPF1A811BF-173F-4E9C-8667-46C3289E196E,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219391",BOEHRINGER INGELHEIM,,54.0,YR,A,F,Y,110.0,KG,20230216,,MD,GB,GB,2023,Q1,Adult
220011221,22001122,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q1,Candida infection,,2023,Q1,1,I,20221215.0,20230216.0,20230216,20230216,EXP,GB-MHRA-INPF1A811BF-173F-4E9C-8667-46C3289E196E,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219391",BOEHRINGER INGELHEIM,,54.0,YR,A,F,Y,110.0,KG,20230216,,MD,GB,GB,2023,Q1,Adult
220011221,22001122,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q1,Pruritus,,2023,Q1,1,I,20221215.0,20230216.0,20230216,20230216,EXP,GB-MHRA-INPF1A811BF-173F-4E9C-8667-46C3289E196E,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219391",BOEHRINGER INGELHEIM,,54.0,YR,A,F,Y,110.0,KG,20230216,,MD,GB,GB,2023,Q1,Adult
220011221,22001122,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q1,Hypersensitivity,,2023,Q1,1,I,20221215.0,20230216.0,20230216,20230216,EXP,GB-MHRA-INPF1A811BF-173F-4E9C-8667-46C3289E196E,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219391",BOEHRINGER INGELHEIM,,54.0,YR,A,F,Y,110.0,KG,20230216,,MD,GB,GB,2023,Q1,Adult
220027991,22002799,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Lactic acidosis,,2023,Q1,1,I,,20230202.0,20230217,20230217,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-378196,RANBAXY,"Gronbeck K, Kruse D. METFORMIN-ASSOCIATED LACTIC ACIDOSIS WITH EUGLYCEMIC DIABETIC KETOACIDOSIS. Crit Care Med. 2023;Jan; 51 (1):216; 92",65.0,YR,,F,Y,,,20230217,,HP,US,US,2023,Q1,Elderly
220027991,22002799,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,1,I,,20230202.0,20230217,20230217,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-378196,RANBAXY,"Gronbeck K, Kruse D. METFORMIN-ASSOCIATED LACTIC ACIDOSIS WITH EUGLYCEMIC DIABETIC KETOACIDOSIS. Crit Care Med. 2023;Jan; 51 (1):216; 92",65.0,YR,,F,Y,,,20230217,,HP,US,US,2023,Q1,Elderly
220051471,22005147,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2023,Q1,Osteoporosis,,2023,Q1,1,I,,20230209.0,20230217,20230217,EXP,,SE-MYLANLABS-2023M1017041,MYLAN,"Lodin K, Rosenborg S, Hemmingsson P. Fanconis syndrom - en ovanlig biverkan av tenofovirdisoproxil. Lakartidningen 2023;null:null.",7.0,DEC,,F,Y,,,20230217,,HP,SE,SE,2023,Q1,Child
220051471,22005147,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2023,Q1,Fanconi syndrome acquired,,2023,Q1,1,I,,20230209.0,20230217,20230217,EXP,,SE-MYLANLABS-2023M1017041,MYLAN,"Lodin K, Rosenborg S, Hemmingsson P. Fanconis syndrom - en ovanlig biverkan av tenofovirdisoproxil. Lakartidningen 2023;null:null.",7.0,DEC,,F,Y,,,20230217,,HP,SE,SE,2023,Q1,Child
220054551,22005455,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,12.5/500,,,Y,U,Unknown,,206111.0,,,,Q12H,2023,Q1,Balanoposthitis,,2023,Q1,1,I,,20230216.0,20230217,20230217,EXP,,"IN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219549",BOEHRINGER INGELHEIM,,52.0,YR,A,M,Y,,,20230217,,MD,IN,IN,2023,Q1,Adult
220054551,22005455,2,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,Y,U,,,206111.0,,,,,2023,Q1,Balanoposthitis,,2023,Q1,1,I,,20230216.0,20230217,20230217,EXP,,"IN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219549",BOEHRINGER INGELHEIM,,52.0,YR,A,M,Y,,,20230217,,MD,IN,IN,2023,Q1,Adult
220057631,22005763,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Atrial fibrillation,,2023,Q1,1,I,20220101.0,20230209.0,20230217,20230217,EXP,,DE-AstraZeneca-2023A036872,ASTRAZENECA,,72.0,YR,,M,Y,96.0,KG,20230217,,MD,DE,,2023,Q1,Elderly
220057631,22005763,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Neuropathy peripheral,,2023,Q1,1,I,20220101.0,20230209.0,20230217,20230217,EXP,,DE-AstraZeneca-2023A036872,ASTRAZENECA,,72.0,YR,,M,Y,96.0,KG,20230217,,MD,DE,,2023,Q1,Elderly
220057631,22005763,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Blood pressure inadequately controlled,,2023,Q1,1,I,20220101.0,20230209.0,20230217,20230217,EXP,,DE-AstraZeneca-2023A036872,ASTRAZENECA,,72.0,YR,,M,Y,96.0,KG,20230217,,MD,DE,,2023,Q1,Elderly
220057631,22005763,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Cerebrovascular accident,,2023,Q1,1,I,20220101.0,20230209.0,20230217,20230217,EXP,,DE-AstraZeneca-2023A036872,ASTRAZENECA,,72.0,YR,,M,Y,96.0,KG,20230217,,MD,DE,,2023,Q1,Elderly
220086222,22008622,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Atrial fibrillation,,2023,Q1,2,F,,20230307.0,20230219,20230309,EXP,,HR-JNJFOC-20230239887,JOHNSON AND JOHNSON,,76.0,YR,E,M,Y,,,20230309,,MD,HR,HR,2023,Q1,Elderly
220090631,22009063,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2023,Q1,Diabetic ketoacidosis,,2023,Q1,1,I,20230210.0,20230219.0,20230220,20230220,EXP,,"SA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219796",BOEHRINGER INGELHEIM,,62.0,YR,A,F,Y,,,20230220,,PH,SA,SA,2023,Q1,Adult
220090631,22009063,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2023,Q1,Pancreatitis,,2023,Q1,1,I,20230210.0,20230219.0,20230220,20230220,EXP,,"SA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219796",BOEHRINGER INGELHEIM,,62.0,YR,A,F,Y,,,20230220,,PH,SA,SA,2023,Q1,Adult
220102262,22010226,7,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2023,Q1,Meningitis,,2023,Q1,2,F,20230214.0,20230224.0,20230220,20230228,EXP,,IL-ROCHE-3287833,ROCHE,,67.0,YR,,M,Y,,,20230228,,MD,IL,,2023,Q1,Elderly
220102262,22010226,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Meningitis,,2023,Q1,2,F,20230214.0,20230224.0,20230220,20230228,EXP,,IL-ROCHE-3287833,ROCHE,,67.0,YR,,M,Y,,,20230228,,MD,IL,,2023,Q1,Elderly
220124521,22012452,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,5/1000mg,,,,,Unknown,,206111.0,,,,Q12H,2023,Q1,Pyrexia,,2023,Q1,1,I,20230201.0,20230219.0,20230220,20230220,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219839",BOEHRINGER INGELHEIM,,55.0,YR,A,F,Y,,,20230220,,MD,IL,IL,2023,Q1,Adult
220124521,22012452,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,5/1000mg,,,,,Unknown,,206111.0,,,,Q12H,2023,Q1,Diabetic ketoacidosis,,2023,Q1,1,I,20230201.0,20230219.0,20230220,20230220,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219839",BOEHRINGER INGELHEIM,,55.0,YR,A,F,Y,,,20230220,,MD,IL,IL,2023,Q1,Adult
220126321,22012632,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 Milligram Daily;,,,,,,,,,,,,2023,Q1,Skin ulcer,,2023,Q1,1,I,20221101.0,20230210.0,20230220,20230220,EXP,,US-TEVA-2023-US-2857183,TEVA,,57.0,YR,A,M,Y,102.0,KG,20230220,,PH,US,US,2023,Q1,Adult
220126321,22012632,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 Milligram Daily;,,,,,,,,,,,,2023,Q1,Blister,,2023,Q1,1,I,20221101.0,20230210.0,20230220,20230220,EXP,,US-TEVA-2023-US-2857183,TEVA,,57.0,YR,A,M,Y,102.0,KG,20230220,,PH,US,US,2023,Q1,Adult
220126321,22012632,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 Milligram Daily;,,,,,,,,,,,,2023,Q1,Cellulitis,,2023,Q1,1,I,20221101.0,20230210.0,20230220,20230220,EXP,,US-TEVA-2023-US-2857183,TEVA,,57.0,YR,A,M,Y,102.0,KG,20230220,,PH,US,US,2023,Q1,Adult
220126321,22012632,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 Milligram Daily;,,,,,,,,,,,,2023,Q1,Fatigue,,2023,Q1,1,I,20221101.0,20230210.0,20230220,20230220,EXP,,US-TEVA-2023-US-2857183,TEVA,,57.0,YR,A,M,Y,102.0,KG,20230220,,PH,US,US,2023,Q1,Adult
220126321,22012632,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 Milligram Daily;,,,,,,,,,,,,2023,Q1,Pain in extremity,,2023,Q1,1,I,20221101.0,20230210.0,20230220,20230220,EXP,,US-TEVA-2023-US-2857183,TEVA,,57.0,YR,A,M,Y,102.0,KG,20230220,,PH,US,US,2023,Q1,Adult
220128551,22012855,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, qd (take one daily)",,,,,,,,,,,QD,2023,Q1,Urticaria,,2023,Q1,1,I,20230214.0,20230215.0,20230220,20230220,EXP,GB-MHRA-TPP41217198C963099YC1676368095767,GB-MYLANLABS-2023M1018390,MYLAN,,55.0,YR,,M,Y,81.0,KG,20230220,,MD,GB,GB,2023,Q1,Adult
220141382,22014138,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,Jardiamet strength 12.5mg/500mg,,,Y,U,Asked But Unknown,,206111.0,,,,,2023,Q1,Eczema,,2023,Q1,2,F,,20230215.0,20230221,20230223,EXP,,"NZ-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-217986",BOEHRINGER INGELHEIM,,48.0,YR,A,F,Y,109.0,KG,20230223,,HP,NZ,NZ,2023,Q1,Adult
220141382,22014138,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,Jardiamet strength 12.5mg/500mg,,,Y,U,Asked But Unknown,,206111.0,,,,,2023,Q1,Abdominal pain,,2023,Q1,2,F,,20230215.0,20230221,20230223,EXP,,"NZ-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-217986",BOEHRINGER INGELHEIM,,48.0,YR,A,F,Y,109.0,KG,20230223,,HP,NZ,NZ,2023,Q1,Adult
220141382,22014138,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,Jardiamet strength 12.5mg/500mg,,,Y,U,Asked But Unknown,,206111.0,,,,,2023,Q1,Candida infection,,2023,Q1,2,F,,20230215.0,20230221,20230223,EXP,,"NZ-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-217986",BOEHRINGER INGELHEIM,,48.0,YR,A,F,Y,109.0,KG,20230223,,HP,NZ,NZ,2023,Q1,Adult
220141382,22014138,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,Jardiamet strength 12.5mg/500mg,,,Y,U,Asked But Unknown,,206111.0,,,,,2023,Q1,Off label use,,2023,Q1,2,F,,20230215.0,20230221,20230223,EXP,,"NZ-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-217986",BOEHRINGER INGELHEIM,,48.0,YR,A,F,Y,109.0,KG,20230223,,HP,NZ,NZ,2023,Q1,Adult
220141382,22014138,2,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,Y,U,,,206111.0,,,,,2023,Q1,Eczema,,2023,Q1,2,F,,20230215.0,20230221,20230223,EXP,,"NZ-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-217986",BOEHRINGER INGELHEIM,,48.0,YR,A,F,Y,109.0,KG,20230223,,HP,NZ,NZ,2023,Q1,Adult
220141382,22014138,2,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,Y,U,,,206111.0,,,,,2023,Q1,Abdominal pain,,2023,Q1,2,F,,20230215.0,20230221,20230223,EXP,,"NZ-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-217986",BOEHRINGER INGELHEIM,,48.0,YR,A,F,Y,109.0,KG,20230223,,HP,NZ,NZ,2023,Q1,Adult
220141382,22014138,2,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,Y,U,,,206111.0,,,,,2023,Q1,Candida infection,,2023,Q1,2,F,,20230215.0,20230221,20230223,EXP,,"NZ-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-217986",BOEHRINGER INGELHEIM,,48.0,YR,A,F,Y,109.0,KG,20230223,,HP,NZ,NZ,2023,Q1,Adult
220141382,22014138,2,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,Y,U,,,206111.0,,,,,2023,Q1,Off label use,,2023,Q1,2,F,,20230215.0,20230221,20230223,EXP,,"NZ-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-217986",BOEHRINGER INGELHEIM,,48.0,YR,A,F,Y,109.0,KG,20230223,,HP,NZ,NZ,2023,Q1,Adult
220164081,22016408,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q1,Metabolic acidosis,,2023,Q1,1,I,,20230214.0,20230221,20230221,EXP,,US-MYLANLABS-2023M1018892,MYLAN,"Spyres MB, Aldy K, Farrugia LA, Kang AM, Love JS, Campleman SL, et al. The Toxicology Investigators Consortium 2020 Annual Report. J-Med-Toxicol 2021;17(4):333-362.",15.0,YR,,M,Y,,,20230221,,HP,US,US,2023,Q1,Youth
220164081,22016408,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q1,Hypotension,,2023,Q1,1,I,,20230214.0,20230221,20230221,EXP,,US-MYLANLABS-2023M1018892,MYLAN,"Spyres MB, Aldy K, Farrugia LA, Kang AM, Love JS, Campleman SL, et al. The Toxicology Investigators Consortium 2020 Annual Report. J-Med-Toxicol 2021;17(4):333-362.",15.0,YR,,M,Y,,,20230221,,HP,US,US,2023,Q1,Youth
220164081,22016408,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q1,Toxicity to various agents,,2023,Q1,1,I,,20230214.0,20230221,20230221,EXP,,US-MYLANLABS-2023M1018892,MYLAN,"Spyres MB, Aldy K, Farrugia LA, Kang AM, Love JS, Campleman SL, et al. The Toxicology Investigators Consortium 2020 Annual Report. J-Med-Toxicol 2021;17(4):333-362.",15.0,YR,,M,Y,,,20230221,,HP,US,US,2023,Q1,Youth
220164081,22016408,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q1,Respiratory depression,,2023,Q1,1,I,,20230214.0,20230221,20230221,EXP,,US-MYLANLABS-2023M1018892,MYLAN,"Spyres MB, Aldy K, Farrugia LA, Kang AM, Love JS, Campleman SL, et al. The Toxicology Investigators Consortium 2020 Annual Report. J-Med-Toxicol 2021;17(4):333-362.",15.0,YR,,M,Y,,,20230221,,HP,US,US,2023,Q1,Youth
220164081,22016408,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q1,Coma,,2023,Q1,1,I,,20230214.0,20230221,20230221,EXP,,US-MYLANLABS-2023M1018892,MYLAN,"Spyres MB, Aldy K, Farrugia LA, Kang AM, Love JS, Campleman SL, et al. The Toxicology Investigators Consortium 2020 Annual Report. J-Med-Toxicol 2021;17(4):333-362.",15.0,YR,,M,Y,,,20230221,,HP,US,US,2023,Q1,Youth
220164081,22016408,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q1,Anion gap,,2023,Q1,1,I,,20230214.0,20230221,20230221,EXP,,US-MYLANLABS-2023M1018892,MYLAN,"Spyres MB, Aldy K, Farrugia LA, Kang AM, Love JS, Campleman SL, et al. The Toxicology Investigators Consortium 2020 Annual Report. J-Med-Toxicol 2021;17(4):333-362.",15.0,YR,,M,Y,,,20230221,,HP,US,US,2023,Q1,Youth
220182711,22018271,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Cyst,,2023,Q1,1,I,,20230216.0,20230221,20230221,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219564",BOEHRINGER INGELHEIM,,59.0,YR,A,F,Y,,,20230222,,HP,CA,CA,2023,Q1,Adult
220182711,22018271,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Osteoarthritis,,2023,Q1,1,I,,20230216.0,20230221,20230221,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219564",BOEHRINGER INGELHEIM,,59.0,YR,A,F,Y,,,20230222,,HP,CA,CA,2023,Q1,Adult
220182711,22018271,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Synovitis,,2023,Q1,1,I,,20230216.0,20230221,20230221,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219564",BOEHRINGER INGELHEIM,,59.0,YR,A,F,Y,,,20230222,,HP,CA,CA,2023,Q1,Adult
220182711,22018271,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Arthritis,,2023,Q1,1,I,,20230216.0,20230221,20230221,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219564",BOEHRINGER INGELHEIM,,59.0,YR,A,F,Y,,,20230222,,HP,CA,CA,2023,Q1,Adult
220182711,22018271,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Nephrolithiasis,,2023,Q1,1,I,,20230216.0,20230221,20230221,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219564",BOEHRINGER INGELHEIM,,59.0,YR,A,F,Y,,,20230222,,HP,CA,CA,2023,Q1,Adult
220182711,22018271,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Rash,,2023,Q1,1,I,,20230216.0,20230221,20230221,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219564",BOEHRINGER INGELHEIM,,59.0,YR,A,F,Y,,,20230222,,HP,CA,CA,2023,Q1,Adult
220182711,22018271,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Arthralgia,,2023,Q1,1,I,,20230216.0,20230221,20230221,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219564",BOEHRINGER INGELHEIM,,59.0,YR,A,F,Y,,,20230222,,HP,CA,CA,2023,Q1,Adult
220182711,22018271,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,C-reactive protein increased,,2023,Q1,1,I,,20230216.0,20230221,20230221,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219564",BOEHRINGER INGELHEIM,,59.0,YR,A,F,Y,,,20230222,,HP,CA,CA,2023,Q1,Adult
220182711,22018271,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Pain in extremity,,2023,Q1,1,I,,20230216.0,20230221,20230221,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219564",BOEHRINGER INGELHEIM,,59.0,YR,A,F,Y,,,20230222,,HP,CA,CA,2023,Q1,Adult
220182711,22018271,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Condition aggravated,,2023,Q1,1,I,,20230216.0,20230221,20230221,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219564",BOEHRINGER INGELHEIM,,59.0,YR,A,F,Y,,,20230222,,HP,CA,CA,2023,Q1,Adult
220182711,22018271,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Joint effusion,,2023,Q1,1,I,,20230216.0,20230221,20230221,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219564",BOEHRINGER INGELHEIM,,59.0,YR,A,F,Y,,,20230222,,HP,CA,CA,2023,Q1,Adult
220182711,22018271,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Arthropathy,,2023,Q1,1,I,,20230216.0,20230221,20230221,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219564",BOEHRINGER INGELHEIM,,59.0,YR,A,F,Y,,,20230222,,HP,CA,CA,2023,Q1,Adult
220182711,22018271,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Alanine aminotransferase increased,,2023,Q1,1,I,,20230216.0,20230221,20230221,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219564",BOEHRINGER INGELHEIM,,59.0,YR,A,F,Y,,,20230222,,HP,CA,CA,2023,Q1,Adult
220182711,22018271,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Renal disorder,,2023,Q1,1,I,,20230216.0,20230221,20230221,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219564",BOEHRINGER INGELHEIM,,59.0,YR,A,F,Y,,,20230222,,HP,CA,CA,2023,Q1,Adult
220182711,22018271,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Synovial disorder,,2023,Q1,1,I,,20230216.0,20230221,20230221,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219564",BOEHRINGER INGELHEIM,,59.0,YR,A,F,Y,,,20230222,,HP,CA,CA,2023,Q1,Adult
220182711,22018271,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Incorrect dose administered,,2023,Q1,1,I,,20230216.0,20230221,20230221,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219564",BOEHRINGER INGELHEIM,,59.0,YR,A,F,Y,,,20230222,,HP,CA,CA,2023,Q1,Adult
220182711,22018271,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Antinuclear antibody positive,,2023,Q1,1,I,,20230216.0,20230221,20230221,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219564",BOEHRINGER INGELHEIM,,59.0,YR,A,F,Y,,,20230222,,HP,CA,CA,2023,Q1,Adult
220182711,22018271,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Hepatic enzyme increased,,2023,Q1,1,I,,20230216.0,20230221,20230221,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219564",BOEHRINGER INGELHEIM,,59.0,YR,A,F,Y,,,20230222,,HP,CA,CA,2023,Q1,Adult
220182711,22018271,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Vitamin B12 decreased,,2023,Q1,1,I,,20230216.0,20230221,20230221,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219564",BOEHRINGER INGELHEIM,,59.0,YR,A,F,Y,,,20230222,,HP,CA,CA,2023,Q1,Adult
220182711,22018271,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Psoriasis,,2023,Q1,1,I,,20230216.0,20230221,20230221,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219564",BOEHRINGER INGELHEIM,,59.0,YR,A,F,Y,,,20230222,,HP,CA,CA,2023,Q1,Adult
220182711,22018271,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Blood iron decreased,,2023,Q1,1,I,,20230216.0,20230221,20230221,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219564",BOEHRINGER INGELHEIM,,59.0,YR,A,F,Y,,,20230222,,HP,CA,CA,2023,Q1,Adult
220182711,22018271,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Joint swelling,,2023,Q1,1,I,,20230216.0,20230221,20230221,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219564",BOEHRINGER INGELHEIM,,59.0,YR,A,F,Y,,,20230222,,HP,CA,CA,2023,Q1,Adult
220182711,22018271,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Tendonitis,,2023,Q1,1,I,,20230216.0,20230221,20230221,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219564",BOEHRINGER INGELHEIM,,59.0,YR,A,F,Y,,,20230222,,HP,CA,CA,2023,Q1,Adult
220182711,22018271,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Pyrexia,,2023,Q1,1,I,,20230216.0,20230221,20230221,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219564",BOEHRINGER INGELHEIM,,59.0,YR,A,F,Y,,,20230222,,HP,CA,CA,2023,Q1,Adult
220182711,22018271,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Injection site pain,,2023,Q1,1,I,,20230216.0,20230221,20230221,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219564",BOEHRINGER INGELHEIM,,59.0,YR,A,F,Y,,,20230222,,HP,CA,CA,2023,Q1,Adult
220182711,22018271,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Allergic sinusitis,,2023,Q1,1,I,,20230216.0,20230221,20230221,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219564",BOEHRINGER INGELHEIM,,59.0,YR,A,F,Y,,,20230222,,HP,CA,CA,2023,Q1,Adult
220182711,22018271,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Drug ineffective,,2023,Q1,1,I,,20230216.0,20230221,20230221,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219564",BOEHRINGER INGELHEIM,,59.0,YR,A,F,Y,,,20230222,,HP,CA,CA,2023,Q1,Adult
220182711,22018271,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Urinary tract infection,,2023,Q1,1,I,,20230216.0,20230221,20230221,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219564",BOEHRINGER INGELHEIM,,59.0,YR,A,F,Y,,,20230222,,HP,CA,CA,2023,Q1,Adult
220182711,22018271,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Sepsis,,2023,Q1,1,I,,20230216.0,20230221,20230221,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219564",BOEHRINGER INGELHEIM,,59.0,YR,A,F,Y,,,20230222,,HP,CA,CA,2023,Q1,Adult
220182711,22018271,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Oedema,,2023,Q1,1,I,,20230216.0,20230221,20230221,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219564",BOEHRINGER INGELHEIM,,59.0,YR,A,F,Y,,,20230222,,HP,CA,CA,2023,Q1,Adult
220182711,22018271,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Pain,,2023,Q1,1,I,,20230216.0,20230221,20230221,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219564",BOEHRINGER INGELHEIM,,59.0,YR,A,F,Y,,,20230222,,HP,CA,CA,2023,Q1,Adult
220182711,22018271,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Injection site warmth,,2023,Q1,1,I,,20230216.0,20230221,20230221,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219564",BOEHRINGER INGELHEIM,,59.0,YR,A,F,Y,,,20230222,,HP,CA,CA,2023,Q1,Adult
220182711,22018271,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Blood uric acid increased,,2023,Q1,1,I,,20230216.0,20230221,20230221,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219564",BOEHRINGER INGELHEIM,,59.0,YR,A,F,Y,,,20230222,,HP,CA,CA,2023,Q1,Adult
220202952,22020295,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,,,,,,10.0,MG,Tablet,QD,2023,Q1,Post procedural haematoma,,2023,Q1,2,F,20230125.0,20230228.0,20230222,20230308,EXP,,NVSC2023US038028,NOVARTIS,,51.0,YR,,F,Y,,,20230308,,CN,US,US,2023,Q1,Adult
220202952,22020295,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,,,,,,10.0,MG,Tablet,QD,2023,Q1,Underdose,,2023,Q1,2,F,20230125.0,20230228.0,20230222,20230308,EXP,,NVSC2023US038028,NOVARTIS,,51.0,YR,,F,Y,,,20230308,,CN,US,US,2023,Q1,Adult
220202952,22020295,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,,,,,,10.0,MG,Tablet,QD,2023,Q1,Weight fluctuation,,2023,Q1,2,F,20230125.0,20230228.0,20230222,20230308,EXP,,NVSC2023US038028,NOVARTIS,,51.0,YR,,F,Y,,,20230308,,CN,US,US,2023,Q1,Adult
220202952,22020295,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,,,,,,10.0,MG,Tablet,QD,2023,Q1,Ventricular extrasystoles,,2023,Q1,2,F,20230125.0,20230228.0,20230222,20230308,EXP,,NVSC2023US038028,NOVARTIS,,51.0,YR,,F,Y,,,20230308,,CN,US,US,2023,Q1,Adult
220202952,22020295,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,,,,,,10.0,MG,Tablet,QD,2023,Q1,Headache,,2023,Q1,2,F,20230125.0,20230228.0,20230222,20230308,EXP,,NVSC2023US038028,NOVARTIS,,51.0,YR,,F,Y,,,20230308,,CN,US,US,2023,Q1,Adult
220202952,22020295,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,,,,,,10.0,MG,Tablet,QD,2023,Q1,Fluid retention,,2023,Q1,2,F,20230125.0,20230228.0,20230222,20230308,EXP,,NVSC2023US038028,NOVARTIS,,51.0,YR,,F,Y,,,20230308,,CN,US,US,2023,Q1,Adult
220202952,22020295,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,,,,,,10.0,MG,Tablet,QD,2023,Q1,Haemoglobin decreased,,2023,Q1,2,F,20230125.0,20230228.0,20230222,20230308,EXP,,NVSC2023US038028,NOVARTIS,,51.0,YR,,F,Y,,,20230308,,CN,US,US,2023,Q1,Adult
220202952,22020295,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,,,,,,10.0,MG,Tablet,QD,2023,Q1,Musculoskeletal discomfort,,2023,Q1,2,F,20230125.0,20230228.0,20230222,20230308,EXP,,NVSC2023US038028,NOVARTIS,,51.0,YR,,F,Y,,,20230308,,CN,US,US,2023,Q1,Adult
220202952,22020295,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,,,,,,10.0,MG,Tablet,QD,2023,Q1,Congestive cardiomyopathy,,2023,Q1,2,F,20230125.0,20230228.0,20230222,20230308,EXP,,NVSC2023US038028,NOVARTIS,,51.0,YR,,F,Y,,,20230308,,CN,US,US,2023,Q1,Adult
220202952,22020295,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,,,,,,10.0,MG,Tablet,QD,2023,Q1,Wrong technique in product usage process,,2023,Q1,2,F,20230125.0,20230228.0,20230222,20230308,EXP,,NVSC2023US038028,NOVARTIS,,51.0,YR,,F,Y,,,20230308,,CN,US,US,2023,Q1,Adult
220202952,22020295,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,,,,,,10.0,MG,Tablet,QD,2023,Q1,Ecchymosis,,2023,Q1,2,F,20230125.0,20230228.0,20230222,20230308,EXP,,NVSC2023US038028,NOVARTIS,,51.0,YR,,F,Y,,,20230308,,CN,US,US,2023,Q1,Adult
220202952,22020295,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,,,,,,10.0,MG,Tablet,QD,2023,Q1,Hypotension,,2023,Q1,2,F,20230125.0,20230228.0,20230222,20230308,EXP,,NVSC2023US038028,NOVARTIS,,51.0,YR,,F,Y,,,20230308,,CN,US,US,2023,Q1,Adult
220202952,22020295,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,,,,,,10.0,MG,Tablet,QD,2023,Q1,Nausea,,2023,Q1,2,F,20230125.0,20230228.0,20230222,20230308,EXP,,NVSC2023US038028,NOVARTIS,,51.0,YR,,F,Y,,,20230308,,CN,US,US,2023,Q1,Adult
220202952,22020295,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,,,,,,10.0,MG,Tablet,QD,2023,Q1,Post procedural haemorrhage,,2023,Q1,2,F,20230125.0,20230228.0,20230222,20230308,EXP,,NVSC2023US038028,NOVARTIS,,51.0,YR,,F,Y,,,20230308,,CN,US,US,2023,Q1,Adult
220207921,22020792,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,take one daily,,,,,,,,,,,QD,2023,Q1,Urticaria,,2023,Q1,1,I,20230214.0,20230215.0,20230222,20230222,EXP,GB-MHRA-TPP41217198C963099YC1676368095767,GB-EMD Serono-E2B_90090815,EMD SERONO INC,,55.0,YR,A,M,Y,81.0,KG,20230222,,MD,GB,,2023,Q1,Adult
220216692,22021669,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,Tablet,QD,2023,Q1,Cardiac failure,,2023,Q1,2,F,20230213.0,20230224.0,20230222,20230303,EXP,,ES-JNJFOC-20230232572,JOHNSON AND JOHNSON,,65.0,YR,E,M,Y,66.4,KG,20230303,,MD,ES,ES,2023,Q1,Elderly
220221572,22022157,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,not known,,204629.0,25.0,MG,Coated tablet,QD,2023,Q1,Fournier's gangrene,,2023,Q1,2,F,,20230329.0,20230222,20230329,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-220519",BOEHRINGER INGELHEIM,,60.0,YR,A,M,Y,,,20230329,,MD,GB,GB,2023,Q1,Adult
220221572,22022157,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,not known,,204629.0,25.0,MG,Coated tablet,QD,2023,Q1,Malaise,,2023,Q1,2,F,,20230329.0,20230222,20230329,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-220519",BOEHRINGER INGELHEIM,,60.0,YR,A,M,Y,,,20230329,,MD,GB,GB,2023,Q1,Adult
220221572,22022157,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,not known,,204629.0,25.0,MG,Coated tablet,QD,2023,Q1,Mass,,2023,Q1,2,F,,20230329.0,20230222,20230329,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-220519",BOEHRINGER INGELHEIM,,60.0,YR,A,M,Y,,,20230329,,MD,GB,GB,2023,Q1,Adult
220232321,22023232,4,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,linagliptin 5 mg/empagliflozin 10 mg combination tablet.,,,,,,,,,,Tablet,,2023,Q1,Angina pectoris,,2023,Q1,1,I,20210101.0,20230213.0,20230223,20230223,EXP,,JP-EMD Serono-9385151,EMD SERONO INC,,74.0,YR,E,F,Y,,,20230223,,HP,JP,,2023,Q1,Elderly
220232321,22023232,4,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,linagliptin 5 mg/empagliflozin 10 mg combination tablet.,,,,,,,,,,Tablet,,2023,Q1,Myocardial ischaemia,,2023,Q1,1,I,20210101.0,20230213.0,20230223,20230223,EXP,,JP-EMD Serono-9385151,EMD SERONO INC,,74.0,YR,E,F,Y,,,20230223,,HP,JP,,2023,Q1,Elderly
220232321,22023232,4,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,linagliptin 5 mg/empagliflozin 10 mg combination tablet.,,,,,,,,,,Tablet,,2023,Q1,Diabetes mellitus inadequate control,,2023,Q1,1,I,20210101.0,20230213.0,20230223,20230223,EXP,,JP-EMD Serono-9385151,EMD SERONO INC,,74.0,YR,E,F,Y,,,20230223,,HP,JP,,2023,Q1,Elderly
220232321,22023232,4,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,linagliptin 5 mg/empagliflozin 10 mg combination tablet.,,,,,,,,,,Tablet,,2023,Q1,Hypoglycaemia,,2023,Q1,1,I,20210101.0,20230213.0,20230223,20230223,EXP,,JP-EMD Serono-9385151,EMD SERONO INC,,74.0,YR,E,F,Y,,,20230223,,HP,JP,,2023,Q1,Elderly
220298782,22029878,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,2,F,,20230224.0,20230223,20230306,EXP,,US-TEVA-2023-US-2857463,TEVA,,65.0,YR,E,F,Y,,,20230306,,HP,US,US,2023,Q1,Elderly
220298782,22029878,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q1,Lactic acidosis,,2023,Q1,2,F,,20230224.0,20230223,20230306,EXP,,US-TEVA-2023-US-2857463,TEVA,,65.0,YR,E,F,Y,,,20230306,,HP,US,US,2023,Q1,Elderly
220298782,22029878,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q1,Renal failure,,2023,Q1,2,F,,20230224.0,20230223,20230306,EXP,,US-TEVA-2023-US-2857463,TEVA,,65.0,YR,E,F,Y,,,20230306,,HP,US,US,2023,Q1,Elderly
220319993,22031999,7,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2023,Q1,Meningitis,,2023,Q1,3,F,20230214.0,20230215.0,20230224,20230224,EXP,,IL-ABBVIE-4309168,ABBVIE,,67.0,YR,,M,Y,,,20230222,,MD,IL,IL,2023,Q1,Elderly
220323471,22032347,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,Y,U,,,,10.0,MG,,QD,2023,Q1,Post procedural complication,,2023,Q1,1,I,,20230215.0,20230224,20230224,EXP,,PT-AUROBINDO-AUR-APL-2023-008078,AUROBINDO,"Fustiga J, Fernandes M, Damaso F, Duarte JA, Rodrigues C. Postop Complication With Euglycemic Diabetic Ketoacidosis in a Patient Receiving Empagliflozin. Cureus. 2022;14:12",77.0,YR,,F,Y,,,20230224,,HP,PT,PT,2023,Q1,Elderly
220323471,22032347,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,Y,U,,,,10.0,MG,,QD,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,1,I,,20230215.0,20230224,20230224,EXP,,PT-AUROBINDO-AUR-APL-2023-008078,AUROBINDO,"Fustiga J, Fernandes M, Damaso F, Duarte JA, Rodrigues C. Postop Complication With Euglycemic Diabetic Ketoacidosis in a Patient Receiving Empagliflozin. Cureus. 2022;14:12",77.0,YR,,F,Y,,,20230224,,HP,PT,PT,2023,Q1,Elderly
220325011,22032501,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,Unknown,,,,,,,2023,Q1,Toxicity to various agents,,2023,Q1,1,I,,20230214.0,20230224,20230224,EXP,,US-LUPIN PHARMACEUTICALS INC.-2023-01339,LUPIN,"Spyres MB, Aldy K, Farrugia LA, Kang AM, Love JS, Campleman SL, et al. The toxicology investigators consortium 2020 annual report. Journal of Medical Toxicology. 2021;17:333-362",15.0,YR,,M,Y,,,20230224,,HP,US,US,2023,Q1,Youth
220325011,22032501,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,Unknown,,,,,,,2023,Q1,Respiratory depression,,2023,Q1,1,I,,20230214.0,20230224,20230224,EXP,,US-LUPIN PHARMACEUTICALS INC.-2023-01339,LUPIN,"Spyres MB, Aldy K, Farrugia LA, Kang AM, Love JS, Campleman SL, et al. The toxicology investigators consortium 2020 annual report. Journal of Medical Toxicology. 2021;17:333-362",15.0,YR,,M,Y,,,20230224,,HP,US,US,2023,Q1,Youth
220325011,22032501,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,Unknown,,,,,,,2023,Q1,Metabolic acidosis,,2023,Q1,1,I,,20230214.0,20230224,20230224,EXP,,US-LUPIN PHARMACEUTICALS INC.-2023-01339,LUPIN,"Spyres MB, Aldy K, Farrugia LA, Kang AM, Love JS, Campleman SL, et al. The toxicology investigators consortium 2020 annual report. Journal of Medical Toxicology. 2021;17:333-362",15.0,YR,,M,Y,,,20230224,,HP,US,US,2023,Q1,Youth
220325011,22032501,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,Unknown,,,,,,,2023,Q1,Depressed level of consciousness,,2023,Q1,1,I,,20230214.0,20230224,20230224,EXP,,US-LUPIN PHARMACEUTICALS INC.-2023-01339,LUPIN,"Spyres MB, Aldy K, Farrugia LA, Kang AM, Love JS, Campleman SL, et al. The toxicology investigators consortium 2020 annual report. Journal of Medical Toxicology. 2021;17:333-362",15.0,YR,,M,Y,,,20230224,,HP,US,US,2023,Q1,Youth
220325011,22032501,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,Unknown,,,,,,,2023,Q1,Hypotension,,2023,Q1,1,I,,20230214.0,20230224,20230224,EXP,,US-LUPIN PHARMACEUTICALS INC.-2023-01339,LUPIN,"Spyres MB, Aldy K, Farrugia LA, Kang AM, Love JS, Campleman SL, et al. The toxicology investigators consortium 2020 annual report. Journal of Medical Toxicology. 2021;17:333-362",15.0,YR,,M,Y,,,20230224,,HP,US,US,2023,Q1,Youth
220325011,22032501,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,Unknown,,,,,,,2023,Q1,Coma,,2023,Q1,1,I,,20230214.0,20230224,20230224,EXP,,US-LUPIN PHARMACEUTICALS INC.-2023-01339,LUPIN,"Spyres MB, Aldy K, Farrugia LA, Kang AM, Love JS, Campleman SL, et al. The toxicology investigators consortium 2020 annual report. Journal of Medical Toxicology. 2021;17:333-362",15.0,YR,,M,Y,,,20230224,,HP,US,US,2023,Q1,Youth
220325011,22032501,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,Unknown,,,,,,,2023,Q1,Anion gap abnormal,,2023,Q1,1,I,,20230214.0,20230224,20230224,EXP,,US-LUPIN PHARMACEUTICALS INC.-2023-01339,LUPIN,"Spyres MB, Aldy K, Farrugia LA, Kang AM, Love JS, Campleman SL, et al. The toxicology investigators consortium 2020 annual report. Journal of Medical Toxicology. 2021;17:333-362",15.0,YR,,M,Y,,,20230224,,HP,US,US,2023,Q1,Youth
220326701,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q1,Rash,,2023,Q1,1,I,,20230215.0,20230224,20230224,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20230224,,HP,CA,CA,2023,Q1,Adult
220326701,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q1,Nephrolithiasis,,2023,Q1,1,I,,20230215.0,20230224,20230224,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20230224,,HP,CA,CA,2023,Q1,Adult
220326701,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q1,Joint swelling,,2023,Q1,1,I,,20230215.0,20230224,20230224,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20230224,,HP,CA,CA,2023,Q1,Adult
220326701,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q1,Psoriasis,,2023,Q1,1,I,,20230215.0,20230224,20230224,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20230224,,HP,CA,CA,2023,Q1,Adult
220326701,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q1,Incorrect dose administered,,2023,Q1,1,I,,20230215.0,20230224,20230224,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20230224,,HP,CA,CA,2023,Q1,Adult
220326701,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q1,Injection site warmth,,2023,Q1,1,I,,20230215.0,20230224,20230224,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20230224,,HP,CA,CA,2023,Q1,Adult
220326701,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q1,Urinary tract infection,,2023,Q1,1,I,,20230215.0,20230224,20230224,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20230224,,HP,CA,CA,2023,Q1,Adult
220326701,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q1,Joint effusion,,2023,Q1,1,I,,20230215.0,20230224,20230224,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20230224,,HP,CA,CA,2023,Q1,Adult
220326701,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q1,C-reactive protein increased,,2023,Q1,1,I,,20230215.0,20230224,20230224,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20230224,,HP,CA,CA,2023,Q1,Adult
220326701,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q1,Sepsis,,2023,Q1,1,I,,20230215.0,20230224,20230224,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20230224,,HP,CA,CA,2023,Q1,Adult
220326701,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q1,Tendonitis,,2023,Q1,1,I,,20230215.0,20230224,20230224,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20230224,,HP,CA,CA,2023,Q1,Adult
220326701,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q1,Synovitis,,2023,Q1,1,I,,20230215.0,20230224,20230224,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20230224,,HP,CA,CA,2023,Q1,Adult
220326701,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q1,Antinuclear antibody positive,,2023,Q1,1,I,,20230215.0,20230224,20230224,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20230224,,HP,CA,CA,2023,Q1,Adult
220326701,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q1,Synovial disorder,,2023,Q1,1,I,,20230215.0,20230224,20230224,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20230224,,HP,CA,CA,2023,Q1,Adult
220326701,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q1,Arthritis,,2023,Q1,1,I,,20230215.0,20230224,20230224,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20230224,,HP,CA,CA,2023,Q1,Adult
220326701,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q1,Oedema,,2023,Q1,1,I,,20230215.0,20230224,20230224,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20230224,,HP,CA,CA,2023,Q1,Adult
220326701,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q1,Pain in extremity,,2023,Q1,1,I,,20230215.0,20230224,20230224,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20230224,,HP,CA,CA,2023,Q1,Adult
220326701,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q1,Blood iron decreased,,2023,Q1,1,I,,20230215.0,20230224,20230224,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20230224,,HP,CA,CA,2023,Q1,Adult
220326701,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q1,Allergic sinusitis,,2023,Q1,1,I,,20230215.0,20230224,20230224,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20230224,,HP,CA,CA,2023,Q1,Adult
220326701,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q1,Hepatic enzyme increased,,2023,Q1,1,I,,20230215.0,20230224,20230224,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20230224,,HP,CA,CA,2023,Q1,Adult
220326701,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q1,Pyrexia,,2023,Q1,1,I,,20230215.0,20230224,20230224,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20230224,,HP,CA,CA,2023,Q1,Adult
220326701,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q1,Drug ineffective,,2023,Q1,1,I,,20230215.0,20230224,20230224,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20230224,,HP,CA,CA,2023,Q1,Adult
220326701,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q1,Cyst,,2023,Q1,1,I,,20230215.0,20230224,20230224,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20230224,,HP,CA,CA,2023,Q1,Adult
220326701,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q1,Pain,,2023,Q1,1,I,,20230215.0,20230224,20230224,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20230224,,HP,CA,CA,2023,Q1,Adult
220326701,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q1,Arthropathy,,2023,Q1,1,I,,20230215.0,20230224,20230224,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20230224,,HP,CA,CA,2023,Q1,Adult
220326701,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q1,Alanine aminotransferase increased,,2023,Q1,1,I,,20230215.0,20230224,20230224,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20230224,,HP,CA,CA,2023,Q1,Adult
220326701,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q1,Condition aggravated,,2023,Q1,1,I,,20230215.0,20230224,20230224,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20230224,,HP,CA,CA,2023,Q1,Adult
220326701,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q1,Arthralgia,,2023,Q1,1,I,,20230215.0,20230224,20230224,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20230224,,HP,CA,CA,2023,Q1,Adult
220326701,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q1,Vitamin B12 decreased,,2023,Q1,1,I,,20230215.0,20230224,20230224,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20230224,,HP,CA,CA,2023,Q1,Adult
220326701,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q1,Osteoarthritis,,2023,Q1,1,I,,20230215.0,20230224,20230224,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20230224,,HP,CA,CA,2023,Q1,Adult
220326701,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q1,Blood uric acid increased,,2023,Q1,1,I,,20230215.0,20230224,20230224,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20230224,,HP,CA,CA,2023,Q1,Adult
220326701,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q1,Injection site pain,,2023,Q1,1,I,,20230215.0,20230224,20230224,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20230224,,HP,CA,CA,2023,Q1,Adult
220326701,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q1,Renal disorder,,2023,Q1,1,I,,20230215.0,20230224,20230224,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20230224,,HP,CA,CA,2023,Q1,Adult
220329951,22032995,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q1,Respiratory depression,,2023,Q1,1,I,,20230214.0,20230224,20230224,EXP,,US-STRIDES ARCOLAB LIMITED-2023SP002577,STRIDES,"Spyres MB, Aldy K, Farrugia LA, Kang AM, Love JS, Campleman SL, et al.. The Toxicology Investigators Consortium 2020 Annual Report.. J-Med-Toxicol. 2021;17(4):333-362",15.0,YR,,M,Y,,,20230224,,HP,US,US,2023,Q1,Youth
220329951,22032995,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q1,Metabolic acidosis,,2023,Q1,1,I,,20230214.0,20230224,20230224,EXP,,US-STRIDES ARCOLAB LIMITED-2023SP002577,STRIDES,"Spyres MB, Aldy K, Farrugia LA, Kang AM, Love JS, Campleman SL, et al.. The Toxicology Investigators Consortium 2020 Annual Report.. J-Med-Toxicol. 2021;17(4):333-362",15.0,YR,,M,Y,,,20230224,,HP,US,US,2023,Q1,Youth
220329951,22032995,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q1,Depressed level of consciousness,,2023,Q1,1,I,,20230214.0,20230224,20230224,EXP,,US-STRIDES ARCOLAB LIMITED-2023SP002577,STRIDES,"Spyres MB, Aldy K, Farrugia LA, Kang AM, Love JS, Campleman SL, et al.. The Toxicology Investigators Consortium 2020 Annual Report.. J-Med-Toxicol. 2021;17(4):333-362",15.0,YR,,M,Y,,,20230224,,HP,US,US,2023,Q1,Youth
220329951,22032995,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q1,Toxicity to various agents,,2023,Q1,1,I,,20230214.0,20230224,20230224,EXP,,US-STRIDES ARCOLAB LIMITED-2023SP002577,STRIDES,"Spyres MB, Aldy K, Farrugia LA, Kang AM, Love JS, Campleman SL, et al.. The Toxicology Investigators Consortium 2020 Annual Report.. J-Med-Toxicol. 2021;17(4):333-362",15.0,YR,,M,Y,,,20230224,,HP,US,US,2023,Q1,Youth
220329951,22032995,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q1,Coma,,2023,Q1,1,I,,20230214.0,20230224,20230224,EXP,,US-STRIDES ARCOLAB LIMITED-2023SP002577,STRIDES,"Spyres MB, Aldy K, Farrugia LA, Kang AM, Love JS, Campleman SL, et al.. The Toxicology Investigators Consortium 2020 Annual Report.. J-Med-Toxicol. 2021;17(4):333-362",15.0,YR,,M,Y,,,20230224,,HP,US,US,2023,Q1,Youth
220329951,22032995,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q1,Hypotension,,2023,Q1,1,I,,20230214.0,20230224,20230224,EXP,,US-STRIDES ARCOLAB LIMITED-2023SP002577,STRIDES,"Spyres MB, Aldy K, Farrugia LA, Kang AM, Love JS, Campleman SL, et al.. The Toxicology Investigators Consortium 2020 Annual Report.. J-Med-Toxicol. 2021;17(4):333-362",15.0,YR,,M,Y,,,20230224,,HP,US,US,2023,Q1,Youth
220329951,22032995,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q1,Anion gap,,2023,Q1,1,I,,20230214.0,20230224,20230224,EXP,,US-STRIDES ARCOLAB LIMITED-2023SP002577,STRIDES,"Spyres MB, Aldy K, Farrugia LA, Kang AM, Love JS, Campleman SL, et al.. The Toxicology Investigators Consortium 2020 Annual Report.. J-Med-Toxicol. 2021;17(4):333-362",15.0,YR,,M,Y,,,20230224,,HP,US,US,2023,Q1,Youth
220348442,22034844,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 mg, QD",,,,,,,,25.0,MG,,QD,2023,Q1,Splenomegaly,,2023,Q1,2,F,20221013.0,20230210.0,20230224,20230301,EXP,,US-BAYER-2023A023401,BAYER,,82.0,YR,E,M,Y,91.36,KG,20230301,,MD,US,US,2023,Q1,Elderly
220348442,22034844,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 mg, QD",,,,,,,,25.0,MG,,QD,2023,Q1,Hepatic cirrhosis,,2023,Q1,2,F,20221013.0,20230210.0,20230224,20230301,EXP,,US-BAYER-2023A023401,BAYER,,82.0,YR,E,M,Y,91.36,KG,20230301,,MD,US,US,2023,Q1,Elderly
220356741,22035674,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,,,,QD,2023,Q1,Disease complication,,2023,Q1,1,I,20230110.0,,20230223,20230223,DIR,649791,,FDA-CTU,,79.0,YR,,F,N,73.35,KG,20230223,N,MD,US,,2023,Q1,Elderly
220356741,22035674,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,,,,QD,2023,Q1,Treatment noncompliance,,2023,Q1,1,I,20230110.0,,20230223,20230223,DIR,649791,,FDA-CTU,,79.0,YR,,F,N,73.35,KG,20230223,N,MD,US,,2023,Q1,Elderly
220356741,22035674,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,,,,QD,2023,Q1,Toe amputation,,2023,Q1,1,I,20230110.0,,20230223,20230223,DIR,649791,,FDA-CTU,,79.0,YR,,F,N,73.35,KG,20230223,N,MD,US,,2023,Q1,Elderly
220359401,22035940,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q1,Diabetic ketoacidosis,,2023,Q1,1,I,20220328.0,20230204.0,20230224,20230224,EXP,AU-TG-0000731445,AU-NOVOPROD-1022811,NOVO NORDISK,,72.0,YR,,F,Y,,,20230215,,PH,AU,AU,2023,Q1,Elderly
220359401,22035940,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q1,Constipation,,2023,Q1,1,I,20220328.0,20230204.0,20230224,20230224,EXP,AU-TG-0000731445,AU-NOVOPROD-1022811,NOVO NORDISK,,72.0,YR,,F,Y,,,20230215,,PH,AU,AU,2023,Q1,Elderly
220359401,22035940,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q1,Acute kidney injury,,2023,Q1,1,I,20220328.0,20230204.0,20230224,20230224,EXP,AU-TG-0000731445,AU-NOVOPROD-1022811,NOVO NORDISK,,72.0,YR,,F,Y,,,20230215,,PH,AU,AU,2023,Q1,Elderly
220359401,22035940,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q1,Gastrooesophageal reflux disease,,2023,Q1,1,I,20220328.0,20230204.0,20230224,20230224,EXP,AU-TG-0000731445,AU-NOVOPROD-1022811,NOVO NORDISK,,72.0,YR,,F,Y,,,20230215,,PH,AU,AU,2023,Q1,Elderly
220359432,22035943,2,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,2 tablets,,,,,,,,,,,,2023,Q1,Urinary tract infection,,2023,Q1,2,F,20221001.0,20230214.0,20230224,20230302,EXP,,CO-NOVOPROD-1002695,NOVO NORDISK,,90.0,YR,,F,Y,72.0,KG,20230227,,CN,CO,CO,2023,Q1,Elderly
220359432,22035943,2,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,2 tablets,,,,,,,,,,,,2023,Q1,Fall,,2023,Q1,2,F,20221001.0,20230214.0,20230224,20230302,EXP,,CO-NOVOPROD-1002695,NOVO NORDISK,,90.0,YR,,F,Y,72.0,KG,20230227,,CN,CO,CO,2023,Q1,Elderly
220359432,22035943,2,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,2 tablets,,,,,,,,,,,,2023,Q1,Spinal fracture,,2023,Q1,2,F,20221001.0,20230214.0,20230224,20230302,EXP,,CO-NOVOPROD-1002695,NOVO NORDISK,,90.0,YR,,F,Y,72.0,KG,20230227,,CN,CO,CO,2023,Q1,Elderly
220359432,22035943,2,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,2 tablets,,,,,,,,,,,,2023,Q1,Somnolence,,2023,Q1,2,F,20221001.0,20230214.0,20230224,20230302,EXP,,CO-NOVOPROD-1002695,NOVO NORDISK,,90.0,YR,,F,Y,72.0,KG,20230227,,CN,CO,CO,2023,Q1,Elderly
220359432,22035943,2,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,2 tablets,,,,,,,,,,,,2023,Q1,Discouragement,,2023,Q1,2,F,20221001.0,20230214.0,20230224,20230302,EXP,,CO-NOVOPROD-1002695,NOVO NORDISK,,90.0,YR,,F,Y,72.0,KG,20230227,,CN,CO,CO,2023,Q1,Elderly
220359432,22035943,2,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,2 tablets,,,,,,,,,,,,2023,Q1,Speech disorder,,2023,Q1,2,F,20221001.0,20230214.0,20230224,20230302,EXP,,CO-NOVOPROD-1002695,NOVO NORDISK,,90.0,YR,,F,Y,72.0,KG,20230227,,CN,CO,CO,2023,Q1,Elderly
220359432,22035943,2,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,2 tablets,,,,,,,,,,,,2023,Q1,Delirium,,2023,Q1,2,F,20221001.0,20230214.0,20230224,20230302,EXP,,CO-NOVOPROD-1002695,NOVO NORDISK,,90.0,YR,,F,Y,72.0,KG,20230227,,CN,CO,CO,2023,Q1,Elderly
220359432,22035943,2,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,2 tablets,,,,,,,,,,,,2023,Q1,Decreased appetite,,2023,Q1,2,F,20221001.0,20230214.0,20230224,20230302,EXP,,CO-NOVOPROD-1002695,NOVO NORDISK,,90.0,YR,,F,Y,72.0,KG,20230227,,CN,CO,CO,2023,Q1,Elderly
220361151,22036115,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 Dosage forms Daily; take one daily,,,,,,,,,,,,2023,Q1,Urticaria,,2023,Q1,1,I,20230214.0,20230215.0,20230224,20230224,EXP,GB-MHRA-TPP41217198C963099YC1676368095767,GB-TEVA-2023-GB-2858117,TEVA,,55.0,YR,A,M,Y,81.0,KG,20230224,,MD,GB,GB,2023,Q1,Adult
220380401,22038040,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,1,I,,20230214.0,20230227,20230227,EXP,,US-MICRO LABS LIMITED-ML2023-01003,MICRO LABS,,65.0,YR,E,F,Y,,,20230227,,HP,US,,2023,Q1,Elderly
220380401,22038040,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q1,Lactic acidosis,,2023,Q1,1,I,,20230214.0,20230227,20230227,EXP,,US-MICRO LABS LIMITED-ML2023-01003,MICRO LABS,,65.0,YR,E,F,Y,,,20230227,,HP,US,,2023,Q1,Elderly
220381782,22038178,4,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,12.5/100 mg,,,,,,,,,,,QOD,2023,Q1,Disseminated tuberculosis,,2023,Q1,2,F,20221001.0,20230316.0,20230227,20230322,EXP,,AU-ABBVIE-4318266,ABBVIE,,69.0,YR,,F,Y,,,20230322,,MD,AU,AU,2023,Q1,Elderly
220391521,22039152,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Mucous stools,,2023,Q1,1,I,20220101.0,20230216.0,20230227,20230227,EXP,,US-Accord-301896,ACCORD,,64.0,YR,A,F,Y,74.84,KG,20230227,,HP,US,US,2023,Q1,Adult
220391521,22039152,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Nausea,,2023,Q1,1,I,20220101.0,20230216.0,20230227,20230227,EXP,,US-Accord-301896,ACCORD,,64.0,YR,A,F,Y,74.84,KG,20230227,,HP,US,US,2023,Q1,Adult
220391521,22039152,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Blood potassium decreased,,2023,Q1,1,I,20220101.0,20230216.0,20230227,20230227,EXP,,US-Accord-301896,ACCORD,,64.0,YR,A,F,Y,74.84,KG,20230227,,HP,US,US,2023,Q1,Adult
220391521,22039152,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Blood thyroid stimulating hormone increased,,2023,Q1,1,I,20220101.0,20230216.0,20230227,20230227,EXP,,US-Accord-301896,ACCORD,,64.0,YR,A,F,Y,74.84,KG,20230227,,HP,US,US,2023,Q1,Adult
220391521,22039152,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Blood pressure increased,,2023,Q1,1,I,20220101.0,20230216.0,20230227,20230227,EXP,,US-Accord-301896,ACCORD,,64.0,YR,A,F,Y,74.84,KG,20230227,,HP,US,US,2023,Q1,Adult
220391521,22039152,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Panic attack,,2023,Q1,1,I,20220101.0,20230216.0,20230227,20230227,EXP,,US-Accord-301896,ACCORD,,64.0,YR,A,F,Y,74.84,KG,20230227,,HP,US,US,2023,Q1,Adult
220391521,22039152,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Dizziness,,2023,Q1,1,I,20220101.0,20230216.0,20230227,20230227,EXP,,US-Accord-301896,ACCORD,,64.0,YR,A,F,Y,74.84,KG,20230227,,HP,US,US,2023,Q1,Adult
220391521,22039152,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Arthralgia,,2023,Q1,1,I,20220101.0,20230216.0,20230227,20230227,EXP,,US-Accord-301896,ACCORD,,64.0,YR,A,F,Y,74.84,KG,20230227,,HP,US,US,2023,Q1,Adult
220391521,22039152,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Vomiting,,2023,Q1,1,I,20220101.0,20230216.0,20230227,20230227,EXP,,US-Accord-301896,ACCORD,,64.0,YR,A,F,Y,74.84,KG,20230227,,HP,US,US,2023,Q1,Adult
220391521,22039152,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Blood glucose decreased,,2023,Q1,1,I,20220101.0,20230216.0,20230227,20230227,EXP,,US-Accord-301896,ACCORD,,64.0,YR,A,F,Y,74.84,KG,20230227,,HP,US,US,2023,Q1,Adult
220391521,22039152,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Diarrhoea,,2023,Q1,1,I,20220101.0,20230216.0,20230227,20230227,EXP,,US-Accord-301896,ACCORD,,64.0,YR,A,F,Y,74.84,KG,20230227,,HP,US,US,2023,Q1,Adult
220391521,22039152,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Breast cancer,,2023,Q1,1,I,20220101.0,20230216.0,20230227,20230227,EXP,,US-Accord-301896,ACCORD,,64.0,YR,A,F,Y,74.84,KG,20230227,,HP,US,US,2023,Q1,Adult
220391521,22039152,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Hypotension,,2023,Q1,1,I,20220101.0,20230216.0,20230227,20230227,EXP,,US-Accord-301896,ACCORD,,64.0,YR,A,F,Y,74.84,KG,20230227,,HP,US,US,2023,Q1,Adult
220391521,22039152,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Hypothyroidism,,2023,Q1,1,I,20220101.0,20230216.0,20230227,20230227,EXP,,US-Accord-301896,ACCORD,,64.0,YR,A,F,Y,74.84,KG,20230227,,HP,US,US,2023,Q1,Adult
220394671,22039467,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2023,Q1,Off label use,,2023,Q1,1,I,20190801.0,20230215.0,20230227,20230227,EXP,,GB-MYLANLABS-2023M1019331,MYLAN,"Mateo H, Seddon B. Pigmented villonodular synovitis successfully managed with imatinib. Pharm-Educ 2020;20(3):88-89.",37.0,YR,,M,Y,,,20230227,,HP,GB,GB,2023,Q1,Adult
220394671,22039467,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2023,Q1,Blood bilirubin increased,,2023,Q1,1,I,20190801.0,20230215.0,20230227,20230227,EXP,,GB-MYLANLABS-2023M1019331,MYLAN,"Mateo H, Seddon B. Pigmented villonodular synovitis successfully managed with imatinib. Pharm-Educ 2020;20(3):88-89.",37.0,YR,,M,Y,,,20230227,,HP,GB,GB,2023,Q1,Adult
220394671,22039467,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2023,Q1,Neutropenia,,2023,Q1,1,I,20190801.0,20230215.0,20230227,20230227,EXP,,GB-MYLANLABS-2023M1019331,MYLAN,"Mateo H, Seddon B. Pigmented villonodular synovitis successfully managed with imatinib. Pharm-Educ 2020;20(3):88-89.",37.0,YR,,M,Y,,,20230227,,HP,GB,GB,2023,Q1,Adult
220394671,22039467,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2023,Q1,Decreased appetite,,2023,Q1,1,I,20190801.0,20230215.0,20230227,20230227,EXP,,GB-MYLANLABS-2023M1019331,MYLAN,"Mateo H, Seddon B. Pigmented villonodular synovitis successfully managed with imatinib. Pharm-Educ 2020;20(3):88-89.",37.0,YR,,M,Y,,,20230227,,HP,GB,GB,2023,Q1,Adult
220394671,22039467,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2023,Q1,Nausea,,2023,Q1,1,I,20190801.0,20230215.0,20230227,20230227,EXP,,GB-MYLANLABS-2023M1019331,MYLAN,"Mateo H, Seddon B. Pigmented villonodular synovitis successfully managed with imatinib. Pharm-Educ 2020;20(3):88-89.",37.0,YR,,M,Y,,,20230227,,HP,GB,GB,2023,Q1,Adult
220394671,22039467,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2023,Q1,Fatigue,,2023,Q1,1,I,20190801.0,20230215.0,20230227,20230227,EXP,,GB-MYLANLABS-2023M1019331,MYLAN,"Mateo H, Seddon B. Pigmented villonodular synovitis successfully managed with imatinib. Pharm-Educ 2020;20(3):88-89.",37.0,YR,,M,Y,,,20230227,,HP,GB,GB,2023,Q1,Adult
220399711,22039971,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,more than 11 months,,,U,,,,,25.0,MG,Tablet,QD,2023,Q1,Blood glucose increased,,2023,Q1,1,I,20211201.0,20230216.0,20230227,20230227,EXP,,JP-EMD Serono-9343540,EMD SERONO INC,,7.0,DEC,E,F,Y,67.0,KG,20230227,,MD,JP,,2023,Q1,Child
220399711,22039971,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,more than 11 months,,,U,,,,,25.0,MG,Tablet,QD,2023,Q1,Glycosylated haemoglobin increased,,2023,Q1,1,I,20211201.0,20230216.0,20230227,20230227,EXP,,JP-EMD Serono-9343540,EMD SERONO INC,,7.0,DEC,E,F,Y,67.0,KG,20230227,,MD,JP,,2023,Q1,Child
220405981,22040598,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2023,Q1,Glycosylated haemoglobin increased,,2023,Q1,1,I,,20230220.0,20230227,20230227,EXP,,GR-MYLANLABS-2023M1019562,MYLAN,,62.0,YR,,M,Y,,,20230227,,HP,GR,GR,2023,Q1,Adult
220405981,22040598,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2023,Q1,Renal impairment,,2023,Q1,1,I,,20230220.0,20230227,20230227,EXP,,GR-MYLANLABS-2023M1019562,MYLAN,,62.0,YR,,M,Y,,,20230227,,HP,GR,GR,2023,Q1,Adult
220405981,22040598,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2023,Q1,Gastroenteritis viral,,2023,Q1,1,I,,20230220.0,20230227,20230227,EXP,,GR-MYLANLABS-2023M1019562,MYLAN,,62.0,YR,,M,Y,,,20230227,,HP,GR,GR,2023,Q1,Adult
220405981,22040598,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2023,Q1,Drug ineffective,,2023,Q1,1,I,,20230220.0,20230227,20230227,EXP,,GR-MYLANLABS-2023M1019562,MYLAN,,62.0,YR,,M,Y,,,20230227,,HP,GR,GR,2023,Q1,Adult
220409151,22040915,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,,,,,,10.0,MG,,,2023,Q1,Oropharyngeal pain,,2023,Q1,1,I,20220107.0,20230224.0,20230227,20230227,EXP,,US-PFIZER INC-202200176392,PFIZER,,66.0,YR,,M,Y,80.0,KG,20230227,,PH,US,US,2023,Q1,Elderly
220409151,22040915,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,,,,,,10.0,MG,,,2023,Q1,Blood pressure increased,,2023,Q1,1,I,20220107.0,20230224.0,20230227,20230227,EXP,,US-PFIZER INC-202200176392,PFIZER,,66.0,YR,,M,Y,80.0,KG,20230227,,PH,US,US,2023,Q1,Elderly
220409151,22040915,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,,,,,,10.0,MG,,,2023,Q1,Dyspnoea,,2023,Q1,1,I,20220107.0,20230224.0,20230227,20230227,EXP,,US-PFIZER INC-202200176392,PFIZER,,66.0,YR,,M,Y,80.0,KG,20230227,,PH,US,US,2023,Q1,Elderly
220409151,22040915,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,,,,,,10.0,MG,,,2023,Q1,Swollen tongue,,2023,Q1,1,I,20220107.0,20230224.0,20230227,20230227,EXP,,US-PFIZER INC-202200176392,PFIZER,,66.0,YR,,M,Y,80.0,KG,20230227,,PH,US,US,2023,Q1,Elderly
220409151,22040915,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,,,,,,10.0,MG,,,2023,Q1,Chest pain,,2023,Q1,1,I,20220107.0,20230224.0,20230227,20230227,EXP,,US-PFIZER INC-202200176392,PFIZER,,66.0,YR,,M,Y,80.0,KG,20230227,,PH,US,US,2023,Q1,Elderly
220409151,22040915,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,,,,,,10.0,MG,,,2023,Q1,Contraindicated product administered,,2023,Q1,1,I,20220107.0,20230224.0,20230227,20230227,EXP,,US-PFIZER INC-202200176392,PFIZER,,66.0,YR,,M,Y,80.0,KG,20230227,,PH,US,US,2023,Q1,Elderly
220414401,22041440,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Ventricular internal diameter abnormal,,2023,Q1,1,I,,20230217.0,20230227,20230227,EXP,,AU-MYLANLABS-2023M1020540,MYLAN,,27.0,YR,,M,Y,,,20230227,,HP,AU,AU,2023,Q1,Young Adult
220414401,22041440,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Blood triglycerides increased,,2023,Q1,1,I,,20230217.0,20230227,20230227,EXP,,AU-MYLANLABS-2023M1020540,MYLAN,,27.0,YR,,M,Y,,,20230227,,HP,AU,AU,2023,Q1,Young Adult
220414401,22041440,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,QRS axis abnormal,,2023,Q1,1,I,,20230217.0,20230227,20230227,EXP,,AU-MYLANLABS-2023M1020540,MYLAN,,27.0,YR,,M,Y,,,20230227,,HP,AU,AU,2023,Q1,Young Adult
220414401,22041440,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Electrocardiogram T wave inversion,,2023,Q1,1,I,,20230217.0,20230227,20230227,EXP,,AU-MYLANLABS-2023M1020540,MYLAN,,27.0,YR,,M,Y,,,20230227,,HP,AU,AU,2023,Q1,Young Adult
220414401,22041440,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Blood lactic acid increased,,2023,Q1,1,I,,20230217.0,20230227,20230227,EXP,,AU-MYLANLABS-2023M1020540,MYLAN,,27.0,YR,,M,Y,,,20230227,,HP,AU,AU,2023,Q1,Young Adult
220414401,22041440,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Left atrial dilatation,,2023,Q1,1,I,,20230217.0,20230227,20230227,EXP,,AU-MYLANLABS-2023M1020540,MYLAN,,27.0,YR,,M,Y,,,20230227,,HP,AU,AU,2023,Q1,Young Adult
220414401,22041440,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Hyperhidrosis,,2023,Q1,1,I,,20230217.0,20230227,20230227,EXP,,AU-MYLANLABS-2023M1020540,MYLAN,,27.0,YR,,M,Y,,,20230227,,HP,AU,AU,2023,Q1,Young Adult
220414401,22041440,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Electrocardiogram ST segment elevation,,2023,Q1,1,I,,20230217.0,20230227,20230227,EXP,,AU-MYLANLABS-2023M1020540,MYLAN,,27.0,YR,,M,Y,,,20230227,,HP,AU,AU,2023,Q1,Young Adult
220414401,22041440,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Dizziness,,2023,Q1,1,I,,20230217.0,20230227,20230227,EXP,,AU-MYLANLABS-2023M1020540,MYLAN,,27.0,YR,,M,Y,,,20230227,,HP,AU,AU,2023,Q1,Young Adult
220414401,22041440,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,"Hallucination, auditory",,2023,Q1,1,I,,20230217.0,20230227,20230227,EXP,,AU-MYLANLABS-2023M1020540,MYLAN,,27.0,YR,,M,Y,,,20230227,,HP,AU,AU,2023,Q1,Young Adult
220414401,22041440,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Myocardial infarction,,2023,Q1,1,I,,20230217.0,20230227,20230227,EXP,,AU-MYLANLABS-2023M1020540,MYLAN,,27.0,YR,,M,Y,,,20230227,,HP,AU,AU,2023,Q1,Young Adult
220414401,22041440,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Hypotension,,2023,Q1,1,I,,20230217.0,20230227,20230227,EXP,,AU-MYLANLABS-2023M1020540,MYLAN,,27.0,YR,,M,Y,,,20230227,,HP,AU,AU,2023,Q1,Young Adult
220414401,22041440,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Blood sodium decreased,,2023,Q1,1,I,,20230217.0,20230227,20230227,EXP,,AU-MYLANLABS-2023M1020540,MYLAN,,27.0,YR,,M,Y,,,20230227,,HP,AU,AU,2023,Q1,Young Adult
220414401,22041440,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Blood pressure systolic decreased,,2023,Q1,1,I,,20230217.0,20230227,20230227,EXP,,AU-MYLANLABS-2023M1020540,MYLAN,,27.0,YR,,M,Y,,,20230227,,HP,AU,AU,2023,Q1,Young Adult
220414401,22041440,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Left ventricular dysfunction,,2023,Q1,1,I,,20230217.0,20230227,20230227,EXP,,AU-MYLANLABS-2023M1020540,MYLAN,,27.0,YR,,M,Y,,,20230227,,HP,AU,AU,2023,Q1,Young Adult
220414401,22041440,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Sinus tachycardia,,2023,Q1,1,I,,20230217.0,20230227,20230227,EXP,,AU-MYLANLABS-2023M1020540,MYLAN,,27.0,YR,,M,Y,,,20230227,,HP,AU,AU,2023,Q1,Young Adult
220414401,22041440,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Mean cell volume decreased,,2023,Q1,1,I,,20230217.0,20230227,20230227,EXP,,AU-MYLANLABS-2023M1020540,MYLAN,,27.0,YR,,M,Y,,,20230227,,HP,AU,AU,2023,Q1,Young Adult
220414401,22041440,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Anion gap increased,,2023,Q1,1,I,,20230217.0,20230227,20230227,EXP,,AU-MYLANLABS-2023M1020540,MYLAN,,27.0,YR,,M,Y,,,20230227,,HP,AU,AU,2023,Q1,Young Adult
220414401,22041440,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Mean cell haemoglobin decreased,,2023,Q1,1,I,,20230217.0,20230227,20230227,EXP,,AU-MYLANLABS-2023M1020540,MYLAN,,27.0,YR,,M,Y,,,20230227,,HP,AU,AU,2023,Q1,Young Adult
220414401,22041440,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Diabetes mellitus inadequate control,,2023,Q1,1,I,,20230217.0,20230227,20230227,EXP,,AU-MYLANLABS-2023M1020540,MYLAN,,27.0,YR,,M,Y,,,20230227,,HP,AU,AU,2023,Q1,Young Adult
220414401,22041440,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Dyspnoea,,2023,Q1,1,I,,20230217.0,20230227,20230227,EXP,,AU-MYLANLABS-2023M1020540,MYLAN,,27.0,YR,,M,Y,,,20230227,,HP,AU,AU,2023,Q1,Young Adult
220414401,22041440,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Glycosylated haemoglobin increased,,2023,Q1,1,I,,20230217.0,20230227,20230227,EXP,,AU-MYLANLABS-2023M1020540,MYLAN,,27.0,YR,,M,Y,,,20230227,,HP,AU,AU,2023,Q1,Young Adult
220414401,22041440,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Electrocardiogram QRS complex prolonged,,2023,Q1,1,I,,20230217.0,20230227,20230227,EXP,,AU-MYLANLABS-2023M1020540,MYLAN,,27.0,YR,,M,Y,,,20230227,,HP,AU,AU,2023,Q1,Young Adult
220414401,22041440,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Cardiomyopathy,,2023,Q1,1,I,,20230217.0,20230227,20230227,EXP,,AU-MYLANLABS-2023M1020540,MYLAN,,27.0,YR,,M,Y,,,20230227,,HP,AU,AU,2023,Q1,Young Adult
220414401,22041440,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Glomerular filtration rate decreased,,2023,Q1,1,I,,20230217.0,20230227,20230227,EXP,,AU-MYLANLABS-2023M1020540,MYLAN,,27.0,YR,,M,Y,,,20230227,,HP,AU,AU,2023,Q1,Young Adult
220414401,22041440,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Blood glucose increased,,2023,Q1,1,I,,20230217.0,20230227,20230227,EXP,,AU-MYLANLABS-2023M1020540,MYLAN,,27.0,YR,,M,Y,,,20230227,,HP,AU,AU,2023,Q1,Young Adult
220414401,22041440,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Ejection fraction decreased,,2023,Q1,1,I,,20230217.0,20230227,20230227,EXP,,AU-MYLANLABS-2023M1020540,MYLAN,,27.0,YR,,M,Y,,,20230227,,HP,AU,AU,2023,Q1,Young Adult
220414401,22041440,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Left ventricular hypertrophy,,2023,Q1,1,I,,20230217.0,20230227,20230227,EXP,,AU-MYLANLABS-2023M1020540,MYLAN,,27.0,YR,,M,Y,,,20230227,,HP,AU,AU,2023,Q1,Young Adult
220414401,22041440,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Electrocardiogram ST-T segment abnormal,,2023,Q1,1,I,,20230217.0,20230227,20230227,EXP,,AU-MYLANLABS-2023M1020540,MYLAN,,27.0,YR,,M,Y,,,20230227,,HP,AU,AU,2023,Q1,Young Adult
220414401,22041440,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Haematocrit decreased,,2023,Q1,1,I,,20230217.0,20230227,20230227,EXP,,AU-MYLANLABS-2023M1020540,MYLAN,,27.0,YR,,M,Y,,,20230227,,HP,AU,AU,2023,Q1,Young Adult
220414401,22041440,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Electrocardiogram QT prolonged,,2023,Q1,1,I,,20230217.0,20230227,20230227,EXP,,AU-MYLANLABS-2023M1020540,MYLAN,,27.0,YR,,M,Y,,,20230227,,HP,AU,AU,2023,Q1,Young Adult
220414401,22041440,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Body temperature increased,,2023,Q1,1,I,,20230217.0,20230227,20230227,EXP,,AU-MYLANLABS-2023M1020540,MYLAN,,27.0,YR,,M,Y,,,20230227,,HP,AU,AU,2023,Q1,Young Adult
220414401,22041440,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Haemoglobin decreased,,2023,Q1,1,I,,20230217.0,20230227,20230227,EXP,,AU-MYLANLABS-2023M1020540,MYLAN,,27.0,YR,,M,Y,,,20230227,,HP,AU,AU,2023,Q1,Young Adult
220414401,22041440,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Drug hypersensitivity,,2023,Q1,1,I,,20230217.0,20230227,20230227,EXP,,AU-MYLANLABS-2023M1020540,MYLAN,,27.0,YR,,M,Y,,,20230227,,HP,AU,AU,2023,Q1,Young Adult
220420201,22042020,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,Unknown,,212614.0,,,,,2023,Q1,General physical health deterioration,,2023,Q1,1,I,20230227.0,20230224.0,20230227,20230227,PER,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-221537",BOEHRINGER INGELHEIM,,63.0,YR,A,M,Y,,,20230227,,CN,US,US,2023,Q1,Adult
220429451,22042945,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,U,Unknown,,204629.0,25.0,MG,Tablet,QD,2023,Q1,Ketosis,,2023,Q1,1,I,20230221.0,20230225.0,20230228,20230228,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-221439",BOEHRINGER INGELHEIM,,49.0,YR,A,M,Y,,,20230228,,HP,GB,GB,2023,Q1,Adult
220433441,22043344,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,take one daily,,,,,,,,,,,QD,2023,Q1,Urticaria,,2023,Q1,1,I,20230214.0,20230215.0,20230228,20230228,EXP,GB-MHRA-TPP41217198C963099YC1676368095767,GB-MICRO LABS LIMITED-ML2023-00956,MICRO LABS,,55.0,YR,A,M,Y,81.0,KG,20230228,,MD,GB,GB,2023,Q1,Adult
220437341,22043734,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,Unknown,,,,,UNK,,2023,Q1,Lactic acidosis,,2023,Q1,1,I,,20230215.0,20230228,20230228,EXP,,US-GRANULES-US-2023GRALIT00054,GRANULES INDIA,Kyle Gronbeck.Metformin-Associated Lactic Acidosis With Euglycemic Diabetic Ketoacidosis.Critical Care Medicine.JAN-2023; 51 (Suppl.): 92 abstr. (1):216,65.0,YR,A,F,Y,,,20230228,,HP,US,US,2023,Q1,Elderly
220437341,22043734,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,Unknown,,,,,UNK,,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,1,I,,20230215.0,20230228,20230228,EXP,,US-GRANULES-US-2023GRALIT00054,GRANULES INDIA,Kyle Gronbeck.Metformin-Associated Lactic Acidosis With Euglycemic Diabetic Ketoacidosis.Critical Care Medicine.JAN-2023; 51 (Suppl.): 92 abstr. (1):216,65.0,YR,A,F,Y,,,20230228,,HP,US,US,2023,Q1,Elderly
220440432,22044043,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,Tablets,,2023,Q1,Malignant neoplasm progression,,2023,Q1,2,F,20230223.0,20230324.0,20230228,20230328,PER,,KR-Eisai Medical Research-EC-2023-135080,EISAI,,66.0,YR,E,M,Y,72.1,KG,20230328,,MD,KR,,2023,Q1,Elderly
220459621,22045962,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,,,,,,10.0,MG,Tablet,,2023,Q1,Thyroiditis,,2023,Q1,1,I,20220617.0,20230220.0,20230228,20230228,EXP,,JP-009507513-2207JPN000526J,MERCK,"Watanabe R, Ishido K, Hirai K, Aono K, Ogarashi K, Ruike Y, et al.. P10-8 A Case of Thyroid crisis due to destructive thyroiditis after pembrolizumab and lenvatinib combination therapy for corpus uteri carcinoma. 65th Annual Meeting of Japanese Thyroid Association.. 90",44.0,YR,,F,Y,85.0,KG,20230228,,MD,JP,JP,2023,Q1,Adult
220459621,22045962,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,,,,,,10.0,MG,Tablet,,2023,Q1,Thyrotoxic crisis,,2023,Q1,1,I,20220617.0,20230220.0,20230228,20230228,EXP,,JP-009507513-2207JPN000526J,MERCK,"Watanabe R, Ishido K, Hirai K, Aono K, Ogarashi K, Ruike Y, et al.. P10-8 A Case of Thyroid crisis due to destructive thyroiditis after pembrolizumab and lenvatinib combination therapy for corpus uteri carcinoma. 65th Annual Meeting of Japanese Thyroid Association.. 90",44.0,YR,,F,Y,85.0,KG,20230228,,MD,JP,JP,2023,Q1,Adult
220459621,22045962,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,,,,,,10.0,MG,Tablet,,2023,Q1,Blood thyroid stimulating hormone increased,,2023,Q1,1,I,20220617.0,20230220.0,20230228,20230228,EXP,,JP-009507513-2207JPN000526J,MERCK,"Watanabe R, Ishido K, Hirai K, Aono K, Ogarashi K, Ruike Y, et al.. P10-8 A Case of Thyroid crisis due to destructive thyroiditis after pembrolizumab and lenvatinib combination therapy for corpus uteri carcinoma. 65th Annual Meeting of Japanese Thyroid Association.. 90",44.0,YR,,F,Y,85.0,KG,20230228,,MD,JP,JP,2023,Q1,Adult
220459621,22045962,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,,,,,,10.0,MG,Tablet,,2023,Q1,Suicidal ideation,,2023,Q1,1,I,20220617.0,20230220.0,20230228,20230228,EXP,,JP-009507513-2207JPN000526J,MERCK,"Watanabe R, Ishido K, Hirai K, Aono K, Ogarashi K, Ruike Y, et al.. P10-8 A Case of Thyroid crisis due to destructive thyroiditis after pembrolizumab and lenvatinib combination therapy for corpus uteri carcinoma. 65th Annual Meeting of Japanese Thyroid Association.. 90",44.0,YR,,F,Y,85.0,KG,20230228,,MD,JP,JP,2023,Q1,Adult
220503323,22050332,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q1,Prescribed underdose,,2023,Q1,3,F,20230203.0,20230324.0,20230301,20230330,EXP,,ES-MYLANLABS-2023M1019925,MYLAN,,76.0,YR,,M,Y,75.0,KG,20230330,,MD,ES,ES,2023,Q1,Elderly
220503323,22050332,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q1,Cerebrovascular accident,,2023,Q1,3,F,20230203.0,20230324.0,20230301,20230330,EXP,,ES-MYLANLABS-2023M1019925,MYLAN,,76.0,YR,,M,Y,75.0,KG,20230330,,MD,ES,ES,2023,Q1,Elderly
220503323,22050332,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q1,Intentional product use issue,,2023,Q1,3,F,20230203.0,20230324.0,20230301,20230330,EXP,,ES-MYLANLABS-2023M1019925,MYLAN,,76.0,YR,,M,Y,75.0,KG,20230330,,MD,ES,ES,2023,Q1,Elderly
220509832,22050983,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,,,,,,,,,2023,Q1,Fanconi syndrome,,2023,Q1,2,F,,20230306.0,20230301,20230316,EXP,,SE-TEVA-2023-SE-2860733,TEVA,,7.0,DEC,E,F,Y,,,20230316,,HP,SE,SE,2023,Q1,Child
220509832,22050983,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,,,,,,,,,2023,Q1,Osteoporosis,,2023,Q1,2,F,,20230306.0,20230301,20230316,EXP,,SE-TEVA-2023-SE-2860733,TEVA,,7.0,DEC,E,F,Y,,,20230316,,HP,SE,SE,2023,Q1,Child
220509881,22050988,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2023,Q1,Neuropsychiatric symptoms,,2023,Q1,1,I,,20230220.0,20230301,20230301,EXP,,ES-TEVA-2023-ES-2860762,TEVA,,65.0,YR,E,M,Y,,,20230301,,HP,ES,ES,2023,Q1,Elderly
220551431,22055143,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Vomiting,,2023,Q1,1,I,20220306.0,,20230301,20230301,DIR,650509,,FDA-CTU,,53.0,YR,,M,N,108.0,KG,20230301,N,CN,US,,2023,Q1,Adult
220551431,22055143,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Dehydration,,2023,Q1,1,I,20220306.0,,20230301,20230301,DIR,650509,,FDA-CTU,,53.0,YR,,M,N,108.0,KG,20230301,N,CN,US,,2023,Q1,Adult
220551431,22055143,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Product supply issue,,2023,Q1,1,I,20220306.0,,20230301,20230301,DIR,650509,,FDA-CTU,,53.0,YR,,M,N,108.0,KG,20230301,N,CN,US,,2023,Q1,Adult
220551431,22055143,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Eructation,,2023,Q1,1,I,20220306.0,,20230301,20230301,DIR,650509,,FDA-CTU,,53.0,YR,,M,N,108.0,KG,20230301,N,CN,US,,2023,Q1,Adult
220551431,22055143,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Diarrhoea,,2023,Q1,1,I,20220306.0,,20230301,20230301,DIR,650509,,FDA-CTU,,53.0,YR,,M,N,108.0,KG,20230301,N,CN,US,,2023,Q1,Adult
220557191,22055719,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q1,Coma,,2023,Q1,1,I,,20230220.0,20230302,20230302,EXP,,US-TEVA-2023-US-2859593,TEVA,,15.0,YR,T,M,Y,,,20230302,,HP,US,US,2023,Q1,Youth
220557191,22055719,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q1,Respiratory depression,,2023,Q1,1,I,,20230220.0,20230302,20230302,EXP,,US-TEVA-2023-US-2859593,TEVA,,15.0,YR,T,M,Y,,,20230302,,HP,US,US,2023,Q1,Youth
220557191,22055719,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q1,Toxicity to various agents,,2023,Q1,1,I,,20230220.0,20230302,20230302,EXP,,US-TEVA-2023-US-2859593,TEVA,,15.0,YR,T,M,Y,,,20230302,,HP,US,US,2023,Q1,Youth
220557191,22055719,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q1,Hypotension,,2023,Q1,1,I,,20230220.0,20230302,20230302,EXP,,US-TEVA-2023-US-2859593,TEVA,,15.0,YR,T,M,Y,,,20230302,,HP,US,US,2023,Q1,Youth
220557191,22055719,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q1,Depressed level of consciousness,,2023,Q1,1,I,,20230220.0,20230302,20230302,EXP,,US-TEVA-2023-US-2859593,TEVA,,15.0,YR,T,M,Y,,,20230302,,HP,US,US,2023,Q1,Youth
220557191,22055719,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q1,Metabolic acidosis,,2023,Q1,1,I,,20230220.0,20230302,20230302,EXP,,US-TEVA-2023-US-2859593,TEVA,,15.0,YR,T,M,Y,,,20230302,,HP,US,US,2023,Q1,Youth
220557191,22055719,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q1,Anion gap,,2023,Q1,1,I,,20230220.0,20230302,20230302,EXP,,US-TEVA-2023-US-2859593,TEVA,,15.0,YR,T,M,Y,,,20230302,,HP,US,US,2023,Q1,Youth
220590021,22059002,9,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2023,Q1,Suicidal ideation,,2023,Q1,1,I,20230228.0,20230228.0,20230303,20230303,EXP,,AU-ROCHE-3297930,ROCHE,,80.0,YR,,M,Y,,,20230303,,MD,AU,,2023,Q1,Elderly
220590021,22059002,9,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2023,Q1,Depression,,2023,Q1,1,I,20230228.0,20230228.0,20230303,20230303,EXP,,AU-ROCHE-3297930,ROCHE,,80.0,YR,,M,Y,,,20230303,,MD,AU,,2023,Q1,Elderly
220592791,22059279,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Paraesthesia,,2023,Q1,1,I,,20230225.0,20230303,20230303,EXP,GB-MHRA-EMIS-6849-b8c9d111-2643-4a59-ad82-c1e6cdd04379,GB-MYLANLABS-2023M1021901,MYLAN,,50.0,YR,,F,Y,112.0,KG,20230303,,PH,GB,GB,2023,Q1,Adult
220592791,22059279,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Rash,,2023,Q1,1,I,,20230225.0,20230303,20230303,EXP,GB-MHRA-EMIS-6849-b8c9d111-2643-4a59-ad82-c1e6cdd04379,GB-MYLANLABS-2023M1021901,MYLAN,,50.0,YR,,F,Y,112.0,KG,20230303,,PH,GB,GB,2023,Q1,Adult
220592791,22059279,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Myalgia,,2023,Q1,1,I,,20230225.0,20230303,20230303,EXP,GB-MHRA-EMIS-6849-b8c9d111-2643-4a59-ad82-c1e6cdd04379,GB-MYLANLABS-2023M1021901,MYLAN,,50.0,YR,,F,Y,112.0,KG,20230303,,PH,GB,GB,2023,Q1,Adult
220601401,22060140,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, qd (in the morning)",,,,,,,,,,Tablet,QD,2023,Q1,Diarrhoea,,2023,Q1,1,I,,20230225.0,20230303,20230303,EXP,GB-MHRA-TPP6873043C8699377YC1677075479707,GB-DSJP-DSE-2023-107743,DAIICHI,,75.0,YR,,F,Y,75.0,KG,20230303,,PH,GB,GB,2023,Q1,Elderly
220605491,22060549,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,U,,,,,10.0,MG,Tablet,QD,2023,Q1,Blood pressure fluctuation,,2023,Q1,1,I,20230128.0,20230226.0,20230303,20230303,EXP,,IR-SA-2023SA069513,SANOFI AVENTIS,,73.0,YR,E,M,Y,71.0,KG,20230303,,CN,IR,IR,2023,Q1,Elderly
220605491,22060549,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,U,,,,,10.0,MG,Tablet,QD,2023,Q1,Balance disorder,,2023,Q1,1,I,20230128.0,20230226.0,20230303,20230303,EXP,,IR-SA-2023SA069513,SANOFI AVENTIS,,73.0,YR,E,M,Y,71.0,KG,20230303,,CN,IR,IR,2023,Q1,Elderly
220605491,22060549,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,U,,,,,10.0,MG,Tablet,QD,2023,Q1,Orthostatic hypotension,,2023,Q1,1,I,20230128.0,20230226.0,20230303,20230303,EXP,,IR-SA-2023SA069513,SANOFI AVENTIS,,73.0,YR,E,M,Y,71.0,KG,20230303,,CN,IR,IR,2023,Q1,Elderly
220611931,22061193,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q1,Post procedural complication,,2023,Q1,1,I,,20230302.0,20230303,20230303,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-222409",BOEHRINGER INGELHEIM,"Creedon M, O^Gorman C, McDonnell C, McNamara E, Boyle B. Fournier?s Gangrene Associated with SGLT-2 Inhibitor Use. Irish Medical Journal. 2022 Dec 15;115:10701-",62.0,YR,A,F,Y,,,20230303,,MD,GB,GB,2023,Q1,Adult
220611931,22061193,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q1,Coronary artery bypass,,2023,Q1,1,I,,20230302.0,20230303,20230303,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-222409",BOEHRINGER INGELHEIM,"Creedon M, O^Gorman C, McDonnell C, McNamara E, Boyle B. Fournier?s Gangrene Associated with SGLT-2 Inhibitor Use. Irish Medical Journal. 2022 Dec 15;115:10701-",62.0,YR,A,F,Y,,,20230303,,MD,GB,GB,2023,Q1,Adult
220611931,22061193,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q1,Fournier's gangrene,,2023,Q1,1,I,,20230302.0,20230303,20230303,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-222409",BOEHRINGER INGELHEIM,"Creedon M, O^Gorman C, McDonnell C, McNamara E, Boyle B. Fournier?s Gangrene Associated with SGLT-2 Inhibitor Use. Irish Medical Journal. 2022 Dec 15;115:10701-",62.0,YR,A,F,Y,,,20230303,,MD,GB,GB,2023,Q1,Adult
220611931,22061193,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q1,Wound dehiscence,,2023,Q1,1,I,,20230302.0,20230303,20230303,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-222409",BOEHRINGER INGELHEIM,"Creedon M, O^Gorman C, McDonnell C, McNamara E, Boyle B. Fournier?s Gangrene Associated with SGLT-2 Inhibitor Use. Irish Medical Journal. 2022 Dec 15;115:10701-",62.0,YR,A,F,Y,,,20230303,,MD,GB,GB,2023,Q1,Adult
220612781,22061278,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,,Unknown,,,,,,,2023,Q1,Nausea,,2023,Q1,1,I,,20230213.0,20230303,20230303,PER,,US-PURACAP-US-2023EPCOTHER00246,PURACAP,,88.0,YR,E,F,Y,,,20230304,,MD,US,US,2023,Q1,Elderly
220612781,22061278,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,,Unknown,,,,,,,2023,Q1,Product use in unapproved indication,,2023,Q1,1,I,,20230213.0,20230303,20230303,PER,,US-PURACAP-US-2023EPCOTHER00246,PURACAP,,88.0,YR,E,F,Y,,,20230304,,MD,US,US,2023,Q1,Elderly
220612781,22061278,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,,Unknown,,,,,,,2023,Q1,Drug resistance,,2023,Q1,1,I,,20230213.0,20230303,20230303,PER,,US-PURACAP-US-2023EPCOTHER00246,PURACAP,,88.0,YR,E,F,Y,,,20230304,,MD,US,US,2023,Q1,Elderly
220612781,22061278,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,,Unknown,,,,,,,2023,Q1,Vomiting,,2023,Q1,1,I,,20230213.0,20230303,20230303,PER,,US-PURACAP-US-2023EPCOTHER00246,PURACAP,,88.0,YR,E,F,Y,,,20230304,,MD,US,US,2023,Q1,Elderly
220622441,22062244,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,80.0,MG,,QD,2023,Q1,Ketoacidosis,,2023,Q1,1,I,20220717.0,20220919.0,20230304,20230304,EXP,,AU-ABBVIE-22P-008-4531097-00,ABBVIE,,75.0,YR,,F,Y,55.0,KG,20221001,,MD,AU,AU,2023,Q1,Elderly
220622441,22062244,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,80.0,MG,,QD,2023,Q1,Hyperglycaemia,,2023,Q1,1,I,20220717.0,20220919.0,20230304,20230304,EXP,,AU-ABBVIE-22P-008-4531097-00,ABBVIE,,75.0,YR,,F,Y,55.0,KG,20221001,,MD,AU,AU,2023,Q1,Elderly
220629811,22062981,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,,Unknown,,,,,,,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,1,I,,20230220.0,20230306,20230306,EXP,,US-EPICPHARMA-US-2023EPCLIT00338,EPIC PHARM,Kyle Gronbeck.Metformin-Associated Lactic Acidosis With Euglycemic Diabetic Ketoacidosis.Critical Care Medicine.JAN-2023; 51 (Suppl.) No. 1:92 abstr. 216,65.0,YR,A,F,Y,,,20230306,,HP,US,US,2023,Q1,Elderly
220629811,22062981,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,,Unknown,,,,,,,2023,Q1,Lactic acidosis,,2023,Q1,1,I,,20230220.0,20230306,20230306,EXP,,US-EPICPHARMA-US-2023EPCLIT00338,EPIC PHARM,Kyle Gronbeck.Metformin-Associated Lactic Acidosis With Euglycemic Diabetic Ketoacidosis.Critical Care Medicine.JAN-2023; 51 (Suppl.) No. 1:92 abstr. 216,65.0,YR,A,F,Y,,,20230306,,HP,US,US,2023,Q1,Elderly
220630281,22063028,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Proctalgia,,2023,Q1,1,I,,20230301.0,20230306,20230306,EXP,,CA-ROCHE-3297461,ROCHE,,70.0,YR,,M,Y,,,20230306,,HP,CA,,2023,Q1,Elderly
220630281,22063028,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Haemoglobin increased,,2023,Q1,1,I,,20230301.0,20230306,20230306,EXP,,CA-ROCHE-3297461,ROCHE,,70.0,YR,,M,Y,,,20230306,,HP,CA,,2023,Q1,Elderly
220630281,22063028,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Injection site pain,,2023,Q1,1,I,,20230301.0,20230306,20230306,EXP,,CA-ROCHE-3297461,ROCHE,,70.0,YR,,M,Y,,,20230306,,HP,CA,,2023,Q1,Elderly
220630281,22063028,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Constipation,,2023,Q1,1,I,,20230301.0,20230306,20230306,EXP,,CA-ROCHE-3297461,ROCHE,,70.0,YR,,M,Y,,,20230306,,HP,CA,,2023,Q1,Elderly
220630281,22063028,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Discomfort,,2023,Q1,1,I,,20230301.0,20230306,20230306,EXP,,CA-ROCHE-3297461,ROCHE,,70.0,YR,,M,Y,,,20230306,,HP,CA,,2023,Q1,Elderly
220630281,22063028,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Blood pressure increased,,2023,Q1,1,I,,20230301.0,20230306,20230306,EXP,,CA-ROCHE-3297461,ROCHE,,70.0,YR,,M,Y,,,20230306,,HP,CA,,2023,Q1,Elderly
220646351,22064635,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,U,,,,,,,,2023,Q1,Blood ketone body increased,,2023,Q1,1,I,,20230302.0,20230306,20230306,EXP,,GB-EMD Serono-E2B_90091005,EMD SERONO INC,,65.0,YR,E,M,Y,,,20230306,,CN,GB,,2023,Q1,Elderly
220646451,22064645,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,Y,U,,,,10.0,MG,,QD,2023,Q1,Post procedural complication,,2023,Q1,1,I,,20230227.0,20230306,20230306,EXP,,PT-MYLANLABS-2023M1023029,MYLAN,"Fustiga J, Fernandes M, Damaso F, Duarte JA, Rodrigues C.. Postop Complication With Euglycemic Diabetic Ketoacidosis in a Patient Receiving Empagliflozin.. Cureus.. 2022;14 (12)",77.0,YR,,F,Y,,,20230306,,HP,PT,PT,2023,Q1,Elderly
220646451,22064645,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,Y,U,,,,10.0,MG,,QD,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,1,I,,20230227.0,20230306,20230306,EXP,,PT-MYLANLABS-2023M1023029,MYLAN,"Fustiga J, Fernandes M, Damaso F, Duarte JA, Rodrigues C.. Postop Complication With Euglycemic Diabetic Ketoacidosis in a Patient Receiving Empagliflozin.. Cureus.. 2022;14 (12)",77.0,YR,,F,Y,,,20230306,,HP,PT,PT,2023,Q1,Elderly
220649731,22064973,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,N,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Bladder tamponade,,2023,Q1,1,I,20220801.0,20230306.0,20230306,20230306,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-222961",BOEHRINGER INGELHEIM,,81.0,YR,E,M,Y,100.0,KG,20230306,,MD,DE,DE,2023,Q1,Elderly
220649731,22064973,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,N,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Bacterial prostatitis,,2023,Q1,1,I,20220801.0,20230306.0,20230306,20230306,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-222961",BOEHRINGER INGELHEIM,,81.0,YR,E,M,Y,100.0,KG,20230306,,MD,DE,DE,2023,Q1,Elderly
220649731,22064973,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,N,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Urine output decreased,,2023,Q1,1,I,20220801.0,20230306.0,20230306,20230306,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-222961",BOEHRINGER INGELHEIM,,81.0,YR,E,M,Y,100.0,KG,20230306,,MD,DE,DE,2023,Q1,Elderly
220649731,22064973,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,N,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Prostatic abscess,,2023,Q1,1,I,20220801.0,20230306.0,20230306,20230306,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-222961",BOEHRINGER INGELHEIM,,81.0,YR,E,M,Y,100.0,KG,20230306,,MD,DE,DE,2023,Q1,Elderly
220649731,22064973,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,N,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Sepsis,,2023,Q1,1,I,20220801.0,20230306.0,20230306,20230306,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-222961",BOEHRINGER INGELHEIM,,81.0,YR,E,M,Y,100.0,KG,20230306,,MD,DE,DE,2023,Q1,Elderly
220659801,22065980,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,N,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q1,Fournier's gangrene,,2023,Q1,1,I,20230227.0,20230304.0,20230306,20230306,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-223018",BOEHRINGER INGELHEIM,,75.0,YR,E,M,Y,87.0,KG,20230306,,MD,GB,GB,2023,Q1,Elderly
220667161,22066716,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,Unknown,,204629.0,,,,,2023,Q1,Palpitations,,2023,Q1,1,I,,20230304.0,20230306,20230306,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-223021",BOEHRINGER INGELHEIM,,38.0,YR,A,,Y,,,20230306,,HP,GB,GB,2023,Q1,Adult
220677761,22067776,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,qd,,,,,,,,,,,,2023,Q1,Skin mass,,2023,Q1,1,I,20230204.0,20230225.0,20230307,20230307,EXP,GB-MHRA-TPP9392458C8137589YC1677165823671,GB-NOVOPROD-1032614,NOVO NORDISK,,70.0,YR,,M,Y,110.0,KG,20230307,,HP,GB,GB,2023,Q1,Elderly
220677761,22067776,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,qd,,,,,,,,,,,,2023,Q1,Vision blurred,,2023,Q1,1,I,20230204.0,20230225.0,20230307,20230307,EXP,GB-MHRA-TPP9392458C8137589YC1677165823671,GB-NOVOPROD-1032614,NOVO NORDISK,,70.0,YR,,M,Y,110.0,KG,20230307,,HP,GB,GB,2023,Q1,Elderly
220677761,22067776,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,qd,,,,,,,,,,,,2023,Q1,Dizziness,,2023,Q1,1,I,20230204.0,20230225.0,20230307,20230307,EXP,GB-MHRA-TPP9392458C8137589YC1677165823671,GB-NOVOPROD-1032614,NOVO NORDISK,,70.0,YR,,M,Y,110.0,KG,20230307,,HP,GB,GB,2023,Q1,Elderly
220677761,22067776,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,qd,,,,,,,,,,,,2023,Q1,Nausea,,2023,Q1,1,I,20230204.0,20230225.0,20230307,20230307,EXP,GB-MHRA-TPP9392458C8137589YC1677165823671,GB-NOVOPROD-1032614,NOVO NORDISK,,70.0,YR,,M,Y,110.0,KG,20230307,,HP,GB,GB,2023,Q1,Elderly
220683241,22068324,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Rash,,2023,Q1,1,I,,20230225.0,20230307,20230307,EXP,GB-MHRA-ADR 27717863,GB-Accord-303393,ACCORD,,50.0,YR,A,F,Y,112.0,KG,20230307,,PH,GB,GB,2023,Q1,Adult
220683241,22068324,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Paraesthesia,,2023,Q1,1,I,,20230225.0,20230307,20230307,EXP,GB-MHRA-ADR 27717863,GB-Accord-303393,ACCORD,,50.0,YR,A,F,Y,112.0,KG,20230307,,PH,GB,GB,2023,Q1,Adult
220683241,22068324,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Myalgia,,2023,Q1,1,I,,20230225.0,20230307,20230307,EXP,GB-MHRA-ADR 27717863,GB-Accord-303393,ACCORD,,50.0,YR,A,F,Y,112.0,KG,20230307,,PH,GB,GB,2023,Q1,Adult
220687121,22068712,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Myalgia,,2023,Q1,1,I,,20230225.0,20230307,20230307,EXP,GB-MHRA-EMIS-6849-b8c9d111-2643-4a59-ad82-c1e6cdd04379,GB-TEVA-2023-GB-2862490,TEVA,,50.0,YR,A,F,Y,112.0,KG,20230307,,PH,GB,GB,2023,Q1,Adult
220687121,22068712,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Paraesthesia,,2023,Q1,1,I,,20230225.0,20230307,20230307,EXP,GB-MHRA-EMIS-6849-b8c9d111-2643-4a59-ad82-c1e6cdd04379,GB-TEVA-2023-GB-2862490,TEVA,,50.0,YR,A,F,Y,112.0,KG,20230307,,PH,GB,GB,2023,Q1,Adult
220687121,22068712,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Rash,,2023,Q1,1,I,,20230225.0,20230307,20230307,EXP,GB-MHRA-EMIS-6849-b8c9d111-2643-4a59-ad82-c1e6cdd04379,GB-TEVA-2023-GB-2862490,TEVA,,50.0,YR,A,F,Y,112.0,KG,20230307,,PH,GB,GB,2023,Q1,Adult
220701091,22070109,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,U,Unknown,,,,,,,2023,Q1,Coma,,2023,Q1,1,I,,20230223.0,20230307,20230307,EXP,,US-P+L Developments of Newyork Corporation-2138770,PL DEVELOPMENTS,"Spyres M, Aldy K, Farrugia L, Kang A, Love J, Campleman S, Li S, Amaducci A, Schwarz E, Wax P, Brent J. The toxicology investigators consortium 2020 annual report. Journal of Medical Toxicology. 2021 Sep 21; 17:333-62. DOI: 10.1007/s13181-021-00854-3.",15.0,YR,,M,Y,,,20230307,,HP,US,US,2023,Q1,Youth
220701091,22070109,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,U,Unknown,,,,,,,2023,Q1,Respiratory depression,,2023,Q1,1,I,,20230223.0,20230307,20230307,EXP,,US-P+L Developments of Newyork Corporation-2138770,PL DEVELOPMENTS,"Spyres M, Aldy K, Farrugia L, Kang A, Love J, Campleman S, Li S, Amaducci A, Schwarz E, Wax P, Brent J. The toxicology investigators consortium 2020 annual report. Journal of Medical Toxicology. 2021 Sep 21; 17:333-62. DOI: 10.1007/s13181-021-00854-3.",15.0,YR,,M,Y,,,20230307,,HP,US,US,2023,Q1,Youth
220701091,22070109,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,U,Unknown,,,,,,,2023,Q1,Anion gap,,2023,Q1,1,I,,20230223.0,20230307,20230307,EXP,,US-P+L Developments of Newyork Corporation-2138770,PL DEVELOPMENTS,"Spyres M, Aldy K, Farrugia L, Kang A, Love J, Campleman S, Li S, Amaducci A, Schwarz E, Wax P, Brent J. The toxicology investigators consortium 2020 annual report. Journal of Medical Toxicology. 2021 Sep 21; 17:333-62. DOI: 10.1007/s13181-021-00854-3.",15.0,YR,,M,Y,,,20230307,,HP,US,US,2023,Q1,Youth
220701091,22070109,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,U,Unknown,,,,,,,2023,Q1,Depressed level of consciousness,,2023,Q1,1,I,,20230223.0,20230307,20230307,EXP,,US-P+L Developments of Newyork Corporation-2138770,PL DEVELOPMENTS,"Spyres M, Aldy K, Farrugia L, Kang A, Love J, Campleman S, Li S, Amaducci A, Schwarz E, Wax P, Brent J. The toxicology investigators consortium 2020 annual report. Journal of Medical Toxicology. 2021 Sep 21; 17:333-62. DOI: 10.1007/s13181-021-00854-3.",15.0,YR,,M,Y,,,20230307,,HP,US,US,2023,Q1,Youth
220701091,22070109,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,U,Unknown,,,,,,,2023,Q1,Hypotension,,2023,Q1,1,I,,20230223.0,20230307,20230307,EXP,,US-P+L Developments of Newyork Corporation-2138770,PL DEVELOPMENTS,"Spyres M, Aldy K, Farrugia L, Kang A, Love J, Campleman S, Li S, Amaducci A, Schwarz E, Wax P, Brent J. The toxicology investigators consortium 2020 annual report. Journal of Medical Toxicology. 2021 Sep 21; 17:333-62. DOI: 10.1007/s13181-021-00854-3.",15.0,YR,,M,Y,,,20230307,,HP,US,US,2023,Q1,Youth
220701091,22070109,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,U,Unknown,,,,,,,2023,Q1,Toxicity to various agents,,2023,Q1,1,I,,20230223.0,20230307,20230307,EXP,,US-P+L Developments of Newyork Corporation-2138770,PL DEVELOPMENTS,"Spyres M, Aldy K, Farrugia L, Kang A, Love J, Campleman S, Li S, Amaducci A, Schwarz E, Wax P, Brent J. The toxicology investigators consortium 2020 annual report. Journal of Medical Toxicology. 2021 Sep 21; 17:333-62. DOI: 10.1007/s13181-021-00854-3.",15.0,YR,,M,Y,,,20230307,,HP,US,US,2023,Q1,Youth
220701091,22070109,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,U,Unknown,,,,,,,2023,Q1,Metabolic acidosis,,2023,Q1,1,I,,20230223.0,20230307,20230307,EXP,,US-P+L Developments of Newyork Corporation-2138770,PL DEVELOPMENTS,"Spyres M, Aldy K, Farrugia L, Kang A, Love J, Campleman S, Li S, Amaducci A, Schwarz E, Wax P, Brent J. The toxicology investigators consortium 2020 annual report. Journal of Medical Toxicology. 2021 Sep 21; 17:333-62. DOI: 10.1007/s13181-021-00854-3.",15.0,YR,,M,Y,,,20230307,,HP,US,US,2023,Q1,Youth
220701871,22070187,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, qd",,,,,,,,,,,QD,2023,Q1,Diarrhoea,,2023,Q1,1,I,20230228.0,20230302.0,20230307,20230307,EXP,GB-MHRA-TPP12701351C1855701YC1677580295238,GB-MYLANLABS-2023M1023970,MYLAN,,72.0,YR,,M,Y,106.0,KG,20230307,,MD,GB,GB,2023,Q1,Elderly
220712811,22071281,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Incorrect dose administered,,2023,Q1,1,I,,20230227.0,20230307,20230307,EXP,,NVSC2023AU051110,NOVARTIS,,74.0,YR,,M,Y,,,20230307,,MD,AU,AU,2023,Q1,Elderly
220712811,22071281,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Arteriosclerosis coronary artery,,2023,Q1,1,I,,20230227.0,20230307,20230307,EXP,,NVSC2023AU051110,NOVARTIS,,74.0,YR,,M,Y,,,20230307,,MD,AU,AU,2023,Q1,Elderly
220712811,22071281,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Ejection fraction decreased,,2023,Q1,1,I,,20230227.0,20230307,20230307,EXP,,NVSC2023AU051110,NOVARTIS,,74.0,YR,,M,Y,,,20230307,,MD,AU,AU,2023,Q1,Elderly
220712811,22071281,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Left ventricular dysfunction,,2023,Q1,1,I,,20230227.0,20230307,20230307,EXP,,NVSC2023AU051110,NOVARTIS,,74.0,YR,,M,Y,,,20230307,,MD,AU,AU,2023,Q1,Elderly
220712811,22071281,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Atrial fibrillation,,2023,Q1,1,I,,20230227.0,20230307,20230307,EXP,,NVSC2023AU051110,NOVARTIS,,74.0,YR,,M,Y,,,20230307,,MD,AU,AU,2023,Q1,Elderly
220712811,22071281,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Weight increased,,2023,Q1,1,I,,20230227.0,20230307,20230307,EXP,,NVSC2023AU051110,NOVARTIS,,74.0,YR,,M,Y,,,20230307,,MD,AU,AU,2023,Q1,Elderly
220712811,22071281,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Bundle branch block left,,2023,Q1,1,I,,20230227.0,20230307,20230307,EXP,,NVSC2023AU051110,NOVARTIS,,74.0,YR,,M,Y,,,20230307,,MD,AU,AU,2023,Q1,Elderly
220712811,22071281,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Peripheral swelling,,2023,Q1,1,I,,20230227.0,20230307,20230307,EXP,,NVSC2023AU051110,NOVARTIS,,74.0,YR,,M,Y,,,20230307,,MD,AU,AU,2023,Q1,Elderly
220712811,22071281,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Decreased appetite,,2023,Q1,1,I,,20230227.0,20230307,20230307,EXP,,NVSC2023AU051110,NOVARTIS,,74.0,YR,,M,Y,,,20230307,,MD,AU,AU,2023,Q1,Elderly
220712811,22071281,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Waist circumference increased,,2023,Q1,1,I,,20230227.0,20230307,20230307,EXP,,NVSC2023AU051110,NOVARTIS,,74.0,YR,,M,Y,,,20230307,,MD,AU,AU,2023,Q1,Elderly
220712811,22071281,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,N-terminal prohormone brain natriuretic peptide abnormal,,2023,Q1,1,I,,20230227.0,20230307,20230307,EXP,,NVSC2023AU051110,NOVARTIS,,74.0,YR,,M,Y,,,20230307,,MD,AU,AU,2023,Q1,Elderly
220712811,22071281,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Dyspnoea,,2023,Q1,1,I,,20230227.0,20230307,20230307,EXP,,NVSC2023AU051110,NOVARTIS,,74.0,YR,,M,Y,,,20230307,,MD,AU,AU,2023,Q1,Elderly
220714121,22071412,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 DF QD,,,U,N,,,,,,,,2023,Q1,Diarrhoea,,2023,Q1,1,I,20230228.0,20230302.0,20230307,20230307,EXP,,GB-ANIPHARMA-2023-UK-000056,ANI,,72.0,YR,,M,Y,106.0,KG,20230307,,MD,GB,GB,2023,Q1,Elderly
220731052,22073105,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg (By mouth daily),,,U,,,,,10.0,MG,Tablet,,2023,Q1,Arterial haemorrhage,,2023,Q1,2,F,20230125.0,20230228.0,20230308,20230309,EXP,,US-GLAXOSMITHKLINE-USCH2023AMR009411,GLAXOSMITHKLINE,,51.0,YR,,F,Y,,,20230309,,HP,US,US,2023,Q1,Adult
220731052,22073105,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg (By mouth daily),,,U,,,,,10.0,MG,Tablet,,2023,Q1,Ventricular extrasystoles,,2023,Q1,2,F,20230125.0,20230228.0,20230308,20230309,EXP,,US-GLAXOSMITHKLINE-USCH2023AMR009411,GLAXOSMITHKLINE,,51.0,YR,,F,Y,,,20230309,,HP,US,US,2023,Q1,Adult
220731052,22073105,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg (By mouth daily),,,U,,,,,10.0,MG,Tablet,,2023,Q1,Weight fluctuation,,2023,Q1,2,F,20230125.0,20230228.0,20230308,20230309,EXP,,US-GLAXOSMITHKLINE-USCH2023AMR009411,GLAXOSMITHKLINE,,51.0,YR,,F,Y,,,20230309,,HP,US,US,2023,Q1,Adult
220747701,22074770,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,D,,,,,,,,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,1,I,20230307.0,,20230308,20230308,DIR,651450,,FDA-CTU,,45.0,YR,,M,N,128.25,KG,20230308,N,PH,US,,2023,Q1,Adult
220765061,22076506,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,D,,,,,,,,,2023,Q1,Maternal exposure during pregnancy,,2023,Q1,1,I,,20221212.0,20230309,20230309,PER,,US-STERISCIENCE B.V.-2022-ST-000306,Steriscience PTE,Maternal exposure during pregnancy: case report. 2022,39.0,YR,,F,Y,,,20230309,,HP,US,US,2023,Q1,Adult
220765061,22076506,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,D,,,,,,,,,2023,Q1,Off label use,,2023,Q1,1,I,,20221212.0,20230309,20230309,PER,,US-STERISCIENCE B.V.-2022-ST-000306,Steriscience PTE,Maternal exposure during pregnancy: case report. 2022,39.0,YR,,F,Y,,,20230309,,HP,US,US,2023,Q1,Adult
220776061,22077606,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Rash,,2023,Q1,1,I,,20230226.0,20230309,20230309,EXP,GB-MHRA-EMIS-6849-b8c9d111-2643-4a59-ad82-c1e6cdd04379,GB-MICRO LABS LIMITED-ML2023-01187,MICRO LABS,,50.0,YR,A,F,Y,112.0,KG,20230309,,PH,GB,GB,2023,Q1,Adult
220776061,22077606,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Myalgia,,2023,Q1,1,I,,20230226.0,20230309,20230309,EXP,GB-MHRA-EMIS-6849-b8c9d111-2643-4a59-ad82-c1e6cdd04379,GB-MICRO LABS LIMITED-ML2023-01187,MICRO LABS,,50.0,YR,A,F,Y,112.0,KG,20230309,,PH,GB,GB,2023,Q1,Adult
220776061,22077606,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Paraesthesia,,2023,Q1,1,I,,20230226.0,20230309,20230309,EXP,GB-MHRA-EMIS-6849-b8c9d111-2643-4a59-ad82-c1e6cdd04379,GB-MICRO LABS LIMITED-ML2023-01187,MICRO LABS,,50.0,YR,A,F,Y,112.0,KG,20230309,,PH,GB,GB,2023,Q1,Adult
220799191,22079919,28,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Abdominal neoplasm,,2023,Q1,1,I,20201201.0,20230301.0,20230309,20230309,EXP,,US-AstraZeneca-2023A052170,ASTRAZENECA,,630.0,MON,,M,Y,134.4,KG,20230309,,LW,US,,2023,Q1,Elderly
220799191,22079919,28,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Oesophageal adenocarcinoma,,2023,Q1,1,I,20201201.0,20230301.0,20230309,20230309,EXP,,US-AstraZeneca-2023A052170,ASTRAZENECA,,630.0,MON,,M,Y,134.4,KG,20230309,,LW,US,,2023,Q1,Elderly
220820811,22082081,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,QD,2023,Q1,Faeces soft,,2023,Q1,1,I,,20230309.0,20230310,20230310,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-154251",BOEHRINGER INGELHEIM,,79.0,YR,E,M,Y,,,20230310,,CN,CA,CA,2023,Q1,Elderly
220820811,22082081,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,QD,2023,Q1,Nausea,,2023,Q1,1,I,,20230309.0,20230310,20230310,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-154251",BOEHRINGER INGELHEIM,,79.0,YR,E,M,Y,,,20230310,,CN,CA,CA,2023,Q1,Elderly
220820811,22082081,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,QD,2023,Q1,Memory impairment,,2023,Q1,1,I,,20230309.0,20230310,20230310,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-154251",BOEHRINGER INGELHEIM,,79.0,YR,E,M,Y,,,20230310,,CN,CA,CA,2023,Q1,Elderly
220820811,22082081,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,QD,2023,Q1,Pneumothorax,,2023,Q1,1,I,,20230309.0,20230310,20230310,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-154251",BOEHRINGER INGELHEIM,,79.0,YR,E,M,Y,,,20230310,,CN,CA,CA,2023,Q1,Elderly
220820811,22082081,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,QD,2023,Q1,Vomiting,,2023,Q1,1,I,,20230309.0,20230310,20230310,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-154251",BOEHRINGER INGELHEIM,,79.0,YR,E,M,Y,,,20230310,,CN,CA,CA,2023,Q1,Elderly
220820811,22082081,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,QD,2023,Q1,Decreased appetite,,2023,Q1,1,I,,20230309.0,20230310,20230310,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-154251",BOEHRINGER INGELHEIM,,79.0,YR,E,M,Y,,,20230310,,CN,CA,CA,2023,Q1,Elderly
220820811,22082081,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,QD,2023,Q1,Weight decreased,,2023,Q1,1,I,,20230309.0,20230310,20230310,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-154251",BOEHRINGER INGELHEIM,,79.0,YR,E,M,Y,,,20230310,,CN,CA,CA,2023,Q1,Elderly
220820811,22082081,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,QD,2023,Q1,Constipation,,2023,Q1,1,I,,20230309.0,20230310,20230310,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-154251",BOEHRINGER INGELHEIM,,79.0,YR,E,M,Y,,,20230310,,CN,CA,CA,2023,Q1,Elderly
220820811,22082081,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,QD,2023,Q1,Diarrhoea,,2023,Q1,1,I,,20230309.0,20230310,20230310,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-154251",BOEHRINGER INGELHEIM,,79.0,YR,E,M,Y,,,20230310,,CN,CA,CA,2023,Q1,Elderly
220820811,22082081,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,QD,2023,Q1,Fatigue,,2023,Q1,1,I,,20230309.0,20230310,20230310,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-154251",BOEHRINGER INGELHEIM,,79.0,YR,E,M,Y,,,20230310,,CN,CA,CA,2023,Q1,Elderly
220820811,22082081,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,20.0,MG,,QD,2023,Q1,Faeces soft,,2023,Q1,1,I,,20230309.0,20230310,20230310,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-154251",BOEHRINGER INGELHEIM,,79.0,YR,E,M,Y,,,20230310,,CN,CA,CA,2023,Q1,Elderly
220820811,22082081,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,20.0,MG,,QD,2023,Q1,Nausea,,2023,Q1,1,I,,20230309.0,20230310,20230310,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-154251",BOEHRINGER INGELHEIM,,79.0,YR,E,M,Y,,,20230310,,CN,CA,CA,2023,Q1,Elderly
220820811,22082081,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,20.0,MG,,QD,2023,Q1,Memory impairment,,2023,Q1,1,I,,20230309.0,20230310,20230310,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-154251",BOEHRINGER INGELHEIM,,79.0,YR,E,M,Y,,,20230310,,CN,CA,CA,2023,Q1,Elderly
220820811,22082081,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,20.0,MG,,QD,2023,Q1,Pneumothorax,,2023,Q1,1,I,,20230309.0,20230310,20230310,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-154251",BOEHRINGER INGELHEIM,,79.0,YR,E,M,Y,,,20230310,,CN,CA,CA,2023,Q1,Elderly
220820811,22082081,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,20.0,MG,,QD,2023,Q1,Vomiting,,2023,Q1,1,I,,20230309.0,20230310,20230310,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-154251",BOEHRINGER INGELHEIM,,79.0,YR,E,M,Y,,,20230310,,CN,CA,CA,2023,Q1,Elderly
220820811,22082081,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,20.0,MG,,QD,2023,Q1,Decreased appetite,,2023,Q1,1,I,,20230309.0,20230310,20230310,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-154251",BOEHRINGER INGELHEIM,,79.0,YR,E,M,Y,,,20230310,,CN,CA,CA,2023,Q1,Elderly
220820811,22082081,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,20.0,MG,,QD,2023,Q1,Weight decreased,,2023,Q1,1,I,,20230309.0,20230310,20230310,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-154251",BOEHRINGER INGELHEIM,,79.0,YR,E,M,Y,,,20230310,,CN,CA,CA,2023,Q1,Elderly
220820811,22082081,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,20.0,MG,,QD,2023,Q1,Constipation,,2023,Q1,1,I,,20230309.0,20230310,20230310,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-154251",BOEHRINGER INGELHEIM,,79.0,YR,E,M,Y,,,20230310,,CN,CA,CA,2023,Q1,Elderly
220820811,22082081,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,20.0,MG,,QD,2023,Q1,Diarrhoea,,2023,Q1,1,I,,20230309.0,20230310,20230310,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-154251",BOEHRINGER INGELHEIM,,79.0,YR,E,M,Y,,,20230310,,CN,CA,CA,2023,Q1,Elderly
220820811,22082081,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,20.0,MG,,QD,2023,Q1,Fatigue,,2023,Q1,1,I,,20230309.0,20230310,20230310,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-154251",BOEHRINGER INGELHEIM,,79.0,YR,E,M,Y,,,20230310,,CN,CA,CA,2023,Q1,Elderly
220823332,22082333,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,Tablet,QD,2023,Q1,Constipation,,2023,Q1,2,F,20230101.0,20230328.0,20230310,20230330,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-2023-034326,BRISTOL MYERS SQUIBB,,57.0,YR,A,M,Y,,,20230330,,CN,US,US,2023,Q1,Adult
220833281,22083328,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,,,,,2023,Q1,Left ventricular dysfunction,,2023,Q1,1,I,,20230309.0,20230310,20230310,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-223924",BOEHRINGER INGELHEIM,"Cao C, Stock J, Emani S. SGLT2I-ASSOCIATED EUGLYCEMIC DIABETIC KETOACIDOSIS IN THE SETTING OF ACUTE CORONARY SYNDROME. Journal of the American College of Cardiology. 2023;81doi:10.1016/S073 5-1097%2823%2903153-4.",63.0,YR,A,M,Y,,,20230310,,HP,US,US,2023,Q1,Adult
220833281,22083328,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,,,,,2023,Q1,Acute coronary syndrome,,2023,Q1,1,I,,20230309.0,20230310,20230310,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-223924",BOEHRINGER INGELHEIM,"Cao C, Stock J, Emani S. SGLT2I-ASSOCIATED EUGLYCEMIC DIABETIC KETOACIDOSIS IN THE SETTING OF ACUTE CORONARY SYNDROME. Journal of the American College of Cardiology. 2023;81doi:10.1016/S073 5-1097%2823%2903153-4.",63.0,YR,A,M,Y,,,20230310,,HP,US,US,2023,Q1,Adult
220833281,22083328,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,,,,,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,1,I,,20230309.0,20230310,20230310,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-223924",BOEHRINGER INGELHEIM,"Cao C, Stock J, Emani S. SGLT2I-ASSOCIATED EUGLYCEMIC DIABETIC KETOACIDOSIS IN THE SETTING OF ACUTE CORONARY SYNDROME. Journal of the American College of Cardiology. 2023;81doi:10.1016/S073 5-1097%2823%2903153-4.",63.0,YR,A,M,Y,,,20230310,,HP,US,US,2023,Q1,Adult
220834981,22083498,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,,,,,2023,Q1,Coronary artery disease,,2023,Q1,1,I,,20230309.0,20230310,20230310,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-223925",BOEHRINGER INGELHEIM,"Cao C, Stock J, Emani S. SGLT2I-ASSOCIATED EUGLYCEMIC DIABETIC KETOACIDOSIS IN THE SETTING OF ACUTE CORONARY SYNDROME. Journal of the American College of Cardiology. 2023;81doi:10.1016/S073 5-1097%2823%2903153-4.",70.0,YR,E,M,Y,,,20230310,,HP,US,US,2023,Q1,Elderly
220834981,22083498,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,,,,,2023,Q1,Left ventricular dysfunction,,2023,Q1,1,I,,20230309.0,20230310,20230310,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-223925",BOEHRINGER INGELHEIM,"Cao C, Stock J, Emani S. SGLT2I-ASSOCIATED EUGLYCEMIC DIABETIC KETOACIDOSIS IN THE SETTING OF ACUTE CORONARY SYNDROME. Journal of the American College of Cardiology. 2023;81doi:10.1016/S073 5-1097%2823%2903153-4.",70.0,YR,E,M,Y,,,20230310,,HP,US,US,2023,Q1,Elderly
220834981,22083498,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,,,,,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,1,I,,20230309.0,20230310,20230310,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-223925",BOEHRINGER INGELHEIM,"Cao C, Stock J, Emani S. SGLT2I-ASSOCIATED EUGLYCEMIC DIABETIC KETOACIDOSIS IN THE SETTING OF ACUTE CORONARY SYNDROME. Journal of the American College of Cardiology. 2023;81doi:10.1016/S073 5-1097%2823%2903153-4.",70.0,YR,E,M,Y,,,20230310,,HP,US,US,2023,Q1,Elderly
220887801,22088780,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25mg once a day; ;,,,Y,U,Unknown,,204629.0,,,Tablet,,2023,Q1,Systemic mycosis,,2023,Q1,1,I,20230302.0,20230309.0,20230313,20230313,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-223887",BOEHRINGER INGELHEIM,,76.0,YR,E,M,Y,,,20230313,,PH,GB,GB,2023,Q1,Elderly
220897054,22089705,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2023,Q1,Portal venous gas,,2023,Q1,4,F,20210501.0,20230320.0,20230313,20230324,EXP,,JP-009507513-2303JPN003777,MERCK,Fukuda M.. A case of portal vein pneumatosis and pneumatosis coli considered due to alpha-glucosidase inhibitor and DPP-4 inhibitor. The Journal of the Saitama Medical Society. 2023;57(1):87-90,74.0,YR,,M,Y,,,20230324,,MD,JP,JP,2023,Q1,Elderly
220897054,22089705,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2023,Q1,Pneumatosis intestinalis,,2023,Q1,4,F,20210501.0,20230320.0,20230313,20230324,EXP,,JP-009507513-2303JPN003777,MERCK,Fukuda M.. A case of portal vein pneumatosis and pneumatosis coli considered due to alpha-glucosidase inhibitor and DPP-4 inhibitor. The Journal of the Saitama Medical Society. 2023;57(1):87-90,74.0,YR,,M,Y,,,20230324,,MD,JP,JP,2023,Q1,Elderly
220897054,22089705,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2023,Q1,Subdural haematoma,,2023,Q1,4,F,20210501.0,20230320.0,20230313,20230324,EXP,,JP-009507513-2303JPN003777,MERCK,Fukuda M.. A case of portal vein pneumatosis and pneumatosis coli considered due to alpha-glucosidase inhibitor and DPP-4 inhibitor. The Journal of the Saitama Medical Society. 2023;57(1):87-90,74.0,YR,,M,Y,,,20230324,,MD,JP,JP,2023,Q1,Elderly
220897054,22089705,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2023,Q1,Portal venous gas,,2023,Q1,4,F,20210501.0,20230320.0,20230313,20230324,EXP,,JP-009507513-2303JPN003777,MERCK,Fukuda M.. A case of portal vein pneumatosis and pneumatosis coli considered due to alpha-glucosidase inhibitor and DPP-4 inhibitor. The Journal of the Saitama Medical Society. 2023;57(1):87-90,74.0,YR,,M,Y,,,20230324,,MD,JP,JP,2023,Q1,Elderly
220897054,22089705,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2023,Q1,Pneumatosis intestinalis,,2023,Q1,4,F,20210501.0,20230320.0,20230313,20230324,EXP,,JP-009507513-2303JPN003777,MERCK,Fukuda M.. A case of portal vein pneumatosis and pneumatosis coli considered due to alpha-glucosidase inhibitor and DPP-4 inhibitor. The Journal of the Saitama Medical Society. 2023;57(1):87-90,74.0,YR,,M,Y,,,20230324,,MD,JP,JP,2023,Q1,Elderly
220897054,22089705,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2023,Q1,Subdural haematoma,,2023,Q1,4,F,20210501.0,20230320.0,20230313,20230324,EXP,,JP-009507513-2303JPN003777,MERCK,Fukuda M.. A case of portal vein pneumatosis and pneumatosis coli considered due to alpha-glucosidase inhibitor and DPP-4 inhibitor. The Journal of the Saitama Medical Society. 2023;57(1):87-90,74.0,YR,,M,Y,,,20230324,,MD,JP,JP,2023,Q1,Elderly
220898122,22089812,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,U,,,,,10.0,MG,Tablet,QD,2023,Q1,Ketoacidosis,,2023,Q1,2,F,,20230213.0,20230313,20230315,EXP,,JP-NOVOPROD-1037632,NOVO NORDISK,"Tsujii Y., et al.. A case of ketoacidosis in a heavy drinker following concomitant use of GLP-1 R agonist and SGLT2 inhibitor.. Program and abstract of the 59th Kinki Regional Meeting of the Japan Diabetes. 2022;127",54.0,YR,,M,Y,,,20230315,,MD,JP,JP,2023,Q1,Adult
220905761,22090576,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,5/1000 mg,,,,,2048094,,206111.0,,,Film-coated tablet,,2023,Q1,Polyneuropathy,,2023,Q1,1,I,,20230310.0,20230313,20230313,EXP,CH-SM-2023-10625,"CH-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-224386",BOEHRINGER INGELHEIM,,59.0,YR,A,M,Y,0.0,KG,20230313,,PH,CH,CH,2023,Q1,Adult
220912362,22091236,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2023,Q1,Blood glucose increased,,2023,Q1,2,F,,20230313.0,20230314,20230319,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-223627",BOEHRINGER INGELHEIM,"Ntoga M, Stamatiou I, Papachristou S, Dimitriadis D, Markatou F, Papanas N. A case of a patient with euglycemic diabetic ketoacidosis caused by a type 2 Sodium-Glucose cotransporter inhibitor (SGLT-2).. 21st Panhellenic Diabetological Conference, 8-11 March 2023, Athens, Divani Caravel Hotel. 2023 Mar;",92.0,YR,E,M,Y,,,20230320,,MD,GR,GR,2023,Q1,Elderly
220912362,22091236,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,2,F,,20230313.0,20230314,20230319,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-223627",BOEHRINGER INGELHEIM,"Ntoga M, Stamatiou I, Papachristou S, Dimitriadis D, Markatou F, Papanas N. A case of a patient with euglycemic diabetic ketoacidosis caused by a type 2 Sodium-Glucose cotransporter inhibitor (SGLT-2).. 21st Panhellenic Diabetological Conference, 8-11 March 2023, Athens, Divani Caravel Hotel. 2023 Mar;",92.0,YR,E,M,Y,,,20230320,,MD,GR,GR,2023,Q1,Elderly
220912362,22091236,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2023,Q1,Depressed level of consciousness,,2023,Q1,2,F,,20230313.0,20230314,20230319,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-223627",BOEHRINGER INGELHEIM,"Ntoga M, Stamatiou I, Papachristou S, Dimitriadis D, Markatou F, Papanas N. A case of a patient with euglycemic diabetic ketoacidosis caused by a type 2 Sodium-Glucose cotransporter inhibitor (SGLT-2).. 21st Panhellenic Diabetological Conference, 8-11 March 2023, Athens, Divani Caravel Hotel. 2023 Mar;",92.0,YR,E,M,Y,,,20230320,,MD,GR,GR,2023,Q1,Elderly
220912362,22091236,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2023,Q1,Asthenia,,2023,Q1,2,F,,20230313.0,20230314,20230319,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-223627",BOEHRINGER INGELHEIM,"Ntoga M, Stamatiou I, Papachristou S, Dimitriadis D, Markatou F, Papanas N. A case of a patient with euglycemic diabetic ketoacidosis caused by a type 2 Sodium-Glucose cotransporter inhibitor (SGLT-2).. 21st Panhellenic Diabetological Conference, 8-11 March 2023, Athens, Divani Caravel Hotel. 2023 Mar;",92.0,YR,E,M,Y,,,20230320,,MD,GR,GR,2023,Q1,Elderly
220912362,22091236,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2023,Q1,Metabolic acidosis,,2023,Q1,2,F,,20230313.0,20230314,20230319,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-223627",BOEHRINGER INGELHEIM,"Ntoga M, Stamatiou I, Papachristou S, Dimitriadis D, Markatou F, Papanas N. A case of a patient with euglycemic diabetic ketoacidosis caused by a type 2 Sodium-Glucose cotransporter inhibitor (SGLT-2).. 21st Panhellenic Diabetological Conference, 8-11 March 2023, Athens, Divani Caravel Hotel. 2023 Mar;",92.0,YR,E,M,Y,,,20230320,,MD,GR,GR,2023,Q1,Elderly
220912362,22091236,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2023,Q1,Renal pain,,2023,Q1,2,F,,20230313.0,20230314,20230319,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-223627",BOEHRINGER INGELHEIM,"Ntoga M, Stamatiou I, Papachristou S, Dimitriadis D, Markatou F, Papanas N. A case of a patient with euglycemic diabetic ketoacidosis caused by a type 2 Sodium-Glucose cotransporter inhibitor (SGLT-2).. 21st Panhellenic Diabetological Conference, 8-11 March 2023, Athens, Divani Caravel Hotel. 2023 Mar;",92.0,YR,E,M,Y,,,20230320,,MD,GR,GR,2023,Q1,Elderly
220912362,22091236,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2023,Q1,Urinary tract infection,,2023,Q1,2,F,,20230313.0,20230314,20230319,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-223627",BOEHRINGER INGELHEIM,"Ntoga M, Stamatiou I, Papachristou S, Dimitriadis D, Markatou F, Papanas N. A case of a patient with euglycemic diabetic ketoacidosis caused by a type 2 Sodium-Glucose cotransporter inhibitor (SGLT-2).. 21st Panhellenic Diabetological Conference, 8-11 March 2023, Athens, Divani Caravel Hotel. 2023 Mar;",92.0,YR,E,M,Y,,,20230320,,MD,GR,GR,2023,Q1,Elderly
220925491,22092549,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg x1,,,,,,,,10.0,MG,Tablet,,2023,Q1,Coronary artery occlusion,,2023,Q1,1,I,,20230302.0,20230314,20230314,EXP,,SE-Accord-303804,ACCORD,"Hoskuldsdottir G, Thorleifsson S J, Ravn-Fischer A, Eliasson B. SGLT2 hammare kan behova sattas ut vid allvarliga sjukdomstillstand Risk for ketoacidos hos personer med diabetes och insulinbrist. Lakartidningen 2023, 120:22113.",64.0,YR,A,,Y,,,20230314,,HP,SE,SE,2023,Q1,Adult
220925491,22092549,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg x1,,,,,,,,10.0,MG,Tablet,,2023,Q1,Atrial fibrillation,,2023,Q1,1,I,,20230302.0,20230314,20230314,EXP,,SE-Accord-303804,ACCORD,"Hoskuldsdottir G, Thorleifsson S J, Ravn-Fischer A, Eliasson B. SGLT2 hammare kan behova sattas ut vid allvarliga sjukdomstillstand Risk for ketoacidos hos personer med diabetes och insulinbrist. Lakartidningen 2023, 120:22113.",64.0,YR,A,,Y,,,20230314,,HP,SE,SE,2023,Q1,Adult
220925491,22092549,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg x1,,,,,,,,10.0,MG,Tablet,,2023,Q1,Chest pain,,2023,Q1,1,I,,20230302.0,20230314,20230314,EXP,,SE-Accord-303804,ACCORD,"Hoskuldsdottir G, Thorleifsson S J, Ravn-Fischer A, Eliasson B. SGLT2 hammare kan behova sattas ut vid allvarliga sjukdomstillstand Risk for ketoacidos hos personer med diabetes och insulinbrist. Lakartidningen 2023, 120:22113.",64.0,YR,A,,Y,,,20230314,,HP,SE,SE,2023,Q1,Adult
220936241,22093624,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,10.0,MG,,QD,2023,Q1,Pleural effusion,,2023,Q1,1,I,20221224.0,,20230313,20230313,DIR,652190,,FDA-CTU,,84.0,YR,,M,N,75.0,KG,20230313,N,PH,US,,2023,Q1,Elderly
220936241,22093624,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,10.0,MG,,QD,2023,Q1,Sleep disorder,,2023,Q1,1,I,20221224.0,,20230313,20230313,DIR,652190,,FDA-CTU,,84.0,YR,,M,N,75.0,KG,20230313,N,PH,US,,2023,Q1,Elderly
220936241,22093624,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,10.0,MG,,QD,2023,Q1,Eructation,,2023,Q1,1,I,20221224.0,,20230313,20230313,DIR,652190,,FDA-CTU,,84.0,YR,,M,N,75.0,KG,20230313,N,PH,US,,2023,Q1,Elderly
220936241,22093624,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,10.0,MG,,QD,2023,Q1,Chest pain,,2023,Q1,1,I,20221224.0,,20230313,20230313,DIR,652190,,FDA-CTU,,84.0,YR,,M,N,75.0,KG,20230313,N,PH,US,,2023,Q1,Elderly
220936241,22093624,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,10.0,MG,,QD,2023,Q1,Atrial fibrillation,,2023,Q1,1,I,20221224.0,,20230313,20230313,DIR,652190,,FDA-CTU,,84.0,YR,,M,N,75.0,KG,20230313,N,PH,US,,2023,Q1,Elderly
220936241,22093624,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,10.0,MG,,QD,2023,Q1,Sepsis,,2023,Q1,1,I,20221224.0,,20230313,20230313,DIR,652190,,FDA-CTU,,84.0,YR,,M,N,75.0,KG,20230313,N,PH,US,,2023,Q1,Elderly
220936241,22093624,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,10.0,MG,,QD,2023,Q1,Pain,,2023,Q1,1,I,20221224.0,,20230313,20230313,DIR,652190,,FDA-CTU,,84.0,YR,,M,N,75.0,KG,20230313,N,PH,US,,2023,Q1,Elderly
220936241,22093624,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,10.0,MG,,QD,2023,Q1,Oedematous pancreatitis,,2023,Q1,1,I,20221224.0,,20230313,20230313,DIR,652190,,FDA-CTU,,84.0,YR,,M,N,75.0,KG,20230313,N,PH,US,,2023,Q1,Elderly
220965731,22096573,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q1,Pain,,2023,Q1,1,I,20230213.0,20230315.0,20230315,20230315,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-225057",BOEHRINGER INGELHEIM,,48.0,YR,A,M,Y,,,20230315,,HP,SG,SG,2023,Q1,Adult
220969671,22096967,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q1,Seizure,,2023,Q1,1,I,20220418.0,20230308.0,20230315,20230315,EXP,,CA-PFIZER INC-202200597420,PFIZER,,64.0,YR,,M,Y,,,20230315,,HP,CA,CA,2023,Q1,Adult
220969671,22096967,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q1,Off label use,,2023,Q1,1,I,20220418.0,20230308.0,20230315,20230315,EXP,,CA-PFIZER INC-202200597420,PFIZER,,64.0,YR,,M,Y,,,20230315,,HP,CA,CA,2023,Q1,Adult
220969671,22096967,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q1,Inappropriate schedule of product administration,,2023,Q1,1,I,20220418.0,20230308.0,20230315,20230315,EXP,,CA-PFIZER INC-202200597420,PFIZER,,64.0,YR,,M,Y,,,20230315,,HP,CA,CA,2023,Q1,Adult
220983361,22098336,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Pancreatic carcinoma metastatic,,2023,Q1,1,I,20230306.0,,20230314,20230314,DIR,652342,,FDA-CTU,,61.0,YR,,M,N,80.3,KG,20230314,Y,PH,US,,2023,Q1,Adult
220984221,22098422,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Pulseless electrical activity,,2023,Q1,1,I,20230313.0,,20230314,20230314,DIR,652387,,FDA-CTU,,61.0,YR,,M,N,107.55,KG,20230314,Y,HP,US,,2023,Q1,Adult
220984221,22098422,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Dyspnoea,,2023,Q1,1,I,20230313.0,,20230314,20230314,DIR,652387,,FDA-CTU,,61.0,YR,,M,N,107.55,KG,20230314,Y,HP,US,,2023,Q1,Adult
220984221,22098422,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Hyperhidrosis,,2023,Q1,1,I,20230313.0,,20230314,20230314,DIR,652387,,FDA-CTU,,61.0,YR,,M,N,107.55,KG,20230314,Y,HP,US,,2023,Q1,Adult
220984221,22098422,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Ventricular fibrillation,,2023,Q1,1,I,20230313.0,,20230314,20230314,DIR,652387,,FDA-CTU,,61.0,YR,,M,N,107.55,KG,20230314,Y,HP,US,,2023,Q1,Adult
220984221,22098422,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Erythema,,2023,Q1,1,I,20230313.0,,20230314,20230314,DIR,652387,,FDA-CTU,,61.0,YR,,M,N,107.55,KG,20230314,Y,HP,US,,2023,Q1,Adult
220984221,22098422,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Dyspnoea,,2023,Q1,1,I,20230313.0,,20230314,20230314,DIR,652387,,FDA-CTU,,61.0,YR,,M,N,107.55,KG,20230314,Y,HP,US,,2023,Q1,Adult
220984221,22098422,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Oxygen saturation decreased,,2023,Q1,1,I,20230313.0,,20230314,20230314,DIR,652387,,FDA-CTU,,61.0,YR,,M,N,107.55,KG,20230314,Y,HP,US,,2023,Q1,Adult
220984221,22098422,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Anaphylactic reaction,,2023,Q1,1,I,20230313.0,,20230314,20230314,DIR,652387,,FDA-CTU,,61.0,YR,,M,N,107.55,KG,20230314,Y,HP,US,,2023,Q1,Adult
220984221,22098422,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Cardio-respiratory arrest,,2023,Q1,1,I,20230313.0,,20230314,20230314,DIR,652387,,FDA-CTU,,61.0,YR,,M,N,107.55,KG,20230314,Y,HP,US,,2023,Q1,Adult
220984221,22098422,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Restlessness,,2023,Q1,1,I,20230313.0,,20230314,20230314,DIR,652387,,FDA-CTU,,61.0,YR,,M,N,107.55,KG,20230314,Y,HP,US,,2023,Q1,Adult
220984221,22098422,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Malaise,,2023,Q1,1,I,20230313.0,,20230314,20230314,DIR,652387,,FDA-CTU,,61.0,YR,,M,N,107.55,KG,20230314,Y,HP,US,,2023,Q1,Adult
220984221,22098422,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Contrast media reaction,,2023,Q1,1,I,20230313.0,,20230314,20230314,DIR,652387,,FDA-CTU,,61.0,YR,,M,N,107.55,KG,20230314,Y,HP,US,,2023,Q1,Adult
220984221,22098422,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Facial pain,,2023,Q1,1,I,20230313.0,,20230314,20230314,DIR,652387,,FDA-CTU,,61.0,YR,,M,N,107.55,KG,20230314,Y,HP,US,,2023,Q1,Adult
221005701,22100570,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q1,Dizziness,,2023,Q1,1,I,20220625.0,20230306.0,20230316,20230316,EXP,,AU-AstraZeneca-2023A061977,ASTRAZENECA,,48.0,YR,,M,Y,,,20230315,,MD,AU,,2023,Q1,Adult
221005701,22100570,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q1,Dyspnoea,,2023,Q1,1,I,20220625.0,20230306.0,20230316,20230316,EXP,,AU-AstraZeneca-2023A061977,ASTRAZENECA,,48.0,YR,,M,Y,,,20230315,,MD,AU,,2023,Q1,Adult
221005701,22100570,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q1,Overdose,,2023,Q1,1,I,20220625.0,20230306.0,20230316,20230316,EXP,,AU-AstraZeneca-2023A061977,ASTRAZENECA,,48.0,YR,,M,Y,,,20230315,,MD,AU,,2023,Q1,Adult
221005701,22100570,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q1,Hyperhidrosis,,2023,Q1,1,I,20220625.0,20230306.0,20230316,20230316,EXP,,AU-AstraZeneca-2023A061977,ASTRAZENECA,,48.0,YR,,M,Y,,,20230315,,MD,AU,,2023,Q1,Adult
221005701,22100570,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q1,Sinus tachycardia,,2023,Q1,1,I,20220625.0,20230306.0,20230316,20230316,EXP,,AU-AstraZeneca-2023A061977,ASTRAZENECA,,48.0,YR,,M,Y,,,20230315,,MD,AU,,2023,Q1,Adult
221005701,22100570,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q1,Cardiomyopathy,,2023,Q1,1,I,20220625.0,20230306.0,20230316,20230316,EXP,,AU-AstraZeneca-2023A061977,ASTRAZENECA,,48.0,YR,,M,Y,,,20230315,,MD,AU,,2023,Q1,Adult
221005701,22100570,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q1,Hypotension,,2023,Q1,1,I,20220625.0,20230306.0,20230316,20230316,EXP,,AU-AstraZeneca-2023A061977,ASTRAZENECA,,48.0,YR,,M,Y,,,20230315,,MD,AU,,2023,Q1,Adult
221005701,22100570,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q1,Body temperature increased,,2023,Q1,1,I,20220625.0,20230306.0,20230316,20230316,EXP,,AU-AstraZeneca-2023A061977,ASTRAZENECA,,48.0,YR,,M,Y,,,20230315,,MD,AU,,2023,Q1,Adult
221005701,22100570,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q1,Hypersensitivity,,2023,Q1,1,I,20220625.0,20230306.0,20230316,20230316,EXP,,AU-AstraZeneca-2023A061977,ASTRAZENECA,,48.0,YR,,M,Y,,,20230315,,MD,AU,,2023,Q1,Adult
221005701,22100570,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q1,"Hallucination, auditory",,2023,Q1,1,I,20220625.0,20230306.0,20230316,20230316,EXP,,AU-AstraZeneca-2023A061977,ASTRAZENECA,,48.0,YR,,M,Y,,,20230315,,MD,AU,,2023,Q1,Adult
221037483,22103748,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,White blood cell count increased,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Thalassaemia alpha,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Blood creatinine increased,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Oedema peripheral,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Blood glucose increased,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Occult blood positive,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Concomitant disease aggravated,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Inappropriate antidiuretic hormone secretion,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Wrong technique in product usage process,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Dizziness,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Hypertension,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Urine protein/creatinine ratio increased,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Cardiac failure acute,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Microcytic anaemia,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,White blood cell count increased,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Thalassaemia alpha,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Blood creatinine increased,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Oedema peripheral,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Blood glucose increased,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Occult blood positive,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Concomitant disease aggravated,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Inappropriate antidiuretic hormone secretion,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Wrong technique in product usage process,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Dizziness,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Hypertension,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Urine protein/creatinine ratio increased,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Cardiac failure acute,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Microcytic anaemia,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,White blood cell count increased,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Thalassaemia alpha,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Blood creatinine increased,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Oedema peripheral,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Blood glucose increased,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Occult blood positive,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Concomitant disease aggravated,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Inappropriate antidiuretic hormone secretion,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Wrong technique in product usage process,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Dizziness,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Hypertension,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Urine protein/creatinine ratio increased,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Cardiac failure acute,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Microcytic anaemia,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,White blood cell count increased,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Thalassaemia alpha,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Blood creatinine increased,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Oedema peripheral,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Blood glucose increased,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Occult blood positive,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Concomitant disease aggravated,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Inappropriate antidiuretic hormone secretion,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Wrong technique in product usage process,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Dizziness,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Hypertension,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Urine protein/creatinine ratio increased,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Cardiac failure acute,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Microcytic anaemia,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,White blood cell count increased,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Thalassaemia alpha,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Blood creatinine increased,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Oedema peripheral,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Blood glucose increased,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Occult blood positive,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Concomitant disease aggravated,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Inappropriate antidiuretic hormone secretion,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Wrong technique in product usage process,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Dizziness,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Hypertension,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Urine protein/creatinine ratio increased,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Cardiac failure acute,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Microcytic anaemia,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,White blood cell count increased,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Thalassaemia alpha,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Blood creatinine increased,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Oedema peripheral,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Blood glucose increased,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Occult blood positive,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Concomitant disease aggravated,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Inappropriate antidiuretic hormone secretion,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Wrong technique in product usage process,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Dizziness,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Hypertension,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Urine protein/creatinine ratio increased,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Cardiac failure acute,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221037483,22103748,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 UNK,,,Y,,,,,,,,,2023,Q1,Microcytic anaemia,,2023,Q1,3,F,,20230308.0,20230316,20230323,EXP,,NVSC2023TH055164,NOVARTIS,,58.0,YR,,F,Y,,,20230323,,MD,TH,TH,2023,Q1,Adult
221041871,22104187,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,N,U,Unknown,,204629.0,,,,,2023,Q1,Skin ulcer,,2023,Q1,1,I,20230215.0,20230316.0,20230316,20230316,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-225471",BOEHRINGER INGELHEIM,,83.0,YR,E,M,Y,74.0,KG,20230316,,HP,GB,GB,2023,Q1,Elderly
221041871,22104187,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,N,U,Unknown,,204629.0,,,,,2023,Q1,Medication error,,2023,Q1,1,I,20230215.0,20230316.0,20230316,20230316,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-225471",BOEHRINGER INGELHEIM,,83.0,YR,E,M,Y,74.0,KG,20230316,,HP,GB,GB,2023,Q1,Elderly
221045272,22104527,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q1,Cutaneous vasculitis,,2023,Q1,2,F,20230201.0,20230314.0,20230316,20230320,EXP,,CO-BRISTOL-MYERS SQUIBB COMPANY-2023-038383,BRISTOL MYERS SQUIBB,,64.0,YR,A,,Y,,,20230320,,MD,CO,CO,2023,Q1,Adult
221045272,22104527,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q1,Leukocytosis,,2023,Q1,2,F,20230201.0,20230314.0,20230316,20230320,EXP,,CO-BRISTOL-MYERS SQUIBB COMPANY-2023-038383,BRISTOL MYERS SQUIBB,,64.0,YR,A,,Y,,,20230320,,MD,CO,CO,2023,Q1,Adult
221045272,22104527,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q1,Purpura,,2023,Q1,2,F,20230201.0,20230314.0,20230316,20230320,EXP,,CO-BRISTOL-MYERS SQUIBB COMPANY-2023-038383,BRISTOL MYERS SQUIBB,,64.0,YR,A,,Y,,,20230320,,MD,CO,CO,2023,Q1,Adult
221045272,22104527,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q1,Cellulitis,,2023,Q1,2,F,20230201.0,20230314.0,20230316,20230320,EXP,,CO-BRISTOL-MYERS SQUIBB COMPANY-2023-038383,BRISTOL MYERS SQUIBB,,64.0,YR,A,,Y,,,20230320,,MD,CO,CO,2023,Q1,Adult
221045502,22104550,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, daily",,,Y,,,,,10.0,MG,Tablet,,2023,Q1,Hypotension,,2023,Q1,2,F,20230226.0,20230316.0,20230316,20230321,EXP,,BE-PFIZER INC-202300106139,PFIZER,,76.0,YR,,F,Y,64.0,KG,20230321,,MD,BE,BE,2023,Q1,Elderly
221045502,22104550,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, daily",,,Y,,,,,10.0,MG,Tablet,,2023,Q1,Diarrhoea,,2023,Q1,2,F,20230226.0,20230316.0,20230316,20230321,EXP,,BE-PFIZER INC-202300106139,PFIZER,,76.0,YR,,F,Y,64.0,KG,20230321,,MD,BE,BE,2023,Q1,Elderly
221045502,22104550,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, daily",,,Y,,,,,10.0,MG,Tablet,,2023,Q1,Acute kidney injury,,2023,Q1,2,F,20230226.0,20230316.0,20230316,20230321,EXP,,BE-PFIZER INC-202300106139,PFIZER,,76.0,YR,,F,Y,64.0,KG,20230321,,MD,BE,BE,2023,Q1,Elderly
221045502,22104550,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, daily",,,Y,,,,,10.0,MG,Tablet,,2023,Q1,Hypotension,,2023,Q1,2,F,20230226.0,20230316.0,20230316,20230321,EXP,,BE-PFIZER INC-202300106139,PFIZER,,76.0,YR,,F,Y,64.0,KG,20230321,,MD,BE,BE,2023,Q1,Elderly
221045502,22104550,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, daily",,,Y,,,,,10.0,MG,Tablet,,2023,Q1,Diarrhoea,,2023,Q1,2,F,20230226.0,20230316.0,20230316,20230321,EXP,,BE-PFIZER INC-202300106139,PFIZER,,76.0,YR,,F,Y,64.0,KG,20230321,,MD,BE,BE,2023,Q1,Elderly
221045502,22104550,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, daily",,,Y,,,,,10.0,MG,Tablet,,2023,Q1,Acute kidney injury,,2023,Q1,2,F,20230226.0,20230316.0,20230316,20230321,EXP,,BE-PFIZER INC-202300106139,PFIZER,,76.0,YR,,F,Y,64.0,KG,20230321,,MD,BE,BE,2023,Q1,Elderly
221047064,22104706,5,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,1-0-1,,,,,,,,,,,,2023,Q1,Platelet anisocytosis,,2023,Q1,4,F,20230101.0,20230309.0,20230316,20230323,EXP,,ES-009507513-2303ESP000464,MERCK,,66.0,YR,,F,Y,48.0,KG,20230323,,MD,ES,ES,2023,Q1,Elderly
221047064,22104706,5,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,1-0-1,,,,,,,,,,,,2023,Q1,Drug ineffective,,2023,Q1,4,F,20230101.0,20230309.0,20230316,20230323,EXP,,ES-009507513-2303ESP000464,MERCK,,66.0,YR,,F,Y,48.0,KG,20230323,,MD,ES,ES,2023,Q1,Elderly
221047064,22104706,5,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,1-0-1,,,,,,,,,,,,2023,Q1,Splenic infarction,,2023,Q1,4,F,20230101.0,20230309.0,20230316,20230323,EXP,,ES-009507513-2303ESP000464,MERCK,,66.0,YR,,F,Y,48.0,KG,20230323,,MD,ES,ES,2023,Q1,Elderly
221047064,22104706,5,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,1-0-1,,,,,,,,,,,,2023,Q1,Monocyte morphology abnormal,,2023,Q1,4,F,20230101.0,20230309.0,20230316,20230323,EXP,,ES-009507513-2303ESP000464,MERCK,,66.0,YR,,F,Y,48.0,KG,20230323,,MD,ES,ES,2023,Q1,Elderly
221047064,22104706,5,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,1-0-1,,,,,,,,,,,,2023,Q1,Leukocytosis,,2023,Q1,4,F,20230101.0,20230309.0,20230316,20230323,EXP,,ES-009507513-2303ESP000464,MERCK,,66.0,YR,,F,Y,48.0,KG,20230323,,MD,ES,ES,2023,Q1,Elderly
221047064,22104706,5,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,1-0-1,,,,,,,,,,,,2023,Q1,Red blood cell anisocytes present,,2023,Q1,4,F,20230101.0,20230309.0,20230316,20230323,EXP,,ES-009507513-2303ESP000464,MERCK,,66.0,YR,,F,Y,48.0,KG,20230323,,MD,ES,ES,2023,Q1,Elderly
221047064,22104706,5,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,1-0-1,,,,,,,,,,,,2023,Q1,Malignant neoplasm progression,,2023,Q1,4,F,20230101.0,20230309.0,20230316,20230323,EXP,,ES-009507513-2303ESP000464,MERCK,,66.0,YR,,F,Y,48.0,KG,20230323,,MD,ES,ES,2023,Q1,Elderly
221047064,22104706,5,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,1-0-1,,,,,,,,,,,,2023,Q1,Bladder disorder,,2023,Q1,4,F,20230101.0,20230309.0,20230316,20230323,EXP,,ES-009507513-2303ESP000464,MERCK,,66.0,YR,,F,Y,48.0,KG,20230323,,MD,ES,ES,2023,Q1,Elderly
221047064,22104706,5,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,1-0-1,,,,,,,,,,,,2023,Q1,Dysuria,,2023,Q1,4,F,20230101.0,20230309.0,20230316,20230323,EXP,,ES-009507513-2303ESP000464,MERCK,,66.0,YR,,F,Y,48.0,KG,20230323,,MD,ES,ES,2023,Q1,Elderly
221106791,22110679,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,Unknown,,204629.0,5.0,MG,Tablet,QD,2023,Q1,Toe amputation,,2023,Q1,1,I,,20230317.0,20230317,20230317,EXP,GB-MHRA-MIDB-581f40e1-d3b1-4a12-ab94-231ffb53a568,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-225768",BOEHRINGER INGELHEIM,,67.0,YR,E,M,Y,,,20230317,,PH,GB,GB,2023,Q1,Elderly
221106791,22110679,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,Unknown,,204629.0,5.0,MG,Tablet,QD,2023,Q1,Skin ulcer,,2023,Q1,1,I,,20230317.0,20230317,20230317,EXP,GB-MHRA-MIDB-581f40e1-d3b1-4a12-ab94-231ffb53a568,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-225768",BOEHRINGER INGELHEIM,,67.0,YR,E,M,Y,,,20230317,,PH,GB,GB,2023,Q1,Elderly
221116061,22111606,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,U,Unknown,,204629.0,,,,QD,2023,Q1,Adverse drug reaction,,2023,Q1,1,I,20230120.0,20230317.0,20230318,20230318,EXP,GB-BoehringerIngelheim-2023-BI-225774,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-225774",BOEHRINGER INGELHEIM,,43.0,YR,A,M,Y,50.0,KG,20230318,,PH,GB,GB,2023,Q1,Adult
221121601,22112160,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,Oral,Dose: 5-2.5-1000,,,N,,Unknown,,212614.0,,,Tablet,QD,2023,Q1,Glycosylated haemoglobin increased,,2023,Q1,1,I,,20230317.0,20230318,20230318,PER,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-225928",BOEHRINGER INGELHEIM,,73.0,YR,E,F,Y,,,20230318,,CN,US,US,2023,Q1,Elderly
221124151,22112415,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"12.5 mg, QD",,,,,,,,12.5,MG,,QD,2023,Q1,Ankle brachial index decreased,,2023,Q1,1,I,,20230310.0,20230319,20230319,EXP,,HR-JNJFOC-20230343844,JOHNSON AND JOHNSON,,71.0,YR,E,,Y,97.0,KG,20230319,,MD,HR,HR,2023,Q1,Elderly
221124151,22112415,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"12.5 mg, QD",,,,,,,,12.5,MG,,QD,2023,Q1,Peripheral artery occlusion,,2023,Q1,1,I,,20230310.0,20230319,20230319,EXP,,HR-JNJFOC-20230343844,JOHNSON AND JOHNSON,,71.0,YR,E,,Y,97.0,KG,20230319,,MD,HR,HR,2023,Q1,Elderly
221126131,22112613,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2023,Q1,Lower respiratory tract infection,,2023,Q1,1,I,20230120.0,20230311.0,20230319,20230319,EXP,,NVSC2023CY027010,NOVARTIS,,61.0,YR,,F,Y,,,20230320,,MD,CY,CY,2023,Q1,Adult
221126131,22112613,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2023,Q1,Hyperglycaemia,,2023,Q1,1,I,20230120.0,20230311.0,20230319,20230319,EXP,,NVSC2023CY027010,NOVARTIS,,61.0,YR,,F,Y,,,20230320,,MD,CY,CY,2023,Q1,Adult
221126131,22112613,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2023,Q1,Glycosylated haemoglobin increased,,2023,Q1,1,I,20230120.0,20230311.0,20230319,20230319,EXP,,NVSC2023CY027010,NOVARTIS,,61.0,YR,,F,Y,,,20230320,,MD,CY,CY,2023,Q1,Adult
221165951,22116595,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 mg.,,,,,,,,,,,,2023,Q1,Hyperglycaemia,,2023,Q1,1,I,,20230313.0,20230320,20230320,EXP,,RU-AstraZeneca-2023A065324,ASTRAZENECA,"D.A. FILONENKO, A.V. BELOGUROVA, A.V. SULTANBAEV, K.V. MENSHIKOV, SH.I. MUSIN, I.A. FOKIN, L.G. ZHUKOV?. Alpelisib Efficacy in luminal HER2-negative breast cancer with brain metastases: clinical cases.. Voprosy Onkologii 2023;69(1):135-142.",56.0,YR,,F,Y,,,20230320,,HP,RU,,2023,Q1,Adult
221165951,22116595,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 mg.,,,,,,,,,,,,2023,Q1,Metastases to lung,,2023,Q1,1,I,,20230313.0,20230320,20230320,EXP,,RU-AstraZeneca-2023A065324,ASTRAZENECA,"D.A. FILONENKO, A.V. BELOGUROVA, A.V. SULTANBAEV, K.V. MENSHIKOV, SH.I. MUSIN, I.A. FOKIN, L.G. ZHUKOV?. Alpelisib Efficacy in luminal HER2-negative breast cancer with brain metastases: clinical cases.. Voprosy Onkologii 2023;69(1):135-142.",56.0,YR,,F,Y,,,20230320,,HP,RU,,2023,Q1,Adult
221165951,22116595,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 mg.,,,,,,,,,,,,2023,Q1,Malignant neoplasm progression,,2023,Q1,1,I,,20230313.0,20230320,20230320,EXP,,RU-AstraZeneca-2023A065324,ASTRAZENECA,"D.A. FILONENKO, A.V. BELOGUROVA, A.V. SULTANBAEV, K.V. MENSHIKOV, SH.I. MUSIN, I.A. FOKIN, L.G. ZHUKOV?. Alpelisib Efficacy in luminal HER2-negative breast cancer with brain metastases: clinical cases.. Voprosy Onkologii 2023;69(1):135-142.",56.0,YR,,F,Y,,,20230320,,HP,RU,,2023,Q1,Adult
221169541,22116954,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,U,,Unknown,,212614.0,,,,,2023,Q1,Leg amputation,,2023,Q1,1,I,20230309.0,20230320.0,20230320,20230320,PER,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-226117",BOEHRINGER INGELHEIM,,47.0,YR,A,M,Y,,,20230320,,CN,US,US,2023,Q1,Adult
221175071,22117507,10,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2023,Q1,Myopathy,,2023,Q1,1,I,20230306.0,20230313.0,20230321,20230321,EXP,CH-SM-2023-11736,CH-GILEAD-2023-0620901,GILEAD,,78.0,YR,E,M,Y,,,20230320,,PH,CH,CH,2023,Q1,Elderly
221180741,22118074,2,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"850 mg, bid",,,,,unk,,,850.0,MG,,BID,2023,Q1,Abdominal pain,,2023,Q1,1,I,20230201.0,20230307.0,20230321,20230321,EXP,,CO-NOVOPROD-1036187,NOVO NORDISK,,55.0,YR,,F,Y,70.0,KG,20230321,,CN,CO,CO,2023,Q1,Adult
221180741,22118074,2,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"850 mg, bid",,,,,unk,,,850.0,MG,,BID,2023,Q1,Cholecystitis,,2023,Q1,1,I,20230201.0,20230307.0,20230321,20230321,EXP,,CO-NOVOPROD-1036187,NOVO NORDISK,,55.0,YR,,F,Y,70.0,KG,20230321,,CN,CO,CO,2023,Q1,Adult
221180741,22118074,2,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"850 mg, bid",,,,,unk,,,850.0,MG,,BID,2023,Q1,Blood glucose increased,,2023,Q1,1,I,20230201.0,20230307.0,20230321,20230321,EXP,,CO-NOVOPROD-1036187,NOVO NORDISK,,55.0,YR,,F,Y,70.0,KG,20230321,,CN,CO,CO,2023,Q1,Adult
221187541,22118754,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,,,,5.0,MG,,,2023,Q1,Skin ulcer,,2023,Q1,1,I,,20230317.0,20230321,20230321,EXP,GB-MHRA-MIDB-581f40e1-d3b1-4a12-ab94-231ffb53a568,GB-EMD Serono-E2B_90091189,EMD SERONO INC,,67.0,YR,E,M,Y,,,20230321,,PH,GB,,2023,Q1,Elderly
221187541,22118754,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,,,,5.0,MG,,,2023,Q1,Toe amputation,,2023,Q1,1,I,,20230317.0,20230321,20230321,EXP,GB-MHRA-MIDB-581f40e1-d3b1-4a12-ab94-231ffb53a568,GB-EMD Serono-E2B_90091189,EMD SERONO INC,,67.0,YR,E,M,Y,,,20230321,,PH,GB,,2023,Q1,Elderly
221189541,22118954,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,Unknown,,206111.0,,,,,2023,Q1,Renal failure,,2023,Q1,1,I,20230101.0,20230320.0,20230321,20230321,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-226215",BOEHRINGER INGELHEIM,,9.0,DEC,E,F,Y,,,20230321,,MD,AU,AU,2023,Q1,Child
221189541,22118954,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,Unknown,,206111.0,,,,,2023,Q1,Urinary tract infection,,2023,Q1,1,I,20230101.0,20230320.0,20230321,20230321,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-226215",BOEHRINGER INGELHEIM,,9.0,DEC,E,F,Y,,,20230321,,MD,AU,AU,2023,Q1,Child
221215632,22121563,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Glycosylated haemoglobin increased,,2023,Q1,2,F,,20230329.0,20230321,20230331,EXP,,"NZ-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-224906",BOEHRINGER INGELHEIM,"Almog J, Jain S, Pybass P, Gupta A. Failure of SGLT-2 inhibitor in the context of new ileal conduit formation. New Zealand Medical Journal. 2023 Mar 10;136(1571): 83-85.",71.0,YR,E,M,Y,,,20230331,,MD,NZ,NZ,2023,Q1,Elderly
221215632,22121563,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Acetonaemia,,2023,Q1,2,F,,20230329.0,20230321,20230331,EXP,,"NZ-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-224906",BOEHRINGER INGELHEIM,"Almog J, Jain S, Pybass P, Gupta A. Failure of SGLT-2 inhibitor in the context of new ileal conduit formation. New Zealand Medical Journal. 2023 Mar 10;136(1571): 83-85.",71.0,YR,E,M,Y,,,20230331,,MD,NZ,NZ,2023,Q1,Elderly
221215632,22121563,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Hyperglycaemia,,2023,Q1,2,F,,20230329.0,20230321,20230331,EXP,,"NZ-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-224906",BOEHRINGER INGELHEIM,"Almog J, Jain S, Pybass P, Gupta A. Failure of SGLT-2 inhibitor in the context of new ileal conduit formation. New Zealand Medical Journal. 2023 Mar 10;136(1571): 83-85.",71.0,YR,E,M,Y,,,20230331,,MD,NZ,NZ,2023,Q1,Elderly
221215632,22121563,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2023,Q1,Glycosylated haemoglobin increased,,2023,Q1,2,F,,20230329.0,20230321,20230331,EXP,,"NZ-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-224906",BOEHRINGER INGELHEIM,"Almog J, Jain S, Pybass P, Gupta A. Failure of SGLT-2 inhibitor in the context of new ileal conduit formation. New Zealand Medical Journal. 2023 Mar 10;136(1571): 83-85.",71.0,YR,E,M,Y,,,20230331,,MD,NZ,NZ,2023,Q1,Elderly
221215632,22121563,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2023,Q1,Acetonaemia,,2023,Q1,2,F,,20230329.0,20230321,20230331,EXP,,"NZ-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-224906",BOEHRINGER INGELHEIM,"Almog J, Jain S, Pybass P, Gupta A. Failure of SGLT-2 inhibitor in the context of new ileal conduit formation. New Zealand Medical Journal. 2023 Mar 10;136(1571): 83-85.",71.0,YR,E,M,Y,,,20230331,,MD,NZ,NZ,2023,Q1,Elderly
221215632,22121563,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2023,Q1,Hyperglycaemia,,2023,Q1,2,F,,20230329.0,20230321,20230331,EXP,,"NZ-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-224906",BOEHRINGER INGELHEIM,"Almog J, Jain S, Pybass P, Gupta A. Failure of SGLT-2 inhibitor in the context of new ileal conduit formation. New Zealand Medical Journal. 2023 Mar 10;136(1571): 83-85.",71.0,YR,E,M,Y,,,20230331,,MD,NZ,NZ,2023,Q1,Elderly
221232772,22123277,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Fluid retention,,2023,Q1,2,F,20221004.0,20230321.0,20230322,20230328,EXP,,US-ROCHE-3214150,ROCHE,,54.0,YR,,M,Y,92.0,KG,20230328,,MD,US,,2023,Q1,Adult
221232772,22123277,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Cardiac failure congestive,,2023,Q1,2,F,20221004.0,20230321.0,20230322,20230328,EXP,,US-ROCHE-3214150,ROCHE,,54.0,YR,,M,Y,92.0,KG,20230328,,MD,US,,2023,Q1,Adult
221232772,22123277,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Oedema,,2023,Q1,2,F,20221004.0,20230321.0,20230322,20230328,EXP,,US-ROCHE-3214150,ROCHE,,54.0,YR,,M,Y,92.0,KG,20230328,,MD,US,,2023,Q1,Adult
221232772,22123277,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Ejection fraction decreased,,2023,Q1,2,F,20221004.0,20230321.0,20230322,20230328,EXP,,US-ROCHE-3214150,ROCHE,,54.0,YR,,M,Y,92.0,KG,20230328,,MD,US,,2023,Q1,Adult
221242131,22124213,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,U,,,,5.0,MG,Tablet,,2023,Q1,Toe amputation,,2023,Q1,1,I,,20230317.0,20230322,20230322,EXP,GB-MHRA-MIDB-581f40e1-d3b1-4a12-ab94-231ffb53a568,GB-MYLANLABS-2023M1029843,MYLAN,,67.0,YR,,M,Y,,,20230322,,PH,GB,GB,2023,Q1,Elderly
221242131,22124213,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,U,,,,5.0,MG,Tablet,,2023,Q1,Skin ulcer,,2023,Q1,1,I,,20230317.0,20230322,20230322,EXP,GB-MHRA-MIDB-581f40e1-d3b1-4a12-ab94-231ffb53a568,GB-MYLANLABS-2023M1029843,MYLAN,,67.0,YR,,M,Y,,,20230322,,PH,GB,GB,2023,Q1,Elderly
221276231,22127623,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,Y,U,Unknown,,206073.0,,,Tablet,QD,2023,Q1,Diabetic ketoacidosis,,2023,Q1,1,I,20221224.0,20230320.0,20230323,20230323,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-226798",BOEHRINGER INGELHEIM,,51.0,YR,A,M,Y,91.0,KG,20230323,,PH,JP,JP,2023,Q1,Adult
221276231,22127623,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,Y,U,Unknown,,206073.0,,,Tablet,QD,2023,Q1,Necrotising oesophagitis,,2023,Q1,1,I,20221224.0,20230320.0,20230323,20230323,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-226798",BOEHRINGER INGELHEIM,,51.0,YR,A,M,Y,91.0,KG,20230323,,PH,JP,JP,2023,Q1,Adult
221276231,22127623,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,Y,U,Unknown,,206073.0,,,Tablet,QD,2023,Q1,Vomiting,,2023,Q1,1,I,20221224.0,20230320.0,20230323,20230323,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-226798",BOEHRINGER INGELHEIM,,51.0,YR,A,M,Y,91.0,KG,20230323,,PH,JP,JP,2023,Q1,Adult
221276231,22127623,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,Y,U,Unknown,,206073.0,,,Tablet,QD,2023,Q1,Hypokalaemia,,2023,Q1,1,I,20221224.0,20230320.0,20230323,20230323,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-226798",BOEHRINGER INGELHEIM,,51.0,YR,A,M,Y,91.0,KG,20230323,,PH,JP,JP,2023,Q1,Adult
221276231,22127623,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,Y,U,Unknown,,206073.0,,,Tablet,QD,2023,Q1,Nausea,,2023,Q1,1,I,20221224.0,20230320.0,20230323,20230323,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-226798",BOEHRINGER INGELHEIM,,51.0,YR,A,M,Y,91.0,KG,20230323,,PH,JP,JP,2023,Q1,Adult
221317141,22131714,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Blood pressure fluctuation,,2023,Q1,1,I,,20230315.0,20230323,20230323,EXP,,NVSC2023CA062732,NOVARTIS,,66.0,YR,,F,Y,85.0,KG,20230323,,HP,CA,CA,2023,Q1,Elderly
221317141,22131714,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Blood pressure systolic increased,,2023,Q1,1,I,,20230315.0,20230323,20230323,EXP,,NVSC2023CA062732,NOVARTIS,,66.0,YR,,F,Y,85.0,KG,20230323,,HP,CA,CA,2023,Q1,Elderly
221317141,22131714,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Weight decreased,,2023,Q1,1,I,,20230315.0,20230323,20230323,EXP,,NVSC2023CA062732,NOVARTIS,,66.0,YR,,F,Y,85.0,KG,20230323,,HP,CA,CA,2023,Q1,Elderly
221317141,22131714,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Weight increased,,2023,Q1,1,I,,20230315.0,20230323,20230323,EXP,,NVSC2023CA062732,NOVARTIS,,66.0,YR,,F,Y,85.0,KG,20230323,,HP,CA,CA,2023,Q1,Elderly
221317141,22131714,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Aortic arteriosclerosis,,2023,Q1,1,I,,20230315.0,20230323,20230323,EXP,,NVSC2023CA062732,NOVARTIS,,66.0,YR,,F,Y,85.0,KG,20230323,,HP,CA,CA,2023,Q1,Elderly
221317141,22131714,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Type 2 diabetes mellitus,,2023,Q1,1,I,,20230315.0,20230323,20230323,EXP,,NVSC2023CA062732,NOVARTIS,,66.0,YR,,F,Y,85.0,KG,20230323,,HP,CA,CA,2023,Q1,Elderly
221317141,22131714,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Blood pressure diastolic decreased,,2023,Q1,1,I,,20230315.0,20230323,20230323,EXP,,NVSC2023CA062732,NOVARTIS,,66.0,YR,,F,Y,85.0,KG,20230323,,HP,CA,CA,2023,Q1,Elderly
221317141,22131714,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Blood glucose increased,,2023,Q1,1,I,,20230315.0,20230323,20230323,EXP,,NVSC2023CA062732,NOVARTIS,,66.0,YR,,F,Y,85.0,KG,20230323,,HP,CA,CA,2023,Q1,Elderly
221317141,22131714,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Blood pressure diastolic abnormal,,2023,Q1,1,I,,20230315.0,20230323,20230323,EXP,,NVSC2023CA062732,NOVARTIS,,66.0,YR,,F,Y,85.0,KG,20230323,,HP,CA,CA,2023,Q1,Elderly
221317141,22131714,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q1,Blood pressure increased,,2023,Q1,1,I,,20230315.0,20230323,20230323,EXP,,NVSC2023CA062732,NOVARTIS,,66.0,YR,,F,Y,85.0,KG,20230323,,HP,CA,CA,2023,Q1,Elderly
221342101,22134210,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 mg,,,U,,,,,5.0,MG,,,2023,Q1,Skin ulcer,,2023,Q1,1,I,,20230317.0,20230324,20230324,EXP,GB-MHRA-MIDB-581f40e1-d3b1-4a12-ab94-231ffb53a568,NVSC2023GB062937,NOVARTIS,,67.0,YR,,M,Y,,,20230324,,PH,GB,GB,2023,Q1,Elderly
221345042,22134504,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,5/1000mg strength.,,,Y,U,Unknown,,206111.0,,,,,2023,Q1,Hypovolaemia,,2023,Q1,2,F,20230101.0,20230324.0,20230324,20230327,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-226555",BOEHRINGER INGELHEIM,,67.0,YR,E,F,Y,,,20230327,,MD,AU,AU,2023,Q1,Elderly
221345042,22134504,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,5/1000mg strength.,,,Y,U,Unknown,,206111.0,,,,,2023,Q1,Illness,,2023,Q1,2,F,20230101.0,20230324.0,20230324,20230327,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-226555",BOEHRINGER INGELHEIM,,67.0,YR,E,F,Y,,,20230327,,MD,AU,AU,2023,Q1,Elderly
221345042,22134504,2,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,Y,U,Unknown,,206111.0,,,,,2023,Q1,Hypovolaemia,,2023,Q1,2,F,20230101.0,20230324.0,20230324,20230327,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-226555",BOEHRINGER INGELHEIM,,67.0,YR,E,F,Y,,,20230327,,MD,AU,AU,2023,Q1,Elderly
221345042,22134504,2,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,Y,U,Unknown,,206111.0,,,,,2023,Q1,Illness,,2023,Q1,2,F,20230101.0,20230324.0,20230324,20230327,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-226555",BOEHRINGER INGELHEIM,,67.0,YR,E,F,Y,,,20230327,,MD,AU,AU,2023,Q1,Elderly
221354211,22135421,10,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2023,Q1,Myopathy,,2023,Q1,1,I,20230306.0,20230317.0,20230324,20230324,EXP,,CH-AstraZeneca-2023A069963,ASTRAZENECA,,78.0,YR,,M,Y,,,20230324,,MD,CH,,2023,Q1,Elderly
221360031,22136003,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q1,Asthenia,,2023,Q1,1,I,,20230323.0,20230324,20230324,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-227217",BOEHRINGER INGELHEIM,,66.0,YR,E,,Y,,,20230324,,CN,GB,GB,2023,Q1,Elderly
221360031,22136003,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q1,Respiratory rate decreased,,2023,Q1,1,I,,20230323.0,20230324,20230324,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-227217",BOEHRINGER INGELHEIM,,66.0,YR,E,,Y,,,20230324,,CN,GB,GB,2023,Q1,Elderly
221360031,22136003,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q1,Feeling cold,,2023,Q1,1,I,,20230323.0,20230324,20230324,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-227217",BOEHRINGER INGELHEIM,,66.0,YR,E,,Y,,,20230324,,CN,GB,GB,2023,Q1,Elderly
221360031,22136003,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q1,Dry mouth,,2023,Q1,1,I,,20230323.0,20230324,20230324,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-227217",BOEHRINGER INGELHEIM,,66.0,YR,E,,Y,,,20230324,,CN,GB,GB,2023,Q1,Elderly
221360031,22136003,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q1,Pain,,2023,Q1,1,I,,20230323.0,20230324,20230324,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-227217",BOEHRINGER INGELHEIM,,66.0,YR,E,,Y,,,20230324,,CN,GB,GB,2023,Q1,Elderly
221360031,22136003,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q1,Visual impairment,,2023,Q1,1,I,,20230323.0,20230324,20230324,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-227217",BOEHRINGER INGELHEIM,,66.0,YR,E,,Y,,,20230324,,CN,GB,GB,2023,Q1,Elderly
221360031,22136003,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q1,Diabetic ketoacidosis,,2023,Q1,1,I,,20230323.0,20230324,20230324,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-227217",BOEHRINGER INGELHEIM,,66.0,YR,E,,Y,,,20230324,,CN,GB,GB,2023,Q1,Elderly
221360031,22136003,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q1,Pruritus,,2023,Q1,1,I,,20230323.0,20230324,20230324,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-227217",BOEHRINGER INGELHEIM,,66.0,YR,E,,Y,,,20230324,,CN,GB,GB,2023,Q1,Elderly
221360031,22136003,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q1,Dehydration,,2023,Q1,1,I,,20230323.0,20230324,20230324,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-227217",BOEHRINGER INGELHEIM,,66.0,YR,E,,Y,,,20230324,,CN,GB,GB,2023,Q1,Elderly
221369771,22136977,5,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2023,Q1,Coronary arterial stent insertion,,2023,Q1,1,I,,20230313.0,20230324,20230324,EXP,,HR-JNJFOC-20230350442,JOHNSON AND JOHNSON,,76.0,YR,E,F,Y,84.0,KG,20230321,,HP,HR,HR,2023,Q1,Elderly
221375791,22137579,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,Tablet,QD,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,1,I,20230221.0,20230324.0,20230325,20230325,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-227283",BOEHRINGER INGELHEIM,,59.0,YR,A,F,Y,,,20230324,,PH,GB,GB,2023,Q1,Adult
221375791,22137579,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,Tablet,QD,2023,Q1,Vulvovaginal ulceration,,2023,Q1,1,I,20230221.0,20230324.0,20230325,20230325,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-227283",BOEHRINGER INGELHEIM,,59.0,YR,A,F,Y,,,20230324,,PH,GB,GB,2023,Q1,Adult
221393931,22139393,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q1,Stillbirth,,2023,Q1,1,I,,20230320.0,20230327,20230327,EXP,,"NZ-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-225975",BOEHRINGER INGELHEIM,,42.0,YR,A,F,Y,,,20230327,,CN,NZ,NZ,2023,Q1,Adult
221393931,22139393,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q1,Caesarean section,,2023,Q1,1,I,,20230320.0,20230327,20230327,EXP,,"NZ-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-225975",BOEHRINGER INGELHEIM,,42.0,YR,A,F,Y,,,20230327,,CN,NZ,NZ,2023,Q1,Adult
221393931,22139393,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q1,Diabetes mellitus inadequate control,,2023,Q1,1,I,,20230320.0,20230327,20230327,EXP,,"NZ-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-225975",BOEHRINGER INGELHEIM,,42.0,YR,A,F,Y,,,20230327,,CN,NZ,NZ,2023,Q1,Adult
221393931,22139393,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q1,Maternal exposure during pregnancy,,2023,Q1,1,I,,20230320.0,20230327,20230327,EXP,,"NZ-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-225975",BOEHRINGER INGELHEIM,,42.0,YR,A,F,Y,,,20230327,,CN,NZ,NZ,2023,Q1,Adult
221400341,22140034,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,,,,5.0,MG,Tablet,,2023,Q1,Toe amputation,,2023,Q1,1,I,,20230317.0,20230327,20230327,EXP,GB-MHRA-MIDB-581f40e1-d3b1-4a12-ab94-231ffb53a568,GB-MICRO LABS LIMITED-ML2023-01668,MICRO LABS,,67.0,YR,E,M,Y,,,20230327,,PH,GB,,2023,Q1,Elderly
221400341,22140034,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,,,,5.0,MG,Tablet,,2023,Q1,Skin ulcer,,2023,Q1,1,I,,20230317.0,20230327,20230327,EXP,GB-MHRA-MIDB-581f40e1-d3b1-4a12-ab94-231ffb53a568,GB-MICRO LABS LIMITED-ML2023-01668,MICRO LABS,,67.0,YR,E,M,Y,,,20230327,,PH,GB,,2023,Q1,Elderly
221408651,22140865,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Pancreatic carcinoma,,2023,Q1,1,I,20230225.0,,20230324,20230324,DIR,653767,,FDA-CTU,,74.0,YR,,F,N,53.55,KG,20230324,N,PH,US,,2023,Q1,Elderly
221426191,22142619,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Pulmonary hypertension,,2023,Q1,1,I,20230324.0,,20230324,20230324,DIR,FDA-CDER-CTU-2023-23112,,FDA-CTU,,79.0,YR,,M,N,,,20230324,Y,PH,US,,2023,Q1,Elderly
221426191,22142619,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Interstitial lung disease,,2023,Q1,1,I,20230324.0,,20230324,20230324,DIR,FDA-CDER-CTU-2023-23112,,FDA-CTU,,79.0,YR,,M,N,,,20230324,Y,PH,US,,2023,Q1,Elderly
221426191,22142619,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Ventilation/perfusion scan abnormal,,2023,Q1,1,I,20230324.0,,20230324,20230324,DIR,FDA-CDER-CTU-2023-23112,,FDA-CTU,,79.0,YR,,M,N,,,20230324,Y,PH,US,,2023,Q1,Elderly
221426191,22142619,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Dyspnoea,,2023,Q1,1,I,20230324.0,,20230324,20230324,DIR,FDA-CDER-CTU-2023-23112,,FDA-CTU,,79.0,YR,,M,N,,,20230324,Y,PH,US,,2023,Q1,Elderly
221426191,22142619,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Chronic obstructive pulmonary disease,,2023,Q1,1,I,20230324.0,,20230324,20230324,DIR,FDA-CDER-CTU-2023-23112,,FDA-CTU,,79.0,YR,,M,N,,,20230324,Y,PH,US,,2023,Q1,Elderly
221437661,22143766,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q1,Essential hypertension,,2023,Q1,1,I,,20230323.0,20230327,20230327,EXP,GB-MHRA-TPP46521458C8320862YC1678894534336,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-227215",BOEHRINGER INGELHEIM,,53.0,YR,A,F,Y,115.0,KG,20230327,,MD,GB,GB,2023,Q1,Adult
221437661,22143766,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q1,Throat tightness,,2023,Q1,1,I,,20230323.0,20230327,20230327,EXP,GB-MHRA-TPP46521458C8320862YC1678894534336,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-227215",BOEHRINGER INGELHEIM,,53.0,YR,A,F,Y,115.0,KG,20230327,,MD,GB,GB,2023,Q1,Adult
221437661,22143766,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q1,Chest discomfort,,2023,Q1,1,I,,20230323.0,20230327,20230327,EXP,GB-MHRA-TPP46521458C8320862YC1678894534336,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-227215",BOEHRINGER INGELHEIM,,53.0,YR,A,F,Y,115.0,KG,20230327,,MD,GB,GB,2023,Q1,Adult
221437661,22143766,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q1,Dyspnoea,,2023,Q1,1,I,,20230323.0,20230327,20230327,EXP,GB-MHRA-TPP46521458C8320862YC1678894534336,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-227215",BOEHRINGER INGELHEIM,,53.0,YR,A,F,Y,115.0,KG,20230327,,MD,GB,GB,2023,Q1,Adult
221441381,22144138,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q1,Death,,2023,Q1,1,I,20230306.0,20230324.0,20230327,20230327,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-2023-043694,BRISTOL MYERS SQUIBB,,53.0,YR,A,M,Y,,,20230328,,CN,US,US,2023,Q1,Adult
221453141,22145314,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,Oral,10/5/1000 mg,,,N,,Unknown,,212614.0,,,Tablet,QD,2023,Q1,Diabetes mellitus inadequate control,,2023,Q1,1,I,,20230323.0,20230328,20230328,PER,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-227143",BOEHRINGER INGELHEIM,,51.0,YR,A,F,Y,,,20230328,,MD,US,US,2023,Q1,Adult
221453771,22145377,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,,,,5.0,MG,Tablet,,2023,Q1,Toe amputation,,2023,Q1,1,I,,20230317.0,20230328,20230328,EXP,GB-MHRA-MIDB-581f40e1-d3b1-4a12-ab94-231ffb53a568,GB-TEVA-2023-GB-2870218,TEVA,,67.0,YR,E,M,Y,,,20230327,,PH,GB,GB,2023,Q1,Elderly
221453771,22145377,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,,,,5.0,MG,Tablet,,2023,Q1,Skin ulcer,,2023,Q1,1,I,,20230317.0,20230328,20230328,EXP,GB-MHRA-MIDB-581f40e1-d3b1-4a12-ab94-231ffb53a568,GB-TEVA-2023-GB-2870218,TEVA,,67.0,YR,E,M,Y,,,20230327,,PH,GB,GB,2023,Q1,Elderly
221457771,22145777,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,U,,,,5.0,MG,Tablet,,2023,Q1,Toe amputation,,2023,Q1,1,I,,20230317.0,20230328,20230328,EXP,,GB-AUROBINDO-AUR-APL-2023-012959,AUROBINDO,,67.0,YR,,M,Y,,,20230328,,PH,GB,GB,2023,Q1,Elderly
221457771,22145777,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,U,,,,5.0,MG,Tablet,,2023,Q1,Skin ulcer,,2023,Q1,1,I,,20230317.0,20230328,20230328,EXP,,GB-AUROBINDO-AUR-APL-2023-012959,AUROBINDO,,67.0,YR,,M,Y,,,20230328,,PH,GB,GB,2023,Q1,Elderly
221481411,22148141,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Wrong technique in product usage process,,2023,Q1,1,I,,20230314.0,20230328,20230328,EXP,,NVSC2023TH061315,NOVARTIS,,75.0,YR,,M,Y,,,20230328,,MD,TH,TH,2023,Q1,Elderly
221481411,22148141,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Blood creatinine increased,,2023,Q1,1,I,,20230314.0,20230328,20230328,EXP,,NVSC2023TH061315,NOVARTIS,,75.0,YR,,M,Y,,,20230328,,MD,TH,TH,2023,Q1,Elderly
221481411,22148141,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Oedema,,2023,Q1,1,I,,20230314.0,20230328,20230328,EXP,,NVSC2023TH061315,NOVARTIS,,75.0,YR,,M,Y,,,20230328,,MD,TH,TH,2023,Q1,Elderly
221481411,22148141,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Underdose,,2023,Q1,1,I,,20230314.0,20230328,20230328,EXP,,NVSC2023TH061315,NOVARTIS,,75.0,YR,,M,Y,,,20230328,,MD,TH,TH,2023,Q1,Elderly
221481411,22148141,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Cardiac failure chronic,,2023,Q1,1,I,,20230314.0,20230328,20230328,EXP,,NVSC2023TH061315,NOVARTIS,,75.0,YR,,M,Y,,,20230328,,MD,TH,TH,2023,Q1,Elderly
221484421,22148442,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Angioedema,,2023,Q1,1,I,,20230318.0,20230328,20230328,PER,,US-BAYER-2023A037614,BAYER,,79.0,YR,E,M,Y,,,20230328,,HP,US,US,2023,Q1,Elderly
221484421,22148442,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q1,Anaphylactic reaction,,2023,Q1,1,I,,20230318.0,20230328,20230328,PER,,US-BAYER-2023A037614,BAYER,,79.0,YR,E,M,Y,,,20230328,,HP,US,US,2023,Q1,Elderly
221527271,22152727,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2023,Q1,Wrong technique in product usage process,,2023,Q1,1,I,,20230321.0,20230329,20230329,EXP,,NVSC2023TH067344,NOVARTIS,,47.0,YR,,F,Y,,,20230329,,MD,TH,TH,2023,Q1,Adult
221527271,22152727,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2023,Q1,Blood potassium decreased,,2023,Q1,1,I,,20230321.0,20230329,20230329,EXP,,NVSC2023TH067344,NOVARTIS,,47.0,YR,,F,Y,,,20230329,,MD,TH,TH,2023,Q1,Adult
221527271,22152727,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2023,Q1,Wrong technique in product usage process,,2023,Q1,1,I,,20230321.0,20230329,20230329,EXP,,NVSC2023TH067344,NOVARTIS,,47.0,YR,,F,Y,,,20230329,,MD,TH,TH,2023,Q1,Adult
221527271,22152727,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2023,Q1,Blood potassium decreased,,2023,Q1,1,I,,20230321.0,20230329,20230329,EXP,,NVSC2023TH067344,NOVARTIS,,47.0,YR,,F,Y,,,20230329,,MD,TH,TH,2023,Q1,Adult
221527271,22152727,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2023,Q1,Wrong technique in product usage process,,2023,Q1,1,I,,20230321.0,20230329,20230329,EXP,,NVSC2023TH067344,NOVARTIS,,47.0,YR,,F,Y,,,20230329,,MD,TH,TH,2023,Q1,Adult
221527271,22152727,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2023,Q1,Blood potassium decreased,,2023,Q1,1,I,,20230321.0,20230329,20230329,EXP,,NVSC2023TH067344,NOVARTIS,,47.0,YR,,F,Y,,,20230329,,MD,TH,TH,2023,Q1,Adult
221527271,22152727,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2023,Q1,Wrong technique in product usage process,,2023,Q1,1,I,,20230321.0,20230329,20230329,EXP,,NVSC2023TH067344,NOVARTIS,,47.0,YR,,F,Y,,,20230329,,MD,TH,TH,2023,Q1,Adult
221527271,22152727,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2023,Q1,Blood potassium decreased,,2023,Q1,1,I,,20230321.0,20230329,20230329,EXP,,NVSC2023TH067344,NOVARTIS,,47.0,YR,,F,Y,,,20230329,,MD,TH,TH,2023,Q1,Adult
221527271,22152727,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2023,Q1,Wrong technique in product usage process,,2023,Q1,1,I,,20230321.0,20230329,20230329,EXP,,NVSC2023TH067344,NOVARTIS,,47.0,YR,,F,Y,,,20230329,,MD,TH,TH,2023,Q1,Adult
221527271,22152727,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2023,Q1,Blood potassium decreased,,2023,Q1,1,I,,20230321.0,20230329,20230329,EXP,,NVSC2023TH067344,NOVARTIS,,47.0,YR,,F,Y,,,20230329,,MD,TH,TH,2023,Q1,Adult
221527271,22152727,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2023,Q1,Wrong technique in product usage process,,2023,Q1,1,I,,20230321.0,20230329,20230329,EXP,,NVSC2023TH067344,NOVARTIS,,47.0,YR,,F,Y,,,20230329,,MD,TH,TH,2023,Q1,Adult
221527271,22152727,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2023,Q1,Blood potassium decreased,,2023,Q1,1,I,,20230321.0,20230329,20230329,EXP,,NVSC2023TH067344,NOVARTIS,,47.0,YR,,F,Y,,,20230329,,MD,TH,TH,2023,Q1,Adult
221527271,22152727,27,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2023,Q1,Wrong technique in product usage process,,2023,Q1,1,I,,20230321.0,20230329,20230329,EXP,,NVSC2023TH067344,NOVARTIS,,47.0,YR,,F,Y,,,20230329,,MD,TH,TH,2023,Q1,Adult
221527271,22152727,27,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2023,Q1,Blood potassium decreased,,2023,Q1,1,I,,20230321.0,20230329,20230329,EXP,,NVSC2023TH067344,NOVARTIS,,47.0,YR,,F,Y,,,20230329,,MD,TH,TH,2023,Q1,Adult
221527271,22152727,28,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2023,Q1,Wrong technique in product usage process,,2023,Q1,1,I,,20230321.0,20230329,20230329,EXP,,NVSC2023TH067344,NOVARTIS,,47.0,YR,,F,Y,,,20230329,,MD,TH,TH,2023,Q1,Adult
221527271,22152727,28,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2023,Q1,Blood potassium decreased,,2023,Q1,1,I,,20230321.0,20230329,20230329,EXP,,NVSC2023TH067344,NOVARTIS,,47.0,YR,,F,Y,,,20230329,,MD,TH,TH,2023,Q1,Adult
221530191,22153019,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 dosage form (10 mg/dL),,,,,,,,,,,,2023,Q1,Diabetes mellitus inadequate control,,2023,Q1,1,I,,20230323.0,20230329,20230329,EXP,PL-EMA-DD-20190819-sahu_k-132941,PL-MYLANLABS-2019M1065931,MYLAN,"Komorowska A, Lelonek M.. Cessation of empagliflozin treatment in a hospitalised patient with exacerbated heart failure and reduced ejection fraction.. Folia Cardiologica. 2019;14(2):206-212",56.0,YR,,M,Y,120.0,KG,20230329,,HP,PL,PL,2023,Q1,Adult
221530191,22153019,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 dosage form (10 mg/dL),,,,,,,,,,,,2023,Q1,Concomitant disease aggravated,,2023,Q1,1,I,,20230323.0,20230329,20230329,EXP,PL-EMA-DD-20190819-sahu_k-132941,PL-MYLANLABS-2019M1065931,MYLAN,"Komorowska A, Lelonek M.. Cessation of empagliflozin treatment in a hospitalised patient with exacerbated heart failure and reduced ejection fraction.. Folia Cardiologica. 2019;14(2):206-212",56.0,YR,,M,Y,120.0,KG,20230329,,HP,PL,PL,2023,Q1,Adult
221530191,22153019,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 dosage form (10 mg/dL),,,,,,,,,,,,2023,Q1,Cardiac failure acute,,2023,Q1,1,I,,20230323.0,20230329,20230329,EXP,PL-EMA-DD-20190819-sahu_k-132941,PL-MYLANLABS-2019M1065931,MYLAN,"Komorowska A, Lelonek M.. Cessation of empagliflozin treatment in a hospitalised patient with exacerbated heart failure and reduced ejection fraction.. Folia Cardiologica. 2019;14(2):206-212",56.0,YR,,M,Y,120.0,KG,20230329,,HP,PL,PL,2023,Q1,Adult
221530191,22153019,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 dosage form (10 mg/dL),,,,,,,,,,,,2023,Q1,Cardiac failure,,2023,Q1,1,I,,20230323.0,20230329,20230329,EXP,PL-EMA-DD-20190819-sahu_k-132941,PL-MYLANLABS-2019M1065931,MYLAN,"Komorowska A, Lelonek M.. Cessation of empagliflozin treatment in a hospitalised patient with exacerbated heart failure and reduced ejection fraction.. Folia Cardiologica. 2019;14(2):206-212",56.0,YR,,M,Y,120.0,KG,20230329,,HP,PL,PL,2023,Q1,Adult
221530191,22153019,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 dosage form (10 mg/dL),,,,,,,,,,,,2023,Q1,Condition aggravated,,2023,Q1,1,I,,20230323.0,20230329,20230329,EXP,PL-EMA-DD-20190819-sahu_k-132941,PL-MYLANLABS-2019M1065931,MYLAN,"Komorowska A, Lelonek M.. Cessation of empagliflozin treatment in a hospitalised patient with exacerbated heart failure and reduced ejection fraction.. Folia Cardiologica. 2019;14(2):206-212",56.0,YR,,M,Y,120.0,KG,20230329,,HP,PL,PL,2023,Q1,Adult
221530191,22153019,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 dosage form (10 mg/dL),,,,,,,,,,,,2023,Q1,Respiratory tract infection,,2023,Q1,1,I,,20230323.0,20230329,20230329,EXP,PL-EMA-DD-20190819-sahu_k-132941,PL-MYLANLABS-2019M1065931,MYLAN,"Komorowska A, Lelonek M.. Cessation of empagliflozin treatment in a hospitalised patient with exacerbated heart failure and reduced ejection fraction.. Folia Cardiologica. 2019;14(2):206-212",56.0,YR,,M,Y,120.0,KG,20230329,,HP,PL,PL,2023,Q1,Adult
221530191,22153019,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 dosage form (10 mg/dL),,,,,,,,,,,,2023,Q1,Cardiac failure chronic,,2023,Q1,1,I,,20230323.0,20230329,20230329,EXP,PL-EMA-DD-20190819-sahu_k-132941,PL-MYLANLABS-2019M1065931,MYLAN,"Komorowska A, Lelonek M.. Cessation of empagliflozin treatment in a hospitalised patient with exacerbated heart failure and reduced ejection fraction.. Folia Cardiologica. 2019;14(2):206-212",56.0,YR,,M,Y,120.0,KG,20230329,,HP,PL,PL,2023,Q1,Adult
221530191,22153019,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 dosage form (10 mg/dL),,,,,,,,,,,,2023,Q1,Drug ineffective,,2023,Q1,1,I,,20230323.0,20230329,20230329,EXP,PL-EMA-DD-20190819-sahu_k-132941,PL-MYLANLABS-2019M1065931,MYLAN,"Komorowska A, Lelonek M.. Cessation of empagliflozin treatment in a hospitalised patient with exacerbated heart failure and reduced ejection fraction.. Folia Cardiologica. 2019;14(2):206-212",56.0,YR,,M,Y,120.0,KG,20230329,,HP,PL,PL,2023,Q1,Adult
221530191,22153019,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,,,,,,10.0,MG,,,2023,Q1,Diabetes mellitus inadequate control,,2023,Q1,1,I,,20230323.0,20230329,20230329,EXP,PL-EMA-DD-20190819-sahu_k-132941,PL-MYLANLABS-2019M1065931,MYLAN,"Komorowska A, Lelonek M.. Cessation of empagliflozin treatment in a hospitalised patient with exacerbated heart failure and reduced ejection fraction.. Folia Cardiologica. 2019;14(2):206-212",56.0,YR,,M,Y,120.0,KG,20230329,,HP,PL,PL,2023,Q1,Adult
221530191,22153019,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,,,,,,10.0,MG,,,2023,Q1,Concomitant disease aggravated,,2023,Q1,1,I,,20230323.0,20230329,20230329,EXP,PL-EMA-DD-20190819-sahu_k-132941,PL-MYLANLABS-2019M1065931,MYLAN,"Komorowska A, Lelonek M.. Cessation of empagliflozin treatment in a hospitalised patient with exacerbated heart failure and reduced ejection fraction.. Folia Cardiologica. 2019;14(2):206-212",56.0,YR,,M,Y,120.0,KG,20230329,,HP,PL,PL,2023,Q1,Adult
221530191,22153019,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,,,,,,10.0,MG,,,2023,Q1,Cardiac failure acute,,2023,Q1,1,I,,20230323.0,20230329,20230329,EXP,PL-EMA-DD-20190819-sahu_k-132941,PL-MYLANLABS-2019M1065931,MYLAN,"Komorowska A, Lelonek M.. Cessation of empagliflozin treatment in a hospitalised patient with exacerbated heart failure and reduced ejection fraction.. Folia Cardiologica. 2019;14(2):206-212",56.0,YR,,M,Y,120.0,KG,20230329,,HP,PL,PL,2023,Q1,Adult
221530191,22153019,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,,,,,,10.0,MG,,,2023,Q1,Cardiac failure,,2023,Q1,1,I,,20230323.0,20230329,20230329,EXP,PL-EMA-DD-20190819-sahu_k-132941,PL-MYLANLABS-2019M1065931,MYLAN,"Komorowska A, Lelonek M.. Cessation of empagliflozin treatment in a hospitalised patient with exacerbated heart failure and reduced ejection fraction.. Folia Cardiologica. 2019;14(2):206-212",56.0,YR,,M,Y,120.0,KG,20230329,,HP,PL,PL,2023,Q1,Adult
221530191,22153019,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,,,,,,10.0,MG,,,2023,Q1,Condition aggravated,,2023,Q1,1,I,,20230323.0,20230329,20230329,EXP,PL-EMA-DD-20190819-sahu_k-132941,PL-MYLANLABS-2019M1065931,MYLAN,"Komorowska A, Lelonek M.. Cessation of empagliflozin treatment in a hospitalised patient with exacerbated heart failure and reduced ejection fraction.. Folia Cardiologica. 2019;14(2):206-212",56.0,YR,,M,Y,120.0,KG,20230329,,HP,PL,PL,2023,Q1,Adult
221530191,22153019,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,,,,,,10.0,MG,,,2023,Q1,Respiratory tract infection,,2023,Q1,1,I,,20230323.0,20230329,20230329,EXP,PL-EMA-DD-20190819-sahu_k-132941,PL-MYLANLABS-2019M1065931,MYLAN,"Komorowska A, Lelonek M.. Cessation of empagliflozin treatment in a hospitalised patient with exacerbated heart failure and reduced ejection fraction.. Folia Cardiologica. 2019;14(2):206-212",56.0,YR,,M,Y,120.0,KG,20230329,,HP,PL,PL,2023,Q1,Adult
221530191,22153019,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,,,,,,10.0,MG,,,2023,Q1,Cardiac failure chronic,,2023,Q1,1,I,,20230323.0,20230329,20230329,EXP,PL-EMA-DD-20190819-sahu_k-132941,PL-MYLANLABS-2019M1065931,MYLAN,"Komorowska A, Lelonek M.. Cessation of empagliflozin treatment in a hospitalised patient with exacerbated heart failure and reduced ejection fraction.. Folia Cardiologica. 2019;14(2):206-212",56.0,YR,,M,Y,120.0,KG,20230329,,HP,PL,PL,2023,Q1,Adult
221530191,22153019,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,,,,,,10.0,MG,,,2023,Q1,Drug ineffective,,2023,Q1,1,I,,20230323.0,20230329,20230329,EXP,PL-EMA-DD-20190819-sahu_k-132941,PL-MYLANLABS-2019M1065931,MYLAN,"Komorowska A, Lelonek M.. Cessation of empagliflozin treatment in a hospitalised patient with exacerbated heart failure and reduced ejection fraction.. Folia Cardiologica. 2019;14(2):206-212",56.0,YR,,M,Y,120.0,KG,20230329,,HP,PL,PL,2023,Q1,Adult
221535821,22153582,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,,,,,,,QD,2023,Q1,Drug hypersensitivity,,2023,Q1,1,I,,20230320.0,20230330,20230330,EXP,GB-MHRA-TPP19409432C6962366YC1657017817474,GB-JNJFOC-20230372820,JOHNSON AND JOHNSON,,40.0,YR,A,F,Y,100.0,KG,20230330,,MD,GB,GB,2023,Q1,Adult
221535821,22153582,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,,,,,,,QD,2023,Q1,Restless legs syndrome,,2023,Q1,1,I,,20230320.0,20230330,20230330,EXP,GB-MHRA-TPP19409432C6962366YC1657017817474,GB-JNJFOC-20230372820,JOHNSON AND JOHNSON,,40.0,YR,A,F,Y,100.0,KG,20230330,,MD,GB,GB,2023,Q1,Adult
221573841,22157384,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,,,,,,10.0,MG,,,2023,Q1,Melaena,,2023,Q1,1,I,,20230327.0,20230330,20230330,EXP,,HR-MYLANLABS-2023M1033452,MYLAN,"Livija S, Ana M S, Majda V K, Lana G, Hrvoje H, Jozefina P, et al. Risk Factors for Rivaroxaban-Related Bleeding Events-Possible Role of Pharmacogenetics: Case Series. Pharmacy. 2023;11:1",75.0,YR,,F,Y,,,20230330,,HP,HR,HR,2023,Q1,Elderly
221573841,22157384,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,,,,,,10.0,MG,,,2023,Q1,Drug interaction,,2023,Q1,1,I,,20230327.0,20230330,20230330,EXP,,HR-MYLANLABS-2023M1033452,MYLAN,"Livija S, Ana M S, Majda V K, Lana G, Hrvoje H, Jozefina P, et al. Risk Factors for Rivaroxaban-Related Bleeding Events-Possible Role of Pharmacogenetics: Case Series. Pharmacy. 2023;11:1",75.0,YR,,F,Y,,,20230330,,HP,HR,HR,2023,Q1,Elderly
221584781,22158478,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Gastroenteritis,,2023,Q1,1,I,,20230324.0,20230331,20230331,EXP,,"AE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-227246",BOEHRINGER INGELHEIM,"Alhelfi M. Another Cause of DKA in T2DM in COVID-19 Pandemic. Dubai Diabetes and Endocrinology Journal. 2021;27,: 76-",47.0,YR,A,F,Y,,,20230331,,HP,AE,AE,2023,Q1,Adult
221584781,22158478,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,Diabetic ketoacidosis,,2023,Q1,1,I,,20230324.0,20230331,20230331,EXP,,"AE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-227246",BOEHRINGER INGELHEIM,"Alhelfi M. Another Cause of DKA in T2DM in COVID-19 Pandemic. Dubai Diabetes and Endocrinology Journal. 2021;27,: 76-",47.0,YR,A,F,Y,,,20230331,,HP,AE,AE,2023,Q1,Adult
221584781,22158478,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q1,COVID-19,,2023,Q1,1,I,,20230324.0,20230331,20230331,EXP,,"AE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-227246",BOEHRINGER INGELHEIM,"Alhelfi M. Another Cause of DKA in T2DM in COVID-19 Pandemic. Dubai Diabetes and Endocrinology Journal. 2021;27,: 76-",47.0,YR,A,F,Y,,,20230331,,HP,AE,AE,2023,Q1,Adult
221587111,22158711,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once Daily (qd)",,,U,,,,,10.0,MG,,QD,2023,Q1,Vascular device infection,,2023,Q1,1,I,20220203.0,20230319.0,20230331,20230331,EXP,,GB-AUROBINDO-AUR-APL-2023-013813,AUROBINDO,,62.0,YR,,M,Y,113.0,KG,20230331,,MD,GB,GB,2023,Q1,Adult
221621021,22162102,16,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg/dL,,,,,,,,,,,,2023,Q1,Diabetes mellitus inadequate control,,2023,Q1,1,I,,20230323.0,20230331,20230331,EXP,,PL-EMD Serono-E2B_90091255,EMD SERONO INC,"Komorowska A, Lelonek M. Cessation of empagliflozin treatment in a hospitalised patient with exacerbated heart failure and reduced ejection fraction. Folia Cardiologica. 2019;14(2):199-212",56.0,YR,A,M,Y,120.0,KG,20230331,,MD,PL,PL,2023,Q1,Adult
221621021,22162102,16,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg/dL,,,,,,,,,,,,2023,Q1,Cardiac failure,,2023,Q1,1,I,,20230323.0,20230331,20230331,EXP,,PL-EMD Serono-E2B_90091255,EMD SERONO INC,"Komorowska A, Lelonek M. Cessation of empagliflozin treatment in a hospitalised patient with exacerbated heart failure and reduced ejection fraction. Folia Cardiologica. 2019;14(2):199-212",56.0,YR,A,M,Y,120.0,KG,20230331,,MD,PL,PL,2023,Q1,Adult
221621021,22162102,16,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg/dL,,,,,,,,,,,,2023,Q1,Drug ineffective,,2023,Q1,1,I,,20230323.0,20230331,20230331,EXP,,PL-EMD Serono-E2B_90091255,EMD SERONO INC,"Komorowska A, Lelonek M. Cessation of empagliflozin treatment in a hospitalised patient with exacerbated heart failure and reduced ejection fraction. Folia Cardiologica. 2019;14(2):199-212",56.0,YR,A,M,Y,120.0,KG,20230331,,MD,PL,PL,2023,Q1,Adult
221621021,22162102,16,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg/dL,,,,,,,,,,,,2023,Q1,Cardiac failure chronic,,2023,Q1,1,I,,20230323.0,20230331,20230331,EXP,,PL-EMD Serono-E2B_90091255,EMD SERONO INC,"Komorowska A, Lelonek M. Cessation of empagliflozin treatment in a hospitalised patient with exacerbated heart failure and reduced ejection fraction. Folia Cardiologica. 2019;14(2):199-212",56.0,YR,A,M,Y,120.0,KG,20230331,,MD,PL,PL,2023,Q1,Adult
221621021,22162102,16,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg/dL,,,,,,,,,,,,2023,Q1,Concomitant disease aggravated,,2023,Q1,1,I,,20230323.0,20230331,20230331,EXP,,PL-EMD Serono-E2B_90091255,EMD SERONO INC,"Komorowska A, Lelonek M. Cessation of empagliflozin treatment in a hospitalised patient with exacerbated heart failure and reduced ejection fraction. Folia Cardiologica. 2019;14(2):199-212",56.0,YR,A,M,Y,120.0,KG,20230331,,MD,PL,PL,2023,Q1,Adult
221621021,22162102,16,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg/dL,,,,,,,,,,,,2023,Q1,Condition aggravated,,2023,Q1,1,I,,20230323.0,20230331,20230331,EXP,,PL-EMD Serono-E2B_90091255,EMD SERONO INC,"Komorowska A, Lelonek M. Cessation of empagliflozin treatment in a hospitalised patient with exacerbated heart failure and reduced ejection fraction. Folia Cardiologica. 2019;14(2):199-212",56.0,YR,A,M,Y,120.0,KG,20230331,,MD,PL,PL,2023,Q1,Adult
221621021,22162102,16,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg/dL,,,,,,,,,,,,2023,Q1,Respiratory tract infection,,2023,Q1,1,I,,20230323.0,20230331,20230331,EXP,,PL-EMD Serono-E2B_90091255,EMD SERONO INC,"Komorowska A, Lelonek M. Cessation of empagliflozin treatment in a hospitalised patient with exacerbated heart failure and reduced ejection fraction. Folia Cardiologica. 2019;14(2):199-212",56.0,YR,A,M,Y,120.0,KG,20230331,,MD,PL,PL,2023,Q1,Adult
902813623,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Fall,,2023,Q1,23,F,20121025.0,20230123.0,20130123,20230131,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20230131,,MD,CA,CA,2023,Q1,Elderly
902813623,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Dizziness,,2023,Q1,23,F,20121025.0,20230123.0,20130123,20230131,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20230131,,MD,CA,CA,2023,Q1,Elderly
902813623,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Rales,,2023,Q1,23,F,20121025.0,20230123.0,20130123,20230131,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20230131,,MD,CA,CA,2023,Q1,Elderly
902813623,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Palpitations,,2023,Q1,23,F,20121025.0,20230123.0,20130123,20230131,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20230131,,MD,CA,CA,2023,Q1,Elderly
902813623,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Blood pressure diastolic increased,,2023,Q1,23,F,20121025.0,20230123.0,20130123,20230131,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20230131,,MD,CA,CA,2023,Q1,Elderly
902813623,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Blood pressure increased,,2023,Q1,23,F,20121025.0,20230123.0,20130123,20230131,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20230131,,MD,CA,CA,2023,Q1,Elderly
902813623,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Dyspnoea,,2023,Q1,23,F,20121025.0,20230123.0,20130123,20230131,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20230131,,MD,CA,CA,2023,Q1,Elderly
902813623,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Inappropriate schedule of product administration,,2023,Q1,23,F,20121025.0,20230123.0,20130123,20230131,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20230131,,MD,CA,CA,2023,Q1,Elderly
902813623,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Oedema peripheral,,2023,Q1,23,F,20121025.0,20230123.0,20130123,20230131,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20230131,,MD,CA,CA,2023,Q1,Elderly
902813623,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Joint injury,,2023,Q1,23,F,20121025.0,20230123.0,20130123,20230131,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20230131,,MD,CA,CA,2023,Q1,Elderly
902813623,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Heart rate increased,,2023,Q1,23,F,20121025.0,20230123.0,20130123,20230131,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20230131,,MD,CA,CA,2023,Q1,Elderly
902813623,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Small intestinal obstruction,,2023,Q1,23,F,20121025.0,20230123.0,20130123,20230131,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20230131,,MD,CA,CA,2023,Q1,Elderly
902813623,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Pneumonia,,2023,Q1,23,F,20121025.0,20230123.0,20130123,20230131,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20230131,,MD,CA,CA,2023,Q1,Elderly
902813623,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Influenza,,2023,Q1,23,F,20121025.0,20230123.0,20130123,20230131,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20230131,,MD,CA,CA,2023,Q1,Elderly
902813623,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Blood pressure systolic increased,,2023,Q1,23,F,20121025.0,20230123.0,20130123,20230131,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20230131,,MD,CA,CA,2023,Q1,Elderly
902813623,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Pericardial effusion,,2023,Q1,23,F,20121025.0,20230123.0,20130123,20230131,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20230131,,MD,CA,CA,2023,Q1,Elderly
902813623,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Heart rate decreased,,2023,Q1,23,F,20121025.0,20230123.0,20130123,20230131,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20230131,,MD,CA,CA,2023,Q1,Elderly
902813623,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Dyspnoea,,2023,Q1,23,F,20121025.0,20230123.0,20130123,20230131,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20230131,,MD,CA,CA,2023,Q1,Elderly
902813623,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Bronchitis,,2023,Q1,23,F,20121025.0,20230123.0,20130123,20230131,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20230131,,MD,CA,CA,2023,Q1,Elderly
902813623,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Blood pressure decreased,,2023,Q1,23,F,20121025.0,20230123.0,20130123,20230131,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20230131,,MD,CA,CA,2023,Q1,Elderly
902813623,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Pneumonia,,2023,Q1,23,F,20121025.0,20230123.0,20130123,20230131,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20230131,,MD,CA,CA,2023,Q1,Elderly
902813623,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Limb injury,,2023,Q1,23,F,20121025.0,20230123.0,20130123,20230131,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20230131,,MD,CA,CA,2023,Q1,Elderly
902813623,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Cough,,2023,Q1,23,F,20121025.0,20230123.0,20130123,20230131,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20230131,,MD,CA,CA,2023,Q1,Elderly
902813623,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Blood pressure fluctuation,,2023,Q1,23,F,20121025.0,20230123.0,20130123,20230131,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20230131,,MD,CA,CA,2023,Q1,Elderly
902813623,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Atrial fibrillation,,2023,Q1,23,F,20121025.0,20230123.0,20130123,20230131,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20230131,,MD,CA,CA,2023,Q1,Elderly
902813623,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Orthopnoea,,2023,Q1,23,F,20121025.0,20230123.0,20130123,20230131,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20230131,,MD,CA,CA,2023,Q1,Elderly
902813623,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Vital functions abnormal,,2023,Q1,23,F,20121025.0,20230123.0,20130123,20230131,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20230131,,MD,CA,CA,2023,Q1,Elderly
902813623,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Pulmonary oedema,,2023,Q1,23,F,20121025.0,20230123.0,20130123,20230131,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20230131,,MD,CA,CA,2023,Q1,Elderly
902813623,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Malaise,,2023,Q1,23,F,20121025.0,20230123.0,20130123,20230131,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20230131,,MD,CA,CA,2023,Q1,Elderly
902813623,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Fatigue,,2023,Q1,23,F,20121025.0,20230123.0,20130123,20230131,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20230131,,MD,CA,CA,2023,Q1,Elderly
902813623,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Cardiac failure congestive,,2023,Q1,23,F,20121025.0,20230123.0,20130123,20230131,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20230131,,MD,CA,CA,2023,Q1,Elderly
1539601931,15396019,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"UNK, QD",,,U,,,,,,,,QD,2023,Q2,Constipation,,2023,Q2,31,F,20180701.0,20230412.0,20180918,20230518,EXP,,PHHY2018CA047386,NOVARTIS,,65.0,YR,,M,Y,,,20230518,,CN,CA,CA,2023,Q2,Elderly
1539601931,15396019,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"UNK, QD",,,U,,,,,,,,QD,2023,Q2,Ligament sprain,,2023,Q2,31,F,20180701.0,20230412.0,20180918,20230518,EXP,,PHHY2018CA047386,NOVARTIS,,65.0,YR,,M,Y,,,20230518,,CN,CA,CA,2023,Q2,Elderly
1539601931,15396019,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"UNK, QD",,,U,,,,,,,,QD,2023,Q2,Needle issue,,2023,Q2,31,F,20180701.0,20230412.0,20180918,20230518,EXP,,PHHY2018CA047386,NOVARTIS,,65.0,YR,,M,Y,,,20230518,,CN,CA,CA,2023,Q2,Elderly
1539601931,15396019,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"UNK, QD",,,U,,,,,,,,QD,2023,Q2,Injection site swelling,,2023,Q2,31,F,20180701.0,20230412.0,20180918,20230518,EXP,,PHHY2018CA047386,NOVARTIS,,65.0,YR,,M,Y,,,20230518,,CN,CA,CA,2023,Q2,Elderly
1539601931,15396019,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"UNK, QD",,,U,,,,,,,,QD,2023,Q2,Abdominal pain lower,,2023,Q2,31,F,20180701.0,20230412.0,20180918,20230518,EXP,,PHHY2018CA047386,NOVARTIS,,65.0,YR,,M,Y,,,20230518,,CN,CA,CA,2023,Q2,Elderly
1539601931,15396019,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"UNK, QD",,,U,,,,,,,,QD,2023,Q2,Blood glucose increased,,2023,Q2,31,F,20180701.0,20230412.0,20180918,20230518,EXP,,PHHY2018CA047386,NOVARTIS,,65.0,YR,,M,Y,,,20230518,,CN,CA,CA,2023,Q2,Elderly
1539601931,15396019,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"UNK, QD",,,U,,,,,,,,QD,2023,Q2,Soft tissue disorder,,2023,Q2,31,F,20180701.0,20230412.0,20180918,20230518,EXP,,PHHY2018CA047386,NOVARTIS,,65.0,YR,,M,Y,,,20230518,,CN,CA,CA,2023,Q2,Elderly
1539601931,15396019,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"UNK, QD",,,U,,,,,,,,QD,2023,Q2,Blood pressure systolic increased,,2023,Q2,31,F,20180701.0,20230412.0,20180918,20230518,EXP,,PHHY2018CA047386,NOVARTIS,,65.0,YR,,M,Y,,,20230518,,CN,CA,CA,2023,Q2,Elderly
1539601931,15396019,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"UNK, QD",,,U,,,,,,,,QD,2023,Q2,Arthralgia,,2023,Q2,31,F,20180701.0,20230412.0,20180918,20230518,EXP,,PHHY2018CA047386,NOVARTIS,,65.0,YR,,M,Y,,,20230518,,CN,CA,CA,2023,Q2,Elderly
1539601931,15396019,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"UNK, QD",,,U,,,,,,,,QD,2023,Q2,Tendon rupture,,2023,Q2,31,F,20180701.0,20230412.0,20180918,20230518,EXP,,PHHY2018CA047386,NOVARTIS,,65.0,YR,,M,Y,,,20230518,,CN,CA,CA,2023,Q2,Elderly
1539601931,15396019,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"UNK, QD",,,U,,,,,,,,QD,2023,Q2,Fatigue,,2023,Q2,31,F,20180701.0,20230412.0,20180918,20230518,EXP,,PHHY2018CA047386,NOVARTIS,,65.0,YR,,M,Y,,,20230518,,CN,CA,CA,2023,Q2,Elderly
1539601931,15396019,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"UNK, QD",,,U,,,,,,,,QD,2023,Q2,Coronary artery occlusion,,2023,Q2,31,F,20180701.0,20230412.0,20180918,20230518,EXP,,PHHY2018CA047386,NOVARTIS,,65.0,YR,,M,Y,,,20230518,,CN,CA,CA,2023,Q2,Elderly
1539601931,15396019,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"UNK, QD",,,U,,,,,,,,QD,2023,Q2,Back pain,,2023,Q2,31,F,20180701.0,20230412.0,20180918,20230518,EXP,,PHHY2018CA047386,NOVARTIS,,65.0,YR,,M,Y,,,20230518,,CN,CA,CA,2023,Q2,Elderly
1539601931,15396019,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"UNK, QD",,,U,,,,,,,,QD,2023,Q2,Metastasis,,2023,Q2,31,F,20180701.0,20230412.0,20180918,20230518,EXP,,PHHY2018CA047386,NOVARTIS,,65.0,YR,,M,Y,,,20230518,,CN,CA,CA,2023,Q2,Elderly
1539601931,15396019,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"UNK, QD",,,U,,,,,,,,QD,2023,Q2,Flatulence,,2023,Q2,31,F,20180701.0,20230412.0,20180918,20230518,EXP,,PHHY2018CA047386,NOVARTIS,,65.0,YR,,M,Y,,,20230518,,CN,CA,CA,2023,Q2,Elderly
1539601931,15396019,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"UNK, QD",,,U,,,,,,,,QD,2023,Q2,Pain,,2023,Q2,31,F,20180701.0,20230412.0,20180918,20230518,EXP,,PHHY2018CA047386,NOVARTIS,,65.0,YR,,M,Y,,,20230518,,CN,CA,CA,2023,Q2,Elderly
1539601931,15396019,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"UNK, QD",,,U,,,,,,,,QD,2023,Q2,Blood pressure increased,,2023,Q2,31,F,20180701.0,20230412.0,20180918,20230518,EXP,,PHHY2018CA047386,NOVARTIS,,65.0,YR,,M,Y,,,20230518,,CN,CA,CA,2023,Q2,Elderly
1539601931,15396019,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"UNK, QD",,,U,,,,,,,,QD,2023,Q2,Injection site pain,,2023,Q2,31,F,20180701.0,20230412.0,20180918,20230518,EXP,,PHHY2018CA047386,NOVARTIS,,65.0,YR,,M,Y,,,20230518,,CN,CA,CA,2023,Q2,Elderly
1539601931,15396019,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"UNK, QD",,,U,,,,,,,,QD,2023,Q2,Injection site mass,,2023,Q2,31,F,20180701.0,20230412.0,20180918,20230518,EXP,,PHHY2018CA047386,NOVARTIS,,65.0,YR,,M,Y,,,20230518,,CN,CA,CA,2023,Q2,Elderly
1539601931,15396019,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"UNK, QD",,,U,,,,,,,,QD,2023,Q2,Dizziness,,2023,Q2,31,F,20180701.0,20230412.0,20180918,20230518,EXP,,PHHY2018CA047386,NOVARTIS,,65.0,YR,,M,Y,,,20230518,,CN,CA,CA,2023,Q2,Elderly
1539601931,15396019,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"UNK, QD",,,U,,,,,,,,QD,2023,Q2,Joint injury,,2023,Q2,31,F,20180701.0,20230412.0,20180918,20230518,EXP,,PHHY2018CA047386,NOVARTIS,,65.0,YR,,M,Y,,,20230518,,CN,CA,CA,2023,Q2,Elderly
1539601931,15396019,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"UNK, QD",,,U,,,,,,,,QD,2023,Q2,Inappropriate schedule of product administration,,2023,Q2,31,F,20180701.0,20230412.0,20180918,20230518,EXP,,PHHY2018CA047386,NOVARTIS,,65.0,YR,,M,Y,,,20230518,,CN,CA,CA,2023,Q2,Elderly
166459853,16645985,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg/dL,,,,,,,,,,,,2023,Q2,Cardiac failure chronic,,2023,Q2,3,F,,20230512.0,20190730,20230526,EXP,,PL-SUN PHARMACEUTICAL INDUSTRIES LTD-2019RR-215650,RANBAXY,,56.0,YR,,M,Y,,,20230526,,MD,PL,PL,2023,Q2,Adult
166459853,16645985,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg/dL,,,,,,,,,,,,2023,Q2,Condition aggravated,,2023,Q2,3,F,,20230512.0,20190730,20230526,EXP,,PL-SUN PHARMACEUTICAL INDUSTRIES LTD-2019RR-215650,RANBAXY,,56.0,YR,,M,Y,,,20230526,,MD,PL,PL,2023,Q2,Adult
166459853,16645985,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg/dL,,,,,,,,,,,,2023,Q2,Respiratory tract infection,,2023,Q2,3,F,,20230512.0,20190730,20230526,EXP,,PL-SUN PHARMACEUTICAL INDUSTRIES LTD-2019RR-215650,RANBAXY,,56.0,YR,,M,Y,,,20230526,,MD,PL,PL,2023,Q2,Adult
166459853,16645985,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg/dL,,,,,,,,,,,,2023,Q2,Diabetes mellitus inadequate control,,2023,Q2,3,F,,20230512.0,20190730,20230526,EXP,,PL-SUN PHARMACEUTICAL INDUSTRIES LTD-2019RR-215650,RANBAXY,,56.0,YR,,M,Y,,,20230526,,MD,PL,PL,2023,Q2,Adult
166459853,16645985,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg/dL,,,,,,,,,,,,2023,Q2,Drug ineffective,,2023,Q2,3,F,,20230512.0,20190730,20230526,EXP,,PL-SUN PHARMACEUTICAL INDUSTRIES LTD-2019RR-215650,RANBAXY,,56.0,YR,,M,Y,,,20230526,,MD,PL,PL,2023,Q2,Adult
166459853,16645985,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg/dL,,,,,,,,,,,,2023,Q2,Concomitant disease aggravated,,2023,Q2,3,F,,20230512.0,20190730,20230526,EXP,,PL-SUN PHARMACEUTICAL INDUSTRIES LTD-2019RR-215650,RANBAXY,,56.0,YR,,M,Y,,,20230526,,MD,PL,PL,2023,Q2,Adult
166459853,16645985,14,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Cardiac failure chronic,,2023,Q2,3,F,,20230512.0,20190730,20230526,EXP,,PL-SUN PHARMACEUTICAL INDUSTRIES LTD-2019RR-215650,RANBAXY,,56.0,YR,,M,Y,,,20230526,,MD,PL,PL,2023,Q2,Adult
166459853,16645985,14,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Condition aggravated,,2023,Q2,3,F,,20230512.0,20190730,20230526,EXP,,PL-SUN PHARMACEUTICAL INDUSTRIES LTD-2019RR-215650,RANBAXY,,56.0,YR,,M,Y,,,20230526,,MD,PL,PL,2023,Q2,Adult
166459853,16645985,14,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Respiratory tract infection,,2023,Q2,3,F,,20230512.0,20190730,20230526,EXP,,PL-SUN PHARMACEUTICAL INDUSTRIES LTD-2019RR-215650,RANBAXY,,56.0,YR,,M,Y,,,20230526,,MD,PL,PL,2023,Q2,Adult
166459853,16645985,14,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Diabetes mellitus inadequate control,,2023,Q2,3,F,,20230512.0,20190730,20230526,EXP,,PL-SUN PHARMACEUTICAL INDUSTRIES LTD-2019RR-215650,RANBAXY,,56.0,YR,,M,Y,,,20230526,,MD,PL,PL,2023,Q2,Adult
166459853,16645985,14,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Drug ineffective,,2023,Q2,3,F,,20230512.0,20190730,20230526,EXP,,PL-SUN PHARMACEUTICAL INDUSTRIES LTD-2019RR-215650,RANBAXY,,56.0,YR,,M,Y,,,20230526,,MD,PL,PL,2023,Q2,Adult
166459853,16645985,14,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Concomitant disease aggravated,,2023,Q2,3,F,,20230512.0,20190730,20230526,EXP,,PL-SUN PHARMACEUTICAL INDUSTRIES LTD-2019RR-215650,RANBAXY,,56.0,YR,,M,Y,,,20230526,,MD,PL,PL,2023,Q2,Adult
179094082,17909408,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day (1-0-0-0)",,,U,U,,,,10.0,MG,,QD,2023,Q2,General physical health deterioration,,2023,Q2,2,F,,20230517.0,20200618,20230527,EXP,,DE-AUROBINDO-AUR-APL-2020-029330,AUROBINDO,,56.0,YR,,F,Y,,,20230527,,MD,DE,DE,2023,Q2,Adult
179094082,17909408,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day (1-0-0-0)",,,U,U,,,,10.0,MG,,QD,2023,Q2,Condition aggravated,,2023,Q2,2,F,,20230517.0,20200618,20230527,EXP,,DE-AUROBINDO-AUR-APL-2020-029330,AUROBINDO,,56.0,YR,,F,Y,,,20230527,,MD,DE,DE,2023,Q2,Adult
179094082,17909408,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day (1-0-0-0)",,,U,U,,,,10.0,MG,,QD,2023,Q2,Epistaxis,,2023,Q2,2,F,,20230517.0,20200618,20230527,EXP,,DE-AUROBINDO-AUR-APL-2020-029330,AUROBINDO,,56.0,YR,,F,Y,,,20230527,,MD,DE,DE,2023,Q2,Adult
179094082,17909408,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day (1-0-0-0)",,,U,U,,,,10.0,MG,,QD,2023,Q2,Pallor,,2023,Q2,2,F,,20230517.0,20200618,20230527,EXP,,DE-AUROBINDO-AUR-APL-2020-029330,AUROBINDO,,56.0,YR,,F,Y,,,20230527,,MD,DE,DE,2023,Q2,Adult
179094082,17909408,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day (1-0-0-0)",,,U,U,,,,10.0,MG,,QD,2023,Q2,Diarrhoea,,2023,Q2,2,F,,20230517.0,20200618,20230527,EXP,,DE-AUROBINDO-AUR-APL-2020-029330,AUROBINDO,,56.0,YR,,F,Y,,,20230527,,MD,DE,DE,2023,Q2,Adult
179094082,17909408,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day (1-0-0-0)",,,U,U,,,,10.0,MG,,QD,2023,Q2,Anaemia,,2023,Q2,2,F,,20230517.0,20200618,20230527,EXP,,DE-AUROBINDO-AUR-APL-2020-029330,AUROBINDO,,56.0,YR,,F,Y,,,20230527,,MD,DE,DE,2023,Q2,Adult
179094082,17909408,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day (1-0-0-0)",,,U,U,,,,10.0,MG,,QD,2023,Q2,Haematochezia,,2023,Q2,2,F,,20230517.0,20200618,20230527,EXP,,DE-AUROBINDO-AUR-APL-2020-029330,AUROBINDO,,56.0,YR,,F,Y,,,20230527,,MD,DE,DE,2023,Q2,Adult
179310172,17931017,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0",,,U,,,,,10.0,MG,UNK,,2023,Q2,General physical health deterioration,,2023,Q2,2,F,,20230518.0,20200623,20230526,EXP,DE-ADRED-05010-01,DE-TORRENT-00017800,TORRENT,,56.0,YR,A,F,Y,,,20230526,,MD,DE,DE,2023,Q2,Adult
179310172,17931017,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0",,,U,,,,,10.0,MG,UNK,,2023,Q2,Diarrhoea,,2023,Q2,2,F,,20230518.0,20200623,20230526,EXP,DE-ADRED-05010-01,DE-TORRENT-00017800,TORRENT,,56.0,YR,A,F,Y,,,20230526,,MD,DE,DE,2023,Q2,Adult
179310172,17931017,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0",,,U,,,,,10.0,MG,UNK,,2023,Q2,Pallor,,2023,Q2,2,F,,20230518.0,20200623,20230526,EXP,DE-ADRED-05010-01,DE-TORRENT-00017800,TORRENT,,56.0,YR,A,F,Y,,,20230526,,MD,DE,DE,2023,Q2,Adult
179310172,17931017,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0",,,U,,,,,10.0,MG,UNK,,2023,Q2,Haematochezia,,2023,Q2,2,F,,20230518.0,20200623,20230526,EXP,DE-ADRED-05010-01,DE-TORRENT-00017800,TORRENT,,56.0,YR,A,F,Y,,,20230526,,MD,DE,DE,2023,Q2,Adult
179310172,17931017,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0",,,U,,,,,10.0,MG,UNK,,2023,Q2,Epistaxis,,2023,Q2,2,F,,20230518.0,20200623,20230526,EXP,DE-ADRED-05010-01,DE-TORRENT-00017800,TORRENT,,56.0,YR,A,F,Y,,,20230526,,MD,DE,DE,2023,Q2,Adult
179310172,17931017,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0",,,U,,,,,10.0,MG,UNK,,2023,Q2,Condition aggravated,,2023,Q2,2,F,,20230518.0,20200623,20230526,EXP,DE-ADRED-05010-01,DE-TORRENT-00017800,TORRENT,,56.0,YR,A,F,Y,,,20230526,,MD,DE,DE,2023,Q2,Adult
179310172,17931017,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0",,,U,,,,,10.0,MG,UNK,,2023,Q2,Anaemia,,2023,Q2,2,F,,20230518.0,20200623,20230526,EXP,DE-ADRED-05010-01,DE-TORRENT-00017800,TORRENT,,56.0,YR,A,F,Y,,,20230526,,MD,DE,DE,2023,Q2,Adult
179318432,17931843,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 Milligram Daily;  1-0-0-0,,,,,,,,10.0,MG,,QD,2023,Q2,Diarrhoea,,2023,Q2,2,F,,20230526.0,20200624,20230605,EXP,,DE-TEVA-2020-DE-1789367,TEVA,,56.0,YR,A,F,Y,,,20230605,,MD,DE,DE,2023,Q2,Adult
179318432,17931843,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 Milligram Daily;  1-0-0-0,,,,,,,,10.0,MG,,QD,2023,Q2,Anaemia,,2023,Q2,2,F,,20230526.0,20200624,20230605,EXP,,DE-TEVA-2020-DE-1789367,TEVA,,56.0,YR,A,F,Y,,,20230605,,MD,DE,DE,2023,Q2,Adult
179318432,17931843,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 Milligram Daily;  1-0-0-0,,,,,,,,10.0,MG,,QD,2023,Q2,Haematochezia,,2023,Q2,2,F,,20230526.0,20200624,20230605,EXP,,DE-TEVA-2020-DE-1789367,TEVA,,56.0,YR,A,F,Y,,,20230605,,MD,DE,DE,2023,Q2,Adult
179318432,17931843,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 Milligram Daily;  1-0-0-0,,,,,,,,10.0,MG,,QD,2023,Q2,Epistaxis,,2023,Q2,2,F,,20230526.0,20200624,20230605,EXP,,DE-TEVA-2020-DE-1789367,TEVA,,56.0,YR,A,F,Y,,,20230605,,MD,DE,DE,2023,Q2,Adult
179318432,17931843,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 Milligram Daily;  1-0-0-0,,,,,,,,10.0,MG,,QD,2023,Q2,Pallor,,2023,Q2,2,F,,20230526.0,20200624,20230605,EXP,,DE-TEVA-2020-DE-1789367,TEVA,,56.0,YR,A,F,Y,,,20230605,,MD,DE,DE,2023,Q2,Adult
179318432,17931843,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 Milligram Daily;  1-0-0-0,,,,,,,,10.0,MG,,QD,2023,Q2,Condition aggravated,,2023,Q2,2,F,,20230526.0,20200624,20230605,EXP,,DE-TEVA-2020-DE-1789367,TEVA,,56.0,YR,A,F,Y,,,20230605,,MD,DE,DE,2023,Q2,Adult
179318432,17931843,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 Milligram Daily;  1-0-0-0,,,,,,,,10.0,MG,,QD,2023,Q2,General physical health deterioration,,2023,Q2,2,F,,20230526.0,20200624,20230605,EXP,,DE-TEVA-2020-DE-1789367,TEVA,,56.0,YR,A,F,Y,,,20230605,,MD,DE,DE,2023,Q2,Adult
179383992,17938399,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, 1-0-0-0",,,,,,,,10.0,MG,,QD,2023,Q2,Anaemia,,2023,Q2,2,F,,20230523.0,20200624,20230530,EXP,,DE-MYLANLABS-2020M1057311,MYLAN,,56.0,YR,,F,Y,,,20230530,,MD,DE,DE,2023,Q2,Adult
179383992,17938399,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, 1-0-0-0",,,,,,,,10.0,MG,,QD,2023,Q2,General physical health deterioration,,2023,Q2,2,F,,20230523.0,20200624,20230530,EXP,,DE-MYLANLABS-2020M1057311,MYLAN,,56.0,YR,,F,Y,,,20230530,,MD,DE,DE,2023,Q2,Adult
179383992,17938399,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, 1-0-0-0",,,,,,,,10.0,MG,,QD,2023,Q2,Haematochezia,,2023,Q2,2,F,,20230523.0,20200624,20230530,EXP,,DE-MYLANLABS-2020M1057311,MYLAN,,56.0,YR,,F,Y,,,20230530,,MD,DE,DE,2023,Q2,Adult
179383992,17938399,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, 1-0-0-0",,,,,,,,10.0,MG,,QD,2023,Q2,Condition aggravated,,2023,Q2,2,F,,20230523.0,20200624,20230530,EXP,,DE-MYLANLABS-2020M1057311,MYLAN,,56.0,YR,,F,Y,,,20230530,,MD,DE,DE,2023,Q2,Adult
179383992,17938399,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, 1-0-0-0",,,,,,,,10.0,MG,,QD,2023,Q2,Diarrhoea,,2023,Q2,2,F,,20230523.0,20200624,20230530,EXP,,DE-MYLANLABS-2020M1057311,MYLAN,,56.0,YR,,F,Y,,,20230530,,MD,DE,DE,2023,Q2,Adult
179383992,17938399,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, 1-0-0-0",,,,,,,,10.0,MG,,QD,2023,Q2,Pallor,,2023,Q2,2,F,,20230523.0,20200624,20230530,EXP,,DE-MYLANLABS-2020M1057311,MYLAN,,56.0,YR,,F,Y,,,20230530,,MD,DE,DE,2023,Q2,Adult
179383992,17938399,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, 1-0-0-0",,,,,,,,10.0,MG,,QD,2023,Q2,Epistaxis,,2023,Q2,2,F,,20230523.0,20200624,20230530,EXP,,DE-MYLANLABS-2020M1057311,MYLAN,,56.0,YR,,F,Y,,,20230530,,MD,DE,DE,2023,Q2,Adult
183846678,18384667,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, QD",,,U,,,,,25.0,MG,,QD,2023,Q2,Metabolic acidosis,,2023,Q2,8,F,,20230403.0,20201015,20230404,EXP,,NVSC2020PT275038,NOVARTIS,"Calaca S, Escaria S, Santos I, Rebocho F, Coutinho D, Canudo D. Intoxicacso por metformina - acidose metabolica multifactorial. MEDICINA INTERNA - CONGRESSOS NACIONAIS, 26 CNMI. 2020;27:535-6",54.0,YR,,M,Y,,,20230405,,HP,PT,PT,2023,Q2,Adult
183846678,18384667,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, QD",,,U,,,,,25.0,MG,,QD,2023,Q2,Acute kidney injury,,2023,Q2,8,F,,20230403.0,20201015,20230404,EXP,,NVSC2020PT275038,NOVARTIS,"Calaca S, Escaria S, Santos I, Rebocho F, Coutinho D, Canudo D. Intoxicacso por metformina - acidose metabolica multifactorial. MEDICINA INTERNA - CONGRESSOS NACIONAIS, 26 CNMI. 2020;27:535-6",54.0,YR,,M,Y,,,20230405,,HP,PT,PT,2023,Q2,Adult
183846678,18384667,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, QD",,,U,,,,,25.0,MG,,QD,2023,Q2,Acidosis,,2023,Q2,8,F,,20230403.0,20201015,20230404,EXP,,NVSC2020PT275038,NOVARTIS,"Calaca S, Escaria S, Santos I, Rebocho F, Coutinho D, Canudo D. Intoxicacso por metformina - acidose metabolica multifactorial. MEDICINA INTERNA - CONGRESSOS NACIONAIS, 26 CNMI. 2020;27:535-6",54.0,YR,,M,Y,,,20230405,,HP,PT,PT,2023,Q2,Adult
183846678,18384667,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, QD",,,U,,,,,25.0,MG,,QD,2023,Q2,Multiple organ dysfunction syndrome,,2023,Q2,8,F,,20230403.0,20201015,20230404,EXP,,NVSC2020PT275038,NOVARTIS,"Calaca S, Escaria S, Santos I, Rebocho F, Coutinho D, Canudo D. Intoxicacso por metformina - acidose metabolica multifactorial. MEDICINA INTERNA - CONGRESSOS NACIONAIS, 26 CNMI. 2020;27:535-6",54.0,YR,,M,Y,,,20230405,,HP,PT,PT,2023,Q2,Adult
183846678,18384667,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, QD",,,U,,,,,25.0,MG,,QD,2023,Q2,Altered state of consciousness,,2023,Q2,8,F,,20230403.0,20201015,20230404,EXP,,NVSC2020PT275038,NOVARTIS,"Calaca S, Escaria S, Santos I, Rebocho F, Coutinho D, Canudo D. Intoxicacso por metformina - acidose metabolica multifactorial. MEDICINA INTERNA - CONGRESSOS NACIONAIS, 26 CNMI. 2020;27:535-6",54.0,YR,,M,Y,,,20230405,,HP,PT,PT,2023,Q2,Adult
183846678,18384667,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, QD",,,U,,,,,25.0,MG,,QD,2023,Q2,Toxicity to various agents,,2023,Q2,8,F,,20230403.0,20201015,20230404,EXP,,NVSC2020PT275038,NOVARTIS,"Calaca S, Escaria S, Santos I, Rebocho F, Coutinho D, Canudo D. Intoxicacso por metformina - acidose metabolica multifactorial. MEDICINA INTERNA - CONGRESSOS NACIONAIS, 26 CNMI. 2020;27:535-6",54.0,YR,,M,Y,,,20230405,,HP,PT,PT,2023,Q2,Adult
183846678,18384667,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, QD",,,U,,,,,25.0,MG,,QD,2023,Q2,Acetonaemia,,2023,Q2,8,F,,20230403.0,20201015,20230404,EXP,,NVSC2020PT275038,NOVARTIS,"Calaca S, Escaria S, Santos I, Rebocho F, Coutinho D, Canudo D. Intoxicacso por metformina - acidose metabolica multifactorial. MEDICINA INTERNA - CONGRESSOS NACIONAIS, 26 CNMI. 2020;27:535-6",54.0,YR,,M,Y,,,20230405,,HP,PT,PT,2023,Q2,Adult
183846678,18384667,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, QD",,,U,,,,,25.0,MG,,QD,2023,Q2,Hyperlactacidaemia,,2023,Q2,8,F,,20230403.0,20201015,20230404,EXP,,NVSC2020PT275038,NOVARTIS,"Calaca S, Escaria S, Santos I, Rebocho F, Coutinho D, Canudo D. Intoxicacso por metformina - acidose metabolica multifactorial. MEDICINA INTERNA - CONGRESSOS NACIONAIS, 26 CNMI. 2020;27:535-6",54.0,YR,,M,Y,,,20230405,,HP,PT,PT,2023,Q2,Adult
183846678,18384667,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, QD",,,U,,,,,25.0,MG,,QD,2023,Q2,Lactic acidosis,,2023,Q2,8,F,,20230403.0,20201015,20230404,EXP,,NVSC2020PT275038,NOVARTIS,"Calaca S, Escaria S, Santos I, Rebocho F, Coutinho D, Canudo D. Intoxicacso por metformina - acidose metabolica multifactorial. MEDICINA INTERNA - CONGRESSOS NACIONAIS, 26 CNMI. 2020;27:535-6",54.0,YR,,M,Y,,,20230405,,HP,PT,PT,2023,Q2,Adult
183846678,18384667,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, QD",,,U,,,,,25.0,MG,,QD,2023,Q2,Hypoglycaemia,,2023,Q2,8,F,,20230403.0,20201015,20230404,EXP,,NVSC2020PT275038,NOVARTIS,"Calaca S, Escaria S, Santos I, Rebocho F, Coutinho D, Canudo D. Intoxicacso por metformina - acidose metabolica multifactorial. MEDICINA INTERNA - CONGRESSOS NACIONAIS, 26 CNMI. 2020;27:535-6",54.0,YR,,M,Y,,,20230405,,HP,PT,PT,2023,Q2,Adult
183846678,18384667,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Metabolic acidosis,,2023,Q2,8,F,,20230403.0,20201015,20230404,EXP,,NVSC2020PT275038,NOVARTIS,"Calaca S, Escaria S, Santos I, Rebocho F, Coutinho D, Canudo D. Intoxicacso por metformina - acidose metabolica multifactorial. MEDICINA INTERNA - CONGRESSOS NACIONAIS, 26 CNMI. 2020;27:535-6",54.0,YR,,M,Y,,,20230405,,HP,PT,PT,2023,Q2,Adult
183846678,18384667,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Acute kidney injury,,2023,Q2,8,F,,20230403.0,20201015,20230404,EXP,,NVSC2020PT275038,NOVARTIS,"Calaca S, Escaria S, Santos I, Rebocho F, Coutinho D, Canudo D. Intoxicacso por metformina - acidose metabolica multifactorial. MEDICINA INTERNA - CONGRESSOS NACIONAIS, 26 CNMI. 2020;27:535-6",54.0,YR,,M,Y,,,20230405,,HP,PT,PT,2023,Q2,Adult
183846678,18384667,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Acidosis,,2023,Q2,8,F,,20230403.0,20201015,20230404,EXP,,NVSC2020PT275038,NOVARTIS,"Calaca S, Escaria S, Santos I, Rebocho F, Coutinho D, Canudo D. Intoxicacso por metformina - acidose metabolica multifactorial. MEDICINA INTERNA - CONGRESSOS NACIONAIS, 26 CNMI. 2020;27:535-6",54.0,YR,,M,Y,,,20230405,,HP,PT,PT,2023,Q2,Adult
183846678,18384667,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Multiple organ dysfunction syndrome,,2023,Q2,8,F,,20230403.0,20201015,20230404,EXP,,NVSC2020PT275038,NOVARTIS,"Calaca S, Escaria S, Santos I, Rebocho F, Coutinho D, Canudo D. Intoxicacso por metformina - acidose metabolica multifactorial. MEDICINA INTERNA - CONGRESSOS NACIONAIS, 26 CNMI. 2020;27:535-6",54.0,YR,,M,Y,,,20230405,,HP,PT,PT,2023,Q2,Adult
183846678,18384667,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Altered state of consciousness,,2023,Q2,8,F,,20230403.0,20201015,20230404,EXP,,NVSC2020PT275038,NOVARTIS,"Calaca S, Escaria S, Santos I, Rebocho F, Coutinho D, Canudo D. Intoxicacso por metformina - acidose metabolica multifactorial. MEDICINA INTERNA - CONGRESSOS NACIONAIS, 26 CNMI. 2020;27:535-6",54.0,YR,,M,Y,,,20230405,,HP,PT,PT,2023,Q2,Adult
183846678,18384667,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Toxicity to various agents,,2023,Q2,8,F,,20230403.0,20201015,20230404,EXP,,NVSC2020PT275038,NOVARTIS,"Calaca S, Escaria S, Santos I, Rebocho F, Coutinho D, Canudo D. Intoxicacso por metformina - acidose metabolica multifactorial. MEDICINA INTERNA - CONGRESSOS NACIONAIS, 26 CNMI. 2020;27:535-6",54.0,YR,,M,Y,,,20230405,,HP,PT,PT,2023,Q2,Adult
183846678,18384667,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Acetonaemia,,2023,Q2,8,F,,20230403.0,20201015,20230404,EXP,,NVSC2020PT275038,NOVARTIS,"Calaca S, Escaria S, Santos I, Rebocho F, Coutinho D, Canudo D. Intoxicacso por metformina - acidose metabolica multifactorial. MEDICINA INTERNA - CONGRESSOS NACIONAIS, 26 CNMI. 2020;27:535-6",54.0,YR,,M,Y,,,20230405,,HP,PT,PT,2023,Q2,Adult
183846678,18384667,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Hyperlactacidaemia,,2023,Q2,8,F,,20230403.0,20201015,20230404,EXP,,NVSC2020PT275038,NOVARTIS,"Calaca S, Escaria S, Santos I, Rebocho F, Coutinho D, Canudo D. Intoxicacso por metformina - acidose metabolica multifactorial. MEDICINA INTERNA - CONGRESSOS NACIONAIS, 26 CNMI. 2020;27:535-6",54.0,YR,,M,Y,,,20230405,,HP,PT,PT,2023,Q2,Adult
183846678,18384667,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Lactic acidosis,,2023,Q2,8,F,,20230403.0,20201015,20230404,EXP,,NVSC2020PT275038,NOVARTIS,"Calaca S, Escaria S, Santos I, Rebocho F, Coutinho D, Canudo D. Intoxicacso por metformina - acidose metabolica multifactorial. MEDICINA INTERNA - CONGRESSOS NACIONAIS, 26 CNMI. 2020;27:535-6",54.0,YR,,M,Y,,,20230405,,HP,PT,PT,2023,Q2,Adult
183846678,18384667,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Hypoglycaemia,,2023,Q2,8,F,,20230403.0,20201015,20230404,EXP,,NVSC2020PT275038,NOVARTIS,"Calaca S, Escaria S, Santos I, Rebocho F, Coutinho D, Canudo D. Intoxicacso por metformina - acidose metabolica multifactorial. MEDICINA INTERNA - CONGRESSOS NACIONAIS, 26 CNMI. 2020;27:535-6",54.0,YR,,M,Y,,,20230405,,HP,PT,PT,2023,Q2,Adult
184155424,18415542,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,U,U,,,,25.0,MG,,QD,2023,Q2,Lactic acidosis,,2023,Q2,4,F,,20230405.0,20201022,20230410,EXP,,PT-MYLANLABS-2020M1089059,MYLAN,"Calaca S, Escaria S, Santos I, Rebocho F, Coutinho D, Canudo D.. PE-362 INTOXICACAO POR METFORMINA - ACIDOSE METABOLICA MULTIFACTORIAL.. Revista da Sociedade Portuguesa de Medicina Interna. 2020;27(Congresso):535-536",54.0,YR,,M,Y,,,20230410,,MD,PT,PT,2023,Q2,Adult
184155424,18415542,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,U,U,,,,25.0,MG,,QD,2023,Q2,Acute kidney injury,,2023,Q2,4,F,,20230405.0,20201022,20230410,EXP,,PT-MYLANLABS-2020M1089059,MYLAN,"Calaca S, Escaria S, Santos I, Rebocho F, Coutinho D, Canudo D.. PE-362 INTOXICACAO POR METFORMINA - ACIDOSE METABOLICA MULTIFACTORIAL.. Revista da Sociedade Portuguesa de Medicina Interna. 2020;27(Congresso):535-536",54.0,YR,,M,Y,,,20230410,,MD,PT,PT,2023,Q2,Adult
184155424,18415542,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,U,U,,,,25.0,MG,,QD,2023,Q2,Diarrhoea,,2023,Q2,4,F,,20230405.0,20201022,20230410,EXP,,PT-MYLANLABS-2020M1089059,MYLAN,"Calaca S, Escaria S, Santos I, Rebocho F, Coutinho D, Canudo D.. PE-362 INTOXICACAO POR METFORMINA - ACIDOSE METABOLICA MULTIFACTORIAL.. Revista da Sociedade Portuguesa de Medicina Interna. 2020;27(Congresso):535-536",54.0,YR,,M,Y,,,20230410,,MD,PT,PT,2023,Q2,Adult
184155424,18415542,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,U,U,,,,25.0,MG,,QD,2023,Q2,Acetonaemia,,2023,Q2,4,F,,20230405.0,20201022,20230410,EXP,,PT-MYLANLABS-2020M1089059,MYLAN,"Calaca S, Escaria S, Santos I, Rebocho F, Coutinho D, Canudo D.. PE-362 INTOXICACAO POR METFORMINA - ACIDOSE METABOLICA MULTIFACTORIAL.. Revista da Sociedade Portuguesa de Medicina Interna. 2020;27(Congresso):535-536",54.0,YR,,M,Y,,,20230410,,MD,PT,PT,2023,Q2,Adult
184155424,18415542,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,U,U,,,,25.0,MG,,QD,2023,Q2,Hyperlactacidaemia,,2023,Q2,4,F,,20230405.0,20201022,20230410,EXP,,PT-MYLANLABS-2020M1089059,MYLAN,"Calaca S, Escaria S, Santos I, Rebocho F, Coutinho D, Canudo D.. PE-362 INTOXICACAO POR METFORMINA - ACIDOSE METABOLICA MULTIFACTORIAL.. Revista da Sociedade Portuguesa de Medicina Interna. 2020;27(Congresso):535-536",54.0,YR,,M,Y,,,20230410,,MD,PT,PT,2023,Q2,Adult
184155424,18415542,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,U,U,,,,25.0,MG,,QD,2023,Q2,Altered state of consciousness,,2023,Q2,4,F,,20230405.0,20201022,20230410,EXP,,PT-MYLANLABS-2020M1089059,MYLAN,"Calaca S, Escaria S, Santos I, Rebocho F, Coutinho D, Canudo D.. PE-362 INTOXICACAO POR METFORMINA - ACIDOSE METABOLICA MULTIFACTORIAL.. Revista da Sociedade Portuguesa de Medicina Interna. 2020;27(Congresso):535-536",54.0,YR,,M,Y,,,20230410,,MD,PT,PT,2023,Q2,Adult
184155424,18415542,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,U,U,,,,25.0,MG,,QD,2023,Q2,Vomiting,,2023,Q2,4,F,,20230405.0,20201022,20230410,EXP,,PT-MYLANLABS-2020M1089059,MYLAN,"Calaca S, Escaria S, Santos I, Rebocho F, Coutinho D, Canudo D.. PE-362 INTOXICACAO POR METFORMINA - ACIDOSE METABOLICA MULTIFACTORIAL.. Revista da Sociedade Portuguesa de Medicina Interna. 2020;27(Congresso):535-536",54.0,YR,,M,Y,,,20230410,,MD,PT,PT,2023,Q2,Adult
184155424,18415542,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,U,U,,,,25.0,MG,,QD,2023,Q2,Multiple organ dysfunction syndrome,,2023,Q2,4,F,,20230405.0,20201022,20230410,EXP,,PT-MYLANLABS-2020M1089059,MYLAN,"Calaca S, Escaria S, Santos I, Rebocho F, Coutinho D, Canudo D.. PE-362 INTOXICACAO POR METFORMINA - ACIDOSE METABOLICA MULTIFACTORIAL.. Revista da Sociedade Portuguesa de Medicina Interna. 2020;27(Congresso):535-536",54.0,YR,,M,Y,,,20230410,,MD,PT,PT,2023,Q2,Adult
184155424,18415542,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,U,U,,,,25.0,MG,,QD,2023,Q2,Toxicity to various agents,,2023,Q2,4,F,,20230405.0,20201022,20230410,EXP,,PT-MYLANLABS-2020M1089059,MYLAN,"Calaca S, Escaria S, Santos I, Rebocho F, Coutinho D, Canudo D.. PE-362 INTOXICACAO POR METFORMINA - ACIDOSE METABOLICA MULTIFACTORIAL.. Revista da Sociedade Portuguesa de Medicina Interna. 2020;27(Congresso):535-536",54.0,YR,,M,Y,,,20230410,,MD,PT,PT,2023,Q2,Adult
184155424,18415542,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,U,U,,,,25.0,MG,,QD,2023,Q2,Metabolic acidosis,,2023,Q2,4,F,,20230405.0,20201022,20230410,EXP,,PT-MYLANLABS-2020M1089059,MYLAN,"Calaca S, Escaria S, Santos I, Rebocho F, Coutinho D, Canudo D.. PE-362 INTOXICACAO POR METFORMINA - ACIDOSE METABOLICA MULTIFACTORIAL.. Revista da Sociedade Portuguesa de Medicina Interna. 2020;27(Congresso):535-536",54.0,YR,,M,Y,,,20230410,,MD,PT,PT,2023,Q2,Adult
184155424,18415542,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,U,U,,,,25.0,MG,,QD,2023,Q2,Hypoglycaemia,,2023,Q2,4,F,,20230405.0,20201022,20230410,EXP,,PT-MYLANLABS-2020M1089059,MYLAN,"Calaca S, Escaria S, Santos I, Rebocho F, Coutinho D, Canudo D.. PE-362 INTOXICACAO POR METFORMINA - ACIDOSE METABOLICA MULTIFACTORIAL.. Revista da Sociedade Portuguesa de Medicina Interna. 2020;27(Congresso):535-536",54.0,YR,,M,Y,,,20230410,,MD,PT,PT,2023,Q2,Adult
184155424,18415542,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,U,U,,,,,,,QD,2023,Q2,Lactic acidosis,,2023,Q2,4,F,,20230405.0,20201022,20230410,EXP,,PT-MYLANLABS-2020M1089059,MYLAN,"Calaca S, Escaria S, Santos I, Rebocho F, Coutinho D, Canudo D.. PE-362 INTOXICACAO POR METFORMINA - ACIDOSE METABOLICA MULTIFACTORIAL.. Revista da Sociedade Portuguesa de Medicina Interna. 2020;27(Congresso):535-536",54.0,YR,,M,Y,,,20230410,,MD,PT,PT,2023,Q2,Adult
184155424,18415542,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,U,U,,,,,,,QD,2023,Q2,Acute kidney injury,,2023,Q2,4,F,,20230405.0,20201022,20230410,EXP,,PT-MYLANLABS-2020M1089059,MYLAN,"Calaca S, Escaria S, Santos I, Rebocho F, Coutinho D, Canudo D.. PE-362 INTOXICACAO POR METFORMINA - ACIDOSE METABOLICA MULTIFACTORIAL.. Revista da Sociedade Portuguesa de Medicina Interna. 2020;27(Congresso):535-536",54.0,YR,,M,Y,,,20230410,,MD,PT,PT,2023,Q2,Adult
184155424,18415542,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,U,U,,,,,,,QD,2023,Q2,Diarrhoea,,2023,Q2,4,F,,20230405.0,20201022,20230410,EXP,,PT-MYLANLABS-2020M1089059,MYLAN,"Calaca S, Escaria S, Santos I, Rebocho F, Coutinho D, Canudo D.. PE-362 INTOXICACAO POR METFORMINA - ACIDOSE METABOLICA MULTIFACTORIAL.. Revista da Sociedade Portuguesa de Medicina Interna. 2020;27(Congresso):535-536",54.0,YR,,M,Y,,,20230410,,MD,PT,PT,2023,Q2,Adult
184155424,18415542,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,U,U,,,,,,,QD,2023,Q2,Acetonaemia,,2023,Q2,4,F,,20230405.0,20201022,20230410,EXP,,PT-MYLANLABS-2020M1089059,MYLAN,"Calaca S, Escaria S, Santos I, Rebocho F, Coutinho D, Canudo D.. PE-362 INTOXICACAO POR METFORMINA - ACIDOSE METABOLICA MULTIFACTORIAL.. Revista da Sociedade Portuguesa de Medicina Interna. 2020;27(Congresso):535-536",54.0,YR,,M,Y,,,20230410,,MD,PT,PT,2023,Q2,Adult
184155424,18415542,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,U,U,,,,,,,QD,2023,Q2,Hyperlactacidaemia,,2023,Q2,4,F,,20230405.0,20201022,20230410,EXP,,PT-MYLANLABS-2020M1089059,MYLAN,"Calaca S, Escaria S, Santos I, Rebocho F, Coutinho D, Canudo D.. PE-362 INTOXICACAO POR METFORMINA - ACIDOSE METABOLICA MULTIFACTORIAL.. Revista da Sociedade Portuguesa de Medicina Interna. 2020;27(Congresso):535-536",54.0,YR,,M,Y,,,20230410,,MD,PT,PT,2023,Q2,Adult
184155424,18415542,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,U,U,,,,,,,QD,2023,Q2,Altered state of consciousness,,2023,Q2,4,F,,20230405.0,20201022,20230410,EXP,,PT-MYLANLABS-2020M1089059,MYLAN,"Calaca S, Escaria S, Santos I, Rebocho F, Coutinho D, Canudo D.. PE-362 INTOXICACAO POR METFORMINA - ACIDOSE METABOLICA MULTIFACTORIAL.. Revista da Sociedade Portuguesa de Medicina Interna. 2020;27(Congresso):535-536",54.0,YR,,M,Y,,,20230410,,MD,PT,PT,2023,Q2,Adult
184155424,18415542,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,U,U,,,,,,,QD,2023,Q2,Vomiting,,2023,Q2,4,F,,20230405.0,20201022,20230410,EXP,,PT-MYLANLABS-2020M1089059,MYLAN,"Calaca S, Escaria S, Santos I, Rebocho F, Coutinho D, Canudo D.. PE-362 INTOXICACAO POR METFORMINA - ACIDOSE METABOLICA MULTIFACTORIAL.. Revista da Sociedade Portuguesa de Medicina Interna. 2020;27(Congresso):535-536",54.0,YR,,M,Y,,,20230410,,MD,PT,PT,2023,Q2,Adult
184155424,18415542,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,U,U,,,,,,,QD,2023,Q2,Multiple organ dysfunction syndrome,,2023,Q2,4,F,,20230405.0,20201022,20230410,EXP,,PT-MYLANLABS-2020M1089059,MYLAN,"Calaca S, Escaria S, Santos I, Rebocho F, Coutinho D, Canudo D.. PE-362 INTOXICACAO POR METFORMINA - ACIDOSE METABOLICA MULTIFACTORIAL.. Revista da Sociedade Portuguesa de Medicina Interna. 2020;27(Congresso):535-536",54.0,YR,,M,Y,,,20230410,,MD,PT,PT,2023,Q2,Adult
184155424,18415542,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,U,U,,,,,,,QD,2023,Q2,Toxicity to various agents,,2023,Q2,4,F,,20230405.0,20201022,20230410,EXP,,PT-MYLANLABS-2020M1089059,MYLAN,"Calaca S, Escaria S, Santos I, Rebocho F, Coutinho D, Canudo D.. PE-362 INTOXICACAO POR METFORMINA - ACIDOSE METABOLICA MULTIFACTORIAL.. Revista da Sociedade Portuguesa de Medicina Interna. 2020;27(Congresso):535-536",54.0,YR,,M,Y,,,20230410,,MD,PT,PT,2023,Q2,Adult
184155424,18415542,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,U,U,,,,,,,QD,2023,Q2,Metabolic acidosis,,2023,Q2,4,F,,20230405.0,20201022,20230410,EXP,,PT-MYLANLABS-2020M1089059,MYLAN,"Calaca S, Escaria S, Santos I, Rebocho F, Coutinho D, Canudo D.. PE-362 INTOXICACAO POR METFORMINA - ACIDOSE METABOLICA MULTIFACTORIAL.. Revista da Sociedade Portuguesa de Medicina Interna. 2020;27(Congresso):535-536",54.0,YR,,M,Y,,,20230410,,MD,PT,PT,2023,Q2,Adult
184155424,18415542,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,U,U,,,,,,,QD,2023,Q2,Hypoglycaemia,,2023,Q2,4,F,,20230405.0,20201022,20230410,EXP,,PT-MYLANLABS-2020M1089059,MYLAN,"Calaca S, Escaria S, Santos I, Rebocho F, Coutinho D, Canudo D.. PE-362 INTOXICACAO POR METFORMINA - ACIDOSE METABOLICA MULTIFACTORIAL.. Revista da Sociedade Portuguesa de Medicina Interna. 2020;27(Congresso):535-536",54.0,YR,,M,Y,,,20230410,,MD,PT,PT,2023,Q2,Adult
1848217514,18482175,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Arthralgia,,2023,Q2,14,F,20201019.0,20230622.0,20201110,20230626,EXP,,JP-ABBVIE-20K-087-3639069-00,ABBVIE,,61.0,YR,,F,Y,,,20230626,,MD,JP,JP,2023,Q2,Adult
1848217514,18482175,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Angina pectoris,,2023,Q2,14,F,20201019.0,20230622.0,20201110,20230626,EXP,,JP-ABBVIE-20K-087-3639069-00,ABBVIE,,61.0,YR,,F,Y,,,20230626,,MD,JP,JP,2023,Q2,Adult
1848217514,18482175,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Rash pruritic,,2023,Q2,14,F,20201019.0,20230622.0,20201110,20230626,EXP,,JP-ABBVIE-20K-087-3639069-00,ABBVIE,,61.0,YR,,F,Y,,,20230626,,MD,JP,JP,2023,Q2,Adult
1848217514,18482175,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Eczema asteatotic,,2023,Q2,14,F,20201019.0,20230622.0,20201110,20230626,EXP,,JP-ABBVIE-20K-087-3639069-00,ABBVIE,,61.0,YR,,F,Y,,,20230626,,MD,JP,JP,2023,Q2,Adult
1848217514,18482175,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Cataract,,2023,Q2,14,F,20201019.0,20230622.0,20201110,20230626,EXP,,JP-ABBVIE-20K-087-3639069-00,ABBVIE,,61.0,YR,,F,Y,,,20230626,,MD,JP,JP,2023,Q2,Adult
188759292,18875929,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,Unknown,,204629.0,,,,,2023,Q2,Fournier's gangrene,,2023,Q2,2,F,,20230328.0,20210210,20230403,EXP,,"IN-B.I. Pharmaceuticals,Inc./Ridgefield-2020-BI-064548",BOEHRINGER INGELHEIM,,56.0,YR,A,M,Y,,,20230404,,MD,IN,IN,2023,Q2,Adult
188759292,18875929,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,Unknown,,204629.0,,,,,2023,Q2,Diabetic ketoacidosis,,2023,Q2,2,F,,20230328.0,20210210,20230403,EXP,,"IN-B.I. Pharmaceuticals,Inc./Ridgefield-2020-BI-064548",BOEHRINGER INGELHEIM,,56.0,YR,A,M,Y,,,20230404,,MD,IN,IN,2023,Q2,Adult
188759292,18875929,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,Unknown,,204629.0,,,,,2023,Q2,Blood glucose decreased,,2023,Q2,2,F,,20230328.0,20210210,20230403,EXP,,"IN-B.I. Pharmaceuticals,Inc./Ridgefield-2020-BI-064548",BOEHRINGER INGELHEIM,,56.0,YR,A,M,Y,,,20230404,,MD,IN,IN,2023,Q2,Adult
196508475,19650847,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, unknown",,,U,,,,,,,,,2023,Q2,Gastric mucosal lesion,,2023,Q2,5,F,20210705.0,20230414.0,20210803,20230426,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202107006194,ELI LILLY AND CO,,67.0,YR,,F,Y,56.0,KG,20230426,,CN,US,CN,2023,Q2,Elderly
199256822,19925682,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,Tablet,QD,2023,Q2,COVID-19,,2023,Q2,2,F,20210701.0,20230616.0,20211007,20230620,EXP,,GB-ROCHE-2925504,ROCHE,,52.0,YR,,F,Y,,,20230620,,MD,GB,,2023,Q2,Adult
200313157,20031315,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,,,,,10.0,MG,,,2023,Q2,Bronchospasm,,2023,Q2,7,F,,20230522.0,20211103,20230526,EXP,,PT-MYLANLABS-2021M1079708,MYLAN,"Fontes J, Falcao M, Paes de Faria V, et al.. PL 0559 Euglycemic diabetic ketoacidosis by iSGLT2- a potentially fatal entity. Journal of the Portuguese Society of Internal Medicine. 2021;28:567",73.0,YR,,M,Y,,,20230526,,MD,PT,PT,2023,Q2,Elderly
200313157,20031315,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,,,,,10.0,MG,,,2023,Q2,Orthopnoea,,2023,Q2,7,F,,20230522.0,20211103,20230526,EXP,,PT-MYLANLABS-2021M1079708,MYLAN,"Fontes J, Falcao M, Paes de Faria V, et al.. PL 0559 Euglycemic diabetic ketoacidosis by iSGLT2- a potentially fatal entity. Journal of the Portuguese Society of Internal Medicine. 2021;28:567",73.0,YR,,M,Y,,,20230526,,MD,PT,PT,2023,Q2,Elderly
200313157,20031315,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,,,,,10.0,MG,,,2023,Q2,Hyperhidrosis,,2023,Q2,7,F,,20230522.0,20211103,20230526,EXP,,PT-MYLANLABS-2021M1079708,MYLAN,"Fontes J, Falcao M, Paes de Faria V, et al.. PL 0559 Euglycemic diabetic ketoacidosis by iSGLT2- a potentially fatal entity. Journal of the Portuguese Society of Internal Medicine. 2021;28:567",73.0,YR,,M,Y,,,20230526,,MD,PT,PT,2023,Q2,Elderly
200313157,20031315,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,,,,,10.0,MG,,,2023,Q2,Metabolic acidosis,,2023,Q2,7,F,,20230522.0,20211103,20230526,EXP,,PT-MYLANLABS-2021M1079708,MYLAN,"Fontes J, Falcao M, Paes de Faria V, et al.. PL 0559 Euglycemic diabetic ketoacidosis by iSGLT2- a potentially fatal entity. Journal of the Portuguese Society of Internal Medicine. 2021;28:567",73.0,YR,,M,Y,,,20230526,,MD,PT,PT,2023,Q2,Elderly
200313157,20031315,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,,,,,10.0,MG,,,2023,Q2,Renal artery thrombosis,,2023,Q2,7,F,,20230522.0,20211103,20230526,EXP,,PT-MYLANLABS-2021M1079708,MYLAN,"Fontes J, Falcao M, Paes de Faria V, et al.. PL 0559 Euglycemic diabetic ketoacidosis by iSGLT2- a potentially fatal entity. Journal of the Portuguese Society of Internal Medicine. 2021;28:567",73.0,YR,,M,Y,,,20230526,,MD,PT,PT,2023,Q2,Elderly
200313157,20031315,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,,,,,10.0,MG,,,2023,Q2,Acidosis,,2023,Q2,7,F,,20230522.0,20211103,20230526,EXP,,PT-MYLANLABS-2021M1079708,MYLAN,"Fontes J, Falcao M, Paes de Faria V, et al.. PL 0559 Euglycemic diabetic ketoacidosis by iSGLT2- a potentially fatal entity. Journal of the Portuguese Society of Internal Medicine. 2021;28:567",73.0,YR,,M,Y,,,20230526,,MD,PT,PT,2023,Q2,Elderly
200313157,20031315,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,,,,,10.0,MG,,,2023,Q2,Renal disorder,,2023,Q2,7,F,,20230522.0,20211103,20230526,EXP,,PT-MYLANLABS-2021M1079708,MYLAN,"Fontes J, Falcao M, Paes de Faria V, et al.. PL 0559 Euglycemic diabetic ketoacidosis by iSGLT2- a potentially fatal entity. Journal of the Portuguese Society of Internal Medicine. 2021;28:567",73.0,YR,,M,Y,,,20230526,,MD,PT,PT,2023,Q2,Elderly
200313157,20031315,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,,,,,10.0,MG,,,2023,Q2,Tachycardia,,2023,Q2,7,F,,20230522.0,20211103,20230526,EXP,,PT-MYLANLABS-2021M1079708,MYLAN,"Fontes J, Falcao M, Paes de Faria V, et al.. PL 0559 Euglycemic diabetic ketoacidosis by iSGLT2- a potentially fatal entity. Journal of the Portuguese Society of Internal Medicine. 2021;28:567",73.0,YR,,M,Y,,,20230526,,MD,PT,PT,2023,Q2,Elderly
200313157,20031315,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,,,,,10.0,MG,,,2023,Q2,Asthenia,,2023,Q2,7,F,,20230522.0,20211103,20230526,EXP,,PT-MYLANLABS-2021M1079708,MYLAN,"Fontes J, Falcao M, Paes de Faria V, et al.. PL 0559 Euglycemic diabetic ketoacidosis by iSGLT2- a potentially fatal entity. Journal of the Portuguese Society of Internal Medicine. 2021;28:567",73.0,YR,,M,Y,,,20230526,,MD,PT,PT,2023,Q2,Elderly
200313157,20031315,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,,,,,10.0,MG,,,2023,Q2,Venous pressure jugular,,2023,Q2,7,F,,20230522.0,20211103,20230526,EXP,,PT-MYLANLABS-2021M1079708,MYLAN,"Fontes J, Falcao M, Paes de Faria V, et al.. PL 0559 Euglycemic diabetic ketoacidosis by iSGLT2- a potentially fatal entity. Journal of the Portuguese Society of Internal Medicine. 2021;28:567",73.0,YR,,M,Y,,,20230526,,MD,PT,PT,2023,Q2,Elderly
200313157,20031315,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,,,,,10.0,MG,,,2023,Q2,Euglycaemic diabetic ketoacidosis,,2023,Q2,7,F,,20230522.0,20211103,20230526,EXP,,PT-MYLANLABS-2021M1079708,MYLAN,"Fontes J, Falcao M, Paes de Faria V, et al.. PL 0559 Euglycemic diabetic ketoacidosis by iSGLT2- a potentially fatal entity. Journal of the Portuguese Society of Internal Medicine. 2021;28:567",73.0,YR,,M,Y,,,20230526,,MD,PT,PT,2023,Q2,Elderly
200313157,20031315,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,,,,,10.0,MG,,,2023,Q2,Tachypnoea,,2023,Q2,7,F,,20230522.0,20211103,20230526,EXP,,PT-MYLANLABS-2021M1079708,MYLAN,"Fontes J, Falcao M, Paes de Faria V, et al.. PL 0559 Euglycemic diabetic ketoacidosis by iSGLT2- a potentially fatal entity. Journal of the Portuguese Society of Internal Medicine. 2021;28:567",73.0,YR,,M,Y,,,20230526,,MD,PT,PT,2023,Q2,Elderly
200313157,20031315,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,,,,,10.0,MG,,,2023,Q2,Multiple organ dysfunction syndrome,,2023,Q2,7,F,,20230522.0,20211103,20230526,EXP,,PT-MYLANLABS-2021M1079708,MYLAN,"Fontes J, Falcao M, Paes de Faria V, et al.. PL 0559 Euglycemic diabetic ketoacidosis by iSGLT2- a potentially fatal entity. Journal of the Portuguese Society of Internal Medicine. 2021;28:567",73.0,YR,,M,Y,,,20230526,,MD,PT,PT,2023,Q2,Elderly
200313157,20031315,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,,,,,10.0,MG,,,2023,Q2,Acute abdomen,,2023,Q2,7,F,,20230522.0,20211103,20230526,EXP,,PT-MYLANLABS-2021M1079708,MYLAN,"Fontes J, Falcao M, Paes de Faria V, et al.. PL 0559 Euglycemic diabetic ketoacidosis by iSGLT2- a potentially fatal entity. Journal of the Portuguese Society of Internal Medicine. 2021;28:567",73.0,YR,,M,Y,,,20230526,,MD,PT,PT,2023,Q2,Elderly
200313157,20031315,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,,,,,10.0,MG,,,2023,Q2,Mesenteric artery thrombosis,,2023,Q2,7,F,,20230522.0,20211103,20230526,EXP,,PT-MYLANLABS-2021M1079708,MYLAN,"Fontes J, Falcao M, Paes de Faria V, et al.. PL 0559 Euglycemic diabetic ketoacidosis by iSGLT2- a potentially fatal entity. Journal of the Portuguese Society of Internal Medicine. 2021;28:567",73.0,YR,,M,Y,,,20230526,,MD,PT,PT,2023,Q2,Elderly
200313157,20031315,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,,,,,10.0,MG,,,2023,Q2,Acute kidney injury,,2023,Q2,7,F,,20230522.0,20211103,20230526,EXP,,PT-MYLANLABS-2021M1079708,MYLAN,"Fontes J, Falcao M, Paes de Faria V, et al.. PL 0559 Euglycemic diabetic ketoacidosis by iSGLT2- a potentially fatal entity. Journal of the Portuguese Society of Internal Medicine. 2021;28:567",73.0,YR,,M,Y,,,20230526,,MD,PT,PT,2023,Q2,Elderly
200313157,20031315,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,,,,,10.0,MG,,,2023,Q2,Shock,,2023,Q2,7,F,,20230522.0,20211103,20230526,EXP,,PT-MYLANLABS-2021M1079708,MYLAN,"Fontes J, Falcao M, Paes de Faria V, et al.. PL 0559 Euglycemic diabetic ketoacidosis by iSGLT2- a potentially fatal entity. Journal of the Portuguese Society of Internal Medicine. 2021;28:567",73.0,YR,,M,Y,,,20230526,,MD,PT,PT,2023,Q2,Elderly
200313157,20031315,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,,,,,10.0,MG,,,2023,Q2,Oliguria,,2023,Q2,7,F,,20230522.0,20211103,20230526,EXP,,PT-MYLANLABS-2021M1079708,MYLAN,"Fontes J, Falcao M, Paes de Faria V, et al.. PL 0559 Euglycemic diabetic ketoacidosis by iSGLT2- a potentially fatal entity. Journal of the Portuguese Society of Internal Medicine. 2021;28:567",73.0,YR,,M,Y,,,20230526,,MD,PT,PT,2023,Q2,Elderly
200313157,20031315,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,,,,,10.0,MG,,,2023,Q2,Aortic thrombosis,,2023,Q2,7,F,,20230522.0,20211103,20230526,EXP,,PT-MYLANLABS-2021M1079708,MYLAN,"Fontes J, Falcao M, Paes de Faria V, et al.. PL 0559 Euglycemic diabetic ketoacidosis by iSGLT2- a potentially fatal entity. Journal of the Portuguese Society of Internal Medicine. 2021;28:567",73.0,YR,,M,Y,,,20230526,,MD,PT,PT,2023,Q2,Elderly
200963115,20096311,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Urinary incontinence,,2023,Q2,5,F,20211015.0,20230511.0,20211122,20230522,EXP,,AU-JNJFOC-20211127221,JOHNSON AND JOHNSON,,67.0,YR,E,M,Y,51.484,KG,20230522,,MD,AU,AU,2023,Q2,Elderly
200963115,20096311,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Urinary retention,,2023,Q2,5,F,20211015.0,20230511.0,20211122,20230522,EXP,,AU-JNJFOC-20211127221,JOHNSON AND JOHNSON,,67.0,YR,E,M,Y,51.484,KG,20230522,,MD,AU,AU,2023,Q2,Elderly
201162335,20116233,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd",,,,,,,,,,,QD,2023,Q2,Glycosuria,,2023,Q2,5,F,20210716.0,20230416.0,20211126,20230425,EXP,,GB-AMGEN-GBRNI2021185238,AMGEN,,69.0,YR,E,F,Y,79.1,KG,20230425,,MD,GB,GB,2023,Q2,Elderly
201162335,20116233,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd",,,,,,,,,,,QD,2023,Q2,Hypothyroidism,,2023,Q2,5,F,20210716.0,20230416.0,20211126,20230425,EXP,,GB-AMGEN-GBRNI2021185238,AMGEN,,69.0,YR,E,F,Y,79.1,KG,20230425,,MD,GB,GB,2023,Q2,Elderly
201162335,20116233,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd",,,,,,,,,,,QD,2023,Q2,Haematuria,,2023,Q2,5,F,20210716.0,20230416.0,20211126,20230425,EXP,,GB-AMGEN-GBRNI2021185238,AMGEN,,69.0,YR,E,F,Y,79.1,KG,20230425,,MD,GB,GB,2023,Q2,Elderly
201162335,20116233,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd",,,,,,,,,,,QD,2023,Q2,Diarrhoea,,2023,Q2,5,F,20210716.0,20230416.0,20211126,20230425,EXP,,GB-AMGEN-GBRNI2021185238,AMGEN,,69.0,YR,E,F,Y,79.1,KG,20230425,,MD,GB,GB,2023,Q2,Elderly
201162335,20116233,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd",,,,,,,,,,,QD,2023,Q2,Hyperthyroidism,,2023,Q2,5,F,20210716.0,20230416.0,20211126,20230425,EXP,,GB-AMGEN-GBRNI2021185238,AMGEN,,69.0,YR,E,F,Y,79.1,KG,20230425,,MD,GB,GB,2023,Q2,Elderly
202171613,20217161,3,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,Y,,,,,10.0,MG,,QD,2023,Q2,Diabetes mellitus,,2023,Q2,3,F,20170520.0,20230407.0,20211222,20230412,EXP,,JP-PFIZER INC-202101756465,PFIZER,"Nawata, T.. Rapid weight loss in a patient with anti-synthetase syndrome treated with sodium-glucose cotransporter 2 inhibitors and corticosteroids.. Rheumatology Advances in Practice. 2021;5(3):1-3",71.0,YR,,F,Y,61.5,KG,20230412,,MD,JP,JP,2023,Q2,Elderly
202171613,20217161,3,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,Y,,,,,10.0,MG,,QD,2023,Q2,Off label use,,2023,Q2,3,F,20170520.0,20230407.0,20211222,20230412,EXP,,JP-PFIZER INC-202101756465,PFIZER,"Nawata, T.. Rapid weight loss in a patient with anti-synthetase syndrome treated with sodium-glucose cotransporter 2 inhibitors and corticosteroids.. Rheumatology Advances in Practice. 2021;5(3):1-3",71.0,YR,,F,Y,61.5,KG,20230412,,MD,JP,JP,2023,Q2,Elderly
202171613,20217161,3,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,Y,,,,,10.0,MG,,QD,2023,Q2,Drug interaction,,2023,Q2,3,F,20170520.0,20230407.0,20211222,20230412,EXP,,JP-PFIZER INC-202101756465,PFIZER,"Nawata, T.. Rapid weight loss in a patient with anti-synthetase syndrome treated with sodium-glucose cotransporter 2 inhibitors and corticosteroids.. Rheumatology Advances in Practice. 2021;5(3):1-3",71.0,YR,,F,Y,61.5,KG,20230412,,MD,JP,JP,2023,Q2,Elderly
202171613,20217161,3,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,Y,,,,,10.0,MG,,QD,2023,Q2,Weight decreased,,2023,Q2,3,F,20170520.0,20230407.0,20211222,20230412,EXP,,JP-PFIZER INC-202101756465,PFIZER,"Nawata, T.. Rapid weight loss in a patient with anti-synthetase syndrome treated with sodium-glucose cotransporter 2 inhibitors and corticosteroids.. Rheumatology Advances in Practice. 2021;5(3):1-3",71.0,YR,,F,Y,61.5,KG,20230412,,MD,JP,JP,2023,Q2,Elderly
202171613,20217161,3,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,Y,,,,,10.0,MG,,QD,2023,Q2,Hyperglycaemia,,2023,Q2,3,F,20170520.0,20230407.0,20211222,20230412,EXP,,JP-PFIZER INC-202101756465,PFIZER,"Nawata, T.. Rapid weight loss in a patient with anti-synthetase syndrome treated with sodium-glucose cotransporter 2 inhibitors and corticosteroids.. Rheumatology Advances in Practice. 2021;5(3):1-3",71.0,YR,,F,Y,61.5,KG,20230412,,MD,JP,JP,2023,Q2,Elderly
202171613,20217161,3,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,Y,,,,,10.0,MG,,QD,2023,Q2,Hypercatabolism,,2023,Q2,3,F,20170520.0,20230407.0,20211222,20230412,EXP,,JP-PFIZER INC-202101756465,PFIZER,"Nawata, T.. Rapid weight loss in a patient with anti-synthetase syndrome treated with sodium-glucose cotransporter 2 inhibitors and corticosteroids.. Rheumatology Advances in Practice. 2021;5(3):1-3",71.0,YR,,F,Y,61.5,KG,20230412,,MD,JP,JP,2023,Q2,Elderly
202171613,20217161,3,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,Y,,,,,10.0,MG,,QD,2023,Q2,Orthostatic hypotension,,2023,Q2,3,F,20170520.0,20230407.0,20211222,20230412,EXP,,JP-PFIZER INC-202101756465,PFIZER,"Nawata, T.. Rapid weight loss in a patient with anti-synthetase syndrome treated with sodium-glucose cotransporter 2 inhibitors and corticosteroids.. Rheumatology Advances in Practice. 2021;5(3):1-3",71.0,YR,,F,Y,61.5,KG,20230412,,MD,JP,JP,2023,Q2,Elderly
202171613,20217161,3,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,Y,,,,,10.0,MG,,QD,2023,Q2,Blood urea increased,,2023,Q2,3,F,20170520.0,20230407.0,20211222,20230412,EXP,,JP-PFIZER INC-202101756465,PFIZER,"Nawata, T.. Rapid weight loss in a patient with anti-synthetase syndrome treated with sodium-glucose cotransporter 2 inhibitors and corticosteroids.. Rheumatology Advances in Practice. 2021;5(3):1-3",71.0,YR,,F,Y,61.5,KG,20230412,,MD,JP,JP,2023,Q2,Elderly
2033327536,20333275,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,Tablets,,2023,Q2,Alanine aminotransferase increased,,2023,Q2,36,F,20220105.0,20230529.0,20220113,20230605,PER,,BR-Eisai Medical Research-EC-2022-106612,EISAI,,64.0,YR,A,F,Y,63.7,KG,20230605,,MD,BR,,2023,Q2,Adult
2033327536,20333275,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,Tablets,,2023,Q2,Anaemia,,2023,Q2,36,F,20220105.0,20230529.0,20220113,20230605,PER,,BR-Eisai Medical Research-EC-2022-106612,EISAI,,64.0,YR,A,F,Y,63.7,KG,20230605,,MD,BR,,2023,Q2,Adult
2033327536,20333275,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,Tablets,,2023,Q2,Adrenal insufficiency,,2023,Q2,36,F,20220105.0,20230529.0,20220113,20230605,PER,,BR-Eisai Medical Research-EC-2022-106612,EISAI,,64.0,YR,A,F,Y,63.7,KG,20230605,,MD,BR,,2023,Q2,Adult
2033327536,20333275,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,Tablets,,2023,Q2,Aspartate aminotransferase increased,Aspartate aminotransferase increased,2023,Q2,36,F,20220105.0,20230529.0,20220113,20230605,PER,,BR-Eisai Medical Research-EC-2022-106612,EISAI,,64.0,YR,A,F,Y,63.7,KG,20230605,,MD,BR,,2023,Q2,Adult
203540142,20354014,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,COVID-19,,2023,Q2,2,F,20211224.0,20230517.0,20220120,20230522,EXP,,DE-ROCHE-2994105,ROCHE,,63.0,YR,,M,Y,,,20230522,,MD,DE,,2023,Q2,Adult
2037504420,20375044,5,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2023,Q2,Weight decreased,,2023,Q2,20,F,20211125.0,20230411.0,20220125,20230418,PER,,CH-Eisai Medical Research-EC-2022-107259,EISAI,,79.0,YR,E,M,Y,80.1,KG,20230418,,MD,CH,,2023,Q2,Elderly
203821447,20382144,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Anxiety,,2023,Q2,7,F,20210930.0,20230607.0,20220127,20230614,EXP,,CA-BAUSCH-BL-2021-034002,BAUSCH AND LOMB,,55.0,YR,,M,Y,,,20230614,,CN,CA,CA,2023,Q2,Adult
203821447,20382144,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Product dose omission issue,,2023,Q2,7,F,20210930.0,20230607.0,20220127,20230614,EXP,,CA-BAUSCH-BL-2021-034002,BAUSCH AND LOMB,,55.0,YR,,M,Y,,,20230614,,CN,CA,CA,2023,Q2,Adult
203821447,20382144,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Hypertension,,2023,Q2,7,F,20210930.0,20230607.0,20220127,20230614,EXP,,CA-BAUSCH-BL-2021-034002,BAUSCH AND LOMB,,55.0,YR,,M,Y,,,20230614,,CN,CA,CA,2023,Q2,Adult
203821447,20382144,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Fatigue,,2023,Q2,7,F,20210930.0,20230607.0,20220127,20230614,EXP,,CA-BAUSCH-BL-2021-034002,BAUSCH AND LOMB,,55.0,YR,,M,Y,,,20230614,,CN,CA,CA,2023,Q2,Adult
203821447,20382144,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Family stress,,2023,Q2,7,F,20210930.0,20230607.0,20220127,20230614,EXP,,CA-BAUSCH-BL-2021-034002,BAUSCH AND LOMB,,55.0,YR,,M,Y,,,20230614,,CN,CA,CA,2023,Q2,Adult
206157334,20615733,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,UNKNOWN,,,10.0,MG,Unknown,QD,2023,Q2,Back pain,,2023,Q2,4,F,20220101.0,20230320.0,20220321,20230403,EXP,,GB-Hikma Pharmaceuticals USA Inc.-GB-H14001-22-57076,HIKMA,,62.0,YR,,M,Y,115.9,KG,20230331,,MD,GB,GB,2023,Q2,Adult
206157334,20615733,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,UNKNOWN,,,10.0,MG,Unknown,QD,2023,Q2,Sepsis,,2023,Q2,4,F,20220101.0,20230320.0,20220321,20230403,EXP,,GB-Hikma Pharmaceuticals USA Inc.-GB-H14001-22-57076,HIKMA,,62.0,YR,,M,Y,115.9,KG,20230331,,MD,GB,GB,2023,Q2,Adult
206157334,20615733,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,UNKNOWN,,,10.0,MG,Unknown,QD,2023,Q2,Vascular device infection,,2023,Q2,4,F,20220101.0,20230320.0,20220321,20230403,EXP,,GB-Hikma Pharmaceuticals USA Inc.-GB-H14001-22-57076,HIKMA,,62.0,YR,,M,Y,115.9,KG,20230331,,MD,GB,GB,2023,Q2,Adult
206157334,20615733,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,UNKNOWN,,,10.0,MG,Unknown,QD,2023,Q2,Ecchymosis,,2023,Q2,4,F,20220101.0,20230320.0,20220321,20230403,EXP,,GB-Hikma Pharmaceuticals USA Inc.-GB-H14001-22-57076,HIKMA,,62.0,YR,,M,Y,115.9,KG,20230331,,MD,GB,GB,2023,Q2,Adult
206157334,20615733,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,UNKNOWN,,,10.0,MG,Unknown,QD,2023,Q2,Haematoma,,2023,Q2,4,F,20220101.0,20230320.0,20220321,20230403,EXP,,GB-Hikma Pharmaceuticals USA Inc.-GB-H14001-22-57076,HIKMA,,62.0,YR,,M,Y,115.9,KG,20230331,,MD,GB,GB,2023,Q2,Adult
206157334,20615733,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,UNKNOWN,,,10.0,MG,Unknown,QD,2023,Q2,Hypotension,,2023,Q2,4,F,20220101.0,20230320.0,20220321,20230403,EXP,,GB-Hikma Pharmaceuticals USA Inc.-GB-H14001-22-57076,HIKMA,,62.0,YR,,M,Y,115.9,KG,20230331,,MD,GB,GB,2023,Q2,Adult
206157334,20615733,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,UNKNOWN,,,10.0,MG,Unknown,QD,2023,Q2,Vomiting,,2023,Q2,4,F,20220101.0,20230320.0,20220321,20230403,EXP,,GB-Hikma Pharmaceuticals USA Inc.-GB-H14001-22-57076,HIKMA,,62.0,YR,,M,Y,115.9,KG,20230331,,MD,GB,GB,2023,Q2,Adult
206157334,20615733,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,UNKNOWN,,,10.0,MG,Unknown,QD,2023,Q2,Pyrexia,,2023,Q2,4,F,20220101.0,20230320.0,20220321,20230403,EXP,,GB-Hikma Pharmaceuticals USA Inc.-GB-H14001-22-57076,HIKMA,,62.0,YR,,M,Y,115.9,KG,20230331,,MD,GB,GB,2023,Q2,Adult
206157334,20615733,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,UNKNOWN,,,10.0,MG,Unknown,QD,2023,Q2,Infusion related reaction,,2023,Q2,4,F,20220101.0,20230320.0,20220321,20230403,EXP,,GB-Hikma Pharmaceuticals USA Inc.-GB-H14001-22-57076,HIKMA,,62.0,YR,,M,Y,115.9,KG,20230331,,MD,GB,GB,2023,Q2,Adult
206157334,20615733,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,UNKNOWN,,,10.0,MG,Unknown,QD,2023,Q2,Diarrhoea,,2023,Q2,4,F,20220101.0,20230320.0,20220321,20230403,EXP,,GB-Hikma Pharmaceuticals USA Inc.-GB-H14001-22-57076,HIKMA,,62.0,YR,,M,Y,115.9,KG,20230331,,MD,GB,GB,2023,Q2,Adult
207003635,20700363,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Unknown,,204629.0,10.0,MG,Tablet,,2023,Q2,Acute kidney injury,,2023,Q2,5,F,20210820.0,20230531.0,20220412,20230602,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-127601",BOEHRINGER INGELHEIM,,76.0,YR,E,F,Y,60.0,KG,20230602,,MD,DE,DE,2023,Q2,Elderly
207003635,20700363,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Unknown,,204629.0,10.0,MG,Tablet,,2023,Q2,Acute kidney injury,,2023,Q2,5,F,20210820.0,20230531.0,20220412,20230602,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-127601",BOEHRINGER INGELHEIM,,76.0,YR,E,F,Y,60.0,KG,20230602,,MD,DE,DE,2023,Q2,Elderly
207078918,20707891,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,Y,U,Unknown,,206073.0,,,Tablet,,2023,Q2,Diabetic ketoacidosis,,2023,Q2,8,F,20220412.0,20230512.0,20220414,20230516,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-165275",BOEHRINGER INGELHEIM,,57.0,YR,A,M,Y,70.0,KG,20230516,,MD,JP,JP,2023,Q2,Adult
207078918,20707891,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,Y,U,Unknown,,206073.0,,,Tablet,,2023,Q2,Appendicitis,,2023,Q2,8,F,20220412.0,20230512.0,20220414,20230516,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-165275",BOEHRINGER INGELHEIM,,57.0,YR,A,M,Y,70.0,KG,20230516,,MD,JP,JP,2023,Q2,Adult
207189663,20718966,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Sepsis,,2023,Q2,3,F,20220126.0,20230427.0,20220418,20230502,EXP,,IL-ABBVIE-22K-082-4361411-00,ABBVIE,,88.0,YR,,M,Y,,,20230502,,MD,IL,IL,2023,Q2,Elderly
207189663,20718966,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Febrile neutropenia,,2023,Q2,3,F,20220126.0,20230427.0,20220418,20230502,EXP,,IL-ABBVIE-22K-082-4361411-00,ABBVIE,,88.0,YR,,M,Y,,,20230502,,MD,IL,IL,2023,Q2,Elderly
207954407,20795440,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,QD,2023,Q2,Ocular vasculitis,,2023,Q2,7,F,20220427.0,20230417.0,20220506,20230421,EXP,,US-ROCHE-3087474,ROCHE,,76.0,YR,,F,Y,70.9,KG,20230421,,MD,US,,2023,Q2,Elderly
210974256,21097425,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,once a day in the morning,,,,,,,,10.0,MG,,QD,2023,Q2,Ischaemic cardiomyopathy,,2023,Q2,6,F,20220531.0,20230613.0,20220719,20230616,EXP,,US-ROCHE-3127711,ROCHE,,71.0,YR,,F,Y,87.3,KG,20230616,,MD,US,,2023,Q2,Elderly
210974256,21097425,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,once a day in the morning,,,,,,,,10.0,MG,,QD,2023,Q2,Acute coronary syndrome,,2023,Q2,6,F,20220531.0,20230613.0,20220719,20230616,EXP,,US-ROCHE-3127711,ROCHE,,71.0,YR,,F,Y,87.3,KG,20230616,,MD,US,,2023,Q2,Elderly
210974256,21097425,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,once a day in the morning,,,,,,,,10.0,MG,,QD,2023,Q2,Coronary artery disease,,2023,Q2,6,F,20220531.0,20230613.0,20220719,20230616,EXP,,US-ROCHE-3127711,ROCHE,,71.0,YR,,F,Y,87.3,KG,20230616,,MD,US,,2023,Q2,Elderly
211165706,21116570,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Toxic encephalopathy,,2023,Q2,6,F,20201020.0,20230615.0,20220722,20230622,EXP,,JP-TAKEDA-2022TUS049042,TAKEDA,,75.0,YR,,M,Y,57.0,KG,20230622,,PH,JP,JP,2023,Q2,Elderly
211165706,21116570,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Drug interaction,,2023,Q2,6,F,20201020.0,20230615.0,20220722,20230622,EXP,,JP-TAKEDA-2022TUS049042,TAKEDA,,75.0,YR,,M,Y,57.0,KG,20230622,,PH,JP,JP,2023,Q2,Elderly
211206764,21120676,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, Once Daily (qd)",,,U,,,,,25.0,MG,,QD,2023,Q2,Depression,,2023,Q2,4,F,20220601.0,20230426.0,20220722,20230428,EXP,,US-UCBSA-2022031861,UCB,,41.0,YR,,F,Y,74.83,KG,20230428,,CN,US,US,2023,Q2,Adult
211206764,21120676,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, Once Daily (qd)",,,U,,,,,25.0,MG,,QD,2023,Q2,Seizure,,2023,Q2,4,F,20220601.0,20230426.0,20220722,20230428,EXP,,US-UCBSA-2022031861,UCB,,41.0,YR,,F,Y,74.83,KG,20230428,,CN,US,US,2023,Q2,Adult
211206764,21120676,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, Once Daily (qd)",,,U,,,,,25.0,MG,,QD,2023,Q2,Cognitive disorder,,2023,Q2,4,F,20220601.0,20230426.0,20220722,20230428,EXP,,US-UCBSA-2022031861,UCB,,41.0,YR,,F,Y,74.83,KG,20230428,,CN,US,US,2023,Q2,Adult
211206764,21120676,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, Once Daily (qd)",,,U,,,,,25.0,MG,,QD,2023,Q2,Therapy interrupted,,2023,Q2,4,F,20220601.0,20230426.0,20220722,20230428,EXP,,US-UCBSA-2022031861,UCB,,41.0,YR,,F,Y,74.83,KG,20230428,,CN,US,US,2023,Q2,Adult
211206764,21120676,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, Once Daily (qd)",,,U,,,,,25.0,MG,,QD,2023,Q2,Product availability issue,,2023,Q2,4,F,20220601.0,20230426.0,20220722,20230428,EXP,,US-UCBSA-2022031861,UCB,,41.0,YR,,F,Y,74.83,KG,20230428,,CN,US,US,2023,Q2,Adult
2113554611,21135546,11,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,Medication dose: 1 Tablet,,,,,,,,,,Tablet,,2023,Q2,Dysphonia,,2023,Q2,11,F,20220708.0,20230419.0,20220727,20230422,EXP,,NZ-ROCHE-3145621,ROCHE,,82.0,YR,,M,Y,56.1,KG,20230422,,MD,NZ,,2023,Q2,Elderly
2116548110,21165481,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Palmar-plantar erythrodysaesthesia syndrome,,2023,Q2,10,F,20220101.0,20230620.0,20220803,20230626,EXP,,JP-009507513-2207JPN001031J,MERCK,,71.0,YR,,M,Y,,,20230626,,MD,JP,JP,2023,Q2,Elderly
2116548110,21165481,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Decreased appetite,,2023,Q2,10,F,20220101.0,20230620.0,20220803,20230626,EXP,,JP-009507513-2207JPN001031J,MERCK,,71.0,YR,,M,Y,,,20230626,,MD,JP,JP,2023,Q2,Elderly
2116548110,21165481,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Nausea,,2023,Q2,10,F,20220101.0,20230620.0,20220803,20230626,EXP,,JP-009507513-2207JPN001031J,MERCK,,71.0,YR,,M,Y,,,20230626,,MD,JP,JP,2023,Q2,Elderly
2116548110,21165481,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Vomiting,,2023,Q2,10,F,20220101.0,20230620.0,20220803,20230626,EXP,,JP-009507513-2207JPN001031J,MERCK,,71.0,YR,,M,Y,,,20230626,,MD,JP,JP,2023,Q2,Elderly
2116548110,21165481,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Hypertension,,2023,Q2,10,F,20220101.0,20230620.0,20220803,20230626,EXP,,JP-009507513-2207JPN001031J,MERCK,,71.0,YR,,M,Y,,,20230626,,MD,JP,JP,2023,Q2,Elderly
2116548110,21165481,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Dysphonia,,2023,Q2,10,F,20220101.0,20230620.0,20220803,20230626,EXP,,JP-009507513-2207JPN001031J,MERCK,,71.0,YR,,M,Y,,,20230626,,MD,JP,JP,2023,Q2,Elderly
2116548110,21165481,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Diarrhoea,,2023,Q2,10,F,20220101.0,20230620.0,20220803,20230626,EXP,,JP-009507513-2207JPN001031J,MERCK,,71.0,YR,,M,Y,,,20230626,,MD,JP,JP,2023,Q2,Elderly
2116548110,21165481,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Haematuria,,2023,Q2,10,F,20220101.0,20230620.0,20220803,20230626,EXP,,JP-009507513-2207JPN001031J,MERCK,,71.0,YR,,M,Y,,,20230626,,MD,JP,JP,2023,Q2,Elderly
2116548110,21165481,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Stomatitis,,2023,Q2,10,F,20220101.0,20230620.0,20220803,20230626,EXP,,JP-009507513-2207JPN001031J,MERCK,,71.0,YR,,M,Y,,,20230626,,MD,JP,JP,2023,Q2,Elderly
2116548110,21165481,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Hypothyroidism,,2023,Q2,10,F,20220101.0,20230620.0,20220803,20230626,EXP,,JP-009507513-2207JPN001031J,MERCK,,71.0,YR,,M,Y,,,20230626,,MD,JP,JP,2023,Q2,Elderly
2116548110,21165481,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Bladder tamponade,,2023,Q2,10,F,20220101.0,20230620.0,20220803,20230626,EXP,,JP-009507513-2207JPN001031J,MERCK,,71.0,YR,,M,Y,,,20230626,,MD,JP,JP,2023,Q2,Elderly
211673806,21167380,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,dose and frequency unknown,,,,,,,,,,,,2023,Q2,Hypertension,,2023,Q2,6,F,20220601.0,20230428.0,20220803,20230504,PER,,JP-Eisai Medical Research-EC-2022-119234,EISAI,,70.0,YR,E,M,Y,,,20230504,,MD,JP,JP,2023,Q2,Elderly
211693132,21169313,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2023,Q2,Product use in unapproved indication,,2023,Q2,2,F,,20230609.0,20220804,20230620,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-18614,SAMSUNG BIOEPIS,,57.0,YR,A,M,Y,103.0,KG,20230620,,HP,CA,CA,2023,Q2,Adult
211693132,21169313,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2023,Q2,Insomnia,,2023,Q2,2,F,,20230609.0,20220804,20230620,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-18614,SAMSUNG BIOEPIS,,57.0,YR,A,M,Y,103.0,KG,20230620,,HP,CA,CA,2023,Q2,Adult
211693132,21169313,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2023,Q2,Cardiac pacemaker insertion,,2023,Q2,2,F,,20230609.0,20220804,20230620,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-18614,SAMSUNG BIOEPIS,,57.0,YR,A,M,Y,103.0,KG,20230620,,HP,CA,CA,2023,Q2,Adult
211693132,21169313,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2023,Q2,Intentional product use issue,,2023,Q2,2,F,,20230609.0,20220804,20230620,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-18614,SAMSUNG BIOEPIS,,57.0,YR,A,M,Y,103.0,KG,20230620,,HP,CA,CA,2023,Q2,Adult
211693132,21169313,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2023,Q2,Loss of consciousness,,2023,Q2,2,F,,20230609.0,20220804,20230620,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-18614,SAMSUNG BIOEPIS,,57.0,YR,A,M,Y,103.0,KG,20230620,,HP,CA,CA,2023,Q2,Adult
211693132,21169313,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2023,Q2,Off label use,,2023,Q2,2,F,,20230609.0,20220804,20230620,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-18614,SAMSUNG BIOEPIS,,57.0,YR,A,M,Y,103.0,KG,20230620,,HP,CA,CA,2023,Q2,Adult
211693132,21169313,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2023,Q2,Asthenia,,2023,Q2,2,F,,20230609.0,20220804,20230620,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-18614,SAMSUNG BIOEPIS,,57.0,YR,A,M,Y,103.0,KG,20230620,,HP,CA,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Frequent bowel movements,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Pain in extremity,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Systemic lupus erythematosus,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Somnolence,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,COVID-19,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Tinnitus,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Tubulointerstitial nephritis,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Migraine,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Loss of personal independence in daily activities,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Adverse drug reaction,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Gingival pain,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Bronchiectasis,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Product use in unapproved indication,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Rash,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Nightmare,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Hypopnoea,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Off label use,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Haematochezia,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Cerebrovascular accident,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Colitis ulcerative,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Parosmia,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Pyrexia,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Condition aggravated,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Impaired quality of life,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Steroid dependence,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Impaired work ability,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Swollen tongue,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Catarrh,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Inappropriate schedule of product administration,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Fatigue,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Fatigue,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Arthritis,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Colitis ulcerative,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Cardiac murmur,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Pulmonary embolism,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Drug ineffective,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Weight decreased,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Dysgeusia,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Medication error,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Loss of personal independence in daily activities,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Pain,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Accidental overdose,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Confusional state,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Stress,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Eczema,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Rash,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Rectal haemorrhage,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Palpitations,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Burns second degree,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Deep vein thrombosis,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Product use in unapproved indication,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Rhinitis,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Headache,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Depression,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Abdominal discomfort,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Tinnitus,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Intentional product use issue,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Vertigo,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Frequent bowel movements,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Pain in extremity,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Systemic lupus erythematosus,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Somnolence,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,COVID-19,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Tinnitus,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Tubulointerstitial nephritis,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Migraine,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Loss of personal independence in daily activities,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Adverse drug reaction,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Gingival pain,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Bronchiectasis,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Product use in unapproved indication,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Rash,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Nightmare,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Hypopnoea,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Off label use,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Haematochezia,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Cerebrovascular accident,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Colitis ulcerative,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Parosmia,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Pyrexia,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Condition aggravated,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Impaired quality of life,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Steroid dependence,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Impaired work ability,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Swollen tongue,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Catarrh,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Inappropriate schedule of product administration,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Fatigue,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Fatigue,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Arthritis,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Colitis ulcerative,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Cardiac murmur,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Pulmonary embolism,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Drug ineffective,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Weight decreased,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Dysgeusia,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Medication error,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Loss of personal independence in daily activities,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Pain,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Accidental overdose,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Confusional state,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Stress,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Eczema,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Rash,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Rectal haemorrhage,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Palpitations,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Burns second degree,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Deep vein thrombosis,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Product use in unapproved indication,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Rhinitis,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Headache,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Depression,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Abdominal discomfort,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Tinnitus,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Intentional product use issue,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211733519,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Vertigo,,2023,Q2,9,F,20080101.0,20230522.0,20220804,20230529,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230529,,MD,GB,CA,2023,Q2,Adult
211972483,21197248,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, 1x/day",,,U,,,,,10.0,MG,,QD,2023,Q2,Oxygen saturation decreased,,2023,Q2,3,F,,20230503.0,20220810,20230509,EXP,,CA-PFIZER INC-202201041435,PFIZER,,66.0,YR,,F,Y,89.0,KG,20230509,,HP,CA,CA,2023,Q2,Elderly
211972483,21197248,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, 1x/day",,,U,,,,,10.0,MG,,QD,2023,Q2,Aortic arteriosclerosis,,2023,Q2,3,F,,20230503.0,20220810,20230509,EXP,,CA-PFIZER INC-202201041435,PFIZER,,66.0,YR,,F,Y,89.0,KG,20230509,,HP,CA,CA,2023,Q2,Elderly
211972483,21197248,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, 1x/day",,,U,,,,,10.0,MG,,QD,2023,Q2,Blood pressure increased,,2023,Q2,3,F,,20230503.0,20220810,20230509,EXP,,CA-PFIZER INC-202201041435,PFIZER,,66.0,YR,,F,Y,89.0,KG,20230509,,HP,CA,CA,2023,Q2,Elderly
211972483,21197248,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, 1x/day",,,U,,,,,10.0,MG,,QD,2023,Q2,Weight decreased,,2023,Q2,3,F,,20230503.0,20220810,20230509,EXP,,CA-PFIZER INC-202201041435,PFIZER,,66.0,YR,,F,Y,89.0,KG,20230509,,HP,CA,CA,2023,Q2,Elderly
211972483,21197248,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, 1x/day",,,U,,,,,10.0,MG,,QD,2023,Q2,Weight increased,,2023,Q2,3,F,,20230503.0,20220810,20230509,EXP,,CA-PFIZER INC-202201041435,PFIZER,,66.0,YR,,F,Y,89.0,KG,20230509,,HP,CA,CA,2023,Q2,Elderly
211972483,21197248,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, 1x/day",,,U,,,,,10.0,MG,,QD,2023,Q2,Blood pressure fluctuation,,2023,Q2,3,F,,20230503.0,20220810,20230509,EXP,,CA-PFIZER INC-202201041435,PFIZER,,66.0,YR,,F,Y,89.0,KG,20230509,,HP,CA,CA,2023,Q2,Elderly
211972483,21197248,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, 1x/day",,,U,,,,,10.0,MG,,QD,2023,Q2,Blood pressure diastolic abnormal,,2023,Q2,3,F,,20230503.0,20220810,20230509,EXP,,CA-PFIZER INC-202201041435,PFIZER,,66.0,YR,,F,Y,89.0,KG,20230509,,HP,CA,CA,2023,Q2,Elderly
211972483,21197248,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, 1x/day",,,U,,,,,10.0,MG,,QD,2023,Q2,Type 2 diabetes mellitus,,2023,Q2,3,F,,20230503.0,20220810,20230509,EXP,,CA-PFIZER INC-202201041435,PFIZER,,66.0,YR,,F,Y,89.0,KG,20230509,,HP,CA,CA,2023,Q2,Elderly
211972483,21197248,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, 1x/day",,,U,,,,,10.0,MG,,QD,2023,Q2,Blood pressure systolic increased,,2023,Q2,3,F,,20230503.0,20220810,20230509,EXP,,CA-PFIZER INC-202201041435,PFIZER,,66.0,YR,,F,Y,89.0,KG,20230509,,HP,CA,CA,2023,Q2,Elderly
211972483,21197248,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, 1x/day",,,U,,,,,10.0,MG,,QD,2023,Q2,Blood glucose increased,,2023,Q2,3,F,,20230503.0,20220810,20230509,EXP,,CA-PFIZER INC-202201041435,PFIZER,,66.0,YR,,F,Y,89.0,KG,20230509,,HP,CA,CA,2023,Q2,Elderly
211972483,21197248,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, 1x/day",,,U,,,,,10.0,MG,,QD,2023,Q2,Blood pressure diastolic decreased,,2023,Q2,3,F,,20230503.0,20220810,20230509,EXP,,CA-PFIZER INC-202201041435,PFIZER,,66.0,YR,,F,Y,89.0,KG,20230509,,HP,CA,CA,2023,Q2,Elderly
212095454,21209545,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q2,Blood pressure diastolic decreased,,2023,Q2,4,F,,20230522.0,20220813,20230530,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230530,,MD,TH,TH,2023,Q2,Elderly
212095454,21209545,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q2,Haemolysis,,2023,Q2,4,F,,20230522.0,20220813,20230530,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230530,,MD,TH,TH,2023,Q2,Elderly
212095454,21209545,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q2,Weight increased,,2023,Q2,4,F,,20230522.0,20220813,20230530,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230530,,MD,TH,TH,2023,Q2,Elderly
212095454,21209545,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q2,Blood glucose increased,,2023,Q2,4,F,,20230522.0,20220813,20230530,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230530,,MD,TH,TH,2023,Q2,Elderly
212095454,21209545,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q2,Body mass index increased,,2023,Q2,4,F,,20230522.0,20220813,20230530,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230530,,MD,TH,TH,2023,Q2,Elderly
212095454,21209545,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q2,Creatinine renal clearance decreased,,2023,Q2,4,F,,20230522.0,20220813,20230530,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230530,,MD,TH,TH,2023,Q2,Elderly
212095454,21209545,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q2,Blood pressure systolic increased,,2023,Q2,4,F,,20230522.0,20220813,20230530,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230530,,MD,TH,TH,2023,Q2,Elderly
212095454,21209545,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q2,Blood creatinine increased,,2023,Q2,4,F,,20230522.0,20220813,20230530,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230530,,MD,TH,TH,2023,Q2,Elderly
212095454,21209545,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q2,Blood potassium increased,,2023,Q2,4,F,,20230522.0,20220813,20230530,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230530,,MD,TH,TH,2023,Q2,Elderly
212095454,21209545,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q2,Glycosylated haemoglobin increased,,2023,Q2,4,F,,20230522.0,20220813,20230530,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230530,,MD,TH,TH,2023,Q2,Elderly
212095454,21209545,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q2,Blood pressure diastolic decreased,,2023,Q2,4,F,,20230522.0,20220813,20230530,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230530,,MD,TH,TH,2023,Q2,Elderly
212095454,21209545,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q2,Haemolysis,,2023,Q2,4,F,,20230522.0,20220813,20230530,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230530,,MD,TH,TH,2023,Q2,Elderly
212095454,21209545,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q2,Weight increased,,2023,Q2,4,F,,20230522.0,20220813,20230530,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230530,,MD,TH,TH,2023,Q2,Elderly
212095454,21209545,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q2,Blood glucose increased,,2023,Q2,4,F,,20230522.0,20220813,20230530,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230530,,MD,TH,TH,2023,Q2,Elderly
212095454,21209545,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q2,Body mass index increased,,2023,Q2,4,F,,20230522.0,20220813,20230530,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230530,,MD,TH,TH,2023,Q2,Elderly
212095454,21209545,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q2,Creatinine renal clearance decreased,,2023,Q2,4,F,,20230522.0,20220813,20230530,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230530,,MD,TH,TH,2023,Q2,Elderly
212095454,21209545,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q2,Blood pressure systolic increased,,2023,Q2,4,F,,20230522.0,20220813,20230530,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230530,,MD,TH,TH,2023,Q2,Elderly
212095454,21209545,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q2,Blood creatinine increased,,2023,Q2,4,F,,20230522.0,20220813,20230530,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230530,,MD,TH,TH,2023,Q2,Elderly
212095454,21209545,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q2,Blood potassium increased,,2023,Q2,4,F,,20230522.0,20220813,20230530,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230530,,MD,TH,TH,2023,Q2,Elderly
212095454,21209545,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q2,Glycosylated haemoglobin increased,,2023,Q2,4,F,,20230522.0,20220813,20230530,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230530,,MD,TH,TH,2023,Q2,Elderly
212095454,21209545,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q2,Blood pressure diastolic decreased,,2023,Q2,4,F,,20230522.0,20220813,20230530,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230530,,MD,TH,TH,2023,Q2,Elderly
212095454,21209545,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q2,Haemolysis,,2023,Q2,4,F,,20230522.0,20220813,20230530,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230530,,MD,TH,TH,2023,Q2,Elderly
212095454,21209545,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q2,Weight increased,,2023,Q2,4,F,,20230522.0,20220813,20230530,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230530,,MD,TH,TH,2023,Q2,Elderly
212095454,21209545,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q2,Blood glucose increased,,2023,Q2,4,F,,20230522.0,20220813,20230530,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230530,,MD,TH,TH,2023,Q2,Elderly
212095454,21209545,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q2,Body mass index increased,,2023,Q2,4,F,,20230522.0,20220813,20230530,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230530,,MD,TH,TH,2023,Q2,Elderly
212095454,21209545,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q2,Creatinine renal clearance decreased,,2023,Q2,4,F,,20230522.0,20220813,20230530,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230530,,MD,TH,TH,2023,Q2,Elderly
212095454,21209545,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q2,Blood pressure systolic increased,,2023,Q2,4,F,,20230522.0,20220813,20230530,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230530,,MD,TH,TH,2023,Q2,Elderly
212095454,21209545,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q2,Blood creatinine increased,,2023,Q2,4,F,,20230522.0,20220813,20230530,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230530,,MD,TH,TH,2023,Q2,Elderly
212095454,21209545,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q2,Blood potassium increased,,2023,Q2,4,F,,20230522.0,20220813,20230530,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230530,,MD,TH,TH,2023,Q2,Elderly
212095454,21209545,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q2,Glycosylated haemoglobin increased,,2023,Q2,4,F,,20230522.0,20220813,20230530,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230530,,MD,TH,TH,2023,Q2,Elderly
212095454,21209545,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q2,Blood pressure diastolic decreased,,2023,Q2,4,F,,20230522.0,20220813,20230530,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230530,,MD,TH,TH,2023,Q2,Elderly
212095454,21209545,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q2,Haemolysis,,2023,Q2,4,F,,20230522.0,20220813,20230530,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230530,,MD,TH,TH,2023,Q2,Elderly
212095454,21209545,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q2,Weight increased,,2023,Q2,4,F,,20230522.0,20220813,20230530,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230530,,MD,TH,TH,2023,Q2,Elderly
212095454,21209545,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q2,Blood glucose increased,,2023,Q2,4,F,,20230522.0,20220813,20230530,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230530,,MD,TH,TH,2023,Q2,Elderly
212095454,21209545,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q2,Body mass index increased,,2023,Q2,4,F,,20230522.0,20220813,20230530,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230530,,MD,TH,TH,2023,Q2,Elderly
212095454,21209545,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q2,Creatinine renal clearance decreased,,2023,Q2,4,F,,20230522.0,20220813,20230530,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230530,,MD,TH,TH,2023,Q2,Elderly
212095454,21209545,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q2,Blood pressure systolic increased,,2023,Q2,4,F,,20230522.0,20220813,20230530,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230530,,MD,TH,TH,2023,Q2,Elderly
212095454,21209545,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q2,Blood creatinine increased,,2023,Q2,4,F,,20230522.0,20220813,20230530,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230530,,MD,TH,TH,2023,Q2,Elderly
212095454,21209545,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q2,Blood potassium increased,,2023,Q2,4,F,,20230522.0,20220813,20230530,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230530,,MD,TH,TH,2023,Q2,Elderly
212095454,21209545,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q2,Glycosylated haemoglobin increased,,2023,Q2,4,F,,20230522.0,20220813,20230530,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230530,,MD,TH,TH,2023,Q2,Elderly
212095454,21209545,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q2,Blood pressure diastolic decreased,,2023,Q2,4,F,,20230522.0,20220813,20230530,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230530,,MD,TH,TH,2023,Q2,Elderly
212095454,21209545,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q2,Haemolysis,,2023,Q2,4,F,,20230522.0,20220813,20230530,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230530,,MD,TH,TH,2023,Q2,Elderly
212095454,21209545,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q2,Weight increased,,2023,Q2,4,F,,20230522.0,20220813,20230530,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230530,,MD,TH,TH,2023,Q2,Elderly
212095454,21209545,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q2,Blood glucose increased,,2023,Q2,4,F,,20230522.0,20220813,20230530,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230530,,MD,TH,TH,2023,Q2,Elderly
212095454,21209545,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q2,Body mass index increased,,2023,Q2,4,F,,20230522.0,20220813,20230530,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230530,,MD,TH,TH,2023,Q2,Elderly
212095454,21209545,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q2,Creatinine renal clearance decreased,,2023,Q2,4,F,,20230522.0,20220813,20230530,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230530,,MD,TH,TH,2023,Q2,Elderly
212095454,21209545,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q2,Blood pressure systolic increased,,2023,Q2,4,F,,20230522.0,20220813,20230530,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230530,,MD,TH,TH,2023,Q2,Elderly
212095454,21209545,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q2,Blood creatinine increased,,2023,Q2,4,F,,20230522.0,20220813,20230530,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230530,,MD,TH,TH,2023,Q2,Elderly
212095454,21209545,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q2,Blood potassium increased,,2023,Q2,4,F,,20230522.0,20220813,20230530,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230530,,MD,TH,TH,2023,Q2,Elderly
212095454,21209545,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q2,Glycosylated haemoglobin increased,,2023,Q2,4,F,,20230522.0,20220813,20230530,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20230530,,MD,TH,TH,2023,Q2,Elderly
2125365111,21253651,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,Tablets,,2023,Q2,Infection,,2023,Q2,11,F,20220816.0,20230405.0,20220825,20230412,EXP,,BR-Eisai Medical Research-EC-2022-121814,EISAI,,65.0,YR,E,F,Y,54.6,KG,20230412,,MD,BR,,2023,Q2,Elderly
212599682,21259968,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, on hospital day 1",,,Y,U,,,,10.0,MG,,,2023,Q2,Hyponatraemia,,2023,Q2,2,F,,20230510.0,20220826,20230512,EXP,,NVSC2022US190545,NOVARTIS,"Corpuz E, Dean J, Cahill M. Pass the salt? Acute asymptomatic hyponatremia following inpatient initiation of angiotensin receptor-neprilysin inhibitor. JOURNAL OF GENERAL INTERNAL MEDICINE. 2022;37:S497",71.0,YR,,F,Y,,,20230512,,HP,US,US,2023,Q2,Elderly
212599682,21259968,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, on hospital day 1",,,Y,U,,,,10.0,MG,,,2023,Q2,Concomitant disease aggravated,,2023,Q2,2,F,,20230510.0,20220826,20230512,EXP,,NVSC2022US190545,NOVARTIS,"Corpuz E, Dean J, Cahill M. Pass the salt? Acute asymptomatic hyponatremia following inpatient initiation of angiotensin receptor-neprilysin inhibitor. JOURNAL OF GENERAL INTERNAL MEDICINE. 2022;37:S497",71.0,YR,,F,Y,,,20230512,,HP,US,US,2023,Q2,Elderly
212599682,21259968,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, on hospital day 1",,,Y,U,,,,10.0,MG,,,2023,Q2,Product use in unapproved indication,,2023,Q2,2,F,,20230510.0,20220826,20230512,EXP,,NVSC2022US190545,NOVARTIS,"Corpuz E, Dean J, Cahill M. Pass the salt? Acute asymptomatic hyponatremia following inpatient initiation of angiotensin receptor-neprilysin inhibitor. JOURNAL OF GENERAL INTERNAL MEDICINE. 2022;37:S497",71.0,YR,,F,Y,,,20230512,,HP,US,US,2023,Q2,Elderly
2129884914,21298849,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,COVID-19,,2023,Q2,14,F,20220827.0,20230516.0,20220906,20230522,EXP,,NVSC2022US198183,NOVARTIS,,71.0,YR,,M,Y,91.8,KG,20230522,,MD,US,US,2023,Q2,Elderly
2129884914,21298849,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Febrile neutropenia,,2023,Q2,14,F,20220827.0,20230516.0,20220906,20230522,EXP,,NVSC2022US198183,NOVARTIS,,71.0,YR,,M,Y,91.8,KG,20230522,,MD,US,US,2023,Q2,Elderly
213052802,21305280,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,,,,,,10.0,MG,,,2023,Q2,Hyponatraemia,,2023,Q2,2,F,,20230503.0,20220907,20230511,EXP,,US-PRINSTON PHARMACEUTICAL INC.-2022PRN00316,PRINSTON PHARMACEUTICAL,"Corpuz E, Dean JHL, Cahill M. Pass The Salt? Acute Asymptomatic Hyponatremia Following Inpatient Initiation of Angiotensin Receptor-Neprilysin Inhibitor. J Gen Intern Med. 2022;37:S497",71.0,YR,,F,Y,,,20230511,,HP,US,US,2023,Q2,Elderly
213052802,21305280,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,,,,,,10.0,MG,,,2023,Q2,Hyponatraemia,,2023,Q2,2,F,,20230503.0,20220907,20230511,EXP,,US-PRINSTON PHARMACEUTICAL INC.-2022PRN00316,PRINSTON PHARMACEUTICAL,"Corpuz E, Dean JHL, Cahill M. Pass The Salt? Acute Asymptomatic Hyponatremia Following Inpatient Initiation of Angiotensin Receptor-Neprilysin Inhibitor. J Gen Intern Med. 2022;37:S497",71.0,YR,,F,Y,,,20230511,,HP,US,US,2023,Q2,Elderly
213262662,21326266,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,25.0,MG,Tablet,QD,2023,Q2,Nausea,,2023,Q2,2,F,,20230523.0,20220913,20230524,EXP,GB-MHRA-TPP6580665C8666846YC1662630000600,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-191607",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,101.0,KG,20230524,,MD,GB,GB,2023,Q2,Elderly
213262662,21326266,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,25.0,MG,Tablet,QD,2023,Q2,Diarrhoea,,2023,Q2,2,F,,20230523.0,20220913,20230524,EXP,GB-MHRA-TPP6580665C8666846YC1662630000600,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-191607",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,101.0,KG,20230524,,MD,GB,GB,2023,Q2,Elderly
213262662,21326266,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,25.0,MG,Tablet,QD,2023,Q2,Abdominal pain,,2023,Q2,2,F,,20230523.0,20220913,20230524,EXP,GB-MHRA-TPP6580665C8666846YC1662630000600,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-191607",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,101.0,KG,20230524,,MD,GB,GB,2023,Q2,Elderly
213262662,21326266,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,,,Tablet,,2023,Q2,Nausea,,2023,Q2,2,F,,20230523.0,20220913,20230524,EXP,GB-MHRA-TPP6580665C8666846YC1662630000600,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-191607",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,101.0,KG,20230524,,MD,GB,GB,2023,Q2,Elderly
213262662,21326266,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,,,Tablet,,2023,Q2,Diarrhoea,,2023,Q2,2,F,,20230523.0,20220913,20230524,EXP,GB-MHRA-TPP6580665C8666846YC1662630000600,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-191607",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,101.0,KG,20230524,,MD,GB,GB,2023,Q2,Elderly
213262662,21326266,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,,,Tablet,,2023,Q2,Abdominal pain,,2023,Q2,2,F,,20230523.0,20220913,20230524,EXP,GB-MHRA-TPP6580665C8666846YC1662630000600,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-191607",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,101.0,KG,20230524,,MD,GB,GB,2023,Q2,Elderly
214022073,21402207,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, 1 tablet after breakfast",,,D,,,,,25.0,MG,Tablet,,2023,Q2,Toxicity to various agents,,2023,Q2,3,F,,20230331.0,20221003,20230403,EXP,,JP-SA-2022SA192762,SANOFI AVENTIS,,56.0,YR,A,M,Y,119.2,KG,20230404,,MD,JP,JP,2023,Q2,Adult
214022073,21402207,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, 1 tablet after breakfast",,,D,,,,,25.0,MG,Tablet,,2023,Q2,Hypotension,,2023,Q2,3,F,,20230331.0,20221003,20230403,EXP,,JP-SA-2022SA192762,SANOFI AVENTIS,,56.0,YR,A,M,Y,119.2,KG,20230404,,MD,JP,JP,2023,Q2,Adult
214022073,21402207,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, 1 tablet after breakfast",,,D,,,,,25.0,MG,Tablet,,2023,Q2,Bradycardia,,2023,Q2,3,F,,20230331.0,20221003,20230403,EXP,,JP-SA-2022SA192762,SANOFI AVENTIS,,56.0,YR,A,M,Y,119.2,KG,20230404,,MD,JP,JP,2023,Q2,Adult
214022073,21402207,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, 1 tablet after breakfast",,,D,,,,,25.0,MG,Tablet,,2023,Q2,Drug ineffective,,2023,Q2,3,F,,20230331.0,20221003,20230403,EXP,,JP-SA-2022SA192762,SANOFI AVENTIS,,56.0,YR,A,M,Y,119.2,KG,20230404,,MD,JP,JP,2023,Q2,Adult
214156756,21415675,105,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2023,Q2,Hypotension,,2023,Q2,6,F,,20230515.0,20221006,20230524,EXP,,NVSC2022CA221484,NOVARTIS,,75.0,YR,,M,Y,,,20230524,,HP,CA,CA,2023,Q2,Elderly
214156756,21415675,105,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2023,Q2,Hypotension,,2023,Q2,6,F,,20230515.0,20221006,20230524,EXP,,NVSC2022CA221484,NOVARTIS,,75.0,YR,,M,Y,,,20230524,,HP,CA,CA,2023,Q2,Elderly
214156756,21415675,105,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2023,Q2,Adrenal insufficiency,,2023,Q2,6,F,,20230515.0,20221006,20230524,EXP,,NVSC2022CA221484,NOVARTIS,,75.0,YR,,M,Y,,,20230524,,HP,CA,CA,2023,Q2,Elderly
214156756,21415675,105,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2023,Q2,Hyperthyroidism,,2023,Q2,6,F,,20230515.0,20221006,20230524,EXP,,NVSC2022CA221484,NOVARTIS,,75.0,YR,,M,Y,,,20230524,,HP,CA,CA,2023,Q2,Elderly
214156756,21415675,105,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2023,Q2,Troponin increased,,2023,Q2,6,F,,20230515.0,20221006,20230524,EXP,,NVSC2022CA221484,NOVARTIS,,75.0,YR,,M,Y,,,20230524,,HP,CA,CA,2023,Q2,Elderly
214156756,21415675,105,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2023,Q2,Hypotension,,2023,Q2,6,F,,20230515.0,20221006,20230524,EXP,,NVSC2022CA221484,NOVARTIS,,75.0,YR,,M,Y,,,20230524,,HP,CA,CA,2023,Q2,Elderly
214156756,21415675,106,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2023,Q2,Hypotension,,2023,Q2,6,F,,20230515.0,20221006,20230524,EXP,,NVSC2022CA221484,NOVARTIS,,75.0,YR,,M,Y,,,20230524,,HP,CA,CA,2023,Q2,Elderly
214156756,21415675,106,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2023,Q2,Hypotension,,2023,Q2,6,F,,20230515.0,20221006,20230524,EXP,,NVSC2022CA221484,NOVARTIS,,75.0,YR,,M,Y,,,20230524,,HP,CA,CA,2023,Q2,Elderly
214156756,21415675,106,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2023,Q2,Adrenal insufficiency,,2023,Q2,6,F,,20230515.0,20221006,20230524,EXP,,NVSC2022CA221484,NOVARTIS,,75.0,YR,,M,Y,,,20230524,,HP,CA,CA,2023,Q2,Elderly
214156756,21415675,106,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2023,Q2,Hyperthyroidism,,2023,Q2,6,F,,20230515.0,20221006,20230524,EXP,,NVSC2022CA221484,NOVARTIS,,75.0,YR,,M,Y,,,20230524,,HP,CA,CA,2023,Q2,Elderly
214156756,21415675,106,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2023,Q2,Troponin increased,,2023,Q2,6,F,,20230515.0,20221006,20230524,EXP,,NVSC2022CA221484,NOVARTIS,,75.0,YR,,M,Y,,,20230524,,HP,CA,CA,2023,Q2,Elderly
214156756,21415675,106,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2023,Q2,Hypotension,,2023,Q2,6,F,,20230515.0,20221006,20230524,EXP,,NVSC2022CA221484,NOVARTIS,,75.0,YR,,M,Y,,,20230524,,HP,CA,CA,2023,Q2,Elderly
215517872,21551787,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Disease progression,,2023,Q2,2,F,20220705.0,20230411.0,20221104,20230414,EXP,,IL-ABBVIE-4186828,ABBVIE,,78.0,YR,,M,Y,98.0,KG,20230414,,MD,IL,IL,2023,Q2,Elderly
215517872,21551787,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Disease recurrence,,2023,Q2,2,F,20220705.0,20230411.0,20221104,20230414,EXP,,IL-ABBVIE-4186828,ABBVIE,,78.0,YR,,M,Y,98.0,KG,20230414,,MD,IL,IL,2023,Q2,Elderly
215837549,21583754,28,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,,,,,,10.0,MG,Oral Drug Unspecified Form,,2023,Q2,Diverticulum intestinal haemorrhagic,,2023,Q2,9,F,20221107.0,20230515.0,20221111,20230528,EXP,,JP-ARGENX-2022-ARGX-JP002363,ARGENX BVBA,,51.0,YR,,M,Y,,,20230528,,MD,JP,JP,2023,Q2,Adult
215837549,21583754,28,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,,,,,,10.0,MG,Oral Drug Unspecified Form,,2023,Q2,Therapeutic product effect delayed,,2023,Q2,9,F,20221107.0,20230515.0,20221111,20230528,EXP,,JP-ARGENX-2022-ARGX-JP002363,ARGENX BVBA,,51.0,YR,,M,Y,,,20230528,,MD,JP,JP,2023,Q2,Adult
215837549,21583754,28,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,,,,,,10.0,MG,Oral Drug Unspecified Form,,2023,Q2,Pigmentation disorder,,2023,Q2,9,F,20221107.0,20230515.0,20221111,20230528,EXP,,JP-ARGENX-2022-ARGX-JP002363,ARGENX BVBA,,51.0,YR,,M,Y,,,20230528,,MD,JP,JP,2023,Q2,Adult
215837549,21583754,28,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,,,,,,10.0,MG,Oral Drug Unspecified Form,,2023,Q2,Haematochezia,,2023,Q2,9,F,20221107.0,20230515.0,20221111,20230528,EXP,,JP-ARGENX-2022-ARGX-JP002363,ARGENX BVBA,,51.0,YR,,M,Y,,,20230528,,MD,JP,JP,2023,Q2,Adult
215859638,21585963,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Pneumonia,,2023,Q2,8,F,20221024.0,20230428.0,20221111,20230505,EXP,,CA-ALXN-A202213314,ALEXION,,84.0,YR,,M,Y,63.0,KG,20230505,,MD,CA,CA,2023,Q2,Elderly
215859638,21585963,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Neisseria infection,,2023,Q2,8,F,20221024.0,20230428.0,20221111,20230505,EXP,,CA-ALXN-A202213314,ALEXION,,84.0,YR,,M,Y,63.0,KG,20230505,,MD,CA,CA,2023,Q2,Elderly
215859638,21585963,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Urinary tract infection,,2023,Q2,8,F,20221024.0,20230428.0,20221111,20230505,EXP,,CA-ALXN-A202213314,ALEXION,,84.0,YR,,M,Y,63.0,KG,20230505,,MD,CA,CA,2023,Q2,Elderly
215859638,21585963,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Cardiac failure congestive,,2023,Q2,8,F,20221024.0,20230428.0,20221111,20230505,EXP,,CA-ALXN-A202213314,ALEXION,,84.0,YR,,M,Y,63.0,KG,20230505,,MD,CA,CA,2023,Q2,Elderly
215859638,21585963,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,,,,,,10.0,MG,Tablet,QD,2023,Q2,COVID-19,,2023,Q2,8,F,20221024.0,20230428.0,20221111,20230505,EXP,,CA-ALXN-A202213314,ALEXION,,84.0,YR,,M,Y,63.0,KG,20230505,,MD,CA,CA,2023,Q2,Elderly
216153613,21615361,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Dose unknown,,,,,,,,,,,,2023,Q2,Cardiac arrest,,2023,Q2,3,F,20221110.0,20230315.0,20221118,20230426,EXP,,JP-AstraZeneca-2022A381586,ASTRAZENECA,,79.0,YR,,F,Y,43.0,KG,20230426,,PH,JP,,2023,Q2,Elderly
216153613,21615361,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Dose unknown,,,,,,,,,,,,2023,Q2,Thrombosis,,2023,Q2,3,F,20221110.0,20230315.0,20221118,20230426,EXP,,JP-AstraZeneca-2022A381586,ASTRAZENECA,,79.0,YR,,F,Y,43.0,KG,20230426,,PH,JP,,2023,Q2,Elderly
216153613,21615361,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Dose unknown,,,,,,,,,,,,2023,Q2,Blood pressure decreased,,2023,Q2,3,F,20221110.0,20230315.0,20221118,20230426,EXP,,JP-AstraZeneca-2022A381586,ASTRAZENECA,,79.0,YR,,F,Y,43.0,KG,20230426,,PH,JP,,2023,Q2,Elderly
216153613,21615361,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Dose unknown,,,,,,,,,,,,2023,Q2,Respiratory disorder,,2023,Q2,3,F,20221110.0,20230315.0,20221118,20230426,EXP,,JP-AstraZeneca-2022A381586,ASTRAZENECA,,79.0,YR,,F,Y,43.0,KG,20230426,,PH,JP,,2023,Q2,Elderly
216369846,21636984,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Sepsis,,2023,Q2,6,F,20221117.0,20230626.0,20221124,20230629,EXP,,NZ-ROCHE-3222704,ROCHE,,49.0,YR,,F,Y,95.3,KG,20230629,,MD,NZ,,2023,Q2,Adult
216703232,21670323,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,,2023,Q2,Pulmonary oedema,,2023,Q2,2,F,,20230509.0,20221201,20230519,EXP,,JP-JNJFOC-20221200218,JOHNSON AND JOHNSON,,81.0,YR,E,M,Y,,,20230519,,MD,JP,JP,2023,Q2,Elderly
216703232,21670323,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,,2023,Q2,Delirium,,2023,Q2,2,F,,20230509.0,20221201,20230519,EXP,,JP-JNJFOC-20221200218,JOHNSON AND JOHNSON,,81.0,YR,E,M,Y,,,20230519,,MD,JP,JP,2023,Q2,Elderly
217438852,21743885,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Product use in unapproved indication,,2023,Q2,2,F,,20221129.0,20221217,20230509,PER,,US-009507513-2212USA001135,MERCK,"Haseeb A, Abu-Rmaileh M, Penfield JG, Liu H, Van Buren PN, Lederer ED, et al.. A Novel Case of Renal Mucormycosis Associated With Empagliflozin Use. Journal of the American Society of Nephrology. 2022;33:335",63.0,YR,,M,Y,,,20230509,,HP,US,US,2023,Q2,Adult
217554092,21755409,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2023,Q2,Pemphigoid,,2023,Q2,2,F,,20230327.0,20221220,20230402,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-207744",BOEHRINGER INGELHEIM,"Dyson SM, Patel PU, Igali L, Millington GW. Bullous pemphigoid in a patient with a neuropsychological disorder and a possible novel drug trigger: A case report and review of the literature. Skin Health and Disease. 2022;2:4: 176-doi:10.1002/ski2.176.",59.0,YR,A,F,Y,,,20230403,,HP,GB,GB,2023,Q2,Adult
217592037,21759203,6,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,"1 DF, Daily",,,,,,,,,,Tablet,QD,2023,Q2,Pneumonia aspiration,,2023,Q2,7,F,20221216.0,20230605.0,20221221,20230609,EXP,,JP-ARGENX-2022-ARGX-JP002747,ARGENX BVBA,,70.0,YR,,M,Y,52.0,KG,20230609,,PH,JP,JP,2023,Q2,Elderly
217725453,21772545,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2023,Q2,Cardiac failure,,2023,Q2,3,F,,20221216.0,20221223,20230609,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-2022-154889,BRISTOL MYERS SQUIBB,,74.0,YR,E,,Y,,,20230609,,MD,US,US,2023,Q2,Elderly
2178761411,21787614,54,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Abdominal pain,,2023,Q2,11,F,20221004.0,20230421.0,20221228,20230501,EXP,,AU-ROCHE-3194260,ROCHE,,63.0,YR,,M,Y,174.0,KG,20230501,,MD,AU,,2023,Q2,Adult
2178761411,21787614,54,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Hypervolaemia,,2023,Q2,11,F,20221004.0,20230421.0,20221228,20230501,EXP,,AU-ROCHE-3194260,ROCHE,,63.0,YR,,M,Y,174.0,KG,20230501,,MD,AU,,2023,Q2,Adult
2178761411,21787614,54,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Pneumonia,,2023,Q2,11,F,20221004.0,20230421.0,20221228,20230501,EXP,,AU-ROCHE-3194260,ROCHE,,63.0,YR,,M,Y,174.0,KG,20230501,,MD,AU,,2023,Q2,Adult
2178761411,21787614,54,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Lumbar vertebral fracture,,2023,Q2,11,F,20221004.0,20230421.0,20221228,20230501,EXP,,AU-ROCHE-3194260,ROCHE,,63.0,YR,,M,Y,174.0,KG,20230501,,MD,AU,,2023,Q2,Adult
2178761411,21787614,54,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Venous thrombosis limb,,2023,Q2,11,F,20221004.0,20230421.0,20221228,20230501,EXP,,AU-ROCHE-3194260,ROCHE,,63.0,YR,,M,Y,174.0,KG,20230501,,MD,AU,,2023,Q2,Adult
2178761411,21787614,54,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Deep vein thrombosis,,2023,Q2,11,F,20221004.0,20230421.0,20221228,20230501,EXP,,AU-ROCHE-3194260,ROCHE,,63.0,YR,,M,Y,174.0,KG,20230501,,MD,AU,,2023,Q2,Adult
218151013,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Dry skin,,2023,Q2,3,F,20220601.0,20230418.0,20230104,20230427,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230427,,CN,US,US,2023,Q2,Adult
218151013,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Oesophageal variceal ligation,,2023,Q2,3,F,20220601.0,20230418.0,20230104,20230427,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230427,,CN,US,US,2023,Q2,Adult
218151013,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Large intestinal polypectomy,,2023,Q2,3,F,20220601.0,20230418.0,20230104,20230427,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230427,,CN,US,US,2023,Q2,Adult
218151013,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Vasodilatation,,2023,Q2,3,F,20220601.0,20230418.0,20230104,20230427,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230427,,CN,US,US,2023,Q2,Adult
218151013,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Ascites,,2023,Q2,3,F,20220601.0,20230418.0,20230104,20230427,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230427,,CN,US,US,2023,Q2,Adult
218151013,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Vertebral foraminal stenosis,,2023,Q2,3,F,20220601.0,20230418.0,20230104,20230427,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230427,,CN,US,US,2023,Q2,Adult
218151013,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Diarrhoea,,2023,Q2,3,F,20220601.0,20230418.0,20230104,20230427,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230427,,CN,US,US,2023,Q2,Adult
218151013,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Vertebral wedging,,2023,Q2,3,F,20220601.0,20230418.0,20230104,20230427,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230427,,CN,US,US,2023,Q2,Adult
218151013,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Splenomegaly,,2023,Q2,3,F,20220601.0,20230418.0,20230104,20230427,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230427,,CN,US,US,2023,Q2,Adult
218151013,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Ileus,,2023,Q2,3,F,20220601.0,20230418.0,20230104,20230427,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230427,,CN,US,US,2023,Q2,Adult
218151013,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Portal hypertension,,2023,Q2,3,F,20220601.0,20230418.0,20230104,20230427,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230427,,CN,US,US,2023,Q2,Adult
218151013,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Urticaria,,2023,Q2,3,F,20220601.0,20230418.0,20230104,20230427,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230427,,CN,US,US,2023,Q2,Adult
218151013,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Haemorrhoids,,2023,Q2,3,F,20220601.0,20230418.0,20230104,20230427,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230427,,CN,US,US,2023,Q2,Adult
218151013,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Peripancreatic fluid collection,,2023,Q2,3,F,20220601.0,20230418.0,20230104,20230427,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230427,,CN,US,US,2023,Q2,Adult
218151013,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Pulmonary oedema,,2023,Q2,3,F,20220601.0,20230418.0,20230104,20230427,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230427,,CN,US,US,2023,Q2,Adult
218151013,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Hernia repair,,2023,Q2,3,F,20220601.0,20230418.0,20230104,20230427,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230427,,CN,US,US,2023,Q2,Adult
218151013,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Red blood cell transfusion,,2023,Q2,3,F,20220601.0,20230418.0,20230104,20230427,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230427,,CN,US,US,2023,Q2,Adult
218151013,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Liver function test increased,,2023,Q2,3,F,20220601.0,20230418.0,20230104,20230427,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230427,,CN,US,US,2023,Q2,Adult
218151013,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Oedema peripheral,,2023,Q2,3,F,20220601.0,20230418.0,20230104,20230427,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230427,,CN,US,US,2023,Q2,Adult
218151013,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Pleural effusion,,2023,Q2,3,F,20220601.0,20230418.0,20230104,20230427,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230427,,CN,US,US,2023,Q2,Adult
218151013,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Portal shunt procedure,,2023,Q2,3,F,20220601.0,20230418.0,20230104,20230427,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230427,,CN,US,US,2023,Q2,Adult
218151013,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Portal hypertensive gastropathy,,2023,Q2,3,F,20220601.0,20230418.0,20230104,20230427,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230427,,CN,US,US,2023,Q2,Adult
218151013,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Off label use,,2023,Q2,3,F,20220601.0,20230418.0,20230104,20230427,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230427,,CN,US,US,2023,Q2,Adult
218151013,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Gastrointestinal wall thickening,,2023,Q2,3,F,20220601.0,20230418.0,20230104,20230427,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230427,,CN,US,US,2023,Q2,Adult
218151013,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Blood loss anaemia,,2023,Q2,3,F,20220601.0,20230418.0,20230104,20230427,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230427,,CN,US,US,2023,Q2,Adult
218151013,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Oesophageal varices haemorrhage,,2023,Q2,3,F,20220601.0,20230418.0,20230104,20230427,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230427,,CN,US,US,2023,Q2,Adult
218151013,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Large intestine polyp,,2023,Q2,3,F,20220601.0,20230418.0,20230104,20230427,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230427,,CN,US,US,2023,Q2,Adult
218151013,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Generalised oedema,,2023,Q2,3,F,20220601.0,20230418.0,20230104,20230427,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230427,,CN,US,US,2023,Q2,Adult
218151013,21815101,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Road traffic accident,,2023,Q2,3,F,20220601.0,20230418.0,20230104,20230427,EXP,,US-INTERCEPT-PM2022002322,INTERCEPT PHARMACEUTICALS,,51.0,YR,,F,Y,80.726,KG,20230427,,CN,US,US,2023,Q2,Adult
218198222,21819822,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2023,Q2,Pancreatitis acute,,2023,Q2,2,F,,20230512.0,20230104,20230519,EXP,,"SA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-210820",BOEHRINGER INGELHEIM,Alqurashe K. Acute Pancreatitis as a Rare Side Effect of Using Empagliflozin. Endocrine Practice. 2022;28(12): doi:10.1016/j.eprac.2022.10.027.,56.0,YR,A,F,Y,,,20230519,,HP,SA,SA,2023,Q2,Adult
218198222,21819822,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2023,Q2,Pancreatitis acute,,2023,Q2,2,F,,20230512.0,20230104,20230519,EXP,,"SA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-210820",BOEHRINGER INGELHEIM,Alqurashe K. Acute Pancreatitis as a Rare Side Effect of Using Empagliflozin. Endocrine Practice. 2022;28(12): doi:10.1016/j.eprac.2022.10.027.,56.0,YR,A,F,Y,,,20230519,,HP,SA,SA,2023,Q2,Adult
218770982,21877098,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,in the morning,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Angina pectoris,,2023,Q2,2,F,20210101.0,20230510.0,20230118,20230519,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-212409",BOEHRINGER INGELHEIM,,75.0,YR,E,F,Y,,,20230519,,MD,SI,SI,2023,Q2,Elderly
218770982,21877098,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,in the morning,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Blood urea increased,,2023,Q2,2,F,20210101.0,20230510.0,20230118,20230519,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-212409",BOEHRINGER INGELHEIM,,75.0,YR,E,F,Y,,,20230519,,MD,SI,SI,2023,Q2,Elderly
218770982,21877098,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,in the morning,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Orthopnoea,,2023,Q2,2,F,20210101.0,20230510.0,20230118,20230519,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-212409",BOEHRINGER INGELHEIM,,75.0,YR,E,F,Y,,,20230519,,MD,SI,SI,2023,Q2,Elderly
218770982,21877098,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,in the morning,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Haemoglobin increased,,2023,Q2,2,F,20210101.0,20230510.0,20230118,20230519,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-212409",BOEHRINGER INGELHEIM,,75.0,YR,E,F,Y,,,20230519,,MD,SI,SI,2023,Q2,Elderly
218770982,21877098,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,in the morning,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Atrial fibrillation,,2023,Q2,2,F,20210101.0,20230510.0,20230118,20230519,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-212409",BOEHRINGER INGELHEIM,,75.0,YR,E,F,Y,,,20230519,,MD,SI,SI,2023,Q2,Elderly
218770982,21877098,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,in the morning,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Dyspnoea,,2023,Q2,2,F,20210101.0,20230510.0,20230118,20230519,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-212409",BOEHRINGER INGELHEIM,,75.0,YR,E,F,Y,,,20230519,,MD,SI,SI,2023,Q2,Elderly
218770982,21877098,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,in the morning,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Tachycardia induced cardiomyopathy,,2023,Q2,2,F,20210101.0,20230510.0,20230118,20230519,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-212409",BOEHRINGER INGELHEIM,,75.0,YR,E,F,Y,,,20230519,,MD,SI,SI,2023,Q2,Elderly
218770982,21877098,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,in the morning,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Hypertension,,2023,Q2,2,F,20210101.0,20230510.0,20230118,20230519,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-212409",BOEHRINGER INGELHEIM,,75.0,YR,E,F,Y,,,20230519,,MD,SI,SI,2023,Q2,Elderly
218770982,21877098,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,in the morning,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Cardiac failure,,2023,Q2,2,F,20210101.0,20230510.0,20230118,20230519,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-212409",BOEHRINGER INGELHEIM,,75.0,YR,E,F,Y,,,20230519,,MD,SI,SI,2023,Q2,Elderly
218770982,21877098,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,in the morning,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Atrial fibrillation,,2023,Q2,2,F,20210101.0,20230510.0,20230118,20230519,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-212409",BOEHRINGER INGELHEIM,,75.0,YR,E,F,Y,,,20230519,,MD,SI,SI,2023,Q2,Elderly
218770982,21877098,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,in the morning,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Dyspnoea,,2023,Q2,2,F,20210101.0,20230510.0,20230118,20230519,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-212409",BOEHRINGER INGELHEIM,,75.0,YR,E,F,Y,,,20230519,,MD,SI,SI,2023,Q2,Elderly
218812692,21881269,8,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,D,,,,,,,,,2023,Q2,Death,,2023,Q2,2,F,20221224.0,20230603.0,20230118,20230612,EXP,,NVSC2023HR008746,NOVARTIS,,64.0,YR,,F,Y,62.0,KG,20230612,,MD,HR,HR,2023,Q2,Adult
219474022,21947402,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10mg / 5mg,,,,,,,,,,Tablet,,2023,Q2,Hypotension,,2023,Q2,2,F,20230111.0,20230606.0,20230202,20230613,EXP,,NVSJ2023JP002270,NOVARTIS,,87.0,YR,,M,Y,,,20230614,,MD,JP,JP,2023,Q2,Elderly
219570575,21957057,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Atrial fibrillation,,2023,Q2,5,F,,20230615.0,20230206,20230622,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-216027",BOEHRINGER INGELHEIM,"Tsigkriki L, Siarkos M, Ntantoy E, Mourvetidis P, Mavrogianni A, Askalidou T. Euglycemic diabetic ketoacidosis related to SGLT2 intake, after acute myocardial infarction.. International congress of Cardiology. 2022 Oct;",57.0,YR,A,M,Y,,,20230622,,MD,GR,GR,2023,Q2,Adult
219570575,21957057,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Euglycaemic diabetic ketoacidosis,,2023,Q2,5,F,,20230615.0,20230206,20230622,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-216027",BOEHRINGER INGELHEIM,"Tsigkriki L, Siarkos M, Ntantoy E, Mourvetidis P, Mavrogianni A, Askalidou T. Euglycemic diabetic ketoacidosis related to SGLT2 intake, after acute myocardial infarction.. International congress of Cardiology. 2022 Oct;",57.0,YR,A,M,Y,,,20230622,,MD,GR,GR,2023,Q2,Adult
219570575,21957057,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Ventricular hypokinesia,,2023,Q2,5,F,,20230615.0,20230206,20230622,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-216027",BOEHRINGER INGELHEIM,"Tsigkriki L, Siarkos M, Ntantoy E, Mourvetidis P, Mavrogianni A, Askalidou T. Euglycemic diabetic ketoacidosis related to SGLT2 intake, after acute myocardial infarction.. International congress of Cardiology. 2022 Oct;",57.0,YR,A,M,Y,,,20230622,,MD,GR,GR,2023,Q2,Adult
219570575,21957057,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Pyrexia,,2023,Q2,5,F,,20230615.0,20230206,20230622,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-216027",BOEHRINGER INGELHEIM,"Tsigkriki L, Siarkos M, Ntantoy E, Mourvetidis P, Mavrogianni A, Askalidou T. Euglycemic diabetic ketoacidosis related to SGLT2 intake, after acute myocardial infarction.. International congress of Cardiology. 2022 Oct;",57.0,YR,A,M,Y,,,20230622,,MD,GR,GR,2023,Q2,Adult
219570575,21957057,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Atrioventricular block,,2023,Q2,5,F,,20230615.0,20230206,20230622,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-216027",BOEHRINGER INGELHEIM,"Tsigkriki L, Siarkos M, Ntantoy E, Mourvetidis P, Mavrogianni A, Askalidou T. Euglycemic diabetic ketoacidosis related to SGLT2 intake, after acute myocardial infarction.. International congress of Cardiology. 2022 Oct;",57.0,YR,A,M,Y,,,20230622,,MD,GR,GR,2023,Q2,Adult
219570575,21957057,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Road traffic accident,,2023,Q2,5,F,,20230615.0,20230206,20230622,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-216027",BOEHRINGER INGELHEIM,"Tsigkriki L, Siarkos M, Ntantoy E, Mourvetidis P, Mavrogianni A, Askalidou T. Euglycemic diabetic ketoacidosis related to SGLT2 intake, after acute myocardial infarction.. International congress of Cardiology. 2022 Oct;",57.0,YR,A,M,Y,,,20230622,,MD,GR,GR,2023,Q2,Adult
219570575,21957057,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Bundle branch block,,2023,Q2,5,F,,20230615.0,20230206,20230622,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-216027",BOEHRINGER INGELHEIM,"Tsigkriki L, Siarkos M, Ntantoy E, Mourvetidis P, Mavrogianni A, Askalidou T. Euglycemic diabetic ketoacidosis related to SGLT2 intake, after acute myocardial infarction.. International congress of Cardiology. 2022 Oct;",57.0,YR,A,M,Y,,,20230622,,MD,GR,GR,2023,Q2,Adult
219570575,21957057,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Tachypnoea,,2023,Q2,5,F,,20230615.0,20230206,20230622,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-216027",BOEHRINGER INGELHEIM,"Tsigkriki L, Siarkos M, Ntantoy E, Mourvetidis P, Mavrogianni A, Askalidou T. Euglycemic diabetic ketoacidosis related to SGLT2 intake, after acute myocardial infarction.. International congress of Cardiology. 2022 Oct;",57.0,YR,A,M,Y,,,20230622,,MD,GR,GR,2023,Q2,Adult
219570575,21957057,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Pneumonia,,2023,Q2,5,F,,20230615.0,20230206,20230622,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-216027",BOEHRINGER INGELHEIM,"Tsigkriki L, Siarkos M, Ntantoy E, Mourvetidis P, Mavrogianni A, Askalidou T. Euglycemic diabetic ketoacidosis related to SGLT2 intake, after acute myocardial infarction.. International congress of Cardiology. 2022 Oct;",57.0,YR,A,M,Y,,,20230622,,MD,GR,GR,2023,Q2,Adult
219570575,21957057,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Cardiac disorder,,2023,Q2,5,F,,20230615.0,20230206,20230622,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-216027",BOEHRINGER INGELHEIM,"Tsigkriki L, Siarkos M, Ntantoy E, Mourvetidis P, Mavrogianni A, Askalidou T. Euglycemic diabetic ketoacidosis related to SGLT2 intake, after acute myocardial infarction.. International congress of Cardiology. 2022 Oct;",57.0,YR,A,M,Y,,,20230622,,MD,GR,GR,2023,Q2,Adult
219570575,21957057,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Acute myocardial infarction,,2023,Q2,5,F,,20230615.0,20230206,20230622,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-216027",BOEHRINGER INGELHEIM,"Tsigkriki L, Siarkos M, Ntantoy E, Mourvetidis P, Mavrogianni A, Askalidou T. Euglycemic diabetic ketoacidosis related to SGLT2 intake, after acute myocardial infarction.. International congress of Cardiology. 2022 Oct;",57.0,YR,A,M,Y,,,20230622,,MD,GR,GR,2023,Q2,Adult
219570575,21957057,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Cardiac contractility decreased,,2023,Q2,5,F,,20230615.0,20230206,20230622,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-216027",BOEHRINGER INGELHEIM,"Tsigkriki L, Siarkos M, Ntantoy E, Mourvetidis P, Mavrogianni A, Askalidou T. Euglycemic diabetic ketoacidosis related to SGLT2 intake, after acute myocardial infarction.. International congress of Cardiology. 2022 Oct;",57.0,YR,A,M,Y,,,20230622,,MD,GR,GR,2023,Q2,Adult
219570575,21957057,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Somnolence,,2023,Q2,5,F,,20230615.0,20230206,20230622,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-216027",BOEHRINGER INGELHEIM,"Tsigkriki L, Siarkos M, Ntantoy E, Mourvetidis P, Mavrogianni A, Askalidou T. Euglycemic diabetic ketoacidosis related to SGLT2 intake, after acute myocardial infarction.. International congress of Cardiology. 2022 Oct;",57.0,YR,A,M,Y,,,20230622,,MD,GR,GR,2023,Q2,Adult
219570575,21957057,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Vomiting,,2023,Q2,5,F,,20230615.0,20230206,20230622,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-216027",BOEHRINGER INGELHEIM,"Tsigkriki L, Siarkos M, Ntantoy E, Mourvetidis P, Mavrogianni A, Askalidou T. Euglycemic diabetic ketoacidosis related to SGLT2 intake, after acute myocardial infarction.. International congress of Cardiology. 2022 Oct;",57.0,YR,A,M,Y,,,20230622,,MD,GR,GR,2023,Q2,Adult
219570575,21957057,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Post procedural complication,,2023,Q2,5,F,,20230615.0,20230206,20230622,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-216027",BOEHRINGER INGELHEIM,"Tsigkriki L, Siarkos M, Ntantoy E, Mourvetidis P, Mavrogianni A, Askalidou T. Euglycemic diabetic ketoacidosis related to SGLT2 intake, after acute myocardial infarction.. International congress of Cardiology. 2022 Oct;",57.0,YR,A,M,Y,,,20230622,,MD,GR,GR,2023,Q2,Adult
219627165,21962716,44,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,,,,,10.0,MG,,,2023,Q2,Anxiety,,2023,Q2,5,F,,20230411.0,20230207,20230417,EXP,,ES-MYLANLABS-2023M1012550,MYLAN,"Bugallo-Carrera C, Facal D, Dominguez-Lenogue C, Alvarez-Vidal V, Gandoy-Crego M, Caamano-Ponte J.. Neuropsychiatric Symptoms after Liver Transplantation in a 65-Year-Old Male Patient. BRAIN SCIENCES. 2022;12(1721):1-10",65.0,YR,,M,Y,,,20230417,,HP,ES,ES,2023,Q2,Elderly
219627165,21962716,44,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,,,,,10.0,MG,,,2023,Q2,Pulmonary embolism,,2023,Q2,5,F,,20230411.0,20230207,20230417,EXP,,ES-MYLANLABS-2023M1012550,MYLAN,"Bugallo-Carrera C, Facal D, Dominguez-Lenogue C, Alvarez-Vidal V, Gandoy-Crego M, Caamano-Ponte J.. Neuropsychiatric Symptoms after Liver Transplantation in a 65-Year-Old Male Patient. BRAIN SCIENCES. 2022;12(1721):1-10",65.0,YR,,M,Y,,,20230417,,HP,ES,ES,2023,Q2,Elderly
219627165,21962716,44,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,,,,,10.0,MG,,,2023,Q2,Irritability,,2023,Q2,5,F,,20230411.0,20230207,20230417,EXP,,ES-MYLANLABS-2023M1012550,MYLAN,"Bugallo-Carrera C, Facal D, Dominguez-Lenogue C, Alvarez-Vidal V, Gandoy-Crego M, Caamano-Ponte J.. Neuropsychiatric Symptoms after Liver Transplantation in a 65-Year-Old Male Patient. BRAIN SCIENCES. 2022;12(1721):1-10",65.0,YR,,M,Y,,,20230417,,HP,ES,ES,2023,Q2,Elderly
219627165,21962716,44,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,,,,,10.0,MG,,,2023,Q2,Delusion,,2023,Q2,5,F,,20230411.0,20230207,20230417,EXP,,ES-MYLANLABS-2023M1012550,MYLAN,"Bugallo-Carrera C, Facal D, Dominguez-Lenogue C, Alvarez-Vidal V, Gandoy-Crego M, Caamano-Ponte J.. Neuropsychiatric Symptoms after Liver Transplantation in a 65-Year-Old Male Patient. BRAIN SCIENCES. 2022;12(1721):1-10",65.0,YR,,M,Y,,,20230417,,HP,ES,ES,2023,Q2,Elderly
219627165,21962716,44,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,,,,,10.0,MG,,,2023,Q2,Obsessive thoughts,,2023,Q2,5,F,,20230411.0,20230207,20230417,EXP,,ES-MYLANLABS-2023M1012550,MYLAN,"Bugallo-Carrera C, Facal D, Dominguez-Lenogue C, Alvarez-Vidal V, Gandoy-Crego M, Caamano-Ponte J.. Neuropsychiatric Symptoms after Liver Transplantation in a 65-Year-Old Male Patient. BRAIN SCIENCES. 2022;12(1721):1-10",65.0,YR,,M,Y,,,20230417,,HP,ES,ES,2023,Q2,Elderly
219627165,21962716,44,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,,,,,10.0,MG,,,2023,Q2,Intrusive thoughts,,2023,Q2,5,F,,20230411.0,20230207,20230417,EXP,,ES-MYLANLABS-2023M1012550,MYLAN,"Bugallo-Carrera C, Facal D, Dominguez-Lenogue C, Alvarez-Vidal V, Gandoy-Crego M, Caamano-Ponte J.. Neuropsychiatric Symptoms after Liver Transplantation in a 65-Year-Old Male Patient. BRAIN SCIENCES. 2022;12(1721):1-10",65.0,YR,,M,Y,,,20230417,,HP,ES,ES,2023,Q2,Elderly
219627165,21962716,44,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,,,,,10.0,MG,,,2023,Q2,Affective disorder,,2023,Q2,5,F,,20230411.0,20230207,20230417,EXP,,ES-MYLANLABS-2023M1012550,MYLAN,"Bugallo-Carrera C, Facal D, Dominguez-Lenogue C, Alvarez-Vidal V, Gandoy-Crego M, Caamano-Ponte J.. Neuropsychiatric Symptoms after Liver Transplantation in a 65-Year-Old Male Patient. BRAIN SCIENCES. 2022;12(1721):1-10",65.0,YR,,M,Y,,,20230417,,HP,ES,ES,2023,Q2,Elderly
219627165,21962716,44,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,,,,,10.0,MG,,,2023,Q2,Depression,,2023,Q2,5,F,,20230411.0,20230207,20230417,EXP,,ES-MYLANLABS-2023M1012550,MYLAN,"Bugallo-Carrera C, Facal D, Dominguez-Lenogue C, Alvarez-Vidal V, Gandoy-Crego M, Caamano-Ponte J.. Neuropsychiatric Symptoms after Liver Transplantation in a 65-Year-Old Male Patient. BRAIN SCIENCES. 2022;12(1721):1-10",65.0,YR,,M,Y,,,20230417,,HP,ES,ES,2023,Q2,Elderly
219627165,21962716,44,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,,,,,10.0,MG,,,2023,Q2,Confusional state,,2023,Q2,5,F,,20230411.0,20230207,20230417,EXP,,ES-MYLANLABS-2023M1012550,MYLAN,"Bugallo-Carrera C, Facal D, Dominguez-Lenogue C, Alvarez-Vidal V, Gandoy-Crego M, Caamano-Ponte J.. Neuropsychiatric Symptoms after Liver Transplantation in a 65-Year-Old Male Patient. BRAIN SCIENCES. 2022;12(1721):1-10",65.0,YR,,M,Y,,,20230417,,HP,ES,ES,2023,Q2,Elderly
219627165,21962716,44,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,,,,,10.0,MG,,,2023,Q2,Delusion of replacement,,2023,Q2,5,F,,20230411.0,20230207,20230417,EXP,,ES-MYLANLABS-2023M1012550,MYLAN,"Bugallo-Carrera C, Facal D, Dominguez-Lenogue C, Alvarez-Vidal V, Gandoy-Crego M, Caamano-Ponte J.. Neuropsychiatric Symptoms after Liver Transplantation in a 65-Year-Old Male Patient. BRAIN SCIENCES. 2022;12(1721):1-10",65.0,YR,,M,Y,,,20230417,,HP,ES,ES,2023,Q2,Elderly
219627165,21962716,44,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,,,,,10.0,MG,,,2023,Q2,Cardiac failure congestive,,2023,Q2,5,F,,20230411.0,20230207,20230417,EXP,,ES-MYLANLABS-2023M1012550,MYLAN,"Bugallo-Carrera C, Facal D, Dominguez-Lenogue C, Alvarez-Vidal V, Gandoy-Crego M, Caamano-Ponte J.. Neuropsychiatric Symptoms after Liver Transplantation in a 65-Year-Old Male Patient. BRAIN SCIENCES. 2022;12(1721):1-10",65.0,YR,,M,Y,,,20230417,,HP,ES,ES,2023,Q2,Elderly
219627165,21962716,44,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,,,,,10.0,MG,,,2023,Q2,Hallucination,,2023,Q2,5,F,,20230411.0,20230207,20230417,EXP,,ES-MYLANLABS-2023M1012550,MYLAN,"Bugallo-Carrera C, Facal D, Dominguez-Lenogue C, Alvarez-Vidal V, Gandoy-Crego M, Caamano-Ponte J.. Neuropsychiatric Symptoms after Liver Transplantation in a 65-Year-Old Male Patient. BRAIN SCIENCES. 2022;12(1721):1-10",65.0,YR,,M,Y,,,20230417,,HP,ES,ES,2023,Q2,Elderly
219627165,21962716,44,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,,,,,10.0,MG,,,2023,Q2,Jealous delusion,,2023,Q2,5,F,,20230411.0,20230207,20230417,EXP,,ES-MYLANLABS-2023M1012550,MYLAN,"Bugallo-Carrera C, Facal D, Dominguez-Lenogue C, Alvarez-Vidal V, Gandoy-Crego M, Caamano-Ponte J.. Neuropsychiatric Symptoms after Liver Transplantation in a 65-Year-Old Male Patient. BRAIN SCIENCES. 2022;12(1721):1-10",65.0,YR,,M,Y,,,20230417,,HP,ES,ES,2023,Q2,Elderly
219627165,21962716,44,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,,,,,10.0,MG,,,2023,Q2,Agitation,,2023,Q2,5,F,,20230411.0,20230207,20230417,EXP,,ES-MYLANLABS-2023M1012550,MYLAN,"Bugallo-Carrera C, Facal D, Dominguez-Lenogue C, Alvarez-Vidal V, Gandoy-Crego M, Caamano-Ponte J.. Neuropsychiatric Symptoms after Liver Transplantation in a 65-Year-Old Male Patient. BRAIN SCIENCES. 2022;12(1721):1-10",65.0,YR,,M,Y,,,20230417,,HP,ES,ES,2023,Q2,Elderly
219627165,21962716,44,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,,,,,10.0,MG,,,2023,Q2,Motor dysfunction,,2023,Q2,5,F,,20230411.0,20230207,20230417,EXP,,ES-MYLANLABS-2023M1012550,MYLAN,"Bugallo-Carrera C, Facal D, Dominguez-Lenogue C, Alvarez-Vidal V, Gandoy-Crego M, Caamano-Ponte J.. Neuropsychiatric Symptoms after Liver Transplantation in a 65-Year-Old Male Patient. BRAIN SCIENCES. 2022;12(1721):1-10",65.0,YR,,M,Y,,,20230417,,HP,ES,ES,2023,Q2,Elderly
219627165,21962716,44,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,,,,,10.0,MG,,,2023,Q2,Atrial fibrillation,,2023,Q2,5,F,,20230411.0,20230207,20230417,EXP,,ES-MYLANLABS-2023M1012550,MYLAN,"Bugallo-Carrera C, Facal D, Dominguez-Lenogue C, Alvarez-Vidal V, Gandoy-Crego M, Caamano-Ponte J.. Neuropsychiatric Symptoms after Liver Transplantation in a 65-Year-Old Male Patient. BRAIN SCIENCES. 2022;12(1721):1-10",65.0,YR,,M,Y,,,20230417,,HP,ES,ES,2023,Q2,Elderly
219627165,21962716,44,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,,,,,10.0,MG,,,2023,Q2,Neuropsychiatric symptoms,,2023,Q2,5,F,,20230411.0,20230207,20230417,EXP,,ES-MYLANLABS-2023M1012550,MYLAN,"Bugallo-Carrera C, Facal D, Dominguez-Lenogue C, Alvarez-Vidal V, Gandoy-Crego M, Caamano-Ponte J.. Neuropsychiatric Symptoms after Liver Transplantation in a 65-Year-Old Male Patient. BRAIN SCIENCES. 2022;12(1721):1-10",65.0,YR,,M,Y,,,20230417,,HP,ES,ES,2023,Q2,Elderly
219627165,21962716,44,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,,,,,10.0,MG,,,2023,Q2,Insomnia,,2023,Q2,5,F,,20230411.0,20230207,20230417,EXP,,ES-MYLANLABS-2023M1012550,MYLAN,"Bugallo-Carrera C, Facal D, Dominguez-Lenogue C, Alvarez-Vidal V, Gandoy-Crego M, Caamano-Ponte J.. Neuropsychiatric Symptoms after Liver Transplantation in a 65-Year-Old Male Patient. BRAIN SCIENCES. 2022;12(1721):1-10",65.0,YR,,M,Y,,,20230417,,HP,ES,ES,2023,Q2,Elderly
219765165,21976516,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,,,Amp im,,2023,Q2,Cerebrovascular accident,,2023,Q2,5,F,20230203.0,20230301.0,20230210,20230405,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-2023-018970,BRISTOL MYERS SQUIBB,,76.0,YR,E,M,Y,75.0,KG,20230405,,MD,ES,ES,2023,Q2,Elderly
2197775611,21977756,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,Tablets,,2023,Q2,Coronary artery disease,,2023,Q2,11,F,20230131.0,20230505.0,20230210,20230512,PER,,CN-Eisai Medical Research-EC-2023-133815,EISAI,,69.0,YR,E,F,Y,63.0,KG,20230512,,MD,CN,,2023,Q2,Elderly
219870602,21987060,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (after breakfast)",,,U,,,,,10.0,MG,Tablet,QD,2023,Q2,Diarrhoea,,2023,Q2,2,F,,20230414.0,20230213,20230419,EXP,,NVSJ2023JP002902,NOVARTIS,Kita K.. Gastrointestinal Symptoms ^Not For^ -Do Not Overlook Other Potential Diseases [Chapter 5] ...... of Patients Who Visit the Hospital with Diarrhea? Drug-induced Diarrhea. Internal Medicine. 2023;131:114-119,72.0,YR,,M,Y,64.5,KG,20230419,,HP,JP,JP,2023,Q2,Elderly
219922812,21992281,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q2,Toxicity to various agents,,2023,Q2,2,F,,20230214.0,20230215,20230522,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-378431,RANBAXY,"Spyres MB, Aldy K, Farrugia LA, Kang AM, Love JS, Campleman SL, et al. The Toxicology Investigators Consortium 2020 Annual Report. J Med Toxicol. 2021;17(4):333-362",15.0,YR,,M,Y,,,20230522,,HP,US,US,2023,Q2,Youth
219922812,21992281,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q2,Metabolic acidosis,,2023,Q2,2,F,,20230214.0,20230215,20230522,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-378431,RANBAXY,"Spyres MB, Aldy K, Farrugia LA, Kang AM, Love JS, Campleman SL, et al. The Toxicology Investigators Consortium 2020 Annual Report. J Med Toxicol. 2021;17(4):333-362",15.0,YR,,M,Y,,,20230522,,HP,US,US,2023,Q2,Youth
219922812,21992281,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q2,Depressed level of consciousness,,2023,Q2,2,F,,20230214.0,20230215,20230522,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-378431,RANBAXY,"Spyres MB, Aldy K, Farrugia LA, Kang AM, Love JS, Campleman SL, et al. The Toxicology Investigators Consortium 2020 Annual Report. J Med Toxicol. 2021;17(4):333-362",15.0,YR,,M,Y,,,20230522,,HP,US,US,2023,Q2,Youth
219922812,21992281,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q2,Coma,,2023,Q2,2,F,,20230214.0,20230215,20230522,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-378431,RANBAXY,"Spyres MB, Aldy K, Farrugia LA, Kang AM, Love JS, Campleman SL, et al. The Toxicology Investigators Consortium 2020 Annual Report. J Med Toxicol. 2021;17(4):333-362",15.0,YR,,M,Y,,,20230522,,HP,US,US,2023,Q2,Youth
219922812,21992281,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q2,Hypotension,,2023,Q2,2,F,,20230214.0,20230215,20230522,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-378431,RANBAXY,"Spyres MB, Aldy K, Farrugia LA, Kang AM, Love JS, Campleman SL, et al. The Toxicology Investigators Consortium 2020 Annual Report. J Med Toxicol. 2021;17(4):333-362",15.0,YR,,M,Y,,,20230522,,HP,US,US,2023,Q2,Youth
219922812,21992281,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q2,Respiratory depression,,2023,Q2,2,F,,20230214.0,20230215,20230522,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-378431,RANBAXY,"Spyres MB, Aldy K, Farrugia LA, Kang AM, Love JS, Campleman SL, et al. The Toxicology Investigators Consortium 2020 Annual Report. J Med Toxicol. 2021;17(4):333-362",15.0,YR,,M,Y,,,20230522,,HP,US,US,2023,Q2,Youth
219922812,21992281,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q2,Anion gap,,2023,Q2,2,F,,20230214.0,20230215,20230522,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-378431,RANBAXY,"Spyres MB, Aldy K, Farrugia LA, Kang AM, Love JS, Campleman SL, et al. The Toxicology Investigators Consortium 2020 Annual Report. J Med Toxicol. 2021;17(4):333-362",15.0,YR,,M,Y,,,20230522,,HP,US,US,2023,Q2,Youth
2199597110,21995971,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,Tablets,,2023,Q2,Oedema,,2023,Q2,10,F,20221221.0,20230417.0,20230215,20230424,PER,,CO-Eisai Medical Research-EC-2023-134172,EISAI,,76.0,YR,E,F,Y,57.2,KG,20230424,,MD,CO,,2023,Q2,Elderly
2199597110,21995971,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,Tablets,,2023,Q2,Urinary tract infection,,2023,Q2,10,F,20221221.0,20230417.0,20230215,20230424,PER,,CO-Eisai Medical Research-EC-2023-134172,EISAI,,76.0,YR,E,F,Y,57.2,KG,20230424,,MD,CO,,2023,Q2,Elderly
2199597110,21995971,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,Tablets,,2023,Q2,Malignant neoplasm progression,,2023,Q2,10,F,20221221.0,20230417.0,20230215,20230424,PER,,CO-Eisai Medical Research-EC-2023-134172,EISAI,,76.0,YR,E,F,Y,57.2,KG,20230424,,MD,CO,,2023,Q2,Elderly
219967414,21996741,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,The dose prescribed of empagliflozin/ metformin was 12.5 mg + 1000 mg,,,Y,U,E42391,,206111.0,,,Tablet,Q12H,2023,Q2,Tachycardia,,2023,Q2,4,F,20230131.0,20230514.0,20230215,20230517,EXP,,"CO-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219121",BOEHRINGER INGELHEIM,,86.0,YR,E,M,Y,55.0,KG,20230517,,CN,CO,CO,2023,Q2,Elderly
219967414,21996741,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,The dose prescribed of empagliflozin/ metformin was 12.5 mg + 1000 mg,,,Y,U,E42391,,206111.0,,,Tablet,Q12H,2023,Q2,Resuscitation,,2023,Q2,4,F,20230131.0,20230514.0,20230215,20230517,EXP,,"CO-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219121",BOEHRINGER INGELHEIM,,86.0,YR,E,M,Y,55.0,KG,20230517,,CN,CO,CO,2023,Q2,Elderly
219967414,21996741,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,The dose prescribed of empagliflozin/ metformin was 12.5 mg + 1000 mg,,,Y,U,E42391,,206111.0,,,Tablet,Q12H,2023,Q2,Delirium,,2023,Q2,4,F,20230131.0,20230514.0,20230215,20230517,EXP,,"CO-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219121",BOEHRINGER INGELHEIM,,86.0,YR,E,M,Y,55.0,KG,20230517,,CN,CO,CO,2023,Q2,Elderly
219967414,21996741,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,The dose prescribed of empagliflozin/ metformin was 12.5 mg + 1000 mg,,,Y,U,E42391,,206111.0,,,Tablet,Q12H,2023,Q2,Pollakiuria,,2023,Q2,4,F,20230131.0,20230514.0,20230215,20230517,EXP,,"CO-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219121",BOEHRINGER INGELHEIM,,86.0,YR,E,M,Y,55.0,KG,20230517,,CN,CO,CO,2023,Q2,Elderly
219967414,21996741,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,The dose prescribed of empagliflozin/ metformin was 12.5 mg + 1000 mg,,,Y,U,E42391,,206111.0,,,Tablet,Q12H,2023,Q2,Fluid retention,,2023,Q2,4,F,20230131.0,20230514.0,20230215,20230517,EXP,,"CO-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219121",BOEHRINGER INGELHEIM,,86.0,YR,E,M,Y,55.0,KG,20230517,,CN,CO,CO,2023,Q2,Elderly
219967414,21996741,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,The dose prescribed of empagliflozin/ metformin was 12.5 mg + 1000 mg,,,Y,U,E42391,,206111.0,,,Tablet,Q12H,2023,Q2,Diabetic ketoacidosis,,2023,Q2,4,F,20230131.0,20230514.0,20230215,20230517,EXP,,"CO-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-219121",BOEHRINGER INGELHEIM,,86.0,YR,E,M,Y,55.0,KG,20230517,,CN,CO,CO,2023,Q2,Elderly
219975643,21997564,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,Tablet,QD,2023,Q2,Erysipelas,,2023,Q2,3,F,20220520.0,20230425.0,20230216,20230502,EXP,,FI-JNJFOC-20230229306,JOHNSON AND JOHNSON,,60.0,YR,,F,Y,,,20230502,,MD,FI,FI,2023,Q2,Adult
220052792,22005279,8,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2023,Q2,Melaena,,2023,Q2,2,F,20230116.0,20230327.0,20230217,20230406,EXP,,JP-BAYER-2023A014766,BAYER,,61.0,YR,A,M,Y,,,20230406,,MD,JP,JP,2023,Q2,Adult
220052792,22005279,8,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2023,Q2,Off label use,,2023,Q2,2,F,20230116.0,20230327.0,20230217,20230406,EXP,,JP-BAYER-2023A014766,BAYER,,61.0,YR,A,M,Y,,,20230406,,MD,JP,JP,2023,Q2,Adult
220052792,22005279,8,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2023,Q2,Non-alcoholic fatty liver,,2023,Q2,2,F,20230116.0,20230327.0,20230217,20230406,EXP,,JP-BAYER-2023A014766,BAYER,,61.0,YR,A,M,Y,,,20230406,,MD,JP,JP,2023,Q2,Adult
220052792,22005279,8,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2023,Q2,Portal hypertension,,2023,Q2,2,F,20230116.0,20230327.0,20230217,20230406,EXP,,JP-BAYER-2023A014766,BAYER,,61.0,YR,A,M,Y,,,20230406,,MD,JP,JP,2023,Q2,Adult
220155074,22015507,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Nausea,,2023,Q2,4,F,20230301.0,20230407.0,20230221,20230427,EXP,,NVSC2023US034723,NOVARTIS,,88.0,YR,,F,Y,55.0,KG,20230427,,MD,US,US,2023,Q2,Elderly
220155074,22015507,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Vomiting,,2023,Q2,4,F,20230301.0,20230407.0,20230221,20230427,EXP,,NVSC2023US034723,NOVARTIS,,88.0,YR,,F,Y,55.0,KG,20230427,,MD,US,US,2023,Q2,Elderly
220155074,22015507,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Decreased appetite,,2023,Q2,4,F,20230301.0,20230407.0,20230221,20230427,EXP,,NVSC2023US034723,NOVARTIS,,88.0,YR,,F,Y,55.0,KG,20230427,,MD,US,US,2023,Q2,Elderly
220155074,22015507,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Drug resistance,,2023,Q2,4,F,20230301.0,20230407.0,20230221,20230427,EXP,,NVSC2023US034723,NOVARTIS,,88.0,YR,,F,Y,55.0,KG,20230427,,MD,US,US,2023,Q2,Elderly
220155074,22015507,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Drug ineffective,,2023,Q2,4,F,20230301.0,20230407.0,20230221,20230427,EXP,,NVSC2023US034723,NOVARTIS,,88.0,YR,,F,Y,55.0,KG,20230427,,MD,US,US,2023,Q2,Elderly
220155074,22015507,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Electrocardiogram QT prolonged,,2023,Q2,4,F,20230301.0,20230407.0,20230221,20230427,EXP,,NVSC2023US034723,NOVARTIS,,88.0,YR,,F,Y,55.0,KG,20230427,,MD,US,US,2023,Q2,Elderly
220202953,22020295,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Post procedural haemorrhage,,2023,Q2,3,F,20230125.0,20230419.0,20230222,20230424,EXP,,NVSC2023US038028,NOVARTIS,,51.0,YR,,F,Y,,,20230424,,CN,US,US,2023,Q2,Adult
220202953,22020295,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Weight fluctuation,,2023,Q2,3,F,20230125.0,20230419.0,20230222,20230424,EXP,,NVSC2023US038028,NOVARTIS,,51.0,YR,,F,Y,,,20230424,,CN,US,US,2023,Q2,Adult
220202953,22020295,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Wrong technique in product usage process,,2023,Q2,3,F,20230125.0,20230419.0,20230222,20230424,EXP,,NVSC2023US038028,NOVARTIS,,51.0,YR,,F,Y,,,20230424,,CN,US,US,2023,Q2,Adult
220202953,22020295,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Musculoskeletal discomfort,,2023,Q2,3,F,20230125.0,20230419.0,20230222,20230424,EXP,,NVSC2023US038028,NOVARTIS,,51.0,YR,,F,Y,,,20230424,,CN,US,US,2023,Q2,Adult
220202953,22020295,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Underdose,,2023,Q2,3,F,20230125.0,20230419.0,20230222,20230424,EXP,,NVSC2023US038028,NOVARTIS,,51.0,YR,,F,Y,,,20230424,,CN,US,US,2023,Q2,Adult
220202953,22020295,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Ecchymosis,,2023,Q2,3,F,20230125.0,20230419.0,20230222,20230424,EXP,,NVSC2023US038028,NOVARTIS,,51.0,YR,,F,Y,,,20230424,,CN,US,US,2023,Q2,Adult
220202953,22020295,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Headache,,2023,Q2,3,F,20230125.0,20230419.0,20230222,20230424,EXP,,NVSC2023US038028,NOVARTIS,,51.0,YR,,F,Y,,,20230424,,CN,US,US,2023,Q2,Adult
220202953,22020295,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Post procedural haematoma,,2023,Q2,3,F,20230125.0,20230419.0,20230222,20230424,EXP,,NVSC2023US038028,NOVARTIS,,51.0,YR,,F,Y,,,20230424,,CN,US,US,2023,Q2,Adult
220202953,22020295,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Haemoglobin decreased,,2023,Q2,3,F,20230125.0,20230419.0,20230222,20230424,EXP,,NVSC2023US038028,NOVARTIS,,51.0,YR,,F,Y,,,20230424,,CN,US,US,2023,Q2,Adult
220202953,22020295,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Ventricular extrasystoles,,2023,Q2,3,F,20230125.0,20230419.0,20230222,20230424,EXP,,NVSC2023US038028,NOVARTIS,,51.0,YR,,F,Y,,,20230424,,CN,US,US,2023,Q2,Adult
220202953,22020295,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Dilated cardiomyopathy,,2023,Q2,3,F,20230125.0,20230419.0,20230222,20230424,EXP,,NVSC2023US038028,NOVARTIS,,51.0,YR,,F,Y,,,20230424,,CN,US,US,2023,Q2,Adult
220202953,22020295,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Nausea,,2023,Q2,3,F,20230125.0,20230419.0,20230222,20230424,EXP,,NVSC2023US038028,NOVARTIS,,51.0,YR,,F,Y,,,20230424,,CN,US,US,2023,Q2,Adult
220202953,22020295,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Hypotension,,2023,Q2,3,F,20230125.0,20230419.0,20230222,20230424,EXP,,NVSC2023US038028,NOVARTIS,,51.0,YR,,F,Y,,,20230424,,CN,US,US,2023,Q2,Adult
220202953,22020295,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Fluid retention,,2023,Q2,3,F,20230125.0,20230419.0,20230222,20230424,EXP,,NVSC2023US038028,NOVARTIS,,51.0,YR,,F,Y,,,20230424,,CN,US,US,2023,Q2,Adult
220205594,22020559,42,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2023,Q2,Depression,,2023,Q2,4,F,,20230331.0,20230222,20230403,EXP,,NVSC2023ES033234,NOVARTIS,"Bugallo-Carrera C, Facal D, Dominguez-Lenogue C, Alvarez-Vidal V, Gandoy-Crego M, Caamano-Ponte J. Neuropsychiatric symptoms after liver transplantation in a 65-year-old male patient. BRAIN SCIENCES. 2022;12(1721):1-10",65.0,YR,,M,Y,,,20230403,,HP,ES,ES,2023,Q2,Elderly
220205594,22020559,42,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2023,Q2,Affective disorder,,2023,Q2,4,F,,20230331.0,20230222,20230403,EXP,,NVSC2023ES033234,NOVARTIS,"Bugallo-Carrera C, Facal D, Dominguez-Lenogue C, Alvarez-Vidal V, Gandoy-Crego M, Caamano-Ponte J. Neuropsychiatric symptoms after liver transplantation in a 65-year-old male patient. BRAIN SCIENCES. 2022;12(1721):1-10",65.0,YR,,M,Y,,,20230403,,HP,ES,ES,2023,Q2,Elderly
220205594,22020559,42,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2023,Q2,Agitation,,2023,Q2,4,F,,20230331.0,20230222,20230403,EXP,,NVSC2023ES033234,NOVARTIS,"Bugallo-Carrera C, Facal D, Dominguez-Lenogue C, Alvarez-Vidal V, Gandoy-Crego M, Caamano-Ponte J. Neuropsychiatric symptoms after liver transplantation in a 65-year-old male patient. BRAIN SCIENCES. 2022;12(1721):1-10",65.0,YR,,M,Y,,,20230403,,HP,ES,ES,2023,Q2,Elderly
220205594,22020559,42,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2023,Q2,Intrusive thoughts,,2023,Q2,4,F,,20230331.0,20230222,20230403,EXP,,NVSC2023ES033234,NOVARTIS,"Bugallo-Carrera C, Facal D, Dominguez-Lenogue C, Alvarez-Vidal V, Gandoy-Crego M, Caamano-Ponte J. Neuropsychiatric symptoms after liver transplantation in a 65-year-old male patient. BRAIN SCIENCES. 2022;12(1721):1-10",65.0,YR,,M,Y,,,20230403,,HP,ES,ES,2023,Q2,Elderly
220205594,22020559,42,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2023,Q2,Irritability,,2023,Q2,4,F,,20230331.0,20230222,20230403,EXP,,NVSC2023ES033234,NOVARTIS,"Bugallo-Carrera C, Facal D, Dominguez-Lenogue C, Alvarez-Vidal V, Gandoy-Crego M, Caamano-Ponte J. Neuropsychiatric symptoms after liver transplantation in a 65-year-old male patient. BRAIN SCIENCES. 2022;12(1721):1-10",65.0,YR,,M,Y,,,20230403,,HP,ES,ES,2023,Q2,Elderly
220205594,22020559,42,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2023,Q2,Delusion,,2023,Q2,4,F,,20230331.0,20230222,20230403,EXP,,NVSC2023ES033234,NOVARTIS,"Bugallo-Carrera C, Facal D, Dominguez-Lenogue C, Alvarez-Vidal V, Gandoy-Crego M, Caamano-Ponte J. Neuropsychiatric symptoms after liver transplantation in a 65-year-old male patient. BRAIN SCIENCES. 2022;12(1721):1-10",65.0,YR,,M,Y,,,20230403,,HP,ES,ES,2023,Q2,Elderly
220205594,22020559,42,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2023,Q2,Confusional state,,2023,Q2,4,F,,20230331.0,20230222,20230403,EXP,,NVSC2023ES033234,NOVARTIS,"Bugallo-Carrera C, Facal D, Dominguez-Lenogue C, Alvarez-Vidal V, Gandoy-Crego M, Caamano-Ponte J. Neuropsychiatric symptoms after liver transplantation in a 65-year-old male patient. BRAIN SCIENCES. 2022;12(1721):1-10",65.0,YR,,M,Y,,,20230403,,HP,ES,ES,2023,Q2,Elderly
220205594,22020559,42,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2023,Q2,Obsessive thoughts,,2023,Q2,4,F,,20230331.0,20230222,20230403,EXP,,NVSC2023ES033234,NOVARTIS,"Bugallo-Carrera C, Facal D, Dominguez-Lenogue C, Alvarez-Vidal V, Gandoy-Crego M, Caamano-Ponte J. Neuropsychiatric symptoms after liver transplantation in a 65-year-old male patient. BRAIN SCIENCES. 2022;12(1721):1-10",65.0,YR,,M,Y,,,20230403,,HP,ES,ES,2023,Q2,Elderly
220205594,22020559,42,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2023,Q2,Insomnia,,2023,Q2,4,F,,20230331.0,20230222,20230403,EXP,,NVSC2023ES033234,NOVARTIS,"Bugallo-Carrera C, Facal D, Dominguez-Lenogue C, Alvarez-Vidal V, Gandoy-Crego M, Caamano-Ponte J. Neuropsychiatric symptoms after liver transplantation in a 65-year-old male patient. BRAIN SCIENCES. 2022;12(1721):1-10",65.0,YR,,M,Y,,,20230403,,HP,ES,ES,2023,Q2,Elderly
220205594,22020559,42,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2023,Q2,Anxiety,,2023,Q2,4,F,,20230331.0,20230222,20230403,EXP,,NVSC2023ES033234,NOVARTIS,"Bugallo-Carrera C, Facal D, Dominguez-Lenogue C, Alvarez-Vidal V, Gandoy-Crego M, Caamano-Ponte J. Neuropsychiatric symptoms after liver transplantation in a 65-year-old male patient. BRAIN SCIENCES. 2022;12(1721):1-10",65.0,YR,,M,Y,,,20230403,,HP,ES,ES,2023,Q2,Elderly
220205594,22020559,42,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2023,Q2,Jealous delusion,,2023,Q2,4,F,,20230331.0,20230222,20230403,EXP,,NVSC2023ES033234,NOVARTIS,"Bugallo-Carrera C, Facal D, Dominguez-Lenogue C, Alvarez-Vidal V, Gandoy-Crego M, Caamano-Ponte J. Neuropsychiatric symptoms after liver transplantation in a 65-year-old male patient. BRAIN SCIENCES. 2022;12(1721):1-10",65.0,YR,,M,Y,,,20230403,,HP,ES,ES,2023,Q2,Elderly
220205594,22020559,42,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2023,Q2,Hallucination,,2023,Q2,4,F,,20230331.0,20230222,20230403,EXP,,NVSC2023ES033234,NOVARTIS,"Bugallo-Carrera C, Facal D, Dominguez-Lenogue C, Alvarez-Vidal V, Gandoy-Crego M, Caamano-Ponte J. Neuropsychiatric symptoms after liver transplantation in a 65-year-old male patient. BRAIN SCIENCES. 2022;12(1721):1-10",65.0,YR,,M,Y,,,20230403,,HP,ES,ES,2023,Q2,Elderly
220205594,22020559,42,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2023,Q2,Delusion of replacement,,2023,Q2,4,F,,20230331.0,20230222,20230403,EXP,,NVSC2023ES033234,NOVARTIS,"Bugallo-Carrera C, Facal D, Dominguez-Lenogue C, Alvarez-Vidal V, Gandoy-Crego M, Caamano-Ponte J. Neuropsychiatric symptoms after liver transplantation in a 65-year-old male patient. BRAIN SCIENCES. 2022;12(1721):1-10",65.0,YR,,M,Y,,,20230403,,HP,ES,ES,2023,Q2,Elderly
220205594,22020559,42,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2023,Q2,Motor dysfunction,,2023,Q2,4,F,,20230331.0,20230222,20230403,EXP,,NVSC2023ES033234,NOVARTIS,"Bugallo-Carrera C, Facal D, Dominguez-Lenogue C, Alvarez-Vidal V, Gandoy-Crego M, Caamano-Ponte J. Neuropsychiatric symptoms after liver transplantation in a 65-year-old male patient. BRAIN SCIENCES. 2022;12(1721):1-10",65.0,YR,,M,Y,,,20230403,,HP,ES,ES,2023,Q2,Elderly
220437475,22043747,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,Tablets,,2023,Q2,Fistula,,2023,Q2,5,F,20221109.0,20230515.0,20230228,20230522,PER,,ES-Eisai Medical Research-EC-2022-127999,EISAI,,62.0,YR,A,M,Y,68.6,KG,20230522,,MD,ES,,2023,Q2,Adult
220503324,22050332,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q2,Prescribed underdose,,2023,Q2,4,F,20230203.0,20230413.0,20230301,20230419,EXP,,ES-MYLANLABS-2023M1019925,MYLAN,,76.0,YR,,M,Y,75.0,KG,20230419,,MD,ES,ES,2023,Q2,Elderly
220503324,22050332,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q2,Cerebrovascular accident,,2023,Q2,4,F,20230203.0,20230413.0,20230301,20230419,EXP,,ES-MYLANLABS-2023M1019925,MYLAN,,76.0,YR,,M,Y,75.0,KG,20230419,,MD,ES,ES,2023,Q2,Elderly
220503324,22050332,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q2,Intentional product use issue,,2023,Q2,4,F,20230203.0,20230413.0,20230301,20230419,EXP,,ES-MYLANLABS-2023M1019925,MYLAN,,76.0,YR,,M,Y,75.0,KG,20230419,,MD,ES,ES,2023,Q2,Elderly
220509833,22050983,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,,,,,,,,,2023,Q2,Fanconi syndrome,,2023,Q2,3,F,,20230424.0,20230301,20230504,EXP,,SE-TEVA-2023-SE-2860733,TEVA,,7.0,DEC,E,F,Y,,,20230504,,HP,SE,SE,2023,Q2,Child
220509833,22050983,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,,,,,,,,,2023,Q2,Osteoporosis,,2023,Q2,3,F,,20230424.0,20230301,20230504,EXP,,SE-TEVA-2023-SE-2860733,TEVA,,7.0,DEC,E,F,Y,,,20230504,,HP,SE,SE,2023,Q2,Child
220605492,22060549,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,U,,,,,10.0,MG,Tablet,QD,2023,Q2,Orthostatic hypotension,,2023,Q2,2,F,20230128.0,20230417.0,20230303,20230421,EXP,,IR-SA-2023SA069513,SANOFI AVENTIS,,73.0,YR,E,M,Y,71.0,KG,20230421,,CN,IR,IR,2023,Q2,Elderly
220605492,22060549,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,U,,,,,10.0,MG,Tablet,QD,2023,Q2,Blood pressure fluctuation,,2023,Q2,2,F,20230128.0,20230417.0,20230303,20230421,EXP,,IR-SA-2023SA069513,SANOFI AVENTIS,,73.0,YR,E,M,Y,71.0,KG,20230421,,CN,IR,IR,2023,Q2,Elderly
220605492,22060549,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,U,,,,,10.0,MG,Tablet,QD,2023,Q2,Balance disorder,,2023,Q2,2,F,20230128.0,20230417.0,20230303,20230421,EXP,,IR-SA-2023SA069513,SANOFI AVENTIS,,73.0,YR,E,M,Y,71.0,KG,20230421,,CN,IR,IR,2023,Q2,Elderly
220969673,22096967,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Off label use,,2023,Q2,3,F,20220418.0,20230419.0,20230315,20230419,EXP,,CA-PFIZER INC-202200597420,PFIZER,,64.0,YR,,M,Y,,,20230419,,HP,CA,CA,2023,Q2,Adult
220969673,22096967,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Inappropriate schedule of product administration,,2023,Q2,3,F,20220418.0,20230419.0,20230315,20230419,EXP,,CA-PFIZER INC-202200597420,PFIZER,,64.0,YR,,M,Y,,,20230419,,HP,CA,CA,2023,Q2,Adult
220969673,22096967,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Seizure,,2023,Q2,3,F,20220418.0,20230419.0,20230315,20230419,EXP,,CA-PFIZER INC-202200597420,PFIZER,,64.0,YR,,M,Y,,,20230419,,HP,CA,CA,2023,Q2,Adult
220969673,22096967,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Back pain,,2023,Q2,3,F,20220418.0,20230419.0,20230315,20230419,EXP,,CA-PFIZER INC-202200597420,PFIZER,,64.0,YR,,M,Y,,,20230419,,HP,CA,CA,2023,Q2,Adult
220969673,22096967,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Malaise,,2023,Q2,3,F,20220418.0,20230419.0,20230315,20230419,EXP,,CA-PFIZER INC-202200597420,PFIZER,,64.0,YR,,M,Y,,,20230419,,HP,CA,CA,2023,Q2,Adult
221173452,22117345,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,25.0,MG,,QD,2023,Q2,Syncope,,2023,Q2,2,F,20220919.0,20230411.0,20230320,20230412,EXP,IT-MINISAL02-914404,"IT-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-226097",BOEHRINGER INGELHEIM,,84.0,YR,E,F,Y,,,20230412,,PH,IT,IT,2023,Q2,Elderly
221173452,22117345,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,25.0,MG,,QD,2023,Q2,Fall,,2023,Q2,2,F,20220919.0,20230411.0,20230320,20230412,EXP,IT-MINISAL02-914404,"IT-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-226097",BOEHRINGER INGELHEIM,,84.0,YR,E,F,Y,,,20230412,,PH,IT,IT,2023,Q2,Elderly
221180742,22118074,2,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"850 mg, bid",,,,,unk,,,850.0,MG,,BID,2023,Q2,Cholecystitis,,2023,Q2,2,F,20230201.0,20230421.0,20230321,20230501,EXP,,CO-NOVOPROD-1036187,NOVO NORDISK,,55.0,YR,,F,Y,70.0,KG,20230501,,CN,CO,CO,2023,Q2,Adult
221180742,22118074,2,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"850 mg, bid",,,,,unk,,,850.0,MG,,BID,2023,Q2,Abdominal pain,,2023,Q2,2,F,20230201.0,20230421.0,20230321,20230501,EXP,,CO-NOVOPROD-1036187,NOVO NORDISK,,55.0,YR,,F,Y,70.0,KG,20230501,,CN,CO,CO,2023,Q2,Adult
221180742,22118074,2,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"850 mg, bid",,,,,unk,,,850.0,MG,,BID,2023,Q2,Blood glucose increased,,2023,Q2,2,F,20230201.0,20230421.0,20230321,20230501,EXP,,CO-NOVOPROD-1036187,NOVO NORDISK,,55.0,YR,,F,Y,70.0,KG,20230501,,CN,CO,CO,2023,Q2,Adult
221276232,22127623,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,Y,U,Unknown,,206073.0,,,Tablet,QD,2023,Q2,Nausea,,2023,Q2,2,F,20221224.0,20230512.0,20230323,20230515,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-226798",BOEHRINGER INGELHEIM,,51.0,YR,A,M,Y,91.0,KG,20230515,,PH,JP,JP,2023,Q2,Adult
221276232,22127623,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,Y,U,Unknown,,206073.0,,,Tablet,QD,2023,Q2,Necrotising oesophagitis,,2023,Q2,2,F,20221224.0,20230512.0,20230323,20230515,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-226798",BOEHRINGER INGELHEIM,,51.0,YR,A,M,Y,91.0,KG,20230515,,PH,JP,JP,2023,Q2,Adult
221276232,22127623,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,Y,U,Unknown,,206073.0,,,Tablet,QD,2023,Q2,Diabetic ketoacidosis,,2023,Q2,2,F,20221224.0,20230512.0,20230323,20230515,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-226798",BOEHRINGER INGELHEIM,,51.0,YR,A,M,Y,91.0,KG,20230515,,PH,JP,JP,2023,Q2,Adult
221276232,22127623,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,Y,U,Unknown,,206073.0,,,Tablet,QD,2023,Q2,Vomiting,,2023,Q2,2,F,20221224.0,20230512.0,20230323,20230515,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-226798",BOEHRINGER INGELHEIM,,51.0,YR,A,M,Y,91.0,KG,20230515,,PH,JP,JP,2023,Q2,Adult
221276232,22127623,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,Y,U,Unknown,,206073.0,,,Tablet,QD,2023,Q2,Hypokalaemia,,2023,Q2,2,F,20221224.0,20230512.0,20230323,20230515,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-226798",BOEHRINGER INGELHEIM,,51.0,YR,A,M,Y,91.0,KG,20230515,,PH,JP,JP,2023,Q2,Adult
221290576,22129057,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Hepatic function abnormal,,2023,Q2,6,F,20230303.0,20230420.0,20230323,20230421,EXP,,NVSC2023JP061389,NOVARTIS,,69.0,YR,,F,Y,57.2,KG,20230421,,MD,JP,JP,2023,Q2,Elderly
221334092,22133409,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 tablet daily,,,,,unknown,,,,,,,2023,Q2,Gastritis,,2023,Q2,2,F,20230127.0,20230427.0,20230324,20230505,EXP,,CO-NOVOPROD-1038908,NOVO NORDISK,,59.0,YR,,F,Y,90.0,KG,20230505,,CN,CO,CO,2023,Q2,Adult
221334092,22133409,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 tablet daily,,,,,unknown,,,,,,,2023,Q2,Discouragement,,2023,Q2,2,F,20230127.0,20230427.0,20230324,20230505,EXP,,CO-NOVOPROD-1038908,NOVO NORDISK,,59.0,YR,,F,Y,90.0,KG,20230505,,CN,CO,CO,2023,Q2,Adult
221334092,22133409,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 tablet daily,,,,,unknown,,,,,,,2023,Q2,Vomiting,,2023,Q2,2,F,20230127.0,20230427.0,20230324,20230505,EXP,,CO-NOVOPROD-1038908,NOVO NORDISK,,59.0,YR,,F,Y,90.0,KG,20230505,,CN,CO,CO,2023,Q2,Adult
221334092,22133409,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 tablet daily,,,,,unknown,,,,,,,2023,Q2,Headache,,2023,Q2,2,F,20230127.0,20230427.0,20230324,20230505,EXP,,CO-NOVOPROD-1038908,NOVO NORDISK,,59.0,YR,,F,Y,90.0,KG,20230505,,CN,CO,CO,2023,Q2,Adult
221334092,22133409,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 tablet daily,,,,,unknown,,,,,,,2023,Q2,Decreased appetite,,2023,Q2,2,F,20230127.0,20230427.0,20230324,20230505,EXP,,CO-NOVOPROD-1038908,NOVO NORDISK,,59.0,YR,,F,Y,90.0,KG,20230505,,CN,CO,CO,2023,Q2,Adult
221525113,22152511,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2023,Q2,Melaena,,2023,Q2,3,F,,20230327.0,20230329,20230403,EXP,,NVSC2023HR070486,NOVARTIS,"Simicevic L, Sliskovic AM, Kirhmajer MV, Ganoci L, Holik H, Palic J et al.. Risk factors for rivaroxaban-related bleeding events-possible role of pharmacogenetics: Case series. PHARMACY (BASEL). 2023;11(1):29",75.0,YR,,F,Y,,,20230403,,HP,HR,HR,2023,Q2,Elderly
221525113,22152511,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2023,Q2,Epistaxis,,2023,Q2,3,F,,20230327.0,20230329,20230403,EXP,,NVSC2023HR070486,NOVARTIS,"Simicevic L, Sliskovic AM, Kirhmajer MV, Ganoci L, Holik H, Palic J et al.. Risk factors for rivaroxaban-related bleeding events-possible role of pharmacogenetics: Case series. PHARMACY (BASEL). 2023;11(1):29",75.0,YR,,F,Y,,,20230403,,HP,HR,HR,2023,Q2,Elderly
221525113,22152511,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2023,Q2,Drug interaction,,2023,Q2,3,F,,20230327.0,20230329,20230403,EXP,,NVSC2023HR070486,NOVARTIS,"Simicevic L, Sliskovic AM, Kirhmajer MV, Ganoci L, Holik H, Palic J et al.. Risk factors for rivaroxaban-related bleeding events-possible role of pharmacogenetics: Case series. PHARMACY (BASEL). 2023;11(1):29",75.0,YR,,F,Y,,,20230403,,HP,HR,HR,2023,Q2,Elderly
221570612,22157061,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Glomerular filtration rate decreased,,2023,Q2,2,F,,20230322.0,20230330,20230404,EXP,,NVSC2023TH069277,NOVARTIS,,78.0,YR,,F,Y,50.0,KG,20230404,,MD,TH,TH,2023,Q2,Elderly
221570612,22157061,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Glycosylated haemoglobin increased,,2023,Q2,2,F,,20230322.0,20230330,20230404,EXP,,NVSC2023TH069277,NOVARTIS,,78.0,YR,,F,Y,50.0,KG,20230404,,MD,TH,TH,2023,Q2,Elderly
221570612,22157061,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Blood triglycerides increased,,2023,Q2,2,F,,20230322.0,20230330,20230404,EXP,,NVSC2023TH069277,NOVARTIS,,78.0,YR,,F,Y,50.0,KG,20230404,,MD,TH,TH,2023,Q2,Elderly
221570612,22157061,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Cardiac failure chronic,,2023,Q2,2,F,,20230322.0,20230330,20230404,EXP,,NVSC2023TH069277,NOVARTIS,,78.0,YR,,F,Y,50.0,KG,20230404,,MD,TH,TH,2023,Q2,Elderly
221570612,22157061,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Blood creatinine increased,,2023,Q2,2,F,,20230322.0,20230330,20230404,EXP,,NVSC2023TH069277,NOVARTIS,,78.0,YR,,F,Y,50.0,KG,20230404,,MD,TH,TH,2023,Q2,Elderly
221570612,22157061,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Blood glucose increased,,2023,Q2,2,F,,20230322.0,20230330,20230404,EXP,,NVSC2023TH069277,NOVARTIS,,78.0,YR,,F,Y,50.0,KG,20230404,,MD,TH,TH,2023,Q2,Elderly
221570612,22157061,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Blood urea increased,,2023,Q2,2,F,,20230322.0,20230330,20230404,EXP,,NVSC2023TH069277,NOVARTIS,,78.0,YR,,F,Y,50.0,KG,20230404,,MD,TH,TH,2023,Q2,Elderly
221582443,22158244,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,Y,U,Unknown,,206073.0,,,Tablet,,2023,Q2,Hyperkalaemia,,2023,Q2,3,F,20221122.0,20230413.0,20230331,20230414,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-226520",BOEHRINGER INGELHEIM,,51.0,YR,A,M,Y,,,20230414,,MD,JP,JP,2023,Q2,Adult
221620892,22162089,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Insomnia,,2023,Q2,2,F,20210701.0,20230406.0,20230331,20230412,EXP,,NVSC2022NG275710,NOVARTIS,,36.0,YR,,F,Y,93.0,KG,20230412,,HP,NG,NG,2023,Q2,Adult
221620892,22162089,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Pain in extremity,,2023,Q2,2,F,20210701.0,20230406.0,20230331,20230412,EXP,,NVSC2022NG275710,NOVARTIS,,36.0,YR,,F,Y,93.0,KG,20230412,,HP,NG,NG,2023,Q2,Adult
221620892,22162089,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Muscle spasms,,2023,Q2,2,F,20210701.0,20230406.0,20230331,20230412,EXP,,NVSC2022NG275710,NOVARTIS,,36.0,YR,,F,Y,93.0,KG,20230412,,HP,NG,NG,2023,Q2,Adult
221620892,22162089,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Abdominal distension,,2023,Q2,2,F,20210701.0,20230406.0,20230331,20230412,EXP,,NVSC2022NG275710,NOVARTIS,,36.0,YR,,F,Y,93.0,KG,20230412,,HP,NG,NG,2023,Q2,Adult
221620892,22162089,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Hypotension,,2023,Q2,2,F,20210701.0,20230406.0,20230331,20230412,EXP,,NVSC2022NG275710,NOVARTIS,,36.0,YR,,F,Y,93.0,KG,20230412,,HP,NG,NG,2023,Q2,Adult
221620892,22162089,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Bone pain,,2023,Q2,2,F,20210701.0,20230406.0,20230331,20230412,EXP,,NVSC2022NG275710,NOVARTIS,,36.0,YR,,F,Y,93.0,KG,20230412,,HP,NG,NG,2023,Q2,Adult
221620892,22162089,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Dizziness,,2023,Q2,2,F,20210701.0,20230406.0,20230331,20230412,EXP,,NVSC2022NG275710,NOVARTIS,,36.0,YR,,F,Y,93.0,KG,20230412,,HP,NG,NG,2023,Q2,Adult
221620892,22162089,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Prescribed underdose,,2023,Q2,2,F,20210701.0,20230406.0,20230331,20230412,EXP,,NVSC2022NG275710,NOVARTIS,,36.0,YR,,F,Y,93.0,KG,20230412,,HP,NG,NG,2023,Q2,Adult
221620892,22162089,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Asthenia,,2023,Q2,2,F,20210701.0,20230406.0,20230331,20230412,EXP,,NVSC2022NG275710,NOVARTIS,,36.0,YR,,F,Y,93.0,KG,20230412,,HP,NG,NG,2023,Q2,Adult
221620892,22162089,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Oedema peripheral,,2023,Q2,2,F,20210701.0,20230406.0,20230331,20230412,EXP,,NVSC2022NG275710,NOVARTIS,,36.0,YR,,F,Y,93.0,KG,20230412,,HP,NG,NG,2023,Q2,Adult
221620892,22162089,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Frequent bowel movements,,2023,Q2,2,F,20210701.0,20230406.0,20230331,20230412,EXP,,NVSC2022NG275710,NOVARTIS,,36.0,YR,,F,Y,93.0,KG,20230412,,HP,NG,NG,2023,Q2,Adult
221620892,22162089,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Urine output decreased,,2023,Q2,2,F,20210701.0,20230406.0,20230331,20230412,EXP,,NVSC2022NG275710,NOVARTIS,,36.0,YR,,F,Y,93.0,KG,20230412,,HP,NG,NG,2023,Q2,Adult
221620892,22162089,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Palpitations,,2023,Q2,2,F,20210701.0,20230406.0,20230331,20230412,EXP,,NVSC2022NG275710,NOVARTIS,,36.0,YR,,F,Y,93.0,KG,20230412,,HP,NG,NG,2023,Q2,Adult
221620892,22162089,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Constipation,,2023,Q2,2,F,20210701.0,20230406.0,20230331,20230412,EXP,,NVSC2022NG275710,NOVARTIS,,36.0,YR,,F,Y,93.0,KG,20230412,,HP,NG,NG,2023,Q2,Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Memory impairment,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Angioedema,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Product prescribing error,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Tinnitus,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Arthralgia,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Fatigue,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Blood glucose increased,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Atrial tachycardia,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Pericarditis,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Rash papular,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Vomiting,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Feeling abnormal,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Cardiospasm,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Palpitations,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Anosmia,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Eye pruritus,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Disturbance in attention,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Cognitive disorder,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Lip swelling,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Tension headache,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Facial pain,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Anxiety,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Ventricular tachycardia,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Dizziness,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Headache,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Hallucination,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Migraine,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Sleep terror,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Diplopia,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Diarrhoea,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Dyspnoea,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Carotid artery occlusion,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Blindness,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Immunisation,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Chest pain,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Pruritus,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Myocardial infarction,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Tachycardia,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Insomnia,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Pain,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Muscle twitching,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Peripheral swelling,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Pyrexia,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Dry skin,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Malaise,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Off label use,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Muscular weakness,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Visual impairment,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,COVID-19,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Subarachnoid haemorrhage,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Alopecia,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Drug abuse,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Abdominal discomfort,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Pruritus genital,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Intentional product use issue,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Pain of skin,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Intentional product misuse,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Vasculitis,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Nausea,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Amnesia,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Dehydration,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Abdominal pain upper,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Back pain,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Hyperhidrosis,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Transient ischaemic attack,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Heart rate increased,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Palmoplantar keratoderma,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221627528,22162752,34,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Eye disorder,,2023,Q2,8,F,20210331.0,20230606.0,20230331,20230630,EXP,,GB-AstraZeneca-2023A076570,ASTRAZENECA,,34.0,YR,,M,Y,70.0,KG,20230630,,MD,GB,,2023,Q2,Young Adult
221634261,22163426,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q2,Cerebrovascular accident,,2023,Q2,1,I,20230203.0,20230321.0,20230401,20230401,EXP,,ES-AUROBINDO-AUR-APL-2023-014151,AUROBINDO,,76.0,YR,,M,Y,75.0,KG,20230401,,MD,ES,ES,2023,Q2,Elderly
221634261,22163426,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q2,Prescribed underdose,,2023,Q2,1,I,20230203.0,20230321.0,20230401,20230401,EXP,,ES-AUROBINDO-AUR-APL-2023-014151,AUROBINDO,,76.0,YR,,M,Y,75.0,KG,20230401,,MD,ES,ES,2023,Q2,Elderly
221634261,22163426,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q2,Intentional product use issue,,2023,Q2,1,I,20230203.0,20230321.0,20230401,20230401,EXP,,ES-AUROBINDO-AUR-APL-2023-014151,AUROBINDO,,76.0,YR,,M,Y,75.0,KG,20230401,,MD,ES,ES,2023,Q2,Elderly
221702791,22170279,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Dehydration,,2023,Q2,1,I,20230201.0,20230330.0,20230404,20230404,EXP,,"CO-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-228635",BOEHRINGER INGELHEIM,,65.0,YR,E,F,Y,,,20230404,,MD,CO,CO,2023,Q2,Elderly
221702791,22170279,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Euglycaemic diabetic ketoacidosis,,2023,Q2,1,I,20230201.0,20230330.0,20230404,20230404,EXP,,"CO-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-228635",BOEHRINGER INGELHEIM,,65.0,YR,E,F,Y,,,20230404,,MD,CO,CO,2023,Q2,Elderly
221702791,22170279,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Gastroenteritis,,2023,Q2,1,I,20230201.0,20230330.0,20230404,20230404,EXP,,"CO-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-228635",BOEHRINGER INGELHEIM,,65.0,YR,E,F,Y,,,20230404,,MD,CO,CO,2023,Q2,Elderly
221721531,22172153,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Off label use,,2023,Q2,1,I,,20230330.0,20230404,20230404,PER,,SK-PFIZER INC-PV202300059631,PFIZER,,75.0,YR,,F,Y,,,20230404,,MD,SK,SK,2023,Q2,Elderly
221721531,22172153,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Contraindicated product administered,,2023,Q2,1,I,,20230330.0,20230404,20230404,PER,,SK-PFIZER INC-PV202300059631,PFIZER,,75.0,YR,,F,Y,,,20230404,,MD,SK,SK,2023,Q2,Elderly
221725256,22172525,9,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,Tablets,,2023,Q2,Cerebral haemorrhage,,2023,Q2,6,F,20230329.0,20230530.0,20230404,20230602,PER,,IL-Eisai Medical Research-EC-2023-137621,EISAI,,71.0,YR,E,M,Y,77.0,KG,20230602,,MD,IL,,2023,Q2,Elderly
221733042,22173304,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,Unknown,,204629.0,,,Tablet,,2023,Q2,Hydronephrosis,,2023,Q2,2,F,20221201.0,20230422.0,20230404,20230426,EXP,,"FR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-220833",BOEHRINGER INGELHEIM,,74.0,YR,E,M,Y,,,20230426,,MD,FR,FR,2023,Q2,Elderly
221747261,22174726,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1.0 tablet before breakfast,,,Y,U,Unknown,,204629.0,,,,QD,2023,Q2,Aphasia,,2023,Q2,1,I,20230324.0,20230405.0,20230405,20230405,EXP,ES-AEMPS-1352467,"ES-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-229726",BOEHRINGER INGELHEIM,,74.0,YR,E,M,Y,106.0,KG,20230405,,MD,ES,ES,2023,Q2,Elderly
221749241,22174924,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,,,,,,10.0,MG,,,2023,Q2,Cardioversion,,2023,Q2,1,I,,20210928.0,20230405,20230405,EXP,,SI-JNJFOC-20210960559,JOHNSON AND JOHNSON,,65.0,YR,E,M,Y,120.0,KG,20230405,,MD,SI,SI,2023,Q2,Elderly
221757296,22175729,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,5.0,MG,Capsule,BID,2023,Q2,Oedema,,2023,Q2,6,F,20221214.0,20230601.0,20230405,20230602,EXP,,IT-ROCHE-3314499,ROCHE,,65.0,YR,,F,Y,61.0,KG,20230602,,MD,IT,,2023,Q2,Elderly
221757296,22175729,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,5.0,MG,Capsule,BID,2023,Q2,Infected skin ulcer,,2023,Q2,6,F,20221214.0,20230601.0,20230405,20230602,EXP,,IT-ROCHE-3314499,ROCHE,,65.0,YR,,F,Y,61.0,KG,20230602,,MD,IT,,2023,Q2,Elderly
221757296,22175729,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,5.0,MG,Capsule,BID,2023,Q2,Ulcer,,2023,Q2,6,F,20221214.0,20230601.0,20230405,20230602,EXP,,IT-ROCHE-3314499,ROCHE,,65.0,YR,,F,Y,61.0,KG,20230602,,MD,IT,,2023,Q2,Elderly
221760901,22176090,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,N,N,,,,,,,,2023,Q2,Euglycaemic diabetic ketoacidosis,,2023,Q2,1,I,20230330.0,,20230404,20230404,DIR,654971,,FDA-CTU,,53.0,YR,,M,N,103.5,KG,20230404,N,PH,US,,2023,Q2,Adult
221760901,22176090,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,N,N,,,,,,,,2023,Q2,Starvation ketoacidosis,,2023,Q2,1,I,20230330.0,,20230404,20230404,DIR,654971,,FDA-CTU,,53.0,YR,,M,N,103.5,KG,20230404,N,PH,US,,2023,Q2,Adult
221760901,22176090,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,N,N,,,,,,,,2023,Q2,Intestinal obstruction,,2023,Q2,1,I,20230330.0,,20230404,20230404,DIR,654971,,FDA-CTU,,53.0,YR,,M,N,103.5,KG,20230404,N,PH,US,,2023,Q2,Adult
221770411,22177041,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2023,Q2,Pemphigoid,,2023,Q2,1,I,,20230329.0,20230405,20230405,EXP,,GB-MYLANLABS-2023M1034334,MYLAN,"Dyson S, Patel P, Millington G. Psychiatric associations in bullous pemphigoid: review and case report. Br-J-Dermatol 2022;187 (Suppl. 1):227 (plus poster) abstr. PS11.",59.0,YR,,F,Y,,,20230405,,HP,GB,GB,2023,Q2,Adult
221770411,22177041,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2023,Q2,Drug ineffective for unapproved indication,,2023,Q2,1,I,,20230329.0,20230405,20230405,EXP,,GB-MYLANLABS-2023M1034334,MYLAN,"Dyson S, Patel P, Millington G. Psychiatric associations in bullous pemphigoid: review and case report. Br-J-Dermatol 2022;187 (Suppl. 1):227 (plus poster) abstr. PS11.",59.0,YR,,F,Y,,,20230405,,HP,GB,GB,2023,Q2,Adult
221770411,22177041,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2023,Q2,Off label use,,2023,Q2,1,I,,20230329.0,20230405,20230405,EXP,,GB-MYLANLABS-2023M1034334,MYLAN,"Dyson S, Patel P, Millington G. Psychiatric associations in bullous pemphigoid: review and case report. Br-J-Dermatol 2022;187 (Suppl. 1):227 (plus poster) abstr. PS11.",59.0,YR,,F,Y,,,20230405,,HP,GB,GB,2023,Q2,Adult
221776151,22177615,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, unknown",,,Y,,,,,,,,,2023,Q2,Diarrhoea,,2023,Q2,1,I,20230130.0,20230328.0,20230405,20230405,EXP,,US-ELI_LILLY_AND_COMPANY-US202303015127,ELI LILLY AND CO,,68.0,YR,,F,Y,89.5,KG,20230405,,CN,US,US,2023,Q2,Elderly
221776151,22177615,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, unknown",,,Y,,,,,,,,,2023,Q2,Hypotension,,2023,Q2,1,I,20230130.0,20230328.0,20230405,20230405,EXP,,US-ELI_LILLY_AND_COMPANY-US202303015127,ELI LILLY AND CO,,68.0,YR,,F,Y,89.5,KG,20230405,,CN,US,US,2023,Q2,Elderly
221776151,22177615,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, unknown",,,Y,,,,,,,,,2023,Q2,Acute kidney injury,,2023,Q2,1,I,20230130.0,20230328.0,20230405,20230405,EXP,,US-ELI_LILLY_AND_COMPANY-US202303015127,ELI LILLY AND CO,,68.0,YR,,F,Y,89.5,KG,20230405,,CN,US,US,2023,Q2,Elderly
221801123,22180112,1,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"850 mg, qd",,,,,UNK,,,850.0,MG,Tablet,QD,2023,Q2,Dyspnoea,,2023,Q2,3,F,20230306.0,20230424.0,20230406,20230504,EXP,,CO-NOVOPROD-1037516,NOVO NORDISK,,66.0,YR,,F,Y,43.0,KG,20230504,,CN,CO,CO,2023,Q2,Elderly
221801123,22180112,1,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"850 mg, qd",,,,,UNK,,,850.0,MG,Tablet,QD,2023,Q2,Vomiting,,2023,Q2,3,F,20230306.0,20230424.0,20230406,20230504,EXP,,CO-NOVOPROD-1037516,NOVO NORDISK,,66.0,YR,,F,Y,43.0,KG,20230504,,CN,CO,CO,2023,Q2,Elderly
221801123,22180112,1,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"850 mg, qd",,,,,UNK,,,850.0,MG,Tablet,QD,2023,Q2,Decreased appetite,,2023,Q2,3,F,20230306.0,20230424.0,20230406,20230504,EXP,,CO-NOVOPROD-1037516,NOVO NORDISK,,66.0,YR,,F,Y,43.0,KG,20230504,,CN,CO,CO,2023,Q2,Elderly
221801123,22180112,1,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"850 mg, qd",,,,,UNK,,,850.0,MG,Tablet,QD,2023,Q2,Nausea,,2023,Q2,3,F,20230306.0,20230424.0,20230406,20230504,EXP,,CO-NOVOPROD-1037516,NOVO NORDISK,,66.0,YR,,F,Y,43.0,KG,20230504,,CN,CO,CO,2023,Q2,Elderly
221801123,22180112,1,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"850 mg, qd",,,,,UNK,,,850.0,MG,Tablet,QD,2023,Q2,Pain,,2023,Q2,3,F,20230306.0,20230424.0,20230406,20230504,EXP,,CO-NOVOPROD-1037516,NOVO NORDISK,,66.0,YR,,F,Y,43.0,KG,20230504,,CN,CO,CO,2023,Q2,Elderly
221801123,22180112,1,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"850 mg, qd",,,,,UNK,,,850.0,MG,Tablet,QD,2023,Q2,Asthenia,,2023,Q2,3,F,20230306.0,20230424.0,20230406,20230504,EXP,,CO-NOVOPROD-1037516,NOVO NORDISK,,66.0,YR,,F,Y,43.0,KG,20230504,,CN,CO,CO,2023,Q2,Elderly
221801123,22180112,1,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"850 mg, qd",,,,,UNK,,,850.0,MG,Tablet,QD,2023,Q2,Abdominal pain,,2023,Q2,3,F,20230306.0,20230424.0,20230406,20230504,EXP,,CO-NOVOPROD-1037516,NOVO NORDISK,,66.0,YR,,F,Y,43.0,KG,20230504,,CN,CO,CO,2023,Q2,Elderly
221801123,22180112,1,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"850 mg, qd",,,,,UNK,,,850.0,MG,Tablet,QD,2023,Q2,Fluid retention,,2023,Q2,3,F,20230306.0,20230424.0,20230406,20230504,EXP,,CO-NOVOPROD-1037516,NOVO NORDISK,,66.0,YR,,F,Y,43.0,KG,20230504,,CN,CO,CO,2023,Q2,Elderly
221801123,22180112,1,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"850 mg, qd",,,,,UNK,,,850.0,MG,Tablet,QD,2023,Q2,Bone pain,,2023,Q2,3,F,20230306.0,20230424.0,20230406,20230504,EXP,,CO-NOVOPROD-1037516,NOVO NORDISK,,66.0,YR,,F,Y,43.0,KG,20230504,,CN,CO,CO,2023,Q2,Elderly
221801123,22180112,1,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"850 mg, qd",,,,,UNK,,,850.0,MG,Tablet,QD,2023,Q2,Coronary artery occlusion,,2023,Q2,3,F,20230306.0,20230424.0,20230406,20230504,EXP,,CO-NOVOPROD-1037516,NOVO NORDISK,,66.0,YR,,F,Y,43.0,KG,20230504,,CN,CO,CO,2023,Q2,Elderly
221801123,22180112,1,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"850 mg, qd",,,,,UNK,,,850.0,MG,Tablet,QD,2023,Q2,Abdominal pain upper,,2023,Q2,3,F,20230306.0,20230424.0,20230406,20230504,EXP,,CO-NOVOPROD-1037516,NOVO NORDISK,,66.0,YR,,F,Y,43.0,KG,20230504,,CN,CO,CO,2023,Q2,Elderly
221804411,22180441,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, qd",,,,,,,,,,,QD,2023,Q2,Fatigue,,2023,Q2,1,I,,20230402.0,20230406,20230406,EXP,GB-MHRA-TPP1374722C835091YC1679588637265,GB-MYLANLABS-2023M1035729,MYLAN,,61.0,YR,,F,Y,94.0,KG,20230406,,HP,GB,GB,2023,Q2,Adult
221804411,22180441,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, qd",,,,,,,,,,,QD,2023,Q2,Vision blurred,,2023,Q2,1,I,,20230402.0,20230406,20230406,EXP,GB-MHRA-TPP1374722C835091YC1679588637265,GB-MYLANLABS-2023M1035729,MYLAN,,61.0,YR,,F,Y,94.0,KG,20230406,,HP,GB,GB,2023,Q2,Adult
221804411,22180441,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, qd",,,,,,,,,,,QD,2023,Q2,Eye swelling,,2023,Q2,1,I,,20230402.0,20230406,20230406,EXP,GB-MHRA-TPP1374722C835091YC1679588637265,GB-MYLANLABS-2023M1035729,MYLAN,,61.0,YR,,F,Y,94.0,KG,20230406,,HP,GB,GB,2023,Q2,Adult
221813801,22181380,6,C,empagliflozin 25 mg daily,,2,,,,,,,,,,,,,,2023,Q2,Pulmonary embolism,,2023,Q2,1,I,20230404.0,,20230406,20230406,DIR,655334,,FDA-CTU,,72.0,YR,,F,N,129.0,KG,20230406,N,PH,US,,2023,Q2,Elderly
221813801,22181380,6,C,empagliflozin 25 mg daily,,2,,,,,,,,,,,,,,2023,Q2,Deep vein thrombosis,,2023,Q2,1,I,20230404.0,,20230406,20230406,DIR,655334,,FDA-CTU,,72.0,YR,,F,N,129.0,KG,20230406,N,PH,US,,2023,Q2,Elderly
221817561,22181756,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2023,Q2,Leg amputation,,2023,Q2,1,I,20221201.0,20230327.0,20230406,20230406,EXP,,BR-AMGEN-BRASP2023053973,AMGEN,,92.0,YR,E,F,Y,48.0,KG,20230406,,CN,BR,BR,2023,Q2,Elderly
221817561,22181756,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2023,Q2,Off label use,,2023,Q2,1,I,20221201.0,20230327.0,20230406,20230406,EXP,,BR-AMGEN-BRASP2023053973,AMGEN,,92.0,YR,E,F,Y,48.0,KG,20230406,,CN,BR,BR,2023,Q2,Elderly
221817561,22181756,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2023,Q2,Cardiac pacemaker insertion,,2023,Q2,1,I,20221201.0,20230327.0,20230406,20230406,EXP,,BR-AMGEN-BRASP2023053973,AMGEN,,92.0,YR,E,F,Y,48.0,KG,20230406,,CN,BR,BR,2023,Q2,Elderly
221817561,22181756,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2023,Q2,Pain,,2023,Q2,1,I,20221201.0,20230327.0,20230406,20230406,EXP,,BR-AMGEN-BRASP2023053973,AMGEN,,92.0,YR,E,F,Y,48.0,KG,20230406,,CN,BR,BR,2023,Q2,Elderly
221817561,22181756,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2023,Q2,Parathyroid tumour benign,,2023,Q2,1,I,20221201.0,20230327.0,20230406,20230406,EXP,,BR-AMGEN-BRASP2023053973,AMGEN,,92.0,YR,E,F,Y,48.0,KG,20230406,,CN,BR,BR,2023,Q2,Elderly
221817561,22181756,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2023,Q2,Angiopathy,,2023,Q2,1,I,20221201.0,20230327.0,20230406,20230406,EXP,,BR-AMGEN-BRASP2023053973,AMGEN,,92.0,YR,E,F,Y,48.0,KG,20230406,,CN,BR,BR,2023,Q2,Elderly
221817561,22181756,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2023,Q2,Ill-defined disorder,,2023,Q2,1,I,20221201.0,20230327.0,20230406,20230406,EXP,,BR-AMGEN-BRASP2023053973,AMGEN,,92.0,YR,E,F,Y,48.0,KG,20230406,,CN,BR,BR,2023,Q2,Elderly
221817561,22181756,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2023,Q2,Cardiac disorder,,2023,Q2,1,I,20221201.0,20230327.0,20230406,20230406,EXP,,BR-AMGEN-BRASP2023053973,AMGEN,,92.0,YR,E,F,Y,48.0,KG,20230406,,CN,BR,BR,2023,Q2,Elderly
221817561,22181756,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2023,Q2,Swelling,,2023,Q2,1,I,20221201.0,20230327.0,20230406,20230406,EXP,,BR-AMGEN-BRASP2023053973,AMGEN,,92.0,YR,E,F,Y,48.0,KG,20230406,,CN,BR,BR,2023,Q2,Elderly
221827642,22182764,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,Unknown,,102145.0,,,,,2023,Q2,Adrenal insufficiency,,2023,Q2,2,F,20230322.0,20230407.0,20230406,20230414,EXP,,"BR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-228345",BOEHRINGER INGELHEIM,,61.0,YR,A,F,Y,,,20230414,,MD,BR,BR,2023,Q2,Adult
221837762,22183776,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,dose and frequency unknown,,,,,,,,,,,,2023,Q2,Haematuria,,2023,Q2,2,F,20230208.0,20230428.0,20230406,20230504,PER,,JP-Eisai Medical Research-EC-2023-137529,EISAI,,70.0,YR,E,M,Y,,,20230504,,MD,JP,JP,2023,Q2,Elderly
221850133,22185013,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,QD,2023,Q2,Pemphigoid,,2023,Q2,3,F,,20230428.0,20230407,20230505,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-229841",BOEHRINGER INGELHEIM,,59.0,YR,A,F,Y,,,20230505,,MD,GB,GB,2023,Q2,Adult
221850133,22185013,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,QD,2023,Q2,Drug ineffective,,2023,Q2,3,F,,20230428.0,20230407,20230505,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-229841",BOEHRINGER INGELHEIM,,59.0,YR,A,F,Y,,,20230505,,MD,GB,GB,2023,Q2,Adult
221872601,22187260,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q2,Drug ineffective,,2023,Q2,1,I,,20230404.0,20230407,20230407,EXP,,US-MYLANLABS-2023M1037445,MYLAN,"Chandramohan D, Awobajo M, Fisher O, Dayton CL, Anstead GM. Flea-Borne Typhus Causing Hemophagocytic Lymphohistiocytosis: An Autopsy Case. Infect-Dis-Rep 2023;15(1):132-141.",71.0,YR,,F,Y,,,20230407,,HP,US,US,2023,Q2,Elderly
221886035,22188603,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,dose 1 unknown unit,,,,,,,,,,,,2023,Q2,Off label use,,2023,Q2,5,F,,20230511.0,20230409,20230524,EXP,GB-STRIDES ARCOLAB LIMITED-2023SP004763,GB-STRIDES ARCOLAB LIMITED-2023SP004763,STRIDES,"Dyson S, Patel P, Millington G.. Psychiatric associations in bullous pemphigoid: review and case report.. British Journal of Dermatology. 2022;187 (Suppl. 1):227 (plus poster) abstr. PS11.",59.0,YR,,F,Y,,,20230524,,MD,GB,GB,2023,Q2,Adult
221886035,22188603,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,dose 1 unknown unit,,,,,,,,,,,,2023,Q2,Drug ineffective,,2023,Q2,5,F,,20230511.0,20230409,20230524,EXP,GB-STRIDES ARCOLAB LIMITED-2023SP004763,GB-STRIDES ARCOLAB LIMITED-2023SP004763,STRIDES,"Dyson S, Patel P, Millington G.. Psychiatric associations in bullous pemphigoid: review and case report.. British Journal of Dermatology. 2022;187 (Suppl. 1):227 (plus poster) abstr. PS11.",59.0,YR,,F,Y,,,20230524,,MD,GB,GB,2023,Q2,Adult
221886035,22188603,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,dose 1 unknown unit,,,,,,,,,,,,2023,Q2,Pemphigoid,,2023,Q2,5,F,,20230511.0,20230409,20230524,EXP,GB-STRIDES ARCOLAB LIMITED-2023SP004763,GB-STRIDES ARCOLAB LIMITED-2023SP004763,STRIDES,"Dyson S, Patel P, Millington G.. Psychiatric associations in bullous pemphigoid: review and case report.. British Journal of Dermatology. 2022;187 (Suppl. 1):227 (plus poster) abstr. PS11.",59.0,YR,,F,Y,,,20230524,,MD,GB,GB,2023,Q2,Adult
221892232,22189223,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,N,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Diabetes mellitus,,2023,Q2,2,F,20210101.0,20230411.0,20230410,20230418,EXP,,"BG-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-229807",BOEHRINGER INGELHEIM,"Vuchkova E. Empagliflozin/Linagliptin ? long-term management, benefits and safety  Emilena Vuchkova, MD, Endocrinologist Individual Practice in Stara Zagora, round table event, date: 10Apr2023. doi:doi.org/10.2337/dc22.",75.0,YR,E,F,Y,69.0,KG,20230418,,MD,BG,BG,2023,Q2,Elderly
221892232,22189223,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,N,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Breast cancer,,2023,Q2,2,F,20210101.0,20230411.0,20230410,20230418,EXP,,"BG-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-229807",BOEHRINGER INGELHEIM,"Vuchkova E. Empagliflozin/Linagliptin ? long-term management, benefits and safety  Emilena Vuchkova, MD, Endocrinologist Individual Practice in Stara Zagora, round table event, date: 10Apr2023. doi:doi.org/10.2337/dc22.",75.0,YR,E,F,Y,69.0,KG,20230418,,MD,BG,BG,2023,Q2,Elderly
221894143,22189414,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,,,Unknown,,2023,Q2,Pemphigoid,,2023,Q2,3,F,,20230519.0,20230410,20230523,EXP,,GB-JNJFOC-20230408864,JOHNSON AND JOHNSON,,59.0,YR,A,F,Y,,,20230523,,HP,GB,GB,2023,Q2,Adult
221894143,22189414,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,,,Unknown,,2023,Q2,Drug ineffective,,2023,Q2,3,F,,20230519.0,20230410,20230523,EXP,,GB-JNJFOC-20230408864,JOHNSON AND JOHNSON,,59.0,YR,A,F,Y,,,20230523,,HP,GB,GB,2023,Q2,Adult
221909051,22190905,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, Once a Day",,,U,,,,,,,,QD,2023,Q2,Restless legs syndrome,,2023,Q2,1,I,,20230329.0,20230410,20230410,EXP,,GB-AUROBINDO-AUR-APL-2023-015422,AUROBINDO,,40.0,YR,,F,Y,100.0,KG,20230410,,MD,GB,GB,2023,Q2,Adult
221909051,22190905,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, Once a Day",,,U,,,,,,,,QD,2023,Q2,Drug hypersensitivity,,2023,Q2,1,I,,20230329.0,20230410,20230410,EXP,,GB-AUROBINDO-AUR-APL-2023-015422,AUROBINDO,,40.0,YR,,F,Y,100.0,KG,20230410,,MD,GB,GB,2023,Q2,Adult
221923151,22192315,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,,,Unknown,,2023,Q2,Pemphigoid,,2023,Q2,1,I,,20230331.0,20230410,20230410,EXP,,GB-JNJFOC-20230375650,JOHNSON AND JOHNSON,,59.0,YR,A,F,Y,,,20230410,,HP,GB,GB,2023,Q2,Adult
221932594,22193259,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,U,,,,,,,,2023,Q2,Pemphigoid,,2023,Q2,4,F,,20230428.0,20230410,20230503,EXP,,GB-ORGANON-O2304GBR000430,ORGANON,"Dyson S, Patel P, Millington G. Psychiatric associations in bullous pemphigoid: review and case report. Br. J. Dermatol. 2022;187 (Suppl. 1):227",59.0,YR,,F,Y,,,20230503,,MD,GB,GB,2023,Q2,Adult
221932594,22193259,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,U,,,,,,,,2023,Q2,Drug ineffective,,2023,Q2,4,F,,20230428.0,20230410,20230503,EXP,,GB-ORGANON-O2304GBR000430,ORGANON,"Dyson S, Patel P, Millington G. Psychiatric associations in bullous pemphigoid: review and case report. Br. J. Dermatol. 2022;187 (Suppl. 1):227",59.0,YR,,F,Y,,,20230503,,MD,GB,GB,2023,Q2,Adult
221938401,22193840,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Unknown,,2023,Q2,Drug ineffective,,2023,Q2,1,I,,20230405.0,20230410,20230410,EXP,,GB-JNJFOC-20230408868,JOHNSON AND JOHNSON,,59.0,YR,A,F,Y,,,20230411,,HP,GB,GB,2023,Q2,Adult
221938401,22193840,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Unknown,,2023,Q2,Pemphigoid,,2023,Q2,1,I,,20230405.0,20230410,20230410,EXP,,GB-JNJFOC-20230408868,JOHNSON AND JOHNSON,,59.0,YR,A,F,Y,,,20230411,,HP,GB,GB,2023,Q2,Adult
221946531,22194653,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2023,Q2,Candida infection,,2023,Q2,1,I,,20230404.0,20230411,20230411,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-229623",BOEHRINGER INGELHEIM,,41.0,YR,A,M,Y,,,20230411,,CN,DE,DE,2023,Q2,Adult
221949631,22194963,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK qd,,,,,UNKNOWN,,,,,,,2023,Q2,Cholecystitis infective,,2023,Q2,1,I,20230124.0,20230331.0,20230411,20230411,EXP,,CO-NOVOPROD-1038145,NOVO NORDISK,,49.0,YR,,F,Y,47.0,KG,20230411,,CN,CO,CO,2023,Q2,Adult
221949631,22194963,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK qd,,,,,UNKNOWN,,,,,,,2023,Q2,Gallbladder obstruction,,2023,Q2,1,I,20230124.0,20230331.0,20230411,20230411,EXP,,CO-NOVOPROD-1038145,NOVO NORDISK,,49.0,YR,,F,Y,47.0,KG,20230411,,CN,CO,CO,2023,Q2,Adult
221949631,22194963,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK qd,,,,,UNKNOWN,,,,,,,2023,Q2,Cholelithiasis,,2023,Q2,1,I,20230124.0,20230331.0,20230411,20230411,EXP,,CO-NOVOPROD-1038145,NOVO NORDISK,,49.0,YR,,F,Y,47.0,KG,20230411,,CN,CO,CO,2023,Q2,Adult
221950191,22195019,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q2,Diabetic foot,,2023,Q2,1,I,,20230406.0,20230411,20230411,EXP,GB-MHRA-TPP24228643C10029607YC1680629363776,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-230431",BOEHRINGER INGELHEIM,,74.0,YR,E,M,Y,89.0,KG,20230411,,HP,GB,GB,2023,Q2,Elderly
221951781,22195178,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,Unknown,,204629.0,25.0,MG,,QD,2023,Q2,Pneumonia aspiration,,2023,Q2,1,I,20230301.0,20230411.0,20230411,20230411,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-230645",BOEHRINGER INGELHEIM,,80.0,YR,E,F,Y,70.0,KG,20230411,,MD,DE,DE,2023,Q2,Elderly
221951781,22195178,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,Unknown,,204629.0,25.0,MG,,QD,2023,Q2,Diabetic ketoacidosis,,2023,Q2,1,I,20230301.0,20230411.0,20230411,20230411,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-230645",BOEHRINGER INGELHEIM,,80.0,YR,E,F,Y,70.0,KG,20230411,,MD,DE,DE,2023,Q2,Elderly
221970572,22197057,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,,,,,2023,Q2,Drug ineffective,,2023,Q2,2,F,,20230416.0,20230411,20230426,EXP,,GB-TEVA-2023-GB-2875674,TEVA,,59.0,YR,A,F,Y,,,20230426,,HP,GB,GB,2023,Q2,Adult
221970572,22197057,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,,,,,2023,Q2,Pemphigoid,,2023,Q2,2,F,,20230416.0,20230411,20230426,EXP,,GB-TEVA-2023-GB-2875674,TEVA,,59.0,YR,A,F,Y,,,20230426,,HP,GB,GB,2023,Q2,Adult
221973251,22197325,3,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Heart rate irregular,,2023,Q2,1,I,20210801.0,20230404.0,20230411,20230411,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-229457",BOEHRINGER INGELHEIM,,78.0,YR,E,F,Y,,,20230411,,MD,SI,SI,2023,Q2,Elderly
221973251,22197325,3,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Dyspnoea,,2023,Q2,1,I,20210801.0,20230404.0,20230411,20230411,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-229457",BOEHRINGER INGELHEIM,,78.0,YR,E,F,Y,,,20230411,,MD,SI,SI,2023,Q2,Elderly
221973251,22197325,3,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Atrial fibrillation,,2023,Q2,1,I,20210801.0,20230404.0,20230411,20230411,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-229457",BOEHRINGER INGELHEIM,,78.0,YR,E,F,Y,,,20230411,,MD,SI,SI,2023,Q2,Elderly
221973251,22197325,3,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Blood glucose increased,,2023,Q2,1,I,20210801.0,20230404.0,20230411,20230411,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-229457",BOEHRINGER INGELHEIM,,78.0,YR,E,F,Y,,,20230411,,MD,SI,SI,2023,Q2,Elderly
221973251,22197325,3,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Chest pain,,2023,Q2,1,I,20210801.0,20230404.0,20230411,20230411,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-229457",BOEHRINGER INGELHEIM,,78.0,YR,E,F,Y,,,20230411,,MD,SI,SI,2023,Q2,Elderly
221973251,22197325,3,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Blood glucose increased,,2023,Q2,1,I,20210801.0,20230404.0,20230411,20230411,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-229457",BOEHRINGER INGELHEIM,,78.0,YR,E,F,Y,,,20230411,,MD,SI,SI,2023,Q2,Elderly
221973251,22197325,3,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Diastolic dysfunction,,2023,Q2,1,I,20210801.0,20230404.0,20230411,20230411,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-229457",BOEHRINGER INGELHEIM,,78.0,YR,E,F,Y,,,20230411,,MD,SI,SI,2023,Q2,Elderly
221991551,22199155,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 Dosage forms Daily;,,,,,,,,,,,QD,2023,Q2,Fatigue,,2023,Q2,1,I,,20230402.0,20230411,20230411,EXP,GB-MHRA-TPP1374722C835091YC1679588637265,GB-TEVA-2023-GB-2874900,TEVA,,61.0,YR,A,F,Y,94.0,KG,20230411,,HP,GB,GB,2023,Q2,Adult
221991551,22199155,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 Dosage forms Daily;,,,,,,,,,,,QD,2023,Q2,Vision blurred,,2023,Q2,1,I,,20230402.0,20230411,20230411,EXP,GB-MHRA-TPP1374722C835091YC1679588637265,GB-TEVA-2023-GB-2874900,TEVA,,61.0,YR,A,F,Y,94.0,KG,20230411,,HP,GB,GB,2023,Q2,Adult
221991551,22199155,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 Dosage forms Daily;,,,,,,,,,,,QD,2023,Q2,Eye swelling,,2023,Q2,1,I,,20230402.0,20230411,20230411,EXP,GB-MHRA-TPP1374722C835091YC1679588637265,GB-TEVA-2023-GB-2874900,TEVA,,61.0,YR,A,F,Y,94.0,KG,20230411,,HP,GB,GB,2023,Q2,Adult
221995791,22199579,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,U,UNKNOWN,,,10.0,MG,,QD,2023,Q2,Ankylosing spondylitis,,2023,Q2,1,I,,20230330.0,20230412,20230412,EXP,,CA-drreddys-SPO/CAN/23/0163559,DR REDDYS,,58.0,YR,A,M,Y,,,20230412,,HP,CA,CA,2023,Q2,Adult
221995791,22199579,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,U,UNKNOWN,,,10.0,MG,,QD,2023,Q2,Pain,,2023,Q2,1,I,,20230330.0,20230412,20230412,EXP,,CA-drreddys-SPO/CAN/23/0163559,DR REDDYS,,58.0,YR,A,M,Y,,,20230412,,HP,CA,CA,2023,Q2,Adult
221995791,22199579,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,U,UNKNOWN,,,10.0,MG,,QD,2023,Q2,Discomfort,,2023,Q2,1,I,,20230330.0,20230412,20230412,EXP,,CA-drreddys-SPO/CAN/23/0163559,DR REDDYS,,58.0,YR,A,M,Y,,,20230412,,HP,CA,CA,2023,Q2,Adult
222005382,22200538,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q2,Pemphigoid,,2023,Q2,2,F,,20230513.0,20230412,20230526,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-383947,RANBAXY,"Dyson S, Patel P, Millington G. Psychiatric associations in bullous pemphigoid: review and case report. Br J Dermatol. 2022;187 (Suppl. 1):227; PS11",59.0,YR,,F,Y,,,20230526,,HP,GB,GB,2023,Q2,Adult
222005382,22200538,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q2,Drug ineffective,,2023,Q2,2,F,,20230513.0,20230412,20230526,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-383947,RANBAXY,"Dyson S, Patel P, Millington G. Psychiatric associations in bullous pemphigoid: review and case report. Br J Dermatol. 2022;187 (Suppl. 1):227; PS11",59.0,YR,,F,Y,,,20230526,,HP,GB,GB,2023,Q2,Adult
222010711,22201071,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,QD,2023,Q2,Fatigue,,2023,Q2,1,I,,20230402.0,20230412,20230412,EXP,GB-MHRA-ADR 27786005,GB-Accord-307939,ACCORD,,61.0,YR,A,F,Y,94.0,KG,20230412,,HP,GB,GB,2023,Q2,Adult
222010711,22201071,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,QD,2023,Q2,Eye swelling,,2023,Q2,1,I,,20230402.0,20230412,20230412,EXP,GB-MHRA-ADR 27786005,GB-Accord-307939,ACCORD,,61.0,YR,A,F,Y,94.0,KG,20230412,,HP,GB,GB,2023,Q2,Adult
222010711,22201071,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,QD,2023,Q2,Vision blurred,,2023,Q2,1,I,,20230402.0,20230412,20230412,EXP,GB-MHRA-ADR 27786005,GB-Accord-307939,ACCORD,,61.0,YR,A,F,Y,94.0,KG,20230412,,HP,GB,GB,2023,Q2,Adult
222027691,22202769,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,12.5 mg,,,,,,,,12.5,MG,,,2023,Q2,Dyspnoea,,2023,Q2,1,I,,20220329.0,20230412,20230412,EXP,,US-JNJFOC-20220406409,JOHNSON AND JOHNSON,,78.0,YR,E,M,Y,,,20230412,,MD,US,SI,2023,Q2,Elderly
222027691,22202769,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,12.5 mg,,,,,,,,12.5,MG,,,2023,Q2,Asthenia,,2023,Q2,1,I,,20220329.0,20230412,20230412,EXP,,US-JNJFOC-20220406409,JOHNSON AND JOHNSON,,78.0,YR,E,M,Y,,,20230412,,MD,US,SI,2023,Q2,Elderly
222027691,22202769,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,12.5 mg,,,,,,,,12.5,MG,,,2023,Q2,Pyrexia,,2023,Q2,1,I,,20220329.0,20230412,20230412,EXP,,US-JNJFOC-20220406409,JOHNSON AND JOHNSON,,78.0,YR,E,M,Y,,,20230412,,MD,US,SI,2023,Q2,Elderly
222028161,22202816,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Drug interaction,,2023,Q2,1,I,20230328.0,,20230412,20230412,DIR,656060,,FDA-CTU,,79.0,YR,,M,N,100.0,KG,20230412,N,PH,US,,2023,Q2,Elderly
222028161,22202816,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Laboratory test abnormal,,2023,Q2,1,I,20230328.0,,20230412,20230412,DIR,656060,,FDA-CTU,,79.0,YR,,M,N,100.0,KG,20230412,N,PH,US,,2023,Q2,Elderly
222037563,22203756,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q2,Drug ineffective for unapproved indication,,2023,Q2,3,F,,20230608.0,20230412,20230613,EXP,,GB-PFIZER INC-202300145621,PFIZER,"Dyson, S.. Psychiatric associations in bullous pemphigoid: review and case report.. British Journal of Dermatology. 2022;187(1):227",59.0,YR,,F,Y,,,20230613,,HP,GB,GB,2023,Q2,Adult
222037563,22203756,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q2,Pemphigoid,,2023,Q2,3,F,,20230608.0,20230412,20230613,EXP,,GB-PFIZER INC-202300145621,PFIZER,"Dyson, S.. Psychiatric associations in bullous pemphigoid: review and case report.. British Journal of Dermatology. 2022;187(1):227",59.0,YR,,F,Y,,,20230613,,HP,GB,GB,2023,Q2,Adult
222037563,22203756,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q2,Off label use,,2023,Q2,3,F,,20230608.0,20230412,20230613,EXP,,GB-PFIZER INC-202300145621,PFIZER,"Dyson, S.. Psychiatric associations in bullous pemphigoid: review and case report.. British Journal of Dermatology. 2022;187(1):227",59.0,YR,,F,Y,,,20230613,,HP,GB,GB,2023,Q2,Adult
222047281,22204728,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1000 mg,,,,,,,,1000.0,MG,,,2023,Q2,Pulmonary embolism,,2023,Q2,1,I,,20220428.0,20230413,20230413,EXP,,SI-JNJFOC-20220443589,JOHNSON AND JOHNSON,,56.0,YR,A,M,Y,,,20230413,,MD,SI,SI,2023,Q2,Adult
222047281,22204728,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1000 mg,,,,,,,,1000.0,MG,,,2023,Q2,Dyspnoea,,2023,Q2,1,I,,20220428.0,20230413,20230413,EXP,,SI-JNJFOC-20220443589,JOHNSON AND JOHNSON,,56.0,YR,A,M,Y,,,20230413,,MD,SI,SI,2023,Q2,Adult
222048341,22204834,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, Once a Day",,,U,,,,,,,,QD,2023,Q2,Fatigue,,2023,Q2,1,I,,20230402.0,20230413,20230413,EXP,,GB-AUROBINDO-AUR-APL-2023-029483,AUROBINDO,,61.0,YR,,F,Y,94.0,KG,20230413,,HP,GB,GB,2023,Q2,Adult
222048341,22204834,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, Once a Day",,,U,,,,,,,,QD,2023,Q2,Eye swelling,,2023,Q2,1,I,,20230402.0,20230413,20230413,EXP,,GB-AUROBINDO-AUR-APL-2023-029483,AUROBINDO,,61.0,YR,,F,Y,94.0,KG,20230413,,HP,GB,GB,2023,Q2,Adult
222048341,22204834,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, Once a Day",,,U,,,,,,,,QD,2023,Q2,Vision blurred,,2023,Q2,1,I,,20230402.0,20230413,20230413,EXP,,GB-AUROBINDO-AUR-APL-2023-029483,AUROBINDO,,61.0,YR,,F,Y,94.0,KG,20230413,,HP,GB,GB,2023,Q2,Adult
222049772,22204977,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q2,Hypophagia,,2023,Q2,2,F,,20230426.0,20230413,20230502,EXP,,JP-SA-2023SA111496,SANOFI AVENTIS,,71.0,YR,E,M,Y,,,20230502,,MD,JP,JP,2023,Q2,Elderly
222049772,22204977,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q2,Nephropathy,,2023,Q2,2,F,,20230426.0,20230413,20230502,EXP,,JP-SA-2023SA111496,SANOFI AVENTIS,,71.0,YR,E,M,Y,,,20230502,,MD,JP,JP,2023,Q2,Elderly
222049772,22204977,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q2,Ketoacidosis,,2023,Q2,2,F,,20230426.0,20230413,20230502,EXP,,JP-SA-2023SA111496,SANOFI AVENTIS,,71.0,YR,E,M,Y,,,20230502,,MD,JP,JP,2023,Q2,Elderly
222049772,22204977,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q2,Hypoglycaemia,,2023,Q2,2,F,,20230426.0,20230413,20230502,EXP,,JP-SA-2023SA111496,SANOFI AVENTIS,,71.0,YR,E,M,Y,,,20230502,,MD,JP,JP,2023,Q2,Elderly
222049772,22204977,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q2,Malaise,,2023,Q2,2,F,,20230426.0,20230413,20230502,EXP,,JP-SA-2023SA111496,SANOFI AVENTIS,,71.0,YR,E,M,Y,,,20230502,,MD,JP,JP,2023,Q2,Elderly
222051641,22205164,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,,2023,Q2,Renal tubular necrosis,,2023,Q2,1,I,,20230410.0,20230413,20230413,EXP,,ES-ROCHE-3328871,ROCHE,"Prado-Mel E, Ciudad-Gutierrez P, Sanchez-Martin A and Martin L. Alectinib - induced acute renal failure. DOI : 10.1177/10781552231167808. Journal of oncology pharmacy practice 2023 Apr 06;:1-5.",68.0,YR,,M,Y,,,20230413,,HP,ES,,2023,Q2,Elderly
222051641,22205164,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,,2023,Q2,Tubulointerstitial nephritis,,2023,Q2,1,I,,20230410.0,20230413,20230413,EXP,,ES-ROCHE-3328871,ROCHE,"Prado-Mel E, Ciudad-Gutierrez P, Sanchez-Martin A and Martin L. Alectinib - induced acute renal failure. DOI : 10.1177/10781552231167808. Journal of oncology pharmacy practice 2023 Apr 06;:1-5.",68.0,YR,,M,Y,,,20230413,,HP,ES,,2023,Q2,Elderly
222051641,22205164,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,,2023,Q2,Acute kidney injury,,2023,Q2,1,I,,20230410.0,20230413,20230413,EXP,,ES-ROCHE-3328871,ROCHE,"Prado-Mel E, Ciudad-Gutierrez P, Sanchez-Martin A and Martin L. Alectinib - induced acute renal failure. DOI : 10.1177/10781552231167808. Journal of oncology pharmacy practice 2023 Apr 06;:1-5.",68.0,YR,,M,Y,,,20230413,,HP,ES,,2023,Q2,Elderly
222062421,22206242,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,UNKNOWN,,,,,,QD,2023,Q2,Fatigue,,2023,Q2,1,I,,20230402.0,20230413,20230413,EXP,GB-MHRA-TPP1374722C835091YC1679588637265,GB-drreddys-SPO/UKI/23/0163533,DR REDDYS,,61.0,YR,A,F,Y,94.0,KG,20230413,,HP,GB,GB,2023,Q2,Adult
222062421,22206242,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,UNKNOWN,,,,,,QD,2023,Q2,Eye swelling,,2023,Q2,1,I,,20230402.0,20230413,20230413,EXP,GB-MHRA-TPP1374722C835091YC1679588637265,GB-drreddys-SPO/UKI/23/0163533,DR REDDYS,,61.0,YR,A,F,Y,94.0,KG,20230413,,HP,GB,GB,2023,Q2,Adult
222062421,22206242,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,UNKNOWN,,,,,,QD,2023,Q2,Vision blurred,,2023,Q2,1,I,,20230402.0,20230413,20230413,EXP,GB-MHRA-TPP1374722C835091YC1679588637265,GB-drreddys-SPO/UKI/23/0163533,DR REDDYS,,61.0,YR,A,F,Y,94.0,KG,20230413,,HP,GB,GB,2023,Q2,Adult
222066371,22206637,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,D,,,,,,,,2023,Q2,Metabolic acidosis,,2023,Q2,1,I,20230409.0,,20230412,20230412,DIR,656133,,FDA-CTU,,38.0,YR,,M,N,,,20230412,N,PH,US,,2023,Q2,Adult
222066371,22206637,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,D,,,,,,,,2023,Q2,Diabetic ketoacidosis,,2023,Q2,1,I,20230409.0,,20230412,20230412,DIR,656133,,FDA-CTU,,38.0,YR,,M,N,,,20230412,N,PH,US,,2023,Q2,Adult
222090701,22209070,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",700.0,MG,,,,,,10.0,MG,,QD,2023,Q2,Basal cell carcinoma,,2023,Q2,1,I,20220803.0,20230405.0,20230413,20230413,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR006387,AEGERION,,39.0,YR,,F,Y,58.5,KG,20230413,,MD,US,US,2023,Q2,Adult
222090701,22209070,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",700.0,MG,,,,,,25.0,MG,,QD,2023,Q2,Basal cell carcinoma,,2023,Q2,1,I,20220803.0,20230405.0,20230413,20230413,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR006387,AEGERION,,39.0,YR,,F,Y,58.5,KG,20230413,,MD,US,US,2023,Q2,Adult
222107373,22210737,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2023,Q2,Coronary artery disease,,2023,Q2,3,F,20230411.0,20230424.0,20230414,20230426,EXP,,NVSC2023DE085218,NOVARTIS,,67.0,YR,,M,Y,95.0,KG,20230426,,MD,DE,DE,2023,Q2,Elderly
222108072,22210807,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q2,Pemphigoid,,2023,Q2,2,F,,20230526.0,20230414,20230604,EXP,,GB-AUROBINDO-AUR-APL-2023-029975,AUROBINDO,"Dyson S, Patel P, Millington G.. Psychiatric associations in bullous pemphigoid: review and case report.. Br-J-Dermatol. 2022;187(1):227",59.0,YR,,F,Y,,,20230604,,HP,GB,GB,2023,Q2,Adult
222143822,22214382,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1x/day",,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Tachycardia,,2023,Q2,2,F,20230325.0,20230508.0,20230414,20230511,EXP,,JP-PFIZER INC-PV202300066666,PFIZER,,77.0,YR,,M,Y,61.5,KG,20230511,,MD,JP,JP,2023,Q2,Elderly
222143822,22214382,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1x/day",,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Blood pressure increased,,2023,Q2,2,F,20230325.0,20230508.0,20230414,20230511,EXP,,JP-PFIZER INC-PV202300066666,PFIZER,,77.0,YR,,M,Y,61.5,KG,20230511,,MD,JP,JP,2023,Q2,Elderly
222143822,22214382,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1x/day",,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Atrial fibrillation,,2023,Q2,2,F,20230325.0,20230508.0,20230414,20230511,EXP,,JP-PFIZER INC-PV202300066666,PFIZER,,77.0,YR,,M,Y,61.5,KG,20230511,,MD,JP,JP,2023,Q2,Elderly
222148924,22214892,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2023,Q2,Pemphigoid,,2023,Q2,4,F,,20230512.0,20230415,20230522,EXP,,GB-AUROBINDO-AUR-APL-2023-029761,AUROBINDO,,59.0,YR,,F,Y,,,20230522,,MD,GB,GB,2023,Q2,Adult
222148924,22214892,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2023,Q2,Drug ineffective,,2023,Q2,4,F,,20230512.0,20230415,20230522,EXP,,GB-AUROBINDO-AUR-APL-2023-029761,AUROBINDO,,59.0,YR,,F,Y,,,20230522,,MD,GB,GB,2023,Q2,Adult
222152391,22215239,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Cerebral hypoperfusion,,2023,Q2,1,I,20220712.0,20230410.0,20230415,20230415,EXP,,NVSC2022CN171864,NOVARTIS,,68.0,YR,,F,Y,65.5,KG,20230415,,MD,CN,CN,2023,Q2,Elderly
222154141,22215414,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,UNKNOWN,,,,,,,2023,Q2,Euglycaemic diabetic ketoacidosis,,2023,Q2,1,I,,20230404.0,20230416,20230416,EXP,,US-drreddys-LIT/USA/23/0163685,DR REDDYS,"Chandramohan D, Awobajo M, Fisher O, Dayton C, Anstead G. Flea-Borne Typhus Causing Hemophagocytic Lymphohistiocytosis: An Autopsy Case. Infect Dis Rep. 2023;15(1):132-41. doi:10.3390/idr15010014",71.0,YR,E,F,Y,,,20230416,,HP,US,US,2023,Q2,Elderly
222154141,22215414,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,UNKNOWN,,,,,,,2023,Q2,Murine typhus,,2023,Q2,1,I,,20230404.0,20230416,20230416,EXP,,US-drreddys-LIT/USA/23/0163685,DR REDDYS,"Chandramohan D, Awobajo M, Fisher O, Dayton C, Anstead G. Flea-Borne Typhus Causing Hemophagocytic Lymphohistiocytosis: An Autopsy Case. Infect Dis Rep. 2023;15(1):132-41. doi:10.3390/idr15010014",71.0,YR,E,F,Y,,,20230416,,HP,US,US,2023,Q2,Elderly
222154141,22215414,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,UNKNOWN,,,,,,,2023,Q2,Lactic acidosis,,2023,Q2,1,I,,20230404.0,20230416,20230416,EXP,,US-drreddys-LIT/USA/23/0163685,DR REDDYS,"Chandramohan D, Awobajo M, Fisher O, Dayton C, Anstead G. Flea-Borne Typhus Causing Hemophagocytic Lymphohistiocytosis: An Autopsy Case. Infect Dis Rep. 2023;15(1):132-41. doi:10.3390/idr15010014",71.0,YR,E,F,Y,,,20230416,,HP,US,US,2023,Q2,Elderly
222154141,22215414,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,UNKNOWN,,,,,,,2023,Q2,Drug ineffective,,2023,Q2,1,I,,20230404.0,20230416,20230416,EXP,,US-drreddys-LIT/USA/23/0163685,DR REDDYS,"Chandramohan D, Awobajo M, Fisher O, Dayton C, Anstead G. Flea-Borne Typhus Causing Hemophagocytic Lymphohistiocytosis: An Autopsy Case. Infect Dis Rep. 2023;15(1):132-41. doi:10.3390/idr15010014",71.0,YR,E,F,Y,,,20230416,,HP,US,US,2023,Q2,Elderly
222154141,22215414,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,UNKNOWN,,,,,,,2023,Q2,Multiple organ dysfunction syndrome,,2023,Q2,1,I,,20230404.0,20230416,20230416,EXP,,US-drreddys-LIT/USA/23/0163685,DR REDDYS,"Chandramohan D, Awobajo M, Fisher O, Dayton C, Anstead G. Flea-Borne Typhus Causing Hemophagocytic Lymphohistiocytosis: An Autopsy Case. Infect Dis Rep. 2023;15(1):132-41. doi:10.3390/idr15010014",71.0,YR,E,F,Y,,,20230416,,HP,US,US,2023,Q2,Elderly
222154141,22215414,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,UNKNOWN,,,,,,,2023,Q2,Haemophagocytic lymphohistiocytosis,,2023,Q2,1,I,,20230404.0,20230416,20230416,EXP,,US-drreddys-LIT/USA/23/0163685,DR REDDYS,"Chandramohan D, Awobajo M, Fisher O, Dayton C, Anstead G. Flea-Borne Typhus Causing Hemophagocytic Lymphohistiocytosis: An Autopsy Case. Infect Dis Rep. 2023;15(1):132-41. doi:10.3390/idr15010014",71.0,YR,E,F,Y,,,20230416,,HP,US,US,2023,Q2,Elderly
222157462,22215746,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 mg,,,,,,,,25.0,MG,,,2023,Q2,Hypotension,,2023,Q2,2,F,,20230515.0,20230416,20230517,EXP,,NVSJ2023JP006405,NOVARTIS,,35.0,YR,,M,Y,,,20230517,,MD,JP,JP,2023,Q2,Adult
222157462,22215746,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 mg,,,,,,,,25.0,MG,,,2023,Q2,Blood pressure increased,,2023,Q2,2,F,,20230515.0,20230416,20230517,EXP,,NVSJ2023JP006405,NOVARTIS,,35.0,YR,,M,Y,,,20230517,,MD,JP,JP,2023,Q2,Adult
222159411,22215941,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q2,Micturition urgency,,2023,Q2,1,I,20230303.0,20230413.0,20230417,20230417,EXP,GB-MHRA-INP8188B849-5E09-499F-A8EF-094A17825FFA,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231268",BOEHRINGER INGELHEIM,,51.0,YR,A,M,Y,102.0,KG,20230417,,MD,GB,GB,2023,Q2,Adult
222174841,22217484,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q2,Drug ineffective,,2023,Q2,1,I,,20230404.0,20230417,20230417,EXP,,US-STERISCIENCE B.V.-2023-ST-001134,Steriscience PTE,"Chandramohan D, Awobajo M, Fisher O, Dayton CL, Anstead GM. Flea-Borne Typhus Causing Hemophagocytic Lymphohistiocytosis: An Autopsy Case. Infect-Dis-Rep. 2023;15(1):132-141",71.0,YR,,F,Y,,,20230417,,HP,US,US,2023,Q2,Elderly
222180581,22218058,3,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q2,Muscle strength abnormal,,2023,Q2,1,I,20230101.0,20230404.0,20230417,20230417,EXP,,"CO-AMICUS THERAPEUTICS, INC.-AMI_2261",AMICUS THERAPEUTICS,,45.0,YR,,F,Y,72.0,KG,20230417,,CN,CO,CO,2023,Q2,Adult
222180581,22218058,3,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q2,Cystitis interstitial,,2023,Q2,1,I,20230101.0,20230404.0,20230417,20230417,EXP,,"CO-AMICUS THERAPEUTICS, INC.-AMI_2261",AMICUS THERAPEUTICS,,45.0,YR,,F,Y,72.0,KG,20230417,,CN,CO,CO,2023,Q2,Adult
222180581,22218058,3,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q2,Vomiting,,2023,Q2,1,I,20230101.0,20230404.0,20230417,20230417,EXP,,"CO-AMICUS THERAPEUTICS, INC.-AMI_2261",AMICUS THERAPEUTICS,,45.0,YR,,F,Y,72.0,KG,20230417,,CN,CO,CO,2023,Q2,Adult
222180581,22218058,3,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q2,Constipation,,2023,Q2,1,I,20230101.0,20230404.0,20230417,20230417,EXP,,"CO-AMICUS THERAPEUTICS, INC.-AMI_2261",AMICUS THERAPEUTICS,,45.0,YR,,F,Y,72.0,KG,20230417,,CN,CO,CO,2023,Q2,Adult
222180581,22218058,3,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q2,Blood glucose increased,,2023,Q2,1,I,20230101.0,20230404.0,20230417,20230417,EXP,,"CO-AMICUS THERAPEUTICS, INC.-AMI_2261",AMICUS THERAPEUTICS,,45.0,YR,,F,Y,72.0,KG,20230417,,CN,CO,CO,2023,Q2,Adult
222180581,22218058,3,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q2,Dyspareunia,,2023,Q2,1,I,20230101.0,20230404.0,20230417,20230417,EXP,,"CO-AMICUS THERAPEUTICS, INC.-AMI_2261",AMICUS THERAPEUTICS,,45.0,YR,,F,Y,72.0,KG,20230417,,CN,CO,CO,2023,Q2,Adult
222180581,22218058,4,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"12.5 +1000 milligram, q12h",,,Y,,,,,,,,BID,2023,Q2,Muscle strength abnormal,,2023,Q2,1,I,20230101.0,20230404.0,20230417,20230417,EXP,,"CO-AMICUS THERAPEUTICS, INC.-AMI_2261",AMICUS THERAPEUTICS,,45.0,YR,,F,Y,72.0,KG,20230417,,CN,CO,CO,2023,Q2,Adult
222180581,22218058,4,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"12.5 +1000 milligram, q12h",,,Y,,,,,,,,BID,2023,Q2,Cystitis interstitial,,2023,Q2,1,I,20230101.0,20230404.0,20230417,20230417,EXP,,"CO-AMICUS THERAPEUTICS, INC.-AMI_2261",AMICUS THERAPEUTICS,,45.0,YR,,F,Y,72.0,KG,20230417,,CN,CO,CO,2023,Q2,Adult
222180581,22218058,4,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"12.5 +1000 milligram, q12h",,,Y,,,,,,,,BID,2023,Q2,Vomiting,,2023,Q2,1,I,20230101.0,20230404.0,20230417,20230417,EXP,,"CO-AMICUS THERAPEUTICS, INC.-AMI_2261",AMICUS THERAPEUTICS,,45.0,YR,,F,Y,72.0,KG,20230417,,CN,CO,CO,2023,Q2,Adult
222180581,22218058,4,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"12.5 +1000 milligram, q12h",,,Y,,,,,,,,BID,2023,Q2,Constipation,,2023,Q2,1,I,20230101.0,20230404.0,20230417,20230417,EXP,,"CO-AMICUS THERAPEUTICS, INC.-AMI_2261",AMICUS THERAPEUTICS,,45.0,YR,,F,Y,72.0,KG,20230417,,CN,CO,CO,2023,Q2,Adult
222180581,22218058,4,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"12.5 +1000 milligram, q12h",,,Y,,,,,,,,BID,2023,Q2,Blood glucose increased,,2023,Q2,1,I,20230101.0,20230404.0,20230417,20230417,EXP,,"CO-AMICUS THERAPEUTICS, INC.-AMI_2261",AMICUS THERAPEUTICS,,45.0,YR,,F,Y,72.0,KG,20230417,,CN,CO,CO,2023,Q2,Adult
222180581,22218058,4,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"12.5 +1000 milligram, q12h",,,Y,,,,,,,,BID,2023,Q2,Dyspareunia,,2023,Q2,1,I,20230101.0,20230404.0,20230417,20230417,EXP,,"CO-AMICUS THERAPEUTICS, INC.-AMI_2261",AMICUS THERAPEUTICS,,45.0,YR,,F,Y,72.0,KG,20230417,,CN,CO,CO,2023,Q2,Adult
222215031,22221503,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,,,,,,,,,2023,Q2,Drug ineffective,,2023,Q2,1,I,,20230410.0,20230418,20230418,EXP,,US-TEVA-2023-US-2876985,TEVA,,71.0,YR,E,F,Y,,,20230417,,HP,US,US,2023,Q2,Elderly
222217422,22221742,5,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Hyponatraemia,,2023,Q2,2,F,,20230524.0,20230418,20230602,EXP,,US-LUPIN PHARMACEUTICALS INC.-2023-02669,LUPIN,"Haluska AD, Davis A, Tarabishy N, Pena ME. Use of Naloxone in angiotensin-converting enzyme inhibitor overdose: A case report. The Journal of emergency medicine. 2023;64(3):397?399",49.0,YR,,M,Y,,,20230602,,MD,US,US,2023,Q2,Adult
222217422,22221742,5,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Syncope,,2023,Q2,2,F,,20230524.0,20230418,20230602,EXP,,US-LUPIN PHARMACEUTICALS INC.-2023-02669,LUPIN,"Haluska AD, Davis A, Tarabishy N, Pena ME. Use of Naloxone in angiotensin-converting enzyme inhibitor overdose: A case report. The Journal of emergency medicine. 2023;64(3):397?399",49.0,YR,,M,Y,,,20230602,,MD,US,US,2023,Q2,Adult
222217422,22221742,5,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Hypotension,,2023,Q2,2,F,,20230524.0,20230418,20230602,EXP,,US-LUPIN PHARMACEUTICALS INC.-2023-02669,LUPIN,"Haluska AD, Davis A, Tarabishy N, Pena ME. Use of Naloxone in angiotensin-converting enzyme inhibitor overdose: A case report. The Journal of emergency medicine. 2023;64(3):397?399",49.0,YR,,M,Y,,,20230602,,MD,US,US,2023,Q2,Adult
222217422,22221742,5,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Metabolic acidosis,,2023,Q2,2,F,,20230524.0,20230418,20230602,EXP,,US-LUPIN PHARMACEUTICALS INC.-2023-02669,LUPIN,"Haluska AD, Davis A, Tarabishy N, Pena ME. Use of Naloxone in angiotensin-converting enzyme inhibitor overdose: A case report. The Journal of emergency medicine. 2023;64(3):397?399",49.0,YR,,M,Y,,,20230602,,MD,US,US,2023,Q2,Adult
222217422,22221742,5,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Accidental overdose,,2023,Q2,2,F,,20230524.0,20230418,20230602,EXP,,US-LUPIN PHARMACEUTICALS INC.-2023-02669,LUPIN,"Haluska AD, Davis A, Tarabishy N, Pena ME. Use of Naloxone in angiotensin-converting enzyme inhibitor overdose: A case report. The Journal of emergency medicine. 2023;64(3):397?399",49.0,YR,,M,Y,,,20230602,,MD,US,US,2023,Q2,Adult
222217422,22221742,5,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Acute kidney injury,,2023,Q2,2,F,,20230524.0,20230418,20230602,EXP,,US-LUPIN PHARMACEUTICALS INC.-2023-02669,LUPIN,"Haluska AD, Davis A, Tarabishy N, Pena ME. Use of Naloxone in angiotensin-converting enzyme inhibitor overdose: A case report. The Journal of emergency medicine. 2023;64(3):397?399",49.0,YR,,M,Y,,,20230602,,MD,US,US,2023,Q2,Adult
222217422,22221742,5,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Hypokalaemia,,2023,Q2,2,F,,20230524.0,20230418,20230602,EXP,,US-LUPIN PHARMACEUTICALS INC.-2023-02669,LUPIN,"Haluska AD, Davis A, Tarabishy N, Pena ME. Use of Naloxone in angiotensin-converting enzyme inhibitor overdose: A case report. The Journal of emergency medicine. 2023;64(3):397?399",49.0,YR,,M,Y,,,20230602,,MD,US,US,2023,Q2,Adult
222227891,22222789,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 every 1 days,,,,,,,,10.0,MG,Tablet,,2023,Q2,Basal cell carcinoma,,2023,Q2,1,I,,20230407.0,20230418,20230418,EXP,CA-MHPD-E2B_06094100,CA-Accord-308197,ACCORD,,32.0,YR,A,M,Y,149.0,KG,20230418,,HP,CA,CA,2023,Q2,Young Adult
222227891,22222789,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 every 1 days,,,,,,,,10.0,MG,Tablet,,2023,Q2,Antineutrophil cytoplasmic antibody positive,,2023,Q2,1,I,,20230407.0,20230418,20230418,EXP,CA-MHPD-E2B_06094100,CA-Accord-308197,ACCORD,,32.0,YR,A,M,Y,149.0,KG,20230418,,HP,CA,CA,2023,Q2,Young Adult
222227891,22222789,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 every 1 days,,,,,,,,10.0,MG,Tablet,,2023,Q2,Microscopic polyangiitis,,2023,Q2,1,I,,20230407.0,20230418,20230418,EXP,CA-MHPD-E2B_06094100,CA-Accord-308197,ACCORD,,32.0,YR,A,M,Y,149.0,KG,20230418,,HP,CA,CA,2023,Q2,Young Adult
222232101,22223210,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Abdominal pain,,2023,Q2,1,I,20210125.0,,20230414,20230414,DIR,FDA-CDER-CTU-2023-28290,,FDA-CTU,,59.0,YR,,M,N,,,20221107,N,HP,US,,2023,Q2,Adult
222232131,22223213,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2023,Q2,Hypoglycaemia,,2023,Q2,1,I,20210513.0,,20230414,20230414,DIR,FDA-CDER-CTU-2023-28292,,FDA-CTU,,65.0,YR,,M,N,,,20211107,N,,US,,2023,Q2,Elderly
222232131,22223213,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2023,Q2,Discontinued product administered,,2023,Q2,1,I,20210513.0,,20230414,20230414,DIR,FDA-CDER-CTU-2023-28292,,FDA-CTU,,65.0,YR,,M,N,,,20211107,N,,US,,2023,Q2,Elderly
222232131,22223213,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2023,Q2,Pancreatitis,,2023,Q2,1,I,20210513.0,,20230414,20230414,DIR,FDA-CDER-CTU-2023-28292,,FDA-CTU,,65.0,YR,,M,N,,,20211107,N,,US,,2023,Q2,Elderly
222232131,22223213,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2023,Q2,Ketosis,,2023,Q2,1,I,20210513.0,,20230414,20230414,DIR,FDA-CDER-CTU-2023-28292,,FDA-CTU,,65.0,YR,,M,N,,,20211107,N,,US,,2023,Q2,Elderly
222294241,22229424,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, qd (take one daily)",,,,,,,,,,,QD,2023,Q2,Myalgia,,2023,Q2,1,I,20230413.0,20230414.0,20230419,20230419,EXP,GB-MHRA-TPP28349089C2567454YC1681383610842,GB-MYLANLABS-2023M1040897,MYLAN,,71.0,YR,,F,Y,114.0,KG,20230419,,MD,GB,GB,2023,Q2,Elderly
222294241,22229424,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, qd (take one daily)",,,,,,,,,,,QD,2023,Q2,Rash,,2023,Q2,1,I,20230413.0,20230414.0,20230419,20230419,EXP,GB-MHRA-TPP28349089C2567454YC1681383610842,GB-MYLANLABS-2023M1040897,MYLAN,,71.0,YR,,F,Y,114.0,KG,20230419,,MD,GB,GB,2023,Q2,Elderly
222302151,22230215,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,Tablet,QD,2023,Q2,Medication error,,2023,Q2,1,I,20230415.0,20230418.0,20230419,20230419,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-232451",BOEHRINGER INGELHEIM,,41.0,YR,A,F,Y,,,20230419,,PH,GB,GB,2023,Q2,Adult
222302151,22230215,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,Tablet,QD,2023,Q2,Euglycaemic diabetic ketoacidosis,,2023,Q2,1,I,20230415.0,20230418.0,20230419,20230419,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-232451",BOEHRINGER INGELHEIM,,41.0,YR,A,F,Y,,,20230419,,PH,GB,GB,2023,Q2,Adult
222302681,22230268,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,Unknown,,212614.0,,,,,2023,Q2,Blood glucose abnormal,,2023,Q2,1,I,20230417.0,20230419.0,20230419,20230419,PER,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-232508",BOEHRINGER INGELHEIM,,52.0,YR,A,M,Y,,,20230419,,CN,US,US,2023,Q2,Adult
222302681,22230268,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,Unknown,,212614.0,,,,,2023,Q2,Expired product administered,,2023,Q2,1,I,20230417.0,20230419.0,20230419,20230419,PER,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-232508",BOEHRINGER INGELHEIM,,52.0,YR,A,M,Y,,,20230419,,CN,US,US,2023,Q2,Adult
222315261,22231526,2,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q2,Cardiomegaly,,2023,Q2,1,I,,20230413.0,20230420,20230420,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231225",BOEHRINGER INGELHEIM,,85.0,YR,E,F,Y,,,20230420,,MD,SI,SI,2023,Q2,Elderly
222315261,22231526,2,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q2,Pulmonary hypertension,,2023,Q2,1,I,,20230413.0,20230420,20230420,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231225",BOEHRINGER INGELHEIM,,85.0,YR,E,F,Y,,,20230420,,MD,SI,SI,2023,Q2,Elderly
222315261,22231526,2,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q2,Pulmonary oedema,,2023,Q2,1,I,,20230413.0,20230420,20230420,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231225",BOEHRINGER INGELHEIM,,85.0,YR,E,F,Y,,,20230420,,MD,SI,SI,2023,Q2,Elderly
222315261,22231526,2,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q2,Respiratory failure,,2023,Q2,1,I,,20230413.0,20230420,20230420,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231225",BOEHRINGER INGELHEIM,,85.0,YR,E,F,Y,,,20230420,,MD,SI,SI,2023,Q2,Elderly
222315261,22231526,2,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q2,Hypertensive heart disease,,2023,Q2,1,I,,20230413.0,20230420,20230420,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231225",BOEHRINGER INGELHEIM,,85.0,YR,E,F,Y,,,20230420,,MD,SI,SI,2023,Q2,Elderly
222315261,22231526,2,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q2,Left ventricular end-diastolic pressure increased,,2023,Q2,1,I,,20230413.0,20230420,20230420,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231225",BOEHRINGER INGELHEIM,,85.0,YR,E,F,Y,,,20230420,,MD,SI,SI,2023,Q2,Elderly
222315261,22231526,2,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q2,Cardiac failure,,2023,Q2,1,I,,20230413.0,20230420,20230420,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231225",BOEHRINGER INGELHEIM,,85.0,YR,E,F,Y,,,20230420,,MD,SI,SI,2023,Q2,Elderly
222315261,22231526,2,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q2,Right ventricular dysfunction,,2023,Q2,1,I,,20230413.0,20230420,20230420,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231225",BOEHRINGER INGELHEIM,,85.0,YR,E,F,Y,,,20230420,,MD,SI,SI,2023,Q2,Elderly
222315261,22231526,2,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q2,Blood creatinine increased,,2023,Q2,1,I,,20230413.0,20230420,20230420,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231225",BOEHRINGER INGELHEIM,,85.0,YR,E,F,Y,,,20230420,,MD,SI,SI,2023,Q2,Elderly
222315261,22231526,2,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q2,Pleural effusion,,2023,Q2,1,I,,20230413.0,20230420,20230420,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231225",BOEHRINGER INGELHEIM,,85.0,YR,E,F,Y,,,20230420,,MD,SI,SI,2023,Q2,Elderly
222315261,22231526,2,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q2,N-terminal prohormone brain natriuretic peptide increased,,2023,Q2,1,I,,20230413.0,20230420,20230420,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231225",BOEHRINGER INGELHEIM,,85.0,YR,E,F,Y,,,20230420,,MD,SI,SI,2023,Q2,Elderly
222328731,22232873,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Blood bilirubin increased,,2023,Q2,1,I,20220701.0,20220824.0,20230420,20230420,EXP,,US-ROCHE-3168194,ROCHE,,55.0,YR,,M,Y,,,20230420,,CN,US,,2023,Q2,Adult
222328731,22232873,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Arthralgia,,2023,Q2,1,I,20220701.0,20220824.0,20230420,20230420,EXP,,US-ROCHE-3168194,ROCHE,,55.0,YR,,M,Y,,,20230420,,CN,US,,2023,Q2,Adult
222328731,22232873,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Upper gastrointestinal haemorrhage,,2023,Q2,1,I,20220701.0,20220824.0,20230420,20230420,EXP,,US-ROCHE-3168194,ROCHE,,55.0,YR,,M,Y,,,20230420,,CN,US,,2023,Q2,Adult
222350231,22235023,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg daily oral,,,Y,D,,,,10.0,MG,,QD,2023,Q2,Diabetic ketoacidosis,,2023,Q2,1,I,20230414.0,,20230419,20230419,DIR,656880,,FDA-CTU,,75.0,YR,,M,N,83.0,KG,20230419,N,HP,US,,2023,Q2,Elderly
222350231,22235023,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg daily oral,,,Y,D,,,,10.0,MG,,QD,2023,Q2,Acute myocardial infarction,,2023,Q2,1,I,20230414.0,,20230419,20230419,DIR,656880,,FDA-CTU,,75.0,YR,,M,N,83.0,KG,20230419,N,HP,US,,2023,Q2,Elderly
222376201,22237620,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,U,,Unknown,,206073.0,,,,,2023,Q2,Systemic lupus erythematosus,,2023,Q2,1,I,,20230419.0,20230421,20230421,EXP,,"MX-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-232814",BOEHRINGER INGELHEIM,,3.0,DEC,A,F,Y,,,20230421,,MD,MX,MX,2023,Q2,Child
222376201,22237620,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,U,,Unknown,,206073.0,,,,,2023,Q2,Vaginal infection,,2023,Q2,1,I,,20230419.0,20230421,20230421,EXP,,"MX-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-232814",BOEHRINGER INGELHEIM,,3.0,DEC,A,F,Y,,,20230421,,MD,MX,MX,2023,Q2,Child
222396051,22239605,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,,,,,,10.0,MG,,,2023,Q2,Pulmonary toxicity,,2023,Q2,1,I,,20230418.0,20230421,20230421,EXP,,CA-PFIZER INC-202300163771,PFIZER,,57.0,YR,,F,Y,,,20230421,,MD,CA,CA,2023,Q2,Adult
222400531,22240053,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 mg, daily",,,Y,,,,,5.0,MG,,QD,2023,Q2,Dizziness,,2023,Q2,1,I,20210309.0,20230409.0,20230421,20230421,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202304004197,ELI LILLY AND CO,,41.0,YR,,F,Y,,,20230421,,MD,CN,CN,2023,Q2,Adult
222400531,22240053,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 mg, daily",,,Y,,,,,5.0,MG,,QD,2023,Q2,Peripheral coldness,,2023,Q2,1,I,20210309.0,20230409.0,20230421,20230421,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202304004197,ELI LILLY AND CO,,41.0,YR,,F,Y,,,20230421,,MD,CN,CN,2023,Q2,Adult
222400531,22240053,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 mg, daily",,,Y,,,,,5.0,MG,,QD,2023,Q2,Asthenia,,2023,Q2,1,I,20210309.0,20230409.0,20230421,20230421,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202304004197,ELI LILLY AND CO,,41.0,YR,,F,Y,,,20230421,,MD,CN,CN,2023,Q2,Adult
222400531,22240053,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 mg, daily",,,Y,,,,,5.0,MG,,QD,2023,Q2,Dry mouth,,2023,Q2,1,I,20210309.0,20230409.0,20230421,20230421,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202304004197,ELI LILLY AND CO,,41.0,YR,,F,Y,,,20230421,,MD,CN,CN,2023,Q2,Adult
222400531,22240053,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 mg, daily",,,Y,,,,,5.0,MG,,QD,2023,Q2,Infection,,2023,Q2,1,I,20210309.0,20230409.0,20230421,20230421,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202304004197,ELI LILLY AND CO,,41.0,YR,,F,Y,,,20230421,,MD,CN,CN,2023,Q2,Adult
222400531,22240053,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 mg, daily",,,Y,,,,,5.0,MG,,QD,2023,Q2,Gastrooesophageal reflux disease,,2023,Q2,1,I,20210309.0,20230409.0,20230421,20230421,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202304004197,ELI LILLY AND CO,,41.0,YR,,F,Y,,,20230421,,MD,CN,CN,2023,Q2,Adult
222400531,22240053,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 mg, daily",,,Y,,,,,5.0,MG,,QD,2023,Q2,Vulvovaginal pruritus,,2023,Q2,1,I,20210309.0,20230409.0,20230421,20230421,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202304004197,ELI LILLY AND CO,,41.0,YR,,F,Y,,,20230421,,MD,CN,CN,2023,Q2,Adult
222400531,22240053,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 mg, daily",,,Y,,,,,5.0,MG,,QD,2023,Q2,Diabetic ketoacidosis,,2023,Q2,1,I,20210309.0,20230409.0,20230421,20230421,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202304004197,ELI LILLY AND CO,,41.0,YR,,F,Y,,,20230421,,MD,CN,CN,2023,Q2,Adult
222400531,22240053,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 mg, daily",,,Y,,,,,5.0,MG,,QD,2023,Q2,Decreased appetite,,2023,Q2,1,I,20210309.0,20230409.0,20230421,20230421,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202304004197,ELI LILLY AND CO,,41.0,YR,,F,Y,,,20230421,,MD,CN,CN,2023,Q2,Adult
222400531,22240053,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 mg, daily",,,Y,,,,,5.0,MG,,QD,2023,Q2,Decreased appetite,,2023,Q2,1,I,20210309.0,20230409.0,20230421,20230421,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202304004197,ELI LILLY AND CO,,41.0,YR,,F,Y,,,20230421,,MD,CN,CN,2023,Q2,Adult
222400531,22240053,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 mg, daily",,,Y,,,,,5.0,MG,,QD,2023,Q2,Hepatic function abnormal,,2023,Q2,1,I,20210309.0,20230409.0,20230421,20230421,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202304004197,ELI LILLY AND CO,,41.0,YR,,F,Y,,,20230421,,MD,CN,CN,2023,Q2,Adult
222400531,22240053,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 mg, daily",,,Y,,,,,5.0,MG,,QD,2023,Q2,Haematemesis,,2023,Q2,1,I,20210309.0,20230409.0,20230421,20230421,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202304004197,ELI LILLY AND CO,,41.0,YR,,F,Y,,,20230421,,MD,CN,CN,2023,Q2,Adult
222400531,22240053,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 mg, daily",,,Y,,,,,5.0,MG,,QD,2023,Q2,Haematochezia,,2023,Q2,1,I,20210309.0,20230409.0,20230421,20230421,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202304004197,ELI LILLY AND CO,,41.0,YR,,F,Y,,,20230421,,MD,CN,CN,2023,Q2,Adult
222400531,22240053,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, daily",,,Y,,,,,10.0,MG,,QD,2023,Q2,Dizziness,,2023,Q2,1,I,20210309.0,20230409.0,20230421,20230421,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202304004197,ELI LILLY AND CO,,41.0,YR,,F,Y,,,20230421,,MD,CN,CN,2023,Q2,Adult
222400531,22240053,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, daily",,,Y,,,,,10.0,MG,,QD,2023,Q2,Peripheral coldness,,2023,Q2,1,I,20210309.0,20230409.0,20230421,20230421,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202304004197,ELI LILLY AND CO,,41.0,YR,,F,Y,,,20230421,,MD,CN,CN,2023,Q2,Adult
222400531,22240053,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, daily",,,Y,,,,,10.0,MG,,QD,2023,Q2,Asthenia,,2023,Q2,1,I,20210309.0,20230409.0,20230421,20230421,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202304004197,ELI LILLY AND CO,,41.0,YR,,F,Y,,,20230421,,MD,CN,CN,2023,Q2,Adult
222400531,22240053,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, daily",,,Y,,,,,10.0,MG,,QD,2023,Q2,Dry mouth,,2023,Q2,1,I,20210309.0,20230409.0,20230421,20230421,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202304004197,ELI LILLY AND CO,,41.0,YR,,F,Y,,,20230421,,MD,CN,CN,2023,Q2,Adult
222400531,22240053,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, daily",,,Y,,,,,10.0,MG,,QD,2023,Q2,Infection,,2023,Q2,1,I,20210309.0,20230409.0,20230421,20230421,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202304004197,ELI LILLY AND CO,,41.0,YR,,F,Y,,,20230421,,MD,CN,CN,2023,Q2,Adult
222400531,22240053,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, daily",,,Y,,,,,10.0,MG,,QD,2023,Q2,Gastrooesophageal reflux disease,,2023,Q2,1,I,20210309.0,20230409.0,20230421,20230421,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202304004197,ELI LILLY AND CO,,41.0,YR,,F,Y,,,20230421,,MD,CN,CN,2023,Q2,Adult
222400531,22240053,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, daily",,,Y,,,,,10.0,MG,,QD,2023,Q2,Vulvovaginal pruritus,,2023,Q2,1,I,20210309.0,20230409.0,20230421,20230421,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202304004197,ELI LILLY AND CO,,41.0,YR,,F,Y,,,20230421,,MD,CN,CN,2023,Q2,Adult
222400531,22240053,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, daily",,,Y,,,,,10.0,MG,,QD,2023,Q2,Diabetic ketoacidosis,,2023,Q2,1,I,20210309.0,20230409.0,20230421,20230421,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202304004197,ELI LILLY AND CO,,41.0,YR,,F,Y,,,20230421,,MD,CN,CN,2023,Q2,Adult
222400531,22240053,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, daily",,,Y,,,,,10.0,MG,,QD,2023,Q2,Decreased appetite,,2023,Q2,1,I,20210309.0,20230409.0,20230421,20230421,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202304004197,ELI LILLY AND CO,,41.0,YR,,F,Y,,,20230421,,MD,CN,CN,2023,Q2,Adult
222400531,22240053,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, daily",,,Y,,,,,10.0,MG,,QD,2023,Q2,Decreased appetite,,2023,Q2,1,I,20210309.0,20230409.0,20230421,20230421,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202304004197,ELI LILLY AND CO,,41.0,YR,,F,Y,,,20230421,,MD,CN,CN,2023,Q2,Adult
222400531,22240053,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, daily",,,Y,,,,,10.0,MG,,QD,2023,Q2,Hepatic function abnormal,,2023,Q2,1,I,20210309.0,20230409.0,20230421,20230421,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202304004197,ELI LILLY AND CO,,41.0,YR,,F,Y,,,20230421,,MD,CN,CN,2023,Q2,Adult
222400531,22240053,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, daily",,,Y,,,,,10.0,MG,,QD,2023,Q2,Haematemesis,,2023,Q2,1,I,20210309.0,20230409.0,20230421,20230421,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202304004197,ELI LILLY AND CO,,41.0,YR,,F,Y,,,20230421,,MD,CN,CN,2023,Q2,Adult
222400531,22240053,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, daily",,,Y,,,,,10.0,MG,,QD,2023,Q2,Haematochezia,,2023,Q2,1,I,20210309.0,20230409.0,20230421,20230421,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202304004197,ELI LILLY AND CO,,41.0,YR,,F,Y,,,20230421,,MD,CN,CN,2023,Q2,Adult
222403292,22240329,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Hypotension,,2023,Q2,2,F,,20230515.0,20230421,20230524,EXP,,US-JNJFOC-20230426415,JOHNSON AND JOHNSON,,74.0,YR,E,M,Y,,,20230524,,CN,US,US,2023,Q2,Elderly
222403292,22240329,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Sleep apnoea syndrome,,2023,Q2,2,F,,20230515.0,20230421,20230524,EXP,,US-JNJFOC-20230426415,JOHNSON AND JOHNSON,,74.0,YR,E,M,Y,,,20230524,,CN,US,US,2023,Q2,Elderly
222403292,22240329,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Constipation,,2023,Q2,2,F,,20230515.0,20230421,20230524,EXP,,US-JNJFOC-20230426415,JOHNSON AND JOHNSON,,74.0,YR,E,M,Y,,,20230524,,CN,US,US,2023,Q2,Elderly
222403292,22240329,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Asthenia,,2023,Q2,2,F,,20230515.0,20230421,20230524,EXP,,US-JNJFOC-20230426415,JOHNSON AND JOHNSON,,74.0,YR,E,M,Y,,,20230524,,CN,US,US,2023,Q2,Elderly
222406401,22240640,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q2,Off label use,,2023,Q2,1,I,,20230418.0,20230421,20230421,EXP,,GB-TAKEDA-2023TUS040221,TAKEDA,,59.0,YR,,F,Y,,,20230421,,HP,GB,GB,2023,Q2,Adult
222406401,22240640,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q2,Pemphigoid,,2023,Q2,1,I,,20230418.0,20230421,20230421,EXP,,GB-TAKEDA-2023TUS040221,TAKEDA,,59.0,YR,,F,Y,,,20230421,,HP,GB,GB,2023,Q2,Adult
222406401,22240640,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q2,Drug ineffective for unapproved indication,,2023,Q2,1,I,,20230418.0,20230421,20230421,EXP,,GB-TAKEDA-2023TUS040221,TAKEDA,,59.0,YR,,F,Y,,,20230421,,HP,GB,GB,2023,Q2,Adult
222416981,22241698,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Product use in unapproved indication,,2023,Q2,1,I,,20230417.0,20230421,20230421,EXP,,NVSC2023US088209,NOVARTIS,"Young MK, Holder KG, Baker TE, Kauffman RP. Vulvovaginal erosive lichen planus refractory to topical therapies: What^s next? A case report. CASE REPORTS IN WOMENS HEALTH. 2023;37:1-5",60.0,YR,,F,Y,,,20230420,,HP,US,US,2023,Q2,Adult
222416981,22241698,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Abdominal discomfort,,2023,Q2,1,I,,20230417.0,20230421,20230421,EXP,,NVSC2023US088209,NOVARTIS,"Young MK, Holder KG, Baker TE, Kauffman RP. Vulvovaginal erosive lichen planus refractory to topical therapies: What^s next? A case report. CASE REPORTS IN WOMENS HEALTH. 2023;37:1-5",60.0,YR,,F,Y,,,20230420,,HP,US,US,2023,Q2,Adult
222416981,22241698,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Rebound effect,,2023,Q2,1,I,,20230417.0,20230421,20230421,EXP,,NVSC2023US088209,NOVARTIS,"Young MK, Holder KG, Baker TE, Kauffman RP. Vulvovaginal erosive lichen planus refractory to topical therapies: What^s next? A case report. CASE REPORTS IN WOMENS HEALTH. 2023;37:1-5",60.0,YR,,F,Y,,,20230420,,HP,US,US,2023,Q2,Adult
222416981,22241698,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Dyspepsia,,2023,Q2,1,I,,20230417.0,20230421,20230421,EXP,,NVSC2023US088209,NOVARTIS,"Young MK, Holder KG, Baker TE, Kauffman RP. Vulvovaginal erosive lichen planus refractory to topical therapies: What^s next? A case report. CASE REPORTS IN WOMENS HEALTH. 2023;37:1-5",60.0,YR,,F,Y,,,20230420,,HP,US,US,2023,Q2,Adult
222416981,22241698,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Myalgia,,2023,Q2,1,I,,20230417.0,20230421,20230421,EXP,,NVSC2023US088209,NOVARTIS,"Young MK, Holder KG, Baker TE, Kauffman RP. Vulvovaginal erosive lichen planus refractory to topical therapies: What^s next? A case report. CASE REPORTS IN WOMENS HEALTH. 2023;37:1-5",60.0,YR,,F,Y,,,20230420,,HP,US,US,2023,Q2,Adult
222444721,22244472,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,N,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q2,Fournier's gangrene,,2023,Q2,1,I,20220403.0,20230421.0,20230424,20230424,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-233097",BOEHRINGER INGELHEIM,,48.0,YR,A,M,Y,,,20230424,,HP,GB,GB,2023,Q2,Adult
222461091,22246109,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,,,,,,10.0,MG,,,2023,Q2,Pulmonary toxicity,,2023,Q2,1,I,,20230418.0,20230424,20230424,EXP,,CA-PFIZER INC-202300163835,PFIZER,,57.0,YR,,F,Y,,,20230424,,MD,CA,CA,2023,Q2,Adult
222461091,22246109,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,,,,,,10.0,MG,,,2023,Q2,Drug ineffective,,2023,Q2,1,I,,20230418.0,20230424,20230424,EXP,,CA-PFIZER INC-202300163835,PFIZER,,57.0,YR,,F,Y,,,20230424,,MD,CA,CA,2023,Q2,Adult
222468141,22246814,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q2,Fournier's gangrene,,2023,Q2,1,I,20230406.0,20230421.0,20230424,20230424,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-233366",BOEHRINGER INGELHEIM,,63.0,YR,A,M,Y,116.0,KG,20230424,,PH,GB,GB,2023,Q2,Adult
222471102,22247110,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,,,,,,10.0,MG,,QD,2023,Q2,Dyspnoea,,2023,Q2,2,F,,20230522.0,20230424,20230527,EXP,,LV-JNJFOC-20230453580,JOHNSON AND JOHNSON,,57.0,YR,A,M,Y,,,20230527,,MD,LV,LV,2023,Q2,Adult
222471102,22247110,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,,,,,,10.0,MG,,QD,2023,Q2,Extrasystoles,,2023,Q2,2,F,,20230522.0,20230424,20230527,EXP,,LV-JNJFOC-20230453580,JOHNSON AND JOHNSON,,57.0,YR,A,M,Y,,,20230527,,MD,LV,LV,2023,Q2,Adult
222471102,22247110,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,,,,,,10.0,MG,,QD,2023,Q2,Cardiac failure,,2023,Q2,2,F,,20230522.0,20230424,20230527,EXP,,LV-JNJFOC-20230453580,JOHNSON AND JOHNSON,,57.0,YR,A,M,Y,,,20230527,,MD,LV,LV,2023,Q2,Adult
222471102,22247110,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,,,,,,10.0,MG,,QD,2023,Q2,Oedema,,2023,Q2,2,F,,20230522.0,20230424,20230527,EXP,,LV-JNJFOC-20230453580,JOHNSON AND JOHNSON,,57.0,YR,A,M,Y,,,20230527,,MD,LV,LV,2023,Q2,Adult
222507552,22250755,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Heart rate decreased,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Product use issue,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Pulmonary arterial pressure increased,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Ejection fraction decreased,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Atrial enlargement,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Scar,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Syncope,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,N-terminal prohormone brain natriuretic peptide increased,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Mitral valve incompetence,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Left ventricular dysfunction,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Syncope,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Myocarditis,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Underdose,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Heart rate decreased,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Product use issue,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Pulmonary arterial pressure increased,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Ejection fraction decreased,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Atrial enlargement,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Scar,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Syncope,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,N-terminal prohormone brain natriuretic peptide increased,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Mitral valve incompetence,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Left ventricular dysfunction,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Syncope,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Myocarditis,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Underdose,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Heart rate decreased,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Product use issue,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Pulmonary arterial pressure increased,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Ejection fraction decreased,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Atrial enlargement,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Scar,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Syncope,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,N-terminal prohormone brain natriuretic peptide increased,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Mitral valve incompetence,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Left ventricular dysfunction,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Syncope,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Myocarditis,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Underdose,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Heart rate decreased,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Product use issue,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Pulmonary arterial pressure increased,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Ejection fraction decreased,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Atrial enlargement,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Scar,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Syncope,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,N-terminal prohormone brain natriuretic peptide increased,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Mitral valve incompetence,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Left ventricular dysfunction,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Syncope,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Myocarditis,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Underdose,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Heart rate decreased,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Product use issue,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Pulmonary arterial pressure increased,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Ejection fraction decreased,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Atrial enlargement,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Scar,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Syncope,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,N-terminal prohormone brain natriuretic peptide increased,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Mitral valve incompetence,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Left ventricular dysfunction,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Syncope,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Myocarditis,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Underdose,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Heart rate decreased,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Product use issue,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Pulmonary arterial pressure increased,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Ejection fraction decreased,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Atrial enlargement,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Scar,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Syncope,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,N-terminal prohormone brain natriuretic peptide increased,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Mitral valve incompetence,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Left ventricular dysfunction,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Syncope,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Myocarditis,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Underdose,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Heart rate decreased,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Product use issue,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Pulmonary arterial pressure increased,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Ejection fraction decreased,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Atrial enlargement,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Scar,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Syncope,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,N-terminal prohormone brain natriuretic peptide increased,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Mitral valve incompetence,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Left ventricular dysfunction,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Syncope,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Myocarditis,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222507552,22250755,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Underdose,,2023,Q2,2,F,,20230418.0,20230425,20230427,EXP,,NVSC2023TH089699,NOVARTIS,,41.0,YR,,F,Y,,,20230427,,MD,TH,TH,2023,Q2,Adult
222536401,22253640,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, Daily",,,U,,,,,,,,,2023,Q2,Adverse drug reaction,,2023,Q2,1,I,20230413.0,20230414.0,20230426,20230426,EXP,,GB-AUROBINDO-AUR-APL-2023-031457,AUROBINDO,,71.0,YR,,F,Y,114.0,KG,20230426,,MD,GB,GB,2023,Q2,Elderly
222565241,22256524,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,U,,,,10.0,MG,,QD,2023,Q2,Drug ineffective,,2023,Q2,1,I,,20230419.0,20230426,20230426,EXP,,AU-MYLANLABS-2023M1044136,MYLAN,"Can AT, Hermens DF, Lagopoulos J. A unique case of very low-dose subcutaneous ketamine use: Maintenance option of ketamine for treatment-resistant depression. Clin-Case-Rep 2022;10:No. 12.",42.0,YR,,M,Y,,,20230426,,HP,AU,AU,2023,Q2,Adult
222565241,22256524,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,U,,,,10.0,MG,,QD,2023,Q2,Daydreaming,,2023,Q2,1,I,,20230419.0,20230426,20230426,EXP,,AU-MYLANLABS-2023M1044136,MYLAN,"Can AT, Hermens DF, Lagopoulos J. A unique case of very low-dose subcutaneous ketamine use: Maintenance option of ketamine for treatment-resistant depression. Clin-Case-Rep 2022;10:No. 12.",42.0,YR,,M,Y,,,20230426,,HP,AU,AU,2023,Q2,Adult
222565241,22256524,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,U,,,,10.0,MG,,QD,2023,Q2,Sedation,,2023,Q2,1,I,,20230419.0,20230426,20230426,EXP,,AU-MYLANLABS-2023M1044136,MYLAN,"Can AT, Hermens DF, Lagopoulos J. A unique case of very low-dose subcutaneous ketamine use: Maintenance option of ketamine for treatment-resistant depression. Clin-Case-Rep 2022;10:No. 12.",42.0,YR,,M,Y,,,20230426,,HP,AU,AU,2023,Q2,Adult
222565241,22256524,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,U,,,,10.0,MG,,QD,2023,Q2,Dizziness,,2023,Q2,1,I,,20230419.0,20230426,20230426,EXP,,AU-MYLANLABS-2023M1044136,MYLAN,"Can AT, Hermens DF, Lagopoulos J. A unique case of very low-dose subcutaneous ketamine use: Maintenance option of ketamine for treatment-resistant depression. Clin-Case-Rep 2022;10:No. 12.",42.0,YR,,M,Y,,,20230426,,HP,AU,AU,2023,Q2,Adult
222565241,22256524,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,U,,,,10.0,MG,,QD,2023,Q2,Lethargy,,2023,Q2,1,I,,20230419.0,20230426,20230426,EXP,,AU-MYLANLABS-2023M1044136,MYLAN,"Can AT, Hermens DF, Lagopoulos J. A unique case of very low-dose subcutaneous ketamine use: Maintenance option of ketamine for treatment-resistant depression. Clin-Case-Rep 2022;10:No. 12.",42.0,YR,,M,Y,,,20230426,,HP,AU,AU,2023,Q2,Adult
222565241,22256524,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,U,,,,10.0,MG,,QD,2023,Q2,Dissociation,,2023,Q2,1,I,,20230419.0,20230426,20230426,EXP,,AU-MYLANLABS-2023M1044136,MYLAN,"Can AT, Hermens DF, Lagopoulos J. A unique case of very low-dose subcutaneous ketamine use: Maintenance option of ketamine for treatment-resistant depression. Clin-Case-Rep 2022;10:No. 12.",42.0,YR,,M,Y,,,20230426,,HP,AU,AU,2023,Q2,Adult
222565241,22256524,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,U,,,,10.0,MG,,QD,2023,Q2,Off label use,,2023,Q2,1,I,,20230419.0,20230426,20230426,EXP,,AU-MYLANLABS-2023M1044136,MYLAN,"Can AT, Hermens DF, Lagopoulos J. A unique case of very low-dose subcutaneous ketamine use: Maintenance option of ketamine for treatment-resistant depression. Clin-Case-Rep 2022;10:No. 12.",42.0,YR,,M,Y,,,20230426,,HP,AU,AU,2023,Q2,Adult
222565641,22256564,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Vulvovaginal pruritus,,2023,Q2,1,I,20210228.0,20230419.0,20230426,20230426,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231398",BOEHRINGER INGELHEIM,"Junling C, Xue Z, Yanli Z, Fan L, Xiao Z. Diabetic ketoacidosis induced by combination use of dulaglutide and empagliflozin. Adverse Drug Reactions Journal. 2022 Mar;24(3): 147-149. doi:10.3760/cma.j.cn114015-20210401-00399.",41.0,YR,A,F,Y,,,20230426,,HP,CN,CN,2023,Q2,Adult
222565641,22256564,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Haematochezia,,2023,Q2,1,I,20210228.0,20230419.0,20230426,20230426,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231398",BOEHRINGER INGELHEIM,"Junling C, Xue Z, Yanli Z, Fan L, Xiao Z. Diabetic ketoacidosis induced by combination use of dulaglutide and empagliflozin. Adverse Drug Reactions Journal. 2022 Mar;24(3): 147-149. doi:10.3760/cma.j.cn114015-20210401-00399.",41.0,YR,A,F,Y,,,20230426,,HP,CN,CN,2023,Q2,Adult
222565641,22256564,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Diabetic ketoacidosis,,2023,Q2,1,I,20210228.0,20230419.0,20230426,20230426,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231398",BOEHRINGER INGELHEIM,"Junling C, Xue Z, Yanli Z, Fan L, Xiao Z. Diabetic ketoacidosis induced by combination use of dulaglutide and empagliflozin. Adverse Drug Reactions Journal. 2022 Mar;24(3): 147-149. doi:10.3760/cma.j.cn114015-20210401-00399.",41.0,YR,A,F,Y,,,20230426,,HP,CN,CN,2023,Q2,Adult
222565641,22256564,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Decreased appetite,,2023,Q2,1,I,20210228.0,20230419.0,20230426,20230426,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231398",BOEHRINGER INGELHEIM,"Junling C, Xue Z, Yanli Z, Fan L, Xiao Z. Diabetic ketoacidosis induced by combination use of dulaglutide and empagliflozin. Adverse Drug Reactions Journal. 2022 Mar;24(3): 147-149. doi:10.3760/cma.j.cn114015-20210401-00399.",41.0,YR,A,F,Y,,,20230426,,HP,CN,CN,2023,Q2,Adult
222565641,22256564,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Type 2 diabetes mellitus,,2023,Q2,1,I,20210228.0,20230419.0,20230426,20230426,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231398",BOEHRINGER INGELHEIM,"Junling C, Xue Z, Yanli Z, Fan L, Xiao Z. Diabetic ketoacidosis induced by combination use of dulaglutide and empagliflozin. Adverse Drug Reactions Journal. 2022 Mar;24(3): 147-149. doi:10.3760/cma.j.cn114015-20210401-00399.",41.0,YR,A,F,Y,,,20230426,,HP,CN,CN,2023,Q2,Adult
222565641,22256564,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Hypothyroidism,,2023,Q2,1,I,20210228.0,20230419.0,20230426,20230426,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231398",BOEHRINGER INGELHEIM,"Junling C, Xue Z, Yanli Z, Fan L, Xiao Z. Diabetic ketoacidosis induced by combination use of dulaglutide and empagliflozin. Adverse Drug Reactions Journal. 2022 Mar;24(3): 147-149. doi:10.3760/cma.j.cn114015-20210401-00399.",41.0,YR,A,F,Y,,,20230426,,HP,CN,CN,2023,Q2,Adult
222565641,22256564,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Haematemesis,,2023,Q2,1,I,20210228.0,20230419.0,20230426,20230426,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231398",BOEHRINGER INGELHEIM,"Junling C, Xue Z, Yanli Z, Fan L, Xiao Z. Diabetic ketoacidosis induced by combination use of dulaglutide and empagliflozin. Adverse Drug Reactions Journal. 2022 Mar;24(3): 147-149. doi:10.3760/cma.j.cn114015-20210401-00399.",41.0,YR,A,F,Y,,,20230426,,HP,CN,CN,2023,Q2,Adult
222565641,22256564,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Lipids abnormal,,2023,Q2,1,I,20210228.0,20230419.0,20230426,20230426,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231398",BOEHRINGER INGELHEIM,"Junling C, Xue Z, Yanli Z, Fan L, Xiao Z. Diabetic ketoacidosis induced by combination use of dulaglutide and empagliflozin. Adverse Drug Reactions Journal. 2022 Mar;24(3): 147-149. doi:10.3760/cma.j.cn114015-20210401-00399.",41.0,YR,A,F,Y,,,20230426,,HP,CN,CN,2023,Q2,Adult
222565641,22256564,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Infection,,2023,Q2,1,I,20210228.0,20230419.0,20230426,20230426,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231398",BOEHRINGER INGELHEIM,"Junling C, Xue Z, Yanli Z, Fan L, Xiao Z. Diabetic ketoacidosis induced by combination use of dulaglutide and empagliflozin. Adverse Drug Reactions Journal. 2022 Mar;24(3): 147-149. doi:10.3760/cma.j.cn114015-20210401-00399.",41.0,YR,A,F,Y,,,20230426,,HP,CN,CN,2023,Q2,Adult
222565641,22256564,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Hepatic function abnormal,,2023,Q2,1,I,20210228.0,20230419.0,20230426,20230426,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231398",BOEHRINGER INGELHEIM,"Junling C, Xue Z, Yanli Z, Fan L, Xiao Z. Diabetic ketoacidosis induced by combination use of dulaglutide and empagliflozin. Adverse Drug Reactions Journal. 2022 Mar;24(3): 147-149. doi:10.3760/cma.j.cn114015-20210401-00399.",41.0,YR,A,F,Y,,,20230426,,HP,CN,CN,2023,Q2,Adult
222565641,22256564,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Gastrooesophageal reflux disease,,2023,Q2,1,I,20210228.0,20230419.0,20230426,20230426,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231398",BOEHRINGER INGELHEIM,"Junling C, Xue Z, Yanli Z, Fan L, Xiao Z. Diabetic ketoacidosis induced by combination use of dulaglutide and empagliflozin. Adverse Drug Reactions Journal. 2022 Mar;24(3): 147-149. doi:10.3760/cma.j.cn114015-20210401-00399.",41.0,YR,A,F,Y,,,20230426,,HP,CN,CN,2023,Q2,Adult
222565641,22256564,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Vulvovaginal pruritus,,2023,Q2,1,I,20210228.0,20230419.0,20230426,20230426,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231398",BOEHRINGER INGELHEIM,"Junling C, Xue Z, Yanli Z, Fan L, Xiao Z. Diabetic ketoacidosis induced by combination use of dulaglutide and empagliflozin. Adverse Drug Reactions Journal. 2022 Mar;24(3): 147-149. doi:10.3760/cma.j.cn114015-20210401-00399.",41.0,YR,A,F,Y,,,20230426,,HP,CN,CN,2023,Q2,Adult
222565641,22256564,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Haematochezia,,2023,Q2,1,I,20210228.0,20230419.0,20230426,20230426,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231398",BOEHRINGER INGELHEIM,"Junling C, Xue Z, Yanli Z, Fan L, Xiao Z. Diabetic ketoacidosis induced by combination use of dulaglutide and empagliflozin. Adverse Drug Reactions Journal. 2022 Mar;24(3): 147-149. doi:10.3760/cma.j.cn114015-20210401-00399.",41.0,YR,A,F,Y,,,20230426,,HP,CN,CN,2023,Q2,Adult
222565641,22256564,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Diabetic ketoacidosis,,2023,Q2,1,I,20210228.0,20230419.0,20230426,20230426,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231398",BOEHRINGER INGELHEIM,"Junling C, Xue Z, Yanli Z, Fan L, Xiao Z. Diabetic ketoacidosis induced by combination use of dulaglutide and empagliflozin. Adverse Drug Reactions Journal. 2022 Mar;24(3): 147-149. doi:10.3760/cma.j.cn114015-20210401-00399.",41.0,YR,A,F,Y,,,20230426,,HP,CN,CN,2023,Q2,Adult
222565641,22256564,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Decreased appetite,,2023,Q2,1,I,20210228.0,20230419.0,20230426,20230426,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231398",BOEHRINGER INGELHEIM,"Junling C, Xue Z, Yanli Z, Fan L, Xiao Z. Diabetic ketoacidosis induced by combination use of dulaglutide and empagliflozin. Adverse Drug Reactions Journal. 2022 Mar;24(3): 147-149. doi:10.3760/cma.j.cn114015-20210401-00399.",41.0,YR,A,F,Y,,,20230426,,HP,CN,CN,2023,Q2,Adult
222565641,22256564,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Type 2 diabetes mellitus,,2023,Q2,1,I,20210228.0,20230419.0,20230426,20230426,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231398",BOEHRINGER INGELHEIM,"Junling C, Xue Z, Yanli Z, Fan L, Xiao Z. Diabetic ketoacidosis induced by combination use of dulaglutide and empagliflozin. Adverse Drug Reactions Journal. 2022 Mar;24(3): 147-149. doi:10.3760/cma.j.cn114015-20210401-00399.",41.0,YR,A,F,Y,,,20230426,,HP,CN,CN,2023,Q2,Adult
222565641,22256564,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Hypothyroidism,,2023,Q2,1,I,20210228.0,20230419.0,20230426,20230426,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231398",BOEHRINGER INGELHEIM,"Junling C, Xue Z, Yanli Z, Fan L, Xiao Z. Diabetic ketoacidosis induced by combination use of dulaglutide and empagliflozin. Adverse Drug Reactions Journal. 2022 Mar;24(3): 147-149. doi:10.3760/cma.j.cn114015-20210401-00399.",41.0,YR,A,F,Y,,,20230426,,HP,CN,CN,2023,Q2,Adult
222565641,22256564,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Haematemesis,,2023,Q2,1,I,20210228.0,20230419.0,20230426,20230426,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231398",BOEHRINGER INGELHEIM,"Junling C, Xue Z, Yanli Z, Fan L, Xiao Z. Diabetic ketoacidosis induced by combination use of dulaglutide and empagliflozin. Adverse Drug Reactions Journal. 2022 Mar;24(3): 147-149. doi:10.3760/cma.j.cn114015-20210401-00399.",41.0,YR,A,F,Y,,,20230426,,HP,CN,CN,2023,Q2,Adult
222565641,22256564,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Lipids abnormal,,2023,Q2,1,I,20210228.0,20230419.0,20230426,20230426,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231398",BOEHRINGER INGELHEIM,"Junling C, Xue Z, Yanli Z, Fan L, Xiao Z. Diabetic ketoacidosis induced by combination use of dulaglutide and empagliflozin. Adverse Drug Reactions Journal. 2022 Mar;24(3): 147-149. doi:10.3760/cma.j.cn114015-20210401-00399.",41.0,YR,A,F,Y,,,20230426,,HP,CN,CN,2023,Q2,Adult
222565641,22256564,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Infection,,2023,Q2,1,I,20210228.0,20230419.0,20230426,20230426,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231398",BOEHRINGER INGELHEIM,"Junling C, Xue Z, Yanli Z, Fan L, Xiao Z. Diabetic ketoacidosis induced by combination use of dulaglutide and empagliflozin. Adverse Drug Reactions Journal. 2022 Mar;24(3): 147-149. doi:10.3760/cma.j.cn114015-20210401-00399.",41.0,YR,A,F,Y,,,20230426,,HP,CN,CN,2023,Q2,Adult
222565641,22256564,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Hepatic function abnormal,,2023,Q2,1,I,20210228.0,20230419.0,20230426,20230426,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231398",BOEHRINGER INGELHEIM,"Junling C, Xue Z, Yanli Z, Fan L, Xiao Z. Diabetic ketoacidosis induced by combination use of dulaglutide and empagliflozin. Adverse Drug Reactions Journal. 2022 Mar;24(3): 147-149. doi:10.3760/cma.j.cn114015-20210401-00399.",41.0,YR,A,F,Y,,,20230426,,HP,CN,CN,2023,Q2,Adult
222565641,22256564,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Gastrooesophageal reflux disease,,2023,Q2,1,I,20210228.0,20230419.0,20230426,20230426,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231398",BOEHRINGER INGELHEIM,"Junling C, Xue Z, Yanli Z, Fan L, Xiao Z. Diabetic ketoacidosis induced by combination use of dulaglutide and empagliflozin. Adverse Drug Reactions Journal. 2022 Mar;24(3): 147-149. doi:10.3760/cma.j.cn114015-20210401-00399.",41.0,YR,A,F,Y,,,20230426,,HP,CN,CN,2023,Q2,Adult
222565641,22256564,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Vulvovaginal pruritus,,2023,Q2,1,I,20210228.0,20230419.0,20230426,20230426,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231398",BOEHRINGER INGELHEIM,"Junling C, Xue Z, Yanli Z, Fan L, Xiao Z. Diabetic ketoacidosis induced by combination use of dulaglutide and empagliflozin. Adverse Drug Reactions Journal. 2022 Mar;24(3): 147-149. doi:10.3760/cma.j.cn114015-20210401-00399.",41.0,YR,A,F,Y,,,20230426,,HP,CN,CN,2023,Q2,Adult
222565641,22256564,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Haematochezia,,2023,Q2,1,I,20210228.0,20230419.0,20230426,20230426,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231398",BOEHRINGER INGELHEIM,"Junling C, Xue Z, Yanli Z, Fan L, Xiao Z. Diabetic ketoacidosis induced by combination use of dulaglutide and empagliflozin. Adverse Drug Reactions Journal. 2022 Mar;24(3): 147-149. doi:10.3760/cma.j.cn114015-20210401-00399.",41.0,YR,A,F,Y,,,20230426,,HP,CN,CN,2023,Q2,Adult
222565641,22256564,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Diabetic ketoacidosis,,2023,Q2,1,I,20210228.0,20230419.0,20230426,20230426,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231398",BOEHRINGER INGELHEIM,"Junling C, Xue Z, Yanli Z, Fan L, Xiao Z. Diabetic ketoacidosis induced by combination use of dulaglutide and empagliflozin. Adverse Drug Reactions Journal. 2022 Mar;24(3): 147-149. doi:10.3760/cma.j.cn114015-20210401-00399.",41.0,YR,A,F,Y,,,20230426,,HP,CN,CN,2023,Q2,Adult
222565641,22256564,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Decreased appetite,,2023,Q2,1,I,20210228.0,20230419.0,20230426,20230426,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231398",BOEHRINGER INGELHEIM,"Junling C, Xue Z, Yanli Z, Fan L, Xiao Z. Diabetic ketoacidosis induced by combination use of dulaglutide and empagliflozin. Adverse Drug Reactions Journal. 2022 Mar;24(3): 147-149. doi:10.3760/cma.j.cn114015-20210401-00399.",41.0,YR,A,F,Y,,,20230426,,HP,CN,CN,2023,Q2,Adult
222565641,22256564,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Type 2 diabetes mellitus,,2023,Q2,1,I,20210228.0,20230419.0,20230426,20230426,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231398",BOEHRINGER INGELHEIM,"Junling C, Xue Z, Yanli Z, Fan L, Xiao Z. Diabetic ketoacidosis induced by combination use of dulaglutide and empagliflozin. Adverse Drug Reactions Journal. 2022 Mar;24(3): 147-149. doi:10.3760/cma.j.cn114015-20210401-00399.",41.0,YR,A,F,Y,,,20230426,,HP,CN,CN,2023,Q2,Adult
222565641,22256564,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Hypothyroidism,,2023,Q2,1,I,20210228.0,20230419.0,20230426,20230426,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231398",BOEHRINGER INGELHEIM,"Junling C, Xue Z, Yanli Z, Fan L, Xiao Z. Diabetic ketoacidosis induced by combination use of dulaglutide and empagliflozin. Adverse Drug Reactions Journal. 2022 Mar;24(3): 147-149. doi:10.3760/cma.j.cn114015-20210401-00399.",41.0,YR,A,F,Y,,,20230426,,HP,CN,CN,2023,Q2,Adult
222565641,22256564,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Haematemesis,,2023,Q2,1,I,20210228.0,20230419.0,20230426,20230426,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231398",BOEHRINGER INGELHEIM,"Junling C, Xue Z, Yanli Z, Fan L, Xiao Z. Diabetic ketoacidosis induced by combination use of dulaglutide and empagliflozin. Adverse Drug Reactions Journal. 2022 Mar;24(3): 147-149. doi:10.3760/cma.j.cn114015-20210401-00399.",41.0,YR,A,F,Y,,,20230426,,HP,CN,CN,2023,Q2,Adult
222565641,22256564,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Lipids abnormal,,2023,Q2,1,I,20210228.0,20230419.0,20230426,20230426,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231398",BOEHRINGER INGELHEIM,"Junling C, Xue Z, Yanli Z, Fan L, Xiao Z. Diabetic ketoacidosis induced by combination use of dulaglutide and empagliflozin. Adverse Drug Reactions Journal. 2022 Mar;24(3): 147-149. doi:10.3760/cma.j.cn114015-20210401-00399.",41.0,YR,A,F,Y,,,20230426,,HP,CN,CN,2023,Q2,Adult
222565641,22256564,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Infection,,2023,Q2,1,I,20210228.0,20230419.0,20230426,20230426,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231398",BOEHRINGER INGELHEIM,"Junling C, Xue Z, Yanli Z, Fan L, Xiao Z. Diabetic ketoacidosis induced by combination use of dulaglutide and empagliflozin. Adverse Drug Reactions Journal. 2022 Mar;24(3): 147-149. doi:10.3760/cma.j.cn114015-20210401-00399.",41.0,YR,A,F,Y,,,20230426,,HP,CN,CN,2023,Q2,Adult
222565641,22256564,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Hepatic function abnormal,,2023,Q2,1,I,20210228.0,20230419.0,20230426,20230426,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231398",BOEHRINGER INGELHEIM,"Junling C, Xue Z, Yanli Z, Fan L, Xiao Z. Diabetic ketoacidosis induced by combination use of dulaglutide and empagliflozin. Adverse Drug Reactions Journal. 2022 Mar;24(3): 147-149. doi:10.3760/cma.j.cn114015-20210401-00399.",41.0,YR,A,F,Y,,,20230426,,HP,CN,CN,2023,Q2,Adult
222565641,22256564,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Gastrooesophageal reflux disease,,2023,Q2,1,I,20210228.0,20230419.0,20230426,20230426,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231398",BOEHRINGER INGELHEIM,"Junling C, Xue Z, Yanli Z, Fan L, Xiao Z. Diabetic ketoacidosis induced by combination use of dulaglutide and empagliflozin. Adverse Drug Reactions Journal. 2022 Mar;24(3): 147-149. doi:10.3760/cma.j.cn114015-20210401-00399.",41.0,YR,A,F,Y,,,20230426,,HP,CN,CN,2023,Q2,Adult
222569562,22256956,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,,,,,,10.0,MG,,,2023,Q2,Atrial fibrillation,,2023,Q2,2,F,20220701.0,20230503.0,20230427,20230510,EXP,,HR-JNJFOC-20230458851,JOHNSON AND JOHNSON,,63.0,YR,A,M,Y,,,20230510,,HP,HR,HR,2023,Q2,Adult
222569562,22256956,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,,,,,,10.0,MG,,,2023,Q2,Palpitations,,2023,Q2,2,F,20220701.0,20230503.0,20230427,20230510,EXP,,HR-JNJFOC-20230458851,JOHNSON AND JOHNSON,,63.0,YR,A,M,Y,,,20230510,,HP,HR,HR,2023,Q2,Adult
222575761,22257576,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,Tablet,QD,2023,Q2,Liver function test abnormal,,2023,Q2,1,I,20230323.0,20230425.0,20230427,20230427,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-233664",BOEHRINGER INGELHEIM,,68.0,YR,E,F,Y,64.0,KG,20230427,,MD,GB,GB,2023,Q2,Elderly
222578501,22257850,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10.0 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Hepatic enzyme increased,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032076,AUROBINDO,,57.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222578501,22257850,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10.0 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Antinuclear antibody positive,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032076,AUROBINDO,,57.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222578501,22257850,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10.0 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Condition aggravated,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032076,AUROBINDO,,57.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222578501,22257850,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10.0 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Synovial disorder,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032076,AUROBINDO,,57.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222578501,22257850,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10.0 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Urinary tract infection,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032076,AUROBINDO,,57.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222578501,22257850,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10.0 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Vitamin B12 decreased,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032076,AUROBINDO,,57.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222578501,22257850,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10.0 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Arthritis,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032076,AUROBINDO,,57.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222578501,22257850,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10.0 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Joint effusion,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032076,AUROBINDO,,57.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222578501,22257850,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10.0 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Arthropathy,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032076,AUROBINDO,,57.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222578501,22257850,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10.0 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Joint swelling,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032076,AUROBINDO,,57.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222578501,22257850,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10.0 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Tendonitis,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032076,AUROBINDO,,57.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222578501,22257850,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10.0 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Renal disorder,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032076,AUROBINDO,,57.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222578501,22257850,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10.0 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Blood uric acid increased,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032076,AUROBINDO,,57.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222578501,22257850,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10.0 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,C-reactive protein increased,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032076,AUROBINDO,,57.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222578501,22257850,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10.0 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Allergic sinusitis,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032076,AUROBINDO,,57.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222578501,22257850,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10.0 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Arthralgia,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032076,AUROBINDO,,57.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222578501,22257850,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10.0 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Drug ineffective,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032076,AUROBINDO,,57.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222578501,22257850,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10.0 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Injection site pain,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032076,AUROBINDO,,57.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222578501,22257850,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10.0 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Injection site warmth,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032076,AUROBINDO,,57.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222578501,22257850,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10.0 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Pain,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032076,AUROBINDO,,57.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222578501,22257850,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10.0 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Psoriasis,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032076,AUROBINDO,,57.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222578501,22257850,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10.0 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Oedema,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032076,AUROBINDO,,57.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222578501,22257850,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10.0 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Pain in extremity,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032076,AUROBINDO,,57.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222578501,22257850,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10.0 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Blood iron decreased,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032076,AUROBINDO,,57.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222578501,22257850,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10.0 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Incorrect dose administered,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032076,AUROBINDO,,57.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222578501,22257850,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10.0 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Rash,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032076,AUROBINDO,,57.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222578501,22257850,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10.0 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Osteoarthritis,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032076,AUROBINDO,,57.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222578501,22257850,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10.0 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Nephrolithiasis,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032076,AUROBINDO,,57.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222578501,22257850,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10.0 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Pyrexia,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032076,AUROBINDO,,57.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222578501,22257850,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10.0 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Sepsis,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032076,AUROBINDO,,57.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222578501,22257850,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10.0 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Synovitis,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032076,AUROBINDO,,57.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222578501,22257850,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10.0 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Alanine aminotransferase increased,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032076,AUROBINDO,,57.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222578501,22257850,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10.0 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Cyst,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032076,AUROBINDO,,57.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222581801,22258180,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Renal disorder,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032084,AUROBINDO,,59.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222581801,22258180,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Synovitis,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032084,AUROBINDO,,59.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222581801,22258180,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Urinary tract infection,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032084,AUROBINDO,,59.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222581801,22258180,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,C-reactive protein increased,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032084,AUROBINDO,,59.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222581801,22258180,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Pain in extremity,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032084,AUROBINDO,,59.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222581801,22258180,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Condition aggravated,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032084,AUROBINDO,,59.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222581801,22258180,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Joint effusion,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032084,AUROBINDO,,59.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222581801,22258180,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Nephrolithiasis,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032084,AUROBINDO,,59.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222581801,22258180,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Hepatic enzyme increased,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032084,AUROBINDO,,59.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222581801,22258180,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Cyst,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032084,AUROBINDO,,59.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222581801,22258180,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Injection site pain,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032084,AUROBINDO,,59.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222581801,22258180,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Joint swelling,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032084,AUROBINDO,,59.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222581801,22258180,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Osteoarthritis,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032084,AUROBINDO,,59.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222581801,22258180,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Antinuclear antibody positive,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032084,AUROBINDO,,59.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222581801,22258180,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Injection site warmth,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032084,AUROBINDO,,59.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222581801,22258180,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Sepsis,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032084,AUROBINDO,,59.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222581801,22258180,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Incorrect dose administered,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032084,AUROBINDO,,59.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222581801,22258180,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Drug ineffective,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032084,AUROBINDO,,59.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222581801,22258180,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Arthralgia,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032084,AUROBINDO,,59.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222581801,22258180,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Pyrexia,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032084,AUROBINDO,,59.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222581801,22258180,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Blood uric acid increased,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032084,AUROBINDO,,59.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222581801,22258180,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Allergic sinusitis,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032084,AUROBINDO,,59.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222581801,22258180,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Rash,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032084,AUROBINDO,,59.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222581801,22258180,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Psoriasis,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032084,AUROBINDO,,59.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222581801,22258180,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Pain,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032084,AUROBINDO,,59.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222581801,22258180,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Oedema,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032084,AUROBINDO,,59.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222581801,22258180,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Arthropathy,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032084,AUROBINDO,,59.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222581801,22258180,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Alanine aminotransferase increased,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032084,AUROBINDO,,59.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222581801,22258180,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Synovial disorder,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032084,AUROBINDO,,59.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222581801,22258180,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Arthritis,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032084,AUROBINDO,,59.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222581801,22258180,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Blood iron decreased,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032084,AUROBINDO,,59.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222581801,22258180,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Vitamin B12 decreased,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032084,AUROBINDO,,59.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222581801,22258180,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Tendonitis,,2023,Q2,1,I,,20230414.0,20230427,20230427,EXP,,CA-AUROBINDO-AUR-APL-2023-032084,AUROBINDO,,59.0,YR,,F,Y,,,20230427,,HP,CA,CA,2023,Q2,Adult
222582353,22258235,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Dyspnoea exertional,,2023,Q2,3,F,20230108.0,20230515.0,20230427,20230517,EXP,,NVSC2023AE009377,NOVARTIS,,78.0,YR,,M,Y,,,20230517,,MD,AE,AE,2023,Q2,Elderly
222582353,22258235,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Dyspnoea at rest,,2023,Q2,3,F,20230108.0,20230515.0,20230427,20230517,EXP,,NVSC2023AE009377,NOVARTIS,,78.0,YR,,M,Y,,,20230517,,MD,AE,AE,2023,Q2,Elderly
222582353,22258235,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Intestinal ischaemia,,2023,Q2,3,F,20230108.0,20230515.0,20230427,20230517,EXP,,NVSC2023AE009377,NOVARTIS,,78.0,YR,,M,Y,,,20230517,,MD,AE,AE,2023,Q2,Elderly
222582353,22258235,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Hypervolaemia,,2023,Q2,3,F,20230108.0,20230515.0,20230427,20230517,EXP,,NVSC2023AE009377,NOVARTIS,,78.0,YR,,M,Y,,,20230517,,MD,AE,AE,2023,Q2,Elderly
222582353,22258235,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Mesenteric vascular occlusion,,2023,Q2,3,F,20230108.0,20230515.0,20230427,20230517,EXP,,NVSC2023AE009377,NOVARTIS,,78.0,YR,,M,Y,,,20230517,,MD,AE,AE,2023,Q2,Elderly
222582353,22258235,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Fatigue,,2023,Q2,3,F,20230108.0,20230515.0,20230427,20230517,EXP,,NVSC2023AE009377,NOVARTIS,,78.0,YR,,M,Y,,,20230517,,MD,AE,AE,2023,Q2,Elderly
222582353,22258235,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Pulmonary congestion,,2023,Q2,3,F,20230108.0,20230515.0,20230427,20230517,EXP,,NVSC2023AE009377,NOVARTIS,,78.0,YR,,M,Y,,,20230517,,MD,AE,AE,2023,Q2,Elderly
222582353,22258235,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Orthopnoea,,2023,Q2,3,F,20230108.0,20230515.0,20230427,20230517,EXP,,NVSC2023AE009377,NOVARTIS,,78.0,YR,,M,Y,,,20230517,,MD,AE,AE,2023,Q2,Elderly
222582353,22258235,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Acute myocardial infarction,,2023,Q2,3,F,20230108.0,20230515.0,20230427,20230517,EXP,,NVSC2023AE009377,NOVARTIS,,78.0,YR,,M,Y,,,20230517,,MD,AE,AE,2023,Q2,Elderly
222582353,22258235,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Cardiac failure acute,,2023,Q2,3,F,20230108.0,20230515.0,20230427,20230517,EXP,,NVSC2023AE009377,NOVARTIS,,78.0,YR,,M,Y,,,20230517,,MD,AE,AE,2023,Q2,Elderly
222582353,22258235,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Abdominal pain upper,,2023,Q2,3,F,20230108.0,20230515.0,20230427,20230517,EXP,,NVSC2023AE009377,NOVARTIS,,78.0,YR,,M,Y,,,20230517,,MD,AE,AE,2023,Q2,Elderly
222599893,22259989,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, qd",,,,,,,,25.0,MG,,QD,2023,Q2,COVID-19,,2023,Q2,3,F,,20230405.0,20230427,20230621,EXP,,BR-DSJP-DSE-2023-116576,DAIICHI,,75.0,YR,,M,Y,90.0,KG,20230621,,MD,BR,BR,2023,Q2,Elderly
222599893,22259989,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, qd",,,,,,,,25.0,MG,,QD,2023,Q2,Cardiac failure,,2023,Q2,3,F,,20230405.0,20230427,20230621,EXP,,BR-DSJP-DSE-2023-116576,DAIICHI,,75.0,YR,,M,Y,90.0,KG,20230621,,MD,BR,BR,2023,Q2,Elderly
222599893,22259989,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, qd",,,,,,,,25.0,MG,,QD,2023,Q2,Product use issue,,2023,Q2,3,F,,20230405.0,20230427,20230621,EXP,,BR-DSJP-DSE-2023-116576,DAIICHI,,75.0,YR,,M,Y,90.0,KG,20230621,,MD,BR,BR,2023,Q2,Elderly
222631921,22263192,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, (take one daily) qd",,,,,Unknown,,,,,,QD,2023,Q2,Rash,,2023,Q2,1,I,20230413.0,20230417.0,20230428,20230428,EXP,GB-MHRA-ADR 27836583,GB-ALKEM LABORATORIES LIMITED-GB-ALKEM-2023-04494,ALKEM,,71.0,YR,,F,Y,114.0,KG,20230428,,MD,GB,GB,2023,Q2,Elderly
222631921,22263192,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, (take one daily) qd",,,,,Unknown,,,,,,QD,2023,Q2,Myalgia,,2023,Q2,1,I,20230413.0,20230417.0,20230428,20230428,EXP,GB-MHRA-ADR 27836583,GB-ALKEM LABORATORIES LIMITED-GB-ALKEM-2023-04494,ALKEM,,71.0,YR,,F,Y,114.0,KG,20230428,,MD,GB,GB,2023,Q2,Elderly
222669222,22266922,119,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Fatigue,,2023,Q2,2,F,20190101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A079044,ASTRAZENECA,,75.0,YR,,M,Y,85.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222669222,22266922,119,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Pyrexia,,2023,Q2,2,F,20190101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A079044,ASTRAZENECA,,75.0,YR,,M,Y,85.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222669222,22266922,119,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Hypopnoea,,2023,Q2,2,F,20190101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A079044,ASTRAZENECA,,75.0,YR,,M,Y,85.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222669222,22266922,119,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Drug ineffective,,2023,Q2,2,F,20190101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A079044,ASTRAZENECA,,75.0,YR,,M,Y,85.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222669222,22266922,119,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Somnolence,,2023,Q2,2,F,20190101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A079044,ASTRAZENECA,,75.0,YR,,M,Y,85.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222669222,22266922,119,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Arthritis,,2023,Q2,2,F,20190101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A079044,ASTRAZENECA,,75.0,YR,,M,Y,85.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222669222,22266922,119,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Deep vein thrombosis,,2023,Q2,2,F,20190101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A079044,ASTRAZENECA,,75.0,YR,,M,Y,85.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222669222,22266922,119,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Condition aggravated,,2023,Q2,2,F,20190101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A079044,ASTRAZENECA,,75.0,YR,,M,Y,85.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222669222,22266922,119,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Bronchiectasis,,2023,Q2,2,F,20190101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A079044,ASTRAZENECA,,75.0,YR,,M,Y,85.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222669222,22266922,119,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Migraine,,2023,Q2,2,F,20190101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A079044,ASTRAZENECA,,75.0,YR,,M,Y,85.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222669222,22266922,119,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Dysgeusia,,2023,Q2,2,F,20190101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A079044,ASTRAZENECA,,75.0,YR,,M,Y,85.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222669222,22266922,119,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Haematochezia,,2023,Q2,2,F,20190101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A079044,ASTRAZENECA,,75.0,YR,,M,Y,85.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222669222,22266922,119,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Rectal haemorrhage,,2023,Q2,2,F,20190101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A079044,ASTRAZENECA,,75.0,YR,,M,Y,85.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222669222,22266922,119,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Inappropriate schedule of product administration,,2023,Q2,2,F,20190101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A079044,ASTRAZENECA,,75.0,YR,,M,Y,85.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222669222,22266922,119,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Rash,,2023,Q2,2,F,20190101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A079044,ASTRAZENECA,,75.0,YR,,M,Y,85.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222669222,22266922,119,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Confusional state,,2023,Q2,2,F,20190101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A079044,ASTRAZENECA,,75.0,YR,,M,Y,85.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222669222,22266922,119,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Adverse drug reaction,,2023,Q2,2,F,20190101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A079044,ASTRAZENECA,,75.0,YR,,M,Y,85.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222669222,22266922,119,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Impaired work ability,,2023,Q2,2,F,20190101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A079044,ASTRAZENECA,,75.0,YR,,M,Y,85.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222669222,22266922,119,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Stress,,2023,Q2,2,F,20190101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A079044,ASTRAZENECA,,75.0,YR,,M,Y,85.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222669222,22266922,119,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Pulmonary embolism,,2023,Q2,2,F,20190101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A079044,ASTRAZENECA,,75.0,YR,,M,Y,85.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222669222,22266922,119,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Pain,,2023,Q2,2,F,20190101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A079044,ASTRAZENECA,,75.0,YR,,M,Y,85.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222669222,22266922,119,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Burns second degree,,2023,Q2,2,F,20190101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A079044,ASTRAZENECA,,75.0,YR,,M,Y,85.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222669222,22266922,119,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,COVID-19,,2023,Q2,2,F,20190101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A079044,ASTRAZENECA,,75.0,YR,,M,Y,85.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222669222,22266922,119,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Rhinitis,,2023,Q2,2,F,20190101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A079044,ASTRAZENECA,,75.0,YR,,M,Y,85.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222669222,22266922,119,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Palpitations,,2023,Q2,2,F,20190101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A079044,ASTRAZENECA,,75.0,YR,,M,Y,85.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222669222,22266922,119,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Intentional product use issue,,2023,Q2,2,F,20190101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A079044,ASTRAZENECA,,75.0,YR,,M,Y,85.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222669222,22266922,119,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Weight decreased,,2023,Q2,2,F,20190101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A079044,ASTRAZENECA,,75.0,YR,,M,Y,85.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222669222,22266922,119,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Nightmare,,2023,Q2,2,F,20190101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A079044,ASTRAZENECA,,75.0,YR,,M,Y,85.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222669222,22266922,119,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Steroid dependence,,2023,Q2,2,F,20190101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A079044,ASTRAZENECA,,75.0,YR,,M,Y,85.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222669222,22266922,119,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Cerebrovascular accident,,2023,Q2,2,F,20190101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A079044,ASTRAZENECA,,75.0,YR,,M,Y,85.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222669222,22266922,119,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Systemic lupus erythematosus,,2023,Q2,2,F,20190101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A079044,ASTRAZENECA,,75.0,YR,,M,Y,85.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222669222,22266922,119,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Depression,,2023,Q2,2,F,20190101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A079044,ASTRAZENECA,,75.0,YR,,M,Y,85.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222669222,22266922,119,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Swollen tongue,,2023,Q2,2,F,20190101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A079044,ASTRAZENECA,,75.0,YR,,M,Y,85.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222669222,22266922,119,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Colitis ulcerative,,2023,Q2,2,F,20190101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A079044,ASTRAZENECA,,75.0,YR,,M,Y,85.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222669222,22266922,119,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Tinnitus,,2023,Q2,2,F,20190101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A079044,ASTRAZENECA,,75.0,YR,,M,Y,85.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222669222,22266922,119,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Tubulointerstitial nephritis,,2023,Q2,2,F,20190101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A079044,ASTRAZENECA,,75.0,YR,,M,Y,85.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222669222,22266922,119,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Frequent bowel movements,,2023,Q2,2,F,20190101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A079044,ASTRAZENECA,,75.0,YR,,M,Y,85.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222669222,22266922,119,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Impaired quality of life,,2023,Q2,2,F,20190101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A079044,ASTRAZENECA,,75.0,YR,,M,Y,85.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222669222,22266922,119,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Medication error,,2023,Q2,2,F,20190101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A079044,ASTRAZENECA,,75.0,YR,,M,Y,85.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222669222,22266922,119,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Off label use,,2023,Q2,2,F,20190101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A079044,ASTRAZENECA,,75.0,YR,,M,Y,85.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222669222,22266922,119,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Pain in extremity,,2023,Q2,2,F,20190101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A079044,ASTRAZENECA,,75.0,YR,,M,Y,85.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222669222,22266922,119,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Gingival pain,,2023,Q2,2,F,20190101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A079044,ASTRAZENECA,,75.0,YR,,M,Y,85.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222669222,22266922,119,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Cardiac murmur,,2023,Q2,2,F,20190101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A079044,ASTRAZENECA,,75.0,YR,,M,Y,85.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222669222,22266922,119,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Abdominal discomfort,,2023,Q2,2,F,20190101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A079044,ASTRAZENECA,,75.0,YR,,M,Y,85.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222669222,22266922,119,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Accidental overdose,,2023,Q2,2,F,20190101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A079044,ASTRAZENECA,,75.0,YR,,M,Y,85.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222669222,22266922,119,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Loss of personal independence in daily activities,,2023,Q2,2,F,20190101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A079044,ASTRAZENECA,,75.0,YR,,M,Y,85.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222669222,22266922,119,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Product use in unapproved indication,,2023,Q2,2,F,20190101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A079044,ASTRAZENECA,,75.0,YR,,M,Y,85.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222669222,22266922,119,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Headache,,2023,Q2,2,F,20190101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A079044,ASTRAZENECA,,75.0,YR,,M,Y,85.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222669222,22266922,119,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Parosmia,,2023,Q2,2,F,20190101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A079044,ASTRAZENECA,,75.0,YR,,M,Y,85.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222669222,22266922,119,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Vertigo,,2023,Q2,2,F,20190101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A079044,ASTRAZENECA,,75.0,YR,,M,Y,85.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222669222,22266922,119,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Eczema,,2023,Q2,2,F,20190101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A079044,ASTRAZENECA,,75.0,YR,,M,Y,85.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Intentional product use issue,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Colitis ulcerative,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Migraine,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Accidental overdose,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Abdominal discomfort,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Systemic lupus erythematosus,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Confusional state,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Cerebrovascular accident,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Haematochezia,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Rash,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Tinnitus,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,COVID-19,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Burns second degree,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Pain,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Vertigo,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Somnolence,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Fatigue,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Medication error,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Frequent bowel movements,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Catarrh,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Parosmia,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Pyrexia,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Cardiac murmur,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Fatigue,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Dysgeusia,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Loss of personal independence in daily activities,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Headache,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Off label use,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Hypopnoea,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Depression,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Bronchiectasis,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Deep vein thrombosis,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Tubulointerstitial nephritis,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Gingival pain,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Swollen tongue,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Stress,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Product use in unapproved indication,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Palpitations,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Tinnitus,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Impaired work ability,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Eczema,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Adverse drug reaction,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Arthritis,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Rash,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Rectal haemorrhage,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Weight decreased,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Inappropriate schedule of product administration,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Drug ineffective,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Colitis ulcerative,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Loss of personal independence in daily activities,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Steroid dependence,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Pain in extremity,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Pulmonary embolism,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Rhinitis,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Impaired quality of life,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Nightmare,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222671762,22267176,178,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Condition aggravated,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230510,EXP,,GB-AstraZeneca-2023A083390,ASTRAZENECA,,46.0,YR,,F,Y,,,20230510,,MD,GB,,2023,Q2,Adult
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Steroid dependence,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Haematochezia,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Eczema,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Gingival pain,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Weight decreased,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Pain,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Systemic lupus erythematosus,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Cardiac murmur,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Cerebrovascular accident,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Burns second degree,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Depression,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Colitis ulcerative,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Deep vein thrombosis,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Inappropriate schedule of product administration,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Pyrexia,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Off label use,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Palpitations,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Dysgeusia,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Nightmare,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Accidental overdose,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Rectal haemorrhage,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Migraine,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Pulmonary embolism,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Swollen tongue,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Rhinitis,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Hypopnoea,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Medication error,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Stress,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Frequent bowel movements,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Confusional state,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Tubulointerstitial nephritis,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Rash,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Catarrh,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Fatigue,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Rash,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Fatigue,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Tinnitus,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Tinnitus,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Abdominal discomfort,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Pain in extremity,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Product use in unapproved indication,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Headache,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Intentional product use issue,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Somnolence,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Bronchiectasis,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Impaired work ability,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Vertigo,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,COVID-19,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Adverse drug reaction,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Condition aggravated,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Loss of personal independence in daily activities,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Impaired quality of life,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Parosmia,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Drug ineffective,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Colitis ulcerative,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222672372,22267237,117,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Arthritis,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230508,EXP,,GB-AstraZeneca-2023A099447,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Headache,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Fatigue,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Stress,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Pyrexia,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Migraine,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Rhinitis,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Systemic lupus erythematosus,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Somnolence,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Burns second degree,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Dysgeusia,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Tinnitus,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Accidental overdose,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Gingival pain,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Inappropriate schedule of product administration,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Drug ineffective,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Deep vein thrombosis,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Tubulointerstitial nephritis,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Product use in unapproved indication,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Swollen tongue,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Pulmonary embolism,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Steroid dependence,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Haematochezia,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Pain in extremity,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Loss of personal independence in daily activities,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Eczema,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Off label use,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Impaired work ability,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Colitis ulcerative,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Condition aggravated,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Colitis ulcerative,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Weight decreased,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Cerebrovascular accident,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Intentional product use issue,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Cardiac murmur,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Impaired quality of life,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Confusional state,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Abdominal discomfort,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,COVID-19,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Hypopnoea,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Rash,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Vertigo,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Bronchiectasis,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Tinnitus,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Depression,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Pain,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Medication error,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Rash,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Fatigue,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Catarrh,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Palpitations,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Frequent bowel movements,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Nightmare,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Rectal haemorrhage,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Adverse drug reaction,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Parosmia,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673062,22267306,100,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Arthritis,,2023,Q2,2,F,20080101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099465,ASTRAZENECA,,76.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Elderly
222673073,22267307,131,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Parosmia,,2023,Q2,3,F,20080101.0,20230426.0,20230428,20230515,EXP,,GB-AstraZeneca-2023A099289,ASTRAZENECA,,58.0,YR,,F,Y,60.0,KG,20230515,,MD,GB,,2023,Q2,Adult
222673073,22267307,131,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Inappropriate schedule of product administration,,2023,Q2,3,F,20080101.0,20230426.0,20230428,20230515,EXP,,GB-AstraZeneca-2023A099289,ASTRAZENECA,,58.0,YR,,F,Y,60.0,KG,20230515,,MD,GB,,2023,Q2,Adult
222673073,22267307,131,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Deep vein thrombosis,,2023,Q2,3,F,20080101.0,20230426.0,20230428,20230515,EXP,,GB-AstraZeneca-2023A099289,ASTRAZENECA,,58.0,YR,,F,Y,60.0,KG,20230515,,MD,GB,,2023,Q2,Adult
222673073,22267307,131,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Arthritis,,2023,Q2,3,F,20080101.0,20230426.0,20230428,20230515,EXP,,GB-AstraZeneca-2023A099289,ASTRAZENECA,,58.0,YR,,F,Y,60.0,KG,20230515,,MD,GB,,2023,Q2,Adult
222673073,22267307,131,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Accidental overdose,,2023,Q2,3,F,20080101.0,20230426.0,20230428,20230515,EXP,,GB-AstraZeneca-2023A099289,ASTRAZENECA,,58.0,YR,,F,Y,60.0,KG,20230515,,MD,GB,,2023,Q2,Adult
222673073,22267307,131,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Vertigo,,2023,Q2,3,F,20080101.0,20230426.0,20230428,20230515,EXP,,GB-AstraZeneca-2023A099289,ASTRAZENECA,,58.0,YR,,F,Y,60.0,KG,20230515,,MD,GB,,2023,Q2,Adult
222673073,22267307,131,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Catarrh,,2023,Q2,3,F,20080101.0,20230426.0,20230428,20230515,EXP,,GB-AstraZeneca-2023A099289,ASTRAZENECA,,58.0,YR,,F,Y,60.0,KG,20230515,,MD,GB,,2023,Q2,Adult
222673073,22267307,131,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Headache,,2023,Q2,3,F,20080101.0,20230426.0,20230428,20230515,EXP,,GB-AstraZeneca-2023A099289,ASTRAZENECA,,58.0,YR,,F,Y,60.0,KG,20230515,,MD,GB,,2023,Q2,Adult
222673073,22267307,131,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Pulmonary embolism,,2023,Q2,3,F,20080101.0,20230426.0,20230428,20230515,EXP,,GB-AstraZeneca-2023A099289,ASTRAZENECA,,58.0,YR,,F,Y,60.0,KG,20230515,,MD,GB,,2023,Q2,Adult
222673073,22267307,131,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Confusional state,,2023,Q2,3,F,20080101.0,20230426.0,20230428,20230515,EXP,,GB-AstraZeneca-2023A099289,ASTRAZENECA,,58.0,YR,,F,Y,60.0,KG,20230515,,MD,GB,,2023,Q2,Adult
222673073,22267307,131,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Depression,,2023,Q2,3,F,20080101.0,20230426.0,20230428,20230515,EXP,,GB-AstraZeneca-2023A099289,ASTRAZENECA,,58.0,YR,,F,Y,60.0,KG,20230515,,MD,GB,,2023,Q2,Adult
222673073,22267307,131,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Loss of personal independence in daily activities,,2023,Q2,3,F,20080101.0,20230426.0,20230428,20230515,EXP,,GB-AstraZeneca-2023A099289,ASTRAZENECA,,58.0,YR,,F,Y,60.0,KG,20230515,,MD,GB,,2023,Q2,Adult
222673073,22267307,131,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Pyrexia,,2023,Q2,3,F,20080101.0,20230426.0,20230428,20230515,EXP,,GB-AstraZeneca-2023A099289,ASTRAZENECA,,58.0,YR,,F,Y,60.0,KG,20230515,,MD,GB,,2023,Q2,Adult
222673073,22267307,131,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Condition aggravated,,2023,Q2,3,F,20080101.0,20230426.0,20230428,20230515,EXP,,GB-AstraZeneca-2023A099289,ASTRAZENECA,,58.0,YR,,F,Y,60.0,KG,20230515,,MD,GB,,2023,Q2,Adult
222673073,22267307,131,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Rash,,2023,Q2,3,F,20080101.0,20230426.0,20230428,20230515,EXP,,GB-AstraZeneca-2023A099289,ASTRAZENECA,,58.0,YR,,F,Y,60.0,KG,20230515,,MD,GB,,2023,Q2,Adult
222673073,22267307,131,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Stress,,2023,Q2,3,F,20080101.0,20230426.0,20230428,20230515,EXP,,GB-AstraZeneca-2023A099289,ASTRAZENECA,,58.0,YR,,F,Y,60.0,KG,20230515,,MD,GB,,2023,Q2,Adult
222673073,22267307,131,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Dysgeusia,,2023,Q2,3,F,20080101.0,20230426.0,20230428,20230515,EXP,,GB-AstraZeneca-2023A099289,ASTRAZENECA,,58.0,YR,,F,Y,60.0,KG,20230515,,MD,GB,,2023,Q2,Adult
222673073,22267307,131,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Rhinitis,,2023,Q2,3,F,20080101.0,20230426.0,20230428,20230515,EXP,,GB-AstraZeneca-2023A099289,ASTRAZENECA,,58.0,YR,,F,Y,60.0,KG,20230515,,MD,GB,,2023,Q2,Adult
222673073,22267307,131,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Migraine,,2023,Q2,3,F,20080101.0,20230426.0,20230428,20230515,EXP,,GB-AstraZeneca-2023A099289,ASTRAZENECA,,58.0,YR,,F,Y,60.0,KG,20230515,,MD,GB,,2023,Q2,Adult
222673073,22267307,131,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Cardiac murmur,,2023,Q2,3,F,20080101.0,20230426.0,20230428,20230515,EXP,,GB-AstraZeneca-2023A099289,ASTRAZENECA,,58.0,YR,,F,Y,60.0,KG,20230515,,MD,GB,,2023,Q2,Adult
222673073,22267307,131,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Nightmare,,2023,Q2,3,F,20080101.0,20230426.0,20230428,20230515,EXP,,GB-AstraZeneca-2023A099289,ASTRAZENECA,,58.0,YR,,F,Y,60.0,KG,20230515,,MD,GB,,2023,Q2,Adult
222673073,22267307,131,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Systemic lupus erythematosus,,2023,Q2,3,F,20080101.0,20230426.0,20230428,20230515,EXP,,GB-AstraZeneca-2023A099289,ASTRAZENECA,,58.0,YR,,F,Y,60.0,KG,20230515,,MD,GB,,2023,Q2,Adult
222673073,22267307,131,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Pain,,2023,Q2,3,F,20080101.0,20230426.0,20230428,20230515,EXP,,GB-AstraZeneca-2023A099289,ASTRAZENECA,,58.0,YR,,F,Y,60.0,KG,20230515,,MD,GB,,2023,Q2,Adult
222673073,22267307,131,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Palpitations,,2023,Q2,3,F,20080101.0,20230426.0,20230428,20230515,EXP,,GB-AstraZeneca-2023A099289,ASTRAZENECA,,58.0,YR,,F,Y,60.0,KG,20230515,,MD,GB,,2023,Q2,Adult
222673073,22267307,131,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Weight decreased,,2023,Q2,3,F,20080101.0,20230426.0,20230428,20230515,EXP,,GB-AstraZeneca-2023A099289,ASTRAZENECA,,58.0,YR,,F,Y,60.0,KG,20230515,,MD,GB,,2023,Q2,Adult
222673073,22267307,131,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Burns second degree,,2023,Q2,3,F,20080101.0,20230426.0,20230428,20230515,EXP,,GB-AstraZeneca-2023A099289,ASTRAZENECA,,58.0,YR,,F,Y,60.0,KG,20230515,,MD,GB,,2023,Q2,Adult
222673073,22267307,131,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Frequent bowel movements,,2023,Q2,3,F,20080101.0,20230426.0,20230428,20230515,EXP,,GB-AstraZeneca-2023A099289,ASTRAZENECA,,58.0,YR,,F,Y,60.0,KG,20230515,,MD,GB,,2023,Q2,Adult
222673073,22267307,131,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Abdominal discomfort,,2023,Q2,3,F,20080101.0,20230426.0,20230428,20230515,EXP,,GB-AstraZeneca-2023A099289,ASTRAZENECA,,58.0,YR,,F,Y,60.0,KG,20230515,,MD,GB,,2023,Q2,Adult
222673073,22267307,131,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Fatigue,,2023,Q2,3,F,20080101.0,20230426.0,20230428,20230515,EXP,,GB-AstraZeneca-2023A099289,ASTRAZENECA,,58.0,YR,,F,Y,60.0,KG,20230515,,MD,GB,,2023,Q2,Adult
222673073,22267307,131,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Impaired quality of life,,2023,Q2,3,F,20080101.0,20230426.0,20230428,20230515,EXP,,GB-AstraZeneca-2023A099289,ASTRAZENECA,,58.0,YR,,F,Y,60.0,KG,20230515,,MD,GB,,2023,Q2,Adult
222673073,22267307,131,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Bronchiectasis,,2023,Q2,3,F,20080101.0,20230426.0,20230428,20230515,EXP,,GB-AstraZeneca-2023A099289,ASTRAZENECA,,58.0,YR,,F,Y,60.0,KG,20230515,,MD,GB,,2023,Q2,Adult
222673073,22267307,131,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Drug ineffective,,2023,Q2,3,F,20080101.0,20230426.0,20230428,20230515,EXP,,GB-AstraZeneca-2023A099289,ASTRAZENECA,,58.0,YR,,F,Y,60.0,KG,20230515,,MD,GB,,2023,Q2,Adult
222673073,22267307,131,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Gingival pain,,2023,Q2,3,F,20080101.0,20230426.0,20230428,20230515,EXP,,GB-AstraZeneca-2023A099289,ASTRAZENECA,,58.0,YR,,F,Y,60.0,KG,20230515,,MD,GB,,2023,Q2,Adult
222673073,22267307,131,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Rectal haemorrhage,,2023,Q2,3,F,20080101.0,20230426.0,20230428,20230515,EXP,,GB-AstraZeneca-2023A099289,ASTRAZENECA,,58.0,YR,,F,Y,60.0,KG,20230515,,MD,GB,,2023,Q2,Adult
222673073,22267307,131,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,COVID-19,,2023,Q2,3,F,20080101.0,20230426.0,20230428,20230515,EXP,,GB-AstraZeneca-2023A099289,ASTRAZENECA,,58.0,YR,,F,Y,60.0,KG,20230515,,MD,GB,,2023,Q2,Adult
222673073,22267307,131,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Colitis ulcerative,,2023,Q2,3,F,20080101.0,20230426.0,20230428,20230515,EXP,,GB-AstraZeneca-2023A099289,ASTRAZENECA,,58.0,YR,,F,Y,60.0,KG,20230515,,MD,GB,,2023,Q2,Adult
222673073,22267307,131,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Swollen tongue,,2023,Q2,3,F,20080101.0,20230426.0,20230428,20230515,EXP,,GB-AstraZeneca-2023A099289,ASTRAZENECA,,58.0,YR,,F,Y,60.0,KG,20230515,,MD,GB,,2023,Q2,Adult
222673073,22267307,131,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Adverse drug reaction,,2023,Q2,3,F,20080101.0,20230426.0,20230428,20230515,EXP,,GB-AstraZeneca-2023A099289,ASTRAZENECA,,58.0,YR,,F,Y,60.0,KG,20230515,,MD,GB,,2023,Q2,Adult
222673073,22267307,131,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Tinnitus,,2023,Q2,3,F,20080101.0,20230426.0,20230428,20230515,EXP,,GB-AstraZeneca-2023A099289,ASTRAZENECA,,58.0,YR,,F,Y,60.0,KG,20230515,,MD,GB,,2023,Q2,Adult
222673073,22267307,131,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Pain in extremity,,2023,Q2,3,F,20080101.0,20230426.0,20230428,20230515,EXP,,GB-AstraZeneca-2023A099289,ASTRAZENECA,,58.0,YR,,F,Y,60.0,KG,20230515,,MD,GB,,2023,Q2,Adult
222673073,22267307,131,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Haematochezia,,2023,Q2,3,F,20080101.0,20230426.0,20230428,20230515,EXP,,GB-AstraZeneca-2023A099289,ASTRAZENECA,,58.0,YR,,F,Y,60.0,KG,20230515,,MD,GB,,2023,Q2,Adult
222673073,22267307,131,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Medication error,,2023,Q2,3,F,20080101.0,20230426.0,20230428,20230515,EXP,,GB-AstraZeneca-2023A099289,ASTRAZENECA,,58.0,YR,,F,Y,60.0,KG,20230515,,MD,GB,,2023,Q2,Adult
222673073,22267307,131,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Hypopnoea,,2023,Q2,3,F,20080101.0,20230426.0,20230428,20230515,EXP,,GB-AstraZeneca-2023A099289,ASTRAZENECA,,58.0,YR,,F,Y,60.0,KG,20230515,,MD,GB,,2023,Q2,Adult
222673073,22267307,131,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Cerebrovascular accident,,2023,Q2,3,F,20080101.0,20230426.0,20230428,20230515,EXP,,GB-AstraZeneca-2023A099289,ASTRAZENECA,,58.0,YR,,F,Y,60.0,KG,20230515,,MD,GB,,2023,Q2,Adult
222673073,22267307,131,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Impaired work ability,,2023,Q2,3,F,20080101.0,20230426.0,20230428,20230515,EXP,,GB-AstraZeneca-2023A099289,ASTRAZENECA,,58.0,YR,,F,Y,60.0,KG,20230515,,MD,GB,,2023,Q2,Adult
222673073,22267307,131,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Steroid dependence,,2023,Q2,3,F,20080101.0,20230426.0,20230428,20230515,EXP,,GB-AstraZeneca-2023A099289,ASTRAZENECA,,58.0,YR,,F,Y,60.0,KG,20230515,,MD,GB,,2023,Q2,Adult
222673073,22267307,131,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Intentional product use issue,,2023,Q2,3,F,20080101.0,20230426.0,20230428,20230515,EXP,,GB-AstraZeneca-2023A099289,ASTRAZENECA,,58.0,YR,,F,Y,60.0,KG,20230515,,MD,GB,,2023,Q2,Adult
222673073,22267307,131,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Tubulointerstitial nephritis,,2023,Q2,3,F,20080101.0,20230426.0,20230428,20230515,EXP,,GB-AstraZeneca-2023A099289,ASTRAZENECA,,58.0,YR,,F,Y,60.0,KG,20230515,,MD,GB,,2023,Q2,Adult
222673073,22267307,131,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Off label use,,2023,Q2,3,F,20080101.0,20230426.0,20230428,20230515,EXP,,GB-AstraZeneca-2023A099289,ASTRAZENECA,,58.0,YR,,F,Y,60.0,KG,20230515,,MD,GB,,2023,Q2,Adult
222673073,22267307,131,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Somnolence,,2023,Q2,3,F,20080101.0,20230426.0,20230428,20230515,EXP,,GB-AstraZeneca-2023A099289,ASTRAZENECA,,58.0,YR,,F,Y,60.0,KG,20230515,,MD,GB,,2023,Q2,Adult
222673073,22267307,131,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Product use in unapproved indication,,2023,Q2,3,F,20080101.0,20230426.0,20230428,20230515,EXP,,GB-AstraZeneca-2023A099289,ASTRAZENECA,,58.0,YR,,F,Y,60.0,KG,20230515,,MD,GB,,2023,Q2,Adult
222673073,22267307,131,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day;,,,,,,,,,,,,2023,Q2,Eczema,,2023,Q2,3,F,20080101.0,20230426.0,20230428,20230515,EXP,,GB-AstraZeneca-2023A099289,ASTRAZENECA,,58.0,YR,,F,Y,60.0,KG,20230515,,MD,GB,,2023,Q2,Adult
222673651,22267365,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Perineal erythema,,2023,Q2,1,I,,20230427.0,20230428,20230428,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-234517",BOEHRINGER INGELHEIM,,39.0,YR,A,F,Y,,,20230428,,HP,GB,GB,2023,Q2,Adult
222673651,22267365,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Perineal pain,,2023,Q2,1,I,,20230427.0,20230428,20230428,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-234517",BOEHRINGER INGELHEIM,,39.0,YR,A,F,Y,,,20230428,,HP,GB,GB,2023,Q2,Adult
222673651,22267365,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Candida infection,,2023,Q2,1,I,,20230427.0,20230428,20230428,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-234517",BOEHRINGER INGELHEIM,,39.0,YR,A,F,Y,,,20230428,,HP,GB,GB,2023,Q2,Adult
222674012,22267401,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Stress,,2023,Q2,2,F,20090101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099398,ASTRAZENECA,,34.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Young Adult
222674012,22267401,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Vertigo,,2023,Q2,2,F,20090101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099398,ASTRAZENECA,,34.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Young Adult
222674012,22267401,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Burns second degree,,2023,Q2,2,F,20090101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099398,ASTRAZENECA,,34.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Young Adult
222674012,22267401,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Off label use,,2023,Q2,2,F,20090101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099398,ASTRAZENECA,,34.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Young Adult
222674012,22267401,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Inappropriate schedule of product administration,,2023,Q2,2,F,20090101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099398,ASTRAZENECA,,34.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Young Adult
222674012,22267401,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Tinnitus,,2023,Q2,2,F,20090101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099398,ASTRAZENECA,,34.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Young Adult
222674012,22267401,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Loss of personal independence in daily activities,,2023,Q2,2,F,20090101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099398,ASTRAZENECA,,34.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Young Adult
222674012,22267401,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Fatigue,,2023,Q2,2,F,20090101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099398,ASTRAZENECA,,34.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Young Adult
222674012,22267401,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Bronchiectasis,,2023,Q2,2,F,20090101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099398,ASTRAZENECA,,34.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Young Adult
222674012,22267401,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Adverse drug reaction,,2023,Q2,2,F,20090101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099398,ASTRAZENECA,,34.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Young Adult
222674012,22267401,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Product use in unapproved indication,,2023,Q2,2,F,20090101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099398,ASTRAZENECA,,34.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Young Adult
222674012,22267401,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Haematochezia,,2023,Q2,2,F,20090101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099398,ASTRAZENECA,,34.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Young Adult
222674012,22267401,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Palpitations,,2023,Q2,2,F,20090101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099398,ASTRAZENECA,,34.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Young Adult
222674012,22267401,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Rash,,2023,Q2,2,F,20090101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099398,ASTRAZENECA,,34.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Young Adult
222674012,22267401,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Tubulointerstitial nephritis,,2023,Q2,2,F,20090101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099398,ASTRAZENECA,,34.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Young Adult
222674012,22267401,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Arthritis,,2023,Q2,2,F,20090101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099398,ASTRAZENECA,,34.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Young Adult
222674012,22267401,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Intentional product use issue,,2023,Q2,2,F,20090101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099398,ASTRAZENECA,,34.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Young Adult
222674012,22267401,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Migraine,,2023,Q2,2,F,20090101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099398,ASTRAZENECA,,34.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Young Adult
222674012,22267401,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Parosmia,,2023,Q2,2,F,20090101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099398,ASTRAZENECA,,34.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Young Adult
222674012,22267401,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Cardiac murmur,,2023,Q2,2,F,20090101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099398,ASTRAZENECA,,34.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Young Adult
222674012,22267401,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Condition aggravated,,2023,Q2,2,F,20090101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099398,ASTRAZENECA,,34.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Young Adult
222674012,22267401,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,COVID-19,,2023,Q2,2,F,20090101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099398,ASTRAZENECA,,34.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Young Adult
222674012,22267401,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Steroid dependence,,2023,Q2,2,F,20090101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099398,ASTRAZENECA,,34.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Young Adult
222674012,22267401,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Abdominal discomfort,,2023,Q2,2,F,20090101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099398,ASTRAZENECA,,34.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Young Adult
222674012,22267401,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Headache,,2023,Q2,2,F,20090101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099398,ASTRAZENECA,,34.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Young Adult
222674012,22267401,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Deep vein thrombosis,,2023,Q2,2,F,20090101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099398,ASTRAZENECA,,34.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Young Adult
222674012,22267401,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Eczema,,2023,Q2,2,F,20090101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099398,ASTRAZENECA,,34.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Young Adult
222674012,22267401,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Catarrh,,2023,Q2,2,F,20090101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099398,ASTRAZENECA,,34.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Young Adult
222674012,22267401,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Tinnitus,,2023,Q2,2,F,20090101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099398,ASTRAZENECA,,34.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Young Adult
222674012,22267401,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Medication error,,2023,Q2,2,F,20090101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099398,ASTRAZENECA,,34.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Young Adult
222674012,22267401,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Confusional state,,2023,Q2,2,F,20090101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099398,ASTRAZENECA,,34.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Young Adult
222674012,22267401,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Pain,,2023,Q2,2,F,20090101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099398,ASTRAZENECA,,34.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Young Adult
222674012,22267401,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Hypopnoea,,2023,Q2,2,F,20090101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099398,ASTRAZENECA,,34.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Young Adult
222674012,22267401,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Pyrexia,,2023,Q2,2,F,20090101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099398,ASTRAZENECA,,34.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Young Adult
222674012,22267401,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Systemic lupus erythematosus,,2023,Q2,2,F,20090101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099398,ASTRAZENECA,,34.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Young Adult
222674012,22267401,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Dysgeusia,,2023,Q2,2,F,20090101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099398,ASTRAZENECA,,34.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Young Adult
222674012,22267401,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Weight decreased,,2023,Q2,2,F,20090101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099398,ASTRAZENECA,,34.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Young Adult
222674012,22267401,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Impaired work ability,,2023,Q2,2,F,20090101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099398,ASTRAZENECA,,34.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Young Adult
222674012,22267401,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Drug ineffective,,2023,Q2,2,F,20090101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099398,ASTRAZENECA,,34.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Young Adult
222674012,22267401,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Pulmonary embolism,,2023,Q2,2,F,20090101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099398,ASTRAZENECA,,34.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Young Adult
222674012,22267401,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Frequent bowel movements,,2023,Q2,2,F,20090101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099398,ASTRAZENECA,,34.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Young Adult
222674012,22267401,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Rhinitis,,2023,Q2,2,F,20090101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099398,ASTRAZENECA,,34.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Young Adult
222674012,22267401,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Swollen tongue,,2023,Q2,2,F,20090101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099398,ASTRAZENECA,,34.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Young Adult
222674012,22267401,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Somnolence,,2023,Q2,2,F,20090101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099398,ASTRAZENECA,,34.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Young Adult
222674012,22267401,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Accidental overdose,,2023,Q2,2,F,20090101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099398,ASTRAZENECA,,34.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Young Adult
222674012,22267401,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Impaired quality of life,,2023,Q2,2,F,20090101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099398,ASTRAZENECA,,34.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Young Adult
222674012,22267401,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Gingival pain,,2023,Q2,2,F,20090101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099398,ASTRAZENECA,,34.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Young Adult
222674012,22267401,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Pain in extremity,,2023,Q2,2,F,20090101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099398,ASTRAZENECA,,34.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Young Adult
222674012,22267401,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Rectal haemorrhage,,2023,Q2,2,F,20090101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099398,ASTRAZENECA,,34.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Young Adult
222674012,22267401,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Nightmare,,2023,Q2,2,F,20090101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099398,ASTRAZENECA,,34.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Young Adult
222674012,22267401,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Cerebrovascular accident,,2023,Q2,2,F,20090101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099398,ASTRAZENECA,,34.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Young Adult
222674012,22267401,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Depression,,2023,Q2,2,F,20090101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099398,ASTRAZENECA,,34.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Young Adult
222674012,22267401,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Colitis ulcerative,,2023,Q2,2,F,20090101.0,20230426.0,20230428,20230509,EXP,,GB-AstraZeneca-2023A099398,ASTRAZENECA,,34.0,YR,,F,Y,,,20230509,,MD,GB,,2023,Q2,Young Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Adverse drug reaction,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Tinnitus,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Medication error,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Impaired quality of life,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Systemic lupus erythematosus,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Colitis ulcerative,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Palpitations,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Stress,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Colitis ulcerative,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Intentional product use issue,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Tinnitus,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Pain,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Frequent bowel movements,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Arthritis,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Somnolence,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,COVID-19,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Pain in extremity,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Confusional state,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Fatigue,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Product use in unapproved indication,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Burns second degree,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Condition aggravated,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Weight decreased,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Loss of personal independence in daily activities,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Cardiac murmur,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Cerebrovascular accident,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Gingival pain,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Fatigue,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Haematochezia,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Depression,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Parosmia,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Hypopnoea,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Migraine,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Vertigo,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Bronchiectasis,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Eczema,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Headache,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Inappropriate schedule of product administration,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Catarrh,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Steroid dependence,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Abdominal discomfort,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Tubulointerstitial nephritis,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Pyrexia,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Rectal haemorrhage,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Pulmonary embolism,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Off label use,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Rash,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Dysgeusia,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Drug ineffective,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Nightmare,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Deep vein thrombosis,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Rhinitis,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Accidental overdose,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Swollen tongue,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Impaired work ability,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Loss of personal independence in daily activities,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222674141,22267414,164,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day,,,,,,,,,,,,2023,Q2,Rash,,2023,Q2,1,I,20080101.0,20230426.0,20230428,20230428,EXP,,GB-AstraZeneca-2023A098928,ASTRAZENECA,,58.0,YR,,M,Y,86.0,KG,20230428,,MD,GB,,2023,Q2,Adult
222677991,22267799,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2023,Q2,Euglycaemic diabetic ketoacidosis,,2023,Q2,1,I,,20230425.0,20230430,20230430,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-233754",BOEHRINGER INGELHEIM,"Chaudhry A, Roels C, Lee J. Sodium-Glucose Cotransporter-2 Inhibitor-associated Euglycemic Diabetic Ketoacidosis: Lessons From a Case Series of 4 Patients Undergoing Coronary Artery Bypass Grafting Surgery. Canadian Journal of Diabetes. 2022;46(8): 843-850. doi:10.1016/j.jcjd.2022.06.007.",70.0,YR,E,M,Y,142.9,KG,20230430,,MD,CA,CA,2023,Q2,Elderly
222677991,22267799,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2023,Q2,Coronary artery disease,,2023,Q2,1,I,,20230425.0,20230430,20230430,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-233754",BOEHRINGER INGELHEIM,"Chaudhry A, Roels C, Lee J. Sodium-Glucose Cotransporter-2 Inhibitor-associated Euglycemic Diabetic Ketoacidosis: Lessons From a Case Series of 4 Patients Undergoing Coronary Artery Bypass Grafting Surgery. Canadian Journal of Diabetes. 2022;46(8): 843-850. doi:10.1016/j.jcjd.2022.06.007.",70.0,YR,E,M,Y,142.9,KG,20230430,,MD,CA,CA,2023,Q2,Elderly
222678031,22267803,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Unknown,,204629.0,25.0,MG,,QD,2023,Q2,Euglycaemic diabetic ketoacidosis,,2023,Q2,1,I,,20230425.0,20230430,20230430,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-233753",BOEHRINGER INGELHEIM,"Chaudhry A, Roels C, Lee J. Sodium-Glucose Cotransporter-2 Inhibitor-associated Euglycemic Diabetic Ketoacidosis: Lessons From a Case Series of 4 Patients Undergoing Coronary Artery Bypass Grafting Surgery. Canadian Journal of Diabetes. 2022;46(8): 843-850. doi:10.1016/j.jcjd.2022.06.007.",70.0,YR,E,M,Y,88.0,KG,20230430,,MD,CA,CA,2023,Q2,Elderly
222678031,22267803,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Unknown,,204629.0,25.0,MG,,QD,2023,Q2,Coronary artery disease,,2023,Q2,1,I,,20230425.0,20230430,20230430,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-233753",BOEHRINGER INGELHEIM,"Chaudhry A, Roels C, Lee J. Sodium-Glucose Cotransporter-2 Inhibitor-associated Euglycemic Diabetic Ketoacidosis: Lessons From a Case Series of 4 Patients Undergoing Coronary Artery Bypass Grafting Surgery. Canadian Journal of Diabetes. 2022;46(8): 843-850. doi:10.1016/j.jcjd.2022.06.007.",70.0,YR,E,M,Y,88.0,KG,20230430,,MD,CA,CA,2023,Q2,Elderly
222692012,22269201,137,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Accidental overdose,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230508,EXP,,GB-AstraZeneca-2023A099226,ASTRAZENECA,,63.0,YR,,,Y,,,20230508,,MD,GB,,2023,Q2,Adult
222692012,22269201,137,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,COVID-19,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230508,EXP,,GB-AstraZeneca-2023A099226,ASTRAZENECA,,63.0,YR,,,Y,,,20230508,,MD,GB,,2023,Q2,Adult
222692012,22269201,137,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Vertigo,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230508,EXP,,GB-AstraZeneca-2023A099226,ASTRAZENECA,,63.0,YR,,,Y,,,20230508,,MD,GB,,2023,Q2,Adult
222692012,22269201,137,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Adverse drug reaction,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230508,EXP,,GB-AstraZeneca-2023A099226,ASTRAZENECA,,63.0,YR,,,Y,,,20230508,,MD,GB,,2023,Q2,Adult
222692012,22269201,137,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Fatigue,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230508,EXP,,GB-AstraZeneca-2023A099226,ASTRAZENECA,,63.0,YR,,,Y,,,20230508,,MD,GB,,2023,Q2,Adult
222692012,22269201,137,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Rash,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230508,EXP,,GB-AstraZeneca-2023A099226,ASTRAZENECA,,63.0,YR,,,Y,,,20230508,,MD,GB,,2023,Q2,Adult
222692012,22269201,137,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Migraine,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230508,EXP,,GB-AstraZeneca-2023A099226,ASTRAZENECA,,63.0,YR,,,Y,,,20230508,,MD,GB,,2023,Q2,Adult
222692012,22269201,137,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Tubulointerstitial nephritis,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230508,EXP,,GB-AstraZeneca-2023A099226,ASTRAZENECA,,63.0,YR,,,Y,,,20230508,,MD,GB,,2023,Q2,Adult
222692012,22269201,137,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Medication error,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230508,EXP,,GB-AstraZeneca-2023A099226,ASTRAZENECA,,63.0,YR,,,Y,,,20230508,,MD,GB,,2023,Q2,Adult
222692012,22269201,137,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Rectal haemorrhage,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230508,EXP,,GB-AstraZeneca-2023A099226,ASTRAZENECA,,63.0,YR,,,Y,,,20230508,,MD,GB,,2023,Q2,Adult
222692012,22269201,137,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Headache,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230508,EXP,,GB-AstraZeneca-2023A099226,ASTRAZENECA,,63.0,YR,,,Y,,,20230508,,MD,GB,,2023,Q2,Adult
222692012,22269201,137,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Condition aggravated,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230508,EXP,,GB-AstraZeneca-2023A099226,ASTRAZENECA,,63.0,YR,,,Y,,,20230508,,MD,GB,,2023,Q2,Adult
222692012,22269201,137,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Hypopnoea,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230508,EXP,,GB-AstraZeneca-2023A099226,ASTRAZENECA,,63.0,YR,,,Y,,,20230508,,MD,GB,,2023,Q2,Adult
222692012,22269201,137,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Pyrexia,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230508,EXP,,GB-AstraZeneca-2023A099226,ASTRAZENECA,,63.0,YR,,,Y,,,20230508,,MD,GB,,2023,Q2,Adult
222692012,22269201,137,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Gingival pain,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230508,EXP,,GB-AstraZeneca-2023A099226,ASTRAZENECA,,63.0,YR,,,Y,,,20230508,,MD,GB,,2023,Q2,Adult
222692012,22269201,137,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Frequent bowel movements,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230508,EXP,,GB-AstraZeneca-2023A099226,ASTRAZENECA,,63.0,YR,,,Y,,,20230508,,MD,GB,,2023,Q2,Adult
222692012,22269201,137,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Dysgeusia,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230508,EXP,,GB-AstraZeneca-2023A099226,ASTRAZENECA,,63.0,YR,,,Y,,,20230508,,MD,GB,,2023,Q2,Adult
222692012,22269201,137,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Rash,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230508,EXP,,GB-AstraZeneca-2023A099226,ASTRAZENECA,,63.0,YR,,,Y,,,20230508,,MD,GB,,2023,Q2,Adult
222692012,22269201,137,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Cardiac murmur,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230508,EXP,,GB-AstraZeneca-2023A099226,ASTRAZENECA,,63.0,YR,,,Y,,,20230508,,MD,GB,,2023,Q2,Adult
222692012,22269201,137,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Stress,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230508,EXP,,GB-AstraZeneca-2023A099226,ASTRAZENECA,,63.0,YR,,,Y,,,20230508,,MD,GB,,2023,Q2,Adult
222692012,22269201,137,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Off label use,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230508,EXP,,GB-AstraZeneca-2023A099226,ASTRAZENECA,,63.0,YR,,,Y,,,20230508,,MD,GB,,2023,Q2,Adult
222692012,22269201,137,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Pain in extremity,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230508,EXP,,GB-AstraZeneca-2023A099226,ASTRAZENECA,,63.0,YR,,,Y,,,20230508,,MD,GB,,2023,Q2,Adult
222692012,22269201,137,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Weight decreased,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230508,EXP,,GB-AstraZeneca-2023A099226,ASTRAZENECA,,63.0,YR,,,Y,,,20230508,,MD,GB,,2023,Q2,Adult
222692012,22269201,137,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Pain,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230508,EXP,,GB-AstraZeneca-2023A099226,ASTRAZENECA,,63.0,YR,,,Y,,,20230508,,MD,GB,,2023,Q2,Adult
222692012,22269201,137,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Bronchiectasis,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230508,EXP,,GB-AstraZeneca-2023A099226,ASTRAZENECA,,63.0,YR,,,Y,,,20230508,,MD,GB,,2023,Q2,Adult
222692012,22269201,137,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Deep vein thrombosis,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230508,EXP,,GB-AstraZeneca-2023A099226,ASTRAZENECA,,63.0,YR,,,Y,,,20230508,,MD,GB,,2023,Q2,Adult
222692012,22269201,137,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Catarrh,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230508,EXP,,GB-AstraZeneca-2023A099226,ASTRAZENECA,,63.0,YR,,,Y,,,20230508,,MD,GB,,2023,Q2,Adult
222692012,22269201,137,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Tinnitus,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230508,EXP,,GB-AstraZeneca-2023A099226,ASTRAZENECA,,63.0,YR,,,Y,,,20230508,,MD,GB,,2023,Q2,Adult
222692012,22269201,137,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Burns second degree,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230508,EXP,,GB-AstraZeneca-2023A099226,ASTRAZENECA,,63.0,YR,,,Y,,,20230508,,MD,GB,,2023,Q2,Adult
222692012,22269201,137,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Colitis ulcerative,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230508,EXP,,GB-AstraZeneca-2023A099226,ASTRAZENECA,,63.0,YR,,,Y,,,20230508,,MD,GB,,2023,Q2,Adult
222692012,22269201,137,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Parosmia,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230508,EXP,,GB-AstraZeneca-2023A099226,ASTRAZENECA,,63.0,YR,,,Y,,,20230508,,MD,GB,,2023,Q2,Adult
222692012,22269201,137,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Swollen tongue,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230508,EXP,,GB-AstraZeneca-2023A099226,ASTRAZENECA,,63.0,YR,,,Y,,,20230508,,MD,GB,,2023,Q2,Adult
222692012,22269201,137,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Impaired quality of life,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230508,EXP,,GB-AstraZeneca-2023A099226,ASTRAZENECA,,63.0,YR,,,Y,,,20230508,,MD,GB,,2023,Q2,Adult
222692012,22269201,137,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Systemic lupus erythematosus,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230508,EXP,,GB-AstraZeneca-2023A099226,ASTRAZENECA,,63.0,YR,,,Y,,,20230508,,MD,GB,,2023,Q2,Adult
222692012,22269201,137,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Somnolence,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230508,EXP,,GB-AstraZeneca-2023A099226,ASTRAZENECA,,63.0,YR,,,Y,,,20230508,,MD,GB,,2023,Q2,Adult
222692012,22269201,137,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Haematochezia,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230508,EXP,,GB-AstraZeneca-2023A099226,ASTRAZENECA,,63.0,YR,,,Y,,,20230508,,MD,GB,,2023,Q2,Adult
222692012,22269201,137,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Pulmonary embolism,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230508,EXP,,GB-AstraZeneca-2023A099226,ASTRAZENECA,,63.0,YR,,,Y,,,20230508,,MD,GB,,2023,Q2,Adult
222692012,22269201,137,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Intentional product use issue,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230508,EXP,,GB-AstraZeneca-2023A099226,ASTRAZENECA,,63.0,YR,,,Y,,,20230508,,MD,GB,,2023,Q2,Adult
222692012,22269201,137,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Depression,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230508,EXP,,GB-AstraZeneca-2023A099226,ASTRAZENECA,,63.0,YR,,,Y,,,20230508,,MD,GB,,2023,Q2,Adult
222692012,22269201,137,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Abdominal discomfort,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230508,EXP,,GB-AstraZeneca-2023A099226,ASTRAZENECA,,63.0,YR,,,Y,,,20230508,,MD,GB,,2023,Q2,Adult
222692012,22269201,137,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Steroid dependence,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230508,EXP,,GB-AstraZeneca-2023A099226,ASTRAZENECA,,63.0,YR,,,Y,,,20230508,,MD,GB,,2023,Q2,Adult
222692012,22269201,137,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Confusional state,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230508,EXP,,GB-AstraZeneca-2023A099226,ASTRAZENECA,,63.0,YR,,,Y,,,20230508,,MD,GB,,2023,Q2,Adult
222692012,22269201,137,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Cerebrovascular accident,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230508,EXP,,GB-AstraZeneca-2023A099226,ASTRAZENECA,,63.0,YR,,,Y,,,20230508,,MD,GB,,2023,Q2,Adult
222692012,22269201,137,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Inappropriate schedule of product administration,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230508,EXP,,GB-AstraZeneca-2023A099226,ASTRAZENECA,,63.0,YR,,,Y,,,20230508,,MD,GB,,2023,Q2,Adult
222692012,22269201,137,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Nightmare,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230508,EXP,,GB-AstraZeneca-2023A099226,ASTRAZENECA,,63.0,YR,,,Y,,,20230508,,MD,GB,,2023,Q2,Adult
222692012,22269201,137,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Eczema,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230508,EXP,,GB-AstraZeneca-2023A099226,ASTRAZENECA,,63.0,YR,,,Y,,,20230508,,MD,GB,,2023,Q2,Adult
222692012,22269201,137,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Tinnitus,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230508,EXP,,GB-AstraZeneca-2023A099226,ASTRAZENECA,,63.0,YR,,,Y,,,20230508,,MD,GB,,2023,Q2,Adult
222692012,22269201,137,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Palpitations,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230508,EXP,,GB-AstraZeneca-2023A099226,ASTRAZENECA,,63.0,YR,,,Y,,,20230508,,MD,GB,,2023,Q2,Adult
222692012,22269201,137,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Arthritis,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230508,EXP,,GB-AstraZeneca-2023A099226,ASTRAZENECA,,63.0,YR,,,Y,,,20230508,,MD,GB,,2023,Q2,Adult
222692012,22269201,137,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Drug ineffective,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230508,EXP,,GB-AstraZeneca-2023A099226,ASTRAZENECA,,63.0,YR,,,Y,,,20230508,,MD,GB,,2023,Q2,Adult
222692012,22269201,137,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Rhinitis,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230508,EXP,,GB-AstraZeneca-2023A099226,ASTRAZENECA,,63.0,YR,,,Y,,,20230508,,MD,GB,,2023,Q2,Adult
222692012,22269201,137,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Fatigue,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230508,EXP,,GB-AstraZeneca-2023A099226,ASTRAZENECA,,63.0,YR,,,Y,,,20230508,,MD,GB,,2023,Q2,Adult
222692012,22269201,137,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Loss of personal independence in daily activities,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230508,EXP,,GB-AstraZeneca-2023A099226,ASTRAZENECA,,63.0,YR,,,Y,,,20230508,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Somnolence,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Cerebrovascular accident,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Hypopnoea,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Arthritis,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Product use in unapproved indication,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Accidental overdose,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Loss of personal independence in daily activities,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Inappropriate schedule of product administration,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Bronchiectasis,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Stress,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Haematochezia,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Intentional product use issue,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Pain in extremity,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Deep vein thrombosis,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Fatigue,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Pyrexia,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Colitis ulcerative,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Dysgeusia,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Steroid dependence,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Impaired quality of life,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Systemic lupus erythematosus,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Swollen tongue,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Depression,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Cardiac murmur,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Eczema,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Rhinitis,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Headache,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Tinnitus,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Abdominal discomfort,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Nightmare,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Tinnitus,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Rash,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Vertigo,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Condition aggravated,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Burns second degree,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Pain,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Colitis ulcerative,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Off label use,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Loss of personal independence in daily activities,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Pulmonary embolism,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Gingival pain,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Adverse drug reaction,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Fatigue,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Tubulointerstitial nephritis,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Catarrh,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Weight decreased,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Frequent bowel movements,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Impaired work ability,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Rash,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Drug ineffective,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Parosmia,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Migraine,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Rectal haemorrhage,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Confusional state,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,COVID-19,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Medication error,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222692022,22269202,155,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Palpitations,,2023,Q2,2,F,20080101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098820,ASTRAZENECA,,40.0,YR,,M,Y,99.0,KG,20230509,,MD,GB,,2023,Q2,Adult
222694092,22269409,151,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Catarrh,,2023,Q2,2,F,20190101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098810,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230509,,MD,GB,,2023,Q2,Elderly
222694092,22269409,151,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Migraine,,2023,Q2,2,F,20190101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098810,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230509,,MD,GB,,2023,Q2,Elderly
222694092,22269409,151,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Bronchiectasis,,2023,Q2,2,F,20190101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098810,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230509,,MD,GB,,2023,Q2,Elderly
222694092,22269409,151,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Cardiac murmur,,2023,Q2,2,F,20190101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098810,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230509,,MD,GB,,2023,Q2,Elderly
222694092,22269409,151,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Headache,,2023,Q2,2,F,20190101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098810,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230509,,MD,GB,,2023,Q2,Elderly
222694092,22269409,151,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Somnolence,,2023,Q2,2,F,20190101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098810,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230509,,MD,GB,,2023,Q2,Elderly
222694092,22269409,151,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Abdominal discomfort,,2023,Q2,2,F,20190101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098810,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230509,,MD,GB,,2023,Q2,Elderly
222694092,22269409,151,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Weight decreased,,2023,Q2,2,F,20190101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098810,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230509,,MD,GB,,2023,Q2,Elderly
222694092,22269409,151,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Off label use,,2023,Q2,2,F,20190101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098810,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230509,,MD,GB,,2023,Q2,Elderly
222694092,22269409,151,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Drug ineffective,,2023,Q2,2,F,20190101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098810,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230509,,MD,GB,,2023,Q2,Elderly
222694092,22269409,151,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Accidental overdose,,2023,Q2,2,F,20190101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098810,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230509,,MD,GB,,2023,Q2,Elderly
222694092,22269409,151,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Pain in extremity,,2023,Q2,2,F,20190101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098810,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230509,,MD,GB,,2023,Q2,Elderly
222694092,22269409,151,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Stress,,2023,Q2,2,F,20190101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098810,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230509,,MD,GB,,2023,Q2,Elderly
222694092,22269409,151,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Steroid dependence,,2023,Q2,2,F,20190101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098810,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230509,,MD,GB,,2023,Q2,Elderly
222694092,22269409,151,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Swollen tongue,,2023,Q2,2,F,20190101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098810,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230509,,MD,GB,,2023,Q2,Elderly
222694092,22269409,151,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Colitis ulcerative,,2023,Q2,2,F,20190101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098810,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230509,,MD,GB,,2023,Q2,Elderly
222694092,22269409,151,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Product use in unapproved indication,,2023,Q2,2,F,20190101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098810,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230509,,MD,GB,,2023,Q2,Elderly
222694092,22269409,151,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Gingival pain,,2023,Q2,2,F,20190101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098810,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230509,,MD,GB,,2023,Q2,Elderly
222694092,22269409,151,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Adverse drug reaction,,2023,Q2,2,F,20190101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098810,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230509,,MD,GB,,2023,Q2,Elderly
222694092,22269409,151,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Condition aggravated,,2023,Q2,2,F,20190101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098810,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230509,,MD,GB,,2023,Q2,Elderly
222694092,22269409,151,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Nightmare,,2023,Q2,2,F,20190101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098810,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230509,,MD,GB,,2023,Q2,Elderly
222694092,22269409,151,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Rhinitis,,2023,Q2,2,F,20190101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098810,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230509,,MD,GB,,2023,Q2,Elderly
222694092,22269409,151,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,COVID-19,,2023,Q2,2,F,20190101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098810,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230509,,MD,GB,,2023,Q2,Elderly
222694092,22269409,151,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Impaired work ability,,2023,Q2,2,F,20190101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098810,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230509,,MD,GB,,2023,Q2,Elderly
222694092,22269409,151,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Frequent bowel movements,,2023,Q2,2,F,20190101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098810,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230509,,MD,GB,,2023,Q2,Elderly
222694092,22269409,151,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Pyrexia,,2023,Q2,2,F,20190101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098810,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230509,,MD,GB,,2023,Q2,Elderly
222694092,22269409,151,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Rectal haemorrhage,,2023,Q2,2,F,20190101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098810,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230509,,MD,GB,,2023,Q2,Elderly
222694092,22269409,151,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Fatigue,,2023,Q2,2,F,20190101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098810,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230509,,MD,GB,,2023,Q2,Elderly
222694092,22269409,151,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Rash,,2023,Q2,2,F,20190101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098810,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230509,,MD,GB,,2023,Q2,Elderly
222694092,22269409,151,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Haematochezia,,2023,Q2,2,F,20190101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098810,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230509,,MD,GB,,2023,Q2,Elderly
222694092,22269409,151,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Loss of personal independence in daily activities,,2023,Q2,2,F,20190101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098810,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230509,,MD,GB,,2023,Q2,Elderly
222694092,22269409,151,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Systemic lupus erythematosus,,2023,Q2,2,F,20190101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098810,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230509,,MD,GB,,2023,Q2,Elderly
222694092,22269409,151,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Medication error,,2023,Q2,2,F,20190101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098810,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230509,,MD,GB,,2023,Q2,Elderly
222694092,22269409,151,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Parosmia,,2023,Q2,2,F,20190101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098810,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230509,,MD,GB,,2023,Q2,Elderly
222694092,22269409,151,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Vertigo,,2023,Q2,2,F,20190101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098810,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230509,,MD,GB,,2023,Q2,Elderly
222694092,22269409,151,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Palpitations,,2023,Q2,2,F,20190101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098810,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230509,,MD,GB,,2023,Q2,Elderly
222694092,22269409,151,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Dysgeusia,,2023,Q2,2,F,20190101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098810,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230509,,MD,GB,,2023,Q2,Elderly
222694092,22269409,151,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Intentional product use issue,,2023,Q2,2,F,20190101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098810,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230509,,MD,GB,,2023,Q2,Elderly
222694092,22269409,151,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Confusional state,,2023,Q2,2,F,20190101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098810,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230509,,MD,GB,,2023,Q2,Elderly
222694092,22269409,151,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Tinnitus,,2023,Q2,2,F,20190101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098810,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230509,,MD,GB,,2023,Q2,Elderly
222694092,22269409,151,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Pain,,2023,Q2,2,F,20190101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098810,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230509,,MD,GB,,2023,Q2,Elderly
222694092,22269409,151,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Inappropriate schedule of product administration,,2023,Q2,2,F,20190101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098810,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230509,,MD,GB,,2023,Q2,Elderly
222694092,22269409,151,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Depression,,2023,Q2,2,F,20190101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098810,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230509,,MD,GB,,2023,Q2,Elderly
222694092,22269409,151,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Impaired quality of life,,2023,Q2,2,F,20190101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098810,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230509,,MD,GB,,2023,Q2,Elderly
222694092,22269409,151,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Arthritis,,2023,Q2,2,F,20190101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098810,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230509,,MD,GB,,2023,Q2,Elderly
222694092,22269409,151,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Eczema,,2023,Q2,2,F,20190101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098810,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230509,,MD,GB,,2023,Q2,Elderly
222694092,22269409,151,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Burns second degree,,2023,Q2,2,F,20190101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098810,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230509,,MD,GB,,2023,Q2,Elderly
222694092,22269409,151,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Deep vein thrombosis,,2023,Q2,2,F,20190101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098810,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230509,,MD,GB,,2023,Q2,Elderly
222694092,22269409,151,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Take one tablet once a day; ;,,,,,,,,,,,,2023,Q2,Hypopnoea,,2023,Q2,2,F,20190101.0,20230426.0,20230501,20230509,EXP,,GB-AstraZeneca-2023A098810,ASTRAZENECA,,86.0,YR,,M,Y,65.0,KG,20230509,,MD,GB,,2023,Q2,Elderly
222711112,22271111,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Myocardial ischaemia,,2023,Q2,2,F,20230418.0,20230504.0,20230501,20230510,EXP,,PL-AMGEN-POLCT2023068328,AMGEN,,64.0,YR,A,F,Y,102.0,KG,20230510,,MD,PL,PL,2023,Q2,Adult
222719802,22271980,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Serratia infection,,2023,Q2,2,F,20230416.0,20230515.0,20230502,20230525,EXP,,NZ-BEH-2023157821,CSL BEHRING,,53.0,YR,A,M,Y,142.0,KG,20230525,,MD,NZ,NZ,2023,Q2,Adult
222719802,22271980,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Incorrect drug administration rate,,2023,Q2,2,F,20230416.0,20230515.0,20230502,20230525,EXP,,NZ-BEH-2023157821,CSL BEHRING,,53.0,YR,A,M,Y,142.0,KG,20230525,,MD,NZ,NZ,2023,Q2,Adult
222719802,22271980,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Drug ineffective for unapproved indication,,2023,Q2,2,F,20230416.0,20230515.0,20230502,20230525,EXP,,NZ-BEH-2023157821,CSL BEHRING,,53.0,YR,A,M,Y,142.0,KG,20230525,,MD,NZ,NZ,2023,Q2,Adult
222719802,22271980,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,No adverse event,,2023,Q2,2,F,20230416.0,20230515.0,20230502,20230525,EXP,,NZ-BEH-2023157821,CSL BEHRING,,53.0,YR,A,M,Y,142.0,KG,20230525,,MD,NZ,NZ,2023,Q2,Adult
222719802,22271980,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Prescribed overdose,,2023,Q2,2,F,20230416.0,20230515.0,20230502,20230525,EXP,,NZ-BEH-2023157821,CSL BEHRING,,53.0,YR,A,M,Y,142.0,KG,20230525,,MD,NZ,NZ,2023,Q2,Adult
222719802,22271980,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Prescribed overdose,,2023,Q2,2,F,20230416.0,20230515.0,20230502,20230525,EXP,,NZ-BEH-2023157821,CSL BEHRING,,53.0,YR,A,M,Y,142.0,KG,20230525,,MD,NZ,NZ,2023,Q2,Adult
222719802,22271980,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Oliguria,,2023,Q2,2,F,20230416.0,20230515.0,20230502,20230525,EXP,,NZ-BEH-2023157821,CSL BEHRING,,53.0,YR,A,M,Y,142.0,KG,20230525,,MD,NZ,NZ,2023,Q2,Adult
222719802,22271980,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Off label use,,2023,Q2,2,F,20230416.0,20230515.0,20230502,20230525,EXP,,NZ-BEH-2023157821,CSL BEHRING,,53.0,YR,A,M,Y,142.0,KG,20230525,,MD,NZ,NZ,2023,Q2,Adult
222719802,22271980,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Device related sepsis,,2023,Q2,2,F,20230416.0,20230515.0,20230502,20230525,EXP,,NZ-BEH-2023157821,CSL BEHRING,,53.0,YR,A,M,Y,142.0,KG,20230525,,MD,NZ,NZ,2023,Q2,Adult
222719802,22271980,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Hyperkalaemia,,2023,Q2,2,F,20230416.0,20230515.0,20230502,20230525,EXP,,NZ-BEH-2023157821,CSL BEHRING,,53.0,YR,A,M,Y,142.0,KG,20230525,,MD,NZ,NZ,2023,Q2,Adult
222719802,22271980,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Acute kidney injury,,2023,Q2,2,F,20230416.0,20230515.0,20230502,20230525,EXP,,NZ-BEH-2023157821,CSL BEHRING,,53.0,YR,A,M,Y,142.0,KG,20230525,,MD,NZ,NZ,2023,Q2,Adult
222719802,22271980,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Incorrect drug administration rate,,2023,Q2,2,F,20230416.0,20230515.0,20230502,20230525,EXP,,NZ-BEH-2023157821,CSL BEHRING,,53.0,YR,A,M,Y,142.0,KG,20230525,,MD,NZ,NZ,2023,Q2,Adult
222719802,22271980,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Pyrexia,,2023,Q2,2,F,20230416.0,20230515.0,20230502,20230525,EXP,,NZ-BEH-2023157821,CSL BEHRING,,53.0,YR,A,M,Y,142.0,KG,20230525,,MD,NZ,NZ,2023,Q2,Adult
222719802,22271980,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Serratia infection,,2023,Q2,2,F,20230416.0,20230515.0,20230502,20230525,EXP,,NZ-BEH-2023157821,CSL BEHRING,,53.0,YR,A,M,Y,142.0,KG,20230525,,MD,NZ,NZ,2023,Q2,Adult
222719802,22271980,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Incorrect drug administration rate,,2023,Q2,2,F,20230416.0,20230515.0,20230502,20230525,EXP,,NZ-BEH-2023157821,CSL BEHRING,,53.0,YR,A,M,Y,142.0,KG,20230525,,MD,NZ,NZ,2023,Q2,Adult
222719802,22271980,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Drug ineffective for unapproved indication,,2023,Q2,2,F,20230416.0,20230515.0,20230502,20230525,EXP,,NZ-BEH-2023157821,CSL BEHRING,,53.0,YR,A,M,Y,142.0,KG,20230525,,MD,NZ,NZ,2023,Q2,Adult
222719802,22271980,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,No adverse event,,2023,Q2,2,F,20230416.0,20230515.0,20230502,20230525,EXP,,NZ-BEH-2023157821,CSL BEHRING,,53.0,YR,A,M,Y,142.0,KG,20230525,,MD,NZ,NZ,2023,Q2,Adult
222719802,22271980,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Prescribed overdose,,2023,Q2,2,F,20230416.0,20230515.0,20230502,20230525,EXP,,NZ-BEH-2023157821,CSL BEHRING,,53.0,YR,A,M,Y,142.0,KG,20230525,,MD,NZ,NZ,2023,Q2,Adult
222719802,22271980,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Prescribed overdose,,2023,Q2,2,F,20230416.0,20230515.0,20230502,20230525,EXP,,NZ-BEH-2023157821,CSL BEHRING,,53.0,YR,A,M,Y,142.0,KG,20230525,,MD,NZ,NZ,2023,Q2,Adult
222719802,22271980,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Oliguria,,2023,Q2,2,F,20230416.0,20230515.0,20230502,20230525,EXP,,NZ-BEH-2023157821,CSL BEHRING,,53.0,YR,A,M,Y,142.0,KG,20230525,,MD,NZ,NZ,2023,Q2,Adult
222719802,22271980,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Off label use,,2023,Q2,2,F,20230416.0,20230515.0,20230502,20230525,EXP,,NZ-BEH-2023157821,CSL BEHRING,,53.0,YR,A,M,Y,142.0,KG,20230525,,MD,NZ,NZ,2023,Q2,Adult
222719802,22271980,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Device related sepsis,,2023,Q2,2,F,20230416.0,20230515.0,20230502,20230525,EXP,,NZ-BEH-2023157821,CSL BEHRING,,53.0,YR,A,M,Y,142.0,KG,20230525,,MD,NZ,NZ,2023,Q2,Adult
222719802,22271980,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Hyperkalaemia,,2023,Q2,2,F,20230416.0,20230515.0,20230502,20230525,EXP,,NZ-BEH-2023157821,CSL BEHRING,,53.0,YR,A,M,Y,142.0,KG,20230525,,MD,NZ,NZ,2023,Q2,Adult
222719802,22271980,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Acute kidney injury,,2023,Q2,2,F,20230416.0,20230515.0,20230502,20230525,EXP,,NZ-BEH-2023157821,CSL BEHRING,,53.0,YR,A,M,Y,142.0,KG,20230525,,MD,NZ,NZ,2023,Q2,Adult
222719802,22271980,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Incorrect drug administration rate,,2023,Q2,2,F,20230416.0,20230515.0,20230502,20230525,EXP,,NZ-BEH-2023157821,CSL BEHRING,,53.0,YR,A,M,Y,142.0,KG,20230525,,MD,NZ,NZ,2023,Q2,Adult
222719802,22271980,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Pyrexia,,2023,Q2,2,F,20230416.0,20230515.0,20230502,20230525,EXP,,NZ-BEH-2023157821,CSL BEHRING,,53.0,YR,A,M,Y,142.0,KG,20230525,,MD,NZ,NZ,2023,Q2,Adult
222722731,22272273,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Nausea,,2023,Q2,1,I,,20220912.0,20230502,20230502,PER,,US-APOTEX-2022AP012922,APOTEX,"Ekanayake PS, Gerwer J, McCowen K. ALPELISIB - INDUCED HYPERGLYCEMIA. Acta Endocrinologica (Buc). 2022;18(1):115-117",44.0,YR,,F,Y,,,20230502,,MD,US,US,2023,Q2,Adult
222722731,22272273,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Vomiting,,2023,Q2,1,I,,20220912.0,20230502,20230502,PER,,US-APOTEX-2022AP012922,APOTEX,"Ekanayake PS, Gerwer J, McCowen K. ALPELISIB - INDUCED HYPERGLYCEMIA. Acta Endocrinologica (Buc). 2022;18(1):115-117",44.0,YR,,F,Y,,,20230502,,MD,US,US,2023,Q2,Adult
222722731,22272273,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Drug intolerance,,2023,Q2,1,I,,20220912.0,20230502,20230502,PER,,US-APOTEX-2022AP012922,APOTEX,"Ekanayake PS, Gerwer J, McCowen K. ALPELISIB - INDUCED HYPERGLYCEMIA. Acta Endocrinologica (Buc). 2022;18(1):115-117",44.0,YR,,F,Y,,,20230502,,MD,US,US,2023,Q2,Adult
222759751,22275975,8,C,LINAGLIPTIN/EMPAGLIFLOZIN,,2,Oral,,,,,,Unknown,,,25.0,MG,,QD,2023,Q2,Dark circles under eyes,,2023,Q2,1,I,20230315.0,20230412.0,20230502,20230502,PER,,US-AstraZeneca-2023A086285,ASTRAZENECA,,66.0,YR,,F,Y,89.8,KG,20230502,,CN,US,,2023,Q2,Elderly
222771501,22277150,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Rhabdomyolysis,,2023,Q2,1,I,,20230502.0,20230503,20230503,EXP,,"CO-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-235084",BOEHRINGER INGELHEIM,,80.0,YR,E,M,Y,,,20230503,,HP,CO,CO,2023,Q2,Elderly
222771501,22277150,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Orthostatic hypotension,,2023,Q2,1,I,,20230502.0,20230503,20230503,EXP,,"CO-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-235084",BOEHRINGER INGELHEIM,,80.0,YR,E,M,Y,,,20230503,,HP,CO,CO,2023,Q2,Elderly
222771501,22277150,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Off label use,,2023,Q2,1,I,,20230502.0,20230503,20230503,EXP,,"CO-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-235084",BOEHRINGER INGELHEIM,,80.0,YR,E,M,Y,,,20230503,,HP,CO,CO,2023,Q2,Elderly
222772821,22277282,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Orthostatic hypotension,,2023,Q2,1,I,,20230502.0,20230503,20230503,EXP,,"CO-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-235082",BOEHRINGER INGELHEIM,,80.0,YR,E,M,Y,,,20230503,,HP,CO,CO,2023,Q2,Elderly
222772821,22277282,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Off label use,,2023,Q2,1,I,,20230502.0,20230503,20230503,EXP,,"CO-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-235082",BOEHRINGER INGELHEIM,,80.0,YR,E,M,Y,,,20230503,,HP,CO,CO,2023,Q2,Elderly
222772821,22277282,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Rhabdomyolysis,,2023,Q2,1,I,,20230502.0,20230503,20230503,EXP,,"CO-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-235082",BOEHRINGER INGELHEIM,,80.0,YR,E,M,Y,,,20230503,,HP,CO,CO,2023,Q2,Elderly
222775171,22277517,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Orthostatic hypotension,,2023,Q2,1,I,,20230502.0,20230503,20230503,EXP,,"CO-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-235085",BOEHRINGER INGELHEIM,,80.0,YR,E,M,Y,,,20230503,,HP,CO,CO,2023,Q2,Elderly
222775171,22277517,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Rhabdomyolysis,,2023,Q2,1,I,,20230502.0,20230503,20230503,EXP,,"CO-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-235085",BOEHRINGER INGELHEIM,,80.0,YR,E,M,Y,,,20230503,,HP,CO,CO,2023,Q2,Elderly
222775171,22277517,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Off label use,,2023,Q2,1,I,,20230502.0,20230503,20230503,EXP,,"CO-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-235085",BOEHRINGER INGELHEIM,,80.0,YR,E,M,Y,,,20230503,,HP,CO,CO,2023,Q2,Elderly
222780321,22278032,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Daily",,,U,,,,,10.0,MG,,,2023,Q2,Drug ineffective,,2023,Q2,1,I,,20230419.0,20230503,20230503,EXP,,AU-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-386511,RANBAXY,"Can AT, Hermens DF, Lagopoulos J. A unique case of very low-dose subcutaneous ketamine use: Maintenance option of ketamine for treatment-resistant depression. Clin Case Rep. 2022;10(12):e6675",42.0,YR,,M,Y,,,20230503,,HP,AU,AU,2023,Q2,Adult
222784801,22278480,14,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2023,Q2,Drug ineffective,,2023,Q2,1,I,,20230428.0,20230503,20230503,EXP,,GB-MYLANLABS-2023M1046164,MYLAN,"Dyson, S, Patel P, Millington G. Psychiatric associations in bullous pemphigoid: review and case report. British Journal of Dermatology. 2022;187-227",59.0,YR,,F,Y,,,20230503,,MD,GB,GB,2023,Q2,Adult
222784801,22278480,14,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2023,Q2,Pemphigoid,,2023,Q2,1,I,,20230428.0,20230503,20230503,EXP,,GB-MYLANLABS-2023M1046164,MYLAN,"Dyson, S, Patel P, Millington G. Psychiatric associations in bullous pemphigoid: review and case report. British Journal of Dermatology. 2022;187-227",59.0,YR,,F,Y,,,20230503,,MD,GB,GB,2023,Q2,Adult
222815781,22281578,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 mg / 1000 mg(1 tablet / qd),,,,,Unknown,,,,,,,2023,Q2,Loss of consciousness,,2023,Q2,1,I,20220801.0,20230424.0,20230504,20230504,EXP,,CO-NOVOPROD-1037662,NOVO NORDISK,,68.0,YR,,F,Y,53.0,KG,20230504,,CN,CO,CO,2023,Q2,Elderly
222815781,22281578,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 mg / 1000 mg(1 tablet / qd),,,,,Unknown,,,,,,,2023,Q2,Malnutrition,,2023,Q2,1,I,20220801.0,20230424.0,20230504,20230504,EXP,,CO-NOVOPROD-1037662,NOVO NORDISK,,68.0,YR,,F,Y,53.0,KG,20230504,,CN,CO,CO,2023,Q2,Elderly
222815781,22281578,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 mg / 1000 mg(1 tablet / qd),,,,,Unknown,,,,,,,2023,Q2,Discouragement,,2023,Q2,1,I,20220801.0,20230424.0,20230504,20230504,EXP,,CO-NOVOPROD-1037662,NOVO NORDISK,,68.0,YR,,F,Y,53.0,KG,20230504,,CN,CO,CO,2023,Q2,Elderly
222815781,22281578,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 mg / 1000 mg(1 tablet / qd),,,,,Unknown,,,,,,,2023,Q2,Dehydration,,2023,Q2,1,I,20220801.0,20230424.0,20230504,20230504,EXP,,CO-NOVOPROD-1037662,NOVO NORDISK,,68.0,YR,,F,Y,53.0,KG,20230504,,CN,CO,CO,2023,Q2,Elderly
222815781,22281578,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 mg / 1000 mg(1 tablet / qd),,,,,Unknown,,,,,,,2023,Q2,Weight decreased,,2023,Q2,1,I,20220801.0,20230424.0,20230504,20230504,EXP,,CO-NOVOPROD-1037662,NOVO NORDISK,,68.0,YR,,F,Y,53.0,KG,20230504,,CN,CO,CO,2023,Q2,Elderly
222815781,22281578,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 mg / 1000 mg(1 tablet / qd),,,,,Unknown,,,,,,,2023,Q2,Gastritis,,2023,Q2,1,I,20220801.0,20230424.0,20230504,20230504,EXP,,CO-NOVOPROD-1037662,NOVO NORDISK,,68.0,YR,,F,Y,53.0,KG,20230504,,CN,CO,CO,2023,Q2,Elderly
222815821,22281582,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Trigger finger,,2023,Q2,1,I,,20230501.0,20230504,20230504,EXP,,CA-ABBVIE-4750568,ABBVIE,,57.0,YR,,F,Y,,,20230504,,HP,CA,CA,2023,Q2,Adult
222815821,22281582,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Psoriatic arthropathy,,2023,Q2,1,I,,20230501.0,20230504,20230504,EXP,,CA-ABBVIE-4750568,ABBVIE,,57.0,YR,,F,Y,,,20230504,,HP,CA,CA,2023,Q2,Adult
222815821,22281582,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Prostatic specific antigen abnormal,,2023,Q2,1,I,,20230501.0,20230504,20230504,EXP,,CA-ABBVIE-4750568,ABBVIE,,57.0,YR,,F,Y,,,20230504,,HP,CA,CA,2023,Q2,Adult
222815821,22281582,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Drug ineffective,,2023,Q2,1,I,,20230501.0,20230504,20230504,EXP,,CA-ABBVIE-4750568,ABBVIE,,57.0,YR,,F,Y,,,20230504,,HP,CA,CA,2023,Q2,Adult
222815821,22281582,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Rheumatoid arthritis,,2023,Q2,1,I,,20230501.0,20230504,20230504,EXP,,CA-ABBVIE-4750568,ABBVIE,,57.0,YR,,F,Y,,,20230504,,HP,CA,CA,2023,Q2,Adult
222815821,22281582,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Respiratory sinus arrhythmia magnitude,,2023,Q2,1,I,,20230501.0,20230504,20230504,EXP,,CA-ABBVIE-4750568,ABBVIE,,57.0,YR,,F,Y,,,20230504,,HP,CA,CA,2023,Q2,Adult
222815821,22281582,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Gastrooesophageal reflux disease,,2023,Q2,1,I,,20230501.0,20230504,20230504,EXP,,CA-ABBVIE-4750568,ABBVIE,,57.0,YR,,F,Y,,,20230504,,HP,CA,CA,2023,Q2,Adult
222815821,22281582,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Hypertension,,2023,Q2,1,I,,20230501.0,20230504,20230504,EXP,,CA-ABBVIE-4750568,ABBVIE,,57.0,YR,,F,Y,,,20230504,,HP,CA,CA,2023,Q2,Adult
222815821,22281582,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Drug ineffective,,2023,Q2,1,I,,20230501.0,20230504,20230504,EXP,,CA-ABBVIE-4750568,ABBVIE,,57.0,YR,,F,Y,,,20230504,,HP,CA,CA,2023,Q2,Adult
222815821,22281582,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Diabetes mellitus,,2023,Q2,1,I,,20230501.0,20230504,20230504,EXP,,CA-ABBVIE-4750568,ABBVIE,,57.0,YR,,F,Y,,,20230504,,HP,CA,CA,2023,Q2,Adult
222815821,22281582,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Pulmonary toxicity,,2023,Q2,1,I,,20230501.0,20230504,20230504,EXP,,CA-ABBVIE-4750568,ABBVIE,,57.0,YR,,F,Y,,,20230504,,HP,CA,CA,2023,Q2,Adult
222815821,22281582,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Hysterectomy,,2023,Q2,1,I,,20230501.0,20230504,20230504,EXP,,CA-ABBVIE-4750568,ABBVIE,,57.0,YR,,F,Y,,,20230504,,HP,CA,CA,2023,Q2,Adult
222815821,22281582,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Umbilical hernia,,2023,Q2,1,I,,20230501.0,20230504,20230504,EXP,,CA-ABBVIE-4750568,ABBVIE,,57.0,YR,,F,Y,,,20230504,,HP,CA,CA,2023,Q2,Adult
222815821,22281582,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Osteoarthritis,,2023,Q2,1,I,,20230501.0,20230504,20230504,EXP,,CA-ABBVIE-4750568,ABBVIE,,57.0,YR,,F,Y,,,20230504,,HP,CA,CA,2023,Q2,Adult
222854861,22285486,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Brain injury,,2023,Q2,1,I,,20230502.0,20230504,20230504,EXP,,"CZ-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-235241",BOEHRINGER INGELHEIM,"Sitina M, Lukes M, Sramek V. Empagliflozin-associated postoperative mixed metabolic acidosis. Case report and review of pathogenesis. BMC Endocrine Disorders. 2023;23:1: 81-doi:10.1186/s12902-023-01339-w.",61.0,YR,A,M,Y,,,20230504,,HP,CZ,CZ,2023,Q2,Adult
222854861,22285486,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Acidosis hyperchloraemic,,2023,Q2,1,I,,20230502.0,20230504,20230504,EXP,,"CZ-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-235241",BOEHRINGER INGELHEIM,"Sitina M, Lukes M, Sramek V. Empagliflozin-associated postoperative mixed metabolic acidosis. Case report and review of pathogenesis. BMC Endocrine Disorders. 2023;23:1: 81-doi:10.1186/s12902-023-01339-w.",61.0,YR,A,M,Y,,,20230504,,HP,CZ,CZ,2023,Q2,Adult
222854861,22285486,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Anuria,,2023,Q2,1,I,,20230502.0,20230504,20230504,EXP,,"CZ-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-235241",BOEHRINGER INGELHEIM,"Sitina M, Lukes M, Sramek V. Empagliflozin-associated postoperative mixed metabolic acidosis. Case report and review of pathogenesis. BMC Endocrine Disorders. 2023;23:1: 81-doi:10.1186/s12902-023-01339-w.",61.0,YR,A,M,Y,,,20230504,,HP,CZ,CZ,2023,Q2,Adult
222854861,22285486,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Ventricular fibrillation,,2023,Q2,1,I,,20230502.0,20230504,20230504,EXP,,"CZ-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-235241",BOEHRINGER INGELHEIM,"Sitina M, Lukes M, Sramek V. Empagliflozin-associated postoperative mixed metabolic acidosis. Case report and review of pathogenesis. BMC Endocrine Disorders. 2023;23:1: 81-doi:10.1186/s12902-023-01339-w.",61.0,YR,A,M,Y,,,20230504,,HP,CZ,CZ,2023,Q2,Adult
222854861,22285486,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Coronary artery stenosis,,2023,Q2,1,I,,20230502.0,20230504,20230504,EXP,,"CZ-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-235241",BOEHRINGER INGELHEIM,"Sitina M, Lukes M, Sramek V. Empagliflozin-associated postoperative mixed metabolic acidosis. Case report and review of pathogenesis. BMC Endocrine Disorders. 2023;23:1: 81-doi:10.1186/s12902-023-01339-w.",61.0,YR,A,M,Y,,,20230504,,HP,CZ,CZ,2023,Q2,Adult
222854861,22285486,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Lactic acidosis,,2023,Q2,1,I,,20230502.0,20230504,20230504,EXP,,"CZ-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-235241",BOEHRINGER INGELHEIM,"Sitina M, Lukes M, Sramek V. Empagliflozin-associated postoperative mixed metabolic acidosis. Case report and review of pathogenesis. BMC Endocrine Disorders. 2023;23:1: 81-doi:10.1186/s12902-023-01339-w.",61.0,YR,A,M,Y,,,20230504,,HP,CZ,CZ,2023,Q2,Adult
222854861,22285486,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Cardiac arrest,,2023,Q2,1,I,,20230502.0,20230504,20230504,EXP,,"CZ-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-235241",BOEHRINGER INGELHEIM,"Sitina M, Lukes M, Sramek V. Empagliflozin-associated postoperative mixed metabolic acidosis. Case report and review of pathogenesis. BMC Endocrine Disorders. 2023;23:1: 81-doi:10.1186/s12902-023-01339-w.",61.0,YR,A,M,Y,,,20230504,,HP,CZ,CZ,2023,Q2,Adult
222854861,22285486,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Circulatory collapse,,2023,Q2,1,I,,20230502.0,20230504,20230504,EXP,,"CZ-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-235241",BOEHRINGER INGELHEIM,"Sitina M, Lukes M, Sramek V. Empagliflozin-associated postoperative mixed metabolic acidosis. Case report and review of pathogenesis. BMC Endocrine Disorders. 2023;23:1: 81-doi:10.1186/s12902-023-01339-w.",61.0,YR,A,M,Y,,,20230504,,HP,CZ,CZ,2023,Q2,Adult
222854861,22285486,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Metabolic acidosis,,2023,Q2,1,I,,20230502.0,20230504,20230504,EXP,,"CZ-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-235241",BOEHRINGER INGELHEIM,"Sitina M, Lukes M, Sramek V. Empagliflozin-associated postoperative mixed metabolic acidosis. Case report and review of pathogenesis. BMC Endocrine Disorders. 2023;23:1: 81-doi:10.1186/s12902-023-01339-w.",61.0,YR,A,M,Y,,,20230504,,HP,CZ,CZ,2023,Q2,Adult
222854861,22285486,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Acute myocardial infarction,,2023,Q2,1,I,,20230502.0,20230504,20230504,EXP,,"CZ-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-235241",BOEHRINGER INGELHEIM,"Sitina M, Lukes M, Sramek V. Empagliflozin-associated postoperative mixed metabolic acidosis. Case report and review of pathogenesis. BMC Endocrine Disorders. 2023;23:1: 81-doi:10.1186/s12902-023-01339-w.",61.0,YR,A,M,Y,,,20230504,,HP,CZ,CZ,2023,Q2,Adult
222854861,22285486,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Ketoacidosis,,2023,Q2,1,I,,20230502.0,20230504,20230504,EXP,,"CZ-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-235241",BOEHRINGER INGELHEIM,"Sitina M, Lukes M, Sramek V. Empagliflozin-associated postoperative mixed metabolic acidosis. Case report and review of pathogenesis. BMC Endocrine Disorders. 2023;23:1: 81-doi:10.1186/s12902-023-01339-w.",61.0,YR,A,M,Y,,,20230504,,HP,CZ,CZ,2023,Q2,Adult
222878121,22287812,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Cardiac failure,,2023,Q2,1,I,,20230427.0,20230505,20230505,EXP,,AU-AstraZeneca-2023A098557,ASTRAZENECA,,57.0,YR,,M,Y,,,20230505,,MD,AU,,2023,Q2,Adult
222878121,22287812,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Glossitis,,2023,Q2,1,I,,20230427.0,20230505,20230505,EXP,,AU-AstraZeneca-2023A098557,ASTRAZENECA,,57.0,YR,,M,Y,,,20230505,,MD,AU,,2023,Q2,Adult
222878121,22287812,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Dysphagia,,2023,Q2,1,I,,20230427.0,20230505,20230505,EXP,,AU-AstraZeneca-2023A098557,ASTRAZENECA,,57.0,YR,,M,Y,,,20230505,,MD,AU,,2023,Q2,Adult
222878121,22287812,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Angioedema,,2023,Q2,1,I,,20230427.0,20230505,20230505,EXP,,AU-AstraZeneca-2023A098557,ASTRAZENECA,,57.0,YR,,M,Y,,,20230505,,MD,AU,,2023,Q2,Adult
222878121,22287812,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Swollen tongue,,2023,Q2,1,I,,20230427.0,20230505,20230505,EXP,,AU-AstraZeneca-2023A098557,ASTRAZENECA,,57.0,YR,,M,Y,,,20230505,,MD,AU,,2023,Q2,Adult
222878121,22287812,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Taste disorder,,2023,Q2,1,I,,20230427.0,20230505,20230505,EXP,,AU-AstraZeneca-2023A098557,ASTRAZENECA,,57.0,YR,,M,Y,,,20230505,,MD,AU,,2023,Q2,Adult
222878121,22287812,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Sepsis,,2023,Q2,1,I,,20230427.0,20230505,20230505,EXP,,AU-AstraZeneca-2023A098557,ASTRAZENECA,,57.0,YR,,M,Y,,,20230505,,MD,AU,,2023,Q2,Adult
222886991,22288699,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK, qd",,,,,,,,,,,QD,2023,Q2,Tinnitus,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-MHRA-TPP16316266C5588118YC1680529406147,GB-TAKEDA-2023TUS043869,TAKEDA,,75.0,YR,,M,Y,85.0,KG,20230505,,LW,GB,GB,2023,Q2,Elderly
222886991,22288699,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK, qd",,,,,,,,,,,QD,2023,Q2,Condition aggravated,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-MHRA-TPP16316266C5588118YC1680529406147,GB-TAKEDA-2023TUS043869,TAKEDA,,75.0,YR,,M,Y,85.0,KG,20230505,,LW,GB,GB,2023,Q2,Elderly
222886991,22288699,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK, qd",,,,,,,,,,,QD,2023,Q2,Confusional state,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-MHRA-TPP16316266C5588118YC1680529406147,GB-TAKEDA-2023TUS043869,TAKEDA,,75.0,YR,,M,Y,85.0,KG,20230505,,LW,GB,GB,2023,Q2,Elderly
222886991,22288699,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK, qd",,,,,,,,,,,QD,2023,Q2,Loss of personal independence in daily activities,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-MHRA-TPP16316266C5588118YC1680529406147,GB-TAKEDA-2023TUS043869,TAKEDA,,75.0,YR,,M,Y,85.0,KG,20230505,,LW,GB,GB,2023,Q2,Elderly
222886991,22288699,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK, qd",,,,,,,,,,,QD,2023,Q2,Cerebrovascular accident,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-MHRA-TPP16316266C5588118YC1680529406147,GB-TAKEDA-2023TUS043869,TAKEDA,,75.0,YR,,M,Y,85.0,KG,20230505,,LW,GB,GB,2023,Q2,Elderly
222886991,22288699,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK, qd",,,,,,,,,,,QD,2023,Q2,Tubulointerstitial nephritis,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-MHRA-TPP16316266C5588118YC1680529406147,GB-TAKEDA-2023TUS043869,TAKEDA,,75.0,YR,,M,Y,85.0,KG,20230505,,LW,GB,GB,2023,Q2,Elderly
222886991,22288699,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK, qd",,,,,,,,,,,QD,2023,Q2,Migraine,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-MHRA-TPP16316266C5588118YC1680529406147,GB-TAKEDA-2023TUS043869,TAKEDA,,75.0,YR,,M,Y,85.0,KG,20230505,,LW,GB,GB,2023,Q2,Elderly
222886991,22288699,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK, qd",,,,,,,,,,,QD,2023,Q2,Rectal haemorrhage,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-MHRA-TPP16316266C5588118YC1680529406147,GB-TAKEDA-2023TUS043869,TAKEDA,,75.0,YR,,M,Y,85.0,KG,20230505,,LW,GB,GB,2023,Q2,Elderly
222886991,22288699,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK, qd",,,,,,,,,,,QD,2023,Q2,Pain,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-MHRA-TPP16316266C5588118YC1680529406147,GB-TAKEDA-2023TUS043869,TAKEDA,,75.0,YR,,M,Y,85.0,KG,20230505,,LW,GB,GB,2023,Q2,Elderly
222886991,22288699,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK, qd",,,,,,,,,,,QD,2023,Q2,Pulmonary embolism,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-MHRA-TPP16316266C5588118YC1680529406147,GB-TAKEDA-2023TUS043869,TAKEDA,,75.0,YR,,M,Y,85.0,KG,20230505,,LW,GB,GB,2023,Q2,Elderly
222886991,22288699,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK, qd",,,,,,,,,,,QD,2023,Q2,Impaired quality of life,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-MHRA-TPP16316266C5588118YC1680529406147,GB-TAKEDA-2023TUS043869,TAKEDA,,75.0,YR,,M,Y,85.0,KG,20230505,,LW,GB,GB,2023,Q2,Elderly
222886991,22288699,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK, qd",,,,,,,,,,,QD,2023,Q2,Adverse drug reaction,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-MHRA-TPP16316266C5588118YC1680529406147,GB-TAKEDA-2023TUS043869,TAKEDA,,75.0,YR,,M,Y,85.0,KG,20230505,,LW,GB,GB,2023,Q2,Elderly
222886991,22288699,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK, qd",,,,,,,,,,,QD,2023,Q2,Drug ineffective,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-MHRA-TPP16316266C5588118YC1680529406147,GB-TAKEDA-2023TUS043869,TAKEDA,,75.0,YR,,M,Y,85.0,KG,20230505,,LW,GB,GB,2023,Q2,Elderly
222886991,22288699,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK, qd",,,,,,,,,,,QD,2023,Q2,Intentional product use issue,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-MHRA-TPP16316266C5588118YC1680529406147,GB-TAKEDA-2023TUS043869,TAKEDA,,75.0,YR,,M,Y,85.0,KG,20230505,,LW,GB,GB,2023,Q2,Elderly
222886991,22288699,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK, qd",,,,,,,,,,,QD,2023,Q2,Arthritis,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-MHRA-TPP16316266C5588118YC1680529406147,GB-TAKEDA-2023TUS043869,TAKEDA,,75.0,YR,,M,Y,85.0,KG,20230505,,LW,GB,GB,2023,Q2,Elderly
222886991,22288699,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK, qd",,,,,,,,,,,QD,2023,Q2,Off label use,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-MHRA-TPP16316266C5588118YC1680529406147,GB-TAKEDA-2023TUS043869,TAKEDA,,75.0,YR,,M,Y,85.0,KG,20230505,,LW,GB,GB,2023,Q2,Elderly
222886991,22288699,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK, qd",,,,,,,,,,,QD,2023,Q2,Dysgeusia,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-MHRA-TPP16316266C5588118YC1680529406147,GB-TAKEDA-2023TUS043869,TAKEDA,,75.0,YR,,M,Y,85.0,KG,20230505,,LW,GB,GB,2023,Q2,Elderly
222886991,22288699,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK, qd",,,,,,,,,,,QD,2023,Q2,Product use in unapproved indication,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-MHRA-TPP16316266C5588118YC1680529406147,GB-TAKEDA-2023TUS043869,TAKEDA,,75.0,YR,,M,Y,85.0,KG,20230505,,LW,GB,GB,2023,Q2,Elderly
222886991,22288699,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK, qd",,,,,,,,,,,QD,2023,Q2,Nightmare,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-MHRA-TPP16316266C5588118YC1680529406147,GB-TAKEDA-2023TUS043869,TAKEDA,,75.0,YR,,M,Y,85.0,KG,20230505,,LW,GB,GB,2023,Q2,Elderly
222886991,22288699,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK, qd",,,,,,,,,,,QD,2023,Q2,Parosmia,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-MHRA-TPP16316266C5588118YC1680529406147,GB-TAKEDA-2023TUS043869,TAKEDA,,75.0,YR,,M,Y,85.0,KG,20230505,,LW,GB,GB,2023,Q2,Elderly
222886991,22288699,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK, qd",,,,,,,,,,,QD,2023,Q2,Weight decreased,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-MHRA-TPP16316266C5588118YC1680529406147,GB-TAKEDA-2023TUS043869,TAKEDA,,75.0,YR,,M,Y,85.0,KG,20230505,,LW,GB,GB,2023,Q2,Elderly
222886991,22288699,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK, qd",,,,,,,,,,,QD,2023,Q2,Hypopnoea,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-MHRA-TPP16316266C5588118YC1680529406147,GB-TAKEDA-2023TUS043869,TAKEDA,,75.0,YR,,M,Y,85.0,KG,20230505,,LW,GB,GB,2023,Q2,Elderly
222886991,22288699,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK, qd",,,,,,,,,,,QD,2023,Q2,Eczema,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-MHRA-TPP16316266C5588118YC1680529406147,GB-TAKEDA-2023TUS043869,TAKEDA,,75.0,YR,,M,Y,85.0,KG,20230505,,LW,GB,GB,2023,Q2,Elderly
222886991,22288699,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK, qd",,,,,,,,,,,QD,2023,Q2,Gingival pain,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-MHRA-TPP16316266C5588118YC1680529406147,GB-TAKEDA-2023TUS043869,TAKEDA,,75.0,YR,,M,Y,85.0,KG,20230505,,LW,GB,GB,2023,Q2,Elderly
222886991,22288699,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK, qd",,,,,,,,,,,QD,2023,Q2,Fatigue,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-MHRA-TPP16316266C5588118YC1680529406147,GB-TAKEDA-2023TUS043869,TAKEDA,,75.0,YR,,M,Y,85.0,KG,20230505,,LW,GB,GB,2023,Q2,Elderly
222886991,22288699,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK, qd",,,,,,,,,,,QD,2023,Q2,Somnolence,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-MHRA-TPP16316266C5588118YC1680529406147,GB-TAKEDA-2023TUS043869,TAKEDA,,75.0,YR,,M,Y,85.0,KG,20230505,,LW,GB,GB,2023,Q2,Elderly
222886991,22288699,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK, qd",,,,,,,,,,,QD,2023,Q2,Rash,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-MHRA-TPP16316266C5588118YC1680529406147,GB-TAKEDA-2023TUS043869,TAKEDA,,75.0,YR,,M,Y,85.0,KG,20230505,,LW,GB,GB,2023,Q2,Elderly
222886991,22288699,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK, qd",,,,,,,,,,,QD,2023,Q2,Systemic lupus erythematosus,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-MHRA-TPP16316266C5588118YC1680529406147,GB-TAKEDA-2023TUS043869,TAKEDA,,75.0,YR,,M,Y,85.0,KG,20230505,,LW,GB,GB,2023,Q2,Elderly
222886991,22288699,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK, qd",,,,,,,,,,,QD,2023,Q2,Headache,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-MHRA-TPP16316266C5588118YC1680529406147,GB-TAKEDA-2023TUS043869,TAKEDA,,75.0,YR,,M,Y,85.0,KG,20230505,,LW,GB,GB,2023,Q2,Elderly
222886991,22288699,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK, qd",,,,,,,,,,,QD,2023,Q2,Inappropriate schedule of product administration,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-MHRA-TPP16316266C5588118YC1680529406147,GB-TAKEDA-2023TUS043869,TAKEDA,,75.0,YR,,M,Y,85.0,KG,20230505,,LW,GB,GB,2023,Q2,Elderly
222886991,22288699,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK, qd",,,,,,,,,,,QD,2023,Q2,Frequent bowel movements,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-MHRA-TPP16316266C5588118YC1680529406147,GB-TAKEDA-2023TUS043869,TAKEDA,,75.0,YR,,M,Y,85.0,KG,20230505,,LW,GB,GB,2023,Q2,Elderly
222886991,22288699,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK, qd",,,,,,,,,,,QD,2023,Q2,Colitis ulcerative,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-MHRA-TPP16316266C5588118YC1680529406147,GB-TAKEDA-2023TUS043869,TAKEDA,,75.0,YR,,M,Y,85.0,KG,20230505,,LW,GB,GB,2023,Q2,Elderly
222886991,22288699,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK, qd",,,,,,,,,,,QD,2023,Q2,Abdominal discomfort,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-MHRA-TPP16316266C5588118YC1680529406147,GB-TAKEDA-2023TUS043869,TAKEDA,,75.0,YR,,M,Y,85.0,KG,20230505,,LW,GB,GB,2023,Q2,Elderly
222886991,22288699,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK, qd",,,,,,,,,,,QD,2023,Q2,Vertigo,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-MHRA-TPP16316266C5588118YC1680529406147,GB-TAKEDA-2023TUS043869,TAKEDA,,75.0,YR,,M,Y,85.0,KG,20230505,,LW,GB,GB,2023,Q2,Elderly
222886991,22288699,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK, qd",,,,,,,,,,,QD,2023,Q2,Impaired work ability,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-MHRA-TPP16316266C5588118YC1680529406147,GB-TAKEDA-2023TUS043869,TAKEDA,,75.0,YR,,M,Y,85.0,KG,20230505,,LW,GB,GB,2023,Q2,Elderly
222886991,22288699,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK, qd",,,,,,,,,,,QD,2023,Q2,Accidental overdose,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-MHRA-TPP16316266C5588118YC1680529406147,GB-TAKEDA-2023TUS043869,TAKEDA,,75.0,YR,,M,Y,85.0,KG,20230505,,LW,GB,GB,2023,Q2,Elderly
222886991,22288699,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK, qd",,,,,,,,,,,QD,2023,Q2,Bronchiectasis,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-MHRA-TPP16316266C5588118YC1680529406147,GB-TAKEDA-2023TUS043869,TAKEDA,,75.0,YR,,M,Y,85.0,KG,20230505,,LW,GB,GB,2023,Q2,Elderly
222886991,22288699,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK, qd",,,,,,,,,,,QD,2023,Q2,Deep vein thrombosis,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-MHRA-TPP16316266C5588118YC1680529406147,GB-TAKEDA-2023TUS043869,TAKEDA,,75.0,YR,,M,Y,85.0,KG,20230505,,LW,GB,GB,2023,Q2,Elderly
222886991,22288699,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK, qd",,,,,,,,,,,QD,2023,Q2,Pain in extremity,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-MHRA-TPP16316266C5588118YC1680529406147,GB-TAKEDA-2023TUS043869,TAKEDA,,75.0,YR,,M,Y,85.0,KG,20230505,,LW,GB,GB,2023,Q2,Elderly
222886991,22288699,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK, qd",,,,,,,,,,,QD,2023,Q2,Cardiac murmur,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-MHRA-TPP16316266C5588118YC1680529406147,GB-TAKEDA-2023TUS043869,TAKEDA,,75.0,YR,,M,Y,85.0,KG,20230505,,LW,GB,GB,2023,Q2,Elderly
222886991,22288699,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK, qd",,,,,,,,,,,QD,2023,Q2,Swollen tongue,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-MHRA-TPP16316266C5588118YC1680529406147,GB-TAKEDA-2023TUS043869,TAKEDA,,75.0,YR,,M,Y,85.0,KG,20230505,,LW,GB,GB,2023,Q2,Elderly
222886991,22288699,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK, qd",,,,,,,,,,,QD,2023,Q2,Medication error,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-MHRA-TPP16316266C5588118YC1680529406147,GB-TAKEDA-2023TUS043869,TAKEDA,,75.0,YR,,M,Y,85.0,KG,20230505,,LW,GB,GB,2023,Q2,Elderly
222886991,22288699,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK, qd",,,,,,,,,,,QD,2023,Q2,Depression,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-MHRA-TPP16316266C5588118YC1680529406147,GB-TAKEDA-2023TUS043869,TAKEDA,,75.0,YR,,M,Y,85.0,KG,20230505,,LW,GB,GB,2023,Q2,Elderly
222886991,22288699,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK, qd",,,,,,,,,,,QD,2023,Q2,Rhinitis,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-MHRA-TPP16316266C5588118YC1680529406147,GB-TAKEDA-2023TUS043869,TAKEDA,,75.0,YR,,M,Y,85.0,KG,20230505,,LW,GB,GB,2023,Q2,Elderly
222886991,22288699,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK, qd",,,,,,,,,,,QD,2023,Q2,Haematochezia,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-MHRA-TPP16316266C5588118YC1680529406147,GB-TAKEDA-2023TUS043869,TAKEDA,,75.0,YR,,M,Y,85.0,KG,20230505,,LW,GB,GB,2023,Q2,Elderly
222886991,22288699,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK, qd",,,,,,,,,,,QD,2023,Q2,Palpitations,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-MHRA-TPP16316266C5588118YC1680529406147,GB-TAKEDA-2023TUS043869,TAKEDA,,75.0,YR,,M,Y,85.0,KG,20230505,,LW,GB,GB,2023,Q2,Elderly
222886991,22288699,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK, qd",,,,,,,,,,,QD,2023,Q2,Steroid dependence,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-MHRA-TPP16316266C5588118YC1680529406147,GB-TAKEDA-2023TUS043869,TAKEDA,,75.0,YR,,M,Y,85.0,KG,20230505,,LW,GB,GB,2023,Q2,Elderly
222886991,22288699,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK, qd",,,,,,,,,,,QD,2023,Q2,Burns second degree,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-MHRA-TPP16316266C5588118YC1680529406147,GB-TAKEDA-2023TUS043869,TAKEDA,,75.0,YR,,M,Y,85.0,KG,20230505,,LW,GB,GB,2023,Q2,Elderly
222886991,22288699,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK, qd",,,,,,,,,,,QD,2023,Q2,Stress,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-MHRA-TPP16316266C5588118YC1680529406147,GB-TAKEDA-2023TUS043869,TAKEDA,,75.0,YR,,M,Y,85.0,KG,20230505,,LW,GB,GB,2023,Q2,Elderly
222886991,22288699,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK, qd",,,,,,,,,,,QD,2023,Q2,Pyrexia,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-MHRA-TPP16316266C5588118YC1680529406147,GB-TAKEDA-2023TUS043869,TAKEDA,,75.0,YR,,M,Y,85.0,KG,20230505,,LW,GB,GB,2023,Q2,Elderly
222886991,22288699,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK, qd",,,,,,,,,,,QD,2023,Q2,COVID-19,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-MHRA-TPP16316266C5588118YC1680529406147,GB-TAKEDA-2023TUS043869,TAKEDA,,75.0,YR,,M,Y,85.0,KG,20230505,,LW,GB,GB,2023,Q2,Elderly
222893482,22289348,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Cardiac murmur,,2023,Q2,2,F,20210212.0,20230426.0,20230505,20230510,EXP,GB-AstraZeneca-2023A099289,GB-TAKEDA-2023TUS043243,TAKEDA,,58.0,YR,,F,Y,60.0,KG,20230510,,MD,GB,GB,2023,Q2,Adult
222893482,22289348,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Confusional state,,2023,Q2,2,F,20210212.0,20230426.0,20230505,20230510,EXP,GB-AstraZeneca-2023A099289,GB-TAKEDA-2023TUS043243,TAKEDA,,58.0,YR,,F,Y,60.0,KG,20230510,,MD,GB,GB,2023,Q2,Adult
222893482,22289348,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Pulmonary embolism,,2023,Q2,2,F,20210212.0,20230426.0,20230505,20230510,EXP,GB-AstraZeneca-2023A099289,GB-TAKEDA-2023TUS043243,TAKEDA,,58.0,YR,,F,Y,60.0,KG,20230510,,MD,GB,GB,2023,Q2,Adult
222893482,22289348,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Palpitations,,2023,Q2,2,F,20210212.0,20230426.0,20230505,20230510,EXP,GB-AstraZeneca-2023A099289,GB-TAKEDA-2023TUS043243,TAKEDA,,58.0,YR,,F,Y,60.0,KG,20230510,,MD,GB,GB,2023,Q2,Adult
222893482,22289348,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Depression,,2023,Q2,2,F,20210212.0,20230426.0,20230505,20230510,EXP,GB-AstraZeneca-2023A099289,GB-TAKEDA-2023TUS043243,TAKEDA,,58.0,YR,,F,Y,60.0,KG,20230510,,MD,GB,GB,2023,Q2,Adult
222893482,22289348,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Intentional product use issue,,2023,Q2,2,F,20210212.0,20230426.0,20230505,20230510,EXP,GB-AstraZeneca-2023A099289,GB-TAKEDA-2023TUS043243,TAKEDA,,58.0,YR,,F,Y,60.0,KG,20230510,,MD,GB,GB,2023,Q2,Adult
222893482,22289348,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Adverse drug reaction,,2023,Q2,2,F,20210212.0,20230426.0,20230505,20230510,EXP,GB-AstraZeneca-2023A099289,GB-TAKEDA-2023TUS043243,TAKEDA,,58.0,YR,,F,Y,60.0,KG,20230510,,MD,GB,GB,2023,Q2,Adult
222893482,22289348,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Pyrexia,,2023,Q2,2,F,20210212.0,20230426.0,20230505,20230510,EXP,GB-AstraZeneca-2023A099289,GB-TAKEDA-2023TUS043243,TAKEDA,,58.0,YR,,F,Y,60.0,KG,20230510,,MD,GB,GB,2023,Q2,Adult
222893482,22289348,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Somnolence,,2023,Q2,2,F,20210212.0,20230426.0,20230505,20230510,EXP,GB-AstraZeneca-2023A099289,GB-TAKEDA-2023TUS043243,TAKEDA,,58.0,YR,,F,Y,60.0,KG,20230510,,MD,GB,GB,2023,Q2,Adult
222893482,22289348,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Abdominal discomfort,,2023,Q2,2,F,20210212.0,20230426.0,20230505,20230510,EXP,GB-AstraZeneca-2023A099289,GB-TAKEDA-2023TUS043243,TAKEDA,,58.0,YR,,F,Y,60.0,KG,20230510,,MD,GB,GB,2023,Q2,Adult
222893482,22289348,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Dysgeusia,,2023,Q2,2,F,20210212.0,20230426.0,20230505,20230510,EXP,GB-AstraZeneca-2023A099289,GB-TAKEDA-2023TUS043243,TAKEDA,,58.0,YR,,F,Y,60.0,KG,20230510,,MD,GB,GB,2023,Q2,Adult
222893482,22289348,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Steroid dependence,,2023,Q2,2,F,20210212.0,20230426.0,20230505,20230510,EXP,GB-AstraZeneca-2023A099289,GB-TAKEDA-2023TUS043243,TAKEDA,,58.0,YR,,F,Y,60.0,KG,20230510,,MD,GB,GB,2023,Q2,Adult
222893482,22289348,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Tinnitus,,2023,Q2,2,F,20210212.0,20230426.0,20230505,20230510,EXP,GB-AstraZeneca-2023A099289,GB-TAKEDA-2023TUS043243,TAKEDA,,58.0,YR,,F,Y,60.0,KG,20230510,,MD,GB,GB,2023,Q2,Adult
222893482,22289348,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Product use in unapproved indication,,2023,Q2,2,F,20210212.0,20230426.0,20230505,20230510,EXP,GB-AstraZeneca-2023A099289,GB-TAKEDA-2023TUS043243,TAKEDA,,58.0,YR,,F,Y,60.0,KG,20230510,,MD,GB,GB,2023,Q2,Adult
222893482,22289348,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Hypopnoea,,2023,Q2,2,F,20210212.0,20230426.0,20230505,20230510,EXP,GB-AstraZeneca-2023A099289,GB-TAKEDA-2023TUS043243,TAKEDA,,58.0,YR,,F,Y,60.0,KG,20230510,,MD,GB,GB,2023,Q2,Adult
222893482,22289348,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Nightmare,,2023,Q2,2,F,20210212.0,20230426.0,20230505,20230510,EXP,GB-AstraZeneca-2023A099289,GB-TAKEDA-2023TUS043243,TAKEDA,,58.0,YR,,F,Y,60.0,KG,20230510,,MD,GB,GB,2023,Q2,Adult
222893482,22289348,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Gingival pain,,2023,Q2,2,F,20210212.0,20230426.0,20230505,20230510,EXP,GB-AstraZeneca-2023A099289,GB-TAKEDA-2023TUS043243,TAKEDA,,58.0,YR,,F,Y,60.0,KG,20230510,,MD,GB,GB,2023,Q2,Adult
222893482,22289348,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Loss of personal independence in daily activities,,2023,Q2,2,F,20210212.0,20230426.0,20230505,20230510,EXP,GB-AstraZeneca-2023A099289,GB-TAKEDA-2023TUS043243,TAKEDA,,58.0,YR,,F,Y,60.0,KG,20230510,,MD,GB,GB,2023,Q2,Adult
222893482,22289348,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Impaired quality of life,,2023,Q2,2,F,20210212.0,20230426.0,20230505,20230510,EXP,GB-AstraZeneca-2023A099289,GB-TAKEDA-2023TUS043243,TAKEDA,,58.0,YR,,F,Y,60.0,KG,20230510,,MD,GB,GB,2023,Q2,Adult
222893482,22289348,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Haematochezia,,2023,Q2,2,F,20210212.0,20230426.0,20230505,20230510,EXP,GB-AstraZeneca-2023A099289,GB-TAKEDA-2023TUS043243,TAKEDA,,58.0,YR,,F,Y,60.0,KG,20230510,,MD,GB,GB,2023,Q2,Adult
222893482,22289348,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Off label use,,2023,Q2,2,F,20210212.0,20230426.0,20230505,20230510,EXP,GB-AstraZeneca-2023A099289,GB-TAKEDA-2023TUS043243,TAKEDA,,58.0,YR,,F,Y,60.0,KG,20230510,,MD,GB,GB,2023,Q2,Adult
222893482,22289348,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Rhinitis,,2023,Q2,2,F,20210212.0,20230426.0,20230505,20230510,EXP,GB-AstraZeneca-2023A099289,GB-TAKEDA-2023TUS043243,TAKEDA,,58.0,YR,,F,Y,60.0,KG,20230510,,MD,GB,GB,2023,Q2,Adult
222893482,22289348,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Stress,,2023,Q2,2,F,20210212.0,20230426.0,20230505,20230510,EXP,GB-AstraZeneca-2023A099289,GB-TAKEDA-2023TUS043243,TAKEDA,,58.0,YR,,F,Y,60.0,KG,20230510,,MD,GB,GB,2023,Q2,Adult
222893482,22289348,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Pain in extremity,,2023,Q2,2,F,20210212.0,20230426.0,20230505,20230510,EXP,GB-AstraZeneca-2023A099289,GB-TAKEDA-2023TUS043243,TAKEDA,,58.0,YR,,F,Y,60.0,KG,20230510,,MD,GB,GB,2023,Q2,Adult
222893482,22289348,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Arthritis,,2023,Q2,2,F,20210212.0,20230426.0,20230505,20230510,EXP,GB-AstraZeneca-2023A099289,GB-TAKEDA-2023TUS043243,TAKEDA,,58.0,YR,,F,Y,60.0,KG,20230510,,MD,GB,GB,2023,Q2,Adult
222893482,22289348,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Vertigo,,2023,Q2,2,F,20210212.0,20230426.0,20230505,20230510,EXP,GB-AstraZeneca-2023A099289,GB-TAKEDA-2023TUS043243,TAKEDA,,58.0,YR,,F,Y,60.0,KG,20230510,,MD,GB,GB,2023,Q2,Adult
222893482,22289348,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Fatigue,,2023,Q2,2,F,20210212.0,20230426.0,20230505,20230510,EXP,GB-AstraZeneca-2023A099289,GB-TAKEDA-2023TUS043243,TAKEDA,,58.0,YR,,F,Y,60.0,KG,20230510,,MD,GB,GB,2023,Q2,Adult
222893482,22289348,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Parosmia,,2023,Q2,2,F,20210212.0,20230426.0,20230505,20230510,EXP,GB-AstraZeneca-2023A099289,GB-TAKEDA-2023TUS043243,TAKEDA,,58.0,YR,,F,Y,60.0,KG,20230510,,MD,GB,GB,2023,Q2,Adult
222893482,22289348,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Medication error,,2023,Q2,2,F,20210212.0,20230426.0,20230505,20230510,EXP,GB-AstraZeneca-2023A099289,GB-TAKEDA-2023TUS043243,TAKEDA,,58.0,YR,,F,Y,60.0,KG,20230510,,MD,GB,GB,2023,Q2,Adult
222893482,22289348,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Pain,,2023,Q2,2,F,20210212.0,20230426.0,20230505,20230510,EXP,GB-AstraZeneca-2023A099289,GB-TAKEDA-2023TUS043243,TAKEDA,,58.0,YR,,F,Y,60.0,KG,20230510,,MD,GB,GB,2023,Q2,Adult
222893482,22289348,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Cerebrovascular accident,,2023,Q2,2,F,20210212.0,20230426.0,20230505,20230510,EXP,GB-AstraZeneca-2023A099289,GB-TAKEDA-2023TUS043243,TAKEDA,,58.0,YR,,F,Y,60.0,KG,20230510,,MD,GB,GB,2023,Q2,Adult
222893482,22289348,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Burns second degree,,2023,Q2,2,F,20210212.0,20230426.0,20230505,20230510,EXP,GB-AstraZeneca-2023A099289,GB-TAKEDA-2023TUS043243,TAKEDA,,58.0,YR,,F,Y,60.0,KG,20230510,,MD,GB,GB,2023,Q2,Adult
222893482,22289348,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Drug ineffective,,2023,Q2,2,F,20210212.0,20230426.0,20230505,20230510,EXP,GB-AstraZeneca-2023A099289,GB-TAKEDA-2023TUS043243,TAKEDA,,58.0,YR,,F,Y,60.0,KG,20230510,,MD,GB,GB,2023,Q2,Adult
222893482,22289348,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Tubulointerstitial nephritis,,2023,Q2,2,F,20210212.0,20230426.0,20230505,20230510,EXP,GB-AstraZeneca-2023A099289,GB-TAKEDA-2023TUS043243,TAKEDA,,58.0,YR,,F,Y,60.0,KG,20230510,,MD,GB,GB,2023,Q2,Adult
222893482,22289348,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Weight decreased,,2023,Q2,2,F,20210212.0,20230426.0,20230505,20230510,EXP,GB-AstraZeneca-2023A099289,GB-TAKEDA-2023TUS043243,TAKEDA,,58.0,YR,,F,Y,60.0,KG,20230510,,MD,GB,GB,2023,Q2,Adult
222893482,22289348,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Rectal haemorrhage,,2023,Q2,2,F,20210212.0,20230426.0,20230505,20230510,EXP,GB-AstraZeneca-2023A099289,GB-TAKEDA-2023TUS043243,TAKEDA,,58.0,YR,,F,Y,60.0,KG,20230510,,MD,GB,GB,2023,Q2,Adult
222893482,22289348,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Eczema,,2023,Q2,2,F,20210212.0,20230426.0,20230505,20230510,EXP,GB-AstraZeneca-2023A099289,GB-TAKEDA-2023TUS043243,TAKEDA,,58.0,YR,,F,Y,60.0,KG,20230510,,MD,GB,GB,2023,Q2,Adult
222893482,22289348,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Rash,,2023,Q2,2,F,20210212.0,20230426.0,20230505,20230510,EXP,GB-AstraZeneca-2023A099289,GB-TAKEDA-2023TUS043243,TAKEDA,,58.0,YR,,F,Y,60.0,KG,20230510,,MD,GB,GB,2023,Q2,Adult
222893482,22289348,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Frequent bowel movements,,2023,Q2,2,F,20210212.0,20230426.0,20230505,20230510,EXP,GB-AstraZeneca-2023A099289,GB-TAKEDA-2023TUS043243,TAKEDA,,58.0,YR,,F,Y,60.0,KG,20230510,,MD,GB,GB,2023,Q2,Adult
222893482,22289348,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Bronchiectasis,,2023,Q2,2,F,20210212.0,20230426.0,20230505,20230510,EXP,GB-AstraZeneca-2023A099289,GB-TAKEDA-2023TUS043243,TAKEDA,,58.0,YR,,F,Y,60.0,KG,20230510,,MD,GB,GB,2023,Q2,Adult
222893482,22289348,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Inappropriate schedule of product administration,,2023,Q2,2,F,20210212.0,20230426.0,20230505,20230510,EXP,GB-AstraZeneca-2023A099289,GB-TAKEDA-2023TUS043243,TAKEDA,,58.0,YR,,F,Y,60.0,KG,20230510,,MD,GB,GB,2023,Q2,Adult
222893482,22289348,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Swollen tongue,,2023,Q2,2,F,20210212.0,20230426.0,20230505,20230510,EXP,GB-AstraZeneca-2023A099289,GB-TAKEDA-2023TUS043243,TAKEDA,,58.0,YR,,F,Y,60.0,KG,20230510,,MD,GB,GB,2023,Q2,Adult
222893482,22289348,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Systemic lupus erythematosus,,2023,Q2,2,F,20210212.0,20230426.0,20230505,20230510,EXP,GB-AstraZeneca-2023A099289,GB-TAKEDA-2023TUS043243,TAKEDA,,58.0,YR,,F,Y,60.0,KG,20230510,,MD,GB,GB,2023,Q2,Adult
222893482,22289348,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Condition aggravated,,2023,Q2,2,F,20210212.0,20230426.0,20230505,20230510,EXP,GB-AstraZeneca-2023A099289,GB-TAKEDA-2023TUS043243,TAKEDA,,58.0,YR,,F,Y,60.0,KG,20230510,,MD,GB,GB,2023,Q2,Adult
222893482,22289348,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Deep vein thrombosis,,2023,Q2,2,F,20210212.0,20230426.0,20230505,20230510,EXP,GB-AstraZeneca-2023A099289,GB-TAKEDA-2023TUS043243,TAKEDA,,58.0,YR,,F,Y,60.0,KG,20230510,,MD,GB,GB,2023,Q2,Adult
222893482,22289348,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Migraine,,2023,Q2,2,F,20210212.0,20230426.0,20230505,20230510,EXP,GB-AstraZeneca-2023A099289,GB-TAKEDA-2023TUS043243,TAKEDA,,58.0,YR,,F,Y,60.0,KG,20230510,,MD,GB,GB,2023,Q2,Adult
222893482,22289348,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Impaired work ability,,2023,Q2,2,F,20210212.0,20230426.0,20230505,20230510,EXP,GB-AstraZeneca-2023A099289,GB-TAKEDA-2023TUS043243,TAKEDA,,58.0,YR,,F,Y,60.0,KG,20230510,,MD,GB,GB,2023,Q2,Adult
222893482,22289348,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Headache,,2023,Q2,2,F,20210212.0,20230426.0,20230505,20230510,EXP,GB-AstraZeneca-2023A099289,GB-TAKEDA-2023TUS043243,TAKEDA,,58.0,YR,,F,Y,60.0,KG,20230510,,MD,GB,GB,2023,Q2,Adult
222893482,22289348,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Accidental overdose,,2023,Q2,2,F,20210212.0,20230426.0,20230505,20230510,EXP,GB-AstraZeneca-2023A099289,GB-TAKEDA-2023TUS043243,TAKEDA,,58.0,YR,,F,Y,60.0,KG,20230510,,MD,GB,GB,2023,Q2,Adult
222893482,22289348,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Catarrh,,2023,Q2,2,F,20210212.0,20230426.0,20230505,20230510,EXP,GB-AstraZeneca-2023A099289,GB-TAKEDA-2023TUS043243,TAKEDA,,58.0,YR,,F,Y,60.0,KG,20230510,,MD,GB,GB,2023,Q2,Adult
222893482,22289348,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,COVID-19,,2023,Q2,2,F,20210212.0,20230426.0,20230505,20230510,EXP,GB-AstraZeneca-2023A099289,GB-TAKEDA-2023TUS043243,TAKEDA,,58.0,YR,,F,Y,60.0,KG,20230510,,MD,GB,GB,2023,Q2,Adult
222893482,22289348,78,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Colitis ulcerative,,2023,Q2,2,F,20210212.0,20230426.0,20230505,20230510,EXP,GB-AstraZeneca-2023A099289,GB-TAKEDA-2023TUS043243,TAKEDA,,58.0,YR,,F,Y,60.0,KG,20230510,,MD,GB,GB,2023,Q2,Adult
222895131,22289513,4,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"0.505 g, BID",2.02,GM,,,2211502,,,0.505,GM,Tablet,BID,2023,Q2,Nephropathy toxic,,2023,Q2,1,I,20230408.0,20230429.0,20230505,20230505,EXP,,CN-BAYER-2023A061924,BAYER,,60.0,YR,A,M,Y,34.0,KG,20230505,,HP,CN,CN,2023,Q2,Adult
222897661,22289766,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Gingival pain,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS044113,TAKEDA,,63.0,YR,,,Y,,,20230505,,MD,GB,GB,2023,Q2,Adult
222897661,22289766,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Depression,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS044113,TAKEDA,,63.0,YR,,,Y,,,20230505,,MD,GB,GB,2023,Q2,Adult
222897661,22289766,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Rash,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS044113,TAKEDA,,63.0,YR,,,Y,,,20230505,,MD,GB,GB,2023,Q2,Adult
222897661,22289766,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Burns second degree,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS044113,TAKEDA,,63.0,YR,,,Y,,,20230505,,MD,GB,GB,2023,Q2,Adult
222897661,22289766,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Cardiac murmur,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS044113,TAKEDA,,63.0,YR,,,Y,,,20230505,,MD,GB,GB,2023,Q2,Adult
222897661,22289766,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Inappropriate schedule of product administration,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS044113,TAKEDA,,63.0,YR,,,Y,,,20230505,,MD,GB,GB,2023,Q2,Adult
222897661,22289766,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Adverse drug reaction,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS044113,TAKEDA,,63.0,YR,,,Y,,,20230505,,MD,GB,GB,2023,Q2,Adult
222897661,22289766,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Stress,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS044113,TAKEDA,,63.0,YR,,,Y,,,20230505,,MD,GB,GB,2023,Q2,Adult
222897661,22289766,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Loss of personal independence in daily activities,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS044113,TAKEDA,,63.0,YR,,,Y,,,20230505,,MD,GB,GB,2023,Q2,Adult
222897661,22289766,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Tubulointerstitial nephritis,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS044113,TAKEDA,,63.0,YR,,,Y,,,20230505,,MD,GB,GB,2023,Q2,Adult
222897661,22289766,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Fatigue,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS044113,TAKEDA,,63.0,YR,,,Y,,,20230505,,MD,GB,GB,2023,Q2,Adult
222897661,22289766,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Haematochezia,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS044113,TAKEDA,,63.0,YR,,,Y,,,20230505,,MD,GB,GB,2023,Q2,Adult
222897661,22289766,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Tinnitus,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS044113,TAKEDA,,63.0,YR,,,Y,,,20230505,,MD,GB,GB,2023,Q2,Adult
222897661,22289766,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Parosmia,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS044113,TAKEDA,,63.0,YR,,,Y,,,20230505,,MD,GB,GB,2023,Q2,Adult
222897661,22289766,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Rash,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS044113,TAKEDA,,63.0,YR,,,Y,,,20230505,,MD,GB,GB,2023,Q2,Adult
222897661,22289766,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Accidental overdose,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS044113,TAKEDA,,63.0,YR,,,Y,,,20230505,,MD,GB,GB,2023,Q2,Adult
222897661,22289766,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Drug ineffective,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS044113,TAKEDA,,63.0,YR,,,Y,,,20230505,,MD,GB,GB,2023,Q2,Adult
222897661,22289766,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Tinnitus,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS044113,TAKEDA,,63.0,YR,,,Y,,,20230505,,MD,GB,GB,2023,Q2,Adult
222897661,22289766,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Swollen tongue,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS044113,TAKEDA,,63.0,YR,,,Y,,,20230505,,MD,GB,GB,2023,Q2,Adult
222897661,22289766,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Rhinitis,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS044113,TAKEDA,,63.0,YR,,,Y,,,20230505,,MD,GB,GB,2023,Q2,Adult
222897661,22289766,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Migraine,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS044113,TAKEDA,,63.0,YR,,,Y,,,20230505,,MD,GB,GB,2023,Q2,Adult
222897661,22289766,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Deep vein thrombosis,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS044113,TAKEDA,,63.0,YR,,,Y,,,20230505,,MD,GB,GB,2023,Q2,Adult
222897661,22289766,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Headache,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS044113,TAKEDA,,63.0,YR,,,Y,,,20230505,,MD,GB,GB,2023,Q2,Adult
222897661,22289766,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Somnolence,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS044113,TAKEDA,,63.0,YR,,,Y,,,20230505,,MD,GB,GB,2023,Q2,Adult
222897661,22289766,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Steroid dependence,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS044113,TAKEDA,,63.0,YR,,,Y,,,20230505,,MD,GB,GB,2023,Q2,Adult
222897661,22289766,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Intentional product use issue,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS044113,TAKEDA,,63.0,YR,,,Y,,,20230505,,MD,GB,GB,2023,Q2,Adult
222897661,22289766,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Eczema,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS044113,TAKEDA,,63.0,YR,,,Y,,,20230505,,MD,GB,GB,2023,Q2,Adult
222897661,22289766,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Dysgeusia,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS044113,TAKEDA,,63.0,YR,,,Y,,,20230505,,MD,GB,GB,2023,Q2,Adult
222897661,22289766,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Confusional state,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS044113,TAKEDA,,63.0,YR,,,Y,,,20230505,,MD,GB,GB,2023,Q2,Adult
222897661,22289766,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Pyrexia,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS044113,TAKEDA,,63.0,YR,,,Y,,,20230505,,MD,GB,GB,2023,Q2,Adult
222897661,22289766,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Palpitations,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS044113,TAKEDA,,63.0,YR,,,Y,,,20230505,,MD,GB,GB,2023,Q2,Adult
222897661,22289766,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Bronchiectasis,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS044113,TAKEDA,,63.0,YR,,,Y,,,20230505,,MD,GB,GB,2023,Q2,Adult
222897661,22289766,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Fatigue,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS044113,TAKEDA,,63.0,YR,,,Y,,,20230505,,MD,GB,GB,2023,Q2,Adult
222897661,22289766,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Arthritis,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS044113,TAKEDA,,63.0,YR,,,Y,,,20230505,,MD,GB,GB,2023,Q2,Adult
222897661,22289766,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Catarrh,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS044113,TAKEDA,,63.0,YR,,,Y,,,20230505,,MD,GB,GB,2023,Q2,Adult
222897661,22289766,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Off label use,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS044113,TAKEDA,,63.0,YR,,,Y,,,20230505,,MD,GB,GB,2023,Q2,Adult
222897661,22289766,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Nightmare,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS044113,TAKEDA,,63.0,YR,,,Y,,,20230505,,MD,GB,GB,2023,Q2,Adult
222897661,22289766,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Weight decreased,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS044113,TAKEDA,,63.0,YR,,,Y,,,20230505,,MD,GB,GB,2023,Q2,Adult
222897661,22289766,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Systemic lupus erythematosus,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS044113,TAKEDA,,63.0,YR,,,Y,,,20230505,,MD,GB,GB,2023,Q2,Adult
222897661,22289766,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Medication error,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS044113,TAKEDA,,63.0,YR,,,Y,,,20230505,,MD,GB,GB,2023,Q2,Adult
222897661,22289766,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Colitis ulcerative,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS044113,TAKEDA,,63.0,YR,,,Y,,,20230505,,MD,GB,GB,2023,Q2,Adult
222897661,22289766,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Impaired quality of life,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS044113,TAKEDA,,63.0,YR,,,Y,,,20230505,,MD,GB,GB,2023,Q2,Adult
222897661,22289766,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Frequent bowel movements,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS044113,TAKEDA,,63.0,YR,,,Y,,,20230505,,MD,GB,GB,2023,Q2,Adult
222897661,22289766,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,COVID-19,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS044113,TAKEDA,,63.0,YR,,,Y,,,20230505,,MD,GB,GB,2023,Q2,Adult
222897661,22289766,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Hypopnoea,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS044113,TAKEDA,,63.0,YR,,,Y,,,20230505,,MD,GB,GB,2023,Q2,Adult
222897661,22289766,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Cerebrovascular accident,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS044113,TAKEDA,,63.0,YR,,,Y,,,20230505,,MD,GB,GB,2023,Q2,Adult
222897661,22289766,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Abdominal discomfort,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS044113,TAKEDA,,63.0,YR,,,Y,,,20230505,,MD,GB,GB,2023,Q2,Adult
222897661,22289766,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Condition aggravated,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS044113,TAKEDA,,63.0,YR,,,Y,,,20230505,,MD,GB,GB,2023,Q2,Adult
222897661,22289766,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Pain in extremity,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS044113,TAKEDA,,63.0,YR,,,Y,,,20230505,,MD,GB,GB,2023,Q2,Adult
222897661,22289766,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Pain,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS044113,TAKEDA,,63.0,YR,,,Y,,,20230505,,MD,GB,GB,2023,Q2,Adult
222897661,22289766,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Vertigo,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS044113,TAKEDA,,63.0,YR,,,Y,,,20230505,,MD,GB,GB,2023,Q2,Adult
222897661,22289766,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Rectal haemorrhage,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS044113,TAKEDA,,63.0,YR,,,Y,,,20230505,,MD,GB,GB,2023,Q2,Adult
222897661,22289766,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Pulmonary embolism,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS044113,TAKEDA,,63.0,YR,,,Y,,,20230505,,MD,GB,GB,2023,Q2,Adult
222898191,22289819,73,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Depression,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043734,TAKEDA,,46.0,YR,,F,Y,,,20230505,,HP,GB,GB,2023,Q2,Adult
222898191,22289819,73,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Migraine,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043734,TAKEDA,,46.0,YR,,F,Y,,,20230505,,HP,GB,GB,2023,Q2,Adult
222898191,22289819,73,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Pyrexia,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043734,TAKEDA,,46.0,YR,,F,Y,,,20230505,,HP,GB,GB,2023,Q2,Adult
222898191,22289819,73,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Haematochezia,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043734,TAKEDA,,46.0,YR,,F,Y,,,20230505,,HP,GB,GB,2023,Q2,Adult
222898191,22289819,73,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Eczema,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043734,TAKEDA,,46.0,YR,,F,Y,,,20230505,,HP,GB,GB,2023,Q2,Adult
222898191,22289819,73,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Gingival pain,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043734,TAKEDA,,46.0,YR,,F,Y,,,20230505,,HP,GB,GB,2023,Q2,Adult
222898191,22289819,73,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Vertigo,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043734,TAKEDA,,46.0,YR,,F,Y,,,20230505,,HP,GB,GB,2023,Q2,Adult
222898191,22289819,73,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Condition aggravated,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043734,TAKEDA,,46.0,YR,,F,Y,,,20230505,,HP,GB,GB,2023,Q2,Adult
222898191,22289819,73,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Pain in extremity,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043734,TAKEDA,,46.0,YR,,F,Y,,,20230505,,HP,GB,GB,2023,Q2,Adult
222898191,22289819,73,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Stress,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043734,TAKEDA,,46.0,YR,,F,Y,,,20230505,,HP,GB,GB,2023,Q2,Adult
222898191,22289819,73,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Hypopnoea,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043734,TAKEDA,,46.0,YR,,F,Y,,,20230505,,HP,GB,GB,2023,Q2,Adult
222898191,22289819,73,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Tinnitus,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043734,TAKEDA,,46.0,YR,,F,Y,,,20230505,,HP,GB,GB,2023,Q2,Adult
222898191,22289819,73,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Adverse drug reaction,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043734,TAKEDA,,46.0,YR,,F,Y,,,20230505,,HP,GB,GB,2023,Q2,Adult
222898191,22289819,73,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Drug ineffective,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043734,TAKEDA,,46.0,YR,,F,Y,,,20230505,,HP,GB,GB,2023,Q2,Adult
222898191,22289819,73,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Palpitations,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043734,TAKEDA,,46.0,YR,,F,Y,,,20230505,,HP,GB,GB,2023,Q2,Adult
222898191,22289819,73,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Dysgeusia,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043734,TAKEDA,,46.0,YR,,F,Y,,,20230505,,HP,GB,GB,2023,Q2,Adult
222898191,22289819,73,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Nightmare,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043734,TAKEDA,,46.0,YR,,F,Y,,,20230505,,HP,GB,GB,2023,Q2,Adult
222898191,22289819,73,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Parosmia,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043734,TAKEDA,,46.0,YR,,F,Y,,,20230505,,HP,GB,GB,2023,Q2,Adult
222898191,22289819,73,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Systemic lupus erythematosus,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043734,TAKEDA,,46.0,YR,,F,Y,,,20230505,,HP,GB,GB,2023,Q2,Adult
222898191,22289819,73,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Cerebrovascular accident,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043734,TAKEDA,,46.0,YR,,F,Y,,,20230505,,HP,GB,GB,2023,Q2,Adult
222898191,22289819,73,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Fatigue,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043734,TAKEDA,,46.0,YR,,F,Y,,,20230505,,HP,GB,GB,2023,Q2,Adult
222898191,22289819,73,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Accidental overdose,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043734,TAKEDA,,46.0,YR,,F,Y,,,20230505,,HP,GB,GB,2023,Q2,Adult
222898191,22289819,73,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Medication error,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043734,TAKEDA,,46.0,YR,,F,Y,,,20230505,,HP,GB,GB,2023,Q2,Adult
222898191,22289819,73,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Swollen tongue,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043734,TAKEDA,,46.0,YR,,F,Y,,,20230505,,HP,GB,GB,2023,Q2,Adult
222898191,22289819,73,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Off label use,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043734,TAKEDA,,46.0,YR,,F,Y,,,20230505,,HP,GB,GB,2023,Q2,Adult
222898191,22289819,73,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Arthritis,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043734,TAKEDA,,46.0,YR,,F,Y,,,20230505,,HP,GB,GB,2023,Q2,Adult
222898191,22289819,73,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Deep vein thrombosis,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043734,TAKEDA,,46.0,YR,,F,Y,,,20230505,,HP,GB,GB,2023,Q2,Adult
222898191,22289819,73,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Intentional product use issue,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043734,TAKEDA,,46.0,YR,,F,Y,,,20230505,,HP,GB,GB,2023,Q2,Adult
222898191,22289819,73,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Pulmonary embolism,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043734,TAKEDA,,46.0,YR,,F,Y,,,20230505,,HP,GB,GB,2023,Q2,Adult
222898191,22289819,73,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Colitis ulcerative,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043734,TAKEDA,,46.0,YR,,F,Y,,,20230505,,HP,GB,GB,2023,Q2,Adult
222898191,22289819,73,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Inappropriate schedule of product administration,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043734,TAKEDA,,46.0,YR,,F,Y,,,20230505,,HP,GB,GB,2023,Q2,Adult
222898191,22289819,73,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Confusional state,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043734,TAKEDA,,46.0,YR,,F,Y,,,20230505,,HP,GB,GB,2023,Q2,Adult
222898191,22289819,73,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Rhinitis,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043734,TAKEDA,,46.0,YR,,F,Y,,,20230505,,HP,GB,GB,2023,Q2,Adult
222898191,22289819,73,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Abdominal discomfort,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043734,TAKEDA,,46.0,YR,,F,Y,,,20230505,,HP,GB,GB,2023,Q2,Adult
222898191,22289819,73,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Impaired work ability,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043734,TAKEDA,,46.0,YR,,F,Y,,,20230505,,HP,GB,GB,2023,Q2,Adult
222898191,22289819,73,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Catarrh,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043734,TAKEDA,,46.0,YR,,F,Y,,,20230505,,HP,GB,GB,2023,Q2,Adult
222898191,22289819,73,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Bronchiectasis,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043734,TAKEDA,,46.0,YR,,F,Y,,,20230505,,HP,GB,GB,2023,Q2,Adult
222898191,22289819,73,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Cardiac murmur,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043734,TAKEDA,,46.0,YR,,F,Y,,,20230505,,HP,GB,GB,2023,Q2,Adult
222898191,22289819,73,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Weight decreased,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043734,TAKEDA,,46.0,YR,,F,Y,,,20230505,,HP,GB,GB,2023,Q2,Adult
222898191,22289819,73,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Rash,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043734,TAKEDA,,46.0,YR,,F,Y,,,20230505,,HP,GB,GB,2023,Q2,Adult
222898191,22289819,73,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Burns second degree,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043734,TAKEDA,,46.0,YR,,F,Y,,,20230505,,HP,GB,GB,2023,Q2,Adult
222898191,22289819,73,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Headache,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043734,TAKEDA,,46.0,YR,,F,Y,,,20230505,,HP,GB,GB,2023,Q2,Adult
222898191,22289819,73,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,COVID-19,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043734,TAKEDA,,46.0,YR,,F,Y,,,20230505,,HP,GB,GB,2023,Q2,Adult
222898191,22289819,73,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Impaired quality of life,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043734,TAKEDA,,46.0,YR,,F,Y,,,20230505,,HP,GB,GB,2023,Q2,Adult
222898191,22289819,73,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Somnolence,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043734,TAKEDA,,46.0,YR,,F,Y,,,20230505,,HP,GB,GB,2023,Q2,Adult
222898191,22289819,73,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Rectal haemorrhage,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043734,TAKEDA,,46.0,YR,,F,Y,,,20230505,,HP,GB,GB,2023,Q2,Adult
222898191,22289819,73,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Tubulointerstitial nephritis,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043734,TAKEDA,,46.0,YR,,F,Y,,,20230505,,HP,GB,GB,2023,Q2,Adult
222898191,22289819,73,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Frequent bowel movements,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043734,TAKEDA,,46.0,YR,,F,Y,,,20230505,,HP,GB,GB,2023,Q2,Adult
222898191,22289819,73,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Loss of personal independence in daily activities,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043734,TAKEDA,,46.0,YR,,F,Y,,,20230505,,HP,GB,GB,2023,Q2,Adult
222898191,22289819,73,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Product use in unapproved indication,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043734,TAKEDA,,46.0,YR,,F,Y,,,20230505,,HP,GB,GB,2023,Q2,Adult
222898191,22289819,73,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Steroid dependence,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043734,TAKEDA,,46.0,YR,,F,Y,,,20230505,,HP,GB,GB,2023,Q2,Adult
222898191,22289819,73,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Pain,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043734,TAKEDA,,46.0,YR,,F,Y,,,20230505,,HP,GB,GB,2023,Q2,Adult
222904631,22290463,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Condition aggravated,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043335,TAKEDA,,74.0,YR,,M,Y,,,20230505,,CN,GB,GB,2023,Q2,Elderly
222904631,22290463,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Deep vein thrombosis,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043335,TAKEDA,,74.0,YR,,M,Y,,,20230505,,CN,GB,GB,2023,Q2,Elderly
222904631,22290463,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Systemic lupus erythematosus,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043335,TAKEDA,,74.0,YR,,M,Y,,,20230505,,CN,GB,GB,2023,Q2,Elderly
222904631,22290463,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Rash,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043335,TAKEDA,,74.0,YR,,M,Y,,,20230505,,CN,GB,GB,2023,Q2,Elderly
222904631,22290463,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Tubulointerstitial nephritis,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043335,TAKEDA,,74.0,YR,,M,Y,,,20230505,,CN,GB,GB,2023,Q2,Elderly
222904631,22290463,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Pain,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043335,TAKEDA,,74.0,YR,,M,Y,,,20230505,,CN,GB,GB,2023,Q2,Elderly
222904631,22290463,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Steroid dependence,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043335,TAKEDA,,74.0,YR,,M,Y,,,20230505,,CN,GB,GB,2023,Q2,Elderly
222904631,22290463,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Dysgeusia,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043335,TAKEDA,,74.0,YR,,M,Y,,,20230505,,CN,GB,GB,2023,Q2,Elderly
222904631,22290463,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Lethargy,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043335,TAKEDA,,74.0,YR,,M,Y,,,20230505,,CN,GB,GB,2023,Q2,Elderly
222904631,22290463,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Off label use,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043335,TAKEDA,,74.0,YR,,M,Y,,,20230505,,CN,GB,GB,2023,Q2,Elderly
222904631,22290463,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Nightmare,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043335,TAKEDA,,74.0,YR,,M,Y,,,20230505,,CN,GB,GB,2023,Q2,Elderly
222904631,22290463,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Rectal haemorrhage,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043335,TAKEDA,,74.0,YR,,M,Y,,,20230505,,CN,GB,GB,2023,Q2,Elderly
222904631,22290463,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Medication error,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043335,TAKEDA,,74.0,YR,,M,Y,,,20230505,,CN,GB,GB,2023,Q2,Elderly
222904631,22290463,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Fatigue,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043335,TAKEDA,,74.0,YR,,M,Y,,,20230505,,CN,GB,GB,2023,Q2,Elderly
222904631,22290463,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Haematochezia,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043335,TAKEDA,,74.0,YR,,M,Y,,,20230505,,CN,GB,GB,2023,Q2,Elderly
222904631,22290463,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Somnolence,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043335,TAKEDA,,74.0,YR,,M,Y,,,20230505,,CN,GB,GB,2023,Q2,Elderly
222904631,22290463,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Swollen tongue,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043335,TAKEDA,,74.0,YR,,M,Y,,,20230505,,CN,GB,GB,2023,Q2,Elderly
222904631,22290463,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Abdominal discomfort,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043335,TAKEDA,,74.0,YR,,M,Y,,,20230505,,CN,GB,GB,2023,Q2,Elderly
222904631,22290463,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Nasopharyngitis,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043335,TAKEDA,,74.0,YR,,M,Y,,,20230505,,CN,GB,GB,2023,Q2,Elderly
222904631,22290463,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Pulmonary embolism,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043335,TAKEDA,,74.0,YR,,M,Y,,,20230505,,CN,GB,GB,2023,Q2,Elderly
222904631,22290463,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Intentional product use issue,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043335,TAKEDA,,74.0,YR,,M,Y,,,20230505,,CN,GB,GB,2023,Q2,Elderly
222904631,22290463,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Influenza,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043335,TAKEDA,,74.0,YR,,M,Y,,,20230505,,CN,GB,GB,2023,Q2,Elderly
222904631,22290463,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Product use in unapproved indication,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043335,TAKEDA,,74.0,YR,,M,Y,,,20230505,,CN,GB,GB,2023,Q2,Elderly
222904631,22290463,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,COVID-19,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043335,TAKEDA,,74.0,YR,,M,Y,,,20230505,,CN,GB,GB,2023,Q2,Elderly
222904631,22290463,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Parosmia,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043335,TAKEDA,,74.0,YR,,M,Y,,,20230505,,CN,GB,GB,2023,Q2,Elderly
222904631,22290463,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Impaired quality of life,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043335,TAKEDA,,74.0,YR,,M,Y,,,20230505,,CN,GB,GB,2023,Q2,Elderly
222904631,22290463,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Weight decreased,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043335,TAKEDA,,74.0,YR,,M,Y,,,20230505,,CN,GB,GB,2023,Q2,Elderly
222904631,22290463,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Colitis ulcerative,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043335,TAKEDA,,74.0,YR,,M,Y,,,20230505,,CN,GB,GB,2023,Q2,Elderly
222904631,22290463,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Stress,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043335,TAKEDA,,74.0,YR,,M,Y,,,20230505,,CN,GB,GB,2023,Q2,Elderly
222904631,22290463,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Drug ineffective,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043335,TAKEDA,,74.0,YR,,M,Y,,,20230505,,CN,GB,GB,2023,Q2,Elderly
222904631,22290463,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Migraine,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043335,TAKEDA,,74.0,YR,,M,Y,,,20230505,,CN,GB,GB,2023,Q2,Elderly
222904631,22290463,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Catarrh,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043335,TAKEDA,,74.0,YR,,M,Y,,,20230505,,CN,GB,GB,2023,Q2,Elderly
222904631,22290463,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Impaired work ability,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043335,TAKEDA,,74.0,YR,,M,Y,,,20230505,,CN,GB,GB,2023,Q2,Elderly
222904631,22290463,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Eczema,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043335,TAKEDA,,74.0,YR,,M,Y,,,20230505,,CN,GB,GB,2023,Q2,Elderly
222904631,22290463,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Burns second degree,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043335,TAKEDA,,74.0,YR,,M,Y,,,20230505,,CN,GB,GB,2023,Q2,Elderly
222904631,22290463,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Accidental overdose,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043335,TAKEDA,,74.0,YR,,M,Y,,,20230505,,CN,GB,GB,2023,Q2,Elderly
222904631,22290463,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Inappropriate schedule of product administration,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043335,TAKEDA,,74.0,YR,,M,Y,,,20230505,,CN,GB,GB,2023,Q2,Elderly
222904631,22290463,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Palpitations,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043335,TAKEDA,,74.0,YR,,M,Y,,,20230505,,CN,GB,GB,2023,Q2,Elderly
222904631,22290463,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Tinnitus,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043335,TAKEDA,,74.0,YR,,M,Y,,,20230505,,CN,GB,GB,2023,Q2,Elderly
222904631,22290463,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Confusional state,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043335,TAKEDA,,74.0,YR,,M,Y,,,20230505,,CN,GB,GB,2023,Q2,Elderly
222904631,22290463,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Vertigo,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043335,TAKEDA,,74.0,YR,,M,Y,,,20230505,,CN,GB,GB,2023,Q2,Elderly
222904631,22290463,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Pyrexia,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043335,TAKEDA,,74.0,YR,,M,Y,,,20230505,,CN,GB,GB,2023,Q2,Elderly
222904631,22290463,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Rhinitis,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043335,TAKEDA,,74.0,YR,,M,Y,,,20230505,,CN,GB,GB,2023,Q2,Elderly
222904631,22290463,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Depression,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043335,TAKEDA,,74.0,YR,,M,Y,,,20230505,,CN,GB,GB,2023,Q2,Elderly
222904631,22290463,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Hypopnoea,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043335,TAKEDA,,74.0,YR,,M,Y,,,20230505,,CN,GB,GB,2023,Q2,Elderly
222904631,22290463,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Frequent bowel movements,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043335,TAKEDA,,74.0,YR,,M,Y,,,20230505,,CN,GB,GB,2023,Q2,Elderly
222904631,22290463,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Headache,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043335,TAKEDA,,74.0,YR,,M,Y,,,20230505,,CN,GB,GB,2023,Q2,Elderly
222904631,22290463,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Loss of personal independence in daily activities,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043335,TAKEDA,,74.0,YR,,M,Y,,,20230505,,CN,GB,GB,2023,Q2,Elderly
222904631,22290463,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Gingival pain,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043335,TAKEDA,,74.0,YR,,M,Y,,,20230505,,CN,GB,GB,2023,Q2,Elderly
222904631,22290463,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Pain in extremity,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043335,TAKEDA,,74.0,YR,,M,Y,,,20230505,,CN,GB,GB,2023,Q2,Elderly
222904631,22290463,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Arthritis,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043335,TAKEDA,,74.0,YR,,M,Y,,,20230505,,CN,GB,GB,2023,Q2,Elderly
222904631,22290463,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Cerebrovascular accident,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043335,TAKEDA,,74.0,YR,,M,Y,,,20230505,,CN,GB,GB,2023,Q2,Elderly
222904631,22290463,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Bronchiectasis,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043335,TAKEDA,,74.0,YR,,M,Y,,,20230505,,CN,GB,GB,2023,Q2,Elderly
222904631,22290463,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Cardiac murmur,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,,GB-TAKEDA-2023TUS043335,TAKEDA,,74.0,YR,,M,Y,,,20230505,,CN,GB,GB,2023,Q2,Elderly
222906801,22290680,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Gingival pain,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-AstraZeneca-2023A099447,GB-TAKEDA-2023TUS043330,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230505,,MD,GB,GB,2023,Q2,Elderly
222906801,22290680,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Inappropriate schedule of product administration,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-AstraZeneca-2023A099447,GB-TAKEDA-2023TUS043330,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230505,,MD,GB,GB,2023,Q2,Elderly
222906801,22290680,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Eczema,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-AstraZeneca-2023A099447,GB-TAKEDA-2023TUS043330,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230505,,MD,GB,GB,2023,Q2,Elderly
222906801,22290680,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Confusional state,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-AstraZeneca-2023A099447,GB-TAKEDA-2023TUS043330,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230505,,MD,GB,GB,2023,Q2,Elderly
222906801,22290680,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Adverse drug reaction,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-AstraZeneca-2023A099447,GB-TAKEDA-2023TUS043330,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230505,,MD,GB,GB,2023,Q2,Elderly
222906801,22290680,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Rectal haemorrhage,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-AstraZeneca-2023A099447,GB-TAKEDA-2023TUS043330,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230505,,MD,GB,GB,2023,Q2,Elderly
222906801,22290680,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Tubulointerstitial nephritis,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-AstraZeneca-2023A099447,GB-TAKEDA-2023TUS043330,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230505,,MD,GB,GB,2023,Q2,Elderly
222906801,22290680,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Drug ineffective,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-AstraZeneca-2023A099447,GB-TAKEDA-2023TUS043330,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230505,,MD,GB,GB,2023,Q2,Elderly
222906801,22290680,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Palpitations,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-AstraZeneca-2023A099447,GB-TAKEDA-2023TUS043330,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230505,,MD,GB,GB,2023,Q2,Elderly
222906801,22290680,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Somnolence,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-AstraZeneca-2023A099447,GB-TAKEDA-2023TUS043330,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230505,,MD,GB,GB,2023,Q2,Elderly
222906801,22290680,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Pain in extremity,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-AstraZeneca-2023A099447,GB-TAKEDA-2023TUS043330,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230505,,MD,GB,GB,2023,Q2,Elderly
222906801,22290680,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Rhinitis,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-AstraZeneca-2023A099447,GB-TAKEDA-2023TUS043330,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230505,,MD,GB,GB,2023,Q2,Elderly
222906801,22290680,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Deep vein thrombosis,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-AstraZeneca-2023A099447,GB-TAKEDA-2023TUS043330,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230505,,MD,GB,GB,2023,Q2,Elderly
222906801,22290680,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Product use in unapproved indication,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-AstraZeneca-2023A099447,GB-TAKEDA-2023TUS043330,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230505,,MD,GB,GB,2023,Q2,Elderly
222906801,22290680,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Cerebrovascular accident,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-AstraZeneca-2023A099447,GB-TAKEDA-2023TUS043330,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230505,,MD,GB,GB,2023,Q2,Elderly
222906801,22290680,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Headache,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-AstraZeneca-2023A099447,GB-TAKEDA-2023TUS043330,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230505,,MD,GB,GB,2023,Q2,Elderly
222906801,22290680,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Vertigo,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-AstraZeneca-2023A099447,GB-TAKEDA-2023TUS043330,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230505,,MD,GB,GB,2023,Q2,Elderly
222906801,22290680,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Pulmonary embolism,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-AstraZeneca-2023A099447,GB-TAKEDA-2023TUS043330,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230505,,MD,GB,GB,2023,Q2,Elderly
222906801,22290680,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Arthritis,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-AstraZeneca-2023A099447,GB-TAKEDA-2023TUS043330,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230505,,MD,GB,GB,2023,Q2,Elderly
222906801,22290680,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Dysgeusia,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-AstraZeneca-2023A099447,GB-TAKEDA-2023TUS043330,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230505,,MD,GB,GB,2023,Q2,Elderly
222906801,22290680,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Off label use,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-AstraZeneca-2023A099447,GB-TAKEDA-2023TUS043330,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230505,,MD,GB,GB,2023,Q2,Elderly
222906801,22290680,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Bronchiectasis,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-AstraZeneca-2023A099447,GB-TAKEDA-2023TUS043330,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230505,,MD,GB,GB,2023,Q2,Elderly
222906801,22290680,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Cardiac murmur,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-AstraZeneca-2023A099447,GB-TAKEDA-2023TUS043330,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230505,,MD,GB,GB,2023,Q2,Elderly
222906801,22290680,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Abdominal discomfort,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-AstraZeneca-2023A099447,GB-TAKEDA-2023TUS043330,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230505,,MD,GB,GB,2023,Q2,Elderly
222906801,22290680,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,COVID-19,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-AstraZeneca-2023A099447,GB-TAKEDA-2023TUS043330,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230505,,MD,GB,GB,2023,Q2,Elderly
222906801,22290680,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Hypopnoea,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-AstraZeneca-2023A099447,GB-TAKEDA-2023TUS043330,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230505,,MD,GB,GB,2023,Q2,Elderly
222906801,22290680,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Migraine,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-AstraZeneca-2023A099447,GB-TAKEDA-2023TUS043330,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230505,,MD,GB,GB,2023,Q2,Elderly
222906801,22290680,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Fatigue,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-AstraZeneca-2023A099447,GB-TAKEDA-2023TUS043330,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230505,,MD,GB,GB,2023,Q2,Elderly
222906801,22290680,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Systemic lupus erythematosus,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-AstraZeneca-2023A099447,GB-TAKEDA-2023TUS043330,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230505,,MD,GB,GB,2023,Q2,Elderly
222906801,22290680,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Nightmare,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-AstraZeneca-2023A099447,GB-TAKEDA-2023TUS043330,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230505,,MD,GB,GB,2023,Q2,Elderly
222906801,22290680,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Haematochezia,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-AstraZeneca-2023A099447,GB-TAKEDA-2023TUS043330,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230505,,MD,GB,GB,2023,Q2,Elderly
222906801,22290680,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Swollen tongue,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-AstraZeneca-2023A099447,GB-TAKEDA-2023TUS043330,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230505,,MD,GB,GB,2023,Q2,Elderly
222906801,22290680,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Medication error,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-AstraZeneca-2023A099447,GB-TAKEDA-2023TUS043330,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230505,,MD,GB,GB,2023,Q2,Elderly
222906801,22290680,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Depression,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-AstraZeneca-2023A099447,GB-TAKEDA-2023TUS043330,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230505,,MD,GB,GB,2023,Q2,Elderly
222906801,22290680,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Steroid dependence,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-AstraZeneca-2023A099447,GB-TAKEDA-2023TUS043330,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230505,,MD,GB,GB,2023,Q2,Elderly
222906801,22290680,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Parosmia,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-AstraZeneca-2023A099447,GB-TAKEDA-2023TUS043330,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230505,,MD,GB,GB,2023,Q2,Elderly
222906801,22290680,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Impaired work ability,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-AstraZeneca-2023A099447,GB-TAKEDA-2023TUS043330,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230505,,MD,GB,GB,2023,Q2,Elderly
222906801,22290680,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Accidental overdose,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-AstraZeneca-2023A099447,GB-TAKEDA-2023TUS043330,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230505,,MD,GB,GB,2023,Q2,Elderly
222906801,22290680,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Rash,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-AstraZeneca-2023A099447,GB-TAKEDA-2023TUS043330,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230505,,MD,GB,GB,2023,Q2,Elderly
222906801,22290680,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Stress,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-AstraZeneca-2023A099447,GB-TAKEDA-2023TUS043330,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230505,,MD,GB,GB,2023,Q2,Elderly
222906801,22290680,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Colitis ulcerative,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-AstraZeneca-2023A099447,GB-TAKEDA-2023TUS043330,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230505,,MD,GB,GB,2023,Q2,Elderly
222906801,22290680,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Intentional product use issue,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-AstraZeneca-2023A099447,GB-TAKEDA-2023TUS043330,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230505,,MD,GB,GB,2023,Q2,Elderly
222906801,22290680,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Tinnitus,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-AstraZeneca-2023A099447,GB-TAKEDA-2023TUS043330,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230505,,MD,GB,GB,2023,Q2,Elderly
222906801,22290680,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Burns second degree,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-AstraZeneca-2023A099447,GB-TAKEDA-2023TUS043330,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230505,,MD,GB,GB,2023,Q2,Elderly
222906801,22290680,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Pain,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-AstraZeneca-2023A099447,GB-TAKEDA-2023TUS043330,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230505,,MD,GB,GB,2023,Q2,Elderly
222906801,22290680,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Loss of personal independence in daily activities,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-AstraZeneca-2023A099447,GB-TAKEDA-2023TUS043330,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230505,,MD,GB,GB,2023,Q2,Elderly
222906801,22290680,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Catarrh,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-AstraZeneca-2023A099447,GB-TAKEDA-2023TUS043330,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230505,,MD,GB,GB,2023,Q2,Elderly
222906801,22290680,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Pyrexia,,2023,Q2,1,I,20190101.0,20230426.0,20230505,20230505,EXP,GB-AstraZeneca-2023A099447,GB-TAKEDA-2023TUS043330,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230505,,MD,GB,GB,2023,Q2,Elderly
222937441,22293744,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg/d,  film-coated tablets",,,Y,,,,,10.0,MG,Film-coated tablet,,2023,Q2,Subcutaneous abscess,,2023,Q2,1,I,20230120.0,20230425.0,20230508,20230508,EXP,FR-AFSSAPS-PA2023000479,FR-Accord-356856,ACCORD,,75.0,YR,E,M,Y,67.0,KG,20230508,,PH,FR,FR,2023,Q2,Elderly
222948551,22294855,80,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Impaired work ability,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045336,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,GB,2023,Q2,Elderly
222948551,22294855,80,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Tinnitus,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045336,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,GB,2023,Q2,Elderly
222948551,22294855,80,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Gingival pain,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045336,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,GB,2023,Q2,Elderly
222948551,22294855,80,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Product use in unapproved indication,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045336,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,GB,2023,Q2,Elderly
222948551,22294855,80,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Abdominal discomfort,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045336,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,GB,2023,Q2,Elderly
222948551,22294855,80,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Pyrexia,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045336,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,GB,2023,Q2,Elderly
222948551,22294855,80,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Dysgeusia,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045336,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,GB,2023,Q2,Elderly
222948551,22294855,80,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Confusional state,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045336,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,GB,2023,Q2,Elderly
222948551,22294855,80,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Swollen tongue,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045336,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,GB,2023,Q2,Elderly
222948551,22294855,80,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Fatigue,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045336,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,GB,2023,Q2,Elderly
222948551,22294855,80,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Rhinitis,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045336,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,GB,2023,Q2,Elderly
222948551,22294855,80,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Headache,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045336,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,GB,2023,Q2,Elderly
222948551,22294855,80,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Palpitations,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045336,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,GB,2023,Q2,Elderly
222948551,22294855,80,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Inappropriate schedule of product administration,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045336,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,GB,2023,Q2,Elderly
222948551,22294855,80,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Migraine,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045336,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,GB,2023,Q2,Elderly
222948551,22294855,80,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Condition aggravated,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045336,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,GB,2023,Q2,Elderly
222948551,22294855,80,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Deep vein thrombosis,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045336,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,GB,2023,Q2,Elderly
222948551,22294855,80,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Systemic lupus erythematosus,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045336,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,GB,2023,Q2,Elderly
222948551,22294855,80,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Rectal haemorrhage,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045336,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,GB,2023,Q2,Elderly
222948551,22294855,80,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Impaired quality of life,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045336,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,GB,2023,Q2,Elderly
222948551,22294855,80,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Pain,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045336,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,GB,2023,Q2,Elderly
222948551,22294855,80,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Off label use,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045336,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,GB,2023,Q2,Elderly
222948551,22294855,80,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Weight decreased,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045336,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,GB,2023,Q2,Elderly
222948551,22294855,80,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Drug ineffective,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045336,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,GB,2023,Q2,Elderly
222948551,22294855,80,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Stress,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045336,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,GB,2023,Q2,Elderly
222948551,22294855,80,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Hypopnoea,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045336,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,GB,2023,Q2,Elderly
222948551,22294855,80,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,COVID-19,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045336,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,GB,2023,Q2,Elderly
222948551,22294855,80,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Medication error,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045336,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,GB,2023,Q2,Elderly
222948551,22294855,80,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Loss of personal independence in daily activities,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045336,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,GB,2023,Q2,Elderly
222948551,22294855,80,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Accidental overdose,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045336,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,GB,2023,Q2,Elderly
222948551,22294855,80,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Catarrh,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045336,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,GB,2023,Q2,Elderly
222948551,22294855,80,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Vertigo,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045336,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,GB,2023,Q2,Elderly
222948551,22294855,80,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Rash,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045336,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,GB,2023,Q2,Elderly
222948551,22294855,80,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Bronchiectasis,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045336,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,GB,2023,Q2,Elderly
222948551,22294855,80,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Pain in extremity,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045336,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,GB,2023,Q2,Elderly
222948551,22294855,80,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Frequent bowel movements,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045336,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,GB,2023,Q2,Elderly
222948551,22294855,80,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Haematochezia,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045336,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,GB,2023,Q2,Elderly
222948551,22294855,80,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Arthritis,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045336,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,GB,2023,Q2,Elderly
222948551,22294855,80,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Colitis ulcerative,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045336,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,GB,2023,Q2,Elderly
222948551,22294855,80,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Eczema,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045336,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,GB,2023,Q2,Elderly
222948551,22294855,80,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Somnolence,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045336,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,GB,2023,Q2,Elderly
222948551,22294855,80,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Cardiac murmur,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045336,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,GB,2023,Q2,Elderly
222948551,22294855,80,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Burns second degree,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045336,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,GB,2023,Q2,Elderly
222948551,22294855,80,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Intentional product use issue,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045336,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,GB,2023,Q2,Elderly
222948551,22294855,80,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Parosmia,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045336,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,GB,2023,Q2,Elderly
222948551,22294855,80,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Adverse drug reaction,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045336,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,GB,2023,Q2,Elderly
222948551,22294855,80,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Nightmare,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045336,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,GB,2023,Q2,Elderly
222948551,22294855,80,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Depression,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045336,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,GB,2023,Q2,Elderly
222948551,22294855,80,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Steroid dependence,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045336,TAKEDA,,86.0,YR,,M,Y,65.0,KG,20230508,,MD,GB,GB,2023,Q2,Elderly
222950531,22295053,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q2,Glomerular filtration rate decreased,,2023,Q2,1,I,,20230505.0,20230508,20230508,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-235868",BOEHRINGER INGELHEIM,,60.0,YR,A,M,Y,,,20230508,,HP,GB,GB,2023,Q2,Adult
222950531,22295053,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q2,Loss of consciousness,,2023,Q2,1,I,,20230505.0,20230508,20230508,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-235868",BOEHRINGER INGELHEIM,,60.0,YR,A,M,Y,,,20230508,,HP,GB,GB,2023,Q2,Adult
222950531,22295053,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q2,Confusional state,,2023,Q2,1,I,,20230505.0,20230508,20230508,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-235868",BOEHRINGER INGELHEIM,,60.0,YR,A,M,Y,,,20230508,,HP,GB,GB,2023,Q2,Adult
222950531,22295053,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q2,Dehydration,,2023,Q2,1,I,,20230505.0,20230508,20230508,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-235868",BOEHRINGER INGELHEIM,,60.0,YR,A,M,Y,,,20230508,,HP,GB,GB,2023,Q2,Adult
222958251,22295825,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Impaired quality of life,,2023,Q2,1,I,20210212.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045360,TAKEDA,,34.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Young Adult
222958251,22295825,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Stress,,2023,Q2,1,I,20210212.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045360,TAKEDA,,34.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Young Adult
222958251,22295825,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Arthritis,,2023,Q2,1,I,20210212.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045360,TAKEDA,,34.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Young Adult
222958251,22295825,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Nightmare,,2023,Q2,1,I,20210212.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045360,TAKEDA,,34.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Young Adult
222958251,22295825,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Medication error,,2023,Q2,1,I,20210212.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045360,TAKEDA,,34.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Young Adult
222958251,22295825,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Cardiac murmur,,2023,Q2,1,I,20210212.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045360,TAKEDA,,34.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Young Adult
222958251,22295825,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Migraine,,2023,Q2,1,I,20210212.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045360,TAKEDA,,34.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Young Adult
222958251,22295825,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Intentional product use issue,,2023,Q2,1,I,20210212.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045360,TAKEDA,,34.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Young Adult
222958251,22295825,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Micturition disorder,,2023,Q2,1,I,20210212.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045360,TAKEDA,,34.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Young Adult
222958251,22295825,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Pulmonary embolism,,2023,Q2,1,I,20210212.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045360,TAKEDA,,34.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Young Adult
222958251,22295825,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Palpitations,,2023,Q2,1,I,20210212.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045360,TAKEDA,,34.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Young Adult
222958251,22295825,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Weight decreased,,2023,Q2,1,I,20210212.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045360,TAKEDA,,34.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Young Adult
222958251,22295825,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Haematochezia,,2023,Q2,1,I,20210212.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045360,TAKEDA,,34.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Young Adult
222958251,22295825,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Drug ineffective,,2023,Q2,1,I,20210212.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045360,TAKEDA,,34.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Young Adult
222958251,22295825,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Rectal haemorrhage,,2023,Q2,1,I,20210212.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045360,TAKEDA,,34.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Young Adult
222958251,22295825,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Pain in extremity,,2023,Q2,1,I,20210212.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045360,TAKEDA,,34.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Young Adult
222958251,22295825,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Hypopnoea,,2023,Q2,1,I,20210212.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045360,TAKEDA,,34.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Young Adult
222958251,22295825,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Swollen tongue,,2023,Q2,1,I,20210212.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045360,TAKEDA,,34.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Young Adult
222958251,22295825,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Deep vein thrombosis,,2023,Q2,1,I,20210212.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045360,TAKEDA,,34.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Young Adult
222958251,22295825,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Eczema,,2023,Q2,1,I,20210212.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045360,TAKEDA,,34.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Young Adult
222958251,22295825,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Bronchiectasis,,2023,Q2,1,I,20210212.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045360,TAKEDA,,34.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Young Adult
222958251,22295825,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Catarrh,,2023,Q2,1,I,20210212.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045360,TAKEDA,,34.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Young Adult
222958251,22295825,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Product use in unapproved indication,,2023,Q2,1,I,20210212.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045360,TAKEDA,,34.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Young Adult
222958251,22295825,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Tubulointerstitial nephritis,,2023,Q2,1,I,20210212.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045360,TAKEDA,,34.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Young Adult
222958251,22295825,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Confusional state,,2023,Q2,1,I,20210212.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045360,TAKEDA,,34.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Young Adult
222958251,22295825,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Somnolence,,2023,Q2,1,I,20210212.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045360,TAKEDA,,34.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Young Adult
222958251,22295825,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Gingival pain,,2023,Q2,1,I,20210212.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045360,TAKEDA,,34.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Young Adult
222958251,22295825,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Dysgeusia,,2023,Q2,1,I,20210212.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045360,TAKEDA,,34.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Young Adult
222958251,22295825,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Systemic lupus erythematosus,,2023,Q2,1,I,20210212.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045360,TAKEDA,,34.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Young Adult
222958251,22295825,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Inappropriate schedule of product administration,,2023,Q2,1,I,20210212.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045360,TAKEDA,,34.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Young Adult
222958251,22295825,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Headache,,2023,Q2,1,I,20210212.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045360,TAKEDA,,34.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Young Adult
222958251,22295825,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Abdominal discomfort,,2023,Q2,1,I,20210212.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045360,TAKEDA,,34.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Young Adult
222958251,22295825,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Vertigo,,2023,Q2,1,I,20210212.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045360,TAKEDA,,34.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Young Adult
222958251,22295825,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Pyrexia,,2023,Q2,1,I,20210212.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045360,TAKEDA,,34.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Young Adult
222958251,22295825,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Colitis ulcerative,,2023,Q2,1,I,20210212.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045360,TAKEDA,,34.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Young Adult
222958251,22295825,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Steroid dependence,,2023,Q2,1,I,20210212.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045360,TAKEDA,,34.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Young Adult
222958251,22295825,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Loss of personal independence in daily activities,,2023,Q2,1,I,20210212.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045360,TAKEDA,,34.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Young Adult
222958251,22295825,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Pain,,2023,Q2,1,I,20210212.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045360,TAKEDA,,34.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Young Adult
222958251,22295825,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Parosmia,,2023,Q2,1,I,20210212.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045360,TAKEDA,,34.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Young Adult
222958251,22295825,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Fatigue,,2023,Q2,1,I,20210212.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045360,TAKEDA,,34.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Young Adult
222958251,22295825,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Frequent bowel movements,,2023,Q2,1,I,20210212.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045360,TAKEDA,,34.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Young Adult
222958251,22295825,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Cerebrovascular accident,,2023,Q2,1,I,20210212.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045360,TAKEDA,,34.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Young Adult
222958251,22295825,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Burns second degree,,2023,Q2,1,I,20210212.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045360,TAKEDA,,34.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Young Adult
222958251,22295825,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Impaired work ability,,2023,Q2,1,I,20210212.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045360,TAKEDA,,34.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Young Adult
222958251,22295825,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Condition aggravated,,2023,Q2,1,I,20210212.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045360,TAKEDA,,34.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Young Adult
222958251,22295825,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Off label use,,2023,Q2,1,I,20210212.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045360,TAKEDA,,34.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Young Adult
222958251,22295825,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Depression,,2023,Q2,1,I,20210212.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045360,TAKEDA,,34.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Young Adult
222958251,22295825,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Tinnitus,,2023,Q2,1,I,20210212.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045360,TAKEDA,,34.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Young Adult
222958251,22295825,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,COVID-19,,2023,Q2,1,I,20210212.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045360,TAKEDA,,34.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Young Adult
222958251,22295825,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Tinnitus,,2023,Q2,1,I,20210212.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045360,TAKEDA,,34.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Young Adult
222958251,22295825,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Rhinitis,,2023,Q2,1,I,20210212.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045360,TAKEDA,,34.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Young Adult
222958251,22295825,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Accidental overdose,,2023,Q2,1,I,20210212.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045360,TAKEDA,,34.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Young Adult
222958251,22295825,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Rash,,2023,Q2,1,I,20210212.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045360,TAKEDA,,34.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Young Adult
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,Off label use,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,Bronchiectasis,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,Pain,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,Eczema,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,Deep vein thrombosis,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,Medication error,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,Rash,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,Steroid dependence,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,Somnolence,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,Stress,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,Swollen tongue,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,Fatigue,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,Migraine,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,Accidental overdose,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,Rhinitis,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,Inappropriate schedule of product administration,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,Pulmonary embolism,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,Gingival pain,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,Abdominal discomfort,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,Haematochezia,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,Palpitations,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,Pyrexia,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,Catarrh,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,Depression,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,COVID-19,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,Confusional state,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,Cardiac murmur,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,Headache,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,Tubulointerstitial nephritis,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,Impaired quality of life,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,Adverse drug reaction,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,Tinnitus,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,Cerebrovascular accident,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,Impaired work ability,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,Pain in extremity,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,Rash,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,Vertigo,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,Dysgeusia,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,Nightmare,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,Colitis ulcerative,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,Fatigue,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,Drug ineffective,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,Frequent bowel movements,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,Arthritis,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,Loss of personal independence in daily activities,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,Tinnitus,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,Rectal haemorrhage,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,Parosmia,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,Product use in unapproved indication,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,Colitis ulcerative,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,Burns second degree,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,Intentional product use issue,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,Weight decreased,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,Systemic lupus erythematosus,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,Hypopnoea,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222958311,22295831,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,UNK,,2023,Q2,Condition aggravated,,2023,Q2,1,I,20080101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045320,TAKEDA,,76.0,YR,,F,Y,,,20230508,,MD,GB,GB,2023,Q2,Elderly
222961911,22296191,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Tinnitus,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045379,TAKEDA,,40.0,YR,,M,Y,99.0,KG,20230508,,CN,GB,GB,2023,Q2,Adult
222961911,22296191,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Weight decreased,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045379,TAKEDA,,40.0,YR,,M,Y,99.0,KG,20230508,,CN,GB,GB,2023,Q2,Adult
222961911,22296191,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Vertigo,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045379,TAKEDA,,40.0,YR,,M,Y,99.0,KG,20230508,,CN,GB,GB,2023,Q2,Adult
222961911,22296191,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Colitis ulcerative,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045379,TAKEDA,,40.0,YR,,M,Y,99.0,KG,20230508,,CN,GB,GB,2023,Q2,Adult
222961911,22296191,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Rhinitis,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045379,TAKEDA,,40.0,YR,,M,Y,99.0,KG,20230508,,CN,GB,GB,2023,Q2,Adult
222961911,22296191,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Dysgeusia,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045379,TAKEDA,,40.0,YR,,M,Y,99.0,KG,20230508,,CN,GB,GB,2023,Q2,Adult
222961911,22296191,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Hypopnoea,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045379,TAKEDA,,40.0,YR,,M,Y,99.0,KG,20230508,,CN,GB,GB,2023,Q2,Adult
222961911,22296191,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Tubulointerstitial nephritis,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045379,TAKEDA,,40.0,YR,,M,Y,99.0,KG,20230508,,CN,GB,GB,2023,Q2,Adult
222961911,22296191,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Off label use,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045379,TAKEDA,,40.0,YR,,M,Y,99.0,KG,20230508,,CN,GB,GB,2023,Q2,Adult
222961911,22296191,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Bronchiectasis,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045379,TAKEDA,,40.0,YR,,M,Y,99.0,KG,20230508,,CN,GB,GB,2023,Q2,Adult
222961911,22296191,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Medication error,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045379,TAKEDA,,40.0,YR,,M,Y,99.0,KG,20230508,,CN,GB,GB,2023,Q2,Adult
222961911,22296191,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Product use in unapproved indication,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045379,TAKEDA,,40.0,YR,,M,Y,99.0,KG,20230508,,CN,GB,GB,2023,Q2,Adult
222961911,22296191,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Impaired work ability,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045379,TAKEDA,,40.0,YR,,M,Y,99.0,KG,20230508,,CN,GB,GB,2023,Q2,Adult
222961911,22296191,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Pain,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045379,TAKEDA,,40.0,YR,,M,Y,99.0,KG,20230508,,CN,GB,GB,2023,Q2,Adult
222961911,22296191,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Eczema,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045379,TAKEDA,,40.0,YR,,M,Y,99.0,KG,20230508,,CN,GB,GB,2023,Q2,Adult
222961911,22296191,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Gingival pain,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045379,TAKEDA,,40.0,YR,,M,Y,99.0,KG,20230508,,CN,GB,GB,2023,Q2,Adult
222961911,22296191,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Tinnitus,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045379,TAKEDA,,40.0,YR,,M,Y,99.0,KG,20230508,,CN,GB,GB,2023,Q2,Adult
222961911,22296191,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,COVID-19,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045379,TAKEDA,,40.0,YR,,M,Y,99.0,KG,20230508,,CN,GB,GB,2023,Q2,Adult
222961911,22296191,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Swollen tongue,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045379,TAKEDA,,40.0,YR,,M,Y,99.0,KG,20230508,,CN,GB,GB,2023,Q2,Adult
222961911,22296191,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Steroid dependence,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045379,TAKEDA,,40.0,YR,,M,Y,99.0,KG,20230508,,CN,GB,GB,2023,Q2,Adult
222961911,22296191,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Loss of personal independence in daily activities,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045379,TAKEDA,,40.0,YR,,M,Y,99.0,KG,20230508,,CN,GB,GB,2023,Q2,Adult
222961911,22296191,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Inappropriate schedule of product administration,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045379,TAKEDA,,40.0,YR,,M,Y,99.0,KG,20230508,,CN,GB,GB,2023,Q2,Adult
222961911,22296191,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Haematochezia,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045379,TAKEDA,,40.0,YR,,M,Y,99.0,KG,20230508,,CN,GB,GB,2023,Q2,Adult
222961911,22296191,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Stress,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045379,TAKEDA,,40.0,YR,,M,Y,99.0,KG,20230508,,CN,GB,GB,2023,Q2,Adult
222961911,22296191,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Fatigue,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045379,TAKEDA,,40.0,YR,,M,Y,99.0,KG,20230508,,CN,GB,GB,2023,Q2,Adult
222961911,22296191,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Migraine,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045379,TAKEDA,,40.0,YR,,M,Y,99.0,KG,20230508,,CN,GB,GB,2023,Q2,Adult
222961911,22296191,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Drug ineffective,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045379,TAKEDA,,40.0,YR,,M,Y,99.0,KG,20230508,,CN,GB,GB,2023,Q2,Adult
222961911,22296191,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Deep vein thrombosis,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045379,TAKEDA,,40.0,YR,,M,Y,99.0,KG,20230508,,CN,GB,GB,2023,Q2,Adult
222961911,22296191,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Rectal haemorrhage,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045379,TAKEDA,,40.0,YR,,M,Y,99.0,KG,20230508,,CN,GB,GB,2023,Q2,Adult
222961911,22296191,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Headache,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045379,TAKEDA,,40.0,YR,,M,Y,99.0,KG,20230508,,CN,GB,GB,2023,Q2,Adult
222961911,22296191,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Parosmia,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045379,TAKEDA,,40.0,YR,,M,Y,99.0,KG,20230508,,CN,GB,GB,2023,Q2,Adult
222961911,22296191,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Pulmonary embolism,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045379,TAKEDA,,40.0,YR,,M,Y,99.0,KG,20230508,,CN,GB,GB,2023,Q2,Adult
222961911,22296191,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Confusional state,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045379,TAKEDA,,40.0,YR,,M,Y,99.0,KG,20230508,,CN,GB,GB,2023,Q2,Adult
222961911,22296191,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Nightmare,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045379,TAKEDA,,40.0,YR,,M,Y,99.0,KG,20230508,,CN,GB,GB,2023,Q2,Adult
222961911,22296191,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Arthritis,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045379,TAKEDA,,40.0,YR,,M,Y,99.0,KG,20230508,,CN,GB,GB,2023,Q2,Adult
222961911,22296191,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Depression,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045379,TAKEDA,,40.0,YR,,M,Y,99.0,KG,20230508,,CN,GB,GB,2023,Q2,Adult
222961911,22296191,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Rash,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045379,TAKEDA,,40.0,YR,,M,Y,99.0,KG,20230508,,CN,GB,GB,2023,Q2,Adult
222961911,22296191,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Intentional product use issue,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045379,TAKEDA,,40.0,YR,,M,Y,99.0,KG,20230508,,CN,GB,GB,2023,Q2,Adult
222961911,22296191,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Impaired quality of life,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045379,TAKEDA,,40.0,YR,,M,Y,99.0,KG,20230508,,CN,GB,GB,2023,Q2,Adult
222961911,22296191,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Catarrh,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045379,TAKEDA,,40.0,YR,,M,Y,99.0,KG,20230508,,CN,GB,GB,2023,Q2,Adult
222961911,22296191,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Adverse drug reaction,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045379,TAKEDA,,40.0,YR,,M,Y,99.0,KG,20230508,,CN,GB,GB,2023,Q2,Adult
222961911,22296191,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Abdominal discomfort,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045379,TAKEDA,,40.0,YR,,M,Y,99.0,KG,20230508,,CN,GB,GB,2023,Q2,Adult
222961911,22296191,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Somnolence,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045379,TAKEDA,,40.0,YR,,M,Y,99.0,KG,20230508,,CN,GB,GB,2023,Q2,Adult
222961911,22296191,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Palpitations,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045379,TAKEDA,,40.0,YR,,M,Y,99.0,KG,20230508,,CN,GB,GB,2023,Q2,Adult
222961911,22296191,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Burns second degree,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045379,TAKEDA,,40.0,YR,,M,Y,99.0,KG,20230508,,CN,GB,GB,2023,Q2,Adult
222961911,22296191,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Systemic lupus erythematosus,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045379,TAKEDA,,40.0,YR,,M,Y,99.0,KG,20230508,,CN,GB,GB,2023,Q2,Adult
222961911,22296191,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Pyrexia,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045379,TAKEDA,,40.0,YR,,M,Y,99.0,KG,20230508,,CN,GB,GB,2023,Q2,Adult
222961911,22296191,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Cerebrovascular accident,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045379,TAKEDA,,40.0,YR,,M,Y,99.0,KG,20230508,,CN,GB,GB,2023,Q2,Adult
222961911,22296191,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Cardiac murmur,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045379,TAKEDA,,40.0,YR,,M,Y,99.0,KG,20230508,,CN,GB,GB,2023,Q2,Adult
222961911,22296191,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Accidental overdose,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045379,TAKEDA,,40.0,YR,,M,Y,99.0,KG,20230508,,CN,GB,GB,2023,Q2,Adult
222961911,22296191,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Condition aggravated,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045379,TAKEDA,,40.0,YR,,M,Y,99.0,KG,20230508,,CN,GB,GB,2023,Q2,Adult
222961911,22296191,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Pain in extremity,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045379,TAKEDA,,40.0,YR,,M,Y,99.0,KG,20230508,,CN,GB,GB,2023,Q2,Adult
222961911,22296191,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2023,Q2,Frequent bowel movements,,2023,Q2,1,I,20190101.0,20230426.0,20230508,20230508,EXP,,GB-TAKEDA-2023TUS045379,TAKEDA,,40.0,YR,,M,Y,99.0,KG,20230508,,CN,GB,GB,2023,Q2,Adult
222966641,22296664,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Ejection fraction decreased,,2023,Q2,1,I,20220416.0,20230504.0,20230508,20230508,EXP,,GB-ABBVIE-4756892,ABBVIE,,65.0,YR,,M,Y,76.0,KG,20230508,,HP,GB,GB,2023,Q2,Elderly
222966641,22296664,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Cardiac failure,,2023,Q2,1,I,20220416.0,20230504.0,20230508,20230508,EXP,,GB-ABBVIE-4756892,ABBVIE,,65.0,YR,,M,Y,76.0,KG,20230508,,HP,GB,GB,2023,Q2,Elderly
222966641,22296664,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Dyspnoea,,2023,Q2,1,I,20220416.0,20230504.0,20230508,20230508,EXP,,GB-ABBVIE-4756892,ABBVIE,,65.0,YR,,M,Y,76.0,KG,20230508,,HP,GB,GB,2023,Q2,Elderly
222971901,22297190,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,U,,Unknown,,212614.0,,,,,2023,Q2,Visual impairment,,2023,Q2,1,I,,20230508.0,20230509,20230509,PER,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-236337",BOEHRINGER INGELHEIM,,80.0,YR,E,F,Y,,,20230509,,CN,US,US,2023,Q2,Elderly
222994961,22299496,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q2,Tongue disorder,,2023,Q2,1,I,20230301.0,20230509.0,20230509,20230509,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-236366",BOEHRINGER INGELHEIM,,54.0,YR,A,F,Y,,,20230509,,HP,SG,SG,2023,Q2,Adult
222997351,22299735,81,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,Unknown,,,,,Tablet,QD,2023,Q2,Bronchiectasis,,2023,Q2,1,I,,20230426.0,20230509,20230509,EXP,,GB-TAKEDA-2023TUS045442,TAKEDA,,58.0,YR,,M,Y,86.0,KG,20230509,,MD,GB,GB,2023,Q2,Adult
222997351,22299735,81,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,Unknown,,,,,Tablet,QD,2023,Q2,Frequent bowel movements,,2023,Q2,1,I,,20230426.0,20230509,20230509,EXP,,GB-TAKEDA-2023TUS045442,TAKEDA,,58.0,YR,,M,Y,86.0,KG,20230509,,MD,GB,GB,2023,Q2,Adult
222997351,22299735,81,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,Unknown,,,,,Tablet,QD,2023,Q2,Dysgeusia,,2023,Q2,1,I,,20230426.0,20230509,20230509,EXP,,GB-TAKEDA-2023TUS045442,TAKEDA,,58.0,YR,,M,Y,86.0,KG,20230509,,MD,GB,GB,2023,Q2,Adult
222997351,22299735,81,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,Unknown,,,,,Tablet,QD,2023,Q2,Palpitations,,2023,Q2,1,I,,20230426.0,20230509,20230509,EXP,,GB-TAKEDA-2023TUS045442,TAKEDA,,58.0,YR,,M,Y,86.0,KG,20230509,,MD,GB,GB,2023,Q2,Adult
222997351,22299735,81,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,Unknown,,,,,Tablet,QD,2023,Q2,Parosmia,,2023,Q2,1,I,,20230426.0,20230509,20230509,EXP,,GB-TAKEDA-2023TUS045442,TAKEDA,,58.0,YR,,M,Y,86.0,KG,20230509,,MD,GB,GB,2023,Q2,Adult
222997351,22299735,81,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,Unknown,,,,,Tablet,QD,2023,Q2,Rash,,2023,Q2,1,I,,20230426.0,20230509,20230509,EXP,,GB-TAKEDA-2023TUS045442,TAKEDA,,58.0,YR,,M,Y,86.0,KG,20230509,,MD,GB,GB,2023,Q2,Adult
222997351,22299735,81,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,Unknown,,,,,Tablet,QD,2023,Q2,Fatigue,,2023,Q2,1,I,,20230426.0,20230509,20230509,EXP,,GB-TAKEDA-2023TUS045442,TAKEDA,,58.0,YR,,M,Y,86.0,KG,20230509,,MD,GB,GB,2023,Q2,Adult
222997351,22299735,81,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,Unknown,,,,,Tablet,QD,2023,Q2,Cerebrovascular accident,,2023,Q2,1,I,,20230426.0,20230509,20230509,EXP,,GB-TAKEDA-2023TUS045442,TAKEDA,,58.0,YR,,M,Y,86.0,KG,20230509,,MD,GB,GB,2023,Q2,Adult
222997351,22299735,81,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,Unknown,,,,,Tablet,QD,2023,Q2,Abdominal discomfort,,2023,Q2,1,I,,20230426.0,20230509,20230509,EXP,,GB-TAKEDA-2023TUS045442,TAKEDA,,58.0,YR,,M,Y,86.0,KG,20230509,,MD,GB,GB,2023,Q2,Adult
222997351,22299735,81,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,Unknown,,,,,Tablet,QD,2023,Q2,Swollen tongue,,2023,Q2,1,I,,20230426.0,20230509,20230509,EXP,,GB-TAKEDA-2023TUS045442,TAKEDA,,58.0,YR,,M,Y,86.0,KG,20230509,,MD,GB,GB,2023,Q2,Adult
222997351,22299735,81,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,Unknown,,,,,Tablet,QD,2023,Q2,Tubulointerstitial nephritis,,2023,Q2,1,I,,20230426.0,20230509,20230509,EXP,,GB-TAKEDA-2023TUS045442,TAKEDA,,58.0,YR,,M,Y,86.0,KG,20230509,,MD,GB,GB,2023,Q2,Adult
222997351,22299735,81,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,Unknown,,,,,Tablet,QD,2023,Q2,Headache,,2023,Q2,1,I,,20230426.0,20230509,20230509,EXP,,GB-TAKEDA-2023TUS045442,TAKEDA,,58.0,YR,,M,Y,86.0,KG,20230509,,MD,GB,GB,2023,Q2,Adult
222997351,22299735,81,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,Unknown,,,,,Tablet,QD,2023,Q2,Depression,,2023,Q2,1,I,,20230426.0,20230509,20230509,EXP,,GB-TAKEDA-2023TUS045442,TAKEDA,,58.0,YR,,M,Y,86.0,KG,20230509,,MD,GB,GB,2023,Q2,Adult
222997351,22299735,81,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,Unknown,,,,,Tablet,QD,2023,Q2,Deep vein thrombosis,,2023,Q2,1,I,,20230426.0,20230509,20230509,EXP,,GB-TAKEDA-2023TUS045442,TAKEDA,,58.0,YR,,M,Y,86.0,KG,20230509,,MD,GB,GB,2023,Q2,Adult
222997351,22299735,81,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,Unknown,,,,,Tablet,QD,2023,Q2,Inappropriate schedule of product administration,,2023,Q2,1,I,,20230426.0,20230509,20230509,EXP,,GB-TAKEDA-2023TUS045442,TAKEDA,,58.0,YR,,M,Y,86.0,KG,20230509,,MD,GB,GB,2023,Q2,Adult
222997351,22299735,81,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,Unknown,,,,,Tablet,QD,2023,Q2,Pyrexia,,2023,Q2,1,I,,20230426.0,20230509,20230509,EXP,,GB-TAKEDA-2023TUS045442,TAKEDA,,58.0,YR,,M,Y,86.0,KG,20230509,,MD,GB,GB,2023,Q2,Adult
222997351,22299735,81,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,Unknown,,,,,Tablet,QD,2023,Q2,Adverse drug reaction,,2023,Q2,1,I,,20230426.0,20230509,20230509,EXP,,GB-TAKEDA-2023TUS045442,TAKEDA,,58.0,YR,,M,Y,86.0,KG,20230509,,MD,GB,GB,2023,Q2,Adult
222997351,22299735,81,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,Unknown,,,,,Tablet,QD,2023,Q2,COVID-19,,2023,Q2,1,I,,20230426.0,20230509,20230509,EXP,,GB-TAKEDA-2023TUS045442,TAKEDA,,58.0,YR,,M,Y,86.0,KG,20230509,,MD,GB,GB,2023,Q2,Adult
222997351,22299735,81,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,Unknown,,,,,Tablet,QD,2023,Q2,Drug ineffective,,2023,Q2,1,I,,20230426.0,20230509,20230509,EXP,,GB-TAKEDA-2023TUS045442,TAKEDA,,58.0,YR,,M,Y,86.0,KG,20230509,,MD,GB,GB,2023,Q2,Adult
222997351,22299735,81,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,Unknown,,,,,Tablet,QD,2023,Q2,Medication error,,2023,Q2,1,I,,20230426.0,20230509,20230509,EXP,,GB-TAKEDA-2023TUS045442,TAKEDA,,58.0,YR,,M,Y,86.0,KG,20230509,,MD,GB,GB,2023,Q2,Adult
222997351,22299735,81,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,Unknown,,,,,Tablet,QD,2023,Q2,Eczema,,2023,Q2,1,I,,20230426.0,20230509,20230509,EXP,,GB-TAKEDA-2023TUS045442,TAKEDA,,58.0,YR,,M,Y,86.0,KG,20230509,,MD,GB,GB,2023,Q2,Adult
222997351,22299735,81,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,Unknown,,,,,Tablet,QD,2023,Q2,Weight decreased,,2023,Q2,1,I,,20230426.0,20230509,20230509,EXP,,GB-TAKEDA-2023TUS045442,TAKEDA,,58.0,YR,,M,Y,86.0,KG,20230509,,MD,GB,GB,2023,Q2,Adult
222997351,22299735,81,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,Unknown,,,,,Tablet,QD,2023,Q2,Nightmare,,2023,Q2,1,I,,20230426.0,20230509,20230509,EXP,,GB-TAKEDA-2023TUS045442,TAKEDA,,58.0,YR,,M,Y,86.0,KG,20230509,,MD,GB,GB,2023,Q2,Adult
222997351,22299735,81,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,Unknown,,,,,Tablet,QD,2023,Q2,Rhinitis,,2023,Q2,1,I,,20230426.0,20230509,20230509,EXP,,GB-TAKEDA-2023TUS045442,TAKEDA,,58.0,YR,,M,Y,86.0,KG,20230509,,MD,GB,GB,2023,Q2,Adult
222997351,22299735,81,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,Unknown,,,,,Tablet,QD,2023,Q2,Impaired quality of life,,2023,Q2,1,I,,20230426.0,20230509,20230509,EXP,,GB-TAKEDA-2023TUS045442,TAKEDA,,58.0,YR,,M,Y,86.0,KG,20230509,,MD,GB,GB,2023,Q2,Adult
222997351,22299735,81,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,Unknown,,,,,Tablet,QD,2023,Q2,Stress,,2023,Q2,1,I,,20230426.0,20230509,20230509,EXP,,GB-TAKEDA-2023TUS045442,TAKEDA,,58.0,YR,,M,Y,86.0,KG,20230509,,MD,GB,GB,2023,Q2,Adult
222997351,22299735,81,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,Unknown,,,,,Tablet,QD,2023,Q2,Tinnitus,,2023,Q2,1,I,,20230426.0,20230509,20230509,EXP,,GB-TAKEDA-2023TUS045442,TAKEDA,,58.0,YR,,M,Y,86.0,KG,20230509,,MD,GB,GB,2023,Q2,Adult
222997351,22299735,81,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,Unknown,,,,,Tablet,QD,2023,Q2,Condition aggravated,,2023,Q2,1,I,,20230426.0,20230509,20230509,EXP,,GB-TAKEDA-2023TUS045442,TAKEDA,,58.0,YR,,M,Y,86.0,KG,20230509,,MD,GB,GB,2023,Q2,Adult
222997351,22299735,81,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,Unknown,,,,,Tablet,QD,2023,Q2,Pulmonary embolism,,2023,Q2,1,I,,20230426.0,20230509,20230509,EXP,,GB-TAKEDA-2023TUS045442,TAKEDA,,58.0,YR,,M,Y,86.0,KG,20230509,,MD,GB,GB,2023,Q2,Adult
222997351,22299735,81,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,Unknown,,,,,Tablet,QD,2023,Q2,Rash,,2023,Q2,1,I,,20230426.0,20230509,20230509,EXP,,GB-TAKEDA-2023TUS045442,TAKEDA,,58.0,YR,,M,Y,86.0,KG,20230509,,MD,GB,GB,2023,Q2,Adult
222997351,22299735,81,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,Unknown,,,,,Tablet,QD,2023,Q2,Haematochezia,,2023,Q2,1,I,,20230426.0,20230509,20230509,EXP,,GB-TAKEDA-2023TUS045442,TAKEDA,,58.0,YR,,M,Y,86.0,KG,20230509,,MD,GB,GB,2023,Q2,Adult
222997351,22299735,81,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,Unknown,,,,,Tablet,QD,2023,Q2,Burns second degree,,2023,Q2,1,I,,20230426.0,20230509,20230509,EXP,,GB-TAKEDA-2023TUS045442,TAKEDA,,58.0,YR,,M,Y,86.0,KG,20230509,,MD,GB,GB,2023,Q2,Adult
222997351,22299735,81,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,Unknown,,,,,Tablet,QD,2023,Q2,Off label use,,2023,Q2,1,I,,20230426.0,20230509,20230509,EXP,,GB-TAKEDA-2023TUS045442,TAKEDA,,58.0,YR,,M,Y,86.0,KG,20230509,,MD,GB,GB,2023,Q2,Adult
222997351,22299735,81,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,Unknown,,,,,Tablet,QD,2023,Q2,Somnolence,,2023,Q2,1,I,,20230426.0,20230509,20230509,EXP,,GB-TAKEDA-2023TUS045442,TAKEDA,,58.0,YR,,M,Y,86.0,KG,20230509,,MD,GB,GB,2023,Q2,Adult
222997351,22299735,81,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,Unknown,,,,,Tablet,QD,2023,Q2,Systemic lupus erythematosus,,2023,Q2,1,I,,20230426.0,20230509,20230509,EXP,,GB-TAKEDA-2023TUS045442,TAKEDA,,58.0,YR,,M,Y,86.0,KG,20230509,,MD,GB,GB,2023,Q2,Adult
222997351,22299735,81,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,Unknown,,,,,Tablet,QD,2023,Q2,Tinnitus,,2023,Q2,1,I,,20230426.0,20230509,20230509,EXP,,GB-TAKEDA-2023TUS045442,TAKEDA,,58.0,YR,,M,Y,86.0,KG,20230509,,MD,GB,GB,2023,Q2,Adult
222997351,22299735,81,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,Unknown,,,,,Tablet,QD,2023,Q2,Steroid dependence,,2023,Q2,1,I,,20230426.0,20230509,20230509,EXP,,GB-TAKEDA-2023TUS045442,TAKEDA,,58.0,YR,,M,Y,86.0,KG,20230509,,MD,GB,GB,2023,Q2,Adult
222997351,22299735,81,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,Unknown,,,,,Tablet,QD,2023,Q2,Gingival pain,,2023,Q2,1,I,,20230426.0,20230509,20230509,EXP,,GB-TAKEDA-2023TUS045442,TAKEDA,,58.0,YR,,M,Y,86.0,KG,20230509,,MD,GB,GB,2023,Q2,Adult
222997351,22299735,81,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,Unknown,,,,,Tablet,QD,2023,Q2,Confusional state,,2023,Q2,1,I,,20230426.0,20230509,20230509,EXP,,GB-TAKEDA-2023TUS045442,TAKEDA,,58.0,YR,,M,Y,86.0,KG,20230509,,MD,GB,GB,2023,Q2,Adult
222997351,22299735,81,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,Unknown,,,,,Tablet,QD,2023,Q2,Loss of personal independence in daily activities,,2023,Q2,1,I,,20230426.0,20230509,20230509,EXP,,GB-TAKEDA-2023TUS045442,TAKEDA,,58.0,YR,,M,Y,86.0,KG,20230509,,MD,GB,GB,2023,Q2,Adult
222997351,22299735,81,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,Unknown,,,,,Tablet,QD,2023,Q2,Impaired work ability,,2023,Q2,1,I,,20230426.0,20230509,20230509,EXP,,GB-TAKEDA-2023TUS045442,TAKEDA,,58.0,YR,,M,Y,86.0,KG,20230509,,MD,GB,GB,2023,Q2,Adult
222997351,22299735,81,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,Unknown,,,,,Tablet,QD,2023,Q2,Cardiac murmur,,2023,Q2,1,I,,20230426.0,20230509,20230509,EXP,,GB-TAKEDA-2023TUS045442,TAKEDA,,58.0,YR,,M,Y,86.0,KG,20230509,,MD,GB,GB,2023,Q2,Adult
222997351,22299735,81,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,Unknown,,,,,Tablet,QD,2023,Q2,Arthritis,,2023,Q2,1,I,,20230426.0,20230509,20230509,EXP,,GB-TAKEDA-2023TUS045442,TAKEDA,,58.0,YR,,M,Y,86.0,KG,20230509,,MD,GB,GB,2023,Q2,Adult
222997351,22299735,81,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,Unknown,,,,,Tablet,QD,2023,Q2,Accidental overdose,,2023,Q2,1,I,,20230426.0,20230509,20230509,EXP,,GB-TAKEDA-2023TUS045442,TAKEDA,,58.0,YR,,M,Y,86.0,KG,20230509,,MD,GB,GB,2023,Q2,Adult
222997351,22299735,81,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,Unknown,,,,,Tablet,QD,2023,Q2,Rectal haemorrhage,,2023,Q2,1,I,,20230426.0,20230509,20230509,EXP,,GB-TAKEDA-2023TUS045442,TAKEDA,,58.0,YR,,M,Y,86.0,KG,20230509,,MD,GB,GB,2023,Q2,Adult
222997351,22299735,81,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,Unknown,,,,,Tablet,QD,2023,Q2,Migraine,,2023,Q2,1,I,,20230426.0,20230509,20230509,EXP,,GB-TAKEDA-2023TUS045442,TAKEDA,,58.0,YR,,M,Y,86.0,KG,20230509,,MD,GB,GB,2023,Q2,Adult
222997351,22299735,81,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,Unknown,,,,,Tablet,QD,2023,Q2,Catarrh,,2023,Q2,1,I,,20230426.0,20230509,20230509,EXP,,GB-TAKEDA-2023TUS045442,TAKEDA,,58.0,YR,,M,Y,86.0,KG,20230509,,MD,GB,GB,2023,Q2,Adult
222997351,22299735,81,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,Unknown,,,,,Tablet,QD,2023,Q2,Colitis ulcerative,,2023,Q2,1,I,,20230426.0,20230509,20230509,EXP,,GB-TAKEDA-2023TUS045442,TAKEDA,,58.0,YR,,M,Y,86.0,KG,20230509,,MD,GB,GB,2023,Q2,Adult
222997351,22299735,81,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,Unknown,,,,,Tablet,QD,2023,Q2,Pain,,2023,Q2,1,I,,20230426.0,20230509,20230509,EXP,,GB-TAKEDA-2023TUS045442,TAKEDA,,58.0,YR,,M,Y,86.0,KG,20230509,,MD,GB,GB,2023,Q2,Adult
222997351,22299735,81,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,Unknown,,,,,Tablet,QD,2023,Q2,Pain in extremity,,2023,Q2,1,I,,20230426.0,20230509,20230509,EXP,,GB-TAKEDA-2023TUS045442,TAKEDA,,58.0,YR,,M,Y,86.0,KG,20230509,,MD,GB,GB,2023,Q2,Adult
222997351,22299735,81,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,Unknown,,,,,Tablet,QD,2023,Q2,Intentional product use issue,,2023,Q2,1,I,,20230426.0,20230509,20230509,EXP,,GB-TAKEDA-2023TUS045442,TAKEDA,,58.0,YR,,M,Y,86.0,KG,20230509,,MD,GB,GB,2023,Q2,Adult
222997351,22299735,81,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,Unknown,,,,,Tablet,QD,2023,Q2,Vertigo,,2023,Q2,1,I,,20230426.0,20230509,20230509,EXP,,GB-TAKEDA-2023TUS045442,TAKEDA,,58.0,YR,,M,Y,86.0,KG,20230509,,MD,GB,GB,2023,Q2,Adult
222997351,22299735,81,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,Unknown,,,,,Tablet,QD,2023,Q2,Hypopnoea,,2023,Q2,1,I,,20230426.0,20230509,20230509,EXP,,GB-TAKEDA-2023TUS045442,TAKEDA,,58.0,YR,,M,Y,86.0,KG,20230509,,MD,GB,GB,2023,Q2,Adult
223015063,22301506,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Aortic arteriosclerosis,,2023,Q2,3,F,20221201.0,20230503.0,20230509,20230512,EXP,,SI-JNJFOC-20230522489,JOHNSON AND JOHNSON,,69.0,YR,E,M,Y,,,20230512,,MD,SI,SI,2023,Q2,Elderly
223015063,22301506,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Pancreatic neoplasm,,2023,Q2,3,F,20221201.0,20230503.0,20230509,20230512,EXP,,SI-JNJFOC-20230522489,JOHNSON AND JOHNSON,,69.0,YR,E,M,Y,,,20230512,,MD,SI,SI,2023,Q2,Elderly
223015063,22301506,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Diverticulitis,,2023,Q2,3,F,20221201.0,20230503.0,20230509,20230512,EXP,,SI-JNJFOC-20230522489,JOHNSON AND JOHNSON,,69.0,YR,E,M,Y,,,20230512,,MD,SI,SI,2023,Q2,Elderly
223021512,22302151,9,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Treatment noncompliance,,2023,Q2,2,F,20120101.0,20230511.0,20230510,20230519,EXP,,PT-AUROBINDO-AUR-APL-2023-035046,AUROBINDO,"Mateus F, Oliveira R.. Simplifying is the best medicine. Portuguese Journal of General and Family Medicine. 2022;39 (suppl 9):S35",70.0,YR,,M,Y,,,20230519,,MD,PT,PT,2023,Q2,Elderly
223021512,22302151,9,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Dyslipidaemia,,2023,Q2,2,F,20120101.0,20230511.0,20230510,20230519,EXP,,PT-AUROBINDO-AUR-APL-2023-035046,AUROBINDO,"Mateus F, Oliveira R.. Simplifying is the best medicine. Portuguese Journal of General and Family Medicine. 2022;39 (suppl 9):S35",70.0,YR,,M,Y,,,20230519,,MD,PT,PT,2023,Q2,Elderly
223021512,22302151,9,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Therapy interrupted,,2023,Q2,2,F,20120101.0,20230511.0,20230510,20230519,EXP,,PT-AUROBINDO-AUR-APL-2023-035046,AUROBINDO,"Mateus F, Oliveira R.. Simplifying is the best medicine. Portuguese Journal of General and Family Medicine. 2022;39 (suppl 9):S35",70.0,YR,,M,Y,,,20230519,,MD,PT,PT,2023,Q2,Elderly
223021512,22302151,9,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Diabetic retinopathy,,2023,Q2,2,F,20120101.0,20230511.0,20230510,20230519,EXP,,PT-AUROBINDO-AUR-APL-2023-035046,AUROBINDO,"Mateus F, Oliveira R.. Simplifying is the best medicine. Portuguese Journal of General and Family Medicine. 2022;39 (suppl 9):S35",70.0,YR,,M,Y,,,20230519,,MD,PT,PT,2023,Q2,Elderly
223021512,22302151,9,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Hyperglycaemia,,2023,Q2,2,F,20120101.0,20230511.0,20230510,20230519,EXP,,PT-AUROBINDO-AUR-APL-2023-035046,AUROBINDO,"Mateus F, Oliveira R.. Simplifying is the best medicine. Portuguese Journal of General and Family Medicine. 2022;39 (suppl 9):S35",70.0,YR,,M,Y,,,20230519,,MD,PT,PT,2023,Q2,Elderly
223021512,22302151,9,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Hypertension,,2023,Q2,2,F,20120101.0,20230511.0,20230510,20230519,EXP,,PT-AUROBINDO-AUR-APL-2023-035046,AUROBINDO,"Mateus F, Oliveira R.. Simplifying is the best medicine. Portuguese Journal of General and Family Medicine. 2022;39 (suppl 9):S35",70.0,YR,,M,Y,,,20230519,,MD,PT,PT,2023,Q2,Elderly
223022151,22302215,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2023,Q2,Diarrhoea,,2023,Q2,1,I,,20230426.0,20230510,20230510,EXP,,AU-ALKEM LABORATORIES LIMITED-AU-ALKEM-2023-04890,ALKEM,,66.0,YR,,F,Y,,,20230510,,HP,AU,AU,2023,Q2,Elderly
223022151,22302215,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2023,Q2,Anuria,,2023,Q2,1,I,,20230426.0,20230510,20230510,EXP,,AU-ALKEM LABORATORIES LIMITED-AU-ALKEM-2023-04890,ALKEM,,66.0,YR,,F,Y,,,20230510,,HP,AU,AU,2023,Q2,Elderly
223022151,22302215,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2023,Q2,Cerebral haemorrhage,,2023,Q2,1,I,,20230426.0,20230510,20230510,EXP,,AU-ALKEM LABORATORIES LIMITED-AU-ALKEM-2023-04890,ALKEM,,66.0,YR,,F,Y,,,20230510,,HP,AU,AU,2023,Q2,Elderly
223022151,22302215,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2023,Q2,Vomiting,,2023,Q2,1,I,,20230426.0,20230510,20230510,EXP,,AU-ALKEM LABORATORIES LIMITED-AU-ALKEM-2023-04890,ALKEM,,66.0,YR,,F,Y,,,20230510,,HP,AU,AU,2023,Q2,Elderly
223022151,22302215,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2023,Q2,Lactic acidosis,,2023,Q2,1,I,,20230426.0,20230510,20230510,EXP,,AU-ALKEM LABORATORIES LIMITED-AU-ALKEM-2023-04890,ALKEM,,66.0,YR,,F,Y,,,20230510,,HP,AU,AU,2023,Q2,Elderly
223022151,22302215,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2023,Q2,Influenza like illness,,2023,Q2,1,I,,20230426.0,20230510,20230510,EXP,,AU-ALKEM LABORATORIES LIMITED-AU-ALKEM-2023-04890,ALKEM,,66.0,YR,,F,Y,,,20230510,,HP,AU,AU,2023,Q2,Elderly
223022151,22302215,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2023,Q2,Oliguria,,2023,Q2,1,I,,20230426.0,20230510,20230510,EXP,,AU-ALKEM LABORATORIES LIMITED-AU-ALKEM-2023-04890,ALKEM,,66.0,YR,,F,Y,,,20230510,,HP,AU,AU,2023,Q2,Elderly
223022151,22302215,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2023,Q2,Acute kidney injury,,2023,Q2,1,I,,20230426.0,20230510,20230510,EXP,,AU-ALKEM LABORATORIES LIMITED-AU-ALKEM-2023-04890,ALKEM,,66.0,YR,,F,Y,,,20230510,,HP,AU,AU,2023,Q2,Elderly
223022151,22302215,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2023,Q2,Pneumonia,,2023,Q2,1,I,,20230426.0,20230510,20230510,EXP,,AU-ALKEM LABORATORIES LIMITED-AU-ALKEM-2023-04890,ALKEM,,66.0,YR,,F,Y,,,20230510,,HP,AU,AU,2023,Q2,Elderly
223052282,22305228,9,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2023,Q2,Cardiac failure,,2023,Q2,2,F,,20230613.0,20230510,20230617,EXP,,SI-JNJFOC-20230524870,JOHNSON AND JOHNSON,,77.0,YR,E,M,Y,,,20230617,,MD,SI,SI,2023,Q2,Elderly
223060582,22306058,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Low density lipoprotein increased,,2023,Q2,2,F,20200101.0,20230512.0,20230511,20230519,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-235535",BOEHRINGER INGELHEIM,,80.0,YR,E,F,Y,68.0,KG,20230519,,MD,SI,SI,2023,Q2,Elderly
223060582,22306058,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Urinary tract infection,,2023,Q2,2,F,20200101.0,20230512.0,20230511,20230519,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-235535",BOEHRINGER INGELHEIM,,80.0,YR,E,F,Y,68.0,KG,20230519,,MD,SI,SI,2023,Q2,Elderly
223060582,22306058,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Glycosylated haemoglobin increased,,2023,Q2,2,F,20200101.0,20230512.0,20230511,20230519,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-235535",BOEHRINGER INGELHEIM,,80.0,YR,E,F,Y,68.0,KG,20230519,,MD,SI,SI,2023,Q2,Elderly
223060582,22306058,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Hypertension,,2023,Q2,2,F,20200101.0,20230512.0,20230511,20230519,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-235535",BOEHRINGER INGELHEIM,,80.0,YR,E,F,Y,68.0,KG,20230519,,MD,SI,SI,2023,Q2,Elderly
223060582,22306058,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Glycosylated haemoglobin increased,,2023,Q2,2,F,20200101.0,20230512.0,20230511,20230519,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-235535",BOEHRINGER INGELHEIM,,80.0,YR,E,F,Y,68.0,KG,20230519,,MD,SI,SI,2023,Q2,Elderly
223060582,22306058,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Blood glucose increased,,2023,Q2,2,F,20200101.0,20230512.0,20230511,20230519,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-235535",BOEHRINGER INGELHEIM,,80.0,YR,E,F,Y,68.0,KG,20230519,,MD,SI,SI,2023,Q2,Elderly
223060582,22306058,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Blood glucose increased,,2023,Q2,2,F,20200101.0,20230512.0,20230511,20230519,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-235535",BOEHRINGER INGELHEIM,,80.0,YR,E,F,Y,68.0,KG,20230519,,MD,SI,SI,2023,Q2,Elderly
223060582,22306058,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Glycosuria,,2023,Q2,2,F,20200101.0,20230512.0,20230511,20230519,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-235535",BOEHRINGER INGELHEIM,,80.0,YR,E,F,Y,68.0,KG,20230519,,MD,SI,SI,2023,Q2,Elderly
223060582,22306058,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Weight increased,,2023,Q2,2,F,20200101.0,20230512.0,20230511,20230519,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-235535",BOEHRINGER INGELHEIM,,80.0,YR,E,F,Y,68.0,KG,20230519,,MD,SI,SI,2023,Q2,Elderly
223060582,22306058,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Diabetes mellitus,,2023,Q2,2,F,20200101.0,20230512.0,20230511,20230519,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-235535",BOEHRINGER INGELHEIM,,80.0,YR,E,F,Y,68.0,KG,20230519,,MD,SI,SI,2023,Q2,Elderly
223060582,22306058,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Hip surgery,,2023,Q2,2,F,20200101.0,20230512.0,20230511,20230519,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-235535",BOEHRINGER INGELHEIM,,80.0,YR,E,F,Y,68.0,KG,20230519,,MD,SI,SI,2023,Q2,Elderly
223060582,22306058,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,25.0,MG,,QD,2023,Q2,Low density lipoprotein increased,,2023,Q2,2,F,20200101.0,20230512.0,20230511,20230519,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-235535",BOEHRINGER INGELHEIM,,80.0,YR,E,F,Y,68.0,KG,20230519,,MD,SI,SI,2023,Q2,Elderly
223060582,22306058,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,25.0,MG,,QD,2023,Q2,Urinary tract infection,,2023,Q2,2,F,20200101.0,20230512.0,20230511,20230519,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-235535",BOEHRINGER INGELHEIM,,80.0,YR,E,F,Y,68.0,KG,20230519,,MD,SI,SI,2023,Q2,Elderly
223060582,22306058,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,25.0,MG,,QD,2023,Q2,Glycosylated haemoglobin increased,,2023,Q2,2,F,20200101.0,20230512.0,20230511,20230519,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-235535",BOEHRINGER INGELHEIM,,80.0,YR,E,F,Y,68.0,KG,20230519,,MD,SI,SI,2023,Q2,Elderly
223060582,22306058,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,25.0,MG,,QD,2023,Q2,Hypertension,,2023,Q2,2,F,20200101.0,20230512.0,20230511,20230519,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-235535",BOEHRINGER INGELHEIM,,80.0,YR,E,F,Y,68.0,KG,20230519,,MD,SI,SI,2023,Q2,Elderly
223060582,22306058,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,25.0,MG,,QD,2023,Q2,Glycosylated haemoglobin increased,,2023,Q2,2,F,20200101.0,20230512.0,20230511,20230519,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-235535",BOEHRINGER INGELHEIM,,80.0,YR,E,F,Y,68.0,KG,20230519,,MD,SI,SI,2023,Q2,Elderly
223060582,22306058,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,25.0,MG,,QD,2023,Q2,Blood glucose increased,,2023,Q2,2,F,20200101.0,20230512.0,20230511,20230519,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-235535",BOEHRINGER INGELHEIM,,80.0,YR,E,F,Y,68.0,KG,20230519,,MD,SI,SI,2023,Q2,Elderly
223060582,22306058,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,25.0,MG,,QD,2023,Q2,Blood glucose increased,,2023,Q2,2,F,20200101.0,20230512.0,20230511,20230519,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-235535",BOEHRINGER INGELHEIM,,80.0,YR,E,F,Y,68.0,KG,20230519,,MD,SI,SI,2023,Q2,Elderly
223060582,22306058,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,25.0,MG,,QD,2023,Q2,Glycosuria,,2023,Q2,2,F,20200101.0,20230512.0,20230511,20230519,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-235535",BOEHRINGER INGELHEIM,,80.0,YR,E,F,Y,68.0,KG,20230519,,MD,SI,SI,2023,Q2,Elderly
223060582,22306058,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,25.0,MG,,QD,2023,Q2,Weight increased,,2023,Q2,2,F,20200101.0,20230512.0,20230511,20230519,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-235535",BOEHRINGER INGELHEIM,,80.0,YR,E,F,Y,68.0,KG,20230519,,MD,SI,SI,2023,Q2,Elderly
223060582,22306058,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,25.0,MG,,QD,2023,Q2,Diabetes mellitus,,2023,Q2,2,F,20200101.0,20230512.0,20230511,20230519,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-235535",BOEHRINGER INGELHEIM,,80.0,YR,E,F,Y,68.0,KG,20230519,,MD,SI,SI,2023,Q2,Elderly
223060582,22306058,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,25.0,MG,,QD,2023,Q2,Hip surgery,,2023,Q2,2,F,20200101.0,20230512.0,20230511,20230519,EXP,,"SI-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-235535",BOEHRINGER INGELHEIM,,80.0,YR,E,F,Y,68.0,KG,20230519,,MD,SI,SI,2023,Q2,Elderly
223091862,22309186,12,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK (2 id),,,,,,,,,,,,2023,Q2,Dyslipidaemia,,2023,Q2,2,F,20120101.0,20230529.0,20230511,20230602,EXP,,PT-MYLANLABS-2023M1042153,MYLAN,"Mateus F, Oliveira R. ePO 53 ? Simplifying is the Best Medicine. Portuguese Magazine of General and Familiar Medicine. 2023;39 (Suppl 9):S35",70.0,YR,,M,Y,,,20230602,,MD,PT,PT,2023,Q2,Elderly
223091862,22309186,12,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK (2 id),,,,,,,,,,,,2023,Q2,Treatment noncompliance,,2023,Q2,2,F,20120101.0,20230529.0,20230511,20230602,EXP,,PT-MYLANLABS-2023M1042153,MYLAN,"Mateus F, Oliveira R. ePO 53 ? Simplifying is the Best Medicine. Portuguese Magazine of General and Familiar Medicine. 2023;39 (Suppl 9):S35",70.0,YR,,M,Y,,,20230602,,MD,PT,PT,2023,Q2,Elderly
223091862,22309186,12,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK (2 id),,,,,,,,,,,,2023,Q2,Hypertension,,2023,Q2,2,F,20120101.0,20230529.0,20230511,20230602,EXP,,PT-MYLANLABS-2023M1042153,MYLAN,"Mateus F, Oliveira R. ePO 53 ? Simplifying is the Best Medicine. Portuguese Magazine of General and Familiar Medicine. 2023;39 (Suppl 9):S35",70.0,YR,,M,Y,,,20230602,,MD,PT,PT,2023,Q2,Elderly
223091862,22309186,12,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK (2 id),,,,,,,,,,,,2023,Q2,Hyperglycaemia,,2023,Q2,2,F,20120101.0,20230529.0,20230511,20230602,EXP,,PT-MYLANLABS-2023M1042153,MYLAN,"Mateus F, Oliveira R. ePO 53 ? Simplifying is the Best Medicine. Portuguese Magazine of General and Familiar Medicine. 2023;39 (Suppl 9):S35",70.0,YR,,M,Y,,,20230602,,MD,PT,PT,2023,Q2,Elderly
223091862,22309186,12,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK (2 id),,,,,,,,,,,,2023,Q2,Diabetic retinopathy,,2023,Q2,2,F,20120101.0,20230529.0,20230511,20230602,EXP,,PT-MYLANLABS-2023M1042153,MYLAN,"Mateus F, Oliveira R. ePO 53 ? Simplifying is the Best Medicine. Portuguese Magazine of General and Familiar Medicine. 2023;39 (Suppl 9):S35",70.0,YR,,M,Y,,,20230602,,MD,PT,PT,2023,Q2,Elderly
223091862,22309186,12,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK (2 id),,,,,,,,,,,,2023,Q2,Therapy interrupted,,2023,Q2,2,F,20120101.0,20230529.0,20230511,20230602,EXP,,PT-MYLANLABS-2023M1042153,MYLAN,"Mateus F, Oliveira R. ePO 53 ? Simplifying is the Best Medicine. Portuguese Magazine of General and Familiar Medicine. 2023;39 (Suppl 9):S35",70.0,YR,,M,Y,,,20230602,,MD,PT,PT,2023,Q2,Elderly
223118152,22311815,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,1 dosage form,,,U,,Unknown,,206073.0,,,Tablet,QD,2023,Q2,Cerebral infarction,,2023,Q2,2,F,20230401.0,20230522.0,20230512,20230523,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-237101",BOEHRINGER INGELHEIM,,88.0,YR,E,,Y,,,20230523,,MD,JP,JP,2023,Q2,Elderly
223150511,22315051,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2023,Q2,Cardiac failure,,2023,Q2,1,I,20230310.0,20230511.0,20230512,20230512,EXP,,NVSC2023AU108375,NOVARTIS,,74.0,YR,,M,Y,75.2,KG,20230512,,MD,AU,AU,2023,Q2,Elderly
223153061,22315306,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2023,Q2,Anaemia,,2023,Q2,1,I,20230414.0,20230504.0,20230512,20230512,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202305002683,ELI LILLY AND CO,,70.0,YR,,F,Y,122.0,KG,20230512,,CN,DE,DE,2023,Q2,Elderly
223153061,22315306,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2023,Q2,Pulmonary hypertension,,2023,Q2,1,I,20230414.0,20230504.0,20230512,20230512,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202305002683,ELI LILLY AND CO,,70.0,YR,,F,Y,122.0,KG,20230512,,CN,DE,DE,2023,Q2,Elderly
223153061,22315306,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2023,Q2,General physical condition abnormal,,2023,Q2,1,I,20230414.0,20230504.0,20230512,20230512,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202305002683,ELI LILLY AND CO,,70.0,YR,,F,Y,122.0,KG,20230512,,CN,DE,DE,2023,Q2,Elderly
223153061,22315306,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2023,Q2,Renal impairment,,2023,Q2,1,I,20230414.0,20230504.0,20230512,20230512,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202305002683,ELI LILLY AND CO,,70.0,YR,,F,Y,122.0,KG,20230512,,CN,DE,DE,2023,Q2,Elderly
223153061,22315306,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2023,Q2,Tachyarrhythmia,,2023,Q2,1,I,20230414.0,20230504.0,20230512,20230512,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202305002683,ELI LILLY AND CO,,70.0,YR,,F,Y,122.0,KG,20230512,,CN,DE,DE,2023,Q2,Elderly
223171324,22317132,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,Unknown,QD,2023,Q2,Decreased appetite,,2023,Q2,4,F,20230412.0,20230613.0,20230514,20230626,EXP,,AU-JNJFOC-20230522488,JOHNSON AND JOHNSON,,80.0,YR,E,M,Y,75.3,KG,20230624,,HP,AU,AU,2023,Q2,Elderly
223171324,22317132,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,Unknown,QD,2023,Q2,Vitamin D deficiency,,2023,Q2,4,F,20230412.0,20230613.0,20230514,20230626,EXP,,AU-JNJFOC-20230522488,JOHNSON AND JOHNSON,,80.0,YR,E,M,Y,75.3,KG,20230624,,HP,AU,AU,2023,Q2,Elderly
223171324,22317132,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,Unknown,QD,2023,Q2,Acute kidney injury,,2023,Q2,4,F,20230412.0,20230613.0,20230514,20230626,EXP,,AU-JNJFOC-20230522488,JOHNSON AND JOHNSON,,80.0,YR,E,M,Y,75.3,KG,20230624,,HP,AU,AU,2023,Q2,Elderly
223171324,22317132,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,Unknown,QD,2023,Q2,Malnutrition,,2023,Q2,4,F,20230412.0,20230613.0,20230514,20230626,EXP,,AU-JNJFOC-20230522488,JOHNSON AND JOHNSON,,80.0,YR,E,M,Y,75.3,KG,20230624,,HP,AU,AU,2023,Q2,Elderly
223171324,22317132,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,Unknown,QD,2023,Q2,Skin ulcer,,2023,Q2,4,F,20230412.0,20230613.0,20230514,20230626,EXP,,AU-JNJFOC-20230522488,JOHNSON AND JOHNSON,,80.0,YR,E,M,Y,75.3,KG,20230624,,HP,AU,AU,2023,Q2,Elderly
223171324,22317132,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,Unknown,QD,2023,Q2,Constipation,,2023,Q2,4,F,20230412.0,20230613.0,20230514,20230626,EXP,,AU-JNJFOC-20230522488,JOHNSON AND JOHNSON,,80.0,YR,E,M,Y,75.3,KG,20230624,,HP,AU,AU,2023,Q2,Elderly
223171324,22317132,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,Unknown,QD,2023,Q2,SARS-CoV-2 test positive,,2023,Q2,4,F,20230412.0,20230613.0,20230514,20230626,EXP,,AU-JNJFOC-20230522488,JOHNSON AND JOHNSON,,80.0,YR,E,M,Y,75.3,KG,20230624,,HP,AU,AU,2023,Q2,Elderly
223171324,22317132,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,Unknown,QD,2023,Q2,Hyperthyroidism,,2023,Q2,4,F,20230412.0,20230613.0,20230514,20230626,EXP,,AU-JNJFOC-20230522488,JOHNSON AND JOHNSON,,80.0,YR,E,M,Y,75.3,KG,20230624,,HP,AU,AU,2023,Q2,Elderly
223171324,22317132,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,Unknown,QD,2023,Q2,Pulmonary hypertension,,2023,Q2,4,F,20230412.0,20230613.0,20230514,20230626,EXP,,AU-JNJFOC-20230522488,JOHNSON AND JOHNSON,,80.0,YR,E,M,Y,75.3,KG,20230624,,HP,AU,AU,2023,Q2,Elderly
223171324,22317132,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,Unknown,QD,2023,Q2,Acute myocardial infarction,,2023,Q2,4,F,20230412.0,20230613.0,20230514,20230626,EXP,,AU-JNJFOC-20230522488,JOHNSON AND JOHNSON,,80.0,YR,E,M,Y,75.3,KG,20230624,,HP,AU,AU,2023,Q2,Elderly
223171324,22317132,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,Unknown,QD,2023,Q2,Cardiac failure congestive,,2023,Q2,4,F,20230412.0,20230613.0,20230514,20230626,EXP,,AU-JNJFOC-20230522488,JOHNSON AND JOHNSON,,80.0,YR,E,M,Y,75.3,KG,20230624,,HP,AU,AU,2023,Q2,Elderly
223171324,22317132,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,Unknown,QD,2023,Q2,Ageusia,,2023,Q2,4,F,20230412.0,20230613.0,20230514,20230626,EXP,,AU-JNJFOC-20230522488,JOHNSON AND JOHNSON,,80.0,YR,E,M,Y,75.3,KG,20230624,,HP,AU,AU,2023,Q2,Elderly
223171324,22317132,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,Unknown,QD,2023,Q2,Neutrophil count decreased,,2023,Q2,4,F,20230412.0,20230613.0,20230514,20230626,EXP,,AU-JNJFOC-20230522488,JOHNSON AND JOHNSON,,80.0,YR,E,M,Y,75.3,KG,20230624,,HP,AU,AU,2023,Q2,Elderly
223188992,22318899,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Colitis ulcerative,,2023,Q2,2,F,20230513.0,20230608.0,20230515,20230612,EXP,,CA-TAKEDA-2023TUS046757,TAKEDA,,65.0,YR,,M,Y,,,20230612,,CN,CA,CA,2023,Q2,Elderly
223188992,22318899,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Off label use,,2023,Q2,2,F,20230513.0,20230608.0,20230515,20230612,EXP,,CA-TAKEDA-2023TUS046757,TAKEDA,,65.0,YR,,M,Y,,,20230612,,CN,CA,CA,2023,Q2,Elderly
223203942,22320394,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 Milligram Daily;,,,U,,,,,10.0,MG,,QD,2023,Q2,Dissociation,,2023,Q2,2,F,,20230518.0,20230515,20230526,EXP,,AU-TEVA-2023-AU-2886638,TEVA,,42.0,YR,A,M,Y,,,20230526,,HP,AU,AU,2023,Q2,Adult
223203942,22320394,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 Milligram Daily;,,,U,,,,,10.0,MG,,QD,2023,Q2,Sedation,,2023,Q2,2,F,,20230518.0,20230515,20230526,EXP,,AU-TEVA-2023-AU-2886638,TEVA,,42.0,YR,A,M,Y,,,20230526,,HP,AU,AU,2023,Q2,Adult
223203942,22320394,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 Milligram Daily;,,,U,,,,,10.0,MG,,QD,2023,Q2,Lethargy,,2023,Q2,2,F,,20230518.0,20230515,20230526,EXP,,AU-TEVA-2023-AU-2886638,TEVA,,42.0,YR,A,M,Y,,,20230526,,HP,AU,AU,2023,Q2,Adult
223203942,22320394,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 Milligram Daily;,,,U,,,,,10.0,MG,,QD,2023,Q2,Dizziness,,2023,Q2,2,F,,20230518.0,20230515,20230526,EXP,,AU-TEVA-2023-AU-2886638,TEVA,,42.0,YR,A,M,Y,,,20230526,,HP,AU,AU,2023,Q2,Adult
223203942,22320394,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 Milligram Daily;,,,U,,,,,10.0,MG,,QD,2023,Q2,Daydreaming,,2023,Q2,2,F,,20230518.0,20230515,20230526,EXP,,AU-TEVA-2023-AU-2886638,TEVA,,42.0,YR,A,M,Y,,,20230526,,HP,AU,AU,2023,Q2,Adult
223203942,22320394,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 Milligram Daily;,,,U,,,,,10.0,MG,,QD,2023,Q2,Drug ineffective,,2023,Q2,2,F,,20230518.0,20230515,20230526,EXP,,AU-TEVA-2023-AU-2886638,TEVA,,42.0,YR,A,M,Y,,,20230526,,HP,AU,AU,2023,Q2,Adult
223210421,22321042,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2023,Q2,Anaemia,,2023,Q2,1,I,20230414.0,20230509.0,20230515,20230515,EXP,,DE-MYLANLABS-2023M1049674,MYLAN,,7.0,DEC,,F,Y,122.0,KG,20230515,,MD,DE,DE,2023,Q2,Child
223210421,22321042,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2023,Q2,Pulmonary hypertension,,2023,Q2,1,I,20230414.0,20230509.0,20230515,20230515,EXP,,DE-MYLANLABS-2023M1049674,MYLAN,,7.0,DEC,,F,Y,122.0,KG,20230515,,MD,DE,DE,2023,Q2,Child
223210421,22321042,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2023,Q2,Tachyarrhythmia,,2023,Q2,1,I,20230414.0,20230509.0,20230515,20230515,EXP,,DE-MYLANLABS-2023M1049674,MYLAN,,7.0,DEC,,F,Y,122.0,KG,20230515,,MD,DE,DE,2023,Q2,Child
223210421,22321042,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2023,Q2,Renal impairment,,2023,Q2,1,I,20230414.0,20230509.0,20230515,20230515,EXP,,DE-MYLANLABS-2023M1049674,MYLAN,,7.0,DEC,,F,Y,122.0,KG,20230515,,MD,DE,DE,2023,Q2,Child
223210421,22321042,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2023,Q2,General physical condition abnormal,,2023,Q2,1,I,20230414.0,20230509.0,20230515,20230515,EXP,,DE-MYLANLABS-2023M1049674,MYLAN,,7.0,DEC,,F,Y,122.0,KG,20230515,,MD,DE,DE,2023,Q2,Child
223215981,22321598,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,,,,,,10.0,MG,,QD,2023,Q2,Peripheral artery stenosis,,2023,Q2,1,I,,20230508.0,20230515,20230515,EXP,,SI-JNJFOC-20230535727,JOHNSON AND JOHNSON,,71.0,YR,E,F,Y,,,20230516,,HP,SI,SI,2023,Q2,Elderly
223228282,22322828,7,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,Y,,,,,,,,BID,2023,Q2,Drug interaction,,2023,Q2,2,F,,20230503.0,20230516,20230607,EXP,,ES-AUROBINDO-AUR-APL-2023-036032,AUROBINDO,"Abdala S, Devora S, Oliva AM, Morales C.. El valor anadido de los servicios profesionales farmaceucos asistenciales. Un caso de SFT (The added value of professional pharmaceucal care services. A case of SFT). Farmaceuticos comunitarios (Community Farms). 2023;15(2):45-51",62.0,YR,,F,Y,,,20230607,,HP,ES,ES,2023,Q2,Adult
223228282,22322828,7,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,Y,,,,,,,,BID,2023,Q2,Somnolence,,2023,Q2,2,F,,20230503.0,20230516,20230607,EXP,,ES-AUROBINDO-AUR-APL-2023-036032,AUROBINDO,"Abdala S, Devora S, Oliva AM, Morales C.. El valor anadido de los servicios profesionales farmaceucos asistenciales. Un caso de SFT (The added value of professional pharmaceucal care services. A case of SFT). Farmaceuticos comunitarios (Community Farms). 2023;15(2):45-51",62.0,YR,,F,Y,,,20230607,,HP,ES,ES,2023,Q2,Adult
223243511,22324351,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2023,Q2,Blood creatinine increased,,2023,Q2,1,I,,20230510.0,20230516,20230516,EXP,,US-MYLANLABS-2023M1049853,MYLAN,"Paster L, Mehtabdin K, Jhaveri KD, Myers A, Barnett RL. A Case of Hyponatremia Associated with SGLT-2 inhibitor Empagliflozin. J-Am-Soc-Nephrol 2016;27:996A.",69.0,YR,,F,Y,,,20230516,,HP,US,US,2023,Q2,Elderly
223243511,22324351,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2023,Q2,Hypovolaemia,,2023,Q2,1,I,,20230510.0,20230516,20230516,EXP,,US-MYLANLABS-2023M1049853,MYLAN,"Paster L, Mehtabdin K, Jhaveri KD, Myers A, Barnett RL. A Case of Hyponatremia Associated with SGLT-2 inhibitor Empagliflozin. J-Am-Soc-Nephrol 2016;27:996A.",69.0,YR,,F,Y,,,20230516,,HP,US,US,2023,Q2,Elderly
223243511,22324351,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2023,Q2,Hyponatraemia,,2023,Q2,1,I,,20230510.0,20230516,20230516,EXP,,US-MYLANLABS-2023M1049853,MYLAN,"Paster L, Mehtabdin K, Jhaveri KD, Myers A, Barnett RL. A Case of Hyponatremia Associated with SGLT-2 inhibitor Empagliflozin. J-Am-Soc-Nephrol 2016;27:996A.",69.0,YR,,F,Y,,,20230516,,HP,US,US,2023,Q2,Elderly
223249661,22324966,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Extrapyramidal disorder,,2023,Q2,1,I,20230101.0,,20230514,20230514,DIR,660135,,FDA-CTU,,58.0,YR,,M,N,114.75,KG,20230514,N,CN,US,,2023,Q2,Adult
223250521,22325052,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MG DAILY ORAL?,,,D,D,,,,25.0,MG,,QD,2023,Q2,Urinary tract infection,,2023,Q2,1,I,20230512.0,,20230514,20230514,DIR,660153,,FDA-CTU,,62.0,YR,,M,N,74.5,KG,20230514,N,HP,US,,2023,Q2,Adult
223250521,22325052,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MG DAILY ORAL?,,,D,D,,,,25.0,MG,,QD,2023,Q2,Disease complication,,2023,Q2,1,I,20230512.0,,20230514,20230514,DIR,660153,,FDA-CTU,,62.0,YR,,M,N,74.5,KG,20230514,N,HP,US,,2023,Q2,Adult
223257421,22325742,4,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,Dose unknown,,,,,,,,,,Tablet,,2023,Q2,Eosinophilic fasciitis,,2023,Q2,1,I,20230202.0,20230508.0,20230516,20230516,EXP,,JP-AstraZeneca-2023A107072,ASTRAZENECA,,55.0,YR,,M,Y,65.0,KG,20230516,,MD,JP,,2023,Q2,Adult
223259281,22325928,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Hyponatraemia,,2023,Q2,1,I,20211001.0,20230509.0,20230516,20230516,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-189782",BOEHRINGER INGELHEIM,"Corpuz E, Dean JL, Cahill MS, Dean JL. PASS THE SALT? ACUTE ASYMPTOMATIC HYPONATREMIA FOLLOWING INPATIENT INITIATION OF ANGIOTENSIN RECEPTOR-NEPRILYSIN INHIBITOR.. Journal of General Internal Medicine. 2022;37: 497-",71.0,YR,E,F,Y,,,20230516,,HP,US,US,2023,Q2,Elderly
223296951,22329695,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,,QD,2023,Q2,No adverse event,,2023,Q2,1,I,,20230130.0,20230517,20230517,EXP,,US-ROCHE-3276608,ROCHE,"Bunch C, Zackariya N, Thomas A, Langford J, Aboukhaled M, Thomas S, Ansari A, Patel S, Buckner H, Miller J, Annis C, Quate-Operacz M, Schmitz L, Pulvirenti J, Konopinski J, Kelley K, Hassna S, Nelligan L and Walsh M. COVID-associated non-vasculitic thrombotic retiform purpura of the face and extremities: A case report. Doi: 10.1002/ccr3.6790. Clinical Case Reports 2022 Dec;10 (12):1-8.",55.0,YR,,F,Y,,,20230517,,HP,US,,2023,Q2,Adult
223296951,22329695,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,,QD,2023,Q2,Off label use,,2023,Q2,1,I,,20230130.0,20230517,20230517,EXP,,US-ROCHE-3276608,ROCHE,"Bunch C, Zackariya N, Thomas A, Langford J, Aboukhaled M, Thomas S, Ansari A, Patel S, Buckner H, Miller J, Annis C, Quate-Operacz M, Schmitz L, Pulvirenti J, Konopinski J, Kelley K, Hassna S, Nelligan L and Walsh M. COVID-associated non-vasculitic thrombotic retiform purpura of the face and extremities: A case report. Doi: 10.1002/ccr3.6790. Clinical Case Reports 2022 Dec;10 (12):1-8.",55.0,YR,,F,Y,,,20230517,,HP,US,,2023,Q2,Adult
223299261,22329926,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Off label use,,2023,Q2,1,I,,20220502.0,20230517,20230517,EXP,,US-ROCHE-3091104,ROCHE,"Verma A, Olagoke O, Moreno J, Rezaee N, P, Liu J, Javaheri A, Lavine K, Masood M and Lin C SARS-CoV-2-Associated Myocarditis: A Case of Direct Myocardial Injury. Doi: 10.1161/CIRCHEARTFAILURE.120.008273. Circulation: Heart Failure 2022 Mar 01;15 (3):294-6.",48.0,YR,,F,Y,,,20230517,,MD,US,,2023,Q2,Adult
223299261,22329926,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,No adverse event,,2023,Q2,1,I,,20220502.0,20230517,20230517,EXP,,US-ROCHE-3091104,ROCHE,"Verma A, Olagoke O, Moreno J, Rezaee N, P, Liu J, Javaheri A, Lavine K, Masood M and Lin C SARS-CoV-2-Associated Myocarditis: A Case of Direct Myocardial Injury. Doi: 10.1161/CIRCHEARTFAILURE.120.008273. Circulation: Heart Failure 2022 Mar 01;15 (3):294-6.",48.0,YR,,F,Y,,,20230517,,MD,US,,2023,Q2,Adult
223306651,22330665,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q2,Pulmonary hypertension,,2023,Q2,1,I,20230414.0,20230504.0,20230517,20230517,EXP,,DE-AUROBINDO-AUR-APL-2023-035769,AUROBINDO,,7.0,DEC,,F,Y,122.0,KG,20230517,,MD,DE,DE,2023,Q2,Child
223306651,22330665,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q2,Tachyarrhythmia,,2023,Q2,1,I,20230414.0,20230504.0,20230517,20230517,EXP,,DE-AUROBINDO-AUR-APL-2023-035769,AUROBINDO,,7.0,DEC,,F,Y,122.0,KG,20230517,,MD,DE,DE,2023,Q2,Child
223306651,22330665,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q2,General physical condition abnormal,,2023,Q2,1,I,20230414.0,20230504.0,20230517,20230517,EXP,,DE-AUROBINDO-AUR-APL-2023-035769,AUROBINDO,,7.0,DEC,,F,Y,122.0,KG,20230517,,MD,DE,DE,2023,Q2,Child
223306651,22330665,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q2,Anaemia,,2023,Q2,1,I,20230414.0,20230504.0,20230517,20230517,EXP,,DE-AUROBINDO-AUR-APL-2023-035769,AUROBINDO,,7.0,DEC,,F,Y,122.0,KG,20230517,,MD,DE,DE,2023,Q2,Child
223306651,22330665,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q2,Renal impairment,,2023,Q2,1,I,20230414.0,20230504.0,20230517,20230517,EXP,,DE-AUROBINDO-AUR-APL-2023-035769,AUROBINDO,,7.0,DEC,,F,Y,122.0,KG,20230517,,MD,DE,DE,2023,Q2,Child
223332972,22333297,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,Tablet,,2023,Q2,Pneumonia,,2023,Q2,2,F,20230212.0,20230607.0,20230517,20230614,EXP,,CN-ABBVIE-4309988,ABBVIE,,73.0,YR,,M,Y,68.6,KG,20230614,,MD,CN,CN,2023,Q2,Elderly
223401701,22340170,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Glycosylated haemoglobin increased,,2023,Q2,1,I,,20230503.0,20230518,20230518,EXP,,GR-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-388918,RANBAXY,"Kitsios K, Trakatelli C-M, Sarigianni M, Tsankof C, Kotsis V. Continuous glucose monitoring for detecting overbasalization; A case-series. Diabetes Technol Ther. 2023;25 (Suppl. 2):A153-A154 (EP157/824)",66.0,YR,,M,Y,,,20230518,,HP,GR,GR,2023,Q2,Elderly
223420322,22342032,3,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"UNK, 10mg/5mg",,,,,,,,,,,,2023,Q2,Intentional product misuse,,2023,Q2,2,F,,20230524.0,20230518,20230603,EXP,,US-STRIDES ARCOLAB LIMITED-2023SP007294,STRIDES,"Haluska AD, Davis A, Tarabishy N, Pena ME.. Use of Naloxone in Angiotensin-Converting Enzyme Inhibitor Overdose: A Case Report. J Emerg Med. 2023;64(3):397-399",49.0,YR,,M,Y,,,20230603,,HP,US,US,2023,Q2,Adult
223420322,22342032,3,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"UNK, 10mg/5mg",,,,,,,,,,,,2023,Q2,Hypotension,,2023,Q2,2,F,,20230524.0,20230518,20230603,EXP,,US-STRIDES ARCOLAB LIMITED-2023SP007294,STRIDES,"Haluska AD, Davis A, Tarabishy N, Pena ME.. Use of Naloxone in Angiotensin-Converting Enzyme Inhibitor Overdose: A Case Report. J Emerg Med. 2023;64(3):397-399",49.0,YR,,M,Y,,,20230603,,HP,US,US,2023,Q2,Adult
223420322,22342032,3,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"UNK, 10mg/5mg",,,,,,,,,,,,2023,Q2,Unresponsive to stimuli,,2023,Q2,2,F,,20230524.0,20230518,20230603,EXP,,US-STRIDES ARCOLAB LIMITED-2023SP007294,STRIDES,"Haluska AD, Davis A, Tarabishy N, Pena ME.. Use of Naloxone in Angiotensin-Converting Enzyme Inhibitor Overdose: A Case Report. J Emerg Med. 2023;64(3):397-399",49.0,YR,,M,Y,,,20230603,,HP,US,US,2023,Q2,Adult
223420322,22342032,3,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"UNK, 10mg/5mg",,,,,,,,,,,,2023,Q2,Syncope,,2023,Q2,2,F,,20230524.0,20230518,20230603,EXP,,US-STRIDES ARCOLAB LIMITED-2023SP007294,STRIDES,"Haluska AD, Davis A, Tarabishy N, Pena ME.. Use of Naloxone in Angiotensin-Converting Enzyme Inhibitor Overdose: A Case Report. J Emerg Med. 2023;64(3):397-399",49.0,YR,,M,Y,,,20230603,,HP,US,US,2023,Q2,Adult
223420322,22342032,3,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"UNK, 10mg/5mg",,,,,,,,,,,,2023,Q2,Acute kidney injury,,2023,Q2,2,F,,20230524.0,20230518,20230603,EXP,,US-STRIDES ARCOLAB LIMITED-2023SP007294,STRIDES,"Haluska AD, Davis A, Tarabishy N, Pena ME.. Use of Naloxone in Angiotensin-Converting Enzyme Inhibitor Overdose: A Case Report. J Emerg Med. 2023;64(3):397-399",49.0,YR,,M,Y,,,20230603,,HP,US,US,2023,Q2,Adult
223420322,22342032,3,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"UNK, 10mg/5mg",,,,,,,,,,,,2023,Q2,Accidental overdose,,2023,Q2,2,F,,20230524.0,20230518,20230603,EXP,,US-STRIDES ARCOLAB LIMITED-2023SP007294,STRIDES,"Haluska AD, Davis A, Tarabishy N, Pena ME.. Use of Naloxone in Angiotensin-Converting Enzyme Inhibitor Overdose: A Case Report. J Emerg Med. 2023;64(3):397-399",49.0,YR,,M,Y,,,20230603,,HP,US,US,2023,Q2,Adult
223424701,22342470,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,Unknown,,,,,,,2023,Q2,Hyponatraemia,,2023,Q2,1,I,,20230510.0,20230519,20230519,EXP,,US-LUPIN PHARMACEUTICALS INC.-2023-03711,LUPIN,"Paster L, Mehtabdin K, Jhaveri KD, Myers A, Barnett RL. A case of hyponatremia associated with SGLT-2 inhibitor empagliflozin. Journal of the American Society of Nephrology. 2016;27:996A",69.0,YR,,F,Y,,,20230519,,HP,US,US,2023,Q2,Elderly
223424701,22342470,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,Unknown,,,,,,,2023,Q2,Blood creatinine increased,,2023,Q2,1,I,,20230510.0,20230519,20230519,EXP,,US-LUPIN PHARMACEUTICALS INC.-2023-03711,LUPIN,"Paster L, Mehtabdin K, Jhaveri KD, Myers A, Barnett RL. A case of hyponatremia associated with SGLT-2 inhibitor empagliflozin. Journal of the American Society of Nephrology. 2016;27:996A",69.0,YR,,F,Y,,,20230519,,HP,US,US,2023,Q2,Elderly
223424701,22342470,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,Unknown,,,,,,,2023,Q2,Hypovolaemia,,2023,Q2,1,I,,20230510.0,20230519,20230519,EXP,,US-LUPIN PHARMACEUTICALS INC.-2023-03711,LUPIN,"Paster L, Mehtabdin K, Jhaveri KD, Myers A, Barnett RL. A case of hyponatremia associated with SGLT-2 inhibitor empagliflozin. Journal of the American Society of Nephrology. 2016;27:996A",69.0,YR,,F,Y,,,20230519,,HP,US,US,2023,Q2,Elderly
223438061,22343806,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2023,Q2,Toxic skin eruption,,2023,Q2,1,I,20230312.0,20230516.0,20230519,20230519,EXP,FR-AFSSAPS-TO2023000608,FR-SA-2023SA108527,SANOFI AVENTIS,,85.0,YR,E,M,Y,58.0,KG,20230519,,MD,FR,FR,2023,Q2,Elderly
223438061,22343806,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2023,Q2,Drug reaction with eosinophilia and systemic symptoms,,2023,Q2,1,I,20230312.0,20230516.0,20230519,20230519,EXP,FR-AFSSAPS-TO2023000608,FR-SA-2023SA108527,SANOFI AVENTIS,,85.0,YR,E,M,Y,58.0,KG,20230519,,MD,FR,FR,2023,Q2,Elderly
223441461,22344146,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,Unknown,,206111.0,,,,QD,2023,Q2,Inappropriate schedule of product administration,,2023,Q2,1,I,20230512.0,20230513.0,20230519,20230519,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-237350",BOEHRINGER INGELHEIM,,72.0,YR,E,F,Y,,,20230519,,CN,AU,AU,2023,Q2,Elderly
223441461,22344146,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,Unknown,,206111.0,,,,QD,2023,Q2,Tooth extraction,,2023,Q2,1,I,20230512.0,20230513.0,20230519,20230519,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-237350",BOEHRINGER INGELHEIM,,72.0,YR,E,F,Y,,,20230519,,CN,AU,AU,2023,Q2,Elderly
223451222,22345122,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,102145.0,10.0,MG,,,2023,Q2,Flank pain,,2023,Q2,2,F,20230113.0,20230603.0,20230519,20230608,EXP,,"NO-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-237353",BOEHRINGER INGELHEIM,,64.0,YR,A,F,Y,,,20230608,,MD,NO,NO,2023,Q2,Adult
223460431,22346043,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 mg,,,,,,,,,,,,2023,Q2,Somnolence,,2023,Q2,1,I,,20230509.0,20230519,20230519,EXP,,ES-TEVA-2023-ES-2887829,TEVA,,62.0,YR,A,F,Y,90.0,KG,20230519,,PH,ES,ES,2023,Q2,Adult
223460431,22346043,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 mg,,,,,,,,,,,,2023,Q2,Parkinsonism,,2023,Q2,1,I,,20230509.0,20230519,20230519,EXP,,ES-TEVA-2023-ES-2887829,TEVA,,62.0,YR,A,F,Y,90.0,KG,20230519,,PH,ES,ES,2023,Q2,Adult
223460431,22346043,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 mg,,,,,,,,,,,,2023,Q2,Drug interaction,,2023,Q2,1,I,,20230509.0,20230519,20230519,EXP,,ES-TEVA-2023-ES-2887829,TEVA,,62.0,YR,A,F,Y,90.0,KG,20230519,,PH,ES,ES,2023,Q2,Adult
223460431,22346043,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 mg,,,,,,,,,,,,2023,Q2,Hypoglycaemia,,2023,Q2,1,I,,20230509.0,20230519,20230519,EXP,,ES-TEVA-2023-ES-2887829,TEVA,,62.0,YR,A,F,Y,90.0,KG,20230519,,PH,ES,ES,2023,Q2,Adult
223460431,22346043,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 mg,,,,,,,,,,,,2023,Q2,Hallucination,,2023,Q2,1,I,,20230509.0,20230519,20230519,EXP,,ES-TEVA-2023-ES-2887829,TEVA,,62.0,YR,A,F,Y,90.0,KG,20230519,,PH,ES,ES,2023,Q2,Adult
223460431,22346043,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 mg,,,,,,,,,,,,2023,Q2,Hypotension,,2023,Q2,1,I,,20230509.0,20230519,20230519,EXP,,ES-TEVA-2023-ES-2887829,TEVA,,62.0,YR,A,F,Y,90.0,KG,20230519,,PH,ES,ES,2023,Q2,Adult
223463022,22346302,2,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q2,Urethritis,,2023,Q2,2,F,,20230613.0,20230519,20230620,EXP,,JP-009507513-2305JPN006330,MERCK,,7.0,DEC,,F,Y,,,20230620,,MD,JP,JP,2023,Q2,Child
223474501,22347450,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 every 1 Days,,,U,,Unknown,,204629.0,5.0,MG,Tablet,QD,2023,Q2,Drug ineffective,,2023,Q2,1,I,,20230516.0,20230521,20230521,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-238024",BOEHRINGER INGELHEIM,,61.0,YR,A,M,Y,,,20230520,,MD,CA,CA,2023,Q2,Adult
223474501,22347450,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 every 1 Days,,,U,,Unknown,,204629.0,5.0,MG,Tablet,QD,2023,Q2,Drug eruption,,2023,Q2,1,I,,20230516.0,20230521,20230521,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-238024",BOEHRINGER INGELHEIM,,61.0,YR,A,M,Y,,,20230520,,MD,CA,CA,2023,Q2,Adult
223474501,22347450,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 every 1 Days,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Drug ineffective,,2023,Q2,1,I,,20230516.0,20230521,20230521,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-238024",BOEHRINGER INGELHEIM,,61.0,YR,A,M,Y,,,20230520,,MD,CA,CA,2023,Q2,Adult
223474501,22347450,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 every 1 Days,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Drug eruption,,2023,Q2,1,I,,20230516.0,20230521,20230521,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-238024",BOEHRINGER INGELHEIM,,61.0,YR,A,M,Y,,,20230520,,MD,CA,CA,2023,Q2,Adult
223480211,22348021,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Tongue oedema,,2023,Q2,1,I,20230327.0,20230511.0,20230522,20230522,EXP,,IT-AUROBINDO-AUR-APL-2023-036923,AUROBINDO,,63.0,YR,,M,Y,,,20230522,,PH,IT,IT,2023,Q2,Adult
223480211,22348021,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Angioedema,,2023,Q2,1,I,20230327.0,20230511.0,20230522,20230522,EXP,,IT-AUROBINDO-AUR-APL-2023-036923,AUROBINDO,,63.0,YR,,M,Y,,,20230522,,PH,IT,IT,2023,Q2,Adult
223480211,22348021,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Dysphonia,,2023,Q2,1,I,20230327.0,20230511.0,20230522,20230522,EXP,,IT-AUROBINDO-AUR-APL-2023-036923,AUROBINDO,,63.0,YR,,M,Y,,,20230522,,PH,IT,IT,2023,Q2,Adult
223481201,22348120,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,once daily,,,,,Unknown,,,,,,,2023,Q2,Rash,,2023,Q2,1,I,,20230511.0,20230522,20230522,EXP,GB-MHRA-TPP14262576C952104YC1683628202189,GB-NOVOPROD-1063998,NOVO NORDISK,,54.0,YR,,M,Y,72.0,KG,20230522,,MD,GB,GB,2023,Q2,Adult
223491571,22349157,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"5 mg, BID",,,,,,,,5.0,MG,,,2023,Q2,Arrhythmia,,2023,Q2,1,I,20230301.0,20230514.0,20230522,20230522,EXP,,HR-JNJFOC-20230547638,JOHNSON AND JOHNSON,,73.0,YR,E,M,Y,,,20230522,,MD,HR,HR,2023,Q2,Elderly
223491571,22349157,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"5 mg, BID",,,,,,,,5.0,MG,,,2023,Q2,Intermittent claudication,,2023,Q2,1,I,20230301.0,20230514.0,20230522,20230522,EXP,,HR-JNJFOC-20230547638,JOHNSON AND JOHNSON,,73.0,YR,E,M,Y,,,20230522,,MD,HR,HR,2023,Q2,Elderly
223492341,22349234,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, At noon",,,Y,,,,,10.0,MG,Film-coated tablet,,2023,Q2,Acute kidney injury,,2023,Q2,1,I,20221110.0,20230512.0,20230522,20230522,EXP,FR-AFSSAPS-DJ2023000354,FR-Accord-359000,ACCORD,,57.0,YR,A,M,Y,,,20230522,,MD,FR,FR,2023,Q2,Adult
223492341,22349234,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, At noon",,,Y,,,,,10.0,MG,Film-coated tablet,,2023,Q2,Condition aggravated,,2023,Q2,1,I,20221110.0,20230512.0,20230522,20230522,EXP,FR-AFSSAPS-DJ2023000354,FR-Accord-359000,ACCORD,,57.0,YR,A,M,Y,,,20230522,,MD,FR,FR,2023,Q2,Adult
223497991,22349799,17,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,1000 mg/5 mg (1-0-1-0),,,U,,,,,,,,,2023,Q2,Parkinsonism,,2023,Q2,1,I,,20230509.0,20230522,20230522,EXP,,ES-AUROBINDO-AUR-APL-2023-036031,AUROBINDO,"Abdala S, Devora S, Oliva AM, Morales C.. The added value of professional pharmaceutical care services. A case of SFT.. Community Farms.. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20230522,,HP,ES,ES,2023,Q2,Adult
223497991,22349799,17,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,1000 mg/5 mg (1-0-1-0),,,U,,,,,,,,,2023,Q2,Hypoglycaemia,,2023,Q2,1,I,,20230509.0,20230522,20230522,EXP,,ES-AUROBINDO-AUR-APL-2023-036031,AUROBINDO,"Abdala S, Devora S, Oliva AM, Morales C.. The added value of professional pharmaceutical care services. A case of SFT.. Community Farms.. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20230522,,HP,ES,ES,2023,Q2,Adult
223497991,22349799,17,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,1000 mg/5 mg (1-0-1-0),,,U,,,,,,,,,2023,Q2,Drug interaction,,2023,Q2,1,I,,20230509.0,20230522,20230522,EXP,,ES-AUROBINDO-AUR-APL-2023-036031,AUROBINDO,"Abdala S, Devora S, Oliva AM, Morales C.. The added value of professional pharmaceutical care services. A case of SFT.. Community Farms.. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20230522,,HP,ES,ES,2023,Q2,Adult
223497991,22349799,17,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,1000 mg/5 mg (1-0-1-0),,,U,,,,,,,,,2023,Q2,Hallucination,,2023,Q2,1,I,,20230509.0,20230522,20230522,EXP,,ES-AUROBINDO-AUR-APL-2023-036031,AUROBINDO,"Abdala S, Devora S, Oliva AM, Morales C.. The added value of professional pharmaceutical care services. A case of SFT.. Community Farms.. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20230522,,HP,ES,ES,2023,Q2,Adult
223497991,22349799,17,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,1000 mg/5 mg (1-0-1-0),,,U,,,,,,,,,2023,Q2,Hypotension,,2023,Q2,1,I,,20230509.0,20230522,20230522,EXP,,ES-AUROBINDO-AUR-APL-2023-036031,AUROBINDO,"Abdala S, Devora S, Oliva AM, Morales C.. The added value of professional pharmaceutical care services. A case of SFT.. Community Farms.. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20230522,,HP,ES,ES,2023,Q2,Adult
223497991,22349799,17,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,1000 mg/5 mg (1-0-1-0),,,U,,,,,,,,,2023,Q2,Somnolence,,2023,Q2,1,I,,20230509.0,20230522,20230522,EXP,,ES-AUROBINDO-AUR-APL-2023-036031,AUROBINDO,"Abdala S, Devora S, Oliva AM, Morales C.. The added value of professional pharmaceutical care services. A case of SFT.. Community Farms.. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20230522,,HP,ES,ES,2023,Q2,Adult
223497991,22349799,29,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Parkinsonism,,2023,Q2,1,I,,20230509.0,20230522,20230522,EXP,,ES-AUROBINDO-AUR-APL-2023-036031,AUROBINDO,"Abdala S, Devora S, Oliva AM, Morales C.. The added value of professional pharmaceutical care services. A case of SFT.. Community Farms.. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20230522,,HP,ES,ES,2023,Q2,Adult
223497991,22349799,29,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Hypoglycaemia,,2023,Q2,1,I,,20230509.0,20230522,20230522,EXP,,ES-AUROBINDO-AUR-APL-2023-036031,AUROBINDO,"Abdala S, Devora S, Oliva AM, Morales C.. The added value of professional pharmaceutical care services. A case of SFT.. Community Farms.. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20230522,,HP,ES,ES,2023,Q2,Adult
223497991,22349799,29,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Drug interaction,,2023,Q2,1,I,,20230509.0,20230522,20230522,EXP,,ES-AUROBINDO-AUR-APL-2023-036031,AUROBINDO,"Abdala S, Devora S, Oliva AM, Morales C.. The added value of professional pharmaceutical care services. A case of SFT.. Community Farms.. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20230522,,HP,ES,ES,2023,Q2,Adult
223497991,22349799,29,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Hallucination,,2023,Q2,1,I,,20230509.0,20230522,20230522,EXP,,ES-AUROBINDO-AUR-APL-2023-036031,AUROBINDO,"Abdala S, Devora S, Oliva AM, Morales C.. The added value of professional pharmaceutical care services. A case of SFT.. Community Farms.. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20230522,,HP,ES,ES,2023,Q2,Adult
223497991,22349799,29,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Hypotension,,2023,Q2,1,I,,20230509.0,20230522,20230522,EXP,,ES-AUROBINDO-AUR-APL-2023-036031,AUROBINDO,"Abdala S, Devora S, Oliva AM, Morales C.. The added value of professional pharmaceutical care services. A case of SFT.. Community Farms.. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20230522,,HP,ES,ES,2023,Q2,Adult
223497991,22349799,29,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Somnolence,,2023,Q2,1,I,,20230509.0,20230522,20230522,EXP,,ES-AUROBINDO-AUR-APL-2023-036031,AUROBINDO,"Abdala S, Devora S, Oliva AM, Morales C.. The added value of professional pharmaceutical care services. A case of SFT.. Community Farms.. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20230522,,HP,ES,ES,2023,Q2,Adult
223506382,22350638,3,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,AP,,,,,Unknown,,,,,Tablet,QD,2023,Q2,Dehydration,,2023,Q2,2,F,20230113.0,20230621.0,20230522,20230630,EXP,,JP-EMD Serono-9380482,EMD SERONO INC,,91.0,YR,E,M,Y,44.0,KG,20230630,,PH,JP,JP,2023,Q2,Elderly
223506382,22350638,3,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,AP,,,,,Unknown,,,,,Tablet,QD,2023,Q2,Renal impairment,,2023,Q2,2,F,20230113.0,20230621.0,20230522,20230630,EXP,,JP-EMD Serono-9380482,EMD SERONO INC,,91.0,YR,E,M,Y,44.0,KG,20230630,,PH,JP,JP,2023,Q2,Elderly
223506382,22350638,3,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,AP,,,,,Unknown,,,,,Tablet,QD,2023,Q2,Atrial fibrillation,,2023,Q2,2,F,20230113.0,20230621.0,20230522,20230630,EXP,,JP-EMD Serono-9380482,EMD SERONO INC,,91.0,YR,E,M,Y,44.0,KG,20230630,,PH,JP,JP,2023,Q2,Elderly
223506382,22350638,3,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,AP,,,,,Unknown,,,,,Tablet,QD,2023,Q2,Hypoglycaemia,,2023,Q2,2,F,20230113.0,20230621.0,20230522,20230630,EXP,,JP-EMD Serono-9380482,EMD SERONO INC,,91.0,YR,E,M,Y,44.0,KG,20230630,,PH,JP,JP,2023,Q2,Elderly
223506382,22350638,3,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,AP,,,,,Unknown,,,,,Tablet,QD,2023,Q2,Bundle branch block right,,2023,Q2,2,F,20230113.0,20230621.0,20230522,20230630,EXP,,JP-EMD Serono-9380482,EMD SERONO INC,,91.0,YR,E,M,Y,44.0,KG,20230630,,PH,JP,JP,2023,Q2,Elderly
223506382,22350638,3,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,AP,,,,,Unknown,,,,,Tablet,QD,2023,Q2,Pneumonia,,2023,Q2,2,F,20230113.0,20230621.0,20230522,20230630,EXP,,JP-EMD Serono-9380482,EMD SERONO INC,,91.0,YR,E,M,Y,44.0,KG,20230630,,PH,JP,JP,2023,Q2,Elderly
223506382,22350638,3,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,AP,,,,,Unknown,,,,,Tablet,QD,2023,Q2,Lactic acidosis,,2023,Q2,2,F,20230113.0,20230621.0,20230522,20230630,EXP,,JP-EMD Serono-9380482,EMD SERONO INC,,91.0,YR,E,M,Y,44.0,KG,20230630,,PH,JP,JP,2023,Q2,Elderly
223506382,22350638,3,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,AP,,,,,Unknown,,,,,Tablet,QD,2023,Q2,Emphysema,,2023,Q2,2,F,20230113.0,20230621.0,20230522,20230630,EXP,,JP-EMD Serono-9380482,EMD SERONO INC,,91.0,YR,E,M,Y,44.0,KG,20230630,,PH,JP,JP,2023,Q2,Elderly
223506382,22350638,3,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,AP,,,,,Unknown,,,,,Tablet,QD,2023,Q2,Syncope,,2023,Q2,2,F,20230113.0,20230621.0,20230522,20230630,EXP,,JP-EMD Serono-9380482,EMD SERONO INC,,91.0,YR,E,M,Y,44.0,KG,20230630,,PH,JP,JP,2023,Q2,Elderly
223507821,22350782,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, qd",,,U,U,,,,,,Tablet,QD,2023,Q2,Renal failure,,2023,Q2,1,I,,20230512.0,20230522,20230522,EXP,,US-MYLANLABS-2023M1049973,MYLAN,,94.0,YR,,F,Y,64.4,KG,20230522,,CN,US,US,2023,Q2,Elderly
223522001,22352200,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/850 mg,,,U,,Asked But Unknown,,206111.0,,,,QD,2023,Q2,Urinary tract infection,,2023,Q2,1,I,20230505.0,20230518.0,20230522,20230522,EXP,,"TW-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-238361",BOEHRINGER INGELHEIM,,79.0,YR,E,M,Y,,,20230522,,MD,TW,TW,2023,Q2,Elderly
223522001,22352200,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/850 mg,,,U,,Asked But Unknown,,206111.0,,,,QD,2023,Q2,Septic shock,,2023,Q2,1,I,20230505.0,20230518.0,20230522,20230522,EXP,,"TW-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-238361",BOEHRINGER INGELHEIM,,79.0,YR,E,M,Y,,,20230522,,MD,TW,TW,2023,Q2,Elderly
223524731,22352473,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Cardiac failure,,2023,Q2,1,I,,20230515.0,20230522,20230522,EXP,,SI-JNJFOC-20230551620,JOHNSON AND JOHNSON,,80.0,YR,E,F,Y,,,20230523,,HP,SI,SI,2023,Q2,Elderly
223524731,22352473,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Pulmonary hypertension,,2023,Q2,1,I,,20230515.0,20230522,20230522,EXP,,SI-JNJFOC-20230551620,JOHNSON AND JOHNSON,,80.0,YR,E,F,Y,,,20230523,,HP,SI,SI,2023,Q2,Elderly
223530181,22353018,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,take one daily,,,,,Unknown,,,,,,,2023,Q2,Dizziness,,2023,Q2,1,I,20230325.0,20230511.0,20230523,20230523,EXP,GB-MHRA-TPP41695729C4757292YC1683703456265,GB-NOVOPROD-1063996,NOVO NORDISK,,64.0,YR,,M,Y,93.0,KG,20230523,,HP,GB,GB,2023,Q2,Adult
223530181,22353018,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,take one daily,,,,,Unknown,,,,,,,2023,Q2,Rash erythematous,,2023,Q2,1,I,20230325.0,20230511.0,20230523,20230523,EXP,GB-MHRA-TPP41695729C4757292YC1683703456265,GB-NOVOPROD-1063996,NOVO NORDISK,,64.0,YR,,M,Y,93.0,KG,20230523,,HP,GB,GB,2023,Q2,Adult
223530181,22353018,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,take one daily,,,,,Unknown,,,,,,,2023,Q2,Vision blurred,,2023,Q2,1,I,20230325.0,20230511.0,20230523,20230523,EXP,GB-MHRA-TPP41695729C4757292YC1683703456265,GB-NOVOPROD-1063996,NOVO NORDISK,,64.0,YR,,M,Y,93.0,KG,20230523,,HP,GB,GB,2023,Q2,Adult
223542532,22354253,14,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q2,Pemphigoid,,2023,Q2,2,F,,20230608.0,20230523,20230619,EXP,,GB-Accord-359060,ACCORD,,59.0,YR,A,F,Y,,,20230619,,MD,GB,GB,2023,Q2,Adult
223542532,22354253,14,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q2,Drug ineffective,,2023,Q2,2,F,,20230608.0,20230523,20230619,EXP,,GB-Accord-359060,ACCORD,,59.0,YR,A,F,Y,,,20230619,,MD,GB,GB,2023,Q2,Adult
223555671,22355567,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Skin exfoliation,,2023,Q2,1,I,20220207.0,20230515.0,20230523,20230523,EXP,,CA-TAKEDA-2022TUS013905,TAKEDA,,63.0,YR,,M,Y,,,20230523,,PH,CA,CA,2023,Q2,Adult
223555671,22355567,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Fatigue,,2023,Q2,1,I,20220207.0,20230515.0,20230523,20230523,EXP,,CA-TAKEDA-2022TUS013905,TAKEDA,,63.0,YR,,M,Y,,,20230523,,PH,CA,CA,2023,Q2,Adult
223555671,22355567,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Off label use,,2023,Q2,1,I,20220207.0,20230515.0,20230523,20230523,EXP,,CA-TAKEDA-2022TUS013905,TAKEDA,,63.0,YR,,M,Y,,,20230523,,PH,CA,CA,2023,Q2,Adult
223555671,22355567,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Pain in extremity,,2023,Q2,1,I,20220207.0,20230515.0,20230523,20230523,EXP,,CA-TAKEDA-2022TUS013905,TAKEDA,,63.0,YR,,M,Y,,,20230523,,PH,CA,CA,2023,Q2,Adult
223555671,22355567,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Abdominal discomfort,,2023,Q2,1,I,20220207.0,20230515.0,20230523,20230523,EXP,,CA-TAKEDA-2022TUS013905,TAKEDA,,63.0,YR,,M,Y,,,20230523,,PH,CA,CA,2023,Q2,Adult
223555671,22355567,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Upper respiratory tract infection,,2023,Q2,1,I,20220207.0,20230515.0,20230523,20230523,EXP,,CA-TAKEDA-2022TUS013905,TAKEDA,,63.0,YR,,M,Y,,,20230523,,PH,CA,CA,2023,Q2,Adult
223555671,22355567,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Dyspepsia,,2023,Q2,1,I,20220207.0,20230515.0,20230523,20230523,EXP,,CA-TAKEDA-2022TUS013905,TAKEDA,,63.0,YR,,M,Y,,,20230523,,PH,CA,CA,2023,Q2,Adult
223555671,22355567,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Diarrhoea,,2023,Q2,1,I,20220207.0,20230515.0,20230523,20230523,EXP,,CA-TAKEDA-2022TUS013905,TAKEDA,,63.0,YR,,M,Y,,,20230523,,PH,CA,CA,2023,Q2,Adult
223555671,22355567,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Illness,,2023,Q2,1,I,20220207.0,20230515.0,20230523,20230523,EXP,,CA-TAKEDA-2022TUS013905,TAKEDA,,63.0,YR,,M,Y,,,20230523,,PH,CA,CA,2023,Q2,Adult
223555671,22355567,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Abdominal pain lower,,2023,Q2,1,I,20220207.0,20230515.0,20230523,20230523,EXP,,CA-TAKEDA-2022TUS013905,TAKEDA,,63.0,YR,,M,Y,,,20230523,,PH,CA,CA,2023,Q2,Adult
223555671,22355567,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,Tablet,QD,2023,Q2,Abdominal rigidity,,2023,Q2,1,I,20220207.0,20230515.0,20230523,20230523,EXP,,CA-TAKEDA-2022TUS013905,TAKEDA,,63.0,YR,,M,Y,,,20230523,,PH,CA,CA,2023,Q2,Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Alopecia,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Anxiety,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Carotid artery occlusion,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Lip swelling,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Angioedema,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,COVID-19,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Off label use,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Peripheral swelling,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Pericarditis,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Pain of skin,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Nausea,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Product prescribing error,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Diplopia,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Heart rate increased,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Abdominal pain upper,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Palmoplantar keratoderma,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Diarrhoea,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Back pain,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Immunisation,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Malaise,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Atrial tachycardia,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Drug abuse,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Pain in extremity,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Rash papular,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Blindness,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Visual impairment,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Migraine,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Abdominal discomfort,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Hallucination,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Transient ischaemic attack,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Sleep terror,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Pruritus genital,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Tachycardia,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Vomiting,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Myocardial infarction,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Amnesia,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Palpitations,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Eye disorder,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Tinnitus,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Chest pain,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Arthralgia,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Vasculitis,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Cognitive disorder,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Dizziness,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Subarachnoid haemorrhage,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Memory impairment,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Facial pain,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Muscle twitching,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Ventricular tachycardia,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Pyrexia,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Blood glucose increased,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Dry skin,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Intentional product use issue,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Hyperhidrosis,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Feeling abnormal,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Dehydration,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Muscular weakness,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Tension headache,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Anosmia,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Intentional product misuse,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Headache,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Dyspnoea,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Insomnia,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Fatigue,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Cardiospasm,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Pain,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Disturbance in attention,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223568885,22356888,27,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"5 milligram, qd",,,U,U,Unknown,,,5.0,MG,,QD,2023,Q2,Pruritus,,2023,Q2,5,F,,20230615.0,20230523,20230629,EXP,,GB-TAKEDA-2023TUS050739,TAKEDA,,34.0,YR,,M,Y,70.0,KG,20230629,,HP,GB,GB,2023,Q2,Young Adult
223590122,22359012,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Paraesthesia,,2023,Q2,2,F,20230501.0,20230523.0,20230524,20230525,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-2023-073375,BRISTOL MYERS SQUIBB,,75.0,YR,E,M,Y,81.65,KG,20230525,,CN,US,US,2023,Q2,Elderly
223590122,22359012,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Urinary tract infection,,2023,Q2,2,F,20230501.0,20230523.0,20230524,20230525,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-2023-073375,BRISTOL MYERS SQUIBB,,75.0,YR,E,M,Y,81.65,KG,20230525,,CN,US,US,2023,Q2,Elderly
223590122,22359012,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Hypoaesthesia,,2023,Q2,2,F,20230501.0,20230523.0,20230524,20230525,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-2023-073375,BRISTOL MYERS SQUIBB,,75.0,YR,E,M,Y,81.65,KG,20230525,,CN,US,US,2023,Q2,Elderly
223593001,22359300,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q2,Dizziness,,2023,Q2,1,I,,20230515.0,20230524,20230524,EXP,,US-AUROBINDO-AUR-APL-2023-037654,AUROBINDO,"Paster L, Mehtabdin K, Jhaveri KD, Myers A, Barnett RL. A Case of Hyponatremia Associated with SGLT-2 inhibitor Empagliflozin. J-Am-Soc-Nephrol. 2016;27996A.",69.0,YR,,F,Y,,,20230524,,HP,US,US,2023,Q2,Elderly
223593001,22359300,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q2,Hyponatraemia,,2023,Q2,1,I,,20230515.0,20230524,20230524,EXP,,US-AUROBINDO-AUR-APL-2023-037654,AUROBINDO,"Paster L, Mehtabdin K, Jhaveri KD, Myers A, Barnett RL. A Case of Hyponatremia Associated with SGLT-2 inhibitor Empagliflozin. J-Am-Soc-Nephrol. 2016;27996A.",69.0,YR,,F,Y,,,20230524,,HP,US,US,2023,Q2,Elderly
223593001,22359300,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q2,Blood creatinine increased,,2023,Q2,1,I,,20230515.0,20230524,20230524,EXP,,US-AUROBINDO-AUR-APL-2023-037654,AUROBINDO,"Paster L, Mehtabdin K, Jhaveri KD, Myers A, Barnett RL. A Case of Hyponatremia Associated with SGLT-2 inhibitor Empagliflozin. J-Am-Soc-Nephrol. 2016;27996A.",69.0,YR,,F,Y,,,20230524,,HP,US,US,2023,Q2,Elderly
223593911,22359391,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Drug ineffective,,2023,Q2,1,I,,20230517.0,20230524,20230524,EXP,,NVSC2023CA114815,NOVARTIS,,61.0,YR,,M,Y,,,20230524,,CN,CA,CA,2023,Q2,Adult
223593911,22359391,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Drug eruption,,2023,Q2,1,I,,20230517.0,20230524,20230524,EXP,,NVSC2023CA114815,NOVARTIS,,61.0,YR,,M,Y,,,20230524,,CN,CA,CA,2023,Q2,Adult
223593911,22359391,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Drug ineffective,,2023,Q2,1,I,,20230517.0,20230524,20230524,EXP,,NVSC2023CA114815,NOVARTIS,,61.0,YR,,M,Y,,,20230524,,CN,CA,CA,2023,Q2,Adult
223593911,22359391,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 mg, QD",,,U,,,,,5.0,MG,,QD,2023,Q2,Drug eruption,,2023,Q2,1,I,,20230517.0,20230524,20230524,EXP,,NVSC2023CA114815,NOVARTIS,,61.0,YR,,M,Y,,,20230524,,CN,CA,CA,2023,Q2,Adult
223626791,22362679,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"12.5 mg, QD",,,,,,,,12.5,MG,,QD,2023,Q2,Lower gastrointestinal haemorrhage,,2023,Q2,1,I,20221221.0,20230516.0,20230524,20230524,PER,,US-JNJFOC-20230555719,JOHNSON AND JOHNSON,,79.0,YR,E,F,Y,79.42,KG,20230525,,MD,US,US,2023,Q2,Elderly
223647081,22364708,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q2,Hypovolaemia,,2023,Q2,1,I,,20230518.0,20230525,20230525,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-238579",BOEHRINGER INGELHEIM,,66.0,YR,E,M,Y,,,20230525,,CN,AU,AU,2023,Q2,Elderly
223647081,22364708,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q2,Hypernatraemia,,2023,Q2,1,I,,20230518.0,20230525,20230525,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-238579",BOEHRINGER INGELHEIM,,66.0,YR,E,M,Y,,,20230525,,CN,AU,AU,2023,Q2,Elderly
223647081,22364708,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q2,Pneumonia,,2023,Q2,1,I,,20230518.0,20230525,20230525,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-238579",BOEHRINGER INGELHEIM,,66.0,YR,E,M,Y,,,20230525,,CN,AU,AU,2023,Q2,Elderly
223647081,22364708,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q2,Acute kidney injury,,2023,Q2,1,I,,20230518.0,20230525,20230525,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-238579",BOEHRINGER INGELHEIM,,66.0,YR,E,M,Y,,,20230525,,CN,AU,AU,2023,Q2,Elderly
223647081,22364708,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q2,Toxicity to various agents,,2023,Q2,1,I,,20230518.0,20230525,20230525,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-238579",BOEHRINGER INGELHEIM,,66.0,YR,E,M,Y,,,20230525,,CN,AU,AU,2023,Q2,Elderly
223647081,22364708,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q2,Ileus,,2023,Q2,1,I,,20230518.0,20230525,20230525,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-238579",BOEHRINGER INGELHEIM,,66.0,YR,E,M,Y,,,20230525,,CN,AU,AU,2023,Q2,Elderly
223647081,22364708,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q2,Nephrogenic diabetes insipidus,,2023,Q2,1,I,,20230518.0,20230525,20230525,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-238579",BOEHRINGER INGELHEIM,,66.0,YR,E,M,Y,,,20230525,,CN,AU,AU,2023,Q2,Elderly
223647081,22364708,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q2,Neurotoxicity,,2023,Q2,1,I,,20230518.0,20230525,20230525,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-238579",BOEHRINGER INGELHEIM,,66.0,YR,E,M,Y,,,20230525,,CN,AU,AU,2023,Q2,Elderly
223671472,22367147,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,,,,,2023,Q2,Blood creatinine increased,,2023,Q2,2,F,,20230531.0,20230525,20230604,EXP,,US-TEVA-2023-US-2889351,TEVA,,69.0,YR,E,F,Y,,,20230604,,HP,US,US,2023,Q2,Elderly
223671472,22367147,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,,,,,2023,Q2,Hypovolaemia,,2023,Q2,2,F,,20230531.0,20230525,20230604,EXP,,US-TEVA-2023-US-2889351,TEVA,,69.0,YR,E,F,Y,,,20230604,,HP,US,US,2023,Q2,Elderly
223671472,22367147,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,,,,,2023,Q2,Hyponatraemia,,2023,Q2,2,F,,20230531.0,20230525,20230604,EXP,,US-TEVA-2023-US-2889351,TEVA,,69.0,YR,E,F,Y,,,20230604,,HP,US,US,2023,Q2,Elderly
223683681,22368368,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 dosage form, qd",,,,,,,,,,Tablet,QD,2023,Q2,Dizziness,,2023,Q2,1,I,20220901.0,20230523.0,20230525,20230525,EXP,GB-MHRA-TPP5931791C4758671YC1662048160239,GB-TAKEDA-2022TUS061549,TAKEDA,,65.0,YR,,M,Y,84.0,KG,20230525,,HP,GB,GB,2023,Q2,Elderly
223683681,22368368,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 dosage form, qd",,,,,,,,,,Tablet,QD,2023,Q2,Adverse drug reaction,,2023,Q2,1,I,20220901.0,20230523.0,20230525,20230525,EXP,GB-MHRA-TPP5931791C4758671YC1662048160239,GB-TAKEDA-2022TUS061549,TAKEDA,,65.0,YR,,M,Y,84.0,KG,20230525,,HP,GB,GB,2023,Q2,Elderly
223683681,22368368,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 dosage form, qd",,,,,,,,,,Tablet,QD,2023,Q2,Rash pruritic,,2023,Q2,1,I,20220901.0,20230523.0,20230525,20230525,EXP,GB-MHRA-TPP5931791C4758671YC1662048160239,GB-TAKEDA-2022TUS061549,TAKEDA,,65.0,YR,,M,Y,84.0,KG,20230525,,HP,GB,GB,2023,Q2,Elderly
223687531,22368753,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,25.0,MG,,QD,2023,Q2,Weight decreased,,2023,Q2,1,I,,20230516.0,20230525,20230525,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-2023-069752,BRISTOL MYERS SQUIBB,,74.0,YR,E,M,Y,102.33,KG,20230525,,PH,US,US,2023,Q2,Elderly
223700931,22370093,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Off label use,,2023,Q2,1,I,,20230524.0,20230526,20230526,EXP,,CA-ROCHE-3356216,ROCHE,,75.0,YR,,M,Y,,,20230526,,HP,CA,,2023,Q2,Elderly
223700931,22370093,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Chills,,2023,Q2,1,I,,20230524.0,20230526,20230526,EXP,,CA-ROCHE-3356216,ROCHE,,75.0,YR,,M,Y,,,20230526,,HP,CA,,2023,Q2,Elderly
223700931,22370093,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Pneumonia,,2023,Q2,1,I,,20230524.0,20230526,20230526,EXP,,CA-ROCHE-3356216,ROCHE,,75.0,YR,,M,Y,,,20230526,,HP,CA,,2023,Q2,Elderly
223700931,22370093,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,COVID-19,,2023,Q2,1,I,,20230524.0,20230526,20230526,EXP,,CA-ROCHE-3356216,ROCHE,,75.0,YR,,M,Y,,,20230526,,HP,CA,,2023,Q2,Elderly
223700931,22370093,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Nasopharyngitis,,2023,Q2,1,I,,20230524.0,20230526,20230526,EXP,,CA-ROCHE-3356216,ROCHE,,75.0,YR,,M,Y,,,20230526,,HP,CA,,2023,Q2,Elderly
223735721,22373572,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 mg,,,U,,"UNKNOWN,UNKNOWN",,,25.0,MG,,,2023,Q2,Musculoskeletal disorder,,2023,Q2,1,I,20181101.0,20230518.0,20230526,20230526,EXP,,HU-TEVA-2023-HU-2890349,TEVA,,69.0,YR,E,M,Y,,,20230526,,MD,HU,HU,2023,Q2,Elderly
223735721,22373572,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 mg,,,U,,"UNKNOWN,UNKNOWN",,,25.0,MG,,,2023,Q2,Weight increased,,2023,Q2,1,I,20181101.0,20230518.0,20230526,20230526,EXP,,HU-TEVA-2023-HU-2890349,TEVA,,69.0,YR,E,M,Y,,,20230526,,MD,HU,HU,2023,Q2,Elderly
223735721,22373572,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 mg,,,U,,"UNKNOWN,UNKNOWN",,,25.0,MG,,,2023,Q2,Blood potassium increased,,2023,Q2,1,I,20181101.0,20230518.0,20230526,20230526,EXP,,HU-TEVA-2023-HU-2890349,TEVA,,69.0,YR,E,M,Y,,,20230526,,MD,HU,HU,2023,Q2,Elderly
223735721,22373572,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 mg,,,U,,"UNKNOWN,UNKNOWN",,,25.0,MG,,,2023,Q2,Hypotension,,2023,Q2,1,I,20181101.0,20230518.0,20230526,20230526,EXP,,HU-TEVA-2023-HU-2890349,TEVA,,69.0,YR,E,M,Y,,,20230526,,MD,HU,HU,2023,Q2,Elderly
223735721,22373572,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 mg,,,U,,"UNKNOWN,UNKNOWN",,,25.0,MG,,,2023,Q2,N-terminal prohormone brain natriuretic peptide decreased,,2023,Q2,1,I,20181101.0,20230518.0,20230526,20230526,EXP,,HU-TEVA-2023-HU-2890349,TEVA,,69.0,YR,E,M,Y,,,20230526,,MD,HU,HU,2023,Q2,Elderly
223735721,22373572,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 mg,,,U,,"UNKNOWN,UNKNOWN",,,25.0,MG,,,2023,Q2,Fluid retention,,2023,Q2,1,I,20181101.0,20230518.0,20230526,20230526,EXP,,HU-TEVA-2023-HU-2890349,TEVA,,69.0,YR,E,M,Y,,,20230526,,MD,HU,HU,2023,Q2,Elderly
223735721,22373572,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 mg,,,U,,"UNKNOWN,UNKNOWN",,,25.0,MG,,,2023,Q2,Cardiac failure chronic,,2023,Q2,1,I,20181101.0,20230518.0,20230526,20230526,EXP,,HU-TEVA-2023-HU-2890349,TEVA,,69.0,YR,E,M,Y,,,20230526,,MD,HU,HU,2023,Q2,Elderly
223735721,22373572,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 mg,,,U,,"UNKNOWN,UNKNOWN",,,25.0,MG,,,2023,Q2,Dyspnoea paroxysmal nocturnal,,2023,Q2,1,I,20181101.0,20230518.0,20230526,20230526,EXP,,HU-TEVA-2023-HU-2890349,TEVA,,69.0,YR,E,M,Y,,,20230526,,MD,HU,HU,2023,Q2,Elderly
223735721,22373572,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 mg,,,U,,"UNKNOWN,UNKNOWN",,,25.0,MG,,,2023,Q2,Iron deficiency,,2023,Q2,1,I,20181101.0,20230518.0,20230526,20230526,EXP,,HU-TEVA-2023-HU-2890349,TEVA,,69.0,YR,E,M,Y,,,20230526,,MD,HU,HU,2023,Q2,Elderly
223735721,22373572,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,U,,"UNKNOWN,UNKNOWN",,,10.0,MG,,,2023,Q2,Musculoskeletal disorder,,2023,Q2,1,I,20181101.0,20230518.0,20230526,20230526,EXP,,HU-TEVA-2023-HU-2890349,TEVA,,69.0,YR,E,M,Y,,,20230526,,MD,HU,HU,2023,Q2,Elderly
223735721,22373572,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,U,,"UNKNOWN,UNKNOWN",,,10.0,MG,,,2023,Q2,Weight increased,,2023,Q2,1,I,20181101.0,20230518.0,20230526,20230526,EXP,,HU-TEVA-2023-HU-2890349,TEVA,,69.0,YR,E,M,Y,,,20230526,,MD,HU,HU,2023,Q2,Elderly
223735721,22373572,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,U,,"UNKNOWN,UNKNOWN",,,10.0,MG,,,2023,Q2,Blood potassium increased,,2023,Q2,1,I,20181101.0,20230518.0,20230526,20230526,EXP,,HU-TEVA-2023-HU-2890349,TEVA,,69.0,YR,E,M,Y,,,20230526,,MD,HU,HU,2023,Q2,Elderly
223735721,22373572,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,U,,"UNKNOWN,UNKNOWN",,,10.0,MG,,,2023,Q2,Hypotension,,2023,Q2,1,I,20181101.0,20230518.0,20230526,20230526,EXP,,HU-TEVA-2023-HU-2890349,TEVA,,69.0,YR,E,M,Y,,,20230526,,MD,HU,HU,2023,Q2,Elderly
223735721,22373572,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,U,,"UNKNOWN,UNKNOWN",,,10.0,MG,,,2023,Q2,N-terminal prohormone brain natriuretic peptide decreased,,2023,Q2,1,I,20181101.0,20230518.0,20230526,20230526,EXP,,HU-TEVA-2023-HU-2890349,TEVA,,69.0,YR,E,M,Y,,,20230526,,MD,HU,HU,2023,Q2,Elderly
223735721,22373572,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,U,,"UNKNOWN,UNKNOWN",,,10.0,MG,,,2023,Q2,Fluid retention,,2023,Q2,1,I,20181101.0,20230518.0,20230526,20230526,EXP,,HU-TEVA-2023-HU-2890349,TEVA,,69.0,YR,E,M,Y,,,20230526,,MD,HU,HU,2023,Q2,Elderly
223735721,22373572,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,U,,"UNKNOWN,UNKNOWN",,,10.0,MG,,,2023,Q2,Cardiac failure chronic,,2023,Q2,1,I,20181101.0,20230518.0,20230526,20230526,EXP,,HU-TEVA-2023-HU-2890349,TEVA,,69.0,YR,E,M,Y,,,20230526,,MD,HU,HU,2023,Q2,Elderly
223735721,22373572,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,U,,"UNKNOWN,UNKNOWN",,,10.0,MG,,,2023,Q2,Dyspnoea paroxysmal nocturnal,,2023,Q2,1,I,20181101.0,20230518.0,20230526,20230526,EXP,,HU-TEVA-2023-HU-2890349,TEVA,,69.0,YR,E,M,Y,,,20230526,,MD,HU,HU,2023,Q2,Elderly
223735721,22373572,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,U,,"UNKNOWN,UNKNOWN",,,10.0,MG,,,2023,Q2,Iron deficiency,,2023,Q2,1,I,20181101.0,20230518.0,20230526,20230526,EXP,,HU-TEVA-2023-HU-2890349,TEVA,,69.0,YR,E,M,Y,,,20230526,,MD,HU,HU,2023,Q2,Elderly
223747931,22374793,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,(morning);,,,Y,U,Unknown,,204629.0,25.0,MG,Tablet,QD,2023,Q2,Diabetic ketoacidosis,,2023,Q2,1,I,20230525.0,20230526.0,20230526,20230526,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-240208",BOEHRINGER INGELHEIM,,45.0,YR,A,M,Y,80.0,KG,20230527,,PH,GB,GB,2023,Q2,Adult
223747931,22374793,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,(morning);,,,Y,U,Unknown,,204629.0,25.0,MG,Tablet,QD,2023,Q2,Medication error,,2023,Q2,1,I,20230525.0,20230526.0,20230526,20230526,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-240208",BOEHRINGER INGELHEIM,,45.0,YR,A,M,Y,80.0,KG,20230527,,PH,GB,GB,2023,Q2,Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Rash papular,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Off label use,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Vasculitis,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Dry skin,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Tachycardia,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Cardiospasm,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Diarrhoea,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Arthralgia,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Cognitive disorder,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Alopecia,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Sleep terror,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Dehydration,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Facial pain,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Angioedema,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Pyrexia,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Pain of skin,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Subarachnoid haemorrhage,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Pericarditis,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Visual impairment,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Eye pruritus,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Back pain,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Nausea,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Muscular weakness,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,COVID-19,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Palpitations,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Lip swelling,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Anxiety,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Dyspnoea,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Dizziness,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Tinnitus,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Fatigue,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Insomnia,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Blood glucose increased,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Memory impairment,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Hallucination,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Blindness,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Intentional product use issue,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Intentional product misuse,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Vomiting,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Palmoplantar keratoderma,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Carotid artery occlusion,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Headache,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Heart rate increased,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Malaise,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Hyperhidrosis,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Feeling abnormal,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Product prescribing error,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Pain,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Anosmia,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Ventricular tachycardia,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Amnesia,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Abdominal discomfort,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Chest pain,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Disturbance in attention,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Atrial tachycardia,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Abdominal pain upper,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Immunisation,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Myocardial infarction,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Pruritus,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Pruritus genital,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Transient ischaemic attack,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Adverse drug reaction,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Diplopia,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Tension headache,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Migraine,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Muscle twitching,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223751872,22375187,23,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,U,,,,,5.0,MG,,,2023,Q2,Peripheral swelling,,2023,Q2,2,F,,20230601.0,20230527,20230612,EXP,,GB-AUROBINDO-AUR-APL-2023-037685,AUROBINDO,,34.0,YR,,M,Y,70.0,KG,20230612,,HP,GB,GB,2023,Q2,Young Adult
223758691,22375869,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (10 mg, 1-0-0-0)",,,U,,,,,10.0,MG,,QD,2023,Q2,Haematochezia,,2023,Q2,1,I,,20230519.0,20230527,20230527,EXP,,NVSC2020DE187308,NOVARTIS,,56.0,YR,,F,Y,,,20230527,,MD,DE,DE,2023,Q2,Adult
223758691,22375869,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (10 mg, 1-0-0-0)",,,U,,,,,10.0,MG,,QD,2023,Q2,General physical health deterioration,,2023,Q2,1,I,,20230519.0,20230527,20230527,EXP,,NVSC2020DE187308,NOVARTIS,,56.0,YR,,F,Y,,,20230527,,MD,DE,DE,2023,Q2,Adult
223758691,22375869,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (10 mg, 1-0-0-0)",,,U,,,,,10.0,MG,,QD,2023,Q2,Diarrhoea,,2023,Q2,1,I,,20230519.0,20230527,20230527,EXP,,NVSC2020DE187308,NOVARTIS,,56.0,YR,,F,Y,,,20230527,,MD,DE,DE,2023,Q2,Adult
223758691,22375869,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (10 mg, 1-0-0-0)",,,U,,,,,10.0,MG,,QD,2023,Q2,Pallor,,2023,Q2,1,I,,20230519.0,20230527,20230527,EXP,,NVSC2020DE187308,NOVARTIS,,56.0,YR,,F,Y,,,20230527,,MD,DE,DE,2023,Q2,Adult
223758691,22375869,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (10 mg, 1-0-0-0)",,,U,,,,,10.0,MG,,QD,2023,Q2,Condition aggravated,,2023,Q2,1,I,,20230519.0,20230527,20230527,EXP,,NVSC2020DE187308,NOVARTIS,,56.0,YR,,F,Y,,,20230527,,MD,DE,DE,2023,Q2,Adult
223758691,22375869,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (10 mg, 1-0-0-0)",,,U,,,,,10.0,MG,,QD,2023,Q2,Anaemia,,2023,Q2,1,I,,20230519.0,20230527,20230527,EXP,,NVSC2020DE187308,NOVARTIS,,56.0,YR,,F,Y,,,20230527,,MD,DE,DE,2023,Q2,Adult
223758691,22375869,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (10 mg, 1-0-0-0)",,,U,,,,,10.0,MG,,QD,2023,Q2,Epistaxis,,2023,Q2,1,I,,20230519.0,20230527,20230527,EXP,,NVSC2020DE187308,NOVARTIS,,56.0,YR,,F,Y,,,20230527,,MD,DE,DE,2023,Q2,Adult
223767182,22376718,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Pneumonia,,2023,Q2,2,F,20230512.0,20230623.0,20230528,20230626,EXP,,FR-BAUSCHBL-2023BNL004526,BAUSCH AND LOMB,,75.0,YR,,F,Y,76.0,KG,20230626,,HP,FR,FR,2023,Q2,Elderly
223770961,22377096,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25mg,,,Y,U,Unknown,,204629.0,25.0,MG,Tablet,QD,2023,Q2,Pancreatitis acute,,2023,Q2,1,I,20230506.0,20230526.0,20230529,20230529,EXP,GB-MHRA-INPF2132B09-6571-4B65-9766-A6E6D373FA82,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-240201",BOEHRINGER INGELHEIM,,60.0,YR,A,M,Y,107.0,KG,20230529,,MD,GB,GB,2023,Q2,Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Pain of skin,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Dizziness,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Atrial tachycardia,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Subarachnoid haemorrhage,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Vasculitis,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Alopecia,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Muscular weakness,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Abdominal pain upper,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Diplopia,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Tension headache,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Insomnia,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Carotid artery occlusion,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Arthralgia,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Cognitive disorder,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Migraine,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Headache,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Angioedema,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Intentional product use issue,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Heart rate increased,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Peripheral swelling,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Transient ischaemic attack,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Pain,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Pruritus genital,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Blindness,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Pruritus,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Intentional product misuse,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Off label use,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Disturbance in attention,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Feeling abnormal,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Tinnitus,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,COVID-19,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Ventricular tachycardia,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Product prescribing error,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Dehydration,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Blood glucose increased,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Hyperhidrosis,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Malaise,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Muscle twitching,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Visual impairment,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Fatigue,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Pyrexia,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Memory impairment,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Diarrhoea,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Tachycardia,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Anosmia,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Cardiospasm,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Lip swelling,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Abdominal discomfort,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Rash papular,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Eye pruritus,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Sleep terror,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Vomiting,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Anxiety,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Amnesia,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Back pain,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Palmoplantar keratoderma,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Palpitations,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Immunisation,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Chest pain,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Dry skin,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Dyspnoea,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Nausea,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Myocardial infarction,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Facial pain,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Nausea,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Hallucination,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223778204,22377820,39,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram, qd",,,U,U,UNKNOWN,,,5.0,MG,,,2023,Q2,Pericarditis,,2023,Q2,4,F,20180207.0,20230615.0,20230529,20230626,EXP,,GB-drreddys-SPO/UKI/23/0165373,DR REDDYS,,34.0,YR,A,M,Y,70.0,KG,20230626,,HP,GB,GB,2023,Q2,Young Adult
223792131,22379213,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, 1 Dose, Notes for patient: If you become suddenly unwell with fever or feverish illn",320.0,MG,U,,,,,10.0,MG,,QD,2023,Q2,Hypomagnesaemia,,2023,Q2,1,I,20230429.0,20230515.0,20230529,20230529,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-390544,RANBAXY,,61.0,YR,,F,Y,90.0,KG,20230529,,MD,GB,GB,2023,Q2,Adult
223833711,22383371,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,Unknown,,206111.0,,,,,2023,Q2,Fournier's gangrene,,2023,Q2,1,I,,20230530.0,20230530,20230530,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-240539",BOEHRINGER INGELHEIM,,51.0,YR,A,M,Y,,,20230530,,CN,AU,AU,2023,Q2,Adult
223843861,22384386,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,U,,,,,,,,BID,2023,Q2,Drug interaction,,2023,Q2,1,I,,20230523.0,20230530,20230530,EXP,,ES-MYLANLABS-2023M1055497,MYLAN,"Abdala S, Devora S, Oliva AM, Morales C. The added value of professional pharmaceutical care services. A case of SFT. Community Farms. 2023;15(2):45-51",62.0,YR,,F,Y,,,20230530,,HP,ES,ES,2023,Q2,Adult
223843861,22384386,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,U,,,,,,,,BID,2023,Q2,Hypotension,,2023,Q2,1,I,,20230523.0,20230530,20230530,EXP,,ES-MYLANLABS-2023M1055497,MYLAN,"Abdala S, Devora S, Oliva AM, Morales C. The added value of professional pharmaceutical care services. A case of SFT. Community Farms. 2023;15(2):45-51",62.0,YR,,F,Y,,,20230530,,HP,ES,ES,2023,Q2,Adult
223849051,22384905,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q2,Abdominal pain,,2023,Q2,1,I,20230504.0,20230528.0,20230530,20230530,EXP,GB-MHRA-TPP12640998C12504289YC1685032402547,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-240579",BOEHRINGER INGELHEIM,,68.0,YR,E,M,Y,100.0,KG,20230530,,PH,GB,GB,2023,Q2,Elderly
223849051,22384905,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q2,Decreased appetite,,2023,Q2,1,I,20230504.0,20230528.0,20230530,20230530,EXP,GB-MHRA-TPP12640998C12504289YC1685032402547,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-240579",BOEHRINGER INGELHEIM,,68.0,YR,E,M,Y,100.0,KG,20230530,,PH,GB,GB,2023,Q2,Elderly
223851131,22385113,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q2,Intestinal obstruction,,2023,Q2,1,I,20230301.0,20230530.0,20230530,20230530,EXP,FR-AFSSAPS-MP2023000707,"FR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-240605",BOEHRINGER INGELHEIM,,85.0,YR,E,F,Y,,,20230530,,MD,FR,FR,2023,Q2,Elderly
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Insomnia,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Carotid artery occlusion,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Atrial tachycardia,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Abdominal pain upper,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Abdominal discomfort,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Cognitive disorder,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Vasculitis,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Eye pruritus,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Headache,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Palmoplantar keratoderma,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Intentional product misuse,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Hallucination,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Arthralgia,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Migraine,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Angioedema,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Dizziness,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Memory impairment,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Pericarditis,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Myocardial infarction,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Lip swelling,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Diplopia,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Immunisation,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Alopecia,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Muscle twitching,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Rash papular,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Pyrexia,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Diarrhoea,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Cardiospasm,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Visual impairment,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Pruritus,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Amnesia,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Facial pain,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Off label use,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Sleep terror,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Feeling abnormal,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Chest pain,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Palpitations,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Dehydration,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Vomiting,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Ventricular tachycardia,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Nausea,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Adverse drug reaction,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Muscular weakness,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Pain of skin,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Subarachnoid haemorrhage,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Intentional product use issue,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Dyspnoea,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,COVID-19,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Malaise,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Peripheral swelling,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Product prescribing error,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Blood glucose increased,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Dry skin,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Anxiety,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Anosmia,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Tension headache,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Back pain,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Heart rate increased,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Pruritus genital,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Tinnitus,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Blindness,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Hyperhidrosis,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Fatigue,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Tachycardia,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Disturbance in attention,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Pain,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223874804,22387480,38,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,,2023,Q2,Transient ischaemic attack,,2023,Q2,4,F,20221230.0,20230619.0,20230531,20230630,EXP,GB-AstraZeneca-2023A076570,GB-STRIDES ARCOLAB LIMITED-2023SP007852,STRIDES,,34.0,YR,,M,Y,70.0,KG,20230630,,HP,GB,GB,2023,Q2,Young Adult
223879671,22387967,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q2,Condition aggravated,,2023,Q2,1,I,,20230524.0,20230531,20230531,EXP,CA-MHPD-E2B_06255381,CA-Accord-359986,ACCORD,,66.0,YR,E,M,Y,,,20230531,,HP,CA,CA,2023,Q2,Elderly
223879671,22387967,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q2,Hepatic cirrhosis,,2023,Q2,1,I,,20230524.0,20230531,20230531,EXP,CA-MHPD-E2B_06255381,CA-Accord-359986,ACCORD,,66.0,YR,E,M,Y,,,20230531,,HP,CA,CA,2023,Q2,Elderly
223879671,22387967,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q2,Treatment failure,,2023,Q2,1,I,,20230524.0,20230531,20230531,EXP,CA-MHPD-E2B_06255381,CA-Accord-359986,ACCORD,,66.0,YR,E,M,Y,,,20230531,,HP,CA,CA,2023,Q2,Elderly
223879671,22387967,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q2,Granulomatosis with polyangiitis,,2023,Q2,1,I,,20230524.0,20230531,20230531,EXP,CA-MHPD-E2B_06255381,CA-Accord-359986,ACCORD,,66.0,YR,E,M,Y,,,20230531,,HP,CA,CA,2023,Q2,Elderly
223891581,22389158,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 milligram,,,,,,,,10.0,MG,,,2023,Q2,Condition aggravated,,2023,Q2,1,I,,20230516.0,20230531,20230531,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-392026,RANBAXY,"Dean J-HL, Patel MP, Corpuz E, Cahill MS, Fentanes E. Acute asymptomatic hyponatraemia following inpatient initiation of angiotensin receptor?neprilysin inhibitor: a case report. Eur Heart J Case Rep. 2023;7(3):1-4",71.0,YR,,F,Y,,,20230531,,HP,US,US,2023,Q2,Elderly
223897982,22389798,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2023,Q2,Pneumonia,,2023,Q2,2,F,20230512.0,20230621.0,20230531,20230621,EXP,,FR-APIL-2316045US,ABBVIE,,75.0,YR,,F,Y,76.0,KG,20230621,,HP,FR,FR,2023,Q2,Elderly
223902232,22390223,36,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, daily",,,,,,,,10.0,MG,,,2023,Q2,Malnutrition,,2023,Q2,2,F,20230505.0,20230616.0,20230531,20230621,EXP,,CN-PFIZER INC-PV202300094381,PFIZER,,48.0,YR,,F,Y,,,20230621,,HP,CN,CN,2023,Q2,Adult
223906092,22390609,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Abdominal pain upper,,2023,Q2,2,F,20230512.0,20230622.0,20230531,20230629,EXP,,US-TAKEDA-2023TUS052560,TAKEDA,,75.0,YR,,F,Y,76.0,KG,20230629,,MD,FR,US,2023,Q2,Elderly
223906092,22390609,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Lower respiratory tract infection,,2023,Q2,2,F,20230512.0,20230622.0,20230531,20230629,EXP,,US-TAKEDA-2023TUS052560,TAKEDA,,75.0,YR,,F,Y,76.0,KG,20230629,,MD,FR,US,2023,Q2,Elderly
223906092,22390609,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,COVID-19,,2023,Q2,2,F,20230512.0,20230622.0,20230531,20230629,EXP,,US-TAKEDA-2023TUS052560,TAKEDA,,75.0,YR,,F,Y,76.0,KG,20230629,,MD,FR,US,2023,Q2,Elderly
223906092,22390609,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Anaemia,,2023,Q2,2,F,20230512.0,20230622.0,20230531,20230629,EXP,,US-TAKEDA-2023TUS052560,TAKEDA,,75.0,YR,,F,Y,76.0,KG,20230629,,MD,FR,US,2023,Q2,Elderly
223906092,22390609,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Chills,,2023,Q2,2,F,20230512.0,20230622.0,20230531,20230629,EXP,,US-TAKEDA-2023TUS052560,TAKEDA,,75.0,YR,,F,Y,76.0,KG,20230629,,MD,FR,US,2023,Q2,Elderly
223906092,22390609,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Cardiac failure,,2023,Q2,2,F,20230512.0,20230622.0,20230531,20230629,EXP,,US-TAKEDA-2023TUS052560,TAKEDA,,75.0,YR,,F,Y,76.0,KG,20230629,,MD,FR,US,2023,Q2,Elderly
223906092,22390609,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Asthenia,,2023,Q2,2,F,20230512.0,20230622.0,20230531,20230629,EXP,,US-TAKEDA-2023TUS052560,TAKEDA,,75.0,YR,,F,Y,76.0,KG,20230629,,MD,FR,US,2023,Q2,Elderly
223938741,22393874,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,,,,,,2023,Q2,Intestinal obstruction,,2023,Q2,1,I,20230124.0,20230530.0,20230601,20230601,EXP,FR-AFSSAPS-MP2023000707,FR-PFIZER INC-202300206470,PFIZER,,85.0,YR,,F,Y,,,20230601,,MD,FR,FR,2023,Q2,Elderly
223938741,22393874,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,,,,,,2023,Q2,Off label use,,2023,Q2,1,I,20230124.0,20230530.0,20230601,20230601,EXP,FR-AFSSAPS-MP2023000707,FR-PFIZER INC-202300206470,PFIZER,,85.0,YR,,F,Y,,,20230601,,MD,FR,FR,2023,Q2,Elderly
223965742,22396574,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,QD,2023,Q2,Myelosuppression,,2023,Q2,2,F,20230414.0,20230619.0,20230601,20230620,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-2023-077294,BRISTOL MYERS SQUIBB,,78.0,YR,E,M,Y,55.34,KG,20230620,,HP,US,US,2023,Q2,Elderly
223976121,22397612,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,UNKNOWN,,,25.0,MG,,QD,2023,Q2,Product communication issue,,2023,Q2,1,I,20230301.0,20230524.0,20230602,20230602,EXP,,US-NOVOPROD-1055533,NOVO NORDISK,,76.0,YR,,M,Y,,,20230602,,CN,US,US,2023,Q2,Elderly
223976121,22397612,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,UNKNOWN,,,25.0,MG,,QD,2023,Q2,Wrong technique in product usage process,,2023,Q2,1,I,20230301.0,20230524.0,20230602,20230602,EXP,,US-NOVOPROD-1055533,NOVO NORDISK,,76.0,YR,,M,Y,,,20230602,,CN,US,US,2023,Q2,Elderly
223976121,22397612,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,UNKNOWN,,,25.0,MG,,QD,2023,Q2,Loss of consciousness,,2023,Q2,1,I,20230301.0,20230524.0,20230602,20230602,EXP,,US-NOVOPROD-1055533,NOVO NORDISK,,76.0,YR,,M,Y,,,20230602,,CN,US,US,2023,Q2,Elderly
224003441,22400344,28,SS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,,,,5.0,MG,,,2023,Q2,Subarachnoid haemorrhage,,2023,Q2,1,I,,20230601.0,20230602,20230602,EXP,,GB-AstraZeneca-2023A127225,ASTRAZENECA,,61.0,YR,,M,Y,76.0,KG,20230602,,MD,GB,,2023,Q2,Adult
224003441,22400344,28,SS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,,,,5.0,MG,,,2023,Q2,Hallucination,,2023,Q2,1,I,,20230601.0,20230602,20230602,EXP,,GB-AstraZeneca-2023A127225,ASTRAZENECA,,61.0,YR,,M,Y,76.0,KG,20230602,,MD,GB,,2023,Q2,Adult
224003441,22400344,28,SS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,,,,5.0,MG,,,2023,Q2,Palpitations,,2023,Q2,1,I,,20230601.0,20230602,20230602,EXP,,GB-AstraZeneca-2023A127225,ASTRAZENECA,,61.0,YR,,M,Y,76.0,KG,20230602,,MD,GB,,2023,Q2,Adult
224003441,22400344,28,SS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,,,,5.0,MG,,,2023,Q2,Cardiospasm,,2023,Q2,1,I,,20230601.0,20230602,20230602,EXP,,GB-AstraZeneca-2023A127225,ASTRAZENECA,,61.0,YR,,M,Y,76.0,KG,20230602,,MD,GB,,2023,Q2,Adult
224003441,22400344,28,SS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,,,,5.0,MG,,,2023,Q2,Visual impairment,,2023,Q2,1,I,,20230601.0,20230602,20230602,EXP,,GB-AstraZeneca-2023A127225,ASTRAZENECA,,61.0,YR,,M,Y,76.0,KG,20230602,,MD,GB,,2023,Q2,Adult
224003441,22400344,28,SS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,,,,5.0,MG,,,2023,Q2,Diarrhoea,,2023,Q2,1,I,,20230601.0,20230602,20230602,EXP,,GB-AstraZeneca-2023A127225,ASTRAZENECA,,61.0,YR,,M,Y,76.0,KG,20230602,,MD,GB,,2023,Q2,Adult
224003441,22400344,28,SS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,,,,5.0,MG,,,2023,Q2,Amnesia,,2023,Q2,1,I,,20230601.0,20230602,20230602,EXP,,GB-AstraZeneca-2023A127225,ASTRAZENECA,,61.0,YR,,M,Y,76.0,KG,20230602,,MD,GB,,2023,Q2,Adult
224003441,22400344,28,SS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,,,,5.0,MG,,,2023,Q2,Intentional product use issue,,2023,Q2,1,I,,20230601.0,20230602,20230602,EXP,,GB-AstraZeneca-2023A127225,ASTRAZENECA,,61.0,YR,,M,Y,76.0,KG,20230602,,MD,GB,,2023,Q2,Adult
224003441,22400344,28,SS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,,,,5.0,MG,,,2023,Q2,Drug abuse,,2023,Q2,1,I,,20230601.0,20230602,20230602,EXP,,GB-AstraZeneca-2023A127225,ASTRAZENECA,,61.0,YR,,M,Y,76.0,KG,20230602,,MD,GB,,2023,Q2,Adult
224003441,22400344,28,SS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,,,,5.0,MG,,,2023,Q2,Angioedema,,2023,Q2,1,I,,20230601.0,20230602,20230602,EXP,,GB-AstraZeneca-2023A127225,ASTRAZENECA,,61.0,YR,,M,Y,76.0,KG,20230602,,MD,GB,,2023,Q2,Adult
224003441,22400344,28,SS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,,,,5.0,MG,,,2023,Q2,Migraine,,2023,Q2,1,I,,20230601.0,20230602,20230602,EXP,,GB-AstraZeneca-2023A127225,ASTRAZENECA,,61.0,YR,,M,Y,76.0,KG,20230602,,MD,GB,,2023,Q2,Adult
224003441,22400344,28,SS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,,,,5.0,MG,,,2023,Q2,COVID-19,,2023,Q2,1,I,,20230601.0,20230602,20230602,EXP,,GB-AstraZeneca-2023A127225,ASTRAZENECA,,61.0,YR,,M,Y,76.0,KG,20230602,,MD,GB,,2023,Q2,Adult
224003441,22400344,28,SS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,,,,5.0,MG,,,2023,Q2,Malaise,,2023,Q2,1,I,,20230601.0,20230602,20230602,EXP,,GB-AstraZeneca-2023A127225,ASTRAZENECA,,61.0,YR,,M,Y,76.0,KG,20230602,,MD,GB,,2023,Q2,Adult
224003441,22400344,28,SS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,,,,5.0,MG,,,2023,Q2,Facial pain,,2023,Q2,1,I,,20230601.0,20230602,20230602,EXP,,GB-AstraZeneca-2023A127225,ASTRAZENECA,,61.0,YR,,M,Y,76.0,KG,20230602,,MD,GB,,2023,Q2,Adult
224003441,22400344,28,SS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,,,,5.0,MG,,,2023,Q2,Abdominal discomfort,,2023,Q2,1,I,,20230601.0,20230602,20230602,EXP,,GB-AstraZeneca-2023A127225,ASTRAZENECA,,61.0,YR,,M,Y,76.0,KG,20230602,,MD,GB,,2023,Q2,Adult
224003441,22400344,28,SS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,,,,5.0,MG,,,2023,Q2,Pruritus,,2023,Q2,1,I,,20230601.0,20230602,20230602,EXP,,GB-AstraZeneca-2023A127225,ASTRAZENECA,,61.0,YR,,M,Y,76.0,KG,20230602,,MD,GB,,2023,Q2,Adult
224003441,22400344,28,SS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,,,,5.0,MG,,,2023,Q2,Disturbance in attention,,2023,Q2,1,I,,20230601.0,20230602,20230602,EXP,,GB-AstraZeneca-2023A127225,ASTRAZENECA,,61.0,YR,,M,Y,76.0,KG,20230602,,MD,GB,,2023,Q2,Adult
224003441,22400344,28,SS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,,,,5.0,MG,,,2023,Q2,Eye pruritus,,2023,Q2,1,I,,20230601.0,20230602,20230602,EXP,,GB-AstraZeneca-2023A127225,ASTRAZENECA,,61.0,YR,,M,Y,76.0,KG,20230602,,MD,GB,,2023,Q2,Adult
224003441,22400344,28,SS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,,,,5.0,MG,,,2023,Q2,Tachycardia,,2023,Q2,1,I,,20230601.0,20230602,20230602,EXP,,GB-AstraZeneca-2023A127225,ASTRAZENECA,,61.0,YR,,M,Y,76.0,KG,20230602,,MD,GB,,2023,Q2,Adult
224003441,22400344,28,SS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,,,,5.0,MG,,,2023,Q2,Atrial tachycardia,,2023,Q2,1,I,,20230601.0,20230602,20230602,EXP,,GB-AstraZeneca-2023A127225,ASTRAZENECA,,61.0,YR,,M,Y,76.0,KG,20230602,,MD,GB,,2023,Q2,Adult
224003441,22400344,28,SS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,,,,5.0,MG,,,2023,Q2,Dehydration,,2023,Q2,1,I,,20230601.0,20230602,20230602,EXP,,GB-AstraZeneca-2023A127225,ASTRAZENECA,,61.0,YR,,M,Y,76.0,KG,20230602,,MD,GB,,2023,Q2,Adult
224003441,22400344,28,SS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,,,,5.0,MG,,,2023,Q2,Feeling abnormal,,2023,Q2,1,I,,20230601.0,20230602,20230602,EXP,,GB-AstraZeneca-2023A127225,ASTRAZENECA,,61.0,YR,,M,Y,76.0,KG,20230602,,MD,GB,,2023,Q2,Adult
224003441,22400344,28,SS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,,,,5.0,MG,,,2023,Q2,Chest pain,,2023,Q2,1,I,,20230601.0,20230602,20230602,EXP,,GB-AstraZeneca-2023A127225,ASTRAZENECA,,61.0,YR,,M,Y,76.0,KG,20230602,,MD,GB,,2023,Q2,Adult
224003441,22400344,28,SS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,,,,5.0,MG,,,2023,Q2,Rash,,2023,Q2,1,I,,20230601.0,20230602,20230602,EXP,,GB-AstraZeneca-2023A127225,ASTRAZENECA,,61.0,YR,,M,Y,76.0,KG,20230602,,MD,GB,,2023,Q2,Adult
224003441,22400344,28,SS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,,,,5.0,MG,,,2023,Q2,Anosmia,,2023,Q2,1,I,,20230601.0,20230602,20230602,EXP,,GB-AstraZeneca-2023A127225,ASTRAZENECA,,61.0,YR,,M,Y,76.0,KG,20230602,,MD,GB,,2023,Q2,Adult
224003441,22400344,28,SS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,,,,5.0,MG,,,2023,Q2,Dry skin,,2023,Q2,1,I,,20230601.0,20230602,20230602,EXP,,GB-AstraZeneca-2023A127225,ASTRAZENECA,,61.0,YR,,M,Y,76.0,KG,20230602,,MD,GB,,2023,Q2,Adult
224003441,22400344,28,SS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,,,,5.0,MG,,,2023,Q2,Pericarditis,,2023,Q2,1,I,,20230601.0,20230602,20230602,EXP,,GB-AstraZeneca-2023A127225,ASTRAZENECA,,61.0,YR,,M,Y,76.0,KG,20230602,,MD,GB,,2023,Q2,Adult
224003441,22400344,28,SS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,,,,5.0,MG,,,2023,Q2,Fatigue,,2023,Q2,1,I,,20230601.0,20230602,20230602,EXP,,GB-AstraZeneca-2023A127225,ASTRAZENECA,,61.0,YR,,M,Y,76.0,KG,20230602,,MD,GB,,2023,Q2,Adult
224003441,22400344,28,SS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,,,,5.0,MG,,,2023,Q2,Intentional product misuse,,2023,Q2,1,I,,20230601.0,20230602,20230602,EXP,,GB-AstraZeneca-2023A127225,ASTRAZENECA,,61.0,YR,,M,Y,76.0,KG,20230602,,MD,GB,,2023,Q2,Adult
224003441,22400344,28,SS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,,,,5.0,MG,,,2023,Q2,Muscular weakness,,2023,Q2,1,I,,20230601.0,20230602,20230602,EXP,,GB-AstraZeneca-2023A127225,ASTRAZENECA,,61.0,YR,,M,Y,76.0,KG,20230602,,MD,GB,,2023,Q2,Adult
224003441,22400344,28,SS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,,,,5.0,MG,,,2023,Q2,Lip swelling,,2023,Q2,1,I,,20230601.0,20230602,20230602,EXP,,GB-AstraZeneca-2023A127225,ASTRAZENECA,,61.0,YR,,M,Y,76.0,KG,20230602,,MD,GB,,2023,Q2,Adult
225177482,22517748,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2023,Q2,Vomiting,,2023,Q2,2,F,,20230615.0,20230604,20230622,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-240438",BOEHRINGER INGELHEIM,"Sotiropoulos C, Konstantakis C, Diamantopoulou G, Ambasis O, Theocharis G, Triantos C. A case of euglycemic diabetic ketoacidosis in grounds of post-ERCP cholangitis and liver abscess, in a patient taking an SGLT-2 inhibitor.. 50th Panhellenic congress of Endocrinology, metabolism and Diabetes Mellitus, 4-6 May 2023, Makedonia Palace Hotel, Thessaloniki. 2023 May;",53.0,YR,A,F,Y,,,20230622,,MD,GR,GR,2023,Q2,Adult
225177482,22517748,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2023,Q2,Pancreatic disorder,,2023,Q2,2,F,,20230615.0,20230604,20230622,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-240438",BOEHRINGER INGELHEIM,"Sotiropoulos C, Konstantakis C, Diamantopoulou G, Ambasis O, Theocharis G, Triantos C. A case of euglycemic diabetic ketoacidosis in grounds of post-ERCP cholangitis and liver abscess, in a patient taking an SGLT-2 inhibitor.. 50th Panhellenic congress of Endocrinology, metabolism and Diabetes Mellitus, 4-6 May 2023, Makedonia Palace Hotel, Thessaloniki. 2023 May;",53.0,YR,A,F,Y,,,20230622,,MD,GR,GR,2023,Q2,Adult
225177482,22517748,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2023,Q2,Abdominal pain upper,,2023,Q2,2,F,,20230615.0,20230604,20230622,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-240438",BOEHRINGER INGELHEIM,"Sotiropoulos C, Konstantakis C, Diamantopoulou G, Ambasis O, Theocharis G, Triantos C. A case of euglycemic diabetic ketoacidosis in grounds of post-ERCP cholangitis and liver abscess, in a patient taking an SGLT-2 inhibitor.. 50th Panhellenic congress of Endocrinology, metabolism and Diabetes Mellitus, 4-6 May 2023, Makedonia Palace Hotel, Thessaloniki. 2023 May;",53.0,YR,A,F,Y,,,20230622,,MD,GR,GR,2023,Q2,Adult
225177482,22517748,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2023,Q2,Biliary dilatation,,2023,Q2,2,F,,20230615.0,20230604,20230622,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-240438",BOEHRINGER INGELHEIM,"Sotiropoulos C, Konstantakis C, Diamantopoulou G, Ambasis O, Theocharis G, Triantos C. A case of euglycemic diabetic ketoacidosis in grounds of post-ERCP cholangitis and liver abscess, in a patient taking an SGLT-2 inhibitor.. 50th Panhellenic congress of Endocrinology, metabolism and Diabetes Mellitus, 4-6 May 2023, Makedonia Palace Hotel, Thessaloniki. 2023 May;",53.0,YR,A,F,Y,,,20230622,,MD,GR,GR,2023,Q2,Adult
225177482,22517748,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2023,Q2,Enzyme level increased,,2023,Q2,2,F,,20230615.0,20230604,20230622,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-240438",BOEHRINGER INGELHEIM,"Sotiropoulos C, Konstantakis C, Diamantopoulou G, Ambasis O, Theocharis G, Triantos C. A case of euglycemic diabetic ketoacidosis in grounds of post-ERCP cholangitis and liver abscess, in a patient taking an SGLT-2 inhibitor.. 50th Panhellenic congress of Endocrinology, metabolism and Diabetes Mellitus, 4-6 May 2023, Makedonia Palace Hotel, Thessaloniki. 2023 May;",53.0,YR,A,F,Y,,,20230622,,MD,GR,GR,2023,Q2,Adult
225177482,22517748,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2023,Q2,Liver abscess,,2023,Q2,2,F,,20230615.0,20230604,20230622,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-240438",BOEHRINGER INGELHEIM,"Sotiropoulos C, Konstantakis C, Diamantopoulou G, Ambasis O, Theocharis G, Triantos C. A case of euglycemic diabetic ketoacidosis in grounds of post-ERCP cholangitis and liver abscess, in a patient taking an SGLT-2 inhibitor.. 50th Panhellenic congress of Endocrinology, metabolism and Diabetes Mellitus, 4-6 May 2023, Makedonia Palace Hotel, Thessaloniki. 2023 May;",53.0,YR,A,F,Y,,,20230622,,MD,GR,GR,2023,Q2,Adult
225177482,22517748,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2023,Q2,Tachypnoea,,2023,Q2,2,F,,20230615.0,20230604,20230622,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-240438",BOEHRINGER INGELHEIM,"Sotiropoulos C, Konstantakis C, Diamantopoulou G, Ambasis O, Theocharis G, Triantos C. A case of euglycemic diabetic ketoacidosis in grounds of post-ERCP cholangitis and liver abscess, in a patient taking an SGLT-2 inhibitor.. 50th Panhellenic congress of Endocrinology, metabolism and Diabetes Mellitus, 4-6 May 2023, Makedonia Palace Hotel, Thessaloniki. 2023 May;",53.0,YR,A,F,Y,,,20230622,,MD,GR,GR,2023,Q2,Adult
225177482,22517748,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2023,Q2,Pyrexia,,2023,Q2,2,F,,20230615.0,20230604,20230622,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-240438",BOEHRINGER INGELHEIM,"Sotiropoulos C, Konstantakis C, Diamantopoulou G, Ambasis O, Theocharis G, Triantos C. A case of euglycemic diabetic ketoacidosis in grounds of post-ERCP cholangitis and liver abscess, in a patient taking an SGLT-2 inhibitor.. 50th Panhellenic congress of Endocrinology, metabolism and Diabetes Mellitus, 4-6 May 2023, Makedonia Palace Hotel, Thessaloniki. 2023 May;",53.0,YR,A,F,Y,,,20230622,,MD,GR,GR,2023,Q2,Adult
225177482,22517748,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2023,Q2,Nausea,,2023,Q2,2,F,,20230615.0,20230604,20230622,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-240438",BOEHRINGER INGELHEIM,"Sotiropoulos C, Konstantakis C, Diamantopoulou G, Ambasis O, Theocharis G, Triantos C. A case of euglycemic diabetic ketoacidosis in grounds of post-ERCP cholangitis and liver abscess, in a patient taking an SGLT-2 inhibitor.. 50th Panhellenic congress of Endocrinology, metabolism and Diabetes Mellitus, 4-6 May 2023, Makedonia Palace Hotel, Thessaloniki. 2023 May;",53.0,YR,A,F,Y,,,20230622,,MD,GR,GR,2023,Q2,Adult
225177482,22517748,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2023,Q2,Pancreatic duct stenosis,,2023,Q2,2,F,,20230615.0,20230604,20230622,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-240438",BOEHRINGER INGELHEIM,"Sotiropoulos C, Konstantakis C, Diamantopoulou G, Ambasis O, Theocharis G, Triantos C. A case of euglycemic diabetic ketoacidosis in grounds of post-ERCP cholangitis and liver abscess, in a patient taking an SGLT-2 inhibitor.. 50th Panhellenic congress of Endocrinology, metabolism and Diabetes Mellitus, 4-6 May 2023, Makedonia Palace Hotel, Thessaloniki. 2023 May;",53.0,YR,A,F,Y,,,20230622,,MD,GR,GR,2023,Q2,Adult
225177482,22517748,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2023,Q2,Tachycardia,,2023,Q2,2,F,,20230615.0,20230604,20230622,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-240438",BOEHRINGER INGELHEIM,"Sotiropoulos C, Konstantakis C, Diamantopoulou G, Ambasis O, Theocharis G, Triantos C. A case of euglycemic diabetic ketoacidosis in grounds of post-ERCP cholangitis and liver abscess, in a patient taking an SGLT-2 inhibitor.. 50th Panhellenic congress of Endocrinology, metabolism and Diabetes Mellitus, 4-6 May 2023, Makedonia Palace Hotel, Thessaloniki. 2023 May;",53.0,YR,A,F,Y,,,20230622,,MD,GR,GR,2023,Q2,Adult
225177482,22517748,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2023,Q2,Inflammatory marker increased,,2023,Q2,2,F,,20230615.0,20230604,20230622,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-240438",BOEHRINGER INGELHEIM,"Sotiropoulos C, Konstantakis C, Diamantopoulou G, Ambasis O, Theocharis G, Triantos C. A case of euglycemic diabetic ketoacidosis in grounds of post-ERCP cholangitis and liver abscess, in a patient taking an SGLT-2 inhibitor.. 50th Panhellenic congress of Endocrinology, metabolism and Diabetes Mellitus, 4-6 May 2023, Makedonia Palace Hotel, Thessaloniki. 2023 May;",53.0,YR,A,F,Y,,,20230622,,MD,GR,GR,2023,Q2,Adult
225177482,22517748,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2023,Q2,Portal vein thrombosis,,2023,Q2,2,F,,20230615.0,20230604,20230622,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-240438",BOEHRINGER INGELHEIM,"Sotiropoulos C, Konstantakis C, Diamantopoulou G, Ambasis O, Theocharis G, Triantos C. A case of euglycemic diabetic ketoacidosis in grounds of post-ERCP cholangitis and liver abscess, in a patient taking an SGLT-2 inhibitor.. 50th Panhellenic congress of Endocrinology, metabolism and Diabetes Mellitus, 4-6 May 2023, Makedonia Palace Hotel, Thessaloniki. 2023 May;",53.0,YR,A,F,Y,,,20230622,,MD,GR,GR,2023,Q2,Adult
225177482,22517748,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2023,Q2,Metabolic acidosis,,2023,Q2,2,F,,20230615.0,20230604,20230622,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-240438",BOEHRINGER INGELHEIM,"Sotiropoulos C, Konstantakis C, Diamantopoulou G, Ambasis O, Theocharis G, Triantos C. A case of euglycemic diabetic ketoacidosis in grounds of post-ERCP cholangitis and liver abscess, in a patient taking an SGLT-2 inhibitor.. 50th Panhellenic congress of Endocrinology, metabolism and Diabetes Mellitus, 4-6 May 2023, Makedonia Palace Hotel, Thessaloniki. 2023 May;",53.0,YR,A,F,Y,,,20230622,,MD,GR,GR,2023,Q2,Adult
225177482,22517748,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2023,Q2,Pseudomonas infection,,2023,Q2,2,F,,20230615.0,20230604,20230622,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-240438",BOEHRINGER INGELHEIM,"Sotiropoulos C, Konstantakis C, Diamantopoulou G, Ambasis O, Theocharis G, Triantos C. A case of euglycemic diabetic ketoacidosis in grounds of post-ERCP cholangitis and liver abscess, in a patient taking an SGLT-2 inhibitor.. 50th Panhellenic congress of Endocrinology, metabolism and Diabetes Mellitus, 4-6 May 2023, Makedonia Palace Hotel, Thessaloniki. 2023 May;",53.0,YR,A,F,Y,,,20230622,,MD,GR,GR,2023,Q2,Adult
225177482,22517748,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2023,Q2,Lethargy,,2023,Q2,2,F,,20230615.0,20230604,20230622,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-240438",BOEHRINGER INGELHEIM,"Sotiropoulos C, Konstantakis C, Diamantopoulou G, Ambasis O, Theocharis G, Triantos C. A case of euglycemic diabetic ketoacidosis in grounds of post-ERCP cholangitis and liver abscess, in a patient taking an SGLT-2 inhibitor.. 50th Panhellenic congress of Endocrinology, metabolism and Diabetes Mellitus, 4-6 May 2023, Makedonia Palace Hotel, Thessaloniki. 2023 May;",53.0,YR,A,F,Y,,,20230622,,MD,GR,GR,2023,Q2,Adult
225177482,22517748,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2023,Q2,Biliary dilatation,,2023,Q2,2,F,,20230615.0,20230604,20230622,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-240438",BOEHRINGER INGELHEIM,"Sotiropoulos C, Konstantakis C, Diamantopoulou G, Ambasis O, Theocharis G, Triantos C. A case of euglycemic diabetic ketoacidosis in grounds of post-ERCP cholangitis and liver abscess, in a patient taking an SGLT-2 inhibitor.. 50th Panhellenic congress of Endocrinology, metabolism and Diabetes Mellitus, 4-6 May 2023, Makedonia Palace Hotel, Thessaloniki. 2023 May;",53.0,YR,A,F,Y,,,20230622,,MD,GR,GR,2023,Q2,Adult
225177482,22517748,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2023,Q2,Jaundice,,2023,Q2,2,F,,20230615.0,20230604,20230622,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-240438",BOEHRINGER INGELHEIM,"Sotiropoulos C, Konstantakis C, Diamantopoulou G, Ambasis O, Theocharis G, Triantos C. A case of euglycemic diabetic ketoacidosis in grounds of post-ERCP cholangitis and liver abscess, in a patient taking an SGLT-2 inhibitor.. 50th Panhellenic congress of Endocrinology, metabolism and Diabetes Mellitus, 4-6 May 2023, Makedonia Palace Hotel, Thessaloniki. 2023 May;",53.0,YR,A,F,Y,,,20230622,,MD,GR,GR,2023,Q2,Adult
225177482,22517748,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2023,Q2,Euglycaemic diabetic ketoacidosis,,2023,Q2,2,F,,20230615.0,20230604,20230622,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-240438",BOEHRINGER INGELHEIM,"Sotiropoulos C, Konstantakis C, Diamantopoulou G, Ambasis O, Theocharis G, Triantos C. A case of euglycemic diabetic ketoacidosis in grounds of post-ERCP cholangitis and liver abscess, in a patient taking an SGLT-2 inhibitor.. 50th Panhellenic congress of Endocrinology, metabolism and Diabetes Mellitus, 4-6 May 2023, Makedonia Palace Hotel, Thessaloniki. 2023 May;",53.0,YR,A,F,Y,,,20230622,,MD,GR,GR,2023,Q2,Adult
225177482,22517748,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2023,Q2,Adenocarcinoma,,2023,Q2,2,F,,20230615.0,20230604,20230622,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-240438",BOEHRINGER INGELHEIM,"Sotiropoulos C, Konstantakis C, Diamantopoulou G, Ambasis O, Theocharis G, Triantos C. A case of euglycemic diabetic ketoacidosis in grounds of post-ERCP cholangitis and liver abscess, in a patient taking an SGLT-2 inhibitor.. 50th Panhellenic congress of Endocrinology, metabolism and Diabetes Mellitus, 4-6 May 2023, Makedonia Palace Hotel, Thessaloniki. 2023 May;",53.0,YR,A,F,Y,,,20230622,,MD,GR,GR,2023,Q2,Adult
225182691,22518269,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,,,2023,Q2,Metabolic acidosis,,2023,Q2,1,I,20230601.0,20230602.0,20230605,20230605,EXP,,"CO-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241714",BOEHRINGER INGELHEIM,,78.0,YR,E,F,Y,,,20230605,,MD,CO,CO,2023,Q2,Elderly
225194731,22519473,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2023,Q2,Urinary tract infection,,2023,Q2,1,I,,20230602.0,20230605,20230605,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241696",BOEHRINGER INGELHEIM,"Balan I, Ganapathiraju VN, Dirisanala S, Taj S, Vekaria P. Case Report: Euglycemic diabetic ketoacidosis led by empagliflozin: A case report and literature review[version 1; peer review: 1 approved]. F1000 Research. 2022 Dec 07;11: 1148-doi:10.12688/f1000research.127382.1.",53.0,YR,A,F,Y,,,20230605,,HP,US,US,2023,Q2,Adult
225194731,22519473,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2023,Q2,Sinus tachycardia,,2023,Q2,1,I,,20230602.0,20230605,20230605,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241696",BOEHRINGER INGELHEIM,"Balan I, Ganapathiraju VN, Dirisanala S, Taj S, Vekaria P. Case Report: Euglycemic diabetic ketoacidosis led by empagliflozin: A case report and literature review[version 1; peer review: 1 approved]. F1000 Research. 2022 Dec 07;11: 1148-doi:10.12688/f1000research.127382.1.",53.0,YR,A,F,Y,,,20230605,,HP,US,US,2023,Q2,Adult
225194731,22519473,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2023,Q2,Sepsis,,2023,Q2,1,I,,20230602.0,20230605,20230605,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241696",BOEHRINGER INGELHEIM,"Balan I, Ganapathiraju VN, Dirisanala S, Taj S, Vekaria P. Case Report: Euglycemic diabetic ketoacidosis led by empagliflozin: A case report and literature review[version 1; peer review: 1 approved]. F1000 Research. 2022 Dec 07;11: 1148-doi:10.12688/f1000research.127382.1.",53.0,YR,A,F,Y,,,20230605,,HP,US,US,2023,Q2,Adult
225194731,22519473,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2023,Q2,Acute kidney injury,,2023,Q2,1,I,,20230602.0,20230605,20230605,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241696",BOEHRINGER INGELHEIM,"Balan I, Ganapathiraju VN, Dirisanala S, Taj S, Vekaria P. Case Report: Euglycemic diabetic ketoacidosis led by empagliflozin: A case report and literature review[version 1; peer review: 1 approved]. F1000 Research. 2022 Dec 07;11: 1148-doi:10.12688/f1000research.127382.1.",53.0,YR,A,F,Y,,,20230605,,HP,US,US,2023,Q2,Adult
225194731,22519473,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2023,Q2,Euglycaemic diabetic ketoacidosis,,2023,Q2,1,I,,20230602.0,20230605,20230605,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241696",BOEHRINGER INGELHEIM,"Balan I, Ganapathiraju VN, Dirisanala S, Taj S, Vekaria P. Case Report: Euglycemic diabetic ketoacidosis led by empagliflozin: A case report and literature review[version 1; peer review: 1 approved]. F1000 Research. 2022 Dec 07;11: 1148-doi:10.12688/f1000research.127382.1.",53.0,YR,A,F,Y,,,20230605,,HP,US,US,2023,Q2,Adult
225199191,22519919,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,,2023,Q2,Haematochezia,,2023,Q2,1,I,,20230526.0,20230605,20230605,EXP,,"DE-Hill Dermaceuticals, Inc.-2142326",HILL DERM,,56.0,YR,,F,Y,,,20230605,,MD,COUNTRY NOT SPECIFIED,DE,2023,Q2,Adult
225199191,22519919,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,,2023,Q2,Diarrhoea,,2023,Q2,1,I,,20230526.0,20230605,20230605,EXP,,"DE-Hill Dermaceuticals, Inc.-2142326",HILL DERM,,56.0,YR,,F,Y,,,20230605,,MD,COUNTRY NOT SPECIFIED,DE,2023,Q2,Adult
225199191,22519919,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,,2023,Q2,Condition aggravated,,2023,Q2,1,I,,20230526.0,20230605,20230605,EXP,,"DE-Hill Dermaceuticals, Inc.-2142326",HILL DERM,,56.0,YR,,F,Y,,,20230605,,MD,COUNTRY NOT SPECIFIED,DE,2023,Q2,Adult
225199191,22519919,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,,2023,Q2,Anaemia,,2023,Q2,1,I,,20230526.0,20230605,20230605,EXP,,"DE-Hill Dermaceuticals, Inc.-2142326",HILL DERM,,56.0,YR,,F,Y,,,20230605,,MD,COUNTRY NOT SPECIFIED,DE,2023,Q2,Adult
225199191,22519919,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,,2023,Q2,Pallor,,2023,Q2,1,I,,20230526.0,20230605,20230605,EXP,,"DE-Hill Dermaceuticals, Inc.-2142326",HILL DERM,,56.0,YR,,F,Y,,,20230605,,MD,COUNTRY NOT SPECIFIED,DE,2023,Q2,Adult
225199191,22519919,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,,2023,Q2,General physical health deterioration,,2023,Q2,1,I,,20230526.0,20230605,20230605,EXP,,"DE-Hill Dermaceuticals, Inc.-2142326",HILL DERM,,56.0,YR,,F,Y,,,20230605,,MD,COUNTRY NOT SPECIFIED,DE,2023,Q2,Adult
225199191,22519919,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,,2023,Q2,Epistaxis,,2023,Q2,1,I,,20230526.0,20230605,20230605,EXP,,"DE-Hill Dermaceuticals, Inc.-2142326",HILL DERM,,56.0,YR,,F,Y,,,20230605,,MD,COUNTRY NOT SPECIFIED,DE,2023,Q2,Adult
225206962,22520696,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,,,,,,5.0,MG,,,2023,Q2,Hypotension,,2023,Q2,2,F,,20230606.0,20230605,20230607,EXP,,ES-MYLANLABS-2023M1057444,MYLAN,Abdala Kuri S.. The added value of Professional Pharmaceutical Assistance Services. A case of pharmaceutical care.. Farmac?uticos comunitarios. 2023;15(2):45-51,62.0,YR,,F,Y,90.0,KG,20230607,,PH,ES,ES,2023,Q2,Adult
225206962,22520696,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,,,,,,5.0,MG,,,2023,Q2,Hallucination,,2023,Q2,2,F,,20230606.0,20230605,20230607,EXP,,ES-MYLANLABS-2023M1057444,MYLAN,Abdala Kuri S.. The added value of Professional Pharmaceutical Assistance Services. A case of pharmaceutical care.. Farmac?uticos comunitarios. 2023;15(2):45-51,62.0,YR,,F,Y,90.0,KG,20230607,,PH,ES,ES,2023,Q2,Adult
225206962,22520696,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,,,,,,5.0,MG,,,2023,Q2,Hypoglycaemia,,2023,Q2,2,F,,20230606.0,20230605,20230607,EXP,,ES-MYLANLABS-2023M1057444,MYLAN,Abdala Kuri S.. The added value of Professional Pharmaceutical Assistance Services. A case of pharmaceutical care.. Farmac?uticos comunitarios. 2023;15(2):45-51,62.0,YR,,F,Y,90.0,KG,20230607,,PH,ES,ES,2023,Q2,Adult
225206962,22520696,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,,,,,,5.0,MG,,,2023,Q2,Somnolence,,2023,Q2,2,F,,20230606.0,20230605,20230607,EXP,,ES-MYLANLABS-2023M1057444,MYLAN,Abdala Kuri S.. The added value of Professional Pharmaceutical Assistance Services. A case of pharmaceutical care.. Farmac?uticos comunitarios. 2023;15(2):45-51,62.0,YR,,F,Y,90.0,KG,20230607,,PH,ES,ES,2023,Q2,Adult
225206962,22520696,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,,,,,,5.0,MG,,,2023,Q2,Drug interaction,,2023,Q2,2,F,,20230606.0,20230605,20230607,EXP,,ES-MYLANLABS-2023M1057444,MYLAN,Abdala Kuri S.. The added value of Professional Pharmaceutical Assistance Services. A case of pharmaceutical care.. Farmac?uticos comunitarios. 2023;15(2):45-51,62.0,YR,,F,Y,90.0,KG,20230607,,PH,ES,ES,2023,Q2,Adult
225206962,22520696,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 milligram,,,,,,,,5.0,MG,,,2023,Q2,Parkinsonism,,2023,Q2,2,F,,20230606.0,20230605,20230607,EXP,,ES-MYLANLABS-2023M1057444,MYLAN,Abdala Kuri S.. The added value of Professional Pharmaceutical Assistance Services. A case of pharmaceutical care.. Farmac?uticos comunitarios. 2023;15(2):45-51,62.0,YR,,F,Y,90.0,KG,20230607,,PH,ES,ES,2023,Q2,Adult
225222901,22522290,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd; unclassified tablet",,,,,,,,25.0,MG,Tablet,QD,2023,Q2,Radiculopathy,,2023,Q2,1,I,20191230.0,20230530.0,20230605,20230605,EXP,,KR-ORGANON-O2305KOR003270,ORGANON,,62.0,YR,,F,Y,67.05,KG,20230605,,MD,KR,KR,2023,Q2,Adult
225230831,22523083,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,unk,,,U,,,,,,,,,2023,Q2,Hypoglycaemia,,2023,Q2,1,I,20230428.0,20230601.0,20230606,20230606,EXP,IT-MINISAL02-927049,IT-SA-2023SA171051,SANOFI AVENTIS,,65.0,YR,E,F,Y,,,20230606,,MD,IT,IT,2023,Q2,Elderly
225230831,22523083,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,unk,,,U,,,,,,,,,2023,Q2,Syncope,,2023,Q2,1,I,20230428.0,20230601.0,20230606,20230606,EXP,IT-MINISAL02-927049,IT-SA-2023SA171051,SANOFI AVENTIS,,65.0,YR,E,F,Y,,,20230606,,MD,IT,IT,2023,Q2,Elderly
225234641,22523464,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 mg,,,U,,,,,,,,,2023,Q2,Pancreatitis acute,,2023,Q2,1,I,20230506.0,20230526.0,20230606,20230606,EXP,GB-MHRA-INPF2132B09-6571-4B65-9766-A6E6D373FA82,GB-NOVOPROD-1070499,NOVO NORDISK,,60.0,YR,,M,Y,107.0,KG,20230606,,MD,GB,GB,2023,Q2,Adult
225241392,22524139,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Peripheral coldness,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Ejection fraction decreased,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Coronary artery disease,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Cardiovascular disorder,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Atrial fibrillation,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Ejection fraction decreased,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Cough,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Cardiac failure,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Feeling cold,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Product use in unapproved indication,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Mitral valve incompetence,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Ventricular extrasystoles,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Coronary artery disease,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Ventricular tachycardia,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Feeling cold,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Left ventricular dysfunction,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Ventricular tachycardia,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Cough,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Hypotension,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Peripheral coldness,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Ejection fraction decreased,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Coronary artery disease,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Cardiovascular disorder,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Atrial fibrillation,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Ejection fraction decreased,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Cough,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Cardiac failure,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Feeling cold,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Product use in unapproved indication,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Mitral valve incompetence,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Ventricular extrasystoles,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Coronary artery disease,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Ventricular tachycardia,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Feeling cold,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Left ventricular dysfunction,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Ventricular tachycardia,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Cough,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Hypotension,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Peripheral coldness,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Ejection fraction decreased,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Coronary artery disease,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Cardiovascular disorder,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Atrial fibrillation,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Ejection fraction decreased,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Cough,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Cardiac failure,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Feeling cold,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Product use in unapproved indication,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Mitral valve incompetence,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Ventricular extrasystoles,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Coronary artery disease,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Ventricular tachycardia,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Feeling cold,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Left ventricular dysfunction,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Ventricular tachycardia,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Cough,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Hypotension,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Peripheral coldness,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Ejection fraction decreased,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Coronary artery disease,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Cardiovascular disorder,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Atrial fibrillation,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Ejection fraction decreased,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Cough,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Cardiac failure,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Feeling cold,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Product use in unapproved indication,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Mitral valve incompetence,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Ventricular extrasystoles,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Coronary artery disease,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Ventricular tachycardia,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Feeling cold,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Left ventricular dysfunction,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Ventricular tachycardia,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Cough,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225241392,22524139,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2023,Q2,Hypotension,,2023,Q2,2,F,20220701.0,20230623.0,20230606,20230630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242145",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,73.0,KG,20230630,,CN,DE,DE,2023,Q2,Elderly
225259651,22525965,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, 1 day",1450.0,MG,,,,,,10.0,MG,Film-coated tablet,QD,2023,Q2,Spleen disorder,,2023,Q2,1,I,20171128.0,20230530.0,20230606,20230606,EXP,,KR-ORGANON-O2305KOR003288,ORGANON,,50.0,YR,,F,Y,80.0,KG,20230606,,MD,KR,KR,2023,Q2,Adult
225259651,22525965,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, 1 day",1450.0,MG,,,,,,10.0,MG,Film-coated tablet,QD,2023,Q2,Cervix disorder,,2023,Q2,1,I,20171128.0,20230530.0,20230606,20230606,EXP,,KR-ORGANON-O2305KOR003288,ORGANON,,50.0,YR,,F,Y,80.0,KG,20230606,,MD,KR,KR,2023,Q2,Adult
225259651,22525965,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, 1 day",1450.0,MG,,,,,,10.0,MG,Film-coated tablet,QD,2023,Q2,Uterine leiomyoma,,2023,Q2,1,I,20171128.0,20230530.0,20230606,20230606,EXP,,KR-ORGANON-O2305KOR003288,ORGANON,,50.0,YR,,F,Y,80.0,KG,20230606,,MD,KR,KR,2023,Q2,Adult
225259751,22525975,8,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2023,Q2,Dyspnoea exertional,,2023,Q2,1,I,,20230525.0,20230606,20230606,EXP,,JP-JNJFOC-20230611449,JOHNSON AND JOHNSON,,8.0,DEC,E,F,Y,42.9,KG,20230606,,MD,JP,JP,2023,Q2,Child
225259751,22525975,8,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2023,Q2,Oedema peripheral,,2023,Q2,1,I,,20230525.0,20230606,20230606,EXP,,JP-JNJFOC-20230611449,JOHNSON AND JOHNSON,,8.0,DEC,E,F,Y,42.9,KG,20230606,,MD,JP,JP,2023,Q2,Child
225259751,22525975,8,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2023,Q2,Spondylitis,,2023,Q2,1,I,,20230525.0,20230606,20230606,EXP,,JP-JNJFOC-20230611449,JOHNSON AND JOHNSON,,8.0,DEC,E,F,Y,42.9,KG,20230606,,MD,JP,JP,2023,Q2,Child
225259751,22525975,8,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2023,Q2,Right ventricular failure,,2023,Q2,1,I,,20230525.0,20230606,20230606,EXP,,JP-JNJFOC-20230611449,JOHNSON AND JOHNSON,,8.0,DEC,E,F,Y,42.9,KG,20230606,,MD,JP,JP,2023,Q2,Child
225267661,22526766,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,Tablet,,2023,Q2,Drug interaction,,2023,Q2,1,I,20201020.0,20230530.0,20230606,20230606,EXP,,JP-TAKEDA-2023TUS055186,TAKEDA,,20.0,YR,,M,Y,57.0,KG,20230606,,HP,JP,JP,2023,Q2,Youth
225267661,22526766,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,Tablet,,2023,Q2,Toxic encephalopathy,,2023,Q2,1,I,20201020.0,20230530.0,20230606,20230606,EXP,,JP-TAKEDA-2023TUS055186,TAKEDA,,20.0,YR,,M,Y,57.0,KG,20230606,,HP,JP,JP,2023,Q2,Youth
225297881,22529788,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,Oral,qam,,,U,,Unknown,,212614.0,25.0,MG,Capsule,QD,2023,Q2,Visual impairment,,2023,Q2,1,I,20230606.0,20230606.0,20230607,20230607,PER,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242388",BOEHRINGER INGELHEIM,,67.0,YR,E,M,Y,,,20230607,,CN,US,US,2023,Q2,Elderly
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Tension headache,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Memory impairment,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Dizziness,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Arthralgia,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Vomiting,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Diarrhoea,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Back pain,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Peripheral swelling,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Carotid artery occlusion,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Abdominal pain upper,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Chest pain,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Intentional product use issue,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Tinnitus,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Pruritus,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Diplopia,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Pain,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Insomnia,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Pericarditis,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Muscle twitching,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Product prescribing error,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Lip swelling,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Intentional product misuse,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Headache,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Cardiospasm,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Pyrexia,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Cognitive disorder,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Subarachnoid haemorrhage,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Tachycardia,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Blindness,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Palmoplantar keratoderma,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Hallucination,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Palpitations,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Immunisation,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Malaise,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Amnesia,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Anosmia,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Feeling abnormal,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Abdominal discomfort,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Dry skin,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Blood glucose increased,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Vasculitis,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Alopecia,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Off label use,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Transient ischaemic attack,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Heart rate increased,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Angioedema,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Rash papular,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Dyspnoea,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Ventricular tachycardia,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Myocardial infarction,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,COVID-19,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Atrial tachycardia,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Migraine,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Visual impairment,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Sleep terror,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Nausea,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Hyperhidrosis,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Muscular weakness,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Disturbance in attention,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Fatigue,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Anxiety,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Pain of skin,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Pruritus genital,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225337831,22533783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,5.0,MG,,QD,2023,Q2,Dehydration,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-241393",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,70.0,KG,20230608,,CN,GB,GB,2023,Q2,Young Adult
225342914,22534291,30,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Delirium,,2023,Q2,4,F,20230531.0,20230614.0,20230608,20230623,EXP,,NVSC2023CA127717,NOVARTIS,,65.0,YR,,M,Y,,,20230622,,MD,CA,CA,2023,Q2,Elderly
225342914,22534291,30,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Salmonellosis,,2023,Q2,4,F,20230531.0,20230614.0,20230608,20230623,EXP,,NVSC2023CA127717,NOVARTIS,,65.0,YR,,M,Y,,,20230622,,MD,CA,CA,2023,Q2,Elderly
225348741,22534874,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q2,Dizziness,,2023,Q2,1,I,20230511.0,20230607.0,20230608,20230608,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242389",BOEHRINGER INGELHEIM,,74.0,YR,E,F,Y,,,20230608,,HP,SG,SG,2023,Q2,Elderly
225348741,22534874,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q2,Headache,,2023,Q2,1,I,20230511.0,20230607.0,20230608,20230608,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242389",BOEHRINGER INGELHEIM,,74.0,YR,E,F,Y,,,20230608,,HP,SG,SG,2023,Q2,Elderly
225348741,22534874,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q2,Myalgia,,2023,Q2,1,I,20230511.0,20230607.0,20230608,20230608,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242389",BOEHRINGER INGELHEIM,,74.0,YR,E,F,Y,,,20230608,,HP,SG,SG,2023,Q2,Elderly
225353073,22535307,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,,,,,,2023,Q2,Anaemia,,2023,Q2,3,F,20230512.0,20230621.0,20230608,20230627,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-2023-070743,BRISTOL MYERS SQUIBB,,75.0,YR,E,F,Y,76.0,KG,20230627,,MD,FR,FR,2023,Q2,Elderly
225353073,22535307,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,,,,,,2023,Q2,COVID-19,,2023,Q2,3,F,20230512.0,20230621.0,20230608,20230627,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-2023-070743,BRISTOL MYERS SQUIBB,,75.0,YR,E,F,Y,76.0,KG,20230627,,MD,FR,FR,2023,Q2,Elderly
225353073,22535307,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,,,,,,2023,Q2,Chills,,2023,Q2,3,F,20230512.0,20230621.0,20230608,20230627,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-2023-070743,BRISTOL MYERS SQUIBB,,75.0,YR,E,F,Y,76.0,KG,20230627,,MD,FR,FR,2023,Q2,Elderly
225353073,22535307,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,,,,,,2023,Q2,Pneumonia,,2023,Q2,3,F,20230512.0,20230621.0,20230608,20230627,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-2023-070743,BRISTOL MYERS SQUIBB,,75.0,YR,E,F,Y,76.0,KG,20230627,,MD,FR,FR,2023,Q2,Elderly
225353073,22535307,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,,,,,,2023,Q2,C-reactive protein increased,,2023,Q2,3,F,20230512.0,20230621.0,20230608,20230627,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-2023-070743,BRISTOL MYERS SQUIBB,,75.0,YR,E,F,Y,76.0,KG,20230627,,MD,FR,FR,2023,Q2,Elderly
225353073,22535307,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,,,,,,2023,Q2,Lower respiratory tract infection,,2023,Q2,3,F,20230512.0,20230621.0,20230608,20230627,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-2023-070743,BRISTOL MYERS SQUIBB,,75.0,YR,E,F,Y,76.0,KG,20230627,,MD,FR,FR,2023,Q2,Elderly
225353073,22535307,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,,,,,,2023,Q2,Cardiac failure,,2023,Q2,3,F,20230512.0,20230621.0,20230608,20230627,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-2023-070743,BRISTOL MYERS SQUIBB,,75.0,YR,E,F,Y,76.0,KG,20230627,,MD,FR,FR,2023,Q2,Elderly
225353073,22535307,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,,,,,,2023,Q2,Asthenia,,2023,Q2,3,F,20230512.0,20230621.0,20230608,20230627,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-2023-070743,BRISTOL MYERS SQUIBB,,75.0,YR,E,F,Y,76.0,KG,20230627,,MD,FR,FR,2023,Q2,Elderly
225353073,22535307,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,,,,,,2023,Q2,Off label use,,2023,Q2,3,F,20230512.0,20230621.0,20230608,20230627,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-2023-070743,BRISTOL MYERS SQUIBB,,75.0,YR,E,F,Y,76.0,KG,20230627,,MD,FR,FR,2023,Q2,Elderly
225353073,22535307,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,,,,,,2023,Q2,Cough,,2023,Q2,3,F,20230512.0,20230621.0,20230608,20230627,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-2023-070743,BRISTOL MYERS SQUIBB,,75.0,YR,E,F,Y,76.0,KG,20230627,,MD,FR,FR,2023,Q2,Elderly
225353073,22535307,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,,,,,,2023,Q2,Abdominal pain upper,,2023,Q2,3,F,20230512.0,20230621.0,20230608,20230627,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-2023-070743,BRISTOL MYERS SQUIBB,,75.0,YR,E,F,Y,76.0,KG,20230627,,MD,FR,FR,2023,Q2,Elderly
225360241,22536024,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Haematuria,,2023,Q2,1,I,,20230601.0,20230608,20230608,EXP,,US-BAYER-2023A079440,BAYER,Schmitz Zachary P.; Su Mark K.; Hoffman Robert S.. ~Vitamin-K antagonist toxicity from empagliflozin dispensing error. d International Congress of the European Association of Poisons Centres and Clin. 2023;217,66.0,YR,E,M,Y,,,20230608,,HP,US,US,2023,Q2,Elderly
225365011,22536501,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 mg 1-0-0,,,,,,,,25.0,MG,,,2023,Q2,Pancreatitis chronic,,2023,Q2,1,I,20221108.0,20230602.0,20230608,20230608,EXP,ES-AEMPS-1365703,ES-Accord-361447,ACCORD,,60.0,YR,A,M,Y,,,20230608,,MD,ES,ES,2023,Q2,Adult
225378391,22537839,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q2,Oesophageal candidiasis,,2023,Q2,1,I,,20230608.0,20230608,20230608,EXP,GB-MHRA-TPP6576175C5308170YC1685957383781,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242780",BOEHRINGER INGELHEIM,,53.0,YR,A,M,Y,101.0,KG,20230608,,MD,GB,GB,2023,Q2,Adult
225378391,22537839,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q2,Oral candidiasis,,2023,Q2,1,I,,20230608.0,20230608,20230608,EXP,GB-MHRA-TPP6576175C5308170YC1685957383781,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-242780",BOEHRINGER INGELHEIM,,53.0,YR,A,M,Y,101.0,KG,20230608,,MD,GB,GB,2023,Q2,Adult
225379403,22537940,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,102145.0,,,Tablet,,2023,Q2,Hyponatraemia,,2023,Q2,3,F,20230508.0,20230615.0,20230608,20230616,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-236299",BOEHRINGER INGELHEIM,,67.0,YR,E,F,Y,68.3,KG,20230616,,MD,US,US,2023,Q2,Elderly
225379403,22537940,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,102145.0,,,Tablet,,2023,Q2,Hyperkalaemia,,2023,Q2,3,F,20230508.0,20230615.0,20230608,20230616,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-236299",BOEHRINGER INGELHEIM,,67.0,YR,E,F,Y,68.3,KG,20230616,,MD,US,US,2023,Q2,Elderly
225380371,22538037,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Tongue oedema,,2023,Q2,1,I,20230327.0,20230603.0,20230608,20230608,EXP,IT-MINISAL02-923820,IT-Accord-361768,ACCORD,,69.0,YR,E,M,Y,,,20230608,,PH,IT,IT,2023,Q2,Elderly
225380371,22538037,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Dysphonia,,2023,Q2,1,I,20230327.0,20230603.0,20230608,20230608,EXP,IT-MINISAL02-923820,IT-Accord-361768,ACCORD,,69.0,YR,E,M,Y,,,20230608,,PH,IT,IT,2023,Q2,Elderly
225380371,22538037,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Angioedema,,2023,Q2,1,I,20230327.0,20230603.0,20230608,20230608,EXP,IT-MINISAL02-923820,IT-Accord-361768,ACCORD,,69.0,YR,E,M,Y,,,20230608,,PH,IT,IT,2023,Q2,Elderly
225387402,22538740,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,International normalised ratio increased,,2023,Q2,2,F,,20230614.0,20230609,20230622,EXP,,JP-AMGEN-JPNSP2023096672,AMGEN,"Sumioki A, Todoroki A, Nakamura Y, Wakatsuki T, Matsumura K, Kato A, et al.. A case of warfarin-induced calciphylaxis with critical limb ischemia in a non-dialysis patient. The Nishinihon Journal of Dermatology. 2023;85 (2):99-103",69.0,YR,E,F,Y,,,20230622,,MD,JP,JP,2023,Q2,Elderly
225387402,22538740,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Calciphylaxis,,2023,Q2,2,F,,20230614.0,20230609,20230622,EXP,,JP-AMGEN-JPNSP2023096672,AMGEN,"Sumioki A, Todoroki A, Nakamura Y, Wakatsuki T, Matsumura K, Kato A, et al.. A case of warfarin-induced calciphylaxis with critical limb ischemia in a non-dialysis patient. The Nishinihon Journal of Dermatology. 2023;85 (2):99-103",69.0,YR,E,F,Y,,,20230622,,MD,JP,JP,2023,Q2,Elderly
225387402,22538740,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Cellulitis,,2023,Q2,2,F,,20230614.0,20230609,20230622,EXP,,JP-AMGEN-JPNSP2023096672,AMGEN,"Sumioki A, Todoroki A, Nakamura Y, Wakatsuki T, Matsumura K, Kato A, et al.. A case of warfarin-induced calciphylaxis with critical limb ischemia in a non-dialysis patient. The Nishinihon Journal of Dermatology. 2023;85 (2):99-103",69.0,YR,E,F,Y,,,20230622,,MD,JP,JP,2023,Q2,Elderly
225387402,22538740,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,International normalised ratio increased,,2023,Q2,2,F,,20230614.0,20230609,20230622,EXP,,JP-AMGEN-JPNSP2023096672,AMGEN,"Sumioki A, Todoroki A, Nakamura Y, Wakatsuki T, Matsumura K, Kato A, et al.. A case of warfarin-induced calciphylaxis with critical limb ischemia in a non-dialysis patient. The Nishinihon Journal of Dermatology. 2023;85 (2):99-103",69.0,YR,E,F,Y,,,20230622,,MD,JP,JP,2023,Q2,Elderly
225387402,22538740,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Calciphylaxis,,2023,Q2,2,F,,20230614.0,20230609,20230622,EXP,,JP-AMGEN-JPNSP2023096672,AMGEN,"Sumioki A, Todoroki A, Nakamura Y, Wakatsuki T, Matsumura K, Kato A, et al.. A case of warfarin-induced calciphylaxis with critical limb ischemia in a non-dialysis patient. The Nishinihon Journal of Dermatology. 2023;85 (2):99-103",69.0,YR,E,F,Y,,,20230622,,MD,JP,JP,2023,Q2,Elderly
225387402,22538740,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Cellulitis,,2023,Q2,2,F,,20230614.0,20230609,20230622,EXP,,JP-AMGEN-JPNSP2023096672,AMGEN,"Sumioki A, Todoroki A, Nakamura Y, Wakatsuki T, Matsumura K, Kato A, et al.. A case of warfarin-induced calciphylaxis with critical limb ischemia in a non-dialysis patient. The Nishinihon Journal of Dermatology. 2023;85 (2):99-103",69.0,YR,E,F,Y,,,20230622,,MD,JP,JP,2023,Q2,Elderly
225398131,22539813,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Angioedema,,2023,Q2,1,I,,20230604.0,20230609,20230609,EXP,,US-Navinta LLC-000446,NAVINTA LLC,US-Navinta LLC-000446-01_Initial Source Document,49.0,YR,A,M,Y,,,20230609,,HP,US,,2023,Q2,Adult
225398131,22539813,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Lupus nephritis,,2023,Q2,1,I,,20230604.0,20230609,20230609,EXP,,US-Navinta LLC-000446,NAVINTA LLC,US-Navinta LLC-000446-01_Initial Source Document,49.0,YR,A,M,Y,,,20230609,,HP,US,,2023,Q2,Adult
225398131,22539813,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Lupus-like syndrome,,2023,Q2,1,I,,20230604.0,20230609,20230609,EXP,,US-Navinta LLC-000446,NAVINTA LLC,US-Navinta LLC-000446-01_Initial Source Document,49.0,YR,A,M,Y,,,20230609,,HP,US,,2023,Q2,Adult
225881041,22588104,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Asthenia,,2023,Q2,1,I,20230525.0,20230602.0,20230612,20230612,EXP,,ES-ROCHE-3363338,ROCHE,,65.0,YR,,M,Y,80.4,KG,20230612,,MD,ES,,2023,Q2,Elderly
225881041,22588104,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Diarrhoea,,2023,Q2,1,I,20230525.0,20230602.0,20230612,20230612,EXP,,ES-ROCHE-3363338,ROCHE,,65.0,YR,,M,Y,80.4,KG,20230612,,MD,ES,,2023,Q2,Elderly
225881041,22588104,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Renal impairment,,2023,Q2,1,I,20230525.0,20230602.0,20230612,20230612,EXP,,ES-ROCHE-3363338,ROCHE,,65.0,YR,,M,Y,80.4,KG,20230612,,MD,ES,,2023,Q2,Elderly
225881041,22588104,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Odynophagia,,2023,Q2,1,I,20230525.0,20230602.0,20230612,20230612,EXP,,ES-ROCHE-3363338,ROCHE,,65.0,YR,,M,Y,80.4,KG,20230612,,MD,ES,,2023,Q2,Elderly
225894121,22589412,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,,,,,10.0,MG,,,2023,Q2,Off label use,,2023,Q2,1,I,,20230606.0,20230612,20230612,EXP,,ES-MYLANLABS-2023M1060699,MYLAN,"Montesa Marin M, Lluna Perez L, Terradez Mas L, Malek Marin T.. Anemia and diarrhea in a woman75-year-old with C3 glomerulonephritis.. NefroPlus.. 2022;14(2):79-84",75.0,YR,,F,Y,,,20230612,,HP,ES,ES,2023,Q2,Elderly
225894121,22589412,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,,,,,10.0,MG,,,2023,Q2,Normochromic normocytic anaemia,,2023,Q2,1,I,,20230606.0,20230612,20230612,EXP,,ES-MYLANLABS-2023M1060699,MYLAN,"Montesa Marin M, Lluna Perez L, Terradez Mas L, Malek Marin T.. Anemia and diarrhea in a woman75-year-old with C3 glomerulonephritis.. NefroPlus.. 2022;14(2):79-84",75.0,YR,,F,Y,,,20230612,,HP,ES,ES,2023,Q2,Elderly
225894121,22589412,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,,,,,10.0,MG,,,2023,Q2,Diarrhoea,,2023,Q2,1,I,,20230606.0,20230612,20230612,EXP,,ES-MYLANLABS-2023M1060699,MYLAN,"Montesa Marin M, Lluna Perez L, Terradez Mas L, Malek Marin T.. Anemia and diarrhea in a woman75-year-old with C3 glomerulonephritis.. NefroPlus.. 2022;14(2):79-84",75.0,YR,,F,Y,,,20230612,,HP,ES,ES,2023,Q2,Elderly
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Cardiospasm,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Dyspnoea,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Pericarditis,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Product prescribing error,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Headache,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Peripheral swelling,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Pyrexia,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Anxiety,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Angioedema,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Rash papular,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,COVID-19,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Palpitations,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Transient ischaemic attack,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Dizziness,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Atrial tachycardia,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Hyperhidrosis,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Diplopia,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Tension headache,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Vasculitis,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Tinnitus,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Chest pain,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Ventricular tachycardia,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Anosmia,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Arthralgia,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Dry skin,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Tachycardia,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Pruritus genital,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Blindness,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Vomiting,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Heart rate increased,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Cognitive disorder,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Sleep terror,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Myocardial infarction,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Fatigue,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Pain of skin,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Intentional product use issue,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Off label use,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Lip swelling,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Memory impairment,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Muscular weakness,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Carotid artery occlusion,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Back pain,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Pruritus,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Disturbance in attention,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Abdominal pain upper,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Subarachnoid haemorrhage,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Blood glucose increased,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Nausea,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Eye disorder,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Muscle twitching,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Amnesia,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Insomnia,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Feeling abnormal,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Intentional product misuse,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Pain,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Migraine,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Dehydration,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Alopecia,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Abdominal discomfort,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Palmoplantar keratoderma,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Diarrhoea,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Facial pain,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Visual impairment,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Pain in extremity,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Malaise,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225904943,22590494,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,,,,,5.0,MG,UNK,,2023,Q2,Hallucination,,2023,Q2,3,F,20210101.0,20230613.0,20230612,20230623,EXP,GB-TAKEDA-2023TUS050739,GB-TORRENT-00031986,TORRENT,,34.0,YR,A,M,Y,70.0,KG,20230623,,HP,GB,GB,2023,Q2,Young Adult
225928161,22592816,2,C,Empagliflozin-linagliptin,,2,Unknown,10mg/5mg,,,U,,,,,,,,,2023,Q2,Intentional product misuse,,2023,Q2,1,I,,20230605.0,20230613,20230613,EXP,,US-TEVA-2023-US-2895425,TEVA,,49.0,YR,A,M,Y,,,20230613,,MD,US,US,2023,Q2,Adult
225928161,22592816,2,C,Empagliflozin-linagliptin,,2,Unknown,10mg/5mg,,,U,,,,,,,,,2023,Q2,Hypotension,,2023,Q2,1,I,,20230605.0,20230613,20230613,EXP,,US-TEVA-2023-US-2895425,TEVA,,49.0,YR,A,M,Y,,,20230613,,MD,US,US,2023,Q2,Adult
225928161,22592816,2,C,Empagliflozin-linagliptin,,2,Unknown,10mg/5mg,,,U,,,,,,,,,2023,Q2,Overdose,,2023,Q2,1,I,,20230605.0,20230613,20230613,EXP,,US-TEVA-2023-US-2895425,TEVA,,49.0,YR,A,M,Y,,,20230613,,MD,US,US,2023,Q2,Adult
225928161,22592816,2,C,Empagliflozin-linagliptin,,2,Unknown,10mg/5mg,,,U,,,,,,,,,2023,Q2,Acute kidney injury,,2023,Q2,1,I,,20230605.0,20230613,20230613,EXP,,US-TEVA-2023-US-2895425,TEVA,,49.0,YR,A,M,Y,,,20230613,,MD,US,US,2023,Q2,Adult
225928161,22592816,2,C,Empagliflozin-linagliptin,,2,Unknown,10mg/5mg,,,U,,,,,,,,,2023,Q2,Syncope,,2023,Q2,1,I,,20230605.0,20230613,20230613,EXP,,US-TEVA-2023-US-2895425,TEVA,,49.0,YR,A,M,Y,,,20230613,,MD,US,US,2023,Q2,Adult
225930421,22593042,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Renal colic,,2023,Q2,1,I,20230401.0,20230608.0,20230613,20230613,EXP,,GB-AMGEN-GBRSP2023099649,AMGEN,,59.0,YR,A,M,Y,79.3,KG,20230613,,HP,GB,GB,2023,Q2,Adult
225931531,22593153,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 mg,,,,,unknown,,,,,,,2023,Q2,Muscle atrophy,,2023,Q2,1,I,20220101.0,20230604.0,20230613,20230613,EXP,GB-MHRA-ADR 27949584,GB-NOVOPROD-1076055,NOVO NORDISK,,57.0,YR,,M,Y,88.0,KG,20230613,,MD,GB,GB,2023,Q2,Adult
225931581,22593158,2,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"1 g, bid",2.0,GM,Y,,2304517,,,1.0,GM,,BID,2023,Q2,Inappropriate schedule of product administration,,2023,Q2,1,I,20230520.0,20230601.0,20230613,20230613,EXP,CN-NMPA-3505021029028202300518,CN-NOVOPROD-1073577,NOVO NORDISK,,48.0,YR,,M,Y,80.0,KG,20230613,,HP,CN,CN,2023,Q2,Adult
225931581,22593158,2,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"1 g, bid",2.0,GM,Y,,2304517,,,1.0,GM,,BID,2023,Q2,Diabetic ketoacidosis,,2023,Q2,1,I,20230520.0,20230601.0,20230613,20230613,EXP,CN-NMPA-3505021029028202300518,CN-NOVOPROD-1073577,NOVO NORDISK,,48.0,YR,,M,Y,80.0,KG,20230613,,HP,CN,CN,2023,Q2,Adult
225944931,22594493,70,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,"5 mg/1000 mg, 2x/day",,,,,,,,,,,BID,2023,Q2,Hospitalisation,,2023,Q2,1,I,20150401.0,20230602.0,20230613,20230613,EXP,,"AU-TASMAN PHARMA, INC.-2023TSM00111",TASMAN PHARMA,,56.0,YR,,M,Y,,,20230613,,HP,AU,AU,2023,Q2,Adult
225944931,22594493,70,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,"5 mg/1000 mg, 2x/day",,,,,,,,,,,BID,2023,Q2,Dilated cardiomyopathy,,2023,Q2,1,I,20150401.0,20230602.0,20230613,20230613,EXP,,"AU-TASMAN PHARMA, INC.-2023TSM00111",TASMAN PHARMA,,56.0,YR,,M,Y,,,20230613,,HP,AU,AU,2023,Q2,Adult
225944931,22594493,70,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,"5 mg/1000 mg, 2x/day",,,,,,,,,,,BID,2023,Q2,Coronary artery disease,,2023,Q2,1,I,20150401.0,20230602.0,20230613,20230613,EXP,,"AU-TASMAN PHARMA, INC.-2023TSM00111",TASMAN PHARMA,,56.0,YR,,M,Y,,,20230613,,HP,AU,AU,2023,Q2,Adult
225944931,22594493,70,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,"5 mg/1000 mg, 2x/day",,,,,,,,,,,BID,2023,Q2,Cardiac dysfunction,,2023,Q2,1,I,20150401.0,20230602.0,20230613,20230613,EXP,,"AU-TASMAN PHARMA, INC.-2023TSM00111",TASMAN PHARMA,,56.0,YR,,M,Y,,,20230613,,HP,AU,AU,2023,Q2,Adult
225944931,22594493,70,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,"5 mg/1000 mg, 2x/day",,,,,,,,,,,BID,2023,Q2,Cardiac disorder,,2023,Q2,1,I,20150401.0,20230602.0,20230613,20230613,EXP,,"AU-TASMAN PHARMA, INC.-2023TSM00111",TASMAN PHARMA,,56.0,YR,,M,Y,,,20230613,,HP,AU,AU,2023,Q2,Adult
225944931,22594493,70,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,"5 mg/1000 mg, 2x/day",,,,,,,,,,,BID,2023,Q2,Electrocardiogram QT prolonged,,2023,Q2,1,I,20150401.0,20230602.0,20230613,20230613,EXP,,"AU-TASMAN PHARMA, INC.-2023TSM00111",TASMAN PHARMA,,56.0,YR,,M,Y,,,20230613,,HP,AU,AU,2023,Q2,Adult
225985251,22598525,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q2,Acidosis,,2023,Q2,1,I,20230518.0,20230613.0,20230614,20230614,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-243531",BOEHRINGER INGELHEIM,,86.0,YR,E,F,Y,,,20230614,,HP,SG,SG,2023,Q2,Elderly
226017531,22601753,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",80.0,MG,,,157230301,,,10.0,MG,Tablet,QD,2023,Q2,Renal injury,,2023,Q2,1,I,20230515.0,20230603.0,20230614,20230614,EXP,,CN-BAYER-2023A078819,BAYER,,54.0,YR,A,M,Y,65.0,KG,20230614,,HP,CN,CN,2023,Q2,Adult
226018851,22601885,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2023,Q2,Angioedema,,2023,Q2,1,I,20230612.0,20230614.0,20230614,20230614,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-243930",BOEHRINGER INGELHEIM,,51.0,YR,A,M,Y,,,20230614,,MD,GB,GB,2023,Q2,Adult
226038741,22603874,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q2,Drug ineffective,,2023,Q2,1,I,,20230605.0,20230615,20230615,EXP,,PL-AUROBINDO-AUR-APL-2023-042151,AUROBINDO,"Nitka A, Lewandowski J. Individualizing the treatment of patients with heart failure with reduced ejection fraction depending on the clinical phenotype (Indywidualizacja terapii niewydolno?ci serca z obni?on? frakcj? wyrzutow? w zale?no?ci od fenotypu pacjenta). MEDYCYNA FAKTOW. 2022;4:458-461",69.0,YR,,M,Y,,,20230615,,HP,PL,PL,2023,Q2,Elderly
226065931,22606593,6,C,Empagliflozin 25 mg tablet,,2,,,,,,,,,,,,,,2023,Q2,Metastases to central nervous system,,2023,Q2,1,I,20230522.0,,20230608,20230608,DIR,662821,,FDA-CTU,,76.0,YR,,M,N,71.94,KG,20230608,Y,HP,US,,2023,Q2,Elderly
226065931,22606593,6,C,Empagliflozin 25 mg tablet,,2,,,,,,,,,,,,,,2023,Q2,Malignant neoplasm progression,,2023,Q2,1,I,20230522.0,,20230608,20230608,DIR,662821,,FDA-CTU,,76.0,YR,,M,N,71.94,KG,20230608,Y,HP,US,,2023,Q2,Elderly
226065931,22606593,6,C,Empagliflozin 25 mg tablet,,2,,,,,,,,,,,,,,2023,Q2,Vasogenic cerebral oedema,,2023,Q2,1,I,20230522.0,,20230608,20230608,DIR,662821,,FDA-CTU,,76.0,YR,,M,N,71.94,KG,20230608,Y,HP,US,,2023,Q2,Elderly
226065931,22606593,6,C,Empagliflozin 25 mg tablet,,2,,,,,,,,,,,,,,2023,Q2,Speech disorder,,2023,Q2,1,I,20230522.0,,20230608,20230608,DIR,662821,,FDA-CTU,,76.0,YR,,M,N,71.94,KG,20230608,Y,HP,US,,2023,Q2,Elderly
226065931,22606593,6,C,Empagliflozin 25 mg tablet,,2,,,,,,,,,,,,,,2023,Q2,Lung neoplasm malignant,,2023,Q2,1,I,20230522.0,,20230608,20230608,DIR,662821,,FDA-CTU,,76.0,YR,,M,N,71.94,KG,20230608,Y,HP,US,,2023,Q2,Elderly
226065931,22606593,6,C,Empagliflozin 25 mg tablet,,2,,,,,,,,,,,,,,2023,Q2,Therapy cessation,,2023,Q2,1,I,20230522.0,,20230608,20230608,DIR,662821,,FDA-CTU,,76.0,YR,,M,N,71.94,KG,20230608,Y,HP,US,,2023,Q2,Elderly
226065931,22606593,6,C,Empagliflozin 25 mg tablet,,2,,,,,,,,,,,,,,2023,Q2,Intracranial mass,,2023,Q2,1,I,20230522.0,,20230608,20230608,DIR,662821,,FDA-CTU,,76.0,YR,,M,N,71.94,KG,20230608,Y,HP,US,,2023,Q2,Elderly
226076361,22607636,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Blood bilirubin increased,,2023,Q2,1,I,,20230609.0,20230616,20230616,EXP,,AU-PFIZER INC-202300207270,PFIZER,,74.0,YR,,F,Y,,,20230616,,PH,AU,AU,2023,Q2,Elderly
226076361,22607636,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Alanine aminotransferase increased,,2023,Q2,1,I,,20230609.0,20230616,20230616,EXP,,AU-PFIZER INC-202300207270,PFIZER,,74.0,YR,,F,Y,,,20230616,,PH,AU,AU,2023,Q2,Elderly
226076361,22607636,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Gamma-glutamyltransferase increased,,2023,Q2,1,I,,20230609.0,20230616,20230616,EXP,,AU-PFIZER INC-202300207270,PFIZER,,74.0,YR,,F,Y,,,20230616,,PH,AU,AU,2023,Q2,Elderly
226081131,22608113,29,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,High-grade B-cell lymphoma,,2023,Q2,1,I,20220707.0,20230614.0,20230616,20230616,EXP,,GB-ABBVIE-5291999,ABBVIE,,62.0,YR,,M,Y,,,20230616,,HP,GB,GB,2023,Q2,Adult
226094741,22609474,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Lupus-like syndrome,,2023,Q2,1,I,,20230604.0,20230616,20230616,EXP,,US-CPL-003450,CADILA,"Everett SC, Ananth D, Alejo AL, Shaub T, Gan J. A Rare Presentation of Hydralazine-Induced Lupus in the Setting of Pericarditis With Concomitant Angioedema. Cureus. 2023 May 1;15(5):e38376.",49.0,YR,A,M,Y,,,20230616,,HP,US,US,2023,Q2,Adult
226094741,22609474,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Lupus nephritis,,2023,Q2,1,I,,20230604.0,20230616,20230616,EXP,,US-CPL-003450,CADILA,"Everett SC, Ananth D, Alejo AL, Shaub T, Gan J. A Rare Presentation of Hydralazine-Induced Lupus in the Setting of Pericarditis With Concomitant Angioedema. Cureus. 2023 May 1;15(5):e38376.",49.0,YR,A,M,Y,,,20230616,,HP,US,US,2023,Q2,Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Immunisation,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Diplopia,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Intentional product use issue,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Product prescribing error,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Anosmia,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Tachycardia,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Chest pain,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Dyspnoea,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Feeling abnormal,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Diarrhoea,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Dry skin,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Muscular weakness,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Disturbance in attention,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Nausea,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Ventricular tachycardia,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Cognitive disorder,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Intentional product misuse,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Dehydration,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,COVID-19,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Amnesia,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Anxiety,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Pruritus,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Tinnitus,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Palmoplantar keratoderma,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Subarachnoid haemorrhage,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Blood glucose increased,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Peripheral swelling,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Memory impairment,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Lip swelling,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Malaise,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Muscle twitching,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Myocardial infarction,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Dizziness,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Vasculitis,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Transient ischaemic attack,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Headache,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Back pain,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Palpitations,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Pruritus genital,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Insomnia,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Pericarditis,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Abdominal pain upper,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Sleep terror,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Vomiting,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Alopecia,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Hyperhidrosis,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Migraine,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Abdominal discomfort,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Pyrexia,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Off label use,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Fatigue,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Tension headache,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Heart rate increased,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Cardiospasm,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Hallucination,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Arthralgia,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Visual impairment,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Carotid artery occlusion,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Atrial tachycardia,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Pain,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Pain of skin,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Blindness,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Angioedema,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226098711,22609871,24,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,"5 milligram,  QD",,,U,,Unknown,,,5.0,MG,,,2023,Q2,Rash papular,,2023,Q2,1,I,,20230602.0,20230616,20230616,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394437,RANBAXY,,34.0,YR,,M,Y,70.0,KG,20230616,,CN,GB,GB,2023,Q2,Young Adult
226109451,22610945,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q2,Hyponatraemia,,2023,Q2,1,I,,20230601.0,20230616,20230616,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-390001,RANBAXY,"Paster L, Mehtabdin K, Jhaveri KD, Myers A, Barnett RL. A Case of Hyponatremia Associated with SGLT-2 inhibitor Empagliflozin. J Am Soc Nephrol. 2016;27:996A (PUB397)",69.0,YR,,F,Y,,,20230616,,HP,US,US,2023,Q2,Elderly
226111671,22611167,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2023,Q2,Pseudomonal sepsis,,2023,Q2,1,I,20230525.0,20230613.0,20230616,20230616,EXP,,DE-GENMAB-2023-00907,GENMAB,,75.0,YR,,M,Y,69.3,KG,20230616,,MD,DE,DE,2023,Q2,Elderly
226114641,22611464,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Metabolic acidosis,,2023,Q2,1,I,20230605.0,20230616.0,20230616,20230616,EXP,DE-BFARM-23004588,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-244412",BOEHRINGER INGELHEIM,,71.0,YR,E,F,Y,98.0,KG,20230616,,MD,DE,DE,2023,Q2,Elderly
226114641,22611464,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Ketoacidosis,,2023,Q2,1,I,20230605.0,20230616.0,20230616,20230616,EXP,DE-BFARM-23004588,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-244412",BOEHRINGER INGELHEIM,,71.0,YR,E,F,Y,98.0,KG,20230616,,MD,DE,DE,2023,Q2,Elderly
226114641,22611464,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Lactic acidosis,,2023,Q2,1,I,20230605.0,20230616.0,20230616,20230616,EXP,DE-BFARM-23004588,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-244412",BOEHRINGER INGELHEIM,,71.0,YR,E,F,Y,98.0,KG,20230616,,MD,DE,DE,2023,Q2,Elderly
226125661,22612566,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Chest discomfort,,2023,Q2,1,I,20230523.0,20230612.0,20230617,20230617,EXP,,NVSC2023GB136110,NOVARTIS,,54.0,YR,,M,Y,,,20230617,,CN,GB,GB,2023,Q2,Adult
226125661,22612566,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Arthralgia,,2023,Q2,1,I,20230523.0,20230612.0,20230617,20230617,EXP,,NVSC2023GB136110,NOVARTIS,,54.0,YR,,M,Y,,,20230617,,CN,GB,GB,2023,Q2,Adult
226125661,22612566,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Chest pain,,2023,Q2,1,I,20230523.0,20230612.0,20230617,20230617,EXP,,NVSC2023GB136110,NOVARTIS,,54.0,YR,,M,Y,,,20230617,,CN,GB,GB,2023,Q2,Adult
226125661,22612566,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Back pain,,2023,Q2,1,I,20230523.0,20230612.0,20230617,20230617,EXP,,NVSC2023GB136110,NOVARTIS,,54.0,YR,,M,Y,,,20230617,,CN,GB,GB,2023,Q2,Adult
226125661,22612566,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Neck pain,,2023,Q2,1,I,20230523.0,20230612.0,20230617,20230617,EXP,,NVSC2023GB136110,NOVARTIS,,54.0,YR,,M,Y,,,20230617,,CN,GB,GB,2023,Q2,Adult
226137641,22613764,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2023,Q2,Off label use,,2023,Q2,1,I,,20230612.0,20230619,20230619,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-243245",BOEHRINGER INGELHEIM,,31.0,YR,A,M,Y,,,20230619,,MD,PL,PL,2023,Q2,Young Adult
226137641,22613764,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2023,Q2,Diabetic metabolic decompensation,,2023,Q2,1,I,,20230612.0,20230619,20230619,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-243245",BOEHRINGER INGELHEIM,,31.0,YR,A,M,Y,,,20230619,,MD,PL,PL,2023,Q2,Young Adult
226137641,22613764,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2023,Q2,Metabolic acidosis,,2023,Q2,1,I,,20230612.0,20230619,20230619,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-243245",BOEHRINGER INGELHEIM,,31.0,YR,A,M,Y,,,20230619,,MD,PL,PL,2023,Q2,Young Adult
226137641,22613764,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,,,204629.0,,,,,2023,Q2,Off label use,,2023,Q2,1,I,,20230612.0,20230619,20230619,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-243245",BOEHRINGER INGELHEIM,,31.0,YR,A,M,Y,,,20230619,,MD,PL,PL,2023,Q2,Young Adult
226137641,22613764,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,,,204629.0,,,,,2023,Q2,Diabetic metabolic decompensation,,2023,Q2,1,I,,20230612.0,20230619,20230619,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-243245",BOEHRINGER INGELHEIM,,31.0,YR,A,M,Y,,,20230619,,MD,PL,PL,2023,Q2,Young Adult
226137641,22613764,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,,,204629.0,,,,,2023,Q2,Metabolic acidosis,,2023,Q2,1,I,,20230612.0,20230619,20230619,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-243245",BOEHRINGER INGELHEIM,,31.0,YR,A,M,Y,,,20230619,,MD,PL,PL,2023,Q2,Young Adult
226144431,22614443,29,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Neutrophil count abnormal,,2023,Q2,1,I,20221113.0,20230614.0,20230619,20230619,EXP,,GB-ABBVIE-5293128,ABBVIE,,63.0,YR,,M,Y,108.0,KG,20230619,,HP,GB,GB,2023,Q2,Adult
226144431,22614443,29,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Incontinence,,2023,Q2,1,I,20221113.0,20230614.0,20230619,20230619,EXP,,GB-ABBVIE-5293128,ABBVIE,,63.0,YR,,M,Y,108.0,KG,20230619,,HP,GB,GB,2023,Q2,Adult
226144431,22614443,29,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Staphylococcal sepsis,,2023,Q2,1,I,20221113.0,20230614.0,20230619,20230619,EXP,,GB-ABBVIE-5293128,ABBVIE,,63.0,YR,,M,Y,108.0,KG,20230619,,HP,GB,GB,2023,Q2,Adult
226144431,22614443,29,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Skin ulcer,,2023,Q2,1,I,20221113.0,20230614.0,20230619,20230619,EXP,,GB-ABBVIE-5293128,ABBVIE,,63.0,YR,,M,Y,108.0,KG,20230619,,HP,GB,GB,2023,Q2,Adult
226144431,22614443,29,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Pyrexia,,2023,Q2,1,I,20221113.0,20230614.0,20230619,20230619,EXP,,GB-ABBVIE-5293128,ABBVIE,,63.0,YR,,M,Y,108.0,KG,20230619,,HP,GB,GB,2023,Q2,Adult
226144431,22614443,29,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Neutropenic sepsis,,2023,Q2,1,I,20221113.0,20230614.0,20230619,20230619,EXP,,GB-ABBVIE-5293128,ABBVIE,,63.0,YR,,M,Y,108.0,KG,20230619,,HP,GB,GB,2023,Q2,Adult
226144431,22614443,29,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Mass,,2023,Q2,1,I,20221113.0,20230614.0,20230619,20230619,EXP,,GB-ABBVIE-5293128,ABBVIE,,63.0,YR,,M,Y,108.0,KG,20230619,,HP,GB,GB,2023,Q2,Adult
226161111,22616111,30,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNKNOWN,,,,,UNKNOWN,,,,,Tablets,,2023,Q2,Adrenal insufficiency,,2023,Q2,1,I,,20230605.0,20230619,20230619,EXP,,CA-Hikma Pharmaceuticals USA Inc.-CA-H14001-23-02030,HIKMA,,75.0,YR,,M,Y,,,20230619,,HP,CA,,2023,Q2,Elderly
226161111,22616111,30,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNKNOWN,,,,,UNKNOWN,,,,,Tablets,,2023,Q2,Hyperthyroidism,,2023,Q2,1,I,,20230605.0,20230619,20230619,EXP,,CA-Hikma Pharmaceuticals USA Inc.-CA-H14001-23-02030,HIKMA,,75.0,YR,,M,Y,,,20230619,,HP,CA,,2023,Q2,Elderly
226161111,22616111,30,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNKNOWN,,,,,UNKNOWN,,,,,Tablets,,2023,Q2,Troponin increased,,2023,Q2,1,I,,20230605.0,20230619,20230619,EXP,,CA-Hikma Pharmaceuticals USA Inc.-CA-H14001-23-02030,HIKMA,,75.0,YR,,M,Y,,,20230619,,HP,CA,,2023,Q2,Elderly
226161111,22616111,30,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNKNOWN,,,,,UNKNOWN,,,,,Tablets,,2023,Q2,Hypotension,,2023,Q2,1,I,,20230605.0,20230619,20230619,EXP,,CA-Hikma Pharmaceuticals USA Inc.-CA-H14001-23-02030,HIKMA,,75.0,YR,,M,Y,,,20230619,,HP,CA,,2023,Q2,Elderly
226167181,22616718,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"1,5/850  mg",,,,,,,,,,,,2023,Q2,Catheterisation cardiac,,2023,Q2,1,I,20230327.0,20230613.0,20230619,20230619,EXP,,"CO-DAIICHI SANKYO, INC.-DSE-2023-124313",DAIICHI,,57.0,YR,,F,Y,,,20230619,,CN,CO,CO,2023,Q2,Adult
226167181,22616718,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"1,5/850  mg",,,,,,,,,,,,2023,Q2,Chest pain,,2023,Q2,1,I,20230327.0,20230613.0,20230619,20230619,EXP,,"CO-DAIICHI SANKYO, INC.-DSE-2023-124313",DAIICHI,,57.0,YR,,F,Y,,,20230619,,CN,CO,CO,2023,Q2,Adult
226167181,22616718,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"1,5/850  mg",,,,,,,,,,,,2023,Q2,Hypoaesthesia,,2023,Q2,1,I,20230327.0,20230613.0,20230619,20230619,EXP,,"CO-DAIICHI SANKYO, INC.-DSE-2023-124313",DAIICHI,,57.0,YR,,F,Y,,,20230619,,CN,CO,CO,2023,Q2,Adult
226168001,22616800,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,25.0,MG,,,2023,Q2,Acute kidney injury,,2023,Q2,1,I,,20230616.0,20230619,20230619,EXP,,"ES-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-244484",BOEHRINGER INGELHEIM,"Ferrer Luna L, Jim?nez Guerrero C, Pax Bosch B. AND IT ONLY LOOKED LIKE GASTROENTERITIS!. 33 SEMES National Congress, 7-9Jun2023 (Madrid). 2023 Jun;1698-1698.",77.0,YR,E,F,Y,,,20230619,,HP,ES,ES,2023,Q2,Elderly
226168001,22616800,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,25.0,MG,,,2023,Q2,Diarrhoea,,2023,Q2,1,I,,20230616.0,20230619,20230619,EXP,,"ES-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-244484",BOEHRINGER INGELHEIM,"Ferrer Luna L, Jim?nez Guerrero C, Pax Bosch B. AND IT ONLY LOOKED LIKE GASTROENTERITIS!. 33 SEMES National Congress, 7-9Jun2023 (Madrid). 2023 Jun;1698-1698.",77.0,YR,E,F,Y,,,20230619,,HP,ES,ES,2023,Q2,Elderly
226171241,22617124,3,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,Form strength is 5mg/500 mg. Unit dose and frequency are not reported.,,,,,Unknown,,206111.0,,,,,2023,Q2,Knee arthroplasty,,2023,Q2,1,I,20230614.0,20230617.0,20230620,20230620,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-244653",BOEHRINGER INGELHEIM,,68.0,YR,E,F,Y,,,20230620,,CN,AU,AU,2023,Q2,Elderly
226197991,22619799,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q2,Pollakiuria,,2023,Q2,1,I,20220427.0,20230614.0,20230620,20230620,EXP,,GB-ABBVIE-5294099,ABBVIE,,62.0,YR,,M,Y,,,20230620,,HP,GB,GB,2023,Q2,Adult
226197991,22619799,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q2,Pyrexia,,2023,Q2,1,I,20220427.0,20230614.0,20230620,20230620,EXP,,GB-ABBVIE-5294099,ABBVIE,,62.0,YR,,M,Y,,,20230620,,HP,GB,GB,2023,Q2,Adult
226197991,22619799,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q2,Flank pain,,2023,Q2,1,I,20220427.0,20230614.0,20230620,20230620,EXP,,GB-ABBVIE-5294099,ABBVIE,,62.0,YR,,M,Y,,,20230620,,HP,GB,GB,2023,Q2,Adult
226202871,22620287,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Pulmonary nocardiosis,,2023,Q2,1,I,20220101.0,20230614.0,20230620,20230620,EXP,,US-AMGEN-USASP2023103140,AMGEN,Raybould; J. E.; Stamos D.B.; Barajas-ochoa A. Nocardia pseudobrasiliensis Co-infection in SARS-CoV-2 Patients. Emerging Infectious Diseases. 2023;29 (4):696-700,52.0,YR,A,M,Y,,,20230620,,MD,US,US,2023,Q2,Adult
226202871,22620287,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,COVID-19 pneumonia,,2023,Q2,1,I,20220101.0,20230614.0,20230620,20230620,EXP,,US-AMGEN-USASP2023103140,AMGEN,Raybould; J. E.; Stamos D.B.; Barajas-ochoa A. Nocardia pseudobrasiliensis Co-infection in SARS-CoV-2 Patients. Emerging Infectious Diseases. 2023;29 (4):696-700,52.0,YR,A,M,Y,,,20230620,,MD,US,US,2023,Q2,Adult
226202871,22620287,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Off label use,,2023,Q2,1,I,20220101.0,20230614.0,20230620,20230620,EXP,,US-AMGEN-USASP2023103140,AMGEN,Raybould; J. E.; Stamos D.B.; Barajas-ochoa A. Nocardia pseudobrasiliensis Co-infection in SARS-CoV-2 Patients. Emerging Infectious Diseases. 2023;29 (4):696-700,52.0,YR,A,M,Y,,,20230620,,MD,US,US,2023,Q2,Adult
226202871,22620287,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Immunosuppression,,2023,Q2,1,I,20220101.0,20230614.0,20230620,20230620,EXP,,US-AMGEN-USASP2023103140,AMGEN,Raybould; J. E.; Stamos D.B.; Barajas-ochoa A. Nocardia pseudobrasiliensis Co-infection in SARS-CoV-2 Patients. Emerging Infectious Diseases. 2023;29 (4):696-700,52.0,YR,A,M,Y,,,20230620,,MD,US,US,2023,Q2,Adult
226220001,22622000,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,ongoing,,,,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Cardiac failure,,2023,Q2,1,I,20220401.0,20230613.0,20230620,20230620,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-243875",BOEHRINGER INGELHEIM,,79.0,YR,E,F,Y,,,20230620,,MD,PL,PL,2023,Q2,Elderly
226220001,22622000,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,ongoing,,,,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Hyperkalaemia,,2023,Q2,1,I,20220401.0,20230613.0,20230620,20230620,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-243875",BOEHRINGER INGELHEIM,,79.0,YR,E,F,Y,,,20230620,,MD,PL,PL,2023,Q2,Elderly
226220001,22622000,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,ongoing,,,,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Sinus bradycardia,,2023,Q2,1,I,20220401.0,20230613.0,20230620,20230620,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-243875",BOEHRINGER INGELHEIM,,79.0,YR,E,F,Y,,,20230620,,MD,PL,PL,2023,Q2,Elderly
226220001,22622000,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,ongoing,,,,,Unknown,,204629.0,10.0,MG,,QD,2023,Q2,Blood creatinine increased,,2023,Q2,1,I,20220401.0,20230613.0,20230620,20230620,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-243875",BOEHRINGER INGELHEIM,,79.0,YR,E,F,Y,,,20230620,,MD,PL,PL,2023,Q2,Elderly
226220363,22622036,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,Dose 25/5mg,,,U,,Unknown,,206073.0,,,,QD,2023,Q2,Body height decreased,,2023,Q2,3,F,20220301.0,20230622.0,20230620,20230626,EXP,,"MX-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-244846",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,65.0,KG,20230626,,CN,MX,MX,2023,Q2,Elderly
226220363,22622036,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,Dose 25/5mg,,,U,,Unknown,,206073.0,,,,QD,2023,Q2,Blood glucose abnormal,,2023,Q2,3,F,20220301.0,20230622.0,20230620,20230626,EXP,,"MX-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-244846",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,65.0,KG,20230626,,CN,MX,MX,2023,Q2,Elderly
226220363,22622036,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,Dose 25/5mg,,,U,,Unknown,,206073.0,,,,QD,2023,Q2,Diabetes mellitus inadequate control,,2023,Q2,3,F,20220301.0,20230622.0,20230620,20230626,EXP,,"MX-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-244846",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,65.0,KG,20230626,,CN,MX,MX,2023,Q2,Elderly
226220363,22622036,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,Dose 25/5mg,,,U,,Unknown,,206073.0,,,,QD,2023,Q2,Pulmonary arterial pressure increased,,2023,Q2,3,F,20220301.0,20230622.0,20230620,20230626,EXP,,"MX-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-244846",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,65.0,KG,20230626,,CN,MX,MX,2023,Q2,Elderly
226220363,22622036,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,Dose 25/5mg,,,U,,Unknown,,206073.0,,,,QD,2023,Q2,Arthralgia,,2023,Q2,3,F,20220301.0,20230622.0,20230620,20230626,EXP,,"MX-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-244846",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,65.0,KG,20230626,,CN,MX,MX,2023,Q2,Elderly
226220363,22622036,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,Dose 25/5mg,,,U,,Unknown,,206073.0,,,,QD,2023,Q2,Pain,,2023,Q2,3,F,20220301.0,20230622.0,20230620,20230626,EXP,,"MX-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-244846",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,65.0,KG,20230626,,CN,MX,MX,2023,Q2,Elderly
226220363,22622036,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,Dose 25/5mg,,,U,,Unknown,,206073.0,,,,QD,2023,Q2,General physical health deterioration,,2023,Q2,3,F,20220301.0,20230622.0,20230620,20230626,EXP,,"MX-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-244846",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,65.0,KG,20230626,,CN,MX,MX,2023,Q2,Elderly
226220701,22622070,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q2,Hyperkalaemia,,2023,Q2,1,I,,20230616.0,20230620,20230620,EXP,,"ES-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-244444",BOEHRINGER INGELHEIM,"Soto Telles A, Prudencio Rodr?guez A, Hern?ndez Gonz?lez C, Higueras S?nchez C, Hijar Jim?nez R, Guerrero Deleg J. MY MOTHER DOES NOT EAT, DOCTOR. 2023 Jun;777-777.",81.0,YR,E,F,Y,,,20230620,,HP,ES,ES,2023,Q2,Elderly
226220701,22622070,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q2,Lactic acidosis,,2023,Q2,1,I,,20230616.0,20230620,20230620,EXP,,"ES-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-244444",BOEHRINGER INGELHEIM,"Soto Telles A, Prudencio Rodr?guez A, Hern?ndez Gonz?lez C, Higueras S?nchez C, Hijar Jim?nez R, Guerrero Deleg J. MY MOTHER DOES NOT EAT, DOCTOR. 2023 Jun;777-777.",81.0,YR,E,F,Y,,,20230620,,HP,ES,ES,2023,Q2,Elderly
226220701,22622070,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q2,Renal failure,,2023,Q2,1,I,,20230616.0,20230620,20230620,EXP,,"ES-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-244444",BOEHRINGER INGELHEIM,"Soto Telles A, Prudencio Rodr?guez A, Hern?ndez Gonz?lez C, Higueras S?nchez C, Hijar Jim?nez R, Guerrero Deleg J. MY MOTHER DOES NOT EAT, DOCTOR. 2023 Jun;777-777.",81.0,YR,E,F,Y,,,20230620,,HP,ES,ES,2023,Q2,Elderly
226221841,22622184,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Diarrhoea,,2023,Q2,1,I,20230525.0,20230615.0,20230620,20230620,EXP,,ES-PFIZER INC-202300223130,PFIZER,,65.0,YR,,M,Y,80.4,KG,20230620,,MD,ES,ES,2023,Q2,Elderly
226221841,22622184,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Renal impairment,,2023,Q2,1,I,20230525.0,20230615.0,20230620,20230620,EXP,,ES-PFIZER INC-202300223130,PFIZER,,65.0,YR,,M,Y,80.4,KG,20230620,,MD,ES,ES,2023,Q2,Elderly
226221841,22622184,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Odynophagia,,2023,Q2,1,I,20230525.0,20230615.0,20230620,20230620,EXP,,ES-PFIZER INC-202300223130,PFIZER,,65.0,YR,,M,Y,80.4,KG,20230620,,MD,ES,ES,2023,Q2,Elderly
226221841,22622184,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q2,Asthenia,,2023,Q2,1,I,20230525.0,20230615.0,20230620,20230620,EXP,,ES-PFIZER INC-202300223130,PFIZER,,65.0,YR,,M,Y,80.4,KG,20230620,,MD,ES,ES,2023,Q2,Elderly
226227661,22622766,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,,,2023,Q2,Osteitis deformans,,2023,Q2,1,I,,20230614.0,20230621,20230621,EXP,,CA-JNJFOC-20230639282,JOHNSON AND JOHNSON,,69.0,YR,E,M,Y,91.0,KG,20230621,,HP,CA,CA,2023,Q2,Elderly
226227661,22622766,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,,,2023,Q2,Malaise,,2023,Q2,1,I,,20230614.0,20230621,20230621,EXP,,CA-JNJFOC-20230639282,JOHNSON AND JOHNSON,,69.0,YR,E,M,Y,91.0,KG,20230621,,HP,CA,CA,2023,Q2,Elderly
226227661,22622766,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,,,2023,Q2,Incorrect dose administered,,2023,Q2,1,I,,20230614.0,20230621,20230621,EXP,,CA-JNJFOC-20230639282,JOHNSON AND JOHNSON,,69.0,YR,E,M,Y,91.0,KG,20230621,,HP,CA,CA,2023,Q2,Elderly
226227661,22622766,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,,,2023,Q2,Drug level below therapeutic,,2023,Q2,1,I,,20230614.0,20230621,20230621,EXP,,CA-JNJFOC-20230639282,JOHNSON AND JOHNSON,,69.0,YR,E,M,Y,91.0,KG,20230621,,HP,CA,CA,2023,Q2,Elderly
226227661,22622766,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,,,2023,Q2,Blood pressure increased,,2023,Q2,1,I,,20230614.0,20230621,20230621,EXP,,CA-JNJFOC-20230639282,JOHNSON AND JOHNSON,,69.0,YR,E,M,Y,91.0,KG,20230621,,HP,CA,CA,2023,Q2,Elderly
226227661,22622766,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,,,2023,Q2,Condition aggravated,,2023,Q2,1,I,,20230614.0,20230621,20230621,EXP,,CA-JNJFOC-20230639282,JOHNSON AND JOHNSON,,69.0,YR,E,M,Y,91.0,KG,20230621,,HP,CA,CA,2023,Q2,Elderly
226227661,22622766,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,,,2023,Q2,Off label use,,2023,Q2,1,I,,20230614.0,20230621,20230621,EXP,,CA-JNJFOC-20230639282,JOHNSON AND JOHNSON,,69.0,YR,E,M,Y,91.0,KG,20230621,,HP,CA,CA,2023,Q2,Elderly
226235361,22623536,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q2,Penile swelling,,2023,Q2,1,I,20230401.0,20230620.0,20230621,20230621,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-244948",BOEHRINGER INGELHEIM,,56.0,YR,A,M,Y,,,20230621,,HP,SG,SG,2023,Q2,Adult
226257371,22625737,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Product use in unapproved indication,,2023,Q2,1,I,20220701.0,20230613.0,20230621,20230621,EXP,,US-009507513-2306USA007608,MERCK,"Stamos DB, Barajas-Ochoa A, Raybould JE.. Nocardia pseudobrasiliensis Co-infection in SARS-CoV-2 Patients. Emerging Infectious Diseases. 2023;29(4):696-700",52.0,YR,,M,Y,,,20230621,,HP,US,US,2023,Q2,Adult
226257371,22625737,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Pathogen resistance,,2023,Q2,1,I,20220701.0,20230613.0,20230621,20230621,EXP,,US-009507513-2306USA007608,MERCK,"Stamos DB, Barajas-Ochoa A, Raybould JE.. Nocardia pseudobrasiliensis Co-infection in SARS-CoV-2 Patients. Emerging Infectious Diseases. 2023;29(4):696-700",52.0,YR,,M,Y,,,20230621,,HP,US,US,2023,Q2,Adult
226262611,22626261,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2023,Q2,Medication error,,2023,Q2,1,I,20230521.0,20230616.0,20230621,20230621,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-244725",BOEHRINGER INGELHEIM,,67.0,YR,E,M,Y,90.0,KG,20230621,,PH,GB,GB,2023,Q2,Elderly
226262611,22626261,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2023,Q2,Euglycaemic diabetic ketoacidosis,,2023,Q2,1,I,20230521.0,20230616.0,20230621,20230621,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-244725",BOEHRINGER INGELHEIM,,67.0,YR,E,M,Y,90.0,KG,20230621,,PH,GB,GB,2023,Q2,Elderly
226271131,22627113,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",200.0,MG,Y,,,,,25.0,MG,,QD,2023,Q2,Vomiting,,2023,Q2,1,I,20230401.0,20230610.0,20230622,20230622,EXP,,CO-NOVOPROD-1078024,NOVO NORDISK,,59.0,YR,,F,Y,63.0,KG,20230622,,CN,CO,CO,2023,Q2,Adult
226271131,22627113,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",200.0,MG,Y,,,,,25.0,MG,,QD,2023,Q2,Nausea,,2023,Q2,1,I,20230401.0,20230610.0,20230622,20230622,EXP,,CO-NOVOPROD-1078024,NOVO NORDISK,,59.0,YR,,F,Y,63.0,KG,20230622,,CN,CO,CO,2023,Q2,Adult
226271131,22627113,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",200.0,MG,Y,,,,,25.0,MG,,QD,2023,Q2,Abdominal pain upper,,2023,Q2,1,I,20230401.0,20230610.0,20230622,20230622,EXP,,CO-NOVOPROD-1078024,NOVO NORDISK,,59.0,YR,,F,Y,63.0,KG,20230622,,CN,CO,CO,2023,Q2,Adult
226271131,22627113,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",200.0,MG,Y,,,,,25.0,MG,,QD,2023,Q2,Dizziness,,2023,Q2,1,I,20230401.0,20230610.0,20230622,20230622,EXP,,CO-NOVOPROD-1078024,NOVO NORDISK,,59.0,YR,,F,Y,63.0,KG,20230622,,CN,CO,CO,2023,Q2,Adult
226271131,22627113,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",200.0,MG,Y,,,,,25.0,MG,,QD,2023,Q2,Dry skin,,2023,Q2,1,I,20230401.0,20230610.0,20230622,20230622,EXP,,CO-NOVOPROD-1078024,NOVO NORDISK,,59.0,YR,,F,Y,63.0,KG,20230622,,CN,CO,CO,2023,Q2,Adult
226271131,22627113,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",200.0,MG,Y,,,,,25.0,MG,,QD,2023,Q2,Weight decreased,,2023,Q2,1,I,20230401.0,20230610.0,20230622,20230622,EXP,,CO-NOVOPROD-1078024,NOVO NORDISK,,59.0,YR,,F,Y,63.0,KG,20230622,,CN,CO,CO,2023,Q2,Adult
226306121,22630612,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,2898.95833,MG,Y,U,Unknown,,204629.0,25.0,MG,Tablet,QD,2023,Q2,Chest pain,,2023,Q2,1,I,20230612.0,20230622.0,20230622,20230622,EXP,GB-MHRA-TPP7943328C8192302YC1687177389939,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-245617",BOEHRINGER INGELHEIM,,48.0,YR,A,M,Y,92.0,KG,20230622,,HP,GB,GB,2023,Q2,Adult
226306121,22630612,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,2898.95833,MG,Y,U,Unknown,,204629.0,25.0,MG,Tablet,QD,2023,Q2,Palpitations,,2023,Q2,1,I,20230612.0,20230622.0,20230622,20230622,EXP,GB-MHRA-TPP7943328C8192302YC1687177389939,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-245617",BOEHRINGER INGELHEIM,,48.0,YR,A,M,Y,92.0,KG,20230622,,HP,GB,GB,2023,Q2,Adult
226314731,22631473,25,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Mitral valve incompetence,,2023,Q2,1,I,20220701.0,20230612.0,20230623,20230623,EXP,,NVSC2023DE138851,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230620,,MD,DE,DE,2023,Q2,Elderly
226314731,22631473,25,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Cardiac failure,,2023,Q2,1,I,20220701.0,20230612.0,20230623,20230623,EXP,,NVSC2023DE138851,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230620,,MD,DE,DE,2023,Q2,Elderly
226314731,22631473,25,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Ventricular extrasystoles,,2023,Q2,1,I,20220701.0,20230612.0,20230623,20230623,EXP,,NVSC2023DE138851,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230620,,MD,DE,DE,2023,Q2,Elderly
226314731,22631473,25,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Peripheral coldness,,2023,Q2,1,I,20220701.0,20230612.0,20230623,20230623,EXP,,NVSC2023DE138851,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230620,,MD,DE,DE,2023,Q2,Elderly
226314731,22631473,25,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Cough,,2023,Q2,1,I,20220701.0,20230612.0,20230623,20230623,EXP,,NVSC2023DE138851,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230620,,MD,DE,DE,2023,Q2,Elderly
226314731,22631473,25,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Product use in unapproved indication,,2023,Q2,1,I,20220701.0,20230612.0,20230623,20230623,EXP,,NVSC2023DE138851,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230620,,MD,DE,DE,2023,Q2,Elderly
226314731,22631473,25,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Ejection fraction decreased,,2023,Q2,1,I,20220701.0,20230612.0,20230623,20230623,EXP,,NVSC2023DE138851,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230620,,MD,DE,DE,2023,Q2,Elderly
226314731,22631473,25,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Hypotension,,2023,Q2,1,I,20220701.0,20230612.0,20230623,20230623,EXP,,NVSC2023DE138851,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230620,,MD,DE,DE,2023,Q2,Elderly
226314731,22631473,25,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Left ventricular dysfunction,,2023,Q2,1,I,20220701.0,20230612.0,20230623,20230623,EXP,,NVSC2023DE138851,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230620,,MD,DE,DE,2023,Q2,Elderly
226314731,22631473,25,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Ventricular tachycardia,,2023,Q2,1,I,20220701.0,20230612.0,20230623,20230623,EXP,,NVSC2023DE138851,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230620,,MD,DE,DE,2023,Q2,Elderly
226314731,22631473,25,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Cardiovascular disorder,,2023,Q2,1,I,20220701.0,20230612.0,20230623,20230623,EXP,,NVSC2023DE138851,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230620,,MD,DE,DE,2023,Q2,Elderly
226314731,22631473,25,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Coronary artery disease,,2023,Q2,1,I,20220701.0,20230612.0,20230623,20230623,EXP,,NVSC2023DE138851,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230620,,MD,DE,DE,2023,Q2,Elderly
226314731,22631473,25,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Feeling cold,,2023,Q2,1,I,20220701.0,20230612.0,20230623,20230623,EXP,,NVSC2023DE138851,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230620,,MD,DE,DE,2023,Q2,Elderly
226314731,22631473,25,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Atrial fibrillation,,2023,Q2,1,I,20220701.0,20230612.0,20230623,20230623,EXP,,NVSC2023DE138851,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230620,,MD,DE,DE,2023,Q2,Elderly
226314731,22631473,26,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Mitral valve incompetence,,2023,Q2,1,I,20220701.0,20230612.0,20230623,20230623,EXP,,NVSC2023DE138851,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230620,,MD,DE,DE,2023,Q2,Elderly
226314731,22631473,26,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Cardiac failure,,2023,Q2,1,I,20220701.0,20230612.0,20230623,20230623,EXP,,NVSC2023DE138851,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230620,,MD,DE,DE,2023,Q2,Elderly
226314731,22631473,26,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Ventricular extrasystoles,,2023,Q2,1,I,20220701.0,20230612.0,20230623,20230623,EXP,,NVSC2023DE138851,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230620,,MD,DE,DE,2023,Q2,Elderly
226314731,22631473,26,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Peripheral coldness,,2023,Q2,1,I,20220701.0,20230612.0,20230623,20230623,EXP,,NVSC2023DE138851,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230620,,MD,DE,DE,2023,Q2,Elderly
226314731,22631473,26,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Cough,,2023,Q2,1,I,20220701.0,20230612.0,20230623,20230623,EXP,,NVSC2023DE138851,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230620,,MD,DE,DE,2023,Q2,Elderly
226314731,22631473,26,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Product use in unapproved indication,,2023,Q2,1,I,20220701.0,20230612.0,20230623,20230623,EXP,,NVSC2023DE138851,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230620,,MD,DE,DE,2023,Q2,Elderly
226314731,22631473,26,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Ejection fraction decreased,,2023,Q2,1,I,20220701.0,20230612.0,20230623,20230623,EXP,,NVSC2023DE138851,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230620,,MD,DE,DE,2023,Q2,Elderly
226314731,22631473,26,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Hypotension,,2023,Q2,1,I,20220701.0,20230612.0,20230623,20230623,EXP,,NVSC2023DE138851,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230620,,MD,DE,DE,2023,Q2,Elderly
226314731,22631473,26,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Left ventricular dysfunction,,2023,Q2,1,I,20220701.0,20230612.0,20230623,20230623,EXP,,NVSC2023DE138851,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230620,,MD,DE,DE,2023,Q2,Elderly
226314731,22631473,26,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Ventricular tachycardia,,2023,Q2,1,I,20220701.0,20230612.0,20230623,20230623,EXP,,NVSC2023DE138851,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230620,,MD,DE,DE,2023,Q2,Elderly
226314731,22631473,26,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Cardiovascular disorder,,2023,Q2,1,I,20220701.0,20230612.0,20230623,20230623,EXP,,NVSC2023DE138851,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230620,,MD,DE,DE,2023,Q2,Elderly
226314731,22631473,26,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Coronary artery disease,,2023,Q2,1,I,20220701.0,20230612.0,20230623,20230623,EXP,,NVSC2023DE138851,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230620,,MD,DE,DE,2023,Q2,Elderly
226314731,22631473,26,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Feeling cold,,2023,Q2,1,I,20220701.0,20230612.0,20230623,20230623,EXP,,NVSC2023DE138851,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230620,,MD,DE,DE,2023,Q2,Elderly
226314731,22631473,26,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Atrial fibrillation,,2023,Q2,1,I,20220701.0,20230612.0,20230623,20230623,EXP,,NVSC2023DE138851,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230620,,MD,DE,DE,2023,Q2,Elderly
226314731,22631473,27,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Mitral valve incompetence,,2023,Q2,1,I,20220701.0,20230612.0,20230623,20230623,EXP,,NVSC2023DE138851,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230620,,MD,DE,DE,2023,Q2,Elderly
226314731,22631473,27,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Cardiac failure,,2023,Q2,1,I,20220701.0,20230612.0,20230623,20230623,EXP,,NVSC2023DE138851,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230620,,MD,DE,DE,2023,Q2,Elderly
226314731,22631473,27,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Ventricular extrasystoles,,2023,Q2,1,I,20220701.0,20230612.0,20230623,20230623,EXP,,NVSC2023DE138851,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230620,,MD,DE,DE,2023,Q2,Elderly
226314731,22631473,27,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Peripheral coldness,,2023,Q2,1,I,20220701.0,20230612.0,20230623,20230623,EXP,,NVSC2023DE138851,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230620,,MD,DE,DE,2023,Q2,Elderly
226314731,22631473,27,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Cough,,2023,Q2,1,I,20220701.0,20230612.0,20230623,20230623,EXP,,NVSC2023DE138851,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230620,,MD,DE,DE,2023,Q2,Elderly
226314731,22631473,27,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Product use in unapproved indication,,2023,Q2,1,I,20220701.0,20230612.0,20230623,20230623,EXP,,NVSC2023DE138851,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230620,,MD,DE,DE,2023,Q2,Elderly
226314731,22631473,27,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Ejection fraction decreased,,2023,Q2,1,I,20220701.0,20230612.0,20230623,20230623,EXP,,NVSC2023DE138851,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230620,,MD,DE,DE,2023,Q2,Elderly
226314731,22631473,27,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Hypotension,,2023,Q2,1,I,20220701.0,20230612.0,20230623,20230623,EXP,,NVSC2023DE138851,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230620,,MD,DE,DE,2023,Q2,Elderly
226314731,22631473,27,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Left ventricular dysfunction,,2023,Q2,1,I,20220701.0,20230612.0,20230623,20230623,EXP,,NVSC2023DE138851,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230620,,MD,DE,DE,2023,Q2,Elderly
226314731,22631473,27,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Ventricular tachycardia,,2023,Q2,1,I,20220701.0,20230612.0,20230623,20230623,EXP,,NVSC2023DE138851,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230620,,MD,DE,DE,2023,Q2,Elderly
226314731,22631473,27,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Cardiovascular disorder,,2023,Q2,1,I,20220701.0,20230612.0,20230623,20230623,EXP,,NVSC2023DE138851,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230620,,MD,DE,DE,2023,Q2,Elderly
226314731,22631473,27,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Coronary artery disease,,2023,Q2,1,I,20220701.0,20230612.0,20230623,20230623,EXP,,NVSC2023DE138851,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230620,,MD,DE,DE,2023,Q2,Elderly
226314731,22631473,27,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Feeling cold,,2023,Q2,1,I,20220701.0,20230612.0,20230623,20230623,EXP,,NVSC2023DE138851,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230620,,MD,DE,DE,2023,Q2,Elderly
226314731,22631473,27,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Atrial fibrillation,,2023,Q2,1,I,20220701.0,20230612.0,20230623,20230623,EXP,,NVSC2023DE138851,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230620,,MD,DE,DE,2023,Q2,Elderly
226322351,22632235,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mmg, ad",,,U,,,,,,,,,2023,Q2,Blood glucose increased,,2023,Q2,1,I,20230528.0,20230614.0,20230623,20230623,EXP,,NVSC2023CN138519,NOVARTIS,,67.0,YR,,F,Y,70.0,KG,20230622,,HP,CN,CN,2023,Q2,Elderly
226322351,22632235,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mmg, ad",,,U,,,,,,,,,2023,Q2,Renal injury,,2023,Q2,1,I,20230528.0,20230614.0,20230623,20230623,EXP,,NVSC2023CN138519,NOVARTIS,,67.0,YR,,F,Y,70.0,KG,20230622,,HP,CN,CN,2023,Q2,Elderly
226322351,22632235,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mmg, ad",,,U,,,,,,,,,2023,Q2,Inappropriate schedule of product administration,,2023,Q2,1,I,20230528.0,20230614.0,20230623,20230623,EXP,,NVSC2023CN138519,NOVARTIS,,67.0,YR,,F,Y,70.0,KG,20230622,,HP,CN,CN,2023,Q2,Elderly
226326091,22632609,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 tab qd EACH MORNING,,,,,Unknown,,,,,,,2023,Q2,Taste disorder,,2023,Q2,1,I,20230607.0,20230613.0,20230623,20230623,EXP,GB-MHRA-TPP8498632C9742646YC1686307844041,GB-NOVOPROD-1080543,NOVO NORDISK,,61.0,YR,,F,Y,100.0,KG,20230623,,HP,GB,GB,2023,Q2,Adult
226326091,22632609,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 tab qd EACH MORNING,,,,,Unknown,,,,,,,2023,Q2,Flatulence,,2023,Q2,1,I,20230607.0,20230613.0,20230623,20230623,EXP,GB-MHRA-TPP8498632C9742646YC1686307844041,GB-NOVOPROD-1080543,NOVO NORDISK,,61.0,YR,,F,Y,100.0,KG,20230623,,HP,GB,GB,2023,Q2,Adult
226328561,22632856,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD (1x1 to be initiated)",,,,,,,,10.0,MG,,QD,2023,Q2,Cardiac failure,,2023,Q2,1,I,,20230618.0,20230623,20230623,EXP,,NVSC2023HR141736,NOVARTIS,,68.0,YR,,M,Y,91.0,KG,20230623,,MD,HR,HR,2023,Q2,Elderly
226328561,22632856,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD (1x1 to be initiated)",,,,,,,,10.0,MG,,QD,2023,Q2,Disease progression,,2023,Q2,1,I,,20230618.0,20230623,20230623,EXP,,NVSC2023HR141736,NOVARTIS,,68.0,YR,,M,Y,91.0,KG,20230623,,MD,HR,HR,2023,Q2,Elderly
226337771,22633777,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Take with a full glass of water,,,,,,,,,,Tablet,QD,2023,Q2,Brain fog,,2023,Q2,1,I,,20230614.0,20230623,20230623,EXP,GB-MHRA-ADR 27972728,GB-Accord-362952,ACCORD,,44.0,YR,A,F,Y,99.0,KG,20230623,,MD,GB,GB,2023,Q2,Adult
226337771,22633777,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Take with a full glass of water,,,,,,,,,,Tablet,QD,2023,Q2,Disorientation,,2023,Q2,1,I,,20230614.0,20230623,20230623,EXP,GB-MHRA-ADR 27972728,GB-Accord-362952,ACCORD,,44.0,YR,A,F,Y,99.0,KG,20230623,,MD,GB,GB,2023,Q2,Adult
226342591,22634259,4,C,empagliflozin 10 mg PO daily,,2,,,,,,,,,,,,,,2023,Q2,Blood pressure systolic increased,,2023,Q2,1,I,20230611.0,,20230622,20230622,DIR,664450,,FDA-CTU,,87.0,YR,,F,N,64.5,KG,20230622,N,PH,US,,2023,Q2,Elderly
226342591,22634259,4,C,empagliflozin 10 mg PO daily,,2,,,,,,,,,,,,,,2023,Q2,Cerebellar haemorrhage,,2023,Q2,1,I,20230611.0,,20230622,20230622,DIR,664450,,FDA-CTU,,87.0,YR,,F,N,64.5,KG,20230622,N,PH,US,,2023,Q2,Elderly
226342591,22634259,4,C,empagliflozin 10 mg PO daily,,2,,,,,,,,,,,,,,2023,Q2,Anticoagulation drug level,,2023,Q2,1,I,20230611.0,,20230622,20230622,DIR,664450,,FDA-CTU,,87.0,YR,,F,N,64.5,KG,20230622,N,PH,US,,2023,Q2,Elderly
226342911,22634291,7,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"1 dosage form, Once a Day",,,D,,,,,,,,QD,2023,Q2,Dyspnoea,,2023,Q2,1,I,20230401.0,20230613.0,20230623,20230623,EXP,,FR-AUROBINDO-AUR-APL-2023-043114,AUROBINDO,,62.0,YR,,F,Y,47.0,KG,20230623,,MD,FR,FR,2023,Q2,Adult
226342911,22634291,7,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"1 dosage form, Once a Day",,,D,,,,,,,,QD,2023,Q2,Cardio-respiratory arrest,,2023,Q2,1,I,20230401.0,20230613.0,20230623,20230623,EXP,,FR-AUROBINDO-AUR-APL-2023-043114,AUROBINDO,,62.0,YR,,F,Y,47.0,KG,20230623,,MD,FR,FR,2023,Q2,Adult
226343081,22634308,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Odynophagia,,2023,Q2,1,I,20230525.0,20230613.0,20230623,20230623,EXP,,ES-AUROBINDO-AUR-APL-2023-043135,AUROBINDO,,65.0,YR,,M,Y,80.4,KG,20230623,,MD,ES,ES,2023,Q2,Elderly
226343081,22634308,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Asthenia,,2023,Q2,1,I,20230525.0,20230613.0,20230623,20230623,EXP,,ES-AUROBINDO-AUR-APL-2023-043135,AUROBINDO,,65.0,YR,,M,Y,80.4,KG,20230623,,MD,ES,ES,2023,Q2,Elderly
226343081,22634308,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Diarrhoea,,2023,Q2,1,I,20230525.0,20230613.0,20230623,20230623,EXP,,ES-AUROBINDO-AUR-APL-2023-043135,AUROBINDO,,65.0,YR,,M,Y,80.4,KG,20230623,,MD,ES,ES,2023,Q2,Elderly
226343081,22634308,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Renal impairment,,2023,Q2,1,I,20230525.0,20230613.0,20230623,20230623,EXP,,ES-AUROBINDO-AUR-APL-2023-043135,AUROBINDO,,65.0,YR,,M,Y,80.4,KG,20230623,,MD,ES,ES,2023,Q2,Elderly
226345641,22634564,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,,,,,,2023,Q2,Diarrhoea,,2023,Q2,1,I,,20230613.0,20230623,20230623,EXP,,GR-EMD Serono-2023455936,EMD SERONO INC,,70.0,YR,E,F,Y,,,20230623,,HP,GR,GR,2023,Q2,Elderly
226345641,22634564,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,,,,,,2023,Q2,Haemodynamic instability,,2023,Q2,1,I,,20230613.0,20230623,20230623,EXP,,GR-EMD Serono-2023455936,EMD SERONO INC,,70.0,YR,E,F,Y,,,20230623,,HP,GR,GR,2023,Q2,Elderly
226345641,22634564,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,,,,,,2023,Q2,Acute kidney injury,,2023,Q2,1,I,,20230613.0,20230623,20230623,EXP,,GR-EMD Serono-2023455936,EMD SERONO INC,,70.0,YR,E,F,Y,,,20230623,,HP,GR,GR,2023,Q2,Elderly
226345641,22634564,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,,,,,,2023,Q2,Euglycaemic diabetic ketoacidosis,,2023,Q2,1,I,,20230613.0,20230623,20230623,EXP,,GR-EMD Serono-2023455936,EMD SERONO INC,,70.0,YR,E,F,Y,,,20230623,,HP,GR,GR,2023,Q2,Elderly
226363381,22636338,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, daily",,,Y,U,,,,25.0,MG,,QD,2023,Q2,Euglycaemic diabetic ketoacidosis,,2023,Q2,1,I,20230613.0,20230620.0,20230623,20230623,EXP,,GB-ELI_LILLY_AND_COMPANY-GB202306012510,ELI LILLY AND CO,,72.0,YR,,F,Y,,,20230623,,CN,GB,GB,2023,Q2,Elderly
226367891,22636789,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q2,Hepatic cirrhosis,,2023,Q2,1,I,,20230614.0,20230626,20230626,EXP,CA-MHPD-E2B_06222171,CA-Accord-362817,ACCORD,,66.0,YR,E,M,Y,,,20230624,,HP,CA,CA,2023,Q2,Elderly
226367891,22636789,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q2,Off label use,,2023,Q2,1,I,,20230614.0,20230626,20230626,EXP,CA-MHPD-E2B_06222171,CA-Accord-362817,ACCORD,,66.0,YR,E,M,Y,,,20230624,,HP,CA,CA,2023,Q2,Elderly
226367891,22636789,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q2,Granulomatosis with polyangiitis,,2023,Q2,1,I,,20230614.0,20230626,20230626,EXP,CA-MHPD-E2B_06222171,CA-Accord-362817,ACCORD,,66.0,YR,E,M,Y,,,20230624,,HP,CA,CA,2023,Q2,Elderly
226367891,22636789,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q2,Condition aggravated,,2023,Q2,1,I,,20230614.0,20230626,20230626,EXP,CA-MHPD-E2B_06222171,CA-Accord-362817,ACCORD,,66.0,YR,E,M,Y,,,20230624,,HP,CA,CA,2023,Q2,Elderly
226387481,22638748,2,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,2  dose unit(s) d,,,U,,,,,,,,,2023,Q2,Medication error,,2023,Q2,1,I,,20230612.0,20230626,20230626,EXP,,NZ-NOVOPROD-1078520,NOVO NORDISK,,57.0,YR,,M,Y,,,20230626,,PH,NZ,NZ,2023,Q2,Adult
226387481,22638748,2,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,2  dose unit(s) d,,,U,,,,,,,,,2023,Q2,Diabetic ketoacidosis,,2023,Q2,1,I,,20230612.0,20230626,20230626,EXP,,NZ-NOVOPROD-1078520,NOVO NORDISK,,57.0,YR,,M,Y,,,20230626,,PH,NZ,NZ,2023,Q2,Adult
226393191,22639319,2,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,25/2000mg,,,,,,,,,,,QD,2023,Q2,Deep vein thrombosis,,2023,Q2,1,I,20210826.0,20230621.0,20230626,20230626,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-245758",BOEHRINGER INGELHEIM,,68.0,YR,E,M,Y,,,20230626,,CN,US,US,2023,Q2,Elderly
226393191,22639319,2,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,25/2000mg,,,,,,,,,,,QD,2023,Q2,Aphasia,,2023,Q2,1,I,20210826.0,20230621.0,20230626,20230626,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-245758",BOEHRINGER INGELHEIM,,68.0,YR,E,M,Y,,,20230626,,CN,US,US,2023,Q2,Elderly
226393191,22639319,2,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,25/2000mg,,,,,,,,,,,QD,2023,Q2,Disorientation,,2023,Q2,1,I,20210826.0,20230621.0,20230626,20230626,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-245758",BOEHRINGER INGELHEIM,,68.0,YR,E,M,Y,,,20230626,,CN,US,US,2023,Q2,Elderly
226393191,22639319,2,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,25/2000mg,,,,,,,,,,,QD,2023,Q2,Dysarthria,,2023,Q2,1,I,20210826.0,20230621.0,20230626,20230626,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-245758",BOEHRINGER INGELHEIM,,68.0,YR,E,M,Y,,,20230626,,CN,US,US,2023,Q2,Elderly
226395981,22639598,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, QD (morning)",,,U,,,,,,,Tablet,QD,2023,Q2,Dry eye,,2023,Q2,1,I,20230509.0,20230621.0,20230626,20230626,EXP,GB-MHRA-TPP2502395C3473839YC1687166456328,NVSC2023GB142647,NOVARTIS,,79.0,YR,,F,Y,56.0,KG,20230626,,PH,GB,GB,2023,Q2,Elderly
226426931,22642693,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,UNK,,,U,,,,,,,,,2023,Q2,Poor venous access,,2023,Q2,1,I,,20230615.0,20230627,20230627,EXP,,GB-AUROBINDO-AUR-APL-2023-044067,AUROBINDO,,78.0,YR,,F,Y,,,20230627,,CN,GB,GB,2023,Q2,Elderly
226426931,22642693,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,UNK,,,U,,,,,,,,,2023,Q2,Peripheral swelling,,2023,Q2,1,I,,20230615.0,20230627,20230627,EXP,,GB-AUROBINDO-AUR-APL-2023-044067,AUROBINDO,,78.0,YR,,F,Y,,,20230627,,CN,GB,GB,2023,Q2,Elderly
226426931,22642693,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,UNK,,,U,,,,,,,,,2023,Q2,Diastolic dysfunction,,2023,Q2,1,I,,20230615.0,20230627,20230627,EXP,,GB-AUROBINDO-AUR-APL-2023-044067,AUROBINDO,,78.0,YR,,F,Y,,,20230627,,CN,GB,GB,2023,Q2,Elderly
226426931,22642693,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,UNK,,,U,,,,,,,,,2023,Q2,Inappropriate schedule of product administration,,2023,Q2,1,I,,20230615.0,20230627,20230627,EXP,,GB-AUROBINDO-AUR-APL-2023-044067,AUROBINDO,,78.0,YR,,F,Y,,,20230627,,CN,GB,GB,2023,Q2,Elderly
226426931,22642693,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,UNK,,,U,,,,,,,,,2023,Q2,Fall,,2023,Q2,1,I,,20230615.0,20230627,20230627,EXP,,GB-AUROBINDO-AUR-APL-2023-044067,AUROBINDO,,78.0,YR,,F,Y,,,20230627,,CN,GB,GB,2023,Q2,Elderly
226426931,22642693,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,UNK,,,U,,,,,,,,,2023,Q2,Tibia fracture,,2023,Q2,1,I,,20230615.0,20230627,20230627,EXP,,GB-AUROBINDO-AUR-APL-2023-044067,AUROBINDO,,78.0,YR,,F,Y,,,20230627,,CN,GB,GB,2023,Q2,Elderly
226426931,22642693,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,UNK,,,U,,,,,,,,,2023,Q2,Dyspnoea exertional,,2023,Q2,1,I,,20230615.0,20230627,20230627,EXP,,GB-AUROBINDO-AUR-APL-2023-044067,AUROBINDO,,78.0,YR,,F,Y,,,20230627,,CN,GB,GB,2023,Q2,Elderly
226426931,22642693,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,UNK,,,U,,,,,,,,,2023,Q2,Pollakiuria,,2023,Q2,1,I,,20230615.0,20230627,20230627,EXP,,GB-AUROBINDO-AUR-APL-2023-044067,AUROBINDO,,78.0,YR,,F,Y,,,20230627,,CN,GB,GB,2023,Q2,Elderly
226426931,22642693,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,UNK,,,U,,,,,,,,,2023,Q2,Cough,,2023,Q2,1,I,,20230615.0,20230627,20230627,EXP,,GB-AUROBINDO-AUR-APL-2023-044067,AUROBINDO,,78.0,YR,,F,Y,,,20230627,,CN,GB,GB,2023,Q2,Elderly
226426931,22642693,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,UNK,,,U,,,,,,,,,2023,Q2,Venous pressure increased,,2023,Q2,1,I,,20230615.0,20230627,20230627,EXP,,GB-AUROBINDO-AUR-APL-2023-044067,AUROBINDO,,78.0,YR,,F,Y,,,20230627,,CN,GB,GB,2023,Q2,Elderly
226426931,22642693,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,UNK,,,U,,,,,,,,,2023,Q2,Product distribution issue,,2023,Q2,1,I,,20230615.0,20230627,20230627,EXP,,GB-AUROBINDO-AUR-APL-2023-044067,AUROBINDO,,78.0,YR,,F,Y,,,20230627,,CN,GB,GB,2023,Q2,Elderly
226426931,22642693,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,UNK,,,U,,,,,,,,,2023,Q2,Pain in extremity,,2023,Q2,1,I,,20230615.0,20230627,20230627,EXP,,GB-AUROBINDO-AUR-APL-2023-044067,AUROBINDO,,78.0,YR,,F,Y,,,20230627,,CN,GB,GB,2023,Q2,Elderly
226426931,22642693,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,UNK,,,U,,,,,,,,,2023,Q2,Device dislocation,,2023,Q2,1,I,,20230615.0,20230627,20230627,EXP,,GB-AUROBINDO-AUR-APL-2023-044067,AUROBINDO,,78.0,YR,,F,Y,,,20230627,,CN,GB,GB,2023,Q2,Elderly
226426931,22642693,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,UNK,,,U,,,,,,,,,2023,Q2,Memory impairment,,2023,Q2,1,I,,20230615.0,20230627,20230627,EXP,,GB-AUROBINDO-AUR-APL-2023-044067,AUROBINDO,,78.0,YR,,F,Y,,,20230627,,CN,GB,GB,2023,Q2,Elderly
226426931,22642693,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,UNK,,,U,,,,,,,,,2023,Q2,COVID-19,,2023,Q2,1,I,,20230615.0,20230627,20230627,EXP,,GB-AUROBINDO-AUR-APL-2023-044067,AUROBINDO,,78.0,YR,,F,Y,,,20230627,,CN,GB,GB,2023,Q2,Elderly
226432812,22643281,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q2,Flushing,,2023,Q2,2,F,20230531.0,20230622.0,20230627,20230629,PER,,US-GE HEALTHCARE-2023CSU004905,GE HEALTHCARE,,50.0,YR,,M,Y,69.0,KG,20230629,,PH,US,US,2023,Q2,Adult
226432812,22643281,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q2,Swelling face,,2023,Q2,2,F,20230531.0,20230622.0,20230627,20230629,PER,,US-GE HEALTHCARE-2023CSU004905,GE HEALTHCARE,,50.0,YR,,M,Y,69.0,KG,20230629,,PH,US,US,2023,Q2,Adult
226432812,22643281,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q2,Pruritus,,2023,Q2,2,F,20230531.0,20230622.0,20230627,20230629,PER,,US-GE HEALTHCARE-2023CSU004905,GE HEALTHCARE,,50.0,YR,,M,Y,69.0,KG,20230629,,PH,US,US,2023,Q2,Adult
226444771,22644477,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Diarrhoea,,2023,Q2,1,I,20230525.0,20230620.0,20230627,20230627,EXP,,ES-MYLANLABS-2023M1065932,MYLAN,,65.0,YR,,M,Y,80.4,KG,20230627,,MD,ES,ES,2023,Q2,Elderly
226444771,22644477,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Odynophagia,,2023,Q2,1,I,20230525.0,20230620.0,20230627,20230627,EXP,,ES-MYLANLABS-2023M1065932,MYLAN,,65.0,YR,,M,Y,80.4,KG,20230627,,MD,ES,ES,2023,Q2,Elderly
226444771,22644477,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Asthenia,,2023,Q2,1,I,20230525.0,20230620.0,20230627,20230627,EXP,,ES-MYLANLABS-2023M1065932,MYLAN,,65.0,YR,,M,Y,80.4,KG,20230627,,MD,ES,ES,2023,Q2,Elderly
226444771,22644477,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Renal impairment,,2023,Q2,1,I,20230525.0,20230620.0,20230627,20230627,EXP,,ES-MYLANLABS-2023M1065932,MYLAN,,65.0,YR,,M,Y,80.4,KG,20230627,,MD,ES,ES,2023,Q2,Elderly
226448772,22644877,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,Unknown,,212614.0,,,,,2023,Q2,Incorrect dose administered,,2023,Q2,2,F,20230626.0,20230626.0,20230627,20230629,PER,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-246394",BOEHRINGER INGELHEIM,,59.0,YR,A,F,Y,,,20230630,,CN,US,US,2023,Q2,Adult
226449841,22644984,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Abdominal discomfort,,2023,Q2,1,I,20230619.0,,20230625,20230625,DIR,664746,,FDA-CTU,,47.0,YR,,F,N,85.5,KG,20230625,N,CN,US,,2023,Q2,Adult
226449841,22644984,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Blood glucose decreased,,2023,Q2,1,I,20230619.0,,20230625,20230625,DIR,664746,,FDA-CTU,,47.0,YR,,F,N,85.5,KG,20230625,N,CN,US,,2023,Q2,Adult
226449841,22644984,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,White blood cell count increased,,2023,Q2,1,I,20230619.0,,20230625,20230625,DIR,664746,,FDA-CTU,,47.0,YR,,F,N,85.5,KG,20230625,N,CN,US,,2023,Q2,Adult
226449841,22644984,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Diarrhoea,,2023,Q2,1,I,20230619.0,,20230625,20230625,DIR,664746,,FDA-CTU,,47.0,YR,,F,N,85.5,KG,20230625,N,CN,US,,2023,Q2,Adult
226449841,22644984,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Drug intolerance,,2023,Q2,1,I,20230619.0,,20230625,20230625,DIR,664746,,FDA-CTU,,47.0,YR,,F,N,85.5,KG,20230625,N,CN,US,,2023,Q2,Adult
226449841,22644984,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Chills,,2023,Q2,1,I,20230619.0,,20230625,20230625,DIR,664746,,FDA-CTU,,47.0,YR,,F,N,85.5,KG,20230625,N,CN,US,,2023,Q2,Adult
226449841,22644984,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Hyperhidrosis,,2023,Q2,1,I,20230619.0,,20230625,20230625,DIR,664746,,FDA-CTU,,47.0,YR,,F,N,85.5,KG,20230625,N,CN,US,,2023,Q2,Adult
226449841,22644984,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Weight decreased,,2023,Q2,1,I,20230619.0,,20230625,20230625,DIR,664746,,FDA-CTU,,47.0,YR,,F,N,85.5,KG,20230625,N,CN,US,,2023,Q2,Adult
226449841,22644984,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Nephrolithiasis,,2023,Q2,1,I,20230619.0,,20230625,20230625,DIR,664746,,FDA-CTU,,47.0,YR,,F,N,85.5,KG,20230625,N,CN,US,,2023,Q2,Adult
226449841,22644984,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Anxiety,,2023,Q2,1,I,20230619.0,,20230625,20230625,DIR,664746,,FDA-CTU,,47.0,YR,,F,N,85.5,KG,20230625,N,CN,US,,2023,Q2,Adult
226449841,22644984,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Abdominal distension,,2023,Q2,1,I,20230619.0,,20230625,20230625,DIR,664746,,FDA-CTU,,47.0,YR,,F,N,85.5,KG,20230625,N,CN,US,,2023,Q2,Adult
226449841,22644984,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Vomiting,,2023,Q2,1,I,20230619.0,,20230625,20230625,DIR,664746,,FDA-CTU,,47.0,YR,,F,N,85.5,KG,20230625,N,CN,US,,2023,Q2,Adult
226449841,22644984,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Dyspepsia,,2023,Q2,1,I,20230619.0,,20230625,20230625,DIR,664746,,FDA-CTU,,47.0,YR,,F,N,85.5,KG,20230625,N,CN,US,,2023,Q2,Adult
226449841,22644984,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Flatulence,,2023,Q2,1,I,20230619.0,,20230625,20230625,DIR,664746,,FDA-CTU,,47.0,YR,,F,N,85.5,KG,20230625,N,CN,US,,2023,Q2,Adult
226449841,22644984,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Eructation,,2023,Q2,1,I,20230619.0,,20230625,20230625,DIR,664746,,FDA-CTU,,47.0,YR,,F,N,85.5,KG,20230625,N,CN,US,,2023,Q2,Adult
226449841,22644984,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Dehydration,,2023,Q2,1,I,20230619.0,,20230625,20230625,DIR,664746,,FDA-CTU,,47.0,YR,,F,N,85.5,KG,20230625,N,CN,US,,2023,Q2,Adult
226449841,22644984,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Heart rate increased,,2023,Q2,1,I,20230619.0,,20230625,20230625,DIR,664746,,FDA-CTU,,47.0,YR,,F,N,85.5,KG,20230625,N,CN,US,,2023,Q2,Adult
226449841,22644984,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Panic attack,,2023,Q2,1,I,20230619.0,,20230625,20230625,DIR,664746,,FDA-CTU,,47.0,YR,,F,N,85.5,KG,20230625,N,CN,US,,2023,Q2,Adult
226457641,22645764,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Cardiovascular disorder,,2023,Q2,1,I,20220701.0,20230623.0,20230627,20230627,EXP,,DE-DSJP-DSE-2023-125592,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230627,,MD,DE,DE,2023,Q2,Elderly
226457641,22645764,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Cough,,2023,Q2,1,I,20220701.0,20230623.0,20230627,20230627,EXP,,DE-DSJP-DSE-2023-125592,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230627,,MD,DE,DE,2023,Q2,Elderly
226457641,22645764,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Coronary artery disease,,2023,Q2,1,I,20220701.0,20230623.0,20230627,20230627,EXP,,DE-DSJP-DSE-2023-125592,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230627,,MD,DE,DE,2023,Q2,Elderly
226457641,22645764,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Ventricular tachycardia,,2023,Q2,1,I,20220701.0,20230623.0,20230627,20230627,EXP,,DE-DSJP-DSE-2023-125592,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230627,,MD,DE,DE,2023,Q2,Elderly
226457641,22645764,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Cardiac failure,,2023,Q2,1,I,20220701.0,20230623.0,20230627,20230627,EXP,,DE-DSJP-DSE-2023-125592,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230627,,MD,DE,DE,2023,Q2,Elderly
226457641,22645764,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Mitral valve incompetence,,2023,Q2,1,I,20220701.0,20230623.0,20230627,20230627,EXP,,DE-DSJP-DSE-2023-125592,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230627,,MD,DE,DE,2023,Q2,Elderly
226457641,22645764,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Feeling cold,,2023,Q2,1,I,20220701.0,20230623.0,20230627,20230627,EXP,,DE-DSJP-DSE-2023-125592,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230627,,MD,DE,DE,2023,Q2,Elderly
226457641,22645764,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Ventricular extrasystoles,,2023,Q2,1,I,20220701.0,20230623.0,20230627,20230627,EXP,,DE-DSJP-DSE-2023-125592,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230627,,MD,DE,DE,2023,Q2,Elderly
226457641,22645764,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Left ventricular dysfunction,,2023,Q2,1,I,20220701.0,20230623.0,20230627,20230627,EXP,,DE-DSJP-DSE-2023-125592,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230627,,MD,DE,DE,2023,Q2,Elderly
226457641,22645764,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Product use in unapproved indication,,2023,Q2,1,I,20220701.0,20230623.0,20230627,20230627,EXP,,DE-DSJP-DSE-2023-125592,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230627,,MD,DE,DE,2023,Q2,Elderly
226457641,22645764,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Peripheral coldness,,2023,Q2,1,I,20220701.0,20230623.0,20230627,20230627,EXP,,DE-DSJP-DSE-2023-125592,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230627,,MD,DE,DE,2023,Q2,Elderly
226457641,22645764,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Ejection fraction decreased,,2023,Q2,1,I,20220701.0,20230623.0,20230627,20230627,EXP,,DE-DSJP-DSE-2023-125592,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230627,,MD,DE,DE,2023,Q2,Elderly
226457641,22645764,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Hypotension,,2023,Q2,1,I,20220701.0,20230623.0,20230627,20230627,EXP,,DE-DSJP-DSE-2023-125592,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230627,,MD,DE,DE,2023,Q2,Elderly
226457641,22645764,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q2,Atrial fibrillation,,2023,Q2,1,I,20220701.0,20230623.0,20230627,20230627,EXP,,DE-DSJP-DSE-2023-125592,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230627,,MD,DE,DE,2023,Q2,Elderly
226457641,22645764,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Cardiovascular disorder,,2023,Q2,1,I,20220701.0,20230623.0,20230627,20230627,EXP,,DE-DSJP-DSE-2023-125592,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230627,,MD,DE,DE,2023,Q2,Elderly
226457641,22645764,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Cough,,2023,Q2,1,I,20220701.0,20230623.0,20230627,20230627,EXP,,DE-DSJP-DSE-2023-125592,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230627,,MD,DE,DE,2023,Q2,Elderly
226457641,22645764,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Coronary artery disease,,2023,Q2,1,I,20220701.0,20230623.0,20230627,20230627,EXP,,DE-DSJP-DSE-2023-125592,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230627,,MD,DE,DE,2023,Q2,Elderly
226457641,22645764,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Ventricular tachycardia,,2023,Q2,1,I,20220701.0,20230623.0,20230627,20230627,EXP,,DE-DSJP-DSE-2023-125592,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230627,,MD,DE,DE,2023,Q2,Elderly
226457641,22645764,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Cardiac failure,,2023,Q2,1,I,20220701.0,20230623.0,20230627,20230627,EXP,,DE-DSJP-DSE-2023-125592,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230627,,MD,DE,DE,2023,Q2,Elderly
226457641,22645764,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Mitral valve incompetence,,2023,Q2,1,I,20220701.0,20230623.0,20230627,20230627,EXP,,DE-DSJP-DSE-2023-125592,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230627,,MD,DE,DE,2023,Q2,Elderly
226457641,22645764,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Feeling cold,,2023,Q2,1,I,20220701.0,20230623.0,20230627,20230627,EXP,,DE-DSJP-DSE-2023-125592,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230627,,MD,DE,DE,2023,Q2,Elderly
226457641,22645764,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Ventricular extrasystoles,,2023,Q2,1,I,20220701.0,20230623.0,20230627,20230627,EXP,,DE-DSJP-DSE-2023-125592,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230627,,MD,DE,DE,2023,Q2,Elderly
226457641,22645764,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Left ventricular dysfunction,,2023,Q2,1,I,20220701.0,20230623.0,20230627,20230627,EXP,,DE-DSJP-DSE-2023-125592,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230627,,MD,DE,DE,2023,Q2,Elderly
226457641,22645764,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Product use in unapproved indication,,2023,Q2,1,I,20220701.0,20230623.0,20230627,20230627,EXP,,DE-DSJP-DSE-2023-125592,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230627,,MD,DE,DE,2023,Q2,Elderly
226457641,22645764,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Peripheral coldness,,2023,Q2,1,I,20220701.0,20230623.0,20230627,20230627,EXP,,DE-DSJP-DSE-2023-125592,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230627,,MD,DE,DE,2023,Q2,Elderly
226457641,22645764,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Ejection fraction decreased,,2023,Q2,1,I,20220701.0,20230623.0,20230627,20230627,EXP,,DE-DSJP-DSE-2023-125592,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230627,,MD,DE,DE,2023,Q2,Elderly
226457641,22645764,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Hypotension,,2023,Q2,1,I,20220701.0,20230623.0,20230627,20230627,EXP,,DE-DSJP-DSE-2023-125592,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230627,,MD,DE,DE,2023,Q2,Elderly
226457641,22645764,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Atrial fibrillation,,2023,Q2,1,I,20220701.0,20230623.0,20230627,20230627,EXP,,DE-DSJP-DSE-2023-125592,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230627,,MD,DE,DE,2023,Q2,Elderly
226457641,22645764,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Cardiovascular disorder,,2023,Q2,1,I,20220701.0,20230623.0,20230627,20230627,EXP,,DE-DSJP-DSE-2023-125592,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230627,,MD,DE,DE,2023,Q2,Elderly
226457641,22645764,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Cough,,2023,Q2,1,I,20220701.0,20230623.0,20230627,20230627,EXP,,DE-DSJP-DSE-2023-125592,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230627,,MD,DE,DE,2023,Q2,Elderly
226457641,22645764,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Coronary artery disease,,2023,Q2,1,I,20220701.0,20230623.0,20230627,20230627,EXP,,DE-DSJP-DSE-2023-125592,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230627,,MD,DE,DE,2023,Q2,Elderly
226457641,22645764,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Ventricular tachycardia,,2023,Q2,1,I,20220701.0,20230623.0,20230627,20230627,EXP,,DE-DSJP-DSE-2023-125592,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230627,,MD,DE,DE,2023,Q2,Elderly
226457641,22645764,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Cardiac failure,,2023,Q2,1,I,20220701.0,20230623.0,20230627,20230627,EXP,,DE-DSJP-DSE-2023-125592,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230627,,MD,DE,DE,2023,Q2,Elderly
226457641,22645764,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Mitral valve incompetence,,2023,Q2,1,I,20220701.0,20230623.0,20230627,20230627,EXP,,DE-DSJP-DSE-2023-125592,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230627,,MD,DE,DE,2023,Q2,Elderly
226457641,22645764,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Feeling cold,,2023,Q2,1,I,20220701.0,20230623.0,20230627,20230627,EXP,,DE-DSJP-DSE-2023-125592,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230627,,MD,DE,DE,2023,Q2,Elderly
226457641,22645764,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Ventricular extrasystoles,,2023,Q2,1,I,20220701.0,20230623.0,20230627,20230627,EXP,,DE-DSJP-DSE-2023-125592,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230627,,MD,DE,DE,2023,Q2,Elderly
226457641,22645764,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Left ventricular dysfunction,,2023,Q2,1,I,20220701.0,20230623.0,20230627,20230627,EXP,,DE-DSJP-DSE-2023-125592,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230627,,MD,DE,DE,2023,Q2,Elderly
226457641,22645764,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Product use in unapproved indication,,2023,Q2,1,I,20220701.0,20230623.0,20230627,20230627,EXP,,DE-DSJP-DSE-2023-125592,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230627,,MD,DE,DE,2023,Q2,Elderly
226457641,22645764,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Peripheral coldness,,2023,Q2,1,I,20220701.0,20230623.0,20230627,20230627,EXP,,DE-DSJP-DSE-2023-125592,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230627,,MD,DE,DE,2023,Q2,Elderly
226457641,22645764,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Ejection fraction decreased,,2023,Q2,1,I,20220701.0,20230623.0,20230627,20230627,EXP,,DE-DSJP-DSE-2023-125592,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230627,,MD,DE,DE,2023,Q2,Elderly
226457641,22645764,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Hypotension,,2023,Q2,1,I,20220701.0,20230623.0,20230627,20230627,EXP,,DE-DSJP-DSE-2023-125592,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230627,,MD,DE,DE,2023,Q2,Elderly
226457641,22645764,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Atrial fibrillation,,2023,Q2,1,I,20220701.0,20230623.0,20230627,20230627,EXP,,DE-DSJP-DSE-2023-125592,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230627,,MD,DE,DE,2023,Q2,Elderly
226484261,22648426,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Off label use,,2023,Q2,1,I,20220101.0,20230619.0,20230628,20230628,EXP,,US-JNJFOC-20230650914,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20230628,,HP,US,US,2023,Q2,Adult
226484261,22648426,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q2,Nocardiosis,,2023,Q2,1,I,20220101.0,20230619.0,20230628,20230628,EXP,,US-JNJFOC-20230650914,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20230628,,HP,US,US,2023,Q2,Adult
226495911,22649591,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Death,,2023,Q2,1,I,20230615.0,20230623.0,20230628,20230628,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-2023-090563,BRISTOL MYERS SQUIBB,,75.0,YR,E,M,Y,,,20230628,,CN,US,US,2023,Q2,Elderly
226496981,22649698,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,morning,,,U,,,,,,,Tablet,,2023,Q2,Dry eye,,2023,Q2,1,I,20230509.0,20230621.0,20230628,20230628,EXP,GB-MHRA-TPP2502395C3473839YC1687166456328,GB-TORRENT-00032146,TORRENT,,79.0,YR,E,F,Y,56.0,KG,20230628,,PH,GB,GB,2023,Q2,Elderly
226508441,22650844,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q2,Tremor,,2023,Q2,1,I,,20230615.0,20230628,20230628,EXP,,CH-TEVA-2023-CH-2901625,TEVA,,72.0,YR,E,M,Y,,,20230628,,HP,CH,CH,2023,Q2,Elderly
226546981,22654698,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,Unknown,,2023,Q2,Anaemia,,2023,Q2,1,I,20230512.0,20230623.0,20230629,20230629,EXP,,FR-BAUSCH-BL-2023-008459,BAUSCH AND LOMB,,75.0,YR,,F,Y,76.0,KG,20230629,,MD,FR,FR,2023,Q2,Elderly
226546981,22654698,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,Unknown,,2023,Q2,Off label use,,2023,Q2,1,I,20230512.0,20230623.0,20230629,20230629,EXP,,FR-BAUSCH-BL-2023-008459,BAUSCH AND LOMB,,75.0,YR,,F,Y,76.0,KG,20230629,,MD,FR,FR,2023,Q2,Elderly
226546981,22654698,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,Unknown,,2023,Q2,Asthenia,,2023,Q2,1,I,20230512.0,20230623.0,20230629,20230629,EXP,,FR-BAUSCH-BL-2023-008459,BAUSCH AND LOMB,,75.0,YR,,F,Y,76.0,KG,20230629,,MD,FR,FR,2023,Q2,Elderly
226546981,22654698,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,Unknown,,2023,Q2,Cardiac failure,,2023,Q2,1,I,20230512.0,20230623.0,20230629,20230629,EXP,,FR-BAUSCH-BL-2023-008459,BAUSCH AND LOMB,,75.0,YR,,F,Y,76.0,KG,20230629,,MD,FR,FR,2023,Q2,Elderly
226546981,22654698,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,Unknown,,2023,Q2,Cough,,2023,Q2,1,I,20230512.0,20230623.0,20230629,20230629,EXP,,FR-BAUSCH-BL-2023-008459,BAUSCH AND LOMB,,75.0,YR,,F,Y,76.0,KG,20230629,,MD,FR,FR,2023,Q2,Elderly
226546981,22654698,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,Unknown,,2023,Q2,Abdominal pain upper,,2023,Q2,1,I,20230512.0,20230623.0,20230629,20230629,EXP,,FR-BAUSCH-BL-2023-008459,BAUSCH AND LOMB,,75.0,YR,,F,Y,76.0,KG,20230629,,MD,FR,FR,2023,Q2,Elderly
226546981,22654698,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,Unknown,,2023,Q2,Chills,,2023,Q2,1,I,20230512.0,20230623.0,20230629,20230629,EXP,,FR-BAUSCH-BL-2023-008459,BAUSCH AND LOMB,,75.0,YR,,F,Y,76.0,KG,20230629,,MD,FR,FR,2023,Q2,Elderly
226546981,22654698,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,Unknown,,2023,Q2,C-reactive protein increased,,2023,Q2,1,I,20230512.0,20230623.0,20230629,20230629,EXP,,FR-BAUSCH-BL-2023-008459,BAUSCH AND LOMB,,75.0,YR,,F,Y,76.0,KG,20230629,,MD,FR,FR,2023,Q2,Elderly
226546981,22654698,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,Unknown,,2023,Q2,Pneumonia,,2023,Q2,1,I,20230512.0,20230623.0,20230629,20230629,EXP,,FR-BAUSCH-BL-2023-008459,BAUSCH AND LOMB,,75.0,YR,,F,Y,76.0,KG,20230629,,MD,FR,FR,2023,Q2,Elderly
226546981,22654698,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,Unknown,,2023,Q2,COVID-19,,2023,Q2,1,I,20230512.0,20230623.0,20230629,20230629,EXP,,FR-BAUSCH-BL-2023-008459,BAUSCH AND LOMB,,75.0,YR,,F,Y,76.0,KG,20230629,,MD,FR,FR,2023,Q2,Elderly
226546981,22654698,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,Unknown,,2023,Q2,Lower respiratory tract infection,,2023,Q2,1,I,20230512.0,20230623.0,20230629,20230629,EXP,,FR-BAUSCH-BL-2023-008459,BAUSCH AND LOMB,,75.0,YR,,F,Y,76.0,KG,20230629,,MD,FR,FR,2023,Q2,Elderly
226576351,22657635,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 mg,,,,,unknown,,,,,,,2023,Q2,Pruritus,,2023,Q2,1,I,20230511.0,20230619.0,20230630,20230630,EXP,PT-INFARMED-E202306-188,PT-NOVOPROD-1080550,NOVO NORDISK,,56.0,YR,,F,Y,98.0,KG,20230630,,HP,PT,PT,2023,Q2,Adult
226581081,22658108,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Pulmonary nocardiosis,,2023,Q2,1,I,20220701.0,20230620.0,20230630,20230630,EXP,,US-Accord-363787,ACCORD,"Beau Stamos D, Barajas-Ochoa A, Raybould JE. Nocardia pseudobrasiliensis Co-infection in SARS-CoV-2 Patients. Emerging Infectious Diseases. 2023, 29(4):696-700 on 13 Jun 2023.",52.0,YR,A,M,Y,,,20230630,,MD,US,US,2023,Q2,Adult
226581081,22658108,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Coinfection,,2023,Q2,1,I,20220701.0,20230620.0,20230630,20230630,EXP,,US-Accord-363787,ACCORD,"Beau Stamos D, Barajas-Ochoa A, Raybould JE. Nocardia pseudobrasiliensis Co-infection in SARS-CoV-2 Patients. Emerging Infectious Diseases. 2023, 29(4):696-700 on 13 Jun 2023.",52.0,YR,A,M,Y,,,20230630,,MD,US,US,2023,Q2,Adult
226581081,22658108,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q2,Pneumonia bacterial,,2023,Q2,1,I,20220701.0,20230620.0,20230630,20230630,EXP,,US-Accord-363787,ACCORD,"Beau Stamos D, Barajas-Ochoa A, Raybould JE. Nocardia pseudobrasiliensis Co-infection in SARS-CoV-2 Patients. Emerging Infectious Diseases. 2023, 29(4):696-700 on 13 Jun 2023.",52.0,YR,A,M,Y,,,20230630,,MD,US,US,2023,Q2,Adult
226587011,22658701,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2023,Q2,Osteoporosis,,2023,Q2,1,I,,20230623.0,20230630,20230630,EXP,,US-MYLANLABS-2023M1069546,MYLAN,"McKeirnan KC, Anderson CB, Powell AJ, Gilbert R, Undeberg MR. The Role of the Pharmacist in Patient Self-Advocacy for Osteoporosis Screening. Sr-Care-Pharm 2022;37(12):612-622.",61.0,YR,,F,Y,,,20230630,,HP,US,US,2023,Q2,Adult
226587011,22658701,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2023,Q2,Hyperthyroidism,,2023,Q2,1,I,,20230623.0,20230630,20230630,EXP,,US-MYLANLABS-2023M1069546,MYLAN,"McKeirnan KC, Anderson CB, Powell AJ, Gilbert R, Undeberg MR. The Role of the Pharmacist in Patient Self-Advocacy for Osteoporosis Screening. Sr-Care-Pharm 2022;37(12):612-622.",61.0,YR,,F,Y,,,20230630,,HP,US,US,2023,Q2,Adult
226592851,22659285,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q2,Paraesthesia,,2023,Q2,1,I,,20230629.0,20230630,20230630,EXP,GB-MHRA-TPP34784986C8317682YC1687777532839,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-246961",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,86.0,KG,20230630,,HP,GB,GB,2023,Q2,Elderly
226592851,22659285,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q2,Oedema peripheral,,2023,Q2,1,I,,20230629.0,20230630,20230630,EXP,GB-MHRA-TPP34784986C8317682YC1687777532839,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-246961",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,86.0,KG,20230630,,HP,GB,GB,2023,Q2,Elderly
226592851,22659285,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q2,Erythema,,2023,Q2,1,I,,20230629.0,20230630,20230630,EXP,GB-MHRA-TPP34784986C8317682YC1687777532839,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-246961",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,86.0,KG,20230630,,HP,GB,GB,2023,Q2,Elderly
226592851,22659285,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q2,Flushing,,2023,Q2,1,I,,20230629.0,20230630,20230630,EXP,GB-MHRA-TPP34784986C8317682YC1687777532839,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-246961",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,86.0,KG,20230630,,HP,GB,GB,2023,Q2,Elderly
226592851,22659285,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q2,Face oedema,,2023,Q2,1,I,,20230629.0,20230630,20230630,EXP,GB-MHRA-TPP34784986C8317682YC1687777532839,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-246961",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,86.0,KG,20230630,,HP,GB,GB,2023,Q2,Elderly
226596871,22659687,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Mitral valve incompetence,,2023,Q2,1,I,20210222.0,20230628.0,20230630,20230630,EXP,,NVSC2023CA148192,NOVARTIS,,64.0,YR,,M,Y,,,20230630,,HP,CA,CA,2023,Q2,Adult
226596871,22659687,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Ventricular extrasystoles,,2023,Q2,1,I,20210222.0,20230628.0,20230630,20230630,EXP,,NVSC2023CA148192,NOVARTIS,,64.0,YR,,M,Y,,,20230630,,HP,CA,CA,2023,Q2,Adult
226596871,22659687,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Drug hypersensitivity,,2023,Q2,1,I,20210222.0,20230628.0,20230630,20230630,EXP,,NVSC2023CA148192,NOVARTIS,,64.0,YR,,M,Y,,,20230630,,HP,CA,CA,2023,Q2,Adult
226596871,22659687,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Blood cholesterol increased,,2023,Q2,1,I,20210222.0,20230628.0,20230630,20230630,EXP,,NVSC2023CA148192,NOVARTIS,,64.0,YR,,M,Y,,,20230630,,HP,CA,CA,2023,Q2,Adult
226596871,22659687,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Left atrial dilatation,,2023,Q2,1,I,20210222.0,20230628.0,20230630,20230630,EXP,,NVSC2023CA148192,NOVARTIS,,64.0,YR,,M,Y,,,20230630,,HP,CA,CA,2023,Q2,Adult
226596871,22659687,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Bundle branch block right,,2023,Q2,1,I,20210222.0,20230628.0,20230630,20230630,EXP,,NVSC2023CA148192,NOVARTIS,,64.0,YR,,M,Y,,,20230630,,HP,CA,CA,2023,Q2,Adult
226596871,22659687,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Non-high-density lipoprotein cholesterol increased,,2023,Q2,1,I,20210222.0,20230628.0,20230630,20230630,EXP,,NVSC2023CA148192,NOVARTIS,,64.0,YR,,M,Y,,,20230630,,HP,CA,CA,2023,Q2,Adult
226596871,22659687,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Supraventricular extrasystoles,,2023,Q2,1,I,20210222.0,20230628.0,20230630,20230630,EXP,,NVSC2023CA148192,NOVARTIS,,64.0,YR,,M,Y,,,20230630,,HP,CA,CA,2023,Q2,Adult
226596871,22659687,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Drug intolerance,,2023,Q2,1,I,20210222.0,20230628.0,20230630,20230630,EXP,,NVSC2023CA148192,NOVARTIS,,64.0,YR,,M,Y,,,20230630,,HP,CA,CA,2023,Q2,Adult
226596871,22659687,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Pruritus genital,,2023,Q2,1,I,20210222.0,20230628.0,20230630,20230630,EXP,,NVSC2023CA148192,NOVARTIS,,64.0,YR,,M,Y,,,20230630,,HP,CA,CA,2023,Q2,Adult
226596871,22659687,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Aortic arteriosclerosis,,2023,Q2,1,I,20210222.0,20230628.0,20230630,20230630,EXP,,NVSC2023CA148192,NOVARTIS,,64.0,YR,,M,Y,,,20230630,,HP,CA,CA,2023,Q2,Adult
226596871,22659687,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Genital infection fungal,,2023,Q2,1,I,20210222.0,20230628.0,20230630,20230630,EXP,,NVSC2023CA148192,NOVARTIS,,64.0,YR,,M,Y,,,20230630,,HP,CA,CA,2023,Q2,Adult
226596871,22659687,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Left ventricular dysfunction,,2023,Q2,1,I,20210222.0,20230628.0,20230630,20230630,EXP,,NVSC2023CA148192,NOVARTIS,,64.0,YR,,M,Y,,,20230630,,HP,CA,CA,2023,Q2,Adult
226596871,22659687,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Hyperkalaemia,,2023,Q2,1,I,20210222.0,20230628.0,20230630,20230630,EXP,,NVSC2023CA148192,NOVARTIS,,64.0,YR,,M,Y,,,20230630,,HP,CA,CA,2023,Q2,Adult
226596871,22659687,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Decreased appetite,,2023,Q2,1,I,20210222.0,20230628.0,20230630,20230630,EXP,,NVSC2023CA148192,NOVARTIS,,64.0,YR,,M,Y,,,20230630,,HP,CA,CA,2023,Q2,Adult
226596871,22659687,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Mitral valve calcification,,2023,Q2,1,I,20210222.0,20230628.0,20230630,20230630,EXP,,NVSC2023CA148192,NOVARTIS,,64.0,YR,,M,Y,,,20230630,,HP,CA,CA,2023,Q2,Adult
226596871,22659687,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Left ventricular hypertrophy,,2023,Q2,1,I,20210222.0,20230628.0,20230630,20230630,EXP,,NVSC2023CA148192,NOVARTIS,,64.0,YR,,M,Y,,,20230630,,HP,CA,CA,2023,Q2,Adult
159613442,15961344,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"Later, the dosage was titrated to 25mg/day",,,,,,,,10.0,MG,,QD,2023,Q3,Gastrointestinal disorder,,2023,Q3,2,F,,20230801.0,20190214,20230810,EXP,,US-TEVA-2019-US-1010358,TEVA,,61.0,YR,A,M,Y,,,20230810,,MD,US,US,2023,Q3,Adult
159613442,15961344,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,,QD,2023,Q3,Gastrointestinal disorder,,2023,Q3,2,F,,20230801.0,20190214,20230810,EXP,,US-TEVA-2019-US-1010358,TEVA,,61.0,YR,A,M,Y,,,20230810,,MD,US,US,2023,Q3,Adult
160192002,16019200,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q3,Hypomagnesaemia,,2023,Q3,2,F,,20230724.0,20190228,20230803,EXP,,AU-TEVA-2019-AU-1017291,TEVA,,66.0,YR,E,M,Y,,,20230803,,HP,US,AU,2023,Q3,Elderly
160192002,16019200,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q3,Hypocalcaemia,,2023,Q3,2,F,,20230724.0,20190228,20230803,EXP,,AU-TEVA-2019-AU-1017291,TEVA,,66.0,YR,E,M,Y,,,20230803,,HP,US,AU,2023,Q3,Elderly
1652766614,16527666,36,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,UNK,,,,,,,,,,,,2023,Q3,Gastroenteritis,,2023,Q3,14,F,20170929.0,20230801.0,20190703,20230808,EXP,,JP-GILEAD-2018-0382287,GILEAD,,31.0,YR,A,M,Y,,,20230808,,MD,JP,JP,2023,Q3,Young Adult
1652766614,16527666,36,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,UNK,,,,,,,,,,,,2023,Q3,Bronchitis,,2023,Q3,14,F,20170929.0,20230801.0,20190703,20230808,EXP,,JP-GILEAD-2018-0382287,GILEAD,,31.0,YR,A,M,Y,,,20230808,,MD,JP,JP,2023,Q3,Young Adult
1652766614,16527666,36,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,UNK,,,,,,,,,,,,2023,Q3,Stomatitis,,2023,Q3,14,F,20170929.0,20230801.0,20190703,20230808,EXP,,JP-GILEAD-2018-0382287,GILEAD,,31.0,YR,A,M,Y,,,20230808,,MD,JP,JP,2023,Q3,Young Adult
1652766614,16527666,36,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,UNK,,,,,,,,,,,,2023,Q3,Schizophrenia,,2023,Q3,14,F,20170929.0,20230801.0,20190703,20230808,EXP,,JP-GILEAD-2018-0382287,GILEAD,,31.0,YR,A,M,Y,,,20230808,,MD,JP,JP,2023,Q3,Young Adult
1652766614,16527666,36,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,UNK,,,,,,,,,,,,2023,Q3,Pruritus genital,,2023,Q3,14,F,20170929.0,20230801.0,20190703,20230808,EXP,,JP-GILEAD-2018-0382287,GILEAD,,31.0,YR,A,M,Y,,,20230808,,MD,JP,JP,2023,Q3,Young Adult
1652766614,16527666,36,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,UNK,,,,,,,,,,,,2023,Q3,Enuresis,,2023,Q3,14,F,20170929.0,20230801.0,20190703,20230808,EXP,,JP-GILEAD-2018-0382287,GILEAD,,31.0,YR,A,M,Y,,,20230808,,MD,JP,JP,2023,Q3,Young Adult
1652766614,16527666,36,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,UNK,,,,,,,,,,,,2023,Q3,Insomnia,,2023,Q3,14,F,20170929.0,20230801.0,20190703,20230808,EXP,,JP-GILEAD-2018-0382287,GILEAD,,31.0,YR,A,M,Y,,,20230808,,MD,JP,JP,2023,Q3,Young Adult
1652766614,16527666,36,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,UNK,,,,,,,,,,,,2023,Q3,Electrocardiogram abnormal,,2023,Q3,14,F,20170929.0,20230801.0,20190703,20230808,EXP,,JP-GILEAD-2018-0382287,GILEAD,,31.0,YR,A,M,Y,,,20230808,,MD,JP,JP,2023,Q3,Young Adult
1652766614,16527666,36,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,UNK,,,,,,,,,,,,2023,Q3,Diabetes mellitus,,2023,Q3,14,F,20170929.0,20230801.0,20190703,20230808,EXP,,JP-GILEAD-2018-0382287,GILEAD,,31.0,YR,A,M,Y,,,20230808,,MD,JP,JP,2023,Q3,Young Adult
173170614,17317061,27,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2023,Q3,Acute kidney injury,,2023,Q3,4,F,20170401.0,20230630.0,20200124,20230703,EXP,,US-AstraZeneca-2020SE08176,ASTRAZENECA,,781.0,MON,,F,Y,119.3,KG,20230703,,LW,US,,2023,Q3,Elderly
173170614,17317061,27,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2023,Q3,Death,,2023,Q3,4,F,20170401.0,20230630.0,20200124,20230703,EXP,,US-AstraZeneca-2020SE08176,ASTRAZENECA,,781.0,MON,,F,Y,119.3,KG,20230703,,LW,US,,2023,Q3,Elderly
173170614,17317061,27,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2023,Q3,Nephrogenic anaemia,,2023,Q3,4,F,20170401.0,20230630.0,20200124,20230703,EXP,,US-AstraZeneca-2020SE08176,ASTRAZENECA,,781.0,MON,,F,Y,119.3,KG,20230703,,LW,US,,2023,Q3,Elderly
173170614,17317061,27,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2023,Q3,Renal failure,,2023,Q3,4,F,20170401.0,20230630.0,20200124,20230703,EXP,,US-AstraZeneca-2020SE08176,ASTRAZENECA,,781.0,MON,,F,Y,119.3,KG,20230703,,LW,US,,2023,Q3,Elderly
173170614,17317061,27,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2023,Q3,Rebound acid hypersecretion,,2023,Q3,4,F,20170401.0,20230630.0,20200124,20230703,EXP,,US-AstraZeneca-2020SE08176,ASTRAZENECA,,781.0,MON,,F,Y,119.3,KG,20230703,,LW,US,,2023,Q3,Elderly
173170614,17317061,27,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2023,Q3,Chronic kidney disease,,2023,Q3,4,F,20170401.0,20230630.0,20200124,20230703,EXP,,US-AstraZeneca-2020SE08176,ASTRAZENECA,,781.0,MON,,F,Y,119.3,KG,20230703,,LW,US,,2023,Q3,Elderly
179094083,17909408,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day (1-0-0-0)",,,U,U,,,,10.0,MG,,QD,2023,Q3,Condition aggravated,,2023,Q3,3,F,,20230915.0,20200618,20230927,EXP,,DE-AUROBINDO-AUR-APL-2020-029330,AUROBINDO,,56.0,YR,,F,Y,,,20230927,,MD,DE,DE,2023,Q3,Adult
179094083,17909408,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day (1-0-0-0)",,,U,U,,,,10.0,MG,,QD,2023,Q3,Anaemia,,2023,Q3,3,F,,20230915.0,20200618,20230927,EXP,,DE-AUROBINDO-AUR-APL-2020-029330,AUROBINDO,,56.0,YR,,F,Y,,,20230927,,MD,DE,DE,2023,Q3,Adult
179094083,17909408,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day (1-0-0-0)",,,U,U,,,,10.0,MG,,QD,2023,Q3,Pallor,,2023,Q3,3,F,,20230915.0,20200618,20230927,EXP,,DE-AUROBINDO-AUR-APL-2020-029330,AUROBINDO,,56.0,YR,,F,Y,,,20230927,,MD,DE,DE,2023,Q3,Adult
179094083,17909408,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day (1-0-0-0)",,,U,U,,,,10.0,MG,,QD,2023,Q3,Epistaxis,,2023,Q3,3,F,,20230915.0,20200618,20230927,EXP,,DE-AUROBINDO-AUR-APL-2020-029330,AUROBINDO,,56.0,YR,,F,Y,,,20230927,,MD,DE,DE,2023,Q3,Adult
179094083,17909408,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day (1-0-0-0)",,,U,U,,,,10.0,MG,,QD,2023,Q3,Diarrhoea,,2023,Q3,3,F,,20230915.0,20200618,20230927,EXP,,DE-AUROBINDO-AUR-APL-2020-029330,AUROBINDO,,56.0,YR,,F,Y,,,20230927,,MD,DE,DE,2023,Q3,Adult
179094083,17909408,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day (1-0-0-0)",,,U,U,,,,10.0,MG,,QD,2023,Q3,General physical health deterioration,,2023,Q3,3,F,,20230915.0,20200618,20230927,EXP,,DE-AUROBINDO-AUR-APL-2020-029330,AUROBINDO,,56.0,YR,,F,Y,,,20230927,,MD,DE,DE,2023,Q3,Adult
179094083,17909408,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day (1-0-0-0)",,,U,U,,,,10.0,MG,,QD,2023,Q3,Haematochezia,,2023,Q3,3,F,,20230915.0,20200618,20230927,EXP,,DE-AUROBINDO-AUR-APL-2020-029330,AUROBINDO,,56.0,YR,,F,Y,,,20230927,,MD,DE,DE,2023,Q3,Adult
181028815,18102881,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, unknown freq.",,,,,Unknown,,,,,Formulation unknown,,2023,Q3,Urinary tract candidiasis,,2023,Q3,5,F,20181217.0,20230908.0,20200803,20230918,EXP,,ES-ASTELLAS-2020US023850,ASTELLAS,,53.0,YR,,F,Y,,,20230918,,CN,ES,ES,2023,Q3,Adult
181028815,18102881,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, unknown freq.",,,,,Unknown,,,,,Formulation unknown,,2023,Q3,Septic shock,,2023,Q3,5,F,20181217.0,20230908.0,20200803,20230918,EXP,,ES-ASTELLAS-2020US023850,ASTELLAS,,53.0,YR,,F,Y,,,20230918,,CN,ES,ES,2023,Q3,Adult
181028815,18102881,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, unknown freq.",,,,,Unknown,,,,,Formulation unknown,,2023,Q3,Candida infection,,2023,Q3,5,F,20181217.0,20230908.0,20200803,20230918,EXP,,ES-ASTELLAS-2020US023850,ASTELLAS,,53.0,YR,,F,Y,,,20230918,,CN,ES,ES,2023,Q3,Adult
181028815,18102881,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, unknown freq.",,,,,Unknown,,,,,Formulation unknown,,2023,Q3,Urinary tract infection,,2023,Q3,5,F,20181217.0,20230908.0,20200803,20230918,EXP,,ES-ASTELLAS-2020US023850,ASTELLAS,,53.0,YR,,F,Y,,,20230918,,CN,ES,ES,2023,Q3,Adult
181028815,18102881,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, unknown freq.",,,,,Unknown,,,,,Formulation unknown,,2023,Q3,Drug ineffective,,2023,Q3,5,F,20181217.0,20230908.0,20200803,20230918,EXP,,ES-ASTELLAS-2020US023850,ASTELLAS,,53.0,YR,,F,Y,,,20230918,,CN,ES,ES,2023,Q3,Adult
181028815,18102881,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, unknown freq.",,,,,Unknown,,,,,Formulation unknown,,2023,Q3,Emphysematous pyelonephritis,,2023,Q3,5,F,20181217.0,20230908.0,20200803,20230918,EXP,,ES-ASTELLAS-2020US023850,ASTELLAS,,53.0,YR,,F,Y,,,20230918,,CN,ES,ES,2023,Q3,Adult
181028815,18102881,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, unknown freq.",,,,,Unknown,,,,,Formulation unknown,,2023,Q3,Candida sepsis,,2023,Q3,5,F,20181217.0,20230908.0,20200803,20230918,EXP,,ES-ASTELLAS-2020US023850,ASTELLAS,,53.0,YR,,F,Y,,,20230918,,CN,ES,ES,2023,Q3,Adult
181028815,18102881,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, unknown freq.",,,,,Unknown,,,,,Formulation unknown,,2023,Q3,Urinary tract infection enterococcal,,2023,Q3,5,F,20181217.0,20230908.0,20200803,20230918,EXP,,ES-ASTELLAS-2020US023850,ASTELLAS,,53.0,YR,,F,Y,,,20230918,,CN,ES,ES,2023,Q3,Adult
181028815,18102881,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, unknown freq.",,,,,Unknown,,,,,Formulation unknown,,2023,Q3,Perinephric abscess,,2023,Q3,5,F,20181217.0,20230908.0,20200803,20230918,EXP,,ES-ASTELLAS-2020US023850,ASTELLAS,,53.0,YR,,F,Y,,,20230918,,CN,ES,ES,2023,Q3,Adult
181028815,18102881,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, unknown freq.",,,,,Unknown,,,,,Formulation unknown,,2023,Q3,Urinary tract candidiasis,,2023,Q3,5,F,20181217.0,20230908.0,20200803,20230918,EXP,,ES-ASTELLAS-2020US023850,ASTELLAS,,53.0,YR,,F,Y,,,20230918,,CN,ES,ES,2023,Q3,Adult
181028815,18102881,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, unknown freq.",,,,,Unknown,,,,,Formulation unknown,,2023,Q3,Septic shock,,2023,Q3,5,F,20181217.0,20230908.0,20200803,20230918,EXP,,ES-ASTELLAS-2020US023850,ASTELLAS,,53.0,YR,,F,Y,,,20230918,,CN,ES,ES,2023,Q3,Adult
181028815,18102881,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, unknown freq.",,,,,Unknown,,,,,Formulation unknown,,2023,Q3,Candida infection,,2023,Q3,5,F,20181217.0,20230908.0,20200803,20230918,EXP,,ES-ASTELLAS-2020US023850,ASTELLAS,,53.0,YR,,F,Y,,,20230918,,CN,ES,ES,2023,Q3,Adult
181028815,18102881,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, unknown freq.",,,,,Unknown,,,,,Formulation unknown,,2023,Q3,Urinary tract infection,,2023,Q3,5,F,20181217.0,20230908.0,20200803,20230918,EXP,,ES-ASTELLAS-2020US023850,ASTELLAS,,53.0,YR,,F,Y,,,20230918,,CN,ES,ES,2023,Q3,Adult
181028815,18102881,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, unknown freq.",,,,,Unknown,,,,,Formulation unknown,,2023,Q3,Drug ineffective,,2023,Q3,5,F,20181217.0,20230908.0,20200803,20230918,EXP,,ES-ASTELLAS-2020US023850,ASTELLAS,,53.0,YR,,F,Y,,,20230918,,CN,ES,ES,2023,Q3,Adult
181028815,18102881,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, unknown freq.",,,,,Unknown,,,,,Formulation unknown,,2023,Q3,Emphysematous pyelonephritis,,2023,Q3,5,F,20181217.0,20230908.0,20200803,20230918,EXP,,ES-ASTELLAS-2020US023850,ASTELLAS,,53.0,YR,,F,Y,,,20230918,,CN,ES,ES,2023,Q3,Adult
181028815,18102881,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, unknown freq.",,,,,Unknown,,,,,Formulation unknown,,2023,Q3,Candida sepsis,,2023,Q3,5,F,20181217.0,20230908.0,20200803,20230918,EXP,,ES-ASTELLAS-2020US023850,ASTELLAS,,53.0,YR,,F,Y,,,20230918,,CN,ES,ES,2023,Q3,Adult
181028815,18102881,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, unknown freq.",,,,,Unknown,,,,,Formulation unknown,,2023,Q3,Urinary tract infection enterococcal,,2023,Q3,5,F,20181217.0,20230908.0,20200803,20230918,EXP,,ES-ASTELLAS-2020US023850,ASTELLAS,,53.0,YR,,F,Y,,,20230918,,CN,ES,ES,2023,Q3,Adult
181028815,18102881,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, unknown freq.",,,,,Unknown,,,,,Formulation unknown,,2023,Q3,Perinephric abscess,,2023,Q3,5,F,20181217.0,20230908.0,20200803,20230918,EXP,,ES-ASTELLAS-2020US023850,ASTELLAS,,53.0,YR,,F,Y,,,20230918,,CN,ES,ES,2023,Q3,Adult
181423286,18142328,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,UNKNOWN,,,,,,,2023,Q3,Candida infection,,2023,Q3,6,F,,20230908.0,20200813,20230912,EXP,,ES-ROCHE-2657950,ROCHE,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno De La Higuera MA, Lucena R, et al. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft.. Nephron. 2020;144(6):304-309.",56.0,YR,,F,Y,,,20230912,,HP,ES,ES,2023,Q3,Adult
181423286,18142328,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,UNKNOWN,,,,,,,2023,Q3,Coagulopathy,,2023,Q3,6,F,,20230908.0,20200813,20230912,EXP,,ES-ROCHE-2657950,ROCHE,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno De La Higuera MA, Lucena R, et al. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft.. Nephron. 2020;144(6):304-309.",56.0,YR,,F,Y,,,20230912,,HP,ES,ES,2023,Q3,Adult
181423286,18142328,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,UNKNOWN,,,,,,,2023,Q3,Product use in unapproved indication,,2023,Q3,6,F,,20230908.0,20200813,20230912,EXP,,ES-ROCHE-2657950,ROCHE,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno De La Higuera MA, Lucena R, et al. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft.. Nephron. 2020;144(6):304-309.",56.0,YR,,F,Y,,,20230912,,HP,ES,ES,2023,Q3,Adult
181423286,18142328,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,UNKNOWN,,,,,,,2023,Q3,Therapy non-responder,,2023,Q3,6,F,,20230908.0,20200813,20230912,EXP,,ES-ROCHE-2657950,ROCHE,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno De La Higuera MA, Lucena R, et al. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft.. Nephron. 2020;144(6):304-309.",56.0,YR,,F,Y,,,20230912,,HP,ES,ES,2023,Q3,Adult
181423286,18142328,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,UNKNOWN,,,,,,,2023,Q3,Urinary tract infection enterococcal,,2023,Q3,6,F,,20230908.0,20200813,20230912,EXP,,ES-ROCHE-2657950,ROCHE,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno De La Higuera MA, Lucena R, et al. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft.. Nephron. 2020;144(6):304-309.",56.0,YR,,F,Y,,,20230912,,HP,ES,ES,2023,Q3,Adult
181423286,18142328,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,UNKNOWN,,,,,,,2023,Q3,Oliguria,,2023,Q3,6,F,,20230908.0,20200813,20230912,EXP,,ES-ROCHE-2657950,ROCHE,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno De La Higuera MA, Lucena R, et al. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft.. Nephron. 2020;144(6):304-309.",56.0,YR,,F,Y,,,20230912,,HP,ES,ES,2023,Q3,Adult
181423286,18142328,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,UNKNOWN,,,,,,,2023,Q3,Urinary tract candidiasis,,2023,Q3,6,F,,20230908.0,20200813,20230912,EXP,,ES-ROCHE-2657950,ROCHE,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno De La Higuera MA, Lucena R, et al. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft.. Nephron. 2020;144(6):304-309.",56.0,YR,,F,Y,,,20230912,,HP,ES,ES,2023,Q3,Adult
181423286,18142328,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,UNKNOWN,,,,,,,2023,Q3,Hypotension,,2023,Q3,6,F,,20230908.0,20200813,20230912,EXP,,ES-ROCHE-2657950,ROCHE,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno De La Higuera MA, Lucena R, et al. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft.. Nephron. 2020;144(6):304-309.",56.0,YR,,F,Y,,,20230912,,HP,ES,ES,2023,Q3,Adult
181423286,18142328,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,UNKNOWN,,,,,,,2023,Q3,Coagulation test abnormal,,2023,Q3,6,F,,20230908.0,20200813,20230912,EXP,,ES-ROCHE-2657950,ROCHE,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno De La Higuera MA, Lucena R, et al. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft.. Nephron. 2020;144(6):304-309.",56.0,YR,,F,Y,,,20230912,,HP,ES,ES,2023,Q3,Adult
181423286,18142328,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,UNKNOWN,,,,,,,2023,Q3,Renal impairment,,2023,Q3,6,F,,20230908.0,20200813,20230912,EXP,,ES-ROCHE-2657950,ROCHE,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno De La Higuera MA, Lucena R, et al. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft.. Nephron. 2020;144(6):304-309.",56.0,YR,,F,Y,,,20230912,,HP,ES,ES,2023,Q3,Adult
181423286,18142328,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,UNKNOWN,,,,,,,2023,Q3,Septic shock,,2023,Q3,6,F,,20230908.0,20200813,20230912,EXP,,ES-ROCHE-2657950,ROCHE,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno De La Higuera MA, Lucena R, et al. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft.. Nephron. 2020;144(6):304-309.",56.0,YR,,F,Y,,,20230912,,HP,ES,ES,2023,Q3,Adult
181423286,18142328,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,UNKNOWN,,,,,,,2023,Q3,Perinephric abscess,,2023,Q3,6,F,,20230908.0,20200813,20230912,EXP,,ES-ROCHE-2657950,ROCHE,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno De La Higuera MA, Lucena R, et al. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft.. Nephron. 2020;144(6):304-309.",56.0,YR,,F,Y,,,20230912,,HP,ES,ES,2023,Q3,Adult
181423286,18142328,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,UNKNOWN,,,,,,,2023,Q3,Pyelonephritis fungal,,2023,Q3,6,F,,20230908.0,20200813,20230912,EXP,,ES-ROCHE-2657950,ROCHE,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno De La Higuera MA, Lucena R, et al. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft.. Nephron. 2020;144(6):304-309.",56.0,YR,,F,Y,,,20230912,,HP,ES,ES,2023,Q3,Adult
181423286,18142328,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,UNKNOWN,,,,,,,2023,Q3,Vesicoureteric reflux,,2023,Q3,6,F,,20230908.0,20200813,20230912,EXP,,ES-ROCHE-2657950,ROCHE,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno De La Higuera MA, Lucena R, et al. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft.. Nephron. 2020;144(6):304-309.",56.0,YR,,F,Y,,,20230912,,HP,ES,ES,2023,Q3,Adult
181423286,18142328,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,UNKNOWN,,,,,,,2023,Q3,Urinary tract infection enterococcal,,2023,Q3,6,F,,20230908.0,20200813,20230912,EXP,,ES-ROCHE-2657950,ROCHE,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno De La Higuera MA, Lucena R, et al. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft.. Nephron. 2020;144(6):304-309.",56.0,YR,,F,Y,,,20230912,,HP,ES,ES,2023,Q3,Adult
181423286,18142328,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,UNKNOWN,,,,,,,2023,Q3,Emphysematous pyelonephritis,,2023,Q3,6,F,,20230908.0,20200813,20230912,EXP,,ES-ROCHE-2657950,ROCHE,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno De La Higuera MA, Lucena R, et al. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft.. Nephron. 2020;144(6):304-309.",56.0,YR,,F,Y,,,20230912,,HP,ES,ES,2023,Q3,Adult
181423286,18142328,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,UNKNOWN,,,,,,,2023,Q3,Candida sepsis,,2023,Q3,6,F,,20230908.0,20200813,20230912,EXP,,ES-ROCHE-2657950,ROCHE,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno De La Higuera MA, Lucena R, et al. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft.. Nephron. 2020;144(6):304-309.",56.0,YR,,F,Y,,,20230912,,HP,ES,ES,2023,Q3,Adult
181423286,18142328,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,UNKNOWN,,,,,,,2023,Q3,Systemic candida,,2023,Q3,6,F,,20230908.0,20200813,20230912,EXP,,ES-ROCHE-2657950,ROCHE,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno De La Higuera MA, Lucena R, et al. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft.. Nephron. 2020;144(6):304-309.",56.0,YR,,F,Y,,,20230912,,HP,ES,ES,2023,Q3,Adult
181759472,18175947,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q3,Candida infection,,2023,Q3,2,F,,20230907.0,20200820,20230908,EXP,,ES-PFIZER INC-2020308112,PFIZER,"Cases-Corona, C.. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft. Nephron. 2020;144(6):304-309",56.0,YR,,F,Y,,,20230908,,HP,ES,ES,2023,Q3,Adult
181759472,18175947,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q3,Coagulation test abnormal,,2023,Q3,2,F,,20230907.0,20200820,20230908,EXP,,ES-PFIZER INC-2020308112,PFIZER,"Cases-Corona, C.. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft. Nephron. 2020;144(6):304-309",56.0,YR,,F,Y,,,20230908,,HP,ES,ES,2023,Q3,Adult
181759472,18175947,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q3,Perinephric abscess,,2023,Q3,2,F,,20230907.0,20200820,20230908,EXP,,ES-PFIZER INC-2020308112,PFIZER,"Cases-Corona, C.. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft. Nephron. 2020;144(6):304-309",56.0,YR,,F,Y,,,20230908,,HP,ES,ES,2023,Q3,Adult
181759472,18175947,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q3,Systemic candida,,2023,Q3,2,F,,20230907.0,20200820,20230908,EXP,,ES-PFIZER INC-2020308112,PFIZER,"Cases-Corona, C.. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft. Nephron. 2020;144(6):304-309",56.0,YR,,F,Y,,,20230908,,HP,ES,ES,2023,Q3,Adult
181759472,18175947,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q3,Perinephric abscess,,2023,Q3,2,F,,20230907.0,20200820,20230908,EXP,,ES-PFIZER INC-2020308112,PFIZER,"Cases-Corona, C.. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft. Nephron. 2020;144(6):304-309",56.0,YR,,F,Y,,,20230908,,HP,ES,ES,2023,Q3,Adult
181759472,18175947,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q3,Candida sepsis,,2023,Q3,2,F,,20230907.0,20200820,20230908,EXP,,ES-PFIZER INC-2020308112,PFIZER,"Cases-Corona, C.. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft. Nephron. 2020;144(6):304-309",56.0,YR,,F,Y,,,20230908,,HP,ES,ES,2023,Q3,Adult
181759472,18175947,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q3,Oliguria,,2023,Q3,2,F,,20230907.0,20200820,20230908,EXP,,ES-PFIZER INC-2020308112,PFIZER,"Cases-Corona, C.. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft. Nephron. 2020;144(6):304-309",56.0,YR,,F,Y,,,20230908,,HP,ES,ES,2023,Q3,Adult
181759472,18175947,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q3,Candida sepsis,,2023,Q3,2,F,,20230907.0,20200820,20230908,EXP,,ES-PFIZER INC-2020308112,PFIZER,"Cases-Corona, C.. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft. Nephron. 2020;144(6):304-309",56.0,YR,,F,Y,,,20230908,,HP,ES,ES,2023,Q3,Adult
181759472,18175947,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q3,Vesicoureteric reflux,,2023,Q3,2,F,,20230907.0,20200820,20230908,EXP,,ES-PFIZER INC-2020308112,PFIZER,"Cases-Corona, C.. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft. Nephron. 2020;144(6):304-309",56.0,YR,,F,Y,,,20230908,,HP,ES,ES,2023,Q3,Adult
181759472,18175947,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q3,Coagulopathy,,2023,Q3,2,F,,20230907.0,20200820,20230908,EXP,,ES-PFIZER INC-2020308112,PFIZER,"Cases-Corona, C.. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft. Nephron. 2020;144(6):304-309",56.0,YR,,F,Y,,,20230908,,HP,ES,ES,2023,Q3,Adult
181759472,18175947,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q3,Emphysematous pyelonephritis,,2023,Q3,2,F,,20230907.0,20200820,20230908,EXP,,ES-PFIZER INC-2020308112,PFIZER,"Cases-Corona, C.. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft. Nephron. 2020;144(6):304-309",56.0,YR,,F,Y,,,20230908,,HP,ES,ES,2023,Q3,Adult
181759472,18175947,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q3,Urinary tract candidiasis,,2023,Q3,2,F,,20230907.0,20200820,20230908,EXP,,ES-PFIZER INC-2020308112,PFIZER,"Cases-Corona, C.. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft. Nephron. 2020;144(6):304-309",56.0,YR,,F,Y,,,20230908,,HP,ES,ES,2023,Q3,Adult
181759472,18175947,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q3,Urinary tract infection enterococcal,,2023,Q3,2,F,,20230907.0,20200820,20230908,EXP,,ES-PFIZER INC-2020308112,PFIZER,"Cases-Corona, C.. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft. Nephron. 2020;144(6):304-309",56.0,YR,,F,Y,,,20230908,,HP,ES,ES,2023,Q3,Adult
181759472,18175947,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q3,Hypotension,,2023,Q3,2,F,,20230907.0,20200820,20230908,EXP,,ES-PFIZER INC-2020308112,PFIZER,"Cases-Corona, C.. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft. Nephron. 2020;144(6):304-309",56.0,YR,,F,Y,,,20230908,,HP,ES,ES,2023,Q3,Adult
181759472,18175947,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q3,Septic shock,,2023,Q3,2,F,,20230907.0,20200820,20230908,EXP,,ES-PFIZER INC-2020308112,PFIZER,"Cases-Corona, C.. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft. Nephron. 2020;144(6):304-309",56.0,YR,,F,Y,,,20230908,,HP,ES,ES,2023,Q3,Adult
181759472,18175947,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q3,Pyelonephritis fungal,,2023,Q3,2,F,,20230907.0,20200820,20230908,EXP,,ES-PFIZER INC-2020308112,PFIZER,"Cases-Corona, C.. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft. Nephron. 2020;144(6):304-309",56.0,YR,,F,Y,,,20230908,,HP,ES,ES,2023,Q3,Adult
181759472,18175947,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q3,Renal impairment,,2023,Q3,2,F,,20230907.0,20200820,20230908,EXP,,ES-PFIZER INC-2020308112,PFIZER,"Cases-Corona, C.. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft. Nephron. 2020;144(6):304-309",56.0,YR,,F,Y,,,20230908,,HP,ES,ES,2023,Q3,Adult
181759472,18175947,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q3,Systemic candida,,2023,Q3,2,F,,20230907.0,20200820,20230908,EXP,,ES-PFIZER INC-2020308112,PFIZER,"Cases-Corona, C.. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft. Nephron. 2020;144(6):304-309",56.0,YR,,F,Y,,,20230908,,HP,ES,ES,2023,Q3,Adult
181759472,18175947,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,,,,,,2023,Q3,Candida infection,,2023,Q3,2,F,,20230907.0,20200820,20230908,EXP,,ES-PFIZER INC-2020308112,PFIZER,"Cases-Corona, C.. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft. Nephron. 2020;144(6):304-309",56.0,YR,,F,Y,,,20230908,,HP,ES,ES,2023,Q3,Adult
181759472,18175947,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,,,,,,2023,Q3,Coagulation test abnormal,,2023,Q3,2,F,,20230907.0,20200820,20230908,EXP,,ES-PFIZER INC-2020308112,PFIZER,"Cases-Corona, C.. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft. Nephron. 2020;144(6):304-309",56.0,YR,,F,Y,,,20230908,,HP,ES,ES,2023,Q3,Adult
181759472,18175947,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,,,,,,2023,Q3,Perinephric abscess,,2023,Q3,2,F,,20230907.0,20200820,20230908,EXP,,ES-PFIZER INC-2020308112,PFIZER,"Cases-Corona, C.. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft. Nephron. 2020;144(6):304-309",56.0,YR,,F,Y,,,20230908,,HP,ES,ES,2023,Q3,Adult
181759472,18175947,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,,,,,,2023,Q3,Systemic candida,,2023,Q3,2,F,,20230907.0,20200820,20230908,EXP,,ES-PFIZER INC-2020308112,PFIZER,"Cases-Corona, C.. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft. Nephron. 2020;144(6):304-309",56.0,YR,,F,Y,,,20230908,,HP,ES,ES,2023,Q3,Adult
181759472,18175947,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,,,,,,2023,Q3,Perinephric abscess,,2023,Q3,2,F,,20230907.0,20200820,20230908,EXP,,ES-PFIZER INC-2020308112,PFIZER,"Cases-Corona, C.. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft. Nephron. 2020;144(6):304-309",56.0,YR,,F,Y,,,20230908,,HP,ES,ES,2023,Q3,Adult
181759472,18175947,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,,,,,,2023,Q3,Candida sepsis,,2023,Q3,2,F,,20230907.0,20200820,20230908,EXP,,ES-PFIZER INC-2020308112,PFIZER,"Cases-Corona, C.. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft. Nephron. 2020;144(6):304-309",56.0,YR,,F,Y,,,20230908,,HP,ES,ES,2023,Q3,Adult
181759472,18175947,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,,,,,,2023,Q3,Oliguria,,2023,Q3,2,F,,20230907.0,20200820,20230908,EXP,,ES-PFIZER INC-2020308112,PFIZER,"Cases-Corona, C.. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft. Nephron. 2020;144(6):304-309",56.0,YR,,F,Y,,,20230908,,HP,ES,ES,2023,Q3,Adult
181759472,18175947,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,,,,,,2023,Q3,Candida sepsis,,2023,Q3,2,F,,20230907.0,20200820,20230908,EXP,,ES-PFIZER INC-2020308112,PFIZER,"Cases-Corona, C.. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft. Nephron. 2020;144(6):304-309",56.0,YR,,F,Y,,,20230908,,HP,ES,ES,2023,Q3,Adult
181759472,18175947,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,,,,,,2023,Q3,Vesicoureteric reflux,,2023,Q3,2,F,,20230907.0,20200820,20230908,EXP,,ES-PFIZER INC-2020308112,PFIZER,"Cases-Corona, C.. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft. Nephron. 2020;144(6):304-309",56.0,YR,,F,Y,,,20230908,,HP,ES,ES,2023,Q3,Adult
181759472,18175947,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,,,,,,2023,Q3,Coagulopathy,,2023,Q3,2,F,,20230907.0,20200820,20230908,EXP,,ES-PFIZER INC-2020308112,PFIZER,"Cases-Corona, C.. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft. Nephron. 2020;144(6):304-309",56.0,YR,,F,Y,,,20230908,,HP,ES,ES,2023,Q3,Adult
181759472,18175947,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,,,,,,2023,Q3,Emphysematous pyelonephritis,,2023,Q3,2,F,,20230907.0,20200820,20230908,EXP,,ES-PFIZER INC-2020308112,PFIZER,"Cases-Corona, C.. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft. Nephron. 2020;144(6):304-309",56.0,YR,,F,Y,,,20230908,,HP,ES,ES,2023,Q3,Adult
181759472,18175947,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,,,,,,2023,Q3,Urinary tract candidiasis,,2023,Q3,2,F,,20230907.0,20200820,20230908,EXP,,ES-PFIZER INC-2020308112,PFIZER,"Cases-Corona, C.. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft. Nephron. 2020;144(6):304-309",56.0,YR,,F,Y,,,20230908,,HP,ES,ES,2023,Q3,Adult
181759472,18175947,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,,,,,,2023,Q3,Urinary tract infection enterococcal,,2023,Q3,2,F,,20230907.0,20200820,20230908,EXP,,ES-PFIZER INC-2020308112,PFIZER,"Cases-Corona, C.. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft. Nephron. 2020;144(6):304-309",56.0,YR,,F,Y,,,20230908,,HP,ES,ES,2023,Q3,Adult
181759472,18175947,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,,,,,,2023,Q3,Hypotension,,2023,Q3,2,F,,20230907.0,20200820,20230908,EXP,,ES-PFIZER INC-2020308112,PFIZER,"Cases-Corona, C.. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft. Nephron. 2020;144(6):304-309",56.0,YR,,F,Y,,,20230908,,HP,ES,ES,2023,Q3,Adult
181759472,18175947,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,,,,,,2023,Q3,Septic shock,,2023,Q3,2,F,,20230907.0,20200820,20230908,EXP,,ES-PFIZER INC-2020308112,PFIZER,"Cases-Corona, C.. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft. Nephron. 2020;144(6):304-309",56.0,YR,,F,Y,,,20230908,,HP,ES,ES,2023,Q3,Adult
181759472,18175947,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,,,,,,2023,Q3,Pyelonephritis fungal,,2023,Q3,2,F,,20230907.0,20200820,20230908,EXP,,ES-PFIZER INC-2020308112,PFIZER,"Cases-Corona, C.. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft. Nephron. 2020;144(6):304-309",56.0,YR,,F,Y,,,20230908,,HP,ES,ES,2023,Q3,Adult
181759472,18175947,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,,,,,,2023,Q3,Renal impairment,,2023,Q3,2,F,,20230907.0,20200820,20230908,EXP,,ES-PFIZER INC-2020308112,PFIZER,"Cases-Corona, C.. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft. Nephron. 2020;144(6):304-309",56.0,YR,,F,Y,,,20230908,,HP,ES,ES,2023,Q3,Adult
181759472,18175947,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,,,,,,2023,Q3,Systemic candida,,2023,Q3,2,F,,20230907.0,20200820,20230908,EXP,,ES-PFIZER INC-2020308112,PFIZER,"Cases-Corona, C.. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft. Nephron. 2020;144(6):304-309",56.0,YR,,F,Y,,,20230908,,HP,ES,ES,2023,Q3,Adult
184309708,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Arthralgia,,2023,Q3,8,F,20200110.0,20230809.0,20201027,20230811,EXP,,NVSC2020CA010601,NOVARTIS,,57.0,YR,,F,Y,,,20230811,,CN,CA,CA,2023,Q3,Adult
184309708,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Alanine aminotransferase increased,,2023,Q3,8,F,20200110.0,20230809.0,20201027,20230811,EXP,,NVSC2020CA010601,NOVARTIS,,57.0,YR,,F,Y,,,20230811,,CN,CA,CA,2023,Q3,Adult
184309708,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Hepatic enzyme increased,,2023,Q3,8,F,20200110.0,20230809.0,20201027,20230811,EXP,,NVSC2020CA010601,NOVARTIS,,57.0,YR,,F,Y,,,20230811,,CN,CA,CA,2023,Q3,Adult
184309708,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Incorrect dose administered,,2023,Q3,8,F,20200110.0,20230809.0,20201027,20230811,EXP,,NVSC2020CA010601,NOVARTIS,,57.0,YR,,F,Y,,,20230811,,CN,CA,CA,2023,Q3,Adult
184309708,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Joint effusion,,2023,Q3,8,F,20200110.0,20230809.0,20201027,20230811,EXP,,NVSC2020CA010601,NOVARTIS,,57.0,YR,,F,Y,,,20230811,,CN,CA,CA,2023,Q3,Adult
184309708,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Injection site warmth,,2023,Q3,8,F,20200110.0,20230809.0,20201027,20230811,EXP,,NVSC2020CA010601,NOVARTIS,,57.0,YR,,F,Y,,,20230811,,CN,CA,CA,2023,Q3,Adult
184309708,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Synovitis,,2023,Q3,8,F,20200110.0,20230809.0,20201027,20230811,EXP,,NVSC2020CA010601,NOVARTIS,,57.0,YR,,F,Y,,,20230811,,CN,CA,CA,2023,Q3,Adult
184309708,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Psoriasis,,2023,Q3,8,F,20200110.0,20230809.0,20201027,20230811,EXP,,NVSC2020CA010601,NOVARTIS,,57.0,YR,,F,Y,,,20230811,,CN,CA,CA,2023,Q3,Adult
184309708,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Drug ineffective,,2023,Q3,8,F,20200110.0,20230809.0,20201027,20230811,EXP,,NVSC2020CA010601,NOVARTIS,,57.0,YR,,F,Y,,,20230811,,CN,CA,CA,2023,Q3,Adult
184309708,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Synovial disorder,,2023,Q3,8,F,20200110.0,20230809.0,20201027,20230811,EXP,,NVSC2020CA010601,NOVARTIS,,57.0,YR,,F,Y,,,20230811,,CN,CA,CA,2023,Q3,Adult
184309708,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Pain in extremity,,2023,Q3,8,F,20200110.0,20230809.0,20201027,20230811,EXP,,NVSC2020CA010601,NOVARTIS,,57.0,YR,,F,Y,,,20230811,,CN,CA,CA,2023,Q3,Adult
184309708,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Tendonitis,,2023,Q3,8,F,20200110.0,20230809.0,20201027,20230811,EXP,,NVSC2020CA010601,NOVARTIS,,57.0,YR,,F,Y,,,20230811,,CN,CA,CA,2023,Q3,Adult
184309708,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Blood uric acid increased,,2023,Q3,8,F,20200110.0,20230809.0,20201027,20230811,EXP,,NVSC2020CA010601,NOVARTIS,,57.0,YR,,F,Y,,,20230811,,CN,CA,CA,2023,Q3,Adult
184309708,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Condition aggravated,,2023,Q3,8,F,20200110.0,20230809.0,20201027,20230811,EXP,,NVSC2020CA010601,NOVARTIS,,57.0,YR,,F,Y,,,20230811,,CN,CA,CA,2023,Q3,Adult
184309708,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Nephrolithiasis,,2023,Q3,8,F,20200110.0,20230809.0,20201027,20230811,EXP,,NVSC2020CA010601,NOVARTIS,,57.0,YR,,F,Y,,,20230811,,CN,CA,CA,2023,Q3,Adult
184309708,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Blood iron decreased,,2023,Q3,8,F,20200110.0,20230809.0,20201027,20230811,EXP,,NVSC2020CA010601,NOVARTIS,,57.0,YR,,F,Y,,,20230811,,CN,CA,CA,2023,Q3,Adult
184309708,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Pyrexia,,2023,Q3,8,F,20200110.0,20230809.0,20201027,20230811,EXP,,NVSC2020CA010601,NOVARTIS,,57.0,YR,,F,Y,,,20230811,,CN,CA,CA,2023,Q3,Adult
184309708,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Vitamin B12 decreased,,2023,Q3,8,F,20200110.0,20230809.0,20201027,20230811,EXP,,NVSC2020CA010601,NOVARTIS,,57.0,YR,,F,Y,,,20230811,,CN,CA,CA,2023,Q3,Adult
184309708,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Cyst,,2023,Q3,8,F,20200110.0,20230809.0,20201027,20230811,EXP,,NVSC2020CA010601,NOVARTIS,,57.0,YR,,F,Y,,,20230811,,CN,CA,CA,2023,Q3,Adult
184309708,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Arthropathy,,2023,Q3,8,F,20200110.0,20230809.0,20201027,20230811,EXP,,NVSC2020CA010601,NOVARTIS,,57.0,YR,,F,Y,,,20230811,,CN,CA,CA,2023,Q3,Adult
184309708,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Injection site pain,,2023,Q3,8,F,20200110.0,20230809.0,20201027,20230811,EXP,,NVSC2020CA010601,NOVARTIS,,57.0,YR,,F,Y,,,20230811,,CN,CA,CA,2023,Q3,Adult
184309708,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Pain,,2023,Q3,8,F,20200110.0,20230809.0,20201027,20230811,EXP,,NVSC2020CA010601,NOVARTIS,,57.0,YR,,F,Y,,,20230811,,CN,CA,CA,2023,Q3,Adult
184309708,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,C-reactive protein increased,,2023,Q3,8,F,20200110.0,20230809.0,20201027,20230811,EXP,,NVSC2020CA010601,NOVARTIS,,57.0,YR,,F,Y,,,20230811,,CN,CA,CA,2023,Q3,Adult
184309708,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Rash,,2023,Q3,8,F,20200110.0,20230809.0,20201027,20230811,EXP,,NVSC2020CA010601,NOVARTIS,,57.0,YR,,F,Y,,,20230811,,CN,CA,CA,2023,Q3,Adult
184309708,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Joint swelling,,2023,Q3,8,F,20200110.0,20230809.0,20201027,20230811,EXP,,NVSC2020CA010601,NOVARTIS,,57.0,YR,,F,Y,,,20230811,,CN,CA,CA,2023,Q3,Adult
184309708,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Allergic sinusitis,,2023,Q3,8,F,20200110.0,20230809.0,20201027,20230811,EXP,,NVSC2020CA010601,NOVARTIS,,57.0,YR,,F,Y,,,20230811,,CN,CA,CA,2023,Q3,Adult
184309708,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Osteoarthritis,,2023,Q3,8,F,20200110.0,20230809.0,20201027,20230811,EXP,,NVSC2020CA010601,NOVARTIS,,57.0,YR,,F,Y,,,20230811,,CN,CA,CA,2023,Q3,Adult
184309708,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Sepsis,,2023,Q3,8,F,20200110.0,20230809.0,20201027,20230811,EXP,,NVSC2020CA010601,NOVARTIS,,57.0,YR,,F,Y,,,20230811,,CN,CA,CA,2023,Q3,Adult
184309708,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Renal disorder,,2023,Q3,8,F,20200110.0,20230809.0,20201027,20230811,EXP,,NVSC2020CA010601,NOVARTIS,,57.0,YR,,F,Y,,,20230811,,CN,CA,CA,2023,Q3,Adult
184309708,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Oedema,,2023,Q3,8,F,20200110.0,20230809.0,20201027,20230811,EXP,,NVSC2020CA010601,NOVARTIS,,57.0,YR,,F,Y,,,20230811,,CN,CA,CA,2023,Q3,Adult
184309708,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Urinary tract infection,,2023,Q3,8,F,20200110.0,20230809.0,20201027,20230811,EXP,,NVSC2020CA010601,NOVARTIS,,57.0,YR,,F,Y,,,20230811,,CN,CA,CA,2023,Q3,Adult
184309708,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Arthritis,,2023,Q3,8,F,20200110.0,20230809.0,20201027,20230811,EXP,,NVSC2020CA010601,NOVARTIS,,57.0,YR,,F,Y,,,20230811,,CN,CA,CA,2023,Q3,Adult
184309708,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Antinuclear antibody positive,,2023,Q3,8,F,20200110.0,20230809.0,20201027,20230811,EXP,,NVSC2020CA010601,NOVARTIS,,57.0,YR,,F,Y,,,20230811,,CN,CA,CA,2023,Q3,Adult
184839364,18483936,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q3,Pain,,2023,Q3,4,F,,20230908.0,20201110,20230913,EXP,,ES-SA-2020SA311347,SANOFI AVENTIS,,56.0,YR,A,F,Y,,,20230913,,MD,ES,ES,2023,Q3,Adult
184839364,18483936,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q3,Tenderness,,2023,Q3,4,F,,20230908.0,20201110,20230913,EXP,,ES-SA-2020SA311347,SANOFI AVENTIS,,56.0,YR,A,F,Y,,,20230913,,MD,ES,ES,2023,Q3,Adult
184839364,18483936,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q3,Emphysematous pyelonephritis,,2023,Q3,4,F,,20230908.0,20201110,20230913,EXP,,ES-SA-2020SA311347,SANOFI AVENTIS,,56.0,YR,A,F,Y,,,20230913,,MD,ES,ES,2023,Q3,Adult
184839364,18483936,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q3,Malaise,,2023,Q3,4,F,,20230908.0,20201110,20230913,EXP,,ES-SA-2020SA311347,SANOFI AVENTIS,,56.0,YR,A,F,Y,,,20230913,,MD,ES,ES,2023,Q3,Adult
184839364,18483936,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q3,Candida sepsis,,2023,Q3,4,F,,20230908.0,20201110,20230913,EXP,,ES-SA-2020SA311347,SANOFI AVENTIS,,56.0,YR,A,F,Y,,,20230913,,MD,ES,ES,2023,Q3,Adult
184839364,18483936,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q3,Pyelonephritis acute,,2023,Q3,4,F,,20230908.0,20201110,20230913,EXP,,ES-SA-2020SA311347,SANOFI AVENTIS,,56.0,YR,A,F,Y,,,20230913,,MD,ES,ES,2023,Q3,Adult
184839364,18483936,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q3,Pyrexia,,2023,Q3,4,F,,20230908.0,20201110,20230913,EXP,,ES-SA-2020SA311347,SANOFI AVENTIS,,56.0,YR,A,F,Y,,,20230913,,MD,ES,ES,2023,Q3,Adult
184839364,18483936,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q3,Renal impairment,,2023,Q3,4,F,,20230908.0,20201110,20230913,EXP,,ES-SA-2020SA311347,SANOFI AVENTIS,,56.0,YR,A,F,Y,,,20230913,,MD,ES,ES,2023,Q3,Adult
184839364,18483936,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q3,Candida infection,,2023,Q3,4,F,,20230908.0,20201110,20230913,EXP,,ES-SA-2020SA311347,SANOFI AVENTIS,,56.0,YR,A,F,Y,,,20230913,,MD,ES,ES,2023,Q3,Adult
184839364,18483936,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q3,Coagulation test abnormal,,2023,Q3,4,F,,20230908.0,20201110,20230913,EXP,,ES-SA-2020SA311347,SANOFI AVENTIS,,56.0,YR,A,F,Y,,,20230913,,MD,ES,ES,2023,Q3,Adult
184839364,18483936,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q3,Hypotension,,2023,Q3,4,F,,20230908.0,20201110,20230913,EXP,,ES-SA-2020SA311347,SANOFI AVENTIS,,56.0,YR,A,F,Y,,,20230913,,MD,ES,ES,2023,Q3,Adult
184839364,18483936,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q3,Septic shock,,2023,Q3,4,F,,20230908.0,20201110,20230913,EXP,,ES-SA-2020SA311347,SANOFI AVENTIS,,56.0,YR,A,F,Y,,,20230913,,MD,ES,ES,2023,Q3,Adult
184839364,18483936,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q3,Pyuria,,2023,Q3,4,F,,20230908.0,20201110,20230913,EXP,,ES-SA-2020SA311347,SANOFI AVENTIS,,56.0,YR,A,F,Y,,,20230913,,MD,ES,ES,2023,Q3,Adult
184839364,18483936,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q3,Oliguria,,2023,Q3,4,F,,20230908.0,20201110,20230913,EXP,,ES-SA-2020SA311347,SANOFI AVENTIS,,56.0,YR,A,F,Y,,,20230913,,MD,ES,ES,2023,Q3,Adult
184839364,18483936,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q3,Pyelonephritis fungal,,2023,Q3,4,F,,20230908.0,20201110,20230913,EXP,,ES-SA-2020SA311347,SANOFI AVENTIS,,56.0,YR,A,F,Y,,,20230913,,MD,ES,ES,2023,Q3,Adult
184839364,18483936,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q3,Chills,,2023,Q3,4,F,,20230908.0,20201110,20230913,EXP,,ES-SA-2020SA311347,SANOFI AVENTIS,,56.0,YR,A,F,Y,,,20230913,,MD,ES,ES,2023,Q3,Adult
184839364,18483936,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q3,Abdominal pain,,2023,Q3,4,F,,20230908.0,20201110,20230913,EXP,,ES-SA-2020SA311347,SANOFI AVENTIS,,56.0,YR,A,F,Y,,,20230913,,MD,ES,ES,2023,Q3,Adult
184839364,18483936,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q3,Urinary tract candidiasis,,2023,Q3,4,F,,20230908.0,20201110,20230913,EXP,,ES-SA-2020SA311347,SANOFI AVENTIS,,56.0,YR,A,F,Y,,,20230913,,MD,ES,ES,2023,Q3,Adult
184839364,18483936,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q3,Perinephric abscess,,2023,Q3,4,F,,20230908.0,20201110,20230913,EXP,,ES-SA-2020SA311347,SANOFI AVENTIS,,56.0,YR,A,F,Y,,,20230913,,MD,ES,ES,2023,Q3,Adult
184839364,18483936,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q3,Vesicoureteric reflux,,2023,Q3,4,F,,20230908.0,20201110,20230913,EXP,,ES-SA-2020SA311347,SANOFI AVENTIS,,56.0,YR,A,F,Y,,,20230913,,MD,ES,ES,2023,Q3,Adult
184839364,18483936,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q3,Tachycardia,,2023,Q3,4,F,,20230908.0,20201110,20230913,EXP,,ES-SA-2020SA311347,SANOFI AVENTIS,,56.0,YR,A,F,Y,,,20230913,,MD,ES,ES,2023,Q3,Adult
184839364,18483936,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q3,Pyelonephritis acute,,2023,Q3,4,F,,20230908.0,20201110,20230913,EXP,,ES-SA-2020SA311347,SANOFI AVENTIS,,56.0,YR,A,F,Y,,,20230913,,MD,ES,ES,2023,Q3,Adult
184839364,18483936,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q3,Urinary tract infection enterococcal,,2023,Q3,4,F,,20230908.0,20201110,20230913,EXP,,ES-SA-2020SA311347,SANOFI AVENTIS,,56.0,YR,A,F,Y,,,20230913,,MD,ES,ES,2023,Q3,Adult
184839364,18483936,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q3,Dysuria,,2023,Q3,4,F,,20230908.0,20201110,20230913,EXP,,ES-SA-2020SA311347,SANOFI AVENTIS,,56.0,YR,A,F,Y,,,20230913,,MD,ES,ES,2023,Q3,Adult
187836983,18783698,23,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2023,Q3,Polyuria,,2023,Q3,3,F,20201022.0,20230920.0,20210125,20230928,EXP,,"CA-REGENERON PHARMACEUTICALS, INC.-2021-14618",REGENERON,,78.0,YR,,M,Y,,,20230928,,MD,CA,CA,2023,Q3,Elderly
187836983,18783698,23,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2023,Q3,Chronic kidney disease,,2023,Q3,3,F,20201022.0,20230920.0,20210125,20230928,EXP,,"CA-REGENERON PHARMACEUTICALS, INC.-2021-14618",REGENERON,,78.0,YR,,M,Y,,,20230928,,MD,CA,CA,2023,Q3,Elderly
187836983,18783698,23,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2023,Q3,Cardiac failure,,2023,Q3,3,F,20201022.0,20230920.0,20210125,20230928,EXP,,"CA-REGENERON PHARMACEUTICALS, INC.-2021-14618",REGENERON,,78.0,YR,,M,Y,,,20230928,,MD,CA,CA,2023,Q3,Elderly
187836983,18783698,23,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2023,Q3,Acute kidney injury,,2023,Q3,3,F,20201022.0,20230920.0,20210125,20230928,EXP,,"CA-REGENERON PHARMACEUTICALS, INC.-2021-14618",REGENERON,,78.0,YR,,M,Y,,,20230928,,MD,CA,CA,2023,Q3,Elderly
187836983,18783698,23,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2023,Q3,Dehydration,,2023,Q3,3,F,20201022.0,20230920.0,20210125,20230928,EXP,,"CA-REGENERON PHARMACEUTICALS, INC.-2021-14618",REGENERON,,78.0,YR,,M,Y,,,20230928,,MD,CA,CA,2023,Q3,Elderly
187836983,18783698,23,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2023,Q3,Syncope,,2023,Q3,3,F,20201022.0,20230920.0,20210125,20230928,EXP,,"CA-REGENERON PHARMACEUTICALS, INC.-2021-14618",REGENERON,,78.0,YR,,M,Y,,,20230928,,MD,CA,CA,2023,Q3,Elderly
196793053,19679305,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Renal impairment,,2023,Q3,3,F,20140601.0,20230915.0,20210809,20230920,PER,,US-GILEAD-2021-0542480,GILEAD,,41.0,YR,A,F,Y,147.39,KG,20230920,,LW,US,US,2023,Q3,Adult
196793053,19679305,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Acute kidney injury,,2023,Q3,3,F,20140601.0,20230915.0,20210809,20230920,PER,,US-GILEAD-2021-0542480,GILEAD,,41.0,YR,A,F,Y,147.39,KG,20230920,,LW,US,US,2023,Q3,Adult
196793053,19679305,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Blood creatinine increased,,2023,Q3,3,F,20140601.0,20230915.0,20210809,20230920,PER,,US-GILEAD-2021-0542480,GILEAD,,41.0,YR,A,F,Y,147.39,KG,20230920,,LW,US,US,2023,Q3,Adult
196793053,19679305,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Anxiety,,2023,Q3,3,F,20140601.0,20230915.0,20210809,20230920,PER,,US-GILEAD-2021-0542480,GILEAD,,41.0,YR,A,F,Y,147.39,KG,20230920,,LW,US,US,2023,Q3,Adult
196793053,19679305,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Anhedonia,,2023,Q3,3,F,20140601.0,20230915.0,20210809,20230920,PER,,US-GILEAD-2021-0542480,GILEAD,,41.0,YR,A,F,Y,147.39,KG,20230920,,LW,US,US,2023,Q3,Adult
196793053,19679305,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Asthenia,,2023,Q3,3,F,20140601.0,20230915.0,20210809,20230920,PER,,US-GILEAD-2021-0542480,GILEAD,,41.0,YR,A,F,Y,147.39,KG,20230920,,LW,US,US,2023,Q3,Adult
196793053,19679305,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Emotional distress,,2023,Q3,3,F,20140601.0,20230915.0,20210809,20230920,PER,,US-GILEAD-2021-0542480,GILEAD,,41.0,YR,A,F,Y,147.39,KG,20230920,,LW,US,US,2023,Q3,Adult
196793053,19679305,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Pain,,2023,Q3,3,F,20140601.0,20230915.0,20210809,20230920,PER,,US-GILEAD-2021-0542480,GILEAD,,41.0,YR,A,F,Y,147.39,KG,20230920,,LW,US,US,2023,Q3,Adult
196793053,19679305,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Fatigue,,2023,Q3,3,F,20140601.0,20230915.0,20210809,20230920,PER,,US-GILEAD-2021-0542480,GILEAD,,41.0,YR,A,F,Y,147.39,KG,20230920,,LW,US,US,2023,Q3,Adult
196793053,19679305,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Blood test abnormal,,2023,Q3,3,F,20140601.0,20230915.0,20210809,20230920,PER,,US-GILEAD-2021-0542480,GILEAD,,41.0,YR,A,F,Y,147.39,KG,20230920,,LW,US,US,2023,Q3,Adult
200475745,20047574,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,D,,,,,10.0,MG,,QD,2023,Q3,Renal disorder,,2023,Q3,5,F,,20220413.0,20211109,20230809,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20230809,,MD,PT,PT,2023,Q3,Elderly
200475745,20047574,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,D,,,,,10.0,MG,,QD,2023,Q3,Shock,,2023,Q3,5,F,,20220413.0,20211109,20230809,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20230809,,MD,PT,PT,2023,Q3,Elderly
200475745,20047574,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,D,,,,,10.0,MG,,QD,2023,Q3,Aortic thrombosis,,2023,Q3,5,F,,20220413.0,20211109,20230809,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20230809,,MD,PT,PT,2023,Q3,Elderly
200475745,20047574,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,D,,,,,10.0,MG,,QD,2023,Q3,Oliguria,,2023,Q3,5,F,,20220413.0,20211109,20230809,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20230809,,MD,PT,PT,2023,Q3,Elderly
200475745,20047574,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,D,,,,,10.0,MG,,QD,2023,Q3,Multiple organ dysfunction syndrome,,2023,Q3,5,F,,20220413.0,20211109,20230809,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20230809,,MD,PT,PT,2023,Q3,Elderly
200475745,20047574,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,D,,,,,10.0,MG,,QD,2023,Q3,Tachycardia,,2023,Q3,5,F,,20220413.0,20211109,20230809,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20230809,,MD,PT,PT,2023,Q3,Elderly
200475745,20047574,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,D,,,,,10.0,MG,,QD,2023,Q3,Mesenteric artery thrombosis,,2023,Q3,5,F,,20220413.0,20211109,20230809,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20230809,,MD,PT,PT,2023,Q3,Elderly
200475745,20047574,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,D,,,,,10.0,MG,,QD,2023,Q3,Euglycaemic diabetic ketoacidosis,,2023,Q3,5,F,,20220413.0,20211109,20230809,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20230809,,MD,PT,PT,2023,Q3,Elderly
200475745,20047574,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,D,,,,,10.0,MG,,QD,2023,Q3,Acidosis,,2023,Q3,5,F,,20220413.0,20211109,20230809,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20230809,,MD,PT,PT,2023,Q3,Elderly
200475745,20047574,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,D,,,,,10.0,MG,,QD,2023,Q3,Death,,2023,Q3,5,F,,20220413.0,20211109,20230809,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20230809,,MD,PT,PT,2023,Q3,Elderly
200475745,20047574,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,D,,,,,10.0,MG,,QD,2023,Q3,Bronchospasm,,2023,Q3,5,F,,20220413.0,20211109,20230809,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20230809,,MD,PT,PT,2023,Q3,Elderly
200475745,20047574,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,D,,,,,10.0,MG,,QD,2023,Q3,Acute kidney injury,,2023,Q3,5,F,,20220413.0,20211109,20230809,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20230809,,MD,PT,PT,2023,Q3,Elderly
200475745,20047574,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,D,,,,,10.0,MG,,QD,2023,Q3,Tachypnoea,,2023,Q3,5,F,,20220413.0,20211109,20230809,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20230809,,MD,PT,PT,2023,Q3,Elderly
200475745,20047574,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,D,,,,,10.0,MG,,QD,2023,Q3,Asthenia,,2023,Q3,5,F,,20220413.0,20211109,20230809,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20230809,,MD,PT,PT,2023,Q3,Elderly
200475745,20047574,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,D,,,,,10.0,MG,,QD,2023,Q3,Hyperhidrosis,,2023,Q3,5,F,,20220413.0,20211109,20230809,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20230809,,MD,PT,PT,2023,Q3,Elderly
200475745,20047574,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,D,,,,,10.0,MG,,QD,2023,Q3,Metabolic acidosis,,2023,Q3,5,F,,20220413.0,20211109,20230809,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20230809,,MD,PT,PT,2023,Q3,Elderly
200475745,20047574,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,D,,,,,10.0,MG,,QD,2023,Q3,Venous pressure jugular,,2023,Q3,5,F,,20220413.0,20211109,20230809,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20230809,,MD,PT,PT,2023,Q3,Elderly
200475745,20047574,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,D,,,,,10.0,MG,,QD,2023,Q3,Renal artery thrombosis,,2023,Q3,5,F,,20220413.0,20211109,20230809,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20230809,,MD,PT,PT,2023,Q3,Elderly
200475745,20047574,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,D,,,,,10.0,MG,,QD,2023,Q3,Orthopnoea,,2023,Q3,5,F,,20220413.0,20211109,20230809,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20230809,,MD,PT,PT,2023,Q3,Elderly
200475745,20047574,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,D,,,,,10.0,MG,,QD,2023,Q3,Acute abdomen,,2023,Q3,5,F,,20220413.0,20211109,20230809,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20230809,,MD,PT,PT,2023,Q3,Elderly
200475745,20047574,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1000 milligram, Once a Day",,,D,,,,,1000.0,MG,,QD,2023,Q3,Renal disorder,,2023,Q3,5,F,,20220413.0,20211109,20230809,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20230809,,MD,PT,PT,2023,Q3,Elderly
200475745,20047574,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1000 milligram, Once a Day",,,D,,,,,1000.0,MG,,QD,2023,Q3,Shock,,2023,Q3,5,F,,20220413.0,20211109,20230809,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20230809,,MD,PT,PT,2023,Q3,Elderly
200475745,20047574,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1000 milligram, Once a Day",,,D,,,,,1000.0,MG,,QD,2023,Q3,Aortic thrombosis,,2023,Q3,5,F,,20220413.0,20211109,20230809,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20230809,,MD,PT,PT,2023,Q3,Elderly
200475745,20047574,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1000 milligram, Once a Day",,,D,,,,,1000.0,MG,,QD,2023,Q3,Oliguria,,2023,Q3,5,F,,20220413.0,20211109,20230809,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20230809,,MD,PT,PT,2023,Q3,Elderly
200475745,20047574,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1000 milligram, Once a Day",,,D,,,,,1000.0,MG,,QD,2023,Q3,Multiple organ dysfunction syndrome,,2023,Q3,5,F,,20220413.0,20211109,20230809,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20230809,,MD,PT,PT,2023,Q3,Elderly
200475745,20047574,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1000 milligram, Once a Day",,,D,,,,,1000.0,MG,,QD,2023,Q3,Tachycardia,,2023,Q3,5,F,,20220413.0,20211109,20230809,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20230809,,MD,PT,PT,2023,Q3,Elderly
200475745,20047574,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1000 milligram, Once a Day",,,D,,,,,1000.0,MG,,QD,2023,Q3,Mesenteric artery thrombosis,,2023,Q3,5,F,,20220413.0,20211109,20230809,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20230809,,MD,PT,PT,2023,Q3,Elderly
200475745,20047574,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1000 milligram, Once a Day",,,D,,,,,1000.0,MG,,QD,2023,Q3,Euglycaemic diabetic ketoacidosis,,2023,Q3,5,F,,20220413.0,20211109,20230809,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20230809,,MD,PT,PT,2023,Q3,Elderly
200475745,20047574,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1000 milligram, Once a Day",,,D,,,,,1000.0,MG,,QD,2023,Q3,Acidosis,,2023,Q3,5,F,,20220413.0,20211109,20230809,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20230809,,MD,PT,PT,2023,Q3,Elderly
200475745,20047574,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1000 milligram, Once a Day",,,D,,,,,1000.0,MG,,QD,2023,Q3,Death,,2023,Q3,5,F,,20220413.0,20211109,20230809,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20230809,,MD,PT,PT,2023,Q3,Elderly
200475745,20047574,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1000 milligram, Once a Day",,,D,,,,,1000.0,MG,,QD,2023,Q3,Bronchospasm,,2023,Q3,5,F,,20220413.0,20211109,20230809,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20230809,,MD,PT,PT,2023,Q3,Elderly
200475745,20047574,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1000 milligram, Once a Day",,,D,,,,,1000.0,MG,,QD,2023,Q3,Acute kidney injury,,2023,Q3,5,F,,20220413.0,20211109,20230809,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20230809,,MD,PT,PT,2023,Q3,Elderly
200475745,20047574,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1000 milligram, Once a Day",,,D,,,,,1000.0,MG,,QD,2023,Q3,Tachypnoea,,2023,Q3,5,F,,20220413.0,20211109,20230809,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20230809,,MD,PT,PT,2023,Q3,Elderly
200475745,20047574,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1000 milligram, Once a Day",,,D,,,,,1000.0,MG,,QD,2023,Q3,Asthenia,,2023,Q3,5,F,,20220413.0,20211109,20230809,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20230809,,MD,PT,PT,2023,Q3,Elderly
200475745,20047574,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1000 milligram, Once a Day",,,D,,,,,1000.0,MG,,QD,2023,Q3,Hyperhidrosis,,2023,Q3,5,F,,20220413.0,20211109,20230809,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20230809,,MD,PT,PT,2023,Q3,Elderly
200475745,20047574,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1000 milligram, Once a Day",,,D,,,,,1000.0,MG,,QD,2023,Q3,Metabolic acidosis,,2023,Q3,5,F,,20220413.0,20211109,20230809,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20230809,,MD,PT,PT,2023,Q3,Elderly
200475745,20047574,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1000 milligram, Once a Day",,,D,,,,,1000.0,MG,,QD,2023,Q3,Venous pressure jugular,,2023,Q3,5,F,,20220413.0,20211109,20230809,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20230809,,MD,PT,PT,2023,Q3,Elderly
200475745,20047574,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1000 milligram, Once a Day",,,D,,,,,1000.0,MG,,QD,2023,Q3,Renal artery thrombosis,,2023,Q3,5,F,,20220413.0,20211109,20230809,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20230809,,MD,PT,PT,2023,Q3,Elderly
200475745,20047574,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1000 milligram, Once a Day",,,D,,,,,1000.0,MG,,QD,2023,Q3,Orthopnoea,,2023,Q3,5,F,,20220413.0,20211109,20230809,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20230809,,MD,PT,PT,2023,Q3,Elderly
200475745,20047574,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1000 milligram, Once a Day",,,D,,,,,1000.0,MG,,QD,2023,Q3,Acute abdomen,,2023,Q3,5,F,,20220413.0,20211109,20230809,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20230809,,MD,PT,PT,2023,Q3,Elderly
200957176,20095717,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q3,C-reactive protein increased,,2023,Q3,6,F,20200309.0,20230712.0,20211122,20230921,EXP,,NVSC2020CA082760,NOVARTIS,,40.0,YR,,F,Y,,,20230921,,MD,CA,CA,2023,Q3,Adult
200957176,20095717,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q3,Weight decreased,,2023,Q3,6,F,20200309.0,20230712.0,20211122,20230921,EXP,,NVSC2020CA082760,NOVARTIS,,40.0,YR,,F,Y,,,20230921,,MD,CA,CA,2023,Q3,Adult
200957176,20095717,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q3,Hepatotoxicity,,2023,Q3,6,F,20200309.0,20230712.0,20211122,20230921,EXP,,NVSC2020CA082760,NOVARTIS,,40.0,YR,,F,Y,,,20230921,,MD,CA,CA,2023,Q3,Adult
200957176,20095717,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q3,Off label use,,2023,Q3,6,F,20200309.0,20230712.0,20211122,20230921,EXP,,NVSC2020CA082760,NOVARTIS,,40.0,YR,,F,Y,,,20230921,,MD,CA,CA,2023,Q3,Adult
200957176,20095717,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q3,Drug ineffective,,2023,Q3,6,F,20200309.0,20230712.0,20211122,20230921,EXP,,NVSC2020CA082760,NOVARTIS,,40.0,YR,,F,Y,,,20230921,,MD,CA,CA,2023,Q3,Adult
200957176,20095717,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q3,Condition aggravated,,2023,Q3,6,F,20200309.0,20230712.0,20211122,20230921,EXP,,NVSC2020CA082760,NOVARTIS,,40.0,YR,,F,Y,,,20230921,,MD,CA,CA,2023,Q3,Adult
200957176,20095717,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q3,Psoriasis,,2023,Q3,6,F,20200309.0,20230712.0,20211122,20230921,EXP,,NVSC2020CA082760,NOVARTIS,,40.0,YR,,F,Y,,,20230921,,MD,CA,CA,2023,Q3,Adult
201162337,20116233,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd",,,,,,,,,,,QD,2023,Q3,Hypothyroidism,,2023,Q3,7,F,20210716.0,20230726.0,20211126,20230731,EXP,,GB-AMGEN-GBRNI2021185238,AMGEN,,69.0,YR,E,F,Y,79.1,KG,20230731,,MD,GB,GB,2023,Q3,Elderly
201162337,20116233,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd",,,,,,,,,,,QD,2023,Q3,Glycosuria,,2023,Q3,7,F,20210716.0,20230726.0,20211126,20230731,EXP,,GB-AMGEN-GBRNI2021185238,AMGEN,,69.0,YR,E,F,Y,79.1,KG,20230731,,MD,GB,GB,2023,Q3,Elderly
201162337,20116233,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd",,,,,,,,,,,QD,2023,Q3,Hyperthyroidism,,2023,Q3,7,F,20210716.0,20230726.0,20211126,20230731,EXP,,GB-AMGEN-GBRNI2021185238,AMGEN,,69.0,YR,E,F,Y,79.1,KG,20230731,,MD,GB,GB,2023,Q3,Elderly
201162337,20116233,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd",,,,,,,,,,,QD,2023,Q3,Diarrhoea,,2023,Q3,7,F,20210716.0,20230726.0,20211126,20230731,EXP,,GB-AMGEN-GBRNI2021185238,AMGEN,,69.0,YR,E,F,Y,79.1,KG,20230731,,MD,GB,GB,2023,Q3,Elderly
201162337,20116233,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd",,,,,,,,,,,QD,2023,Q3,Haematuria,,2023,Q3,7,F,20210716.0,20230726.0,20211126,20230731,EXP,,GB-AMGEN-GBRNI2021185238,AMGEN,,69.0,YR,E,F,Y,79.1,KG,20230731,,MD,GB,GB,2023,Q3,Elderly
201162337,20116233,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Hypothyroidism,,2023,Q3,7,F,20210716.0,20230726.0,20211126,20230731,EXP,,GB-AMGEN-GBRNI2021185238,AMGEN,,69.0,YR,E,F,Y,79.1,KG,20230731,,MD,GB,GB,2023,Q3,Elderly
201162337,20116233,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Glycosuria,,2023,Q3,7,F,20210716.0,20230726.0,20211126,20230731,EXP,,GB-AMGEN-GBRNI2021185238,AMGEN,,69.0,YR,E,F,Y,79.1,KG,20230731,,MD,GB,GB,2023,Q3,Elderly
201162337,20116233,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Hyperthyroidism,,2023,Q3,7,F,20210716.0,20230726.0,20211126,20230731,EXP,,GB-AMGEN-GBRNI2021185238,AMGEN,,69.0,YR,E,F,Y,79.1,KG,20230731,,MD,GB,GB,2023,Q3,Elderly
201162337,20116233,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Diarrhoea,,2023,Q3,7,F,20210716.0,20230726.0,20211126,20230731,EXP,,GB-AMGEN-GBRNI2021185238,AMGEN,,69.0,YR,E,F,Y,79.1,KG,20230731,,MD,GB,GB,2023,Q3,Elderly
201162337,20116233,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Haematuria,,2023,Q3,7,F,20210716.0,20230726.0,20211126,20230731,EXP,,GB-AMGEN-GBRNI2021185238,AMGEN,,69.0,YR,E,F,Y,79.1,KG,20230731,,MD,GB,GB,2023,Q3,Elderly
201793168,20179316,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q3,Haemorrhoids,,2023,Q3,8,F,,20230710.0,20211214,20230712,EXP,,CA-BAUSCH-BL-2021-040795,BAUSCH AND LOMB,,67.0,YR,,F,Y,,,20230712,,PH,CA,CA,2023,Q3,Elderly
201793168,20179316,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q3,Blood pressure increased,,2023,Q3,8,F,,20230710.0,20211214,20230712,EXP,,CA-BAUSCH-BL-2021-040795,BAUSCH AND LOMB,,67.0,YR,,F,Y,,,20230712,,PH,CA,CA,2023,Q3,Elderly
201793168,20179316,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q3,Neoplasm skin,,2023,Q3,8,F,,20230710.0,20211214,20230712,EXP,,CA-BAUSCH-BL-2021-040795,BAUSCH AND LOMB,,67.0,YR,,F,Y,,,20230712,,PH,CA,CA,2023,Q3,Elderly
201793168,20179316,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q3,Neuropathy peripheral,,2023,Q3,8,F,,20230710.0,20211214,20230712,EXP,,CA-BAUSCH-BL-2021-040795,BAUSCH AND LOMB,,67.0,YR,,F,Y,,,20230712,,PH,CA,CA,2023,Q3,Elderly
201793168,20179316,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q3,Cataract,,2023,Q3,8,F,,20230710.0,20211214,20230712,EXP,,CA-BAUSCH-BL-2021-040795,BAUSCH AND LOMB,,67.0,YR,,F,Y,,,20230712,,PH,CA,CA,2023,Q3,Elderly
201793168,20179316,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q3,Vulvovaginal mycotic infection,,2023,Q3,8,F,,20230710.0,20211214,20230712,EXP,,CA-BAUSCH-BL-2021-040795,BAUSCH AND LOMB,,67.0,YR,,F,Y,,,20230712,,PH,CA,CA,2023,Q3,Elderly
201793168,20179316,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q3,Clostridium difficile colitis,,2023,Q3,8,F,,20230710.0,20211214,20230712,EXP,,CA-BAUSCH-BL-2021-040795,BAUSCH AND LOMB,,67.0,YR,,F,Y,,,20230712,,PH,CA,CA,2023,Q3,Elderly
201793168,20179316,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q3,Cardiac failure,,2023,Q3,8,F,,20230710.0,20211214,20230712,EXP,,CA-BAUSCH-BL-2021-040795,BAUSCH AND LOMB,,67.0,YR,,F,Y,,,20230712,,PH,CA,CA,2023,Q3,Elderly
201793168,20179316,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q3,Dyspnoea,,2023,Q3,8,F,,20230710.0,20211214,20230712,EXP,,CA-BAUSCH-BL-2021-040795,BAUSCH AND LOMB,,67.0,YR,,F,Y,,,20230712,,PH,CA,CA,2023,Q3,Elderly
201793168,20179316,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q3,Abdominal pain upper,,2023,Q3,8,F,,20230710.0,20211214,20230712,EXP,,CA-BAUSCH-BL-2021-040795,BAUSCH AND LOMB,,67.0,YR,,F,Y,,,20230712,,PH,CA,CA,2023,Q3,Elderly
201793168,20179316,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q3,Fall,,2023,Q3,8,F,,20230710.0,20211214,20230712,EXP,,CA-BAUSCH-BL-2021-040795,BAUSCH AND LOMB,,67.0,YR,,F,Y,,,20230712,,PH,CA,CA,2023,Q3,Elderly
201793168,20179316,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q3,Pneumonia,,2023,Q3,8,F,,20230710.0,20211214,20230712,EXP,,CA-BAUSCH-BL-2021-040795,BAUSCH AND LOMB,,67.0,YR,,F,Y,,,20230712,,PH,CA,CA,2023,Q3,Elderly
201793168,20179316,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q3,Chest discomfort,,2023,Q3,8,F,,20230710.0,20211214,20230712,EXP,,CA-BAUSCH-BL-2021-040795,BAUSCH AND LOMB,,67.0,YR,,F,Y,,,20230712,,PH,CA,CA,2023,Q3,Elderly
201793168,20179316,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q3,Product use issue,,2023,Q3,8,F,,20230710.0,20211214,20230712,EXP,,CA-BAUSCH-BL-2021-040795,BAUSCH AND LOMB,,67.0,YR,,F,Y,,,20230712,,PH,CA,CA,2023,Q3,Elderly
201793168,20179316,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q3,Transient ischaemic attack,,2023,Q3,8,F,,20230710.0,20211214,20230712,EXP,,CA-BAUSCH-BL-2021-040795,BAUSCH AND LOMB,,67.0,YR,,F,Y,,,20230712,,PH,CA,CA,2023,Q3,Elderly
201793168,20179316,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q3,Drug ineffective,,2023,Q3,8,F,,20230710.0,20211214,20230712,EXP,,CA-BAUSCH-BL-2021-040795,BAUSCH AND LOMB,,67.0,YR,,F,Y,,,20230712,,PH,CA,CA,2023,Q3,Elderly
201793168,20179316,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q3,Off label use,,2023,Q3,8,F,,20230710.0,20211214,20230712,EXP,,CA-BAUSCH-BL-2021-040795,BAUSCH AND LOMB,,67.0,YR,,F,Y,,,20230712,,PH,CA,CA,2023,Q3,Elderly
201793168,20179316,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q3,Constipation,,2023,Q3,8,F,,20230710.0,20211214,20230712,EXP,,CA-BAUSCH-BL-2021-040795,BAUSCH AND LOMB,,67.0,YR,,F,Y,,,20230712,,PH,CA,CA,2023,Q3,Elderly
201793168,20179316,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q3,Haemorrhoidal haemorrhage,,2023,Q3,8,F,,20230710.0,20211214,20230712,EXP,,CA-BAUSCH-BL-2021-040795,BAUSCH AND LOMB,,67.0,YR,,F,Y,,,20230712,,PH,CA,CA,2023,Q3,Elderly
201793168,20179316,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q3,COVID-19,,2023,Q3,8,F,,20230710.0,20211214,20230712,EXP,,CA-BAUSCH-BL-2021-040795,BAUSCH AND LOMB,,67.0,YR,,F,Y,,,20230712,,PH,CA,CA,2023,Q3,Elderly
201793168,20179316,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q3,COVID-19 immunisation,,2023,Q3,8,F,,20230710.0,20211214,20230712,EXP,,CA-BAUSCH-BL-2021-040795,BAUSCH AND LOMB,,67.0,YR,,F,Y,,,20230712,,PH,CA,CA,2023,Q3,Elderly
202531992,20253199,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q3,Abdominal pain upper,,2023,Q3,2,F,,20230814.0,20211229,20230827,EXP,,CA-AUROBINDO-AUR-APL-2021-052872,AUROBINDO,,67.0,YR,,F,Y,,,20230827,,PH,CA,CA,2023,Q3,Elderly
202531992,20253199,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q3,Clostridium difficile colitis,,2023,Q3,2,F,,20230814.0,20211229,20230827,EXP,,CA-AUROBINDO-AUR-APL-2021-052872,AUROBINDO,,67.0,YR,,F,Y,,,20230827,,PH,CA,CA,2023,Q3,Elderly
202531992,20253199,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q3,Chest discomfort,,2023,Q3,2,F,,20230814.0,20211229,20230827,EXP,,CA-AUROBINDO-AUR-APL-2021-052872,AUROBINDO,,67.0,YR,,F,Y,,,20230827,,PH,CA,CA,2023,Q3,Elderly
202531992,20253199,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q3,Dyspnoea,,2023,Q3,2,F,,20230814.0,20211229,20230827,EXP,,CA-AUROBINDO-AUR-APL-2021-052872,AUROBINDO,,67.0,YR,,F,Y,,,20230827,,PH,CA,CA,2023,Q3,Elderly
202531992,20253199,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q3,Haemorrhoids,,2023,Q3,2,F,,20230814.0,20211229,20230827,EXP,,CA-AUROBINDO-AUR-APL-2021-052872,AUROBINDO,,67.0,YR,,F,Y,,,20230827,,PH,CA,CA,2023,Q3,Elderly
202531992,20253199,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q3,Product use issue,,2023,Q3,2,F,,20230814.0,20211229,20230827,EXP,,CA-AUROBINDO-AUR-APL-2021-052872,AUROBINDO,,67.0,YR,,F,Y,,,20230827,,PH,CA,CA,2023,Q3,Elderly
202531992,20253199,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q3,Chest pain,,2023,Q3,2,F,,20230814.0,20211229,20230827,EXP,,CA-AUROBINDO-AUR-APL-2021-052872,AUROBINDO,,67.0,YR,,F,Y,,,20230827,,PH,CA,CA,2023,Q3,Elderly
202531992,20253199,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q3,Cataract,,2023,Q3,2,F,,20230814.0,20211229,20230827,EXP,,CA-AUROBINDO-AUR-APL-2021-052872,AUROBINDO,,67.0,YR,,F,Y,,,20230827,,PH,CA,CA,2023,Q3,Elderly
202531992,20253199,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q3,Neuropathy peripheral,,2023,Q3,2,F,,20230814.0,20211229,20230827,EXP,,CA-AUROBINDO-AUR-APL-2021-052872,AUROBINDO,,67.0,YR,,F,Y,,,20230827,,PH,CA,CA,2023,Q3,Elderly
202531992,20253199,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q3,Transient ischaemic attack,,2023,Q3,2,F,,20230814.0,20211229,20230827,EXP,,CA-AUROBINDO-AUR-APL-2021-052872,AUROBINDO,,67.0,YR,,F,Y,,,20230827,,PH,CA,CA,2023,Q3,Elderly
202531992,20253199,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q3,Hypoaesthesia,,2023,Q3,2,F,,20230814.0,20211229,20230827,EXP,,CA-AUROBINDO-AUR-APL-2021-052872,AUROBINDO,,67.0,YR,,F,Y,,,20230827,,PH,CA,CA,2023,Q3,Elderly
202531992,20253199,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q3,Constipation,,2023,Q3,2,F,,20230814.0,20211229,20230827,EXP,,CA-AUROBINDO-AUR-APL-2021-052872,AUROBINDO,,67.0,YR,,F,Y,,,20230827,,PH,CA,CA,2023,Q3,Elderly
202531992,20253199,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q3,Fall,,2023,Q3,2,F,,20230814.0,20211229,20230827,EXP,,CA-AUROBINDO-AUR-APL-2021-052872,AUROBINDO,,67.0,YR,,F,Y,,,20230827,,PH,CA,CA,2023,Q3,Elderly
202531992,20253199,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q3,Vulvovaginal mycotic infection,,2023,Q3,2,F,,20230814.0,20211229,20230827,EXP,,CA-AUROBINDO-AUR-APL-2021-052872,AUROBINDO,,67.0,YR,,F,Y,,,20230827,,PH,CA,CA,2023,Q3,Elderly
202531992,20253199,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q3,Pain in extremity,,2023,Q3,2,F,,20230814.0,20211229,20230827,EXP,,CA-AUROBINDO-AUR-APL-2021-052872,AUROBINDO,,67.0,YR,,F,Y,,,20230827,,PH,CA,CA,2023,Q3,Elderly
202531992,20253199,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q3,Cardiac failure,,2023,Q3,2,F,,20230814.0,20211229,20230827,EXP,,CA-AUROBINDO-AUR-APL-2021-052872,AUROBINDO,,67.0,YR,,F,Y,,,20230827,,PH,CA,CA,2023,Q3,Elderly
202531992,20253199,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q3,COVID-19 immunisation,,2023,Q3,2,F,,20230814.0,20211229,20230827,EXP,,CA-AUROBINDO-AUR-APL-2021-052872,AUROBINDO,,67.0,YR,,F,Y,,,20230827,,PH,CA,CA,2023,Q3,Elderly
202531992,20253199,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q3,Neoplasm skin,,2023,Q3,2,F,,20230814.0,20211229,20230827,EXP,,CA-AUROBINDO-AUR-APL-2021-052872,AUROBINDO,,67.0,YR,,F,Y,,,20230827,,PH,CA,CA,2023,Q3,Elderly
202531992,20253199,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q3,Off label use,,2023,Q3,2,F,,20230814.0,20211229,20230827,EXP,,CA-AUROBINDO-AUR-APL-2021-052872,AUROBINDO,,67.0,YR,,F,Y,,,20230827,,PH,CA,CA,2023,Q3,Elderly
202531992,20253199,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q3,Haemorrhoidal haemorrhage,,2023,Q3,2,F,,20230814.0,20211229,20230827,EXP,,CA-AUROBINDO-AUR-APL-2021-052872,AUROBINDO,,67.0,YR,,F,Y,,,20230827,,PH,CA,CA,2023,Q3,Elderly
202531992,20253199,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q3,COVID-19,,2023,Q3,2,F,,20230814.0,20211229,20230827,EXP,,CA-AUROBINDO-AUR-APL-2021-052872,AUROBINDO,,67.0,YR,,F,Y,,,20230827,,PH,CA,CA,2023,Q3,Elderly
202531992,20253199,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q3,Blood pressure increased,,2023,Q3,2,F,,20230814.0,20211229,20230827,EXP,,CA-AUROBINDO-AUR-APL-2021-052872,AUROBINDO,,67.0,YR,,F,Y,,,20230827,,PH,CA,CA,2023,Q3,Elderly
202531992,20253199,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q3,Drug ineffective,,2023,Q3,2,F,,20230814.0,20211229,20230827,EXP,,CA-AUROBINDO-AUR-APL-2021-052872,AUROBINDO,,67.0,YR,,F,Y,,,20230827,,PH,CA,CA,2023,Q3,Elderly
202531992,20253199,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q3,Pneumonia,,2023,Q3,2,F,,20230814.0,20211229,20230827,EXP,,CA-AUROBINDO-AUR-APL-2021-052872,AUROBINDO,,67.0,YR,,F,Y,,,20230827,,PH,CA,CA,2023,Q3,Elderly
202531992,20253199,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q3,Cardiomegaly,,2023,Q3,2,F,,20230814.0,20211229,20230827,EXP,,CA-AUROBINDO-AUR-APL-2021-052872,AUROBINDO,,67.0,YR,,F,Y,,,20230827,,PH,CA,CA,2023,Q3,Elderly
203821448,20382144,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Fear of injection,,2023,Q3,8,F,20210930.0,20230830.0,20220127,20230904,EXP,,CA-BAUSCH-BL-2021-034002,BAUSCH AND LOMB,,55.0,YR,,M,Y,,,20230904,,CN,CA,CA,2023,Q3,Adult
203821448,20382144,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Family stress,,2023,Q3,8,F,20210930.0,20230830.0,20220127,20230904,EXP,,CA-BAUSCH-BL-2021-034002,BAUSCH AND LOMB,,55.0,YR,,M,Y,,,20230904,,CN,CA,CA,2023,Q3,Adult
203821448,20382144,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Hypertension,,2023,Q3,8,F,20210930.0,20230830.0,20220127,20230904,EXP,,CA-BAUSCH-BL-2021-034002,BAUSCH AND LOMB,,55.0,YR,,M,Y,,,20230904,,CN,CA,CA,2023,Q3,Adult
203821448,20382144,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Product dose omission issue,,2023,Q3,8,F,20210930.0,20230830.0,20220127,20230904,EXP,,CA-BAUSCH-BL-2021-034002,BAUSCH AND LOMB,,55.0,YR,,M,Y,,,20230904,,CN,CA,CA,2023,Q3,Adult
203821448,20382144,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Fatigue,,2023,Q3,8,F,20210930.0,20230830.0,20220127,20230904,EXP,,CA-BAUSCH-BL-2021-034002,BAUSCH AND LOMB,,55.0,YR,,M,Y,,,20230904,,CN,CA,CA,2023,Q3,Adult
206293968,20629396,7,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,Y,U,,,,25.0,MG,Unknown,QD,2023,Q3,Nausea,,2023,Q3,8,F,,20230922.0,20220323,20230928,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230928,,MD,PT,PT,2023,Q3,Elderly
206293968,20629396,7,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,Y,U,,,,25.0,MG,Unknown,QD,2023,Q3,Dehydration,,2023,Q3,8,F,,20230922.0,20220323,20230928,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230928,,MD,PT,PT,2023,Q3,Elderly
206293968,20629396,7,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,Y,U,,,,25.0,MG,Unknown,QD,2023,Q3,Oliguria,,2023,Q3,8,F,,20230922.0,20220323,20230928,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230928,,MD,PT,PT,2023,Q3,Elderly
206293968,20629396,7,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,Y,U,,,,25.0,MG,Unknown,QD,2023,Q3,Vomiting,,2023,Q3,8,F,,20230922.0,20220323,20230928,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230928,,MD,PT,PT,2023,Q3,Elderly
206293968,20629396,7,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,Y,U,,,,25.0,MG,Unknown,QD,2023,Q3,Off label use,,2023,Q3,8,F,,20230922.0,20220323,20230928,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230928,,MD,PT,PT,2023,Q3,Elderly
206293968,20629396,7,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,Y,U,,,,25.0,MG,Unknown,QD,2023,Q3,Acetonaemia,,2023,Q3,8,F,,20230922.0,20220323,20230928,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230928,,MD,PT,PT,2023,Q3,Elderly
206293968,20629396,7,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,Y,U,,,,25.0,MG,Unknown,QD,2023,Q3,Normochromic normocytic anaemia,,2023,Q3,8,F,,20230922.0,20220323,20230928,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230928,,MD,PT,PT,2023,Q3,Elderly
206293968,20629396,7,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,Y,U,,,,25.0,MG,Unknown,QD,2023,Q3,Dry skin,,2023,Q3,8,F,,20230922.0,20220323,20230928,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230928,,MD,PT,PT,2023,Q3,Elderly
206293968,20629396,7,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,Y,U,,,,25.0,MG,Unknown,QD,2023,Q3,Blood lactic acid increased,,2023,Q3,8,F,,20230922.0,20220323,20230928,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230928,,MD,PT,PT,2023,Q3,Elderly
206293968,20629396,7,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,Y,U,,,,25.0,MG,Unknown,QD,2023,Q3,Ketoacidosis,,2023,Q3,8,F,,20230922.0,20220323,20230928,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230928,,MD,PT,PT,2023,Q3,Elderly
206293968,20629396,7,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,Y,U,,,,25.0,MG,Unknown,QD,2023,Q3,Drug interaction,,2023,Q3,8,F,,20230922.0,20220323,20230928,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230928,,MD,PT,PT,2023,Q3,Elderly
206293968,20629396,7,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,Y,U,,,,25.0,MG,Unknown,QD,2023,Q3,Pallor,,2023,Q3,8,F,,20230922.0,20220323,20230928,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230928,,MD,PT,PT,2023,Q3,Elderly
206293968,20629396,7,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,Y,U,,,,25.0,MG,Unknown,QD,2023,Q3,Euglycaemic diabetic ketoacidosis,,2023,Q3,8,F,,20230922.0,20220323,20230928,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230928,,MD,PT,PT,2023,Q3,Elderly
206293968,20629396,7,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,Y,U,,,,25.0,MG,Unknown,QD,2023,Q3,Decreased appetite,,2023,Q3,8,F,,20230922.0,20220323,20230928,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230928,,MD,PT,PT,2023,Q3,Elderly
206293968,20629396,7,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,Y,U,,,,25.0,MG,Unknown,QD,2023,Q3,Diabetic ketoacidosis,,2023,Q3,8,F,,20230922.0,20220323,20230928,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230928,,MD,PT,PT,2023,Q3,Elderly
206293968,20629396,7,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,Y,U,,,,25.0,MG,Unknown,QD,2023,Q3,Dysphagia,,2023,Q3,8,F,,20230922.0,20220323,20230928,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230928,,MD,PT,PT,2023,Q3,Elderly
206293968,20629396,7,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,Y,U,,,,25.0,MG,Unknown,QD,2023,Q3,Breast cancer,,2023,Q3,8,F,,20230922.0,20220323,20230928,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230928,,MD,PT,PT,2023,Q3,Elderly
206293968,20629396,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 milligram,,,Y,U,,,,25.0,MG,Unknown,,2023,Q3,Nausea,,2023,Q3,8,F,,20230922.0,20220323,20230928,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230928,,MD,PT,PT,2023,Q3,Elderly
206293968,20629396,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 milligram,,,Y,U,,,,25.0,MG,Unknown,,2023,Q3,Dehydration,,2023,Q3,8,F,,20230922.0,20220323,20230928,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230928,,MD,PT,PT,2023,Q3,Elderly
206293968,20629396,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 milligram,,,Y,U,,,,25.0,MG,Unknown,,2023,Q3,Oliguria,,2023,Q3,8,F,,20230922.0,20220323,20230928,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230928,,MD,PT,PT,2023,Q3,Elderly
206293968,20629396,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 milligram,,,Y,U,,,,25.0,MG,Unknown,,2023,Q3,Vomiting,,2023,Q3,8,F,,20230922.0,20220323,20230928,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230928,,MD,PT,PT,2023,Q3,Elderly
206293968,20629396,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 milligram,,,Y,U,,,,25.0,MG,Unknown,,2023,Q3,Off label use,,2023,Q3,8,F,,20230922.0,20220323,20230928,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230928,,MD,PT,PT,2023,Q3,Elderly
206293968,20629396,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 milligram,,,Y,U,,,,25.0,MG,Unknown,,2023,Q3,Acetonaemia,,2023,Q3,8,F,,20230922.0,20220323,20230928,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230928,,MD,PT,PT,2023,Q3,Elderly
206293968,20629396,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 milligram,,,Y,U,,,,25.0,MG,Unknown,,2023,Q3,Normochromic normocytic anaemia,,2023,Q3,8,F,,20230922.0,20220323,20230928,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230928,,MD,PT,PT,2023,Q3,Elderly
206293968,20629396,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 milligram,,,Y,U,,,,25.0,MG,Unknown,,2023,Q3,Dry skin,,2023,Q3,8,F,,20230922.0,20220323,20230928,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230928,,MD,PT,PT,2023,Q3,Elderly
206293968,20629396,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 milligram,,,Y,U,,,,25.0,MG,Unknown,,2023,Q3,Blood lactic acid increased,,2023,Q3,8,F,,20230922.0,20220323,20230928,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230928,,MD,PT,PT,2023,Q3,Elderly
206293968,20629396,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 milligram,,,Y,U,,,,25.0,MG,Unknown,,2023,Q3,Ketoacidosis,,2023,Q3,8,F,,20230922.0,20220323,20230928,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230928,,MD,PT,PT,2023,Q3,Elderly
206293968,20629396,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 milligram,,,Y,U,,,,25.0,MG,Unknown,,2023,Q3,Drug interaction,,2023,Q3,8,F,,20230922.0,20220323,20230928,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230928,,MD,PT,PT,2023,Q3,Elderly
206293968,20629396,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 milligram,,,Y,U,,,,25.0,MG,Unknown,,2023,Q3,Pallor,,2023,Q3,8,F,,20230922.0,20220323,20230928,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230928,,MD,PT,PT,2023,Q3,Elderly
206293968,20629396,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 milligram,,,Y,U,,,,25.0,MG,Unknown,,2023,Q3,Euglycaemic diabetic ketoacidosis,,2023,Q3,8,F,,20230922.0,20220323,20230928,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230928,,MD,PT,PT,2023,Q3,Elderly
206293968,20629396,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 milligram,,,Y,U,,,,25.0,MG,Unknown,,2023,Q3,Decreased appetite,,2023,Q3,8,F,,20230922.0,20220323,20230928,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230928,,MD,PT,PT,2023,Q3,Elderly
206293968,20629396,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 milligram,,,Y,U,,,,25.0,MG,Unknown,,2023,Q3,Diabetic ketoacidosis,,2023,Q3,8,F,,20230922.0,20220323,20230928,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230928,,MD,PT,PT,2023,Q3,Elderly
206293968,20629396,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 milligram,,,Y,U,,,,25.0,MG,Unknown,,2023,Q3,Dysphagia,,2023,Q3,8,F,,20230922.0,20220323,20230928,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230928,,MD,PT,PT,2023,Q3,Elderly
206293968,20629396,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 milligram,,,Y,U,,,,25.0,MG,Unknown,,2023,Q3,Breast cancer,,2023,Q3,8,F,,20230922.0,20220323,20230928,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20230928,,MD,PT,PT,2023,Q3,Elderly
2064662510,20646625,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,Y,,,,,25.0,MG,,QD,2023,Q3,Breast cancer,,2023,Q3,10,F,,20230914.0,20220329,20230922,EXP,,PT-AUROBINDO-AUR-APL-2022-009438,AUROBINDO,"Rodrigues S,Esteves VL.. Cetoacidose euglicemica em doente idoso sob empagliflozina e metformina (Clinical Cases euglycemic ketoacidosis in elderly patient on empagliflozin and metformin). Revista Portuguesa de Diabetes (Portuguese Journal of diabetes). 2022;17(1):69-74",82.0,YR,,F,Y,,,20230922,,MD,PT,PT,2023,Q3,Elderly
2064662510,20646625,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,Y,,,,,25.0,MG,,QD,2023,Q3,Dehydration,,2023,Q3,10,F,,20230914.0,20220329,20230922,EXP,,PT-AUROBINDO-AUR-APL-2022-009438,AUROBINDO,"Rodrigues S,Esteves VL.. Cetoacidose euglicemica em doente idoso sob empagliflozina e metformina (Clinical Cases euglycemic ketoacidosis in elderly patient on empagliflozin and metformin). Revista Portuguesa de Diabetes (Portuguese Journal of diabetes). 2022;17(1):69-74",82.0,YR,,F,Y,,,20230922,,MD,PT,PT,2023,Q3,Elderly
2064662510,20646625,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,Y,,,,,25.0,MG,,QD,2023,Q3,Dry skin,,2023,Q3,10,F,,20230914.0,20220329,20230922,EXP,,PT-AUROBINDO-AUR-APL-2022-009438,AUROBINDO,"Rodrigues S,Esteves VL.. Cetoacidose euglicemica em doente idoso sob empagliflozina e metformina (Clinical Cases euglycemic ketoacidosis in elderly patient on empagliflozin and metformin). Revista Portuguesa de Diabetes (Portuguese Journal of diabetes). 2022;17(1):69-74",82.0,YR,,F,Y,,,20230922,,MD,PT,PT,2023,Q3,Elderly
2064662510,20646625,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,Y,,,,,25.0,MG,,QD,2023,Q3,Dysphagia,,2023,Q3,10,F,,20230914.0,20220329,20230922,EXP,,PT-AUROBINDO-AUR-APL-2022-009438,AUROBINDO,"Rodrigues S,Esteves VL.. Cetoacidose euglicemica em doente idoso sob empagliflozina e metformina (Clinical Cases euglycemic ketoacidosis in elderly patient on empagliflozin and metformin). Revista Portuguesa de Diabetes (Portuguese Journal of diabetes). 2022;17(1):69-74",82.0,YR,,F,Y,,,20230922,,MD,PT,PT,2023,Q3,Elderly
2064662510,20646625,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,Y,,,,,25.0,MG,,QD,2023,Q3,Normochromic normocytic anaemia,,2023,Q3,10,F,,20230914.0,20220329,20230922,EXP,,PT-AUROBINDO-AUR-APL-2022-009438,AUROBINDO,"Rodrigues S,Esteves VL.. Cetoacidose euglicemica em doente idoso sob empagliflozina e metformina (Clinical Cases euglycemic ketoacidosis in elderly patient on empagliflozin and metformin). Revista Portuguesa de Diabetes (Portuguese Journal of diabetes). 2022;17(1):69-74",82.0,YR,,F,Y,,,20230922,,MD,PT,PT,2023,Q3,Elderly
2064662510,20646625,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,Y,,,,,25.0,MG,,QD,2023,Q3,Ketoacidosis,,2023,Q3,10,F,,20230914.0,20220329,20230922,EXP,,PT-AUROBINDO-AUR-APL-2022-009438,AUROBINDO,"Rodrigues S,Esteves VL.. Cetoacidose euglicemica em doente idoso sob empagliflozina e metformina (Clinical Cases euglycemic ketoacidosis in elderly patient on empagliflozin and metformin). Revista Portuguesa de Diabetes (Portuguese Journal of diabetes). 2022;17(1):69-74",82.0,YR,,F,Y,,,20230922,,MD,PT,PT,2023,Q3,Elderly
2064662510,20646625,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,Y,,,,,25.0,MG,,QD,2023,Q3,Euglycaemic diabetic ketoacidosis,,2023,Q3,10,F,,20230914.0,20220329,20230922,EXP,,PT-AUROBINDO-AUR-APL-2022-009438,AUROBINDO,"Rodrigues S,Esteves VL.. Cetoacidose euglicemica em doente idoso sob empagliflozina e metformina (Clinical Cases euglycemic ketoacidosis in elderly patient on empagliflozin and metformin). Revista Portuguesa de Diabetes (Portuguese Journal of diabetes). 2022;17(1):69-74",82.0,YR,,F,Y,,,20230922,,MD,PT,PT,2023,Q3,Elderly
2064662510,20646625,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,Y,,,,,25.0,MG,,QD,2023,Q3,Diabetic ketoacidosis,,2023,Q3,10,F,,20230914.0,20220329,20230922,EXP,,PT-AUROBINDO-AUR-APL-2022-009438,AUROBINDO,"Rodrigues S,Esteves VL.. Cetoacidose euglicemica em doente idoso sob empagliflozina e metformina (Clinical Cases euglycemic ketoacidosis in elderly patient on empagliflozin and metformin). Revista Portuguesa de Diabetes (Portuguese Journal of diabetes). 2022;17(1):69-74",82.0,YR,,F,Y,,,20230922,,MD,PT,PT,2023,Q3,Elderly
2064662510,20646625,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,Y,,,,,25.0,MG,,QD,2023,Q3,Acetonaemia,,2023,Q3,10,F,,20230914.0,20220329,20230922,EXP,,PT-AUROBINDO-AUR-APL-2022-009438,AUROBINDO,"Rodrigues S,Esteves VL.. Cetoacidose euglicemica em doente idoso sob empagliflozina e metformina (Clinical Cases euglycemic ketoacidosis in elderly patient on empagliflozin and metformin). Revista Portuguesa de Diabetes (Portuguese Journal of diabetes). 2022;17(1):69-74",82.0,YR,,F,Y,,,20230922,,MD,PT,PT,2023,Q3,Elderly
2064662510,20646625,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,Y,,,,,25.0,MG,,QD,2023,Q3,Pallor,,2023,Q3,10,F,,20230914.0,20220329,20230922,EXP,,PT-AUROBINDO-AUR-APL-2022-009438,AUROBINDO,"Rodrigues S,Esteves VL.. Cetoacidose euglicemica em doente idoso sob empagliflozina e metformina (Clinical Cases euglycemic ketoacidosis in elderly patient on empagliflozin and metformin). Revista Portuguesa de Diabetes (Portuguese Journal of diabetes). 2022;17(1):69-74",82.0,YR,,F,Y,,,20230922,,MD,PT,PT,2023,Q3,Elderly
2064662510,20646625,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,Y,,,,,25.0,MG,,QD,2023,Q3,Drug interaction,,2023,Q3,10,F,,20230914.0,20220329,20230922,EXP,,PT-AUROBINDO-AUR-APL-2022-009438,AUROBINDO,"Rodrigues S,Esteves VL.. Cetoacidose euglicemica em doente idoso sob empagliflozina e metformina (Clinical Cases euglycemic ketoacidosis in elderly patient on empagliflozin and metformin). Revista Portuguesa de Diabetes (Portuguese Journal of diabetes). 2022;17(1):69-74",82.0,YR,,F,Y,,,20230922,,MD,PT,PT,2023,Q3,Elderly
2064662510,20646625,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,Y,,,,,25.0,MG,,QD,2023,Q3,Blood lactic acid increased,,2023,Q3,10,F,,20230914.0,20220329,20230922,EXP,,PT-AUROBINDO-AUR-APL-2022-009438,AUROBINDO,"Rodrigues S,Esteves VL.. Cetoacidose euglicemica em doente idoso sob empagliflozina e metformina (Clinical Cases euglycemic ketoacidosis in elderly patient on empagliflozin and metformin). Revista Portuguesa de Diabetes (Portuguese Journal of diabetes). 2022;17(1):69-74",82.0,YR,,F,Y,,,20230922,,MD,PT,PT,2023,Q3,Elderly
2064662510,20646625,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,Y,,,,,25.0,MG,,QD,2023,Q3,Nausea,,2023,Q3,10,F,,20230914.0,20220329,20230922,EXP,,PT-AUROBINDO-AUR-APL-2022-009438,AUROBINDO,"Rodrigues S,Esteves VL.. Cetoacidose euglicemica em doente idoso sob empagliflozina e metformina (Clinical Cases euglycemic ketoacidosis in elderly patient on empagliflozin and metformin). Revista Portuguesa de Diabetes (Portuguese Journal of diabetes). 2022;17(1):69-74",82.0,YR,,F,Y,,,20230922,,MD,PT,PT,2023,Q3,Elderly
2064662510,20646625,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,Y,,,,,25.0,MG,,QD,2023,Q3,Oliguria,,2023,Q3,10,F,,20230914.0,20220329,20230922,EXP,,PT-AUROBINDO-AUR-APL-2022-009438,AUROBINDO,"Rodrigues S,Esteves VL.. Cetoacidose euglicemica em doente idoso sob empagliflozina e metformina (Clinical Cases euglycemic ketoacidosis in elderly patient on empagliflozin and metformin). Revista Portuguesa de Diabetes (Portuguese Journal of diabetes). 2022;17(1):69-74",82.0,YR,,F,Y,,,20230922,,MD,PT,PT,2023,Q3,Elderly
2064662510,20646625,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,Y,,,,,25.0,MG,,QD,2023,Q3,Decreased appetite,,2023,Q3,10,F,,20230914.0,20220329,20230922,EXP,,PT-AUROBINDO-AUR-APL-2022-009438,AUROBINDO,"Rodrigues S,Esteves VL.. Cetoacidose euglicemica em doente idoso sob empagliflozina e metformina (Clinical Cases euglycemic ketoacidosis in elderly patient on empagliflozin and metformin). Revista Portuguesa de Diabetes (Portuguese Journal of diabetes). 2022;17(1):69-74",82.0,YR,,F,Y,,,20230922,,MD,PT,PT,2023,Q3,Elderly
2064662510,20646625,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,Y,,,,,25.0,MG,,QD,2023,Q3,Vomiting,,2023,Q3,10,F,,20230914.0,20220329,20230922,EXP,,PT-AUROBINDO-AUR-APL-2022-009438,AUROBINDO,"Rodrigues S,Esteves VL.. Cetoacidose euglicemica em doente idoso sob empagliflozina e metformina (Clinical Cases euglycemic ketoacidosis in elderly patient on empagliflozin and metformin). Revista Portuguesa de Diabetes (Portuguese Journal of diabetes). 2022;17(1):69-74",82.0,YR,,F,Y,,,20230922,,MD,PT,PT,2023,Q3,Elderly
206920784,20692078,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2023,Q3,Mobility decreased,,2023,Q3,4,F,,20230825.0,20220409,20230831,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-08060,SAMSUNG BIOEPIS,,49.0,YR,A,M,Y,118.0,KG,20230831,,HP,CA,CA,2023,Q3,Adult
206920784,20692078,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2023,Q3,Condition aggravated,,2023,Q3,4,F,,20230825.0,20220409,20230831,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-08060,SAMSUNG BIOEPIS,,49.0,YR,A,M,Y,118.0,KG,20230831,,HP,CA,CA,2023,Q3,Adult
206920784,20692078,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2023,Q3,Nasal congestion,,2023,Q3,4,F,,20230825.0,20220409,20230831,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-08060,SAMSUNG BIOEPIS,,49.0,YR,A,M,Y,118.0,KG,20230831,,HP,CA,CA,2023,Q3,Adult
206920784,20692078,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2023,Q3,Cough,,2023,Q3,4,F,,20230825.0,20220409,20230831,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-08060,SAMSUNG BIOEPIS,,49.0,YR,A,M,Y,118.0,KG,20230831,,HP,CA,CA,2023,Q3,Adult
206920784,20692078,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2023,Q3,Arthralgia,,2023,Q3,4,F,,20230825.0,20220409,20230831,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-08060,SAMSUNG BIOEPIS,,49.0,YR,A,M,Y,118.0,KG,20230831,,HP,CA,CA,2023,Q3,Adult
206920784,20692078,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2023,Q3,Rectal haemorrhage,,2023,Q3,4,F,,20230825.0,20220409,20230831,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-08060,SAMSUNG BIOEPIS,,49.0,YR,A,M,Y,118.0,KG,20230831,,HP,CA,CA,2023,Q3,Adult
206920784,20692078,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2023,Q3,COVID-19,,2023,Q3,4,F,,20230825.0,20220409,20230831,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-08060,SAMSUNG BIOEPIS,,49.0,YR,A,M,Y,118.0,KG,20230831,,HP,CA,CA,2023,Q3,Adult
206920784,20692078,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2023,Q3,Therapeutic response shortened,,2023,Q3,4,F,,20230825.0,20220409,20230831,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-08060,SAMSUNG BIOEPIS,,49.0,YR,A,M,Y,118.0,KG,20230831,,HP,CA,CA,2023,Q3,Adult
206920784,20692078,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2023,Q3,Gouty arthritis,,2023,Q3,4,F,,20230825.0,20220409,20230831,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-08060,SAMSUNG BIOEPIS,,49.0,YR,A,M,Y,118.0,KG,20230831,,HP,CA,CA,2023,Q3,Adult
206920784,20692078,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2023,Q3,Anal fissure,,2023,Q3,4,F,,20230825.0,20220409,20230831,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-08060,SAMSUNG BIOEPIS,,49.0,YR,A,M,Y,118.0,KG,20230831,,HP,CA,CA,2023,Q3,Adult
207954408,20795440,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,QD,2023,Q3,Ocular vasculitis,,2023,Q3,8,F,20220427.0,20230804.0,20220506,20230808,EXP,,US-ROCHE-3087474,ROCHE,,76.0,YR,,F,Y,70.9,KG,20230808,,MD,US,,2023,Q3,Elderly
208468723,20846872,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,5/1000 mg,,,Y,,Unknown,,206111.0,,,,QD,2023,Q3,Urinary tract candidiasis,,2023,Q3,3,F,20211129.0,20230629.0,20220519,20230706,EXP,CH-SM-2022-15075,"CH-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-170552",BOEHRINGER INGELHEIM,,74.0,YR,E,M,Y,,,20230706,,MD,CH,CH,2023,Q3,Elderly
208468723,20846872,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,5/1000 mg,,,Y,,Unknown,,206111.0,,,,QD,2023,Q3,Pyelonephritis,,2023,Q3,3,F,20211129.0,20230629.0,20220519,20230706,EXP,CH-SM-2022-15075,"CH-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-170552",BOEHRINGER INGELHEIM,,74.0,YR,E,M,Y,,,20230706,,MD,CH,CH,2023,Q3,Elderly
208468723,20846872,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,5/1000 mg,,,Y,,Unknown,,206111.0,,,,QD,2023,Q3,Fungaemia,,2023,Q3,3,F,20211129.0,20230629.0,20220519,20230706,EXP,CH-SM-2022-15075,"CH-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-170552",BOEHRINGER INGELHEIM,,74.0,YR,E,M,Y,,,20230706,,MD,CH,CH,2023,Q3,Elderly
208591313,20859131,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2023,Q3,Pain in extremity,,2023,Q3,3,F,20120101.0,20230807.0,20220523,20230810,EXP,,US-GILEAD-2022-0582477,GILEAD,,57.0,YR,A,F,Y,103.86,KG,20230810,,LW,US,US,2023,Q3,Adult
208591313,20859131,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2023,Q3,Abdominal pain lower,,2023,Q3,3,F,20120101.0,20230807.0,20220523,20230810,EXP,,US-GILEAD-2022-0582477,GILEAD,,57.0,YR,A,F,Y,103.86,KG,20230810,,LW,US,US,2023,Q3,Adult
208591313,20859131,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2023,Q3,Back pain,,2023,Q3,3,F,20120101.0,20230807.0,20220523,20230810,EXP,,US-GILEAD-2022-0582477,GILEAD,,57.0,YR,A,F,Y,103.86,KG,20230810,,LW,US,US,2023,Q3,Adult
208591313,20859131,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2023,Q3,Periarthritis,,2023,Q3,3,F,20120101.0,20230807.0,20220523,20230810,EXP,,US-GILEAD-2022-0582477,GILEAD,,57.0,YR,A,F,Y,103.86,KG,20230810,,LW,US,US,2023,Q3,Adult
208591313,20859131,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2023,Q3,Quality of life decreased,,2023,Q3,3,F,20120101.0,20230807.0,20220523,20230810,EXP,,US-GILEAD-2022-0582477,GILEAD,,57.0,YR,A,F,Y,103.86,KG,20230810,,LW,US,US,2023,Q3,Adult
208591313,20859131,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2023,Q3,Muscular weakness,,2023,Q3,3,F,20120101.0,20230807.0,20220523,20230810,EXP,,US-GILEAD-2022-0582477,GILEAD,,57.0,YR,A,F,Y,103.86,KG,20230810,,LW,US,US,2023,Q3,Adult
208591313,20859131,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2023,Q3,Anxiety,,2023,Q3,3,F,20120101.0,20230807.0,20220523,20230810,EXP,,US-GILEAD-2022-0582477,GILEAD,,57.0,YR,A,F,Y,103.86,KG,20230810,,LW,US,US,2023,Q3,Adult
208591313,20859131,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2023,Q3,Back pain,,2023,Q3,3,F,20120101.0,20230807.0,20220523,20230810,EXP,,US-GILEAD-2022-0582477,GILEAD,,57.0,YR,A,F,Y,103.86,KG,20230810,,LW,US,US,2023,Q3,Adult
208591313,20859131,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2023,Q3,Anhedonia,,2023,Q3,3,F,20120101.0,20230807.0,20220523,20230810,EXP,,US-GILEAD-2022-0582477,GILEAD,,57.0,YR,A,F,Y,103.86,KG,20230810,,LW,US,US,2023,Q3,Adult
208591313,20859131,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2023,Q3,Osteonecrosis,,2023,Q3,3,F,20120101.0,20230807.0,20220523,20230810,EXP,,US-GILEAD-2022-0582477,GILEAD,,57.0,YR,A,F,Y,103.86,KG,20230810,,LW,US,US,2023,Q3,Adult
208591313,20859131,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2023,Q3,Osteoporosis,,2023,Q3,3,F,20120101.0,20230807.0,20220523,20230810,EXP,,US-GILEAD-2022-0582477,GILEAD,,57.0,YR,A,F,Y,103.86,KG,20230810,,LW,US,US,2023,Q3,Adult
208591313,20859131,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2023,Q3,Bone demineralisation,,2023,Q3,3,F,20120101.0,20230807.0,20220523,20230810,EXP,,US-GILEAD-2022-0582477,GILEAD,,57.0,YR,A,F,Y,103.86,KG,20230810,,LW,US,US,2023,Q3,Adult
208591313,20859131,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2023,Q3,Pain,,2023,Q3,3,F,20120101.0,20230807.0,20220523,20230810,EXP,,US-GILEAD-2022-0582477,GILEAD,,57.0,YR,A,F,Y,103.86,KG,20230810,,LW,US,US,2023,Q3,Adult
208591313,20859131,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2023,Q3,Depression,,2023,Q3,3,F,20120101.0,20230807.0,20220523,20230810,EXP,,US-GILEAD-2022-0582477,GILEAD,,57.0,YR,A,F,Y,103.86,KG,20230810,,LW,US,US,2023,Q3,Adult
208591313,20859131,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2023,Q3,Arthralgia,,2023,Q3,3,F,20120101.0,20230807.0,20220523,20230810,EXP,,US-GILEAD-2022-0582477,GILEAD,,57.0,YR,A,F,Y,103.86,KG,20230810,,LW,US,US,2023,Q3,Adult
208591313,20859131,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2023,Q3,Emotional distress,,2023,Q3,3,F,20120101.0,20230807.0,20220523,20230810,EXP,,US-GILEAD-2022-0582477,GILEAD,,57.0,YR,A,F,Y,103.86,KG,20230810,,LW,US,US,2023,Q3,Adult
210789937,21078993,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,Tablets,,2023,Q3,Thyrotoxic crisis,,2023,Q3,7,F,20220701.0,20230905.0,20220713,20230915,EXP,,JP-Eisai Medical Research-EC-2022-118611,EISAI,,44.0,YR,A,F,Y,85.0,KG,20230915,,MD,JP,JP,2023,Q3,Adult
210789937,21078993,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,Tablets,,2023,Q3,Thyroiditis,,2023,Q3,7,F,20220701.0,20230905.0,20220713,20230915,EXP,,JP-Eisai Medical Research-EC-2022-118611,EISAI,,44.0,YR,A,F,Y,85.0,KG,20230915,,MD,JP,JP,2023,Q3,Adult
211401903,21140190,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,,2023,Q3,Acute generalised exanthematous pustulosis,,2023,Q3,3,F,20220201.0,20230911.0,20220728,20230914,EXP,,ES-ABBVIE-22K-144-4482794-00,ABBVIE,,47.0,YR,,M,Y,,,20230914,,MD,ES,ES,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Catarrh,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Haematochezia,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,COVID-19,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Loss of personal independence in daily activities,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Somnolence,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Swollen tongue,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Palpitations,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Headache,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Adverse drug reaction,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Pain,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Frequent bowel movements,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Impaired quality of life,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Gingival pain,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Stress,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Tinnitus,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Weight decreased,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Tubulointerstitial nephritis,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Pulmonary embolism,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Pain in extremity,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Drug ineffective,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Impaired work ability,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Rash,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Pyrexia,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Eczema,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Steroid dependence,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Colitis ulcerative,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Off label use,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Arthritis,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Bronchiectasis,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Nightmare,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Intentional product use issue,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Inappropriate schedule of product administration,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Vertigo,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Fatigue,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Parosmia,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Condition aggravated,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Colitis ulcerative,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Product use in unapproved indication,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Confusional state,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Rectal haemorrhage,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Rhinitis,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Deep vein thrombosis,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Loss of personal independence in daily activities,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Medication error,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Depression,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Migraine,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Tinnitus,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Accidental overdose,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Product use in unapproved indication,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Cerebrovascular accident,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Abdominal discomfort,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Rash,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Burns second degree,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Dysgeusia,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Systemic lupus erythematosus,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Cardiac murmur,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Hypopnoea,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,527,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Fatigue,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Catarrh,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Haematochezia,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,COVID-19,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Loss of personal independence in daily activities,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Somnolence,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Swollen tongue,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Palpitations,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Headache,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Adverse drug reaction,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Pain,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Frequent bowel movements,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Impaired quality of life,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Gingival pain,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Stress,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Tinnitus,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Weight decreased,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Tubulointerstitial nephritis,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Pulmonary embolism,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Pain in extremity,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Drug ineffective,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Impaired work ability,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Rash,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Pyrexia,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Eczema,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Steroid dependence,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Colitis ulcerative,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Off label use,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Arthritis,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Bronchiectasis,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Nightmare,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Intentional product use issue,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Inappropriate schedule of product administration,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Vertigo,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Fatigue,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Parosmia,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Condition aggravated,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Colitis ulcerative,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Product use in unapproved indication,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Confusional state,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Rectal haemorrhage,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Rhinitis,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Deep vein thrombosis,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Loss of personal independence in daily activities,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Medication error,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Depression,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Migraine,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Tinnitus,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Accidental overdose,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Product use in unapproved indication,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Cerebrovascular accident,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Abdominal discomfort,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Rash,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Burns second degree,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Dysgeusia,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Systemic lupus erythematosus,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Cardiac murmur,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Hypopnoea,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
2117335113,21173351,528,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Fatigue,,2023,Q3,13,F,20080101.0,20230830.0,20220804,20230906,EXP,,CA-AstraZeneca-2017SF10587,ASTRAZENECA,,53.0,YR,,M,Y,,,20230906,,MD,GB,CA,2023,Q3,Adult
212868634,21286863,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Acute kidney injury,,2023,Q3,4,F,,20230731.0,20220902,20230808,EXP,,AU-DSJP-DSJ-2022-131393,DAIICHI,"Reimann F, Whyte I. Chronic lithium toxicity. Aust Prescr. 2022;45(3):93-94",66.0,YR,,M,Y,,,20230808,,HP,AU,AU,2023,Q3,Elderly
212868634,21286863,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Nephrogenic diabetes insipidus,,2023,Q3,4,F,,20230731.0,20220902,20230808,EXP,,AU-DSJP-DSJ-2022-131393,DAIICHI,"Reimann F, Whyte I. Chronic lithium toxicity. Aust Prescr. 2022;45(3):93-94",66.0,YR,,M,Y,,,20230808,,HP,AU,AU,2023,Q3,Elderly
212868634,21286863,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Neurotoxicity,,2023,Q3,4,F,,20230731.0,20220902,20230808,EXP,,AU-DSJP-DSJ-2022-131393,DAIICHI,"Reimann F, Whyte I. Chronic lithium toxicity. Aust Prescr. 2022;45(3):93-94",66.0,YR,,M,Y,,,20230808,,HP,AU,AU,2023,Q3,Elderly
212868634,21286863,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Ileus,,2023,Q3,4,F,,20230731.0,20220902,20230808,EXP,,AU-DSJP-DSJ-2022-131393,DAIICHI,"Reimann F, Whyte I. Chronic lithium toxicity. Aust Prescr. 2022;45(3):93-94",66.0,YR,,M,Y,,,20230808,,HP,AU,AU,2023,Q3,Elderly
212868634,21286863,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Metabolic acidosis,,2023,Q3,4,F,,20230731.0,20220902,20230808,EXP,,AU-DSJP-DSJ-2022-131393,DAIICHI,"Reimann F, Whyte I. Chronic lithium toxicity. Aust Prescr. 2022;45(3):93-94",66.0,YR,,M,Y,,,20230808,,HP,AU,AU,2023,Q3,Elderly
212868634,21286863,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Drug interaction,,2023,Q3,4,F,,20230731.0,20220902,20230808,EXP,,AU-DSJP-DSJ-2022-131393,DAIICHI,"Reimann F, Whyte I. Chronic lithium toxicity. Aust Prescr. 2022;45(3):93-94",66.0,YR,,M,Y,,,20230808,,HP,AU,AU,2023,Q3,Elderly
212868634,21286863,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Hypovolaemia,,2023,Q3,4,F,,20230731.0,20220902,20230808,EXP,,AU-DSJP-DSJ-2022-131393,DAIICHI,"Reimann F, Whyte I. Chronic lithium toxicity. Aust Prescr. 2022;45(3):93-94",66.0,YR,,M,Y,,,20230808,,HP,AU,AU,2023,Q3,Elderly
212868634,21286863,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Toxicity to various agents,,2023,Q3,4,F,,20230731.0,20220902,20230808,EXP,,AU-DSJP-DSJ-2022-131393,DAIICHI,"Reimann F, Whyte I. Chronic lithium toxicity. Aust Prescr. 2022;45(3):93-94",66.0,YR,,M,Y,,,20230808,,HP,AU,AU,2023,Q3,Elderly
212868634,21286863,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Pneumonia,,2023,Q3,4,F,,20230731.0,20220902,20230808,EXP,,AU-DSJP-DSJ-2022-131393,DAIICHI,"Reimann F, Whyte I. Chronic lithium toxicity. Aust Prescr. 2022;45(3):93-94",66.0,YR,,M,Y,,,20230808,,HP,AU,AU,2023,Q3,Elderly
212868634,21286863,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Hypernatraemia,,2023,Q3,4,F,,20230731.0,20220902,20230808,EXP,,AU-DSJP-DSJ-2022-131393,DAIICHI,"Reimann F, Whyte I. Chronic lithium toxicity. Aust Prescr. 2022;45(3):93-94",66.0,YR,,M,Y,,,20230808,,HP,AU,AU,2023,Q3,Elderly
212898865,21289886,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Hypernatraemia,,2023,Q3,5,F,,20230731.0,20220902,20230809,EXP,,AU-ORGANON-O2209AUS000148,ORGANON,"Reimann F, Whyte I.. Chronic lithium toxicity.. Aust Prescr.. 2022;45(3):93-94",66.0,YR,,M,Y,,,20230809,,HP,AU,AU,2023,Q3,Elderly
212898865,21289886,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Ileus,,2023,Q3,5,F,,20230731.0,20220902,20230809,EXP,,AU-ORGANON-O2209AUS000148,ORGANON,"Reimann F, Whyte I.. Chronic lithium toxicity.. Aust Prescr.. 2022;45(3):93-94",66.0,YR,,M,Y,,,20230809,,HP,AU,AU,2023,Q3,Elderly
212898865,21289886,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Neurotoxicity,,2023,Q3,5,F,,20230731.0,20220902,20230809,EXP,,AU-ORGANON-O2209AUS000148,ORGANON,"Reimann F, Whyte I.. Chronic lithium toxicity.. Aust Prescr.. 2022;45(3):93-94",66.0,YR,,M,Y,,,20230809,,HP,AU,AU,2023,Q3,Elderly
212898865,21289886,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Hypovolaemia,,2023,Q3,5,F,,20230731.0,20220902,20230809,EXP,,AU-ORGANON-O2209AUS000148,ORGANON,"Reimann F, Whyte I.. Chronic lithium toxicity.. Aust Prescr.. 2022;45(3):93-94",66.0,YR,,M,Y,,,20230809,,HP,AU,AU,2023,Q3,Elderly
212898865,21289886,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Drug interaction,,2023,Q3,5,F,,20230731.0,20220902,20230809,EXP,,AU-ORGANON-O2209AUS000148,ORGANON,"Reimann F, Whyte I.. Chronic lithium toxicity.. Aust Prescr.. 2022;45(3):93-94",66.0,YR,,M,Y,,,20230809,,HP,AU,AU,2023,Q3,Elderly
212898865,21289886,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Pneumonia,,2023,Q3,5,F,,20230731.0,20220902,20230809,EXP,,AU-ORGANON-O2209AUS000148,ORGANON,"Reimann F, Whyte I.. Chronic lithium toxicity.. Aust Prescr.. 2022;45(3):93-94",66.0,YR,,M,Y,,,20230809,,HP,AU,AU,2023,Q3,Elderly
212898865,21289886,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Acute kidney injury,,2023,Q3,5,F,,20230731.0,20220902,20230809,EXP,,AU-ORGANON-O2209AUS000148,ORGANON,"Reimann F, Whyte I.. Chronic lithium toxicity.. Aust Prescr.. 2022;45(3):93-94",66.0,YR,,M,Y,,,20230809,,HP,AU,AU,2023,Q3,Elderly
212898865,21289886,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Metabolic acidosis,,2023,Q3,5,F,,20230731.0,20220902,20230809,EXP,,AU-ORGANON-O2209AUS000148,ORGANON,"Reimann F, Whyte I.. Chronic lithium toxicity.. Aust Prescr.. 2022;45(3):93-94",66.0,YR,,M,Y,,,20230809,,HP,AU,AU,2023,Q3,Elderly
212898865,21289886,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Toxicity to various agents,,2023,Q3,5,F,,20230731.0,20220902,20230809,EXP,,AU-ORGANON-O2209AUS000148,ORGANON,"Reimann F, Whyte I.. Chronic lithium toxicity.. Aust Prescr.. 2022;45(3):93-94",66.0,YR,,M,Y,,,20230809,,HP,AU,AU,2023,Q3,Elderly
212898865,21289886,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Nephrogenic diabetes insipidus,,2023,Q3,5,F,,20230731.0,20220902,20230809,EXP,,AU-ORGANON-O2209AUS000148,ORGANON,"Reimann F, Whyte I.. Chronic lithium toxicity.. Aust Prescr.. 2022;45(3):93-94",66.0,YR,,M,Y,,,20230809,,HP,AU,AU,2023,Q3,Elderly
213073682,21307368,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,,,,,,2023,Q3,Acute kidney injury,,2023,Q3,2,F,,20230627.0,20220908,20230707,EXP,,AU-COSETTE-CP2022AU000268,COSETTE PHARMACEUTICALS,F Reimann.Chronic lithium toxicity.Aust Prescr.2022;45(3):93-94,66.0,YR,A,M,Y,,,20230707,,HP,AU,AU,2023,Q3,Elderly
213073682,21307368,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,,,,,,2023,Q3,Nephrogenic diabetes insipidus,,2023,Q3,2,F,,20230627.0,20220908,20230707,EXP,,AU-COSETTE-CP2022AU000268,COSETTE PHARMACEUTICALS,F Reimann.Chronic lithium toxicity.Aust Prescr.2022;45(3):93-94,66.0,YR,A,M,Y,,,20230707,,HP,AU,AU,2023,Q3,Elderly
213073682,21307368,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,,,,,,2023,Q3,Metabolic acidosis,,2023,Q3,2,F,,20230627.0,20220908,20230707,EXP,,AU-COSETTE-CP2022AU000268,COSETTE PHARMACEUTICALS,F Reimann.Chronic lithium toxicity.Aust Prescr.2022;45(3):93-94,66.0,YR,A,M,Y,,,20230707,,HP,AU,AU,2023,Q3,Elderly
213073682,21307368,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,,,,,,2023,Q3,Toxicity to various agents,,2023,Q3,2,F,,20230627.0,20220908,20230707,EXP,,AU-COSETTE-CP2022AU000268,COSETTE PHARMACEUTICALS,F Reimann.Chronic lithium toxicity.Aust Prescr.2022;45(3):93-94,66.0,YR,A,M,Y,,,20230707,,HP,AU,AU,2023,Q3,Elderly
213073682,21307368,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,,,,,,2023,Q3,Neurotoxicity,,2023,Q3,2,F,,20230627.0,20220908,20230707,EXP,,AU-COSETTE-CP2022AU000268,COSETTE PHARMACEUTICALS,F Reimann.Chronic lithium toxicity.Aust Prescr.2022;45(3):93-94,66.0,YR,A,M,Y,,,20230707,,HP,AU,AU,2023,Q3,Elderly
213073682,21307368,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,,,,,,2023,Q3,Hypovolaemia,,2023,Q3,2,F,,20230627.0,20220908,20230707,EXP,,AU-COSETTE-CP2022AU000268,COSETTE PHARMACEUTICALS,F Reimann.Chronic lithium toxicity.Aust Prescr.2022;45(3):93-94,66.0,YR,A,M,Y,,,20230707,,HP,AU,AU,2023,Q3,Elderly
213073682,21307368,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,,,,,,2023,Q3,Pneumonia,,2023,Q3,2,F,,20230627.0,20220908,20230707,EXP,,AU-COSETTE-CP2022AU000268,COSETTE PHARMACEUTICALS,F Reimann.Chronic lithium toxicity.Aust Prescr.2022;45(3):93-94,66.0,YR,A,M,Y,,,20230707,,HP,AU,AU,2023,Q3,Elderly
213073682,21307368,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,,,,,,2023,Q3,Drug interaction,,2023,Q3,2,F,,20230627.0,20220908,20230707,EXP,,AU-COSETTE-CP2022AU000268,COSETTE PHARMACEUTICALS,F Reimann.Chronic lithium toxicity.Aust Prescr.2022;45(3):93-94,66.0,YR,A,M,Y,,,20230707,,HP,AU,AU,2023,Q3,Elderly
213073682,21307368,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,,,,,,2023,Q3,Ileus,,2023,Q3,2,F,,20230627.0,20220908,20230707,EXP,,AU-COSETTE-CP2022AU000268,COSETTE PHARMACEUTICALS,F Reimann.Chronic lithium toxicity.Aust Prescr.2022;45(3):93-94,66.0,YR,A,M,Y,,,20230707,,HP,AU,AU,2023,Q3,Elderly
213073682,21307368,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,,,,,,2023,Q3,Hypernatraemia,,2023,Q3,2,F,,20230627.0,20220908,20230707,EXP,,AU-COSETTE-CP2022AU000268,COSETTE PHARMACEUTICALS,F Reimann.Chronic lithium toxicity.Aust Prescr.2022;45(3):93-94,66.0,YR,A,M,Y,,,20230707,,HP,AU,AU,2023,Q3,Elderly
213599413,21359941,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2023,Q3,Oedema peripheral,,2023,Q3,3,F,,20230818.0,20220921,20230824,EXP,,CA-PFIZER INC-PV202200067155,PFIZER,,66.0,YR,,M,Y,,,20230824,,MD,CA,CA,2023,Q3,Elderly
213599413,21359941,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2023,Q3,Dyspnoea,,2023,Q3,3,F,,20230818.0,20220921,20230824,EXP,,CA-PFIZER INC-PV202200067155,PFIZER,,66.0,YR,,M,Y,,,20230824,,MD,CA,CA,2023,Q3,Elderly
213599413,21359941,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2023,Q3,Death,,2023,Q3,3,F,,20230818.0,20220921,20230824,EXP,,CA-PFIZER INC-PV202200067155,PFIZER,,66.0,YR,,M,Y,,,20230824,,MD,CA,CA,2023,Q3,Elderly
213599413,21359941,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2023,Q3,Pleural effusion,,2023,Q3,3,F,,20230818.0,20220921,20230824,EXP,,CA-PFIZER INC-PV202200067155,PFIZER,,66.0,YR,,M,Y,,,20230824,,MD,CA,CA,2023,Q3,Elderly
213599413,21359941,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2023,Q3,Cardiac failure congestive,,2023,Q3,3,F,,20230818.0,20220921,20230824,EXP,,CA-PFIZER INC-PV202200067155,PFIZER,,66.0,YR,,M,Y,,,20230824,,MD,CA,CA,2023,Q3,Elderly
213599413,21359941,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2023,Q3,Fluid retention,,2023,Q3,3,F,,20230818.0,20220921,20230824,EXP,,CA-PFIZER INC-PV202200067155,PFIZER,,66.0,YR,,M,Y,,,20230824,,MD,CA,CA,2023,Q3,Elderly
213599413,21359941,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2023,Q3,Cognitive disorder,,2023,Q3,3,F,,20230818.0,20220921,20230824,EXP,,CA-PFIZER INC-PV202200067155,PFIZER,,66.0,YR,,M,Y,,,20230824,,MD,CA,CA,2023,Q3,Elderly
213750934,21375093,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q3,Renal failure,,2023,Q3,4,F,20220824.0,20230920.0,20220926,20230927,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-193061",BOEHRINGER INGELHEIM,,63.0,YR,A,F,Y,,,20230927,,MD,PL,PL,2023,Q3,Adult
213782342,21378234,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Daily",,,,,,,,10.0,MG,,,2023,Q3,Polycythaemia,,2023,Q3,2,F,,20230720.0,20220927,20230802,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-355712,RANBAXY,"Schumacher KA, Gosmanov AR. Hemochromatosis Gene Mutation in Persons Developing Erythrocytosis on Combined Testosterone and SGLT-2 Inhibitor Therapy. J Investig Med High Impact Case Rep. 2022;10:1-6",63.0,YR,,M,Y,,,20230802,,HP,US,US,2023,Q3,Adult
213782352,21378235,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Daily",,,,,,,,10.0,MG,,,2023,Q3,Polycythaemia,,2023,Q3,2,F,,20230720.0,20220927,20230802,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-355711,RANBAXY,"Schumacher KA, Gosmanov AR. Hemochromatosis Gene Mutation in Persons Developing Erythrocytosis on Combined Testosterone and SGLT-2 Inhibitor Therapy. J Investig Med High Impact Case Rep. 2022;10:1-6",69.0,YR,,M,Y,,,20230802,,HP,US,US,2023,Q3,Elderly
213782392,21378239,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Daily",,,,,,,,10.0,MG,,,2023,Q3,Polycythaemia,,2023,Q3,2,F,,20230720.0,20220927,20230802,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-355714,RANBAXY,"Schumacher KA, Gosmanov AR. Hemochromatosis Gene Mutation in Persons Developing Erythrocytosis on Combined Testosterone and SGLT-2 Inhibitor Therapy. J Investig Med High Impact Case Rep. 2022;10:1-6",63.0,YR,,M,Y,,,20230802,,HP,US,US,2023,Q3,Adult
213782392,21378239,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Daily",,,,,,,,25.0,MG,,,2023,Q3,Polycythaemia,,2023,Q3,2,F,,20230720.0,20220927,20230802,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-355714,RANBAXY,"Schumacher KA, Gosmanov AR. Hemochromatosis Gene Mutation in Persons Developing Erythrocytosis on Combined Testosterone and SGLT-2 Inhibitor Therapy. J Investig Med High Impact Case Rep. 2022;10:1-6",63.0,YR,,M,Y,,,20230802,,HP,US,US,2023,Q3,Adult
214999443,21499944,11,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,UNK,,,,,,,,,,Tablet,,2023,Q3,Cardiac failure chronic,,2023,Q3,3,F,20221007.0,20230810.0,20221024,20230815,EXP,,JP-PFIZER INC-PV202200087039,PFIZER,,73.0,YR,,M,Y,54.1,KG,20230815,,MD,JP,JP,2023,Q3,Elderly
2158375411,21583754,28,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,,,,,,10.0,MG,Oral Drug Unspecified Form,,2023,Q3,Therapeutic product effect delayed,,2023,Q3,11,F,20221107.0,20230821.0,20221111,20230828,EXP,,JP-ARGENX-2022-ARGX-JP002363,ARGENX BVBA,,52.0,YR,,M,Y,95.0,KG,20230825,,MD,JP,JP,2023,Q3,Adult
2158375411,21583754,28,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,,,,,,10.0,MG,Oral Drug Unspecified Form,,2023,Q3,Pigmentation disorder,,2023,Q3,11,F,20221107.0,20230821.0,20221111,20230828,EXP,,JP-ARGENX-2022-ARGX-JP002363,ARGENX BVBA,,52.0,YR,,M,Y,95.0,KG,20230825,,MD,JP,JP,2023,Q3,Adult
2158375411,21583754,28,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,,,,,,10.0,MG,Oral Drug Unspecified Form,,2023,Q3,Haematochezia,,2023,Q3,11,F,20221107.0,20230821.0,20221111,20230828,EXP,,JP-ARGENX-2022-ARGX-JP002363,ARGENX BVBA,,52.0,YR,,M,Y,95.0,KG,20230825,,MD,JP,JP,2023,Q3,Adult
2158375411,21583754,28,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,,,,,,10.0,MG,Oral Drug Unspecified Form,,2023,Q3,Symptom recurrence,,2023,Q3,11,F,20221107.0,20230821.0,20221111,20230828,EXP,,JP-ARGENX-2022-ARGX-JP002363,ARGENX BVBA,,52.0,YR,,M,Y,95.0,KG,20230825,,MD,JP,JP,2023,Q3,Adult
2158375411,21583754,28,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,,,,,,10.0,MG,Oral Drug Unspecified Form,,2023,Q3,Diverticulum intestinal haemorrhagic,,2023,Q3,11,F,20221107.0,20230821.0,20221111,20230828,EXP,,JP-ARGENX-2022-ARGX-JP002363,ARGENX BVBA,,52.0,YR,,M,Y,95.0,KG,20230825,,MD,JP,JP,2023,Q3,Adult
215894388,21589438,41,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1 every 1 days)",,,U,,,,,10.0,MG,,QD,2023,Q3,Neoplasm skin,,2023,Q3,8,F,,20230712.0,20221114,20230720,EXP,,NVSC2022CA251360,NOVARTIS,,67.0,YR,,F,Y,,,20230720,,CN,CA,CA,2023,Q3,Elderly
215894388,21589438,41,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1 every 1 days)",,,U,,,,,10.0,MG,,QD,2023,Q3,Haemorrhoids,,2023,Q3,8,F,,20230712.0,20221114,20230720,EXP,,NVSC2022CA251360,NOVARTIS,,67.0,YR,,F,Y,,,20230720,,CN,CA,CA,2023,Q3,Elderly
215894388,21589438,41,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1 every 1 days)",,,U,,,,,10.0,MG,,QD,2023,Q3,Cataract,,2023,Q3,8,F,,20230712.0,20221114,20230720,EXP,,NVSC2022CA251360,NOVARTIS,,67.0,YR,,F,Y,,,20230720,,CN,CA,CA,2023,Q3,Elderly
215894388,21589438,41,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1 every 1 days)",,,U,,,,,10.0,MG,,QD,2023,Q3,Product use issue,,2023,Q3,8,F,,20230712.0,20221114,20230720,EXP,,NVSC2022CA251360,NOVARTIS,,67.0,YR,,F,Y,,,20230720,,CN,CA,CA,2023,Q3,Elderly
215894388,21589438,41,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1 every 1 days)",,,U,,,,,10.0,MG,,QD,2023,Q3,Drug ineffective,,2023,Q3,8,F,,20230712.0,20221114,20230720,EXP,,NVSC2022CA251360,NOVARTIS,,67.0,YR,,F,Y,,,20230720,,CN,CA,CA,2023,Q3,Elderly
215894388,21589438,41,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1 every 1 days)",,,U,,,,,10.0,MG,,QD,2023,Q3,Dyspnoea,,2023,Q3,8,F,,20230712.0,20221114,20230720,EXP,,NVSC2022CA251360,NOVARTIS,,67.0,YR,,F,Y,,,20230720,,CN,CA,CA,2023,Q3,Elderly
215894388,21589438,41,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1 every 1 days)",,,U,,,,,10.0,MG,,QD,2023,Q3,Vulvovaginal mycotic infection,,2023,Q3,8,F,,20230712.0,20221114,20230720,EXP,,NVSC2022CA251360,NOVARTIS,,67.0,YR,,F,Y,,,20230720,,CN,CA,CA,2023,Q3,Elderly
215894388,21589438,41,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1 every 1 days)",,,U,,,,,10.0,MG,,QD,2023,Q3,Neuropathy peripheral,,2023,Q3,8,F,,20230712.0,20221114,20230720,EXP,,NVSC2022CA251360,NOVARTIS,,67.0,YR,,F,Y,,,20230720,,CN,CA,CA,2023,Q3,Elderly
215894388,21589438,41,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1 every 1 days)",,,U,,,,,10.0,MG,,QD,2023,Q3,Haemorrhoidal haemorrhage,,2023,Q3,8,F,,20230712.0,20221114,20230720,EXP,,NVSC2022CA251360,NOVARTIS,,67.0,YR,,F,Y,,,20230720,,CN,CA,CA,2023,Q3,Elderly
215894388,21589438,41,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1 every 1 days)",,,U,,,,,10.0,MG,,QD,2023,Q3,Cardiac failure,,2023,Q3,8,F,,20230712.0,20221114,20230720,EXP,,NVSC2022CA251360,NOVARTIS,,67.0,YR,,F,Y,,,20230720,,CN,CA,CA,2023,Q3,Elderly
215894388,21589438,41,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1 every 1 days)",,,U,,,,,10.0,MG,,QD,2023,Q3,Chest discomfort,,2023,Q3,8,F,,20230712.0,20221114,20230720,EXP,,NVSC2022CA251360,NOVARTIS,,67.0,YR,,F,Y,,,20230720,,CN,CA,CA,2023,Q3,Elderly
215894388,21589438,41,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1 every 1 days)",,,U,,,,,10.0,MG,,QD,2023,Q3,Blood pressure increased,,2023,Q3,8,F,,20230712.0,20221114,20230720,EXP,,NVSC2022CA251360,NOVARTIS,,67.0,YR,,F,Y,,,20230720,,CN,CA,CA,2023,Q3,Elderly
215894388,21589438,41,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1 every 1 days)",,,U,,,,,10.0,MG,,QD,2023,Q3,Constipation,,2023,Q3,8,F,,20230712.0,20221114,20230720,EXP,,NVSC2022CA251360,NOVARTIS,,67.0,YR,,F,Y,,,20230720,,CN,CA,CA,2023,Q3,Elderly
215894388,21589438,41,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1 every 1 days)",,,U,,,,,10.0,MG,,QD,2023,Q3,COVID-19,,2023,Q3,8,F,,20230712.0,20221114,20230720,EXP,,NVSC2022CA251360,NOVARTIS,,67.0,YR,,F,Y,,,20230720,,CN,CA,CA,2023,Q3,Elderly
215894388,21589438,41,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1 every 1 days)",,,U,,,,,10.0,MG,,QD,2023,Q3,Transient ischaemic attack,,2023,Q3,8,F,,20230712.0,20221114,20230720,EXP,,NVSC2022CA251360,NOVARTIS,,67.0,YR,,F,Y,,,20230720,,CN,CA,CA,2023,Q3,Elderly
215894388,21589438,41,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1 every 1 days)",,,U,,,,,10.0,MG,,QD,2023,Q3,Abdominal pain upper,,2023,Q3,8,F,,20230712.0,20221114,20230720,EXP,,NVSC2022CA251360,NOVARTIS,,67.0,YR,,F,Y,,,20230720,,CN,CA,CA,2023,Q3,Elderly
215894388,21589438,41,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1 every 1 days)",,,U,,,,,10.0,MG,,QD,2023,Q3,Fall,,2023,Q3,8,F,,20230712.0,20221114,20230720,EXP,,NVSC2022CA251360,NOVARTIS,,67.0,YR,,F,Y,,,20230720,,CN,CA,CA,2023,Q3,Elderly
215894388,21589438,41,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1 every 1 days)",,,U,,,,,10.0,MG,,QD,2023,Q3,Clostridium difficile colitis,,2023,Q3,8,F,,20230712.0,20221114,20230720,EXP,,NVSC2022CA251360,NOVARTIS,,67.0,YR,,F,Y,,,20230720,,CN,CA,CA,2023,Q3,Elderly
215894388,21589438,41,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1 every 1 days)",,,U,,,,,10.0,MG,,QD,2023,Q3,Pneumonia,,2023,Q3,8,F,,20230712.0,20221114,20230720,EXP,,NVSC2022CA251360,NOVARTIS,,67.0,YR,,F,Y,,,20230720,,CN,CA,CA,2023,Q3,Elderly
216703233,21670323,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,,2023,Q3,Pulmonary oedema,,2023,Q3,3,F,,20230809.0,20221201,20230820,EXP,,JP-JNJFOC-20221200218,JOHNSON AND JOHNSON,,81.0,YR,E,M,Y,,,20230820,,MD,JP,JP,2023,Q3,Elderly
216703233,21670323,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,,2023,Q3,Delirium,,2023,Q3,3,F,,20230809.0,20221201,20230820,EXP,,JP-JNJFOC-20221200218,JOHNSON AND JOHNSON,,81.0,YR,E,M,Y,,,20230820,,MD,JP,JP,2023,Q3,Elderly
217592038,21759203,6,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,"1 DF, Daily",,,,,,,,,,Tablet,QD,2023,Q3,Pneumonia aspiration,,2023,Q3,8,F,20221216.0,20230822.0,20221221,20230824,EXP,,JP-ARGENX-2022-ARGX-JP002747,ARGENX BVBA,,70.0,YR,,M,Y,52.0,KG,20230823,,PH,JP,JP,2023,Q3,Elderly
217823003,21782300,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,UNKNOWN,,,10.0,MG,,QD,2023,Q3,Weight increased,,2023,Q3,3,F,,20230921.0,20221227,20230923,EXP,,CA-ROCHE-3250633,ROCHE,,66.0,YR,,F,Y,89.0,KG,20230923,,HP,CA,,2023,Q3,Elderly
217823003,21782300,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,UNKNOWN,,,10.0,MG,,QD,2023,Q3,Aortic arteriosclerosis,,2023,Q3,3,F,,20230921.0,20221227,20230923,EXP,,CA-ROCHE-3250633,ROCHE,,66.0,YR,,F,Y,89.0,KG,20230923,,HP,CA,,2023,Q3,Elderly
217823003,21782300,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,UNKNOWN,,,10.0,MG,,QD,2023,Q3,Weight decreased,,2023,Q3,3,F,,20230921.0,20221227,20230923,EXP,,CA-ROCHE-3250633,ROCHE,,66.0,YR,,F,Y,89.0,KG,20230923,,HP,CA,,2023,Q3,Elderly
217823003,21782300,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,UNKNOWN,,,10.0,MG,,QD,2023,Q3,Blood pressure systolic increased,,2023,Q3,3,F,,20230921.0,20221227,20230923,EXP,,CA-ROCHE-3250633,ROCHE,,66.0,YR,,F,Y,89.0,KG,20230923,,HP,CA,,2023,Q3,Elderly
217823003,21782300,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,UNKNOWN,,,10.0,MG,,QD,2023,Q3,Blood pressure diastolic decreased,,2023,Q3,3,F,,20230921.0,20221227,20230923,EXP,,CA-ROCHE-3250633,ROCHE,,66.0,YR,,F,Y,89.0,KG,20230923,,HP,CA,,2023,Q3,Elderly
217823003,21782300,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,UNKNOWN,,,10.0,MG,,QD,2023,Q3,Type 2 diabetes mellitus,,2023,Q3,3,F,,20230921.0,20221227,20230923,EXP,,CA-ROCHE-3250633,ROCHE,,66.0,YR,,F,Y,89.0,KG,20230923,,HP,CA,,2023,Q3,Elderly
217823003,21782300,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,UNKNOWN,,,10.0,MG,,QD,2023,Q3,Oxygen saturation decreased,,2023,Q3,3,F,,20230921.0,20221227,20230923,EXP,,CA-ROCHE-3250633,ROCHE,,66.0,YR,,F,Y,89.0,KG,20230923,,HP,CA,,2023,Q3,Elderly
217823003,21782300,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,UNKNOWN,,,10.0,MG,,QD,2023,Q3,Blood pressure fluctuation,,2023,Q3,3,F,,20230921.0,20221227,20230923,EXP,,CA-ROCHE-3250633,ROCHE,,66.0,YR,,F,Y,89.0,KG,20230923,,HP,CA,,2023,Q3,Elderly
217823003,21782300,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,UNKNOWN,,,10.0,MG,,QD,2023,Q3,Blood glucose increased,,2023,Q3,3,F,,20230921.0,20221227,20230923,EXP,,CA-ROCHE-3250633,ROCHE,,66.0,YR,,F,Y,89.0,KG,20230923,,HP,CA,,2023,Q3,Elderly
217823003,21782300,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,UNKNOWN,,,10.0,MG,,QD,2023,Q3,Blood pressure increased,,2023,Q3,3,F,,20230921.0,20221227,20230923,EXP,,CA-ROCHE-3250633,ROCHE,,66.0,YR,,F,Y,89.0,KG,20230923,,HP,CA,,2023,Q3,Elderly
217823003,21782300,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,UNKNOWN,,,10.0,MG,,QD,2023,Q3,Blood pressure diastolic abnormal,,2023,Q3,3,F,,20230921.0,20221227,20230923,EXP,,CA-ROCHE-3250633,ROCHE,,66.0,YR,,F,Y,89.0,KG,20230923,,HP,CA,,2023,Q3,Elderly
2178761412,21787614,53,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Deep vein thrombosis,,2023,Q3,12,F,20221004.0,20230728.0,20221228,20230801,EXP,,AU-ROCHE-3194260,ROCHE,,63.0,YR,,M,Y,174.0,KG,20230801,,MD,AU,,2023,Q3,Adult
2178761412,21787614,53,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Pneumonia,,2023,Q3,12,F,20221004.0,20230728.0,20221228,20230801,EXP,,AU-ROCHE-3194260,ROCHE,,63.0,YR,,M,Y,174.0,KG,20230801,,MD,AU,,2023,Q3,Adult
2178761412,21787614,53,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Abdominal pain,,2023,Q3,12,F,20221004.0,20230728.0,20221228,20230801,EXP,,AU-ROCHE-3194260,ROCHE,,63.0,YR,,M,Y,174.0,KG,20230801,,MD,AU,,2023,Q3,Adult
2178761412,21787614,53,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Venous thrombosis limb,,2023,Q3,12,F,20221004.0,20230728.0,20221228,20230801,EXP,,AU-ROCHE-3194260,ROCHE,,63.0,YR,,M,Y,174.0,KG,20230801,,MD,AU,,2023,Q3,Adult
2178761412,21787614,53,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Hypervolaemia,,2023,Q3,12,F,20221004.0,20230728.0,20221228,20230801,EXP,,AU-ROCHE-3194260,ROCHE,,63.0,YR,,M,Y,174.0,KG,20230801,,MD,AU,,2023,Q3,Adult
2178761412,21787614,53,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Lumbar vertebral fracture,,2023,Q3,12,F,20221004.0,20230728.0,20221228,20230801,EXP,,AU-ROCHE-3194260,ROCHE,,63.0,YR,,M,Y,174.0,KG,20230801,,MD,AU,,2023,Q3,Adult
218622834,21862283,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Drug ineffective,,2023,Q3,4,F,,20230712.0,20230114,20230717,EXP,,NVSC2023CA005723,NOVARTIS,,67.0,YR,,F,Y,,,20230717,,PH,CA,CA,2023,Q3,Elderly
218622834,21862283,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,COVID-19,,2023,Q3,4,F,,20230712.0,20230114,20230717,EXP,,NVSC2023CA005723,NOVARTIS,,67.0,YR,,F,Y,,,20230717,,PH,CA,CA,2023,Q3,Elderly
218622834,21862283,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Dyspnoea,,2023,Q3,4,F,,20230712.0,20230114,20230717,EXP,,NVSC2023CA005723,NOVARTIS,,67.0,YR,,F,Y,,,20230717,,PH,CA,CA,2023,Q3,Elderly
218622834,21862283,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Haemorrhoidal haemorrhage,,2023,Q3,4,F,,20230712.0,20230114,20230717,EXP,,NVSC2023CA005723,NOVARTIS,,67.0,YR,,F,Y,,,20230717,,PH,CA,CA,2023,Q3,Elderly
218622834,21862283,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Constipation,,2023,Q3,4,F,,20230712.0,20230114,20230717,EXP,,NVSC2023CA005723,NOVARTIS,,67.0,YR,,F,Y,,,20230717,,PH,CA,CA,2023,Q3,Elderly
218622834,21862283,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Haemorrhoids,,2023,Q3,4,F,,20230712.0,20230114,20230717,EXP,,NVSC2023CA005723,NOVARTIS,,67.0,YR,,F,Y,,,20230717,,PH,CA,CA,2023,Q3,Elderly
218622834,21862283,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Neuropathy peripheral,,2023,Q3,4,F,,20230712.0,20230114,20230717,EXP,,NVSC2023CA005723,NOVARTIS,,67.0,YR,,F,Y,,,20230717,,PH,CA,CA,2023,Q3,Elderly
218622834,21862283,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Vulvovaginal mycotic infection,,2023,Q3,4,F,,20230712.0,20230114,20230717,EXP,,NVSC2023CA005723,NOVARTIS,,67.0,YR,,F,Y,,,20230717,,PH,CA,CA,2023,Q3,Elderly
218622834,21862283,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Cardiomegaly,,2023,Q3,4,F,,20230712.0,20230114,20230717,EXP,,NVSC2023CA005723,NOVARTIS,,67.0,YR,,F,Y,,,20230717,,PH,CA,CA,2023,Q3,Elderly
218622834,21862283,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Pain in extremity,,2023,Q3,4,F,,20230712.0,20230114,20230717,EXP,,NVSC2023CA005723,NOVARTIS,,67.0,YR,,F,Y,,,20230717,,PH,CA,CA,2023,Q3,Elderly
218622834,21862283,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Cardiac failure,,2023,Q3,4,F,,20230712.0,20230114,20230717,EXP,,NVSC2023CA005723,NOVARTIS,,67.0,YR,,F,Y,,,20230717,,PH,CA,CA,2023,Q3,Elderly
218622834,21862283,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Abdominal pain upper,,2023,Q3,4,F,,20230712.0,20230114,20230717,EXP,,NVSC2023CA005723,NOVARTIS,,67.0,YR,,F,Y,,,20230717,,PH,CA,CA,2023,Q3,Elderly
218622834,21862283,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Transient ischaemic attack,,2023,Q3,4,F,,20230712.0,20230114,20230717,EXP,,NVSC2023CA005723,NOVARTIS,,67.0,YR,,F,Y,,,20230717,,PH,CA,CA,2023,Q3,Elderly
218622834,21862283,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Product use issue,,2023,Q3,4,F,,20230712.0,20230114,20230717,EXP,,NVSC2023CA005723,NOVARTIS,,67.0,YR,,F,Y,,,20230717,,PH,CA,CA,2023,Q3,Elderly
218622834,21862283,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Blood pressure increased,,2023,Q3,4,F,,20230712.0,20230114,20230717,EXP,,NVSC2023CA005723,NOVARTIS,,67.0,YR,,F,Y,,,20230717,,PH,CA,CA,2023,Q3,Elderly
218622834,21862283,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Off label use,,2023,Q3,4,F,,20230712.0,20230114,20230717,EXP,,NVSC2023CA005723,NOVARTIS,,67.0,YR,,F,Y,,,20230717,,PH,CA,CA,2023,Q3,Elderly
218622834,21862283,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Chest pain,,2023,Q3,4,F,,20230712.0,20230114,20230717,EXP,,NVSC2023CA005723,NOVARTIS,,67.0,YR,,F,Y,,,20230717,,PH,CA,CA,2023,Q3,Elderly
218622834,21862283,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Chest discomfort,,2023,Q3,4,F,,20230712.0,20230114,20230717,EXP,,NVSC2023CA005723,NOVARTIS,,67.0,YR,,F,Y,,,20230717,,PH,CA,CA,2023,Q3,Elderly
218622834,21862283,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Neoplasm skin,,2023,Q3,4,F,,20230712.0,20230114,20230717,EXP,,NVSC2023CA005723,NOVARTIS,,67.0,YR,,F,Y,,,20230717,,PH,CA,CA,2023,Q3,Elderly
218622834,21862283,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Pneumonia,,2023,Q3,4,F,,20230712.0,20230114,20230717,EXP,,NVSC2023CA005723,NOVARTIS,,67.0,YR,,F,Y,,,20230717,,PH,CA,CA,2023,Q3,Elderly
218622834,21862283,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Clostridium difficile colitis,,2023,Q3,4,F,,20230712.0,20230114,20230717,EXP,,NVSC2023CA005723,NOVARTIS,,67.0,YR,,F,Y,,,20230717,,PH,CA,CA,2023,Q3,Elderly
218622834,21862283,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Fall,,2023,Q3,4,F,,20230712.0,20230114,20230717,EXP,,NVSC2023CA005723,NOVARTIS,,67.0,YR,,F,Y,,,20230717,,PH,CA,CA,2023,Q3,Elderly
218622834,21862283,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Hypoaesthesia,,2023,Q3,4,F,,20230712.0,20230114,20230717,EXP,,NVSC2023CA005723,NOVARTIS,,67.0,YR,,F,Y,,,20230717,,PH,CA,CA,2023,Q3,Elderly
218622834,21862283,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Cataract,,2023,Q3,4,F,,20230712.0,20230114,20230717,EXP,,NVSC2023CA005723,NOVARTIS,,67.0,YR,,F,Y,,,20230717,,PH,CA,CA,2023,Q3,Elderly
219209549,21920954,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,Tablet,,2023,Q3,Liver function test increased,,2023,Q3,9,F,20221103.0,20230716.0,20230127,20230726,EXP,,IL-PFIZER INC-PV202200115137,PFIZER,,64.0,YR,,M,Y,67.0,KG,20230726,,MD,IL,IL,2023,Q3,Adult
2197775612,21977756,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,Tablets,,2023,Q3,Coronary artery disease,,2023,Q3,12,F,20230131.0,20230823.0,20230210,20230830,PER,,CN-Eisai Medical Research-EC-2023-133815,EISAI,,69.0,YR,E,F,Y,63.0,KG,20230830,,MD,CN,,2023,Q3,Elderly
220319994,22031999,7,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2023,Q3,Meningitis,,2023,Q3,4,F,20230214.0,20230224.0,20230224,20230808,EXP,,IL-ABBVIE-4309168,ABBVIE,,67.0,YR,,M,Y,,,20230301,,MD,IL,IL,2023,Q3,Elderly
220399713,22039971,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,more than 11 months,,,U,,Unknown,,,25.0,MG,Tablet,QD,2023,Q3,Glycosylated haemoglobin increased,,2023,Q3,3,F,20211201.0,20230621.0,20230227,20230704,EXP,,JP-EMD Serono-9343540,EMD SERONO INC,,7.0,DEC,E,F,Y,68.0,KG,20230704,,HP,JP,JP,2023,Q3,Child
220399713,22039971,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,more than 11 months,,,U,,Unknown,,,25.0,MG,Tablet,QD,2023,Q3,Blood glucose increased,,2023,Q3,3,F,20211201.0,20230621.0,20230227,20230704,EXP,,JP-EMD Serono-9343540,EMD SERONO INC,,7.0,DEC,E,F,Y,68.0,KG,20230704,,HP,JP,JP,2023,Q3,Child
220969674,22096967,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q3,Inappropriate schedule of product administration,,2023,Q3,4,F,20220418.0,20230715.0,20230315,20230721,EXP,,CA-PFIZER INC-202200597420,PFIZER,,64.0,YR,,M,Y,,,20230721,,HP,CA,CA,2023,Q3,Adult
220969674,22096967,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q3,Off label use,,2023,Q3,4,F,20220418.0,20230715.0,20230315,20230721,EXP,,CA-PFIZER INC-202200597420,PFIZER,,64.0,YR,,M,Y,,,20230721,,HP,CA,CA,2023,Q3,Adult
220969674,22096967,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q3,Seizure,,2023,Q3,4,F,20220418.0,20230715.0,20230315,20230721,EXP,,CA-PFIZER INC-202200597420,PFIZER,,64.0,YR,,M,Y,,,20230721,,HP,CA,CA,2023,Q3,Adult
220969674,22096967,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q3,Malaise,,2023,Q3,4,F,20220418.0,20230715.0,20230315,20230721,EXP,,CA-PFIZER INC-202200597420,PFIZER,,64.0,YR,,M,Y,,,20230721,,HP,CA,CA,2023,Q3,Adult
220969674,22096967,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q3,Back pain,,2023,Q3,4,F,20220418.0,20230715.0,20230315,20230721,EXP,,CA-PFIZER INC-202200597420,PFIZER,,64.0,YR,,M,Y,,,20230721,,HP,CA,CA,2023,Q3,Adult
221589224,22158922,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2023,Q3,Upper gastrointestinal haemorrhage,,2023,Q3,4,F,20230203.0,20230804.0,20230331,20230809,EXP,,US-SA-2023SA094179,SANOFI AVENTIS,,73.0,YR,E,M,Y,86.7,KG,20230809,,HP,US,US,2023,Q3,Elderly
221589224,22158922,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2023,Q3,Cardiac failure acute,,2023,Q3,4,F,20230203.0,20230804.0,20230331,20230809,EXP,,US-SA-2023SA094179,SANOFI AVENTIS,,73.0,YR,E,M,Y,86.7,KG,20230809,,HP,US,US,2023,Q3,Elderly
221589224,22158922,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2023,Q3,Staphylococcal sepsis,,2023,Q3,4,F,20230203.0,20230804.0,20230331,20230809,EXP,,US-SA-2023SA094179,SANOFI AVENTIS,,73.0,YR,E,M,Y,86.7,KG,20230809,,HP,US,US,2023,Q3,Elderly
221875373,22187537,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 milligram, qd (morning)",,,,,,,,10.0,MG,,QD,2023,Q3,Myocardial infarction,,2023,Q3,3,F,20220616.0,20230517.0,20230407,20230705,PER,,US-SAREPTA THERAPEUTICS INC.-SRP2023-003234,SAREPTA THERAPEUTICS,,23.0,YR,,M,Y,58.49,KG,20230705,,HP,US,US,2023,Q3,Youth
221968615,22196861,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2023,Q3,Sneezing,,2023,Q3,5,F,20230101.0,20230728.0,20230411,20230803,EXP,,CA-SA-2023SA110517,SANOFI AVENTIS,,61.0,YR,A,F,Y,,,20230803,,CN,CA,CA,2023,Q3,Adult
221968615,22196861,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2023,Q3,Cough,,2023,Q3,5,F,20230101.0,20230728.0,20230411,20230803,EXP,,CA-SA-2023SA110517,SANOFI AVENTIS,,61.0,YR,A,F,Y,,,20230803,,CN,CA,CA,2023,Q3,Adult
221968615,22196861,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2023,Q3,Chest discomfort,,2023,Q3,5,F,20230101.0,20230728.0,20230411,20230803,EXP,,CA-SA-2023SA110517,SANOFI AVENTIS,,61.0,YR,A,F,Y,,,20230803,,CN,CA,CA,2023,Q3,Adult
221968615,22196861,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2023,Q3,Restlessness,,2023,Q3,5,F,20230101.0,20230728.0,20230411,20230803,EXP,,CA-SA-2023SA110517,SANOFI AVENTIS,,61.0,YR,A,F,Y,,,20230803,,CN,CA,CA,2023,Q3,Adult
221968615,22196861,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2023,Q3,Heart rate increased,,2023,Q3,5,F,20230101.0,20230728.0,20230411,20230803,EXP,,CA-SA-2023SA110517,SANOFI AVENTIS,,61.0,YR,A,F,Y,,,20230803,,CN,CA,CA,2023,Q3,Adult
221968615,22196861,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2023,Q3,Diarrhoea,,2023,Q3,5,F,20230101.0,20230728.0,20230411,20230803,EXP,,CA-SA-2023SA110517,SANOFI AVENTIS,,61.0,YR,A,F,Y,,,20230803,,CN,CA,CA,2023,Q3,Adult
221968615,22196861,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2023,Q3,Cold sweat,,2023,Q3,5,F,20230101.0,20230728.0,20230411,20230803,EXP,,CA-SA-2023SA110517,SANOFI AVENTIS,,61.0,YR,A,F,Y,,,20230803,,CN,CA,CA,2023,Q3,Adult
221968615,22196861,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2023,Q3,Erythema,,2023,Q3,5,F,20230101.0,20230728.0,20230411,20230803,EXP,,CA-SA-2023SA110517,SANOFI AVENTIS,,61.0,YR,A,F,Y,,,20230803,,CN,CA,CA,2023,Q3,Adult
221968615,22196861,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2023,Q3,Dyspnoea,,2023,Q3,5,F,20230101.0,20230728.0,20230411,20230803,EXP,,CA-SA-2023SA110517,SANOFI AVENTIS,,61.0,YR,A,F,Y,,,20230803,,CN,CA,CA,2023,Q3,Adult
221968615,22196861,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2023,Q3,Flushing,,2023,Q3,5,F,20230101.0,20230728.0,20230411,20230803,EXP,,CA-SA-2023SA110517,SANOFI AVENTIS,,61.0,YR,A,F,Y,,,20230803,,CN,CA,CA,2023,Q3,Adult
221968615,22196861,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2023,Q3,Nausea,,2023,Q3,5,F,20230101.0,20230728.0,20230411,20230803,EXP,,CA-SA-2023SA110517,SANOFI AVENTIS,,61.0,YR,A,F,Y,,,20230803,,CN,CA,CA,2023,Q3,Adult
221968615,22196861,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2023,Q3,Oxygen saturation decreased,,2023,Q3,5,F,20230101.0,20230728.0,20230411,20230803,EXP,,CA-SA-2023SA110517,SANOFI AVENTIS,,61.0,YR,A,F,Y,,,20230803,,CN,CA,CA,2023,Q3,Adult
221968615,22196861,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2023,Q3,Respiratory rate increased,,2023,Q3,5,F,20230101.0,20230728.0,20230411,20230803,EXP,,CA-SA-2023SA110517,SANOFI AVENTIS,,61.0,YR,A,F,Y,,,20230803,,CN,CA,CA,2023,Q3,Adult
221968615,22196861,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2023,Q3,Hypersensitivity,,2023,Q3,5,F,20230101.0,20230728.0,20230411,20230803,EXP,,CA-SA-2023SA110517,SANOFI AVENTIS,,61.0,YR,A,F,Y,,,20230803,,CN,CA,CA,2023,Q3,Adult
221968615,22196861,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2023,Q3,Pneumonia,,2023,Q3,5,F,20230101.0,20230728.0,20230411,20230803,EXP,,CA-SA-2023SA110517,SANOFI AVENTIS,,61.0,YR,A,F,Y,,,20230803,,CN,CA,CA,2023,Q3,Adult
221968615,22196861,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2023,Q3,Throat tightness,,2023,Q3,5,F,20230101.0,20230728.0,20230411,20230803,EXP,,CA-SA-2023SA110517,SANOFI AVENTIS,,61.0,YR,A,F,Y,,,20230803,,CN,CA,CA,2023,Q3,Adult
221968615,22196861,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2023,Q3,Cyanosis,,2023,Q3,5,F,20230101.0,20230728.0,20230411,20230803,EXP,,CA-SA-2023SA110517,SANOFI AVENTIS,,61.0,YR,A,F,Y,,,20230803,,CN,CA,CA,2023,Q3,Adult
221968615,22196861,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2023,Q3,Antibody test abnormal,,2023,Q3,5,F,20230101.0,20230728.0,20230411,20230803,EXP,,CA-SA-2023SA110517,SANOFI AVENTIS,,61.0,YR,A,F,Y,,,20230803,,CN,CA,CA,2023,Q3,Adult
222090702,22209070,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",700.0,MG,,,,,,10.0,MG,,QD,2023,Q3,Basal cell carcinoma,,2023,Q3,2,F,20220803.0,20230822.0,20230413,20230829,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR006387,AEGERION,,39.0,YR,,F,Y,58.5,KG,20230829,,MD,US,US,2023,Q3,Adult
222090702,22209070,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",700.0,MG,,,,,,25.0,MG,,QD,2023,Q3,Basal cell carcinoma,,2023,Q3,2,F,20220803.0,20230822.0,20230413,20230829,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR006387,AEGERION,,39.0,YR,,F,Y,58.5,KG,20230829,,MD,US,US,2023,Q3,Adult
222566914,22256691,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,dose and frequency unknown,,,,,,,,,,,,2023,Q3,Thrombotic cerebral infarction,,2023,Q3,4,F,20230416.0,20230913.0,20230426,20230915,PER,,JP-Eisai Medical Research-EC-2023-138783,EISAI,,69.0,YR,E,M,Y,,,20230915,,MD,JP,JP,2023,Q3,Elderly
222797533,22279753,6,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Thrombotic cerebral infarction,,2023,Q3,3,F,20230106.0,20230913.0,20230503,20230920,EXP,,JP-009507513-2301JPN002328J,MERCK,,69.0,YR,,M,Y,,,20230920,,MD,JP,JP,2023,Q3,Elderly
222797533,22279753,6,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Hypertension,,2023,Q3,3,F,20230106.0,20230913.0,20230503,20230920,EXP,,JP-009507513-2301JPN002328J,MERCK,,69.0,YR,,M,Y,,,20230920,,MD,JP,JP,2023,Q3,Elderly
222797533,22279753,6,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Dysphonia,,2023,Q3,3,F,20230106.0,20230913.0,20230503,20230920,EXP,,JP-009507513-2301JPN002328J,MERCK,,69.0,YR,,M,Y,,,20230920,,MD,JP,JP,2023,Q3,Elderly
223171325,22317132,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,Unknown,QD,2023,Q3,Neutrophil count decreased,,2023,Q3,5,F,20230412.0,20230802.0,20230514,20230807,EXP,,AU-JNJFOC-20230522488,JOHNSON AND JOHNSON,,80.0,YR,E,M,Y,75.3,KG,20230807,,HP,AU,AU,2023,Q3,Elderly
223171325,22317132,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,Unknown,QD,2023,Q3,Hyperthyroidism,,2023,Q3,5,F,20230412.0,20230802.0,20230514,20230807,EXP,,AU-JNJFOC-20230522488,JOHNSON AND JOHNSON,,80.0,YR,E,M,Y,75.3,KG,20230807,,HP,AU,AU,2023,Q3,Elderly
223171325,22317132,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,Unknown,QD,2023,Q3,Pulmonary hypertension,,2023,Q3,5,F,20230412.0,20230802.0,20230514,20230807,EXP,,AU-JNJFOC-20230522488,JOHNSON AND JOHNSON,,80.0,YR,E,M,Y,75.3,KG,20230807,,HP,AU,AU,2023,Q3,Elderly
223171325,22317132,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,Unknown,QD,2023,Q3,Decreased appetite,,2023,Q3,5,F,20230412.0,20230802.0,20230514,20230807,EXP,,AU-JNJFOC-20230522488,JOHNSON AND JOHNSON,,80.0,YR,E,M,Y,75.3,KG,20230807,,HP,AU,AU,2023,Q3,Elderly
223171325,22317132,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,Unknown,QD,2023,Q3,Acute myocardial infarction,,2023,Q3,5,F,20230412.0,20230802.0,20230514,20230807,EXP,,AU-JNJFOC-20230522488,JOHNSON AND JOHNSON,,80.0,YR,E,M,Y,75.3,KG,20230807,,HP,AU,AU,2023,Q3,Elderly
223171325,22317132,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,Unknown,QD,2023,Q3,Skin ulcer,,2023,Q3,5,F,20230412.0,20230802.0,20230514,20230807,EXP,,AU-JNJFOC-20230522488,JOHNSON AND JOHNSON,,80.0,YR,E,M,Y,75.3,KG,20230807,,HP,AU,AU,2023,Q3,Elderly
223171325,22317132,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,Unknown,QD,2023,Q3,Malnutrition,,2023,Q3,5,F,20230412.0,20230802.0,20230514,20230807,EXP,,AU-JNJFOC-20230522488,JOHNSON AND JOHNSON,,80.0,YR,E,M,Y,75.3,KG,20230807,,HP,AU,AU,2023,Q3,Elderly
223171325,22317132,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,Unknown,QD,2023,Q3,Ageusia,,2023,Q3,5,F,20230412.0,20230802.0,20230514,20230807,EXP,,AU-JNJFOC-20230522488,JOHNSON AND JOHNSON,,80.0,YR,E,M,Y,75.3,KG,20230807,,HP,AU,AU,2023,Q3,Elderly
223171325,22317132,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,Unknown,QD,2023,Q3,Acute kidney injury,,2023,Q3,5,F,20230412.0,20230802.0,20230514,20230807,EXP,,AU-JNJFOC-20230522488,JOHNSON AND JOHNSON,,80.0,YR,E,M,Y,75.3,KG,20230807,,HP,AU,AU,2023,Q3,Elderly
223171325,22317132,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,Unknown,QD,2023,Q3,SARS-CoV-2 test positive,,2023,Q3,5,F,20230412.0,20230802.0,20230514,20230807,EXP,,AU-JNJFOC-20230522488,JOHNSON AND JOHNSON,,80.0,YR,E,M,Y,75.3,KG,20230807,,HP,AU,AU,2023,Q3,Elderly
223171325,22317132,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,Unknown,QD,2023,Q3,Vitamin D deficiency,,2023,Q3,5,F,20230412.0,20230802.0,20230514,20230807,EXP,,AU-JNJFOC-20230522488,JOHNSON AND JOHNSON,,80.0,YR,E,M,Y,75.3,KG,20230807,,HP,AU,AU,2023,Q3,Elderly
223171325,22317132,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,Unknown,QD,2023,Q3,Constipation,,2023,Q3,5,F,20230412.0,20230802.0,20230514,20230807,EXP,,AU-JNJFOC-20230522488,JOHNSON AND JOHNSON,,80.0,YR,E,M,Y,75.3,KG,20230807,,HP,AU,AU,2023,Q3,Elderly
223171325,22317132,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,Unknown,QD,2023,Q3,Cardiac failure congestive,,2023,Q3,5,F,20230412.0,20230802.0,20230514,20230807,EXP,,AU-JNJFOC-20230522488,JOHNSON AND JOHNSON,,80.0,YR,E,M,Y,75.3,KG,20230807,,HP,AU,AU,2023,Q3,Elderly
223228283,22322828,7,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,Y,,,,,,,,BID,2023,Q3,Somnolence,,2023,Q3,3,F,,20230717.0,20230516,20230726,EXP,,ES-AUROBINDO-AUR-APL-2023-036032,AUROBINDO,"Abdala S, Devora S, Oliva AM, Morales C.. El valor anadido de los servicios profesionales farmaceucos asistenciales. Un caso de SFT (The added value of professional pharmaceucal care services. A case of SFT). Farmaceuticos comunitarios (Community Farms). 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20230726,,HP,ES,ES,2023,Q3,Adult
223228283,22322828,7,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,Y,,,,,,,,BID,2023,Q3,Off label use,,2023,Q3,3,F,,20230717.0,20230516,20230726,EXP,,ES-AUROBINDO-AUR-APL-2023-036032,AUROBINDO,"Abdala S, Devora S, Oliva AM, Morales C.. El valor anadido de los servicios profesionales farmaceucos asistenciales. Un caso de SFT (The added value of professional pharmaceucal care services. A case of SFT). Farmaceuticos comunitarios (Community Farms). 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20230726,,HP,ES,ES,2023,Q3,Adult
223228283,22322828,7,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,Y,,,,,,,,BID,2023,Q3,Drug interaction,,2023,Q3,3,F,,20230717.0,20230516,20230726,EXP,,ES-AUROBINDO-AUR-APL-2023-036032,AUROBINDO,"Abdala S, Devora S, Oliva AM, Morales C.. El valor anadido de los servicios profesionales farmaceucos asistenciales. Un caso de SFT (The added value of professional pharmaceucal care services. A case of SFT). Farmaceuticos comunitarios (Community Farms). 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20230726,,HP,ES,ES,2023,Q3,Adult
223228283,22322828,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, Two Times a Day(used dosage of 1-0-1-0)",,,,,,,,5.0,MG,,BID,2023,Q3,Somnolence,,2023,Q3,3,F,,20230717.0,20230516,20230726,EXP,,ES-AUROBINDO-AUR-APL-2023-036032,AUROBINDO,"Abdala S, Devora S, Oliva AM, Morales C.. El valor anadido de los servicios profesionales farmaceucos asistenciales. Un caso de SFT (The added value of professional pharmaceucal care services. A case of SFT). Farmaceuticos comunitarios (Community Farms). 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20230726,,HP,ES,ES,2023,Q3,Adult
223228283,22322828,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, Two Times a Day(used dosage of 1-0-1-0)",,,,,,,,5.0,MG,,BID,2023,Q3,Off label use,,2023,Q3,3,F,,20230717.0,20230516,20230726,EXP,,ES-AUROBINDO-AUR-APL-2023-036032,AUROBINDO,"Abdala S, Devora S, Oliva AM, Morales C.. El valor anadido de los servicios profesionales farmaceucos asistenciales. Un caso de SFT (The added value of professional pharmaceucal care services. A case of SFT). Farmaceuticos comunitarios (Community Farms). 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20230726,,HP,ES,ES,2023,Q3,Adult
223228283,22322828,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, Two Times a Day(used dosage of 1-0-1-0)",,,,,,,,5.0,MG,,BID,2023,Q3,Drug interaction,,2023,Q3,3,F,,20230717.0,20230516,20230726,EXP,,ES-AUROBINDO-AUR-APL-2023-036032,AUROBINDO,"Abdala S, Devora S, Oliva AM, Morales C.. El valor anadido de los servicios profesionales farmaceucos asistenciales. Un caso de SFT (The added value of professional pharmaceucal care services. A case of SFT). Farmaceuticos comunitarios (Community Farms). 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20230726,,HP,ES,ES,2023,Q3,Adult
223257422,22325742,4,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,Dose unknown,,,,,,,,,,Tablet,,2023,Q3,Eosinophilic fasciitis,,2023,Q3,2,F,20220906.0,20230808.0,20230516,20230816,EXP,,JP-AstraZeneca-2023A107072,ASTRAZENECA,,55.0,YR,,M,Y,65.0,KG,20230816,,MD,JP,,2023,Q3,Adult
223257422,22325742,4,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,Dose unknown,,,,,,,,,,Tablet,,2023,Q3,Hyperthyroidism,,2023,Q3,2,F,20220906.0,20230808.0,20230516,20230816,EXP,,JP-AstraZeneca-2023A107072,ASTRAZENECA,,55.0,YR,,M,Y,65.0,KG,20230816,,MD,JP,,2023,Q3,Adult
2233952610,22339526,26,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK (1-0-1-0) (0.5/day),,,Y,,,,,,,,,2023,Q3,Hypoglycaemia,,2023,Q3,10,F,,20230724.0,20230518,20230726,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20230726,,HP,ES,ES,2023,Q3,Adult
2233952610,22339526,26,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK (1-0-1-0) (0.5/day),,,Y,,,,,,,,,2023,Q3,Hypotension,,2023,Q3,10,F,,20230724.0,20230518,20230726,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20230726,,HP,ES,ES,2023,Q3,Adult
2233952610,22339526,26,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK (1-0-1-0) (0.5/day),,,Y,,,,,,,,,2023,Q3,Hallucination,,2023,Q3,10,F,,20230724.0,20230518,20230726,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20230726,,HP,ES,ES,2023,Q3,Adult
2233952610,22339526,26,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK (1-0-1-0) (0.5/day),,,Y,,,,,,,,,2023,Q3,Parkinsonism,,2023,Q3,10,F,,20230724.0,20230518,20230726,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20230726,,HP,ES,ES,2023,Q3,Adult
2233952610,22339526,26,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK (1-0-1-0) (0.5/day),,,Y,,,,,,,,,2023,Q3,Drug interaction,,2023,Q3,10,F,,20230724.0,20230518,20230726,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20230726,,HP,ES,ES,2023,Q3,Adult
2233952610,22339526,26,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK (1-0-1-0) (0.5/day),,,Y,,,,,,,,,2023,Q3,Somnolence,,2023,Q3,10,F,,20230724.0,20230518,20230726,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20230726,,HP,ES,ES,2023,Q3,Adult
2233952610,22339526,27,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,Y,,,,,,,,BID,2023,Q3,Hypoglycaemia,,2023,Q3,10,F,,20230724.0,20230518,20230726,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20230726,,HP,ES,ES,2023,Q3,Adult
2233952610,22339526,27,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,Y,,,,,,,,BID,2023,Q3,Hypotension,,2023,Q3,10,F,,20230724.0,20230518,20230726,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20230726,,HP,ES,ES,2023,Q3,Adult
2233952610,22339526,27,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,Y,,,,,,,,BID,2023,Q3,Hallucination,,2023,Q3,10,F,,20230724.0,20230518,20230726,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20230726,,HP,ES,ES,2023,Q3,Adult
2233952610,22339526,27,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,Y,,,,,,,,BID,2023,Q3,Parkinsonism,,2023,Q3,10,F,,20230724.0,20230518,20230726,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20230726,,HP,ES,ES,2023,Q3,Adult
2233952610,22339526,27,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,Y,,,,,,,,BID,2023,Q3,Drug interaction,,2023,Q3,10,F,,20230724.0,20230518,20230726,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20230726,,HP,ES,ES,2023,Q3,Adult
2233952610,22339526,27,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,Y,,,,,,,,BID,2023,Q3,Somnolence,,2023,Q3,10,F,,20230724.0,20230518,20230726,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20230726,,HP,ES,ES,2023,Q3,Adult
2233952610,22339526,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 mg, BID (1000 mg/5 mg (1-0-1-0), Two Times a Day)",,,,,,,,5.0,MG,,BID,2023,Q3,Hypoglycaemia,,2023,Q3,10,F,,20230724.0,20230518,20230726,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20230726,,HP,ES,ES,2023,Q3,Adult
2233952610,22339526,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 mg, BID (1000 mg/5 mg (1-0-1-0), Two Times a Day)",,,,,,,,5.0,MG,,BID,2023,Q3,Hypotension,,2023,Q3,10,F,,20230724.0,20230518,20230726,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20230726,,HP,ES,ES,2023,Q3,Adult
2233952610,22339526,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 mg, BID (1000 mg/5 mg (1-0-1-0), Two Times a Day)",,,,,,,,5.0,MG,,BID,2023,Q3,Hallucination,,2023,Q3,10,F,,20230724.0,20230518,20230726,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20230726,,HP,ES,ES,2023,Q3,Adult
2233952610,22339526,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 mg, BID (1000 mg/5 mg (1-0-1-0), Two Times a Day)",,,,,,,,5.0,MG,,BID,2023,Q3,Parkinsonism,,2023,Q3,10,F,,20230724.0,20230518,20230726,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20230726,,HP,ES,ES,2023,Q3,Adult
2233952610,22339526,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 mg, BID (1000 mg/5 mg (1-0-1-0), Two Times a Day)",,,,,,,,5.0,MG,,BID,2023,Q3,Drug interaction,,2023,Q3,10,F,,20230724.0,20230518,20230726,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20230726,,HP,ES,ES,2023,Q3,Adult
2233952610,22339526,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 mg, BID (1000 mg/5 mg (1-0-1-0), Two Times a Day)",,,,,,,,5.0,MG,,BID,2023,Q3,Somnolence,,2023,Q3,10,F,,20230724.0,20230518,20230726,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20230726,,HP,ES,ES,2023,Q3,Adult
2233952610,22339526,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Hypoglycaemia,,2023,Q3,10,F,,20230724.0,20230518,20230726,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20230726,,HP,ES,ES,2023,Q3,Adult
2233952610,22339526,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Hypotension,,2023,Q3,10,F,,20230724.0,20230518,20230726,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20230726,,HP,ES,ES,2023,Q3,Adult
2233952610,22339526,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Hallucination,,2023,Q3,10,F,,20230724.0,20230518,20230726,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20230726,,HP,ES,ES,2023,Q3,Adult
2233952610,22339526,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Parkinsonism,,2023,Q3,10,F,,20230724.0,20230518,20230726,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20230726,,HP,ES,ES,2023,Q3,Adult
2233952610,22339526,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Drug interaction,,2023,Q3,10,F,,20230724.0,20230518,20230726,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20230726,,HP,ES,ES,2023,Q3,Adult
2233952610,22339526,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Somnolence,,2023,Q3,10,F,,20230724.0,20230518,20230726,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20230726,,HP,ES,ES,2023,Q3,Adult
223699538,22369953,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q3,Anaemia,,2023,Q3,8,F,20220930.0,20230829.0,20230526,20230901,EXP,,US-JNJFOC-20230547708,JOHNSON AND JOHNSON,,75.0,YR,E,F,Y,76.0,KG,20230901,,HP,US,US,2023,Q3,Elderly
223699538,22369953,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q3,Pneumonia,,2023,Q3,8,F,20220930.0,20230829.0,20230526,20230901,EXP,,US-JNJFOC-20230547708,JOHNSON AND JOHNSON,,75.0,YR,E,F,Y,76.0,KG,20230901,,HP,US,US,2023,Q3,Elderly
223699538,22369953,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q3,Abdominal pain upper,,2023,Q3,8,F,20220930.0,20230829.0,20230526,20230901,EXP,,US-JNJFOC-20230547708,JOHNSON AND JOHNSON,,75.0,YR,E,F,Y,76.0,KG,20230901,,HP,US,US,2023,Q3,Elderly
223699538,22369953,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q3,C-reactive protein increased,,2023,Q3,8,F,20220930.0,20230829.0,20230526,20230901,EXP,,US-JNJFOC-20230547708,JOHNSON AND JOHNSON,,75.0,YR,E,F,Y,76.0,KG,20230901,,HP,US,US,2023,Q3,Elderly
223699538,22369953,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q3,COVID-19,,2023,Q3,8,F,20220930.0,20230829.0,20230526,20230901,EXP,,US-JNJFOC-20230547708,JOHNSON AND JOHNSON,,75.0,YR,E,F,Y,76.0,KG,20230901,,HP,US,US,2023,Q3,Elderly
223699538,22369953,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q3,Asthenia,,2023,Q3,8,F,20220930.0,20230829.0,20230526,20230901,EXP,,US-JNJFOC-20230547708,JOHNSON AND JOHNSON,,75.0,YR,E,F,Y,76.0,KG,20230901,,HP,US,US,2023,Q3,Elderly
223699538,22369953,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q3,Off label use,,2023,Q3,8,F,20220930.0,20230829.0,20230526,20230901,EXP,,US-JNJFOC-20230547708,JOHNSON AND JOHNSON,,75.0,YR,E,F,Y,76.0,KG,20230901,,HP,US,US,2023,Q3,Elderly
223699538,22369953,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q3,Off label use,,2023,Q3,8,F,20220930.0,20230829.0,20230526,20230901,EXP,,US-JNJFOC-20230547708,JOHNSON AND JOHNSON,,75.0,YR,E,F,Y,76.0,KG,20230901,,HP,US,US,2023,Q3,Elderly
223699538,22369953,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q3,Lower respiratory tract infection,,2023,Q3,8,F,20220930.0,20230829.0,20230526,20230901,EXP,,US-JNJFOC-20230547708,JOHNSON AND JOHNSON,,75.0,YR,E,F,Y,76.0,KG,20230901,,HP,US,US,2023,Q3,Elderly
223699538,22369953,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q3,Cough,,2023,Q3,8,F,20220930.0,20230829.0,20230526,20230901,EXP,,US-JNJFOC-20230547708,JOHNSON AND JOHNSON,,75.0,YR,E,F,Y,76.0,KG,20230901,,HP,US,US,2023,Q3,Elderly
223699538,22369953,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q3,Lower respiratory tract infection,,2023,Q3,8,F,20220930.0,20230829.0,20230526,20230901,EXP,,US-JNJFOC-20230547708,JOHNSON AND JOHNSON,,75.0,YR,E,F,Y,76.0,KG,20230901,,HP,US,US,2023,Q3,Elderly
223699538,22369953,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q3,Chills,,2023,Q3,8,F,20220930.0,20230829.0,20230526,20230901,EXP,,US-JNJFOC-20230547708,JOHNSON AND JOHNSON,,75.0,YR,E,F,Y,76.0,KG,20230901,,HP,US,US,2023,Q3,Elderly
223699538,22369953,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q3,Cardiac failure,,2023,Q3,8,F,20220930.0,20230829.0,20230526,20230901,EXP,,US-JNJFOC-20230547708,JOHNSON AND JOHNSON,,75.0,YR,E,F,Y,76.0,KG,20230901,,HP,US,US,2023,Q3,Elderly
223724932,22372493,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,Unknown,,102145.0,10.0,MG,,QD,2023,Q3,Glucocorticoid deficiency,,2023,Q3,2,F,20230416.0,20230627.0,20230526,20230705,EXP,,"BR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-234056",BOEHRINGER INGELHEIM,,67.0,YR,E,M,Y,70.5,KG,20230705,,MD,BR,BR,2023,Q3,Elderly
223767183,22376718,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Pneumonia,,2023,Q3,3,F,20230512.0,20230720.0,20230528,20230721,EXP,,FR-BAUSCHBL-2023BNL004526,BAUSCH AND LOMB,,75.0,YR,,F,Y,76.0,KG,20230721,,HP,FR,FR,2023,Q3,Elderly
223843862,22384386,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,U,,,,,,,Unknown,BID,2023,Q3,Hypotension,,2023,Q3,2,F,,20230819.0,20230530,20230822,EXP,,ES-MYLANLABS-2023M1055497,MYLAN,"Abdala S, Devora S, Oliva AM, Morales C. The added value of professional pharmaceutical care services. A case of SFT. Community Farms. 2023;15(2):45-51",62.0,YR,,F,Y,,,20230822,,HP,ES,ES,2023,Q3,Adult
223843862,22384386,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,U,,,,,,,Unknown,BID,2023,Q3,Drug interaction,,2023,Q3,2,F,,20230819.0,20230530,20230822,EXP,,ES-MYLANLABS-2023M1055497,MYLAN,"Abdala S, Devora S, Oliva AM, Morales C. The added value of professional pharmaceutical care services. A case of SFT. Community Farms. 2023;15(2):45-51",62.0,YR,,F,Y,,,20230822,,HP,ES,ES,2023,Q3,Adult
223951315,22395131,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Hypotension,,2023,Q3,5,F,20220701.0,20230713.0,20230601,20230725,EXP,,DE-MYLANLABS-2023M1047952,SANDOZ,,77.0,YR,,F,Y,73.0,KG,20230725,,CN,DE,DE,2023,Q3,Elderly
223951315,22395131,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Ejection fraction decreased,,2023,Q3,5,F,20220701.0,20230713.0,20230601,20230725,EXP,,DE-MYLANLABS-2023M1047952,SANDOZ,,77.0,YR,,F,Y,73.0,KG,20230725,,CN,DE,DE,2023,Q3,Elderly
223951315,22395131,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Coronary artery disease,,2023,Q3,5,F,20220701.0,20230713.0,20230601,20230725,EXP,,DE-MYLANLABS-2023M1047952,SANDOZ,,77.0,YR,,F,Y,73.0,KG,20230725,,CN,DE,DE,2023,Q3,Elderly
223951315,22395131,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Off label use,,2023,Q3,5,F,20220701.0,20230713.0,20230601,20230725,EXP,,DE-MYLANLABS-2023M1047952,SANDOZ,,77.0,YR,,F,Y,73.0,KG,20230725,,CN,DE,DE,2023,Q3,Elderly
223951315,22395131,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Feeling cold,,2023,Q3,5,F,20220701.0,20230713.0,20230601,20230725,EXP,,DE-MYLANLABS-2023M1047952,SANDOZ,,77.0,YR,,F,Y,73.0,KG,20230725,,CN,DE,DE,2023,Q3,Elderly
223951315,22395131,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Mitral valve incompetence,,2023,Q3,5,F,20220701.0,20230713.0,20230601,20230725,EXP,,DE-MYLANLABS-2023M1047952,SANDOZ,,77.0,YR,,F,Y,73.0,KG,20230725,,CN,DE,DE,2023,Q3,Elderly
223951315,22395131,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Ventricular extrasystoles,,2023,Q3,5,F,20220701.0,20230713.0,20230601,20230725,EXP,,DE-MYLANLABS-2023M1047952,SANDOZ,,77.0,YR,,F,Y,73.0,KG,20230725,,CN,DE,DE,2023,Q3,Elderly
223951315,22395131,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Left ventricular dysfunction,,2023,Q3,5,F,20220701.0,20230713.0,20230601,20230725,EXP,,DE-MYLANLABS-2023M1047952,SANDOZ,,77.0,YR,,F,Y,73.0,KG,20230725,,CN,DE,DE,2023,Q3,Elderly
223951315,22395131,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Cough,,2023,Q3,5,F,20220701.0,20230713.0,20230601,20230725,EXP,,DE-MYLANLABS-2023M1047952,SANDOZ,,77.0,YR,,F,Y,73.0,KG,20230725,,CN,DE,DE,2023,Q3,Elderly
223951315,22395131,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Cardiovascular disorder,,2023,Q3,5,F,20220701.0,20230713.0,20230601,20230725,EXP,,DE-MYLANLABS-2023M1047952,SANDOZ,,77.0,YR,,F,Y,73.0,KG,20230725,,CN,DE,DE,2023,Q3,Elderly
223951315,22395131,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Atrial fibrillation,,2023,Q3,5,F,20220701.0,20230713.0,20230601,20230725,EXP,,DE-MYLANLABS-2023M1047952,SANDOZ,,77.0,YR,,F,Y,73.0,KG,20230725,,CN,DE,DE,2023,Q3,Elderly
223951315,22395131,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Ventricular tachycardia,,2023,Q3,5,F,20220701.0,20230713.0,20230601,20230725,EXP,,DE-MYLANLABS-2023M1047952,SANDOZ,,77.0,YR,,F,Y,73.0,KG,20230725,,CN,DE,DE,2023,Q3,Elderly
223951315,22395131,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Product use in unapproved indication,,2023,Q3,5,F,20220701.0,20230713.0,20230601,20230725,EXP,,DE-MYLANLABS-2023M1047952,SANDOZ,,77.0,YR,,F,Y,73.0,KG,20230725,,CN,DE,DE,2023,Q3,Elderly
223951315,22395131,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Cardiac failure,,2023,Q3,5,F,20220701.0,20230713.0,20230601,20230725,EXP,,DE-MYLANLABS-2023M1047952,SANDOZ,,77.0,YR,,F,Y,73.0,KG,20230725,,CN,DE,DE,2023,Q3,Elderly
223951315,22395131,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Peripheral coldness,,2023,Q3,5,F,20220701.0,20230713.0,20230601,20230725,EXP,,DE-MYLANLABS-2023M1047952,SANDOZ,,77.0,YR,,F,Y,73.0,KG,20230725,,CN,DE,DE,2023,Q3,Elderly
223951315,22395131,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Hypotension,,2023,Q3,5,F,20220701.0,20230713.0,20230601,20230725,EXP,,DE-MYLANLABS-2023M1047952,SANDOZ,,77.0,YR,,F,Y,73.0,KG,20230725,,CN,DE,DE,2023,Q3,Elderly
223951315,22395131,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Ejection fraction decreased,,2023,Q3,5,F,20220701.0,20230713.0,20230601,20230725,EXP,,DE-MYLANLABS-2023M1047952,SANDOZ,,77.0,YR,,F,Y,73.0,KG,20230725,,CN,DE,DE,2023,Q3,Elderly
223951315,22395131,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Coronary artery disease,,2023,Q3,5,F,20220701.0,20230713.0,20230601,20230725,EXP,,DE-MYLANLABS-2023M1047952,SANDOZ,,77.0,YR,,F,Y,73.0,KG,20230725,,CN,DE,DE,2023,Q3,Elderly
223951315,22395131,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Off label use,,2023,Q3,5,F,20220701.0,20230713.0,20230601,20230725,EXP,,DE-MYLANLABS-2023M1047952,SANDOZ,,77.0,YR,,F,Y,73.0,KG,20230725,,CN,DE,DE,2023,Q3,Elderly
223951315,22395131,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Feeling cold,,2023,Q3,5,F,20220701.0,20230713.0,20230601,20230725,EXP,,DE-MYLANLABS-2023M1047952,SANDOZ,,77.0,YR,,F,Y,73.0,KG,20230725,,CN,DE,DE,2023,Q3,Elderly
223951315,22395131,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Mitral valve incompetence,,2023,Q3,5,F,20220701.0,20230713.0,20230601,20230725,EXP,,DE-MYLANLABS-2023M1047952,SANDOZ,,77.0,YR,,F,Y,73.0,KG,20230725,,CN,DE,DE,2023,Q3,Elderly
223951315,22395131,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Ventricular extrasystoles,,2023,Q3,5,F,20220701.0,20230713.0,20230601,20230725,EXP,,DE-MYLANLABS-2023M1047952,SANDOZ,,77.0,YR,,F,Y,73.0,KG,20230725,,CN,DE,DE,2023,Q3,Elderly
223951315,22395131,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Left ventricular dysfunction,,2023,Q3,5,F,20220701.0,20230713.0,20230601,20230725,EXP,,DE-MYLANLABS-2023M1047952,SANDOZ,,77.0,YR,,F,Y,73.0,KG,20230725,,CN,DE,DE,2023,Q3,Elderly
223951315,22395131,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Cough,,2023,Q3,5,F,20220701.0,20230713.0,20230601,20230725,EXP,,DE-MYLANLABS-2023M1047952,SANDOZ,,77.0,YR,,F,Y,73.0,KG,20230725,,CN,DE,DE,2023,Q3,Elderly
223951315,22395131,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Cardiovascular disorder,,2023,Q3,5,F,20220701.0,20230713.0,20230601,20230725,EXP,,DE-MYLANLABS-2023M1047952,SANDOZ,,77.0,YR,,F,Y,73.0,KG,20230725,,CN,DE,DE,2023,Q3,Elderly
223951315,22395131,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Atrial fibrillation,,2023,Q3,5,F,20220701.0,20230713.0,20230601,20230725,EXP,,DE-MYLANLABS-2023M1047952,SANDOZ,,77.0,YR,,F,Y,73.0,KG,20230725,,CN,DE,DE,2023,Q3,Elderly
223951315,22395131,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Ventricular tachycardia,,2023,Q3,5,F,20220701.0,20230713.0,20230601,20230725,EXP,,DE-MYLANLABS-2023M1047952,SANDOZ,,77.0,YR,,F,Y,73.0,KG,20230725,,CN,DE,DE,2023,Q3,Elderly
223951315,22395131,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Product use in unapproved indication,,2023,Q3,5,F,20220701.0,20230713.0,20230601,20230725,EXP,,DE-MYLANLABS-2023M1047952,SANDOZ,,77.0,YR,,F,Y,73.0,KG,20230725,,CN,DE,DE,2023,Q3,Elderly
223951315,22395131,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Cardiac failure,,2023,Q3,5,F,20220701.0,20230713.0,20230601,20230725,EXP,,DE-MYLANLABS-2023M1047952,SANDOZ,,77.0,YR,,F,Y,73.0,KG,20230725,,CN,DE,DE,2023,Q3,Elderly
223951315,22395131,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Peripheral coldness,,2023,Q3,5,F,20220701.0,20230713.0,20230601,20230725,EXP,,DE-MYLANLABS-2023M1047952,SANDOZ,,77.0,YR,,F,Y,73.0,KG,20230725,,CN,DE,DE,2023,Q3,Elderly
223951315,22395131,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Hypotension,,2023,Q3,5,F,20220701.0,20230713.0,20230601,20230725,EXP,,DE-MYLANLABS-2023M1047952,SANDOZ,,77.0,YR,,F,Y,73.0,KG,20230725,,CN,DE,DE,2023,Q3,Elderly
223951315,22395131,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Ejection fraction decreased,,2023,Q3,5,F,20220701.0,20230713.0,20230601,20230725,EXP,,DE-MYLANLABS-2023M1047952,SANDOZ,,77.0,YR,,F,Y,73.0,KG,20230725,,CN,DE,DE,2023,Q3,Elderly
223951315,22395131,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Coronary artery disease,,2023,Q3,5,F,20220701.0,20230713.0,20230601,20230725,EXP,,DE-MYLANLABS-2023M1047952,SANDOZ,,77.0,YR,,F,Y,73.0,KG,20230725,,CN,DE,DE,2023,Q3,Elderly
223951315,22395131,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Off label use,,2023,Q3,5,F,20220701.0,20230713.0,20230601,20230725,EXP,,DE-MYLANLABS-2023M1047952,SANDOZ,,77.0,YR,,F,Y,73.0,KG,20230725,,CN,DE,DE,2023,Q3,Elderly
223951315,22395131,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Feeling cold,,2023,Q3,5,F,20220701.0,20230713.0,20230601,20230725,EXP,,DE-MYLANLABS-2023M1047952,SANDOZ,,77.0,YR,,F,Y,73.0,KG,20230725,,CN,DE,DE,2023,Q3,Elderly
223951315,22395131,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Mitral valve incompetence,,2023,Q3,5,F,20220701.0,20230713.0,20230601,20230725,EXP,,DE-MYLANLABS-2023M1047952,SANDOZ,,77.0,YR,,F,Y,73.0,KG,20230725,,CN,DE,DE,2023,Q3,Elderly
223951315,22395131,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Ventricular extrasystoles,,2023,Q3,5,F,20220701.0,20230713.0,20230601,20230725,EXP,,DE-MYLANLABS-2023M1047952,SANDOZ,,77.0,YR,,F,Y,73.0,KG,20230725,,CN,DE,DE,2023,Q3,Elderly
223951315,22395131,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Left ventricular dysfunction,,2023,Q3,5,F,20220701.0,20230713.0,20230601,20230725,EXP,,DE-MYLANLABS-2023M1047952,SANDOZ,,77.0,YR,,F,Y,73.0,KG,20230725,,CN,DE,DE,2023,Q3,Elderly
223951315,22395131,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Cough,,2023,Q3,5,F,20220701.0,20230713.0,20230601,20230725,EXP,,DE-MYLANLABS-2023M1047952,SANDOZ,,77.0,YR,,F,Y,73.0,KG,20230725,,CN,DE,DE,2023,Q3,Elderly
223951315,22395131,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Cardiovascular disorder,,2023,Q3,5,F,20220701.0,20230713.0,20230601,20230725,EXP,,DE-MYLANLABS-2023M1047952,SANDOZ,,77.0,YR,,F,Y,73.0,KG,20230725,,CN,DE,DE,2023,Q3,Elderly
223951315,22395131,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Atrial fibrillation,,2023,Q3,5,F,20220701.0,20230713.0,20230601,20230725,EXP,,DE-MYLANLABS-2023M1047952,SANDOZ,,77.0,YR,,F,Y,73.0,KG,20230725,,CN,DE,DE,2023,Q3,Elderly
223951315,22395131,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Ventricular tachycardia,,2023,Q3,5,F,20220701.0,20230713.0,20230601,20230725,EXP,,DE-MYLANLABS-2023M1047952,SANDOZ,,77.0,YR,,F,Y,73.0,KG,20230725,,CN,DE,DE,2023,Q3,Elderly
223951315,22395131,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Product use in unapproved indication,,2023,Q3,5,F,20220701.0,20230713.0,20230601,20230725,EXP,,DE-MYLANLABS-2023M1047952,SANDOZ,,77.0,YR,,F,Y,73.0,KG,20230725,,CN,DE,DE,2023,Q3,Elderly
223951315,22395131,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Cardiac failure,,2023,Q3,5,F,20220701.0,20230713.0,20230601,20230725,EXP,,DE-MYLANLABS-2023M1047952,SANDOZ,,77.0,YR,,F,Y,73.0,KG,20230725,,CN,DE,DE,2023,Q3,Elderly
223951315,22395131,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Peripheral coldness,,2023,Q3,5,F,20220701.0,20230713.0,20230601,20230725,EXP,,DE-MYLANLABS-2023M1047952,SANDOZ,,77.0,YR,,F,Y,73.0,KG,20230725,,CN,DE,DE,2023,Q3,Elderly
223973842,22397384,30,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2023,Q3,Pneumonia,,2023,Q3,2,F,20230101.0,20230705.0,20230602,20230707,EXP,,DE-TAKEDA-2023TUS053538,TAKEDA,,56.0,YR,,M,Y,142.0,KG,20230707,,MD,DE,DE,2023,Q3,Adult
223973842,22397384,30,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2023,Q3,Coronary artery disease,,2023,Q3,2,F,20230101.0,20230705.0,20230602,20230707,EXP,,DE-TAKEDA-2023TUS053538,TAKEDA,,56.0,YR,,M,Y,142.0,KG,20230707,,MD,DE,DE,2023,Q3,Adult
223994762,22399476,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"5 mg, bid",,,,,,,,5.0,MG,,BID,2023,Q3,Head injury,,2023,Q3,2,F,20230523.0,20230629.0,20230602,20230704,EXP,,PT-ELI_LILLY_AND_COMPANY-PT202305016991,ELI LILLY AND CO,,50.0,YR,,M,Y,,,20230704,,MD,PT,PT,2023,Q3,Adult
223994762,22399476,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"5 mg, bid",,,,,,,,5.0,MG,,BID,2023,Q3,Fall,,2023,Q3,2,F,20230523.0,20230629.0,20230602,20230704,EXP,,PT-ELI_LILLY_AND_COMPANY-PT202305016991,ELI LILLY AND CO,,50.0,YR,,M,Y,,,20230704,,MD,PT,PT,2023,Q3,Adult
223994762,22399476,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"5 mg, bid",,,,,,,,5.0,MG,,BID,2023,Q3,Status epilepticus,,2023,Q3,2,F,20230523.0,20230629.0,20230602,20230704,EXP,,PT-ELI_LILLY_AND_COMPANY-PT202305016991,ELI LILLY AND CO,,50.0,YR,,M,Y,,,20230704,,MD,PT,PT,2023,Q3,Adult
223994762,22399476,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"5 mg, bid",,,,,,,,5.0,MG,,BID,2023,Q3,Platelet count decreased,,2023,Q3,2,F,20230523.0,20230629.0,20230602,20230704,EXP,,PT-ELI_LILLY_AND_COMPANY-PT202305016991,ELI LILLY AND CO,,50.0,YR,,M,Y,,,20230704,,MD,PT,PT,2023,Q3,Adult
223994762,22399476,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"5 mg, bid",,,,,,,,5.0,MG,,BID,2023,Q3,Facial paralysis,,2023,Q3,2,F,20230523.0,20230629.0,20230602,20230704,EXP,,PT-ELI_LILLY_AND_COMPANY-PT202305016991,ELI LILLY AND CO,,50.0,YR,,M,Y,,,20230704,,MD,PT,PT,2023,Q3,Adult
223994762,22399476,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"5 mg, bid",,,,,,,,5.0,MG,,BID,2023,Q3,Sinusitis,,2023,Q3,2,F,20230523.0,20230629.0,20230602,20230704,EXP,,PT-ELI_LILLY_AND_COMPANY-PT202305016991,ELI LILLY AND CO,,50.0,YR,,M,Y,,,20230704,,MD,PT,PT,2023,Q3,Adult
223994762,22399476,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"5 mg, bid",,,,,,,,5.0,MG,,BID,2023,Q3,Malignant neoplasm progression,,2023,Q3,2,F,20230523.0,20230629.0,20230602,20230704,EXP,,PT-ELI_LILLY_AND_COMPANY-PT202305016991,ELI LILLY AND CO,,50.0,YR,,M,Y,,,20230704,,MD,PT,PT,2023,Q3,Adult
223994762,22399476,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"5 mg, bid",,,,,,,,5.0,MG,,BID,2023,Q3,Joint injury,,2023,Q3,2,F,20230523.0,20230629.0,20230602,20230704,EXP,,PT-ELI_LILLY_AND_COMPANY-PT202305016991,ELI LILLY AND CO,,50.0,YR,,M,Y,,,20230704,,MD,PT,PT,2023,Q3,Adult
223994762,22399476,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"5 mg, bid",,,,,,,,5.0,MG,,BID,2023,Q3,Central nervous system haemorrhage,,2023,Q3,2,F,20230523.0,20230629.0,20230602,20230704,EXP,,PT-ELI_LILLY_AND_COMPANY-PT202305016991,ELI LILLY AND CO,,50.0,YR,,M,Y,,,20230704,,MD,PT,PT,2023,Q3,Adult
225236222,22523622,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Pneumonia,,2023,Q3,2,F,20230512.0,20230621.0,20230606,20230704,EXP,,FR-AUROBINDO-AUR-APL-2023-039938,AUROBINDO,,75.0,YR,,F,Y,76.0,KG,20230704,,MD,FR,FR,2023,Q3,Elderly
225236222,22523622,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Off label use,,2023,Q3,2,F,20230512.0,20230621.0,20230606,20230704,EXP,,FR-AUROBINDO-AUR-APL-2023-039938,AUROBINDO,,75.0,YR,,F,Y,76.0,KG,20230704,,MD,FR,FR,2023,Q3,Elderly
225236222,22523622,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Cough,,2023,Q3,2,F,20230512.0,20230621.0,20230606,20230704,EXP,,FR-AUROBINDO-AUR-APL-2023-039938,AUROBINDO,,75.0,YR,,F,Y,76.0,KG,20230704,,MD,FR,FR,2023,Q3,Elderly
225236222,22523622,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Anaemia,,2023,Q3,2,F,20230512.0,20230621.0,20230606,20230704,EXP,,FR-AUROBINDO-AUR-APL-2023-039938,AUROBINDO,,75.0,YR,,F,Y,76.0,KG,20230704,,MD,FR,FR,2023,Q3,Elderly
225236222,22523622,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Cardiac failure,,2023,Q3,2,F,20230512.0,20230621.0,20230606,20230704,EXP,,FR-AUROBINDO-AUR-APL-2023-039938,AUROBINDO,,75.0,YR,,F,Y,76.0,KG,20230704,,MD,FR,FR,2023,Q3,Elderly
225236222,22523622,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Asthenia,,2023,Q3,2,F,20230512.0,20230621.0,20230606,20230704,EXP,,FR-AUROBINDO-AUR-APL-2023-039938,AUROBINDO,,75.0,YR,,F,Y,76.0,KG,20230704,,MD,FR,FR,2023,Q3,Elderly
225236222,22523622,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,COVID-19,,2023,Q3,2,F,20230512.0,20230621.0,20230606,20230704,EXP,,FR-AUROBINDO-AUR-APL-2023-039938,AUROBINDO,,75.0,YR,,F,Y,76.0,KG,20230704,,MD,FR,FR,2023,Q3,Elderly
225236222,22523622,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,C-reactive protein increased,,2023,Q3,2,F,20230512.0,20230621.0,20230606,20230704,EXP,,FR-AUROBINDO-AUR-APL-2023-039938,AUROBINDO,,75.0,YR,,F,Y,76.0,KG,20230704,,MD,FR,FR,2023,Q3,Elderly
225236222,22523622,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Chills,,2023,Q3,2,F,20230512.0,20230621.0,20230606,20230704,EXP,,FR-AUROBINDO-AUR-APL-2023-039938,AUROBINDO,,75.0,YR,,F,Y,76.0,KG,20230704,,MD,FR,FR,2023,Q3,Elderly
225236222,22523622,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Abdominal pain upper,,2023,Q3,2,F,20230512.0,20230621.0,20230606,20230704,EXP,,FR-AUROBINDO-AUR-APL-2023-039938,AUROBINDO,,75.0,YR,,F,Y,76.0,KG,20230704,,MD,FR,FR,2023,Q3,Elderly
225236222,22523622,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Lower respiratory tract infection,,2023,Q3,2,F,20230512.0,20230621.0,20230606,20230704,EXP,,FR-AUROBINDO-AUR-APL-2023-039938,AUROBINDO,,75.0,YR,,F,Y,76.0,KG,20230704,,MD,FR,FR,2023,Q3,Elderly
225236373,22523637,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Off label use,,2023,Q3,3,F,20230512.0,20230622.0,20230606,20230705,EXP,,FR-AUROBINDO-AUR-APL-2023-039977,AUROBINDO,,75.0,YR,,F,Y,76.0,KG,20230705,,MD,FR,FR,2023,Q3,Elderly
225236373,22523637,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Anaemia,,2023,Q3,3,F,20230512.0,20230622.0,20230606,20230705,EXP,,FR-AUROBINDO-AUR-APL-2023-039977,AUROBINDO,,75.0,YR,,F,Y,76.0,KG,20230705,,MD,FR,FR,2023,Q3,Elderly
225236373,22523637,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Pneumonia,,2023,Q3,3,F,20230512.0,20230622.0,20230606,20230705,EXP,,FR-AUROBINDO-AUR-APL-2023-039977,AUROBINDO,,75.0,YR,,F,Y,76.0,KG,20230705,,MD,FR,FR,2023,Q3,Elderly
225236373,22523637,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Asthenia,,2023,Q3,3,F,20230512.0,20230622.0,20230606,20230705,EXP,,FR-AUROBINDO-AUR-APL-2023-039977,AUROBINDO,,75.0,YR,,F,Y,76.0,KG,20230705,,MD,FR,FR,2023,Q3,Elderly
225236373,22523637,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,COVID-19,,2023,Q3,3,F,20230512.0,20230622.0,20230606,20230705,EXP,,FR-AUROBINDO-AUR-APL-2023-039977,AUROBINDO,,75.0,YR,,F,Y,76.0,KG,20230705,,MD,FR,FR,2023,Q3,Elderly
225236373,22523637,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Lower respiratory tract infection,,2023,Q3,3,F,20230512.0,20230622.0,20230606,20230705,EXP,,FR-AUROBINDO-AUR-APL-2023-039977,AUROBINDO,,75.0,YR,,F,Y,76.0,KG,20230705,,MD,FR,FR,2023,Q3,Elderly
225236373,22523637,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,C-reactive protein increased,,2023,Q3,3,F,20230512.0,20230622.0,20230606,20230705,EXP,,FR-AUROBINDO-AUR-APL-2023-039977,AUROBINDO,,75.0,YR,,F,Y,76.0,KG,20230705,,MD,FR,FR,2023,Q3,Elderly
225236373,22523637,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Cardiac failure,,2023,Q3,3,F,20230512.0,20230622.0,20230606,20230705,EXP,,FR-AUROBINDO-AUR-APL-2023-039977,AUROBINDO,,75.0,YR,,F,Y,76.0,KG,20230705,,MD,FR,FR,2023,Q3,Elderly
225236373,22523637,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Cough,,2023,Q3,3,F,20230512.0,20230622.0,20230606,20230705,EXP,,FR-AUROBINDO-AUR-APL-2023-039977,AUROBINDO,,75.0,YR,,F,Y,76.0,KG,20230705,,MD,FR,FR,2023,Q3,Elderly
225236373,22523637,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Abdominal pain upper,,2023,Q3,3,F,20230512.0,20230622.0,20230606,20230705,EXP,,FR-AUROBINDO-AUR-APL-2023-039977,AUROBINDO,,75.0,YR,,F,Y,76.0,KG,20230705,,MD,FR,FR,2023,Q3,Elderly
225236373,22523637,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Chills,,2023,Q3,3,F,20230512.0,20230622.0,20230606,20230705,EXP,,FR-AUROBINDO-AUR-APL-2023-039977,AUROBINDO,,75.0,YR,,F,Y,76.0,KG,20230705,,MD,FR,FR,2023,Q3,Elderly
225259753,22525975,8,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2023,Q3,Spondylitis,,2023,Q3,3,F,20210322.0,20230727.0,20230606,20230807,EXP,,JP-JNJFOC-20230611449,JOHNSON AND JOHNSON,,72.0,YR,E,F,Y,42.9,KG,20230807,,MD,JP,JP,2023,Q3,Elderly
225259753,22525975,8,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2023,Q3,Right ventricular failure,,2023,Q3,3,F,20210322.0,20230727.0,20230606,20230807,EXP,,JP-JNJFOC-20230611449,JOHNSON AND JOHNSON,,72.0,YR,E,F,Y,42.9,KG,20230807,,MD,JP,JP,2023,Q3,Elderly
225259753,22525975,8,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2023,Q3,Dyspnoea exertional,,2023,Q3,3,F,20210322.0,20230727.0,20230606,20230807,EXP,,JP-JNJFOC-20230611449,JOHNSON AND JOHNSON,,72.0,YR,E,F,Y,42.9,KG,20230807,,MD,JP,JP,2023,Q3,Elderly
225259753,22525975,8,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2023,Q3,Oedema peripheral,,2023,Q3,3,F,20210322.0,20230727.0,20230606,20230807,EXP,,JP-JNJFOC-20230611449,JOHNSON AND JOHNSON,,72.0,YR,E,F,Y,42.9,KG,20230807,,MD,JP,JP,2023,Q3,Elderly
225325652,22532565,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, qd",,,U,,,,,10.0,MG,,QD,2023,Q3,Cardiac failure,,2023,Q3,2,F,20220701.0,20230710.0,20230607,20230712,EXP,,DE-DSJP-DSE-2023-122541,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230712,,CN,DE,DE,2023,Q3,Elderly
225325652,22532565,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, qd",,,U,,,,,10.0,MG,,QD,2023,Q3,Ejection fraction decreased,,2023,Q3,2,F,20220701.0,20230710.0,20230607,20230712,EXP,,DE-DSJP-DSE-2023-122541,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230712,,CN,DE,DE,2023,Q3,Elderly
225325652,22532565,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, qd",,,U,,,,,10.0,MG,,QD,2023,Q3,Mitral valve incompetence,,2023,Q3,2,F,20220701.0,20230710.0,20230607,20230712,EXP,,DE-DSJP-DSE-2023-122541,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230712,,CN,DE,DE,2023,Q3,Elderly
225325652,22532565,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, qd",,,U,,,,,10.0,MG,,QD,2023,Q3,Ventricular extrasystoles,,2023,Q3,2,F,20220701.0,20230710.0,20230607,20230712,EXP,,DE-DSJP-DSE-2023-122541,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230712,,CN,DE,DE,2023,Q3,Elderly
225325652,22532565,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, qd",,,U,,,,,10.0,MG,,QD,2023,Q3,Feeling cold,,2023,Q3,2,F,20220701.0,20230710.0,20230607,20230712,EXP,,DE-DSJP-DSE-2023-122541,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230712,,CN,DE,DE,2023,Q3,Elderly
225325652,22532565,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, qd",,,U,,,,,10.0,MG,,QD,2023,Q3,Coronary artery disease,,2023,Q3,2,F,20220701.0,20230710.0,20230607,20230712,EXP,,DE-DSJP-DSE-2023-122541,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230712,,CN,DE,DE,2023,Q3,Elderly
225325652,22532565,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, qd",,,U,,,,,10.0,MG,,QD,2023,Q3,Off label use,,2023,Q3,2,F,20220701.0,20230710.0,20230607,20230712,EXP,,DE-DSJP-DSE-2023-122541,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230712,,CN,DE,DE,2023,Q3,Elderly
225325652,22532565,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, qd",,,U,,,,,10.0,MG,,QD,2023,Q3,Atrial fibrillation,,2023,Q3,2,F,20220701.0,20230710.0,20230607,20230712,EXP,,DE-DSJP-DSE-2023-122541,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230712,,CN,DE,DE,2023,Q3,Elderly
225325652,22532565,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, qd",,,U,,,,,10.0,MG,,QD,2023,Q3,Product use in unapproved indication,,2023,Q3,2,F,20220701.0,20230710.0,20230607,20230712,EXP,,DE-DSJP-DSE-2023-122541,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230712,,CN,DE,DE,2023,Q3,Elderly
225325652,22532565,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, qd",,,U,,,,,10.0,MG,,QD,2023,Q3,Peripheral coldness,,2023,Q3,2,F,20220701.0,20230710.0,20230607,20230712,EXP,,DE-DSJP-DSE-2023-122541,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230712,,CN,DE,DE,2023,Q3,Elderly
225325652,22532565,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, qd",,,U,,,,,10.0,MG,,QD,2023,Q3,Ventricular tachycardia,,2023,Q3,2,F,20220701.0,20230710.0,20230607,20230712,EXP,,DE-DSJP-DSE-2023-122541,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230712,,CN,DE,DE,2023,Q3,Elderly
225325652,22532565,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, qd",,,U,,,,,10.0,MG,,QD,2023,Q3,Cough,,2023,Q3,2,F,20220701.0,20230710.0,20230607,20230712,EXP,,DE-DSJP-DSE-2023-122541,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230712,,CN,DE,DE,2023,Q3,Elderly
225325652,22532565,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, qd",,,U,,,,,10.0,MG,,QD,2023,Q3,Cardiovascular disorder,,2023,Q3,2,F,20220701.0,20230710.0,20230607,20230712,EXP,,DE-DSJP-DSE-2023-122541,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230712,,CN,DE,DE,2023,Q3,Elderly
225325652,22532565,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, qd",,,U,,,,,10.0,MG,,QD,2023,Q3,Left ventricular dysfunction,,2023,Q3,2,F,20220701.0,20230710.0,20230607,20230712,EXP,,DE-DSJP-DSE-2023-122541,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230712,,CN,DE,DE,2023,Q3,Elderly
225325652,22532565,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, qd",,,U,,,,,10.0,MG,,QD,2023,Q3,Hypotension,,2023,Q3,2,F,20220701.0,20230710.0,20230607,20230712,EXP,,DE-DSJP-DSE-2023-122541,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230712,,CN,DE,DE,2023,Q3,Elderly
225325652,22532565,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Cardiac failure,,2023,Q3,2,F,20220701.0,20230710.0,20230607,20230712,EXP,,DE-DSJP-DSE-2023-122541,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230712,,CN,DE,DE,2023,Q3,Elderly
225325652,22532565,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Ejection fraction decreased,,2023,Q3,2,F,20220701.0,20230710.0,20230607,20230712,EXP,,DE-DSJP-DSE-2023-122541,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230712,,CN,DE,DE,2023,Q3,Elderly
225325652,22532565,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Mitral valve incompetence,,2023,Q3,2,F,20220701.0,20230710.0,20230607,20230712,EXP,,DE-DSJP-DSE-2023-122541,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230712,,CN,DE,DE,2023,Q3,Elderly
225325652,22532565,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Ventricular extrasystoles,,2023,Q3,2,F,20220701.0,20230710.0,20230607,20230712,EXP,,DE-DSJP-DSE-2023-122541,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230712,,CN,DE,DE,2023,Q3,Elderly
225325652,22532565,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Feeling cold,,2023,Q3,2,F,20220701.0,20230710.0,20230607,20230712,EXP,,DE-DSJP-DSE-2023-122541,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230712,,CN,DE,DE,2023,Q3,Elderly
225325652,22532565,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Coronary artery disease,,2023,Q3,2,F,20220701.0,20230710.0,20230607,20230712,EXP,,DE-DSJP-DSE-2023-122541,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230712,,CN,DE,DE,2023,Q3,Elderly
225325652,22532565,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Off label use,,2023,Q3,2,F,20220701.0,20230710.0,20230607,20230712,EXP,,DE-DSJP-DSE-2023-122541,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230712,,CN,DE,DE,2023,Q3,Elderly
225325652,22532565,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Atrial fibrillation,,2023,Q3,2,F,20220701.0,20230710.0,20230607,20230712,EXP,,DE-DSJP-DSE-2023-122541,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230712,,CN,DE,DE,2023,Q3,Elderly
225325652,22532565,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Product use in unapproved indication,,2023,Q3,2,F,20220701.0,20230710.0,20230607,20230712,EXP,,DE-DSJP-DSE-2023-122541,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230712,,CN,DE,DE,2023,Q3,Elderly
225325652,22532565,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Peripheral coldness,,2023,Q3,2,F,20220701.0,20230710.0,20230607,20230712,EXP,,DE-DSJP-DSE-2023-122541,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230712,,CN,DE,DE,2023,Q3,Elderly
225325652,22532565,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Ventricular tachycardia,,2023,Q3,2,F,20220701.0,20230710.0,20230607,20230712,EXP,,DE-DSJP-DSE-2023-122541,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230712,,CN,DE,DE,2023,Q3,Elderly
225325652,22532565,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Cough,,2023,Q3,2,F,20220701.0,20230710.0,20230607,20230712,EXP,,DE-DSJP-DSE-2023-122541,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230712,,CN,DE,DE,2023,Q3,Elderly
225325652,22532565,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Cardiovascular disorder,,2023,Q3,2,F,20220701.0,20230710.0,20230607,20230712,EXP,,DE-DSJP-DSE-2023-122541,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230712,,CN,DE,DE,2023,Q3,Elderly
225325652,22532565,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Left ventricular dysfunction,,2023,Q3,2,F,20220701.0,20230710.0,20230607,20230712,EXP,,DE-DSJP-DSE-2023-122541,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230712,,CN,DE,DE,2023,Q3,Elderly
225325652,22532565,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Hypotension,,2023,Q3,2,F,20220701.0,20230710.0,20230607,20230712,EXP,,DE-DSJP-DSE-2023-122541,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230712,,CN,DE,DE,2023,Q3,Elderly
225325652,22532565,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Cardiac failure,,2023,Q3,2,F,20220701.0,20230710.0,20230607,20230712,EXP,,DE-DSJP-DSE-2023-122541,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230712,,CN,DE,DE,2023,Q3,Elderly
225325652,22532565,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Ejection fraction decreased,,2023,Q3,2,F,20220701.0,20230710.0,20230607,20230712,EXP,,DE-DSJP-DSE-2023-122541,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230712,,CN,DE,DE,2023,Q3,Elderly
225325652,22532565,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Mitral valve incompetence,,2023,Q3,2,F,20220701.0,20230710.0,20230607,20230712,EXP,,DE-DSJP-DSE-2023-122541,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230712,,CN,DE,DE,2023,Q3,Elderly
225325652,22532565,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Ventricular extrasystoles,,2023,Q3,2,F,20220701.0,20230710.0,20230607,20230712,EXP,,DE-DSJP-DSE-2023-122541,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230712,,CN,DE,DE,2023,Q3,Elderly
225325652,22532565,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Feeling cold,,2023,Q3,2,F,20220701.0,20230710.0,20230607,20230712,EXP,,DE-DSJP-DSE-2023-122541,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230712,,CN,DE,DE,2023,Q3,Elderly
225325652,22532565,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Coronary artery disease,,2023,Q3,2,F,20220701.0,20230710.0,20230607,20230712,EXP,,DE-DSJP-DSE-2023-122541,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230712,,CN,DE,DE,2023,Q3,Elderly
225325652,22532565,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Off label use,,2023,Q3,2,F,20220701.0,20230710.0,20230607,20230712,EXP,,DE-DSJP-DSE-2023-122541,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230712,,CN,DE,DE,2023,Q3,Elderly
225325652,22532565,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Atrial fibrillation,,2023,Q3,2,F,20220701.0,20230710.0,20230607,20230712,EXP,,DE-DSJP-DSE-2023-122541,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230712,,CN,DE,DE,2023,Q3,Elderly
225325652,22532565,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Product use in unapproved indication,,2023,Q3,2,F,20220701.0,20230710.0,20230607,20230712,EXP,,DE-DSJP-DSE-2023-122541,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230712,,CN,DE,DE,2023,Q3,Elderly
225325652,22532565,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Peripheral coldness,,2023,Q3,2,F,20220701.0,20230710.0,20230607,20230712,EXP,,DE-DSJP-DSE-2023-122541,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230712,,CN,DE,DE,2023,Q3,Elderly
225325652,22532565,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Ventricular tachycardia,,2023,Q3,2,F,20220701.0,20230710.0,20230607,20230712,EXP,,DE-DSJP-DSE-2023-122541,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230712,,CN,DE,DE,2023,Q3,Elderly
225325652,22532565,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Cough,,2023,Q3,2,F,20220701.0,20230710.0,20230607,20230712,EXP,,DE-DSJP-DSE-2023-122541,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230712,,CN,DE,DE,2023,Q3,Elderly
225325652,22532565,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Cardiovascular disorder,,2023,Q3,2,F,20220701.0,20230710.0,20230607,20230712,EXP,,DE-DSJP-DSE-2023-122541,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230712,,CN,DE,DE,2023,Q3,Elderly
225325652,22532565,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Left ventricular dysfunction,,2023,Q3,2,F,20220701.0,20230710.0,20230607,20230712,EXP,,DE-DSJP-DSE-2023-122541,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230712,,CN,DE,DE,2023,Q3,Elderly
225325652,22532565,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Hypotension,,2023,Q3,2,F,20220701.0,20230710.0,20230607,20230712,EXP,,DE-DSJP-DSE-2023-122541,DAIICHI,,77.0,YR,,F,Y,73.0,KG,20230712,,CN,DE,DE,2023,Q3,Elderly
225345244,22534524,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,500.0,MG,,,2023,Q3,Gastrointestinal perforation,,2023,Q3,4,F,20230530.0,20230717.0,20230608,20230719,EXP,,CN-ROCHE-3361469,ROCHE,,61.0,YR,,M,Y,65.0,KG,20230719,,MD,CN,,2023,Q3,Adult
225856722,22585672,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Hypotension,,2023,Q3,2,F,20220701.0,20230713.0,20230610,20230719,EXP,,NVSC2023DE127809,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230719,,CN,DE,DE,2023,Q3,Elderly
225856722,22585672,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Ventricular tachycardia,,2023,Q3,2,F,20220701.0,20230713.0,20230610,20230719,EXP,,NVSC2023DE127809,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230719,,CN,DE,DE,2023,Q3,Elderly
225856722,22585672,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Feeling cold,,2023,Q3,2,F,20220701.0,20230713.0,20230610,20230719,EXP,,NVSC2023DE127809,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230719,,CN,DE,DE,2023,Q3,Elderly
225856722,22585672,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Coronary artery disease,,2023,Q3,2,F,20220701.0,20230713.0,20230610,20230719,EXP,,NVSC2023DE127809,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230719,,CN,DE,DE,2023,Q3,Elderly
225856722,22585672,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Left ventricular dysfunction,,2023,Q3,2,F,20220701.0,20230713.0,20230610,20230719,EXP,,NVSC2023DE127809,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230719,,CN,DE,DE,2023,Q3,Elderly
225856722,22585672,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Mitral valve incompetence,,2023,Q3,2,F,20220701.0,20230713.0,20230610,20230719,EXP,,NVSC2023DE127809,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230719,,CN,DE,DE,2023,Q3,Elderly
225856722,22585672,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Cardiac failure,,2023,Q3,2,F,20220701.0,20230713.0,20230610,20230719,EXP,,NVSC2023DE127809,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230719,,CN,DE,DE,2023,Q3,Elderly
225856722,22585672,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Cardiovascular disorder,,2023,Q3,2,F,20220701.0,20230713.0,20230610,20230719,EXP,,NVSC2023DE127809,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230719,,CN,DE,DE,2023,Q3,Elderly
225856722,22585672,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Peripheral coldness,,2023,Q3,2,F,20220701.0,20230713.0,20230610,20230719,EXP,,NVSC2023DE127809,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230719,,CN,DE,DE,2023,Q3,Elderly
225856722,22585672,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Off label use,,2023,Q3,2,F,20220701.0,20230713.0,20230610,20230719,EXP,,NVSC2023DE127809,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230719,,CN,DE,DE,2023,Q3,Elderly
225856722,22585672,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Cough,,2023,Q3,2,F,20220701.0,20230713.0,20230610,20230719,EXP,,NVSC2023DE127809,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230719,,CN,DE,DE,2023,Q3,Elderly
225856722,22585672,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Ventricular extrasystoles,,2023,Q3,2,F,20220701.0,20230713.0,20230610,20230719,EXP,,NVSC2023DE127809,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230719,,CN,DE,DE,2023,Q3,Elderly
225856722,22585672,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Product use in unapproved indication,,2023,Q3,2,F,20220701.0,20230713.0,20230610,20230719,EXP,,NVSC2023DE127809,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230719,,CN,DE,DE,2023,Q3,Elderly
225856722,22585672,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Atrial fibrillation,,2023,Q3,2,F,20220701.0,20230713.0,20230610,20230719,EXP,,NVSC2023DE127809,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230719,,CN,DE,DE,2023,Q3,Elderly
225856722,22585672,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Ejection fraction decreased,,2023,Q3,2,F,20220701.0,20230713.0,20230610,20230719,EXP,,NVSC2023DE127809,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230719,,CN,DE,DE,2023,Q3,Elderly
225856722,22585672,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Hypotension,,2023,Q3,2,F,20220701.0,20230713.0,20230610,20230719,EXP,,NVSC2023DE127809,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230719,,CN,DE,DE,2023,Q3,Elderly
225856722,22585672,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Ventricular tachycardia,,2023,Q3,2,F,20220701.0,20230713.0,20230610,20230719,EXP,,NVSC2023DE127809,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230719,,CN,DE,DE,2023,Q3,Elderly
225856722,22585672,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Feeling cold,,2023,Q3,2,F,20220701.0,20230713.0,20230610,20230719,EXP,,NVSC2023DE127809,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230719,,CN,DE,DE,2023,Q3,Elderly
225856722,22585672,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Coronary artery disease,,2023,Q3,2,F,20220701.0,20230713.0,20230610,20230719,EXP,,NVSC2023DE127809,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230719,,CN,DE,DE,2023,Q3,Elderly
225856722,22585672,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Left ventricular dysfunction,,2023,Q3,2,F,20220701.0,20230713.0,20230610,20230719,EXP,,NVSC2023DE127809,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230719,,CN,DE,DE,2023,Q3,Elderly
225856722,22585672,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Mitral valve incompetence,,2023,Q3,2,F,20220701.0,20230713.0,20230610,20230719,EXP,,NVSC2023DE127809,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230719,,CN,DE,DE,2023,Q3,Elderly
225856722,22585672,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Cardiac failure,,2023,Q3,2,F,20220701.0,20230713.0,20230610,20230719,EXP,,NVSC2023DE127809,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230719,,CN,DE,DE,2023,Q3,Elderly
225856722,22585672,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Cardiovascular disorder,,2023,Q3,2,F,20220701.0,20230713.0,20230610,20230719,EXP,,NVSC2023DE127809,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230719,,CN,DE,DE,2023,Q3,Elderly
225856722,22585672,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Peripheral coldness,,2023,Q3,2,F,20220701.0,20230713.0,20230610,20230719,EXP,,NVSC2023DE127809,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230719,,CN,DE,DE,2023,Q3,Elderly
225856722,22585672,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Off label use,,2023,Q3,2,F,20220701.0,20230713.0,20230610,20230719,EXP,,NVSC2023DE127809,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230719,,CN,DE,DE,2023,Q3,Elderly
225856722,22585672,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Cough,,2023,Q3,2,F,20220701.0,20230713.0,20230610,20230719,EXP,,NVSC2023DE127809,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230719,,CN,DE,DE,2023,Q3,Elderly
225856722,22585672,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Ventricular extrasystoles,,2023,Q3,2,F,20220701.0,20230713.0,20230610,20230719,EXP,,NVSC2023DE127809,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230719,,CN,DE,DE,2023,Q3,Elderly
225856722,22585672,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Product use in unapproved indication,,2023,Q3,2,F,20220701.0,20230713.0,20230610,20230719,EXP,,NVSC2023DE127809,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230719,,CN,DE,DE,2023,Q3,Elderly
225856722,22585672,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Atrial fibrillation,,2023,Q3,2,F,20220701.0,20230713.0,20230610,20230719,EXP,,NVSC2023DE127809,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230719,,CN,DE,DE,2023,Q3,Elderly
225856722,22585672,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Ejection fraction decreased,,2023,Q3,2,F,20220701.0,20230713.0,20230610,20230719,EXP,,NVSC2023DE127809,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230719,,CN,DE,DE,2023,Q3,Elderly
225856722,22585672,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Hypotension,,2023,Q3,2,F,20220701.0,20230713.0,20230610,20230719,EXP,,NVSC2023DE127809,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230719,,CN,DE,DE,2023,Q3,Elderly
225856722,22585672,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Ventricular tachycardia,,2023,Q3,2,F,20220701.0,20230713.0,20230610,20230719,EXP,,NVSC2023DE127809,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230719,,CN,DE,DE,2023,Q3,Elderly
225856722,22585672,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Feeling cold,,2023,Q3,2,F,20220701.0,20230713.0,20230610,20230719,EXP,,NVSC2023DE127809,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230719,,CN,DE,DE,2023,Q3,Elderly
225856722,22585672,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Coronary artery disease,,2023,Q3,2,F,20220701.0,20230713.0,20230610,20230719,EXP,,NVSC2023DE127809,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230719,,CN,DE,DE,2023,Q3,Elderly
225856722,22585672,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Left ventricular dysfunction,,2023,Q3,2,F,20220701.0,20230713.0,20230610,20230719,EXP,,NVSC2023DE127809,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230719,,CN,DE,DE,2023,Q3,Elderly
225856722,22585672,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Mitral valve incompetence,,2023,Q3,2,F,20220701.0,20230713.0,20230610,20230719,EXP,,NVSC2023DE127809,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230719,,CN,DE,DE,2023,Q3,Elderly
225856722,22585672,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Cardiac failure,,2023,Q3,2,F,20220701.0,20230713.0,20230610,20230719,EXP,,NVSC2023DE127809,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230719,,CN,DE,DE,2023,Q3,Elderly
225856722,22585672,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Cardiovascular disorder,,2023,Q3,2,F,20220701.0,20230713.0,20230610,20230719,EXP,,NVSC2023DE127809,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230719,,CN,DE,DE,2023,Q3,Elderly
225856722,22585672,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Peripheral coldness,,2023,Q3,2,F,20220701.0,20230713.0,20230610,20230719,EXP,,NVSC2023DE127809,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230719,,CN,DE,DE,2023,Q3,Elderly
225856722,22585672,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Off label use,,2023,Q3,2,F,20220701.0,20230713.0,20230610,20230719,EXP,,NVSC2023DE127809,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230719,,CN,DE,DE,2023,Q3,Elderly
225856722,22585672,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Cough,,2023,Q3,2,F,20220701.0,20230713.0,20230610,20230719,EXP,,NVSC2023DE127809,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230719,,CN,DE,DE,2023,Q3,Elderly
225856722,22585672,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Ventricular extrasystoles,,2023,Q3,2,F,20220701.0,20230713.0,20230610,20230719,EXP,,NVSC2023DE127809,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230719,,CN,DE,DE,2023,Q3,Elderly
225856722,22585672,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Product use in unapproved indication,,2023,Q3,2,F,20220701.0,20230713.0,20230610,20230719,EXP,,NVSC2023DE127809,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230719,,CN,DE,DE,2023,Q3,Elderly
225856722,22585672,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Atrial fibrillation,,2023,Q3,2,F,20220701.0,20230713.0,20230610,20230719,EXP,,NVSC2023DE127809,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230719,,CN,DE,DE,2023,Q3,Elderly
225856722,22585672,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Ejection fraction decreased,,2023,Q3,2,F,20220701.0,20230713.0,20230610,20230719,EXP,,NVSC2023DE127809,NOVARTIS,,77.0,YR,,F,Y,73.0,KG,20230719,,CN,DE,DE,2023,Q3,Elderly
225925773,22592577,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q3,Mitral valve incompetence,,2023,Q3,3,F,20220701.0,20230707.0,20230613,20230717,EXP,,DE-AUROBINDO-AUR-APL-2023-041171,AUROBINDO,,77.0,YR,,F,Y,73.0,KG,20230717,,MD,DE,DE,2023,Q3,Elderly
225925773,22592577,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q3,Atrial fibrillation,,2023,Q3,3,F,20220701.0,20230707.0,20230613,20230717,EXP,,DE-AUROBINDO-AUR-APL-2023-041171,AUROBINDO,,77.0,YR,,F,Y,73.0,KG,20230717,,MD,DE,DE,2023,Q3,Elderly
225925773,22592577,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q3,Cough,,2023,Q3,3,F,20220701.0,20230707.0,20230613,20230717,EXP,,DE-AUROBINDO-AUR-APL-2023-041171,AUROBINDO,,77.0,YR,,F,Y,73.0,KG,20230717,,MD,DE,DE,2023,Q3,Elderly
225925773,22592577,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q3,Ventricular tachycardia,,2023,Q3,3,F,20220701.0,20230707.0,20230613,20230717,EXP,,DE-AUROBINDO-AUR-APL-2023-041171,AUROBINDO,,77.0,YR,,F,Y,73.0,KG,20230717,,MD,DE,DE,2023,Q3,Elderly
225925773,22592577,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q3,Cardiac failure,,2023,Q3,3,F,20220701.0,20230707.0,20230613,20230717,EXP,,DE-AUROBINDO-AUR-APL-2023-041171,AUROBINDO,,77.0,YR,,F,Y,73.0,KG,20230717,,MD,DE,DE,2023,Q3,Elderly
225925773,22592577,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q3,Ventricular extrasystoles,,2023,Q3,3,F,20220701.0,20230707.0,20230613,20230717,EXP,,DE-AUROBINDO-AUR-APL-2023-041171,AUROBINDO,,77.0,YR,,F,Y,73.0,KG,20230717,,MD,DE,DE,2023,Q3,Elderly
225925773,22592577,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q3,Off label use,,2023,Q3,3,F,20220701.0,20230707.0,20230613,20230717,EXP,,DE-AUROBINDO-AUR-APL-2023-041171,AUROBINDO,,77.0,YR,,F,Y,73.0,KG,20230717,,MD,DE,DE,2023,Q3,Elderly
225925773,22592577,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q3,Product use in unapproved indication,,2023,Q3,3,F,20220701.0,20230707.0,20230613,20230717,EXP,,DE-AUROBINDO-AUR-APL-2023-041171,AUROBINDO,,77.0,YR,,F,Y,73.0,KG,20230717,,MD,DE,DE,2023,Q3,Elderly
225925773,22592577,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q3,Cardiovascular disorder,,2023,Q3,3,F,20220701.0,20230707.0,20230613,20230717,EXP,,DE-AUROBINDO-AUR-APL-2023-041171,AUROBINDO,,77.0,YR,,F,Y,73.0,KG,20230717,,MD,DE,DE,2023,Q3,Elderly
225925773,22592577,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q3,Coronary artery disease,,2023,Q3,3,F,20220701.0,20230707.0,20230613,20230717,EXP,,DE-AUROBINDO-AUR-APL-2023-041171,AUROBINDO,,77.0,YR,,F,Y,73.0,KG,20230717,,MD,DE,DE,2023,Q3,Elderly
225925773,22592577,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q3,Peripheral coldness,,2023,Q3,3,F,20220701.0,20230707.0,20230613,20230717,EXP,,DE-AUROBINDO-AUR-APL-2023-041171,AUROBINDO,,77.0,YR,,F,Y,73.0,KG,20230717,,MD,DE,DE,2023,Q3,Elderly
225925773,22592577,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q3,Ejection fraction decreased,,2023,Q3,3,F,20220701.0,20230707.0,20230613,20230717,EXP,,DE-AUROBINDO-AUR-APL-2023-041171,AUROBINDO,,77.0,YR,,F,Y,73.0,KG,20230717,,MD,DE,DE,2023,Q3,Elderly
225925773,22592577,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q3,Hypotension,,2023,Q3,3,F,20220701.0,20230707.0,20230613,20230717,EXP,,DE-AUROBINDO-AUR-APL-2023-041171,AUROBINDO,,77.0,YR,,F,Y,73.0,KG,20230717,,MD,DE,DE,2023,Q3,Elderly
225925773,22592577,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q3,Feeling cold,,2023,Q3,3,F,20220701.0,20230707.0,20230613,20230717,EXP,,DE-AUROBINDO-AUR-APL-2023-041171,AUROBINDO,,77.0,YR,,F,Y,73.0,KG,20230717,,MD,DE,DE,2023,Q3,Elderly
225925773,22592577,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q3,Left ventricular dysfunction,,2023,Q3,3,F,20220701.0,20230707.0,20230613,20230717,EXP,,DE-AUROBINDO-AUR-APL-2023-041171,AUROBINDO,,77.0,YR,,F,Y,73.0,KG,20230717,,MD,DE,DE,2023,Q3,Elderly
225925773,22592577,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Mitral valve incompetence,,2023,Q3,3,F,20220701.0,20230707.0,20230613,20230717,EXP,,DE-AUROBINDO-AUR-APL-2023-041171,AUROBINDO,,77.0,YR,,F,Y,73.0,KG,20230717,,MD,DE,DE,2023,Q3,Elderly
225925773,22592577,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Atrial fibrillation,,2023,Q3,3,F,20220701.0,20230707.0,20230613,20230717,EXP,,DE-AUROBINDO-AUR-APL-2023-041171,AUROBINDO,,77.0,YR,,F,Y,73.0,KG,20230717,,MD,DE,DE,2023,Q3,Elderly
225925773,22592577,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Cough,,2023,Q3,3,F,20220701.0,20230707.0,20230613,20230717,EXP,,DE-AUROBINDO-AUR-APL-2023-041171,AUROBINDO,,77.0,YR,,F,Y,73.0,KG,20230717,,MD,DE,DE,2023,Q3,Elderly
225925773,22592577,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Ventricular tachycardia,,2023,Q3,3,F,20220701.0,20230707.0,20230613,20230717,EXP,,DE-AUROBINDO-AUR-APL-2023-041171,AUROBINDO,,77.0,YR,,F,Y,73.0,KG,20230717,,MD,DE,DE,2023,Q3,Elderly
225925773,22592577,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Cardiac failure,,2023,Q3,3,F,20220701.0,20230707.0,20230613,20230717,EXP,,DE-AUROBINDO-AUR-APL-2023-041171,AUROBINDO,,77.0,YR,,F,Y,73.0,KG,20230717,,MD,DE,DE,2023,Q3,Elderly
225925773,22592577,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Ventricular extrasystoles,,2023,Q3,3,F,20220701.0,20230707.0,20230613,20230717,EXP,,DE-AUROBINDO-AUR-APL-2023-041171,AUROBINDO,,77.0,YR,,F,Y,73.0,KG,20230717,,MD,DE,DE,2023,Q3,Elderly
225925773,22592577,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Off label use,,2023,Q3,3,F,20220701.0,20230707.0,20230613,20230717,EXP,,DE-AUROBINDO-AUR-APL-2023-041171,AUROBINDO,,77.0,YR,,F,Y,73.0,KG,20230717,,MD,DE,DE,2023,Q3,Elderly
225925773,22592577,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Product use in unapproved indication,,2023,Q3,3,F,20220701.0,20230707.0,20230613,20230717,EXP,,DE-AUROBINDO-AUR-APL-2023-041171,AUROBINDO,,77.0,YR,,F,Y,73.0,KG,20230717,,MD,DE,DE,2023,Q3,Elderly
225925773,22592577,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Cardiovascular disorder,,2023,Q3,3,F,20220701.0,20230707.0,20230613,20230717,EXP,,DE-AUROBINDO-AUR-APL-2023-041171,AUROBINDO,,77.0,YR,,F,Y,73.0,KG,20230717,,MD,DE,DE,2023,Q3,Elderly
225925773,22592577,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Coronary artery disease,,2023,Q3,3,F,20220701.0,20230707.0,20230613,20230717,EXP,,DE-AUROBINDO-AUR-APL-2023-041171,AUROBINDO,,77.0,YR,,F,Y,73.0,KG,20230717,,MD,DE,DE,2023,Q3,Elderly
225925773,22592577,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Peripheral coldness,,2023,Q3,3,F,20220701.0,20230707.0,20230613,20230717,EXP,,DE-AUROBINDO-AUR-APL-2023-041171,AUROBINDO,,77.0,YR,,F,Y,73.0,KG,20230717,,MD,DE,DE,2023,Q3,Elderly
225925773,22592577,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Ejection fraction decreased,,2023,Q3,3,F,20220701.0,20230707.0,20230613,20230717,EXP,,DE-AUROBINDO-AUR-APL-2023-041171,AUROBINDO,,77.0,YR,,F,Y,73.0,KG,20230717,,MD,DE,DE,2023,Q3,Elderly
225925773,22592577,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Hypotension,,2023,Q3,3,F,20220701.0,20230707.0,20230613,20230717,EXP,,DE-AUROBINDO-AUR-APL-2023-041171,AUROBINDO,,77.0,YR,,F,Y,73.0,KG,20230717,,MD,DE,DE,2023,Q3,Elderly
225925773,22592577,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Feeling cold,,2023,Q3,3,F,20220701.0,20230707.0,20230613,20230717,EXP,,DE-AUROBINDO-AUR-APL-2023-041171,AUROBINDO,,77.0,YR,,F,Y,73.0,KG,20230717,,MD,DE,DE,2023,Q3,Elderly
225925773,22592577,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Left ventricular dysfunction,,2023,Q3,3,F,20220701.0,20230707.0,20230613,20230717,EXP,,DE-AUROBINDO-AUR-APL-2023-041171,AUROBINDO,,77.0,YR,,F,Y,73.0,KG,20230717,,MD,DE,DE,2023,Q3,Elderly
225925773,22592577,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Mitral valve incompetence,,2023,Q3,3,F,20220701.0,20230707.0,20230613,20230717,EXP,,DE-AUROBINDO-AUR-APL-2023-041171,AUROBINDO,,77.0,YR,,F,Y,73.0,KG,20230717,,MD,DE,DE,2023,Q3,Elderly
225925773,22592577,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Atrial fibrillation,,2023,Q3,3,F,20220701.0,20230707.0,20230613,20230717,EXP,,DE-AUROBINDO-AUR-APL-2023-041171,AUROBINDO,,77.0,YR,,F,Y,73.0,KG,20230717,,MD,DE,DE,2023,Q3,Elderly
225925773,22592577,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Cough,,2023,Q3,3,F,20220701.0,20230707.0,20230613,20230717,EXP,,DE-AUROBINDO-AUR-APL-2023-041171,AUROBINDO,,77.0,YR,,F,Y,73.0,KG,20230717,,MD,DE,DE,2023,Q3,Elderly
225925773,22592577,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Ventricular tachycardia,,2023,Q3,3,F,20220701.0,20230707.0,20230613,20230717,EXP,,DE-AUROBINDO-AUR-APL-2023-041171,AUROBINDO,,77.0,YR,,F,Y,73.0,KG,20230717,,MD,DE,DE,2023,Q3,Elderly
225925773,22592577,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Cardiac failure,,2023,Q3,3,F,20220701.0,20230707.0,20230613,20230717,EXP,,DE-AUROBINDO-AUR-APL-2023-041171,AUROBINDO,,77.0,YR,,F,Y,73.0,KG,20230717,,MD,DE,DE,2023,Q3,Elderly
225925773,22592577,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Ventricular extrasystoles,,2023,Q3,3,F,20220701.0,20230707.0,20230613,20230717,EXP,,DE-AUROBINDO-AUR-APL-2023-041171,AUROBINDO,,77.0,YR,,F,Y,73.0,KG,20230717,,MD,DE,DE,2023,Q3,Elderly
225925773,22592577,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Off label use,,2023,Q3,3,F,20220701.0,20230707.0,20230613,20230717,EXP,,DE-AUROBINDO-AUR-APL-2023-041171,AUROBINDO,,77.0,YR,,F,Y,73.0,KG,20230717,,MD,DE,DE,2023,Q3,Elderly
225925773,22592577,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Product use in unapproved indication,,2023,Q3,3,F,20220701.0,20230707.0,20230613,20230717,EXP,,DE-AUROBINDO-AUR-APL-2023-041171,AUROBINDO,,77.0,YR,,F,Y,73.0,KG,20230717,,MD,DE,DE,2023,Q3,Elderly
225925773,22592577,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Cardiovascular disorder,,2023,Q3,3,F,20220701.0,20230707.0,20230613,20230717,EXP,,DE-AUROBINDO-AUR-APL-2023-041171,AUROBINDO,,77.0,YR,,F,Y,73.0,KG,20230717,,MD,DE,DE,2023,Q3,Elderly
225925773,22592577,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Coronary artery disease,,2023,Q3,3,F,20220701.0,20230707.0,20230613,20230717,EXP,,DE-AUROBINDO-AUR-APL-2023-041171,AUROBINDO,,77.0,YR,,F,Y,73.0,KG,20230717,,MD,DE,DE,2023,Q3,Elderly
225925773,22592577,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Peripheral coldness,,2023,Q3,3,F,20220701.0,20230707.0,20230613,20230717,EXP,,DE-AUROBINDO-AUR-APL-2023-041171,AUROBINDO,,77.0,YR,,F,Y,73.0,KG,20230717,,MD,DE,DE,2023,Q3,Elderly
225925773,22592577,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Ejection fraction decreased,,2023,Q3,3,F,20220701.0,20230707.0,20230613,20230717,EXP,,DE-AUROBINDO-AUR-APL-2023-041171,AUROBINDO,,77.0,YR,,F,Y,73.0,KG,20230717,,MD,DE,DE,2023,Q3,Elderly
225925773,22592577,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Hypotension,,2023,Q3,3,F,20220701.0,20230707.0,20230613,20230717,EXP,,DE-AUROBINDO-AUR-APL-2023-041171,AUROBINDO,,77.0,YR,,F,Y,73.0,KG,20230717,,MD,DE,DE,2023,Q3,Elderly
225925773,22592577,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Feeling cold,,2023,Q3,3,F,20220701.0,20230707.0,20230613,20230717,EXP,,DE-AUROBINDO-AUR-APL-2023-041171,AUROBINDO,,77.0,YR,,F,Y,73.0,KG,20230717,,MD,DE,DE,2023,Q3,Elderly
225925773,22592577,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Left ventricular dysfunction,,2023,Q3,3,F,20220701.0,20230707.0,20230613,20230717,EXP,,DE-AUROBINDO-AUR-APL-2023-041171,AUROBINDO,,77.0,YR,,F,Y,73.0,KG,20230717,,MD,DE,DE,2023,Q3,Elderly
226001283,22600128,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,QD,2023,Q3,Off label use,,2023,Q3,3,F,20220701.0,20230712.0,20230614,20230720,EXP,,DE-PFIZER INC-202300218109,PFIZER,,77.0,YR,,F,Y,73.0,KG,20230720,,CN,DE,DE,2023,Q3,Elderly
226001283,22600128,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,QD,2023,Q3,Feeling cold,,2023,Q3,3,F,20220701.0,20230712.0,20230614,20230720,EXP,,DE-PFIZER INC-202300218109,PFIZER,,77.0,YR,,F,Y,73.0,KG,20230720,,CN,DE,DE,2023,Q3,Elderly
226001283,22600128,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,QD,2023,Q3,Peripheral coldness,,2023,Q3,3,F,20220701.0,20230712.0,20230614,20230720,EXP,,DE-PFIZER INC-202300218109,PFIZER,,77.0,YR,,F,Y,73.0,KG,20230720,,CN,DE,DE,2023,Q3,Elderly
226001283,22600128,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,QD,2023,Q3,Left ventricular dysfunction,,2023,Q3,3,F,20220701.0,20230712.0,20230614,20230720,EXP,,DE-PFIZER INC-202300218109,PFIZER,,77.0,YR,,F,Y,73.0,KG,20230720,,CN,DE,DE,2023,Q3,Elderly
226001283,22600128,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,QD,2023,Q3,Ejection fraction decreased,,2023,Q3,3,F,20220701.0,20230712.0,20230614,20230720,EXP,,DE-PFIZER INC-202300218109,PFIZER,,77.0,YR,,F,Y,73.0,KG,20230720,,CN,DE,DE,2023,Q3,Elderly
226001283,22600128,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,QD,2023,Q3,Atrial fibrillation,,2023,Q3,3,F,20220701.0,20230712.0,20230614,20230720,EXP,,DE-PFIZER INC-202300218109,PFIZER,,77.0,YR,,F,Y,73.0,KG,20230720,,CN,DE,DE,2023,Q3,Elderly
226001283,22600128,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,QD,2023,Q3,Cardiovascular disorder,,2023,Q3,3,F,20220701.0,20230712.0,20230614,20230720,EXP,,DE-PFIZER INC-202300218109,PFIZER,,77.0,YR,,F,Y,73.0,KG,20230720,,CN,DE,DE,2023,Q3,Elderly
226001283,22600128,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,QD,2023,Q3,Ventricular extrasystoles,,2023,Q3,3,F,20220701.0,20230712.0,20230614,20230720,EXP,,DE-PFIZER INC-202300218109,PFIZER,,77.0,YR,,F,Y,73.0,KG,20230720,,CN,DE,DE,2023,Q3,Elderly
226001283,22600128,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,QD,2023,Q3,Cardiac failure,,2023,Q3,3,F,20220701.0,20230712.0,20230614,20230720,EXP,,DE-PFIZER INC-202300218109,PFIZER,,77.0,YR,,F,Y,73.0,KG,20230720,,CN,DE,DE,2023,Q3,Elderly
226001283,22600128,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,QD,2023,Q3,Cough,,2023,Q3,3,F,20220701.0,20230712.0,20230614,20230720,EXP,,DE-PFIZER INC-202300218109,PFIZER,,77.0,YR,,F,Y,73.0,KG,20230720,,CN,DE,DE,2023,Q3,Elderly
226001283,22600128,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,QD,2023,Q3,Mitral valve incompetence,,2023,Q3,3,F,20220701.0,20230712.0,20230614,20230720,EXP,,DE-PFIZER INC-202300218109,PFIZER,,77.0,YR,,F,Y,73.0,KG,20230720,,CN,DE,DE,2023,Q3,Elderly
226001283,22600128,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,QD,2023,Q3,Ventricular tachycardia,,2023,Q3,3,F,20220701.0,20230712.0,20230614,20230720,EXP,,DE-PFIZER INC-202300218109,PFIZER,,77.0,YR,,F,Y,73.0,KG,20230720,,CN,DE,DE,2023,Q3,Elderly
226001283,22600128,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,QD,2023,Q3,Coronary artery disease,,2023,Q3,3,F,20220701.0,20230712.0,20230614,20230720,EXP,,DE-PFIZER INC-202300218109,PFIZER,,77.0,YR,,F,Y,73.0,KG,20230720,,CN,DE,DE,2023,Q3,Elderly
226001283,22600128,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,QD,2023,Q3,Hypotension,,2023,Q3,3,F,20220701.0,20230712.0,20230614,20230720,EXP,,DE-PFIZER INC-202300218109,PFIZER,,77.0,YR,,F,Y,73.0,KG,20230720,,CN,DE,DE,2023,Q3,Elderly
226001283,22600128,14,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Off label use,,2023,Q3,3,F,20220701.0,20230712.0,20230614,20230720,EXP,,DE-PFIZER INC-202300218109,PFIZER,,77.0,YR,,F,Y,73.0,KG,20230720,,CN,DE,DE,2023,Q3,Elderly
226001283,22600128,14,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Feeling cold,,2023,Q3,3,F,20220701.0,20230712.0,20230614,20230720,EXP,,DE-PFIZER INC-202300218109,PFIZER,,77.0,YR,,F,Y,73.0,KG,20230720,,CN,DE,DE,2023,Q3,Elderly
226001283,22600128,14,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Peripheral coldness,,2023,Q3,3,F,20220701.0,20230712.0,20230614,20230720,EXP,,DE-PFIZER INC-202300218109,PFIZER,,77.0,YR,,F,Y,73.0,KG,20230720,,CN,DE,DE,2023,Q3,Elderly
226001283,22600128,14,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Left ventricular dysfunction,,2023,Q3,3,F,20220701.0,20230712.0,20230614,20230720,EXP,,DE-PFIZER INC-202300218109,PFIZER,,77.0,YR,,F,Y,73.0,KG,20230720,,CN,DE,DE,2023,Q3,Elderly
226001283,22600128,14,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Ejection fraction decreased,,2023,Q3,3,F,20220701.0,20230712.0,20230614,20230720,EXP,,DE-PFIZER INC-202300218109,PFIZER,,77.0,YR,,F,Y,73.0,KG,20230720,,CN,DE,DE,2023,Q3,Elderly
226001283,22600128,14,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Atrial fibrillation,,2023,Q3,3,F,20220701.0,20230712.0,20230614,20230720,EXP,,DE-PFIZER INC-202300218109,PFIZER,,77.0,YR,,F,Y,73.0,KG,20230720,,CN,DE,DE,2023,Q3,Elderly
226001283,22600128,14,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Cardiovascular disorder,,2023,Q3,3,F,20220701.0,20230712.0,20230614,20230720,EXP,,DE-PFIZER INC-202300218109,PFIZER,,77.0,YR,,F,Y,73.0,KG,20230720,,CN,DE,DE,2023,Q3,Elderly
226001283,22600128,14,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Ventricular extrasystoles,,2023,Q3,3,F,20220701.0,20230712.0,20230614,20230720,EXP,,DE-PFIZER INC-202300218109,PFIZER,,77.0,YR,,F,Y,73.0,KG,20230720,,CN,DE,DE,2023,Q3,Elderly
226001283,22600128,14,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Cardiac failure,,2023,Q3,3,F,20220701.0,20230712.0,20230614,20230720,EXP,,DE-PFIZER INC-202300218109,PFIZER,,77.0,YR,,F,Y,73.0,KG,20230720,,CN,DE,DE,2023,Q3,Elderly
226001283,22600128,14,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Cough,,2023,Q3,3,F,20220701.0,20230712.0,20230614,20230720,EXP,,DE-PFIZER INC-202300218109,PFIZER,,77.0,YR,,F,Y,73.0,KG,20230720,,CN,DE,DE,2023,Q3,Elderly
226001283,22600128,14,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Mitral valve incompetence,,2023,Q3,3,F,20220701.0,20230712.0,20230614,20230720,EXP,,DE-PFIZER INC-202300218109,PFIZER,,77.0,YR,,F,Y,73.0,KG,20230720,,CN,DE,DE,2023,Q3,Elderly
226001283,22600128,14,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Ventricular tachycardia,,2023,Q3,3,F,20220701.0,20230712.0,20230614,20230720,EXP,,DE-PFIZER INC-202300218109,PFIZER,,77.0,YR,,F,Y,73.0,KG,20230720,,CN,DE,DE,2023,Q3,Elderly
226001283,22600128,14,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Coronary artery disease,,2023,Q3,3,F,20220701.0,20230712.0,20230614,20230720,EXP,,DE-PFIZER INC-202300218109,PFIZER,,77.0,YR,,F,Y,73.0,KG,20230720,,CN,DE,DE,2023,Q3,Elderly
226001283,22600128,14,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Hypotension,,2023,Q3,3,F,20220701.0,20230712.0,20230614,20230720,EXP,,DE-PFIZER INC-202300218109,PFIZER,,77.0,YR,,F,Y,73.0,KG,20230720,,CN,DE,DE,2023,Q3,Elderly
226001283,22600128,15,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Off label use,,2023,Q3,3,F,20220701.0,20230712.0,20230614,20230720,EXP,,DE-PFIZER INC-202300218109,PFIZER,,77.0,YR,,F,Y,73.0,KG,20230720,,CN,DE,DE,2023,Q3,Elderly
226001283,22600128,15,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Feeling cold,,2023,Q3,3,F,20220701.0,20230712.0,20230614,20230720,EXP,,DE-PFIZER INC-202300218109,PFIZER,,77.0,YR,,F,Y,73.0,KG,20230720,,CN,DE,DE,2023,Q3,Elderly
226001283,22600128,15,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Peripheral coldness,,2023,Q3,3,F,20220701.0,20230712.0,20230614,20230720,EXP,,DE-PFIZER INC-202300218109,PFIZER,,77.0,YR,,F,Y,73.0,KG,20230720,,CN,DE,DE,2023,Q3,Elderly
226001283,22600128,15,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Left ventricular dysfunction,,2023,Q3,3,F,20220701.0,20230712.0,20230614,20230720,EXP,,DE-PFIZER INC-202300218109,PFIZER,,77.0,YR,,F,Y,73.0,KG,20230720,,CN,DE,DE,2023,Q3,Elderly
226001283,22600128,15,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Ejection fraction decreased,,2023,Q3,3,F,20220701.0,20230712.0,20230614,20230720,EXP,,DE-PFIZER INC-202300218109,PFIZER,,77.0,YR,,F,Y,73.0,KG,20230720,,CN,DE,DE,2023,Q3,Elderly
226001283,22600128,15,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Atrial fibrillation,,2023,Q3,3,F,20220701.0,20230712.0,20230614,20230720,EXP,,DE-PFIZER INC-202300218109,PFIZER,,77.0,YR,,F,Y,73.0,KG,20230720,,CN,DE,DE,2023,Q3,Elderly
226001283,22600128,15,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Cardiovascular disorder,,2023,Q3,3,F,20220701.0,20230712.0,20230614,20230720,EXP,,DE-PFIZER INC-202300218109,PFIZER,,77.0,YR,,F,Y,73.0,KG,20230720,,CN,DE,DE,2023,Q3,Elderly
226001283,22600128,15,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Ventricular extrasystoles,,2023,Q3,3,F,20220701.0,20230712.0,20230614,20230720,EXP,,DE-PFIZER INC-202300218109,PFIZER,,77.0,YR,,F,Y,73.0,KG,20230720,,CN,DE,DE,2023,Q3,Elderly
226001283,22600128,15,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Cardiac failure,,2023,Q3,3,F,20220701.0,20230712.0,20230614,20230720,EXP,,DE-PFIZER INC-202300218109,PFIZER,,77.0,YR,,F,Y,73.0,KG,20230720,,CN,DE,DE,2023,Q3,Elderly
226001283,22600128,15,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Cough,,2023,Q3,3,F,20220701.0,20230712.0,20230614,20230720,EXP,,DE-PFIZER INC-202300218109,PFIZER,,77.0,YR,,F,Y,73.0,KG,20230720,,CN,DE,DE,2023,Q3,Elderly
226001283,22600128,15,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Mitral valve incompetence,,2023,Q3,3,F,20220701.0,20230712.0,20230614,20230720,EXP,,DE-PFIZER INC-202300218109,PFIZER,,77.0,YR,,F,Y,73.0,KG,20230720,,CN,DE,DE,2023,Q3,Elderly
226001283,22600128,15,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Ventricular tachycardia,,2023,Q3,3,F,20220701.0,20230712.0,20230614,20230720,EXP,,DE-PFIZER INC-202300218109,PFIZER,,77.0,YR,,F,Y,73.0,KG,20230720,,CN,DE,DE,2023,Q3,Elderly
226001283,22600128,15,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Coronary artery disease,,2023,Q3,3,F,20220701.0,20230712.0,20230614,20230720,EXP,,DE-PFIZER INC-202300218109,PFIZER,,77.0,YR,,F,Y,73.0,KG,20230720,,CN,DE,DE,2023,Q3,Elderly
226001283,22600128,15,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Hypotension,,2023,Q3,3,F,20220701.0,20230712.0,20230614,20230720,EXP,,DE-PFIZER INC-202300218109,PFIZER,,77.0,YR,,F,Y,73.0,KG,20230720,,CN,DE,DE,2023,Q3,Elderly
226125662,22612566,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Chest discomfort,,2023,Q3,2,F,20230523.0,20230815.0,20230617,20230816,EXP,,NVSC2023GB136110,NOVARTIS,,54.0,YR,,M,Y,,,20230816,,CN,GB,GB,2023,Q3,Adult
226125662,22612566,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Arthralgia,,2023,Q3,2,F,20230523.0,20230815.0,20230617,20230816,EXP,,NVSC2023GB136110,NOVARTIS,,54.0,YR,,M,Y,,,20230816,,CN,GB,GB,2023,Q3,Adult
226125662,22612566,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Neck pain,,2023,Q3,2,F,20230523.0,20230815.0,20230617,20230816,EXP,,NVSC2023GB136110,NOVARTIS,,54.0,YR,,M,Y,,,20230816,,CN,GB,GB,2023,Q3,Adult
226125662,22612566,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Chest pain,,2023,Q3,2,F,20230523.0,20230815.0,20230617,20230816,EXP,,NVSC2023GB136110,NOVARTIS,,54.0,YR,,M,Y,,,20230816,,CN,GB,GB,2023,Q3,Adult
226125662,22612566,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Back pain,,2023,Q3,2,F,20230523.0,20230815.0,20230617,20230816,EXP,,NVSC2023GB136110,NOVARTIS,,54.0,YR,,M,Y,,,20230816,,CN,GB,GB,2023,Q3,Adult
226239413,22623941,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,,2023,Q3,Hypoglycaemia,,2023,Q3,3,F,20230613.0,20230704.0,20230621,20230714,EXP,,ES-ROCHE-3372479,ROCHE,,70.0,YR,,M,Y,,,20230714,,MD,ES,,2023,Q3,Elderly
226271133,22627113,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",200.0,MG,Y,,,,,25.0,MG,,QD,2023,Q3,Dry skin,,2023,Q3,3,F,20230101.0,20230828.0,20230622,20230908,EXP,,CO-NOVOPROD-1078024,NOVO NORDISK,,59.0,YR,,F,Y,63.0,KG,20230908,,CN,CO,CO,2023,Q3,Adult
226271133,22627113,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",200.0,MG,Y,,,,,25.0,MG,,QD,2023,Q3,Dehydration,,2023,Q3,3,F,20230101.0,20230828.0,20230622,20230908,EXP,,CO-NOVOPROD-1078024,NOVO NORDISK,,59.0,YR,,F,Y,63.0,KG,20230908,,CN,CO,CO,2023,Q3,Adult
226271133,22627113,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",200.0,MG,Y,,,,,25.0,MG,,QD,2023,Q3,Vomiting,,2023,Q3,3,F,20230101.0,20230828.0,20230622,20230908,EXP,,CO-NOVOPROD-1078024,NOVO NORDISK,,59.0,YR,,F,Y,63.0,KG,20230908,,CN,CO,CO,2023,Q3,Adult
226271133,22627113,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",200.0,MG,Y,,,,,25.0,MG,,QD,2023,Q3,Dizziness,,2023,Q3,3,F,20230101.0,20230828.0,20230622,20230908,EXP,,CO-NOVOPROD-1078024,NOVO NORDISK,,59.0,YR,,F,Y,63.0,KG,20230908,,CN,CO,CO,2023,Q3,Adult
226271133,22627113,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",200.0,MG,Y,,,,,25.0,MG,,QD,2023,Q3,Abdominal pain upper,,2023,Q3,3,F,20230101.0,20230828.0,20230622,20230908,EXP,,CO-NOVOPROD-1078024,NOVO NORDISK,,59.0,YR,,F,Y,63.0,KG,20230908,,CN,CO,CO,2023,Q3,Adult
226271133,22627113,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",200.0,MG,Y,,,,,25.0,MG,,QD,2023,Q3,Weight decreased,,2023,Q3,3,F,20230101.0,20230828.0,20230622,20230908,EXP,,CO-NOVOPROD-1078024,NOVO NORDISK,,59.0,YR,,F,Y,63.0,KG,20230908,,CN,CO,CO,2023,Q3,Adult
226271133,22627113,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",200.0,MG,Y,,,,,25.0,MG,,QD,2023,Q3,Nausea,,2023,Q3,3,F,20230101.0,20230828.0,20230622,20230908,EXP,,CO-NOVOPROD-1078024,NOVO NORDISK,,59.0,YR,,F,Y,63.0,KG,20230908,,CN,CO,CO,2023,Q3,Adult
226309633,22630963,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,,,,,,Unknown,,206073.0,,,Tablet,,2023,Q3,Euglycaemic diabetic ketoacidosis,,2023,Q3,3,F,,20230720.0,20230622,20230721,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-245732",BOEHRINGER INGELHEIM,,8.0,DEC,E,,Y,,,20230721,,MD,JP,JP,2023,Q3,Child
226309633,22630963,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,,,,,,Unknown,,206073.0,,,Tablet,,2023,Q3,Urinary tract infection,,2023,Q3,3,F,,20230720.0,20230622,20230721,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-245732",BOEHRINGER INGELHEIM,,8.0,DEC,E,,Y,,,20230721,,MD,JP,JP,2023,Q3,Child
226309633,22630963,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,,,,,,Unknown,,206073.0,,,Tablet,,2023,Q3,Coronavirus infection,,2023,Q3,3,F,,20230720.0,20230622,20230721,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-245732",BOEHRINGER INGELHEIM,,8.0,DEC,E,,Y,,,20230721,,MD,JP,JP,2023,Q3,Child
226345642,22634564,2,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,Y,,Unknown,,,,,,,2023,Q3,Anuria,,2023,Q3,2,F,,20230802.0,20230623,20230811,EXP,,GR-EMD Serono-2023455936,EMD SERONO INC,,70.0,YR,E,F,Y,,,20230811,,HP,GR,GR,2023,Q3,Elderly
226345642,22634564,2,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,Y,,Unknown,,,,,,,2023,Q3,Euglycaemic diabetic ketoacidosis,,2023,Q3,2,F,,20230802.0,20230623,20230811,EXP,,GR-EMD Serono-2023455936,EMD SERONO INC,,70.0,YR,E,F,Y,,,20230811,,HP,GR,GR,2023,Q3,Elderly
226345642,22634564,2,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,Y,,Unknown,,,,,,,2023,Q3,Haemodynamic instability,,2023,Q3,2,F,,20230802.0,20230623,20230811,EXP,,GR-EMD Serono-2023455936,EMD SERONO INC,,70.0,YR,E,F,Y,,,20230811,,HP,GR,GR,2023,Q3,Elderly
226345642,22634564,2,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,Y,,Unknown,,,,,,,2023,Q3,Diarrhoea,,2023,Q3,2,F,,20230802.0,20230623,20230811,EXP,,GR-EMD Serono-2023455936,EMD SERONO INC,,70.0,YR,E,F,Y,,,20230811,,HP,GR,GR,2023,Q3,Elderly
226448773,22644877,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,Unknown,,212614.0,,,Tablet,QD,2023,Q3,Incorrect dose administered,,2023,Q3,3,F,20230626.0,20230807.0,20230627,20230808,PER,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-246394",BOEHRINGER INGELHEIM,,59.0,YR,A,F,Y,,,20230808,,CN,US,US,2023,Q3,Adult
226469164,22646916,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,Unknown,,204629.0,10.0,MG,Tablet,,2023,Q3,Anal abscess,,2023,Q3,4,F,20230621.0,20230812.0,20230627,20230816,EXP,,"AR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-245737",BOEHRINGER INGELHEIM,,60.0,YR,A,M,Y,81.0,KG,20230816,,MD,AR,AR,2023,Q3,Adult
226508442,22650844,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q3,Tremor,,2023,Q3,2,F,,20230802.0,20230628,20230811,EXP,,CH-TEVA-2023-CH-2901625,TEVA,,72.0,YR,E,M,Y,,,20230811,,HP,CH,CH,2023,Q3,Elderly
226516982,22651698,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2023,Q3,Hypomagnesaemia,,2023,Q3,2,F,,20230622.0,20230628,20230705,EXP,,CH-MYLANLABS-2023M1067130,MYLAN,"Dr. med. (RS) Lazic M, Dr. med. Dr. sc. nat. Henzi A, PD Dr. med. Brack T. Tremor in the polymedicated patient. Schweizerische Arztezeitung+Swiss Medical Forum. 2023;1-5",72.0,YR,,M,Y,,,20230705,,MD,CH,CH,2023,Q3,Elderly
226529422,22652942,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Blood glucose increased,,2023,Q3,2,F,20230601.0,20230628.0,20230629,20230705,EXP,,ES-SA-2023SA197191,SANOFI AVENTIS,,73.0,YR,E,F,Y,,,20230705,,CN,ES,ES,2023,Q3,Elderly
226529422,22652942,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Hospitalisation,,2023,Q3,2,F,20230601.0,20230628.0,20230629,20230705,EXP,,ES-SA-2023SA197191,SANOFI AVENTIS,,73.0,YR,E,F,Y,,,20230705,,CN,ES,ES,2023,Q3,Elderly
226529422,22652942,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Injection site bruising,,2023,Q3,2,F,20230601.0,20230628.0,20230629,20230705,EXP,,ES-SA-2023SA197191,SANOFI AVENTIS,,73.0,YR,E,F,Y,,,20230705,,CN,ES,ES,2023,Q3,Elderly
226529422,22652942,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Dementia,,2023,Q3,2,F,20230601.0,20230628.0,20230629,20230705,EXP,,ES-SA-2023SA197191,SANOFI AVENTIS,,73.0,YR,E,F,Y,,,20230705,,CN,ES,ES,2023,Q3,Elderly
226537864,22653786,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Lower respiratory tract infection,,2023,Q3,4,F,,20230727.0,20230629,20230728,EXP,,IT-ROCHE-3375698,ROCHE,"Valenti C, Moretti G, Copelli S, Cicilia R, Manca F, Cioni E, Gasparini E, Pinto C, Navazio A and Tarantini L Teamwork is successful (1): Favoureable re-challenge of double ANTI-HER2 Treatment in severe myocardial dysfunction in patient with Advanced breast cancer and occult type II diabetes. (Abstract number: P280). DOI: 10.1093/eurheartjsupp/suad111.354.. European Heart Journal 2023 May;25 (SUPPLEMENT D):D149-50.",55.0,YR,,F,Y,,,20230728,,HP,IT,IT,2023,Q3,Adult
226537864,22653786,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Disease progression,,2023,Q3,4,F,,20230727.0,20230629,20230728,EXP,,IT-ROCHE-3375698,ROCHE,"Valenti C, Moretti G, Copelli S, Cicilia R, Manca F, Cioni E, Gasparini E, Pinto C, Navazio A and Tarantini L Teamwork is successful (1): Favoureable re-challenge of double ANTI-HER2 Treatment in severe myocardial dysfunction in patient with Advanced breast cancer and occult type II diabetes. (Abstract number: P280). DOI: 10.1093/eurheartjsupp/suad111.354.. European Heart Journal 2023 May;25 (SUPPLEMENT D):D149-50.",55.0,YR,,F,Y,,,20230728,,HP,IT,IT,2023,Q3,Adult
226537864,22653786,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Cardiac failure congestive,,2023,Q3,4,F,,20230727.0,20230629,20230728,EXP,,IT-ROCHE-3375698,ROCHE,"Valenti C, Moretti G, Copelli S, Cicilia R, Manca F, Cioni E, Gasparini E, Pinto C, Navazio A and Tarantini L Teamwork is successful (1): Favoureable re-challenge of double ANTI-HER2 Treatment in severe myocardial dysfunction in patient with Advanced breast cancer and occult type II diabetes. (Abstract number: P280). DOI: 10.1093/eurheartjsupp/suad111.354.. European Heart Journal 2023 May;25 (SUPPLEMENT D):D149-50.",55.0,YR,,F,Y,,,20230728,,HP,IT,IT,2023,Q3,Adult
226537864,22653786,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Left ventricular dysfunction,,2023,Q3,4,F,,20230727.0,20230629,20230728,EXP,,IT-ROCHE-3375698,ROCHE,"Valenti C, Moretti G, Copelli S, Cicilia R, Manca F, Cioni E, Gasparini E, Pinto C, Navazio A and Tarantini L Teamwork is successful (1): Favoureable re-challenge of double ANTI-HER2 Treatment in severe myocardial dysfunction in patient with Advanced breast cancer and occult type II diabetes. (Abstract number: P280). DOI: 10.1093/eurheartjsupp/suad111.354.. European Heart Journal 2023 May;25 (SUPPLEMENT D):D149-50.",55.0,YR,,F,Y,,,20230728,,HP,IT,IT,2023,Q3,Adult
226552822,22655282,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q3,Diarrhoea,,2023,Q3,2,F,,20230717.0,20230629,20230717,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-246922",BOEHRINGER INGELHEIM,,70.0,YR,E,F,Y,,,20230717,,MD,GR,GR,2023,Q3,Elderly
226552822,22655282,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q3,Euglycaemic diabetic ketoacidosis,,2023,Q3,2,F,,20230717.0,20230629,20230717,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-246922",BOEHRINGER INGELHEIM,,70.0,YR,E,F,Y,,,20230717,,MD,GR,GR,2023,Q3,Elderly
226552822,22655282,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q3,Acute kidney injury,,2023,Q3,2,F,,20230717.0,20230629,20230717,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-246922",BOEHRINGER INGELHEIM,,70.0,YR,E,F,Y,,,20230717,,MD,GR,GR,2023,Q3,Elderly
226552822,22655282,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q3,Haemodynamic instability,,2023,Q3,2,F,,20230717.0,20230629,20230717,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-246922",BOEHRINGER INGELHEIM,,70.0,YR,E,F,Y,,,20230717,,MD,GR,GR,2023,Q3,Elderly
226576352,22657635,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 mg,,,,,unknown,,,,,,,2023,Q3,Pruritus,,2023,Q3,2,F,20230511.0,20230711.0,20230630,20230724,EXP,PT-INFARMED-E202306-188,PT-NOVOPROD-1080550,NOVO NORDISK,,56.0,YR,,F,Y,98.0,KG,20230724,,HP,PT,PT,2023,Q3,Adult
226617142,22661714,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,,,,,,10.0,MG,,,2023,Q3,Hypoglycaemia,,2023,Q3,2,F,20230411.0,20230704.0,20230630,20230707,EXP,,ES-PFIZER INC-202300232551,PFIZER,,70.0,YR,,M,Y,,,20230707,,MD,ES,ES,2023,Q3,Elderly
226617142,22661714,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,,,,,,10.0,MG,,,2023,Q3,Off label use,,2023,Q3,2,F,20230411.0,20230704.0,20230630,20230707,EXP,,ES-PFIZER INC-202300232551,PFIZER,,70.0,YR,,M,Y,,,20230707,,MD,ES,ES,2023,Q3,Elderly
226622411,22662241,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Coinfection,,2023,Q3,1,I,20220701.0,20230620.0,20230701,20230701,EXP,,US-AUROBINDO-AUR-APL-2023-044148,AUROBINDO,"Beau Stamos D, Barajas-Ochoa A, Raybould JE.. Nocardia pseudobrasiliensis Co-infection in SARS-CoV-2 Patients. Emerging Infectious Diseases. 2023;29(4):696-700",52.0,YR,,M,Y,,,20230701,,MD,US,US,2023,Q3,Adult
226622411,22662241,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Pneumonia bacterial,,2023,Q3,1,I,20220701.0,20230620.0,20230701,20230701,EXP,,US-AUROBINDO-AUR-APL-2023-044148,AUROBINDO,"Beau Stamos D, Barajas-Ochoa A, Raybould JE.. Nocardia pseudobrasiliensis Co-infection in SARS-CoV-2 Patients. Emerging Infectious Diseases. 2023;29(4):696-700",52.0,YR,,M,Y,,,20230701,,MD,US,US,2023,Q3,Adult
226622411,22662241,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Pulmonary nocardiosis,,2023,Q3,1,I,20220701.0,20230620.0,20230701,20230701,EXP,,US-AUROBINDO-AUR-APL-2023-044148,AUROBINDO,"Beau Stamos D, Barajas-Ochoa A, Raybould JE.. Nocardia pseudobrasiliensis Co-infection in SARS-CoV-2 Patients. Emerging Infectious Diseases. 2023;29(4):696-700",52.0,YR,,M,Y,,,20230701,,MD,US,US,2023,Q3,Adult
226624161,22662416,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 Dosage forms Daily; morning,",,,,,,,,,,Tablet,QD,2023,Q3,Dry eye,,2023,Q3,1,I,20230509.0,20230621.0,20230701,20230701,EXP,GB-MHRA-TPP2502395C3473839YC1687166456328,GB-TEVA-2023-GB-2901394,TEVA,,79.0,YR,E,F,Y,56.0,KG,20230701,,PH,GB,GB,2023,Q3,Elderly
226632141,22663214,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,Unknown,,206111.0,,,,,2023,Q3,Necrotising fasciitis,,2023,Q3,1,I,,20230703.0,20230703,20230703,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-247353",BOEHRINGER INGELHEIM,,62.0,YR,A,F,Y,,,20230703,,CN,AU,AU,2023,Q3,Adult
226642981,22664298,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,morning,,,,,,,,,,Tablet,QD,2023,Q3,Dry eye,,2023,Q3,1,I,20230509.0,20230621.0,20230703,20230703,EXP,GB-MHRA-ADR 27988768,GB-Accord-364723,ACCORD,,79.0,YR,E,F,Y,56.0,KG,20230703,,PH,GB,GB,2023,Q3,Elderly
226651451,22665145,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Myalgia,,2023,Q3,1,I,,20230225.0,20230703,20230703,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-383807,RANBAXY,,50.0,YR,,F,Y,112.0,KG,20230703,,PH,GB,GB,2023,Q3,Adult
226651451,22665145,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Rash,,2023,Q3,1,I,,20230225.0,20230703,20230703,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-383807,RANBAXY,,50.0,YR,,F,Y,112.0,KG,20230703,,PH,GB,GB,2023,Q3,Adult
226651451,22665145,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Paraesthesia,,2023,Q3,1,I,,20230225.0,20230703,20230703,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-383807,RANBAXY,,50.0,YR,,F,Y,112.0,KG,20230703,,PH,GB,GB,2023,Q3,Adult
226654511,22665451,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg x1,,,U,,,,,10.0,MG,,,2023,Q3,Chest pain,,2023,Q3,1,I,,20230222.0,20230703,20230703,EXP,,SE-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-384293,RANBAXY,,64.0,YR,,,Y,,,20230703,,HP,SE,SE,2023,Q3,Adult
226654511,22665451,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg x1,,,U,,,,,10.0,MG,,,2023,Q3,Coronary artery occlusion,,2023,Q3,1,I,,20230222.0,20230703,20230703,EXP,,SE-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-384293,RANBAXY,,64.0,YR,,,Y,,,20230703,,HP,SE,SE,2023,Q3,Adult
226654511,22665451,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg x1,,,U,,,,,10.0,MG,,,2023,Q3,Atrial fibrillation,,2023,Q3,1,I,,20230222.0,20230703,20230703,EXP,,SE-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-384293,RANBAXY,,64.0,YR,,,Y,,,20230703,,HP,SE,SE,2023,Q3,Adult
226673611,22667361,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q3,Pancreatitis acute,,2023,Q3,1,I,,20230627.0,20230704,20230704,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-246502",BOEHRINGER INGELHEIM,"Poloju A, Majety P, Groysman A. Pancreatitis in a 57-Year-Old Female Two Weeks After Initiation of Empagliflozin. AACE Clinical Case Reports. 2023;doi:10.1016/j.aace.2023.04.005.",57.0,YR,A,F,Y,,,20230704,,MD,US,US,2023,Q3,Adult
226673611,22667361,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q3,Hepatic steatosis,,2023,Q3,1,I,,20230627.0,20230704,20230704,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-246502",BOEHRINGER INGELHEIM,"Poloju A, Majety P, Groysman A. Pancreatitis in a 57-Year-Old Female Two Weeks After Initiation of Empagliflozin. AACE Clinical Case Reports. 2023;doi:10.1016/j.aace.2023.04.005.",57.0,YR,A,F,Y,,,20230704,,MD,US,US,2023,Q3,Adult
226673901,22667390,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q3,Post procedural complication,,2023,Q3,1,I,,20230627.0,20230704,20230704,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-246469",BOEHRINGER INGELHEIM,"Ahmed S, Malhotra G, Sheikh MR. ANION GAP ACIDOSIS AFTER PANCREATICODUODENECTOMY IN PATIENT TAKING EMPAGLIFLOZIN. HPB. 2023;25: 174-doi:10.1016/j.hpb. 2023.05.337.",74.0,YR,E,M,Y,,,20230704,,HP,US,US,2023,Q3,Elderly
226673901,22667390,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q3,Euglycaemic diabetic ketoacidosis,,2023,Q3,1,I,,20230627.0,20230704,20230704,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-246469",BOEHRINGER INGELHEIM,"Ahmed S, Malhotra G, Sheikh MR. ANION GAP ACIDOSIS AFTER PANCREATICODUODENECTOMY IN PATIENT TAKING EMPAGLIFLOZIN. HPB. 2023;25: 174-doi:10.1016/j.hpb. 2023.05.337.",74.0,YR,E,M,Y,,,20230704,,HP,US,US,2023,Q3,Elderly
226673901,22667390,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q3,Metabolic acidosis,,2023,Q3,1,I,,20230627.0,20230704,20230704,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-246469",BOEHRINGER INGELHEIM,"Ahmed S, Malhotra G, Sheikh MR. ANION GAP ACIDOSIS AFTER PANCREATICODUODENECTOMY IN PATIENT TAKING EMPAGLIFLOZIN. HPB. 2023;25: 174-doi:10.1016/j.hpb. 2023.05.337.",74.0,YR,E,M,Y,,,20230704,,HP,US,US,2023,Q3,Elderly
226681111,22668111,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2023,Q3,Pneumonia pseudomonal,,2023,Q3,1,I,20230323.0,20230626.0,20230704,20230704,EXP,,DE-GENMAB-2023-00514,GENMAB,,75.0,YR,,M,Y,69.3,KG,20230704,,MD,DE,DE,2023,Q3,Elderly
226685031,22668503,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,UNKNOWN,,,,,,,2023,Q3,Coinfection,,2023,Q3,1,I,20220701.0,20230620.0,20230704,20230704,EXP,,US-drreddys-SPO/USA/23/0168809,DR REDDYS,"Raybould J, Beau Stamos, Barajas-Ochoa A. Nocardia pseudobrasiliensis Co-infection in SARS-CoV-2 Patients. Emerg Infect Dis. 2023;29(4):696-700. doi:10.3201/eid2904.221439.",52.0,YR,A,M,Y,,,20230704,,MD,US,US,2023,Q3,Adult
226685031,22668503,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,UNKNOWN,,,,,,,2023,Q3,Product use in unapproved indication,,2023,Q3,1,I,20220701.0,20230620.0,20230704,20230704,EXP,,US-drreddys-SPO/USA/23/0168809,DR REDDYS,"Raybould J, Beau Stamos, Barajas-Ochoa A. Nocardia pseudobrasiliensis Co-infection in SARS-CoV-2 Patients. Emerg Infect Dis. 2023;29(4):696-700. doi:10.3201/eid2904.221439.",52.0,YR,A,M,Y,,,20230704,,MD,US,US,2023,Q3,Adult
226685031,22668503,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,UNKNOWN,,,,,,,2023,Q3,Pulmonary nocardiosis,,2023,Q3,1,I,20220701.0,20230620.0,20230704,20230704,EXP,,US-drreddys-SPO/USA/23/0168809,DR REDDYS,"Raybould J, Beau Stamos, Barajas-Ochoa A. Nocardia pseudobrasiliensis Co-infection in SARS-CoV-2 Patients. Emerg Infect Dis. 2023;29(4):696-700. doi:10.3201/eid2904.221439.",52.0,YR,A,M,Y,,,20230704,,MD,US,US,2023,Q3,Adult
226685031,22668503,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,UNKNOWN,,,,,,,2023,Q3,Pneumonia bacterial,,2023,Q3,1,I,20220701.0,20230620.0,20230704,20230704,EXP,,US-drreddys-SPO/USA/23/0168809,DR REDDYS,"Raybould J, Beau Stamos, Barajas-Ochoa A. Nocardia pseudobrasiliensis Co-infection in SARS-CoV-2 Patients. Emerg Infect Dis. 2023;29(4):696-700. doi:10.3201/eid2904.221439.",52.0,YR,A,M,Y,,,20230704,,MD,US,US,2023,Q3,Adult
226685491,22668549,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,,,,,,,QD,2023,Q3,Anaphylactic reaction,,2023,Q3,1,I,,20230623.0,20230704,20230704,EXP,,US-LUPIN PHARMACEUTICALS INC.-2023-05256,LUPIN,"McKeirnan KC, Anderson CB, Powell AJ, Gilbert R, Undeberg MR. The role of the Pharmacist in patient self-advocacy for osteoporosis screening. The Senior Care Pharmacist. 2022;37:612-622",61.0,YR,,F,Y,,,20230704,,PH,US,US,2023,Q3,Adult
226685491,22668549,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,,,,,,,QD,2023,Q3,Osteoporosis,,2023,Q3,1,I,,20230623.0,20230704,20230704,EXP,,US-LUPIN PHARMACEUTICALS INC.-2023-05256,LUPIN,"McKeirnan KC, Anderson CB, Powell AJ, Gilbert R, Undeberg MR. The role of the Pharmacist in patient self-advocacy for osteoporosis screening. The Senior Care Pharmacist. 2022;37:612-622",61.0,YR,,F,Y,,,20230704,,PH,US,US,2023,Q3,Adult
226685491,22668549,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,,,,,,,QD,2023,Q3,Diarrhoea,,2023,Q3,1,I,,20230623.0,20230704,20230704,EXP,,US-LUPIN PHARMACEUTICALS INC.-2023-05256,LUPIN,"McKeirnan KC, Anderson CB, Powell AJ, Gilbert R, Undeberg MR. The role of the Pharmacist in patient self-advocacy for osteoporosis screening. The Senior Care Pharmacist. 2022;37:612-622",61.0,YR,,F,Y,,,20230704,,PH,US,US,2023,Q3,Adult
226685491,22668549,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,,,,,,,QD,2023,Q3,Vomiting,,2023,Q3,1,I,,20230623.0,20230704,20230704,EXP,,US-LUPIN PHARMACEUTICALS INC.-2023-05256,LUPIN,"McKeirnan KC, Anderson CB, Powell AJ, Gilbert R, Undeberg MR. The role of the Pharmacist in patient self-advocacy for osteoporosis screening. The Senior Care Pharmacist. 2022;37:612-622",61.0,YR,,F,Y,,,20230704,,PH,US,US,2023,Q3,Adult
226685491,22668549,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,,,,,,,QD,2023,Q3,Pruritus,,2023,Q3,1,I,,20230623.0,20230704,20230704,EXP,,US-LUPIN PHARMACEUTICALS INC.-2023-05256,LUPIN,"McKeirnan KC, Anderson CB, Powell AJ, Gilbert R, Undeberg MR. The role of the Pharmacist in patient self-advocacy for osteoporosis screening. The Senior Care Pharmacist. 2022;37:612-622",61.0,YR,,F,Y,,,20230704,,PH,US,US,2023,Q3,Adult
226685491,22668549,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,,,,,,,QD,2023,Q3,Urticaria,,2023,Q3,1,I,,20230623.0,20230704,20230704,EXP,,US-LUPIN PHARMACEUTICALS INC.-2023-05256,LUPIN,"McKeirnan KC, Anderson CB, Powell AJ, Gilbert R, Undeberg MR. The role of the Pharmacist in patient self-advocacy for osteoporosis screening. The Senior Care Pharmacist. 2022;37:612-622",61.0,YR,,F,Y,,,20230704,,PH,US,US,2023,Q3,Adult
226685491,22668549,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,,,,,,,QD,2023,Q3,Nausea,,2023,Q3,1,I,,20230623.0,20230704,20230704,EXP,,US-LUPIN PHARMACEUTICALS INC.-2023-05256,LUPIN,"McKeirnan KC, Anderson CB, Powell AJ, Gilbert R, Undeberg MR. The role of the Pharmacist in patient self-advocacy for osteoporosis screening. The Senior Care Pharmacist. 2022;37:612-622",61.0,YR,,F,Y,,,20230704,,PH,US,US,2023,Q3,Adult
226685491,22668549,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,,,,,,,QD,2023,Q3,Hyperthyroidism,,2023,Q3,1,I,,20230623.0,20230704,20230704,EXP,,US-LUPIN PHARMACEUTICALS INC.-2023-05256,LUPIN,"McKeirnan KC, Anderson CB, Powell AJ, Gilbert R, Undeberg MR. The role of the Pharmacist in patient self-advocacy for osteoporosis screening. The Senior Care Pharmacist. 2022;37:612-622",61.0,YR,,F,Y,,,20230704,,PH,US,US,2023,Q3,Adult
226693801,22669380,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,,,,,,10.0,MG,,,2023,Q3,Urinary tract infection,,2023,Q3,1,I,20230517.0,20230628.0,20230704,20230704,EXP,,ES-PFIZER INC-202300234443,PFIZER,,71.0,YR,,M,Y,,,20230704,,MD,ES,ES,2023,Q3,Elderly
226706961,22670696,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q3,Dizziness,,2023,Q3,1,I,20220630.0,20230704.0,20230705,20230705,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-247814",BOEHRINGER INGELHEIM,,49.0,YR,A,M,Y,,,20230705,,HP,SG,SG,2023,Q3,Adult
226709291,22670929,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 milligram, qd (every morning)",,,,,,,,10.0,MG,,QD,2023,Q3,Catheter site extravasation,,2023,Q3,1,I,20230328.0,20230411.0,20230705,20230705,PER,,US-SAREPTA THERAPEUTICS INC.-SRP2023-003217,SAREPTA THERAPEUTICS,,23.0,YR,,M,Y,58.49,KG,20230705,,HP,US,US,2023,Q3,Youth
226709291,22670929,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 milligram, qd (every morning)",,,,,,,,10.0,MG,,QD,2023,Q3,Device dislocation,,2023,Q3,1,I,20230328.0,20230411.0,20230705,20230705,PER,,US-SAREPTA THERAPEUTICS INC.-SRP2023-003217,SAREPTA THERAPEUTICS,,23.0,YR,,M,Y,58.49,KG,20230705,,HP,US,US,2023,Q3,Youth
226709291,22670929,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 milligram, qd (every morning)",,,,,,,,10.0,MG,,QD,2023,Q3,Catheter site swelling,,2023,Q3,1,I,20230328.0,20230411.0,20230705,20230705,PER,,US-SAREPTA THERAPEUTICS INC.-SRP2023-003217,SAREPTA THERAPEUTICS,,23.0,YR,,M,Y,58.49,KG,20230705,,HP,US,US,2023,Q3,Youth
226713661,22671366,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"0.5 DF, once daily (? half a day)",,,U,,,,,,,Tablet,QD,2023,Q3,Balanoposthitis,,2023,Q3,1,I,20230522.0,20230626.0,20230705,20230705,EXP,,IR-SA-2023SA203007,SANOFI AVENTIS,,61.0,YR,A,M,Y,73.0,KG,20230705,,CN,IR,IR,2023,Q3,Adult
226713661,22671366,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"0.5 DF, once daily (? half a day)",,,U,,,,,,,Tablet,QD,2023,Q3,Penile burning sensation,,2023,Q3,1,I,20230522.0,20230626.0,20230705,20230705,EXP,,IR-SA-2023SA203007,SANOFI AVENTIS,,61.0,YR,A,M,Y,73.0,KG,20230705,,CN,IR,IR,2023,Q3,Adult
226715424,22671542,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25mg every 24 hours,,,U,,,,,25.0,MG,,,2023,Q3,Hypovolaemic shock,,2023,Q3,4,F,,20230711.0,20230705,20230720,EXP,,ES-009507513-2306ESP012285,MERCK,"Ferrer Luna L, Jimenez Guerrero C, Pax Bosch B.. AND IT ONLY LOOKED LIKE GASTROENTERITIS!. 33 SEMES National Congress. 2023;1698",77.0,YR,,F,Y,,,20230720,,HP,ES,ES,2023,Q3,Elderly
226715424,22671542,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25mg every 24 hours,,,U,,,,,25.0,MG,,,2023,Q3,Acute kidney injury,,2023,Q3,4,F,,20230711.0,20230705,20230720,EXP,,ES-009507513-2306ESP012285,MERCK,"Ferrer Luna L, Jimenez Guerrero C, Pax Bosch B.. AND IT ONLY LOOKED LIKE GASTROENTERITIS!. 33 SEMES National Congress. 2023;1698",77.0,YR,,F,Y,,,20230720,,HP,ES,ES,2023,Q3,Elderly
226715424,22671542,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25mg every 24 hours,,,U,,,,,25.0,MG,,,2023,Q3,Drug effect less than expected,,2023,Q3,4,F,,20230711.0,20230705,20230720,EXP,,ES-009507513-2306ESP012285,MERCK,"Ferrer Luna L, Jimenez Guerrero C, Pax Bosch B.. AND IT ONLY LOOKED LIKE GASTROENTERITIS!. 33 SEMES National Congress. 2023;1698",77.0,YR,,F,Y,,,20230720,,HP,ES,ES,2023,Q3,Elderly
226715424,22671542,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25mg every 24 hours,,,U,,,,,25.0,MG,,,2023,Q3,Metabolic acidosis,,2023,Q3,4,F,,20230711.0,20230705,20230720,EXP,,ES-009507513-2306ESP012285,MERCK,"Ferrer Luna L, Jimenez Guerrero C, Pax Bosch B.. AND IT ONLY LOOKED LIKE GASTROENTERITIS!. 33 SEMES National Congress. 2023;1698",77.0,YR,,F,Y,,,20230720,,HP,ES,ES,2023,Q3,Elderly
226715424,22671542,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25mg every 24 hours,,,U,,,,,25.0,MG,,,2023,Q3,Dehydration,,2023,Q3,4,F,,20230711.0,20230705,20230720,EXP,,ES-009507513-2306ESP012285,MERCK,"Ferrer Luna L, Jimenez Guerrero C, Pax Bosch B.. AND IT ONLY LOOKED LIKE GASTROENTERITIS!. 33 SEMES National Congress. 2023;1698",77.0,YR,,F,Y,,,20230720,,HP,ES,ES,2023,Q3,Elderly
226715424,22671542,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25mg every 24 hours,,,U,,,,,25.0,MG,,,2023,Q3,Diarrhoea,,2023,Q3,4,F,,20230711.0,20230705,20230720,EXP,,ES-009507513-2306ESP012285,MERCK,"Ferrer Luna L, Jimenez Guerrero C, Pax Bosch B.. AND IT ONLY LOOKED LIKE GASTROENTERITIS!. 33 SEMES National Congress. 2023;1698",77.0,YR,,F,Y,,,20230720,,HP,ES,ES,2023,Q3,Elderly
226749331,22674933,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Lactic acidosis,,2023,Q3,1,I,,20230622.0,20230706,20230706,EXP,,ES-AUROBINDO-AUR-APL-2023-045299,AUROBINDO,"Soto Telles A, Prudencio Rodr?guez A, Hern?ndez Gonz?lez C, Higueras S?nchez C, Hijar Jim?nez R, Guerrero Deleg J.. MY MOTHER DOES NOT EAT. DOCTOR.. 2023;777-777",81.0,YR,,F,Y,,,20230706,,HP,ES,ES,2023,Q3,Elderly
226749331,22674933,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Hyperkalaemia,,2023,Q3,1,I,,20230622.0,20230706,20230706,EXP,,ES-AUROBINDO-AUR-APL-2023-045299,AUROBINDO,"Soto Telles A, Prudencio Rodr?guez A, Hern?ndez Gonz?lez C, Higueras S?nchez C, Hijar Jim?nez R, Guerrero Deleg J.. MY MOTHER DOES NOT EAT. DOCTOR.. 2023;777-777",81.0,YR,,F,Y,,,20230706,,HP,ES,ES,2023,Q3,Elderly
226749331,22674933,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Renal failure,,2023,Q3,1,I,,20230622.0,20230706,20230706,EXP,,ES-AUROBINDO-AUR-APL-2023-045299,AUROBINDO,"Soto Telles A, Prudencio Rodr?guez A, Hern?ndez Gonz?lez C, Higueras S?nchez C, Hijar Jim?nez R, Guerrero Deleg J.. MY MOTHER DOES NOT EAT. DOCTOR.. 2023;777-777",81.0,YR,,F,Y,,,20230706,,HP,ES,ES,2023,Q3,Elderly
226754091,22675409,28,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,,,,,,,,,,2023,Q3,Hypoglycaemia,,2023,Q3,1,I,,20230628.0,20230706,20230706,EXP,ES-TEVA-2023-ES-2887829,ES-EMD Serono-2023459019,EMD SERONO INC,,62.0,YR,A,F,Y,90.0,KG,20230706,,PH,ES,ES,2023,Q3,Adult
226754091,22675409,28,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,,,,,,,,,,2023,Q3,Hallucination,,2023,Q3,1,I,,20230628.0,20230706,20230706,EXP,ES-TEVA-2023-ES-2887829,ES-EMD Serono-2023459019,EMD SERONO INC,,62.0,YR,A,F,Y,90.0,KG,20230706,,PH,ES,ES,2023,Q3,Adult
226754091,22675409,28,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,,,,,,,,,,2023,Q3,Parkinsonism,,2023,Q3,1,I,,20230628.0,20230706,20230706,EXP,ES-TEVA-2023-ES-2887829,ES-EMD Serono-2023459019,EMD SERONO INC,,62.0,YR,A,F,Y,90.0,KG,20230706,,PH,ES,ES,2023,Q3,Adult
226754091,22675409,28,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,,,,,,,,,,2023,Q3,Somnolence,,2023,Q3,1,I,,20230628.0,20230706,20230706,EXP,ES-TEVA-2023-ES-2887829,ES-EMD Serono-2023459019,EMD SERONO INC,,62.0,YR,A,F,Y,90.0,KG,20230706,,PH,ES,ES,2023,Q3,Adult
226754091,22675409,28,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,,,,,,,,,,2023,Q3,Hypotension,,2023,Q3,1,I,,20230628.0,20230706,20230706,EXP,ES-TEVA-2023-ES-2887829,ES-EMD Serono-2023459019,EMD SERONO INC,,62.0,YR,A,F,Y,90.0,KG,20230706,,PH,ES,ES,2023,Q3,Adult
226754091,22675409,29,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,,,,,,,,,QD,2023,Q3,Hypoglycaemia,,2023,Q3,1,I,,20230628.0,20230706,20230706,EXP,ES-TEVA-2023-ES-2887829,ES-EMD Serono-2023459019,EMD SERONO INC,,62.0,YR,A,F,Y,90.0,KG,20230706,,PH,ES,ES,2023,Q3,Adult
226754091,22675409,29,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,,,,,,,,,QD,2023,Q3,Hallucination,,2023,Q3,1,I,,20230628.0,20230706,20230706,EXP,ES-TEVA-2023-ES-2887829,ES-EMD Serono-2023459019,EMD SERONO INC,,62.0,YR,A,F,Y,90.0,KG,20230706,,PH,ES,ES,2023,Q3,Adult
226754091,22675409,29,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,,,,,,,,,QD,2023,Q3,Parkinsonism,,2023,Q3,1,I,,20230628.0,20230706,20230706,EXP,ES-TEVA-2023-ES-2887829,ES-EMD Serono-2023459019,EMD SERONO INC,,62.0,YR,A,F,Y,90.0,KG,20230706,,PH,ES,ES,2023,Q3,Adult
226754091,22675409,29,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,,,,,,,,,QD,2023,Q3,Somnolence,,2023,Q3,1,I,,20230628.0,20230706,20230706,EXP,ES-TEVA-2023-ES-2887829,ES-EMD Serono-2023459019,EMD SERONO INC,,62.0,YR,A,F,Y,90.0,KG,20230706,,PH,ES,ES,2023,Q3,Adult
226754091,22675409,29,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,,,,,,,,,QD,2023,Q3,Hypotension,,2023,Q3,1,I,,20230628.0,20230706,20230706,EXP,ES-TEVA-2023-ES-2887829,ES-EMD Serono-2023459019,EMD SERONO INC,,62.0,YR,A,F,Y,90.0,KG,20230706,,PH,ES,ES,2023,Q3,Adult
226754091,22675409,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,,,,,,,,,QD,2023,Q3,Hypoglycaemia,,2023,Q3,1,I,,20230628.0,20230706,20230706,EXP,ES-TEVA-2023-ES-2887829,ES-EMD Serono-2023459019,EMD SERONO INC,,62.0,YR,A,F,Y,90.0,KG,20230706,,PH,ES,ES,2023,Q3,Adult
226754091,22675409,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,,,,,,,,,QD,2023,Q3,Hallucination,,2023,Q3,1,I,,20230628.0,20230706,20230706,EXP,ES-TEVA-2023-ES-2887829,ES-EMD Serono-2023459019,EMD SERONO INC,,62.0,YR,A,F,Y,90.0,KG,20230706,,PH,ES,ES,2023,Q3,Adult
226754091,22675409,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,,,,,,,,,QD,2023,Q3,Parkinsonism,,2023,Q3,1,I,,20230628.0,20230706,20230706,EXP,ES-TEVA-2023-ES-2887829,ES-EMD Serono-2023459019,EMD SERONO INC,,62.0,YR,A,F,Y,90.0,KG,20230706,,PH,ES,ES,2023,Q3,Adult
226754091,22675409,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,,,,,,,,,QD,2023,Q3,Somnolence,,2023,Q3,1,I,,20230628.0,20230706,20230706,EXP,ES-TEVA-2023-ES-2887829,ES-EMD Serono-2023459019,EMD SERONO INC,,62.0,YR,A,F,Y,90.0,KG,20230706,,PH,ES,ES,2023,Q3,Adult
226754091,22675409,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,,,,,,,,,QD,2023,Q3,Hypotension,,2023,Q3,1,I,,20230628.0,20230706,20230706,EXP,ES-TEVA-2023-ES-2887829,ES-EMD Serono-2023459019,EMD SERONO INC,,62.0,YR,A,F,Y,90.0,KG,20230706,,PH,ES,ES,2023,Q3,Adult
226754091,22675409,36,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,,,,,,,,,QD,2023,Q3,Hypoglycaemia,,2023,Q3,1,I,,20230628.0,20230706,20230706,EXP,ES-TEVA-2023-ES-2887829,ES-EMD Serono-2023459019,EMD SERONO INC,,62.0,YR,A,F,Y,90.0,KG,20230706,,PH,ES,ES,2023,Q3,Adult
226754091,22675409,36,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,,,,,,,,,QD,2023,Q3,Hallucination,,2023,Q3,1,I,,20230628.0,20230706,20230706,EXP,ES-TEVA-2023-ES-2887829,ES-EMD Serono-2023459019,EMD SERONO INC,,62.0,YR,A,F,Y,90.0,KG,20230706,,PH,ES,ES,2023,Q3,Adult
226754091,22675409,36,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,,,,,,,,,QD,2023,Q3,Parkinsonism,,2023,Q3,1,I,,20230628.0,20230706,20230706,EXP,ES-TEVA-2023-ES-2887829,ES-EMD Serono-2023459019,EMD SERONO INC,,62.0,YR,A,F,Y,90.0,KG,20230706,,PH,ES,ES,2023,Q3,Adult
226754091,22675409,36,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,,,,,,,,,QD,2023,Q3,Somnolence,,2023,Q3,1,I,,20230628.0,20230706,20230706,EXP,ES-TEVA-2023-ES-2887829,ES-EMD Serono-2023459019,EMD SERONO INC,,62.0,YR,A,F,Y,90.0,KG,20230706,,PH,ES,ES,2023,Q3,Adult
226754091,22675409,36,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,,,,,,,,,QD,2023,Q3,Hypotension,,2023,Q3,1,I,,20230628.0,20230706,20230706,EXP,ES-TEVA-2023-ES-2887829,ES-EMD Serono-2023459019,EMD SERONO INC,,62.0,YR,A,F,Y,90.0,KG,20230706,,PH,ES,ES,2023,Q3,Adult
226762221,22676222,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Pulmonary embolism,,2023,Q3,1,I,20230612.0,20230626.0,20230706,20230706,EXP,,ES-ROCHE-3380057,ROCHE,,65.0,YR,,M,Y,77.6,KG,20230706,,MD,ES,,2023,Q3,Elderly
226777311,22677731,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2023,Q3,Lower respiratory tract infection,,2023,Q3,1,I,20230512.0,20230626.0,20230706,20230706,EXP,,FR-FreseniusKabi-FK202307949,FRESENIUS KABI,,75.0,YR,E,F,Y,76.0,KG,20230706,,HP,FR,FR,2023,Q3,Elderly
226777311,22677731,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2023,Q3,Anaemia,,2023,Q3,1,I,20230512.0,20230626.0,20230706,20230706,EXP,,FR-FreseniusKabi-FK202307949,FRESENIUS KABI,,75.0,YR,E,F,Y,76.0,KG,20230706,,HP,FR,FR,2023,Q3,Elderly
226777311,22677731,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2023,Q3,Chills,,2023,Q3,1,I,20230512.0,20230626.0,20230706,20230706,EXP,,FR-FreseniusKabi-FK202307949,FRESENIUS KABI,,75.0,YR,E,F,Y,76.0,KG,20230706,,HP,FR,FR,2023,Q3,Elderly
226777311,22677731,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2023,Q3,Abdominal pain upper,,2023,Q3,1,I,20230512.0,20230626.0,20230706,20230706,EXP,,FR-FreseniusKabi-FK202307949,FRESENIUS KABI,,75.0,YR,E,F,Y,76.0,KG,20230706,,HP,FR,FR,2023,Q3,Elderly
226777311,22677731,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2023,Q3,Off label use,,2023,Q3,1,I,20230512.0,20230626.0,20230706,20230706,EXP,,FR-FreseniusKabi-FK202307949,FRESENIUS KABI,,75.0,YR,E,F,Y,76.0,KG,20230706,,HP,FR,FR,2023,Q3,Elderly
226777311,22677731,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2023,Q3,C-reactive protein increased,,2023,Q3,1,I,20230512.0,20230626.0,20230706,20230706,EXP,,FR-FreseniusKabi-FK202307949,FRESENIUS KABI,,75.0,YR,E,F,Y,76.0,KG,20230706,,HP,FR,FR,2023,Q3,Elderly
226777311,22677731,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2023,Q3,Pneumonia,,2023,Q3,1,I,20230512.0,20230626.0,20230706,20230706,EXP,,FR-FreseniusKabi-FK202307949,FRESENIUS KABI,,75.0,YR,E,F,Y,76.0,KG,20230706,,HP,FR,FR,2023,Q3,Elderly
226777311,22677731,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2023,Q3,Cardiac failure,,2023,Q3,1,I,20230512.0,20230626.0,20230706,20230706,EXP,,FR-FreseniusKabi-FK202307949,FRESENIUS KABI,,75.0,YR,E,F,Y,76.0,KG,20230706,,HP,FR,FR,2023,Q3,Elderly
226777311,22677731,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2023,Q3,Asthenia,,2023,Q3,1,I,20230512.0,20230626.0,20230706,20230706,EXP,,FR-FreseniusKabi-FK202307949,FRESENIUS KABI,,75.0,YR,E,F,Y,76.0,KG,20230706,,HP,FR,FR,2023,Q3,Elderly
226777311,22677731,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2023,Q3,COVID-19,,2023,Q3,1,I,20230512.0,20230626.0,20230706,20230706,EXP,,FR-FreseniusKabi-FK202307949,FRESENIUS KABI,,75.0,YR,E,F,Y,76.0,KG,20230706,,HP,FR,FR,2023,Q3,Elderly
226777311,22677731,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2023,Q3,Cough,,2023,Q3,1,I,20230512.0,20230626.0,20230706,20230706,EXP,,FR-FreseniusKabi-FK202307949,FRESENIUS KABI,,75.0,YR,E,F,Y,76.0,KG,20230706,,HP,FR,FR,2023,Q3,Elderly
226797043,22679704,12,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,Tablets,,2023,Q3,Alanine aminotransferase increased,,2023,Q3,3,F,20230518.0,20230718.0,20230707,20230725,PER,,AU-Eisai Medical Research-EC-2023-143775,EISAI,,78.0,YR,E,M,Y,80.0,KG,20230725,,MD,AU,,2023,Q3,Elderly
226808323,22680832,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Left ventricular dysfunction,,2023,Q3,3,F,,20230724.0,20230707,20230807,EXP,,IT-AUROBINDO-AUR-APL-2023-046480,AUROBINDO,"Valenti C, Moretti G, Copelli S, Cicilia R, Manca F, Cioni E, Gasparini E, Pinto C, Navazio A and Tarantini L.. Teamwork is successful (1): Favoureable re-challenge of double ANTI-HER2 Treatment in severe myocardial dysfunction in patient with Advanced breast cancer and occult type II diabetes.. European Heart Journal, Supplement. 2023;25 (SUP: D):D149-150.",55.0,YR,,F,Y,,,20230807,,HP,IT,IT,2023,Q3,Adult
226808323,22680832,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Off label use,,2023,Q3,3,F,,20230724.0,20230707,20230807,EXP,,IT-AUROBINDO-AUR-APL-2023-046480,AUROBINDO,"Valenti C, Moretti G, Copelli S, Cicilia R, Manca F, Cioni E, Gasparini E, Pinto C, Navazio A and Tarantini L.. Teamwork is successful (1): Favoureable re-challenge of double ANTI-HER2 Treatment in severe myocardial dysfunction in patient with Advanced breast cancer and occult type II diabetes.. European Heart Journal, Supplement. 2023;25 (SUP: D):D149-150.",55.0,YR,,F,Y,,,20230807,,HP,IT,IT,2023,Q3,Adult
226808323,22680832,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Breast cancer,,2023,Q3,3,F,,20230724.0,20230707,20230807,EXP,,IT-AUROBINDO-AUR-APL-2023-046480,AUROBINDO,"Valenti C, Moretti G, Copelli S, Cicilia R, Manca F, Cioni E, Gasparini E, Pinto C, Navazio A and Tarantini L.. Teamwork is successful (1): Favoureable re-challenge of double ANTI-HER2 Treatment in severe myocardial dysfunction in patient with Advanced breast cancer and occult type II diabetes.. European Heart Journal, Supplement. 2023;25 (SUP: D):D149-150.",55.0,YR,,F,Y,,,20230807,,HP,IT,IT,2023,Q3,Adult
226808323,22680832,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Cardiac failure congestive,,2023,Q3,3,F,,20230724.0,20230707,20230807,EXP,,IT-AUROBINDO-AUR-APL-2023-046480,AUROBINDO,"Valenti C, Moretti G, Copelli S, Cicilia R, Manca F, Cioni E, Gasparini E, Pinto C, Navazio A and Tarantini L.. Teamwork is successful (1): Favoureable re-challenge of double ANTI-HER2 Treatment in severe myocardial dysfunction in patient with Advanced breast cancer and occult type II diabetes.. European Heart Journal, Supplement. 2023;25 (SUP: D):D149-150.",55.0,YR,,F,Y,,,20230807,,HP,IT,IT,2023,Q3,Adult
226808323,22680832,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Disease progression,,2023,Q3,3,F,,20230724.0,20230707,20230807,EXP,,IT-AUROBINDO-AUR-APL-2023-046480,AUROBINDO,"Valenti C, Moretti G, Copelli S, Cicilia R, Manca F, Cioni E, Gasparini E, Pinto C, Navazio A and Tarantini L.. Teamwork is successful (1): Favoureable re-challenge of double ANTI-HER2 Treatment in severe myocardial dysfunction in patient with Advanced breast cancer and occult type II diabetes.. European Heart Journal, Supplement. 2023;25 (SUP: D):D149-150.",55.0,YR,,F,Y,,,20230807,,HP,IT,IT,2023,Q3,Adult
226808323,22680832,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Lower respiratory tract infection,,2023,Q3,3,F,,20230724.0,20230707,20230807,EXP,,IT-AUROBINDO-AUR-APL-2023-046480,AUROBINDO,"Valenti C, Moretti G, Copelli S, Cicilia R, Manca F, Cioni E, Gasparini E, Pinto C, Navazio A and Tarantini L.. Teamwork is successful (1): Favoureable re-challenge of double ANTI-HER2 Treatment in severe myocardial dysfunction in patient with Advanced breast cancer and occult type II diabetes.. European Heart Journal, Supplement. 2023;25 (SUP: D):D149-150.",55.0,YR,,F,Y,,,20230807,,HP,IT,IT,2023,Q3,Adult
226808323,22680832,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Intracardiac thrombus,,2023,Q3,3,F,,20230724.0,20230707,20230807,EXP,,IT-AUROBINDO-AUR-APL-2023-046480,AUROBINDO,"Valenti C, Moretti G, Copelli S, Cicilia R, Manca F, Cioni E, Gasparini E, Pinto C, Navazio A and Tarantini L.. Teamwork is successful (1): Favoureable re-challenge of double ANTI-HER2 Treatment in severe myocardial dysfunction in patient with Advanced breast cancer and occult type II diabetes.. European Heart Journal, Supplement. 2023;25 (SUP: D):D149-150.",55.0,YR,,F,Y,,,20230807,,HP,IT,IT,2023,Q3,Adult
226808323,22680832,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Type 2 diabetes mellitus,,2023,Q3,3,F,,20230724.0,20230707,20230807,EXP,,IT-AUROBINDO-AUR-APL-2023-046480,AUROBINDO,"Valenti C, Moretti G, Copelli S, Cicilia R, Manca F, Cioni E, Gasparini E, Pinto C, Navazio A and Tarantini L.. Teamwork is successful (1): Favoureable re-challenge of double ANTI-HER2 Treatment in severe myocardial dysfunction in patient with Advanced breast cancer and occult type II diabetes.. European Heart Journal, Supplement. 2023;25 (SUP: D):D149-150.",55.0,YR,,F,Y,,,20230807,,HP,IT,IT,2023,Q3,Adult
226808323,22680832,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Cardiac ventricular thrombosis,,2023,Q3,3,F,,20230724.0,20230707,20230807,EXP,,IT-AUROBINDO-AUR-APL-2023-046480,AUROBINDO,"Valenti C, Moretti G, Copelli S, Cicilia R, Manca F, Cioni E, Gasparini E, Pinto C, Navazio A and Tarantini L.. Teamwork is successful (1): Favoureable re-challenge of double ANTI-HER2 Treatment in severe myocardial dysfunction in patient with Advanced breast cancer and occult type II diabetes.. European Heart Journal, Supplement. 2023;25 (SUP: D):D149-150.",55.0,YR,,F,Y,,,20230807,,HP,IT,IT,2023,Q3,Adult
226814221,22681422,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,Tablet,,2023,Q3,Diabetic complication,,2023,Q3,1,I,20230705.0,20230707.0,20230707,20230707,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-248415",BOEHRINGER INGELHEIM,,74.0,YR,E,M,Y,,,20230707,,HP,GB,GB,2023,Q3,Elderly
226814221,22681422,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,Tablet,,2023,Q3,Medication error,,2023,Q3,1,I,20230705.0,20230707.0,20230707,20230707,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-248415",BOEHRINGER INGELHEIM,,74.0,YR,E,M,Y,,,20230707,,HP,GB,GB,2023,Q3,Elderly
226832011,22683201,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Sinus bradycardia,,2023,Q3,1,I,20230607.0,20230628.0,20230707,20230707,EXP,FR-AFSSAPS-RE2023000549,FR-TEVA-2023-FR-2903800,TEVA,,92.0,YR,E,F,Y,63.0,KG,20230707,,MD,FR,FR,2023,Q3,Elderly
226832011,22683201,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Overdose,,2023,Q3,1,I,20230607.0,20230628.0,20230707,20230707,EXP,FR-AFSSAPS-RE2023000549,FR-TEVA-2023-FR-2903800,TEVA,,92.0,YR,E,F,Y,63.0,KG,20230707,,MD,FR,FR,2023,Q3,Elderly
226844822,22684482,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1T/Morning",,,U,,,,,10.0,MG,Tablet,QD,2023,Q3,Glomerular filtration rate decreased,,2023,Q3,2,F,,20230722.0,20230710,20230725,EXP,,NVSJ2023JP010720,NOVARTIS,,76.0,YR,,F,Y,57.8,KG,20230726,,MD,JP,JP,2023,Q3,Elderly
226844822,22684482,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1T/Morning",,,U,,,,,10.0,MG,Tablet,QD,2023,Q3,Aortic valve incompetence,,2023,Q3,2,F,,20230722.0,20230710,20230725,EXP,,NVSJ2023JP010720,NOVARTIS,,76.0,YR,,F,Y,57.8,KG,20230726,,MD,JP,JP,2023,Q3,Elderly
226844822,22684482,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1T/Morning",,,U,,,,,10.0,MG,Tablet,QD,2023,Q3,Dyspnoea exertional,,2023,Q3,2,F,,20230722.0,20230710,20230725,EXP,,NVSJ2023JP010720,NOVARTIS,,76.0,YR,,F,Y,57.8,KG,20230726,,MD,JP,JP,2023,Q3,Elderly
226846202,22684620,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Diabetic metabolic decompensation,,2023,Q3,2,F,,20230712.0,20230710,20230725,EXP,,PL-AUROBINDO-AUR-APL-2023-046036,AUROBINDO,Naskret D.. Empagliflozin in the treatment of type 2 diabetes. THE WORLD OF MEDICINE AND PHARMACY. 2023;260(5):14-20,68.0,YR,,M,Y,81.0,KG,20230725,,MD,PL,PL,2023,Q3,Elderly
226846202,22684620,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Atrial fibrillation,,2023,Q3,2,F,,20230712.0,20230710,20230725,EXP,,PL-AUROBINDO-AUR-APL-2023-046036,AUROBINDO,Naskret D.. Empagliflozin in the treatment of type 2 diabetes. THE WORLD OF MEDICINE AND PHARMACY. 2023;260(5):14-20,68.0,YR,,M,Y,81.0,KG,20230725,,MD,PL,PL,2023,Q3,Elderly
226846202,22684620,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Weight increased,,2023,Q3,2,F,,20230712.0,20230710,20230725,EXP,,PL-AUROBINDO-AUR-APL-2023-046036,AUROBINDO,Naskret D.. Empagliflozin in the treatment of type 2 diabetes. THE WORLD OF MEDICINE AND PHARMACY. 2023;260(5):14-20,68.0,YR,,M,Y,81.0,KG,20230725,,MD,PL,PL,2023,Q3,Elderly
226846202,22684620,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Cardiac failure,,2023,Q3,2,F,,20230712.0,20230710,20230725,EXP,,PL-AUROBINDO-AUR-APL-2023-046036,AUROBINDO,Naskret D.. Empagliflozin in the treatment of type 2 diabetes. THE WORLD OF MEDICINE AND PHARMACY. 2023;260(5):14-20,68.0,YR,,M,Y,81.0,KG,20230725,,MD,PL,PL,2023,Q3,Elderly
226846202,22684620,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Medication error,,2023,Q3,2,F,,20230712.0,20230710,20230725,EXP,,PL-AUROBINDO-AUR-APL-2023-046036,AUROBINDO,Naskret D.. Empagliflozin in the treatment of type 2 diabetes. THE WORLD OF MEDICINE AND PHARMACY. 2023;260(5):14-20,68.0,YR,,M,Y,81.0,KG,20230725,,MD,PL,PL,2023,Q3,Elderly
226846202,22684620,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Intentional product misuse,,2023,Q3,2,F,,20230712.0,20230710,20230725,EXP,,PL-AUROBINDO-AUR-APL-2023-046036,AUROBINDO,Naskret D.. Empagliflozin in the treatment of type 2 diabetes. THE WORLD OF MEDICINE AND PHARMACY. 2023;260(5):14-20,68.0,YR,,M,Y,81.0,KG,20230725,,MD,PL,PL,2023,Q3,Elderly
226856231,22685623,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 dosage form, qd",,,U,,,,,,,Tablet,,2023,Q3,Hypoglycaemia,,2023,Q3,1,I,,20220816.0,20230710,20230710,PER,,US-APOTEX-2022AP011433,APOTEX,"Meyer KS, Roberts J, Sasser Croley K.. Identifying, Managing, and Preventing Adverse Effects of Diabetes Medications. The Senior Care Pharmacist. 2022;37(8):310-316",81.0,YR,,F,Y,,,20230710,,PH,US,US,2023,Q3,Elderly
226856231,22685623,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 dosage form, qd",,,U,,,,,,,Tablet,,2023,Q3,Fall,,2023,Q3,1,I,,20220816.0,20230710,20230710,PER,,US-APOTEX-2022AP011433,APOTEX,"Meyer KS, Roberts J, Sasser Croley K.. Identifying, Managing, and Preventing Adverse Effects of Diabetes Medications. The Senior Care Pharmacist. 2022;37(8):310-316",81.0,YR,,F,Y,,,20230710,,PH,US,US,2023,Q3,Elderly
226865511,22686551,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Cardiac failure chronic,,2023,Q3,1,I,,20230710.0,20230710,20230710,EXP,,"CZ-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-248598",BOEHRINGER INGELHEIM,"Melenovsk? V. XXXI Annual Congress of the Czech Society of Cardiology including the Heart Failure Symposium for Practice, organized by Boehringer Ingelheim. Srde?n? selh?n? v praxi, in Medical Tribune. 2023;XIX (12):C2-C3.",78.0,YR,E,M,Y,99.0,KG,20230710,,MD,CZ,CZ,2023,Q3,Elderly
226875991,22687599,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 Milligram Daily;,,,,,,,,25.0,MG,,QD,2023,Q3,Hyperthyroidism,,2023,Q3,1,I,,20230703.0,20230710,20230710,EXP,,US-TEVA-2023-US-2904501,TEVA,,61.0,YR,A,F,Y,,,20230710,,HP,US,US,2023,Q3,Adult
226875991,22687599,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 Milligram Daily;,,,,,,,,25.0,MG,,QD,2023,Q3,Osteoporosis,,2023,Q3,1,I,,20230703.0,20230710,20230710,EXP,,US-TEVA-2023-US-2904501,TEVA,,61.0,YR,A,F,Y,,,20230710,,HP,US,US,2023,Q3,Adult
226879872,22687987,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Pulmonary hypertension,,2023,Q3,2,F,20171201.0,20230715.0,20230710,20230724,EXP,,CZ-MYLANLABS-2023M1072109,MYLAN,Svarcova T. Dapagliflozin in the treatment of heart failure with preserved ejection fraction. INTERNAL MEDICINE. 2023;69(4):261-264,72.0,YR,,M,Y,,,20230724,,MD,CZ,CZ,2023,Q3,Elderly
226879872,22687987,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Drug intolerance,,2023,Q3,2,F,20171201.0,20230715.0,20230710,20230724,EXP,,CZ-MYLANLABS-2023M1072109,MYLAN,Svarcova T. Dapagliflozin in the treatment of heart failure with preserved ejection fraction. INTERNAL MEDICINE. 2023;69(4):261-264,72.0,YR,,M,Y,,,20230724,,MD,CZ,CZ,2023,Q3,Elderly
226879872,22687987,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Bradycardia,,2023,Q3,2,F,20171201.0,20230715.0,20230710,20230724,EXP,,CZ-MYLANLABS-2023M1072109,MYLAN,Svarcova T. Dapagliflozin in the treatment of heart failure with preserved ejection fraction. INTERNAL MEDICINE. 2023;69(4):261-264,72.0,YR,,M,Y,,,20230724,,MD,CZ,CZ,2023,Q3,Elderly
226879872,22687987,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Cardiac failure,,2023,Q3,2,F,20171201.0,20230715.0,20230710,20230724,EXP,,CZ-MYLANLABS-2023M1072109,MYLAN,Svarcova T. Dapagliflozin in the treatment of heart failure with preserved ejection fraction. INTERNAL MEDICINE. 2023;69(4):261-264,72.0,YR,,M,Y,,,20230724,,MD,CZ,CZ,2023,Q3,Elderly
226896791,22689679,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Eye infection,,2023,Q3,1,I,,20230706.0,20230711,20230711,EXP,,CA-ROCHE-3383581,ROCHE,,71.0,YR,,F,Y,,,20230711,,HP,CA,,2023,Q3,Elderly
226896791,22689679,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Aphthous ulcer,,2023,Q3,1,I,,20230706.0,20230711,20230711,EXP,,CA-ROCHE-3383581,ROCHE,,71.0,YR,,F,Y,,,20230711,,HP,CA,,2023,Q3,Elderly
226896791,22689679,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Viral infection,,2023,Q3,1,I,,20230706.0,20230711,20230711,EXP,,CA-ROCHE-3383581,ROCHE,,71.0,YR,,F,Y,,,20230711,,HP,CA,,2023,Q3,Elderly
226896791,22689679,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Corneal infection,,2023,Q3,1,I,,20230706.0,20230711,20230711,EXP,,CA-ROCHE-3383581,ROCHE,,71.0,YR,,F,Y,,,20230711,,HP,CA,,2023,Q3,Elderly
226900082,22690008,6,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,UNK,,,,,,,,,,,,2023,Q3,Anaphylactic shock,,2023,Q3,2,F,20230701.0,20230731.0,20230711,20230802,EXP,,JP-GILEAD-2023-0634854,GILEAD,,86.0,YR,E,M,Y,63.8,KG,20230802,,PH,JP,JP,2023,Q3,Elderly
226916131,22691613,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,D,,,,,25.0,MG,,,2023,Q3,Osteoporosis,,2023,Q3,1,I,20210101.0,20230630.0,20230711,20230711,EXP,,US-APOTEX-2023AP010127,APOTEX,"McKeirnan KC, Anderson CB, Powell AJ, Gilbert R, Undeberg MR.. The Role of the Pharmacist in Patient Self-Advocacy for Osteoporosis Screening. THE SENIOR CARE PHARMACIST. 2022;37(12):612-622",61.0,YR,,F,Y,,,20230711,,PH,US,US,2023,Q3,Adult
226916131,22691613,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,D,,,,,25.0,MG,,,2023,Q3,Vomiting,,2023,Q3,1,I,20210101.0,20230630.0,20230711,20230711,EXP,,US-APOTEX-2023AP010127,APOTEX,"McKeirnan KC, Anderson CB, Powell AJ, Gilbert R, Undeberg MR.. The Role of the Pharmacist in Patient Self-Advocacy for Osteoporosis Screening. THE SENIOR CARE PHARMACIST. 2022;37(12):612-622",61.0,YR,,F,Y,,,20230711,,PH,US,US,2023,Q3,Adult
226916131,22691613,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,D,,,,,25.0,MG,,,2023,Q3,Anaphylactic reaction,,2023,Q3,1,I,20210101.0,20230630.0,20230711,20230711,EXP,,US-APOTEX-2023AP010127,APOTEX,"McKeirnan KC, Anderson CB, Powell AJ, Gilbert R, Undeberg MR.. The Role of the Pharmacist in Patient Self-Advocacy for Osteoporosis Screening. THE SENIOR CARE PHARMACIST. 2022;37(12):612-622",61.0,YR,,F,Y,,,20230711,,PH,US,US,2023,Q3,Adult
226916131,22691613,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,D,,,,,25.0,MG,,,2023,Q3,Nausea,,2023,Q3,1,I,20210101.0,20230630.0,20230711,20230711,EXP,,US-APOTEX-2023AP010127,APOTEX,"McKeirnan KC, Anderson CB, Powell AJ, Gilbert R, Undeberg MR.. The Role of the Pharmacist in Patient Self-Advocacy for Osteoporosis Screening. THE SENIOR CARE PHARMACIST. 2022;37(12):612-622",61.0,YR,,F,Y,,,20230711,,PH,US,US,2023,Q3,Adult
226920182,22692018,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,Tablets,,2023,Q3,Pleural effusion,,2023,Q3,2,F,20230621.0,20230713.0,20230711,20230720,EXP,,CN-Eisai Medical Research-EC-2023-144147,EISAI,,69.0,YR,E,F,Y,60.0,KG,20230720,,MD,CN,,2023,Q3,Elderly
226922631,22692263,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q3,Pyrexia,,2023,Q3,1,I,20230703.0,20230705.0,20230711,20230711,EXP,,AU-SA-2023SA206212,SANOFI AVENTIS,,63.0,YR,A,M,Y,,,20230711,,MD,AU,AU,2023,Q3,Adult
226939431,22693943,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2023,Q3,Lactic acidosis,,2023,Q3,1,I,,20230703.0,20230711,20230711,EXP,,ES-MYLANLABS-2023M1071730,MYLAN,"Soto Telles A, Prudencio Rodr?guez A, Hern?ndez Gonz?lez C, Higueras S?nchez C, Hijar Jim?nez R, Guerrero Deleg J.. My mother does not eat, doctor. 2023;777-777",81.0,YR,,F,Y,,,20230711,,HP,ES,ES,2023,Q3,Elderly
226939431,22693943,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2023,Q3,Hyperkalaemia,,2023,Q3,1,I,,20230703.0,20230711,20230711,EXP,,ES-MYLANLABS-2023M1071730,MYLAN,"Soto Telles A, Prudencio Rodr?guez A, Hern?ndez Gonz?lez C, Higueras S?nchez C, Hijar Jim?nez R, Guerrero Deleg J.. My mother does not eat, doctor. 2023;777-777",81.0,YR,,F,Y,,,20230711,,HP,ES,ES,2023,Q3,Elderly
226939431,22693943,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2023,Q3,Renal failure,,2023,Q3,1,I,,20230703.0,20230711,20230711,EXP,,ES-MYLANLABS-2023M1071730,MYLAN,"Soto Telles A, Prudencio Rodr?guez A, Hern?ndez Gonz?lez C, Higueras S?nchez C, Hijar Jim?nez R, Guerrero Deleg J.. My mother does not eat, doctor. 2023;777-777",81.0,YR,,F,Y,,,20230711,,HP,ES,ES,2023,Q3,Elderly
226952761,22695276,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q3,Pruritus,,2023,Q3,1,I,20230612.0,20230711.0,20230712,20230712,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-248950",BOEHRINGER INGELHEIM,,71.0,YR,E,M,Y,,,20230712,,HP,SG,SG,2023,Q3,Elderly
226953461,22695346,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q3,Fournier's gangrene,,2023,Q3,1,I,,20230712.0,20230712,20230712,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-249104",BOEHRINGER INGELHEIM,,43.0,YR,A,M,Y,,,20230712,,CN,AU,AU,2023,Q3,Adult
226956691,22695669,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q3,Diabetic metabolic decompensation,,2023,Q3,1,I,,20230626.0,20230712,20230712,EXP,,PL-SANDOZ INC.-SDZ2023PL000068,SANDOZ,,68.0,YR,,M,Y,81.0,KG,20230711,,HP,PL,PL,2023,Q3,Elderly
226956691,22695669,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q3,Intentional product misuse,,2023,Q3,1,I,,20230626.0,20230712,20230712,EXP,,PL-SANDOZ INC.-SDZ2023PL000068,SANDOZ,,68.0,YR,,M,Y,81.0,KG,20230711,,HP,PL,PL,2023,Q3,Elderly
226956691,22695669,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q3,Cardiac failure,,2023,Q3,1,I,,20230626.0,20230712,20230712,EXP,,PL-SANDOZ INC.-SDZ2023PL000068,SANDOZ,,68.0,YR,,M,Y,81.0,KG,20230711,,HP,PL,PL,2023,Q3,Elderly
226956691,22695669,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q3,Weight increased,,2023,Q3,1,I,,20230626.0,20230712,20230712,EXP,,PL-SANDOZ INC.-SDZ2023PL000068,SANDOZ,,68.0,YR,,M,Y,81.0,KG,20230711,,HP,PL,PL,2023,Q3,Elderly
226956691,22695669,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q3,Atrial fibrillation,,2023,Q3,1,I,,20230626.0,20230712,20230712,EXP,,PL-SANDOZ INC.-SDZ2023PL000068,SANDOZ,,68.0,YR,,M,Y,81.0,KG,20230711,,HP,PL,PL,2023,Q3,Elderly
226982292,22698229,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Haemodynamic instability,,2023,Q3,2,F,,20230725.0,20230712,20230731,EXP,,GR-MYLANLABS-2023M1073207,MYLAN,,70.0,YR,,F,Y,,,20230731,,MD,GR,GR,2023,Q3,Elderly
226982292,22698229,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Euglycaemic diabetic ketoacidosis,,2023,Q3,2,F,,20230725.0,20230712,20230731,EXP,,GR-MYLANLABS-2023M1073207,MYLAN,,70.0,YR,,F,Y,,,20230731,,MD,GR,GR,2023,Q3,Elderly
226982292,22698229,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Diarrhoea,,2023,Q3,2,F,,20230725.0,20230712,20230731,EXP,,GR-MYLANLABS-2023M1073207,MYLAN,,70.0,YR,,F,Y,,,20230731,,MD,GR,GR,2023,Q3,Elderly
226982292,22698229,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Acute kidney injury,,2023,Q3,2,F,,20230725.0,20230712,20230731,EXP,,GR-MYLANLABS-2023M1073207,MYLAN,,70.0,YR,,F,Y,,,20230731,,MD,GR,GR,2023,Q3,Elderly
226983771,22698377,9,C,JARDIANCE 10 mg film-coated tablets[EMPAGLIFLOZINE],,2,Oral,,,,U,,,,,,,,QD,2023,Q3,Ischaemic stroke,,2023,Q3,1,I,20230505.0,20230704.0,20230712,20230712,EXP,FR-AFSSAPS-NY2023000885,FR-FreseniusKabi-FK202310163,FRESENIUS KABI,,72.0,YR,A,F,Y,,,20230712,,PH,FR,FR,2023,Q3,Elderly
226990022,22699002,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,Y,,Unknown,,206111.0,,,,,2023,Q3,Diarrhoea,,2023,Q3,2,F,,20230725.0,20230713,20230801,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-248200",BOEHRINGER INGELHEIM,"Papanikolaou D. 49th Annual Panhellenic Medical congress. 11-13 May 2023, Divani Caravel Hotel, Athens. 2023 May;",70.0,YR,E,F,Y,,,20230801,,MD,GR,GR,2023,Q3,Elderly
226990022,22699002,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,Y,,Unknown,,206111.0,,,,,2023,Q3,Anuria,,2023,Q3,2,F,,20230725.0,20230713,20230801,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-248200",BOEHRINGER INGELHEIM,"Papanikolaou D. 49th Annual Panhellenic Medical congress. 11-13 May 2023, Divani Caravel Hotel, Athens. 2023 May;",70.0,YR,E,F,Y,,,20230801,,MD,GR,GR,2023,Q3,Elderly
226990022,22699002,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,Y,,Unknown,,206111.0,,,,,2023,Q3,Haemodynamic instability,,2023,Q3,2,F,,20230725.0,20230713,20230801,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-248200",BOEHRINGER INGELHEIM,"Papanikolaou D. 49th Annual Panhellenic Medical congress. 11-13 May 2023, Divani Caravel Hotel, Athens. 2023 May;",70.0,YR,E,F,Y,,,20230801,,MD,GR,GR,2023,Q3,Elderly
226990022,22699002,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,Y,,Unknown,,206111.0,,,,,2023,Q3,Euglycaemic diabetic ketoacidosis,,2023,Q3,2,F,,20230725.0,20230713,20230801,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-248200",BOEHRINGER INGELHEIM,"Papanikolaou D. 49th Annual Panhellenic Medical congress. 11-13 May 2023, Divani Caravel Hotel, Athens. 2023 May;",70.0,YR,E,F,Y,,,20230801,,MD,GR,GR,2023,Q3,Elderly
227010751,22701075,9,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"10 mg, QD (1x1 to be initiated)",,,,,,,,10.0,MG,,QD,2023,Q3,Disease progression,,2023,Q3,1,I,,20230705.0,20230713,20230713,EXP,,HR-MYLANLABS-2023M1072592,MYLAN,,68.0,YR,,M,Y,91.0,KG,20230713,,MD,HR,HR,2023,Q3,Elderly
227010751,22701075,9,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"10 mg, QD (1x1 to be initiated)",,,,,,,,10.0,MG,,QD,2023,Q3,Cardiac failure,,2023,Q3,1,I,,20230705.0,20230713,20230713,EXP,,HR-MYLANLABS-2023M1072592,MYLAN,,68.0,YR,,M,Y,91.0,KG,20230713,,MD,HR,HR,2023,Q3,Elderly
227010821,22701082,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Back pain,,2023,Q3,1,I,20220908.0,20230705.0,20230713,20230713,EXP,IT-MINISAL02-932172,IT-MYLANLABS-2023M1072627,MYLAN,,65.0,YR,,M,Y,,,20230713,,MD,IT,IT,2023,Q3,Elderly
227010821,22701082,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Spinal fracture,,2023,Q3,1,I,20220908.0,20230705.0,20230713,20230713,EXP,IT-MINISAL02-932172,IT-MYLANLABS-2023M1072627,MYLAN,,65.0,YR,,M,Y,,,20230713,,MD,IT,IT,2023,Q3,Elderly
227024081,22702408,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Swelling face,,2023,Q3,1,I,,20230703.0,20230713,20230713,EXP,,CA-FreseniusKabi-FK202310189,FRESENIUS KABI,,71.0,YR,E,M,Y,,,20230713,,PH,CA,CA,2023,Q3,Elderly
227024081,22702408,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Rash,,2023,Q3,1,I,,20230703.0,20230713,20230713,EXP,,CA-FreseniusKabi-FK202310189,FRESENIUS KABI,,71.0,YR,E,M,Y,,,20230713,,PH,CA,CA,2023,Q3,Elderly
227024081,22702408,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Throat tightness,,2023,Q3,1,I,,20230703.0,20230713,20230713,EXP,,CA-FreseniusKabi-FK202310189,FRESENIUS KABI,,71.0,YR,E,M,Y,,,20230713,,PH,CA,CA,2023,Q3,Elderly
227044961,22704496,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q3,Spinal fracture,,2023,Q3,1,I,20220908.0,20230704.0,20230714,20230714,EXP,IT-MINISAL02-932172,IT-TEVA-2023-IT-2905125,TEVA,,65.0,YR,E,M,Y,,,20230714,,MD,IT,IT,2023,Q3,Elderly
227044961,22704496,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q3,Back pain,,2023,Q3,1,I,20220908.0,20230704.0,20230714,20230714,EXP,IT-MINISAL02-932172,IT-TEVA-2023-IT-2905125,TEVA,,65.0,YR,E,M,Y,,,20230714,,MD,IT,IT,2023,Q3,Elderly
227048631,22704863,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Unknown,,204629.0,10.0,MG,,QD,2023,Q3,Polydipsia,,2023,Q3,1,I,20230210.0,20230714.0,20230714,20230714,EXP,ES-AEMPS-1378095,"ES-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-249619",BOEHRINGER INGELHEIM,,88.0,YR,E,F,Y,,,20230714,,PH,ES,ES,2023,Q3,Elderly
227048631,22704863,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Unknown,,204629.0,10.0,MG,,QD,2023,Q3,Polyuria,,2023,Q3,1,I,20230210.0,20230714.0,20230714,20230714,EXP,ES-AEMPS-1378095,"ES-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-249619",BOEHRINGER INGELHEIM,,88.0,YR,E,F,Y,,,20230714,,PH,ES,ES,2023,Q3,Elderly
227048631,22704863,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Unknown,,204629.0,10.0,MG,,QD,2023,Q3,Weight decreased,,2023,Q3,1,I,20230210.0,20230714.0,20230714,20230714,EXP,ES-AEMPS-1378095,"ES-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-249619",BOEHRINGER INGELHEIM,,88.0,YR,E,F,Y,,,20230714,,PH,ES,ES,2023,Q3,Elderly
227057281,22705728,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,,,Unknown,,206073.0,,,Tablet,QD,2023,Q3,Cholangitis,,2023,Q3,1,I,20230524.0,20230713.0,20230714,20230714,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-240320",BOEHRINGER INGELHEIM,,91.0,YR,E,M,Y,,,20230714,,PH,JP,JP,2023,Q3,Elderly
227068331,22706833,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,UNKNOWN,,,,,,,2023,Q3,Decreased appetite,,2023,Q3,1,I,20230620.0,20230710.0,20230714,20230714,EXP,,"DE-REGENERON PHARMACEUTICALS, INC.-2023-082835",REGENERON,,82.0,YR,,F,Y,,,20230714,,HP,DE,DE,2023,Q3,Elderly
227068331,22706833,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,UNKNOWN,,,,,,,2023,Q3,Weight decreased,,2023,Q3,1,I,20230620.0,20230710.0,20230714,20230714,EXP,,"DE-REGENERON PHARMACEUTICALS, INC.-2023-082835",REGENERON,,82.0,YR,,F,Y,,,20230714,,HP,DE,DE,2023,Q3,Elderly
227068331,22706833,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,UNKNOWN,,,,,,,2023,Q3,Dehydration,,2023,Q3,1,I,20230620.0,20230710.0,20230714,20230714,EXP,,"DE-REGENERON PHARMACEUTICALS, INC.-2023-082835",REGENERON,,82.0,YR,,F,Y,,,20230714,,HP,DE,DE,2023,Q3,Elderly
227068331,22706833,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,UNKNOWN,,,,,,,2023,Q3,Condition aggravated,,2023,Q3,1,I,20230620.0,20230710.0,20230714,20230714,EXP,,"DE-REGENERON PHARMACEUTICALS, INC.-2023-082835",REGENERON,,82.0,YR,,F,Y,,,20230714,,HP,DE,DE,2023,Q3,Elderly
227086341,22708634,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg film-coated tablets,,,,,,,,,,Film-coated tablet,,2023,Q3,Dyspnoea,,2023,Q3,1,I,20230401.0,20230704.0,20230716,20230716,EXP,FR-AFSSAPS-AM2023000455,FR-Accord-367258,ACCORD,,62.0,YR,A,F,Y,47.0,KG,20230715,,MD,FR,FR,2023,Q3,Adult
227086341,22708634,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg film-coated tablets,,,,,,,,,,Film-coated tablet,,2023,Q3,Cardio-respiratory arrest,,2023,Q3,1,I,20230401.0,20230704.0,20230716,20230716,EXP,FR-AFSSAPS-AM2023000455,FR-Accord-367258,ACCORD,,62.0,YR,A,F,Y,47.0,KG,20230715,,MD,FR,FR,2023,Q3,Adult
227099633,22709963,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q3,Atrial flutter,,2023,Q3,3,F,20230522.0,20230717.0,20230717,20230719,EXP,,CA-ABBVIE-5328429,ABBVIE,,69.0,YR,,M,Y,,,20230719,,MD,CA,CA,2023,Q3,Elderly
227107022,22710702,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,Tablets,,2023,Q3,Pneumonia,,2023,Q3,2,F,20230630.0,20230717.0,20230717,20230724,EXP,,US-Eisai Medical Research-EC-2023-144160,EISAI,,62.0,YR,A,F,Y,105.7,KG,20230724,,MD,US,,2023,Q3,Adult
227107022,22710702,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,Tablets,,2023,Q3,Clostridium difficile infection,,2023,Q3,2,F,20230630.0,20230717.0,20230717,20230724,EXP,,US-Eisai Medical Research-EC-2023-144160,EISAI,,62.0,YR,A,F,Y,105.7,KG,20230724,,MD,US,,2023,Q3,Adult
227107022,22710702,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,Tablets,,2023,Q3,Diarrhoea,,2023,Q3,2,F,20230630.0,20230717.0,20230717,20230724,EXP,,US-Eisai Medical Research-EC-2023-144160,EISAI,,62.0,YR,A,F,Y,105.7,KG,20230724,,MD,US,,2023,Q3,Adult
227107022,22710702,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,Tablets,,2023,Q3,Hypoxia,,2023,Q3,2,F,20230630.0,20230717.0,20230717,20230724,EXP,,US-Eisai Medical Research-EC-2023-144160,EISAI,,62.0,YR,A,F,Y,105.7,KG,20230724,,MD,US,,2023,Q3,Adult
227107022,22710702,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,Tablets,,2023,Q3,Dehydration,,2023,Q3,2,F,20230630.0,20230717.0,20230717,20230724,EXP,,US-Eisai Medical Research-EC-2023-144160,EISAI,,62.0,YR,A,F,Y,105.7,KG,20230724,,MD,US,,2023,Q3,Adult
227107022,22710702,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,Tablets,,2023,Q3,Chronic obstructive pulmonary disease,,2023,Q3,2,F,20230630.0,20230717.0,20230717,20230724,EXP,,US-Eisai Medical Research-EC-2023-144160,EISAI,,62.0,YR,A,F,Y,105.7,KG,20230724,,MD,US,,2023,Q3,Adult
227107022,22710702,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,Tablets,,2023,Q3,Norovirus infection,,2023,Q3,2,F,20230630.0,20230717.0,20230717,20230724,EXP,,US-Eisai Medical Research-EC-2023-144160,EISAI,,62.0,YR,A,F,Y,105.7,KG,20230724,,MD,US,,2023,Q3,Adult
227124262,22712426,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,25.0,MG,Tablet,,2023,Q3,Inappropriate schedule of product administration,,2023,Q3,2,F,,20230828.0,20230717,20230910,EXP,CA-MHPD-E2B_06307631,CA-Accord-366639,ACCORD,,42.0,YR,A,M,Y,,,20230908,,CN,CA,CA,2023,Q3,Adult
227124262,22712426,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,25.0,MG,Tablet,,2023,Q3,Substance use,,2023,Q3,2,F,,20230828.0,20230717,20230910,EXP,CA-MHPD-E2B_06307631,CA-Accord-366639,ACCORD,,42.0,YR,A,M,Y,,,20230908,,CN,CA,CA,2023,Q3,Adult
227124262,22712426,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,25.0,MG,Tablet,,2023,Q3,Psychotic disorder,,2023,Q3,2,F,,20230828.0,20230717,20230910,EXP,CA-MHPD-E2B_06307631,CA-Accord-366639,ACCORD,,42.0,YR,A,M,Y,,,20230908,,CN,CA,CA,2023,Q3,Adult
227124262,22712426,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,25.0,MG,Tablet,,2023,Q3,Aggression,,2023,Q3,2,F,,20230828.0,20230717,20230910,EXP,CA-MHPD-E2B_06307631,CA-Accord-366639,ACCORD,,42.0,YR,A,M,Y,,,20230908,,CN,CA,CA,2023,Q3,Adult
227124262,22712426,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,25.0,MG,Tablet,,2023,Q3,Product dose omission issue,,2023,Q3,2,F,,20230828.0,20230717,20230910,EXP,CA-MHPD-E2B_06307631,CA-Accord-366639,ACCORD,,42.0,YR,A,M,Y,,,20230908,,CN,CA,CA,2023,Q3,Adult
227126391,22712639,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2023,Q3,Euglycaemic diabetic ketoacidosis,,2023,Q3,1,I,,20230712.0,20230717,20230717,EXP,,"CH-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-249210",BOEHRINGER INGELHEIM,"Massie E, Nzomessia D, Garianib K, Giraudc R, Meyera P. Combined lactic acidosis and ketoacidosis in a female diabetic patient with severe heart failure. Cardiovascular Endocrinology + Metabolism. 2023;12:3: 0287-doi:10.1097/XCE.0000000000000287.",58.0,YR,A,F,Y,,,20230717,,MD,CH,CH,2023,Q3,Adult
227126391,22712639,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2023,Q3,Lactic acidosis,,2023,Q3,1,I,,20230712.0,20230717,20230717,EXP,,"CH-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-249210",BOEHRINGER INGELHEIM,"Massie E, Nzomessia D, Garianib K, Giraudc R, Meyera P. Combined lactic acidosis and ketoacidosis in a female diabetic patient with severe heart failure. Cardiovascular Endocrinology + Metabolism. 2023;12:3: 0287-doi:10.1097/XCE.0000000000000287.",58.0,YR,A,F,Y,,,20230717,,MD,CH,CH,2023,Q3,Adult
227134412,22713441,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,,,,,,10.0,MG,,,2023,Q3,Neutropenia,,2023,Q3,2,F,20230306.0,20230717.0,20230717,20230724,EXP,,DE-MYLANLABS-2023M1074171,MYLAN,,78.0,YR,,M,Y,76.0,KG,20230724,,MD,DE,DE,2023,Q3,Elderly
227134412,22713441,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,,,,,,10.0,MG,,,2023,Q3,Anaemia,,2023,Q3,2,F,20230306.0,20230717.0,20230717,20230724,EXP,,DE-MYLANLABS-2023M1074171,MYLAN,,78.0,YR,,M,Y,76.0,KG,20230724,,MD,DE,DE,2023,Q3,Elderly
227134412,22713441,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,,,,,,10.0,MG,,,2023,Q3,Mucosal inflammation,,2023,Q3,2,F,20230306.0,20230717.0,20230717,20230724,EXP,,DE-MYLANLABS-2023M1074171,MYLAN,,78.0,YR,,M,Y,76.0,KG,20230724,,MD,DE,DE,2023,Q3,Elderly
227134412,22713441,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,,,,,,10.0,MG,,,2023,Q3,Thrombocytopenia,,2023,Q3,2,F,20230306.0,20230717.0,20230717,20230724,EXP,,DE-MYLANLABS-2023M1074171,MYLAN,,78.0,YR,,M,Y,76.0,KG,20230724,,MD,DE,DE,2023,Q3,Elderly
227153221,22715322,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Rash,,2023,Q3,1,I,20230615.0,20230717.0,20230718,20230718,EXP,,IT-ROCHE-3389341,ROCHE,,64.0,YR,,M,Y,89.0,KG,20230718,,MD,IT,,2023,Q3,Adult
227170963,22717096,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q3,Acute kidney injury,,2023,Q3,3,F,20230514.0,20230817.0,20230718,20230823,EXP,,CA-ABBVIE-5330108,ABBVIE,,69.0,YR,,M,Y,,,20230821,,MD,CA,CA,2023,Q3,Elderly
227172951,22717295,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2023,Q3,Decreased appetite,,2023,Q3,1,I,20230620.0,20230711.0,20230718,20230718,EXP,,DE-MYLANLABS-2023M1074317,MYLAN,,82.0,YR,,F,Y,62.0,KG,20230718,,HP,DE,DE,2023,Q3,Elderly
227172951,22717295,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2023,Q3,General physical health deterioration,,2023,Q3,1,I,20230620.0,20230711.0,20230718,20230718,EXP,,DE-MYLANLABS-2023M1074317,MYLAN,,82.0,YR,,F,Y,62.0,KG,20230718,,HP,DE,DE,2023,Q3,Elderly
227172951,22717295,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2023,Q3,Weight decreased,,2023,Q3,1,I,20230620.0,20230711.0,20230718,20230718,EXP,,DE-MYLANLABS-2023M1074317,MYLAN,,82.0,YR,,F,Y,62.0,KG,20230718,,HP,DE,DE,2023,Q3,Elderly
227172951,22717295,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2023,Q3,Dehydration,,2023,Q3,1,I,20230620.0,20230711.0,20230718,20230718,EXP,,DE-MYLANLABS-2023M1074317,MYLAN,,82.0,YR,,F,Y,62.0,KG,20230718,,HP,DE,DE,2023,Q3,Elderly
227177051,22717705,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Daily",,,U,,,,,25.0,MG,,,2023,Q3,Euglycaemic diabetic ketoacidosis,,2023,Q3,1,I,,20230703.0,20230718,20230718,EXP,,SA-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-399828,RANBAXY,"Alduraibi RK, Alrebdi YM, Altowayan YF. Euglycemic diabetic ketoacidosis after the initiation of dulaglutide in patient with type 2 diabetes. Medicine. 2023;102(23):e34027(1-3)",45.0,YR,,M,Y,,,20230718,,MD,SA,SA,2023,Q3,Adult
227208762,22720876,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q3,Endocarditis,,2023,Q3,2,F,20230421.0,20230717.0,20230719,20230719,EXP,,CA-ABBVIE-5330762,ABBVIE,,69.0,YR,,M,Y,,,20230719,,MD,CA,CA,2023,Q3,Elderly
227208762,22720876,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q3,Hospitalisation,,2023,Q3,2,F,20230421.0,20230717.0,20230719,20230719,EXP,,CA-ABBVIE-5330762,ABBVIE,,69.0,YR,,M,Y,,,20230719,,MD,CA,CA,2023,Q3,Elderly
227228934,22722893,5,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"0.1 milligram, qd",,,,,,,,0.1,MG,Tablet,QD,2023,Q3,Paralysis,,2023,Q3,4,F,20230617.0,20230920.0,20230719,20230925,EXP,,KR-MYLANLABS-2023M1066536,MYLAN,,67.0,YR,,M,Y,86.0,KG,20230925,,CN,KR,KR,2023,Q3,Elderly
227228934,22722893,5,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"0.1 milligram, qd",,,,,,,,0.1,MG,Tablet,QD,2023,Q3,Drug ineffective for unapproved indication,,2023,Q3,4,F,20230617.0,20230920.0,20230719,20230925,EXP,,KR-MYLANLABS-2023M1066536,MYLAN,,67.0,YR,,M,Y,86.0,KG,20230925,,CN,KR,KR,2023,Q3,Elderly
227228934,22722893,5,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"0.1 milligram, qd",,,,,,,,0.1,MG,Tablet,QD,2023,Q3,Glycosylated haemoglobin abnormal,,2023,Q3,4,F,20230617.0,20230920.0,20230719,20230925,EXP,,KR-MYLANLABS-2023M1066536,MYLAN,,67.0,YR,,M,Y,86.0,KG,20230925,,CN,KR,KR,2023,Q3,Elderly
227228934,22722893,5,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"0.1 milligram, qd",,,,,,,,0.1,MG,Tablet,QD,2023,Q3,Somnolence,,2023,Q3,4,F,20230617.0,20230920.0,20230719,20230925,EXP,,KR-MYLANLABS-2023M1066536,MYLAN,,67.0,YR,,M,Y,86.0,KG,20230925,,CN,KR,KR,2023,Q3,Elderly
227228934,22722893,5,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"0.1 milligram, qd",,,,,,,,0.1,MG,Tablet,QD,2023,Q3,Chest pain,,2023,Q3,4,F,20230617.0,20230920.0,20230719,20230925,EXP,,KR-MYLANLABS-2023M1066536,MYLAN,,67.0,YR,,M,Y,86.0,KG,20230925,,CN,KR,KR,2023,Q3,Elderly
227228934,22722893,5,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"0.1 milligram, qd",,,,,,,,0.1,MG,Tablet,QD,2023,Q3,Logorrhoea,,2023,Q3,4,F,20230617.0,20230920.0,20230719,20230925,EXP,,KR-MYLANLABS-2023M1066536,MYLAN,,67.0,YR,,M,Y,86.0,KG,20230925,,CN,KR,KR,2023,Q3,Elderly
227228934,22722893,5,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"0.1 milligram, qd",,,,,,,,0.1,MG,Tablet,QD,2023,Q3,Sensory disturbance,,2023,Q3,4,F,20230617.0,20230920.0,20230719,20230925,EXP,,KR-MYLANLABS-2023M1066536,MYLAN,,67.0,YR,,M,Y,86.0,KG,20230925,,CN,KR,KR,2023,Q3,Elderly
227228934,22722893,5,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"0.1 milligram, qd",,,,,,,,0.1,MG,Tablet,QD,2023,Q3,Speech disorder,,2023,Q3,4,F,20230617.0,20230920.0,20230719,20230925,EXP,,KR-MYLANLABS-2023M1066536,MYLAN,,67.0,YR,,M,Y,86.0,KG,20230925,,CN,KR,KR,2023,Q3,Elderly
227228934,22722893,5,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"0.1 milligram, qd",,,,,,,,0.1,MG,Tablet,QD,2023,Q3,Abnormal behaviour,,2023,Q3,4,F,20230617.0,20230920.0,20230719,20230925,EXP,,KR-MYLANLABS-2023M1066536,MYLAN,,67.0,YR,,M,Y,86.0,KG,20230925,,CN,KR,KR,2023,Q3,Elderly
227228934,22722893,5,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"0.1 milligram, qd",,,,,,,,0.1,MG,Tablet,QD,2023,Q3,Gait disturbance,,2023,Q3,4,F,20230617.0,20230920.0,20230719,20230925,EXP,,KR-MYLANLABS-2023M1066536,MYLAN,,67.0,YR,,M,Y,86.0,KG,20230925,,CN,KR,KR,2023,Q3,Elderly
227260072,22726007,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,dose and frequency unknown,,,,,,,,,,,,2023,Q3,Dysphonia,,2023,Q3,2,F,20230106.0,20230913.0,20230719,20230920,PER,,JP-Eisai Medical Research-EC-2023-132561,EISAI,,69.0,YR,E,M,Y,,,20230920,,MD,JP,JP,2023,Q3,Elderly
227260072,22726007,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,dose and frequency unknown,,,,,,,,,,,,2023,Q3,Hypertension,,2023,Q3,2,F,20230106.0,20230913.0,20230719,20230920,PER,,JP-Eisai Medical Research-EC-2023-132561,EISAI,,69.0,YR,E,M,Y,,,20230920,,MD,JP,JP,2023,Q3,Elderly
227265346,22726534,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,QD,2023,Q3,Coma,,2023,Q3,6,F,20230601.0,20230830.0,20230720,20230901,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-2023-100837,BRISTOL MYERS SQUIBB,,83.0,YR,E,M,Y,67.0,KG,20230901,,MD,DE,DE,2023,Q3,Elderly
227265346,22726534,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,QD,2023,Q3,Haemoptysis,,2023,Q3,6,F,20230601.0,20230830.0,20230720,20230901,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-2023-100837,BRISTOL MYERS SQUIBB,,83.0,YR,E,M,Y,67.0,KG,20230901,,MD,DE,DE,2023,Q3,Elderly
227265346,22726534,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,QD,2023,Q3,Renal impairment,,2023,Q3,6,F,20230601.0,20230830.0,20230720,20230901,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-2023-100837,BRISTOL MYERS SQUIBB,,83.0,YR,E,M,Y,67.0,KG,20230901,,MD,DE,DE,2023,Q3,Elderly
227265346,22726534,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,QD,2023,Q3,Asthenia,,2023,Q3,6,F,20230601.0,20230830.0,20230720,20230901,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-2023-100837,BRISTOL MYERS SQUIBB,,83.0,YR,E,M,Y,67.0,KG,20230901,,MD,DE,DE,2023,Q3,Elderly
227265346,22726534,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,QD,2023,Q3,Urinary retention,,2023,Q3,6,F,20230601.0,20230830.0,20230720,20230901,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-2023-100837,BRISTOL MYERS SQUIBB,,83.0,YR,E,M,Y,67.0,KG,20230901,,MD,DE,DE,2023,Q3,Elderly
227265346,22726534,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,QD,2023,Q3,Delirium,,2023,Q3,6,F,20230601.0,20230830.0,20230720,20230901,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-2023-100837,BRISTOL MYERS SQUIBB,,83.0,YR,E,M,Y,67.0,KG,20230901,,MD,DE,DE,2023,Q3,Elderly
227265346,22726534,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,QD,2023,Q3,Acute kidney injury,,2023,Q3,6,F,20230601.0,20230830.0,20230720,20230901,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-2023-100837,BRISTOL MYERS SQUIBB,,83.0,YR,E,M,Y,67.0,KG,20230901,,MD,DE,DE,2023,Q3,Elderly
227265346,22726534,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,QD,2023,Q3,Mental fatigue,,2023,Q3,6,F,20230601.0,20230830.0,20230720,20230901,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-2023-100837,BRISTOL MYERS SQUIBB,,83.0,YR,E,M,Y,67.0,KG,20230901,,MD,DE,DE,2023,Q3,Elderly
227265346,22726534,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,QD,2023,Q3,Malaise,,2023,Q3,6,F,20230601.0,20230830.0,20230720,20230901,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-2023-100837,BRISTOL MYERS SQUIBB,,83.0,YR,E,M,Y,67.0,KG,20230901,,MD,DE,DE,2023,Q3,Elderly
227265346,22726534,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,QD,2023,Q3,Cognitive disorder,,2023,Q3,6,F,20230601.0,20230830.0,20230720,20230901,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-2023-100837,BRISTOL MYERS SQUIBB,,83.0,YR,E,M,Y,67.0,KG,20230901,,MD,DE,DE,2023,Q3,Elderly
227265346,22726534,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,QD,2023,Q3,Immobile,,2023,Q3,6,F,20230601.0,20230830.0,20230720,20230901,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-2023-100837,BRISTOL MYERS SQUIBB,,83.0,YR,E,M,Y,67.0,KG,20230901,,MD,DE,DE,2023,Q3,Elderly
227265346,22726534,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,QD,2023,Q3,Chronic obstructive pulmonary disease,,2023,Q3,6,F,20230601.0,20230830.0,20230720,20230901,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-2023-100837,BRISTOL MYERS SQUIBB,,83.0,YR,E,M,Y,67.0,KG,20230901,,MD,DE,DE,2023,Q3,Elderly
227265346,22726534,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,QD,2023,Q3,Pneumonia aspiration,,2023,Q3,6,F,20230601.0,20230830.0,20230720,20230901,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-2023-100837,BRISTOL MYERS SQUIBB,,83.0,YR,E,M,Y,67.0,KG,20230901,,MD,DE,DE,2023,Q3,Elderly
227265346,22726534,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,QD,2023,Q3,Confusional state,,2023,Q3,6,F,20230601.0,20230830.0,20230720,20230901,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-2023-100837,BRISTOL MYERS SQUIBB,,83.0,YR,E,M,Y,67.0,KG,20230901,,MD,DE,DE,2023,Q3,Elderly
227265346,22726534,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,QD,2023,Q3,Depression,,2023,Q3,6,F,20230601.0,20230830.0,20230720,20230901,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-2023-100837,BRISTOL MYERS SQUIBB,,83.0,YR,E,M,Y,67.0,KG,20230901,,MD,DE,DE,2023,Q3,Elderly
227265346,22726534,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,QD,2023,Q3,Autonomic nervous system imbalance,,2023,Q3,6,F,20230601.0,20230830.0,20230720,20230901,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-2023-100837,BRISTOL MYERS SQUIBB,,83.0,YR,E,M,Y,67.0,KG,20230901,,MD,DE,DE,2023,Q3,Elderly
227265346,22726534,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,QD,2023,Q3,Illness,,2023,Q3,6,F,20230601.0,20230830.0,20230720,20230901,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-2023-100837,BRISTOL MYERS SQUIBB,,83.0,YR,E,M,Y,67.0,KG,20230901,,MD,DE,DE,2023,Q3,Elderly
227265346,22726534,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,QD,2023,Q3,Respiratory failure,,2023,Q3,6,F,20230601.0,20230830.0,20230720,20230901,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-2023-100837,BRISTOL MYERS SQUIBB,,83.0,YR,E,M,Y,67.0,KG,20230901,,MD,DE,DE,2023,Q3,Elderly
227273411,22727341,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,N,,,,,10.0,MG,,,2023,Q3,Chronic obstructive pulmonary disease,,2023,Q3,1,I,20230623.0,20230711.0,20230720,20230720,EXP,,CO-002147023-NVSC2023CO149110,SANDOZ,,69.0,YR,,M,Y,55.0,KG,20230720,,MD,CO,CO,2023,Q3,Elderly
227278821,22727882,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q3,Drug-induced liver injury,,2023,Q3,1,I,,20230711.0,20230720,20230720,EXP,,CA-APOTEX-2023AP010370,APOTEX,,71.0,YR,,F,Y,154.0,KG,20230720,,PH,CA,CA,2023,Q3,Elderly
227278821,22727882,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q3,International normalised ratio increased,,2023,Q3,1,I,,20230711.0,20230720,20230720,EXP,,CA-APOTEX-2023AP010370,APOTEX,,71.0,YR,,F,Y,154.0,KG,20230720,,PH,CA,CA,2023,Q3,Elderly
227307602,22730760,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,Jardiance met 12.5/500 mg,,,U,,Unknown,,206111.0,,,,,2023,Q3,Penile swelling,,2023,Q3,2,F,20230101.0,20230721.0,20230720,20230724,EXP,,"IN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-249906",BOEHRINGER INGELHEIM,,62.0,YR,A,M,Y,95.0,KG,20230724,,MD,IN,IN,2023,Q3,Adult
227307602,22730760,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,Jardiance met 12.5/500 mg,,,U,,Unknown,,206111.0,,,,,2023,Q3,Dysuria,,2023,Q3,2,F,20230101.0,20230721.0,20230720,20230724,EXP,,"IN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-249906",BOEHRINGER INGELHEIM,,62.0,YR,A,M,Y,95.0,KG,20230724,,MD,IN,IN,2023,Q3,Adult
227307602,22730760,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,Jardiance met 12.5/500 mg,,,U,,Unknown,,206111.0,,,,,2023,Q3,Fungal skin infection,,2023,Q3,2,F,20230101.0,20230721.0,20230720,20230724,EXP,,"IN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-249906",BOEHRINGER INGELHEIM,,62.0,YR,A,M,Y,95.0,KG,20230724,,MD,IN,IN,2023,Q3,Adult
227307602,22730760,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,Jardiance met 12.5/500 mg,,,U,,Unknown,,206111.0,,,,,2023,Q3,Skin exfoliation,,2023,Q3,2,F,20230101.0,20230721.0,20230720,20230724,EXP,,"IN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-249906",BOEHRINGER INGELHEIM,,62.0,YR,A,M,Y,95.0,KG,20230724,,MD,IN,IN,2023,Q3,Adult
227307602,22730760,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,Jardiance met 12.5/500 mg,,,U,,Unknown,,206111.0,,,,,2023,Q3,Skin hypertrophy,,2023,Q3,2,F,20230101.0,20230721.0,20230720,20230724,EXP,,"IN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-249906",BOEHRINGER INGELHEIM,,62.0,YR,A,M,Y,95.0,KG,20230724,,MD,IN,IN,2023,Q3,Adult
227307602,22730760,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,Jardiance met 12.5/500 mg,,,U,,Unknown,,206111.0,,,,,2023,Q3,Genital injury,,2023,Q3,2,F,20230101.0,20230721.0,20230720,20230724,EXP,,"IN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-249906",BOEHRINGER INGELHEIM,,62.0,YR,A,M,Y,95.0,KG,20230724,,MD,IN,IN,2023,Q3,Adult
227346911,22734691,27,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,,,,,,10.0,MG,,QD,2023,Q3,Constipation,,2023,Q3,1,I,,20230712.0,20230721,20230721,EXP,,CA-002147023-NVSC2022CA251360,SANDOZ,,67.0,YR,,F,Y,,,20230721,,CN,CA,CA,2023,Q3,Elderly
227346911,22734691,27,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,,,,,,10.0,MG,,QD,2023,Q3,Pneumonia,,2023,Q3,1,I,,20230712.0,20230721,20230721,EXP,,CA-002147023-NVSC2022CA251360,SANDOZ,,67.0,YR,,F,Y,,,20230721,,CN,CA,CA,2023,Q3,Elderly
227346911,22734691,27,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,,,,,,10.0,MG,,QD,2023,Q3,Fall,,2023,Q3,1,I,,20230712.0,20230721,20230721,EXP,,CA-002147023-NVSC2022CA251360,SANDOZ,,67.0,YR,,F,Y,,,20230721,,CN,CA,CA,2023,Q3,Elderly
227346911,22734691,27,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,,,,,,10.0,MG,,QD,2023,Q3,Clostridium difficile colitis,,2023,Q3,1,I,,20230712.0,20230721,20230721,EXP,,CA-002147023-NVSC2022CA251360,SANDOZ,,67.0,YR,,F,Y,,,20230721,,CN,CA,CA,2023,Q3,Elderly
227346911,22734691,27,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,,,,,,10.0,MG,,QD,2023,Q3,Haemorrhoidal haemorrhage,,2023,Q3,1,I,,20230712.0,20230721,20230721,EXP,,CA-002147023-NVSC2022CA251360,SANDOZ,,67.0,YR,,F,Y,,,20230721,,CN,CA,CA,2023,Q3,Elderly
227346911,22734691,27,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,,,,,,10.0,MG,,QD,2023,Q3,Dyspnoea,,2023,Q3,1,I,,20230712.0,20230721,20230721,EXP,,CA-002147023-NVSC2022CA251360,SANDOZ,,67.0,YR,,F,Y,,,20230721,,CN,CA,CA,2023,Q3,Elderly
227346911,22734691,27,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,,,,,,10.0,MG,,QD,2023,Q3,Cataract,,2023,Q3,1,I,,20230712.0,20230721,20230721,EXP,,CA-002147023-NVSC2022CA251360,SANDOZ,,67.0,YR,,F,Y,,,20230721,,CN,CA,CA,2023,Q3,Elderly
227346911,22734691,27,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,,,,,,10.0,MG,,QD,2023,Q3,Neoplasm skin,,2023,Q3,1,I,,20230712.0,20230721,20230721,EXP,,CA-002147023-NVSC2022CA251360,SANDOZ,,67.0,YR,,F,Y,,,20230721,,CN,CA,CA,2023,Q3,Elderly
227346911,22734691,27,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,,,,,,10.0,MG,,QD,2023,Q3,Transient ischaemic attack,,2023,Q3,1,I,,20230712.0,20230721,20230721,EXP,,CA-002147023-NVSC2022CA251360,SANDOZ,,67.0,YR,,F,Y,,,20230721,,CN,CA,CA,2023,Q3,Elderly
227346911,22734691,27,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,,,,,,10.0,MG,,QD,2023,Q3,Product use issue,,2023,Q3,1,I,,20230712.0,20230721,20230721,EXP,,CA-002147023-NVSC2022CA251360,SANDOZ,,67.0,YR,,F,Y,,,20230721,,CN,CA,CA,2023,Q3,Elderly
227346911,22734691,27,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,,,,,,10.0,MG,,QD,2023,Q3,Neuropathy peripheral,,2023,Q3,1,I,,20230712.0,20230721,20230721,EXP,,CA-002147023-NVSC2022CA251360,SANDOZ,,67.0,YR,,F,Y,,,20230721,,CN,CA,CA,2023,Q3,Elderly
227346911,22734691,27,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,,,,,,10.0,MG,,QD,2023,Q3,Chest discomfort,,2023,Q3,1,I,,20230712.0,20230721,20230721,EXP,,CA-002147023-NVSC2022CA251360,SANDOZ,,67.0,YR,,F,Y,,,20230721,,CN,CA,CA,2023,Q3,Elderly
227346911,22734691,27,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,,,,,,10.0,MG,,QD,2023,Q3,Off label use,,2023,Q3,1,I,,20230712.0,20230721,20230721,EXP,,CA-002147023-NVSC2022CA251360,SANDOZ,,67.0,YR,,F,Y,,,20230721,,CN,CA,CA,2023,Q3,Elderly
227346911,22734691,27,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,,,,,,10.0,MG,,QD,2023,Q3,COVID-19,,2023,Q3,1,I,,20230712.0,20230721,20230721,EXP,,CA-002147023-NVSC2022CA251360,SANDOZ,,67.0,YR,,F,Y,,,20230721,,CN,CA,CA,2023,Q3,Elderly
227346911,22734691,27,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,,,,,,10.0,MG,,QD,2023,Q3,Haemorrhoids,,2023,Q3,1,I,,20230712.0,20230721,20230721,EXP,,CA-002147023-NVSC2022CA251360,SANDOZ,,67.0,YR,,F,Y,,,20230721,,CN,CA,CA,2023,Q3,Elderly
227346911,22734691,27,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,,,,,,10.0,MG,,QD,2023,Q3,Abdominal pain upper,,2023,Q3,1,I,,20230712.0,20230721,20230721,EXP,,CA-002147023-NVSC2022CA251360,SANDOZ,,67.0,YR,,F,Y,,,20230721,,CN,CA,CA,2023,Q3,Elderly
227346911,22734691,27,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,,,,,,10.0,MG,,QD,2023,Q3,Drug ineffective,,2023,Q3,1,I,,20230712.0,20230721,20230721,EXP,,CA-002147023-NVSC2022CA251360,SANDOZ,,67.0,YR,,F,Y,,,20230721,,CN,CA,CA,2023,Q3,Elderly
227346911,22734691,27,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,,,,,,10.0,MG,,QD,2023,Q3,Vulvovaginal mycotic infection,,2023,Q3,1,I,,20230712.0,20230721,20230721,EXP,,CA-002147023-NVSC2022CA251360,SANDOZ,,67.0,YR,,F,Y,,,20230721,,CN,CA,CA,2023,Q3,Elderly
227346911,22734691,27,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,,,,,,10.0,MG,,QD,2023,Q3,Cardiac failure,,2023,Q3,1,I,,20230712.0,20230721,20230721,EXP,,CA-002147023-NVSC2022CA251360,SANDOZ,,67.0,YR,,F,Y,,,20230721,,CN,CA,CA,2023,Q3,Elderly
227346911,22734691,27,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,,,,,,10.0,MG,,QD,2023,Q3,Blood pressure increased,,2023,Q3,1,I,,20230712.0,20230721,20230721,EXP,,CA-002147023-NVSC2022CA251360,SANDOZ,,67.0,YR,,F,Y,,,20230721,,CN,CA,CA,2023,Q3,Elderly
227348711,22734871,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1 every 1 days)",,,U,,,,,10.0,MG,,QD,2023,Q3,Chest discomfort,,2023,Q3,1,I,,20230712.0,20230721,20230721,EXP,CA-HEALTHCANVIG-05218938,CA-SANDOZ-SDZ2023CA003535,SANDOZ,,67.0,YR,,F,Y,,,20230721,,CN,CA,CA,2023,Q3,Elderly
227348711,22734871,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1 every 1 days)",,,U,,,,,10.0,MG,,QD,2023,Q3,Abdominal pain upper,,2023,Q3,1,I,,20230712.0,20230721,20230721,EXP,CA-HEALTHCANVIG-05218938,CA-SANDOZ-SDZ2023CA003535,SANDOZ,,67.0,YR,,F,Y,,,20230721,,CN,CA,CA,2023,Q3,Elderly
227348711,22734871,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1 every 1 days)",,,U,,,,,10.0,MG,,QD,2023,Q3,Neuropathy peripheral,,2023,Q3,1,I,,20230712.0,20230721,20230721,EXP,CA-HEALTHCANVIG-05218938,CA-SANDOZ-SDZ2023CA003535,SANDOZ,,67.0,YR,,F,Y,,,20230721,,CN,CA,CA,2023,Q3,Elderly
227348711,22734871,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1 every 1 days)",,,U,,,,,10.0,MG,,QD,2023,Q3,Drug ineffective,,2023,Q3,1,I,,20230712.0,20230721,20230721,EXP,CA-HEALTHCANVIG-05218938,CA-SANDOZ-SDZ2023CA003535,SANDOZ,,67.0,YR,,F,Y,,,20230721,,CN,CA,CA,2023,Q3,Elderly
227348711,22734871,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1 every 1 days)",,,U,,,,,10.0,MG,,QD,2023,Q3,Constipation,,2023,Q3,1,I,,20230712.0,20230721,20230721,EXP,CA-HEALTHCANVIG-05218938,CA-SANDOZ-SDZ2023CA003535,SANDOZ,,67.0,YR,,F,Y,,,20230721,,CN,CA,CA,2023,Q3,Elderly
227348711,22734871,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1 every 1 days)",,,U,,,,,10.0,MG,,QD,2023,Q3,Fall,,2023,Q3,1,I,,20230712.0,20230721,20230721,EXP,CA-HEALTHCANVIG-05218938,CA-SANDOZ-SDZ2023CA003535,SANDOZ,,67.0,YR,,F,Y,,,20230721,,CN,CA,CA,2023,Q3,Elderly
227348711,22734871,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1 every 1 days)",,,U,,,,,10.0,MG,,QD,2023,Q3,Clostridium difficile colitis,,2023,Q3,1,I,,20230712.0,20230721,20230721,EXP,CA-HEALTHCANVIG-05218938,CA-SANDOZ-SDZ2023CA003535,SANDOZ,,67.0,YR,,F,Y,,,20230721,,CN,CA,CA,2023,Q3,Elderly
227348711,22734871,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1 every 1 days)",,,U,,,,,10.0,MG,,QD,2023,Q3,Pneumonia,,2023,Q3,1,I,,20230712.0,20230721,20230721,EXP,CA-HEALTHCANVIG-05218938,CA-SANDOZ-SDZ2023CA003535,SANDOZ,,67.0,YR,,F,Y,,,20230721,,CN,CA,CA,2023,Q3,Elderly
227348711,22734871,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1 every 1 days)",,,U,,,,,10.0,MG,,QD,2023,Q3,Haemorrhoids,,2023,Q3,1,I,,20230712.0,20230721,20230721,EXP,CA-HEALTHCANVIG-05218938,CA-SANDOZ-SDZ2023CA003535,SANDOZ,,67.0,YR,,F,Y,,,20230721,,CN,CA,CA,2023,Q3,Elderly
227348711,22734871,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1 every 1 days)",,,U,,,,,10.0,MG,,QD,2023,Q3,Vulvovaginal mycotic infection,,2023,Q3,1,I,,20230712.0,20230721,20230721,EXP,CA-HEALTHCANVIG-05218938,CA-SANDOZ-SDZ2023CA003535,SANDOZ,,67.0,YR,,F,Y,,,20230721,,CN,CA,CA,2023,Q3,Elderly
227348711,22734871,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1 every 1 days)",,,U,,,,,10.0,MG,,QD,2023,Q3,Cardiac failure,,2023,Q3,1,I,,20230712.0,20230721,20230721,EXP,CA-HEALTHCANVIG-05218938,CA-SANDOZ-SDZ2023CA003535,SANDOZ,,67.0,YR,,F,Y,,,20230721,,CN,CA,CA,2023,Q3,Elderly
227348711,22734871,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1 every 1 days)",,,U,,,,,10.0,MG,,QD,2023,Q3,Blood pressure increased,,2023,Q3,1,I,,20230712.0,20230721,20230721,EXP,CA-HEALTHCANVIG-05218938,CA-SANDOZ-SDZ2023CA003535,SANDOZ,,67.0,YR,,F,Y,,,20230721,,CN,CA,CA,2023,Q3,Elderly
227348711,22734871,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1 every 1 days)",,,U,,,,,10.0,MG,,QD,2023,Q3,Transient ischaemic attack,,2023,Q3,1,I,,20230712.0,20230721,20230721,EXP,CA-HEALTHCANVIG-05218938,CA-SANDOZ-SDZ2023CA003535,SANDOZ,,67.0,YR,,F,Y,,,20230721,,CN,CA,CA,2023,Q3,Elderly
227348711,22734871,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1 every 1 days)",,,U,,,,,10.0,MG,,QD,2023,Q3,COVID-19,,2023,Q3,1,I,,20230712.0,20230721,20230721,EXP,CA-HEALTHCANVIG-05218938,CA-SANDOZ-SDZ2023CA003535,SANDOZ,,67.0,YR,,F,Y,,,20230721,,CN,CA,CA,2023,Q3,Elderly
227348711,22734871,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1 every 1 days)",,,U,,,,,10.0,MG,,QD,2023,Q3,Neoplasm skin,,2023,Q3,1,I,,20230712.0,20230721,20230721,EXP,CA-HEALTHCANVIG-05218938,CA-SANDOZ-SDZ2023CA003535,SANDOZ,,67.0,YR,,F,Y,,,20230721,,CN,CA,CA,2023,Q3,Elderly
227348711,22734871,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1 every 1 days)",,,U,,,,,10.0,MG,,QD,2023,Q3,Cataract,,2023,Q3,1,I,,20230712.0,20230721,20230721,EXP,CA-HEALTHCANVIG-05218938,CA-SANDOZ-SDZ2023CA003535,SANDOZ,,67.0,YR,,F,Y,,,20230721,,CN,CA,CA,2023,Q3,Elderly
227348711,22734871,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1 every 1 days)",,,U,,,,,10.0,MG,,QD,2023,Q3,Haemorrhoidal haemorrhage,,2023,Q3,1,I,,20230712.0,20230721,20230721,EXP,CA-HEALTHCANVIG-05218938,CA-SANDOZ-SDZ2023CA003535,SANDOZ,,67.0,YR,,F,Y,,,20230721,,CN,CA,CA,2023,Q3,Elderly
227348711,22734871,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1 every 1 days)",,,U,,,,,10.0,MG,,QD,2023,Q3,Dyspnoea,,2023,Q3,1,I,,20230712.0,20230721,20230721,EXP,CA-HEALTHCANVIG-05218938,CA-SANDOZ-SDZ2023CA003535,SANDOZ,,67.0,YR,,F,Y,,,20230721,,CN,CA,CA,2023,Q3,Elderly
227348711,22734871,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1 every 1 days)",,,U,,,,,10.0,MG,,QD,2023,Q3,Product use issue,,2023,Q3,1,I,,20230712.0,20230721,20230721,EXP,CA-HEALTHCANVIG-05218938,CA-SANDOZ-SDZ2023CA003535,SANDOZ,,67.0,YR,,F,Y,,,20230721,,CN,CA,CA,2023,Q3,Elderly
227376401,22737640,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Unknown,,,10.0,MG,,QD,2023,Q3,Euglycaemic diabetic ketoacidosis,,2023,Q3,1,I,,20230711.0,20230721,20230721,EXP,,CH-EMD Serono-2023461165,EMD SERONO INC,"Massie E, Nzomessi D, Giraud R, Meyer P. Combined lactic acidosis and ketoacidosis in a female diabetic patient with severe heart failure. Cardiovascular endocrinology + metabolism. 2023;12: 1-3.",58.0,YR,A,F,Y,,,20230721,,HP,CH,CH,2023,Q3,Adult
227376401,22737640,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Unknown,,,10.0,MG,,QD,2023,Q3,Lactic acidosis,,2023,Q3,1,I,,20230711.0,20230721,20230721,EXP,,CH-EMD Serono-2023461165,EMD SERONO INC,"Massie E, Nzomessi D, Giraud R, Meyer P. Combined lactic acidosis and ketoacidosis in a female diabetic patient with severe heart failure. Cardiovascular endocrinology + metabolism. 2023;12: 1-3.",58.0,YR,A,F,Y,,,20230721,,HP,CH,CH,2023,Q3,Adult
227376401,22737640,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Unknown,,,10.0,MG,,QD,2023,Q3,Acute kidney injury,,2023,Q3,1,I,,20230711.0,20230721,20230721,EXP,,CH-EMD Serono-2023461165,EMD SERONO INC,"Massie E, Nzomessi D, Giraud R, Meyer P. Combined lactic acidosis and ketoacidosis in a female diabetic patient with severe heart failure. Cardiovascular endocrinology + metabolism. 2023;12: 1-3.",58.0,YR,A,F,Y,,,20230721,,HP,CH,CH,2023,Q3,Adult
227376401,22737640,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Unknown,,,10.0,MG,,QD,2023,Q3,Toxicity to various agents,,2023,Q3,1,I,,20230711.0,20230721,20230721,EXP,,CH-EMD Serono-2023461165,EMD SERONO INC,"Massie E, Nzomessi D, Giraud R, Meyer P. Combined lactic acidosis and ketoacidosis in a female diabetic patient with severe heart failure. Cardiovascular endocrinology + metabolism. 2023;12: 1-3.",58.0,YR,A,F,Y,,,20230721,,HP,CH,CH,2023,Q3,Adult
227395621,22739562,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Cardiac failure,,2023,Q3,1,I,20171201.0,20230710.0,20230722,20230722,EXP,,CZ-AUROBINDO-AUR-APL-2023-048168,AUROBINDO,Svarcova T.. Dapagliflozin in the treatment of heart failure with preserved ejection fraction.. INTERNAL MEDICINE.. 2023;69(4):261-264,72.0,YR,,M,Y,,,20230722,,MD,CZ,CZ,2023,Q3,Elderly
227395621,22739562,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Bradycardia,,2023,Q3,1,I,20171201.0,20230710.0,20230722,20230722,EXP,,CZ-AUROBINDO-AUR-APL-2023-048168,AUROBINDO,Svarcova T.. Dapagliflozin in the treatment of heart failure with preserved ejection fraction.. INTERNAL MEDICINE.. 2023;69(4):261-264,72.0,YR,,M,Y,,,20230722,,MD,CZ,CZ,2023,Q3,Elderly
227395621,22739562,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Pulmonary hypertension,,2023,Q3,1,I,20171201.0,20230710.0,20230722,20230722,EXP,,CZ-AUROBINDO-AUR-APL-2023-048168,AUROBINDO,Svarcova T.. Dapagliflozin in the treatment of heart failure with preserved ejection fraction.. INTERNAL MEDICINE.. 2023;69(4):261-264,72.0,YR,,M,Y,,,20230722,,MD,CZ,CZ,2023,Q3,Elderly
227395621,22739562,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Drug intolerance,,2023,Q3,1,I,20171201.0,20230710.0,20230722,20230722,EXP,,CZ-AUROBINDO-AUR-APL-2023-048168,AUROBINDO,Svarcova T.. Dapagliflozin in the treatment of heart failure with preserved ejection fraction.. INTERNAL MEDICINE.. 2023;69(4):261-264,72.0,YR,,M,Y,,,20230722,,MD,CZ,CZ,2023,Q3,Elderly
227412242,22741224,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,,10.0,MG,,,2023,Q3,Infection,,2023,Q3,2,F,,20230822.0,20230724,20230828,EXP,,GB-EMD Serono-2023461848,EMD SERONO INC,,8.0,DEC,E,M,Y,,,20230828,,HP,GB,GB,2023,Q3,Child
227412242,22741224,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,,10.0,MG,,,2023,Q3,Diabetic ketoacidosis,,2023,Q3,2,F,,20230822.0,20230724,20230828,EXP,,GB-EMD Serono-2023461848,EMD SERONO INC,,8.0,DEC,E,M,Y,,,20230828,,HP,GB,GB,2023,Q3,Child
227412242,22741224,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,,,,,,2023,Q3,Infection,,2023,Q3,2,F,,20230822.0,20230724,20230828,EXP,,GB-EMD Serono-2023461848,EMD SERONO INC,,8.0,DEC,E,M,Y,,,20230828,,HP,GB,GB,2023,Q3,Child
227412242,22741224,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,,,,,,2023,Q3,Diabetic ketoacidosis,,2023,Q3,2,F,,20230822.0,20230724,20230828,EXP,,GB-EMD Serono-2023461848,EMD SERONO INC,,8.0,DEC,E,M,Y,,,20230828,,HP,GB,GB,2023,Q3,Child
227430411,22743041,4,C,empagliflozin 10 mg QD,,2,,,,,,,,,,,,,,2023,Q3,Radiation pneumonitis,,2023,Q3,1,I,20221207.0,,20230721,20230721,DIR,667699,,FDA-CTU,,60.0,YR,,M,N,63.0,KG,20230721,N,MD,US,,2023,Q3,Adult
227430411,22743041,4,C,empagliflozin 10 mg QD,,2,,,,,,,,,,,,,,2023,Q3,Adverse drug reaction,,2023,Q3,1,I,20221207.0,,20230721,20230721,DIR,667699,,FDA-CTU,,60.0,YR,,M,N,63.0,KG,20230721,N,MD,US,,2023,Q3,Adult
227430411,22743041,4,C,empagliflozin 10 mg QD,,2,,,,,,,,,,,,,,2023,Q3,Pulmonary radiation injury,,2023,Q3,1,I,20221207.0,,20230721,20230721,DIR,667699,,FDA-CTU,,60.0,YR,,M,N,63.0,KG,20230721,N,MD,US,,2023,Q3,Adult
227430411,22743041,4,C,empagliflozin 10 mg QD,,2,,,,,,,,,,,,,,2023,Q3,Pneumonitis,,2023,Q3,1,I,20221207.0,,20230721,20230721,DIR,667699,,FDA-CTU,,60.0,YR,,M,N,63.0,KG,20230721,N,MD,US,,2023,Q3,Adult
227430411,22743041,4,C,empagliflozin 10 mg QD,,2,,,,,,,,,,,,,,2023,Q3,Metastases to lymph nodes,,2023,Q3,1,I,20221207.0,,20230721,20230721,DIR,667699,,FDA-CTU,,60.0,YR,,M,N,63.0,KG,20230721,N,MD,US,,2023,Q3,Adult
227430411,22743041,4,C,empagliflozin 10 mg QD,,2,,,,,,,,,,,,,,2023,Q3,Infection masked,,2023,Q3,1,I,20221207.0,,20230721,20230721,DIR,667699,,FDA-CTU,,60.0,YR,,M,N,63.0,KG,20230721,N,MD,US,,2023,Q3,Adult
227430411,22743041,4,C,empagliflozin 10 mg QD,,2,,,,,,,,,,,,,,2023,Q3,Acute respiratory distress syndrome,,2023,Q3,1,I,20221207.0,,20230721,20230721,DIR,667699,,FDA-CTU,,60.0,YR,,M,N,63.0,KG,20230721,N,MD,US,,2023,Q3,Adult
227432472,22743247,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,unit dose: 10mg,,,U,U,UNKNOWN,,,10.0,MG,,,2023,Q3,Diabetic ketoacidosis,,2023,Q3,2,F,,20230822.0,20230724,20230901,EXP,,GB-TEVA-2023-GB-2908579,TEVA,,8.0,DEC,E,M,Y,,,20230901,,HP,GB,GB,2023,Q3,Child
227432472,22743247,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,unit dose: 10mg,,,U,U,UNKNOWN,,,10.0,MG,,,2023,Q3,Infection,,2023,Q3,2,F,,20230822.0,20230724,20230901,EXP,,GB-TEVA-2023-GB-2908579,TEVA,,8.0,DEC,E,M,Y,,,20230901,,HP,GB,GB,2023,Q3,Child
227433263,22743326,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Unknown,,2023,Q3,Cardiac failure chronic,,2023,Q3,3,F,,20230808.0,20230724,20230815,EXP,,CZ-MYLANLABS-2023M1077168,MYLAN,"Melenovsk? V. Heart failure in practice, in Medical Tribune. Annual Congress of the Czech Society of Cardiology including the Heart Failure S. 2023;19(12):C2-C3.",78.0,YR,,M,Y,99.0,KG,20230815,,MD,CZ,CZ,2023,Q3,Elderly
227433263,22743326,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Unknown,,2023,Q3,Aortic stenosis,,2023,Q3,3,F,,20230808.0,20230724,20230815,EXP,,CZ-MYLANLABS-2023M1077168,MYLAN,"Melenovsk? V. Heart failure in practice, in Medical Tribune. Annual Congress of the Czech Society of Cardiology including the Heart Failure S. 2023;19(12):C2-C3.",78.0,YR,,M,Y,99.0,KG,20230815,,MD,CZ,CZ,2023,Q3,Elderly
227433263,22743326,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Unknown,,2023,Q3,Cardiac failure,,2023,Q3,3,F,,20230808.0,20230724,20230815,EXP,,CZ-MYLANLABS-2023M1077168,MYLAN,"Melenovsk? V. Heart failure in practice, in Medical Tribune. Annual Congress of the Czech Society of Cardiology including the Heart Failure S. 2023;19(12):C2-C3.",78.0,YR,,M,Y,99.0,KG,20230815,,MD,CZ,CZ,2023,Q3,Elderly
227433263,22743326,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Unknown,,2023,Q3,Off label use,,2023,Q3,3,F,,20230808.0,20230724,20230815,EXP,,CZ-MYLANLABS-2023M1077168,MYLAN,"Melenovsk? V. Heart failure in practice, in Medical Tribune. Annual Congress of the Czech Society of Cardiology including the Heart Failure S. 2023;19(12):C2-C3.",78.0,YR,,M,Y,99.0,KG,20230815,,MD,CZ,CZ,2023,Q3,Elderly
227433263,22743326,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Unknown,,2023,Q3,Myocardial infarction,,2023,Q3,3,F,,20230808.0,20230724,20230815,EXP,,CZ-MYLANLABS-2023M1077168,MYLAN,"Melenovsk? V. Heart failure in practice, in Medical Tribune. Annual Congress of the Czech Society of Cardiology including the Heart Failure S. 2023;19(12):C2-C3.",78.0,YR,,M,Y,99.0,KG,20230815,,MD,CZ,CZ,2023,Q3,Elderly
227433263,22743326,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Unknown,,2023,Q3,Atrial fibrillation,,2023,Q3,3,F,,20230808.0,20230724,20230815,EXP,,CZ-MYLANLABS-2023M1077168,MYLAN,"Melenovsk? V. Heart failure in practice, in Medical Tribune. Annual Congress of the Czech Society of Cardiology including the Heart Failure S. 2023;19(12):C2-C3.",78.0,YR,,M,Y,99.0,KG,20230815,,MD,CZ,CZ,2023,Q3,Elderly
227433263,22743326,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Unknown,,2023,Q3,Drug ineffective,,2023,Q3,3,F,,20230808.0,20230724,20230815,EXP,,CZ-MYLANLABS-2023M1077168,MYLAN,"Melenovsk? V. Heart failure in practice, in Medical Tribune. Annual Congress of the Czech Society of Cardiology including the Heart Failure S. 2023;19(12):C2-C3.",78.0,YR,,M,Y,99.0,KG,20230815,,MD,CZ,CZ,2023,Q3,Elderly
227433263,22743326,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Unknown,,2023,Q3,Arteriosclerosis coronary artery,,2023,Q3,3,F,,20230808.0,20230724,20230815,EXP,,CZ-MYLANLABS-2023M1077168,MYLAN,"Melenovsk? V. Heart failure in practice, in Medical Tribune. Annual Congress of the Czech Society of Cardiology including the Heart Failure S. 2023;19(12):C2-C3.",78.0,YR,,M,Y,99.0,KG,20230815,,MD,CZ,CZ,2023,Q3,Elderly
227433263,22743326,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Unknown,,2023,Q3,Angina pectoris,,2023,Q3,3,F,,20230808.0,20230724,20230815,EXP,,CZ-MYLANLABS-2023M1077168,MYLAN,"Melenovsk? V. Heart failure in practice, in Medical Tribune. Annual Congress of the Czech Society of Cardiology including the Heart Failure S. 2023;19(12):C2-C3.",78.0,YR,,M,Y,99.0,KG,20230815,,MD,CZ,CZ,2023,Q3,Elderly
227433263,22743326,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Unknown,,2023,Q3,Atrioventricular block complete,,2023,Q3,3,F,,20230808.0,20230724,20230815,EXP,,CZ-MYLANLABS-2023M1077168,MYLAN,"Melenovsk? V. Heart failure in practice, in Medical Tribune. Annual Congress of the Czech Society of Cardiology including the Heart Failure S. 2023;19(12):C2-C3.",78.0,YR,,M,Y,99.0,KG,20230815,,MD,CZ,CZ,2023,Q3,Elderly
227443732,22744373,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,Oral,12.5 mg- 2.5 mg - 1000 mg twice daily,,,D,,Unknown,,212614.0,,,Tablet,Q12H,2023,Q3,Death,,2023,Q3,2,F,20230101.0,20230830.0,20230724,20230830,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-251307",BOEHRINGER INGELHEIM,,81.0,YR,E,F,Y,,,20230830,,CN,US,US,2023,Q3,Elderly
227449561,22744956,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Off label use,,2023,Q3,1,I,,20230712.0,20230725,20230725,EXP,,CA-002147023-NVSC2023CA005723,SANDOZ,,67.0,YR,,F,Y,,,20230725,,PH,CA,CA,2023,Q3,Elderly
227449561,22744956,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Hypoaesthesia,,2023,Q3,1,I,,20230712.0,20230725,20230725,EXP,,CA-002147023-NVSC2023CA005723,SANDOZ,,67.0,YR,,F,Y,,,20230725,,PH,CA,CA,2023,Q3,Elderly
227449561,22744956,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Abdominal pain upper,,2023,Q3,1,I,,20230712.0,20230725,20230725,EXP,,CA-002147023-NVSC2023CA005723,SANDOZ,,67.0,YR,,F,Y,,,20230725,,PH,CA,CA,2023,Q3,Elderly
227449561,22744956,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Product use issue,,2023,Q3,1,I,,20230712.0,20230725,20230725,EXP,,CA-002147023-NVSC2023CA005723,SANDOZ,,67.0,YR,,F,Y,,,20230725,,PH,CA,CA,2023,Q3,Elderly
227449561,22744956,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Dyspnoea,,2023,Q3,1,I,,20230712.0,20230725,20230725,EXP,,CA-002147023-NVSC2023CA005723,SANDOZ,,67.0,YR,,F,Y,,,20230725,,PH,CA,CA,2023,Q3,Elderly
227449561,22744956,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Constipation,,2023,Q3,1,I,,20230712.0,20230725,20230725,EXP,,CA-002147023-NVSC2023CA005723,SANDOZ,,67.0,YR,,F,Y,,,20230725,,PH,CA,CA,2023,Q3,Elderly
227449561,22744956,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Vulvovaginal mycotic infection,,2023,Q3,1,I,,20230712.0,20230725,20230725,EXP,,CA-002147023-NVSC2023CA005723,SANDOZ,,67.0,YR,,F,Y,,,20230725,,PH,CA,CA,2023,Q3,Elderly
227449561,22744956,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Cardiac failure,,2023,Q3,1,I,,20230712.0,20230725,20230725,EXP,,CA-002147023-NVSC2023CA005723,SANDOZ,,67.0,YR,,F,Y,,,20230725,,PH,CA,CA,2023,Q3,Elderly
227449561,22744956,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Pain in extremity,,2023,Q3,1,I,,20230712.0,20230725,20230725,EXP,,CA-002147023-NVSC2023CA005723,SANDOZ,,67.0,YR,,F,Y,,,20230725,,PH,CA,CA,2023,Q3,Elderly
227449561,22744956,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Cataract,,2023,Q3,1,I,,20230712.0,20230725,20230725,EXP,,CA-002147023-NVSC2023CA005723,SANDOZ,,67.0,YR,,F,Y,,,20230725,,PH,CA,CA,2023,Q3,Elderly
227449561,22744956,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Pneumonia,,2023,Q3,1,I,,20230712.0,20230725,20230725,EXP,,CA-002147023-NVSC2023CA005723,SANDOZ,,67.0,YR,,F,Y,,,20230725,,PH,CA,CA,2023,Q3,Elderly
227449561,22744956,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Neoplasm skin,,2023,Q3,1,I,,20230712.0,20230725,20230725,EXP,,CA-002147023-NVSC2023CA005723,SANDOZ,,67.0,YR,,F,Y,,,20230725,,PH,CA,CA,2023,Q3,Elderly
227449561,22744956,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Chest discomfort,,2023,Q3,1,I,,20230712.0,20230725,20230725,EXP,,CA-002147023-NVSC2023CA005723,SANDOZ,,67.0,YR,,F,Y,,,20230725,,PH,CA,CA,2023,Q3,Elderly
227449561,22744956,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Blood pressure increased,,2023,Q3,1,I,,20230712.0,20230725,20230725,EXP,,CA-002147023-NVSC2023CA005723,SANDOZ,,67.0,YR,,F,Y,,,20230725,,PH,CA,CA,2023,Q3,Elderly
227449561,22744956,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Transient ischaemic attack,,2023,Q3,1,I,,20230712.0,20230725,20230725,EXP,,CA-002147023-NVSC2023CA005723,SANDOZ,,67.0,YR,,F,Y,,,20230725,,PH,CA,CA,2023,Q3,Elderly
227449561,22744956,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Fall,,2023,Q3,1,I,,20230712.0,20230725,20230725,EXP,,CA-002147023-NVSC2023CA005723,SANDOZ,,67.0,YR,,F,Y,,,20230725,,PH,CA,CA,2023,Q3,Elderly
227449561,22744956,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Drug ineffective,,2023,Q3,1,I,,20230712.0,20230725,20230725,EXP,,CA-002147023-NVSC2023CA005723,SANDOZ,,67.0,YR,,F,Y,,,20230725,,PH,CA,CA,2023,Q3,Elderly
227449561,22744956,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Neuropathy peripheral,,2023,Q3,1,I,,20230712.0,20230725,20230725,EXP,,CA-002147023-NVSC2023CA005723,SANDOZ,,67.0,YR,,F,Y,,,20230725,,PH,CA,CA,2023,Q3,Elderly
227449561,22744956,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Clostridium difficile colitis,,2023,Q3,1,I,,20230712.0,20230725,20230725,EXP,,CA-002147023-NVSC2023CA005723,SANDOZ,,67.0,YR,,F,Y,,,20230725,,PH,CA,CA,2023,Q3,Elderly
227449561,22744956,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Haemorrhoidal haemorrhage,,2023,Q3,1,I,,20230712.0,20230725,20230725,EXP,,CA-002147023-NVSC2023CA005723,SANDOZ,,67.0,YR,,F,Y,,,20230725,,PH,CA,CA,2023,Q3,Elderly
227449561,22744956,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Cardiomegaly,,2023,Q3,1,I,,20230712.0,20230725,20230725,EXP,,CA-002147023-NVSC2023CA005723,SANDOZ,,67.0,YR,,F,Y,,,20230725,,PH,CA,CA,2023,Q3,Elderly
227449561,22744956,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Haemorrhoids,,2023,Q3,1,I,,20230712.0,20230725,20230725,EXP,,CA-002147023-NVSC2023CA005723,SANDOZ,,67.0,YR,,F,Y,,,20230725,,PH,CA,CA,2023,Q3,Elderly
227449561,22744956,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Chest pain,,2023,Q3,1,I,,20230712.0,20230725,20230725,EXP,,CA-002147023-NVSC2023CA005723,SANDOZ,,67.0,YR,,F,Y,,,20230725,,PH,CA,CA,2023,Q3,Elderly
227449561,22744956,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,COVID-19,,2023,Q3,1,I,,20230712.0,20230725,20230725,EXP,,CA-002147023-NVSC2023CA005723,SANDOZ,,67.0,YR,,F,Y,,,20230725,,PH,CA,CA,2023,Q3,Elderly
227453911,22745391,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,Oral,12.5-2.5-1000 mg twice daily,,,U,,Unknown,,212614.0,,,Tablet,Q12H,2023,Q3,Blood pressure increased,,2023,Q3,1,I,,20230724.0,20230725,20230725,PER,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-251403",BOEHRINGER INGELHEIM,,68.0,YR,E,M,Y,,,20230725,,CN,US,US,2023,Q3,Elderly
227455362,22745536,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,,,,10.0,MG,,,2023,Q3,Infection,,2023,Q3,2,F,,20230822.0,20230725,20230904,EXP,,GB-MICRO LABS LIMITED-ML2023-04059,MICRO LABS,,8.0,DEC,E,M,Y,,,20230904,,HP,GB,GB,2023,Q3,Child
227455362,22745536,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,,,,10.0,MG,,,2023,Q3,Diabetic ketoacidosis,,2023,Q3,2,F,,20230822.0,20230725,20230904,EXP,,GB-MICRO LABS LIMITED-ML2023-04059,MICRO LABS,,8.0,DEC,E,M,Y,,,20230904,,HP,GB,GB,2023,Q3,Child
227465321,22746532,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2023,Q3,Hyperkalaemia,,2023,Q3,1,I,,20230717.0,20230725,20230725,EXP,,US-MYLANLABS-2023M1078130,MYLAN,"Beau Stamos D, Barajas-Ochoa A, Raybould JE. Nocardia pseudobrasiliensis Co-infection in SARS-CoV-2 Patients. Emerging-Infect-Dis 2023;29(4):696-700.",52.0,YR,,M,Y,,,20230725,,HP,US,US,2023,Q3,Adult
227465321,22746532,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2023,Q3,Off label use,,2023,Q3,1,I,,20230717.0,20230725,20230725,EXP,,US-MYLANLABS-2023M1078130,MYLAN,"Beau Stamos D, Barajas-Ochoa A, Raybould JE. Nocardia pseudobrasiliensis Co-infection in SARS-CoV-2 Patients. Emerging-Infect-Dis 2023;29(4):696-700.",52.0,YR,,M,Y,,,20230725,,HP,US,US,2023,Q3,Adult
227481831,22748183,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 milligram daily,,,U,,Unk,,,25.0,MG,,,2023,Q3,Acute kidney injury,,2023,Q3,1,I,,20230712.0,20230725,20230725,EXP,,US-LAURUS LABS LIMITED-2023LAU000058,LAURUS LABS LIMITED,"Sardarli K, Leong R, Gill I, Zarouk SS.. A patient with combined metformin-induced lactic acidosis and euglycemic diabetic ketoacidosis.. J Am Soc Nephrol.. 2021;32(Suppl 2):384",66.0,YR,,F,Y,,,20230725,,HP,US,US,2023,Q3,Elderly
227481831,22748183,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 milligram daily,,,U,,Unk,,,25.0,MG,,,2023,Q3,Euglycaemic diabetic ketoacidosis,,2023,Q3,1,I,,20230712.0,20230725,20230725,EXP,,US-LAURUS LABS LIMITED-2023LAU000058,LAURUS LABS LIMITED,"Sardarli K, Leong R, Gill I, Zarouk SS.. A patient with combined metformin-induced lactic acidosis and euglycemic diabetic ketoacidosis.. J Am Soc Nephrol.. 2021;32(Suppl 2):384",66.0,YR,,F,Y,,,20230725,,HP,US,US,2023,Q3,Elderly
227481831,22748183,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 milligram daily,,,U,,Unk,,,25.0,MG,,,2023,Q3,Lactic acidosis,,2023,Q3,1,I,,20230712.0,20230725,20230725,EXP,,US-LAURUS LABS LIMITED-2023LAU000058,LAURUS LABS LIMITED,"Sardarli K, Leong R, Gill I, Zarouk SS.. A patient with combined metformin-induced lactic acidosis and euglycemic diabetic ketoacidosis.. J Am Soc Nephrol.. 2021;32(Suppl 2):384",66.0,YR,,F,Y,,,20230725,,HP,US,US,2023,Q3,Elderly
227481851,22748185,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,Y,,Unk,,,10.0,MG,,,2023,Q3,Lactic acidosis,,2023,Q3,1,I,,20230712.0,20230725,20230725,EXP,,CH-LAURUS LABS LIMITED-2023LAU000057,LAURUS LABS LIMITED,"Nzomessi D, Massie E, Gariani K, Giraud R, Meyer P.. Combined lactic acidosis and ketoacidosis in a female diabetic patient with severe heart failure.. Cardiovasc Endocrinol Metab.. 2023;12(3)",58.0,YR,,F,Y,,,20230725,,HP,CH,CH,2023,Q3,Adult
227481851,22748185,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,Y,,Unk,,,10.0,MG,,,2023,Q3,Acute kidney injury,,2023,Q3,1,I,,20230712.0,20230725,20230725,EXP,,CH-LAURUS LABS LIMITED-2023LAU000057,LAURUS LABS LIMITED,"Nzomessi D, Massie E, Gariani K, Giraud R, Meyer P.. Combined lactic acidosis and ketoacidosis in a female diabetic patient with severe heart failure.. Cardiovasc Endocrinol Metab.. 2023;12(3)",58.0,YR,,F,Y,,,20230725,,HP,CH,CH,2023,Q3,Adult
227481851,22748185,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,Y,,Unk,,,10.0,MG,,,2023,Q3,Respiratory distress,,2023,Q3,1,I,,20230712.0,20230725,20230725,EXP,,CH-LAURUS LABS LIMITED-2023LAU000057,LAURUS LABS LIMITED,"Nzomessi D, Massie E, Gariani K, Giraud R, Meyer P.. Combined lactic acidosis and ketoacidosis in a female diabetic patient with severe heart failure.. Cardiovasc Endocrinol Metab.. 2023;12(3)",58.0,YR,,F,Y,,,20230725,,HP,CH,CH,2023,Q3,Adult
227481851,22748185,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,Y,,Unk,,,10.0,MG,,,2023,Q3,Euglycaemic diabetic ketoacidosis,,2023,Q3,1,I,,20230712.0,20230725,20230725,EXP,,CH-LAURUS LABS LIMITED-2023LAU000057,LAURUS LABS LIMITED,"Nzomessi D, Massie E, Gariani K, Giraud R, Meyer P.. Combined lactic acidosis and ketoacidosis in a female diabetic patient with severe heart failure.. Cardiovasc Endocrinol Metab.. 2023;12(3)",58.0,YR,,F,Y,,,20230725,,HP,CH,CH,2023,Q3,Adult
227483743,22748374,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, daily",,,,,,,,10.0,MG,,QD,2023,Q3,Renal ischaemia,,2023,Q3,3,F,20220913.0,20230802.0,20230725,20230809,EXP,,PL-ELI_LILLY_AND_COMPANY-PL202307010366,ELI LILLY AND CO,,53.0,YR,,M,Y,154.0,KG,20230809,,CN,PL,PL,2023,Q3,Adult
227483743,22748374,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, daily",,,,,,,,10.0,MG,,QD,2023,Q3,Chronic kidney disease,,2023,Q3,3,F,20220913.0,20230802.0,20230725,20230809,EXP,,PL-ELI_LILLY_AND_COMPANY-PL202307010366,ELI LILLY AND CO,,53.0,YR,,M,Y,154.0,KG,20230809,,CN,PL,PL,2023,Q3,Adult
227483743,22748374,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, daily",,,,,,,,10.0,MG,,QD,2023,Q3,Hypotension,,2023,Q3,3,F,20220913.0,20230802.0,20230725,20230809,EXP,,PL-ELI_LILLY_AND_COMPANY-PL202307010366,ELI LILLY AND CO,,53.0,YR,,M,Y,154.0,KG,20230809,,CN,PL,PL,2023,Q3,Adult
227483743,22748374,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, daily",,,,,,,,10.0,MG,,QD,2023,Q3,Cardiac output decreased,,2023,Q3,3,F,20220913.0,20230802.0,20230725,20230809,EXP,,PL-ELI_LILLY_AND_COMPANY-PL202307010366,ELI LILLY AND CO,,53.0,YR,,M,Y,154.0,KG,20230809,,CN,PL,PL,2023,Q3,Adult
227496243,22749624,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 TABLET ONCE DAILY,,,U,,,,,,,Tablet,,2023,Q3,Hot flush,,2023,Q3,3,F,20230705.0,20230810.0,20230726,20230821,EXP,GB-MHRA-INP12F9238B-6F3B-4B05-A564-3501AE3D5FDB,GB-TORRENT-00032451,TORRENT,,26.0,YR,A,M,Y,77.0,KG,20230821,,MD,GB,GB,2023,Q3,Young Adult
227496243,22749624,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 TABLET ONCE DAILY,,,U,,,,,,,Tablet,,2023,Q3,Dizziness,,2023,Q3,3,F,20230705.0,20230810.0,20230726,20230821,EXP,GB-MHRA-INP12F9238B-6F3B-4B05-A564-3501AE3D5FDB,GB-TORRENT-00032451,TORRENT,,26.0,YR,A,M,Y,77.0,KG,20230821,,MD,GB,GB,2023,Q3,Young Adult
227496243,22749624,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 TABLET ONCE DAILY,,,U,,,,,,,Tablet,,2023,Q3,Off label use,,2023,Q3,3,F,20230705.0,20230810.0,20230726,20230821,EXP,GB-MHRA-INP12F9238B-6F3B-4B05-A564-3501AE3D5FDB,GB-TORRENT-00032451,TORRENT,,26.0,YR,A,M,Y,77.0,KG,20230821,,MD,GB,GB,2023,Q3,Young Adult
227503792,22750379,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, qd",,,Y,,,,,10.0,MG,,QD,2023,Q3,Acute kidney injury,,2023,Q3,2,F,,20230711.0,20230726,20230801,EXP,,CH-SANDOZ-SDZ2023CH005253,SANDOZ,"Nzomessia D, Massiea E, Garianib K, Giraudc R, Meyera P. Combined lactic acidosis and ketoacidosis in a femalediabetic patient with severe heart failure. Cardiovascular Endocrinology + Metabolism. 2023;12:1-4",58.0,YR,,F,Y,,,20230801,,HP,CH,CH,2023,Q3,Adult
227503792,22750379,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, qd",,,Y,,,,,10.0,MG,,QD,2023,Q3,Euglycaemic diabetic ketoacidosis,,2023,Q3,2,F,,20230711.0,20230726,20230801,EXP,,CH-SANDOZ-SDZ2023CH005253,SANDOZ,"Nzomessia D, Massiea E, Garianib K, Giraudc R, Meyera P. Combined lactic acidosis and ketoacidosis in a femalediabetic patient with severe heart failure. Cardiovascular Endocrinology + Metabolism. 2023;12:1-4",58.0,YR,,F,Y,,,20230801,,HP,CH,CH,2023,Q3,Adult
227503792,22750379,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, qd",,,Y,,,,,10.0,MG,,QD,2023,Q3,Off label use,,2023,Q3,2,F,,20230711.0,20230726,20230801,EXP,,CH-SANDOZ-SDZ2023CH005253,SANDOZ,"Nzomessia D, Massiea E, Garianib K, Giraudc R, Meyera P. Combined lactic acidosis and ketoacidosis in a femalediabetic patient with severe heart failure. Cardiovascular Endocrinology + Metabolism. 2023;12:1-4",58.0,YR,,F,Y,,,20230801,,HP,CH,CH,2023,Q3,Adult
227503792,22750379,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, qd",,,Y,,,,,10.0,MG,,QD,2023,Q3,Lactic acidosis,,2023,Q3,2,F,,20230711.0,20230726,20230801,EXP,,CH-SANDOZ-SDZ2023CH005253,SANDOZ,"Nzomessia D, Massiea E, Garianib K, Giraudc R, Meyera P. Combined lactic acidosis and ketoacidosis in a femalediabetic patient with severe heart failure. Cardiovascular Endocrinology + Metabolism. 2023;12:1-4",58.0,YR,,F,Y,,,20230801,,HP,CH,CH,2023,Q3,Adult
227523491,22752349,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,U,UNK,,,10.0,MG,,,2023,Q3,Respiratory distress,,2023,Q3,1,I,,20230714.0,20230726,20230726,EXP,,CH-NOVAST LABORATORIES INC.-2023NOV000278,NOVAST,"Nzomessi D, Massie E, Gariani K, Giraud R, Meyer P.. Combined lactic acidosis and ketoacidosis in a female diabetic patient with severe heart failure.. Cardiovasc Endocrinol Metab. 2023;12(3)",58.0,YR,,F,Y,,,20230726,,HP,CH,CH,2023,Q3,Adult
227523491,22752349,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,U,UNK,,,10.0,MG,,,2023,Q3,Lactic acidosis,,2023,Q3,1,I,,20230714.0,20230726,20230726,EXP,,CH-NOVAST LABORATORIES INC.-2023NOV000278,NOVAST,"Nzomessi D, Massie E, Gariani K, Giraud R, Meyer P.. Combined lactic acidosis and ketoacidosis in a female diabetic patient with severe heart failure.. Cardiovasc Endocrinol Metab. 2023;12(3)",58.0,YR,,F,Y,,,20230726,,HP,CH,CH,2023,Q3,Adult
227523491,22752349,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,U,UNK,,,10.0,MG,,,2023,Q3,Acute kidney injury,,2023,Q3,1,I,,20230714.0,20230726,20230726,EXP,,CH-NOVAST LABORATORIES INC.-2023NOV000278,NOVAST,"Nzomessi D, Massie E, Gariani K, Giraud R, Meyer P.. Combined lactic acidosis and ketoacidosis in a female diabetic patient with severe heart failure.. Cardiovasc Endocrinol Metab. 2023;12(3)",58.0,YR,,F,Y,,,20230726,,HP,CH,CH,2023,Q3,Adult
227523491,22752349,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,U,UNK,,,10.0,MG,,,2023,Q3,Euglycaemic diabetic ketoacidosis,,2023,Q3,1,I,,20230714.0,20230726,20230726,EXP,,CH-NOVAST LABORATORIES INC.-2023NOV000278,NOVAST,"Nzomessi D, Massie E, Gariani K, Giraud R, Meyer P.. Combined lactic acidosis and ketoacidosis in a female diabetic patient with severe heart failure.. Cardiovasc Endocrinol Metab. 2023;12(3)",58.0,YR,,F,Y,,,20230726,,HP,CH,CH,2023,Q3,Adult
227525825,22752582,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 mg,,,U,,,,,25.0,MG,,,2023,Q3,Lower respiratory tract infection,,2023,Q3,5,F,20230718.0,20230808.0,20230726,20230814,EXP,,GR-SA-2023SA223121,SANOFI AVENTIS,,62.0,YR,A,F,Y,,,20230814,,HP,GR,GR,2023,Q3,Adult
227529771,22752977,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,D,,,,25.0,MG,,QD,2023,Q3,Bone disorder,,2023,Q3,1,I,20230507.0,,20230726,20230726,DIR,668128,,FDA-CTU,,51.0,YR,,M,N,156.0,KG,20230726,N,PH,US,,2023,Q3,Adult
227529771,22752977,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,D,,,,25.0,MG,,QD,2023,Q3,Foot fracture,,2023,Q3,1,I,20230507.0,,20230726,20230726,DIR,668128,,FDA-CTU,,51.0,YR,,M,N,156.0,KG,20230726,N,PH,US,,2023,Q3,Adult
227529771,22752977,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,D,,,,25.0,MG,,QD,2023,Q3,Condition aggravated,,2023,Q3,1,I,20230507.0,,20230726,20230726,DIR,668128,,FDA-CTU,,51.0,YR,,M,N,156.0,KG,20230726,N,PH,US,,2023,Q3,Adult
227529771,22752977,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,D,,,,25.0,MG,,QD,2023,Q3,Necrotising soft tissue infection,,2023,Q3,1,I,20230507.0,,20230726,20230726,DIR,668128,,FDA-CTU,,51.0,YR,,M,N,156.0,KG,20230726,N,PH,US,,2023,Q3,Adult
227529771,22752977,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,D,,,,25.0,MG,,QD,2023,Q3,Pseudomonas infection,,2023,Q3,1,I,20230507.0,,20230726,20230726,DIR,668128,,FDA-CTU,,51.0,YR,,M,N,156.0,KG,20230726,N,PH,US,,2023,Q3,Adult
227529771,22752977,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,D,,,,25.0,MG,,QD,2023,Q3,Skin hypertrophy,,2023,Q3,1,I,20230507.0,,20230726,20230726,DIR,668128,,FDA-CTU,,51.0,YR,,M,N,156.0,KG,20230726,N,PH,US,,2023,Q3,Adult
227529771,22752977,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,D,,,,25.0,MG,,QD,2023,Q3,Gangrene,,2023,Q3,1,I,20230507.0,,20230726,20230726,DIR,668128,,FDA-CTU,,51.0,YR,,M,N,156.0,KG,20230726,N,PH,US,,2023,Q3,Adult
227529771,22752977,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,D,,,,25.0,MG,,QD,2023,Q3,Sensory disturbance,,2023,Q3,1,I,20230507.0,,20230726,20230726,DIR,668128,,FDA-CTU,,51.0,YR,,M,N,156.0,KG,20230726,N,PH,US,,2023,Q3,Adult
227529771,22752977,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,D,,,,25.0,MG,,QD,2023,Q3,Finger amputation,,2023,Q3,1,I,20230507.0,,20230726,20230726,DIR,668128,,FDA-CTU,,51.0,YR,,M,N,156.0,KG,20230726,N,PH,US,,2023,Q3,Adult
227531971,22753197,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2023,Q3,Surgery,,2023,Q3,1,I,20230501.0,20230719.0,20230726,20230726,EXP,,"CO-DAIICHI SANKYO, INC.-DSE-2023-130046",DAIICHI,,58.0,YR,,F,Y,68.0,KG,20230726,,CN,CO,CO,2023,Q3,Adult
227531971,22753197,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2023,Q3,Fall,,2023,Q3,1,I,20230501.0,20230719.0,20230726,20230726,EXP,,"CO-DAIICHI SANKYO, INC.-DSE-2023-130046",DAIICHI,,58.0,YR,,F,Y,68.0,KG,20230726,,CN,CO,CO,2023,Q3,Adult
227531971,22753197,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2023,Q3,Foot fracture,,2023,Q3,1,I,20230501.0,20230719.0,20230726,20230726,EXP,,"CO-DAIICHI SANKYO, INC.-DSE-2023-130046",DAIICHI,,58.0,YR,,F,Y,68.0,KG,20230726,,CN,CO,CO,2023,Q3,Adult
227531971,22753197,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2023,Q3,Gait disturbance,,2023,Q3,1,I,20230501.0,20230719.0,20230726,20230726,EXP,,"CO-DAIICHI SANKYO, INC.-DSE-2023-130046",DAIICHI,,58.0,YR,,F,Y,68.0,KG,20230726,,CN,CO,CO,2023,Q3,Adult
227531971,22753197,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2023,Q3,Lower limb fracture,,2023,Q3,1,I,20230501.0,20230719.0,20230726,20230726,EXP,,"CO-DAIICHI SANKYO, INC.-DSE-2023-130046",DAIICHI,,58.0,YR,,F,Y,68.0,KG,20230726,,CN,CO,CO,2023,Q3,Adult
227553791,22755379,32,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Cardiac failure chronic,,2023,Q3,1,I,20230703.0,20230720.0,20230727,20230727,EXP,,NVSC2023US161424,NOVARTIS,,80.0,YR,,M,Y,,,20230727,,HP,US,US,2023,Q3,Elderly
227553791,22755379,32,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Left ventricular dilatation,,2023,Q3,1,I,20230703.0,20230720.0,20230727,20230727,EXP,,NVSC2023US161424,NOVARTIS,,80.0,YR,,M,Y,,,20230727,,HP,US,US,2023,Q3,Elderly
227553791,22755379,32,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Neurotoxicity,,2023,Q3,1,I,20230703.0,20230720.0,20230727,20230727,EXP,,NVSC2023US161424,NOVARTIS,,80.0,YR,,M,Y,,,20230727,,HP,US,US,2023,Q3,Elderly
227553791,22755379,32,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Pleural effusion,,2023,Q3,1,I,20230703.0,20230720.0,20230727,20230727,EXP,,NVSC2023US161424,NOVARTIS,,80.0,YR,,M,Y,,,20230727,,HP,US,US,2023,Q3,Elderly
227553791,22755379,32,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Immune effector cell-associated neurotoxicity syndrome,,2023,Q3,1,I,20230703.0,20230720.0,20230727,20230727,EXP,,NVSC2023US161424,NOVARTIS,,80.0,YR,,M,Y,,,20230727,,HP,US,US,2023,Q3,Elderly
227553791,22755379,32,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Cytokine release syndrome,,2023,Q3,1,I,20230703.0,20230720.0,20230727,20230727,EXP,,NVSC2023US161424,NOVARTIS,,80.0,YR,,M,Y,,,20230727,,HP,US,US,2023,Q3,Elderly
227553791,22755379,32,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Oedema peripheral,,2023,Q3,1,I,20230703.0,20230720.0,20230727,20230727,EXP,,NVSC2023US161424,NOVARTIS,,80.0,YR,,M,Y,,,20230727,,HP,US,US,2023,Q3,Elderly
227553791,22755379,32,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Pyrexia,,2023,Q3,1,I,20230703.0,20230720.0,20230727,20230727,EXP,,NVSC2023US161424,NOVARTIS,,80.0,YR,,M,Y,,,20230727,,HP,US,US,2023,Q3,Elderly
227553791,22755379,32,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Mitral valve incompetence,,2023,Q3,1,I,20230703.0,20230720.0,20230727,20230727,EXP,,NVSC2023US161424,NOVARTIS,,80.0,YR,,M,Y,,,20230727,,HP,US,US,2023,Q3,Elderly
227553951,22755395,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,OD,,,Y,,,,,10.0,MG,,,2023,Q3,Euglycaemic diabetic ketoacidosis,,2023,Q3,1,I,,20230716.0,20230727,20230727,EXP,,CH-Inventia-000647,INVENTIA HEALTHCARE,"Nzomessi D, Massie E, Gariani K, Giraud R, Meyer P. Combined lactic acidosis and ketoacidosis in a female diabetic patient with severe heart failure. Cardiovasc Endocrinol Metab. 2023 Jul 4;12(3) :e0287.",58.0,YR,A,F,Y,,,20230727,,HP,CH,CH,2023,Q3,Adult
227553951,22755395,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,OD,,,Y,,,,,10.0,MG,,,2023,Q3,Lactic acidosis,,2023,Q3,1,I,,20230716.0,20230727,20230727,EXP,,CH-Inventia-000647,INVENTIA HEALTHCARE,"Nzomessi D, Massie E, Gariani K, Giraud R, Meyer P. Combined lactic acidosis and ketoacidosis in a female diabetic patient with severe heart failure. Cardiovasc Endocrinol Metab. 2023 Jul 4;12(3) :e0287.",58.0,YR,A,F,Y,,,20230727,,HP,CH,CH,2023,Q3,Adult
227553961,22755396,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,OD,,,Y,,,,,10.0,MG,,,2023,Q3,Euglycaemic diabetic ketoacidosis,,2023,Q3,1,I,,20230716.0,20230727,20230727,EXP,,CH-Indicus Pharma-000963,INDICUS,"Nzomessi D, Massie E, Gariani K, Giraud R, Meyer P. Combined lactic acidosis and ketoacidosis in a female diabetic patient with severe heart failure. Cardiovasc Endocrinol Metab. 2023 Jul 4;12(3):e0287.",58.0,YR,A,F,Y,,,20230727,,HP,CH,CH,2023,Q3,Adult
227553961,22755396,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,OD,,,Y,,,,,10.0,MG,,,2023,Q3,Lactic acidosis,,2023,Q3,1,I,,20230716.0,20230727,20230727,EXP,,CH-Indicus Pharma-000963,INDICUS,"Nzomessi D, Massie E, Gariani K, Giraud R, Meyer P. Combined lactic acidosis and ketoacidosis in a female diabetic patient with severe heart failure. Cardiovasc Endocrinol Metab. 2023 Jul 4;12(3):e0287.",58.0,YR,A,F,Y,,,20230727,,HP,CH,CH,2023,Q3,Adult
227568291,22756829,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Necrotising fasciitis,,2023,Q3,1,I,20230717.0,,20230726,20230726,DIR,FDA-CDER-CTU-2023-54881,,FDA-CTU,,41.0,YR,,M,N,147.0,KG,20230726,N,PH,US,,2023,Q3,Adult
227568291,22756829,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,HIV infection,,2023,Q3,1,I,20230717.0,,20230726,20230726,DIR,FDA-CDER-CTU-2023-54881,,FDA-CTU,,41.0,YR,,M,N,147.0,KG,20230726,N,PH,US,,2023,Q3,Adult
227568291,22756829,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Perineal cellulitis,,2023,Q3,1,I,20230717.0,,20230726,20230726,DIR,FDA-CDER-CTU-2023-54881,,FDA-CTU,,41.0,YR,,M,N,147.0,KG,20230726,N,PH,US,,2023,Q3,Adult
227568291,22756829,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Therapy cessation,,2023,Q3,1,I,20230717.0,,20230726,20230726,DIR,FDA-CDER-CTU-2023-54881,,FDA-CTU,,41.0,YR,,M,N,147.0,KG,20230726,N,PH,US,,2023,Q3,Adult
227572231,22757223,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, qd (take one daily)",,,,,,,,,,,QD,2023,Q3,Swelling face,,2023,Q3,1,I,20230720.0,20230722.0,20230727,20230727,EXP,GB-MHRA-TPP17067954C13778973YC1689856283441,GB-MYLANLABS-2023M1078763,MYLAN,,50.0,YR,,M,Y,100.0,KG,20230727,,HP,GB,GB,2023,Q3,Adult
227578692,22757869,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,Tablet,QD,2023,Q3,Off label use,,2023,Q3,2,F,20230705.0,20230810.0,20230727,20230815,EXP,,GB-MYLANLABS-2023M1078885,MYLAN,,26.0,YR,,M,Y,77.0,KG,20230815,,MD,GB,GB,2023,Q3,Young Adult
227578692,22757869,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,Tablet,QD,2023,Q3,Dizziness,,2023,Q3,2,F,20230705.0,20230810.0,20230727,20230815,EXP,,GB-MYLANLABS-2023M1078885,MYLAN,,26.0,YR,,M,Y,77.0,KG,20230815,,MD,GB,GB,2023,Q3,Young Adult
227578692,22757869,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,Tablet,QD,2023,Q3,Hot flush,,2023,Q3,2,F,20230705.0,20230810.0,20230727,20230815,EXP,,GB-MYLANLABS-2023M1078885,MYLAN,,26.0,YR,,M,Y,77.0,KG,20230815,,MD,GB,GB,2023,Q3,Young Adult
227588661,22758866,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Infection,,2023,Q3,1,I,,20230714.0,20230728,20230728,EXP,,GB-AUROBINDO-AUR-APL-2023-049356,AUROBINDO,,8.0,DEC,,M,Y,,,20230728,,HP,GB,GB,2023,Q3,Child
227588661,22758866,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Diabetic ketoacidosis,,2023,Q3,1,I,,20230714.0,20230728,20230728,EXP,,GB-AUROBINDO-AUR-APL-2023-049356,AUROBINDO,,8.0,DEC,,M,Y,,,20230728,,HP,GB,GB,2023,Q3,Child
227600261,22760026,9,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"The patient takes 1 tablet containing 10 mg of empagliflozin + 5 mg of linagliptin, once a day.",,,,,,,,10.0,MG,Tablet,,2023,Q3,Thrombocytopenia,,2023,Q3,1,I,20230614.0,20230719.0,20230728,20230728,EXP,IT-MINISAL02-934431,IT-TEVA-2023-IT-2910992,TEVA,,79.0,YR,E,M,Y,94.0,KG,20230728,,PH,IT,IT,2023,Q3,Elderly
227600261,22760026,10,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"The patient takes 1 tablet containing 10 mg of empagliflozin + 5 mg of linagliptin, once a day.",,,,,,,,5.0,MG,Tablet,,2023,Q3,Thrombocytopenia,,2023,Q3,1,I,20230614.0,20230719.0,20230728,20230728,EXP,IT-MINISAL02-934431,IT-TEVA-2023-IT-2910992,TEVA,,79.0,YR,E,M,Y,94.0,KG,20230728,,PH,IT,IT,2023,Q3,Elderly
227610671,22761067,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 milligram daily,,,,,UNK,,,25.0,MG,,,2023,Q3,Acute kidney injury,,2023,Q3,1,I,,20230717.0,20230728,20230728,EXP,,US-NOVAST LABORATORIES INC.-2023NOV000279,NOVAST,"Sardarli K, Leong R, Gill I, Zarouk SS.. A patient with combined metformin-induced lactic acidosis and euglycemic diabetic ketoacidosis.. J Am Soc Nephrol.. 2021;32(Suppl 2):384",66.0,YR,,F,Y,,,20230728,,HP,US,US,2023,Q3,Elderly
227610671,22761067,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 milligram daily,,,,,UNK,,,25.0,MG,,,2023,Q3,Lactic acidosis,,2023,Q3,1,I,,20230717.0,20230728,20230728,EXP,,US-NOVAST LABORATORIES INC.-2023NOV000279,NOVAST,"Sardarli K, Leong R, Gill I, Zarouk SS.. A patient with combined metformin-induced lactic acidosis and euglycemic diabetic ketoacidosis.. J Am Soc Nephrol.. 2021;32(Suppl 2):384",66.0,YR,,F,Y,,,20230728,,HP,US,US,2023,Q3,Elderly
227610671,22761067,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 milligram daily,,,,,UNK,,,25.0,MG,,,2023,Q3,Euglycaemic diabetic ketoacidosis,,2023,Q3,1,I,,20230717.0,20230728,20230728,EXP,,US-NOVAST LABORATORIES INC.-2023NOV000279,NOVAST,"Sardarli K, Leong R, Gill I, Zarouk SS.. A patient with combined metformin-induced lactic acidosis and euglycemic diabetic ketoacidosis.. J Am Soc Nephrol.. 2021;32(Suppl 2):384",66.0,YR,,F,Y,,,20230728,,HP,US,US,2023,Q3,Elderly
227613201,22761320,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,D,,,,,,,QD,2023,Q3,Euglycaemic diabetic ketoacidosis,,2023,Q3,1,I,20230726.0,,20230727,20230727,DIR,668342,,FDA-CTU,,54.0,YR,,F,N,52.0,KG,20230727,N,PH,US,,2023,Q3,Adult
227640651,22764065,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,ongoing,,,,,Unknown,,204629.0,10.0,MG,,QD,2023,Q3,Chronic kidney disease,,2023,Q3,1,I,,20230725.0,20230731,20230731,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-251685",BOEHRINGER INGELHEIM,,69.0,YR,E,F,Y,,,20230731,,MD,PL,PL,2023,Q3,Elderly
227640651,22764065,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,ongoing,,,,,Unknown,,204629.0,10.0,MG,,QD,2023,Q3,Enteritis,,2023,Q3,1,I,,20230725.0,20230731,20230731,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-251685",BOEHRINGER INGELHEIM,,69.0,YR,E,F,Y,,,20230731,,MD,PL,PL,2023,Q3,Elderly
227640651,22764065,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,ongoing,,,,,Unknown,,204629.0,10.0,MG,,QD,2023,Q3,Dehydration,,2023,Q3,1,I,,20230725.0,20230731,20230731,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-251685",BOEHRINGER INGELHEIM,,69.0,YR,E,F,Y,,,20230731,,MD,PL,PL,2023,Q3,Elderly
227657641,22765764,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Unknown,,204629.0,10.0,MG,,QD,2023,Q3,Ketoacidosis,,2023,Q3,1,I,20220619.0,20230731.0,20230731,20230731,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-252425",BOEHRINGER INGELHEIM,,88.0,YR,E,M,Y,75.0,KG,20230731,,MD,DE,DE,2023,Q3,Elderly
227657641,22765764,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Unknown,,204629.0,10.0,MG,,QD,2023,Q3,Dehydration,,2023,Q3,1,I,20220619.0,20230731.0,20230731,20230731,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-252425",BOEHRINGER INGELHEIM,,88.0,YR,E,M,Y,75.0,KG,20230731,,MD,DE,DE,2023,Q3,Elderly
227657641,22765764,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Unknown,,204629.0,10.0,MG,,QD,2023,Q3,Asthenia,,2023,Q3,1,I,20220619.0,20230731.0,20230731,20230731,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-252425",BOEHRINGER INGELHEIM,,88.0,YR,E,M,Y,75.0,KG,20230731,,MD,DE,DE,2023,Q3,Elderly
227657641,22765764,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Unknown,,204629.0,10.0,MG,,QD,2023,Q3,Disturbance in attention,,2023,Q3,1,I,20220619.0,20230731.0,20230731,20230731,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-252425",BOEHRINGER INGELHEIM,,88.0,YR,E,M,Y,75.0,KG,20230731,,MD,DE,DE,2023,Q3,Elderly
227667041,22766704,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,Tablet,,2023,Q3,Amputation,,2023,Q3,1,I,20230723.0,20230730.0,20230731,20230731,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-252443",BOEHRINGER INGELHEIM,,74.0,YR,E,M,Y,70.0,KG,20230731,,HP,GB,GB,2023,Q3,Elderly
227676571,22767657,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Diabetes mellitus inadequate control,,2023,Q3,1,I,,20230724.0,20230731,20230731,EXP,,PL-MYLANLABS-2023M1079094,MYLAN,Naskret D.. Empagliflozin in the treatment of type 2 diabetes.. THE WORLD OF MEDICINE AND PHARMACY.. 2023;260(5):14-20,68.0,YR,,M,Y,81.0,KG,20230731,,MD,PL,PL,2023,Q3,Elderly
227676571,22767657,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Weight increased,,2023,Q3,1,I,,20230724.0,20230731,20230731,EXP,,PL-MYLANLABS-2023M1079094,MYLAN,Naskret D.. Empagliflozin in the treatment of type 2 diabetes.. THE WORLD OF MEDICINE AND PHARMACY.. 2023;260(5):14-20,68.0,YR,,M,Y,81.0,KG,20230731,,MD,PL,PL,2023,Q3,Elderly
227676571,22767657,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Medication error,,2023,Q3,1,I,,20230724.0,20230731,20230731,EXP,,PL-MYLANLABS-2023M1079094,MYLAN,Naskret D.. Empagliflozin in the treatment of type 2 diabetes.. THE WORLD OF MEDICINE AND PHARMACY.. 2023;260(5):14-20,68.0,YR,,M,Y,81.0,KG,20230731,,MD,PL,PL,2023,Q3,Elderly
227676571,22767657,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Atrial fibrillation,,2023,Q3,1,I,,20230724.0,20230731,20230731,EXP,,PL-MYLANLABS-2023M1079094,MYLAN,Naskret D.. Empagliflozin in the treatment of type 2 diabetes.. THE WORLD OF MEDICINE AND PHARMACY.. 2023;260(5):14-20,68.0,YR,,M,Y,81.0,KG,20230731,,MD,PL,PL,2023,Q3,Elderly
227676571,22767657,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Diabetic metabolic decompensation,,2023,Q3,1,I,,20230724.0,20230731,20230731,EXP,,PL-MYLANLABS-2023M1079094,MYLAN,Naskret D.. Empagliflozin in the treatment of type 2 diabetes.. THE WORLD OF MEDICINE AND PHARMACY.. 2023;260(5):14-20,68.0,YR,,M,Y,81.0,KG,20230731,,MD,PL,PL,2023,Q3,Elderly
227676571,22767657,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Intentional product misuse,,2023,Q3,1,I,,20230724.0,20230731,20230731,EXP,,PL-MYLANLABS-2023M1079094,MYLAN,Naskret D.. Empagliflozin in the treatment of type 2 diabetes.. THE WORLD OF MEDICINE AND PHARMACY.. 2023;260(5):14-20,68.0,YR,,M,Y,81.0,KG,20230731,,MD,PL,PL,2023,Q3,Elderly
227676571,22767657,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Cardiac failure,,2023,Q3,1,I,,20230724.0,20230731,20230731,EXP,,PL-MYLANLABS-2023M1079094,MYLAN,Naskret D.. Empagliflozin in the treatment of type 2 diabetes.. THE WORLD OF MEDICINE AND PHARMACY.. 2023;260(5):14-20,68.0,YR,,M,Y,81.0,KG,20230731,,MD,PL,PL,2023,Q3,Elderly
227676571,22767657,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Drug abuse,,2023,Q3,1,I,,20230724.0,20230731,20230731,EXP,,PL-MYLANLABS-2023M1079094,MYLAN,Naskret D.. Empagliflozin in the treatment of type 2 diabetes.. THE WORLD OF MEDICINE AND PHARMACY.. 2023;260(5):14-20,68.0,YR,,M,Y,81.0,KG,20230731,,MD,PL,PL,2023,Q3,Elderly
227699711,22769971,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Pain in extremity,,2023,Q3,1,I,,20230414.0,20230801,20230801,PER,,US-STRIDES ARCOLAB LIMITED-2023SP005694,STRIDES,"Young MK, Holder KG, Baker TE, Kauffman RP.. Vulvovaginal erosive lichen planus refractory to topical therapies: What+amp;apos;s next? A case report.. Case-Rep-Women-Health. 2023;37:1-5",60.0,YR,,F,Y,,,20230801,,HP,US,US,2023,Q3,Adult
227699711,22769971,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Off label use,,2023,Q3,1,I,,20230414.0,20230801,20230801,PER,,US-STRIDES ARCOLAB LIMITED-2023SP005694,STRIDES,"Young MK, Holder KG, Baker TE, Kauffman RP.. Vulvovaginal erosive lichen planus refractory to topical therapies: What+amp;apos;s next? A case report.. Case-Rep-Women-Health. 2023;37:1-5",60.0,YR,,F,Y,,,20230801,,HP,US,US,2023,Q3,Adult
227699711,22769971,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Myalgia,,2023,Q3,1,I,,20230414.0,20230801,20230801,PER,,US-STRIDES ARCOLAB LIMITED-2023SP005694,STRIDES,"Young MK, Holder KG, Baker TE, Kauffman RP.. Vulvovaginal erosive lichen planus refractory to topical therapies: What+amp;apos;s next? A case report.. Case-Rep-Women-Health. 2023;37:1-5",60.0,YR,,F,Y,,,20230801,,HP,US,US,2023,Q3,Adult
227699711,22769971,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Therapy partial responder,,2023,Q3,1,I,,20230414.0,20230801,20230801,PER,,US-STRIDES ARCOLAB LIMITED-2023SP005694,STRIDES,"Young MK, Holder KG, Baker TE, Kauffman RP.. Vulvovaginal erosive lichen planus refractory to topical therapies: What+amp;apos;s next? A case report.. Case-Rep-Women-Health. 2023;37:1-5",60.0,YR,,F,Y,,,20230801,,HP,US,US,2023,Q3,Adult
227711781,22771178,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg film-coated tablets,,,,,,,,,,Film-coated tablet,,2023,Q3,Ischaemic stroke,,2023,Q3,1,I,20230505.0,20230720.0,20230801,20230801,EXP,FR-AFSSAPS-NY2023000885,FR-Accord-370166,ACCORD,,72.0,YR,E,F,Y,,,20230801,,PH,FR,FR,2023,Q3,Elderly
227712981,22771298,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,take one daily,,,,,,,,,,,,2023,Q3,Swelling face,,2023,Q3,1,I,20230720.0,20230722.0,20230801,20230801,EXP,GB-MHRA-TPP17067954C13778973YC1689856283441,GB-INSUD PHARMA-2307GB04905,INSUD PHARMA,,50.0,YR,,M,Y,100.0,KG,20230801,,HP,GB,GB,2023,Q3,Adult
227725331,22772533,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,0.4 mg/kg/24 h,,,U,,,,,,,,,2023,Q3,Ear infection,,2023,Q3,1,I,,20230717.0,20230801,20230801,EXP,,PL-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-401859,RANBAXY,"Kaczor M, Greczan M, Kierus K, Ehmke Vel Emczynska-Seliga E, Ciara E, et al. Sodium-glucose cotransporter type 2 channel inhibitor: Breakthrough in the treatment of neutropenia in patients with glycogen storage disease type 1b?. JIMD Rep. 2022;63:199-206",9.0,YR,,F,Y,,,20230801,,HP,PL,PL,2023,Q3,Child
227725331,22772533,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,0.4 mg/kg/24 h,,,U,,,,,,,,,2023,Q3,Sinusitis,,2023,Q3,1,I,,20230717.0,20230801,20230801,EXP,,PL-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-401859,RANBAXY,"Kaczor M, Greczan M, Kierus K, Ehmke Vel Emczynska-Seliga E, Ciara E, et al. Sodium-glucose cotransporter type 2 channel inhibitor: Breakthrough in the treatment of neutropenia in patients with glycogen storage disease type 1b?. JIMD Rep. 2022;63:199-206",9.0,YR,,F,Y,,,20230801,,HP,PL,PL,2023,Q3,Child
227725331,22772533,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,0.4 mg/kg/24 h,,,U,,,,,,,,,2023,Q3,Oral pain,,2023,Q3,1,I,,20230717.0,20230801,20230801,EXP,,PL-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-401859,RANBAXY,"Kaczor M, Greczan M, Kierus K, Ehmke Vel Emczynska-Seliga E, Ciara E, et al. Sodium-glucose cotransporter type 2 channel inhibitor: Breakthrough in the treatment of neutropenia in patients with glycogen storage disease type 1b?. JIMD Rep. 2022;63:199-206",9.0,YR,,F,Y,,,20230801,,HP,PL,PL,2023,Q3,Child
227725331,22772533,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,0.4 mg/kg/24 h,,,U,,,,,,,,,2023,Q3,Drug ineffective,,2023,Q3,1,I,,20230717.0,20230801,20230801,EXP,,PL-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-401859,RANBAXY,"Kaczor M, Greczan M, Kierus K, Ehmke Vel Emczynska-Seliga E, Ciara E, et al. Sodium-glucose cotransporter type 2 channel inhibitor: Breakthrough in the treatment of neutropenia in patients with glycogen storage disease type 1b?. JIMD Rep. 2022;63:199-206",9.0,YR,,F,Y,,,20230801,,HP,PL,PL,2023,Q3,Child
227725401,22772540,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Drug ineffective,,2023,Q3,1,I,,20230717.0,20230801,20230801,EXP,,PL-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-401857,RANBAXY,"Kaczor M, Greczan M, Kierus K, Ehmke Vel Emczynska-Seliga E, Ciara E, et al. Sodium-glucose cotransporter type 2 channel inhibitor: Breakthrough in the treatment of neutropenia in patients with glycogen storage disease type 1b?. JIMD Rep. 2022;63:199-206",17.0,YR,,M,Y,,,20230801,,HP,PL,PL,2023,Q3,Youth
227725401,22772540,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Infection,,2023,Q3,1,I,,20230717.0,20230801,20230801,EXP,,PL-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-401857,RANBAXY,"Kaczor M, Greczan M, Kierus K, Ehmke Vel Emczynska-Seliga E, Ciara E, et al. Sodium-glucose cotransporter type 2 channel inhibitor: Breakthrough in the treatment of neutropenia in patients with glycogen storage disease type 1b?. JIMD Rep. 2022;63:199-206",17.0,YR,,M,Y,,,20230801,,HP,PL,PL,2023,Q3,Youth
227725401,22772540,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Lung disorder,,2023,Q3,1,I,,20230717.0,20230801,20230801,EXP,,PL-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-401857,RANBAXY,"Kaczor M, Greczan M, Kierus K, Ehmke Vel Emczynska-Seliga E, Ciara E, et al. Sodium-glucose cotransporter type 2 channel inhibitor: Breakthrough in the treatment of neutropenia in patients with glycogen storage disease type 1b?. JIMD Rep. 2022;63:199-206",17.0,YR,,M,Y,,,20230801,,HP,PL,PL,2023,Q3,Youth
227730021,22773002,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 Dosage forms Daily; take one daily,,,,,,,,,,,QD,2023,Q3,Swelling face,,2023,Q3,1,I,20230720.0,20230722.0,20230801,20230801,EXP,GB-MHRA-TPP17067954C13778973YC1689856283441,GB-TEVA-2023-GB-2913089,TEVA,,50.0,YR,A,M,Y,100.0,KG,20230801,,HP,GB,GB,2023,Q3,Adult
227753151,22775315,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,10.0,MG,,,E91527,,204629.0,10.0,MG,Tablet,QD,2023,Q3,Vision blurred,,2023,Q3,1,I,20230730.0,20230730.0,20230802,20230802,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-252784",BOEHRINGER INGELHEIM,,51.0,YR,A,F,Y,,,20230802,,CN,GB,GB,2023,Q3,Adult
227758343,22775834,2,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,"UNK UNK, unknown freq.",,,,,,,,,,Per oral NOS,,2023,Q3,Glycosylated haemoglobin increased,,2023,Q3,3,F,20230530.0,20230925.0,20230802,20230927,EXP,,JP-ASTELLAS-2023JP006344,ASTELLAS,,8.0,DEC,,F,Y,,,20230927,,PH,JP,JP,2023,Q3,Child
227758343,22775834,2,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,"UNK UNK, unknown freq.",,,,,,,,,,Per oral NOS,,2023,Q3,Urinary incontinence,,2023,Q3,3,F,20230530.0,20230925.0,20230802,20230927,EXP,,JP-ASTELLAS-2023JP006344,ASTELLAS,,8.0,DEC,,F,Y,,,20230927,,PH,JP,JP,2023,Q3,Child
227758343,22775834,2,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,"UNK UNK, unknown freq.",,,,,,,,,,Per oral NOS,,2023,Q3,Blood glucose increased,,2023,Q3,3,F,20230530.0,20230925.0,20230802,20230927,EXP,,JP-ASTELLAS-2023JP006344,ASTELLAS,,8.0,DEC,,F,Y,,,20230927,,PH,JP,JP,2023,Q3,Child
227758343,22775834,2,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,"UNK UNK, unknown freq.",,,,,,,,,,Per oral NOS,,2023,Q3,Diabetes mellitus,,2023,Q3,3,F,20230530.0,20230925.0,20230802,20230927,EXP,,JP-ASTELLAS-2023JP006344,ASTELLAS,,8.0,DEC,,F,Y,,,20230927,,PH,JP,JP,2023,Q3,Child
227758343,22775834,2,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,"UNK UNK, unknown freq.",,,,,,,,,,Per oral NOS,,2023,Q3,Pollakiuria,,2023,Q3,3,F,20230530.0,20230925.0,20230802,20230927,EXP,,JP-ASTELLAS-2023JP006344,ASTELLAS,,8.0,DEC,,F,Y,,,20230927,,PH,JP,JP,2023,Q3,Child
227763831,22776383,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2023,Q3,Visual impairment,,2023,Q3,1,I,20230401.0,20230722.0,20230802,20230802,EXP,FR-AFSSAPS-NY2023000849,FR-Accord-370400,ACCORD,,78.0,YR,E,F,Y,,,20230802,,MD,FR,FR,2023,Q3,Elderly
227763831,22776383,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2023,Q3,Polyuria,,2023,Q3,1,I,20230401.0,20230722.0,20230802,20230802,EXP,FR-AFSSAPS-NY2023000849,FR-Accord-370400,ACCORD,,78.0,YR,E,F,Y,,,20230802,,MD,FR,FR,2023,Q3,Elderly
227763831,22776383,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2023,Q3,Loss of consciousness,,2023,Q3,1,I,20230401.0,20230722.0,20230802,20230802,EXP,FR-AFSSAPS-NY2023000849,FR-Accord-370400,ACCORD,,78.0,YR,E,F,Y,,,20230802,,MD,FR,FR,2023,Q3,Elderly
227763831,22776383,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2023,Q3,Myalgia,,2023,Q3,1,I,20230401.0,20230722.0,20230802,20230802,EXP,FR-AFSSAPS-NY2023000849,FR-Accord-370400,ACCORD,,78.0,YR,E,F,Y,,,20230802,,MD,FR,FR,2023,Q3,Elderly
227763831,22776383,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2023,Q3,Fatigue,,2023,Q3,1,I,20230401.0,20230722.0,20230802,20230802,EXP,FR-AFSSAPS-NY2023000849,FR-Accord-370400,ACCORD,,78.0,YR,E,F,Y,,,20230802,,MD,FR,FR,2023,Q3,Elderly
227763831,22776383,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2023,Q3,Dizziness,,2023,Q3,1,I,20230401.0,20230722.0,20230802,20230802,EXP,FR-AFSSAPS-NY2023000849,FR-Accord-370400,ACCORD,,78.0,YR,E,F,Y,,,20230802,,MD,FR,FR,2023,Q3,Elderly
227772501,22777250,2,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q3,Euglycaemic diabetic ketoacidosis,,2023,Q3,1,I,,20230726.0,20230802,20230802,EXP,,GR-MYLANLABS-2023M1080406,MYLAN,"Papanikolaou D.. 49th Annual Panhellenic Medical congress. 11-13 May 2023, Divani Caravel Hotel, Athens.. Not reported. 2023",70.0,YR,,F,Y,,,20230802,,MD,GR,GR,2023,Q3,Elderly
227772501,22777250,2,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q3,Haemodynamic instability,,2023,Q3,1,I,,20230726.0,20230802,20230802,EXP,,GR-MYLANLABS-2023M1080406,MYLAN,"Papanikolaou D.. 49th Annual Panhellenic Medical congress. 11-13 May 2023, Divani Caravel Hotel, Athens.. Not reported. 2023",70.0,YR,,F,Y,,,20230802,,MD,GR,GR,2023,Q3,Elderly
227772501,22777250,2,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q3,Diarrhoea,,2023,Q3,1,I,,20230726.0,20230802,20230802,EXP,,GR-MYLANLABS-2023M1080406,MYLAN,"Papanikolaou D.. 49th Annual Panhellenic Medical congress. 11-13 May 2023, Divani Caravel Hotel, Athens.. Not reported. 2023",70.0,YR,,F,Y,,,20230802,,MD,GR,GR,2023,Q3,Elderly
227772501,22777250,2,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q3,Anuria,,2023,Q3,1,I,,20230726.0,20230802,20230802,EXP,,GR-MYLANLABS-2023M1080406,MYLAN,"Papanikolaou D.. 49th Annual Panhellenic Medical congress. 11-13 May 2023, Divani Caravel Hotel, Athens.. Not reported. 2023",70.0,YR,,F,Y,,,20230802,,MD,GR,GR,2023,Q3,Elderly
227784651,22778465,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2023,Q3,Necrotising fasciitis,,2023,Q3,1,I,20220811.0,20230802.0,20230802,20230802,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-253155",BOEHRINGER INGELHEIM,,66.0,YR,E,F,Y,,,20230802,,HP,GB,GB,2023,Q3,Elderly
227802101,22780210,2,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"505 mg, qd",,,,,2212703,,,505.0,MG,,QD,2023,Q3,Marasmus,,2023,Q3,1,I,20230627.0,20230726.0,20230803,20230803,EXP,CN-NMPA-3303011655707202300530,CN-NOVOPROD-1097205,NOVO NORDISK,,54.0,YR,,M,Y,52.0,KG,20230803,,HP,CN,CN,2023,Q3,Adult
227807341,22780734,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q3,Asthenia,,2023,Q3,1,I,20230703.0,20230802.0,20230803,20230803,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-253065",BOEHRINGER INGELHEIM,,63.0,YR,A,F,Y,,,20230803,,HP,SG,SG,2023,Q3,Adult
227807341,22780734,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q3,Headache,,2023,Q3,1,I,20230703.0,20230802.0,20230803,20230803,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-253065",BOEHRINGER INGELHEIM,,63.0,YR,A,F,Y,,,20230803,,HP,SG,SG,2023,Q3,Adult
227818691,22781869,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q3,Ketosis,,2023,Q3,1,I,20230701.0,20230802.0,20230803,20230803,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-253072",BOEHRINGER INGELHEIM,,55.0,YR,A,M,Y,,,20230803,,HP,SG,SG,2023,Q3,Adult
227843641,22784364,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,204629.0,,,,,2023,Q3,Diabetic ketoacidotic hyperglycaemic coma,,2023,Q3,1,I,,20230731.0,20230803,20230803,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-252437",BOEHRINGER INGELHEIM,,56.0,YR,A,F,Y,,,20230804,,MD,DE,DE,2023,Q3,Adult
227843641,22784364,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,204629.0,,,,,2023,Q3,Hyperkalaemia,,2023,Q3,1,I,,20230731.0,20230803,20230803,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-252437",BOEHRINGER INGELHEIM,,56.0,YR,A,F,Y,,,20230804,,MD,DE,DE,2023,Q3,Adult
227843641,22784364,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,204629.0,,,,,2023,Q3,Dehydration,,2023,Q3,1,I,,20230731.0,20230803,20230803,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-252437",BOEHRINGER INGELHEIM,,56.0,YR,A,F,Y,,,20230804,,MD,DE,DE,2023,Q3,Adult
227843641,22784364,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,204629.0,,,,,2023,Q3,Acute kidney injury,,2023,Q3,1,I,,20230731.0,20230803,20230803,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-252437",BOEHRINGER INGELHEIM,,56.0,YR,A,F,Y,,,20230804,,MD,DE,DE,2023,Q3,Adult
227843641,22784364,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,204629.0,,,,,2023,Q3,Gastroenteritis,,2023,Q3,1,I,,20230731.0,20230803,20230803,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-252437",BOEHRINGER INGELHEIM,,56.0,YR,A,F,Y,,,20230804,,MD,DE,DE,2023,Q3,Adult
227917451,22791745,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,0.4 milligram/kilogram/day,,,,,,,,0.4,MG/KG,,,2023,Q3,Drug ineffective,,2023,Q3,1,I,,20230724.0,20230807,20230807,EXP,,PL-AUROBINDO-AUR-APL-2023-050765,AUROBINDO,"Kaczor M, Greczan M, Kierus K, Ehmke vel Emczynska-Seliga E, Ciara E, Piatosa B, et al. Sodium-glucose cotransporter type 2 channel inhibitor: Breakthrough in the treatment of neutropenia in patients with glycogen storage disease type 1b?. JIMD-Rep. 2022;63(3):199-206",8.0,MON,,F,Y,,,20230807,,HP,PL,PL,2023,Q3,Child
227921774,22792177,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Asked But Unknown,,204629.0,10.0,MG,Coated tablet,QD,2023,Q3,Tracheal stenosis,,2023,Q3,4,F,20230726.0,20230821.0,20230807,20230822,EXP,,"VN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-253851",BOEHRINGER INGELHEIM,,62.0,YR,A,F,Y,55.0,KG,20230822,,MD,VN,VN,2023,Q3,Adult
227943521,22794352,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, Daily",,,U,,,,,,,,,2023,Q3,Swelling face,,2023,Q3,1,I,20230720.0,20230723.0,20230807,20230807,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-402189,RANBAXY,,50.0,YR,,M,Y,100.0,KG,20230807,,HP,GB,GB,2023,Q3,Adult
227945181,22794518,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2023,Q3,Cardiac failure,,2023,Q3,1,I,20230501.0,20230804.0,20230807,20230807,EXP,,ES-TAKEDA-2023TUS077005,TAKEDA,,70.0,YR,,F,Y,,,20230807,,HP,ES,ES,2023,Q3,Elderly
227947861,22794786,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,,,,,,,,,,2023,Q3,Somnolence,,2023,Q3,1,I,,20230727.0,20230807,20230807,EXP,ES-TEVA-2023-ES-2887829,ES-EMD Serono-2023464907,EMD SERONO INC,"Abdala Kuri S, Devora S, Oliva AM, Morales C. The added value of professional pharmaceutical care services. A case of SFT. Community Farms. 2023;15 (2): 45-51. doi:10.33620/FC.2173- 9218.(2023).13.",62.0,YR,A,F,Y,90.0,KG,20230807,,HP,ES,ES,2023,Q3,Adult
227947861,22794786,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,,,,,,,,,,2023,Q3,Hypotension,,2023,Q3,1,I,,20230727.0,20230807,20230807,EXP,ES-TEVA-2023-ES-2887829,ES-EMD Serono-2023464907,EMD SERONO INC,"Abdala Kuri S, Devora S, Oliva AM, Morales C. The added value of professional pharmaceutical care services. A case of SFT. Community Farms. 2023;15 (2): 45-51. doi:10.33620/FC.2173- 9218.(2023).13.",62.0,YR,A,F,Y,90.0,KG,20230807,,HP,ES,ES,2023,Q3,Adult
227947861,22794786,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,,,,,,,,,,2023,Q3,Hallucination,,2023,Q3,1,I,,20230727.0,20230807,20230807,EXP,ES-TEVA-2023-ES-2887829,ES-EMD Serono-2023464907,EMD SERONO INC,"Abdala Kuri S, Devora S, Oliva AM, Morales C. The added value of professional pharmaceutical care services. A case of SFT. Community Farms. 2023;15 (2): 45-51. doi:10.33620/FC.2173- 9218.(2023).13.",62.0,YR,A,F,Y,90.0,KG,20230807,,HP,ES,ES,2023,Q3,Adult
227947861,22794786,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,,,,,,,,,,2023,Q3,Parkinsonism,,2023,Q3,1,I,,20230727.0,20230807,20230807,EXP,ES-TEVA-2023-ES-2887829,ES-EMD Serono-2023464907,EMD SERONO INC,"Abdala Kuri S, Devora S, Oliva AM, Morales C. The added value of professional pharmaceutical care services. A case of SFT. Community Farms. 2023;15 (2): 45-51. doi:10.33620/FC.2173- 9218.(2023).13.",62.0,YR,A,F,Y,90.0,KG,20230807,,HP,ES,ES,2023,Q3,Adult
227947861,22794786,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,,,,,,,,,,2023,Q3,Hypoglycaemia,,2023,Q3,1,I,,20230727.0,20230807,20230807,EXP,ES-TEVA-2023-ES-2887829,ES-EMD Serono-2023464907,EMD SERONO INC,"Abdala Kuri S, Devora S, Oliva AM, Morales C. The added value of professional pharmaceutical care services. A case of SFT. Community Farms. 2023;15 (2): 45-51. doi:10.33620/FC.2173- 9218.(2023).13.",62.0,YR,A,F,Y,90.0,KG,20230807,,HP,ES,ES,2023,Q3,Adult
227947861,22794786,30,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,,,,,,,,,,2023,Q3,Somnolence,,2023,Q3,1,I,,20230727.0,20230807,20230807,EXP,ES-TEVA-2023-ES-2887829,ES-EMD Serono-2023464907,EMD SERONO INC,"Abdala Kuri S, Devora S, Oliva AM, Morales C. The added value of professional pharmaceutical care services. A case of SFT. Community Farms. 2023;15 (2): 45-51. doi:10.33620/FC.2173- 9218.(2023).13.",62.0,YR,A,F,Y,90.0,KG,20230807,,HP,ES,ES,2023,Q3,Adult
227947861,22794786,30,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,,,,,,,,,,2023,Q3,Hypotension,,2023,Q3,1,I,,20230727.0,20230807,20230807,EXP,ES-TEVA-2023-ES-2887829,ES-EMD Serono-2023464907,EMD SERONO INC,"Abdala Kuri S, Devora S, Oliva AM, Morales C. The added value of professional pharmaceutical care services. A case of SFT. Community Farms. 2023;15 (2): 45-51. doi:10.33620/FC.2173- 9218.(2023).13.",62.0,YR,A,F,Y,90.0,KG,20230807,,HP,ES,ES,2023,Q3,Adult
227947861,22794786,30,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,,,,,,,,,,2023,Q3,Hallucination,,2023,Q3,1,I,,20230727.0,20230807,20230807,EXP,ES-TEVA-2023-ES-2887829,ES-EMD Serono-2023464907,EMD SERONO INC,"Abdala Kuri S, Devora S, Oliva AM, Morales C. The added value of professional pharmaceutical care services. A case of SFT. Community Farms. 2023;15 (2): 45-51. doi:10.33620/FC.2173- 9218.(2023).13.",62.0,YR,A,F,Y,90.0,KG,20230807,,HP,ES,ES,2023,Q3,Adult
227947861,22794786,30,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,,,,,,,,,,2023,Q3,Parkinsonism,,2023,Q3,1,I,,20230727.0,20230807,20230807,EXP,ES-TEVA-2023-ES-2887829,ES-EMD Serono-2023464907,EMD SERONO INC,"Abdala Kuri S, Devora S, Oliva AM, Morales C. The added value of professional pharmaceutical care services. A case of SFT. Community Farms. 2023;15 (2): 45-51. doi:10.33620/FC.2173- 9218.(2023).13.",62.0,YR,A,F,Y,90.0,KG,20230807,,HP,ES,ES,2023,Q3,Adult
227947861,22794786,30,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,,,,,,,,,,2023,Q3,Hypoglycaemia,,2023,Q3,1,I,,20230727.0,20230807,20230807,EXP,ES-TEVA-2023-ES-2887829,ES-EMD Serono-2023464907,EMD SERONO INC,"Abdala Kuri S, Devora S, Oliva AM, Morales C. The added value of professional pharmaceutical care services. A case of SFT. Community Farms. 2023;15 (2): 45-51. doi:10.33620/FC.2173- 9218.(2023).13.",62.0,YR,A,F,Y,90.0,KG,20230807,,HP,ES,ES,2023,Q3,Adult
227960411,22796041,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,Tablet,QD,2023,Q3,Toe amputation,,2023,Q3,1,I,20230729.0,20230804.0,20230808,20230808,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-253857",BOEHRINGER INGELHEIM,,69.0,YR,E,M,Y,115.0,KG,20230808,,PH,GB,GB,2023,Q3,Elderly
227964791,22796479,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 g, qd",,,,,,,,1.0,GM,,QD,2023,Q3,Arthralgia,,2023,Q3,1,I,,20230726.0,20230808,20230808,EXP,GB-MHRA-TPP44378636C7379339YC1689867482381,"GB-ESPERION THERAPEUTICS, INC-2023GBR00812",ESPERION THERAPEUTICS,,75.0,YR,,F,Y,99.0,KG,20230808,,HP,GB,GB,2023,Q3,Elderly
227965362,22796536,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,Y,Unknown,,204629.0,,,Coated tablet,,2023,Q3,Vulvovaginal pruritus,Vulvovaginal pruritus,2023,Q3,2,F,20230607.0,20230815.0,20230808,20230822,EXP,,"RO-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-252852",BOEHRINGER INGELHEIM,,65.0,YR,E,F,Y,113.0,KG,20230822,,MD,RO,RO,2023,Q3,Elderly
227993971,22799397,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,5mg/1000mg dose twice daily,,,Y,,Asked But Unknown,,208658.0,,,,Q12H,2023,Q3,Cardiac valve abscess,,2023,Q3,1,I,20171226.0,20230806.0,20230808,20230808,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-251629",BOEHRINGER INGELHEIM,,66.0,YR,E,M,Y,87.4,KG,20230808,,MD,AU,AU,2023,Q3,Elderly
227993971,22799397,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,5mg/1000mg dose twice daily,,,Y,,Asked But Unknown,,208658.0,,,,Q12H,2023,Q3,Endocarditis,,2023,Q3,1,I,20171226.0,20230806.0,20230808,20230808,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-251629",BOEHRINGER INGELHEIM,,66.0,YR,E,M,Y,87.4,KG,20230808,,MD,AU,AU,2023,Q3,Elderly
227993971,22799397,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,5mg/1000mg dose twice daily,,,Y,,Asked But Unknown,,208658.0,,,,Q12H,2023,Q3,Euglycaemic diabetic ketoacidosis,,2023,Q3,1,I,20171226.0,20230806.0,20230808,20230808,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-251629",BOEHRINGER INGELHEIM,,66.0,YR,E,M,Y,87.4,KG,20230808,,MD,AU,AU,2023,Q3,Elderly
227993971,22799397,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,5mg/1000mg dose twice daily,,,Y,,Asked But Unknown,,208658.0,,,,Q12H,2023,Q3,Aortic valve incompetence,,2023,Q3,1,I,20171226.0,20230806.0,20230808,20230808,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-251629",BOEHRINGER INGELHEIM,,66.0,YR,E,M,Y,87.4,KG,20230808,,MD,AU,AU,2023,Q3,Elderly
227993971,22799397,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,5mg/1000mg dose twice daily,,,Y,,Asked But Unknown,,208658.0,,,,Q12H,2023,Q3,Aortic stenosis,,2023,Q3,1,I,20171226.0,20230806.0,20230808,20230808,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-251629",BOEHRINGER INGELHEIM,,66.0,YR,E,M,Y,87.4,KG,20230808,,MD,AU,AU,2023,Q3,Elderly
228000491,22800049,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,25.0,MG,,,2023,Q3,Condition aggravated,,2023,Q3,1,I,,20230731.0,20230808,20230808,EXP,,CA-SAMSUNG BIOEPIS-SB-2023-20626,SAMSUNG BIOEPIS,,69.0,YR,E,M,Y,91.0,KG,20230808,,HP,CA,CA,2023,Q3,Elderly
228000491,22800049,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,25.0,MG,,,2023,Q3,Off label use,,2023,Q3,1,I,,20230731.0,20230808,20230808,EXP,,CA-SAMSUNG BIOEPIS-SB-2023-20626,SAMSUNG BIOEPIS,,69.0,YR,E,M,Y,91.0,KG,20230808,,HP,CA,CA,2023,Q3,Elderly
228000491,22800049,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,25.0,MG,,,2023,Q3,Drug level below therapeutic,,2023,Q3,1,I,,20230731.0,20230808,20230808,EXP,,CA-SAMSUNG BIOEPIS-SB-2023-20626,SAMSUNG BIOEPIS,,69.0,YR,E,M,Y,91.0,KG,20230808,,HP,CA,CA,2023,Q3,Elderly
228000491,22800049,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,25.0,MG,,,2023,Q3,Arthralgia,,2023,Q3,1,I,,20230731.0,20230808,20230808,EXP,,CA-SAMSUNG BIOEPIS-SB-2023-20626,SAMSUNG BIOEPIS,,69.0,YR,E,M,Y,91.0,KG,20230808,,HP,CA,CA,2023,Q3,Elderly
228000491,22800049,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,25.0,MG,,,2023,Q3,Osteitis deformans,,2023,Q3,1,I,,20230731.0,20230808,20230808,EXP,,CA-SAMSUNG BIOEPIS-SB-2023-20626,SAMSUNG BIOEPIS,,69.0,YR,E,M,Y,91.0,KG,20230808,,HP,CA,CA,2023,Q3,Elderly
228000491,22800049,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,25.0,MG,,,2023,Q3,Malaise,,2023,Q3,1,I,,20230731.0,20230808,20230808,EXP,,CA-SAMSUNG BIOEPIS-SB-2023-20626,SAMSUNG BIOEPIS,,69.0,YR,E,M,Y,91.0,KG,20230808,,HP,CA,CA,2023,Q3,Elderly
228000491,22800049,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,25.0,MG,,,2023,Q3,Blood pressure increased,,2023,Q3,1,I,,20230731.0,20230808,20230808,EXP,,CA-SAMSUNG BIOEPIS-SB-2023-20626,SAMSUNG BIOEPIS,,69.0,YR,E,M,Y,91.0,KG,20230808,,HP,CA,CA,2023,Q3,Elderly
228000491,22800049,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,25.0,MG,,,2023,Q3,Incorrect dose administered,,2023,Q3,1,I,,20230731.0,20230808,20230808,EXP,,CA-SAMSUNG BIOEPIS-SB-2023-20626,SAMSUNG BIOEPIS,,69.0,YR,E,M,Y,91.0,KG,20230808,,HP,CA,CA,2023,Q3,Elderly
228002441,22800244,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"UNK, mg",,,,,,,,,,,,2023,Q3,Joint swelling,,2023,Q3,1,I,20230726.0,20230803.0,20230808,20230808,EXP,,"CO-DAIICHI SANKYO, INC.-DSE-2023-132403",DAIICHI,,71.0,YR,,F,Y,75.0,KG,20230808,,CN,CO,CO,2023,Q3,Elderly
228011901,22801190,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,,,E91527,,,10.0,MG,Tablet,QD,2023,Q3,Vision blurred,,2023,Q3,1,I,20230730.0,20230801.0,20230809,20230809,EXP,,GB-SANDOZ INC.-SDZ2023GB010932,SANDOZ,,51.0,YR,,F,Y,,,20230809,,CN,GB,GB,2023,Q3,Adult
228014541,22801454,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q3,Hepatotoxicity,,2023,Q3,1,I,20200309.0,20230712.0,20230809,20230809,EXP,,CA-002147023-NVSC2020CA082760,SANDOZ,,40.0,YR,,F,Y,,,20230809,,MD,CA,CA,2023,Q3,Adult
228014541,22801454,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q3,Drug ineffective,,2023,Q3,1,I,20200309.0,20230712.0,20230809,20230809,EXP,,CA-002147023-NVSC2020CA082760,SANDOZ,,40.0,YR,,F,Y,,,20230809,,MD,CA,CA,2023,Q3,Adult
228014541,22801454,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q3,Psoriasis,,2023,Q3,1,I,20200309.0,20230712.0,20230809,20230809,EXP,,CA-002147023-NVSC2020CA082760,SANDOZ,,40.0,YR,,F,Y,,,20230809,,MD,CA,CA,2023,Q3,Adult
228014541,22801454,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q3,Weight decreased,,2023,Q3,1,I,20200309.0,20230712.0,20230809,20230809,EXP,,CA-002147023-NVSC2020CA082760,SANDOZ,,40.0,YR,,F,Y,,,20230809,,MD,CA,CA,2023,Q3,Adult
228014541,22801454,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q3,Condition aggravated,,2023,Q3,1,I,20200309.0,20230712.0,20230809,20230809,EXP,,CA-002147023-NVSC2020CA082760,SANDOZ,,40.0,YR,,F,Y,,,20230809,,MD,CA,CA,2023,Q3,Adult
228014541,22801454,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q3,C-reactive protein increased,,2023,Q3,1,I,20200309.0,20230712.0,20230809,20230809,EXP,,CA-002147023-NVSC2020CA082760,SANDOZ,,40.0,YR,,F,Y,,,20230809,,MD,CA,CA,2023,Q3,Adult
228014541,22801454,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q3,Off label use,,2023,Q3,1,I,20200309.0,20230712.0,20230809,20230809,EXP,,CA-002147023-NVSC2020CA082760,SANDOZ,,40.0,YR,,F,Y,,,20230809,,MD,CA,CA,2023,Q3,Adult
228016561,22801656,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q3,Hyponatraemia,,2023,Q3,1,I,,20230802.0,20230809,20230809,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-253150",BOEHRINGER INGELHEIM,"Mirza TM, Ali R, Lippold C. A case of hyponatremia precipitated by discontinuing of empagliflozin. American Journal of Respiratory and Critical Care Medicine. 2023;207: 3489-",81.0,YR,E,F,Y,,,20230809,,HP,US,US,2023,Q3,Elderly
228016561,22801656,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q3,Abdominal pain upper,,2023,Q3,1,I,,20230802.0,20230809,20230809,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-253150",BOEHRINGER INGELHEIM,"Mirza TM, Ali R, Lippold C. A case of hyponatremia precipitated by discontinuing of empagliflozin. American Journal of Respiratory and Critical Care Medicine. 2023;207: 3489-",81.0,YR,E,F,Y,,,20230809,,HP,US,US,2023,Q3,Elderly
228016561,22801656,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q3,Diarrhoea,,2023,Q3,1,I,,20230802.0,20230809,20230809,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-253150",BOEHRINGER INGELHEIM,"Mirza TM, Ali R, Lippold C. A case of hyponatremia precipitated by discontinuing of empagliflozin. American Journal of Respiratory and Critical Care Medicine. 2023;207: 3489-",81.0,YR,E,F,Y,,,20230809,,HP,US,US,2023,Q3,Elderly
228016561,22801656,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q3,Inappropriate antidiuretic hormone secretion,,2023,Q3,1,I,,20230802.0,20230809,20230809,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-253150",BOEHRINGER INGELHEIM,"Mirza TM, Ali R, Lippold C. A case of hyponatremia precipitated by discontinuing of empagliflozin. American Journal of Respiratory and Critical Care Medicine. 2023;207: 3489-",81.0,YR,E,F,Y,,,20230809,,HP,US,US,2023,Q3,Elderly
228023991,22802399,54,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Heart rate increased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,54,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Cardiac failure,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,54,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Blood creatine increased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,54,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Acute kidney injury,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,54,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Pulmonary congestion,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,54,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Cardiorenal syndrome,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,54,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Hypotension,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,54,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Heart rate decreased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,55,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Heart rate increased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,55,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Cardiac failure,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,55,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Blood creatine increased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,55,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Acute kidney injury,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,55,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Pulmonary congestion,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,55,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Cardiorenal syndrome,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,55,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Hypotension,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,55,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Heart rate decreased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,56,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Heart rate increased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,56,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Cardiac failure,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,56,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Blood creatine increased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,56,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Acute kidney injury,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,56,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Pulmonary congestion,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,56,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Cardiorenal syndrome,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,56,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Hypotension,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,56,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Heart rate decreased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Heart rate increased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Cardiac failure,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Blood creatine increased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Acute kidney injury,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Pulmonary congestion,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Cardiorenal syndrome,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Hypotension,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,57,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Heart rate decreased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Heart rate increased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Cardiac failure,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Blood creatine increased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Acute kidney injury,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Pulmonary congestion,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Cardiorenal syndrome,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Hypotension,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,58,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Heart rate decreased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,59,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Heart rate increased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,59,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Cardiac failure,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,59,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Blood creatine increased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,59,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Acute kidney injury,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,59,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Pulmonary congestion,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,59,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Cardiorenal syndrome,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,59,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Hypotension,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,59,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Heart rate decreased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,60,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Heart rate increased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,60,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Cardiac failure,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,60,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Blood creatine increased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,60,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Acute kidney injury,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,60,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Pulmonary congestion,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,60,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Cardiorenal syndrome,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,60,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Hypotension,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,60,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Heart rate decreased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,61,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Heart rate increased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,61,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Cardiac failure,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,61,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Blood creatine increased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,61,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Acute kidney injury,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,61,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Pulmonary congestion,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,61,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Cardiorenal syndrome,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,61,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Hypotension,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,61,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Heart rate decreased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,62,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Heart rate increased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,62,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Cardiac failure,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,62,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Blood creatine increased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,62,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Acute kidney injury,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,62,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Pulmonary congestion,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,62,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Cardiorenal syndrome,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,62,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Hypotension,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,62,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Heart rate decreased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,63,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Heart rate increased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,63,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Cardiac failure,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,63,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Blood creatine increased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,63,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Acute kidney injury,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,63,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Pulmonary congestion,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,63,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Cardiorenal syndrome,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,63,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Hypotension,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,63,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Heart rate decreased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,64,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Heart rate increased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,64,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Cardiac failure,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,64,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Blood creatine increased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,64,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Acute kidney injury,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,64,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Pulmonary congestion,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,64,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Cardiorenal syndrome,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,64,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Hypotension,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,64,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Heart rate decreased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,65,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Heart rate increased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,65,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Cardiac failure,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,65,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Blood creatine increased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,65,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Acute kidney injury,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,65,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Pulmonary congestion,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,65,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Cardiorenal syndrome,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,65,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Hypotension,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,65,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Heart rate decreased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Heart rate increased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Cardiac failure,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Blood creatine increased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Acute kidney injury,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Pulmonary congestion,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Cardiorenal syndrome,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Hypotension,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,66,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Heart rate decreased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Heart rate increased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Cardiac failure,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Blood creatine increased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Acute kidney injury,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Pulmonary congestion,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Cardiorenal syndrome,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Hypotension,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,67,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Heart rate decreased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Heart rate increased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Cardiac failure,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Blood creatine increased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Acute kidney injury,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Pulmonary congestion,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Cardiorenal syndrome,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Hypotension,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,68,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Heart rate decreased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,69,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Heart rate increased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,69,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Cardiac failure,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,69,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Blood creatine increased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,69,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Acute kidney injury,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,69,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Pulmonary congestion,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,69,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Cardiorenal syndrome,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,69,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Hypotension,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,69,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Heart rate decreased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,70,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Heart rate increased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,70,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Cardiac failure,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,70,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Blood creatine increased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,70,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Acute kidney injury,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,70,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Pulmonary congestion,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,70,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Cardiorenal syndrome,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,70,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Hypotension,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,70,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Heart rate decreased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,71,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Heart rate increased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,71,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Cardiac failure,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,71,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Blood creatine increased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,71,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Acute kidney injury,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,71,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Pulmonary congestion,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,71,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Cardiorenal syndrome,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,71,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Hypotension,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,71,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Heart rate decreased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,72,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Heart rate increased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,72,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Cardiac failure,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,72,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Blood creatine increased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,72,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Acute kidney injury,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,72,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Pulmonary congestion,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,72,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Cardiorenal syndrome,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,72,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Hypotension,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228023991,22802399,72,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Heart rate decreased,,2023,Q3,1,I,,20230803.0,20230809,20230809,EXP,,NVSC2023TH171146,NOVARTIS,,27.0,YR,,M,Y,,,20230809,,MD,TH,TH,2023,Q3,Young Adult
228028391,22802839,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Wrong technique in product usage process,,2023,Q3,1,I,20230712.0,20230803.0,20230809,20230809,EXP,,NVSC2023CN172093,NOVARTIS,,57.0,YR,,F,Y,60.0,KG,20230809,,HP,CN,CN,2023,Q3,Adult
228028391,22802839,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Off label use,,2023,Q3,1,I,20230712.0,20230803.0,20230809,20230809,EXP,,NVSC2023CN172093,NOVARTIS,,57.0,YR,,F,Y,60.0,KG,20230809,,HP,CN,CN,2023,Q3,Adult
228028391,22802839,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Prescribed underdose,,2023,Q3,1,I,20230712.0,20230803.0,20230809,20230809,EXP,,NVSC2023CN172093,NOVARTIS,,57.0,YR,,F,Y,60.0,KG,20230809,,HP,CN,CN,2023,Q3,Adult
228028391,22802839,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Hyperkalaemia,,2023,Q3,1,I,20230712.0,20230803.0,20230809,20230809,EXP,,NVSC2023CN172093,NOVARTIS,,57.0,YR,,F,Y,60.0,KG,20230809,,HP,CN,CN,2023,Q3,Adult
228032621,22803262,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,N,D,,,,,,,,2023,Q3,Sepsis,,2023,Q3,1,I,20230807.0,,20230808,20230808,DIR,669689,,FDA-CTU,,57.0,YR,,F,N,74.3,KG,20230808,N,,US,,2023,Q3,Adult
228032621,22803262,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,N,D,,,,,,,,2023,Q3,Necrotising fasciitis,,2023,Q3,1,I,20230807.0,,20230808,20230808,DIR,669689,,FDA-CTU,,57.0,YR,,F,N,74.3,KG,20230808,N,,US,,2023,Q3,Adult
228032621,22803262,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Sepsis,,2023,Q3,1,I,20230807.0,,20230808,20230808,DIR,669689,,FDA-CTU,,57.0,YR,,F,N,74.3,KG,20230808,N,,US,,2023,Q3,Adult
228032621,22803262,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Necrotising fasciitis,,2023,Q3,1,I,20230807.0,,20230808,20230808,DIR,669689,,FDA-CTU,,57.0,YR,,F,N,74.3,KG,20230808,N,,US,,2023,Q3,Adult
228034291,22803429,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,Unknown,,2023,Q3,Pulmonary embolism,,2023,Q3,1,I,20230615.0,20230802.0,20230809,20230809,EXP,,US-JNJFOC-20230808973,JOHNSON AND JOHNSON,,67.0,YR,,M,Y,107.0,KG,20230809,,PH,US,US,2023,Q3,Elderly
228034291,22803429,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,Unknown,,2023,Q3,Suspected counterfeit product,,2023,Q3,1,I,20230615.0,20230802.0,20230809,20230809,EXP,,US-JNJFOC-20230808973,JOHNSON AND JOHNSON,,67.0,YR,,M,Y,107.0,KG,20230809,,PH,US,US,2023,Q3,Elderly
228042062,22804206,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, bid",,,U,,,,,25.0,MG,,Q12H,2023,Q3,Drug ineffective,,2023,Q3,2,F,,20230829.0,20230809,20230913,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-402828,RANBAXY,"Goff CB, Plaxe SC, White W, Dasanu CA. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic mucosal melanoma. J Oncol Pharm Pract. 2023;29(5):1259-1263",76.0,YR,,M,Y,,,20230913,,HP,US,US,2023,Q3,Elderly
228065642,22806564,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, Daily(1 TABLET ONCE DAILY)",,,U,,,,,,,Tablet,,2023,Q3,Dizziness,,2023,Q3,2,F,20230705.0,20230810.0,20230810,20230822,EXP,,GB-AUROBINDO-AUR-APL-2023-049528,AUROBINDO,,26.0,YR,,M,Y,77.0,KG,20230822,,MD,GB,GB,2023,Q3,Young Adult
228065642,22806564,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, Daily(1 TABLET ONCE DAILY)",,,U,,,,,,,Tablet,,2023,Q3,Hot flush,,2023,Q3,2,F,20230705.0,20230810.0,20230810,20230822,EXP,,GB-AUROBINDO-AUR-APL-2023-049528,AUROBINDO,,26.0,YR,,M,Y,77.0,KG,20230822,,MD,GB,GB,2023,Q3,Young Adult
228065642,22806564,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, Daily(1 TABLET ONCE DAILY)",,,U,,,,,,,Tablet,,2023,Q3,Off label use,,2023,Q3,2,F,20230705.0,20230810.0,20230810,20230822,EXP,,GB-AUROBINDO-AUR-APL-2023-049528,AUROBINDO,,26.0,YR,,M,Y,77.0,KG,20230822,,MD,GB,GB,2023,Q3,Young Adult
228065642,22806564,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, Daily(1 TABLET ONCE DAILY)",,,U,,,,,,,Tablet,,2023,Q3,Dizziness,,2023,Q3,2,F,20230705.0,20230810.0,20230810,20230822,EXP,,GB-AUROBINDO-AUR-APL-2023-049528,AUROBINDO,,26.0,YR,,M,Y,77.0,KG,20230822,,MD,GB,GB,2023,Q3,Young Adult
228065642,22806564,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, Daily(1 TABLET ONCE DAILY)",,,U,,,,,,,Tablet,,2023,Q3,Hot flush,,2023,Q3,2,F,20230705.0,20230810.0,20230810,20230822,EXP,,GB-AUROBINDO-AUR-APL-2023-049528,AUROBINDO,,26.0,YR,,M,Y,77.0,KG,20230822,,MD,GB,GB,2023,Q3,Young Adult
228065642,22806564,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, Daily(1 TABLET ONCE DAILY)",,,U,,,,,,,Tablet,,2023,Q3,Off label use,,2023,Q3,2,F,20230705.0,20230810.0,20230810,20230822,EXP,,GB-AUROBINDO-AUR-APL-2023-049528,AUROBINDO,,26.0,YR,,M,Y,77.0,KG,20230822,,MD,GB,GB,2023,Q3,Young Adult
228065642,22806564,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, Daily(1 TABLET ONCE DAILY)",,,U,,,,,,,Tablet,,2023,Q3,Dizziness,,2023,Q3,2,F,20230705.0,20230810.0,20230810,20230822,EXP,,GB-AUROBINDO-AUR-APL-2023-049528,AUROBINDO,,26.0,YR,,M,Y,77.0,KG,20230822,,MD,GB,GB,2023,Q3,Young Adult
228065642,22806564,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, Daily(1 TABLET ONCE DAILY)",,,U,,,,,,,Tablet,,2023,Q3,Hot flush,,2023,Q3,2,F,20230705.0,20230810.0,20230810,20230822,EXP,,GB-AUROBINDO-AUR-APL-2023-049528,AUROBINDO,,26.0,YR,,M,Y,77.0,KG,20230822,,MD,GB,GB,2023,Q3,Young Adult
228065642,22806564,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, Daily(1 TABLET ONCE DAILY)",,,U,,,,,,,Tablet,,2023,Q3,Off label use,,2023,Q3,2,F,20230705.0,20230810.0,20230810,20230822,EXP,,GB-AUROBINDO-AUR-APL-2023-049528,AUROBINDO,,26.0,YR,,M,Y,77.0,KG,20230822,,MD,GB,GB,2023,Q3,Young Adult
228065642,22806564,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,Tablet,QD,2023,Q3,Dizziness,,2023,Q3,2,F,20230705.0,20230810.0,20230810,20230822,EXP,,GB-AUROBINDO-AUR-APL-2023-049528,AUROBINDO,,26.0,YR,,M,Y,77.0,KG,20230822,,MD,GB,GB,2023,Q3,Young Adult
228065642,22806564,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,Tablet,QD,2023,Q3,Hot flush,,2023,Q3,2,F,20230705.0,20230810.0,20230810,20230822,EXP,,GB-AUROBINDO-AUR-APL-2023-049528,AUROBINDO,,26.0,YR,,M,Y,77.0,KG,20230822,,MD,GB,GB,2023,Q3,Young Adult
228065642,22806564,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,Tablet,QD,2023,Q3,Off label use,,2023,Q3,2,F,20230705.0,20230810.0,20230810,20230822,EXP,,GB-AUROBINDO-AUR-APL-2023-049528,AUROBINDO,,26.0,YR,,M,Y,77.0,KG,20230822,,MD,GB,GB,2023,Q3,Young Adult
228165211,22816521,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 Milligram Daily; Unit dose : 10 mg, OD, Therapy End date: NASK",10.0,MG,,U,E91527,,,10.0,MG,Tablet,QD,2023,Q3,Vision blurred,,2023,Q3,1,I,20230730.0,20230801.0,20230811,20230811,EXP,,GB-TEVA-2023-GB-2914369,TEVA,,51.0,YR,A,F,Y,,,20230811,,CN,GB,GB,2023,Q3,Adult
228207211,22820721,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,204629.0,25.0,MG,Tablet,QD,2023,Q3,Malaise,,2023,Q3,1,I,20230617.0,20230814.0,20230814,20230814,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-255303",BOEHRINGER INGELHEIM,,58.0,YR,A,M,Y,73.0,KG,20230814,,MD,GB,GB,2023,Q3,Adult
228219441,22821944,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2023,Q3,Fatigue,,2023,Q3,1,I,20230630.0,20230809.0,20230814,20230814,EXP,,"CO-DAIICHI SANKYO, INC.-DSE-2023-133232",DAIICHI,,68.0,YR,,M,Y,68.0,KG,20230814,,CN,CO,CO,2023,Q3,Elderly
228219441,22821944,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2023,Q3,Syncope,,2023,Q3,1,I,20230630.0,20230809.0,20230814,20230814,EXP,,"CO-DAIICHI SANKYO, INC.-DSE-2023-133232",DAIICHI,,68.0,YR,,M,Y,68.0,KG,20230814,,CN,CO,CO,2023,Q3,Elderly
228219441,22821944,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2023,Q3,Chest discomfort,,2023,Q3,1,I,20230630.0,20230809.0,20230814,20230814,EXP,,"CO-DAIICHI SANKYO, INC.-DSE-2023-133232",DAIICHI,,68.0,YR,,M,Y,68.0,KG,20230814,,CN,CO,CO,2023,Q3,Elderly
228219441,22821944,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2023,Q3,Vertigo,,2023,Q3,1,I,20230630.0,20230809.0,20230814,20230814,EXP,,"CO-DAIICHI SANKYO, INC.-DSE-2023-133232",DAIICHI,,68.0,YR,,M,Y,68.0,KG,20230814,,CN,CO,CO,2023,Q3,Elderly
228219441,22821944,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2023,Q3,Choking sensation,,2023,Q3,1,I,20230630.0,20230809.0,20230814,20230814,EXP,,"CO-DAIICHI SANKYO, INC.-DSE-2023-133232",DAIICHI,,68.0,YR,,M,Y,68.0,KG,20230814,,CN,CO,CO,2023,Q3,Elderly
228262681,22826268,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Sepsis,,2023,Q3,1,I,20200110.0,20230809.0,20230816,20230816,EXP,,CA-002147023-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230816,,CN,CA,CA,2023,Q3,Adult
228262681,22826268,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,C-reactive protein increased,,2023,Q3,1,I,20200110.0,20230809.0,20230816,20230816,EXP,,CA-002147023-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230816,,CN,CA,CA,2023,Q3,Adult
228262681,22826268,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Pain in extremity,,2023,Q3,1,I,20200110.0,20230809.0,20230816,20230816,EXP,,CA-002147023-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230816,,CN,CA,CA,2023,Q3,Adult
228262681,22826268,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Drug ineffective,,2023,Q3,1,I,20200110.0,20230809.0,20230816,20230816,EXP,,CA-002147023-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230816,,CN,CA,CA,2023,Q3,Adult
228262681,22826268,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Osteoarthritis,,2023,Q3,1,I,20200110.0,20230809.0,20230816,20230816,EXP,,CA-002147023-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230816,,CN,CA,CA,2023,Q3,Adult
228262681,22826268,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Arthropathy,,2023,Q3,1,I,20200110.0,20230809.0,20230816,20230816,EXP,,CA-002147023-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230816,,CN,CA,CA,2023,Q3,Adult
228262681,22826268,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Arthralgia,,2023,Q3,1,I,20200110.0,20230809.0,20230816,20230816,EXP,,CA-002147023-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230816,,CN,CA,CA,2023,Q3,Adult
228262681,22826268,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Blood uric acid increased,,2023,Q3,1,I,20200110.0,20230809.0,20230816,20230816,EXP,,CA-002147023-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230816,,CN,CA,CA,2023,Q3,Adult
228262681,22826268,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Blood iron decreased,,2023,Q3,1,I,20200110.0,20230809.0,20230816,20230816,EXP,,CA-002147023-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230816,,CN,CA,CA,2023,Q3,Adult
228262681,22826268,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Condition aggravated,,2023,Q3,1,I,20200110.0,20230809.0,20230816,20230816,EXP,,CA-002147023-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230816,,CN,CA,CA,2023,Q3,Adult
228262681,22826268,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Synovial disorder,,2023,Q3,1,I,20200110.0,20230809.0,20230816,20230816,EXP,,CA-002147023-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230816,,CN,CA,CA,2023,Q3,Adult
228262681,22826268,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Arthritis,,2023,Q3,1,I,20200110.0,20230809.0,20230816,20230816,EXP,,CA-002147023-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230816,,CN,CA,CA,2023,Q3,Adult
228262681,22826268,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Urinary tract infection,,2023,Q3,1,I,20200110.0,20230809.0,20230816,20230816,EXP,,CA-002147023-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230816,,CN,CA,CA,2023,Q3,Adult
228262681,22826268,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Nephrolithiasis,,2023,Q3,1,I,20200110.0,20230809.0,20230816,20230816,EXP,,CA-002147023-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230816,,CN,CA,CA,2023,Q3,Adult
228262681,22826268,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Cyst,,2023,Q3,1,I,20200110.0,20230809.0,20230816,20230816,EXP,,CA-002147023-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230816,,CN,CA,CA,2023,Q3,Adult
228262681,22826268,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Vitamin B12 decreased,,2023,Q3,1,I,20200110.0,20230809.0,20230816,20230816,EXP,,CA-002147023-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230816,,CN,CA,CA,2023,Q3,Adult
228262681,22826268,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Alanine aminotransferase increased,,2023,Q3,1,I,20200110.0,20230809.0,20230816,20230816,EXP,,CA-002147023-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230816,,CN,CA,CA,2023,Q3,Adult
228262681,22826268,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Hepatic enzyme increased,,2023,Q3,1,I,20200110.0,20230809.0,20230816,20230816,EXP,,CA-002147023-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230816,,CN,CA,CA,2023,Q3,Adult
228262681,22826268,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Synovitis,,2023,Q3,1,I,20200110.0,20230809.0,20230816,20230816,EXP,,CA-002147023-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230816,,CN,CA,CA,2023,Q3,Adult
228262681,22826268,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Pain,,2023,Q3,1,I,20200110.0,20230809.0,20230816,20230816,EXP,,CA-002147023-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230816,,CN,CA,CA,2023,Q3,Adult
228262681,22826268,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Rash,,2023,Q3,1,I,20200110.0,20230809.0,20230816,20230816,EXP,,CA-002147023-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230816,,CN,CA,CA,2023,Q3,Adult
228262681,22826268,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Oedema,,2023,Q3,1,I,20200110.0,20230809.0,20230816,20230816,EXP,,CA-002147023-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230816,,CN,CA,CA,2023,Q3,Adult
228262681,22826268,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Tendonitis,,2023,Q3,1,I,20200110.0,20230809.0,20230816,20230816,EXP,,CA-002147023-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230816,,CN,CA,CA,2023,Q3,Adult
228262681,22826268,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Injection site pain,,2023,Q3,1,I,20200110.0,20230809.0,20230816,20230816,EXP,,CA-002147023-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230816,,CN,CA,CA,2023,Q3,Adult
228262681,22826268,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Psoriasis,,2023,Q3,1,I,20200110.0,20230809.0,20230816,20230816,EXP,,CA-002147023-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230816,,CN,CA,CA,2023,Q3,Adult
228262681,22826268,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Joint swelling,,2023,Q3,1,I,20200110.0,20230809.0,20230816,20230816,EXP,,CA-002147023-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230816,,CN,CA,CA,2023,Q3,Adult
228262681,22826268,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Renal disorder,,2023,Q3,1,I,20200110.0,20230809.0,20230816,20230816,EXP,,CA-002147023-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230816,,CN,CA,CA,2023,Q3,Adult
228262681,22826268,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Pyrexia,,2023,Q3,1,I,20200110.0,20230809.0,20230816,20230816,EXP,,CA-002147023-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230816,,CN,CA,CA,2023,Q3,Adult
228262681,22826268,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Antinuclear antibody positive,,2023,Q3,1,I,20200110.0,20230809.0,20230816,20230816,EXP,,CA-002147023-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230816,,CN,CA,CA,2023,Q3,Adult
228262681,22826268,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Allergic sinusitis,,2023,Q3,1,I,20200110.0,20230809.0,20230816,20230816,EXP,,CA-002147023-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230816,,CN,CA,CA,2023,Q3,Adult
228262681,22826268,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Incorrect dose administered,,2023,Q3,1,I,20200110.0,20230809.0,20230816,20230816,EXP,,CA-002147023-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230816,,CN,CA,CA,2023,Q3,Adult
228262681,22826268,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Joint effusion,,2023,Q3,1,I,20200110.0,20230809.0,20230816,20230816,EXP,,CA-002147023-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230816,,CN,CA,CA,2023,Q3,Adult
228262681,22826268,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Injection site warmth,,2023,Q3,1,I,20200110.0,20230809.0,20230816,20230816,EXP,,CA-002147023-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230816,,CN,CA,CA,2023,Q3,Adult
228272721,22827272,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2023,Q3,Cardiac failure acute,,2023,Q3,1,I,20230203.0,20230804.0,20230816,20230816,EXP,,US-CHATTEMPRD-2023SA094179,CHATTEM,,73.0,YR,E,M,Y,86.7,KG,20230816,,HP,US,US,2023,Q3,Elderly
228272721,22827272,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2023,Q3,Upper gastrointestinal haemorrhage,,2023,Q3,1,I,20230203.0,20230804.0,20230816,20230816,EXP,,US-CHATTEMPRD-2023SA094179,CHATTEM,,73.0,YR,E,M,Y,86.7,KG,20230816,,HP,US,US,2023,Q3,Elderly
228272721,22827272,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2023,Q3,Staphylococcal sepsis,,2023,Q3,1,I,20230203.0,20230804.0,20230816,20230816,EXP,,US-CHATTEMPRD-2023SA094179,CHATTEM,,73.0,YR,E,M,Y,86.7,KG,20230816,,HP,US,US,2023,Q3,Elderly
228283831,22828383,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,,,E91527,,,10.0,MG,Tablet,,2023,Q3,Vision blurred,,2023,Q3,1,I,20230730.0,20230803.0,20230816,20230816,EXP,,GB-LAURUS LABS LIMITED-2023LAU000071,LAURUS LABS LIMITED,,51.0,YR,,F,Y,,,20230816,,CN,GB,GB,2023,Q3,Adult
228284311,22828431,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, qd",,,U,,,,,,,,,2023,Q3,Anaphylactic reaction,,2023,Q3,1,I,,20230228.0,20230816,20230816,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-383632,RANBAXY,,75.0,YR,,M,Y,70.0,KG,20230816,,MD,GB,GB,2023,Q3,Elderly
228284891,22828489,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,Unknown,,2023,Q3,International normalised ratio increased,,2023,Q3,1,I,,20230807.0,20230816,20230816,EXP,,CA-JNJFOC-20230819708,JOHNSON AND JOHNSON,,71.0,YR,E,F,Y,154.0,KG,20230816,,PH,CA,CA,2023,Q3,Elderly
228284891,22828489,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,Unknown,,2023,Q3,Drug-induced liver injury,,2023,Q3,1,I,,20230807.0,20230816,20230816,EXP,,CA-JNJFOC-20230819708,JOHNSON AND JOHNSON,,71.0,YR,E,F,Y,154.0,KG,20230816,,PH,CA,CA,2023,Q3,Elderly
228285721,22828572,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, QD",,,U,,,,,,,,QD,2023,Q3,Ventricular hypokinesia,,2023,Q3,1,I,,20230809.0,20230816,20230816,EXP,,NVSC2023TH174860,NOVARTIS,,60.0,YR,,M,Y,,,20230816,,MD,TH,TH,2023,Q3,Adult
228285721,22828572,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, QD",,,U,,,,,,,,QD,2023,Q3,Heart rate decreased,,2023,Q3,1,I,,20230809.0,20230816,20230816,EXP,,NVSC2023TH174860,NOVARTIS,,60.0,YR,,M,Y,,,20230816,,MD,TH,TH,2023,Q3,Adult
228285721,22828572,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, QD",,,U,,,,,,,,QD,2023,Q3,Left ventricular dilatation,,2023,Q3,1,I,,20230809.0,20230816,20230816,EXP,,NVSC2023TH174860,NOVARTIS,,60.0,YR,,M,Y,,,20230816,,MD,TH,TH,2023,Q3,Adult
228285721,22828572,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, QD",,,U,,,,,,,,QD,2023,Q3,Ejection fraction decreased,,2023,Q3,1,I,,20230809.0,20230816,20230816,EXP,,NVSC2023TH174860,NOVARTIS,,60.0,YR,,M,Y,,,20230816,,MD,TH,TH,2023,Q3,Adult
228285721,22828572,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, QD",,,U,,,,,,,,QD,2023,Q3,Ventricular hypokinesia,,2023,Q3,1,I,,20230809.0,20230816,20230816,EXP,,NVSC2023TH174860,NOVARTIS,,60.0,YR,,M,Y,,,20230816,,MD,TH,TH,2023,Q3,Adult
228285721,22828572,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, QD",,,U,,,,,,,,QD,2023,Q3,Heart rate decreased,,2023,Q3,1,I,,20230809.0,20230816,20230816,EXP,,NVSC2023TH174860,NOVARTIS,,60.0,YR,,M,Y,,,20230816,,MD,TH,TH,2023,Q3,Adult
228285721,22828572,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, QD",,,U,,,,,,,,QD,2023,Q3,Left ventricular dilatation,,2023,Q3,1,I,,20230809.0,20230816,20230816,EXP,,NVSC2023TH174860,NOVARTIS,,60.0,YR,,M,Y,,,20230816,,MD,TH,TH,2023,Q3,Adult
228285721,22828572,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, QD",,,U,,,,,,,,QD,2023,Q3,Ejection fraction decreased,,2023,Q3,1,I,,20230809.0,20230816,20230816,EXP,,NVSC2023TH174860,NOVARTIS,,60.0,YR,,M,Y,,,20230816,,MD,TH,TH,2023,Q3,Adult
228285721,22828572,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, QD",,,U,,,,,,,,QD,2023,Q3,Ventricular hypokinesia,,2023,Q3,1,I,,20230809.0,20230816,20230816,EXP,,NVSC2023TH174860,NOVARTIS,,60.0,YR,,M,Y,,,20230816,,MD,TH,TH,2023,Q3,Adult
228285721,22828572,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, QD",,,U,,,,,,,,QD,2023,Q3,Heart rate decreased,,2023,Q3,1,I,,20230809.0,20230816,20230816,EXP,,NVSC2023TH174860,NOVARTIS,,60.0,YR,,M,Y,,,20230816,,MD,TH,TH,2023,Q3,Adult
228285721,22828572,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, QD",,,U,,,,,,,,QD,2023,Q3,Left ventricular dilatation,,2023,Q3,1,I,,20230809.0,20230816,20230816,EXP,,NVSC2023TH174860,NOVARTIS,,60.0,YR,,M,Y,,,20230816,,MD,TH,TH,2023,Q3,Adult
228285721,22828572,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, QD",,,U,,,,,,,,QD,2023,Q3,Ejection fraction decreased,,2023,Q3,1,I,,20230809.0,20230816,20230816,EXP,,NVSC2023TH174860,NOVARTIS,,60.0,YR,,M,Y,,,20230816,,MD,TH,TH,2023,Q3,Adult
228318761,22831876,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q3,Psoriatic arthropathy,,2023,Q3,1,I,,20230807.0,20230817,20230817,EXP,CA-MHPD-E2B_06371146,CA-Accord-372366,ACCORD,,63.0,YR,A,F,Y,,,20230817,,HP,CA,CA,2023,Q3,Adult
228318761,22831876,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q3,Odynophagia,,2023,Q3,1,I,,20230807.0,20230817,20230817,EXP,CA-MHPD-E2B_06371146,CA-Accord-372366,ACCORD,,63.0,YR,A,F,Y,,,20230817,,HP,CA,CA,2023,Q3,Adult
228318761,22831876,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q3,Joint destruction,,2023,Q3,1,I,,20230807.0,20230817,20230817,EXP,CA-MHPD-E2B_06371146,CA-Accord-372366,ACCORD,,63.0,YR,A,F,Y,,,20230817,,HP,CA,CA,2023,Q3,Adult
228318761,22831876,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q3,Nausea,,2023,Q3,1,I,,20230807.0,20230817,20230817,EXP,CA-MHPD-E2B_06371146,CA-Accord-372366,ACCORD,,63.0,YR,A,F,Y,,,20230817,,HP,CA,CA,2023,Q3,Adult
228318761,22831876,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q3,Anaemia,,2023,Q3,1,I,,20230807.0,20230817,20230817,EXP,CA-MHPD-E2B_06371146,CA-Accord-372366,ACCORD,,63.0,YR,A,F,Y,,,20230817,,HP,CA,CA,2023,Q3,Adult
228318761,22831876,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q3,Enthesopathy,,2023,Q3,1,I,,20230807.0,20230817,20230817,EXP,CA-MHPD-E2B_06371146,CA-Accord-372366,ACCORD,,63.0,YR,A,F,Y,,,20230817,,HP,CA,CA,2023,Q3,Adult
228318761,22831876,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q3,Tenosynovitis stenosans,,2023,Q3,1,I,,20230807.0,20230817,20230817,EXP,CA-MHPD-E2B_06371146,CA-Accord-372366,ACCORD,,63.0,YR,A,F,Y,,,20230817,,HP,CA,CA,2023,Q3,Adult
228318761,22831876,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q3,Knee arthroplasty,,2023,Q3,1,I,,20230807.0,20230817,20230817,EXP,CA-MHPD-E2B_06371146,CA-Accord-372366,ACCORD,,63.0,YR,A,F,Y,,,20230817,,HP,CA,CA,2023,Q3,Adult
228318761,22831876,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q3,Fatigue,,2023,Q3,1,I,,20230807.0,20230817,20230817,EXP,CA-MHPD-E2B_06371146,CA-Accord-372366,ACCORD,,63.0,YR,A,F,Y,,,20230817,,HP,CA,CA,2023,Q3,Adult
228318761,22831876,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q3,Product quality issue,,2023,Q3,1,I,,20230807.0,20230817,20230817,EXP,CA-MHPD-E2B_06371146,CA-Accord-372366,ACCORD,,63.0,YR,A,F,Y,,,20230817,,HP,CA,CA,2023,Q3,Adult
228318761,22831876,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q3,Therapeutic product effect incomplete,,2023,Q3,1,I,,20230807.0,20230817,20230817,EXP,CA-MHPD-E2B_06371146,CA-Accord-372366,ACCORD,,63.0,YR,A,F,Y,,,20230817,,HP,CA,CA,2023,Q3,Adult
228318761,22831876,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q3,Angina pectoris,,2023,Q3,1,I,,20230807.0,20230817,20230817,EXP,CA-MHPD-E2B_06371146,CA-Accord-372366,ACCORD,,63.0,YR,A,F,Y,,,20230817,,HP,CA,CA,2023,Q3,Adult
228318761,22831876,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q3,Coronary artery disease,,2023,Q3,1,I,,20230807.0,20230817,20230817,EXP,CA-MHPD-E2B_06371146,CA-Accord-372366,ACCORD,,63.0,YR,A,F,Y,,,20230817,,HP,CA,CA,2023,Q3,Adult
228318761,22831876,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q3,Nerve compression,,2023,Q3,1,I,,20230807.0,20230817,20230817,EXP,CA-MHPD-E2B_06371146,CA-Accord-372366,ACCORD,,63.0,YR,A,F,Y,,,20230817,,HP,CA,CA,2023,Q3,Adult
228318761,22831876,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q3,Psychological trauma,,2023,Q3,1,I,,20230807.0,20230817,20230817,EXP,CA-MHPD-E2B_06371146,CA-Accord-372366,ACCORD,,63.0,YR,A,F,Y,,,20230817,,HP,CA,CA,2023,Q3,Adult
228318761,22831876,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q3,Compartment syndrome,,2023,Q3,1,I,,20230807.0,20230817,20230817,EXP,CA-MHPD-E2B_06371146,CA-Accord-372366,ACCORD,,63.0,YR,A,F,Y,,,20230817,,HP,CA,CA,2023,Q3,Adult
228318761,22831876,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q3,Malaise,,2023,Q3,1,I,,20230807.0,20230817,20230817,EXP,CA-MHPD-E2B_06371146,CA-Accord-372366,ACCORD,,63.0,YR,A,F,Y,,,20230817,,HP,CA,CA,2023,Q3,Adult
228332912,22833291,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,Y,,B230305K71,,,10.0,MG,,QD,2023,Q3,Nausea,,2023,Q3,2,F,20230620.0,20230803.0,20230817,20230818,EXP,CN-NMPA-5101221103085202300126,CN-NOVOPROD-1100041,NOVO NORDISK,,50.0,YR,,F,Y,62.7,KG,20230818,,HP,CN,CN,2023,Q3,Adult
228332912,22833291,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,Y,,B230305K71,,,10.0,MG,,QD,2023,Q3,Inappropriate schedule of product administration,,2023,Q3,2,F,20230620.0,20230803.0,20230817,20230818,EXP,CN-NMPA-5101221103085202300126,CN-NOVOPROD-1100041,NOVO NORDISK,,50.0,YR,,F,Y,62.7,KG,20230818,,HP,CN,CN,2023,Q3,Adult
228332912,22833291,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,Y,,B230305K71,,,10.0,MG,,QD,2023,Q3,Vomiting,,2023,Q3,2,F,20230620.0,20230803.0,20230817,20230818,EXP,CN-NMPA-5101221103085202300126,CN-NOVOPROD-1100041,NOVO NORDISK,,50.0,YR,,F,Y,62.7,KG,20230818,,HP,CN,CN,2023,Q3,Adult
228332912,22833291,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,Y,,B230305K71,,,10.0,MG,,QD,2023,Q3,Ketoacidosis,,2023,Q3,2,F,20230620.0,20230803.0,20230817,20230818,EXP,CN-NMPA-5101221103085202300126,CN-NOVOPROD-1100041,NOVO NORDISK,,50.0,YR,,F,Y,62.7,KG,20230818,,HP,CN,CN,2023,Q3,Adult
228336652,22833665,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,qAM,,,,,,,,25.0,MG,,,2023,Q3,Ageusia,,2023,Q3,2,F,20230810.0,20230914.0,20230817,20230918,EXP,,US-ROCHE-3406183,ROCHE,,79.0,YR,,M,Y,103.6,KG,20230918,,CN,US,,2023,Q3,Elderly
228336652,22833665,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,qAM,,,,,,,,25.0,MG,,,2023,Q3,Dysgeusia,,2023,Q3,2,F,20230810.0,20230914.0,20230817,20230918,EXP,,US-ROCHE-3406183,ROCHE,,79.0,YR,,M,Y,103.6,KG,20230918,,CN,US,,2023,Q3,Elderly
228336652,22833665,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,qAM,,,,,,,,25.0,MG,,,2023,Q3,Death,,2023,Q3,2,F,20230810.0,20230914.0,20230817,20230918,EXP,,US-ROCHE-3406183,ROCHE,,79.0,YR,,M,Y,103.6,KG,20230918,,CN,US,,2023,Q3,Elderly
228345001,22834500,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Hepatic enzyme increased,,2023,Q3,1,I,20230601.0,20230807.0,20230817,20230817,EXP,,DE-Calliditas-2023CAL00991,CALLIDITAS THERAPEUTICS,,55.0,YR,A,M,Y,,,20230817,,HP,DE,DE,2023,Q3,Adult
228345001,22834500,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Gamma-glutamyltransferase increased,,2023,Q3,1,I,20230601.0,20230807.0,20230817,20230817,EXP,,DE-Calliditas-2023CAL00991,CALLIDITAS THERAPEUTICS,,55.0,YR,A,M,Y,,,20230817,,HP,DE,DE,2023,Q3,Adult
228368971,22836897,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,UNKNOWN,,,10.0,MG,,,2023,Q3,Ketonuria,,2023,Q3,1,I,20220611.0,20230808.0,20230818,20230818,EXP,,DE-TEVA-2023-DE-2917353,TEVA,,42.0,YR,A,M,Y,,,20230818,,MD,DE,DE,2023,Q3,Adult
228368971,22836897,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,UNKNOWN,,,10.0,MG,,,2023,Q3,Metabolic acidosis,,2023,Q3,1,I,20220611.0,20230808.0,20230818,20230818,EXP,,DE-TEVA-2023-DE-2917353,TEVA,,42.0,YR,A,M,Y,,,20230818,,MD,DE,DE,2023,Q3,Adult
228368971,22836897,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,UNKNOWN,,,10.0,MG,,,2023,Q3,Vomiting,,2023,Q3,1,I,20220611.0,20230808.0,20230818,20230818,EXP,,DE-TEVA-2023-DE-2917353,TEVA,,42.0,YR,A,M,Y,,,20230818,,MD,DE,DE,2023,Q3,Adult
228368971,22836897,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,UNKNOWN,,,,,,,2023,Q3,Ketonuria,,2023,Q3,1,I,20220611.0,20230808.0,20230818,20230818,EXP,,DE-TEVA-2023-DE-2917353,TEVA,,42.0,YR,A,M,Y,,,20230818,,MD,DE,DE,2023,Q3,Adult
228368971,22836897,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,UNKNOWN,,,,,,,2023,Q3,Metabolic acidosis,,2023,Q3,1,I,20220611.0,20230808.0,20230818,20230818,EXP,,DE-TEVA-2023-DE-2917353,TEVA,,42.0,YR,A,M,Y,,,20230818,,MD,DE,DE,2023,Q3,Adult
228368971,22836897,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,UNKNOWN,,,,,,,2023,Q3,Vomiting,,2023,Q3,1,I,20220611.0,20230808.0,20230818,20230818,EXP,,DE-TEVA-2023-DE-2917353,TEVA,,42.0,YR,A,M,Y,,,20230818,,MD,DE,DE,2023,Q3,Adult
228381571,22838157,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, qd",,,,,,,,,,Unknown,QD,2023,Q3,Drug intolerance,,2023,Q3,1,I,,20230813.0,20230818,20230818,EXP,GB-MHRA-TPP30040947C3806782YC1690899895056,GB-MYLANLABS-2023M1085811,MYLAN,,64.0,YR,,F,Y,80.0,KG,20230818,,PH,GB,GB,2023,Q3,Adult
228381571,22838157,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, qd",,,,,,,,,,Unknown,QD,2023,Q3,Abdominal discomfort,,2023,Q3,1,I,,20230813.0,20230818,20230818,EXP,GB-MHRA-TPP30040947C3806782YC1690899895056,GB-MYLANLABS-2023M1085811,MYLAN,,64.0,YR,,F,Y,80.0,KG,20230818,,PH,GB,GB,2023,Q3,Adult
228387251,22838725,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Fournier's gangrene,,2023,Q3,1,I,20230724.0,,20230818,20230818,DIR,FDA-CDER-CTU-2023-60482,,FDA-CTU,,59.0,YR,,M,N,103.0,KG,20230818,N,PH,US,,2023,Q3,Adult
228387251,22838725,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Scrotal cellulitis,,2023,Q3,1,I,20230724.0,,20230818,20230818,DIR,FDA-CDER-CTU-2023-60482,,FDA-CTU,,59.0,YR,,M,N,103.0,KG,20230818,N,PH,US,,2023,Q3,Adult
228389412,22838941,2,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q3,Hypoglycaemia,,2023,Q3,2,F,,20230911.0,20230818,20230925,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-404722,RANBAXY,"Gor J, Rittenberg A. A presentation of euglycemic diabetic ketoacidosis. J Gen Intern Med. 2023;38 (Suppl 2):S412 (Control ID #3868962)",57.0,YR,,F,Y,,,20230925,,HP,US,US,2023,Q3,Adult
228408602,22840860,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 Dosage forms Daily;,,,,,,,,,,Tablet,QD,2023,Q3,Dizziness,,2023,Q3,2,F,20230705.0,20230814.0,20230819,20230825,EXP,GB-MHRA-INP12F9238B-6F3B-4B05-A564-3501AE3D5FDB,GB-TEVA-2023-GB-2908589,TEVA,,26.0,YR,A,M,Y,77.0,KG,20230825,,MD,GB,GB,2023,Q3,Young Adult
228408602,22840860,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 Dosage forms Daily;,,,,,,,,,,Tablet,QD,2023,Q3,Hot flush,,2023,Q3,2,F,20230705.0,20230814.0,20230819,20230825,EXP,GB-MHRA-INP12F9238B-6F3B-4B05-A564-3501AE3D5FDB,GB-TEVA-2023-GB-2908589,TEVA,,26.0,YR,A,M,Y,77.0,KG,20230825,,MD,GB,GB,2023,Q3,Young Adult
228408602,22840860,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 Dosage forms Daily;,,,,,,,,,,Tablet,QD,2023,Q3,Off label use,,2023,Q3,2,F,20230705.0,20230814.0,20230819,20230825,EXP,GB-MHRA-INP12F9238B-6F3B-4B05-A564-3501AE3D5FDB,GB-TEVA-2023-GB-2908589,TEVA,,26.0,YR,A,M,Y,77.0,KG,20230825,,MD,GB,GB,2023,Q3,Young Adult
228408602,22840860,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 Milligram Daily;,,,,,,,,10.0,MG,Tablet,QD,2023,Q3,Dizziness,,2023,Q3,2,F,20230705.0,20230814.0,20230819,20230825,EXP,GB-MHRA-INP12F9238B-6F3B-4B05-A564-3501AE3D5FDB,GB-TEVA-2023-GB-2908589,TEVA,,26.0,YR,A,M,Y,77.0,KG,20230825,,MD,GB,GB,2023,Q3,Young Adult
228408602,22840860,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 Milligram Daily;,,,,,,,,10.0,MG,Tablet,QD,2023,Q3,Hot flush,,2023,Q3,2,F,20230705.0,20230814.0,20230819,20230825,EXP,GB-MHRA-INP12F9238B-6F3B-4B05-A564-3501AE3D5FDB,GB-TEVA-2023-GB-2908589,TEVA,,26.0,YR,A,M,Y,77.0,KG,20230825,,MD,GB,GB,2023,Q3,Young Adult
228408602,22840860,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 Milligram Daily;,,,,,,,,10.0,MG,Tablet,QD,2023,Q3,Off label use,,2023,Q3,2,F,20230705.0,20230814.0,20230819,20230825,EXP,GB-MHRA-INP12F9238B-6F3B-4B05-A564-3501AE3D5FDB,GB-TEVA-2023-GB-2908589,TEVA,,26.0,YR,A,M,Y,77.0,KG,20230825,,MD,GB,GB,2023,Q3,Young Adult
228408602,22840860,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 Dosage forms Daily;,,,,,,,,,,Tablet,QD,2023,Q3,Dizziness,,2023,Q3,2,F,20230705.0,20230814.0,20230819,20230825,EXP,GB-MHRA-INP12F9238B-6F3B-4B05-A564-3501AE3D5FDB,GB-TEVA-2023-GB-2908589,TEVA,,26.0,YR,A,M,Y,77.0,KG,20230825,,MD,GB,GB,2023,Q3,Young Adult
228408602,22840860,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 Dosage forms Daily;,,,,,,,,,,Tablet,QD,2023,Q3,Hot flush,,2023,Q3,2,F,20230705.0,20230814.0,20230819,20230825,EXP,GB-MHRA-INP12F9238B-6F3B-4B05-A564-3501AE3D5FDB,GB-TEVA-2023-GB-2908589,TEVA,,26.0,YR,A,M,Y,77.0,KG,20230825,,MD,GB,GB,2023,Q3,Young Adult
228408602,22840860,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 Dosage forms Daily;,,,,,,,,,,Tablet,QD,2023,Q3,Off label use,,2023,Q3,2,F,20230705.0,20230814.0,20230819,20230825,EXP,GB-MHRA-INP12F9238B-6F3B-4B05-A564-3501AE3D5FDB,GB-TEVA-2023-GB-2908589,TEVA,,26.0,YR,A,M,Y,77.0,KG,20230825,,MD,GB,GB,2023,Q3,Young Adult
228427451,22842745,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,,,Unknown,,206073.0,,,Tablet,,2023,Q3,Blindness,,2023,Q3,1,I,,20230818.0,20230821,20230821,EXP,,"KR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-256441",BOEHRINGER INGELHEIM,,47.0,YR,A,F,Y,,,20230821,,MD,KR,KR,2023,Q3,Adult
228439401,22843940,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,ASKU,,204629.0,25.0,MG,Tablet,QD,2023,Q3,Pancreatitis,,2023,Q3,1,I,20230807.0,20230818.0,20230821,20230821,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-256491",BOEHRINGER INGELHEIM,,44.0,YR,A,M,Y,,,20230821,,HP,GB,GB,2023,Q3,Adult
228443741,22844374,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,,,,,,10.0,MG,,,2023,Q3,Cardiac failure,,2023,Q3,1,I,,20230814.0,20230821,20230821,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202308008114,ELI LILLY AND CO,,61.0,YR,,F,Y,,,20230821,,CN,IE,DE,2023,Q3,Adult
228451631,22845163,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,0 mg,,,,,,,,,,,,2023,Q3,Catheterisation cardiac,,2023,Q3,1,I,20230724.0,20230815.0,20230821,20230821,EXP,,"CO-DAIICHI SANKYO, INC.-DSE-2023-133876",DAIICHI,,65.0,YR,,M,Y,92.0,KG,20230821,,CN,CO,CO,2023,Q3,Elderly
228451631,22845163,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,0 mg,,,,,,,,,,,,2023,Q3,Chest pain,,2023,Q3,1,I,20230724.0,20230815.0,20230821,20230821,EXP,,"CO-DAIICHI SANKYO, INC.-DSE-2023-133876",DAIICHI,,65.0,YR,,M,Y,92.0,KG,20230821,,CN,CO,CO,2023,Q3,Elderly
228456552,22845655,5,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,,,,,,,,Unknown,,2023,Q3,Nausea,,2023,Q3,2,F,20230810.0,20230904.0,20230821,20230908,EXP,,ES-MYLANLABS-2023M1086355,MYLAN,,70.0,YR,,M,Y,,,20230908,,MD,ES,ES,2023,Q3,Elderly
228456552,22845655,5,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,,,,,,,,Unknown,,2023,Q3,Disease progression,,2023,Q3,2,F,20230810.0,20230904.0,20230821,20230908,EXP,,ES-MYLANLABS-2023M1086355,MYLAN,,70.0,YR,,M,Y,,,20230908,,MD,ES,ES,2023,Q3,Elderly
228456552,22845655,5,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,,,,,,,,Unknown,,2023,Q3,Fall,,2023,Q3,2,F,20230810.0,20230904.0,20230821,20230908,EXP,,ES-MYLANLABS-2023M1086355,MYLAN,,70.0,YR,,M,Y,,,20230908,,MD,ES,ES,2023,Q3,Elderly
228456552,22845655,5,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,,,,,,,,Unknown,,2023,Q3,Haemolysis,,2023,Q3,2,F,20230810.0,20230904.0,20230821,20230908,EXP,,ES-MYLANLABS-2023M1086355,MYLAN,,70.0,YR,,M,Y,,,20230908,,MD,ES,ES,2023,Q3,Elderly
228456552,22845655,5,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,,,,,,,,Unknown,,2023,Q3,Haemoglobin decreased,,2023,Q3,2,F,20230810.0,20230904.0,20230821,20230908,EXP,,ES-MYLANLABS-2023M1086355,MYLAN,,70.0,YR,,M,Y,,,20230908,,MD,ES,ES,2023,Q3,Elderly
228456552,22845655,5,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,,,,,,,,Unknown,,2023,Q3,Hyperhidrosis,,2023,Q3,2,F,20230810.0,20230904.0,20230821,20230908,EXP,,ES-MYLANLABS-2023M1086355,MYLAN,,70.0,YR,,M,Y,,,20230908,,MD,ES,ES,2023,Q3,Elderly
228456552,22845655,5,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,,,,,,,,Unknown,,2023,Q3,Febrile neutropenia,,2023,Q3,2,F,20230810.0,20230904.0,20230821,20230908,EXP,,ES-MYLANLABS-2023M1086355,MYLAN,,70.0,YR,,M,Y,,,20230908,,MD,ES,ES,2023,Q3,Elderly
228472091,22847209,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,end date: ongoing,,,,,,,,,,,,2023,Q3,Lymphopenia,,2023,Q3,1,I,20230101.0,20230809.0,20230822,20230822,EXP,,IT-TEVA-2023-IT-2917193,TEVA,,73.0,YR,E,M,Y,59.0,KG,20230822,,MD,IT,IT,2023,Q3,Elderly
228472091,22847209,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,end date: ongoing,,,,,,,,,,,,2023,Q3,Pneumonia legionella,,2023,Q3,1,I,20230101.0,20230809.0,20230822,20230822,EXP,,IT-TEVA-2023-IT-2917193,TEVA,,73.0,YR,E,M,Y,59.0,KG,20230822,,MD,IT,IT,2023,Q3,Elderly
228472091,22847209,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,end date: ongoing,,,,,,,,,,,,2023,Q3,Asthenia,,2023,Q3,1,I,20230101.0,20230809.0,20230822,20230822,EXP,,IT-TEVA-2023-IT-2917193,TEVA,,73.0,YR,E,M,Y,59.0,KG,20230822,,MD,IT,IT,2023,Q3,Elderly
228472091,22847209,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,end date: ongoing,,,,,,,,,,,,2023,Q3,Anaemia,,2023,Q3,1,I,20230101.0,20230809.0,20230822,20230822,EXP,,IT-TEVA-2023-IT-2917193,TEVA,,73.0,YR,E,M,Y,59.0,KG,20230822,,MD,IT,IT,2023,Q3,Elderly
228472091,22847209,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,end date: ongoing,,,,,,,,,,,,2023,Q3,Pyrexia,,2023,Q3,1,I,20230101.0,20230809.0,20230822,20230822,EXP,,IT-TEVA-2023-IT-2917193,TEVA,,73.0,YR,E,M,Y,59.0,KG,20230822,,MD,IT,IT,2023,Q3,Elderly
228502851,22850285,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Acute kidney injury,,2023,Q3,1,I,20230724.0,20230821.0,20230822,20230822,EXP,FR-AFSSAPS-AN2023001097,NVSC2023FR181936,NOVARTIS,,67.0,YR,,M,Y,80.2,KG,20230822,,MD,FR,FR,2023,Q3,Elderly
228502851,22850285,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Drug interaction,,2023,Q3,1,I,20230724.0,20230821.0,20230822,20230822,EXP,FR-AFSSAPS-AN2023001097,NVSC2023FR181936,NOVARTIS,,67.0,YR,,M,Y,80.2,KG,20230822,,MD,FR,FR,2023,Q3,Elderly
228502851,22850285,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q3,Hyperkalaemia,,2023,Q3,1,I,20230724.0,20230821.0,20230822,20230822,EXP,FR-AFSSAPS-AN2023001097,NVSC2023FR181936,NOVARTIS,,67.0,YR,,M,Y,80.2,KG,20230822,,MD,FR,FR,2023,Q3,Elderly
228521821,22852182,5,C,"EMPAGLIFLOZIN, METFORMIN",,2,Oral,,,,,,,,,,,,,2023,Q3,Asthenia,,2023,Q3,1,I,20230702.0,20230811.0,20230823,20230823,EXP,IT-MINISAL02-935590,IT-Accord-374027,ACCORD,,30.0,YR,A,F,Y,,,20230823,,PH,IT,IT,2023,Q3,Young Adult
228521821,22852182,5,C,"EMPAGLIFLOZIN, METFORMIN",,2,Oral,,,,,,,,,,,,,2023,Q3,Dizziness,,2023,Q3,1,I,20230702.0,20230811.0,20230823,20230823,EXP,IT-MINISAL02-935590,IT-Accord-374027,ACCORD,,30.0,YR,A,F,Y,,,20230823,,PH,IT,IT,2023,Q3,Young Adult
228521821,22852182,5,C,"EMPAGLIFLOZIN, METFORMIN",,2,Oral,,,,,,,,,,,,,2023,Q3,Hyperglycaemia,,2023,Q3,1,I,20230702.0,20230811.0,20230823,20230823,EXP,IT-MINISAL02-935590,IT-Accord-374027,ACCORD,,30.0,YR,A,F,Y,,,20230823,,PH,IT,IT,2023,Q3,Young Adult
228521821,22852182,5,C,"EMPAGLIFLOZIN, METFORMIN",,2,Oral,,,,,,,,,,,,,2023,Q3,Tremor,,2023,Q3,1,I,20230702.0,20230811.0,20230823,20230823,EXP,IT-MINISAL02-935590,IT-Accord-374027,ACCORD,,30.0,YR,A,F,Y,,,20230823,,PH,IT,IT,2023,Q3,Young Adult
228521821,22852182,5,C,"EMPAGLIFLOZIN, METFORMIN",,2,Oral,,,,,,,,,,,,,2023,Q3,Polydipsia,,2023,Q3,1,I,20230702.0,20230811.0,20230823,20230823,EXP,IT-MINISAL02-935590,IT-Accord-374027,ACCORD,,30.0,YR,A,F,Y,,,20230823,,PH,IT,IT,2023,Q3,Young Adult
228521821,22852182,5,C,"EMPAGLIFLOZIN, METFORMIN",,2,Oral,,,,,,,,,,,,,2023,Q3,Chest pain,,2023,Q3,1,I,20230702.0,20230811.0,20230823,20230823,EXP,IT-MINISAL02-935590,IT-Accord-374027,ACCORD,,30.0,YR,A,F,Y,,,20230823,,PH,IT,IT,2023,Q3,Young Adult
228521992,22852199,11,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,Tablet,,2023,Q3,Contraindicated product administered,,2023,Q3,2,F,20220912.0,20230913.0,20230823,20230920,EXP,,JP-EMD Serono-2023468610,EMD SERONO INC,,72.0,YR,E,M,Y,74.0,KG,20230920,,HP,JP,JP,2023,Q3,Elderly
228521992,22852199,11,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,Tablet,,2023,Q3,Hypopharyngeal cancer,,2023,Q3,2,F,20220912.0,20230913.0,20230823,20230920,EXP,,JP-EMD Serono-2023468610,EMD SERONO INC,,72.0,YR,E,M,Y,74.0,KG,20230920,,HP,JP,JP,2023,Q3,Elderly
228522541,22852254,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,,,,Tablet,,2023,Q3,Vision blurred,,2023,Q3,1,I,20230730.0,20230815.0,20230823,20230823,EXP,,GB-EMD Serono-2023468653,EMD SERONO INC,,51.0,YR,A,F,Y,,,20230823,,CN,GB,GB,2023,Q3,Adult
228526001,22852600,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,QD,2023,Q3,Drug intolerance,,2023,Q3,1,I,,20230813.0,20230823,20230823,EXP,GB-MHRA-TPP30040947C3806782YC1690899895056,GB-MICRO LABS LIMITED-ML2023-04708,MICRO LABS,,64.0,YR,A,F,Y,80.0,KG,20230823,,PH,GB,GB,2023,Q3,Adult
228526001,22852600,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,QD,2023,Q3,Abdominal discomfort,,2023,Q3,1,I,,20230813.0,20230823,20230823,EXP,GB-MHRA-TPP30040947C3806782YC1690899895056,GB-MICRO LABS LIMITED-ML2023-04708,MICRO LABS,,64.0,YR,A,F,Y,80.0,KG,20230823,,PH,GB,GB,2023,Q3,Adult
228534002,22853400,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd (each 24h)",,,,,,,,25.0,MG,,QD,2023,Q3,Cardiac failure,,2023,Q3,2,F,20230718.0,20230823.0,20230823,20230829,EXP,,ES-DSJP-DSE-2023-134192,DAIICHI,,68.0,YR,,F,Y,,,20230829,,MD,ES,ES,2023,Q3,Elderly
228534002,22853400,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd (each 24h)",,,,,,,,25.0,MG,,QD,2023,Q3,Diarrhoea,,2023,Q3,2,F,20230718.0,20230823.0,20230823,20230829,EXP,,ES-DSJP-DSE-2023-134192,DAIICHI,,68.0,YR,,F,Y,,,20230829,,MD,ES,ES,2023,Q3,Elderly
228534002,22853400,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd (each 24h)",,,,,,,,25.0,MG,,QD,2023,Q3,Bronchitis,,2023,Q3,2,F,20230718.0,20230823.0,20230823,20230829,EXP,,ES-DSJP-DSE-2023-134192,DAIICHI,,68.0,YR,,F,Y,,,20230829,,MD,ES,ES,2023,Q3,Elderly
228534002,22853400,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd (each 24h)",,,,,,,,25.0,MG,,QD,2023,Q3,Death,,2023,Q3,2,F,20230718.0,20230823.0,20230823,20230829,EXP,,ES-DSJP-DSE-2023-134192,DAIICHI,,68.0,YR,,F,Y,,,20230829,,MD,ES,ES,2023,Q3,Elderly
228534002,22853400,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Cardiac failure,,2023,Q3,2,F,20230718.0,20230823.0,20230823,20230829,EXP,,ES-DSJP-DSE-2023-134192,DAIICHI,,68.0,YR,,F,Y,,,20230829,,MD,ES,ES,2023,Q3,Elderly
228534002,22853400,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Diarrhoea,,2023,Q3,2,F,20230718.0,20230823.0,20230823,20230829,EXP,,ES-DSJP-DSE-2023-134192,DAIICHI,,68.0,YR,,F,Y,,,20230829,,MD,ES,ES,2023,Q3,Elderly
228534002,22853400,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Bronchitis,,2023,Q3,2,F,20230718.0,20230823.0,20230823,20230829,EXP,,ES-DSJP-DSE-2023-134192,DAIICHI,,68.0,YR,,F,Y,,,20230829,,MD,ES,ES,2023,Q3,Elderly
228534002,22853400,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Death,,2023,Q3,2,F,20230718.0,20230823.0,20230823,20230829,EXP,,ES-DSJP-DSE-2023-134192,DAIICHI,,68.0,YR,,F,Y,,,20230829,,MD,ES,ES,2023,Q3,Elderly
228560561,22856056,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK (10 mg),,,Y,,,,,,,,,2023,Q3,Polymyalgia rheumatica,,2023,Q3,1,I,,20230808.0,20230823,20230823,EXP,,JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-404638,RANBAXY,"Takahashi Y, Deshpande GA, Kanai Y, Seok Yan K, Naito T. RS3PE SYNDROME WITH SUBSEQUENT PMR CAUSED BY LONG-TERM DPP-4 INHIBITOR USE. Eur J Case Rep Intern Med. 2023;10(7):1-3",73.0,YR,,M,Y,,,20230823,,HP,JP,JP,2023,Q3,Elderly
228560561,22856056,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK (10 mg),,,Y,,,,,,,,,2023,Q3,Seronegative arthritis,,2023,Q3,1,I,,20230808.0,20230823,20230823,EXP,,JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-404638,RANBAXY,"Takahashi Y, Deshpande GA, Kanai Y, Seok Yan K, Naito T. RS3PE SYNDROME WITH SUBSEQUENT PMR CAUSED BY LONG-TERM DPP-4 INHIBITOR USE. Eur J Case Rep Intern Med. 2023;10(7):1-3",73.0,YR,,M,Y,,,20230823,,HP,JP,JP,2023,Q3,Elderly
228564331,22856433,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1x/day",,,,,Unknown,,,10.0,MG,,QD,2023,Q3,Hyperkalaemia,,2023,Q3,1,I,20230724.0,20230821.0,20230823,20230823,EXP,FR-AFSSAPS-AN2023001097,FR-PFIZER INC-202300280990,PFIZER,,67.0,YR,,M,Y,80.2,KG,20230823,,MD,FR,FR,2023,Q3,Elderly
228564331,22856433,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1x/day",,,,,Unknown,,,10.0,MG,,QD,2023,Q3,Drug interaction,,2023,Q3,1,I,20230724.0,20230821.0,20230823,20230823,EXP,FR-AFSSAPS-AN2023001097,FR-PFIZER INC-202300280990,PFIZER,,67.0,YR,,M,Y,80.2,KG,20230823,,MD,FR,FR,2023,Q3,Elderly
228564331,22856433,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1x/day",,,,,Unknown,,,10.0,MG,,QD,2023,Q3,Acute kidney injury,,2023,Q3,1,I,20230724.0,20230821.0,20230823,20230823,EXP,FR-AFSSAPS-AN2023001097,FR-PFIZER INC-202300280990,PFIZER,,67.0,YR,,M,Y,80.2,KG,20230823,,MD,FR,FR,2023,Q3,Elderly
228583081,22858308,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Film-coated tablet,,2023,Q3,Weight decreased,,2023,Q3,1,I,20221101.0,20230731.0,20230824,20230824,EXP,,US-SANDOZ INC.-SDZ2023US017862,SANDOZ,,62.0,YR,,M,Y,,,20230824,,CN,US,US,2023,Q3,Adult
228583081,22858308,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Film-coated tablet,,2023,Q3,Dizziness,,2023,Q3,1,I,20221101.0,20230731.0,20230824,20230824,EXP,,US-SANDOZ INC.-SDZ2023US017862,SANDOZ,,62.0,YR,,M,Y,,,20230824,,CN,US,US,2023,Q3,Adult
228583081,22858308,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Film-coated tablet,,2023,Q3,Glycosylated haemoglobin decreased,,2023,Q3,1,I,20221101.0,20230731.0,20230824,20230824,EXP,,US-SANDOZ INC.-SDZ2023US017862,SANDOZ,,62.0,YR,,M,Y,,,20230824,,CN,US,US,2023,Q3,Adult
228583081,22858308,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Film-coated tablet,,2023,Q3,Haemoglobin increased,,2023,Q3,1,I,20221101.0,20230731.0,20230824,20230824,EXP,,US-SANDOZ INC.-SDZ2023US017862,SANDOZ,,62.0,YR,,M,Y,,,20230824,,CN,US,US,2023,Q3,Adult
228583081,22858308,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Film-coated tablet,,2023,Q3,Red blood cell count increased,,2023,Q3,1,I,20221101.0,20230731.0,20230824,20230824,EXP,,US-SANDOZ INC.-SDZ2023US017862,SANDOZ,,62.0,YR,,M,Y,,,20230824,,CN,US,US,2023,Q3,Adult
228589861,22858986,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,,,,,2023,Q3,Bladder neck obstruction,,2023,Q3,1,I,20230726.0,20230823.0,20230824,20230824,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-257157",BOEHRINGER INGELHEIM,,55.0,YR,A,F,Y,,,20230824,,HP,SG,SG,2023,Q3,Adult
228631481,22863148,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,204629.0,,,Tablet,,2023,Q3,Epididymitis,,2023,Q3,1,I,20230721.0,20230824.0,20230824,20230824,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-257316",BOEHRINGER INGELHEIM,,72.0,YR,E,M,Y,,,20230824,,HP,GB,GB,2023,Q3,Elderly
228681602,22868160,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg 1X1,,,U,,,,,10.0,MG,,QD,2023,Q3,Renal impairment,,2023,Q3,2,F,,20230828.0,20230825,20230904,EXP,,NVSC2023DE184833,NOVARTIS,,28.0,YR,,M,Y,,,20230904,,MD,DE,DE,2023,Q3,Young Adult
228681602,22868160,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg 1X1,,,U,,,,,10.0,MG,,QD,2023,Q3,Hypertension,,2023,Q3,2,F,,20230828.0,20230825,20230904,EXP,,NVSC2023DE184833,NOVARTIS,,28.0,YR,,M,Y,,,20230904,,MD,DE,DE,2023,Q3,Young Adult
228681602,22868160,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg 1X1,,,U,,,,,10.0,MG,,QD,2023,Q3,Hyperkalaemia,,2023,Q3,2,F,,20230828.0,20230825,20230904,EXP,,NVSC2023DE184833,NOVARTIS,,28.0,YR,,M,Y,,,20230904,,MD,DE,DE,2023,Q3,Young Adult
228695781,22869578,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, Once a Day",,,U,,,,,,,,QD,2023,Q3,Drug intolerance,,2023,Q3,1,I,,20230813.0,20230826,20230826,EXP,,GB-AUROBINDO-AUR-APL-2023-054052,AUROBINDO,,64.0,YR,,F,Y,80.0,KG,20230826,,PH,GB,GB,2023,Q3,Adult
228695781,22869578,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, Once a Day",,,U,,,,,,,,QD,2023,Q3,Abdominal discomfort,,2023,Q3,1,I,,20230813.0,20230826,20230826,EXP,,GB-AUROBINDO-AUR-APL-2023-054052,AUROBINDO,,64.0,YR,,F,Y,80.0,KG,20230826,,PH,GB,GB,2023,Q3,Adult
228712331,22871233,4,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 DF, QD",,,,,221208,,,,,Tablet,QD,2023,Q3,Dizziness,,2023,Q3,1,I,20230520.0,20230824.0,20230828,20230828,EXP,,CN-BAYER-2023A120048,BAYER,,82.0,YR,E,F,Y,52.0,KG,20230828,,HP,CN,CN,2023,Q3,Elderly
228712331,22871233,4,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 DF, QD",,,,,221208,,,,,Tablet,QD,2023,Q3,Cold sweat,,2023,Q3,1,I,20230520.0,20230824.0,20230828,20230828,EXP,,CN-BAYER-2023A120048,BAYER,,82.0,YR,E,F,Y,52.0,KG,20230828,,HP,CN,CN,2023,Q3,Elderly
228712331,22871233,4,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 DF, QD",,,,,221208,,,,,Tablet,QD,2023,Q3,Palpitations,,2023,Q3,1,I,20230520.0,20230824.0,20230828,20230828,EXP,,CN-BAYER-2023A120048,BAYER,,82.0,YR,E,F,Y,52.0,KG,20230828,,HP,CN,CN,2023,Q3,Elderly
228712331,22871233,4,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 DF, QD",,,,,221208,,,,,Tablet,QD,2023,Q3,Hypoglycaemia,,2023,Q3,1,I,20230520.0,20230824.0,20230828,20230828,EXP,,CN-BAYER-2023A120048,BAYER,,82.0,YR,E,F,Y,52.0,KG,20230828,,HP,CN,CN,2023,Q3,Elderly
228712331,22871233,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 DF, QD",,,,,221208,,,,,Tablet,QD,2023,Q3,Dizziness,,2023,Q3,1,I,20230520.0,20230824.0,20230828,20230828,EXP,,CN-BAYER-2023A120048,BAYER,,82.0,YR,E,F,Y,52.0,KG,20230828,,HP,CN,CN,2023,Q3,Elderly
228712331,22871233,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 DF, QD",,,,,221208,,,,,Tablet,QD,2023,Q3,Cold sweat,,2023,Q3,1,I,20230520.0,20230824.0,20230828,20230828,EXP,,CN-BAYER-2023A120048,BAYER,,82.0,YR,E,F,Y,52.0,KG,20230828,,HP,CN,CN,2023,Q3,Elderly
228712331,22871233,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 DF, QD",,,,,221208,,,,,Tablet,QD,2023,Q3,Palpitations,,2023,Q3,1,I,20230520.0,20230824.0,20230828,20230828,EXP,,CN-BAYER-2023A120048,BAYER,,82.0,YR,E,F,Y,52.0,KG,20230828,,HP,CN,CN,2023,Q3,Elderly
228712331,22871233,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 DF, QD",,,,,221208,,,,,Tablet,QD,2023,Q3,Hypoglycaemia,,2023,Q3,1,I,20230520.0,20230824.0,20230828,20230828,EXP,,CN-BAYER-2023A120048,BAYER,,82.0,YR,E,F,Y,52.0,KG,20230828,,HP,CN,CN,2023,Q3,Elderly
228716351,22871635,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,U,,UNKNOWN,,,10.0,MG,,QD,2023,Q3,Cerebrovascular accident,,2023,Q3,1,I,20230420.0,20230823.0,20230828,20230828,EXP,GB-MHRA-ADR 28133826,"GB-REGENERON PHARMACEUTICALS, INC.-2023-105481",REGENERON,,62.0,YR,,M,Y,,,20230828,,PH,GB,GB,2023,Q3,Adult
228716351,22871635,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,U,,UNKNOWN,,,10.0,MG,,QD,2023,Q3,Lacunar infarction,,2023,Q3,1,I,20230420.0,20230823.0,20230828,20230828,EXP,GB-MHRA-ADR 28133826,"GB-REGENERON PHARMACEUTICALS, INC.-2023-105481",REGENERON,,62.0,YR,,M,Y,,,20230828,,PH,GB,GB,2023,Q3,Adult
228744593,22874459,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q3,Hypertension,,2023,Q3,3,F,,20230907.0,20230828,20230914,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-257747",BOEHRINGER INGELHEIM,,28.0,YR,A,M,Y,,,20230914,,HP,DE,DE,2023,Q3,Young Adult
228744593,22874459,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q3,Renal impairment,,2023,Q3,3,F,,20230907.0,20230828,20230914,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-257747",BOEHRINGER INGELHEIM,,28.0,YR,A,M,Y,,,20230914,,HP,DE,DE,2023,Q3,Young Adult
228744593,22874459,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q3,Hyperkalaemia,,2023,Q3,3,F,,20230907.0,20230828,20230914,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-257747",BOEHRINGER INGELHEIM,,28.0,YR,A,M,Y,,,20230914,,HP,DE,DE,2023,Q3,Young Adult
228754091,22875409,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,D,,Unknown,,206073.0,,,,,2023,Q3,Vomiting,,2023,Q3,1,I,20200101.0,20230825.0,20230829,20230829,EXP,,"MX-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-257892",BOEHRINGER INGELHEIM,,6.0,DEC,A,M,Y,,,20230829,,MD,MX,MX,2023,Q3,Child
228754091,22875409,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,D,,Unknown,,206073.0,,,,,2023,Q3,Hepatic cancer,,2023,Q3,1,I,20200101.0,20230825.0,20230829,20230829,EXP,,"MX-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-257892",BOEHRINGER INGELHEIM,,6.0,DEC,A,M,Y,,,20230829,,MD,MX,MX,2023,Q3,Child
228754091,22875409,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,D,,Unknown,,206073.0,,,,,2023,Q3,Weight decreased,,2023,Q3,1,I,20200101.0,20230825.0,20230829,20230829,EXP,,"MX-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-257892",BOEHRINGER INGELHEIM,,6.0,DEC,A,M,Y,,,20230829,,MD,MX,MX,2023,Q3,Child
228754091,22875409,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,D,,Unknown,,206073.0,,,,,2023,Q3,Malaise,,2023,Q3,1,I,20200101.0,20230825.0,20230829,20230829,EXP,,"MX-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-257892",BOEHRINGER INGELHEIM,,6.0,DEC,A,M,Y,,,20230829,,MD,MX,MX,2023,Q3,Child
228755561,22875556,8,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,"After breakfast, AP",,,,,,,,,,Tablet,QD,2023,Q3,Neutrophil count decreased,,2023,Q3,1,I,20230315.0,20230824.0,20230829,20230829,EXP,,JP-AstraZeneca-2023A194532,ASTRAZENECA,,72.0,YR,,M,Y,69.0,KG,20230829,,MD,JP,,2023,Q3,Elderly
228755561,22875556,8,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,"After breakfast, AP",,,,,,,,,,Tablet,QD,2023,Q3,Platelet count decreased,,2023,Q3,1,I,20230315.0,20230824.0,20230829,20230829,EXP,,JP-AstraZeneca-2023A194532,ASTRAZENECA,,72.0,YR,,M,Y,69.0,KG,20230829,,MD,JP,,2023,Q3,Elderly
228755561,22875556,8,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,"After breakfast, AP",,,,,,,,,,Tablet,QD,2023,Q3,Hypochromic anaemia,,2023,Q3,1,I,20230315.0,20230824.0,20230829,20230829,EXP,,JP-AstraZeneca-2023A194532,ASTRAZENECA,,72.0,YR,,M,Y,69.0,KG,20230829,,MD,JP,,2023,Q3,Elderly
228766971,22876697,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,N,,Unknown,,204629.0,10.0,MG,,,2023,Q3,Hyperglycaemia,,2023,Q3,1,I,20230815.0,20230829.0,20230829,20230829,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-258027",BOEHRINGER INGELHEIM,,82.0,YR,E,F,Y,,,20230829,,MD,DE,DE,2023,Q3,Elderly
228766971,22876697,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,N,,Unknown,,204629.0,10.0,MG,,,2023,Q3,Abdominal pain,,2023,Q3,1,I,20230815.0,20230829.0,20230829,20230829,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-258027",BOEHRINGER INGELHEIM,,82.0,YR,E,F,Y,,,20230829,,MD,DE,DE,2023,Q3,Elderly
228766971,22876697,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,N,,Unknown,,204629.0,10.0,MG,,,2023,Q3,Ketoacidosis,,2023,Q3,1,I,20230815.0,20230829.0,20230829,20230829,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-258027",BOEHRINGER INGELHEIM,,82.0,YR,E,F,Y,,,20230829,,MD,DE,DE,2023,Q3,Elderly
228766971,22876697,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,N,,Unknown,,204629.0,10.0,MG,,,2023,Q3,Disorientation,,2023,Q3,1,I,20230815.0,20230829.0,20230829,20230829,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-258027",BOEHRINGER INGELHEIM,,82.0,YR,E,F,Y,,,20230829,,MD,DE,DE,2023,Q3,Elderly
228766971,22876697,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,N,,Unknown,,204629.0,10.0,MG,,,2023,Q3,Abdominal rigidity,,2023,Q3,1,I,20230815.0,20230829.0,20230829,20230829,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-258027",BOEHRINGER INGELHEIM,,82.0,YR,E,F,Y,,,20230829,,MD,DE,DE,2023,Q3,Elderly
228766971,22876697,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,N,,Unknown,,204629.0,10.0,MG,,,2023,Q3,Monoparesis,,2023,Q3,1,I,20230815.0,20230829.0,20230829,20230829,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-258027",BOEHRINGER INGELHEIM,,82.0,YR,E,F,Y,,,20230829,,MD,DE,DE,2023,Q3,Elderly
228766971,22876697,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,N,,Unknown,,204629.0,10.0,MG,,,2023,Q3,Disturbance in attention,,2023,Q3,1,I,20230815.0,20230829.0,20230829,20230829,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-258027",BOEHRINGER INGELHEIM,,82.0,YR,E,F,Y,,,20230829,,MD,DE,DE,2023,Q3,Elderly
228768301,22876830,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,,,Tablet,,2023,Q3,Pancreatitis acute,,2023,Q3,1,I,,20230829.0,20230829,20230829,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-258058",BOEHRINGER INGELHEIM,,44.0,YR,A,M,Y,,,20230829,,PH,GB,GB,2023,Q3,Adult
228776411,22877641,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10mg 1-0-0, long course",,,Y,,,,,,,Film-coated tablet,,2023,Q3,Hyponatraemia,,2023,Q3,1,I,20230626.0,20230818.0,20230829,20230829,EXP,FR-AFSSAPS-TO2023001315,FR-Accord-375303,ACCORD,,85.0,YR,E,F,Y,,,20230829,,MD,FR,FR,2023,Q3,Elderly
228862881,22886288,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,,,,,,,,2023,Q3,Cough,,2023,Q3,1,I,,20230828.0,20230831,20230831,EXP,GB-MHRA-ADR 28141431,GB-JNJFOC-20230863320,JOHNSON AND JOHNSON,,61.0,YR,A,F,Y,81.4,KG,20230831,,HP,GB,GB,2023,Q3,Adult
228862881,22886288,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,,,,,,,,2023,Q3,Dyspnoea,,2023,Q3,1,I,,20230828.0,20230831,20230831,EXP,GB-MHRA-ADR 28141431,GB-JNJFOC-20230863320,JOHNSON AND JOHNSON,,61.0,YR,A,F,Y,81.4,KG,20230831,,HP,GB,GB,2023,Q3,Adult
228862881,22886288,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,,,,,,,,2023,Q3,Organising pneumonia,,2023,Q3,1,I,,20230828.0,20230831,20230831,EXP,GB-MHRA-ADR 28141431,GB-JNJFOC-20230863320,JOHNSON AND JOHNSON,,61.0,YR,A,F,Y,81.4,KG,20230831,,HP,GB,GB,2023,Q3,Adult
228862881,22886288,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,,,,,,,,2023,Q3,Lung infiltration,,2023,Q3,1,I,,20230828.0,20230831,20230831,EXP,GB-MHRA-ADR 28141431,GB-JNJFOC-20230863320,JOHNSON AND JOHNSON,,61.0,YR,A,F,Y,81.4,KG,20230831,,HP,GB,GB,2023,Q3,Adult
228928751,22892875,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,,2023,Q3,Drug reaction with eosinophilia and systemic symptoms,,2023,Q3,1,I,20230326.0,20230822.0,20230901,20230901,EXP,FR-AFSSAPS-RE2023000345,FR-Accord-375988,ACCORD,,75.0,YR,E,F,Y,73.0,KG,20230901,,PH,FR,FR,2023,Q3,Elderly
228937892,22893789,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg 1X1,,,U,,UNKNOWN,,,10.0,MG,,QD,2023,Q3,Hyperkalaemia,,2023,Q3,2,F,,20230908.0,20230901,20230914,EXP,,DE-ROCHE-3413725,ROCHE,,28.0,YR,,M,Y,,,20230914,,MD,DE,DE,2023,Q3,Young Adult
228937892,22893789,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg 1X1,,,U,,UNKNOWN,,,10.0,MG,,QD,2023,Q3,Hypertension,,2023,Q3,2,F,,20230908.0,20230901,20230914,EXP,,DE-ROCHE-3413725,ROCHE,,28.0,YR,,M,Y,,,20230914,,MD,DE,DE,2023,Q3,Young Adult
228937892,22893789,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg 1X1,,,U,,UNKNOWN,,,10.0,MG,,QD,2023,Q3,Renal impairment,,2023,Q3,2,F,,20230908.0,20230901,20230914,EXP,,DE-ROCHE-3413725,ROCHE,,28.0,YR,,M,Y,,,20230914,,MD,DE,DE,2023,Q3,Young Adult
228939465,22893946,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,Tablets,,2023,Q3,Infected dermal cyst,,2023,Q3,5,F,20230621.0,20230918.0,20230901,20230925,EXP,,BR-Eisai Medical Research-EC-2023-145364,EISAI,,66.0,YR,E,F,Y,50.2,KG,20230925,,MD,BR,,2023,Q3,Elderly
228977291,22897729,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,N,,,,,10.0,MG,,,2023,Q3,Chronic obstructive pulmonary disease,,2023,Q3,1,I,20230623.0,20230831.0,20230902,20230902,EXP,,CO-SANDOZ INC.-NVSC2023CO149110,SANDOZ,,69.0,YR,,M,Y,55.1,KG,20230902,,MD,CO,CO,2023,Q3,Elderly
229004121,22900412,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,,,,,2023,Q3,Vertebrobasilar stroke,,2023,Q3,1,I,20230731.0,20230828.0,20230904,20230904,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-257982",BOEHRINGER INGELHEIM,,66.0,YR,E,M,Y,,,20230904,,HP,SG,SG,2023,Q3,Elderly
229004121,22900412,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,,,,,2023,Q3,Atrioventricular block second degree,,2023,Q3,1,I,20230731.0,20230828.0,20230904,20230904,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-257982",BOEHRINGER INGELHEIM,,66.0,YR,E,M,Y,,,20230904,,HP,SG,SG,2023,Q3,Elderly
229004121,22900412,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,,,,,2023,Q3,Diabetic ketoacidosis,,2023,Q3,1,I,20230731.0,20230828.0,20230904,20230904,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-257982",BOEHRINGER INGELHEIM,,66.0,YR,E,M,Y,,,20230904,,HP,SG,SG,2023,Q3,Elderly
229004121,22900412,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,,,,,2023,Q3,Myocardial ischaemia,,2023,Q3,1,I,20230731.0,20230828.0,20230904,20230904,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-257982",BOEHRINGER INGELHEIM,,66.0,YR,E,M,Y,,,20230904,,HP,SG,SG,2023,Q3,Elderly
229004121,22900412,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,,,,,2023,Q3,Deafness neurosensory,,2023,Q3,1,I,20230731.0,20230828.0,20230904,20230904,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-257982",BOEHRINGER INGELHEIM,,66.0,YR,E,M,Y,,,20230904,,HP,SG,SG,2023,Q3,Elderly
229004121,22900412,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,,,,,2023,Q3,Cognitive disorder,,2023,Q3,1,I,20230731.0,20230828.0,20230904,20230904,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-257982",BOEHRINGER INGELHEIM,,66.0,YR,E,M,Y,,,20230904,,HP,SG,SG,2023,Q3,Elderly
229014163,22901416,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg 1X1,,,U,,,,,10.0,MG,,QD,2023,Q3,Renal impairment,,2023,Q3,3,F,,20230905.0,20230904,20230926,EXP,,DE-ABBVIE-5390322,ABBVIE,,28.0,YR,,M,Y,,,20230926,,MD,DE,DE,2023,Q3,Young Adult
229014163,22901416,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg 1X1,,,U,,,,,10.0,MG,,QD,2023,Q3,Hyperkalaemia,,2023,Q3,3,F,,20230905.0,20230904,20230926,EXP,,DE-ABBVIE-5390322,ABBVIE,,28.0,YR,,M,Y,,,20230926,,MD,DE,DE,2023,Q3,Young Adult
229014163,22901416,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg 1X1,,,U,,,,,10.0,MG,,QD,2023,Q3,Hypertension,,2023,Q3,3,F,,20230905.0,20230904,20230926,EXP,,DE-ABBVIE-5390322,ABBVIE,,28.0,YR,,M,Y,,,20230926,,MD,DE,DE,2023,Q3,Young Adult
229017811,22901781,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Product use in unapproved indication,,2023,Q3,1,I,,20230828.0,20230904,20230904,EXP,,LB-CHEPLA-2023010826,CHEPLAPHARM,"Fares R, Matar M. Human herpesvirus-7 meningitis in an immunocompetent adult patient: a case report. Future Sci OA. 2023 Jun 23;9(8):FSO876. doi: 10.2144/fsoa-2023-0021. PMID: 37621843; PMCID: PMC10445589.",53.0,YR,,F,Y,,,20230904,,HP,COUNTRY NOT SPECIFIED,LB,2023,Q3,Adult
229017811,22901781,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Cardiac arrest,,2023,Q3,1,I,,20230828.0,20230904,20230904,EXP,,LB-CHEPLA-2023010826,CHEPLAPHARM,"Fares R, Matar M. Human herpesvirus-7 meningitis in an immunocompetent adult patient: a case report. Future Sci OA. 2023 Jun 23;9(8):FSO876. doi: 10.2144/fsoa-2023-0021. PMID: 37621843; PMCID: PMC10445589.",53.0,YR,,F,Y,,,20230904,,HP,COUNTRY NOT SPECIFIED,LB,2023,Q3,Adult
229029751,22902975,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,,QD,2023,Q3,Drug ineffective,,2023,Q3,1,I,,20230902.0,20230904,20230904,EXP,,IT-BAUSCHBL-2023BNL007937,BAUSCH AND LOMB,,63.0,YR,,F,Y,73.0,KG,20230905,,MD,IT,IT,2023,Q3,Adult
229029751,22902975,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,,QD,2023,Q3,Off label use,,2023,Q3,1,I,,20230902.0,20230904,20230904,EXP,,IT-BAUSCHBL-2023BNL007937,BAUSCH AND LOMB,,63.0,YR,,F,Y,73.0,KG,20230905,,MD,IT,IT,2023,Q3,Adult
229029751,22902975,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,,QD,2023,Q3,Cardiac failure,,2023,Q3,1,I,,20230902.0,20230904,20230904,EXP,,IT-BAUSCHBL-2023BNL007937,BAUSCH AND LOMB,,63.0,YR,,F,Y,73.0,KG,20230905,,MD,IT,IT,2023,Q3,Adult
229038991,22903899,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 DF qd,,,,,unknown,,,,,,,2023,Q3,Fatigue,,2023,Q3,1,I,20230821.0,20230823.0,20230905,20230905,EXP,GB-MHRA-TPP51060526C7894837YC1692613783622,GB-NOVOPROD-1108291,NOVO NORDISK,,60.0,YR,,M,Y,111.0,KG,20230905,,HP,GB,GB,2023,Q3,Adult
229038991,22903899,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 DF qd,,,,,unknown,,,,,,,2023,Q3,Diarrhoea,,2023,Q3,1,I,20230821.0,20230823.0,20230905,20230905,EXP,GB-MHRA-TPP51060526C7894837YC1692613783622,GB-NOVOPROD-1108291,NOVO NORDISK,,60.0,YR,,M,Y,111.0,KG,20230905,,HP,GB,GB,2023,Q3,Adult
229038991,22903899,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 DF qd,,,,,unknown,,,,,,,2023,Q3,Muscle atrophy,,2023,Q3,1,I,20230821.0,20230823.0,20230905,20230905,EXP,GB-MHRA-TPP51060526C7894837YC1692613783622,GB-NOVOPROD-1108291,NOVO NORDISK,,60.0,YR,,M,Y,111.0,KG,20230905,,HP,GB,GB,2023,Q3,Adult
229067211,22906721,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,U,U,,,,25.0,MG,Unknown,QD,2023,Q3,Drug ineffective,,2023,Q3,1,I,,20230823.0,20230905,20230905,EXP,,US-MYLANLABS-2023M1090714,MYLAN,"Goff CB, Plaxe SC, White W, Dasanu CA. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic mucosal melanoma. J-Oncol-Pharm-Pract 2023;29(5):1259-1263.",8.0,DEC,,M,Y,,,20230905,,HP,US,US,2023,Q3,Child
229144252,22914425,4,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,Tablets,,2023,Q3,Hyponatraemia,,2023,Q3,2,F,20230817.0,20230904.0,20230906,20230911,PER,,CN-Eisai Medical Research-EC-2023-148115,EISAI,,59.0,YR,A,F,Y,54.0,KG,20230911,,MD,CN,,2023,Q3,Adult
229145671,22914567,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q3,Hypertension,,2023,Q3,1,I,20220701.0,20230825.0,20230907,20230907,EXP,,DE-AUROBINDO-AUR-APL-2023-056347,AUROBINDO,,28.0,YR,,M,Y,,,20230907,,MD,DE,DE,2023,Q3,Young Adult
229145671,22914567,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q3,Renal impairment,,2023,Q3,1,I,20220701.0,20230825.0,20230907,20230907,EXP,,DE-AUROBINDO-AUR-APL-2023-056347,AUROBINDO,,28.0,YR,,M,Y,,,20230907,,MD,DE,DE,2023,Q3,Young Adult
229145671,22914567,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q3,Fatigue,,2023,Q3,1,I,20220701.0,20230825.0,20230907,20230907,EXP,,DE-AUROBINDO-AUR-APL-2023-056347,AUROBINDO,,28.0,YR,,M,Y,,,20230907,,MD,DE,DE,2023,Q3,Young Adult
229145671,22914567,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q3,Chronic kidney disease,,2023,Q3,1,I,20220701.0,20230825.0,20230907,20230907,EXP,,DE-AUROBINDO-AUR-APL-2023-056347,AUROBINDO,,28.0,YR,,M,Y,,,20230907,,MD,DE,DE,2023,Q3,Young Adult
229145671,22914567,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q3,C3 glomerulopathy,,2023,Q3,1,I,20220701.0,20230825.0,20230907,20230907,EXP,,DE-AUROBINDO-AUR-APL-2023-056347,AUROBINDO,,28.0,YR,,M,Y,,,20230907,,MD,DE,DE,2023,Q3,Young Adult
229145671,22914567,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q3,Hyperkalaemia,,2023,Q3,1,I,20220701.0,20230825.0,20230907,20230907,EXP,,DE-AUROBINDO-AUR-APL-2023-056347,AUROBINDO,,28.0,YR,,M,Y,,,20230907,,MD,DE,DE,2023,Q3,Young Adult
229145671,22914567,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, Once a Day",,,U,,,,,,,,QD,2023,Q3,Hypertension,,2023,Q3,1,I,20220701.0,20230825.0,20230907,20230907,EXP,,DE-AUROBINDO-AUR-APL-2023-056347,AUROBINDO,,28.0,YR,,M,Y,,,20230907,,MD,DE,DE,2023,Q3,Young Adult
229145671,22914567,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, Once a Day",,,U,,,,,,,,QD,2023,Q3,Renal impairment,,2023,Q3,1,I,20220701.0,20230825.0,20230907,20230907,EXP,,DE-AUROBINDO-AUR-APL-2023-056347,AUROBINDO,,28.0,YR,,M,Y,,,20230907,,MD,DE,DE,2023,Q3,Young Adult
229145671,22914567,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, Once a Day",,,U,,,,,,,,QD,2023,Q3,Fatigue,,2023,Q3,1,I,20220701.0,20230825.0,20230907,20230907,EXP,,DE-AUROBINDO-AUR-APL-2023-056347,AUROBINDO,,28.0,YR,,M,Y,,,20230907,,MD,DE,DE,2023,Q3,Young Adult
229145671,22914567,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, Once a Day",,,U,,,,,,,,QD,2023,Q3,Chronic kidney disease,,2023,Q3,1,I,20220701.0,20230825.0,20230907,20230907,EXP,,DE-AUROBINDO-AUR-APL-2023-056347,AUROBINDO,,28.0,YR,,M,Y,,,20230907,,MD,DE,DE,2023,Q3,Young Adult
229145671,22914567,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, Once a Day",,,U,,,,,,,,QD,2023,Q3,C3 glomerulopathy,,2023,Q3,1,I,20220701.0,20230825.0,20230907,20230907,EXP,,DE-AUROBINDO-AUR-APL-2023-056347,AUROBINDO,,28.0,YR,,M,Y,,,20230907,,MD,DE,DE,2023,Q3,Young Adult
229145671,22914567,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, Once a Day",,,U,,,,,,,,QD,2023,Q3,Hyperkalaemia,,2023,Q3,1,I,20220701.0,20230825.0,20230907,20230907,EXP,,DE-AUROBINDO-AUR-APL-2023-056347,AUROBINDO,,28.0,YR,,M,Y,,,20230907,,MD,DE,DE,2023,Q3,Young Adult
229147331,22914733,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,5/1000 bid,,,Y,,Unknown,,204629.0,,,,,2023,Q3,Appendicitis,,2023,Q3,1,I,20220701.0,20230905.0,20230907,20230907,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-251525",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,50.0,KG,20230907,,MD,CA,CA,2023,Q3,Adult
229147331,22914733,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,5/1000 bid,,,Y,,Unknown,,204629.0,,,,,2023,Q3,Tachypnoea,,2023,Q3,1,I,20220701.0,20230905.0,20230907,20230907,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-251525",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,50.0,KG,20230907,,MD,CA,CA,2023,Q3,Adult
229147331,22914733,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,5/1000 bid,,,Y,,Unknown,,204629.0,,,,,2023,Q3,Blood creatinine increased,,2023,Q3,1,I,20220701.0,20230905.0,20230907,20230907,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-251525",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,50.0,KG,20230907,,MD,CA,CA,2023,Q3,Adult
229147331,22914733,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,5/1000 bid,,,Y,,Unknown,,204629.0,,,,,2023,Q3,Hypotension,,2023,Q3,1,I,20220701.0,20230905.0,20230907,20230907,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-251525",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,50.0,KG,20230907,,MD,CA,CA,2023,Q3,Adult
229147331,22914733,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,5/1000 bid,,,Y,,Unknown,,204629.0,,,,,2023,Q3,Diabetic ketoacidosis,,2023,Q3,1,I,20220701.0,20230905.0,20230907,20230907,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-251525",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,50.0,KG,20230907,,MD,CA,CA,2023,Q3,Adult
229149321,22914932,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,U,Unknown,,,10.0,MG,,,2023,Q3,Hyperkalaemia,,2023,Q3,1,I,,20230825.0,20230907,20230907,EXP,,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2023-09966,ALKEM,,28.0,YR,,M,Y,,,20230907,,MD,DE,DE,2023,Q3,Young Adult
229149321,22914932,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,U,Unknown,,,10.0,MG,,,2023,Q3,Hypertension,,2023,Q3,1,I,,20230825.0,20230907,20230907,EXP,,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2023-09966,ALKEM,,28.0,YR,,M,Y,,,20230907,,MD,DE,DE,2023,Q3,Young Adult
229149321,22914932,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,U,Unknown,,,10.0,MG,,,2023,Q3,Renal impairment,,2023,Q3,1,I,,20230825.0,20230907,20230907,EXP,,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2023-09966,ALKEM,,28.0,YR,,M,Y,,,20230907,,MD,DE,DE,2023,Q3,Young Adult
229160251,22916025,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Therapy non-responder,,2023,Q3,1,I,,20230904.0,20230907,20230907,EXP,,IE-BAUSCHBL-2023BNL007998,BAUSCH AND LOMB,"Tansey D, O^Connell J, McQuillan R, Frohlich S, Griffin M, Lyne J, Moran C. Treatment resistant Amiodarone-induced Thyrotoxicosis in a patient with laminopathy requiring salvage thyroidectomy. Thyroid Research. 2023;16(S1):7.",53.0,YR,,M,Y,,,20230907,,HP,IE,IE,2023,Q3,Adult
229225592,22922559,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,204629.0,,,,,2023,Q3,Urosepsis,,2023,Q3,2,F,20230701.0,20230912.0,20230908,20230912,EXP,IT-MINISAL02-942981,"IT-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-260056",BOEHRINGER INGELHEIM,,74.0,YR,E,M,Y,,,20230912,,MD,IT,IT,2023,Q3,Elderly
229274491,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Pain,,2023,Q3,1,I,20200110.0,20230814.0,20230911,20230911,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230911,,CN,CA,CA,2023,Q3,Adult
229274491,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Osteoarthritis,,2023,Q3,1,I,20200110.0,20230814.0,20230911,20230911,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230911,,CN,CA,CA,2023,Q3,Adult
229274491,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Antinuclear antibody positive,,2023,Q3,1,I,20200110.0,20230814.0,20230911,20230911,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230911,,CN,CA,CA,2023,Q3,Adult
229274491,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Rash,,2023,Q3,1,I,20200110.0,20230814.0,20230911,20230911,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230911,,CN,CA,CA,2023,Q3,Adult
229274491,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Joint effusion,,2023,Q3,1,I,20200110.0,20230814.0,20230911,20230911,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230911,,CN,CA,CA,2023,Q3,Adult
229274491,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Injection site warmth,,2023,Q3,1,I,20200110.0,20230814.0,20230911,20230911,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230911,,CN,CA,CA,2023,Q3,Adult
229274491,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Sepsis,,2023,Q3,1,I,20200110.0,20230814.0,20230911,20230911,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230911,,CN,CA,CA,2023,Q3,Adult
229274491,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Injection site pain,,2023,Q3,1,I,20200110.0,20230814.0,20230911,20230911,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230911,,CN,CA,CA,2023,Q3,Adult
229274491,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Synovial disorder,,2023,Q3,1,I,20200110.0,20230814.0,20230911,20230911,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230911,,CN,CA,CA,2023,Q3,Adult
229274491,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Urinary tract infection,,2023,Q3,1,I,20200110.0,20230814.0,20230911,20230911,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230911,,CN,CA,CA,2023,Q3,Adult
229274491,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Drug ineffective,,2023,Q3,1,I,20200110.0,20230814.0,20230911,20230911,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230911,,CN,CA,CA,2023,Q3,Adult
229274491,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Joint swelling,,2023,Q3,1,I,20200110.0,20230814.0,20230911,20230911,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230911,,CN,CA,CA,2023,Q3,Adult
229274491,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Renal disorder,,2023,Q3,1,I,20200110.0,20230814.0,20230911,20230911,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230911,,CN,CA,CA,2023,Q3,Adult
229274491,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Vitamin B12 decreased,,2023,Q3,1,I,20200110.0,20230814.0,20230911,20230911,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230911,,CN,CA,CA,2023,Q3,Adult
229274491,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Allergic sinusitis,,2023,Q3,1,I,20200110.0,20230814.0,20230911,20230911,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230911,,CN,CA,CA,2023,Q3,Adult
229274491,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Nephrolithiasis,,2023,Q3,1,I,20200110.0,20230814.0,20230911,20230911,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230911,,CN,CA,CA,2023,Q3,Adult
229274491,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Incorrect dose administered,,2023,Q3,1,I,20200110.0,20230814.0,20230911,20230911,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230911,,CN,CA,CA,2023,Q3,Adult
229274491,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Blood uric acid increased,,2023,Q3,1,I,20200110.0,20230814.0,20230911,20230911,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230911,,CN,CA,CA,2023,Q3,Adult
229274491,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Cyst,,2023,Q3,1,I,20200110.0,20230814.0,20230911,20230911,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230911,,CN,CA,CA,2023,Q3,Adult
229274491,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Psoriasis,,2023,Q3,1,I,20200110.0,20230814.0,20230911,20230911,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230911,,CN,CA,CA,2023,Q3,Adult
229274491,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Alanine aminotransferase increased,,2023,Q3,1,I,20200110.0,20230814.0,20230911,20230911,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230911,,CN,CA,CA,2023,Q3,Adult
229274491,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Condition aggravated,,2023,Q3,1,I,20200110.0,20230814.0,20230911,20230911,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230911,,CN,CA,CA,2023,Q3,Adult
229274491,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Arthralgia,,2023,Q3,1,I,20200110.0,20230814.0,20230911,20230911,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230911,,CN,CA,CA,2023,Q3,Adult
229274491,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Blood iron decreased,,2023,Q3,1,I,20200110.0,20230814.0,20230911,20230911,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230911,,CN,CA,CA,2023,Q3,Adult
229274491,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Synovitis,,2023,Q3,1,I,20200110.0,20230814.0,20230911,20230911,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230911,,CN,CA,CA,2023,Q3,Adult
229274491,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Hepatic enzyme increased,,2023,Q3,1,I,20200110.0,20230814.0,20230911,20230911,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230911,,CN,CA,CA,2023,Q3,Adult
229274491,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Tendonitis,,2023,Q3,1,I,20200110.0,20230814.0,20230911,20230911,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230911,,CN,CA,CA,2023,Q3,Adult
229274491,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Wrong technique in device usage process,,2023,Q3,1,I,20200110.0,20230814.0,20230911,20230911,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230911,,CN,CA,CA,2023,Q3,Adult
229274491,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Oedema,,2023,Q3,1,I,20200110.0,20230814.0,20230911,20230911,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230911,,CN,CA,CA,2023,Q3,Adult
229274491,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Device issue,,2023,Q3,1,I,20200110.0,20230814.0,20230911,20230911,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230911,,CN,CA,CA,2023,Q3,Adult
229274491,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Arthritis,,2023,Q3,1,I,20200110.0,20230814.0,20230911,20230911,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230911,,CN,CA,CA,2023,Q3,Adult
229274491,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Arthropathy,,2023,Q3,1,I,20200110.0,20230814.0,20230911,20230911,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230911,,CN,CA,CA,2023,Q3,Adult
229274491,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,C-reactive protein increased,,2023,Q3,1,I,20200110.0,20230814.0,20230911,20230911,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230911,,CN,CA,CA,2023,Q3,Adult
229274491,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Pain in extremity,,2023,Q3,1,I,20200110.0,20230814.0,20230911,20230911,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230911,,CN,CA,CA,2023,Q3,Adult
229274491,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q3,Pyrexia,,2023,Q3,1,I,20200110.0,20230814.0,20230911,20230911,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20230911,,CN,CA,CA,2023,Q3,Adult
229284141,22928414,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Asked But Unknown,,204629.0,,,,,2023,Q3,Bladder cancer,,2023,Q3,1,I,20230731.0,20230910.0,20230911,20230911,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-260368",BOEHRINGER INGELHEIM,,67.0,YR,E,F,Y,,,20230911,,MD,GB,GB,2023,Q3,Elderly
229284651,22928465,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,N,,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q3,Fournier's gangrene,,2023,Q3,1,I,20230904.0,20230908.0,20230911,20230911,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-260358",BOEHRINGER INGELHEIM,,75.0,YR,E,M,Y,85.0,KG,20230911,,MD,GB,GB,2023,Q3,Elderly
229284651,22928465,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,N,,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q3,Abdominal pain,,2023,Q3,1,I,20230904.0,20230908.0,20230911,20230911,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-260358",BOEHRINGER INGELHEIM,,75.0,YR,E,M,Y,85.0,KG,20230911,,MD,GB,GB,2023,Q3,Elderly
229291931,22929193,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg 1X1,,,U,,,,,10.0,MG,UNK,,2023,Q3,Hypertension,,2023,Q3,1,I,,20230831.0,20230911,20230911,EXP,DE-SANDOZ-SDZ2023DE017381,DE-TORRENT-00025301,TORRENT,,28.0,YR,A,M,Y,,,20230911,,MD,DE,DE,2023,Q3,Young Adult
229291931,22929193,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg 1X1,,,U,,,,,10.0,MG,UNK,,2023,Q3,Hyperkalaemia,,2023,Q3,1,I,,20230831.0,20230911,20230911,EXP,DE-SANDOZ-SDZ2023DE017381,DE-TORRENT-00025301,TORRENT,,28.0,YR,A,M,Y,,,20230911,,MD,DE,DE,2023,Q3,Young Adult
229291931,22929193,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg 1X1,,,U,,,,,10.0,MG,UNK,,2023,Q3,Renal impairment,,2023,Q3,1,I,,20230831.0,20230911,20230911,EXP,DE-SANDOZ-SDZ2023DE017381,DE-TORRENT-00025301,TORRENT,,28.0,YR,A,M,Y,,,20230911,,MD,DE,DE,2023,Q3,Young Adult
229304622,22930462,7,C,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2023,Q3,Calcinosis,,2023,Q3,2,F,20230101.0,20230908.0,20230911,20230925,PER,,US-PFIZER INC-202300296396,PFIZER,,50.0,YR,,F,Y,85.28,KG,20230925,,CN,US,US,2023,Q3,Adult
229304622,22930462,7,C,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2023,Q3,Neoplasm progression,,2023,Q3,2,F,20230101.0,20230908.0,20230911,20230925,PER,,US-PFIZER INC-202300296396,PFIZER,,50.0,YR,,F,Y,85.28,KG,20230925,,CN,US,US,2023,Q3,Adult
229305141,22930514,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, qd",,,,,,,,,,Tablet,QD,2023,Q3,Peripheral swelling,,2023,Q3,1,I,,20230905.0,20230911,20230911,EXP,GB-MHRA-TPP41562309C8808880YC1693592144385,GB-MYLANLABS-2023M1095604,MYLAN,,45.0,YR,,F,Y,125.0,KG,20230911,,PH,GB,GB,2023,Q3,Adult
229305141,22930514,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, qd",,,,,,,,,,Tablet,QD,2023,Q3,Joint swelling,,2023,Q3,1,I,,20230905.0,20230911,20230911,EXP,GB-MHRA-TPP41562309C8808880YC1693592144385,GB-MYLANLABS-2023M1095604,MYLAN,,45.0,YR,,F,Y,125.0,KG,20230911,,PH,GB,GB,2023,Q3,Adult
229306931,22930693,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Dyspnoea,,2023,Q3,1,I,20191009.0,20230905.0,20230911,20230911,EXP,,BR-DSJP-DSE-2023-136933,DAIICHI,,83.0,YR,,F,Y,61.0,KG,20230911,,MD,BR,BR,2023,Q3,Elderly
229306931,22930693,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Coronary artery disease,,2023,Q3,1,I,20191009.0,20230905.0,20230911,20230911,EXP,,BR-DSJP-DSE-2023-136933,DAIICHI,,83.0,YR,,F,Y,61.0,KG,20230911,,MD,BR,BR,2023,Q3,Elderly
229306931,22930693,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Atrial fibrillation,,2023,Q3,1,I,20191009.0,20230905.0,20230911,20230911,EXP,,BR-DSJP-DSE-2023-136933,DAIICHI,,83.0,YR,,F,Y,61.0,KG,20230911,,MD,BR,BR,2023,Q3,Elderly
229306931,22930693,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Atrial fibrillation,,2023,Q3,1,I,20191009.0,20230905.0,20230911,20230911,EXP,,BR-DSJP-DSE-2023-136933,DAIICHI,,83.0,YR,,F,Y,61.0,KG,20230911,,MD,BR,BR,2023,Q3,Elderly
229306931,22930693,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Sinus bradycardia,,2023,Q3,1,I,20191009.0,20230905.0,20230911,20230911,EXP,,BR-DSJP-DSE-2023-136933,DAIICHI,,83.0,YR,,F,Y,61.0,KG,20230911,,MD,BR,BR,2023,Q3,Elderly
229306931,22930693,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Sinus node dysfunction,,2023,Q3,1,I,20191009.0,20230905.0,20230911,20230911,EXP,,BR-DSJP-DSE-2023-136933,DAIICHI,,83.0,YR,,F,Y,61.0,KG,20230911,,MD,BR,BR,2023,Q3,Elderly
229306931,22930693,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Hypertension,,2023,Q3,1,I,20191009.0,20230905.0,20230911,20230911,EXP,,BR-DSJP-DSE-2023-136933,DAIICHI,,83.0,YR,,F,Y,61.0,KG,20230911,,MD,BR,BR,2023,Q3,Elderly
229322152,22932215,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Upper respiratory tract infection,,2023,Q3,2,F,20230301.0,20230907.0,20230912,20230913,EXP,,US-ABBVIE-5399598,ABBVIE,,70.0,YR,,F,Y,106.0,KG,20230913,,HP,US,US,2023,Q3,Elderly
229322152,22932215,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Cardiac failure,,2023,Q3,2,F,20230301.0,20230907.0,20230912,20230913,EXP,,US-ABBVIE-5399598,ABBVIE,,70.0,YR,,F,Y,106.0,KG,20230913,,HP,US,US,2023,Q3,Elderly
229325321,22932532,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,Tablet,,2023,Q3,Haemoptysis,,2023,Q3,1,I,20221214.0,20230907.0,20230912,20230912,EXP,,US-ABBVIE-5329879,ABBVIE,,67.0,YR,,M,Y,80.0,KG,20230912,,HP,US,US,2023,Q3,Elderly
229325321,22932532,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,Tablet,,2023,Q3,Therapeutic product effect decreased,,2023,Q3,1,I,20221214.0,20230907.0,20230912,20230912,EXP,,US-ABBVIE-5329879,ABBVIE,,67.0,YR,,M,Y,80.0,KG,20230912,,HP,US,US,2023,Q3,Elderly
229325321,22932532,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,Tablet,,2023,Q3,Throat cancer,,2023,Q3,1,I,20221214.0,20230907.0,20230912,20230912,EXP,,US-ABBVIE-5329879,ABBVIE,,67.0,YR,,M,Y,80.0,KG,20230912,,HP,US,US,2023,Q3,Elderly
229325321,22932532,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,Tablet,,2023,Q3,Cardiac disorder,,2023,Q3,1,I,20221214.0,20230907.0,20230912,20230912,EXP,,US-ABBVIE-5329879,ABBVIE,,67.0,YR,,M,Y,80.0,KG,20230912,,HP,US,US,2023,Q3,Elderly
229325321,22932532,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,Tablet,,2023,Q3,Productive cough,,2023,Q3,1,I,20221214.0,20230907.0,20230912,20230912,EXP,,US-ABBVIE-5329879,ABBVIE,,67.0,YR,,M,Y,80.0,KG,20230912,,HP,US,US,2023,Q3,Elderly
229325321,22932532,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,Tablet,,2023,Q3,Squamous cell carcinoma of the tongue,,2023,Q3,1,I,20221214.0,20230907.0,20230912,20230912,EXP,,US-ABBVIE-5329879,ABBVIE,,67.0,YR,,M,Y,80.0,KG,20230912,,HP,US,US,2023,Q3,Elderly
229325661,22932566,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,10.0,MG,,,2023,Q3,Euglycaemic diabetic ketoacidosis,,2023,Q3,1,I,,20230906.0,20230912,20230912,EXP,,CH-Harman-000013,HARMAN FINOCHEM,"Nzomessi D, Massie E, Gariani K, Giraud R, Meyer P. Combined lactic acidosis and ketoacidosis in a female diabetic patient with severe heart failure. Cardiovasc Endocrinol Metab. 2023 Jul 4;12(3):e0287. doi: 10.1097/XCE.0000000000000287. PMID: 37424794",58.0,YR,,F,Y,,,20230908,,MD,CH,,2023,Q3,Adult
229325661,22932566,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,10.0,MG,,,2023,Q3,Lactic acidosis,,2023,Q3,1,I,,20230906.0,20230912,20230912,EXP,,CH-Harman-000013,HARMAN FINOCHEM,"Nzomessi D, Massie E, Gariani K, Giraud R, Meyer P. Combined lactic acidosis and ketoacidosis in a female diabetic patient with severe heart failure. Cardiovasc Endocrinol Metab. 2023 Jul 4;12(3):e0287. doi: 10.1097/XCE.0000000000000287. PMID: 37424794",58.0,YR,,F,Y,,,20230908,,MD,CH,,2023,Q3,Adult
229354831,22935483,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q3,Off label use,,2023,Q3,1,I,,20230911.0,20230912,20230912,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-2023-129024,BRISTOL MYERS SQUIBB,,57.0,YR,A,F,Y,,,20230912,,HP,US,US,2023,Q3,Adult
229360432,22936043,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,,,Tablet,,2023,Q3,Peripheral swelling,,2023,Q3,2,F,,20230917.0,20230912,20230926,EXP,GB-MHRA-TPP41562309C8808880YC1693592144385,GB-TORRENT-00033095,TORRENT,,45.0,YR,A,F,Y,125.0,KG,20230926,,PH,GB,GB,2023,Q3,Adult
229360432,22936043,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,,,Tablet,,2023,Q3,Gait inability,,2023,Q3,2,F,,20230917.0,20230912,20230926,EXP,GB-MHRA-TPP41562309C8808880YC1693592144385,GB-TORRENT-00033095,TORRENT,,45.0,YR,A,F,Y,125.0,KG,20230926,,PH,GB,GB,2023,Q3,Adult
229360432,22936043,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,,,Tablet,,2023,Q3,Joint swelling,,2023,Q3,2,F,,20230917.0,20230912,20230926,EXP,GB-MHRA-TPP41562309C8808880YC1693592144385,GB-TORRENT-00033095,TORRENT,,45.0,YR,A,F,Y,125.0,KG,20230926,,PH,GB,GB,2023,Q3,Adult
229376841,22937684,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,,,unknown,,,,,,,2023,Q3,Peripheral swelling,,2023,Q3,1,I,20230703.0,20230830.0,20230913,20230913,EXP,IE-HPRA-2023-106932,IE-NOVOPROD-1110335,NOVO NORDISK,,67.0,YR,,F,Y,68.0,KG,20230913,,MD,IE,IE,2023,Q3,Elderly
229376841,22937684,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,,,unknown,,,,,,,2023,Q3,Muscular weakness,,2023,Q3,1,I,20230703.0,20230830.0,20230913,20230913,EXP,IE-HPRA-2023-106932,IE-NOVOPROD-1110335,NOVO NORDISK,,67.0,YR,,F,Y,68.0,KG,20230913,,MD,IE,IE,2023,Q3,Elderly
229376841,22937684,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,,,unknown,,,,,,,2023,Q3,Arthralgia,,2023,Q3,1,I,20230703.0,20230830.0,20230913,20230913,EXP,IE-HPRA-2023-106932,IE-NOVOPROD-1110335,NOVO NORDISK,,67.0,YR,,F,Y,68.0,KG,20230913,,MD,IE,IE,2023,Q3,Elderly
229376841,22937684,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,,,unknown,,,,,,,2023,Q3,Pain in extremity,,2023,Q3,1,I,20230703.0,20230830.0,20230913,20230913,EXP,IE-HPRA-2023-106932,IE-NOVOPROD-1110335,NOVO NORDISK,,67.0,YR,,F,Y,68.0,KG,20230913,,MD,IE,IE,2023,Q3,Elderly
229376841,22937684,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 mg,,,,,unknown,,,,,,,2023,Q3,Peripheral swelling,,2023,Q3,1,I,20230703.0,20230830.0,20230913,20230913,EXP,IE-HPRA-2023-106932,IE-NOVOPROD-1110335,NOVO NORDISK,,67.0,YR,,F,Y,68.0,KG,20230913,,MD,IE,IE,2023,Q3,Elderly
229376841,22937684,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 mg,,,,,unknown,,,,,,,2023,Q3,Muscular weakness,,2023,Q3,1,I,20230703.0,20230830.0,20230913,20230913,EXP,IE-HPRA-2023-106932,IE-NOVOPROD-1110335,NOVO NORDISK,,67.0,YR,,F,Y,68.0,KG,20230913,,MD,IE,IE,2023,Q3,Elderly
229376841,22937684,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 mg,,,,,unknown,,,,,,,2023,Q3,Arthralgia,,2023,Q3,1,I,20230703.0,20230830.0,20230913,20230913,EXP,IE-HPRA-2023-106932,IE-NOVOPROD-1110335,NOVO NORDISK,,67.0,YR,,F,Y,68.0,KG,20230913,,MD,IE,IE,2023,Q3,Elderly
229376841,22937684,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 mg,,,,,unknown,,,,,,,2023,Q3,Pain in extremity,,2023,Q3,1,I,20230703.0,20230830.0,20230913,20230913,EXP,IE-HPRA-2023-106932,IE-NOVOPROD-1110335,NOVO NORDISK,,67.0,YR,,F,Y,68.0,KG,20230913,,MD,IE,IE,2023,Q3,Elderly
229385051,22938505,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Psoriatic arthropathy,,2023,Q3,1,I,,20230908.0,20230913,20230913,EXP,,CA-Orion Corporation ORION PHARMA-23_00025583,ORION,,57.0,YR,A,F,Y,,,20230913,,HP,CA,,2023,Q3,Adult
229385051,22938505,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Gastrooesophageal reflux disease,,2023,Q3,1,I,,20230908.0,20230913,20230913,EXP,,CA-Orion Corporation ORION PHARMA-23_00025583,ORION,,57.0,YR,A,F,Y,,,20230913,,HP,CA,,2023,Q3,Adult
229385051,22938505,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Osteoarthritis,,2023,Q3,1,I,,20230908.0,20230913,20230913,EXP,,CA-Orion Corporation ORION PHARMA-23_00025583,ORION,,57.0,YR,A,F,Y,,,20230913,,HP,CA,,2023,Q3,Adult
229385051,22938505,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Pulmonary toxicity,,2023,Q3,1,I,,20230908.0,20230913,20230913,EXP,,CA-Orion Corporation ORION PHARMA-23_00025583,ORION,,57.0,YR,A,F,Y,,,20230913,,HP,CA,,2023,Q3,Adult
229385051,22938505,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Respiratory sinus arrhythmia magnitude,,2023,Q3,1,I,,20230908.0,20230913,20230913,EXP,,CA-Orion Corporation ORION PHARMA-23_00025583,ORION,,57.0,YR,A,F,Y,,,20230913,,HP,CA,,2023,Q3,Adult
229385051,22938505,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Trigger finger,,2023,Q3,1,I,,20230908.0,20230913,20230913,EXP,,CA-Orion Corporation ORION PHARMA-23_00025583,ORION,,57.0,YR,A,F,Y,,,20230913,,HP,CA,,2023,Q3,Adult
229385051,22938505,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Diabetes mellitus,,2023,Q3,1,I,,20230908.0,20230913,20230913,EXP,,CA-Orion Corporation ORION PHARMA-23_00025583,ORION,,57.0,YR,A,F,Y,,,20230913,,HP,CA,,2023,Q3,Adult
229385051,22938505,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Hypertension,,2023,Q3,1,I,,20230908.0,20230913,20230913,EXP,,CA-Orion Corporation ORION PHARMA-23_00025583,ORION,,57.0,YR,A,F,Y,,,20230913,,HP,CA,,2023,Q3,Adult
229385051,22938505,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Prostatic specific antigen abnormal,,2023,Q3,1,I,,20230908.0,20230913,20230913,EXP,,CA-Orion Corporation ORION PHARMA-23_00025583,ORION,,57.0,YR,A,F,Y,,,20230913,,HP,CA,,2023,Q3,Adult
229385051,22938505,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Rheumatoid arthritis,,2023,Q3,1,I,,20230908.0,20230913,20230913,EXP,,CA-Orion Corporation ORION PHARMA-23_00025583,ORION,,57.0,YR,A,F,Y,,,20230913,,HP,CA,,2023,Q3,Adult
229385051,22938505,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Drug ineffective,,2023,Q3,1,I,,20230908.0,20230913,20230913,EXP,,CA-Orion Corporation ORION PHARMA-23_00025583,ORION,,57.0,YR,A,F,Y,,,20230913,,HP,CA,,2023,Q3,Adult
229385051,22938505,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Hysterectomy,,2023,Q3,1,I,,20230908.0,20230913,20230913,EXP,,CA-Orion Corporation ORION PHARMA-23_00025583,ORION,,57.0,YR,A,F,Y,,,20230913,,HP,CA,,2023,Q3,Adult
229385051,22938505,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Umbilical hernia,,2023,Q3,1,I,,20230908.0,20230913,20230913,EXP,,CA-Orion Corporation ORION PHARMA-23_00025583,ORION,,57.0,YR,A,F,Y,,,20230913,,HP,CA,,2023,Q3,Adult
229385632,22938563,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, qd",,,,,,,,,,,QD,2023,Q3,Peripheral swelling,,2023,Q3,2,F,,20230917.0,20230913,20230926,EXP,GB-MHRA-TPP41562309C8808880YC1693592144385,GB-SANDOZ INC.-SDZ2023GB027223,SANDOZ,,45.0,YR,,F,Y,125.0,KG,20230926,,PH,GB,GB,2023,Q3,Adult
229385632,22938563,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, qd",,,,,,,,,,,QD,2023,Q3,Joint swelling,,2023,Q3,2,F,,20230917.0,20230913,20230926,EXP,GB-MHRA-TPP41562309C8808880YC1693592144385,GB-SANDOZ INC.-SDZ2023GB027223,SANDOZ,,45.0,YR,,F,Y,125.0,KG,20230926,,PH,GB,GB,2023,Q3,Adult
229386741,22938674,7,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"UNK UNK, bid, 5 mg-1000 mg",,,U,U,,,,,,Unknown,BID,2023,Q3,Thrombotic thrombocytopenic purpura,,2023,Q3,1,I,,20230906.0,20230913,20230913,EXP,,ES-MYLANLABS-2023M1097223,MYLAN,"Macia-Rivas L, Maray I, Fernandez-Laguna CL, Alvarez-Asteinza C, Lozano-Blazquez A. Exacerbation of a thrombotic thrombocytopenic purpura episode linked to different P2Y12 inhibitors in the same patient. Case report. Farm-Hosp 2023;null:null.",7.0,DEC,,M,Y,,,20230913,,HP,ES,ES,2023,Q3,Child
229386741,22938674,7,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"UNK UNK, bid, 5 mg-1000 mg",,,U,U,,,,,,Unknown,BID,2023,Q3,Condition aggravated,,2023,Q3,1,I,,20230906.0,20230913,20230913,EXP,,ES-MYLANLABS-2023M1097223,MYLAN,"Macia-Rivas L, Maray I, Fernandez-Laguna CL, Alvarez-Asteinza C, Lozano-Blazquez A. Exacerbation of a thrombotic thrombocytopenic purpura episode linked to different P2Y12 inhibitors in the same patient. Case report. Farm-Hosp 2023;null:null.",7.0,DEC,,M,Y,,,20230913,,HP,ES,ES,2023,Q3,Child
229414101,22941410,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 milligram,,,,,,,,,,Tablet,,2023,Q3,Drug ineffective,,2023,Q3,1,I,20230710.0,20230714.0,20230914,20230914,EXP,,US-AMNEAL PHARMACEUTICALS-2023-AMRX-02607,AMNEAL,,75.0,YR,,M,Y,89.342,KG,20230914,,CN,US,US,2023,Q3,Elderly
229414101,22941410,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 milligram,,,,,,,,,,Tablet,,2023,Q3,Balance disorder,,2023,Q3,1,I,20230710.0,20230714.0,20230914,20230914,EXP,,US-AMNEAL PHARMACEUTICALS-2023-AMRX-02607,AMNEAL,,75.0,YR,,M,Y,89.342,KG,20230914,,CN,US,US,2023,Q3,Elderly
229414101,22941410,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 milligram,,,,,,,,,,Tablet,,2023,Q3,Fall,,2023,Q3,1,I,20230710.0,20230714.0,20230914,20230914,EXP,,US-AMNEAL PHARMACEUTICALS-2023-AMRX-02607,AMNEAL,,75.0,YR,,M,Y,89.342,KG,20230914,,CN,US,US,2023,Q3,Elderly
229433071,22943307,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Psoriatic arthropathy,,2023,Q3,1,I,,20230908.0,20230914,20230914,EXP,,CA-PFIZER INC-202300297544,PFIZER,,57.0,YR,,F,Y,,,20230914,,HP,CA,CA,2023,Q3,Adult
229433071,22943307,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Respiratory sinus arrhythmia magnitude,,2023,Q3,1,I,,20230908.0,20230914,20230914,EXP,,CA-PFIZER INC-202300297544,PFIZER,,57.0,YR,,F,Y,,,20230914,,HP,CA,CA,2023,Q3,Adult
229433071,22943307,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Drug ineffective,,2023,Q3,1,I,,20230908.0,20230914,20230914,EXP,,CA-PFIZER INC-202300297544,PFIZER,,57.0,YR,,F,Y,,,20230914,,HP,CA,CA,2023,Q3,Adult
229433071,22943307,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Rheumatoid arthritis,,2023,Q3,1,I,,20230908.0,20230914,20230914,EXP,,CA-PFIZER INC-202300297544,PFIZER,,57.0,YR,,F,Y,,,20230914,,HP,CA,CA,2023,Q3,Adult
229433071,22943307,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Gastrooesophageal reflux disease,,2023,Q3,1,I,,20230908.0,20230914,20230914,EXP,,CA-PFIZER INC-202300297544,PFIZER,,57.0,YR,,F,Y,,,20230914,,HP,CA,CA,2023,Q3,Adult
229433071,22943307,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Osteoarthritis,,2023,Q3,1,I,,20230908.0,20230914,20230914,EXP,,CA-PFIZER INC-202300297544,PFIZER,,57.0,YR,,F,Y,,,20230914,,HP,CA,CA,2023,Q3,Adult
229433071,22943307,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Hysterectomy,,2023,Q3,1,I,,20230908.0,20230914,20230914,EXP,,CA-PFIZER INC-202300297544,PFIZER,,57.0,YR,,F,Y,,,20230914,,HP,CA,CA,2023,Q3,Adult
229433071,22943307,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Pulmonary toxicity,,2023,Q3,1,I,,20230908.0,20230914,20230914,EXP,,CA-PFIZER INC-202300297544,PFIZER,,57.0,YR,,F,Y,,,20230914,,HP,CA,CA,2023,Q3,Adult
229433071,22943307,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Trigger finger,,2023,Q3,1,I,,20230908.0,20230914,20230914,EXP,,CA-PFIZER INC-202300297544,PFIZER,,57.0,YR,,F,Y,,,20230914,,HP,CA,CA,2023,Q3,Adult
229433071,22943307,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Diabetes mellitus,,2023,Q3,1,I,,20230908.0,20230914,20230914,EXP,,CA-PFIZER INC-202300297544,PFIZER,,57.0,YR,,F,Y,,,20230914,,HP,CA,CA,2023,Q3,Adult
229433071,22943307,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Hypertension,,2023,Q3,1,I,,20230908.0,20230914,20230914,EXP,,CA-PFIZER INC-202300297544,PFIZER,,57.0,YR,,F,Y,,,20230914,,HP,CA,CA,2023,Q3,Adult
229433071,22943307,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Umbilical hernia,,2023,Q3,1,I,,20230908.0,20230914,20230914,EXP,,CA-PFIZER INC-202300297544,PFIZER,,57.0,YR,,F,Y,,,20230914,,HP,CA,CA,2023,Q3,Adult
229433071,22943307,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Prostatic specific antigen abnormal,,2023,Q3,1,I,,20230908.0,20230914,20230914,EXP,,CA-PFIZER INC-202300297544,PFIZER,,57.0,YR,,F,Y,,,20230914,,HP,CA,CA,2023,Q3,Adult
229445011,22944501,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,,,,,,,Unknown,,212614.0,,,,,2023,Q3,Drug ineffective,,2023,Q3,1,I,,20230914.0,20230914,20230914,PER,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-261272",BOEHRINGER INGELHEIM,,76.0,YR,E,M,Y,,,20230914,,HP,US,US,2023,Q3,Elderly
229451981,22945198,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,25.0,MG,,QD,2023,Q3,Acute respiratory distress syndrome,,2023,Q3,1,I,,20230907.0,20230914,20230914,EXP,,"BE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-260095",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,98.0,KG,20230914,,HP,BE,BE,2023,Q3,Elderly
229451981,22945198,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,25.0,MG,,QD,2023,Q3,Euglycaemic diabetic ketoacidosis,,2023,Q3,1,I,,20230907.0,20230914,20230914,EXP,,"BE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-260095",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,98.0,KG,20230914,,HP,BE,BE,2023,Q3,Elderly
229451981,22945198,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,25.0,MG,,QD,2023,Q3,Weight decreased,,2023,Q3,1,I,,20230907.0,20230914,20230914,EXP,,"BE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-260095",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,98.0,KG,20230914,,HP,BE,BE,2023,Q3,Elderly
229451981,22945198,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,25.0,MG,,QD,2023,Q3,Acute myocardial infarction,,2023,Q3,1,I,,20230907.0,20230914,20230914,EXP,,"BE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-260095",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,98.0,KG,20230914,,HP,BE,BE,2023,Q3,Elderly
229451981,22945198,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,25.0,MG,,QD,2023,Q3,Pneumonia,,2023,Q3,1,I,,20230907.0,20230914,20230914,EXP,,"BE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-260095",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,98.0,KG,20230914,,HP,BE,BE,2023,Q3,Elderly
229451981,22945198,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,25.0,MG,,QD,2023,Q3,Atrial fibrillation,,2023,Q3,1,I,,20230907.0,20230914,20230914,EXP,,"BE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-260095",BOEHRINGER INGELHEIM,,77.0,YR,E,F,Y,98.0,KG,20230914,,HP,BE,BE,2023,Q3,Elderly
229452801,22945280,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, qd (one tablet daily since 5 month)",,,,,,,,,,Tablet,QD,2023,Q3,Basal cell carcinoma,,2023,Q3,1,I,,20230908.0,20230914,20230914,EXP,BG-BDA-25868,BG-MYLANLABS-2023M1096998,MYLAN,"NITROSOGENESIS OF SKIN CANCER: THE NITROSAMINE CONTAMINATION IN THE CALCIUM CHANNEL BLOCKERS (AMLODIPINE), BETA BLOCKERS (BISOPROLOL), SARTANS (VALSARTAN/LOSARTAN), ACE INHIBITORS (PERINDOPRIL/ENALAPRIL), TRICYCLIC ANTIDEPRESSANTS (MELITRACEN), SSRIS (PAROXETINE), SNRIS (VENLAFAXINE) AND METFORMIN: THE MOST PROBABLE EXPLANATION FOR THE RISING SKIN CANCER INCIDENCE. NOT REPORTED",69.0,YR,,M,Y,,,20230914,,MD,BG,BG,2023,Q3,Elderly
229455271,22945527,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q3,Penile discomfort,,2023,Q3,1,I,20230912.0,20230914.0,20230914,20230914,EXP,GB-MHRA-TPP20362149C9798951YC1694537331342,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-261249",BOEHRINGER INGELHEIM,,72.0,YR,E,M,Y,69.0,KG,20230914,,MD,GB,GB,2023,Q3,Elderly
229455271,22945527,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q3,Fournier's gangrene,,2023,Q3,1,I,20230912.0,20230914.0,20230914,20230914,EXP,GB-MHRA-TPP20362149C9798951YC1694537331342,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-261249",BOEHRINGER INGELHEIM,,72.0,YR,E,M,Y,69.0,KG,20230914,,MD,GB,GB,2023,Q3,Elderly
229455271,22945527,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q3,Skin exfoliation,,2023,Q3,1,I,20230912.0,20230914.0,20230914,20230914,EXP,GB-MHRA-TPP20362149C9798951YC1694537331342,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-261249",BOEHRINGER INGELHEIM,,72.0,YR,E,M,Y,69.0,KG,20230914,,MD,GB,GB,2023,Q3,Elderly
229455271,22945527,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q3,Penile pain,,2023,Q3,1,I,20230912.0,20230914.0,20230914,20230914,EXP,GB-MHRA-TPP20362149C9798951YC1694537331342,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-261249",BOEHRINGER INGELHEIM,,72.0,YR,E,M,Y,69.0,KG,20230914,,MD,GB,GB,2023,Q3,Elderly
229471531,22947153,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,10.0,MG,,QD,2023,Q3,Lactic acidosis,,2023,Q3,1,I,,20230904.0,20230915,20230915,EXP,,CH-AJANTA-2023AJA00208,AJANTA PHARMA,,58.0,YR,A,F,Y,,,20230915,,HP,CH,CH,2023,Q3,Adult
229471531,22947153,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,10.0,MG,,QD,2023,Q3,Euglycaemic diabetic ketoacidosis,,2023,Q3,1,I,,20230904.0,20230915,20230915,EXP,,CH-AJANTA-2023AJA00208,AJANTA PHARMA,,58.0,YR,A,F,Y,,,20230915,,HP,CH,CH,2023,Q3,Adult
229475551,22947555,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Asked But Unknown,,204629.0,,,,,2023,Q3,Medication error,,2023,Q3,1,I,20230912.0,20230914.0,20230915,20230915,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-261429",BOEHRINGER INGELHEIM,,76.0,YR,E,M,Y,77.0,KG,20230915,,MD,GB,GB,2023,Q3,Elderly
229475551,22947555,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Asked But Unknown,,204629.0,,,,,2023,Q3,Euglycaemic diabetic ketoacidosis,,2023,Q3,1,I,20230912.0,20230914.0,20230915,20230915,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-261429",BOEHRINGER INGELHEIM,,76.0,YR,E,M,Y,77.0,KG,20230915,,MD,GB,GB,2023,Q3,Elderly
229477541,22947754,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2023,Q3,Fall,,2023,Q3,1,I,20230909.0,20230911.0,20230915,20230915,EXP,,CA-UCBSA-2023044889,UCB,,77.0,YR,,M,Y,,,20230915,,CN,CA,CA,2023,Q3,Elderly
229480732,22948073,7,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"1 dosage form, Two Times a Day",,,U,,,,,,,,BID,2023,Q3,Thrombotic thrombocytopenic purpura,,2023,Q3,2,F,,20230918.0,20230915,20230929,EXP,,ES-AUROBINDO-AUR-APL-2023-057463,AUROBINDO,"Macia-Rivas L, Maray I, Fernandez-Laguna CL, Alvarez-Asteinza C, Lozano-Blazquez A.. Exacerbation of a thrombotic thrombocytopenic purpura episode linked to different P2Y12 inhibitors in the same patient. Case report.. Farmacia Hospitalaria.. 2023",7.0,DEC,,M,Y,,,20230929,,PH,ES,ES,2023,Q3,Child
229480732,22948073,7,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"1 dosage form, Two Times a Day",,,U,,,,,,,,BID,2023,Q3,Condition aggravated,,2023,Q3,2,F,,20230918.0,20230915,20230929,EXP,,ES-AUROBINDO-AUR-APL-2023-057463,AUROBINDO,"Macia-Rivas L, Maray I, Fernandez-Laguna CL, Alvarez-Asteinza C, Lozano-Blazquez A.. Exacerbation of a thrombotic thrombocytopenic purpura episode linked to different P2Y12 inhibitors in the same patient. Case report.. Farmacia Hospitalaria.. 2023",7.0,DEC,,M,Y,,,20230929,,PH,ES,ES,2023,Q3,Child
229492851,22949285,17,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,1000 mg/5 mg (1-0-1-0),,,,,,,,,,,,2023,Q3,Hallucination,,2023,Q3,1,I,,20230906.0,20230915,20230915,EXP,ES-Merck Healthcare KGaA-2023473377,ES-EMD Serono-2023473377,EMD SERONO INC,"Abdala S, Devora S, Oliva AM, Morales C.. El valor anadido de los servicios profesionales farmaceucos asistenciales.. Un caso de SFT. (The added value of professionalpharmaceucal care services. A case of SFT). Farmaceuticos comunitarios (Community Farms). 2023 Apr 14;15(2): 45-51. doi:10.33620/FC.2173- 9218.(2023).13.",62.0,YR,A,F,Y,90.0,KG,20230915,,HP,ES,ES,2023,Q3,Adult
229492851,22949285,17,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,1000 mg/5 mg (1-0-1-0),,,,,,,,,,,,2023,Q3,Somnolence,,2023,Q3,1,I,,20230906.0,20230915,20230915,EXP,ES-Merck Healthcare KGaA-2023473377,ES-EMD Serono-2023473377,EMD SERONO INC,"Abdala S, Devora S, Oliva AM, Morales C.. El valor anadido de los servicios profesionales farmaceucos asistenciales.. Un caso de SFT. (The added value of professionalpharmaceucal care services. A case of SFT). Farmaceuticos comunitarios (Community Farms). 2023 Apr 14;15(2): 45-51. doi:10.33620/FC.2173- 9218.(2023).13.",62.0,YR,A,F,Y,90.0,KG,20230915,,HP,ES,ES,2023,Q3,Adult
229492851,22949285,17,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,1000 mg/5 mg (1-0-1-0),,,,,,,,,,,,2023,Q3,Hypoglycaemia,,2023,Q3,1,I,,20230906.0,20230915,20230915,EXP,ES-Merck Healthcare KGaA-2023473377,ES-EMD Serono-2023473377,EMD SERONO INC,"Abdala S, Devora S, Oliva AM, Morales C.. El valor anadido de los servicios profesionales farmaceucos asistenciales.. Un caso de SFT. (The added value of professionalpharmaceucal care services. A case of SFT). Farmaceuticos comunitarios (Community Farms). 2023 Apr 14;15(2): 45-51. doi:10.33620/FC.2173- 9218.(2023).13.",62.0,YR,A,F,Y,90.0,KG,20230915,,HP,ES,ES,2023,Q3,Adult
229492851,22949285,17,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,1000 mg/5 mg (1-0-1-0),,,,,,,,,,,,2023,Q3,Parkinsonism,,2023,Q3,1,I,,20230906.0,20230915,20230915,EXP,ES-Merck Healthcare KGaA-2023473377,ES-EMD Serono-2023473377,EMD SERONO INC,"Abdala S, Devora S, Oliva AM, Morales C.. El valor anadido de los servicios profesionales farmaceucos asistenciales.. Un caso de SFT. (The added value of professionalpharmaceucal care services. A case of SFT). Farmaceuticos comunitarios (Community Farms). 2023 Apr 14;15(2): 45-51. doi:10.33620/FC.2173- 9218.(2023).13.",62.0,YR,A,F,Y,90.0,KG,20230915,,HP,ES,ES,2023,Q3,Adult
229492851,22949285,17,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,1000 mg/5 mg (1-0-1-0),,,,,,,,,,,,2023,Q3,Hypotension,,2023,Q3,1,I,,20230906.0,20230915,20230915,EXP,ES-Merck Healthcare KGaA-2023473377,ES-EMD Serono-2023473377,EMD SERONO INC,"Abdala S, Devora S, Oliva AM, Morales C.. El valor anadido de los servicios profesionales farmaceucos asistenciales.. Un caso de SFT. (The added value of professionalpharmaceucal care services. A case of SFT). Farmaceuticos comunitarios (Community Farms). 2023 Apr 14;15(2): 45-51. doi:10.33620/FC.2173- 9218.(2023).13.",62.0,YR,A,F,Y,90.0,KG,20230915,,HP,ES,ES,2023,Q3,Adult
229492851,22949285,32,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,,,,,,,,,,2023,Q3,Hallucination,,2023,Q3,1,I,,20230906.0,20230915,20230915,EXP,ES-Merck Healthcare KGaA-2023473377,ES-EMD Serono-2023473377,EMD SERONO INC,"Abdala S, Devora S, Oliva AM, Morales C.. El valor anadido de los servicios profesionales farmaceucos asistenciales.. Un caso de SFT. (The added value of professionalpharmaceucal care services. A case of SFT). Farmaceuticos comunitarios (Community Farms). 2023 Apr 14;15(2): 45-51. doi:10.33620/FC.2173- 9218.(2023).13.",62.0,YR,A,F,Y,90.0,KG,20230915,,HP,ES,ES,2023,Q3,Adult
229492851,22949285,32,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,,,,,,,,,,2023,Q3,Somnolence,,2023,Q3,1,I,,20230906.0,20230915,20230915,EXP,ES-Merck Healthcare KGaA-2023473377,ES-EMD Serono-2023473377,EMD SERONO INC,"Abdala S, Devora S, Oliva AM, Morales C.. El valor anadido de los servicios profesionales farmaceucos asistenciales.. Un caso de SFT. (The added value of professionalpharmaceucal care services. A case of SFT). Farmaceuticos comunitarios (Community Farms). 2023 Apr 14;15(2): 45-51. doi:10.33620/FC.2173- 9218.(2023).13.",62.0,YR,A,F,Y,90.0,KG,20230915,,HP,ES,ES,2023,Q3,Adult
229492851,22949285,32,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,,,,,,,,,,2023,Q3,Hypoglycaemia,,2023,Q3,1,I,,20230906.0,20230915,20230915,EXP,ES-Merck Healthcare KGaA-2023473377,ES-EMD Serono-2023473377,EMD SERONO INC,"Abdala S, Devora S, Oliva AM, Morales C.. El valor anadido de los servicios profesionales farmaceucos asistenciales.. Un caso de SFT. (The added value of professionalpharmaceucal care services. A case of SFT). Farmaceuticos comunitarios (Community Farms). 2023 Apr 14;15(2): 45-51. doi:10.33620/FC.2173- 9218.(2023).13.",62.0,YR,A,F,Y,90.0,KG,20230915,,HP,ES,ES,2023,Q3,Adult
229492851,22949285,32,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,,,,,,,,,,2023,Q3,Parkinsonism,,2023,Q3,1,I,,20230906.0,20230915,20230915,EXP,ES-Merck Healthcare KGaA-2023473377,ES-EMD Serono-2023473377,EMD SERONO INC,"Abdala S, Devora S, Oliva AM, Morales C.. El valor anadido de los servicios profesionales farmaceucos asistenciales.. Un caso de SFT. (The added value of professionalpharmaceucal care services. A case of SFT). Farmaceuticos comunitarios (Community Farms). 2023 Apr 14;15(2): 45-51. doi:10.33620/FC.2173- 9218.(2023).13.",62.0,YR,A,F,Y,90.0,KG,20230915,,HP,ES,ES,2023,Q3,Adult
229492851,22949285,32,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,,,,,,,,,,2023,Q3,Hypotension,,2023,Q3,1,I,,20230906.0,20230915,20230915,EXP,ES-Merck Healthcare KGaA-2023473377,ES-EMD Serono-2023473377,EMD SERONO INC,"Abdala S, Devora S, Oliva AM, Morales C.. El valor anadido de los servicios profesionales farmaceucos asistenciales.. Un caso de SFT. (The added value of professionalpharmaceucal care services. A case of SFT). Farmaceuticos comunitarios (Community Farms). 2023 Apr 14;15(2): 45-51. doi:10.33620/FC.2173- 9218.(2023).13.",62.0,YR,A,F,Y,90.0,KG,20230915,,HP,ES,ES,2023,Q3,Adult
229512511,22951251,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q3,Oliguria,,2023,Q3,1,I,,20230908.0,20230917,20230917,EXP,,"ES-VELOXIS PHARMACEUTICALS, INC.-2020-VEL-00479",VELOXIS PHARMACEUTICALS,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno de la Higuera MA, Lucena R et al.. Fulminant ephysematous pyelonephritis by candida glabrata in a kidney allograft. Nephron clinical practice. 2020;144(6):304-9",56.0,YR,,F,Y,,,20230917,,MD,ES,ES,2023,Q3,Adult
229512511,22951251,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q3,Vesicoureteric reflux,,2023,Q3,1,I,,20230908.0,20230917,20230917,EXP,,"ES-VELOXIS PHARMACEUTICALS, INC.-2020-VEL-00479",VELOXIS PHARMACEUTICALS,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno de la Higuera MA, Lucena R et al.. Fulminant ephysematous pyelonephritis by candida glabrata in a kidney allograft. Nephron clinical practice. 2020;144(6):304-9",56.0,YR,,F,Y,,,20230917,,MD,ES,ES,2023,Q3,Adult
229512511,22951251,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q3,Candida infection,,2023,Q3,1,I,,20230908.0,20230917,20230917,EXP,,"ES-VELOXIS PHARMACEUTICALS, INC.-2020-VEL-00479",VELOXIS PHARMACEUTICALS,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno de la Higuera MA, Lucena R et al.. Fulminant ephysematous pyelonephritis by candida glabrata in a kidney allograft. Nephron clinical practice. 2020;144(6):304-9",56.0,YR,,F,Y,,,20230917,,MD,ES,ES,2023,Q3,Adult
229512511,22951251,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q3,Pyelonephritis fungal,,2023,Q3,1,I,,20230908.0,20230917,20230917,EXP,,"ES-VELOXIS PHARMACEUTICALS, INC.-2020-VEL-00479",VELOXIS PHARMACEUTICALS,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno de la Higuera MA, Lucena R et al.. Fulminant ephysematous pyelonephritis by candida glabrata in a kidney allograft. Nephron clinical practice. 2020;144(6):304-9",56.0,YR,,F,Y,,,20230917,,MD,ES,ES,2023,Q3,Adult
229512511,22951251,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q3,Septic shock,,2023,Q3,1,I,,20230908.0,20230917,20230917,EXP,,"ES-VELOXIS PHARMACEUTICALS, INC.-2020-VEL-00479",VELOXIS PHARMACEUTICALS,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno de la Higuera MA, Lucena R et al.. Fulminant ephysematous pyelonephritis by candida glabrata in a kidney allograft. Nephron clinical practice. 2020;144(6):304-9",56.0,YR,,F,Y,,,20230917,,MD,ES,ES,2023,Q3,Adult
229512511,22951251,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q3,Emphysematous pyelonephritis,,2023,Q3,1,I,,20230908.0,20230917,20230917,EXP,,"ES-VELOXIS PHARMACEUTICALS, INC.-2020-VEL-00479",VELOXIS PHARMACEUTICALS,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno de la Higuera MA, Lucena R et al.. Fulminant ephysematous pyelonephritis by candida glabrata in a kidney allograft. Nephron clinical practice. 2020;144(6):304-9",56.0,YR,,F,Y,,,20230917,,MD,ES,ES,2023,Q3,Adult
229512511,22951251,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q3,Perinephric abscess,,2023,Q3,1,I,,20230908.0,20230917,20230917,EXP,,"ES-VELOXIS PHARMACEUTICALS, INC.-2020-VEL-00479",VELOXIS PHARMACEUTICALS,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno de la Higuera MA, Lucena R et al.. Fulminant ephysematous pyelonephritis by candida glabrata in a kidney allograft. Nephron clinical practice. 2020;144(6):304-9",56.0,YR,,F,Y,,,20230917,,MD,ES,ES,2023,Q3,Adult
229512511,22951251,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q3,Urinary tract infection enterococcal,,2023,Q3,1,I,,20230908.0,20230917,20230917,EXP,,"ES-VELOXIS PHARMACEUTICALS, INC.-2020-VEL-00479",VELOXIS PHARMACEUTICALS,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno de la Higuera MA, Lucena R et al.. Fulminant ephysematous pyelonephritis by candida glabrata in a kidney allograft. Nephron clinical practice. 2020;144(6):304-9",56.0,YR,,F,Y,,,20230917,,MD,ES,ES,2023,Q3,Adult
229512511,22951251,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q3,Urinary tract infection enterococcal,,2023,Q3,1,I,,20230908.0,20230917,20230917,EXP,,"ES-VELOXIS PHARMACEUTICALS, INC.-2020-VEL-00479",VELOXIS PHARMACEUTICALS,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno de la Higuera MA, Lucena R et al.. Fulminant ephysematous pyelonephritis by candida glabrata in a kidney allograft. Nephron clinical practice. 2020;144(6):304-9",56.0,YR,,F,Y,,,20230917,,MD,ES,ES,2023,Q3,Adult
229512511,22951251,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q3,Coagulation test abnormal,,2023,Q3,1,I,,20230908.0,20230917,20230917,EXP,,"ES-VELOXIS PHARMACEUTICALS, INC.-2020-VEL-00479",VELOXIS PHARMACEUTICALS,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno de la Higuera MA, Lucena R et al.. Fulminant ephysematous pyelonephritis by candida glabrata in a kidney allograft. Nephron clinical practice. 2020;144(6):304-9",56.0,YR,,F,Y,,,20230917,,MD,ES,ES,2023,Q3,Adult
229512511,22951251,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q3,Candida sepsis,,2023,Q3,1,I,,20230908.0,20230917,20230917,EXP,,"ES-VELOXIS PHARMACEUTICALS, INC.-2020-VEL-00479",VELOXIS PHARMACEUTICALS,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno de la Higuera MA, Lucena R et al.. Fulminant ephysematous pyelonephritis by candida glabrata in a kidney allograft. Nephron clinical practice. 2020;144(6):304-9",56.0,YR,,F,Y,,,20230917,,MD,ES,ES,2023,Q3,Adult
229512511,22951251,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q3,Coagulopathy,,2023,Q3,1,I,,20230908.0,20230917,20230917,EXP,,"ES-VELOXIS PHARMACEUTICALS, INC.-2020-VEL-00479",VELOXIS PHARMACEUTICALS,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno de la Higuera MA, Lucena R et al.. Fulminant ephysematous pyelonephritis by candida glabrata in a kidney allograft. Nephron clinical practice. 2020;144(6):304-9",56.0,YR,,F,Y,,,20230917,,MD,ES,ES,2023,Q3,Adult
229512511,22951251,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q3,Renal impairment,,2023,Q3,1,I,,20230908.0,20230917,20230917,EXP,,"ES-VELOXIS PHARMACEUTICALS, INC.-2020-VEL-00479",VELOXIS PHARMACEUTICALS,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno de la Higuera MA, Lucena R et al.. Fulminant ephysematous pyelonephritis by candida glabrata in a kidney allograft. Nephron clinical practice. 2020;144(6):304-9",56.0,YR,,F,Y,,,20230917,,MD,ES,ES,2023,Q3,Adult
229512511,22951251,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q3,Hypotension,,2023,Q3,1,I,,20230908.0,20230917,20230917,EXP,,"ES-VELOXIS PHARMACEUTICALS, INC.-2020-VEL-00479",VELOXIS PHARMACEUTICALS,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno de la Higuera MA, Lucena R et al.. Fulminant ephysematous pyelonephritis by candida glabrata in a kidney allograft. Nephron clinical practice. 2020;144(6):304-9",56.0,YR,,F,Y,,,20230917,,MD,ES,ES,2023,Q3,Adult
229512511,22951251,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q3,Urinary tract candidiasis,,2023,Q3,1,I,,20230908.0,20230917,20230917,EXP,,"ES-VELOXIS PHARMACEUTICALS, INC.-2020-VEL-00479",VELOXIS PHARMACEUTICALS,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno de la Higuera MA, Lucena R et al.. Fulminant ephysematous pyelonephritis by candida glabrata in a kidney allograft. Nephron clinical practice. 2020;144(6):304-9",56.0,YR,,F,Y,,,20230917,,MD,ES,ES,2023,Q3,Adult
229512511,22951251,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q3,Systemic candida,,2023,Q3,1,I,,20230908.0,20230917,20230917,EXP,,"ES-VELOXIS PHARMACEUTICALS, INC.-2020-VEL-00479",VELOXIS PHARMACEUTICALS,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno de la Higuera MA, Lucena R et al.. Fulminant ephysematous pyelonephritis by candida glabrata in a kidney allograft. Nephron clinical practice. 2020;144(6):304-9",56.0,YR,,F,Y,,,20230917,,MD,ES,ES,2023,Q3,Adult
229516961,22951696,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,QD,2023,Q3,Peripheral swelling,,2023,Q3,1,I,,20230905.0,20230918,20230918,EXP,GB-MHRA-ADR 28161080,GB-Accord-378678,ACCORD,,45.0,YR,A,F,Y,125.0,KG,20230917,,PH,GB,GB,2023,Q3,Adult
229516961,22951696,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,QD,2023,Q3,Joint swelling,,2023,Q3,1,I,,20230905.0,20230918,20230918,EXP,GB-MHRA-ADR 28161080,GB-Accord-378678,ACCORD,,45.0,YR,A,F,Y,125.0,KG,20230917,,PH,GB,GB,2023,Q3,Adult
229517561,22951756,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,25.0,MG,,QD,2023,Q3,Polyuria,,2023,Q3,1,I,,20230915.0,20230918,20230918,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-261472",BOEHRINGER INGELHEIM,"Renieris I, Kitsinelis V, Psarrou G, Giannoutsos S, Skyllas G, Rizos M et.al.. euglycemic ketoacidosis in the immediate postoperative period of coronary artery bypass surgery. 16th panhellenic congress on cardiometabolic risk factors. 2023",65.0,YR,E,M,Y,,,20230918,,MD,GR,GR,2023,Q3,Elderly
229517561,22951756,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,25.0,MG,,QD,2023,Q3,Euglycaemic diabetic ketoacidosis,,2023,Q3,1,I,,20230915.0,20230918,20230918,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-261472",BOEHRINGER INGELHEIM,"Renieris I, Kitsinelis V, Psarrou G, Giannoutsos S, Skyllas G, Rizos M et.al.. euglycemic ketoacidosis in the immediate postoperative period of coronary artery bypass surgery. 16th panhellenic congress on cardiometabolic risk factors. 2023",65.0,YR,E,M,Y,,,20230918,,MD,GR,GR,2023,Q3,Elderly
229517561,22951756,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,25.0,MG,,QD,2023,Q3,Tachycardia,,2023,Q3,1,I,,20230915.0,20230918,20230918,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-261472",BOEHRINGER INGELHEIM,"Renieris I, Kitsinelis V, Psarrou G, Giannoutsos S, Skyllas G, Rizos M et.al.. euglycemic ketoacidosis in the immediate postoperative period of coronary artery bypass surgery. 16th panhellenic congress on cardiometabolic risk factors. 2023",65.0,YR,E,M,Y,,,20230918,,MD,GR,GR,2023,Q3,Elderly
229517561,22951756,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,25.0,MG,,QD,2023,Q3,Blood pressure decreased,,2023,Q3,1,I,,20230915.0,20230918,20230918,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-261472",BOEHRINGER INGELHEIM,"Renieris I, Kitsinelis V, Psarrou G, Giannoutsos S, Skyllas G, Rizos M et.al.. euglycemic ketoacidosis in the immediate postoperative period of coronary artery bypass surgery. 16th panhellenic congress on cardiometabolic risk factors. 2023",65.0,YR,E,M,Y,,,20230918,,MD,GR,GR,2023,Q3,Elderly
229519432,22951943,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, od",,,Y,,Unknown,,,10.0,MG,,QD,2023,Q3,Euglycaemic diabetic ketoacidosis,,2023,Q3,2,F,,20230911.0,20230918,20230925,EXP,,CH-ALKEM LABORATORIES LIMITED-CH-ALKEM-2023-10401,ALKEM,"Nzomessi D, Massie E, Gariani K, Giraud R, Meyer P.. Combined lactic acidosis and ketoacidosis in a female diabetic patient with severe heart failure. Cardiovascular Endocrinology and Metabolism. 2023;12 (3):1-3",58.0,YR,,F,Y,,,20230925,,HP,CH,CH,2023,Q3,Adult
229519432,22951943,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, od",,,Y,,Unknown,,,10.0,MG,,QD,2023,Q3,Acute kidney injury,,2023,Q3,2,F,,20230911.0,20230918,20230925,EXP,,CH-ALKEM LABORATORIES LIMITED-CH-ALKEM-2023-10401,ALKEM,"Nzomessi D, Massie E, Gariani K, Giraud R, Meyer P.. Combined lactic acidosis and ketoacidosis in a female diabetic patient with severe heart failure. Cardiovascular Endocrinology and Metabolism. 2023;12 (3):1-3",58.0,YR,,F,Y,,,20230925,,HP,CH,CH,2023,Q3,Adult
229519432,22951943,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, od",,,Y,,Unknown,,,10.0,MG,,QD,2023,Q3,Drug level increased,,2023,Q3,2,F,,20230911.0,20230918,20230925,EXP,,CH-ALKEM LABORATORIES LIMITED-CH-ALKEM-2023-10401,ALKEM,"Nzomessi D, Massie E, Gariani K, Giraud R, Meyer P.. Combined lactic acidosis and ketoacidosis in a female diabetic patient with severe heart failure. Cardiovascular Endocrinology and Metabolism. 2023;12 (3):1-3",58.0,YR,,F,Y,,,20230925,,HP,CH,CH,2023,Q3,Adult
229519432,22951943,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, od",,,Y,,Unknown,,,10.0,MG,,QD,2023,Q3,Lactic acidosis,,2023,Q3,2,F,,20230911.0,20230918,20230925,EXP,,CH-ALKEM LABORATORIES LIMITED-CH-ALKEM-2023-10401,ALKEM,"Nzomessi D, Massie E, Gariani K, Giraud R, Meyer P.. Combined lactic acidosis and ketoacidosis in a female diabetic patient with severe heart failure. Cardiovascular Endocrinology and Metabolism. 2023;12 (3):1-3",58.0,YR,,F,Y,,,20230925,,HP,CH,CH,2023,Q3,Adult
229519432,22951943,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2023,Q3,Euglycaemic diabetic ketoacidosis,,2023,Q3,2,F,,20230911.0,20230918,20230925,EXP,,CH-ALKEM LABORATORIES LIMITED-CH-ALKEM-2023-10401,ALKEM,"Nzomessi D, Massie E, Gariani K, Giraud R, Meyer P.. Combined lactic acidosis and ketoacidosis in a female diabetic patient with severe heart failure. Cardiovascular Endocrinology and Metabolism. 2023;12 (3):1-3",58.0,YR,,F,Y,,,20230925,,HP,CH,CH,2023,Q3,Adult
229519432,22951943,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2023,Q3,Acute kidney injury,,2023,Q3,2,F,,20230911.0,20230918,20230925,EXP,,CH-ALKEM LABORATORIES LIMITED-CH-ALKEM-2023-10401,ALKEM,"Nzomessi D, Massie E, Gariani K, Giraud R, Meyer P.. Combined lactic acidosis and ketoacidosis in a female diabetic patient with severe heart failure. Cardiovascular Endocrinology and Metabolism. 2023;12 (3):1-3",58.0,YR,,F,Y,,,20230925,,HP,CH,CH,2023,Q3,Adult
229519432,22951943,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2023,Q3,Drug level increased,,2023,Q3,2,F,,20230911.0,20230918,20230925,EXP,,CH-ALKEM LABORATORIES LIMITED-CH-ALKEM-2023-10401,ALKEM,"Nzomessi D, Massie E, Gariani K, Giraud R, Meyer P.. Combined lactic acidosis and ketoacidosis in a female diabetic patient with severe heart failure. Cardiovascular Endocrinology and Metabolism. 2023;12 (3):1-3",58.0,YR,,F,Y,,,20230925,,HP,CH,CH,2023,Q3,Adult
229519432,22951943,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2023,Q3,Lactic acidosis,,2023,Q3,2,F,,20230911.0,20230918,20230925,EXP,,CH-ALKEM LABORATORIES LIMITED-CH-ALKEM-2023-10401,ALKEM,"Nzomessi D, Massie E, Gariani K, Giraud R, Meyer P.. Combined lactic acidosis and ketoacidosis in a female diabetic patient with severe heart failure. Cardiovascular Endocrinology and Metabolism. 2023;12 (3):1-3",58.0,YR,,F,Y,,,20230925,,HP,CH,CH,2023,Q3,Adult
229525961,22952596,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg 1X1,,,U,,,,,10.0,MG,Unknown,QD,2023,Q3,Hypertension,,2023,Q3,1,I,20220701.0,20230907.0,20230918,20230918,EXP,,DE-MYLANLABS-2023M1096219,MYLAN,,28.0,YR,,M,Y,,,20230918,,MD,DE,DE,2023,Q3,Young Adult
229525961,22952596,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg 1X1,,,U,,,,,10.0,MG,Unknown,QD,2023,Q3,Hyperkalaemia,,2023,Q3,1,I,20220701.0,20230907.0,20230918,20230918,EXP,,DE-MYLANLABS-2023M1096219,MYLAN,,28.0,YR,,M,Y,,,20230918,,MD,DE,DE,2023,Q3,Young Adult
229525961,22952596,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg 1X1,,,U,,,,,10.0,MG,Unknown,QD,2023,Q3,Fatigue,,2023,Q3,1,I,20220701.0,20230907.0,20230918,20230918,EXP,,DE-MYLANLABS-2023M1096219,MYLAN,,28.0,YR,,M,Y,,,20230918,,MD,DE,DE,2023,Q3,Young Adult
229525961,22952596,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg 1X1,,,U,,,,,10.0,MG,Unknown,QD,2023,Q3,C3 glomerulopathy,,2023,Q3,1,I,20220701.0,20230907.0,20230918,20230918,EXP,,DE-MYLANLABS-2023M1096219,MYLAN,,28.0,YR,,M,Y,,,20230918,,MD,DE,DE,2023,Q3,Young Adult
229525961,22952596,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg 1X1,,,U,,,,,10.0,MG,Unknown,QD,2023,Q3,Renal impairment,,2023,Q3,1,I,20220701.0,20230907.0,20230918,20230918,EXP,,DE-MYLANLABS-2023M1096219,MYLAN,,28.0,YR,,M,Y,,,20230918,,MD,DE,DE,2023,Q3,Young Adult
229525961,22952596,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg 1X1,,,U,,,,,10.0,MG,Unknown,QD,2023,Q3,Chronic kidney disease,,2023,Q3,1,I,20220701.0,20230907.0,20230918,20230918,EXP,,DE-MYLANLABS-2023M1096219,MYLAN,,28.0,YR,,M,Y,,,20230918,,MD,DE,DE,2023,Q3,Young Adult
229548341,22954834,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK (1 tablet daily),,,U,,UNK,,,,,Tablet,,2023,Q3,Hypoglycaemic unconsciousness,,2023,Q3,1,I,20230601.0,20230905.0,20230918,20230918,EXP,,CO-NOVOPROD-1091586,NOVO NORDISK,,78.0,YR,,F,Y,69.0,KG,20230918,,CN,CO,CO,2023,Q3,Elderly
229548341,22954834,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK (1 tablet daily),,,U,,UNK,,,,,Tablet,,2023,Q3,Device failure,,2023,Q3,1,I,20230601.0,20230905.0,20230918,20230918,EXP,,CO-NOVOPROD-1091586,NOVO NORDISK,,78.0,YR,,F,Y,69.0,KG,20230918,,CN,CO,CO,2023,Q3,Elderly
229548341,22954834,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK (1 tablet daily),,,U,,UNK,,,,,Tablet,,2023,Q3,Blood glucose increased,,2023,Q3,1,I,20230601.0,20230905.0,20230918,20230918,EXP,,CO-NOVOPROD-1091586,NOVO NORDISK,,78.0,YR,,F,Y,69.0,KG,20230918,,CN,CO,CO,2023,Q3,Elderly
229553931,22955393,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,25.0,MG,Tablet,QD,2023,Q3,Pruritus,,2023,Q3,1,I,,20230915.0,20230918,20230918,EXP,GB-MHRA-TPP44387839C13371753YC1694618501273,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-261665",BOEHRINGER INGELHEIM,,73.0,YR,E,M,Y,66.0,KG,20230918,,MD,GB,GB,2023,Q3,Elderly
229557961,22955796,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q3,Medication error,,2023,Q3,1,I,20230913.0,20230918.0,20230919,20230919,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-261781",BOEHRINGER INGELHEIM,,49.0,YR,A,F,Y,105.0,KG,20230919,,MD,GB,GB,2023,Q3,Adult
229557961,22955796,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q3,Blood glucose increased,,2023,Q3,1,I,20230913.0,20230918.0,20230919,20230919,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-261781",BOEHRINGER INGELHEIM,,49.0,YR,A,F,Y,105.0,KG,20230919,,MD,GB,GB,2023,Q3,Adult
229557961,22955796,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q3,Euglycaemic diabetic ketoacidosis,,2023,Q3,1,I,20230913.0,20230918.0,20230919,20230919,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-261781",BOEHRINGER INGELHEIM,,49.0,YR,A,F,Y,105.0,KG,20230919,,MD,GB,GB,2023,Q3,Adult
229557961,22955796,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q3,Hip arthroplasty,,2023,Q3,1,I,20230913.0,20230918.0,20230919,20230919,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-261781",BOEHRINGER INGELHEIM,,49.0,YR,A,F,Y,105.0,KG,20230919,,MD,GB,GB,2023,Q3,Adult
229557961,22955796,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q3,Blood pH decreased,,2023,Q3,1,I,20230913.0,20230918.0,20230919,20230919,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-261781",BOEHRINGER INGELHEIM,,49.0,YR,A,F,Y,105.0,KG,20230919,,MD,GB,GB,2023,Q3,Adult
229557961,22955796,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q3,Malaise,,2023,Q3,1,I,20230913.0,20230918.0,20230919,20230919,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-261781",BOEHRINGER INGELHEIM,,49.0,YR,A,F,Y,105.0,KG,20230919,,MD,GB,GB,2023,Q3,Adult
229561221,22956122,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,25.0,MG,,QD,2023,Q3,Euglycaemic diabetic ketoacidosis,,2023,Q3,1,I,,20230918.0,20230919,20230919,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-261809",BOEHRINGER INGELHEIM,"Renieris I, Kitsinelis V, Psarrou G, Skyllas G, Giannoutsos S, Rizos M et.al.. Euglycemic ketoacidosis in the immediate postoperative period of coronary artery bypass surgery. 16th panhellenic congress on cardiometabolic risk factors. 2023;42",63.0,YR,A,F,Y,,,20230919,,MD,GR,GR,2023,Q3,Adult
229561221,22956122,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,25.0,MG,,QD,2023,Q3,Blood pressure decreased,,2023,Q3,1,I,,20230918.0,20230919,20230919,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-261809",BOEHRINGER INGELHEIM,"Renieris I, Kitsinelis V, Psarrou G, Skyllas G, Giannoutsos S, Rizos M et.al.. Euglycemic ketoacidosis in the immediate postoperative period of coronary artery bypass surgery. 16th panhellenic congress on cardiometabolic risk factors. 2023;42",63.0,YR,A,F,Y,,,20230919,,MD,GR,GR,2023,Q3,Adult
229561221,22956122,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,25.0,MG,,QD,2023,Q3,Tachycardia,,2023,Q3,1,I,,20230918.0,20230919,20230919,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-261809",BOEHRINGER INGELHEIM,"Renieris I, Kitsinelis V, Psarrou G, Skyllas G, Giannoutsos S, Rizos M et.al.. Euglycemic ketoacidosis in the immediate postoperative period of coronary artery bypass surgery. 16th panhellenic congress on cardiometabolic risk factors. 2023;42",63.0,YR,A,F,Y,,,20230919,,MD,GR,GR,2023,Q3,Adult
229561221,22956122,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,25.0,MG,,QD,2023,Q3,Polyuria,,2023,Q3,1,I,,20230918.0,20230919,20230919,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-261809",BOEHRINGER INGELHEIM,"Renieris I, Kitsinelis V, Psarrou G, Skyllas G, Giannoutsos S, Rizos M et.al.. Euglycemic ketoacidosis in the immediate postoperative period of coronary artery bypass surgery. 16th panhellenic congress on cardiometabolic risk factors. 2023;42",63.0,YR,A,F,Y,,,20230919,,MD,GR,GR,2023,Q3,Adult
229565381,22956538,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,10.0,MG,,,2023,Q3,Lactic acidosis,,2023,Q3,1,I,20230821.0,20230919.0,20230919,20230919,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-261969",BOEHRINGER INGELHEIM,,82.0,YR,E,M,Y,,,20230919,,MD,DE,DE,2023,Q3,Elderly
229597941,22959794,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,,2023,Q3,Discouragement,,2023,Q3,1,I,20210101.0,20230605.0,20230920,20230920,EXP,,"CO-Ipsen Biopharmaceuticals, Inc.-2023-14080",IPSEN,,69.0,YR,E,F,Y,72.0,KG,20230920,,CN,CO,CO,2023,Q3,Elderly
229597941,22959794,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,,2023,Q3,Inflammation,,2023,Q3,1,I,20210101.0,20230605.0,20230920,20230920,EXP,,"CO-Ipsen Biopharmaceuticals, Inc.-2023-14080",IPSEN,,69.0,YR,E,F,Y,72.0,KG,20230920,,CN,CO,CO,2023,Q3,Elderly
229597941,22959794,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,,2023,Q3,Weight decreased,,2023,Q3,1,I,20210101.0,20230605.0,20230920,20230920,EXP,,"CO-Ipsen Biopharmaceuticals, Inc.-2023-14080",IPSEN,,69.0,YR,E,F,Y,72.0,KG,20230920,,CN,CO,CO,2023,Q3,Elderly
229597941,22959794,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,,2023,Q3,Diarrhoea,,2023,Q3,1,I,20210101.0,20230605.0,20230920,20230920,EXP,,"CO-Ipsen Biopharmaceuticals, Inc.-2023-14080",IPSEN,,69.0,YR,E,F,Y,72.0,KG,20230920,,CN,CO,CO,2023,Q3,Elderly
229597941,22959794,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,,2023,Q3,Cough,,2023,Q3,1,I,20210101.0,20230605.0,20230920,20230920,EXP,,"CO-Ipsen Biopharmaceuticals, Inc.-2023-14080",IPSEN,,69.0,YR,E,F,Y,72.0,KG,20230920,,CN,CO,CO,2023,Q3,Elderly
229597941,22959794,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,,2023,Q3,Influenza,,2023,Q3,1,I,20210101.0,20230605.0,20230920,20230920,EXP,,"CO-Ipsen Biopharmaceuticals, Inc.-2023-14080",IPSEN,,69.0,YR,E,F,Y,72.0,KG,20230920,,CN,CO,CO,2023,Q3,Elderly
229597941,22959794,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,,2023,Q3,Gait disturbance,,2023,Q3,1,I,20210101.0,20230605.0,20230920,20230920,EXP,,"CO-Ipsen Biopharmaceuticals, Inc.-2023-14080",IPSEN,,69.0,YR,E,F,Y,72.0,KG,20230920,,CN,CO,CO,2023,Q3,Elderly
229597941,22959794,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,,2023,Q3,Gait disturbance,,2023,Q3,1,I,20210101.0,20230605.0,20230920,20230920,EXP,,"CO-Ipsen Biopharmaceuticals, Inc.-2023-14080",IPSEN,,69.0,YR,E,F,Y,72.0,KG,20230920,,CN,CO,CO,2023,Q3,Elderly
229597941,22959794,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,,2023,Q3,Nasopharyngitis,,2023,Q3,1,I,20210101.0,20230605.0,20230920,20230920,EXP,,"CO-Ipsen Biopharmaceuticals, Inc.-2023-14080",IPSEN,,69.0,YR,E,F,Y,72.0,KG,20230920,,CN,CO,CO,2023,Q3,Elderly
229597941,22959794,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,,2023,Q3,Product supply issue,,2023,Q3,1,I,20210101.0,20230605.0,20230920,20230920,EXP,,"CO-Ipsen Biopharmaceuticals, Inc.-2023-14080",IPSEN,,69.0,YR,E,F,Y,72.0,KG,20230920,,CN,CO,CO,2023,Q3,Elderly
229597941,22959794,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,,2023,Q3,Weight increased,,2023,Q3,1,I,20210101.0,20230605.0,20230920,20230920,EXP,,"CO-Ipsen Biopharmaceuticals, Inc.-2023-14080",IPSEN,,69.0,YR,E,F,Y,72.0,KG,20230920,,CN,CO,CO,2023,Q3,Elderly
229597941,22959794,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,,2023,Q3,Inflammation,,2023,Q3,1,I,20210101.0,20230605.0,20230920,20230920,EXP,,"CO-Ipsen Biopharmaceuticals, Inc.-2023-14080",IPSEN,,69.0,YR,E,F,Y,72.0,KG,20230920,,CN,CO,CO,2023,Q3,Elderly
229597941,22959794,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,,2023,Q3,Pulmonary oedema,,2023,Q3,1,I,20210101.0,20230605.0,20230920,20230920,EXP,,"CO-Ipsen Biopharmaceuticals, Inc.-2023-14080",IPSEN,,69.0,YR,E,F,Y,72.0,KG,20230920,,CN,CO,CO,2023,Q3,Elderly
229597941,22959794,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,,2023,Q3,Arthralgia,,2023,Q3,1,I,20210101.0,20230605.0,20230920,20230920,EXP,,"CO-Ipsen Biopharmaceuticals, Inc.-2023-14080",IPSEN,,69.0,YR,E,F,Y,72.0,KG,20230920,,CN,CO,CO,2023,Q3,Elderly
229597941,22959794,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,,2023,Q3,Osteoporosis,,2023,Q3,1,I,20210101.0,20230605.0,20230920,20230920,EXP,,"CO-Ipsen Biopharmaceuticals, Inc.-2023-14080",IPSEN,,69.0,YR,E,F,Y,72.0,KG,20230920,,CN,CO,CO,2023,Q3,Elderly
229597941,22959794,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,,2023,Q3,Headache,,2023,Q3,1,I,20210101.0,20230605.0,20230920,20230920,EXP,,"CO-Ipsen Biopharmaceuticals, Inc.-2023-14080",IPSEN,,69.0,YR,E,F,Y,72.0,KG,20230920,,CN,CO,CO,2023,Q3,Elderly
229597941,22959794,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,,2023,Q3,Product supply issue,,2023,Q3,1,I,20210101.0,20230605.0,20230920,20230920,EXP,,"CO-Ipsen Biopharmaceuticals, Inc.-2023-14080",IPSEN,,69.0,YR,E,F,Y,72.0,KG,20230920,,CN,CO,CO,2023,Q3,Elderly
229597941,22959794,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,,2023,Q3,Therapy interrupted,,2023,Q3,1,I,20210101.0,20230605.0,20230920,20230920,EXP,,"CO-Ipsen Biopharmaceuticals, Inc.-2023-14080",IPSEN,,69.0,YR,E,F,Y,72.0,KG,20230920,,CN,CO,CO,2023,Q3,Elderly
229597941,22959794,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,,2023,Q3,Off label use,,2023,Q3,1,I,20210101.0,20230605.0,20230920,20230920,EXP,,"CO-Ipsen Biopharmaceuticals, Inc.-2023-14080",IPSEN,,69.0,YR,E,F,Y,72.0,KG,20230920,,CN,CO,CO,2023,Q3,Elderly
229597941,22959794,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,,2023,Q3,Product supply issue,,2023,Q3,1,I,20210101.0,20230605.0,20230920,20230920,EXP,,"CO-Ipsen Biopharmaceuticals, Inc.-2023-14080",IPSEN,,69.0,YR,E,F,Y,72.0,KG,20230920,,CN,CO,CO,2023,Q3,Elderly
229621011,22962101,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNKNOWN,,,,,UNKNOWN,,,,,,,2023,Q3,Dehydration,,2023,Q3,1,I,,20230905.0,20230920,20230920,EXP,,CA-HIKMA PHARMACEUTICALS-CA-H14001-23-65166,HIKMA,,78.0,YR,,M,Y,,,20230920,,MD,CA,CA,2023,Q3,Elderly
229621011,22962101,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNKNOWN,,,,,UNKNOWN,,,,,,,2023,Q3,Acute kidney injury,,2023,Q3,1,I,,20230905.0,20230920,20230920,EXP,,CA-HIKMA PHARMACEUTICALS-CA-H14001-23-65166,HIKMA,,78.0,YR,,M,Y,,,20230920,,MD,CA,CA,2023,Q3,Elderly
229622731,22962273,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Daily. tablet",,,,,,,,10.0,MG,,,2023,Q3,Acidosis,,2023,Q3,1,I,,20230905.0,20230920,20230920,EXP,,QA-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-408824,RANBAXY,"Alsaleh H, Faleh MF, Salameh R, Elmalik A, Afzal MS, Chabalout MN, et al. Case report of empagliflozin-induced euglycemic diabetic ketoacidosis. J Emerg Med Trauma Acute Care. 2023;(2)19:1-5",43.0,YR,,M,Y,,,20230920,,HP,QA,QA,2023,Q3,Adult
229622731,22962273,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Daily. tablet",,,,,,,,10.0,MG,,,2023,Q3,Vomiting,,2023,Q3,1,I,,20230905.0,20230920,20230920,EXP,,QA-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-408824,RANBAXY,"Alsaleh H, Faleh MF, Salameh R, Elmalik A, Afzal MS, Chabalout MN, et al. Case report of empagliflozin-induced euglycemic diabetic ketoacidosis. J Emerg Med Trauma Acute Care. 2023;(2)19:1-5",43.0,YR,,M,Y,,,20230920,,HP,QA,QA,2023,Q3,Adult
229622731,22962273,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Daily. tablet",,,,,,,,10.0,MG,,,2023,Q3,Nausea,,2023,Q3,1,I,,20230905.0,20230920,20230920,EXP,,QA-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-408824,RANBAXY,"Alsaleh H, Faleh MF, Salameh R, Elmalik A, Afzal MS, Chabalout MN, et al. Case report of empagliflozin-induced euglycemic diabetic ketoacidosis. J Emerg Med Trauma Acute Care. 2023;(2)19:1-5",43.0,YR,,M,Y,,,20230920,,HP,QA,QA,2023,Q3,Adult
229622731,22962273,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Daily. tablet",,,,,,,,10.0,MG,,,2023,Q3,Euglycaemic diabetic ketoacidosis,,2023,Q3,1,I,,20230905.0,20230920,20230920,EXP,,QA-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-408824,RANBAXY,"Alsaleh H, Faleh MF, Salameh R, Elmalik A, Afzal MS, Chabalout MN, et al. Case report of empagliflozin-induced euglycemic diabetic ketoacidosis. J Emerg Med Trauma Acute Care. 2023;(2)19:1-5",43.0,YR,,M,Y,,,20230920,,HP,QA,QA,2023,Q3,Adult
229622731,22962273,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Daily. tablet",,,,,,,,10.0,MG,,,2023,Q3,Tachypnoea,,2023,Q3,1,I,,20230905.0,20230920,20230920,EXP,,QA-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-408824,RANBAXY,"Alsaleh H, Faleh MF, Salameh R, Elmalik A, Afzal MS, Chabalout MN, et al. Case report of empagliflozin-induced euglycemic diabetic ketoacidosis. J Emerg Med Trauma Acute Care. 2023;(2)19:1-5",43.0,YR,,M,Y,,,20230920,,HP,QA,QA,2023,Q3,Adult
229622731,22962273,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Daily. tablet",,,,,,,,10.0,MG,,,2023,Q3,Tachycardia,,2023,Q3,1,I,,20230905.0,20230920,20230920,EXP,,QA-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-408824,RANBAXY,"Alsaleh H, Faleh MF, Salameh R, Elmalik A, Afzal MS, Chabalout MN, et al. Case report of empagliflozin-induced euglycemic diabetic ketoacidosis. J Emerg Med Trauma Acute Care. 2023;(2)19:1-5",43.0,YR,,M,Y,,,20230920,,HP,QA,QA,2023,Q3,Adult
229624942,22962494,12,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,"(12.5/500) mg, twice per day",,,,,,,,,,Tablet,,2023,Q3,Anaphylactic shock,,2023,Q3,2,F,20230911.0,20230922.0,20230920,20230928,EXP,,IN-GE HEALTHCARE-2023CSU008088,GE HEALTHCARE,,68.0,YR,,F,Y,78.0,KG,20230928,,HP,IN,IN,2023,Q3,Elderly
229630381,22963038,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,ASKU,,204629.0,25.0,MG,Tablet,QD,2023,Q3,Acetonaemia,,2023,Q3,1,I,20230919.0,20230920.0,20230920,20230920,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-262326",BOEHRINGER INGELHEIM,,51.0,YR,A,F,Y,70.0,KG,20230920,,MD,GB,GB,2023,Q3,Adult
229636081,22963608,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Diabetic complication,,2023,Q3,1,I,,20230911.0,20230921,20230921,EXP,,JP-EMD Serono-2023475157,EMD SERONO INC,,52.0,YR,A,M,Y,68.0,KG,20230921,,MD,JP,JP,2023,Q3,Adult
229636081,22963608,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Metastases to lymph nodes,,2023,Q3,1,I,,20230911.0,20230921,20230921,EXP,,JP-EMD Serono-2023475157,EMD SERONO INC,,52.0,YR,A,M,Y,68.0,KG,20230921,,MD,JP,JP,2023,Q3,Adult
229636081,22963608,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Contraindicated product administered,,2023,Q3,1,I,,20230911.0,20230921,20230921,EXP,,JP-EMD Serono-2023475157,EMD SERONO INC,,52.0,YR,A,M,Y,68.0,KG,20230921,,MD,JP,JP,2023,Q3,Adult
229636081,22963608,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Pancreatic carcinoma metastatic,,2023,Q3,1,I,,20230911.0,20230921,20230921,EXP,,JP-EMD Serono-2023475157,EMD SERONO INC,,52.0,YR,A,M,Y,68.0,KG,20230921,,MD,JP,JP,2023,Q3,Adult
229636081,22963608,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Metastases to peritoneum,,2023,Q3,1,I,,20230911.0,20230921,20230921,EXP,,JP-EMD Serono-2023475157,EMD SERONO INC,,52.0,YR,A,M,Y,68.0,KG,20230921,,MD,JP,JP,2023,Q3,Adult
229636081,22963608,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Metastases to lung,,2023,Q3,1,I,,20230911.0,20230921,20230921,EXP,,JP-EMD Serono-2023475157,EMD SERONO INC,,52.0,YR,A,M,Y,68.0,KG,20230921,,MD,JP,JP,2023,Q3,Adult
229644021,22964402,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,,,,,2023,Q3,Dysuria,,2023,Q3,1,I,20230818.0,20230920.0,20230921,20230921,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-262450",BOEHRINGER INGELHEIM,,58.0,YR,A,M,Y,,,20230921,,HP,SG,SG,2023,Q3,Adult
229648552,22964855,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q3,Thyrotoxic myopathy,,2023,Q3,2,F,,20230922.0,20230921,20230930,EXP,,IE-TEVA-2023-IE-2927672,TEVA,,53.0,YR,A,M,Y,,,20230930,,MD,IE,IE,2023,Q3,Adult
229648552,22964855,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q3,Cardiac failure,,2023,Q3,2,F,,20230922.0,20230921,20230930,EXP,,IE-TEVA-2023-IE-2927672,TEVA,,53.0,YR,A,M,Y,,,20230930,,MD,IE,IE,2023,Q3,Adult
229648552,22964855,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q3,Hyperthyroidism,,2023,Q3,2,F,,20230922.0,20230921,20230930,EXP,,IE-TEVA-2023-IE-2927672,TEVA,,53.0,YR,A,M,Y,,,20230930,,MD,IE,IE,2023,Q3,Adult
229648552,22964855,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q3,Drug ineffective,,2023,Q3,2,F,,20230922.0,20230921,20230930,EXP,,IE-TEVA-2023-IE-2927672,TEVA,,53.0,YR,A,M,Y,,,20230930,,MD,IE,IE,2023,Q3,Adult
229652931,22965293,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Angioedema,,2023,Q3,1,I,,20230911.0,20230921,20230921,EXP,,US-STRIDES ARCOLAB LIMITED-2023SP014389,STRIDES,"Everett S C, Ananth D, Alejo A L, Shaub T, Gan J.. A Rare Presentation of Hydralazine-Induced Lupus in the Setting of Pericarditis with Concomitant Angioedema.. Cureus. 2023;15(5):e38376",49.0,YR,,M,Y,,,20230921,,HP,US,US,2023,Q3,Adult
229652931,22965293,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Lupus-like syndrome,,2023,Q3,1,I,,20230911.0,20230921,20230921,EXP,,US-STRIDES ARCOLAB LIMITED-2023SP014389,STRIDES,"Everett S C, Ananth D, Alejo A L, Shaub T, Gan J.. A Rare Presentation of Hydralazine-Induced Lupus in the Setting of Pericarditis with Concomitant Angioedema.. Cureus. 2023;15(5):e38376",49.0,YR,,M,Y,,,20230921,,HP,US,US,2023,Q3,Adult
229652931,22965293,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Lupus nephritis,,2023,Q3,1,I,,20230911.0,20230921,20230921,EXP,,US-STRIDES ARCOLAB LIMITED-2023SP014389,STRIDES,"Everett S C, Ananth D, Alejo A L, Shaub T, Gan J.. A Rare Presentation of Hydralazine-Induced Lupus in the Setting of Pericarditis with Concomitant Angioedema.. Cureus. 2023;15(5):e38376",49.0,YR,,M,Y,,,20230921,,HP,US,US,2023,Q3,Adult
229652931,22965293,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Pericarditis,,2023,Q3,1,I,,20230911.0,20230921,20230921,EXP,,US-STRIDES ARCOLAB LIMITED-2023SP014389,STRIDES,"Everett S C, Ananth D, Alejo A L, Shaub T, Gan J.. A Rare Presentation of Hydralazine-Induced Lupus in the Setting of Pericarditis with Concomitant Angioedema.. Cureus. 2023;15(5):e38376",49.0,YR,,M,Y,,,20230921,,HP,US,US,2023,Q3,Adult
229686791,22968679,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,,10.0,MG,,,2023,Q3,Diabetic ketoacidosis,,2023,Q3,1,I,,20230822.0,20230921,20230921,EXP,GB-MHRA-ADR 28045727,GB-Novartis Pharma AG-NVSC2023GB157354,SANDOZ,,8.0,DEC,,M,Y,,,20230921,,HP,GB,GB,2023,Q3,Child
229686791,22968679,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,,10.0,MG,,,2023,Q3,Infection,,2023,Q3,1,I,,20230822.0,20230921,20230921,EXP,GB-MHRA-ADR 28045727,GB-Novartis Pharma AG-NVSC2023GB157354,SANDOZ,,8.0,DEC,,M,Y,,,20230921,,HP,GB,GB,2023,Q3,Child
229702361,22970236,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25mg,,,U,,Unknown,,204629.0,,,,,2023,Q3,Metabolic acidosis,,2023,Q3,1,I,20230912.0,20230922.0,20230922,20230922,EXP,DE-CADRBFARM-2023322518,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-262753",BOEHRINGER INGELHEIM,,76.0,YR,E,F,Y,,,20230922,,MD,DE,DE,2023,Q3,Elderly
229702361,22970236,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25mg,,,U,,Unknown,,204629.0,,,,,2023,Q3,Tachycardia,,2023,Q3,1,I,20230912.0,20230922.0,20230922,20230922,EXP,DE-CADRBFARM-2023322518,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-262753",BOEHRINGER INGELHEIM,,76.0,YR,E,F,Y,,,20230922,,MD,DE,DE,2023,Q3,Elderly
229707611,22970761,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg 1X1,,,U,,UNKNOWN,,,10.0,MG,,,2023,Q3,Hyperkalaemia,,2023,Q3,1,I,,20230914.0,20230922,20230922,EXP,,DE-TEVA-2023-DE-2927788,TEVA,,28.0,YR,A,M,Y,,,20230922,,MD,DE,DE,2023,Q3,Young Adult
229707611,22970761,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg 1X1,,,U,,UNKNOWN,,,10.0,MG,,,2023,Q3,Hypertension,,2023,Q3,1,I,,20230914.0,20230922,20230922,EXP,,DE-TEVA-2023-DE-2927788,TEVA,,28.0,YR,A,M,Y,,,20230922,,MD,DE,DE,2023,Q3,Young Adult
229707611,22970761,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg 1X1,,,U,,UNKNOWN,,,10.0,MG,,,2023,Q3,Renal impairment,,2023,Q3,1,I,,20230914.0,20230922,20230922,EXP,,DE-TEVA-2023-DE-2927788,TEVA,,28.0,YR,A,M,Y,,,20230922,,MD,DE,DE,2023,Q3,Young Adult
229720911,22972091,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (midday)",,,U,,,,,10.0,MG,,QD,2023,Q3,Dermatitis allergic,,2023,Q3,1,I,20230719.0,20230919.0,20230922,20230922,EXP,,NVSC2023AU178800,NOVARTIS,,49.0,YR,,M,Y,138.0,KG,20230922,,MD,AU,AU,2023,Q3,Adult
229720911,22972091,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (midday)",,,U,,,,,10.0,MG,,QD,2023,Q3,Lip swelling,,2023,Q3,1,I,20230719.0,20230919.0,20230922,20230922,EXP,,NVSC2023AU178800,NOVARTIS,,49.0,YR,,M,Y,138.0,KG,20230922,,MD,AU,AU,2023,Q3,Adult
229720911,22972091,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (midday)",,,U,,,,,10.0,MG,,QD,2023,Q3,Pruritus,,2023,Q3,1,I,20230719.0,20230919.0,20230922,20230922,EXP,,NVSC2023AU178800,NOVARTIS,,49.0,YR,,M,Y,138.0,KG,20230922,,MD,AU,AU,2023,Q3,Adult
229720911,22972091,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (midday)",,,U,,,,,10.0,MG,,QD,2023,Q3,Peripheral swelling,,2023,Q3,1,I,20230719.0,20230919.0,20230922,20230922,EXP,,NVSC2023AU178800,NOVARTIS,,49.0,YR,,M,Y,138.0,KG,20230922,,MD,AU,AU,2023,Q3,Adult
229720911,22972091,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (midday)",,,U,,,,,10.0,MG,,QD,2023,Q3,Swollen tongue,,2023,Q3,1,I,20230719.0,20230919.0,20230922,20230922,EXP,,NVSC2023AU178800,NOVARTIS,,49.0,YR,,M,Y,138.0,KG,20230922,,MD,AU,AU,2023,Q3,Adult
229720911,22972091,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (midday)",,,U,,,,,10.0,MG,,QD,2023,Q3,Eye swelling,,2023,Q3,1,I,20230719.0,20230919.0,20230922,20230922,EXP,,NVSC2023AU178800,NOVARTIS,,49.0,YR,,M,Y,138.0,KG,20230922,,MD,AU,AU,2023,Q3,Adult
229720911,22972091,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (midday)",,,U,,,,,10.0,MG,,QD,2023,Q3,Angioedema,,2023,Q3,1,I,20230719.0,20230919.0,20230922,20230922,EXP,,NVSC2023AU178800,NOVARTIS,,49.0,YR,,M,Y,138.0,KG,20230922,,MD,AU,AU,2023,Q3,Adult
229720911,22972091,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (midday)",,,U,,,,,10.0,MG,,QD,2023,Q3,Urticaria,,2023,Q3,1,I,20230719.0,20230919.0,20230922,20230922,EXP,,NVSC2023AU178800,NOVARTIS,,49.0,YR,,M,Y,138.0,KG,20230922,,MD,AU,AU,2023,Q3,Adult
229720911,22972091,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (midday)",,,U,,,,,10.0,MG,,QD,2023,Q3,Rash,,2023,Q3,1,I,20230719.0,20230919.0,20230922,20230922,EXP,,NVSC2023AU178800,NOVARTIS,,49.0,YR,,M,Y,138.0,KG,20230922,,MD,AU,AU,2023,Q3,Adult
229753341,22975334,4,C,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2023,Q3,Injection site pain,,2023,Q3,1,I,20230920.0,20230920.0,20230924,20230924,PER,,US-ELI_LILLY_AND_COMPANY-US202309011728,ELI LILLY AND CO,,48.0,YR,,F,Y,,,20230924,,HP,US,US,2023,Q3,Adult
229753341,22975334,4,C,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2023,Q3,Incorrect dose administered,,2023,Q3,1,I,20230920.0,20230920.0,20230924,20230924,PER,,US-ELI_LILLY_AND_COMPANY-US202309011728,ELI LILLY AND CO,,48.0,YR,,F,Y,,,20230924,,HP,US,US,2023,Q3,Adult
229758281,22975828,11,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,,,,,,,,,,,,,2023,Q3,Clostridium test positive,,2023,Q3,1,I,,20230920.0,20230925,20230925,EXP,,CA-SANDOZ INC.-SDZ2023CA032706,SANDOZ,,77.0,YR,,F,Y,79.0,KG,20230925,,PH,CA,CA,2023,Q3,Elderly
229758281,22975828,11,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,,,,,,,,,,,,,2023,Q3,Hyperhidrosis,,2023,Q3,1,I,,20230920.0,20230925,20230925,EXP,,CA-SANDOZ INC.-SDZ2023CA032706,SANDOZ,,77.0,YR,,F,Y,79.0,KG,20230925,,PH,CA,CA,2023,Q3,Elderly
229758281,22975828,11,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,,,,,,,,,,,,,2023,Q3,Nausea,,2023,Q3,1,I,,20230920.0,20230925,20230925,EXP,,CA-SANDOZ INC.-SDZ2023CA032706,SANDOZ,,77.0,YR,,F,Y,79.0,KG,20230925,,PH,CA,CA,2023,Q3,Elderly
229758281,22975828,11,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,,,,,,,,,,,,,2023,Q3,Epigastric discomfort,,2023,Q3,1,I,,20230920.0,20230925,20230925,EXP,,CA-SANDOZ INC.-SDZ2023CA032706,SANDOZ,,77.0,YR,,F,Y,79.0,KG,20230925,,PH,CA,CA,2023,Q3,Elderly
229758281,22975828,11,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,,,,,,,,,,,,,2023,Q3,Cardiogenic shock,,2023,Q3,1,I,,20230920.0,20230925,20230925,EXP,,CA-SANDOZ INC.-SDZ2023CA032706,SANDOZ,,77.0,YR,,F,Y,79.0,KG,20230925,,PH,CA,CA,2023,Q3,Elderly
229758281,22975828,11,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,,,,,,,,,,,,,2023,Q3,Cardiac arrest,,2023,Q3,1,I,,20230920.0,20230925,20230925,EXP,,CA-SANDOZ INC.-SDZ2023CA032706,SANDOZ,,77.0,YR,,F,Y,79.0,KG,20230925,,PH,CA,CA,2023,Q3,Elderly
229758281,22975828,11,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,,,,,,,,,,,,,2023,Q3,Anuria,,2023,Q3,1,I,,20230920.0,20230925,20230925,EXP,,CA-SANDOZ INC.-SDZ2023CA032706,SANDOZ,,77.0,YR,,F,Y,79.0,KG,20230925,,PH,CA,CA,2023,Q3,Elderly
229758281,22975828,11,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,,,,,,,,,,,,,2023,Q3,Eructation,,2023,Q3,1,I,,20230920.0,20230925,20230925,EXP,,CA-SANDOZ INC.-SDZ2023CA032706,SANDOZ,,77.0,YR,,F,Y,79.0,KG,20230925,,PH,CA,CA,2023,Q3,Elderly
229758281,22975828,11,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,,,,,,,,,,,,,2023,Q3,Dyspnoea,,2023,Q3,1,I,,20230920.0,20230925,20230925,EXP,,CA-SANDOZ INC.-SDZ2023CA032706,SANDOZ,,77.0,YR,,F,Y,79.0,KG,20230925,,PH,CA,CA,2023,Q3,Elderly
229758281,22975828,11,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,,,,,,,,,,,,,2023,Q3,Diarrhoea,,2023,Q3,1,I,,20230920.0,20230925,20230925,EXP,,CA-SANDOZ INC.-SDZ2023CA032706,SANDOZ,,77.0,YR,,F,Y,79.0,KG,20230925,,PH,CA,CA,2023,Q3,Elderly
229758281,22975828,12,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,,,,,,,,,,,,,2023,Q3,Clostridium test positive,,2023,Q3,1,I,,20230920.0,20230925,20230925,EXP,,CA-SANDOZ INC.-SDZ2023CA032706,SANDOZ,,77.0,YR,,F,Y,79.0,KG,20230925,,PH,CA,CA,2023,Q3,Elderly
229758281,22975828,12,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,,,,,,,,,,,,,2023,Q3,Hyperhidrosis,,2023,Q3,1,I,,20230920.0,20230925,20230925,EXP,,CA-SANDOZ INC.-SDZ2023CA032706,SANDOZ,,77.0,YR,,F,Y,79.0,KG,20230925,,PH,CA,CA,2023,Q3,Elderly
229758281,22975828,12,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,,,,,,,,,,,,,2023,Q3,Nausea,,2023,Q3,1,I,,20230920.0,20230925,20230925,EXP,,CA-SANDOZ INC.-SDZ2023CA032706,SANDOZ,,77.0,YR,,F,Y,79.0,KG,20230925,,PH,CA,CA,2023,Q3,Elderly
229758281,22975828,12,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,,,,,,,,,,,,,2023,Q3,Epigastric discomfort,,2023,Q3,1,I,,20230920.0,20230925,20230925,EXP,,CA-SANDOZ INC.-SDZ2023CA032706,SANDOZ,,77.0,YR,,F,Y,79.0,KG,20230925,,PH,CA,CA,2023,Q3,Elderly
229758281,22975828,12,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,,,,,,,,,,,,,2023,Q3,Cardiogenic shock,,2023,Q3,1,I,,20230920.0,20230925,20230925,EXP,,CA-SANDOZ INC.-SDZ2023CA032706,SANDOZ,,77.0,YR,,F,Y,79.0,KG,20230925,,PH,CA,CA,2023,Q3,Elderly
229758281,22975828,12,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,,,,,,,,,,,,,2023,Q3,Cardiac arrest,,2023,Q3,1,I,,20230920.0,20230925,20230925,EXP,,CA-SANDOZ INC.-SDZ2023CA032706,SANDOZ,,77.0,YR,,F,Y,79.0,KG,20230925,,PH,CA,CA,2023,Q3,Elderly
229758281,22975828,12,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,,,,,,,,,,,,,2023,Q3,Anuria,,2023,Q3,1,I,,20230920.0,20230925,20230925,EXP,,CA-SANDOZ INC.-SDZ2023CA032706,SANDOZ,,77.0,YR,,F,Y,79.0,KG,20230925,,PH,CA,CA,2023,Q3,Elderly
229758281,22975828,12,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,,,,,,,,,,,,,2023,Q3,Eructation,,2023,Q3,1,I,,20230920.0,20230925,20230925,EXP,,CA-SANDOZ INC.-SDZ2023CA032706,SANDOZ,,77.0,YR,,F,Y,79.0,KG,20230925,,PH,CA,CA,2023,Q3,Elderly
229758281,22975828,12,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,,,,,,,,,,,,,2023,Q3,Dyspnoea,,2023,Q3,1,I,,20230920.0,20230925,20230925,EXP,,CA-SANDOZ INC.-SDZ2023CA032706,SANDOZ,,77.0,YR,,F,Y,79.0,KG,20230925,,PH,CA,CA,2023,Q3,Elderly
229758281,22975828,12,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,,,,,,,,,,,,,2023,Q3,Diarrhoea,,2023,Q3,1,I,,20230920.0,20230925,20230925,EXP,,CA-SANDOZ INC.-SDZ2023CA032706,SANDOZ,,77.0,YR,,F,Y,79.0,KG,20230925,,PH,CA,CA,2023,Q3,Elderly
229764111,22976411,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,D,,,,,10.0,MG,Tablet,,2023,Q3,Skin exfoliation,,2023,Q3,1,I,,20230913.0,20230925,20230925,EXP,,CA-APOTEX-2023AP013766,APOTEX,,63.0,YR,,M,Y,,,20230925,,PH,CA,CA,2023,Q3,Adult
229764111,22976411,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,D,,,,,10.0,MG,Tablet,,2023,Q3,Abdominal rigidity,,2023,Q3,1,I,,20230913.0,20230925,20230925,EXP,,CA-APOTEX-2023AP013766,APOTEX,,63.0,YR,,M,Y,,,20230925,,PH,CA,CA,2023,Q3,Adult
229764111,22976411,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,D,,,,,10.0,MG,Tablet,,2023,Q3,Fatigue,,2023,Q3,1,I,,20230913.0,20230925,20230925,EXP,,CA-APOTEX-2023AP013766,APOTEX,,63.0,YR,,M,Y,,,20230925,,PH,CA,CA,2023,Q3,Adult
229764111,22976411,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,D,,,,,10.0,MG,Tablet,,2023,Q3,Upper respiratory tract infection,,2023,Q3,1,I,,20230913.0,20230925,20230925,EXP,,CA-APOTEX-2023AP013766,APOTEX,,63.0,YR,,M,Y,,,20230925,,PH,CA,CA,2023,Q3,Adult
229764111,22976411,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,D,,,,,10.0,MG,Tablet,,2023,Q3,Illness,,2023,Q3,1,I,,20230913.0,20230925,20230925,EXP,,CA-APOTEX-2023AP013766,APOTEX,,63.0,YR,,M,Y,,,20230925,,PH,CA,CA,2023,Q3,Adult
229764111,22976411,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,D,,,,,10.0,MG,Tablet,,2023,Q3,Off label use,,2023,Q3,1,I,,20230913.0,20230925,20230925,EXP,,CA-APOTEX-2023AP013766,APOTEX,,63.0,YR,,M,Y,,,20230925,,PH,CA,CA,2023,Q3,Adult
229764111,22976411,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,D,,,,,10.0,MG,Tablet,,2023,Q3,Diarrhoea,,2023,Q3,1,I,,20230913.0,20230925,20230925,EXP,,CA-APOTEX-2023AP013766,APOTEX,,63.0,YR,,M,Y,,,20230925,,PH,CA,CA,2023,Q3,Adult
229764111,22976411,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,D,,,,,10.0,MG,Tablet,,2023,Q3,Pain in extremity,,2023,Q3,1,I,,20230913.0,20230925,20230925,EXP,,CA-APOTEX-2023AP013766,APOTEX,,63.0,YR,,M,Y,,,20230925,,PH,CA,CA,2023,Q3,Adult
229764111,22976411,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,D,,,,,10.0,MG,Tablet,,2023,Q3,Abdominal discomfort,,2023,Q3,1,I,,20230913.0,20230925,20230925,EXP,,CA-APOTEX-2023AP013766,APOTEX,,63.0,YR,,M,Y,,,20230925,,PH,CA,CA,2023,Q3,Adult
229764111,22976411,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,D,,,,,10.0,MG,Tablet,,2023,Q3,Abdominal pain lower,,2023,Q3,1,I,,20230913.0,20230925,20230925,EXP,,CA-APOTEX-2023AP013766,APOTEX,,63.0,YR,,M,Y,,,20230925,,PH,CA,CA,2023,Q3,Adult
229764111,22976411,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,D,,,,,10.0,MG,Tablet,,2023,Q3,Dyspepsia,,2023,Q3,1,I,,20230913.0,20230925,20230925,EXP,,CA-APOTEX-2023AP013766,APOTEX,,63.0,YR,,M,Y,,,20230925,,PH,CA,CA,2023,Q3,Adult
229768201,22976820,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Pneumonia,,2023,Q3,1,I,20230512.0,20230922.0,20230925,20230925,EXP,,FR-SANDOZ INC.-NVSC2023FR118646,SANDOZ,,75.0,YR,,F,Y,76.0,KG,20230925,,MD,FR,FR,2023,Q3,Elderly
229768201,22976820,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Cardiac failure,,2023,Q3,1,I,20230512.0,20230922.0,20230925,20230925,EXP,,FR-SANDOZ INC.-NVSC2023FR118646,SANDOZ,,75.0,YR,,F,Y,76.0,KG,20230925,,MD,FR,FR,2023,Q3,Elderly
229768201,22976820,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Asthenia,,2023,Q3,1,I,20230512.0,20230922.0,20230925,20230925,EXP,,FR-SANDOZ INC.-NVSC2023FR118646,SANDOZ,,75.0,YR,,F,Y,76.0,KG,20230925,,MD,FR,FR,2023,Q3,Elderly
229768201,22976820,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,C-reactive protein increased,,2023,Q3,1,I,20230512.0,20230922.0,20230925,20230925,EXP,,FR-SANDOZ INC.-NVSC2023FR118646,SANDOZ,,75.0,YR,,F,Y,76.0,KG,20230925,,MD,FR,FR,2023,Q3,Elderly
229768201,22976820,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Off label use,,2023,Q3,1,I,20230512.0,20230922.0,20230925,20230925,EXP,,FR-SANDOZ INC.-NVSC2023FR118646,SANDOZ,,75.0,YR,,F,Y,76.0,KG,20230925,,MD,FR,FR,2023,Q3,Elderly
229768201,22976820,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Lower respiratory tract infection,,2023,Q3,1,I,20230512.0,20230922.0,20230925,20230925,EXP,,FR-SANDOZ INC.-NVSC2023FR118646,SANDOZ,,75.0,YR,,F,Y,76.0,KG,20230925,,MD,FR,FR,2023,Q3,Elderly
229768201,22976820,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Chills,,2023,Q3,1,I,20230512.0,20230922.0,20230925,20230925,EXP,,FR-SANDOZ INC.-NVSC2023FR118646,SANDOZ,,75.0,YR,,F,Y,76.0,KG,20230925,,MD,FR,FR,2023,Q3,Elderly
229768201,22976820,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Abdominal pain upper,,2023,Q3,1,I,20230512.0,20230922.0,20230925,20230925,EXP,,FR-SANDOZ INC.-NVSC2023FR118646,SANDOZ,,75.0,YR,,F,Y,76.0,KG,20230925,,MD,FR,FR,2023,Q3,Elderly
229768201,22976820,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,COVID-19,,2023,Q3,1,I,20230512.0,20230922.0,20230925,20230925,EXP,,FR-SANDOZ INC.-NVSC2023FR118646,SANDOZ,,75.0,YR,,F,Y,76.0,KG,20230925,,MD,FR,FR,2023,Q3,Elderly
229768201,22976820,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Anaemia,,2023,Q3,1,I,20230512.0,20230922.0,20230925,20230925,EXP,,FR-SANDOZ INC.-NVSC2023FR118646,SANDOZ,,75.0,YR,,F,Y,76.0,KG,20230925,,MD,FR,FR,2023,Q3,Elderly
229768201,22976820,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Cough,,2023,Q3,1,I,20230512.0,20230922.0,20230925,20230925,EXP,,FR-SANDOZ INC.-NVSC2023FR118646,SANDOZ,,75.0,YR,,F,Y,76.0,KG,20230925,,MD,FR,FR,2023,Q3,Elderly
229771381,22977138,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q3,Drug ineffective for unapproved indication,,2023,Q3,1,I,,20230915.0,20230925,20230925,EXP,,LB-STERISCIENCE B.V.-2023-ST-001944,Steriscience PTE,"Fares R, Matar M.. Human herpesvirus-7 meningitis in an immunocompetent adult patient: a case report.. Future-Sci-OA. 2023;9 No.8",53.0,YR,,F,Y,,,20230925,,HP,LB,LB,2023,Q3,Adult
229822481,22982248,3,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,5/1000 mg x 2,,,,,unk,,,,,,,2023,Q3,Inflammation,,2023,Q3,1,I,20171101.0,20230914.0,20230926,20230926,EXP,,LV-NOVOPROD-1117634,NOVO NORDISK,,60.0,YR,,F,Y,,,20230926,,MD,LV,LV,2023,Q3,Adult
229822481,22982248,3,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,5/1000 mg x 2,,,,,unk,,,,,,,2023,Q3,Limb injury,,2023,Q3,1,I,20171101.0,20230914.0,20230926,20230926,EXP,,LV-NOVOPROD-1117634,NOVO NORDISK,,60.0,YR,,F,Y,,,20230926,,MD,LV,LV,2023,Q3,Adult
229822481,22982248,3,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,5/1000 mg x 2,,,,,unk,,,,,,,2023,Q3,Inappropriate schedule of product administration,,2023,Q3,1,I,20171101.0,20230914.0,20230926,20230926,EXP,,LV-NOVOPROD-1117634,NOVO NORDISK,,60.0,YR,,F,Y,,,20230926,,MD,LV,LV,2023,Q3,Adult
229822481,22982248,3,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,5/1000 mg x 2,,,,,unk,,,,,,,2023,Q3,Hypoaesthesia,,2023,Q3,1,I,20171101.0,20230914.0,20230926,20230926,EXP,,LV-NOVOPROD-1117634,NOVO NORDISK,,60.0,YR,,F,Y,,,20230926,,MD,LV,LV,2023,Q3,Adult
229849061,22984906,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,,2 pills daily,,,U,,Unknown,,204629.0,12.5,MG,,,2023,Q3,Blood glucose increased,,2023,Q3,1,I,20230725.0,20230925.0,20230926,20230926,PER,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-263198",BOEHRINGER INGELHEIM,,65.0,YR,E,F,Y,,,20230926,,CN,US,US,2023,Q3,Elderly
229874591,22987459,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 dosage form, QD",,,U,,,,,,,,QD,2023,Q3,Death,,2023,Q3,1,I,20230723.0,20230922.0,20230926,20230926,EXP,,NVSC2023CA208108,NOVARTIS,,28.0,YR,,M,Y,,,20230926,,CN,CA,CA,2023,Q3,Young Adult
229885141,22988514,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q3,Headache,,2023,Q3,1,I,20230920.0,20230925.0,20230926,20230926,EXP,GB-MHRA-TPP27495637C9750495YC1695206769771,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-263275",BOEHRINGER INGELHEIM,,59.0,YR,A,F,Y,123.0,KG,20230926,,MD,GB,GB,2023,Q3,Adult
229885841,22988584,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,,,,,2023,Q3,Necrotising fasciitis,,2023,Q3,1,I,20230701.0,20230925.0,20230926,20230926,EXP,GB-MHRA-TPP8397960C1146057YC1695296780388,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-263263",BOEHRINGER INGELHEIM,,59.0,YR,A,M,Y,105.0,KG,20230926,,HP,GB,GB,2023,Q3,Adult
229885841,22988584,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,25.0,MG,Tablet,,2023,Q3,Necrotising fasciitis,,2023,Q3,1,I,20230701.0,20230925.0,20230926,20230926,EXP,GB-MHRA-TPP8397960C1146057YC1695296780388,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-263263",BOEHRINGER INGELHEIM,,59.0,YR,A,M,Y,105.0,KG,20230926,,HP,GB,GB,2023,Q3,Adult
229885841,22988584,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,QD,2023,Q3,Necrotising fasciitis,,2023,Q3,1,I,20230701.0,20230925.0,20230926,20230926,EXP,GB-MHRA-TPP8397960C1146057YC1695296780388,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-263263",BOEHRINGER INGELHEIM,,59.0,YR,A,M,Y,105.0,KG,20230926,,HP,GB,GB,2023,Q3,Adult
229897561,22989756,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q3,Pruritus,,2023,Q3,1,I,20230828.0,20230926.0,20230927,20230927,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-263571",BOEHRINGER INGELHEIM,,67.0,YR,E,F,Y,,,20230927,,HP,SG,SG,2023,Q3,Elderly
229909001,22990900,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q3,Pruritus,,2023,Q3,1,I,20230520.0,20230926.0,20230927,20230927,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-263573",BOEHRINGER INGELHEIM,,52.0,YR,A,M,Y,,,20230927,,HP,SG,SG,2023,Q3,Adult
230036071,23003607,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Blood glucose increased,,2023,Q3,1,I,20230727.0,,20230928,20230928,DIR,FDA-CDER-CTU-2023-71542,,FDA-CTU,,52.0,YR,,,N,65.0,KG,20230928,N,PH,US,,2023,Q3,Adult
230036071,23003607,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Metabolic acidosis,,2023,Q3,1,I,20230727.0,,20230928,20230928,DIR,FDA-CDER-CTU-2023-71542,,FDA-CTU,,52.0,YR,,,N,65.0,KG,20230928,N,PH,US,,2023,Q3,Adult
230036071,23003607,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Urinary incontinence,,2023,Q3,1,I,20230727.0,,20230928,20230928,DIR,FDA-CDER-CTU-2023-71542,,FDA-CTU,,52.0,YR,,,N,65.0,KG,20230928,N,PH,US,,2023,Q3,Adult
230036071,23003607,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Discoloured vomit,,2023,Q3,1,I,20230727.0,,20230928,20230928,DIR,FDA-CDER-CTU-2023-71542,,FDA-CTU,,52.0,YR,,,N,65.0,KG,20230928,N,PH,US,,2023,Q3,Adult
230036071,23003607,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Shock,,2023,Q3,1,I,20230727.0,,20230928,20230928,DIR,FDA-CDER-CTU-2023-71542,,FDA-CTU,,52.0,YR,,,N,65.0,KG,20230928,N,PH,US,,2023,Q3,Adult
230036071,23003607,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Unresponsive to stimuli,,2023,Q3,1,I,20230727.0,,20230928,20230928,DIR,FDA-CDER-CTU-2023-71542,,FDA-CTU,,52.0,YR,,,N,65.0,KG,20230928,N,PH,US,,2023,Q3,Adult
230036071,23003607,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Treatment noncompliance,,2023,Q3,1,I,20230727.0,,20230928,20230928,DIR,FDA-CDER-CTU-2023-71542,,FDA-CTU,,52.0,YR,,,N,65.0,KG,20230928,N,PH,US,,2023,Q3,Adult
230041061,23004106,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q3,Glycosylated haemoglobin increased,,2023,Q3,1,I,20181001.0,20230919.0,20230928,20230928,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20230928,,MD,DE,DE,2023,Q3,Adult
230041061,23004106,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q3,Intervertebral disc protrusion,,2023,Q3,1,I,20181001.0,20230919.0,20230928,20230928,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20230928,,MD,DE,DE,2023,Q3,Adult
230041061,23004106,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q3,Vulvovaginal mycotic infection,,2023,Q3,1,I,20181001.0,20230919.0,20230928,20230928,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20230928,,MD,DE,DE,2023,Q3,Adult
230041061,23004106,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q3,Blood glucose increased,,2023,Q3,1,I,20181001.0,20230919.0,20230928,20230928,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20230928,,MD,DE,DE,2023,Q3,Adult
230041061,23004106,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q3,Renal impairment,,2023,Q3,1,I,20181001.0,20230919.0,20230928,20230928,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20230928,,MD,DE,DE,2023,Q3,Adult
230041061,23004106,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q3,Weight increased,,2023,Q3,1,I,20181001.0,20230919.0,20230928,20230928,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20230928,,MD,DE,DE,2023,Q3,Adult
230041061,23004106,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q3,Blood glucose abnormal,,2023,Q3,1,I,20181001.0,20230919.0,20230928,20230928,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20230928,,MD,DE,DE,2023,Q3,Adult
230041061,23004106,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q3,Coronary artery disease,,2023,Q3,1,I,20181001.0,20230919.0,20230928,20230928,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20230928,,MD,DE,DE,2023,Q3,Adult
230041061,23004106,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q3,Osteoarthritis,,2023,Q3,1,I,20181001.0,20230919.0,20230928,20230928,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20230928,,MD,DE,DE,2023,Q3,Adult
230041061,23004106,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2023,Q3,Intervertebral disc disorder,,2023,Q3,1,I,20181001.0,20230919.0,20230928,20230928,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20230928,,MD,DE,DE,2023,Q3,Adult
230048771,23004877,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Septic shock,,2023,Q3,1,I,,20230918.0,20230929,20230929,EXP,,CA-AUROBINDO-AUR-APL-2023-059937,AUROBINDO,"Mah J, Lieu A, Heck E, Quickfall D, Ugarte-Torres A. Primary varicella in 2 adult immigrants to Canada. CMAJ. 2023;195(8):E300-E303",50.0,YR,,M,Y,,,20230929,,MD,CA,CA,2023,Q3,Adult
230048771,23004877,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Varicella zoster pneumonia,,2023,Q3,1,I,,20230918.0,20230929,20230929,EXP,,CA-AUROBINDO-AUR-APL-2023-059937,AUROBINDO,"Mah J, Lieu A, Heck E, Quickfall D, Ugarte-Torres A. Primary varicella in 2 adult immigrants to Canada. CMAJ. 2023;195(8):E300-E303",50.0,YR,,M,Y,,,20230929,,MD,CA,CA,2023,Q3,Adult
230048771,23004877,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Respiratory failure,,2023,Q3,1,I,,20230918.0,20230929,20230929,EXP,,CA-AUROBINDO-AUR-APL-2023-059937,AUROBINDO,"Mah J, Lieu A, Heck E, Quickfall D, Ugarte-Torres A. Primary varicella in 2 adult immigrants to Canada. CMAJ. 2023;195(8):E300-E303",50.0,YR,,M,Y,,,20230929,,MD,CA,CA,2023,Q3,Adult
230048771,23004877,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Enterobacter infection,,2023,Q3,1,I,,20230918.0,20230929,20230929,EXP,,CA-AUROBINDO-AUR-APL-2023-059937,AUROBINDO,"Mah J, Lieu A, Heck E, Quickfall D, Ugarte-Torres A. Primary varicella in 2 adult immigrants to Canada. CMAJ. 2023;195(8):E300-E303",50.0,YR,,M,Y,,,20230929,,MD,CA,CA,2023,Q3,Adult
230048771,23004877,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Staphylococcal bacteraemia,,2023,Q3,1,I,,20230918.0,20230929,20230929,EXP,,CA-AUROBINDO-AUR-APL-2023-059937,AUROBINDO,"Mah J, Lieu A, Heck E, Quickfall D, Ugarte-Torres A. Primary varicella in 2 adult immigrants to Canada. CMAJ. 2023;195(8):E300-E303",50.0,YR,,M,Y,,,20230929,,MD,CA,CA,2023,Q3,Adult
230048771,23004877,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Thrombocytopenia,,2023,Q3,1,I,,20230918.0,20230929,20230929,EXP,,CA-AUROBINDO-AUR-APL-2023-059937,AUROBINDO,"Mah J, Lieu A, Heck E, Quickfall D, Ugarte-Torres A. Primary varicella in 2 adult immigrants to Canada. CMAJ. 2023;195(8):E300-E303",50.0,YR,,M,Y,,,20230929,,MD,CA,CA,2023,Q3,Adult
230048771,23004877,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Pneumonia,,2023,Q3,1,I,,20230918.0,20230929,20230929,EXP,,CA-AUROBINDO-AUR-APL-2023-059937,AUROBINDO,"Mah J, Lieu A, Heck E, Quickfall D, Ugarte-Torres A. Primary varicella in 2 adult immigrants to Canada. CMAJ. 2023;195(8):E300-E303",50.0,YR,,M,Y,,,20230929,,MD,CA,CA,2023,Q3,Adult
230103631,23010363,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q3,Osteomyelitis acute,,2023,Q3,1,I,20230920.0,20230925.0,20230929,20230929,EXP,GB-MHRA-TPP2310367C15548630YC1695209178085,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-263268",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,136.0,KG,20230929,,MD,GB,GB,2023,Q3,Adult
230118521,23011852,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"Tablet, 25 mg (milligram)",,,,,,,,,,,,2023,Q3,Diarrhoea,,2023,Q3,1,I,20230824.0,20230919.0,20230929,20230929,EXP,NL-LRB-00908912,NL-NOVOPROD-1118803,NOVO NORDISK,,64.0,YR,,M,Y,108.0,KG,20230929,,MD,NL,NL,2023,Q3,Adult
230118521,23011852,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"Tablet, 25 mg (milligram)",,,,,,,,,,,,2023,Q3,Gastroenteritis,,2023,Q3,1,I,20230824.0,20230919.0,20230929,20230929,EXP,NL-LRB-00908912,NL-NOVOPROD-1118803,NOVO NORDISK,,64.0,YR,,M,Y,108.0,KG,20230929,,MD,NL,NL,2023,Q3,Adult
230118521,23011852,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"Tablet, 25 mg (milligram)",,,,,,,,,,,,2023,Q3,Nausea,,2023,Q3,1,I,20230824.0,20230919.0,20230929,20230929,EXP,NL-LRB-00908912,NL-NOVOPROD-1118803,NOVO NORDISK,,64.0,YR,,M,Y,108.0,KG,20230929,,MD,NL,NL,2023,Q3,Adult
230118521,23011852,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"Tablet, 25 mg (milligram)",,,,,,,,,,,,2023,Q3,Vomiting,,2023,Q3,1,I,20230824.0,20230919.0,20230929,20230929,EXP,NL-LRB-00908912,NL-NOVOPROD-1118803,NOVO NORDISK,,64.0,YR,,M,Y,108.0,KG,20230929,,MD,NL,NL,2023,Q3,Adult
230149931,23014993,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Weight decreased,,2023,Q3,1,I,20230925.0,,20230929,20230929,DIR,675819,,FDA-CTU,,80.0,YR,,M,N,61.24,KG,20230929,N,PH,US,,2023,Q3,Elderly
230149931,23014993,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q3,Therapy change,,2023,Q3,1,I,20230925.0,,20230929,20230929,DIR,675819,,FDA-CTU,,80.0,YR,,M,N,61.24,KG,20230929,N,PH,US,,2023,Q3,Elderly
155722449,15572244,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,,,,,,10.0,MG,Unknown,,2023,Q4,Glycosylated haemoglobin increased,,2023,Q4,9,F,20050801.0,20231010.0,20181031,20231016,EXP,,SK-MYLANLABS-2018M1081194,MYLAN,Polko J.. Compensation of glycemia in patient with type II DM and cardiac primorbidity. Internal Medicine. 2018;52:10-11,66.0,YR,,M,Y,,,20231016,,MD,SK,SK,2023,Q4,Elderly
155722449,15572244,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,,,,,,10.0,MG,Unknown,,2023,Q4,Hyperlipidaemia,,2023,Q4,9,F,20050801.0,20231010.0,20181031,20231016,EXP,,SK-MYLANLABS-2018M1081194,MYLAN,Polko J.. Compensation of glycemia in patient with type II DM and cardiac primorbidity. Internal Medicine. 2018;52:10-11,66.0,YR,,M,Y,,,20231016,,MD,SK,SK,2023,Q4,Elderly
155722449,15572244,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,,,,,,10.0,MG,Unknown,,2023,Q4,Myocardial infarction,,2023,Q4,9,F,20050801.0,20231010.0,20181031,20231016,EXP,,SK-MYLANLABS-2018M1081194,MYLAN,Polko J.. Compensation of glycemia in patient with type II DM and cardiac primorbidity. Internal Medicine. 2018;52:10-11,66.0,YR,,M,Y,,,20231016,,MD,SK,SK,2023,Q4,Elderly
155722449,15572244,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,,,,,,10.0,MG,Unknown,,2023,Q4,Diabetes mellitus,,2023,Q4,9,F,20050801.0,20231010.0,20181031,20231016,EXP,,SK-MYLANLABS-2018M1081194,MYLAN,Polko J.. Compensation of glycemia in patient with type II DM and cardiac primorbidity. Internal Medicine. 2018;52:10-11,66.0,YR,,M,Y,,,20231016,,MD,SK,SK,2023,Q4,Elderly
155722449,15572244,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,,,,,,10.0,MG,Unknown,,2023,Q4,Drug ineffective,,2023,Q4,9,F,20050801.0,20231010.0,20181031,20231016,EXP,,SK-MYLANLABS-2018M1081194,MYLAN,Polko J.. Compensation of glycemia in patient with type II DM and cardiac primorbidity. Internal Medicine. 2018;52:10-11,66.0,YR,,M,Y,,,20231016,,MD,SK,SK,2023,Q4,Elderly
155722449,15572244,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,,,,,,10.0,MG,Unknown,,2023,Q4,Weight increased,,2023,Q4,9,F,20050801.0,20231010.0,20181031,20231016,EXP,,SK-MYLANLABS-2018M1081194,MYLAN,Polko J.. Compensation of glycemia in patient with type II DM and cardiac primorbidity. Internal Medicine. 2018;52:10-11,66.0,YR,,M,Y,,,20231016,,MD,SK,SK,2023,Q4,Elderly
155722449,15572244,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,,,,,,10.0,MG,Unknown,,2023,Q4,Glycosylated haemoglobin decreased,,2023,Q4,9,F,20050801.0,20231010.0,20181031,20231016,EXP,,SK-MYLANLABS-2018M1081194,MYLAN,Polko J.. Compensation of glycemia in patient with type II DM and cardiac primorbidity. Internal Medicine. 2018;52:10-11,66.0,YR,,M,Y,,,20231016,,MD,SK,SK,2023,Q4,Elderly
155722449,15572244,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,,,,,,10.0,MG,Unknown,,2023,Q4,Acute myocardial infarction,,2023,Q4,9,F,20050801.0,20231010.0,20181031,20231016,EXP,,SK-MYLANLABS-2018M1081194,MYLAN,Polko J.. Compensation of glycemia in patient with type II DM and cardiac primorbidity. Internal Medicine. 2018;52:10-11,66.0,YR,,M,Y,,,20231016,,MD,SK,SK,2023,Q4,Elderly
155722449,15572244,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,,,,,,10.0,MG,Unknown,,2023,Q4,Hypertension,,2023,Q4,9,F,20050801.0,20231010.0,20181031,20231016,EXP,,SK-MYLANLABS-2018M1081194,MYLAN,Polko J.. Compensation of glycemia in patient with type II DM and cardiac primorbidity. Internal Medicine. 2018;52:10-11,66.0,YR,,M,Y,,,20231016,,MD,SK,SK,2023,Q4,Elderly
177197086,17719708,112,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Nephrogenic anaemia,,2023,Q4,6,F,20111028.0,20231012.0,20200428,20231020,EXP,,US-AstraZeneca-2020SE53588,ASTRAZENECA,,25607.0,DY,,M,Y,74.8,KG,20231020,,CN,US,,2023,Q4,Elderly
177197086,17719708,112,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Tubulointerstitial nephritis,,2023,Q4,6,F,20111028.0,20231012.0,20200428,20231020,EXP,,US-AstraZeneca-2020SE53588,ASTRAZENECA,,25607.0,DY,,M,Y,74.8,KG,20231020,,CN,US,,2023,Q4,Elderly
177197086,17719708,112,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Chronic kidney disease-mineral and bone disorder,,2023,Q4,6,F,20111028.0,20231012.0,20200428,20231020,EXP,,US-AstraZeneca-2020SE53588,ASTRAZENECA,,25607.0,DY,,M,Y,74.8,KG,20231020,,CN,US,,2023,Q4,Elderly
177197086,17719708,112,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Chronic kidney disease,,2023,Q4,6,F,20111028.0,20231012.0,20200428,20231020,EXP,,US-AstraZeneca-2020SE53588,ASTRAZENECA,,25607.0,DY,,M,Y,74.8,KG,20231020,,CN,US,,2023,Q4,Elderly
177197086,17719708,112,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Renal failure,,2023,Q4,6,F,20111028.0,20231012.0,20200428,20231020,EXP,,US-AstraZeneca-2020SE53588,ASTRAZENECA,,25607.0,DY,,M,Y,74.8,KG,20231020,,CN,US,,2023,Q4,Elderly
177197086,17719708,112,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Gastrooesophageal reflux disease,,2023,Q4,6,F,20111028.0,20231012.0,20200428,20231020,EXP,,US-AstraZeneca-2020SE53588,ASTRAZENECA,,25607.0,DY,,M,Y,74.8,KG,20231020,,CN,US,,2023,Q4,Elderly
177197086,17719708,112,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Renal impairment,,2023,Q4,6,F,20111028.0,20231012.0,20200428,20231020,EXP,,US-AstraZeneca-2020SE53588,ASTRAZENECA,,25607.0,DY,,M,Y,74.8,KG,20231020,,CN,US,,2023,Q4,Elderly
177197086,17719708,112,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Acute kidney injury,,2023,Q4,6,F,20111028.0,20231012.0,20200428,20231020,EXP,,US-AstraZeneca-2020SE53588,ASTRAZENECA,,25607.0,DY,,M,Y,74.8,KG,20231020,,CN,US,,2023,Q4,Elderly
182842913,18284291,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,unknown,,,,,,,,,,,,2023,Q4,Sepsis,,2023,Q4,3,F,20180530.0,20231129.0,20200918,20231207,EXP,,CA-AstraZeneca-2020SF17007,ASTRAZENECA,,66.0,YR,,M,Y,,,20231207,,MD,CA,,2023,Q4,Elderly
182842913,18284291,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,unknown,,,,,,,,,,,,2023,Q4,Vomiting,,2023,Q4,3,F,20180530.0,20231129.0,20200918,20231207,EXP,,CA-AstraZeneca-2020SF17007,ASTRAZENECA,,66.0,YR,,M,Y,,,20231207,,MD,CA,,2023,Q4,Elderly
182842913,18284291,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,unknown,,,,,,,,,,,,2023,Q4,Chills,,2023,Q4,3,F,20180530.0,20231129.0,20200918,20231207,EXP,,CA-AstraZeneca-2020SF17007,ASTRAZENECA,,66.0,YR,,M,Y,,,20231207,,MD,CA,,2023,Q4,Elderly
183113563,18311356,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK (daily dose),,,,,,,,,,,,2023,Q4,Acute myocardial infarction,,2023,Q4,3,F,20050801.0,20231010.0,20200925,20231020,EXP,SK-SAKK-2018SA150955AA,SK-STRIDES ARCOLAB LIMITED-2019SP008025,STRIDES,Polko J.. Compensation of glycemia in patient with type II DM and cardiac primorbidity.. Internal Medicine.. 2018;52:10-11.,66.0,YR,,M,Y,,,20231020,,MD,SK,SK,2023,Q4,Elderly
183113563,18311356,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK (daily dose),,,,,,,,,,,,2023,Q4,Diabetes mellitus,,2023,Q4,3,F,20050801.0,20231010.0,20200925,20231020,EXP,SK-SAKK-2018SA150955AA,SK-STRIDES ARCOLAB LIMITED-2019SP008025,STRIDES,Polko J.. Compensation of glycemia in patient with type II DM and cardiac primorbidity.. Internal Medicine.. 2018;52:10-11.,66.0,YR,,M,Y,,,20231020,,MD,SK,SK,2023,Q4,Elderly
183113563,18311356,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK (daily dose),,,,,,,,,,,,2023,Q4,Hypertension,,2023,Q4,3,F,20050801.0,20231010.0,20200925,20231020,EXP,SK-SAKK-2018SA150955AA,SK-STRIDES ARCOLAB LIMITED-2019SP008025,STRIDES,Polko J.. Compensation of glycemia in patient with type II DM and cardiac primorbidity.. Internal Medicine.. 2018;52:10-11.,66.0,YR,,M,Y,,,20231020,,MD,SK,SK,2023,Q4,Elderly
183113563,18311356,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK (daily dose),,,,,,,,,,,,2023,Q4,Myocardial infarction,,2023,Q4,3,F,20050801.0,20231010.0,20200925,20231020,EXP,SK-SAKK-2018SA150955AA,SK-STRIDES ARCOLAB LIMITED-2019SP008025,STRIDES,Polko J.. Compensation of glycemia in patient with type II DM and cardiac primorbidity.. Internal Medicine.. 2018;52:10-11.,66.0,YR,,M,Y,,,20231020,,MD,SK,SK,2023,Q4,Elderly
183113563,18311356,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK (daily dose),,,,,,,,,,,,2023,Q4,Glycosylated haemoglobin decreased,,2023,Q4,3,F,20050801.0,20231010.0,20200925,20231020,EXP,SK-SAKK-2018SA150955AA,SK-STRIDES ARCOLAB LIMITED-2019SP008025,STRIDES,Polko J.. Compensation of glycemia in patient with type II DM and cardiac primorbidity.. Internal Medicine.. 2018;52:10-11.,66.0,YR,,M,Y,,,20231020,,MD,SK,SK,2023,Q4,Elderly
183113563,18311356,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK (daily dose),,,,,,,,,,,,2023,Q4,Hyperlipidaemia,,2023,Q4,3,F,20050801.0,20231010.0,20200925,20231020,EXP,SK-SAKK-2018SA150955AA,SK-STRIDES ARCOLAB LIMITED-2019SP008025,STRIDES,Polko J.. Compensation of glycemia in patient with type II DM and cardiac primorbidity.. Internal Medicine.. 2018;52:10-11.,66.0,YR,,M,Y,,,20231020,,MD,SK,SK,2023,Q4,Elderly
183113563,18311356,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK (daily dose),,,,,,,,,,,,2023,Q4,Weight increased,,2023,Q4,3,F,20050801.0,20231010.0,20200925,20231020,EXP,SK-SAKK-2018SA150955AA,SK-STRIDES ARCOLAB LIMITED-2019SP008025,STRIDES,Polko J.. Compensation of glycemia in patient with type II DM and cardiac primorbidity.. Internal Medicine.. 2018;52:10-11.,66.0,YR,,M,Y,,,20231020,,MD,SK,SK,2023,Q4,Elderly
183113563,18311356,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK (daily dose),,,,,,,,,,,,2023,Q4,Glycosylated haemoglobin increased,,2023,Q4,3,F,20050801.0,20231010.0,20200925,20231020,EXP,SK-SAKK-2018SA150955AA,SK-STRIDES ARCOLAB LIMITED-2019SP008025,STRIDES,Polko J.. Compensation of glycemia in patient with type II DM and cardiac primorbidity.. Internal Medicine.. 2018;52:10-11.,66.0,YR,,M,Y,,,20231020,,MD,SK,SK,2023,Q4,Elderly
183336843,18333684,60,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Tooth abscess,,2023,Q4,3,F,20161201.0,20231115.0,20201001,20231123,EXP,,US-AstraZeneca-2020SF25322,ASTRAZENECA,,469.0,MON,,M,Y,147.1,KG,20231123,,LW,US,,2023,Q4,Elderly
183336843,18333684,60,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Scar,,2023,Q4,3,F,20161201.0,20231115.0,20201001,20231123,EXP,,US-AstraZeneca-2020SF25322,ASTRAZENECA,,469.0,MON,,M,Y,147.1,KG,20231123,,LW,US,,2023,Q4,Elderly
183336843,18333684,60,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Anal incontinence,,2023,Q4,3,F,20161201.0,20231115.0,20201001,20231123,EXP,,US-AstraZeneca-2020SF25322,ASTRAZENECA,,469.0,MON,,M,Y,147.1,KG,20231123,,LW,US,,2023,Q4,Elderly
183336843,18333684,60,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Anal abscess,,2023,Q4,3,F,20161201.0,20231115.0,20201001,20231123,EXP,,US-AstraZeneca-2020SF25322,ASTRAZENECA,,469.0,MON,,M,Y,147.1,KG,20231123,,LW,US,,2023,Q4,Elderly
183336843,18333684,60,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Fournier's gangrene,,2023,Q4,3,F,20161201.0,20231115.0,20201001,20231123,EXP,,US-AstraZeneca-2020SF25322,ASTRAZENECA,,469.0,MON,,M,Y,147.1,KG,20231123,,LW,US,,2023,Q4,Elderly
183336843,18333684,60,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Scrotum erosion,,2023,Q4,3,F,20161201.0,20231115.0,20201001,20231123,EXP,,US-AstraZeneca-2020SF25322,ASTRAZENECA,,469.0,MON,,M,Y,147.1,KG,20231123,,LW,US,,2023,Q4,Elderly
183336843,18333684,60,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Cellulitis,,2023,Q4,3,F,20161201.0,20231115.0,20201001,20231123,EXP,,US-AstraZeneca-2020SF25322,ASTRAZENECA,,469.0,MON,,M,Y,147.1,KG,20231123,,LW,US,,2023,Q4,Elderly
183336843,18333684,60,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Sepsis,,2023,Q4,3,F,20161201.0,20231115.0,20201001,20231123,EXP,,US-AstraZeneca-2020SF25322,ASTRAZENECA,,469.0,MON,,M,Y,147.1,KG,20231123,,LW,US,,2023,Q4,Elderly
183336843,18333684,60,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Groin abscess,,2023,Q4,3,F,20161201.0,20231115.0,20201001,20231123,EXP,,US-AstraZeneca-2020SF25322,ASTRAZENECA,,469.0,MON,,M,Y,147.1,KG,20231123,,LW,US,,2023,Q4,Elderly
183336843,18333684,60,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Pain,,2023,Q4,3,F,20161201.0,20231115.0,20201001,20231123,EXP,,US-AstraZeneca-2020SF25322,ASTRAZENECA,,469.0,MON,,M,Y,147.1,KG,20231123,,LW,US,,2023,Q4,Elderly
183336843,18333684,60,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Necrotising fasciitis,,2023,Q4,3,F,20161201.0,20231115.0,20201001,20231123,EXP,,US-AstraZeneca-2020SF25322,ASTRAZENECA,,469.0,MON,,M,Y,147.1,KG,20231123,,LW,US,,2023,Q4,Elderly
183336843,18333684,60,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Genital abscess,,2023,Q4,3,F,20161201.0,20231115.0,20201001,20231123,EXP,,US-AstraZeneca-2020SF25322,ASTRAZENECA,,469.0,MON,,M,Y,147.1,KG,20231123,,LW,US,,2023,Q4,Elderly
183336843,18333684,60,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Nerve injury,,2023,Q4,3,F,20161201.0,20231115.0,20201001,20231123,EXP,,US-AstraZeneca-2020SF25322,ASTRAZENECA,,469.0,MON,,M,Y,147.1,KG,20231123,,LW,US,,2023,Q4,Elderly
1845526412,18455264,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Type 2 diabetes mellitus,,2023,Q4,12,F,20200423.0,20231213.0,20201102,20231218,EXP,,CO-TAKEDA-CO202019165,TAKEDA,,78.0,YR,,M,Y,69.0,KG,20231218,,CN,CO,CO,2023,Q4,Elderly
1845526412,18455264,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Weight increased,,2023,Q4,12,F,20200423.0,20231213.0,20201102,20231218,EXP,,CO-TAKEDA-CO202019165,TAKEDA,,78.0,YR,,M,Y,69.0,KG,20231218,,CN,CO,CO,2023,Q4,Elderly
1845526412,18455264,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Hyperthyroidism,,2023,Q4,12,F,20200423.0,20231213.0,20201102,20231218,EXP,,CO-TAKEDA-CO202019165,TAKEDA,,78.0,YR,,M,Y,69.0,KG,20231218,,CN,CO,CO,2023,Q4,Elderly
1845526412,18455264,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Expired product administered,,2023,Q4,12,F,20200423.0,20231213.0,20201102,20231218,EXP,,CO-TAKEDA-CO202019165,TAKEDA,,78.0,YR,,M,Y,69.0,KG,20231218,,CN,CO,CO,2023,Q4,Elderly
1845526412,18455264,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Hypothyroidism,,2023,Q4,12,F,20200423.0,20231213.0,20201102,20231218,EXP,,CO-TAKEDA-CO202019165,TAKEDA,,78.0,YR,,M,Y,69.0,KG,20231218,,CN,CO,CO,2023,Q4,Elderly
1845526412,18455264,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Weight decreased,,2023,Q4,12,F,20200423.0,20231213.0,20201102,20231218,EXP,,CO-TAKEDA-CO202019165,TAKEDA,,78.0,YR,,M,Y,69.0,KG,20231218,,CN,CO,CO,2023,Q4,Elderly
1845526412,18455264,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Body height increased,,2023,Q4,12,F,20200423.0,20231213.0,20201102,20231218,EXP,,CO-TAKEDA-CO202019165,TAKEDA,,78.0,YR,,M,Y,69.0,KG,20231218,,CN,CO,CO,2023,Q4,Elderly
1845526412,18455264,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Chronic obstructive pulmonary disease,,2023,Q4,12,F,20200423.0,20231213.0,20201102,20231218,EXP,,CO-TAKEDA-CO202019165,TAKEDA,,78.0,YR,,M,Y,69.0,KG,20231218,,CN,CO,CO,2023,Q4,Elderly
184614682,18461468,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,,,,,2023,Q4,Urinary tract candidiasis,,2023,Q4,2,F,,20230927.0,20201104,20231009,EXP,ES-EMA-DD-20201029-PAWAR_P-112841,ES-Accord-207265,ACCORD,,56.0,YR,A,F,Y,,,20231009,,MD,ES,ES,2023,Q4,Adult
184614682,18461468,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,,,,,2023,Q4,Drug ineffective,,2023,Q4,2,F,,20230927.0,20201104,20231009,EXP,ES-EMA-DD-20201029-PAWAR_P-112841,ES-Accord-207265,ACCORD,,56.0,YR,A,F,Y,,,20231009,,MD,ES,ES,2023,Q4,Adult
184614682,18461468,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,,,,,2023,Q4,Hypotension,,2023,Q4,2,F,,20230927.0,20201104,20231009,EXP,ES-EMA-DD-20201029-PAWAR_P-112841,ES-Accord-207265,ACCORD,,56.0,YR,A,F,Y,,,20231009,,MD,ES,ES,2023,Q4,Adult
184614682,18461468,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,,,,,2023,Q4,Perinephric abscess,,2023,Q4,2,F,,20230927.0,20201104,20231009,EXP,ES-EMA-DD-20201029-PAWAR_P-112841,ES-Accord-207265,ACCORD,,56.0,YR,A,F,Y,,,20231009,,MD,ES,ES,2023,Q4,Adult
184614682,18461468,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,,,,,2023,Q4,Oliguria,,2023,Q4,2,F,,20230927.0,20201104,20231009,EXP,ES-EMA-DD-20201029-PAWAR_P-112841,ES-Accord-207265,ACCORD,,56.0,YR,A,F,Y,,,20231009,,MD,ES,ES,2023,Q4,Adult
184614682,18461468,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,,,,,2023,Q4,Candida infection,,2023,Q4,2,F,,20230927.0,20201104,20231009,EXP,ES-EMA-DD-20201029-PAWAR_P-112841,ES-Accord-207265,ACCORD,,56.0,YR,A,F,Y,,,20231009,,MD,ES,ES,2023,Q4,Adult
184614682,18461468,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,,,,,2023,Q4,Pyelonephritis fungal,,2023,Q4,2,F,,20230927.0,20201104,20231009,EXP,ES-EMA-DD-20201029-PAWAR_P-112841,ES-Accord-207265,ACCORD,,56.0,YR,A,F,Y,,,20231009,,MD,ES,ES,2023,Q4,Adult
184614682,18461468,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,,,,,2023,Q4,Systemic candida,,2023,Q4,2,F,,20230927.0,20201104,20231009,EXP,ES-EMA-DD-20201029-PAWAR_P-112841,ES-Accord-207265,ACCORD,,56.0,YR,A,F,Y,,,20231009,,MD,ES,ES,2023,Q4,Adult
184614682,18461468,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,,,,,2023,Q4,Renal impairment,,2023,Q4,2,F,,20230927.0,20201104,20231009,EXP,ES-EMA-DD-20201029-PAWAR_P-112841,ES-Accord-207265,ACCORD,,56.0,YR,A,F,Y,,,20231009,,MD,ES,ES,2023,Q4,Adult
184614682,18461468,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,,,,,2023,Q4,Emphysematous pyelonephritis,,2023,Q4,2,F,,20230927.0,20201104,20231009,EXP,ES-EMA-DD-20201029-PAWAR_P-112841,ES-Accord-207265,ACCORD,,56.0,YR,A,F,Y,,,20231009,,MD,ES,ES,2023,Q4,Adult
184614682,18461468,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,,,,,2023,Q4,Candida sepsis,,2023,Q4,2,F,,20230927.0,20201104,20231009,EXP,ES-EMA-DD-20201029-PAWAR_P-112841,ES-Accord-207265,ACCORD,,56.0,YR,A,F,Y,,,20231009,,MD,ES,ES,2023,Q4,Adult
184614682,18461468,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,,,,,2023,Q4,Coagulopathy,,2023,Q4,2,F,,20230927.0,20201104,20231009,EXP,ES-EMA-DD-20201029-PAWAR_P-112841,ES-Accord-207265,ACCORD,,56.0,YR,A,F,Y,,,20231009,,MD,ES,ES,2023,Q4,Adult
184614682,18461468,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,,,,,2023,Q4,Urinary tract infection enterococcal,,2023,Q4,2,F,,20230927.0,20201104,20231009,EXP,ES-EMA-DD-20201029-PAWAR_P-112841,ES-Accord-207265,ACCORD,,56.0,YR,A,F,Y,,,20231009,,MD,ES,ES,2023,Q4,Adult
184614682,18461468,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,,,,,2023,Q4,Vesicoureteric reflux,,2023,Q4,2,F,,20230927.0,20201104,20231009,EXP,ES-EMA-DD-20201029-PAWAR_P-112841,ES-Accord-207265,ACCORD,,56.0,YR,A,F,Y,,,20231009,,MD,ES,ES,2023,Q4,Adult
184614682,18461468,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,,,,,2023,Q4,Coagulation test abnormal,,2023,Q4,2,F,,20230927.0,20201104,20231009,EXP,ES-EMA-DD-20201029-PAWAR_P-112841,ES-Accord-207265,ACCORD,,56.0,YR,A,F,Y,,,20231009,,MD,ES,ES,2023,Q4,Adult
184614682,18461468,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,,,,,2023,Q4,Septic shock,,2023,Q4,2,F,,20230927.0,20201104,20231009,EXP,ES-EMA-DD-20201029-PAWAR_P-112841,ES-Accord-207265,ACCORD,,56.0,YR,A,F,Y,,,20231009,,MD,ES,ES,2023,Q4,Adult
1915538710,19155387,63,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2023,Q4,Adrenal insufficiency,,2023,Q4,10,F,20201101.0,20231103.0,20210419,20231108,EXP,,CA-BAUSCH-BL-2021-012331,BAUSCH AND LOMB,,75.0,YR,,M,Y,,,20231108,,MD,CA,CA,2023,Q4,Elderly
1915538710,19155387,63,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2023,Q4,Hyperthyroidism,,2023,Q4,10,F,20201101.0,20231103.0,20210419,20231108,EXP,,CA-BAUSCH-BL-2021-012331,BAUSCH AND LOMB,,75.0,YR,,M,Y,,,20231108,,MD,CA,CA,2023,Q4,Elderly
1915538710,19155387,63,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2023,Q4,Hypotension,,2023,Q4,10,F,20201101.0,20231103.0,20210419,20231108,EXP,,CA-BAUSCH-BL-2021-012331,BAUSCH AND LOMB,,75.0,YR,,M,Y,,,20231108,,MD,CA,CA,2023,Q4,Elderly
1915538710,19155387,63,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2023,Q4,Hypotension,,2023,Q4,10,F,20201101.0,20231103.0,20210419,20231108,EXP,,CA-BAUSCH-BL-2021-012331,BAUSCH AND LOMB,,75.0,YR,,M,Y,,,20231108,,MD,CA,CA,2023,Q4,Elderly
1915538710,19155387,63,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2023,Q4,Troponin increased,,2023,Q4,10,F,20201101.0,20231103.0,20210419,20231108,EXP,,CA-BAUSCH-BL-2021-012331,BAUSCH AND LOMB,,75.0,YR,,M,Y,,,20231108,,MD,CA,CA,2023,Q4,Elderly
201793169,20179316,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q4,Drug ineffective,,2023,Q4,9,F,,20231120.0,20211214,20231127,EXP,,CA-BAUSCH-BL-2021-040795,BAUSCH AND LOMB,,67.0,YR,,F,Y,,,20231127,,PH,CA,CA,2023,Q4,Elderly
201793169,20179316,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q4,Neuropathy peripheral,,2023,Q4,9,F,,20231120.0,20211214,20231127,EXP,,CA-BAUSCH-BL-2021-040795,BAUSCH AND LOMB,,67.0,YR,,F,Y,,,20231127,,PH,CA,CA,2023,Q4,Elderly
201793169,20179316,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q4,COVID-19,,2023,Q4,9,F,,20231120.0,20211214,20231127,EXP,,CA-BAUSCH-BL-2021-040795,BAUSCH AND LOMB,,67.0,YR,,F,Y,,,20231127,,PH,CA,CA,2023,Q4,Elderly
201793169,20179316,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q4,Transient ischaemic attack,,2023,Q4,9,F,,20231120.0,20211214,20231127,EXP,,CA-BAUSCH-BL-2021-040795,BAUSCH AND LOMB,,67.0,YR,,F,Y,,,20231127,,PH,CA,CA,2023,Q4,Elderly
201793169,20179316,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q4,Neoplasm skin,,2023,Q4,9,F,,20231120.0,20211214,20231127,EXP,,CA-BAUSCH-BL-2021-040795,BAUSCH AND LOMB,,67.0,YR,,F,Y,,,20231127,,PH,CA,CA,2023,Q4,Elderly
201793169,20179316,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q4,Constipation,,2023,Q4,9,F,,20231120.0,20211214,20231127,EXP,,CA-BAUSCH-BL-2021-040795,BAUSCH AND LOMB,,67.0,YR,,F,Y,,,20231127,,PH,CA,CA,2023,Q4,Elderly
201793169,20179316,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q4,Off label use,,2023,Q4,9,F,,20231120.0,20211214,20231127,EXP,,CA-BAUSCH-BL-2021-040795,BAUSCH AND LOMB,,67.0,YR,,F,Y,,,20231127,,PH,CA,CA,2023,Q4,Elderly
201793169,20179316,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q4,Abdominal pain upper,,2023,Q4,9,F,,20231120.0,20211214,20231127,EXP,,CA-BAUSCH-BL-2021-040795,BAUSCH AND LOMB,,67.0,YR,,F,Y,,,20231127,,PH,CA,CA,2023,Q4,Elderly
201793169,20179316,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q4,Blood pressure increased,,2023,Q4,9,F,,20231120.0,20211214,20231127,EXP,,CA-BAUSCH-BL-2021-040795,BAUSCH AND LOMB,,67.0,YR,,F,Y,,,20231127,,PH,CA,CA,2023,Q4,Elderly
201793169,20179316,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q4,COVID-19 immunisation,,2023,Q4,9,F,,20231120.0,20211214,20231127,EXP,,CA-BAUSCH-BL-2021-040795,BAUSCH AND LOMB,,67.0,YR,,F,Y,,,20231127,,PH,CA,CA,2023,Q4,Elderly
201793169,20179316,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q4,Product use issue,,2023,Q4,9,F,,20231120.0,20211214,20231127,EXP,,CA-BAUSCH-BL-2021-040795,BAUSCH AND LOMB,,67.0,YR,,F,Y,,,20231127,,PH,CA,CA,2023,Q4,Elderly
201793169,20179316,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q4,Cardiac failure,,2023,Q4,9,F,,20231120.0,20211214,20231127,EXP,,CA-BAUSCH-BL-2021-040795,BAUSCH AND LOMB,,67.0,YR,,F,Y,,,20231127,,PH,CA,CA,2023,Q4,Elderly
201793169,20179316,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q4,Haemorrhoids,,2023,Q4,9,F,,20231120.0,20211214,20231127,EXP,,CA-BAUSCH-BL-2021-040795,BAUSCH AND LOMB,,67.0,YR,,F,Y,,,20231127,,PH,CA,CA,2023,Q4,Elderly
201793169,20179316,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q4,Chest discomfort,,2023,Q4,9,F,,20231120.0,20211214,20231127,EXP,,CA-BAUSCH-BL-2021-040795,BAUSCH AND LOMB,,67.0,YR,,F,Y,,,20231127,,PH,CA,CA,2023,Q4,Elderly
201793169,20179316,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q4,Pain in extremity,,2023,Q4,9,F,,20231120.0,20211214,20231127,EXP,,CA-BAUSCH-BL-2021-040795,BAUSCH AND LOMB,,67.0,YR,,F,Y,,,20231127,,PH,CA,CA,2023,Q4,Elderly
201793169,20179316,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q4,Fall,,2023,Q4,9,F,,20231120.0,20211214,20231127,EXP,,CA-BAUSCH-BL-2021-040795,BAUSCH AND LOMB,,67.0,YR,,F,Y,,,20231127,,PH,CA,CA,2023,Q4,Elderly
201793169,20179316,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q4,Haemorrhoidal haemorrhage,,2023,Q4,9,F,,20231120.0,20211214,20231127,EXP,,CA-BAUSCH-BL-2021-040795,BAUSCH AND LOMB,,67.0,YR,,F,Y,,,20231127,,PH,CA,CA,2023,Q4,Elderly
201793169,20179316,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q4,Chest pain,,2023,Q4,9,F,,20231120.0,20211214,20231127,EXP,,CA-BAUSCH-BL-2021-040795,BAUSCH AND LOMB,,67.0,YR,,F,Y,,,20231127,,PH,CA,CA,2023,Q4,Elderly
201793169,20179316,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q4,Cataract,,2023,Q4,9,F,,20231120.0,20211214,20231127,EXP,,CA-BAUSCH-BL-2021-040795,BAUSCH AND LOMB,,67.0,YR,,F,Y,,,20231127,,PH,CA,CA,2023,Q4,Elderly
201793169,20179316,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q4,Cardiomegaly,,2023,Q4,9,F,,20231120.0,20211214,20231127,EXP,,CA-BAUSCH-BL-2021-040795,BAUSCH AND LOMB,,67.0,YR,,F,Y,,,20231127,,PH,CA,CA,2023,Q4,Elderly
201793169,20179316,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q4,Pneumonia,,2023,Q4,9,F,,20231120.0,20211214,20231127,EXP,,CA-BAUSCH-BL-2021-040795,BAUSCH AND LOMB,,67.0,YR,,F,Y,,,20231127,,PH,CA,CA,2023,Q4,Elderly
201793169,20179316,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q4,Hypoaesthesia,,2023,Q4,9,F,,20231120.0,20211214,20231127,EXP,,CA-BAUSCH-BL-2021-040795,BAUSCH AND LOMB,,67.0,YR,,F,Y,,,20231127,,PH,CA,CA,2023,Q4,Elderly
201793169,20179316,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q4,Vulvovaginal mycotic infection,,2023,Q4,9,F,,20231120.0,20211214,20231127,EXP,,CA-BAUSCH-BL-2021-040795,BAUSCH AND LOMB,,67.0,YR,,F,Y,,,20231127,,PH,CA,CA,2023,Q4,Elderly
201793169,20179316,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q4,Clostridium difficile colitis,,2023,Q4,9,F,,20231120.0,20211214,20231127,EXP,,CA-BAUSCH-BL-2021-040795,BAUSCH AND LOMB,,67.0,YR,,F,Y,,,20231127,,PH,CA,CA,2023,Q4,Elderly
201793169,20179316,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2023,Q4,Dyspnoea,,2023,Q4,9,F,,20231120.0,20211214,20231127,EXP,,CA-BAUSCH-BL-2021-040795,BAUSCH AND LOMB,,67.0,YR,,F,Y,,,20231127,,PH,CA,CA,2023,Q4,Elderly
202263084,20226308,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,D,,,,,10.0,MG,,,2023,Q4,Hypoaesthesia,,2023,Q4,4,F,,20231129.0,20211224,20231208,EXP,,CA-APOTEX-2021AP046753,APOTEX,,67.0,YR,,F,Y,,,20231208,,PH,CA,CA,2023,Q4,Elderly
202263084,20226308,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,D,,,,,10.0,MG,,,2023,Q4,Neoplasm skin,,2023,Q4,4,F,,20231129.0,20211224,20231208,EXP,,CA-APOTEX-2021AP046753,APOTEX,,67.0,YR,,F,Y,,,20231208,,PH,CA,CA,2023,Q4,Elderly
202263084,20226308,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,D,,,,,10.0,MG,,,2023,Q4,Drug ineffective,,2023,Q4,4,F,,20231129.0,20211224,20231208,EXP,,CA-APOTEX-2021AP046753,APOTEX,,67.0,YR,,F,Y,,,20231208,,PH,CA,CA,2023,Q4,Elderly
202263084,20226308,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,D,,,,,10.0,MG,,,2023,Q4,Haemorrhoids,,2023,Q4,4,F,,20231129.0,20211224,20231208,EXP,,CA-APOTEX-2021AP046753,APOTEX,,67.0,YR,,F,Y,,,20231208,,PH,CA,CA,2023,Q4,Elderly
202263084,20226308,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,D,,,,,10.0,MG,,,2023,Q4,Fall,,2023,Q4,4,F,,20231129.0,20211224,20231208,EXP,,CA-APOTEX-2021AP046753,APOTEX,,67.0,YR,,F,Y,,,20231208,,PH,CA,CA,2023,Q4,Elderly
202263084,20226308,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,D,,,,,10.0,MG,,,2023,Q4,Pain in extremity,,2023,Q4,4,F,,20231129.0,20211224,20231208,EXP,,CA-APOTEX-2021AP046753,APOTEX,,67.0,YR,,F,Y,,,20231208,,PH,CA,CA,2023,Q4,Elderly
202263084,20226308,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,D,,,,,10.0,MG,,,2023,Q4,Off label use,,2023,Q4,4,F,,20231129.0,20211224,20231208,EXP,,CA-APOTEX-2021AP046753,APOTEX,,67.0,YR,,F,Y,,,20231208,,PH,CA,CA,2023,Q4,Elderly
202263084,20226308,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,D,,,,,10.0,MG,,,2023,Q4,Dyspnoea,,2023,Q4,4,F,,20231129.0,20211224,20231208,EXP,,CA-APOTEX-2021AP046753,APOTEX,,67.0,YR,,F,Y,,,20231208,,PH,CA,CA,2023,Q4,Elderly
202263084,20226308,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,D,,,,,10.0,MG,,,2023,Q4,Chest pain,,2023,Q4,4,F,,20231129.0,20211224,20231208,EXP,,CA-APOTEX-2021AP046753,APOTEX,,67.0,YR,,F,Y,,,20231208,,PH,CA,CA,2023,Q4,Elderly
202263084,20226308,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,D,,,,,10.0,MG,,,2023,Q4,Cardiomegaly,,2023,Q4,4,F,,20231129.0,20211224,20231208,EXP,,CA-APOTEX-2021AP046753,APOTEX,,67.0,YR,,F,Y,,,20231208,,PH,CA,CA,2023,Q4,Elderly
202263084,20226308,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,D,,,,,10.0,MG,,,2023,Q4,Cataract,,2023,Q4,4,F,,20231129.0,20211224,20231208,EXP,,CA-APOTEX-2021AP046753,APOTEX,,67.0,YR,,F,Y,,,20231208,,PH,CA,CA,2023,Q4,Elderly
202263084,20226308,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,D,,,,,10.0,MG,,,2023,Q4,Chest discomfort,,2023,Q4,4,F,,20231129.0,20211224,20231208,EXP,,CA-APOTEX-2021AP046753,APOTEX,,67.0,YR,,F,Y,,,20231208,,PH,CA,CA,2023,Q4,Elderly
202263084,20226308,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,D,,,,,10.0,MG,,,2023,Q4,COVID-19,,2023,Q4,4,F,,20231129.0,20211224,20231208,EXP,,CA-APOTEX-2021AP046753,APOTEX,,67.0,YR,,F,Y,,,20231208,,PH,CA,CA,2023,Q4,Elderly
202263084,20226308,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,D,,,,,10.0,MG,,,2023,Q4,Neuropathy peripheral,,2023,Q4,4,F,,20231129.0,20211224,20231208,EXP,,CA-APOTEX-2021AP046753,APOTEX,,67.0,YR,,F,Y,,,20231208,,PH,CA,CA,2023,Q4,Elderly
202263084,20226308,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,D,,,,,10.0,MG,,,2023,Q4,Blood pressure increased,,2023,Q4,4,F,,20231129.0,20211224,20231208,EXP,,CA-APOTEX-2021AP046753,APOTEX,,67.0,YR,,F,Y,,,20231208,,PH,CA,CA,2023,Q4,Elderly
202263084,20226308,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,D,,,,,10.0,MG,,,2023,Q4,Constipation,,2023,Q4,4,F,,20231129.0,20211224,20231208,EXP,,CA-APOTEX-2021AP046753,APOTEX,,67.0,YR,,F,Y,,,20231208,,PH,CA,CA,2023,Q4,Elderly
202263084,20226308,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,D,,,,,10.0,MG,,,2023,Q4,Vulvovaginal mycotic infection,,2023,Q4,4,F,,20231129.0,20211224,20231208,EXP,,CA-APOTEX-2021AP046753,APOTEX,,67.0,YR,,F,Y,,,20231208,,PH,CA,CA,2023,Q4,Elderly
202263084,20226308,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,D,,,,,10.0,MG,,,2023,Q4,Cardiac failure,,2023,Q4,4,F,,20231129.0,20211224,20231208,EXP,,CA-APOTEX-2021AP046753,APOTEX,,67.0,YR,,F,Y,,,20231208,,PH,CA,CA,2023,Q4,Elderly
202263084,20226308,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,D,,,,,10.0,MG,,,2023,Q4,Clostridium difficile colitis,,2023,Q4,4,F,,20231129.0,20211224,20231208,EXP,,CA-APOTEX-2021AP046753,APOTEX,,67.0,YR,,F,Y,,,20231208,,PH,CA,CA,2023,Q4,Elderly
202263084,20226308,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,D,,,,,10.0,MG,,,2023,Q4,Pneumonia,,2023,Q4,4,F,,20231129.0,20211224,20231208,EXP,,CA-APOTEX-2021AP046753,APOTEX,,67.0,YR,,F,Y,,,20231208,,PH,CA,CA,2023,Q4,Elderly
202263084,20226308,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,D,,,,,10.0,MG,,,2023,Q4,Haemorrhoidal haemorrhage,,2023,Q4,4,F,,20231129.0,20211224,20231208,EXP,,CA-APOTEX-2021AP046753,APOTEX,,67.0,YR,,F,Y,,,20231208,,PH,CA,CA,2023,Q4,Elderly
202263084,20226308,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,D,,,,,10.0,MG,,,2023,Q4,Product use issue,,2023,Q4,4,F,,20231129.0,20211224,20231208,EXP,,CA-APOTEX-2021AP046753,APOTEX,,67.0,YR,,F,Y,,,20231208,,PH,CA,CA,2023,Q4,Elderly
202263084,20226308,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,D,,,,,10.0,MG,,,2023,Q4,Transient ischaemic attack,,2023,Q4,4,F,,20231129.0,20211224,20231208,EXP,,CA-APOTEX-2021AP046753,APOTEX,,67.0,YR,,F,Y,,,20231208,,PH,CA,CA,2023,Q4,Elderly
202263084,20226308,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,D,,,,,10.0,MG,,,2023,Q4,Abdominal pain upper,,2023,Q4,4,F,,20231129.0,20211224,20231208,EXP,,CA-APOTEX-2021AP046753,APOTEX,,67.0,YR,,F,Y,,,20231208,,PH,CA,CA,2023,Q4,Elderly
205814294,20581429,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2023,Q4,Drug ineffective,,2023,Q4,4,F,,20231214.0,20220311,20231222,EXP,,CA-APOTEX-2022AP004206,APOTEX,,40.0,YR,,F,Y,,,20231222,,HP,CA,CA,2023,Q4,Adult
205814294,20581429,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2023,Q4,Weight decreased,,2023,Q4,4,F,,20231214.0,20220311,20231222,EXP,,CA-APOTEX-2022AP004206,APOTEX,,40.0,YR,,F,Y,,,20231222,,HP,CA,CA,2023,Q4,Adult
205814294,20581429,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2023,Q4,C-reactive protein increased,,2023,Q4,4,F,,20231214.0,20220311,20231222,EXP,,CA-APOTEX-2022AP004206,APOTEX,,40.0,YR,,F,Y,,,20231222,,HP,CA,CA,2023,Q4,Adult
205814294,20581429,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2023,Q4,Hepatotoxicity,,2023,Q4,4,F,,20231214.0,20220311,20231222,EXP,,CA-APOTEX-2022AP004206,APOTEX,,40.0,YR,,F,Y,,,20231222,,HP,CA,CA,2023,Q4,Adult
205814294,20581429,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2023,Q4,Off label use,,2023,Q4,4,F,,20231214.0,20220311,20231222,EXP,,CA-APOTEX-2022AP004206,APOTEX,,40.0,YR,,F,Y,,,20231222,,HP,CA,CA,2023,Q4,Adult
205814294,20581429,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2023,Q4,Condition aggravated,,2023,Q4,4,F,,20231214.0,20220311,20231222,EXP,,CA-APOTEX-2022AP004206,APOTEX,,40.0,YR,,F,Y,,,20231222,,HP,CA,CA,2023,Q4,Adult
205814294,20581429,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2023,Q4,Psoriasis,,2023,Q4,4,F,,20231214.0,20220311,20231222,EXP,,CA-APOTEX-2022AP004206,APOTEX,,40.0,YR,,F,Y,,,20231222,,HP,CA,CA,2023,Q4,Adult
205876064,20587606,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q4,C-reactive protein increased,,2023,Q4,4,F,20200309.0,20231123.0,20220314,20231204,EXP,,CA-SA-2022SA081665,SANOFI AVENTIS,,40.0,YR,A,F,Y,,,20231204,,MD,CA,CA,2023,Q4,Adult
205876064,20587606,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q4,Weight decreased,,2023,Q4,4,F,20200309.0,20231123.0,20220314,20231204,EXP,,CA-SA-2022SA081665,SANOFI AVENTIS,,40.0,YR,A,F,Y,,,20231204,,MD,CA,CA,2023,Q4,Adult
205876064,20587606,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q4,Drug ineffective,,2023,Q4,4,F,20200309.0,20231123.0,20220314,20231204,EXP,,CA-SA-2022SA081665,SANOFI AVENTIS,,40.0,YR,A,F,Y,,,20231204,,MD,CA,CA,2023,Q4,Adult
205876064,20587606,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q4,Pustular psoriasis,,2023,Q4,4,F,20200309.0,20231123.0,20220314,20231204,EXP,,CA-SA-2022SA081665,SANOFI AVENTIS,,40.0,YR,A,F,Y,,,20231204,,MD,CA,CA,2023,Q4,Adult
205876064,20587606,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q4,Condition aggravated,,2023,Q4,4,F,20200309.0,20231123.0,20220314,20231204,EXP,,CA-SA-2022SA081665,SANOFI AVENTIS,,40.0,YR,A,F,Y,,,20231204,,MD,CA,CA,2023,Q4,Adult
205876064,20587606,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q4,Psoriasis,,2023,Q4,4,F,20200309.0,20231123.0,20220314,20231204,EXP,,CA-SA-2022SA081665,SANOFI AVENTIS,,40.0,YR,A,F,Y,,,20231204,,MD,CA,CA,2023,Q4,Adult
205876064,20587606,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q4,Hepatotoxicity,,2023,Q4,4,F,20200309.0,20231123.0,20220314,20231204,EXP,,CA-SA-2022SA081665,SANOFI AVENTIS,,40.0,YR,A,F,Y,,,20231204,,MD,CA,CA,2023,Q4,Adult
205876064,20587606,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q4,Off label use,,2023,Q4,4,F,20200309.0,20231123.0,20220314,20231204,EXP,,CA-SA-2022SA081665,SANOFI AVENTIS,,40.0,YR,A,F,Y,,,20231204,,MD,CA,CA,2023,Q4,Adult
206675455,20667545,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2023,Q4,C-reactive protein increased,,2023,Q4,5,F,,20231213.0,20220404,20231215,EXP,,CA-BAUSCH-BL-2022-008136,BAUSCH AND LOMB,,40.0,YR,,F,Y,,,20231215,,CN,CA,CA,2023,Q4,Adult
206675455,20667545,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2023,Q4,Drug ineffective,,2023,Q4,5,F,,20231213.0,20220404,20231215,EXP,,CA-BAUSCH-BL-2022-008136,BAUSCH AND LOMB,,40.0,YR,,F,Y,,,20231215,,CN,CA,CA,2023,Q4,Adult
206675455,20667545,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2023,Q4,Psoriasis,,2023,Q4,5,F,,20231213.0,20220404,20231215,EXP,,CA-BAUSCH-BL-2022-008136,BAUSCH AND LOMB,,40.0,YR,,F,Y,,,20231215,,CN,CA,CA,2023,Q4,Adult
206675455,20667545,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2023,Q4,Weight decreased,,2023,Q4,5,F,,20231213.0,20220404,20231215,EXP,,CA-BAUSCH-BL-2022-008136,BAUSCH AND LOMB,,40.0,YR,,F,Y,,,20231215,,CN,CA,CA,2023,Q4,Adult
206675455,20667545,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2023,Q4,Hepatotoxicity,,2023,Q4,5,F,,20231213.0,20220404,20231215,EXP,,CA-BAUSCH-BL-2022-008136,BAUSCH AND LOMB,,40.0,YR,,F,Y,,,20231215,,CN,CA,CA,2023,Q4,Adult
206675455,20667545,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2023,Q4,Off label use,,2023,Q4,5,F,,20231213.0,20220404,20231215,EXP,,CA-BAUSCH-BL-2022-008136,BAUSCH AND LOMB,,40.0,YR,,F,Y,,,20231215,,CN,CA,CA,2023,Q4,Adult
206675455,20667545,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2023,Q4,Condition aggravated,,2023,Q4,5,F,,20231213.0,20220404,20231215,EXP,,CA-BAUSCH-BL-2022-008136,BAUSCH AND LOMB,,40.0,YR,,F,Y,,,20231215,,CN,CA,CA,2023,Q4,Adult
206958405,20695840,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,Unknown,,102145.0,,,Tablet,,2023,Q4,Pancreatitis,,2023,Q4,5,F,20220406.0,20231010.0,20220411,20231016,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-164476",BOEHRINGER INGELHEIM,,89.0,YR,E,F,Y,68.0,KG,20231016,,MD,DE,DE,2023,Q4,Elderly
2075229026,20752290,136,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q4,Cellulitis,,2023,Q4,26,F,20220205.0,20231127.0,20220426,20231129,EXP,,CN-ROCHE-3072722,ROCHE,,75.0,YR,,M,Y,63.8,KG,20231129,,MD,CN,,2023,Q4,Elderly
2077195215,20771952,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2023,Q4,Vitreous haemorrhage,,2023,Q4,15,F,20220418.0,20231106.0,20220501,20231108,EXP,,NVSC2022CN095120,NOVARTIS,,22.0,YR,,F,Y,,,20231108,,MD,CN,CN,2023,Q4,Youth
208987962,20898796,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,204629.0,,,,,2023,Q4,Ankle fracture,,2023,Q4,2,F,,20231109.0,20220601,20231113,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-172804",BOEHRINGER INGELHEIM,"Hester JC, Nimmo T, Liu J, Sukpraprut-Braaten S, Pasquel F, Zimmerman S, et al. Euglycemic Diabetic Ketoacidosis Secondary to SGLT2- inhibitor Use in Combination with a Ketogenic Diet: A Case Report. Endocrine Practice. 2021;27: 25-25.",72.0,YR,E,F,Y,,,20231113,,MD,US,US,2023,Q4,Elderly
208987962,20898796,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,204629.0,,,,,2023,Q4,Lower limb fracture,,2023,Q4,2,F,,20231109.0,20220601,20231113,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-172804",BOEHRINGER INGELHEIM,"Hester JC, Nimmo T, Liu J, Sukpraprut-Braaten S, Pasquel F, Zimmerman S, et al. Euglycemic Diabetic Ketoacidosis Secondary to SGLT2- inhibitor Use in Combination with a Ketogenic Diet: A Case Report. Endocrine Practice. 2021;27: 25-25.",72.0,YR,E,F,Y,,,20231113,,MD,US,US,2023,Q4,Elderly
208987962,20898796,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,204629.0,,,,,2023,Q4,Euglycaemic diabetic ketoacidosis,,2023,Q4,2,F,,20231109.0,20220601,20231113,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-172804",BOEHRINGER INGELHEIM,"Hester JC, Nimmo T, Liu J, Sukpraprut-Braaten S, Pasquel F, Zimmerman S, et al. Euglycemic Diabetic Ketoacidosis Secondary to SGLT2- inhibitor Use in Combination with a Ketogenic Diet: A Case Report. Endocrine Practice. 2021;27: 25-25.",72.0,YR,E,F,Y,,,20231113,,MD,US,US,2023,Q4,Elderly
208987962,20898796,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,204629.0,,,,,2023,Q4,Nocturia,,2023,Q4,2,F,,20231109.0,20220601,20231113,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-172804",BOEHRINGER INGELHEIM,"Hester JC, Nimmo T, Liu J, Sukpraprut-Braaten S, Pasquel F, Zimmerman S, et al. Euglycemic Diabetic Ketoacidosis Secondary to SGLT2- inhibitor Use in Combination with a Ketogenic Diet: A Case Report. Endocrine Practice. 2021;27: 25-25.",72.0,YR,E,F,Y,,,20231113,,MD,US,US,2023,Q4,Elderly
208987962,20898796,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,204629.0,,,,,2023,Q4,Fall,,2023,Q4,2,F,,20231109.0,20220601,20231113,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-172804",BOEHRINGER INGELHEIM,"Hester JC, Nimmo T, Liu J, Sukpraprut-Braaten S, Pasquel F, Zimmerman S, et al. Euglycemic Diabetic Ketoacidosis Secondary to SGLT2- inhibitor Use in Combination with a Ketogenic Diet: A Case Report. Endocrine Practice. 2021;27: 25-25.",72.0,YR,E,F,Y,,,20231113,,MD,US,US,2023,Q4,Elderly
210670884,21067088,31,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q4,Fall,,2023,Q4,4,F,,20230927.0,20220712,20231007,EXP,,CA-AUROBINDO-AUR-APL-2022-025049,AUROBINDO,,67.0,YR,,F,Y,,,20231007,,HP,CA,CA,2023,Q4,Elderly
210670884,21067088,31,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q4,Neuropathy peripheral,,2023,Q4,4,F,,20230927.0,20220712,20231007,EXP,,CA-AUROBINDO-AUR-APL-2022-025049,AUROBINDO,,67.0,YR,,F,Y,,,20231007,,HP,CA,CA,2023,Q4,Elderly
210670884,21067088,31,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q4,Product use issue,,2023,Q4,4,F,,20230927.0,20220712,20231007,EXP,,CA-AUROBINDO-AUR-APL-2022-025049,AUROBINDO,,67.0,YR,,F,Y,,,20231007,,HP,CA,CA,2023,Q4,Elderly
210670884,21067088,31,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q4,Drug ineffective,,2023,Q4,4,F,,20230927.0,20220712,20231007,EXP,,CA-AUROBINDO-AUR-APL-2022-025049,AUROBINDO,,67.0,YR,,F,Y,,,20231007,,HP,CA,CA,2023,Q4,Elderly
210670884,21067088,31,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q4,Abdominal pain upper,,2023,Q4,4,F,,20230927.0,20220712,20231007,EXP,,CA-AUROBINDO-AUR-APL-2022-025049,AUROBINDO,,67.0,YR,,F,Y,,,20231007,,HP,CA,CA,2023,Q4,Elderly
210670884,21067088,31,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q4,Pneumonia,,2023,Q4,4,F,,20230927.0,20220712,20231007,EXP,,CA-AUROBINDO-AUR-APL-2022-025049,AUROBINDO,,67.0,YR,,F,Y,,,20231007,,HP,CA,CA,2023,Q4,Elderly
210670884,21067088,31,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q4,Constipation,,2023,Q4,4,F,,20230927.0,20220712,20231007,EXP,,CA-AUROBINDO-AUR-APL-2022-025049,AUROBINDO,,67.0,YR,,F,Y,,,20231007,,HP,CA,CA,2023,Q4,Elderly
210670884,21067088,31,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q4,Haemorrhoidal haemorrhage,,2023,Q4,4,F,,20230927.0,20220712,20231007,EXP,,CA-AUROBINDO-AUR-APL-2022-025049,AUROBINDO,,67.0,YR,,F,Y,,,20231007,,HP,CA,CA,2023,Q4,Elderly
210670884,21067088,31,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q4,Chest discomfort,,2023,Q4,4,F,,20230927.0,20220712,20231007,EXP,,CA-AUROBINDO-AUR-APL-2022-025049,AUROBINDO,,67.0,YR,,F,Y,,,20231007,,HP,CA,CA,2023,Q4,Elderly
210670884,21067088,31,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q4,Vulvovaginal mycotic infection,,2023,Q4,4,F,,20230927.0,20220712,20231007,EXP,,CA-AUROBINDO-AUR-APL-2022-025049,AUROBINDO,,67.0,YR,,F,Y,,,20231007,,HP,CA,CA,2023,Q4,Elderly
210670884,21067088,31,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q4,Dyspnoea,,2023,Q4,4,F,,20230927.0,20220712,20231007,EXP,,CA-AUROBINDO-AUR-APL-2022-025049,AUROBINDO,,67.0,YR,,F,Y,,,20231007,,HP,CA,CA,2023,Q4,Elderly
210670884,21067088,31,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q4,Neoplasm skin,,2023,Q4,4,F,,20230927.0,20220712,20231007,EXP,,CA-AUROBINDO-AUR-APL-2022-025049,AUROBINDO,,67.0,YR,,F,Y,,,20231007,,HP,CA,CA,2023,Q4,Elderly
210670884,21067088,31,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q4,Haemorrhoids,,2023,Q4,4,F,,20230927.0,20220712,20231007,EXP,,CA-AUROBINDO-AUR-APL-2022-025049,AUROBINDO,,67.0,YR,,F,Y,,,20231007,,HP,CA,CA,2023,Q4,Elderly
210670884,21067088,31,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q4,Cardiac failure,,2023,Q4,4,F,,20230927.0,20220712,20231007,EXP,,CA-AUROBINDO-AUR-APL-2022-025049,AUROBINDO,,67.0,YR,,F,Y,,,20231007,,HP,CA,CA,2023,Q4,Elderly
210670884,21067088,31,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q4,Clostridium difficile colitis,,2023,Q4,4,F,,20230927.0,20220712,20231007,EXP,,CA-AUROBINDO-AUR-APL-2022-025049,AUROBINDO,,67.0,YR,,F,Y,,,20231007,,HP,CA,CA,2023,Q4,Elderly
210670884,21067088,31,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q4,Transient ischaemic attack,,2023,Q4,4,F,,20230927.0,20220712,20231007,EXP,,CA-AUROBINDO-AUR-APL-2022-025049,AUROBINDO,,67.0,YR,,F,Y,,,20231007,,HP,CA,CA,2023,Q4,Elderly
210670884,21067088,31,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q4,Blood pressure increased,,2023,Q4,4,F,,20230927.0,20220712,20231007,EXP,,CA-AUROBINDO-AUR-APL-2022-025049,AUROBINDO,,67.0,YR,,F,Y,,,20231007,,HP,CA,CA,2023,Q4,Elderly
210670884,21067088,31,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q4,Cataract,,2023,Q4,4,F,,20230927.0,20220712,20231007,EXP,,CA-AUROBINDO-AUR-APL-2022-025049,AUROBINDO,,67.0,YR,,F,Y,,,20231007,,HP,CA,CA,2023,Q4,Elderly
210670884,21067088,31,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2023,Q4,COVID-19,,2023,Q4,4,F,,20230927.0,20220712,20231007,EXP,,CA-AUROBINDO-AUR-APL-2022-025049,AUROBINDO,,67.0,YR,,F,Y,,,20231007,,HP,CA,CA,2023,Q4,Elderly
211513013,21151301,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 dosage form (strength: 12.5/1000),,,U,,,,,,,,,2023,Q4,NYHA classification,,2023,Q4,3,F,,20231212.0,20220730,20231221,EXP,,NVSC2022TH168150,NOVARTIS,,68.0,YR,,M,Y,,,20231221,,MD,TH,TH,2023,Q4,Elderly
211513013,21151301,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 dosage form (strength: 12.5/1000),,,U,,,,,,,,,2023,Q4,Weight decreased,,2023,Q4,3,F,,20231212.0,20220730,20231221,EXP,,NVSC2022TH168150,NOVARTIS,,68.0,YR,,M,Y,,,20231221,,MD,TH,TH,2023,Q4,Elderly
211513013,21151301,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 dosage form (strength: 12.5/1000),,,U,,,,,,,,,2023,Q4,N-terminal prohormone brain natriuretic peptide increased,,2023,Q4,3,F,,20231212.0,20220730,20231221,EXP,,NVSC2022TH168150,NOVARTIS,,68.0,YR,,M,Y,,,20231221,,MD,TH,TH,2023,Q4,Elderly
211513013,21151301,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 dosage form (strength: 12.5/1000),,,U,,,,,,,,,2023,Q4,Blood creatinine increased,,2023,Q4,3,F,,20231212.0,20220730,20231221,EXP,,NVSC2022TH168150,NOVARTIS,,68.0,YR,,M,Y,,,20231221,,MD,TH,TH,2023,Q4,Elderly
211513013,21151301,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 dosage form (strength: 12.5/1000),,,U,,,,,,,,,2023,Q4,Ischaemia,,2023,Q4,3,F,,20231212.0,20220730,20231221,EXP,,NVSC2022TH168150,NOVARTIS,,68.0,YR,,M,Y,,,20231221,,MD,TH,TH,2023,Q4,Elderly
211513013,21151301,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 dosage form (strength: 12.5/1000),,,U,,,,,,,,,2023,Q4,Ejection fraction decreased,,2023,Q4,3,F,,20231212.0,20220730,20231221,EXP,,NVSC2022TH168150,NOVARTIS,,68.0,YR,,M,Y,,,20231221,,MD,TH,TH,2023,Q4,Elderly
211513013,21151301,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 dosage form (strength: 12.5/1000),,,U,,,,,,,,,2023,Q4,Angiocardiogram,,2023,Q4,3,F,,20231212.0,20220730,20231221,EXP,,NVSC2022TH168150,NOVARTIS,,68.0,YR,,M,Y,,,20231221,,MD,TH,TH,2023,Q4,Elderly
211513013,21151301,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 dosage form (strength: 12.5/1000),,,U,,,,,,,,,2023,Q4,Hypertension,,2023,Q4,3,F,,20231212.0,20220730,20231221,EXP,,NVSC2022TH168150,NOVARTIS,,68.0,YR,,M,Y,,,20231221,,MD,TH,TH,2023,Q4,Elderly
211513013,21151301,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 dosage form (strength: 12.5/1000),,,U,,,,,,,,,2023,Q4,Obstructive sleep apnoea syndrome,,2023,Q4,3,F,,20231212.0,20220730,20231221,EXP,,NVSC2022TH168150,NOVARTIS,,68.0,YR,,M,Y,,,20231221,,MD,TH,TH,2023,Q4,Elderly
211513013,21151301,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 dosage form (strength: 12.5/1000),,,U,,,,,,,,,2023,Q4,Venous pressure jugular increased,,2023,Q4,3,F,,20231212.0,20220730,20231221,EXP,,NVSC2022TH168150,NOVARTIS,,68.0,YR,,M,Y,,,20231221,,MD,TH,TH,2023,Q4,Elderly
211513013,21151301,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 dosage form (strength: 12.5/1000),,,U,,,,,,,,,2023,Q4,Wrong technique in product usage process,,2023,Q4,3,F,,20231212.0,20220730,20231221,EXP,,NVSC2022TH168150,NOVARTIS,,68.0,YR,,M,Y,,,20231221,,MD,TH,TH,2023,Q4,Elderly
211513013,21151301,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 dosage form (strength: 12.5/1000),,,U,,,,,,,,,2023,Q4,Cardiac failure chronic,,2023,Q4,3,F,,20231212.0,20220730,20231221,EXP,,NVSC2022TH168150,NOVARTIS,,68.0,YR,,M,Y,,,20231221,,MD,TH,TH,2023,Q4,Elderly
2116548111,21165481,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Immune-mediated hypothyroidism,,2023,Q4,11,F,20220101.0,20231122.0,20220803,20231127,EXP,,JP-009507513-2207JPN001031J,MERCK,,71.0,YR,,M,Y,,,20231127,,MD,JP,JP,2023,Q4,Elderly
2116548111,21165481,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Nausea,,2023,Q4,11,F,20220101.0,20231122.0,20220803,20231127,EXP,,JP-009507513-2207JPN001031J,MERCK,,71.0,YR,,M,Y,,,20231127,,MD,JP,JP,2023,Q4,Elderly
2116548111,21165481,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Dysphonia,,2023,Q4,11,F,20220101.0,20231122.0,20220803,20231127,EXP,,JP-009507513-2207JPN001031J,MERCK,,71.0,YR,,M,Y,,,20231127,,MD,JP,JP,2023,Q4,Elderly
2116548111,21165481,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Decreased appetite,,2023,Q4,11,F,20220101.0,20231122.0,20220803,20231127,EXP,,JP-009507513-2207JPN001031J,MERCK,,71.0,YR,,M,Y,,,20231127,,MD,JP,JP,2023,Q4,Elderly
2116548111,21165481,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Diarrhoea,,2023,Q4,11,F,20220101.0,20231122.0,20220803,20231127,EXP,,JP-009507513-2207JPN001031J,MERCK,,71.0,YR,,M,Y,,,20231127,,MD,JP,JP,2023,Q4,Elderly
2116548111,21165481,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Hypertension,,2023,Q4,11,F,20220101.0,20231122.0,20220803,20231127,EXP,,JP-009507513-2207JPN001031J,MERCK,,71.0,YR,,M,Y,,,20231127,,MD,JP,JP,2023,Q4,Elderly
2116548111,21165481,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Haematuria,,2023,Q4,11,F,20220101.0,20231122.0,20220803,20231127,EXP,,JP-009507513-2207JPN001031J,MERCK,,71.0,YR,,M,Y,,,20231127,,MD,JP,JP,2023,Q4,Elderly
2116548111,21165481,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Bladder tamponade,,2023,Q4,11,F,20220101.0,20231122.0,20220803,20231127,EXP,,JP-009507513-2207JPN001031J,MERCK,,71.0,YR,,M,Y,,,20231127,,MD,JP,JP,2023,Q4,Elderly
2116548111,21165481,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Palmar-plantar erythrodysaesthesia syndrome,,2023,Q4,11,F,20220101.0,20231122.0,20220803,20231127,EXP,,JP-009507513-2207JPN001031J,MERCK,,71.0,YR,,M,Y,,,20231127,,MD,JP,JP,2023,Q4,Elderly
2116548111,21165481,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Vomiting,,2023,Q4,11,F,20220101.0,20231122.0,20220803,20231127,EXP,,JP-009507513-2207JPN001031J,MERCK,,71.0,YR,,M,Y,,,20231127,,MD,JP,JP,2023,Q4,Elderly
2116548111,21165481,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Stomatitis,,2023,Q4,11,F,20220101.0,20231122.0,20220803,20231127,EXP,,JP-009507513-2207JPN001031J,MERCK,,71.0,YR,,M,Y,,,20231127,,MD,JP,JP,2023,Q4,Elderly
214119093,21411909,10,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,5/1000 mg 1-0-1-0,,,,,,,,,,,,2023,Q4,Acute kidney injury,,2023,Q4,3,F,20220906.0,20231205.0,20221005,20231206,EXP,,CH-BAYER-2022A133478,BAYER,,64.0,YR,A,M,Y,127.0,KG,20231206,,MD,CH,CH,2023,Q4,Adult
214119093,21411909,10,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,5/1000 mg 1-0-1-0,,,,,,,,,,,,2023,Q4,Anaphylactic reaction,,2023,Q4,3,F,20220906.0,20231205.0,20221005,20231206,EXP,,CH-BAYER-2022A133478,BAYER,,64.0,YR,A,M,Y,127.0,KG,20231206,,MD,CH,CH,2023,Q4,Adult
214119093,21411909,10,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,5/1000 mg 1-0-1-0,,,,,,,,,,,,2023,Q4,Contrast media reaction,,2023,Q4,3,F,20220906.0,20231205.0,20221005,20231206,EXP,,CH-BAYER-2022A133478,BAYER,,64.0,YR,A,M,Y,127.0,KG,20231206,,MD,CH,CH,2023,Q4,Adult
214119093,21411909,10,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,5/1000 mg 1-0-1-0,,,,,,,,,,,,2023,Q4,Sternal fracture,,2023,Q4,3,F,20220906.0,20231205.0,20221005,20231206,EXP,,CH-BAYER-2022A133478,BAYER,,64.0,YR,A,M,Y,127.0,KG,20231206,,MD,CH,CH,2023,Q4,Adult
214119093,21411909,10,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,5/1000 mg 1-0-1-0,,,,,,,,,,,,2023,Q4,Chest pain,,2023,Q4,3,F,20220906.0,20231205.0,20221005,20231206,EXP,,CH-BAYER-2022A133478,BAYER,,64.0,YR,A,M,Y,127.0,KG,20231206,,MD,CH,CH,2023,Q4,Adult
214119093,21411909,10,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,5/1000 mg 1-0-1-0,,,,,,,,,,,,2023,Q4,Dyspnoea,,2023,Q4,3,F,20220906.0,20231205.0,20221005,20231206,EXP,,CH-BAYER-2022A133478,BAYER,,64.0,YR,A,M,Y,127.0,KG,20231206,,MD,CH,CH,2023,Q4,Adult
214119093,21411909,10,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,5/1000 mg 1-0-1-0,,,,,,,,,,,,2023,Q4,Loss of consciousness,,2023,Q4,3,F,20220906.0,20231205.0,20221005,20231206,EXP,,CH-BAYER-2022A133478,BAYER,,64.0,YR,A,M,Y,127.0,KG,20231206,,MD,CH,CH,2023,Q4,Adult
214119093,21411909,10,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,5/1000 mg 1-0-1-0,,,,,,,,,,,,2023,Q4,Pneumothorax,,2023,Q4,3,F,20220906.0,20231205.0,20221005,20231206,EXP,,CH-BAYER-2022A133478,BAYER,,64.0,YR,A,M,Y,127.0,KG,20231206,,MD,CH,CH,2023,Q4,Adult
214119093,21411909,10,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,5/1000 mg 1-0-1-0,,,,,,,,,,,,2023,Q4,Cardiac arrest,,2023,Q4,3,F,20220906.0,20231205.0,20221005,20231206,EXP,,CH-BAYER-2022A133478,BAYER,,64.0,YR,A,M,Y,127.0,KG,20231206,,MD,CH,CH,2023,Q4,Adult
214119093,21411909,10,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,5/1000 mg 1-0-1-0,,,,,,,,,,,,2023,Q4,Pneumonia aspiration,,2023,Q4,3,F,20220906.0,20231205.0,20221005,20231206,EXP,,CH-BAYER-2022A133478,BAYER,,64.0,YR,A,M,Y,127.0,KG,20231206,,MD,CH,CH,2023,Q4,Adult
214119093,21411909,10,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,5/1000 mg 1-0-1-0,,,,,,,,,,,,2023,Q4,Subcutaneous emphysema,,2023,Q4,3,F,20220906.0,20231205.0,20221005,20231206,EXP,,CH-BAYER-2022A133478,BAYER,,64.0,YR,A,M,Y,127.0,KG,20231206,,MD,CH,CH,2023,Q4,Adult
214119093,21411909,10,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,5/1000 mg 1-0-1-0,,,,,,,,,,,,2023,Q4,Rib fracture,,2023,Q4,3,F,20220906.0,20231205.0,20221005,20231206,EXP,,CH-BAYER-2022A133478,BAYER,,64.0,YR,A,M,Y,127.0,KG,20231206,,MD,CH,CH,2023,Q4,Adult
214119093,21411909,10,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,5/1000 mg 1-0-1-0,,,,,,,,,,,,2023,Q4,Hypoxic-ischaemic encephalopathy,,2023,Q4,3,F,20220906.0,20231205.0,20221005,20231206,EXP,,CH-BAYER-2022A133478,BAYER,,64.0,YR,A,M,Y,127.0,KG,20231206,,MD,CH,CH,2023,Q4,Adult
214692334,21469233,5,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,U,,,,,,,Tablet,,2023,Q4,Off label use,,2023,Q4,4,F,20220929.0,20231017.0,20221018,20231025,EXP,,JP-UCBSA-2022060320,UCB,,68.0,YR,,M,Y,54.5,KG,20231025,,PH,JP,JP,2023,Q4,Elderly
214692334,21469233,5,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,U,,,,,,,Tablet,,2023,Q4,Malaise,,2023,Q4,4,F,20220929.0,20231017.0,20221018,20231025,EXP,,JP-UCBSA-2022060320,UCB,,68.0,YR,,M,Y,54.5,KG,20231025,,PH,JP,JP,2023,Q4,Elderly
214692334,21469233,5,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,U,,,,,,,Tablet,,2023,Q4,Drug eruption,,2023,Q4,4,F,20220929.0,20231017.0,20221018,20231025,EXP,,JP-UCBSA-2022060320,UCB,,68.0,YR,,M,Y,54.5,KG,20231025,,PH,JP,JP,2023,Q4,Elderly
214692334,21469233,5,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,U,,,,,,,Tablet,,2023,Q4,Ocular hyperaemia,,2023,Q4,4,F,20220929.0,20231017.0,20221018,20231025,EXP,,JP-UCBSA-2022060320,UCB,,68.0,YR,,M,Y,54.5,KG,20231025,,PH,JP,JP,2023,Q4,Elderly
214692334,21469233,5,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,U,,,,,,,Tablet,,2023,Q4,Pyrexia,,2023,Q4,4,F,20220929.0,20231017.0,20221018,20231025,EXP,,JP-UCBSA-2022060320,UCB,,68.0,YR,,M,Y,54.5,KG,20231025,,PH,JP,JP,2023,Q4,Elderly
214692334,21469233,6,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,U,,,,,,,Tablet,,2023,Q4,Off label use,,2023,Q4,4,F,20220929.0,20231017.0,20221018,20231025,EXP,,JP-UCBSA-2022060320,UCB,,68.0,YR,,M,Y,54.5,KG,20231025,,PH,JP,JP,2023,Q4,Elderly
214692334,21469233,6,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,U,,,,,,,Tablet,,2023,Q4,Malaise,,2023,Q4,4,F,20220929.0,20231017.0,20221018,20231025,EXP,,JP-UCBSA-2022060320,UCB,,68.0,YR,,M,Y,54.5,KG,20231025,,PH,JP,JP,2023,Q4,Elderly
214692334,21469233,6,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,U,,,,,,,Tablet,,2023,Q4,Drug eruption,,2023,Q4,4,F,20220929.0,20231017.0,20221018,20231025,EXP,,JP-UCBSA-2022060320,UCB,,68.0,YR,,M,Y,54.5,KG,20231025,,PH,JP,JP,2023,Q4,Elderly
214692334,21469233,6,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,U,,,,,,,Tablet,,2023,Q4,Ocular hyperaemia,,2023,Q4,4,F,20220929.0,20231017.0,20221018,20231025,EXP,,JP-UCBSA-2022060320,UCB,,68.0,YR,,M,Y,54.5,KG,20231025,,PH,JP,JP,2023,Q4,Elderly
214692334,21469233,6,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,U,,,,,,,Tablet,,2023,Q4,Pyrexia,,2023,Q4,4,F,20220929.0,20231017.0,20221018,20231025,EXP,,JP-UCBSA-2022060320,UCB,,68.0,YR,,M,Y,54.5,KG,20231025,,PH,JP,JP,2023,Q4,Elderly
214698552,21469855,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,N,,Unknown,,204629.0,25.0,MG,Film-coated tablet,QD,2023,Q4,Euglycaemic diabetic ketoacidosis,,2023,Q4,2,F,20220101.0,20231102.0,20221018,20231102,EXP,DE-BFARM-22008460,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-197818",BOEHRINGER INGELHEIM,,51.0,YR,A,M,Y,76.0,KG,20231102,,MD,DE,DE,2023,Q4,Adult
214698552,21469855,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,N,,Unknown,,204629.0,25.0,MG,Film-coated tablet,QD,2023,Q4,Glycosuria,,2023,Q4,2,F,20220101.0,20231102.0,20221018,20231102,EXP,DE-BFARM-22008460,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-197818",BOEHRINGER INGELHEIM,,51.0,YR,A,M,Y,76.0,KG,20231102,,MD,DE,DE,2023,Q4,Adult
216323495,21632349,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q4,Rash,,2023,Q4,5,F,20230821.0,20231023.0,20221123,20231031,EXP,,PHHY2019CA014011,NOVARTIS,,52.0,YR,,F,Y,,,20231031,,CN,CA,CA,2023,Q4,Adult
216323495,21632349,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q4,C-reactive protein increased,,2023,Q4,5,F,20230821.0,20231023.0,20221123,20231031,EXP,,PHHY2019CA014011,NOVARTIS,,52.0,YR,,F,Y,,,20231031,,CN,CA,CA,2023,Q4,Adult
216323495,21632349,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q4,Alanine aminotransferase increased,,2023,Q4,5,F,20230821.0,20231023.0,20221123,20231031,EXP,,PHHY2019CA014011,NOVARTIS,,52.0,YR,,F,Y,,,20231031,,CN,CA,CA,2023,Q4,Adult
216323495,21632349,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q4,Pain in extremity,,2023,Q4,5,F,20230821.0,20231023.0,20221123,20231031,EXP,,PHHY2019CA014011,NOVARTIS,,52.0,YR,,F,Y,,,20231031,,CN,CA,CA,2023,Q4,Adult
216323495,21632349,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q4,Malaise,,2023,Q4,5,F,20230821.0,20231023.0,20221123,20231031,EXP,,PHHY2019CA014011,NOVARTIS,,52.0,YR,,F,Y,,,20231031,,CN,CA,CA,2023,Q4,Adult
216323495,21632349,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q4,Colon cancer stage II,,2023,Q4,5,F,20230821.0,20231023.0,20221123,20231031,EXP,,PHHY2019CA014011,NOVARTIS,,52.0,YR,,F,Y,,,20231031,,CN,CA,CA,2023,Q4,Adult
216323495,21632349,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q4,Platelet count decreased,,2023,Q4,5,F,20230821.0,20231023.0,20221123,20231031,EXP,,PHHY2019CA014011,NOVARTIS,,52.0,YR,,F,Y,,,20231031,,CN,CA,CA,2023,Q4,Adult
216323495,21632349,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q4,Heart rate increased,,2023,Q4,5,F,20230821.0,20231023.0,20221123,20231031,EXP,,PHHY2019CA014011,NOVARTIS,,52.0,YR,,F,Y,,,20231031,,CN,CA,CA,2023,Q4,Adult
216323495,21632349,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q4,Cough,,2023,Q4,5,F,20230821.0,20231023.0,20221123,20231031,EXP,,PHHY2019CA014011,NOVARTIS,,52.0,YR,,F,Y,,,20231031,,CN,CA,CA,2023,Q4,Adult
216323495,21632349,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q4,Peripheral swelling,,2023,Q4,5,F,20230821.0,20231023.0,20221123,20231031,EXP,,PHHY2019CA014011,NOVARTIS,,52.0,YR,,F,Y,,,20231031,,CN,CA,CA,2023,Q4,Adult
216323495,21632349,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q4,Swelling,,2023,Q4,5,F,20230821.0,20231023.0,20221123,20231031,EXP,,PHHY2019CA014011,NOVARTIS,,52.0,YR,,F,Y,,,20231031,,CN,CA,CA,2023,Q4,Adult
216323495,21632349,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q4,Muscle spasms,,2023,Q4,5,F,20230821.0,20231023.0,20221123,20231031,EXP,,PHHY2019CA014011,NOVARTIS,,52.0,YR,,F,Y,,,20231031,,CN,CA,CA,2023,Q4,Adult
2174576615,21745766,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, QD (in afternoon)",,,U,,,,,,,Tablet,QD,2023,Q4,Skin depigmentation,,2023,Q4,15,F,20221201.0,20231011.0,20221219,20231019,EXP,,NVSC2022AR189231,NOVARTIS,,68.0,YR,,M,Y,,,20231019,,CN,AR,AR,2023,Q4,Elderly
2174576615,21745766,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, QD (in afternoon)",,,U,,,,,,,Tablet,QD,2023,Q4,Arterial occlusive disease,,2023,Q4,15,F,20221201.0,20231011.0,20221219,20231019,EXP,,NVSC2022AR189231,NOVARTIS,,68.0,YR,,M,Y,,,20231019,,CN,AR,AR,2023,Q4,Elderly
2174576615,21745766,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, QD (in afternoon)",,,U,,,,,,,Tablet,QD,2023,Q4,COVID-19,,2023,Q4,15,F,20221201.0,20231011.0,20221219,20231019,EXP,,NVSC2022AR189231,NOVARTIS,,68.0,YR,,M,Y,,,20231019,,CN,AR,AR,2023,Q4,Elderly
2174576615,21745766,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, QD (in afternoon)",,,U,,,,,,,Tablet,QD,2023,Q4,Blood glucose increased,,2023,Q4,15,F,20221201.0,20231011.0,20221219,20231019,EXP,,NVSC2022AR189231,NOVARTIS,,68.0,YR,,M,Y,,,20231019,,CN,AR,AR,2023,Q4,Elderly
2174576615,21745766,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, QD (in afternoon)",,,U,,,,,,,Tablet,QD,2023,Q4,Cardiac valve disease,,2023,Q4,15,F,20221201.0,20231011.0,20221219,20231019,EXP,,NVSC2022AR189231,NOVARTIS,,68.0,YR,,M,Y,,,20231019,,CN,AR,AR,2023,Q4,Elderly
2174576615,21745766,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, QD (in afternoon)",,,U,,,,,,,Tablet,QD,2023,Q4,Psoriasis,,2023,Q4,15,F,20221201.0,20231011.0,20221219,20231019,EXP,,NVSC2022AR189231,NOVARTIS,,68.0,YR,,M,Y,,,20231019,,CN,AR,AR,2023,Q4,Elderly
2174576615,21745766,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, QD (in afternoon)",,,U,,,,,,,Tablet,QD,2023,Q4,Somnolence,,2023,Q4,15,F,20221201.0,20231011.0,20221219,20231019,EXP,,NVSC2022AR189231,NOVARTIS,,68.0,YR,,M,Y,,,20231019,,CN,AR,AR,2023,Q4,Elderly
2174576615,21745766,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, QD (in afternoon)",,,U,,,,,,,Tablet,QD,2023,Q4,Varicose vein,,2023,Q4,15,F,20221201.0,20231011.0,20221219,20231019,EXP,,NVSC2022AR189231,NOVARTIS,,68.0,YR,,M,Y,,,20231019,,CN,AR,AR,2023,Q4,Elderly
2174576615,21745766,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, QD (in afternoon)",,,U,,,,,,,Tablet,QD,2023,Q4,Aortic occlusion,,2023,Q4,15,F,20221201.0,20231011.0,20221219,20231019,EXP,,NVSC2022AR189231,NOVARTIS,,68.0,YR,,M,Y,,,20231019,,CN,AR,AR,2023,Q4,Elderly
2174576615,21745766,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, QD (in afternoon)",,,U,,,,,,,Tablet,QD,2023,Q4,Procedural pain,,2023,Q4,15,F,20221201.0,20231011.0,20221219,20231019,EXP,,NVSC2022AR189231,NOVARTIS,,68.0,YR,,M,Y,,,20231019,,CN,AR,AR,2023,Q4,Elderly
2174576615,21745766,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, QD (in afternoon)",,,U,,,,,,,Tablet,QD,2023,Q4,Back pain,,2023,Q4,15,F,20221201.0,20231011.0,20221219,20231019,EXP,,NVSC2022AR189231,NOVARTIS,,68.0,YR,,M,Y,,,20231019,,CN,AR,AR,2023,Q4,Elderly
2174576615,21745766,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, QD (in afternoon)",,,U,,,,,,,Tablet,QD,2023,Q4,Cardiac failure,,2023,Q4,15,F,20221201.0,20231011.0,20221219,20231019,EXP,,NVSC2022AR189231,NOVARTIS,,68.0,YR,,M,Y,,,20231019,,CN,AR,AR,2023,Q4,Elderly
2174576615,21745766,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, QD (in afternoon)",,,U,,,,,,,Tablet,QD,2023,Q4,Bronchiolitis,,2023,Q4,15,F,20221201.0,20231011.0,20221219,20231019,EXP,,NVSC2022AR189231,NOVARTIS,,68.0,YR,,M,Y,,,20231019,,CN,AR,AR,2023,Q4,Elderly
2174576615,21745766,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, QD (in afternoon)",,,U,,,,,,,Tablet,QD,2023,Q4,Pain in extremity,,2023,Q4,15,F,20221201.0,20231011.0,20221219,20231019,EXP,,NVSC2022AR189231,NOVARTIS,,68.0,YR,,M,Y,,,20231019,,CN,AR,AR,2023,Q4,Elderly
2174576615,21745766,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, QD (in afternoon)",,,U,,,,,,,Tablet,QD,2023,Q4,Malaise,,2023,Q4,15,F,20221201.0,20231011.0,20221219,20231019,EXP,,NVSC2022AR189231,NOVARTIS,,68.0,YR,,M,Y,,,20231019,,CN,AR,AR,2023,Q4,Elderly
2174576615,21745766,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, QD (in afternoon)",,,U,,,,,,,Tablet,QD,2023,Q4,Dyspnoea,,2023,Q4,15,F,20221201.0,20231011.0,20221219,20231019,EXP,,NVSC2022AR189231,NOVARTIS,,68.0,YR,,M,Y,,,20231019,,CN,AR,AR,2023,Q4,Elderly
2174576615,21745766,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, QD (in afternoon)",,,U,,,,,,,Tablet,QD,2023,Q4,Scar,,2023,Q4,15,F,20221201.0,20231011.0,20221219,20231019,EXP,,NVSC2022AR189231,NOVARTIS,,68.0,YR,,M,Y,,,20231019,,CN,AR,AR,2023,Q4,Elderly
2174576615,21745766,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, QD (in afternoon)",,,U,,,,,,,Tablet,QD,2023,Q4,Cardiac disorder,,2023,Q4,15,F,20221201.0,20231011.0,20221219,20231019,EXP,,NVSC2022AR189231,NOVARTIS,,68.0,YR,,M,Y,,,20231019,,CN,AR,AR,2023,Q4,Elderly
2174576615,21745766,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, QD (in afternoon)",,,U,,,,,,,Tablet,QD,2023,Q4,Weight decreased,,2023,Q4,15,F,20221201.0,20231011.0,20221219,20231019,EXP,,NVSC2022AR189231,NOVARTIS,,68.0,YR,,M,Y,,,20231019,,CN,AR,AR,2023,Q4,Elderly
2178761413,21787614,51,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Hypervolaemia,,2023,Q4,13,F,20221004.0,20231103.0,20221228,20231107,EXP,,AU-ROCHE-3194260,ROCHE,,63.0,YR,,M,Y,181.3,KG,20231107,,MD,AU,,2023,Q4,Adult
2178761413,21787614,51,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Lumbar vertebral fracture,,2023,Q4,13,F,20221004.0,20231103.0,20221228,20231107,EXP,,AU-ROCHE-3194260,ROCHE,,63.0,YR,,M,Y,181.3,KG,20231107,,MD,AU,,2023,Q4,Adult
2178761413,21787614,51,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Venous thrombosis limb,,2023,Q4,13,F,20221004.0,20231103.0,20221228,20231107,EXP,,AU-ROCHE-3194260,ROCHE,,63.0,YR,,M,Y,181.3,KG,20231107,,MD,AU,,2023,Q4,Adult
2178761413,21787614,51,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Abdominal pain,,2023,Q4,13,F,20221004.0,20231103.0,20221228,20231107,EXP,,AU-ROCHE-3194260,ROCHE,,63.0,YR,,M,Y,181.3,KG,20231107,,MD,AU,,2023,Q4,Adult
2178761413,21787614,51,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Deep vein thrombosis,,2023,Q4,13,F,20221004.0,20231103.0,20221228,20231107,EXP,,AU-ROCHE-3194260,ROCHE,,63.0,YR,,M,Y,181.3,KG,20231107,,MD,AU,,2023,Q4,Adult
2178761413,21787614,51,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Pneumonia,,2023,Q4,13,F,20221004.0,20231103.0,20221228,20231107,EXP,,AU-ROCHE-3194260,ROCHE,,63.0,YR,,M,Y,181.3,KG,20231107,,MD,AU,,2023,Q4,Adult
219329953,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q4,Blood uric acid increased,,2023,Q4,3,F,,20231213.0,20230131,20231221,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,57.0,YR,,F,Y,,,20231221,,CN,CA,CA,2023,Q4,Adult
219329953,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q4,Hepatic enzyme increased,,2023,Q4,3,F,,20231213.0,20230131,20231221,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,57.0,YR,,F,Y,,,20231221,,CN,CA,CA,2023,Q4,Adult
219329953,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q4,Pain in extremity,,2023,Q4,3,F,,20231213.0,20230131,20231221,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,57.0,YR,,F,Y,,,20231221,,CN,CA,CA,2023,Q4,Adult
219329953,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q4,Renal disorder,,2023,Q4,3,F,,20231213.0,20230131,20231221,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,57.0,YR,,F,Y,,,20231221,,CN,CA,CA,2023,Q4,Adult
219329953,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q4,Drug ineffective,,2023,Q4,3,F,,20231213.0,20230131,20231221,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,57.0,YR,,F,Y,,,20231221,,CN,CA,CA,2023,Q4,Adult
219329953,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q4,Injection site pain,,2023,Q4,3,F,,20231213.0,20230131,20231221,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,57.0,YR,,F,Y,,,20231221,,CN,CA,CA,2023,Q4,Adult
219329953,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q4,Sepsis,,2023,Q4,3,F,,20231213.0,20230131,20231221,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,57.0,YR,,F,Y,,,20231221,,CN,CA,CA,2023,Q4,Adult
219329953,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q4,Synovial disorder,,2023,Q4,3,F,,20231213.0,20230131,20231221,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,57.0,YR,,F,Y,,,20231221,,CN,CA,CA,2023,Q4,Adult
219329953,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q4,Pain,,2023,Q4,3,F,,20231213.0,20230131,20231221,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,57.0,YR,,F,Y,,,20231221,,CN,CA,CA,2023,Q4,Adult
219329953,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q4,Rash,,2023,Q4,3,F,,20231213.0,20230131,20231221,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,57.0,YR,,F,Y,,,20231221,,CN,CA,CA,2023,Q4,Adult
219329953,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q4,Nephrolithiasis,,2023,Q4,3,F,,20231213.0,20230131,20231221,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,57.0,YR,,F,Y,,,20231221,,CN,CA,CA,2023,Q4,Adult
219329953,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q4,Alanine aminotransferase increased,,2023,Q4,3,F,,20231213.0,20230131,20231221,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,57.0,YR,,F,Y,,,20231221,,CN,CA,CA,2023,Q4,Adult
219329953,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q4,Condition aggravated,,2023,Q4,3,F,,20231213.0,20230131,20231221,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,57.0,YR,,F,Y,,,20231221,,CN,CA,CA,2023,Q4,Adult
219329953,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q4,Injection site warmth,,2023,Q4,3,F,,20231213.0,20230131,20231221,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,57.0,YR,,F,Y,,,20231221,,CN,CA,CA,2023,Q4,Adult
219329953,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q4,Antinuclear antibody positive,,2023,Q4,3,F,,20231213.0,20230131,20231221,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,57.0,YR,,F,Y,,,20231221,,CN,CA,CA,2023,Q4,Adult
219329953,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q4,Vitamin B12 decreased,,2023,Q4,3,F,,20231213.0,20230131,20231221,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,57.0,YR,,F,Y,,,20231221,,CN,CA,CA,2023,Q4,Adult
219329953,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q4,Synovitis,,2023,Q4,3,F,,20231213.0,20230131,20231221,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,57.0,YR,,F,Y,,,20231221,,CN,CA,CA,2023,Q4,Adult
219329953,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q4,Psoriasis,,2023,Q4,3,F,,20231213.0,20230131,20231221,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,57.0,YR,,F,Y,,,20231221,,CN,CA,CA,2023,Q4,Adult
219329953,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q4,Tendonitis,,2023,Q4,3,F,,20231213.0,20230131,20231221,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,57.0,YR,,F,Y,,,20231221,,CN,CA,CA,2023,Q4,Adult
219329953,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q4,Urinary tract infection,,2023,Q4,3,F,,20231213.0,20230131,20231221,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,57.0,YR,,F,Y,,,20231221,,CN,CA,CA,2023,Q4,Adult
219329953,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q4,Pyrexia,,2023,Q4,3,F,,20231213.0,20230131,20231221,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,57.0,YR,,F,Y,,,20231221,,CN,CA,CA,2023,Q4,Adult
219329953,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q4,Arthropathy,,2023,Q4,3,F,,20231213.0,20230131,20231221,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,57.0,YR,,F,Y,,,20231221,,CN,CA,CA,2023,Q4,Adult
219329953,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q4,Arthritis,,2023,Q4,3,F,,20231213.0,20230131,20231221,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,57.0,YR,,F,Y,,,20231221,,CN,CA,CA,2023,Q4,Adult
219329953,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q4,Arthralgia,,2023,Q4,3,F,,20231213.0,20230131,20231221,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,57.0,YR,,F,Y,,,20231221,,CN,CA,CA,2023,Q4,Adult
219329953,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q4,Joint swelling,,2023,Q4,3,F,,20231213.0,20230131,20231221,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,57.0,YR,,F,Y,,,20231221,,CN,CA,CA,2023,Q4,Adult
219329953,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q4,Osteoarthritis,,2023,Q4,3,F,,20231213.0,20230131,20231221,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,57.0,YR,,F,Y,,,20231221,,CN,CA,CA,2023,Q4,Adult
219329953,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q4,Cyst,,2023,Q4,3,F,,20231213.0,20230131,20231221,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,57.0,YR,,F,Y,,,20231221,,CN,CA,CA,2023,Q4,Adult
219329953,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q4,Blood iron decreased,,2023,Q4,3,F,,20231213.0,20230131,20231221,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,57.0,YR,,F,Y,,,20231221,,CN,CA,CA,2023,Q4,Adult
219329953,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q4,Joint effusion,,2023,Q4,3,F,,20231213.0,20230131,20231221,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,57.0,YR,,F,Y,,,20231221,,CN,CA,CA,2023,Q4,Adult
219329953,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q4,Incorrect dose administered,,2023,Q4,3,F,,20231213.0,20230131,20231221,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,57.0,YR,,F,Y,,,20231221,,CN,CA,CA,2023,Q4,Adult
219329953,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q4,C-reactive protein increased,,2023,Q4,3,F,,20231213.0,20230131,20231221,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,57.0,YR,,F,Y,,,20231221,,CN,CA,CA,2023,Q4,Adult
219329953,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q4,Oedema,,2023,Q4,3,F,,20231213.0,20230131,20231221,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,57.0,YR,,F,Y,,,20231221,,CN,CA,CA,2023,Q4,Adult
219329953,21932995,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2023,Q4,Allergic sinusitis,,2023,Q4,3,F,,20231213.0,20230131,20231221,EXP,,CA-BAUSCH-BL-2023-001265,BAUSCH AND LOMB,,57.0,YR,,F,Y,,,20231221,,CN,CA,CA,2023,Q4,Adult
219516423,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,D,,,,,10.0,MG,,QD,2023,Q4,Arthralgia,,2023,Q4,3,F,,20231218.0,20230203,20231227,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20231227,,HP,CA,CA,2023,Q4,Adult
219516423,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,D,,,,,10.0,MG,,QD,2023,Q4,Renal disorder,,2023,Q4,3,F,,20231218.0,20230203,20231227,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20231227,,HP,CA,CA,2023,Q4,Adult
219516423,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,D,,,,,10.0,MG,,QD,2023,Q4,Nephrolithiasis,,2023,Q4,3,F,,20231218.0,20230203,20231227,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20231227,,HP,CA,CA,2023,Q4,Adult
219516423,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,D,,,,,10.0,MG,,QD,2023,Q4,Rash,,2023,Q4,3,F,,20231218.0,20230203,20231227,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20231227,,HP,CA,CA,2023,Q4,Adult
219516423,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,D,,,,,10.0,MG,,QD,2023,Q4,Sepsis,,2023,Q4,3,F,,20231218.0,20230203,20231227,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20231227,,HP,CA,CA,2023,Q4,Adult
219516423,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,D,,,,,10.0,MG,,QD,2023,Q4,Antinuclear antibody positive,,2023,Q4,3,F,,20231218.0,20230203,20231227,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20231227,,HP,CA,CA,2023,Q4,Adult
219516423,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,D,,,,,10.0,MG,,QD,2023,Q4,Cyst,,2023,Q4,3,F,,20231218.0,20230203,20231227,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20231227,,HP,CA,CA,2023,Q4,Adult
219516423,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,D,,,,,10.0,MG,,QD,2023,Q4,Joint effusion,,2023,Q4,3,F,,20231218.0,20230203,20231227,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20231227,,HP,CA,CA,2023,Q4,Adult
219516423,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,D,,,,,10.0,MG,,QD,2023,Q4,Vitamin B12 decreased,,2023,Q4,3,F,,20231218.0,20230203,20231227,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20231227,,HP,CA,CA,2023,Q4,Adult
219516423,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,D,,,,,10.0,MG,,QD,2023,Q4,Joint swelling,,2023,Q4,3,F,,20231218.0,20230203,20231227,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20231227,,HP,CA,CA,2023,Q4,Adult
219516423,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,D,,,,,10.0,MG,,QD,2023,Q4,Pyrexia,,2023,Q4,3,F,,20231218.0,20230203,20231227,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20231227,,HP,CA,CA,2023,Q4,Adult
219516423,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,D,,,,,10.0,MG,,QD,2023,Q4,Psoriasis,,2023,Q4,3,F,,20231218.0,20230203,20231227,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20231227,,HP,CA,CA,2023,Q4,Adult
219516423,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,D,,,,,10.0,MG,,QD,2023,Q4,Incorrect dose administered,,2023,Q4,3,F,,20231218.0,20230203,20231227,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20231227,,HP,CA,CA,2023,Q4,Adult
219516423,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,D,,,,,10.0,MG,,QD,2023,Q4,Urinary tract infection,,2023,Q4,3,F,,20231218.0,20230203,20231227,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20231227,,HP,CA,CA,2023,Q4,Adult
219516423,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,D,,,,,10.0,MG,,QD,2023,Q4,Blood iron decreased,,2023,Q4,3,F,,20231218.0,20230203,20231227,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20231227,,HP,CA,CA,2023,Q4,Adult
219516423,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,D,,,,,10.0,MG,,QD,2023,Q4,Condition aggravated,,2023,Q4,3,F,,20231218.0,20230203,20231227,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20231227,,HP,CA,CA,2023,Q4,Adult
219516423,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,D,,,,,10.0,MG,,QD,2023,Q4,Pain in extremity,,2023,Q4,3,F,,20231218.0,20230203,20231227,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20231227,,HP,CA,CA,2023,Q4,Adult
219516423,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,D,,,,,10.0,MG,,QD,2023,Q4,Osteoarthritis,,2023,Q4,3,F,,20231218.0,20230203,20231227,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20231227,,HP,CA,CA,2023,Q4,Adult
219516423,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,D,,,,,10.0,MG,,QD,2023,Q4,Synovial disorder,,2023,Q4,3,F,,20231218.0,20230203,20231227,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20231227,,HP,CA,CA,2023,Q4,Adult
219516423,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,D,,,,,10.0,MG,,QD,2023,Q4,Blood uric acid increased,,2023,Q4,3,F,,20231218.0,20230203,20231227,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20231227,,HP,CA,CA,2023,Q4,Adult
219516423,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,D,,,,,10.0,MG,,QD,2023,Q4,Drug ineffective,,2023,Q4,3,F,,20231218.0,20230203,20231227,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20231227,,HP,CA,CA,2023,Q4,Adult
219516423,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,D,,,,,10.0,MG,,QD,2023,Q4,Hepatic enzyme increased,,2023,Q4,3,F,,20231218.0,20230203,20231227,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20231227,,HP,CA,CA,2023,Q4,Adult
219516423,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,D,,,,,10.0,MG,,QD,2023,Q4,Alanine aminotransferase increased,,2023,Q4,3,F,,20231218.0,20230203,20231227,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20231227,,HP,CA,CA,2023,Q4,Adult
219516423,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,D,,,,,10.0,MG,,QD,2023,Q4,Arthritis,,2023,Q4,3,F,,20231218.0,20230203,20231227,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20231227,,HP,CA,CA,2023,Q4,Adult
219516423,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,D,,,,,10.0,MG,,QD,2023,Q4,Synovitis,,2023,Q4,3,F,,20231218.0,20230203,20231227,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20231227,,HP,CA,CA,2023,Q4,Adult
219516423,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,D,,,,,10.0,MG,,QD,2023,Q4,C-reactive protein increased,,2023,Q4,3,F,,20231218.0,20230203,20231227,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20231227,,HP,CA,CA,2023,Q4,Adult
219516423,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,D,,,,,10.0,MG,,QD,2023,Q4,Allergic sinusitis,,2023,Q4,3,F,,20231218.0,20230203,20231227,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20231227,,HP,CA,CA,2023,Q4,Adult
219516423,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,D,,,,,10.0,MG,,QD,2023,Q4,Arthropathy,,2023,Q4,3,F,,20231218.0,20230203,20231227,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20231227,,HP,CA,CA,2023,Q4,Adult
219516423,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,D,,,,,10.0,MG,,QD,2023,Q4,Injection site pain,,2023,Q4,3,F,,20231218.0,20230203,20231227,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20231227,,HP,CA,CA,2023,Q4,Adult
219516423,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,D,,,,,10.0,MG,,QD,2023,Q4,Injection site warmth,,2023,Q4,3,F,,20231218.0,20230203,20231227,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20231227,,HP,CA,CA,2023,Q4,Adult
219516423,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,D,,,,,10.0,MG,,QD,2023,Q4,Oedema,,2023,Q4,3,F,,20231218.0,20230203,20231227,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20231227,,HP,CA,CA,2023,Q4,Adult
219516423,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,D,,,,,10.0,MG,,QD,2023,Q4,Tendonitis,,2023,Q4,3,F,,20231218.0,20230203,20231227,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20231227,,HP,CA,CA,2023,Q4,Adult
219516423,21951642,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,D,,,,,10.0,MG,,QD,2023,Q4,Pain,,2023,Q4,3,F,,20231218.0,20230203,20231227,EXP,,CA-SA-2023SA036473,SANOFI AVENTIS,,59.0,YR,A,F,Y,,,20231227,,HP,CA,CA,2023,Q4,Adult
220326702,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q4,Blood iron decreased,,2023,Q4,2,F,,20231208.0,20230224,20231218,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20231218,,HP,CA,CA,2023,Q4,Adult
220326702,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q4,Nephrolithiasis,,2023,Q4,2,F,,20231208.0,20230224,20231218,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20231218,,HP,CA,CA,2023,Q4,Adult
220326702,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q4,Alanine aminotransferase increased,,2023,Q4,2,F,,20231208.0,20230224,20231218,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20231218,,HP,CA,CA,2023,Q4,Adult
220326702,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q4,Condition aggravated,,2023,Q4,2,F,,20231208.0,20230224,20231218,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20231218,,HP,CA,CA,2023,Q4,Adult
220326702,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q4,Pain,,2023,Q4,2,F,,20231208.0,20230224,20231218,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20231218,,HP,CA,CA,2023,Q4,Adult
220326702,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q4,Renal disorder,,2023,Q4,2,F,,20231208.0,20230224,20231218,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20231218,,HP,CA,CA,2023,Q4,Adult
220326702,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q4,Antinuclear antibody positive,,2023,Q4,2,F,,20231208.0,20230224,20231218,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20231218,,HP,CA,CA,2023,Q4,Adult
220326702,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q4,Joint swelling,,2023,Q4,2,F,,20231208.0,20230224,20231218,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20231218,,HP,CA,CA,2023,Q4,Adult
220326702,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q4,Pain in extremity,,2023,Q4,2,F,,20231208.0,20230224,20231218,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20231218,,HP,CA,CA,2023,Q4,Adult
220326702,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q4,Tendonitis,,2023,Q4,2,F,,20231208.0,20230224,20231218,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20231218,,HP,CA,CA,2023,Q4,Adult
220326702,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q4,Incorrect dose administered,,2023,Q4,2,F,,20231208.0,20230224,20231218,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20231218,,HP,CA,CA,2023,Q4,Adult
220326702,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q4,Joint effusion,,2023,Q4,2,F,,20231208.0,20230224,20231218,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20231218,,HP,CA,CA,2023,Q4,Adult
220326702,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q4,Synovial disorder,,2023,Q4,2,F,,20231208.0,20230224,20231218,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20231218,,HP,CA,CA,2023,Q4,Adult
220326702,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q4,Osteoarthritis,,2023,Q4,2,F,,20231208.0,20230224,20231218,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20231218,,HP,CA,CA,2023,Q4,Adult
220326702,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q4,Injection site warmth,,2023,Q4,2,F,,20231208.0,20230224,20231218,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20231218,,HP,CA,CA,2023,Q4,Adult
220326702,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q4,Pyrexia,,2023,Q4,2,F,,20231208.0,20230224,20231218,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20231218,,HP,CA,CA,2023,Q4,Adult
220326702,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q4,Vitamin B12 decreased,,2023,Q4,2,F,,20231208.0,20230224,20231218,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20231218,,HP,CA,CA,2023,Q4,Adult
220326702,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q4,Arthralgia,,2023,Q4,2,F,,20231208.0,20230224,20231218,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20231218,,HP,CA,CA,2023,Q4,Adult
220326702,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q4,Rash,,2023,Q4,2,F,,20231208.0,20230224,20231218,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20231218,,HP,CA,CA,2023,Q4,Adult
220326702,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q4,Oedema,,2023,Q4,2,F,,20231208.0,20230224,20231218,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20231218,,HP,CA,CA,2023,Q4,Adult
220326702,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q4,Hepatic enzyme increased,,2023,Q4,2,F,,20231208.0,20230224,20231218,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20231218,,HP,CA,CA,2023,Q4,Adult
220326702,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q4,Sepsis,,2023,Q4,2,F,,20231208.0,20230224,20231218,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20231218,,HP,CA,CA,2023,Q4,Adult
220326702,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q4,Drug ineffective,,2023,Q4,2,F,,20231208.0,20230224,20231218,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20231218,,HP,CA,CA,2023,Q4,Adult
220326702,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q4,C-reactive protein increased,,2023,Q4,2,F,,20231208.0,20230224,20231218,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20231218,,HP,CA,CA,2023,Q4,Adult
220326702,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q4,Allergic sinusitis,,2023,Q4,2,F,,20231208.0,20230224,20231218,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20231218,,HP,CA,CA,2023,Q4,Adult
220326702,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q4,Arthropathy,,2023,Q4,2,F,,20231208.0,20230224,20231218,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20231218,,HP,CA,CA,2023,Q4,Adult
220326702,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q4,Psoriasis,,2023,Q4,2,F,,20231208.0,20230224,20231218,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20231218,,HP,CA,CA,2023,Q4,Adult
220326702,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q4,Arthritis,,2023,Q4,2,F,,20231208.0,20230224,20231218,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20231218,,HP,CA,CA,2023,Q4,Adult
220326702,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q4,Synovitis,,2023,Q4,2,F,,20231208.0,20230224,20231218,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20231218,,HP,CA,CA,2023,Q4,Adult
220326702,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q4,Injection site pain,,2023,Q4,2,F,,20231208.0,20230224,20231218,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20231218,,HP,CA,CA,2023,Q4,Adult
220326702,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q4,Cyst,,2023,Q4,2,F,,20231208.0,20230224,20231218,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20231218,,HP,CA,CA,2023,Q4,Adult
220326702,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q4,Blood uric acid increased,,2023,Q4,2,F,,20231208.0,20230224,20231218,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20231218,,HP,CA,CA,2023,Q4,Adult
220326702,22032670,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2023,Q4,Urinary tract infection,,2023,Q4,2,F,,20231208.0,20230224,20231218,EXP,,CA-APOTEX-2023AP003736,APOTEX,,57.0,YR,,F,Y,,,20231218,,HP,CA,CA,2023,Q4,Adult
220399714,22039971,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,more than 11 months,,,U,,Unknown,,,25.0,MG,Tablet,QD,2023,Q4,Blood glucose increased,,2023,Q4,4,F,20211201.0,20231208.0,20230227,20231218,EXP,,JP-EMD Serono-9343540,EMD SERONO INC,,7.0,DEC,E,F,Y,68.0,KG,20231217,,MD,JP,JP,2023,Q4,Child
220399714,22039971,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,more than 11 months,,,U,,Unknown,,,25.0,MG,Tablet,QD,2023,Q4,Glycosylated haemoglobin increased,,2023,Q4,4,F,20211201.0,20231208.0,20230227,20231218,EXP,,JP-EMD Serono-9343540,EMD SERONO INC,,7.0,DEC,E,F,Y,68.0,KG,20231217,,MD,JP,JP,2023,Q4,Child
220406315,22040631,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2023,Q4,Dehydration,,2023,Q4,5,F,20220916.0,20231116.0,20230227,20231128,EXP,,JP-PFIZER INC-PV202300022437,PFIZER,,56.0,YR,,M,Y,76.2,KG,20231127,,PH,JP,JP,2023,Q4,Adult
220406315,22040631,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2023,Q4,Labelled drug-drug interaction medication error,,2023,Q4,5,F,20220916.0,20231116.0,20230227,20231128,EXP,,JP-PFIZER INC-PV202300022437,PFIZER,,56.0,YR,,M,Y,76.2,KG,20231127,,PH,JP,JP,2023,Q4,Adult
220406315,22040631,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2023,Q4,Renal impairment,,2023,Q4,5,F,20220916.0,20231116.0,20230227,20231128,EXP,,JP-PFIZER INC-PV202300022437,PFIZER,,56.0,YR,,M,Y,76.2,KG,20231127,,PH,JP,JP,2023,Q4,Adult
220406315,22040631,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2023,Q4,Immunosuppressant drug level increased,,2023,Q4,5,F,20220916.0,20231116.0,20230227,20231128,EXP,,JP-PFIZER INC-PV202300022437,PFIZER,,56.0,YR,,M,Y,76.2,KG,20231127,,PH,JP,JP,2023,Q4,Adult
220406315,22040631,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2023,Q4,Off label use,,2023,Q4,5,F,20220916.0,20231116.0,20230227,20231128,EXP,,JP-PFIZER INC-PV202300022437,PFIZER,,56.0,YR,,M,Y,76.2,KG,20231127,,PH,JP,JP,2023,Q4,Adult
220406315,22040631,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2023,Q4,Drug interaction,,2023,Q4,5,F,20220916.0,20231116.0,20230227,20231128,EXP,,JP-PFIZER INC-PV202300022437,PFIZER,,56.0,YR,,M,Y,76.2,KG,20231127,,PH,JP,JP,2023,Q4,Adult
220406315,22040631,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2023,Q4,Ileus paralytic,,2023,Q4,5,F,20220916.0,20231116.0,20230227,20231128,EXP,,JP-PFIZER INC-PV202300022437,PFIZER,,56.0,YR,,M,Y,76.2,KG,20231127,,PH,JP,JP,2023,Q4,Adult
220406315,22040631,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2023,Q4,Acute kidney injury,,2023,Q4,5,F,20220916.0,20231116.0,20230227,20231128,EXP,,JP-PFIZER INC-PV202300022437,PFIZER,,56.0,YR,,M,Y,76.2,KG,20231127,,PH,JP,JP,2023,Q4,Adult
220459622,22045962,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,,,,,,10.0,MG,Tablet,,2023,Q4,Blood thyroid stimulating hormone increased,,2023,Q4,2,F,20220617.0,20231130.0,20230228,20231207,EXP,,JP-009507513-2207JPN000526J,MERCK,"Watanabe R, Ishido K, Hirai K, Aono K, Ogarashi K, Ruike Y, et al.. P10-8 A Case of Thyroid crisis due to destructive thyroiditis after pembrolizumab and lenvatinib combination therapy for corpus uteri carcinoma. 65th Annual Meeting of Japanese Thyroid Association.. 90",44.0,YR,,F,Y,85.0,KG,20231207,,MD,JP,JP,2023,Q4,Adult
220459622,22045962,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,,,,,,10.0,MG,Tablet,,2023,Q4,Thyrotoxic crisis,,2023,Q4,2,F,20220617.0,20231130.0,20230228,20231207,EXP,,JP-009507513-2207JPN000526J,MERCK,"Watanabe R, Ishido K, Hirai K, Aono K, Ogarashi K, Ruike Y, et al.. P10-8 A Case of Thyroid crisis due to destructive thyroiditis after pembrolizumab and lenvatinib combination therapy for corpus uteri carcinoma. 65th Annual Meeting of Japanese Thyroid Association.. 90",44.0,YR,,F,Y,85.0,KG,20231207,,MD,JP,JP,2023,Q4,Adult
220459622,22045962,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,,,,,,10.0,MG,Tablet,,2023,Q4,Thyroiditis,,2023,Q4,2,F,20220617.0,20231130.0,20230228,20231207,EXP,,JP-009507513-2207JPN000526J,MERCK,"Watanabe R, Ishido K, Hirai K, Aono K, Ogarashi K, Ruike Y, et al.. P10-8 A Case of Thyroid crisis due to destructive thyroiditis after pembrolizumab and lenvatinib combination therapy for corpus uteri carcinoma. 65th Annual Meeting of Japanese Thyroid Association.. 90",44.0,YR,,F,Y,85.0,KG,20231207,,MD,JP,JP,2023,Q4,Adult
220459622,22045962,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,,,,,,10.0,MG,Tablet,,2023,Q4,Suicidal ideation,,2023,Q4,2,F,20220617.0,20231130.0,20230228,20231207,EXP,,JP-009507513-2207JPN000526J,MERCK,"Watanabe R, Ishido K, Hirai K, Aono K, Ogarashi K, Ruike Y, et al.. P10-8 A Case of Thyroid crisis due to destructive thyroiditis after pembrolizumab and lenvatinib combination therapy for corpus uteri carcinoma. 65th Annual Meeting of Japanese Thyroid Association.. 90",44.0,YR,,F,Y,85.0,KG,20231207,,MD,JP,JP,2023,Q4,Adult
220685806,22068580,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 Milligram,,,,,,,,,,,,2023,Q4,Multiple organ dysfunction syndrome,,2023,Q4,6,F,20190406.0,20231107.0,20230307,20231108,EXP,,JP-ABBVIE-19S-087-2776146-00,ABBVIE,,60.0,YR,,M,Y,79.0,KG,20231108,,CN,JP,JP,2023,Q4,Adult
220685806,22068580,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 Milligram,,,,,,,,,,,,2023,Q4,Intestinal obstruction,,2023,Q4,6,F,20190406.0,20231107.0,20230307,20231108,EXP,,JP-ABBVIE-19S-087-2776146-00,ABBVIE,,60.0,YR,,M,Y,79.0,KG,20231108,,CN,JP,JP,2023,Q4,Adult
220685806,22068580,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 Milligram,,,,,,,,,,,,2023,Q4,Stoma site inflammation,,2023,Q4,6,F,20190406.0,20231107.0,20230307,20231108,EXP,,JP-ABBVIE-19S-087-2776146-00,ABBVIE,,60.0,YR,,M,Y,79.0,KG,20231108,,CN,JP,JP,2023,Q4,Adult
220685806,22068580,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 Milligram,,,,,,,,,,,,2023,Q4,Melaena,,2023,Q4,6,F,20190406.0,20231107.0,20230307,20231108,EXP,,JP-ABBVIE-19S-087-2776146-00,ABBVIE,,60.0,YR,,M,Y,79.0,KG,20231108,,CN,JP,JP,2023,Q4,Adult
220685806,22068580,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 Milligram,,,,,,,,,,,,2023,Q4,Stoma site pain,,2023,Q4,6,F,20190406.0,20231107.0,20230307,20231108,EXP,,JP-ABBVIE-19S-087-2776146-00,ABBVIE,,60.0,YR,,M,Y,79.0,KG,20231108,,CN,JP,JP,2023,Q4,Adult
220685806,22068580,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 Milligram,,,,,,,,,,,,2023,Q4,Stoma site oedema,,2023,Q4,6,F,20190406.0,20231107.0,20230307,20231108,EXP,,JP-ABBVIE-19S-087-2776146-00,ABBVIE,,60.0,YR,,M,Y,79.0,KG,20231108,,CN,JP,JP,2023,Q4,Adult
220685806,22068580,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 Milligram,,,,,,,,,,,,2023,Q4,Duodenal ulcer haemorrhage,,2023,Q4,6,F,20190406.0,20231107.0,20230307,20231108,EXP,,JP-ABBVIE-19S-087-2776146-00,ABBVIE,,60.0,YR,,M,Y,79.0,KG,20231108,,CN,JP,JP,2023,Q4,Adult
220685806,22068580,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 Milligram,,,,,,,,,,,,2023,Q4,Duodenal ulcer,,2023,Q4,6,F,20190406.0,20231107.0,20230307,20231108,EXP,,JP-ABBVIE-19S-087-2776146-00,ABBVIE,,60.0,YR,,M,Y,79.0,KG,20231108,,CN,JP,JP,2023,Q4,Adult
220685806,22068580,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 Milligram,,,,,,,,,,,,2023,Q4,Stoma creation,,2023,Q4,6,F,20190406.0,20231107.0,20230307,20231108,EXP,,JP-ABBVIE-19S-087-2776146-00,ABBVIE,,60.0,YR,,M,Y,79.0,KG,20231108,,CN,JP,JP,2023,Q4,Adult
220685806,22068580,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 Milligram,,,,,,,,,,,,2023,Q4,Stoma site hypergranulation,,2023,Q4,6,F,20190406.0,20231107.0,20230307,20231108,EXP,,JP-ABBVIE-19S-087-2776146-00,ABBVIE,,60.0,YR,,M,Y,79.0,KG,20231108,,CN,JP,JP,2023,Q4,Adult
220798995,22079899,3,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,U,,,,,,,Tablet,QD,2023,Q4,Immune-mediated cholangitis,,2023,Q4,5,F,20230124.0,20231003.0,20230309,20231003,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-2023-034193,BRISTOL MYERS SQUIBB,,74.0,YR,E,M,Y,54.9,KG,20231003,,MD,JP,JP,2023,Q4,Elderly
221634262,22163426,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q4,Prescribed underdose,,2023,Q4,2,F,20230203.0,20231117.0,20230401,20231127,EXP,,ES-AUROBINDO-AUR-APL-2023-014151,AUROBINDO,,76.0,YR,,M,Y,75.0,KG,20231127,,MD,ES,ES,2023,Q4,Elderly
221634262,22163426,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q4,Intentional product use issue,,2023,Q4,2,F,20230203.0,20231117.0,20230401,20231127,EXP,,ES-AUROBINDO-AUR-APL-2023-014151,AUROBINDO,,76.0,YR,,M,Y,75.0,KG,20231127,,MD,ES,ES,2023,Q4,Elderly
221634262,22163426,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q4,Cerebrovascular accident,,2023,Q4,2,F,20230203.0,20231117.0,20230401,20231127,EXP,,ES-AUROBINDO-AUR-APL-2023-014151,AUROBINDO,,76.0,YR,,M,Y,75.0,KG,20231127,,MD,ES,ES,2023,Q4,Elderly
222722732,22272273,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Vomiting,,2023,Q4,2,F,,20231115.0,20230502,20231222,PER,,US-APOTEX-2022AP012922,APOTEX,"Ekanayake PS, Gerwer J, McCowen K. ALPELISIB - INDUCED HYPERGLYCEMIA. Acta Endocrinologica (Buc). 2022;18(1):115-117",44.0,YR,,F,Y,,,20231222,,MD,US,US,2023,Q4,Adult
222722732,22272273,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Nausea,,2023,Q4,2,F,,20231115.0,20230502,20231222,PER,,US-APOTEX-2022AP012922,APOTEX,"Ekanayake PS, Gerwer J, McCowen K. ALPELISIB - INDUCED HYPERGLYCEMIA. Acta Endocrinologica (Buc). 2022;18(1):115-117",44.0,YR,,F,Y,,,20231222,,MD,US,US,2023,Q4,Adult
222722732,22272273,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Drug intolerance,,2023,Q4,2,F,,20231115.0,20230502,20231222,PER,,US-APOTEX-2022AP012922,APOTEX,"Ekanayake PS, Gerwer J, McCowen K. ALPELISIB - INDUCED HYPERGLYCEMIA. Acta Endocrinologica (Buc). 2022;18(1):115-117",44.0,YR,,F,Y,,,20231222,,MD,US,US,2023,Q4,Adult
222857163,22285716,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,AP,,,,,,,,,,Tablet,,2023,Q4,Gangrene,,2023,Q4,3,F,20230301.0,20231005.0,20230504,20231010,EXP,,NVSJ2023JP007252,NOVARTIS,,79.0,YR,,M,Y,74.8,KG,20231011,,MD,JP,JP,2023,Q4,Elderly
222857163,22285716,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,AP,,,,,,,,,,Tablet,,2023,Q4,Pulse absent,,2023,Q4,3,F,20230301.0,20231005.0,20230504,20231010,EXP,,NVSJ2023JP007252,NOVARTIS,,79.0,YR,,M,Y,74.8,KG,20231011,,MD,JP,JP,2023,Q4,Elderly
222857163,22285716,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,AP,,,,,,,,,,Tablet,,2023,Q4,Decreased appetite,,2023,Q4,3,F,20230301.0,20231005.0,20230504,20231010,EXP,,NVSJ2023JP007252,NOVARTIS,,79.0,YR,,M,Y,74.8,KG,20231011,,MD,JP,JP,2023,Q4,Elderly
222857163,22285716,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,AP,,,,,,,,,,Tablet,,2023,Q4,Pain,,2023,Q4,3,F,20230301.0,20231005.0,20230504,20231010,EXP,,NVSJ2023JP007252,NOVARTIS,,79.0,YR,,M,Y,74.8,KG,20231011,,MD,JP,JP,2023,Q4,Elderly
222857163,22285716,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,AP,,,,,,,,,,Tablet,,2023,Q4,Dehydration,,2023,Q4,3,F,20230301.0,20231005.0,20230504,20231010,EXP,,NVSJ2023JP007252,NOVARTIS,,79.0,YR,,M,Y,74.8,KG,20231011,,MD,JP,JP,2023,Q4,Elderly
222857163,22285716,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,AP,,,,,,,,,,Tablet,,2023,Q4,Peripheral arterial occlusive disease,,2023,Q4,3,F,20230301.0,20231005.0,20230504,20231010,EXP,,NVSJ2023JP007252,NOVARTIS,,79.0,YR,,M,Y,74.8,KG,20231011,,MD,JP,JP,2023,Q4,Elderly
222857163,22285716,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,BP,,,,,,,,,,Tablet,,2023,Q4,Gangrene,,2023,Q4,3,F,20230301.0,20231005.0,20230504,20231010,EXP,,NVSJ2023JP007252,NOVARTIS,,79.0,YR,,M,Y,74.8,KG,20231011,,MD,JP,JP,2023,Q4,Elderly
222857163,22285716,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,BP,,,,,,,,,,Tablet,,2023,Q4,Pulse absent,,2023,Q4,3,F,20230301.0,20231005.0,20230504,20231010,EXP,,NVSJ2023JP007252,NOVARTIS,,79.0,YR,,M,Y,74.8,KG,20231011,,MD,JP,JP,2023,Q4,Elderly
222857163,22285716,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,BP,,,,,,,,,,Tablet,,2023,Q4,Decreased appetite,,2023,Q4,3,F,20230301.0,20231005.0,20230504,20231010,EXP,,NVSJ2023JP007252,NOVARTIS,,79.0,YR,,M,Y,74.8,KG,20231011,,MD,JP,JP,2023,Q4,Elderly
222857163,22285716,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,BP,,,,,,,,,,Tablet,,2023,Q4,Pain,,2023,Q4,3,F,20230301.0,20231005.0,20230504,20231010,EXP,,NVSJ2023JP007252,NOVARTIS,,79.0,YR,,M,Y,74.8,KG,20231011,,MD,JP,JP,2023,Q4,Elderly
222857163,22285716,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,BP,,,,,,,,,,Tablet,,2023,Q4,Dehydration,,2023,Q4,3,F,20230301.0,20231005.0,20230504,20231010,EXP,,NVSJ2023JP007252,NOVARTIS,,79.0,YR,,M,Y,74.8,KG,20231011,,MD,JP,JP,2023,Q4,Elderly
222857163,22285716,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,BP,,,,,,,,,,Tablet,,2023,Q4,Peripheral arterial occlusive disease,,2023,Q4,3,F,20230301.0,20231005.0,20230504,20231010,EXP,,NVSJ2023JP007252,NOVARTIS,,79.0,YR,,M,Y,74.8,KG,20231011,,MD,JP,JP,2023,Q4,Elderly
222895132,22289513,4,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"0.505 g, BID",2.02,GM,,,2211502,,,0.505,GM,Tablet,BID,2023,Q4,Nephropathy toxic,,2023,Q4,2,F,20230408.0,20230429.0,20230505,20231006,EXP,,CN-BAYER-2023A061924,BAYER,,60.0,YR,A,M,Y,34.0,KG,20231006,,HP,CN,CN,2023,Q4,Adult
223150512,22315051,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2023,Q4,Cardiogenic shock,,2023,Q4,2,F,20230310.0,20231103.0,20230512,20231107,EXP,,NVSC2023AU108375,NOVARTIS,,74.0,YR,,M,Y,75.2,KG,20231107,,MD,AU,AU,2023,Q4,Elderly
2233952611,22339526,31,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK (1-0-1-0) (0.5/day),,,Y,,,,,,,,,2023,Q4,Hypotension,,2023,Q4,11,F,,20231206.0,20230518,20231220,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231220,,HP,ES,ES,2023,Q4,Adult
2233952611,22339526,31,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK (1-0-1-0) (0.5/day),,,Y,,,,,,,,,2023,Q4,Somnolence,,2023,Q4,11,F,,20231206.0,20230518,20231220,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231220,,HP,ES,ES,2023,Q4,Adult
2233952611,22339526,31,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK (1-0-1-0) (0.5/day),,,Y,,,,,,,,,2023,Q4,Hypoglycaemia,,2023,Q4,11,F,,20231206.0,20230518,20231220,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231220,,HP,ES,ES,2023,Q4,Adult
2233952611,22339526,31,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK (1-0-1-0) (0.5/day),,,Y,,,,,,,,,2023,Q4,Hyperhidrosis,,2023,Q4,11,F,,20231206.0,20230518,20231220,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231220,,HP,ES,ES,2023,Q4,Adult
2233952611,22339526,31,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK (1-0-1-0) (0.5/day),,,Y,,,,,,,,,2023,Q4,Tachycardia,,2023,Q4,11,F,,20231206.0,20230518,20231220,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231220,,HP,ES,ES,2023,Q4,Adult
2233952611,22339526,31,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK (1-0-1-0) (0.5/day),,,Y,,,,,,,,,2023,Q4,Parkinsonism,,2023,Q4,11,F,,20231206.0,20230518,20231220,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231220,,HP,ES,ES,2023,Q4,Adult
2233952611,22339526,31,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK (1-0-1-0) (0.5/day),,,Y,,,,,,,,,2023,Q4,Drug interaction,,2023,Q4,11,F,,20231206.0,20230518,20231220,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231220,,HP,ES,ES,2023,Q4,Adult
2233952611,22339526,31,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK (1-0-1-0) (0.5/day),,,Y,,,,,,,,,2023,Q4,Hallucination,,2023,Q4,11,F,,20231206.0,20230518,20231220,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231220,,HP,ES,ES,2023,Q4,Adult
2233952611,22339526,32,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,Y,,,,,,,,BID,2023,Q4,Hypotension,,2023,Q4,11,F,,20231206.0,20230518,20231220,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231220,,HP,ES,ES,2023,Q4,Adult
2233952611,22339526,32,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,Y,,,,,,,,BID,2023,Q4,Somnolence,,2023,Q4,11,F,,20231206.0,20230518,20231220,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231220,,HP,ES,ES,2023,Q4,Adult
2233952611,22339526,32,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,Y,,,,,,,,BID,2023,Q4,Hypoglycaemia,,2023,Q4,11,F,,20231206.0,20230518,20231220,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231220,,HP,ES,ES,2023,Q4,Adult
2233952611,22339526,32,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,Y,,,,,,,,BID,2023,Q4,Hyperhidrosis,,2023,Q4,11,F,,20231206.0,20230518,20231220,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231220,,HP,ES,ES,2023,Q4,Adult
2233952611,22339526,32,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,Y,,,,,,,,BID,2023,Q4,Tachycardia,,2023,Q4,11,F,,20231206.0,20230518,20231220,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231220,,HP,ES,ES,2023,Q4,Adult
2233952611,22339526,32,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,Y,,,,,,,,BID,2023,Q4,Parkinsonism,,2023,Q4,11,F,,20231206.0,20230518,20231220,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231220,,HP,ES,ES,2023,Q4,Adult
2233952611,22339526,32,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,Y,,,,,,,,BID,2023,Q4,Drug interaction,,2023,Q4,11,F,,20231206.0,20230518,20231220,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231220,,HP,ES,ES,2023,Q4,Adult
2233952611,22339526,32,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,Y,,,,,,,,BID,2023,Q4,Hallucination,,2023,Q4,11,F,,20231206.0,20230518,20231220,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231220,,HP,ES,ES,2023,Q4,Adult
2233952611,22339526,38,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 mg, BID (1000 mg/5 mg (1-0-1-0), Two Times a Day)",,,,,,,,5.0,MG,,BID,2023,Q4,Hypotension,,2023,Q4,11,F,,20231206.0,20230518,20231220,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231220,,HP,ES,ES,2023,Q4,Adult
2233952611,22339526,38,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 mg, BID (1000 mg/5 mg (1-0-1-0), Two Times a Day)",,,,,,,,5.0,MG,,BID,2023,Q4,Somnolence,,2023,Q4,11,F,,20231206.0,20230518,20231220,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231220,,HP,ES,ES,2023,Q4,Adult
2233952611,22339526,38,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 mg, BID (1000 mg/5 mg (1-0-1-0), Two Times a Day)",,,,,,,,5.0,MG,,BID,2023,Q4,Hypoglycaemia,,2023,Q4,11,F,,20231206.0,20230518,20231220,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231220,,HP,ES,ES,2023,Q4,Adult
2233952611,22339526,38,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 mg, BID (1000 mg/5 mg (1-0-1-0), Two Times a Day)",,,,,,,,5.0,MG,,BID,2023,Q4,Hyperhidrosis,,2023,Q4,11,F,,20231206.0,20230518,20231220,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231220,,HP,ES,ES,2023,Q4,Adult
2233952611,22339526,38,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 mg, BID (1000 mg/5 mg (1-0-1-0), Two Times a Day)",,,,,,,,5.0,MG,,BID,2023,Q4,Tachycardia,,2023,Q4,11,F,,20231206.0,20230518,20231220,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231220,,HP,ES,ES,2023,Q4,Adult
2233952611,22339526,38,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 mg, BID (1000 mg/5 mg (1-0-1-0), Two Times a Day)",,,,,,,,5.0,MG,,BID,2023,Q4,Parkinsonism,,2023,Q4,11,F,,20231206.0,20230518,20231220,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231220,,HP,ES,ES,2023,Q4,Adult
2233952611,22339526,38,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 mg, BID (1000 mg/5 mg (1-0-1-0), Two Times a Day)",,,,,,,,5.0,MG,,BID,2023,Q4,Drug interaction,,2023,Q4,11,F,,20231206.0,20230518,20231220,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231220,,HP,ES,ES,2023,Q4,Adult
2233952611,22339526,38,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 mg, BID (1000 mg/5 mg (1-0-1-0), Two Times a Day)",,,,,,,,5.0,MG,,BID,2023,Q4,Hallucination,,2023,Q4,11,F,,20231206.0,20230518,20231220,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231220,,HP,ES,ES,2023,Q4,Adult
2233952611,22339526,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,,,,,,,,,,2023,Q4,Hypotension,,2023,Q4,11,F,,20231206.0,20230518,20231220,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231220,,HP,ES,ES,2023,Q4,Adult
2233952611,22339526,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,,,,,,,,,,2023,Q4,Somnolence,,2023,Q4,11,F,,20231206.0,20230518,20231220,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231220,,HP,ES,ES,2023,Q4,Adult
2233952611,22339526,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,,,,,,,,,,2023,Q4,Hypoglycaemia,,2023,Q4,11,F,,20231206.0,20230518,20231220,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231220,,HP,ES,ES,2023,Q4,Adult
2233952611,22339526,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,,,,,,,,,,2023,Q4,Hyperhidrosis,,2023,Q4,11,F,,20231206.0,20230518,20231220,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231220,,HP,ES,ES,2023,Q4,Adult
2233952611,22339526,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,,,,,,,,,,2023,Q4,Tachycardia,,2023,Q4,11,F,,20231206.0,20230518,20231220,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231220,,HP,ES,ES,2023,Q4,Adult
2233952611,22339526,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,,,,,,,,,,2023,Q4,Parkinsonism,,2023,Q4,11,F,,20231206.0,20230518,20231220,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231220,,HP,ES,ES,2023,Q4,Adult
2233952611,22339526,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,,,,,,,,,,2023,Q4,Drug interaction,,2023,Q4,11,F,,20231206.0,20230518,20231220,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231220,,HP,ES,ES,2023,Q4,Adult
2233952611,22339526,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,,,,,,,,,,2023,Q4,Hallucination,,2023,Q4,11,F,,20231206.0,20230518,20231220,EXP,,NVSC2023ES111967,NOVARTIS,"Abdala KS, Devora GS, Oliva MAM, Morales MC. El valor anadido de los servicios profesionales farmaceuocos asistenciales Un caso de SFT [The added value of professional pharmaceutical care services. A case of SFT]. FARMACEUTICOS COMUNITARIOS [COMMUNITY FARMS]. 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231220,,HP,ES,ES,2023,Q4,Adult
223531896,22353189,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2023,Q4,Acute coronary syndrome,,2023,Q4,6,F,20230517.0,20231013.0,20230523,20231018,EXP,,NVSC2023CN114745,NOVARTIS,,44.0,YR,,M,Y,101.0,KG,20231018,,MD,CN,CN,2023,Q4,Adult
223555672,22355567,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,Tablet,QD,2023,Q4,Skin exfoliation,,2023,Q4,2,F,20220207.0,20231122.0,20230523,20231129,EXP,,CA-TAKEDA-2022TUS013905,TAKEDA,,62.0,YR,,M,Y,,,20231129,,PH,CA,CA,2023,Q4,Adult
223555672,22355567,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,Tablet,QD,2023,Q4,Abdominal pain lower,,2023,Q4,2,F,20220207.0,20231122.0,20230523,20231129,EXP,,CA-TAKEDA-2022TUS013905,TAKEDA,,62.0,YR,,M,Y,,,20231129,,PH,CA,CA,2023,Q4,Adult
223555672,22355567,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,Tablet,QD,2023,Q4,Upper respiratory tract infection,,2023,Q4,2,F,20220207.0,20231122.0,20230523,20231129,EXP,,CA-TAKEDA-2022TUS013905,TAKEDA,,62.0,YR,,M,Y,,,20231129,,PH,CA,CA,2023,Q4,Adult
223555672,22355567,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,Tablet,QD,2023,Q4,Diarrhoea,,2023,Q4,2,F,20220207.0,20231122.0,20230523,20231129,EXP,,CA-TAKEDA-2022TUS013905,TAKEDA,,62.0,YR,,M,Y,,,20231129,,PH,CA,CA,2023,Q4,Adult
223555672,22355567,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,Tablet,QD,2023,Q4,Abdominal discomfort,,2023,Q4,2,F,20220207.0,20231122.0,20230523,20231129,EXP,,CA-TAKEDA-2022TUS013905,TAKEDA,,62.0,YR,,M,Y,,,20231129,,PH,CA,CA,2023,Q4,Adult
223555672,22355567,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,Tablet,QD,2023,Q4,Abdominal rigidity,,2023,Q4,2,F,20220207.0,20231122.0,20230523,20231129,EXP,,CA-TAKEDA-2022TUS013905,TAKEDA,,62.0,YR,,M,Y,,,20231129,,PH,CA,CA,2023,Q4,Adult
223555672,22355567,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,Tablet,QD,2023,Q4,Off label use,,2023,Q4,2,F,20220207.0,20231122.0,20230523,20231129,EXP,,CA-TAKEDA-2022TUS013905,TAKEDA,,62.0,YR,,M,Y,,,20231129,,PH,CA,CA,2023,Q4,Adult
223555672,22355567,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,Tablet,QD,2023,Q4,Pain in extremity,,2023,Q4,2,F,20220207.0,20231122.0,20230523,20231129,EXP,,CA-TAKEDA-2022TUS013905,TAKEDA,,62.0,YR,,M,Y,,,20231129,,PH,CA,CA,2023,Q4,Adult
223555672,22355567,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,Tablet,QD,2023,Q4,Dyspepsia,,2023,Q4,2,F,20220207.0,20231122.0,20230523,20231129,EXP,,CA-TAKEDA-2022TUS013905,TAKEDA,,62.0,YR,,M,Y,,,20231129,,PH,CA,CA,2023,Q4,Adult
223555672,22355567,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,Tablet,QD,2023,Q4,Illness,,2023,Q4,2,F,20220207.0,20231122.0,20230523,20231129,EXP,,CA-TAKEDA-2022TUS013905,TAKEDA,,62.0,YR,,M,Y,,,20231129,,PH,CA,CA,2023,Q4,Adult
223555672,22355567,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,Tablet,QD,2023,Q4,Fatigue,,2023,Q4,2,F,20220207.0,20231122.0,20230523,20231129,EXP,,CA-TAKEDA-2022TUS013905,TAKEDA,,62.0,YR,,M,Y,,,20231129,,PH,CA,CA,2023,Q4,Adult
223555672,22355567,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,Tablet,QD,2023,Q4,Influenza,,2023,Q4,2,F,20220207.0,20231122.0,20230523,20231129,EXP,,CA-TAKEDA-2022TUS013905,TAKEDA,,62.0,YR,,M,Y,,,20231129,,PH,CA,CA,2023,Q4,Adult
223792132,22379213,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, 1 Dose, Notes for patient: If you become suddenly unwell with fever or feverish illn",320.0,MG,U,,,,,10.0,MG,,QD,2023,Q4,Hypomagnesaemia,,2023,Q4,2,F,20230429.0,20231029.0,20230529,20231110,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-390544,RANBAXY,,61.0,YR,,F,Y,90.0,KG,20231110,,MD,GB,GB,2023,Q4,Adult
2238438710,22384387,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"5 mg, qd (1000 mg/5 mg (1-0-1-0), Two Times a Day)",,,Y,,,,,5.0,MG,Unknown,QD,2023,Q4,Somnolence,,2023,Q4,10,F,,20230927.0,20230530,20231003,EXP,,ES-MYLANLABS-2023M1054925,MYLAN,"Abdala S, Devora S, Oliva AM, Morales C. The added value of Professional Pharmaceutical Assistance Services. A case of pharmaceutical care. Farmaceuticos comunitarios (Community Farms). 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231003,,HP,ES,ES,2023,Q4,Adult
2238438710,22384387,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"5 mg, qd (1000 mg/5 mg (1-0-1-0), Two Times a Day)",,,Y,,,,,5.0,MG,Unknown,QD,2023,Q4,Off label use,,2023,Q4,10,F,,20230927.0,20230530,20231003,EXP,,ES-MYLANLABS-2023M1054925,MYLAN,"Abdala S, Devora S, Oliva AM, Morales C. The added value of Professional Pharmaceutical Assistance Services. A case of pharmaceutical care. Farmaceuticos comunitarios (Community Farms). 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231003,,HP,ES,ES,2023,Q4,Adult
2238438710,22384387,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"5 mg, qd (1000 mg/5 mg (1-0-1-0), Two Times a Day)",,,Y,,,,,5.0,MG,Unknown,QD,2023,Q4,Parkinsonism,,2023,Q4,10,F,,20230927.0,20230530,20231003,EXP,,ES-MYLANLABS-2023M1054925,MYLAN,"Abdala S, Devora S, Oliva AM, Morales C. The added value of Professional Pharmaceutical Assistance Services. A case of pharmaceutical care. Farmaceuticos comunitarios (Community Farms). 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231003,,HP,ES,ES,2023,Q4,Adult
2238438710,22384387,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"5 mg, qd (1000 mg/5 mg (1-0-1-0), Two Times a Day)",,,Y,,,,,5.0,MG,Unknown,QD,2023,Q4,Drug interaction,,2023,Q4,10,F,,20230927.0,20230530,20231003,EXP,,ES-MYLANLABS-2023M1054925,MYLAN,"Abdala S, Devora S, Oliva AM, Morales C. The added value of Professional Pharmaceutical Assistance Services. A case of pharmaceutical care. Farmaceuticos comunitarios (Community Farms). 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231003,,HP,ES,ES,2023,Q4,Adult
2238438710,22384387,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"5 mg, qd (1000 mg/5 mg (1-0-1-0), Two Times a Day)",,,Y,,,,,5.0,MG,Unknown,QD,2023,Q4,Hyperhidrosis,,2023,Q4,10,F,,20230927.0,20230530,20231003,EXP,,ES-MYLANLABS-2023M1054925,MYLAN,"Abdala S, Devora S, Oliva AM, Morales C. The added value of Professional Pharmaceutical Assistance Services. A case of pharmaceutical care. Farmaceuticos comunitarios (Community Farms). 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231003,,HP,ES,ES,2023,Q4,Adult
2238438710,22384387,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"5 mg, qd (1000 mg/5 mg (1-0-1-0), Two Times a Day)",,,Y,,,,,5.0,MG,Unknown,QD,2023,Q4,Hypotension,,2023,Q4,10,F,,20230927.0,20230530,20231003,EXP,,ES-MYLANLABS-2023M1054925,MYLAN,"Abdala S, Devora S, Oliva AM, Morales C. The added value of Professional Pharmaceutical Assistance Services. A case of pharmaceutical care. Farmaceuticos comunitarios (Community Farms). 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231003,,HP,ES,ES,2023,Q4,Adult
2238438710,22384387,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"5 mg, qd (1000 mg/5 mg (1-0-1-0), Two Times a Day)",,,Y,,,,,5.0,MG,Unknown,QD,2023,Q4,Hypoglycaemia,,2023,Q4,10,F,,20230927.0,20230530,20231003,EXP,,ES-MYLANLABS-2023M1054925,MYLAN,"Abdala S, Devora S, Oliva AM, Morales C. The added value of Professional Pharmaceutical Assistance Services. A case of pharmaceutical care. Farmaceuticos comunitarios (Community Farms). 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231003,,HP,ES,ES,2023,Q4,Adult
2238438710,22384387,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"5 mg, qd (1000 mg/5 mg (1-0-1-0), Two Times a Day)",,,Y,,,,,5.0,MG,Unknown,QD,2023,Q4,Tachycardia,,2023,Q4,10,F,,20230927.0,20230530,20231003,EXP,,ES-MYLANLABS-2023M1054925,MYLAN,"Abdala S, Devora S, Oliva AM, Morales C. The added value of Professional Pharmaceutical Assistance Services. A case of pharmaceutical care. Farmaceuticos comunitarios (Community Farms). 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231003,,HP,ES,ES,2023,Q4,Adult
2238438710,22384387,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"5 mg, qd (1000 mg/5 mg (1-0-1-0), Two Times a Day)",,,Y,,,,,5.0,MG,Unknown,QD,2023,Q4,Hallucination,,2023,Q4,10,F,,20230927.0,20230530,20231003,EXP,,ES-MYLANLABS-2023M1054925,MYLAN,"Abdala S, Devora S, Oliva AM, Morales C. The added value of Professional Pharmaceutical Assistance Services. A case of pharmaceutical care. Farmaceuticos comunitarios (Community Farms). 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231003,,HP,ES,ES,2023,Q4,Adult
2238438710,22384387,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,,,,,,5.0,MG,Unknown,QD,2023,Q4,Somnolence,,2023,Q4,10,F,,20230927.0,20230530,20231003,EXP,,ES-MYLANLABS-2023M1054925,MYLAN,"Abdala S, Devora S, Oliva AM, Morales C. The added value of Professional Pharmaceutical Assistance Services. A case of pharmaceutical care. Farmaceuticos comunitarios (Community Farms). 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231003,,HP,ES,ES,2023,Q4,Adult
2238438710,22384387,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,,,,,,5.0,MG,Unknown,QD,2023,Q4,Off label use,,2023,Q4,10,F,,20230927.0,20230530,20231003,EXP,,ES-MYLANLABS-2023M1054925,MYLAN,"Abdala S, Devora S, Oliva AM, Morales C. The added value of Professional Pharmaceutical Assistance Services. A case of pharmaceutical care. Farmaceuticos comunitarios (Community Farms). 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231003,,HP,ES,ES,2023,Q4,Adult
2238438710,22384387,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,,,,,,5.0,MG,Unknown,QD,2023,Q4,Parkinsonism,,2023,Q4,10,F,,20230927.0,20230530,20231003,EXP,,ES-MYLANLABS-2023M1054925,MYLAN,"Abdala S, Devora S, Oliva AM, Morales C. The added value of Professional Pharmaceutical Assistance Services. A case of pharmaceutical care. Farmaceuticos comunitarios (Community Farms). 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231003,,HP,ES,ES,2023,Q4,Adult
2238438710,22384387,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,,,,,,5.0,MG,Unknown,QD,2023,Q4,Drug interaction,,2023,Q4,10,F,,20230927.0,20230530,20231003,EXP,,ES-MYLANLABS-2023M1054925,MYLAN,"Abdala S, Devora S, Oliva AM, Morales C. The added value of Professional Pharmaceutical Assistance Services. A case of pharmaceutical care. Farmaceuticos comunitarios (Community Farms). 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231003,,HP,ES,ES,2023,Q4,Adult
2238438710,22384387,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,,,,,,5.0,MG,Unknown,QD,2023,Q4,Hyperhidrosis,,2023,Q4,10,F,,20230927.0,20230530,20231003,EXP,,ES-MYLANLABS-2023M1054925,MYLAN,"Abdala S, Devora S, Oliva AM, Morales C. The added value of Professional Pharmaceutical Assistance Services. A case of pharmaceutical care. Farmaceuticos comunitarios (Community Farms). 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231003,,HP,ES,ES,2023,Q4,Adult
2238438710,22384387,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,,,,,,5.0,MG,Unknown,QD,2023,Q4,Hypotension,,2023,Q4,10,F,,20230927.0,20230530,20231003,EXP,,ES-MYLANLABS-2023M1054925,MYLAN,"Abdala S, Devora S, Oliva AM, Morales C. The added value of Professional Pharmaceutical Assistance Services. A case of pharmaceutical care. Farmaceuticos comunitarios (Community Farms). 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231003,,HP,ES,ES,2023,Q4,Adult
2238438710,22384387,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,,,,,,5.0,MG,Unknown,QD,2023,Q4,Hypoglycaemia,,2023,Q4,10,F,,20230927.0,20230530,20231003,EXP,,ES-MYLANLABS-2023M1054925,MYLAN,"Abdala S, Devora S, Oliva AM, Morales C. The added value of Professional Pharmaceutical Assistance Services. A case of pharmaceutical care. Farmaceuticos comunitarios (Community Farms). 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231003,,HP,ES,ES,2023,Q4,Adult
2238438710,22384387,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,,,,,,5.0,MG,Unknown,QD,2023,Q4,Tachycardia,,2023,Q4,10,F,,20230927.0,20230530,20231003,EXP,,ES-MYLANLABS-2023M1054925,MYLAN,"Abdala S, Devora S, Oliva AM, Morales C. The added value of Professional Pharmaceutical Assistance Services. A case of pharmaceutical care. Farmaceuticos comunitarios (Community Farms). 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231003,,HP,ES,ES,2023,Q4,Adult
2238438710,22384387,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,,,,,,5.0,MG,Unknown,QD,2023,Q4,Hallucination,,2023,Q4,10,F,,20230927.0,20230530,20231003,EXP,,ES-MYLANLABS-2023M1054925,MYLAN,"Abdala S, Devora S, Oliva AM, Morales C. The added value of Professional Pharmaceutical Assistance Services. A case of pharmaceutical care. Farmaceuticos comunitarios (Community Farms). 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231003,,HP,ES,ES,2023,Q4,Adult
223864847,22386484,23,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,1 dosage form,,,Y,,,,,,,,,2023,Q4,Somnolence,,2023,Q4,7,F,,20231019.0,20230531,20231026,EXP,,ES-AUROBINDO-AUR-APL-2023-036025,AUROBINDO,"Abdala S, Devora S, Oliva AM, Morales C. El valor a?adido de los servicios profesionales farmac?uticos asistenciales. Un caso de SFT (The added value of professional pharmaceutical care services. A case of SFT),. Farmaceuticos comunitarios (Community Farms). 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231026,,PH,ES,ES,2023,Q4,Adult
223864847,22386484,23,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,1 dosage form,,,Y,,,,,,,,,2023,Q4,Hypotension,,2023,Q4,7,F,,20231019.0,20230531,20231026,EXP,,ES-AUROBINDO-AUR-APL-2023-036025,AUROBINDO,"Abdala S, Devora S, Oliva AM, Morales C. El valor a?adido de los servicios profesionales farmac?uticos asistenciales. Un caso de SFT (The added value of professional pharmaceutical care services. A case of SFT),. Farmaceuticos comunitarios (Community Farms). 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231026,,PH,ES,ES,2023,Q4,Adult
223864847,22386484,23,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,1 dosage form,,,Y,,,,,,,,,2023,Q4,Parkinsonism,,2023,Q4,7,F,,20231019.0,20230531,20231026,EXP,,ES-AUROBINDO-AUR-APL-2023-036025,AUROBINDO,"Abdala S, Devora S, Oliva AM, Morales C. El valor a?adido de los servicios profesionales farmac?uticos asistenciales. Un caso de SFT (The added value of professional pharmaceutical care services. A case of SFT),. Farmaceuticos comunitarios (Community Farms). 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231026,,PH,ES,ES,2023,Q4,Adult
223864847,22386484,23,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,1 dosage form,,,Y,,,,,,,,,2023,Q4,Drug interaction,,2023,Q4,7,F,,20231019.0,20230531,20231026,EXP,,ES-AUROBINDO-AUR-APL-2023-036025,AUROBINDO,"Abdala S, Devora S, Oliva AM, Morales C. El valor a?adido de los servicios profesionales farmac?uticos asistenciales. Un caso de SFT (The added value of professional pharmaceutical care services. A case of SFT),. Farmaceuticos comunitarios (Community Farms). 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231026,,PH,ES,ES,2023,Q4,Adult
223864847,22386484,23,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,1 dosage form,,,Y,,,,,,,,,2023,Q4,Tachycardia,,2023,Q4,7,F,,20231019.0,20230531,20231026,EXP,,ES-AUROBINDO-AUR-APL-2023-036025,AUROBINDO,"Abdala S, Devora S, Oliva AM, Morales C. El valor a?adido de los servicios profesionales farmac?uticos asistenciales. Un caso de SFT (The added value of professional pharmaceutical care services. A case of SFT),. Farmaceuticos comunitarios (Community Farms). 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231026,,PH,ES,ES,2023,Q4,Adult
223864847,22386484,23,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,1 dosage form,,,Y,,,,,,,,,2023,Q4,Hallucination,,2023,Q4,7,F,,20231019.0,20230531,20231026,EXP,,ES-AUROBINDO-AUR-APL-2023-036025,AUROBINDO,"Abdala S, Devora S, Oliva AM, Morales C. El valor a?adido de los servicios profesionales farmac?uticos asistenciales. Un caso de SFT (The added value of professional pharmaceutical care services. A case of SFT),. Farmaceuticos comunitarios (Community Farms). 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231026,,PH,ES,ES,2023,Q4,Adult
223864847,22386484,23,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,1 dosage form,,,Y,,,,,,,,,2023,Q4,Hypoglycaemia,,2023,Q4,7,F,,20231019.0,20230531,20231026,EXP,,ES-AUROBINDO-AUR-APL-2023-036025,AUROBINDO,"Abdala S, Devora S, Oliva AM, Morales C. El valor a?adido de los servicios profesionales farmac?uticos asistenciales. Un caso de SFT (The added value of professional pharmaceutical care services. A case of SFT),. Farmaceuticos comunitarios (Community Farms). 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231026,,PH,ES,ES,2023,Q4,Adult
223864847,22386484,23,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,1 dosage form,,,Y,,,,,,,,,2023,Q4,Hyperhidrosis,,2023,Q4,7,F,,20231019.0,20230531,20231026,EXP,,ES-AUROBINDO-AUR-APL-2023-036025,AUROBINDO,"Abdala S, Devora S, Oliva AM, Morales C. El valor a?adido de los servicios profesionales farmac?uticos asistenciales. Un caso de SFT (The added value of professional pharmaceutical care services. A case of SFT),. Farmaceuticos comunitarios (Community Farms). 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231026,,PH,ES,ES,2023,Q4,Adult
223864847,22386484,24,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"5 milligram, Two Times a Day (1000 mg/5 mg (ax1-0-1-0), Two Times a Day",,,Y,,,,,5.0,MG,,BID,2023,Q4,Somnolence,,2023,Q4,7,F,,20231019.0,20230531,20231026,EXP,,ES-AUROBINDO-AUR-APL-2023-036025,AUROBINDO,"Abdala S, Devora S, Oliva AM, Morales C. El valor a?adido de los servicios profesionales farmac?uticos asistenciales. Un caso de SFT (The added value of professional pharmaceutical care services. A case of SFT),. Farmaceuticos comunitarios (Community Farms). 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231026,,PH,ES,ES,2023,Q4,Adult
223864847,22386484,24,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"5 milligram, Two Times a Day (1000 mg/5 mg (ax1-0-1-0), Two Times a Day",,,Y,,,,,5.0,MG,,BID,2023,Q4,Hypotension,,2023,Q4,7,F,,20231019.0,20230531,20231026,EXP,,ES-AUROBINDO-AUR-APL-2023-036025,AUROBINDO,"Abdala S, Devora S, Oliva AM, Morales C. El valor a?adido de los servicios profesionales farmac?uticos asistenciales. Un caso de SFT (The added value of professional pharmaceutical care services. A case of SFT),. Farmaceuticos comunitarios (Community Farms). 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231026,,PH,ES,ES,2023,Q4,Adult
223864847,22386484,24,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"5 milligram, Two Times a Day (1000 mg/5 mg (ax1-0-1-0), Two Times a Day",,,Y,,,,,5.0,MG,,BID,2023,Q4,Parkinsonism,,2023,Q4,7,F,,20231019.0,20230531,20231026,EXP,,ES-AUROBINDO-AUR-APL-2023-036025,AUROBINDO,"Abdala S, Devora S, Oliva AM, Morales C. El valor a?adido de los servicios profesionales farmac?uticos asistenciales. Un caso de SFT (The added value of professional pharmaceutical care services. A case of SFT),. Farmaceuticos comunitarios (Community Farms). 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231026,,PH,ES,ES,2023,Q4,Adult
223864847,22386484,24,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"5 milligram, Two Times a Day (1000 mg/5 mg (ax1-0-1-0), Two Times a Day",,,Y,,,,,5.0,MG,,BID,2023,Q4,Drug interaction,,2023,Q4,7,F,,20231019.0,20230531,20231026,EXP,,ES-AUROBINDO-AUR-APL-2023-036025,AUROBINDO,"Abdala S, Devora S, Oliva AM, Morales C. El valor a?adido de los servicios profesionales farmac?uticos asistenciales. Un caso de SFT (The added value of professional pharmaceutical care services. A case of SFT),. Farmaceuticos comunitarios (Community Farms). 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231026,,PH,ES,ES,2023,Q4,Adult
223864847,22386484,24,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"5 milligram, Two Times a Day (1000 mg/5 mg (ax1-0-1-0), Two Times a Day",,,Y,,,,,5.0,MG,,BID,2023,Q4,Tachycardia,,2023,Q4,7,F,,20231019.0,20230531,20231026,EXP,,ES-AUROBINDO-AUR-APL-2023-036025,AUROBINDO,"Abdala S, Devora S, Oliva AM, Morales C. El valor a?adido de los servicios profesionales farmac?uticos asistenciales. Un caso de SFT (The added value of professional pharmaceutical care services. A case of SFT),. Farmaceuticos comunitarios (Community Farms). 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231026,,PH,ES,ES,2023,Q4,Adult
223864847,22386484,24,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"5 milligram, Two Times a Day (1000 mg/5 mg (ax1-0-1-0), Two Times a Day",,,Y,,,,,5.0,MG,,BID,2023,Q4,Hallucination,,2023,Q4,7,F,,20231019.0,20230531,20231026,EXP,,ES-AUROBINDO-AUR-APL-2023-036025,AUROBINDO,"Abdala S, Devora S, Oliva AM, Morales C. El valor a?adido de los servicios profesionales farmac?uticos asistenciales. Un caso de SFT (The added value of professional pharmaceutical care services. A case of SFT),. Farmaceuticos comunitarios (Community Farms). 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231026,,PH,ES,ES,2023,Q4,Adult
223864847,22386484,24,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"5 milligram, Two Times a Day (1000 mg/5 mg (ax1-0-1-0), Two Times a Day",,,Y,,,,,5.0,MG,,BID,2023,Q4,Hypoglycaemia,,2023,Q4,7,F,,20231019.0,20230531,20231026,EXP,,ES-AUROBINDO-AUR-APL-2023-036025,AUROBINDO,"Abdala S, Devora S, Oliva AM, Morales C. El valor a?adido de los servicios profesionales farmac?uticos asistenciales. Un caso de SFT (The added value of professional pharmaceutical care services. A case of SFT),. Farmaceuticos comunitarios (Community Farms). 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231026,,PH,ES,ES,2023,Q4,Adult
223864847,22386484,24,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"5 milligram, Two Times a Day (1000 mg/5 mg (ax1-0-1-0), Two Times a Day",,,Y,,,,,5.0,MG,,BID,2023,Q4,Hyperhidrosis,,2023,Q4,7,F,,20231019.0,20230531,20231026,EXP,,ES-AUROBINDO-AUR-APL-2023-036025,AUROBINDO,"Abdala S, Devora S, Oliva AM, Morales C. El valor a?adido de los servicios profesionales farmac?uticos asistenciales. Un caso de SFT (The added value of professional pharmaceutical care services. A case of SFT),. Farmaceuticos comunitarios (Community Farms). 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231026,,PH,ES,ES,2023,Q4,Adult
223864847,22386484,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, Daily (1-0-1-0)",,,Y,,,,,,,,,2023,Q4,Somnolence,,2023,Q4,7,F,,20231019.0,20230531,20231026,EXP,,ES-AUROBINDO-AUR-APL-2023-036025,AUROBINDO,"Abdala S, Devora S, Oliva AM, Morales C. El valor a?adido de los servicios profesionales farmac?uticos asistenciales. Un caso de SFT (The added value of professional pharmaceutical care services. A case of SFT),. Farmaceuticos comunitarios (Community Farms). 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231026,,PH,ES,ES,2023,Q4,Adult
223864847,22386484,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, Daily (1-0-1-0)",,,Y,,,,,,,,,2023,Q4,Hypotension,,2023,Q4,7,F,,20231019.0,20230531,20231026,EXP,,ES-AUROBINDO-AUR-APL-2023-036025,AUROBINDO,"Abdala S, Devora S, Oliva AM, Morales C. El valor a?adido de los servicios profesionales farmac?uticos asistenciales. Un caso de SFT (The added value of professional pharmaceutical care services. A case of SFT),. Farmaceuticos comunitarios (Community Farms). 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231026,,PH,ES,ES,2023,Q4,Adult
223864847,22386484,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, Daily (1-0-1-0)",,,Y,,,,,,,,,2023,Q4,Parkinsonism,,2023,Q4,7,F,,20231019.0,20230531,20231026,EXP,,ES-AUROBINDO-AUR-APL-2023-036025,AUROBINDO,"Abdala S, Devora S, Oliva AM, Morales C. El valor a?adido de los servicios profesionales farmac?uticos asistenciales. Un caso de SFT (The added value of professional pharmaceutical care services. A case of SFT),. Farmaceuticos comunitarios (Community Farms). 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231026,,PH,ES,ES,2023,Q4,Adult
223864847,22386484,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, Daily (1-0-1-0)",,,Y,,,,,,,,,2023,Q4,Drug interaction,,2023,Q4,7,F,,20231019.0,20230531,20231026,EXP,,ES-AUROBINDO-AUR-APL-2023-036025,AUROBINDO,"Abdala S, Devora S, Oliva AM, Morales C. El valor a?adido de los servicios profesionales farmac?uticos asistenciales. Un caso de SFT (The added value of professional pharmaceutical care services. A case of SFT),. Farmaceuticos comunitarios (Community Farms). 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231026,,PH,ES,ES,2023,Q4,Adult
223864847,22386484,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, Daily (1-0-1-0)",,,Y,,,,,,,,,2023,Q4,Tachycardia,,2023,Q4,7,F,,20231019.0,20230531,20231026,EXP,,ES-AUROBINDO-AUR-APL-2023-036025,AUROBINDO,"Abdala S, Devora S, Oliva AM, Morales C. El valor a?adido de los servicios profesionales farmac?uticos asistenciales. Un caso de SFT (The added value of professional pharmaceutical care services. A case of SFT),. Farmaceuticos comunitarios (Community Farms). 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231026,,PH,ES,ES,2023,Q4,Adult
223864847,22386484,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, Daily (1-0-1-0)",,,Y,,,,,,,,,2023,Q4,Hallucination,,2023,Q4,7,F,,20231019.0,20230531,20231026,EXP,,ES-AUROBINDO-AUR-APL-2023-036025,AUROBINDO,"Abdala S, Devora S, Oliva AM, Morales C. El valor a?adido de los servicios profesionales farmac?uticos asistenciales. Un caso de SFT (The added value of professional pharmaceutical care services. A case of SFT),. Farmaceuticos comunitarios (Community Farms). 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231026,,PH,ES,ES,2023,Q4,Adult
223864847,22386484,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, Daily (1-0-1-0)",,,Y,,,,,,,,,2023,Q4,Hypoglycaemia,,2023,Q4,7,F,,20231019.0,20230531,20231026,EXP,,ES-AUROBINDO-AUR-APL-2023-036025,AUROBINDO,"Abdala S, Devora S, Oliva AM, Morales C. El valor a?adido de los servicios profesionales farmac?uticos asistenciales. Un caso de SFT (The added value of professional pharmaceutical care services. A case of SFT),. Farmaceuticos comunitarios (Community Farms). 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231026,,PH,ES,ES,2023,Q4,Adult
223864847,22386484,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, Daily (1-0-1-0)",,,Y,,,,,,,,,2023,Q4,Hyperhidrosis,,2023,Q4,7,F,,20231019.0,20230531,20231026,EXP,,ES-AUROBINDO-AUR-APL-2023-036025,AUROBINDO,"Abdala S, Devora S, Oliva AM, Morales C. El valor a?adido de los servicios profesionales farmac?uticos asistenciales. Un caso de SFT (The added value of professional pharmaceutical care services. A case of SFT),. Farmaceuticos comunitarios (Community Farms). 2023;15(2):45-51",62.0,YR,,F,Y,90.0,KG,20231026,,PH,ES,ES,2023,Q4,Adult
223971438,22397143,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 MONTH AND A HALF THAT YOU STOPPED THE MEDICATION?1 tablet every 24 hours,,,,,,,,5.0,MG,,,2023,Q4,Balance disorder,,2023,Q4,8,F,20230511.0,20231207.0,20230602,20231212,EXP,,"CO-Ipsen Biopharmaceuticals, Inc.-2023-12985",IPSEN,,74.0,YR,E,F,Y,54.0,KG,20231212,,CN,CO,CO,2023,Q4,Elderly
223971438,22397143,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 MONTH AND A HALF THAT YOU STOPPED THE MEDICATION?1 tablet every 24 hours,,,,,,,,5.0,MG,,,2023,Q4,Arthralgia,,2023,Q4,8,F,20230511.0,20231207.0,20230602,20231212,EXP,,"CO-Ipsen Biopharmaceuticals, Inc.-2023-12985",IPSEN,,74.0,YR,E,F,Y,54.0,KG,20231212,,CN,CO,CO,2023,Q4,Elderly
223971438,22397143,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 MONTH AND A HALF THAT YOU STOPPED THE MEDICATION?1 tablet every 24 hours,,,,,,,,5.0,MG,,,2023,Q4,Fall,,2023,Q4,8,F,20230511.0,20231207.0,20230602,20231212,EXP,,"CO-Ipsen Biopharmaceuticals, Inc.-2023-12985",IPSEN,,74.0,YR,E,F,Y,54.0,KG,20231212,,CN,CO,CO,2023,Q4,Elderly
223971438,22397143,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 MONTH AND A HALF THAT YOU STOPPED THE MEDICATION?1 tablet every 24 hours,,,,,,,,5.0,MG,,,2023,Q4,Nasopharyngitis,,2023,Q4,8,F,20230511.0,20231207.0,20230602,20231212,EXP,,"CO-Ipsen Biopharmaceuticals, Inc.-2023-12985",IPSEN,,74.0,YR,E,F,Y,54.0,KG,20231212,,CN,CO,CO,2023,Q4,Elderly
223971438,22397143,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 MONTH AND A HALF THAT YOU STOPPED THE MEDICATION?1 tablet every 24 hours,,,,,,,,5.0,MG,,,2023,Q4,Pain in jaw,,2023,Q4,8,F,20230511.0,20231207.0,20230602,20231212,EXP,,"CO-Ipsen Biopharmaceuticals, Inc.-2023-12985",IPSEN,,74.0,YR,E,F,Y,54.0,KG,20231212,,CN,CO,CO,2023,Q4,Elderly
223971438,22397143,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 MONTH AND A HALF THAT YOU STOPPED THE MEDICATION?1 tablet every 24 hours,,,,,,,,5.0,MG,,,2023,Q4,Laryngitis,,2023,Q4,8,F,20230511.0,20231207.0,20230602,20231212,EXP,,"CO-Ipsen Biopharmaceuticals, Inc.-2023-12985",IPSEN,,74.0,YR,E,F,Y,54.0,KG,20231212,,CN,CO,CO,2023,Q4,Elderly
223971438,22397143,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 MONTH AND A HALF THAT YOU STOPPED THE MEDICATION?1 tablet every 24 hours,,,,,,,,5.0,MG,,,2023,Q4,Fibromyalgia,,2023,Q4,8,F,20230511.0,20231207.0,20230602,20231212,EXP,,"CO-Ipsen Biopharmaceuticals, Inc.-2023-12985",IPSEN,,74.0,YR,E,F,Y,54.0,KG,20231212,,CN,CO,CO,2023,Q4,Elderly
223971438,22397143,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 MONTH AND A HALF THAT YOU STOPPED THE MEDICATION?1 tablet every 24 hours,,,,,,,,5.0,MG,,,2023,Q4,Blood sodium decreased,,2023,Q4,8,F,20230511.0,20231207.0,20230602,20231212,EXP,,"CO-Ipsen Biopharmaceuticals, Inc.-2023-12985",IPSEN,,74.0,YR,E,F,Y,54.0,KG,20231212,,CN,CO,CO,2023,Q4,Elderly
223971438,22397143,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 MONTH AND A HALF THAT YOU STOPPED THE MEDICATION?1 tablet every 24 hours,,,,,,,,5.0,MG,,,2023,Q4,Gastritis,,2023,Q4,8,F,20230511.0,20231207.0,20230602,20231212,EXP,,"CO-Ipsen Biopharmaceuticals, Inc.-2023-12985",IPSEN,,74.0,YR,E,F,Y,54.0,KG,20231212,,CN,CO,CO,2023,Q4,Elderly
223971438,22397143,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 MONTH AND A HALF THAT YOU STOPPED THE MEDICATION?1 tablet every 24 hours,,,,,,,,5.0,MG,,,2023,Q4,Migraine,,2023,Q4,8,F,20230511.0,20231207.0,20230602,20231212,EXP,,"CO-Ipsen Biopharmaceuticals, Inc.-2023-12985",IPSEN,,74.0,YR,E,F,Y,54.0,KG,20231212,,CN,CO,CO,2023,Q4,Elderly
223971438,22397143,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 MONTH AND A HALF THAT YOU STOPPED THE MEDICATION?1 tablet every 24 hours,,,,,,,,5.0,MG,,,2023,Q4,Angina pectoris,,2023,Q4,8,F,20230511.0,20231207.0,20230602,20231212,EXP,,"CO-Ipsen Biopharmaceuticals, Inc.-2023-12985",IPSEN,,74.0,YR,E,F,Y,54.0,KG,20231212,,CN,CO,CO,2023,Q4,Elderly
223971438,22397143,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 MONTH AND A HALF THAT YOU STOPPED THE MEDICATION?1 tablet every 24 hours,,,,,,,,5.0,MG,,,2023,Q4,Cerebrovascular accident,,2023,Q4,8,F,20230511.0,20231207.0,20230602,20231212,EXP,,"CO-Ipsen Biopharmaceuticals, Inc.-2023-12985",IPSEN,,74.0,YR,E,F,Y,54.0,KG,20231212,,CN,CO,CO,2023,Q4,Elderly
223971438,22397143,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 MONTH AND A HALF THAT YOU STOPPED THE MEDICATION?1 tablet every 24 hours,,,,,,,,5.0,MG,,,2023,Q4,Product dose omission issue,,2023,Q4,8,F,20230511.0,20231207.0,20230602,20231212,EXP,,"CO-Ipsen Biopharmaceuticals, Inc.-2023-12985",IPSEN,,74.0,YR,E,F,Y,54.0,KG,20231212,,CN,CO,CO,2023,Q4,Elderly
223971438,22397143,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 MONTH AND A HALF THAT YOU STOPPED THE MEDICATION?1 tablet every 24 hours,,,,,,,,5.0,MG,,,2023,Q4,Toothache,,2023,Q4,8,F,20230511.0,20231207.0,20230602,20231212,EXP,,"CO-Ipsen Biopharmaceuticals, Inc.-2023-12985",IPSEN,,74.0,YR,E,F,Y,54.0,KG,20231212,,CN,CO,CO,2023,Q4,Elderly
223971438,22397143,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 MONTH AND A HALF THAT YOU STOPPED THE MEDICATION?1 tablet every 24 hours,,,,,,,,5.0,MG,,,2023,Q4,Insomnia,,2023,Q4,8,F,20230511.0,20231207.0,20230602,20231212,EXP,,"CO-Ipsen Biopharmaceuticals, Inc.-2023-12985",IPSEN,,74.0,YR,E,F,Y,54.0,KG,20231212,,CN,CO,CO,2023,Q4,Elderly
223971438,22397143,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 MONTH AND A HALF THAT YOU STOPPED THE MEDICATION?1 tablet every 24 hours,,,,,,,,5.0,MG,,,2023,Q4,Rhinalgia,,2023,Q4,8,F,20230511.0,20231207.0,20230602,20231212,EXP,,"CO-Ipsen Biopharmaceuticals, Inc.-2023-12985",IPSEN,,74.0,YR,E,F,Y,54.0,KG,20231212,,CN,CO,CO,2023,Q4,Elderly
223971438,22397143,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 MONTH AND A HALF THAT YOU STOPPED THE MEDICATION?1 tablet every 24 hours,,,,,,,,5.0,MG,,,2023,Q4,Hypertension,,2023,Q4,8,F,20230511.0,20231207.0,20230602,20231212,EXP,,"CO-Ipsen Biopharmaceuticals, Inc.-2023-12985",IPSEN,,74.0,YR,E,F,Y,54.0,KG,20231212,,CN,CO,CO,2023,Q4,Elderly
223971438,22397143,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 MONTH AND A HALF THAT YOU STOPPED THE MEDICATION?1 tablet every 24 hours,,,,,,,,5.0,MG,,,2023,Q4,Product supply issue,,2023,Q4,8,F,20230511.0,20231207.0,20230602,20231212,EXP,,"CO-Ipsen Biopharmaceuticals, Inc.-2023-12985",IPSEN,,74.0,YR,E,F,Y,54.0,KG,20231212,,CN,CO,CO,2023,Q4,Elderly
223971438,22397143,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 MONTH AND A HALF THAT YOU STOPPED THE MEDICATION?1 tablet every 24 hours,,,,,,,,5.0,MG,,,2023,Q4,Insulin-like growth factor,,2023,Q4,8,F,20230511.0,20231207.0,20230602,20231212,EXP,,"CO-Ipsen Biopharmaceuticals, Inc.-2023-12985",IPSEN,,74.0,YR,E,F,Y,54.0,KG,20231212,,CN,CO,CO,2023,Q4,Elderly
223971438,22397143,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 MONTH AND A HALF THAT YOU STOPPED THE MEDICATION?1 tablet every 24 hours,,,,,,,,5.0,MG,,,2023,Q4,Body height decreased,,2023,Q4,8,F,20230511.0,20231207.0,20230602,20231212,EXP,,"CO-Ipsen Biopharmaceuticals, Inc.-2023-12985",IPSEN,,74.0,YR,E,F,Y,54.0,KG,20231212,,CN,CO,CO,2023,Q4,Elderly
223973843,22397384,30,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2023,Q4,Coronary artery disease,,2023,Q4,3,F,20230114.0,20231026.0,20230602,20231030,EXP,,DE-TAKEDA-2023TUS053538,TAKEDA,,56.0,YR,,M,Y,142.0,KG,20231030,,MD,DE,DE,2023,Q4,Adult
223973843,22397384,30,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2023,Q4,Pneumonia,,2023,Q4,3,F,20230114.0,20231026.0,20230602,20231030,EXP,,DE-TAKEDA-2023TUS053538,TAKEDA,,56.0,YR,,M,Y,142.0,KG,20231030,,MD,DE,DE,2023,Q4,Adult
225353076,22535307,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q4,Anaemia,,2023,Q4,6,F,20230512.0,20231115.0,20230608,20231121,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-2023-070743,BRISTOL MYERS SQUIBB,,75.0,YR,E,F,Y,76.0,KG,20231121,,MD,FR,FR,2023,Q4,Elderly
225353076,22535307,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q4,Pneumonia,,2023,Q4,6,F,20230512.0,20231115.0,20230608,20231121,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-2023-070743,BRISTOL MYERS SQUIBB,,75.0,YR,E,F,Y,76.0,KG,20231121,,MD,FR,FR,2023,Q4,Elderly
225353076,22535307,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q4,COVID-19,,2023,Q4,6,F,20230512.0,20231115.0,20230608,20231121,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-2023-070743,BRISTOL MYERS SQUIBB,,75.0,YR,E,F,Y,76.0,KG,20231121,,MD,FR,FR,2023,Q4,Elderly
225353076,22535307,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q4,Asthenia,,2023,Q4,6,F,20230512.0,20231115.0,20230608,20231121,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-2023-070743,BRISTOL MYERS SQUIBB,,75.0,YR,E,F,Y,76.0,KG,20231121,,MD,FR,FR,2023,Q4,Elderly
225353076,22535307,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q4,Off label use,,2023,Q4,6,F,20230512.0,20231115.0,20230608,20231121,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-2023-070743,BRISTOL MYERS SQUIBB,,75.0,YR,E,F,Y,76.0,KG,20231121,,MD,FR,FR,2023,Q4,Elderly
225353076,22535307,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q4,Cardiac failure,,2023,Q4,6,F,20230512.0,20231115.0,20230608,20231121,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-2023-070743,BRISTOL MYERS SQUIBB,,75.0,YR,E,F,Y,76.0,KG,20231121,,MD,FR,FR,2023,Q4,Elderly
225353076,22535307,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q4,Lower respiratory tract infection,,2023,Q4,6,F,20230512.0,20231115.0,20230608,20231121,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-2023-070743,BRISTOL MYERS SQUIBB,,75.0,YR,E,F,Y,76.0,KG,20231121,,MD,FR,FR,2023,Q4,Elderly
225353076,22535307,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q4,Cough,,2023,Q4,6,F,20230512.0,20231115.0,20230608,20231121,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-2023-070743,BRISTOL MYERS SQUIBB,,75.0,YR,E,F,Y,76.0,KG,20231121,,MD,FR,FR,2023,Q4,Elderly
225353076,22535307,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q4,Abdominal pain upper,,2023,Q4,6,F,20230512.0,20231115.0,20230608,20231121,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-2023-070743,BRISTOL MYERS SQUIBB,,75.0,YR,E,F,Y,76.0,KG,20231121,,MD,FR,FR,2023,Q4,Elderly
225353076,22535307,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q4,Chills,,2023,Q4,6,F,20230512.0,20231115.0,20230608,20231121,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-2023-070743,BRISTOL MYERS SQUIBB,,75.0,YR,E,F,Y,76.0,KG,20231121,,MD,FR,FR,2023,Q4,Elderly
225353076,22535307,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q4,C-reactive protein increased,,2023,Q4,6,F,20230512.0,20231115.0,20230608,20231121,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-2023-070743,BRISTOL MYERS SQUIBB,,75.0,YR,E,F,Y,76.0,KG,20231121,,MD,FR,FR,2023,Q4,Elderly
225883863,22588386,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Asthenia,,2023,Q4,3,F,20230512.0,20230929.0,20230612,20231008,EXP,,FR-AUROBINDO-AUR-APL-2023-040963,AUROBINDO,,75.0,YR,,F,Y,76.0,KG,20231008,,MD,FR,FR,2023,Q4,Elderly
225883863,22588386,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Chills,,2023,Q4,3,F,20230512.0,20230929.0,20230612,20231008,EXP,,FR-AUROBINDO-AUR-APL-2023-040963,AUROBINDO,,75.0,YR,,F,Y,76.0,KG,20231008,,MD,FR,FR,2023,Q4,Elderly
225883863,22588386,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Abdominal pain upper,,2023,Q4,3,F,20230512.0,20230929.0,20230612,20231008,EXP,,FR-AUROBINDO-AUR-APL-2023-040963,AUROBINDO,,75.0,YR,,F,Y,76.0,KG,20231008,,MD,FR,FR,2023,Q4,Elderly
225883863,22588386,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Anaemia,,2023,Q4,3,F,20230512.0,20230929.0,20230612,20231008,EXP,,FR-AUROBINDO-AUR-APL-2023-040963,AUROBINDO,,75.0,YR,,F,Y,76.0,KG,20231008,,MD,FR,FR,2023,Q4,Elderly
225883863,22588386,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,COVID-19,,2023,Q4,3,F,20230512.0,20230929.0,20230612,20231008,EXP,,FR-AUROBINDO-AUR-APL-2023-040963,AUROBINDO,,75.0,YR,,F,Y,76.0,KG,20231008,,MD,FR,FR,2023,Q4,Elderly
225883863,22588386,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Cardiac failure,,2023,Q4,3,F,20230512.0,20230929.0,20230612,20231008,EXP,,FR-AUROBINDO-AUR-APL-2023-040963,AUROBINDO,,75.0,YR,,F,Y,76.0,KG,20231008,,MD,FR,FR,2023,Q4,Elderly
225883863,22588386,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Lower respiratory tract infection,,2023,Q4,3,F,20230512.0,20230929.0,20230612,20231008,EXP,,FR-AUROBINDO-AUR-APL-2023-040963,AUROBINDO,,75.0,YR,,F,Y,76.0,KG,20231008,,MD,FR,FR,2023,Q4,Elderly
225885555,22588555,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q4,Pyrexia,,2023,Q4,5,F,20230604.0,20231031.0,20230612,20231107,EXP,,AU-SA-2023SA172106,SANOFI AVENTIS,,63.0,YR,A,M,Y,81.0,KG,20231107,,MD,AU,AU,2023,Q4,Adult
225913579,22591357,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2023,Q4,Anaemia,,2023,Q4,9,F,20220930.0,20231127.0,20230612,20231201,EXP,,FR-MYLANLABS-2023M1058102,MYLAN,,75.0,YR,,F,Y,76.0,KG,20231201,,HP,FR,FR,2023,Q4,Elderly
225913579,22591357,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2023,Q4,Cardiac failure,,2023,Q4,9,F,20220930.0,20231127.0,20230612,20231201,EXP,,FR-MYLANLABS-2023M1058102,MYLAN,,75.0,YR,,F,Y,76.0,KG,20231201,,HP,FR,FR,2023,Q4,Elderly
225913579,22591357,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2023,Q4,Pneumonia,,2023,Q4,9,F,20220930.0,20231127.0,20230612,20231201,EXP,,FR-MYLANLABS-2023M1058102,MYLAN,,75.0,YR,,F,Y,76.0,KG,20231201,,HP,FR,FR,2023,Q4,Elderly
225913579,22591357,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2023,Q4,Abdominal pain upper,,2023,Q4,9,F,20220930.0,20231127.0,20230612,20231201,EXP,,FR-MYLANLABS-2023M1058102,MYLAN,,75.0,YR,,F,Y,76.0,KG,20231201,,HP,FR,FR,2023,Q4,Elderly
225913579,22591357,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2023,Q4,COVID-19,,2023,Q4,9,F,20220930.0,20231127.0,20230612,20231201,EXP,,FR-MYLANLABS-2023M1058102,MYLAN,,75.0,YR,,F,Y,76.0,KG,20231201,,HP,FR,FR,2023,Q4,Elderly
225913579,22591357,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2023,Q4,Chills,,2023,Q4,9,F,20220930.0,20231127.0,20230612,20231201,EXP,,FR-MYLANLABS-2023M1058102,MYLAN,,75.0,YR,,F,Y,76.0,KG,20231201,,HP,FR,FR,2023,Q4,Elderly
225913579,22591357,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2023,Q4,Lower respiratory tract infection,,2023,Q4,9,F,20220930.0,20231127.0,20230612,20231201,EXP,,FR-MYLANLABS-2023M1058102,MYLAN,,75.0,YR,,F,Y,76.0,KG,20231201,,HP,FR,FR,2023,Q4,Elderly
225913579,22591357,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2023,Q4,Off label use,,2023,Q4,9,F,20220930.0,20231127.0,20230612,20231201,EXP,,FR-MYLANLABS-2023M1058102,MYLAN,,75.0,YR,,F,Y,76.0,KG,20231201,,HP,FR,FR,2023,Q4,Elderly
225913579,22591357,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2023,Q4,C-reactive protein increased,,2023,Q4,9,F,20220930.0,20231127.0,20230612,20231201,EXP,,FR-MYLANLABS-2023M1058102,MYLAN,,75.0,YR,,F,Y,76.0,KG,20231201,,HP,FR,FR,2023,Q4,Elderly
225913579,22591357,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2023,Q4,Cough,,2023,Q4,9,F,20220930.0,20231127.0,20230612,20231201,EXP,,FR-MYLANLABS-2023M1058102,MYLAN,,75.0,YR,,F,Y,76.0,KG,20231201,,HP,FR,FR,2023,Q4,Elderly
225913579,22591357,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2023,Q4,Asthenia,,2023,Q4,9,F,20220930.0,20231127.0,20230612,20231201,EXP,,FR-MYLANLABS-2023M1058102,MYLAN,,75.0,YR,,F,Y,76.0,KG,20231201,,HP,FR,FR,2023,Q4,Elderly
226125663,22612566,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Neck pain,,2023,Q4,3,F,20230523.0,20231106.0,20230617,20231110,EXP,,NVSC2023GB136110,NOVARTIS,,54.0,YR,,M,Y,,,20231110,,CN,GB,GB,2023,Q4,Adult
226125663,22612566,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Back pain,,2023,Q4,3,F,20230523.0,20231106.0,20230617,20231110,EXP,,NVSC2023GB136110,NOVARTIS,,54.0,YR,,M,Y,,,20231110,,CN,GB,GB,2023,Q4,Adult
226125663,22612566,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Condition aggravated,,2023,Q4,3,F,20230523.0,20231106.0,20230617,20231110,EXP,,NVSC2023GB136110,NOVARTIS,,54.0,YR,,M,Y,,,20231110,,CN,GB,GB,2023,Q4,Adult
226125663,22612566,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Psoriasis,,2023,Q4,3,F,20230523.0,20231106.0,20230617,20231110,EXP,,NVSC2023GB136110,NOVARTIS,,54.0,YR,,M,Y,,,20231110,,CN,GB,GB,2023,Q4,Adult
226125663,22612566,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,COVID-19,,2023,Q4,3,F,20230523.0,20231106.0,20230617,20231110,EXP,,NVSC2023GB136110,NOVARTIS,,54.0,YR,,M,Y,,,20231110,,CN,GB,GB,2023,Q4,Adult
226125663,22612566,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Chest discomfort,,2023,Q4,3,F,20230523.0,20231106.0,20230617,20231110,EXP,,NVSC2023GB136110,NOVARTIS,,54.0,YR,,M,Y,,,20231110,,CN,GB,GB,2023,Q4,Adult
226125663,22612566,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Chest pain,,2023,Q4,3,F,20230523.0,20231106.0,20230617,20231110,EXP,,NVSC2023GB136110,NOVARTIS,,54.0,YR,,M,Y,,,20231110,,CN,GB,GB,2023,Q4,Adult
226125663,22612566,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Arthralgia,,2023,Q4,3,F,20230523.0,20231106.0,20230617,20231110,EXP,,NVSC2023GB136110,NOVARTIS,,54.0,YR,,M,Y,,,20231110,,CN,GB,GB,2023,Q4,Adult
226125663,22612566,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Lower respiratory tract infection,,2023,Q4,3,F,20230523.0,20231106.0,20230617,20231110,EXP,,NVSC2023GB136110,NOVARTIS,,54.0,YR,,M,Y,,,20231110,,CN,GB,GB,2023,Q4,Adult
226387482,22638748,2,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,2  dose unit(s) d,,,U,,,,,,,,,2023,Q4,Medication error,,2023,Q4,2,F,20220921.0,20231215.0,20230626,20231228,EXP,,NZ-NOVOPROD-1078520,NOVO NORDISK,,57.0,YR,,M,Y,,,20231228,,PH,NZ,NZ,2023,Q4,Adult
226387482,22638748,2,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,2  dose unit(s) d,,,U,,,,,,,,,2023,Q4,Diabetic ketoacidosis,,2023,Q4,2,F,20220921.0,20231215.0,20230626,20231228,EXP,,NZ-NOVOPROD-1078520,NOVO NORDISK,,57.0,YR,,M,Y,,,20231228,,PH,NZ,NZ,2023,Q4,Adult
226426934,22642693,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,UNK,,,U,U,,,,,,,,2023,Q4,Memory impairment,,2023,Q4,4,F,,20231010.0,20230627,20231018,EXP,,GB-AUROBINDO-AUR-APL-2023-044067,AUROBINDO,,78.0,YR,,F,Y,,,20231018,,CN,GB,GB,2023,Q4,Elderly
226426934,22642693,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,UNK,,,U,U,,,,,,,,2023,Q4,Dyspnoea exertional,,2023,Q4,4,F,,20231010.0,20230627,20231018,EXP,,GB-AUROBINDO-AUR-APL-2023-044067,AUROBINDO,,78.0,YR,,F,Y,,,20231018,,CN,GB,GB,2023,Q4,Elderly
226426934,22642693,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,UNK,,,U,U,,,,,,,,2023,Q4,Depression,,2023,Q4,4,F,,20231010.0,20230627,20231018,EXP,,GB-AUROBINDO-AUR-APL-2023-044067,AUROBINDO,,78.0,YR,,F,Y,,,20231018,,CN,GB,GB,2023,Q4,Elderly
226426934,22642693,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,UNK,,,U,U,,,,,,,,2023,Q4,Product prescribing issue,,2023,Q4,4,F,,20231010.0,20230627,20231018,EXP,,GB-AUROBINDO-AUR-APL-2023-044067,AUROBINDO,,78.0,YR,,F,Y,,,20231018,,CN,GB,GB,2023,Q4,Elderly
226426934,22642693,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,UNK,,,U,U,,,,,,,,2023,Q4,Pollakiuria,,2023,Q4,4,F,,20231010.0,20230627,20231018,EXP,,GB-AUROBINDO-AUR-APL-2023-044067,AUROBINDO,,78.0,YR,,F,Y,,,20231018,,CN,GB,GB,2023,Q4,Elderly
226426934,22642693,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,UNK,,,U,U,,,,,,,,2023,Q4,Fatigue,,2023,Q4,4,F,,20231010.0,20230627,20231018,EXP,,GB-AUROBINDO-AUR-APL-2023-044067,AUROBINDO,,78.0,YR,,F,Y,,,20231018,,CN,GB,GB,2023,Q4,Elderly
226426934,22642693,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,UNK,,,U,U,,,,,,,,2023,Q4,Cough,,2023,Q4,4,F,,20231010.0,20230627,20231018,EXP,,GB-AUROBINDO-AUR-APL-2023-044067,AUROBINDO,,78.0,YR,,F,Y,,,20231018,,CN,GB,GB,2023,Q4,Elderly
226426934,22642693,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,UNK,,,U,U,,,,,,,,2023,Q4,Inappropriate schedule of product administration,,2023,Q4,4,F,,20231010.0,20230627,20231018,EXP,,GB-AUROBINDO-AUR-APL-2023-044067,AUROBINDO,,78.0,YR,,F,Y,,,20231018,,CN,GB,GB,2023,Q4,Elderly
226426934,22642693,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,UNK,,,U,U,,,,,,,,2023,Q4,Device dislocation,,2023,Q4,4,F,,20231010.0,20230627,20231018,EXP,,GB-AUROBINDO-AUR-APL-2023-044067,AUROBINDO,,78.0,YR,,F,Y,,,20231018,,CN,GB,GB,2023,Q4,Elderly
226426934,22642693,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,UNK,,,U,U,,,,,,,,2023,Q4,Peripheral swelling,,2023,Q4,4,F,,20231010.0,20230627,20231018,EXP,,GB-AUROBINDO-AUR-APL-2023-044067,AUROBINDO,,78.0,YR,,F,Y,,,20231018,,CN,GB,GB,2023,Q4,Elderly
226426934,22642693,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,UNK,,,U,U,,,,,,,,2023,Q4,Muscle strain,,2023,Q4,4,F,,20231010.0,20230627,20231018,EXP,,GB-AUROBINDO-AUR-APL-2023-044067,AUROBINDO,,78.0,YR,,F,Y,,,20231018,,CN,GB,GB,2023,Q4,Elderly
226426934,22642693,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,UNK,,,U,U,,,,,,,,2023,Q4,Diastolic dysfunction,,2023,Q4,4,F,,20231010.0,20230627,20231018,EXP,,GB-AUROBINDO-AUR-APL-2023-044067,AUROBINDO,,78.0,YR,,F,Y,,,20231018,,CN,GB,GB,2023,Q4,Elderly
226426934,22642693,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,UNK,,,U,U,,,,,,,,2023,Q4,Poor venous access,,2023,Q4,4,F,,20231010.0,20230627,20231018,EXP,,GB-AUROBINDO-AUR-APL-2023-044067,AUROBINDO,,78.0,YR,,F,Y,,,20231018,,CN,GB,GB,2023,Q4,Elderly
226426934,22642693,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,UNK,,,U,U,,,,,,,,2023,Q4,Product distribution issue,,2023,Q4,4,F,,20231010.0,20230627,20231018,EXP,,GB-AUROBINDO-AUR-APL-2023-044067,AUROBINDO,,78.0,YR,,F,Y,,,20231018,,CN,GB,GB,2023,Q4,Elderly
226426934,22642693,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,UNK,,,U,U,,,,,,,,2023,Q4,Venous pressure increased,,2023,Q4,4,F,,20231010.0,20230627,20231018,EXP,,GB-AUROBINDO-AUR-APL-2023-044067,AUROBINDO,,78.0,YR,,F,Y,,,20231018,,CN,GB,GB,2023,Q4,Elderly
226426934,22642693,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,UNK,,,U,U,,,,,,,,2023,Q4,COVID-19,,2023,Q4,4,F,,20231010.0,20230627,20231018,EXP,,GB-AUROBINDO-AUR-APL-2023-044067,AUROBINDO,,78.0,YR,,F,Y,,,20231018,,CN,GB,GB,2023,Q4,Elderly
226426934,22642693,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,UNK,,,U,U,,,,,,,,2023,Q4,Pain in extremity,,2023,Q4,4,F,,20231010.0,20230627,20231018,EXP,,GB-AUROBINDO-AUR-APL-2023-044067,AUROBINDO,,78.0,YR,,F,Y,,,20231018,,CN,GB,GB,2023,Q4,Elderly
226426934,22642693,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,UNK,,,U,U,,,,,,,,2023,Q4,Fall,,2023,Q4,4,F,,20231010.0,20230627,20231018,EXP,,GB-AUROBINDO-AUR-APL-2023-044067,AUROBINDO,,78.0,YR,,F,Y,,,20231018,,CN,GB,GB,2023,Q4,Elderly
226426934,22642693,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Other,UNK,,,U,U,,,,,,,,2023,Q4,Tibia fracture,,2023,Q4,4,F,,20231010.0,20230627,20231018,EXP,,GB-AUROBINDO-AUR-APL-2023-044067,AUROBINDO,,78.0,YR,,F,Y,,,20231018,,CN,GB,GB,2023,Q4,Elderly
226426934,22642693,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK; ;,,,U,U,,,,,,,,2023,Q4,Memory impairment,,2023,Q4,4,F,,20231010.0,20230627,20231018,EXP,,GB-AUROBINDO-AUR-APL-2023-044067,AUROBINDO,,78.0,YR,,F,Y,,,20231018,,CN,GB,GB,2023,Q4,Elderly
226426934,22642693,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK; ;,,,U,U,,,,,,,,2023,Q4,Dyspnoea exertional,,2023,Q4,4,F,,20231010.0,20230627,20231018,EXP,,GB-AUROBINDO-AUR-APL-2023-044067,AUROBINDO,,78.0,YR,,F,Y,,,20231018,,CN,GB,GB,2023,Q4,Elderly
226426934,22642693,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK; ;,,,U,U,,,,,,,,2023,Q4,Depression,,2023,Q4,4,F,,20231010.0,20230627,20231018,EXP,,GB-AUROBINDO-AUR-APL-2023-044067,AUROBINDO,,78.0,YR,,F,Y,,,20231018,,CN,GB,GB,2023,Q4,Elderly
226426934,22642693,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK; ;,,,U,U,,,,,,,,2023,Q4,Product prescribing issue,,2023,Q4,4,F,,20231010.0,20230627,20231018,EXP,,GB-AUROBINDO-AUR-APL-2023-044067,AUROBINDO,,78.0,YR,,F,Y,,,20231018,,CN,GB,GB,2023,Q4,Elderly
226426934,22642693,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK; ;,,,U,U,,,,,,,,2023,Q4,Pollakiuria,,2023,Q4,4,F,,20231010.0,20230627,20231018,EXP,,GB-AUROBINDO-AUR-APL-2023-044067,AUROBINDO,,78.0,YR,,F,Y,,,20231018,,CN,GB,GB,2023,Q4,Elderly
226426934,22642693,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK; ;,,,U,U,,,,,,,,2023,Q4,Fatigue,,2023,Q4,4,F,,20231010.0,20230627,20231018,EXP,,GB-AUROBINDO-AUR-APL-2023-044067,AUROBINDO,,78.0,YR,,F,Y,,,20231018,,CN,GB,GB,2023,Q4,Elderly
226426934,22642693,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK; ;,,,U,U,,,,,,,,2023,Q4,Cough,,2023,Q4,4,F,,20231010.0,20230627,20231018,EXP,,GB-AUROBINDO-AUR-APL-2023-044067,AUROBINDO,,78.0,YR,,F,Y,,,20231018,,CN,GB,GB,2023,Q4,Elderly
226426934,22642693,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK; ;,,,U,U,,,,,,,,2023,Q4,Inappropriate schedule of product administration,,2023,Q4,4,F,,20231010.0,20230627,20231018,EXP,,GB-AUROBINDO-AUR-APL-2023-044067,AUROBINDO,,78.0,YR,,F,Y,,,20231018,,CN,GB,GB,2023,Q4,Elderly
226426934,22642693,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK; ;,,,U,U,,,,,,,,2023,Q4,Device dislocation,,2023,Q4,4,F,,20231010.0,20230627,20231018,EXP,,GB-AUROBINDO-AUR-APL-2023-044067,AUROBINDO,,78.0,YR,,F,Y,,,20231018,,CN,GB,GB,2023,Q4,Elderly
226426934,22642693,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK; ;,,,U,U,,,,,,,,2023,Q4,Peripheral swelling,,2023,Q4,4,F,,20231010.0,20230627,20231018,EXP,,GB-AUROBINDO-AUR-APL-2023-044067,AUROBINDO,,78.0,YR,,F,Y,,,20231018,,CN,GB,GB,2023,Q4,Elderly
226426934,22642693,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK; ;,,,U,U,,,,,,,,2023,Q4,Muscle strain,,2023,Q4,4,F,,20231010.0,20230627,20231018,EXP,,GB-AUROBINDO-AUR-APL-2023-044067,AUROBINDO,,78.0,YR,,F,Y,,,20231018,,CN,GB,GB,2023,Q4,Elderly
226426934,22642693,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK; ;,,,U,U,,,,,,,,2023,Q4,Diastolic dysfunction,,2023,Q4,4,F,,20231010.0,20230627,20231018,EXP,,GB-AUROBINDO-AUR-APL-2023-044067,AUROBINDO,,78.0,YR,,F,Y,,,20231018,,CN,GB,GB,2023,Q4,Elderly
226426934,22642693,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK; ;,,,U,U,,,,,,,,2023,Q4,Poor venous access,,2023,Q4,4,F,,20231010.0,20230627,20231018,EXP,,GB-AUROBINDO-AUR-APL-2023-044067,AUROBINDO,,78.0,YR,,F,Y,,,20231018,,CN,GB,GB,2023,Q4,Elderly
226426934,22642693,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK; ;,,,U,U,,,,,,,,2023,Q4,Product distribution issue,,2023,Q4,4,F,,20231010.0,20230627,20231018,EXP,,GB-AUROBINDO-AUR-APL-2023-044067,AUROBINDO,,78.0,YR,,F,Y,,,20231018,,CN,GB,GB,2023,Q4,Elderly
226426934,22642693,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK; ;,,,U,U,,,,,,,,2023,Q4,Venous pressure increased,,2023,Q4,4,F,,20231010.0,20230627,20231018,EXP,,GB-AUROBINDO-AUR-APL-2023-044067,AUROBINDO,,78.0,YR,,F,Y,,,20231018,,CN,GB,GB,2023,Q4,Elderly
226426934,22642693,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK; ;,,,U,U,,,,,,,,2023,Q4,COVID-19,,2023,Q4,4,F,,20231010.0,20230627,20231018,EXP,,GB-AUROBINDO-AUR-APL-2023-044067,AUROBINDO,,78.0,YR,,F,Y,,,20231018,,CN,GB,GB,2023,Q4,Elderly
226426934,22642693,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK; ;,,,U,U,,,,,,,,2023,Q4,Pain in extremity,,2023,Q4,4,F,,20231010.0,20230627,20231018,EXP,,GB-AUROBINDO-AUR-APL-2023-044067,AUROBINDO,,78.0,YR,,F,Y,,,20231018,,CN,GB,GB,2023,Q4,Elderly
226426934,22642693,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK; ;,,,U,U,,,,,,,,2023,Q4,Fall,,2023,Q4,4,F,,20231010.0,20230627,20231018,EXP,,GB-AUROBINDO-AUR-APL-2023-044067,AUROBINDO,,78.0,YR,,F,Y,,,20231018,,CN,GB,GB,2023,Q4,Elderly
226426934,22642693,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK; ;,,,U,U,,,,,,,,2023,Q4,Tibia fracture,,2023,Q4,4,F,,20231010.0,20230627,20231018,EXP,,GB-AUROBINDO-AUR-APL-2023-044067,AUROBINDO,,78.0,YR,,F,Y,,,20231018,,CN,GB,GB,2023,Q4,Elderly
226592612,22659261,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg le matin,,,,,,,,,,,,2023,Q4,Pulmonary embolism,,2023,Q4,2,F,20230101.0,20231006.0,20230630,20231013,EXP,,FR-JNJFOC-20230655646,JOHNSON AND JOHNSON,,73.0,YR,E,M,Y,91.0,KG,20231013,,PH,FR,FR,2023,Q4,Elderly
226592612,22659261,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg le matin,,,,,,,,,,,,2023,Q4,Respiratory distress,,2023,Q4,2,F,20230101.0,20231006.0,20230630,20231013,EXP,,FR-JNJFOC-20230655646,JOHNSON AND JOHNSON,,73.0,YR,E,M,Y,91.0,KG,20231013,,PH,FR,FR,2023,Q4,Elderly
226592612,22659261,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg le matin,,,,,,,,,,,,2023,Q4,Acute myocardial infarction,,2023,Q4,2,F,20230101.0,20231006.0,20230630,20231013,EXP,,FR-JNJFOC-20230655646,JOHNSON AND JOHNSON,,73.0,YR,E,M,Y,91.0,KG,20231013,,PH,FR,FR,2023,Q4,Elderly
226592612,22659261,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg le matin,,,,,,,,,,,,2023,Q4,Sepsis,,2023,Q4,2,F,20230101.0,20231006.0,20230630,20231013,EXP,,FR-JNJFOC-20230655646,JOHNSON AND JOHNSON,,73.0,YR,E,M,Y,91.0,KG,20231013,,PH,FR,FR,2023,Q4,Elderly
226673612,22667361,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q4,Hepatic steatosis,,2023,Q4,2,F,,20231120.0,20230704,20231123,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-246502",BOEHRINGER INGELHEIM,"Poloju A, Majety P, Groysman A. Pancreatitis in a 57-Year-Old Female Two Weeks After Initiation of Empagliflozin. AACE Clinical Case Reports. 2023;doi:10.1016/j.aace.2023.04.005.",57.0,YR,A,F,Y,,,20231124,,MD,US,US,2023,Q4,Adult
226673612,22667361,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q4,Pancreatitis acute,,2023,Q4,2,F,,20231120.0,20230704,20231123,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-246502",BOEHRINGER INGELHEIM,"Poloju A, Majety P, Groysman A. Pancreatitis in a 57-Year-Old Female Two Weeks After Initiation of Empagliflozin. AACE Clinical Case Reports. 2023;doi:10.1016/j.aace.2023.04.005.",57.0,YR,A,F,Y,,,20231124,,MD,US,US,2023,Q4,Adult
226922633,22692263,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q4,Respiratory syncytial virus infection,,2023,Q4,3,F,20230703.0,20231031.0,20230711,20231107,EXP,,AU-SA-2023SA206212,SANOFI AVENTIS,,63.0,YR,A,M,Y,76.9,KG,20231107,,MD,AU,AU,2023,Q4,Adult
226951622,22695162,4,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5 + 1000,,,,,unknown,,,,,,,2023,Q4,Peripheral vascular disorder,,2023,Q4,2,F,20230329.0,20231005.0,20230712,20231016,EXP,PT-INFARMED-J202306-948,PT-NOVOPROD-1087040,NOVO NORDISK,,66.0,YR,,F,Y,88.0,KG,20231016,,PH,PT,PT,2023,Q4,Elderly
227150573,22715057,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Unknown,,204629.0,10.0,MG,,QD,2023,Q4,Scrotal abscess,,2023,Q4,3,F,20220601.0,20231124.0,20230718,20231128,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-250149",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,66.0,KG,20231128,,MD,DE,DE,2023,Q4,Elderly
227150573,22715057,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Unknown,,204629.0,10.0,MG,,QD,2023,Q4,Cellulitis,,2023,Q4,3,F,20220601.0,20231124.0,20230718,20231128,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-250149",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,66.0,KG,20231128,,MD,DE,DE,2023,Q4,Elderly
227150573,22715057,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Unknown,,204629.0,10.0,MG,,QD,2023,Q4,Urogenital infection bacterial,,2023,Q4,3,F,20220601.0,20231124.0,20230718,20231128,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-250149",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,66.0,KG,20231128,,MD,DE,DE,2023,Q4,Elderly
227150573,22715057,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Unknown,,204629.0,10.0,MG,,QD,2023,Q4,Renal disorder,,2023,Q4,3,F,20220601.0,20231124.0,20230718,20231128,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-250149",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,66.0,KG,20231128,,MD,DE,DE,2023,Q4,Elderly
227150573,22715057,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Unknown,,204629.0,10.0,MG,,QD,2023,Q4,Allergy to arthropod bite,,2023,Q4,3,F,20220601.0,20231124.0,20230718,20231128,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-250149",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,66.0,KG,20231128,,MD,DE,DE,2023,Q4,Elderly
227150573,22715057,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Unknown,,204629.0,10.0,MG,,QD,2023,Q4,Epididymitis,,2023,Q4,3,F,20220601.0,20231124.0,20230718,20231128,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-250149",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,66.0,KG,20231128,,MD,DE,DE,2023,Q4,Elderly
227150573,22715057,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Unknown,,204629.0,10.0,MG,,QD,2023,Q4,Cyst,,2023,Q4,3,F,20220601.0,20231124.0,20230718,20231128,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-250149",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,66.0,KG,20231128,,MD,DE,DE,2023,Q4,Elderly
227150573,22715057,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Unknown,,204629.0,10.0,MG,,QD,2023,Q4,Orchitis,,2023,Q4,3,F,20220601.0,20231124.0,20230718,20231128,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-250149",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,66.0,KG,20231128,,MD,DE,DE,2023,Q4,Elderly
227231344,22723134,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, every 1 days, start date: in 2008",,,,,,,,,,,,2023,Q4,Febrile neutropenia,,2023,Q4,4,F,20230703.0,20231005.0,20230719,20231011,EXP,,IL-BAXTER-2023BAX026447,BAXTER,,68.0,YR,,F,Y,67.0,KG,20231011,,HP,IL,IL,2023,Q4,Elderly
227372084,22737208,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2023,Q4,Hyperglycaemia,,2023,Q4,4,F,20230714.0,20231025.0,20230721,20231101,EXP,,AU-SA-2023SA219807,SANOFI AVENTIS,,63.0,YR,A,M,Y,76.9,KG,20231101,,MD,AU,AU,2023,Q4,Adult
227395622,22739562,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Bradycardia,,2023,Q4,2,F,20171201.0,20231127.0,20230722,20231207,EXP,,CZ-AUROBINDO-AUR-APL-2023-048168,AUROBINDO,Svarcova T.. Dapagliflozin in the treatment of heart failure with preserved ejection fraction.. INTERNAL MEDICINE.. 2023;69(4):261-264,72.0,YR,,M,Y,,,20231207,,MD,CZ,CZ,2023,Q4,Elderly
227395622,22739562,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Cardiac failure,,2023,Q4,2,F,20171201.0,20231127.0,20230722,20231207,EXP,,CZ-AUROBINDO-AUR-APL-2023-048168,AUROBINDO,Svarcova T.. Dapagliflozin in the treatment of heart failure with preserved ejection fraction.. INTERNAL MEDICINE.. 2023;69(4):261-264,72.0,YR,,M,Y,,,20231207,,MD,CZ,CZ,2023,Q4,Elderly
227395622,22739562,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Pulmonary hypertension,,2023,Q4,2,F,20171201.0,20231127.0,20230722,20231207,EXP,,CZ-AUROBINDO-AUR-APL-2023-048168,AUROBINDO,Svarcova T.. Dapagliflozin in the treatment of heart failure with preserved ejection fraction.. INTERNAL MEDICINE.. 2023;69(4):261-264,72.0,YR,,M,Y,,,20231207,,MD,CZ,CZ,2023,Q4,Elderly
227395622,22739562,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Drug intolerance,,2023,Q4,2,F,20171201.0,20231127.0,20230722,20231207,EXP,,CZ-AUROBINDO-AUR-APL-2023-048168,AUROBINDO,Svarcova T.. Dapagliflozin in the treatment of heart failure with preserved ejection fraction.. INTERNAL MEDICINE.. 2023;69(4):261-264,72.0,YR,,M,Y,,,20231207,,MD,CZ,CZ,2023,Q4,Elderly
227512334,22751233,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,used dosage of 1-0-1-0,,,Y,,,,,5.0,MG,,,2023,Q4,Hyperhidrosis,,2023,Q4,4,F,,20231005.0,20230726,20231017,EXP,,ES-Accord-365213,ACCORD,"Abdala S, Devora S, Oliva AM, Morales C.. El valor anadido de los servicios profesionales farmaceucos asistenciales. Un caso de SFT (The added value of professional pharmaceucal care services. A case of SFT). Farmaceuticos comunitarios (Community Farms). 2023,15(2):45-51.",62.0,YR,A,F,Y,90.0,KG,20231017,,HP,ES,ES,2023,Q4,Adult
227512334,22751233,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,used dosage of 1-0-1-0,,,Y,,,,,5.0,MG,,,2023,Q4,Drug interaction,,2023,Q4,4,F,,20231005.0,20230726,20231017,EXP,,ES-Accord-365213,ACCORD,"Abdala S, Devora S, Oliva AM, Morales C.. El valor anadido de los servicios profesionales farmaceucos asistenciales. Un caso de SFT (The added value of professional pharmaceucal care services. A case of SFT). Farmaceuticos comunitarios (Community Farms). 2023,15(2):45-51.",62.0,YR,A,F,Y,90.0,KG,20231017,,HP,ES,ES,2023,Q4,Adult
227512334,22751233,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,used dosage of 1-0-1-0,,,Y,,,,,5.0,MG,,,2023,Q4,Somnolence,,2023,Q4,4,F,,20231005.0,20230726,20231017,EXP,,ES-Accord-365213,ACCORD,"Abdala S, Devora S, Oliva AM, Morales C.. El valor anadido de los servicios profesionales farmaceucos asistenciales. Un caso de SFT (The added value of professional pharmaceucal care services. A case of SFT). Farmaceuticos comunitarios (Community Farms). 2023,15(2):45-51.",62.0,YR,A,F,Y,90.0,KG,20231017,,HP,ES,ES,2023,Q4,Adult
227512334,22751233,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,used dosage of 1-0-1-0,,,Y,,,,,5.0,MG,,,2023,Q4,Tachycardia,,2023,Q4,4,F,,20231005.0,20230726,20231017,EXP,,ES-Accord-365213,ACCORD,"Abdala S, Devora S, Oliva AM, Morales C.. El valor anadido de los servicios profesionales farmaceucos asistenciales. Un caso de SFT (The added value of professional pharmaceucal care services. A case of SFT). Farmaceuticos comunitarios (Community Farms). 2023,15(2):45-51.",62.0,YR,A,F,Y,90.0,KG,20231017,,HP,ES,ES,2023,Q4,Adult
227512334,22751233,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,used dosage of 1-0-1-0,,,Y,,,,,5.0,MG,,,2023,Q4,Hypotension,,2023,Q4,4,F,,20231005.0,20230726,20231017,EXP,,ES-Accord-365213,ACCORD,"Abdala S, Devora S, Oliva AM, Morales C.. El valor anadido de los servicios profesionales farmaceucos asistenciales. Un caso de SFT (The added value of professional pharmaceucal care services. A case of SFT). Farmaceuticos comunitarios (Community Farms). 2023,15(2):45-51.",62.0,YR,A,F,Y,90.0,KG,20231017,,HP,ES,ES,2023,Q4,Adult
227512334,22751233,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,used dosage of 1-0-1-0,,,Y,,,,,5.0,MG,,,2023,Q4,Parkinsonism,,2023,Q4,4,F,,20231005.0,20230726,20231017,EXP,,ES-Accord-365213,ACCORD,"Abdala S, Devora S, Oliva AM, Morales C.. El valor anadido de los servicios profesionales farmaceucos asistenciales. Un caso de SFT (The added value of professional pharmaceucal care services. A case of SFT). Farmaceuticos comunitarios (Community Farms). 2023,15(2):45-51.",62.0,YR,A,F,Y,90.0,KG,20231017,,HP,ES,ES,2023,Q4,Adult
227512334,22751233,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,used dosage of 1-0-1-0,,,Y,,,,,5.0,MG,,,2023,Q4,Hallucination,,2023,Q4,4,F,,20231005.0,20230726,20231017,EXP,,ES-Accord-365213,ACCORD,"Abdala S, Devora S, Oliva AM, Morales C.. El valor anadido de los servicios profesionales farmaceucos asistenciales. Un caso de SFT (The added value of professional pharmaceucal care services. A case of SFT). Farmaceuticos comunitarios (Community Farms). 2023,15(2):45-51.",62.0,YR,A,F,Y,90.0,KG,20231017,,HP,ES,ES,2023,Q4,Adult
227512334,22751233,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,used dosage of 1-0-1-0,,,Y,,,,,5.0,MG,,,2023,Q4,Hypoglycaemia,,2023,Q4,4,F,,20231005.0,20230726,20231017,EXP,,ES-Accord-365213,ACCORD,"Abdala S, Devora S, Oliva AM, Morales C.. El valor anadido de los servicios profesionales farmaceucos asistenciales. Un caso de SFT (The added value of professional pharmaceucal care services. A case of SFT). Farmaceuticos comunitarios (Community Farms). 2023,15(2):45-51.",62.0,YR,A,F,Y,90.0,KG,20231017,,HP,ES,ES,2023,Q4,Adult
227512334,22751233,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,used dosage of 1-0-1-0,,,Y,,,,,5.0,MG,,,2023,Q4,Off label use,,2023,Q4,4,F,,20231005.0,20230726,20231017,EXP,,ES-Accord-365213,ACCORD,"Abdala S, Devora S, Oliva AM, Morales C.. El valor anadido de los servicios profesionales farmaceucos asistenciales. Un caso de SFT (The added value of professional pharmaceucal care services. A case of SFT). Farmaceuticos comunitarios (Community Farms). 2023,15(2):45-51.",62.0,YR,A,F,Y,90.0,KG,20231017,,HP,ES,ES,2023,Q4,Adult
227657642,22765764,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Asked But Unknown,,204629.0,10.0,MG,,QD,2023,Q4,Ketoacidosis,,2023,Q4,2,F,20220619.0,20231120.0,20230731,20231121,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-252425",BOEHRINGER INGELHEIM,,89.0,YR,E,M,Y,75.0,KG,20231121,,MD,DE,DE,2023,Q4,Elderly
227657642,22765764,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Asked But Unknown,,204629.0,10.0,MG,,QD,2023,Q4,Disturbance in attention,,2023,Q4,2,F,20220619.0,20231120.0,20230731,20231121,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-252425",BOEHRINGER INGELHEIM,,89.0,YR,E,M,Y,75.0,KG,20231121,,MD,DE,DE,2023,Q4,Elderly
227657642,22765764,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Asked But Unknown,,204629.0,10.0,MG,,QD,2023,Q4,Asthenia,,2023,Q4,2,F,20220619.0,20231120.0,20230731,20231121,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-252425",BOEHRINGER INGELHEIM,,89.0,YR,E,M,Y,75.0,KG,20231121,,MD,DE,DE,2023,Q4,Elderly
227657642,22765764,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Asked But Unknown,,204629.0,10.0,MG,,QD,2023,Q4,Dehydration,,2023,Q4,2,F,20220619.0,20231120.0,20230731,20231121,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-252425",BOEHRINGER INGELHEIM,,89.0,YR,E,M,Y,75.0,KG,20231121,,MD,DE,DE,2023,Q4,Elderly
227897574,22789757,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,,,,,,,,2023,Q4,Haemoglobin decreased,,2023,Q4,4,F,20230810.0,20231026.0,20230804,20231103,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-2023-108400,BRISTOL MYERS SQUIBB,,70.0,YR,E,M,Y,,,20231103,,MD,ES,ES,2023,Q4,Elderly
227897574,22789757,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,,,,,,,,2023,Q4,Febrile neutropenia,,2023,Q4,4,F,20230810.0,20231026.0,20230804,20231103,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-2023-108400,BRISTOL MYERS SQUIBB,,70.0,YR,E,M,Y,,,20231103,,MD,ES,ES,2023,Q4,Elderly
227897574,22789757,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,,,,,,,,2023,Q4,Hyperhidrosis,,2023,Q4,4,F,20230810.0,20231026.0,20230804,20231103,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-2023-108400,BRISTOL MYERS SQUIBB,,70.0,YR,E,M,Y,,,20231103,,MD,ES,ES,2023,Q4,Elderly
227897574,22789757,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,,,,,,,,2023,Q4,Fall,,2023,Q4,4,F,20230810.0,20231026.0,20230804,20231103,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-2023-108400,BRISTOL MYERS SQUIBB,,70.0,YR,E,M,Y,,,20231103,,MD,ES,ES,2023,Q4,Elderly
227897574,22789757,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,,,,,,,,2023,Q4,Nausea,,2023,Q4,4,F,20230810.0,20231026.0,20230804,20231103,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-2023-108400,BRISTOL MYERS SQUIBB,,70.0,YR,E,M,Y,,,20231103,,MD,ES,ES,2023,Q4,Elderly
227897574,22789757,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,,,,,,,,2023,Q4,Acute myeloid leukaemia,,2023,Q4,4,F,20230810.0,20231026.0,20230804,20231103,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-2023-108400,BRISTOL MYERS SQUIBB,,70.0,YR,E,M,Y,,,20231103,,MD,ES,ES,2023,Q4,Elderly
227897574,22789757,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,,,,,,,,2023,Q4,Haemolysis,,2023,Q4,4,F,20230810.0,20231026.0,20230804,20231103,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-2023-108400,BRISTOL MYERS SQUIBB,,70.0,YR,E,M,Y,,,20231103,,MD,ES,ES,2023,Q4,Elderly
227943522,22794352,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, Daily",,,U,,,,,,,,,2023,Q4,Swelling face,,2023,Q4,2,F,20230720.0,20231106.0,20230807,20231110,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-402189,RANBAXY,,50.0,YR,,M,Y,100.0,KG,20231110,,HP,GB,GB,2023,Q4,Adult
228054883,22805488,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q4,Hypovolaemic shock,,2023,Q4,3,F,20230707.0,20231128.0,20230809,20231208,PER,,US-JAZZ PHARMACEUTICALS-2023-US-016933,JAZZ,,74.0,YR,,M,Y,81.0,KG,20231208,,MD,US,US,2023,Q4,Elderly
228266474,22826647,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Febrile neutropenia,,2023,Q4,4,F,20230801.0,20231026.0,20230816,20231104,EXP,,ES-AUROBINDO-AUR-APL-2023-053945,AUROBINDO,,70.0,YR,,M,Y,,,20231104,,MD,ES,ES,2023,Q4,Elderly
228266474,22826647,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Haemoglobin decreased,,2023,Q4,4,F,20230801.0,20231026.0,20230816,20231104,EXP,,ES-AUROBINDO-AUR-APL-2023-053945,AUROBINDO,,70.0,YR,,M,Y,,,20231104,,MD,ES,ES,2023,Q4,Elderly
228266474,22826647,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Haemolysis,,2023,Q4,4,F,20230801.0,20231026.0,20230816,20231104,EXP,,ES-AUROBINDO-AUR-APL-2023-053945,AUROBINDO,,70.0,YR,,M,Y,,,20231104,,MD,ES,ES,2023,Q4,Elderly
228266474,22826647,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Hyperhidrosis,,2023,Q4,4,F,20230801.0,20231026.0,20230816,20231104,EXP,,ES-AUROBINDO-AUR-APL-2023-053945,AUROBINDO,,70.0,YR,,M,Y,,,20231104,,MD,ES,ES,2023,Q4,Elderly
228266474,22826647,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Nausea,,2023,Q4,4,F,20230801.0,20231026.0,20230816,20231104,EXP,,ES-AUROBINDO-AUR-APL-2023-053945,AUROBINDO,,70.0,YR,,M,Y,,,20231104,,MD,ES,ES,2023,Q4,Elderly
228266474,22826647,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Fall,,2023,Q4,4,F,20230801.0,20231026.0,20230816,20231104,EXP,,ES-AUROBINDO-AUR-APL-2023-053945,AUROBINDO,,70.0,YR,,M,Y,,,20231104,,MD,ES,ES,2023,Q4,Elderly
228266474,22826647,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Disease progression,,2023,Q4,4,F,20230801.0,20231026.0,20230816,20231104,EXP,,ES-AUROBINDO-AUR-APL-2023-053945,AUROBINDO,,70.0,YR,,M,Y,,,20231104,,MD,ES,ES,2023,Q4,Elderly
228284892,22828489,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"Empagliflozin 10mg po once daily (started January 12),",,,,,,,,10.0,MG,Unknown,QD,2023,Q4,Encephalopathy,,2023,Q4,2,F,20230118.0,20231020.0,20230816,20231031,EXP,,CA-JNJFOC-20230819708,JOHNSON AND JOHNSON,,71.0,YR,E,F,Y,154.0,KG,20231031,,PH,CA,CA,2023,Q4,Elderly
228284892,22828489,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"Empagliflozin 10mg po once daily (started January 12),",,,,,,,,10.0,MG,Unknown,QD,2023,Q4,Aspartate aminotransferase increased,,2023,Q4,2,F,20230118.0,20231020.0,20230816,20231031,EXP,,CA-JNJFOC-20230819708,JOHNSON AND JOHNSON,,71.0,YR,E,F,Y,154.0,KG,20231031,,PH,CA,CA,2023,Q4,Elderly
228284892,22828489,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"Empagliflozin 10mg po once daily (started January 12),",,,,,,,,10.0,MG,Unknown,QD,2023,Q4,Blood alkaline phosphatase increased,,2023,Q4,2,F,20230118.0,20231020.0,20230816,20231031,EXP,,CA-JNJFOC-20230819708,JOHNSON AND JOHNSON,,71.0,YR,E,F,Y,154.0,KG,20231031,,PH,CA,CA,2023,Q4,Elderly
228284892,22828489,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"Empagliflozin 10mg po once daily (started January 12),",,,,,,,,10.0,MG,Unknown,QD,2023,Q4,Blood lactate dehydrogenase increased,,2023,Q4,2,F,20230118.0,20231020.0,20230816,20231031,EXP,,CA-JNJFOC-20230819708,JOHNSON AND JOHNSON,,71.0,YR,E,F,Y,154.0,KG,20231031,,PH,CA,CA,2023,Q4,Elderly
228284892,22828489,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"Empagliflozin 10mg po once daily (started January 12),",,,,,,,,10.0,MG,Unknown,QD,2023,Q4,International normalised ratio increased,,2023,Q4,2,F,20230118.0,20231020.0,20230816,20231031,EXP,,CA-JNJFOC-20230819708,JOHNSON AND JOHNSON,,71.0,YR,E,F,Y,154.0,KG,20231031,,PH,CA,CA,2023,Q4,Elderly
228284892,22828489,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"Empagliflozin 10mg po once daily (started January 12),",,,,,,,,10.0,MG,Unknown,QD,2023,Q4,Alanine aminotransferase increased,,2023,Q4,2,F,20230118.0,20231020.0,20230816,20231031,EXP,,CA-JNJFOC-20230819708,JOHNSON AND JOHNSON,,71.0,YR,E,F,Y,154.0,KG,20231031,,PH,CA,CA,2023,Q4,Elderly
228284892,22828489,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"Empagliflozin 10mg po once daily (started January 12),",,,,,,,,10.0,MG,Unknown,QD,2023,Q4,Drug-induced liver injury,,2023,Q4,2,F,20230118.0,20231020.0,20230816,20231031,EXP,,CA-JNJFOC-20230819708,JOHNSON AND JOHNSON,,71.0,YR,E,F,Y,154.0,KG,20231031,,PH,CA,CA,2023,Q4,Elderly
228284892,22828489,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"Empagliflozin 10mg po once daily (started January 12),",,,,,,,,10.0,MG,Unknown,QD,2023,Q4,Blood bilirubin increased,,2023,Q4,2,F,20230118.0,20231020.0,20230816,20231031,EXP,,CA-JNJFOC-20230819708,JOHNSON AND JOHNSON,,71.0,YR,E,F,Y,154.0,KG,20231031,,PH,CA,CA,2023,Q4,Elderly
228284892,22828489,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"Empagliflozin 10mg po once daily (started January 12),",,,,,,,,10.0,MG,Unknown,QD,2023,Q4,Drug level increased,,2023,Q4,2,F,20230118.0,20231020.0,20230816,20231031,EXP,,CA-JNJFOC-20230819708,JOHNSON AND JOHNSON,,71.0,YR,E,F,Y,154.0,KG,20231031,,PH,CA,CA,2023,Q4,Elderly
228368972,22836897,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,UNKNOWN,,,10.0,MG,,,2023,Q4,Metabolic acidosis,,2023,Q4,2,F,20220611.0,20231120.0,20230818,20231124,EXP,,DE-TEVA-2023-DE-2917353,TEVA,,42.0,YR,A,M,Y,,,20231124,,MD,DE,DE,2023,Q4,Adult
228368972,22836897,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,UNKNOWN,,,10.0,MG,,,2023,Q4,Ketonuria,,2023,Q4,2,F,20220611.0,20231120.0,20230818,20231124,EXP,,DE-TEVA-2023-DE-2917353,TEVA,,42.0,YR,A,M,Y,,,20231124,,MD,DE,DE,2023,Q4,Adult
228368972,22836897,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,UNKNOWN,,,10.0,MG,,,2023,Q4,Vomiting,,2023,Q4,2,F,20220611.0,20231120.0,20230818,20231124,EXP,,DE-TEVA-2023-DE-2917353,TEVA,,42.0,YR,A,M,Y,,,20231124,,MD,DE,DE,2023,Q4,Adult
228368972,22836897,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,UNKNOWN,,,,,,,2023,Q4,Metabolic acidosis,,2023,Q4,2,F,20220611.0,20231120.0,20230818,20231124,EXP,,DE-TEVA-2023-DE-2917353,TEVA,,42.0,YR,A,M,Y,,,20231124,,MD,DE,DE,2023,Q4,Adult
228368972,22836897,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,UNKNOWN,,,,,,,2023,Q4,Ketonuria,,2023,Q4,2,F,20220611.0,20231120.0,20230818,20231124,EXP,,DE-TEVA-2023-DE-2917353,TEVA,,42.0,YR,A,M,Y,,,20231124,,MD,DE,DE,2023,Q4,Adult
228368972,22836897,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,UNKNOWN,,,,,,,2023,Q4,Vomiting,,2023,Q4,2,F,20220611.0,20231120.0,20230818,20231124,EXP,,DE-TEVA-2023-DE-2917353,TEVA,,42.0,YR,A,M,Y,,,20231124,,MD,DE,DE,2023,Q4,Adult
228383632,22838363,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Hepatitis C,,2023,Q4,2,F,20230714.0,20231019.0,20230818,20231026,EXP,,NVSC2023US180119,NOVARTIS,,62.0,YR,,M,Y,,,20231026,,CN,US,US,2023,Q4,Adult
228456554,22845655,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,,,,,,,,Unknown,,2023,Q4,Haemoglobin decreased,,2023,Q4,4,F,20230801.0,20231102.0,20230821,20231107,EXP,,ES-MYLANLABS-2023M1086355,MYLAN,,70.0,YR,,M,Y,,,20231107,,MD,ES,ES,2023,Q4,Elderly
228456554,22845655,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,,,,,,,,Unknown,,2023,Q4,Disease progression,,2023,Q4,4,F,20230801.0,20231102.0,20230821,20231107,EXP,,ES-MYLANLABS-2023M1086355,MYLAN,,70.0,YR,,M,Y,,,20231107,,MD,ES,ES,2023,Q4,Elderly
228456554,22845655,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,,,,,,,,Unknown,,2023,Q4,Febrile neutropenia,,2023,Q4,4,F,20230801.0,20231102.0,20230821,20231107,EXP,,ES-MYLANLABS-2023M1086355,MYLAN,,70.0,YR,,M,Y,,,20231107,,MD,ES,ES,2023,Q4,Elderly
228456554,22845655,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,,,,,,,,Unknown,,2023,Q4,Nausea,,2023,Q4,4,F,20230801.0,20231102.0,20230821,20231107,EXP,,ES-MYLANLABS-2023M1086355,MYLAN,,70.0,YR,,M,Y,,,20231107,,MD,ES,ES,2023,Q4,Elderly
228456554,22845655,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,,,,,,,,Unknown,,2023,Q4,Fall,,2023,Q4,4,F,20230801.0,20231102.0,20230821,20231107,EXP,,ES-MYLANLABS-2023M1086355,MYLAN,,70.0,YR,,M,Y,,,20231107,,MD,ES,ES,2023,Q4,Elderly
228456554,22845655,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,,,,,,,,Unknown,,2023,Q4,Haemolysis,,2023,Q4,4,F,20230801.0,20231102.0,20230821,20231107,EXP,,ES-MYLANLABS-2023M1086355,MYLAN,,70.0,YR,,M,Y,,,20231107,,MD,ES,ES,2023,Q4,Elderly
228456554,22845655,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,,,,,,,,Unknown,,2023,Q4,Hyperhidrosis,,2023,Q4,4,F,20230801.0,20231102.0,20230821,20231107,EXP,,ES-MYLANLABS-2023M1086355,MYLAN,,70.0,YR,,M,Y,,,20231107,,MD,ES,ES,2023,Q4,Elderly
228472092,22847209,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,end date: ongoing,,,,,,,,,,,,2023,Q4,Asthenia,,2023,Q4,2,F,20230101.0,20231117.0,20230822,20231123,EXP,,IT-TEVA-2023-IT-2917193,TEVA,,73.0,YR,E,M,Y,59.0,KG,20231124,,MD,IT,IT,2023,Q4,Elderly
228472092,22847209,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,end date: ongoing,,,,,,,,,,,,2023,Q4,Lymphopenia,,2023,Q4,2,F,20230101.0,20231117.0,20230822,20231123,EXP,,IT-TEVA-2023-IT-2917193,TEVA,,73.0,YR,E,M,Y,59.0,KG,20231124,,MD,IT,IT,2023,Q4,Elderly
228472092,22847209,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,end date: ongoing,,,,,,,,,,,,2023,Q4,Pneumonia legionella,,2023,Q4,2,F,20230101.0,20231117.0,20230822,20231123,EXP,,IT-TEVA-2023-IT-2917193,TEVA,,73.0,YR,E,M,Y,59.0,KG,20231124,,MD,IT,IT,2023,Q4,Elderly
228472092,22847209,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,end date: ongoing,,,,,,,,,,,,2023,Q4,Anaemia,,2023,Q4,2,F,20230101.0,20231117.0,20230822,20231123,EXP,,IT-TEVA-2023-IT-2917193,TEVA,,73.0,YR,E,M,Y,59.0,KG,20231124,,MD,IT,IT,2023,Q4,Elderly
228472092,22847209,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,end date: ongoing,,,,,,,,,,,,2023,Q4,Pyrexia,,2023,Q4,2,F,20230101.0,20231117.0,20230822,20231123,EXP,,IT-TEVA-2023-IT-2917193,TEVA,,73.0,YR,E,M,Y,59.0,KG,20231124,,MD,IT,IT,2023,Q4,Elderly
228534003,22853400,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd (each 24h)",,,,,,,,25.0,MG,,QD,2023,Q4,Diarrhoea,,2023,Q4,3,F,20230718.0,20231130.0,20230823,20231207,EXP,,ES-DSJP-DSE-2023-134192,DAIICHI,,68.0,YR,,F,Y,,,20231207,,MD,ES,ES,2023,Q4,Elderly
228534003,22853400,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd (each 24h)",,,,,,,,25.0,MG,,QD,2023,Q4,Bronchitis,,2023,Q4,3,F,20230718.0,20231130.0,20230823,20231207,EXP,,ES-DSJP-DSE-2023-134192,DAIICHI,,68.0,YR,,F,Y,,,20231207,,MD,ES,ES,2023,Q4,Elderly
228534003,22853400,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd (each 24h)",,,,,,,,25.0,MG,,QD,2023,Q4,Death,,2023,Q4,3,F,20230718.0,20231130.0,20230823,20231207,EXP,,ES-DSJP-DSE-2023-134192,DAIICHI,,68.0,YR,,F,Y,,,20231207,,MD,ES,ES,2023,Q4,Elderly
228534003,22853400,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd (each 24h)",,,,,,,,25.0,MG,,QD,2023,Q4,Cardiac failure,,2023,Q4,3,F,20230718.0,20231130.0,20230823,20231207,EXP,,ES-DSJP-DSE-2023-134192,DAIICHI,,68.0,YR,,F,Y,,,20231207,,MD,ES,ES,2023,Q4,Elderly
228534003,22853400,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Diarrhoea,,2023,Q4,3,F,20230718.0,20231130.0,20230823,20231207,EXP,,ES-DSJP-DSE-2023-134192,DAIICHI,,68.0,YR,,F,Y,,,20231207,,MD,ES,ES,2023,Q4,Elderly
228534003,22853400,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Bronchitis,,2023,Q4,3,F,20230718.0,20231130.0,20230823,20231207,EXP,,ES-DSJP-DSE-2023-134192,DAIICHI,,68.0,YR,,F,Y,,,20231207,,MD,ES,ES,2023,Q4,Elderly
228534003,22853400,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Death,,2023,Q4,3,F,20230718.0,20231130.0,20230823,20231207,EXP,,ES-DSJP-DSE-2023-134192,DAIICHI,,68.0,YR,,F,Y,,,20231207,,MD,ES,ES,2023,Q4,Elderly
228534003,22853400,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Cardiac failure,,2023,Q4,3,F,20230718.0,20231130.0,20230823,20231207,EXP,,ES-DSJP-DSE-2023-134192,DAIICHI,,68.0,YR,,F,Y,,,20231207,,MD,ES,ES,2023,Q4,Elderly
228673027,22867302,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,,,,,,,,Tablet,,2023,Q4,Death,,2023,Q4,7,F,20230610.0,20230929.0,20230825,20231003,EXP,,JP-ROCHE-3410409,ROCHE,,73.0,YR,,M,Y,,,20231003,,MD,JP,,2023,Q4,Elderly
228871312,22887131,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Pain in extremity,,2023,Q4,2,F,20230821.0,20231023.0,20230831,20231102,EXP,,CA-SANDOZ INC.-PHHY2019CA014011,SANDOZ,,53.0,YR,,F,Y,,,20231102,,CN,CA,CA,2023,Q4,Adult
228871312,22887131,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Rash,,2023,Q4,2,F,20230821.0,20231023.0,20230831,20231102,EXP,,CA-SANDOZ INC.-PHHY2019CA014011,SANDOZ,,53.0,YR,,F,Y,,,20231102,,CN,CA,CA,2023,Q4,Adult
228871312,22887131,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Peripheral swelling,,2023,Q4,2,F,20230821.0,20231023.0,20230831,20231102,EXP,,CA-SANDOZ INC.-PHHY2019CA014011,SANDOZ,,53.0,YR,,F,Y,,,20231102,,CN,CA,CA,2023,Q4,Adult
228871312,22887131,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,C-reactive protein increased,,2023,Q4,2,F,20230821.0,20231023.0,20230831,20231102,EXP,,CA-SANDOZ INC.-PHHY2019CA014011,SANDOZ,,53.0,YR,,F,Y,,,20231102,,CN,CA,CA,2023,Q4,Adult
228871312,22887131,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Platelet count decreased,,2023,Q4,2,F,20230821.0,20231023.0,20230831,20231102,EXP,,CA-SANDOZ INC.-PHHY2019CA014011,SANDOZ,,53.0,YR,,F,Y,,,20231102,,CN,CA,CA,2023,Q4,Adult
228871312,22887131,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Malaise,,2023,Q4,2,F,20230821.0,20231023.0,20230831,20231102,EXP,,CA-SANDOZ INC.-PHHY2019CA014011,SANDOZ,,53.0,YR,,F,Y,,,20231102,,CN,CA,CA,2023,Q4,Adult
228871312,22887131,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Alanine aminotransferase increased,,2023,Q4,2,F,20230821.0,20231023.0,20230831,20231102,EXP,,CA-SANDOZ INC.-PHHY2019CA014011,SANDOZ,,53.0,YR,,F,Y,,,20231102,,CN,CA,CA,2023,Q4,Adult
228871312,22887131,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Heart rate increased,,2023,Q4,2,F,20230821.0,20231023.0,20230831,20231102,EXP,,CA-SANDOZ INC.-PHHY2019CA014011,SANDOZ,,53.0,YR,,F,Y,,,20231102,,CN,CA,CA,2023,Q4,Adult
228871312,22887131,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Swelling,,2023,Q4,2,F,20230821.0,20231023.0,20230831,20231102,EXP,,CA-SANDOZ INC.-PHHY2019CA014011,SANDOZ,,53.0,YR,,F,Y,,,20231102,,CN,CA,CA,2023,Q4,Adult
228871312,22887131,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Muscle spasms,,2023,Q4,2,F,20230821.0,20231023.0,20230831,20231102,EXP,,CA-SANDOZ INC.-PHHY2019CA014011,SANDOZ,,53.0,YR,,F,Y,,,20231102,,CN,CA,CA,2023,Q4,Adult
228871312,22887131,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Cough,,2023,Q4,2,F,20230821.0,20231023.0,20230831,20231102,EXP,,CA-SANDOZ INC.-PHHY2019CA014011,SANDOZ,,53.0,YR,,F,Y,,,20231102,,CN,CA,CA,2023,Q4,Adult
228871312,22887131,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Colon cancer stage II,,2023,Q4,2,F,20230821.0,20231023.0,20230831,20231102,EXP,,CA-SANDOZ INC.-PHHY2019CA014011,SANDOZ,,53.0,YR,,F,Y,,,20231102,,CN,CA,CA,2023,Q4,Adult
229274492,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q4,Sepsis,,2023,Q4,2,F,20200110.0,20231101.0,20230911,20231107,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20231107,,CN,CA,CA,2023,Q4,Adult
229274492,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q4,Psoriasis,,2023,Q4,2,F,20200110.0,20231101.0,20230911,20231107,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20231107,,CN,CA,CA,2023,Q4,Adult
229274492,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q4,Incorrect dose administered,,2023,Q4,2,F,20200110.0,20231101.0,20230911,20231107,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20231107,,CN,CA,CA,2023,Q4,Adult
229274492,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q4,Pain,,2023,Q4,2,F,20200110.0,20231101.0,20230911,20231107,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20231107,,CN,CA,CA,2023,Q4,Adult
229274492,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q4,Arthropathy,,2023,Q4,2,F,20200110.0,20231101.0,20230911,20231107,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20231107,,CN,CA,CA,2023,Q4,Adult
229274492,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q4,Joint effusion,,2023,Q4,2,F,20200110.0,20231101.0,20230911,20231107,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20231107,,CN,CA,CA,2023,Q4,Adult
229274492,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q4,Cyst,,2023,Q4,2,F,20200110.0,20231101.0,20230911,20231107,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20231107,,CN,CA,CA,2023,Q4,Adult
229274492,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q4,Synovitis,,2023,Q4,2,F,20200110.0,20231101.0,20230911,20231107,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20231107,,CN,CA,CA,2023,Q4,Adult
229274492,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q4,Osteoarthritis,,2023,Q4,2,F,20200110.0,20231101.0,20230911,20231107,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20231107,,CN,CA,CA,2023,Q4,Adult
229274492,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q4,Pyrexia,,2023,Q4,2,F,20200110.0,20231101.0,20230911,20231107,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20231107,,CN,CA,CA,2023,Q4,Adult
229274492,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q4,Tendonitis,,2023,Q4,2,F,20200110.0,20231101.0,20230911,20231107,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20231107,,CN,CA,CA,2023,Q4,Adult
229274492,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q4,Rash,,2023,Q4,2,F,20200110.0,20231101.0,20230911,20231107,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20231107,,CN,CA,CA,2023,Q4,Adult
229274492,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q4,Arthritis,,2023,Q4,2,F,20200110.0,20231101.0,20230911,20231107,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20231107,,CN,CA,CA,2023,Q4,Adult
229274492,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q4,Nephrolithiasis,,2023,Q4,2,F,20200110.0,20231101.0,20230911,20231107,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20231107,,CN,CA,CA,2023,Q4,Adult
229274492,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q4,Antinuclear antibody positive,,2023,Q4,2,F,20200110.0,20231101.0,20230911,20231107,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20231107,,CN,CA,CA,2023,Q4,Adult
229274492,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q4,Vitamin B12 decreased,,2023,Q4,2,F,20200110.0,20231101.0,20230911,20231107,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20231107,,CN,CA,CA,2023,Q4,Adult
229274492,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q4,Injection site pain,,2023,Q4,2,F,20200110.0,20231101.0,20230911,20231107,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20231107,,CN,CA,CA,2023,Q4,Adult
229274492,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q4,Allergic sinusitis,,2023,Q4,2,F,20200110.0,20231101.0,20230911,20231107,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20231107,,CN,CA,CA,2023,Q4,Adult
229274492,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q4,C-reactive protein increased,,2023,Q4,2,F,20200110.0,20231101.0,20230911,20231107,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20231107,,CN,CA,CA,2023,Q4,Adult
229274492,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q4,Synovial disorder,,2023,Q4,2,F,20200110.0,20231101.0,20230911,20231107,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20231107,,CN,CA,CA,2023,Q4,Adult
229274492,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q4,Pain in extremity,,2023,Q4,2,F,20200110.0,20231101.0,20230911,20231107,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20231107,,CN,CA,CA,2023,Q4,Adult
229274492,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q4,Renal disorder,,2023,Q4,2,F,20200110.0,20231101.0,20230911,20231107,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20231107,,CN,CA,CA,2023,Q4,Adult
229274492,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q4,Joint swelling,,2023,Q4,2,F,20200110.0,20231101.0,20230911,20231107,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20231107,,CN,CA,CA,2023,Q4,Adult
229274492,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q4,Device issue,,2023,Q4,2,F,20200110.0,20231101.0,20230911,20231107,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20231107,,CN,CA,CA,2023,Q4,Adult
229274492,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q4,Wrong technique in device usage process,,2023,Q4,2,F,20200110.0,20231101.0,20230911,20231107,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20231107,,CN,CA,CA,2023,Q4,Adult
229274492,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q4,Oedema,,2023,Q4,2,F,20200110.0,20231101.0,20230911,20231107,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20231107,,CN,CA,CA,2023,Q4,Adult
229274492,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q4,Condition aggravated,,2023,Q4,2,F,20200110.0,20231101.0,20230911,20231107,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20231107,,CN,CA,CA,2023,Q4,Adult
229274492,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q4,Alanine aminotransferase increased,,2023,Q4,2,F,20200110.0,20231101.0,20230911,20231107,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20231107,,CN,CA,CA,2023,Q4,Adult
229274492,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q4,Blood uric acid increased,,2023,Q4,2,F,20200110.0,20231101.0,20230911,20231107,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20231107,,CN,CA,CA,2023,Q4,Adult
229274492,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q4,Drug ineffective,,2023,Q4,2,F,20200110.0,20231101.0,20230911,20231107,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20231107,,CN,CA,CA,2023,Q4,Adult
229274492,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q4,Injection site warmth,,2023,Q4,2,F,20200110.0,20231101.0,20230911,20231107,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20231107,,CN,CA,CA,2023,Q4,Adult
229274492,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q4,Blood iron decreased,,2023,Q4,2,F,20200110.0,20231101.0,20230911,20231107,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20231107,,CN,CA,CA,2023,Q4,Adult
229274492,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q4,Urinary tract infection,,2023,Q4,2,F,20200110.0,20231101.0,20230911,20231107,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20231107,,CN,CA,CA,2023,Q4,Adult
229274492,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q4,Hepatic enzyme increased,,2023,Q4,2,F,20200110.0,20231101.0,20230911,20231107,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20231107,,CN,CA,CA,2023,Q4,Adult
229274492,22927449,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Film-coated tablet,QD,2023,Q4,Arthralgia,,2023,Q4,2,F,20200110.0,20231101.0,20230911,20231107,EXP,,CA-SANDOZ INC.-NVSC2020CA010601,SANDOZ,,56.0,YR,,F,Y,,,20231107,,CN,CA,CA,2023,Q4,Adult
229322154,22932215,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Upper respiratory tract infection,,2023,Q4,4,F,20230301.0,20231130.0,20230912,20231211,EXP,,US-ABBVIE-5399598,ABBVIE,,70.0,YR,,F,Y,106.0,KG,20231211,,HP,US,US,2023,Q4,Elderly
229322154,22932215,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Left ventricular failure,,2023,Q4,4,F,20230301.0,20231130.0,20230912,20231211,EXP,,US-ABBVIE-5399598,ABBVIE,,70.0,YR,,F,Y,106.0,KG,20231211,,HP,US,US,2023,Q4,Elderly
229323934,22932393,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Malaise,,2023,Q4,4,F,20230627.0,20231113.0,20230912,20231117,EXP,,TR-JNJFOC-20230917596,JOHNSON AND JOHNSON,,40.0,YR,A,F,Y,,,20231117,,MD,TR,TR,2023,Q4,Adult
229323934,22932393,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Vomiting,,2023,Q4,4,F,20230627.0,20231113.0,20230912,20231117,EXP,,TR-JNJFOC-20230917596,JOHNSON AND JOHNSON,,40.0,YR,A,F,Y,,,20231117,,MD,TR,TR,2023,Q4,Adult
229323934,22932393,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Diarrhoea,,2023,Q4,4,F,20230627.0,20231113.0,20230912,20231117,EXP,,TR-JNJFOC-20230917596,JOHNSON AND JOHNSON,,40.0,YR,A,F,Y,,,20231117,,MD,TR,TR,2023,Q4,Adult
229323934,22932393,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Myocardial infarction,,2023,Q4,4,F,20230627.0,20231113.0,20230912,20231117,EXP,,TR-JNJFOC-20230917596,JOHNSON AND JOHNSON,,40.0,YR,A,F,Y,,,20231117,,MD,TR,TR,2023,Q4,Adult
229370352,22937035,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,25.0,MG,,QD,2023,Q4,Fournier's gangrene,,2023,Q4,2,F,20230103.0,20231012.0,20230912,20231016,EXP,,"NZ-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-259698",BOEHRINGER INGELHEIM,Cheer V. Gathering knowledge from adverse reaction reports: September 2023. Prescriber Update. 2023 Sep 07;3(44): 67-68.,51.0,YR,A,M,Y,,,20231016,,HP,NZ,NZ,2023,Q4,Adult
229379217,22937921,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q4,Chills,,2023,Q4,7,F,20220930.0,20231123.0,20230913,20231129,EXP,,FR-JNJFOC-20230547708,JOHNSON AND JOHNSON,,75.0,YR,E,F,Y,76.0,KG,20231129,,HP,FR,FR,2023,Q4,Elderly
229379217,22937921,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q4,Asthenia,,2023,Q4,7,F,20220930.0,20231123.0,20230913,20231129,EXP,,FR-JNJFOC-20230547708,JOHNSON AND JOHNSON,,75.0,YR,E,F,Y,76.0,KG,20231129,,HP,FR,FR,2023,Q4,Elderly
229379217,22937921,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q4,Abdominal pain upper,,2023,Q4,7,F,20220930.0,20231123.0,20230913,20231129,EXP,,FR-JNJFOC-20230547708,JOHNSON AND JOHNSON,,75.0,YR,E,F,Y,76.0,KG,20231129,,HP,FR,FR,2023,Q4,Elderly
229379217,22937921,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q4,Off label use,,2023,Q4,7,F,20220930.0,20231123.0,20230913,20231129,EXP,,FR-JNJFOC-20230547708,JOHNSON AND JOHNSON,,75.0,YR,E,F,Y,76.0,KG,20231129,,HP,FR,FR,2023,Q4,Elderly
229379217,22937921,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q4,Lower respiratory tract infection,,2023,Q4,7,F,20220930.0,20231123.0,20230913,20231129,EXP,,FR-JNJFOC-20230547708,JOHNSON AND JOHNSON,,75.0,YR,E,F,Y,76.0,KG,20231129,,HP,FR,FR,2023,Q4,Elderly
229379217,22937921,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q4,C-reactive protein increased,,2023,Q4,7,F,20220930.0,20231123.0,20230913,20231129,EXP,,FR-JNJFOC-20230547708,JOHNSON AND JOHNSON,,75.0,YR,E,F,Y,76.0,KG,20231129,,HP,FR,FR,2023,Q4,Elderly
229379217,22937921,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q4,Off label use,,2023,Q4,7,F,20220930.0,20231123.0,20230913,20231129,EXP,,FR-JNJFOC-20230547708,JOHNSON AND JOHNSON,,75.0,YR,E,F,Y,76.0,KG,20231129,,HP,FR,FR,2023,Q4,Elderly
229379217,22937921,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q4,Pneumonia,,2023,Q4,7,F,20220930.0,20231123.0,20230913,20231129,EXP,,FR-JNJFOC-20230547708,JOHNSON AND JOHNSON,,75.0,YR,E,F,Y,76.0,KG,20231129,,HP,FR,FR,2023,Q4,Elderly
229379217,22937921,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q4,Anaemia,,2023,Q4,7,F,20220930.0,20231123.0,20230913,20231129,EXP,,FR-JNJFOC-20230547708,JOHNSON AND JOHNSON,,75.0,YR,E,F,Y,76.0,KG,20231129,,HP,FR,FR,2023,Q4,Elderly
229379217,22937921,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q4,COVID-19,,2023,Q4,7,F,20220930.0,20231123.0,20230913,20231129,EXP,,FR-JNJFOC-20230547708,JOHNSON AND JOHNSON,,75.0,YR,E,F,Y,76.0,KG,20231129,,HP,FR,FR,2023,Q4,Elderly
229379217,22937921,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q4,Cardiac failure,,2023,Q4,7,F,20220930.0,20231123.0,20230913,20231129,EXP,,FR-JNJFOC-20230547708,JOHNSON AND JOHNSON,,75.0,YR,E,F,Y,76.0,KG,20231129,,HP,FR,FR,2023,Q4,Elderly
229379217,22937921,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q4,Cough,,2023,Q4,7,F,20220930.0,20231123.0,20230913,20231129,EXP,,FR-JNJFOC-20230547708,JOHNSON AND JOHNSON,,75.0,YR,E,F,Y,76.0,KG,20231129,,HP,FR,FR,2023,Q4,Elderly
229385922,22938592,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,Tablet,,2023,Q4,Discomfort,,2023,Q4,2,F,20190329.0,20230905.0,20230913,20231017,EXP,,"CO-Ipsen Biopharmaceuticals, Inc.-2023-18105",IPSEN,,70.0,YR,E,M,Y,80.0,KG,20231017,,CN,CO,CO,2023,Q4,Elderly
229385922,22938592,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,Tablet,,2023,Q4,Headache,,2023,Q4,2,F,20190329.0,20230905.0,20230913,20231017,EXP,,"CO-Ipsen Biopharmaceuticals, Inc.-2023-18105",IPSEN,,70.0,YR,E,M,Y,80.0,KG,20231017,,CN,CO,CO,2023,Q4,Elderly
229385922,22938592,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,Tablet,,2023,Q4,Diarrhoea,,2023,Q4,2,F,20190329.0,20230905.0,20230913,20231017,EXP,,"CO-Ipsen Biopharmaceuticals, Inc.-2023-18105",IPSEN,,70.0,YR,E,M,Y,80.0,KG,20231017,,CN,CO,CO,2023,Q4,Elderly
229385922,22938592,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,Tablet,,2023,Q4,Drug ineffective,,2023,Q4,2,F,20190329.0,20230905.0,20230913,20231017,EXP,,"CO-Ipsen Biopharmaceuticals, Inc.-2023-18105",IPSEN,,70.0,YR,E,M,Y,80.0,KG,20231017,,CN,CO,CO,2023,Q4,Elderly
229385922,22938592,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,Tablet,,2023,Q4,Diarrhoea,,2023,Q4,2,F,20190329.0,20230905.0,20230913,20231017,EXP,,"CO-Ipsen Biopharmaceuticals, Inc.-2023-18105",IPSEN,,70.0,YR,E,M,Y,80.0,KG,20231017,,CN,CO,CO,2023,Q4,Elderly
229385922,22938592,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,Tablet,,2023,Q4,Gait disturbance,,2023,Q4,2,F,20190329.0,20230905.0,20230913,20231017,EXP,,"CO-Ipsen Biopharmaceuticals, Inc.-2023-18105",IPSEN,,70.0,YR,E,M,Y,80.0,KG,20231017,,CN,CO,CO,2023,Q4,Elderly
229385922,22938592,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,Tablet,,2023,Q4,Neoplasm progression,,2023,Q4,2,F,20190329.0,20230905.0,20230913,20231017,EXP,,"CO-Ipsen Biopharmaceuticals, Inc.-2023-18105",IPSEN,,70.0,YR,E,M,Y,80.0,KG,20231017,,CN,CO,CO,2023,Q4,Elderly
229420552,22942055,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 Dosage forms Daily;,,,,,,,,,,Tablet,QD,2023,Q4,Joint swelling,,2023,Q4,2,F,,20230917.0,20230914,20231001,EXP,GB-MHRA-TPP41562309C8808880YC1693592144385,GB-TEVA-2023-GB-2925701,TEVA,,45.0,YR,A,F,Y,125.0,KG,20231001,,PH,GB,GB,2023,Q4,Adult
229420552,22942055,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 Dosage forms Daily;,,,,,,,,,,Tablet,QD,2023,Q4,Peripheral swelling,,2023,Q4,2,F,,20230917.0,20230914,20231001,EXP,GB-MHRA-TPP41562309C8808880YC1693592144385,GB-TEVA-2023-GB-2925701,TEVA,,45.0,YR,A,F,Y,125.0,KG,20231001,,PH,GB,GB,2023,Q4,Adult
229480735,22948073,11,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"1 dosage form, Two Times a Day",,,U,,,,,,,,BID,2023,Q4,Neurological symptom,,2023,Q4,5,F,,20231211.0,20230915,20231224,EXP,,ES-AUROBINDO-AUR-APL-2023-057463,AUROBINDO,"Macia-Rivas L, Maray I, Fernandez-Laguna CL, Alvarez-Asteinza C, Lozano-Blazquez A.. Exacerbation of a thrombotic thrombocytopenic purpura episode linked to different P2Y12 inhibitors in the same patient. Case report.. Farmacia Hospitalaria.. 2023;47:T294?T296",7.0,DEC,,M,Y,,,20231224,,PH,ES,ES,2023,Q4,Child
229480735,22948073,11,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"1 dosage form, Two Times a Day",,,U,,,,,,,,BID,2023,Q4,Condition aggravated,,2023,Q4,5,F,,20231211.0,20230915,20231224,EXP,,ES-AUROBINDO-AUR-APL-2023-057463,AUROBINDO,"Macia-Rivas L, Maray I, Fernandez-Laguna CL, Alvarez-Asteinza C, Lozano-Blazquez A.. Exacerbation of a thrombotic thrombocytopenic purpura episode linked to different P2Y12 inhibitors in the same patient. Case report.. Farmacia Hospitalaria.. 2023;47:T294?T296",7.0,DEC,,M,Y,,,20231224,,PH,ES,ES,2023,Q4,Child
229480735,22948073,11,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"1 dosage form, Two Times a Day",,,U,,,,,,,,BID,2023,Q4,Thrombotic thrombocytopenic purpura,,2023,Q4,5,F,,20231211.0,20230915,20231224,EXP,,ES-AUROBINDO-AUR-APL-2023-057463,AUROBINDO,"Macia-Rivas L, Maray I, Fernandez-Laguna CL, Alvarez-Asteinza C, Lozano-Blazquez A.. Exacerbation of a thrombotic thrombocytopenic purpura episode linked to different P2Y12 inhibitors in the same patient. Case report.. Farmacia Hospitalaria.. 2023;47:T294?T296",7.0,DEC,,M,Y,,,20231224,,PH,ES,ES,2023,Q4,Child
229484743,22948474,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Asthenia,,2023,Q4,3,F,20230507.0,20231122.0,20230915,20231201,EXP,,FR-TAKEDA-2023TUS088929,TAKEDA,,75.0,YR,,F,Y,76.0,KG,20231201,,HP,FR,FR,2023,Q4,Elderly
229484743,22948474,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Abdominal pain upper,,2023,Q4,3,F,20230507.0,20231122.0,20230915,20231201,EXP,,FR-TAKEDA-2023TUS088929,TAKEDA,,75.0,YR,,F,Y,76.0,KG,20231201,,HP,FR,FR,2023,Q4,Elderly
229484743,22948474,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Pneumonia,,2023,Q4,3,F,20230507.0,20231122.0,20230915,20231201,EXP,,FR-TAKEDA-2023TUS088929,TAKEDA,,75.0,YR,,F,Y,76.0,KG,20231201,,HP,FR,FR,2023,Q4,Elderly
229484743,22948474,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Cough,,2023,Q4,3,F,20230507.0,20231122.0,20230915,20231201,EXP,,FR-TAKEDA-2023TUS088929,TAKEDA,,75.0,YR,,F,Y,76.0,KG,20231201,,HP,FR,FR,2023,Q4,Elderly
229484743,22948474,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Lower respiratory tract infection,,2023,Q4,3,F,20230507.0,20231122.0,20230915,20231201,EXP,,FR-TAKEDA-2023TUS088929,TAKEDA,,75.0,YR,,F,Y,76.0,KG,20231201,,HP,FR,FR,2023,Q4,Elderly
229484743,22948474,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Off label use,,2023,Q4,3,F,20230507.0,20231122.0,20230915,20231201,EXP,,FR-TAKEDA-2023TUS088929,TAKEDA,,75.0,YR,,F,Y,76.0,KG,20231201,,HP,FR,FR,2023,Q4,Elderly
229484743,22948474,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Chills,,2023,Q4,3,F,20230507.0,20231122.0,20230915,20231201,EXP,,FR-TAKEDA-2023TUS088929,TAKEDA,,75.0,YR,,F,Y,76.0,KG,20231201,,HP,FR,FR,2023,Q4,Elderly
229484743,22948474,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Anaemia,,2023,Q4,3,F,20230507.0,20231122.0,20230915,20231201,EXP,,FR-TAKEDA-2023TUS088929,TAKEDA,,75.0,YR,,F,Y,76.0,KG,20231201,,HP,FR,FR,2023,Q4,Elderly
229484743,22948474,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,COVID-19,,2023,Q4,3,F,20230507.0,20231122.0,20230915,20231201,EXP,,FR-TAKEDA-2023TUS088929,TAKEDA,,75.0,YR,,F,Y,76.0,KG,20231201,,HP,FR,FR,2023,Q4,Elderly
229484743,22948474,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,C-reactive protein increased,,2023,Q4,3,F,20230507.0,20231122.0,20230915,20231201,EXP,,FR-TAKEDA-2023TUS088929,TAKEDA,,75.0,YR,,F,Y,76.0,KG,20231201,,HP,FR,FR,2023,Q4,Elderly
229484743,22948474,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Cardiac failure,,2023,Q4,3,F,20230507.0,20231122.0,20230915,20231201,EXP,,FR-TAKEDA-2023TUS088929,TAKEDA,,75.0,YR,,F,Y,76.0,KG,20231201,,HP,FR,FR,2023,Q4,Elderly
229518063,22951806,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,U,,Unknown,,204629.0,25.0,MG,Unknown (other/unspecified),,2023,Q4,Blood pressure decreased,,2023,Q4,3,F,,20231027.0,20230918,20231027,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-261467",BOEHRINGER INGELHEIM,,73.0,YR,E,M,Y,,,20231027,,MD,GR,GR,2023,Q4,Elderly
229518063,22951806,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,U,,Unknown,,204629.0,25.0,MG,Unknown (other/unspecified),,2023,Q4,Polyuria,,2023,Q4,3,F,,20231027.0,20230918,20231027,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-261467",BOEHRINGER INGELHEIM,,73.0,YR,E,M,Y,,,20231027,,MD,GR,GR,2023,Q4,Elderly
229518063,22951806,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,U,,Unknown,,204629.0,25.0,MG,Unknown (other/unspecified),,2023,Q4,Tachycardia,,2023,Q4,3,F,,20231027.0,20230918,20231027,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-261467",BOEHRINGER INGELHEIM,,73.0,YR,E,M,Y,,,20231027,,MD,GR,GR,2023,Q4,Elderly
229518063,22951806,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,U,,Unknown,,204629.0,25.0,MG,Unknown (other/unspecified),,2023,Q4,Euglycaemic diabetic ketoacidosis,,2023,Q4,3,F,,20231027.0,20230918,20231027,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-261467",BOEHRINGER INGELHEIM,,73.0,YR,E,M,Y,,,20231027,,MD,GR,GR,2023,Q4,Elderly
229518063,22951806,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,25.0,MG,,QD,2023,Q4,Blood pressure decreased,,2023,Q4,3,F,,20231027.0,20230918,20231027,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-261467",BOEHRINGER INGELHEIM,,73.0,YR,E,M,Y,,,20231027,,MD,GR,GR,2023,Q4,Elderly
229518063,22951806,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,25.0,MG,,QD,2023,Q4,Polyuria,,2023,Q4,3,F,,20231027.0,20230918,20231027,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-261467",BOEHRINGER INGELHEIM,,73.0,YR,E,M,Y,,,20231027,,MD,GR,GR,2023,Q4,Elderly
229518063,22951806,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,25.0,MG,,QD,2023,Q4,Tachycardia,,2023,Q4,3,F,,20231027.0,20230918,20231027,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-261467",BOEHRINGER INGELHEIM,,73.0,YR,E,M,Y,,,20231027,,MD,GR,GR,2023,Q4,Elderly
229518063,22951806,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,25.0,MG,,QD,2023,Q4,Euglycaemic diabetic ketoacidosis,,2023,Q4,3,F,,20231027.0,20230918,20231027,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-261467",BOEHRINGER INGELHEIM,,73.0,YR,E,M,Y,,,20231027,,MD,GR,GR,2023,Q4,Elderly
229548343,22954834,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK (1 tablet daily),,,U,,UNK,,,,,Tablet,,2023,Q4,Blood glucose increased,,2023,Q4,3,F,20230601.0,20231129.0,20230918,20231207,30DAY,,CO-NOVOPROD-1091586,NOVO NORDISK,,78.0,YR,,F,Y,69.0,KG,20231207,,CN,CO,CO,2023,Q4,Elderly
229548343,22954834,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK (1 tablet daily),,,U,,UNK,,,,,Tablet,,2023,Q4,Hypoglycaemic unconsciousness,,2023,Q4,3,F,20230601.0,20231129.0,20230918,20231207,30DAY,,CO-NOVOPROD-1091586,NOVO NORDISK,,78.0,YR,,F,Y,69.0,KG,20231207,,CN,CO,CO,2023,Q4,Elderly
229548343,22954834,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK (1 tablet daily),,,U,,UNK,,,,,Tablet,,2023,Q4,Device failure,,2023,Q4,3,F,20230601.0,20231129.0,20230918,20231207,30DAY,,CO-NOVOPROD-1091586,NOVO NORDISK,,78.0,YR,,F,Y,69.0,KG,20231207,,CN,CO,CO,2023,Q4,Elderly
229548343,22954834,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK (1 tablet daily),,,U,,UNK,,,,,Tablet,,2023,Q4,Drug ineffective,,2023,Q4,3,F,20230601.0,20231129.0,20230918,20231207,30DAY,,CO-NOVOPROD-1091586,NOVO NORDISK,,78.0,YR,,F,Y,69.0,KG,20231207,,CN,CO,CO,2023,Q4,Elderly
229565382,22956538,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Unknown,,204629.0,10.0,MG,,,2023,Q4,Lactic acidosis,,2023,Q4,2,F,20230821.0,20231120.0,20230919,20231120,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-261969",BOEHRINGER INGELHEIM,,82.0,YR,E,M,Y,,,20231120,,MD,DE,DE,2023,Q4,Elderly
229678926,22967892,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Lipase increased,,2023,Q4,6,F,20230821.0,20231109.0,20230921,20231115,EXP,,NVSC2023BR196646,NOVARTIS,,73.0,YR,,F,Y,66.8,KG,20231115,,MD,BR,BR,2023,Q4,Elderly
229684522,22968452,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q4,Gastroenteritis,,2023,Q4,2,F,20230831.0,20230928.0,20230921,20231005,EXP,,"TH-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-261449",BOEHRINGER INGELHEIM,,43.0,YR,A,F,Y,66.0,KG,20231005,,CN,TH,TH,2023,Q4,Adult
229684522,22968452,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q4,Euglycaemic diabetic ketoacidosis,,2023,Q4,2,F,20230831.0,20230928.0,20230921,20231005,EXP,,"TH-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-261449",BOEHRINGER INGELHEIM,,43.0,YR,A,F,Y,66.0,KG,20231005,,CN,TH,TH,2023,Q4,Adult
229685112,22968511,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 mg, QD",,,U,,,,,25.0,MG,,QD,2023,Q4,Hepatitis,,2023,Q4,2,F,20230901.0,20230930.0,20230921,20231006,EXP,,TH-SA-2023SA284213,SANOFI AVENTIS,,62.0,YR,A,M,Y,75.0,KG,20231006,,MD,TH,TH,2023,Q4,Adult
229685112,22968511,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 mg, QD",,,U,,,,,25.0,MG,,QD,2023,Q4,Alanine aminotransferase increased,,2023,Q4,2,F,20230901.0,20230930.0,20230921,20231006,EXP,,TH-SA-2023SA284213,SANOFI AVENTIS,,62.0,YR,A,M,Y,75.0,KG,20231006,,MD,TH,TH,2023,Q4,Adult
229685112,22968511,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 mg, QD",,,U,,,,,25.0,MG,,QD,2023,Q4,Aspartate aminotransferase increased,,2023,Q4,2,F,20230901.0,20230930.0,20230921,20231006,EXP,,TH-SA-2023SA284213,SANOFI AVENTIS,,62.0,YR,A,M,Y,75.0,KG,20231006,,MD,TH,TH,2023,Q4,Adult
229760732,22976073,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Leukopenia,,2023,Q4,2,F,20230630.0,20231005.0,20230925,20231015,EXP,,ES-JNJFOC-20230952163,JOHNSON AND JOHNSON,,87.0,YR,E,M,Y,80.0,KG,20231015,,MD,ES,ES,2023,Q4,Elderly
229760732,22976073,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Neutropenia,,2023,Q4,2,F,20230630.0,20231005.0,20230925,20231015,EXP,,ES-JNJFOC-20230952163,JOHNSON AND JOHNSON,,87.0,YR,E,M,Y,80.0,KG,20231015,,MD,ES,ES,2023,Q4,Elderly
229760732,22976073,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Pseudomonal sepsis,,2023,Q4,2,F,20230630.0,20231005.0,20230925,20231015,EXP,,ES-JNJFOC-20230952163,JOHNSON AND JOHNSON,,87.0,YR,E,M,Y,80.0,KG,20231015,,MD,ES,ES,2023,Q4,Elderly
229768065,22976806,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2023,Q4,Cholelithiasis,,2023,Q4,5,F,20230901.0,20231214.0,20230925,20231221,EXP,,CA-UCBSA-2023027853,UCB,,75.0,YR,,F,Y,,,20231221,,CN,CA,CA,2023,Q4,Elderly
229768065,22976806,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2023,Q4,Malaise,,2023,Q4,5,F,20230901.0,20231214.0,20230925,20231221,EXP,,CA-UCBSA-2023027853,UCB,,75.0,YR,,F,Y,,,20231221,,CN,CA,CA,2023,Q4,Elderly
229768065,22976806,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2023,Q4,Inappropriate schedule of product administration,,2023,Q4,5,F,20230901.0,20231214.0,20230925,20231221,EXP,,CA-UCBSA-2023027853,UCB,,75.0,YR,,F,Y,,,20231221,,CN,CA,CA,2023,Q4,Elderly
229768065,22976806,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2023,Q4,Product availability issue,,2023,Q4,5,F,20230901.0,20231214.0,20230925,20231221,EXP,,CA-UCBSA-2023027853,UCB,,75.0,YR,,F,Y,,,20231221,,CN,CA,CA,2023,Q4,Elderly
229768065,22976806,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2023,Q4,Intentional dose omission,,2023,Q4,5,F,20230901.0,20231214.0,20230925,20231221,EXP,,CA-UCBSA-2023027853,UCB,,75.0,YR,,F,Y,,,20231221,,CN,CA,CA,2023,Q4,Elderly
229768204,22976820,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,C-reactive protein increased,,2023,Q4,4,F,20230507.0,20231204.0,20230925,20231208,EXP,,FR-SANDOZ INC.-NVSC2023FR118646,SANDOZ,,75.0,YR,,F,Y,76.0,KG,20231208,,MD,FR,FR,2023,Q4,Elderly
229768204,22976820,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Cardiac failure,,2023,Q4,4,F,20230507.0,20231204.0,20230925,20231208,EXP,,FR-SANDOZ INC.-NVSC2023FR118646,SANDOZ,,75.0,YR,,F,Y,76.0,KG,20231208,,MD,FR,FR,2023,Q4,Elderly
229768204,22976820,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Pneumonia,,2023,Q4,4,F,20230507.0,20231204.0,20230925,20231208,EXP,,FR-SANDOZ INC.-NVSC2023FR118646,SANDOZ,,75.0,YR,,F,Y,76.0,KG,20231208,,MD,FR,FR,2023,Q4,Elderly
229768204,22976820,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Chills,,2023,Q4,4,F,20230507.0,20231204.0,20230925,20231208,EXP,,FR-SANDOZ INC.-NVSC2023FR118646,SANDOZ,,75.0,YR,,F,Y,76.0,KG,20231208,,MD,FR,FR,2023,Q4,Elderly
229768204,22976820,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Lower respiratory tract infection,,2023,Q4,4,F,20230507.0,20231204.0,20230925,20231208,EXP,,FR-SANDOZ INC.-NVSC2023FR118646,SANDOZ,,75.0,YR,,F,Y,76.0,KG,20231208,,MD,FR,FR,2023,Q4,Elderly
229768204,22976820,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Off label use,,2023,Q4,4,F,20230507.0,20231204.0,20230925,20231208,EXP,,FR-SANDOZ INC.-NVSC2023FR118646,SANDOZ,,75.0,YR,,F,Y,76.0,KG,20231208,,MD,FR,FR,2023,Q4,Elderly
229768204,22976820,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Abdominal pain upper,,2023,Q4,4,F,20230507.0,20231204.0,20230925,20231208,EXP,,FR-SANDOZ INC.-NVSC2023FR118646,SANDOZ,,75.0,YR,,F,Y,76.0,KG,20231208,,MD,FR,FR,2023,Q4,Elderly
229768204,22976820,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Asthenia,,2023,Q4,4,F,20230507.0,20231204.0,20230925,20231208,EXP,,FR-SANDOZ INC.-NVSC2023FR118646,SANDOZ,,75.0,YR,,F,Y,76.0,KG,20231208,,MD,FR,FR,2023,Q4,Elderly
229768204,22976820,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Anaemia,,2023,Q4,4,F,20230507.0,20231204.0,20230925,20231208,EXP,,FR-SANDOZ INC.-NVSC2023FR118646,SANDOZ,,75.0,YR,,F,Y,76.0,KG,20231208,,MD,FR,FR,2023,Q4,Elderly
229768204,22976820,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Cough,,2023,Q4,4,F,20230507.0,20231204.0,20230925,20231208,EXP,,FR-SANDOZ INC.-NVSC2023FR118646,SANDOZ,,75.0,YR,,F,Y,76.0,KG,20231208,,MD,FR,FR,2023,Q4,Elderly
229768204,22976820,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,COVID-19,,2023,Q4,4,F,20230507.0,20231204.0,20230925,20231208,EXP,,FR-SANDOZ INC.-NVSC2023FR118646,SANDOZ,,75.0,YR,,F,Y,76.0,KG,20231208,,MD,FR,FR,2023,Q4,Elderly
229834174,22983417,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Pneumonia,,2023,Q4,4,F,20220930.0,20231115.0,20230926,20231118,EXP,,FR-AUROBINDO-AUR-APL-2023-039176,AUROBINDO,,75.0,YR,,F,Y,76.0,KG,20231118,,MD,FR,FR,2023,Q4,Elderly
229834174,22983417,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,COVID-19,,2023,Q4,4,F,20220930.0,20231115.0,20230926,20231118,EXP,,FR-AUROBINDO-AUR-APL-2023-039176,AUROBINDO,,75.0,YR,,F,Y,76.0,KG,20231118,,MD,FR,FR,2023,Q4,Elderly
229834174,22983417,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Chills,,2023,Q4,4,F,20220930.0,20231115.0,20230926,20231118,EXP,,FR-AUROBINDO-AUR-APL-2023-039176,AUROBINDO,,75.0,YR,,F,Y,76.0,KG,20231118,,MD,FR,FR,2023,Q4,Elderly
229834174,22983417,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,C-reactive protein increased,,2023,Q4,4,F,20220930.0,20231115.0,20230926,20231118,EXP,,FR-AUROBINDO-AUR-APL-2023-039176,AUROBINDO,,75.0,YR,,F,Y,76.0,KG,20231118,,MD,FR,FR,2023,Q4,Elderly
229834174,22983417,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Lower respiratory tract infection,,2023,Q4,4,F,20220930.0,20231115.0,20230926,20231118,EXP,,FR-AUROBINDO-AUR-APL-2023-039176,AUROBINDO,,75.0,YR,,F,Y,76.0,KG,20231118,,MD,FR,FR,2023,Q4,Elderly
229834174,22983417,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Cardiac failure,,2023,Q4,4,F,20220930.0,20231115.0,20230926,20231118,EXP,,FR-AUROBINDO-AUR-APL-2023-039176,AUROBINDO,,75.0,YR,,F,Y,76.0,KG,20231118,,MD,FR,FR,2023,Q4,Elderly
229834174,22983417,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Off label use,,2023,Q4,4,F,20220930.0,20231115.0,20230926,20231118,EXP,,FR-AUROBINDO-AUR-APL-2023-039176,AUROBINDO,,75.0,YR,,F,Y,76.0,KG,20231118,,MD,FR,FR,2023,Q4,Elderly
229834174,22983417,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Abdominal pain upper,,2023,Q4,4,F,20220930.0,20231115.0,20230926,20231118,EXP,,FR-AUROBINDO-AUR-APL-2023-039176,AUROBINDO,,75.0,YR,,F,Y,76.0,KG,20231118,,MD,FR,FR,2023,Q4,Elderly
229834174,22983417,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Anaemia,,2023,Q4,4,F,20220930.0,20231115.0,20230926,20231118,EXP,,FR-AUROBINDO-AUR-APL-2023-039176,AUROBINDO,,75.0,YR,,F,Y,76.0,KG,20231118,,MD,FR,FR,2023,Q4,Elderly
229834174,22983417,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Asthenia,,2023,Q4,4,F,20220930.0,20231115.0,20230926,20231118,EXP,,FR-AUROBINDO-AUR-APL-2023-039176,AUROBINDO,,75.0,YR,,F,Y,76.0,KG,20231118,,MD,FR,FR,2023,Q4,Elderly
229834174,22983417,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Cough,,2023,Q4,4,F,20220930.0,20231115.0,20230926,20231118,EXP,,FR-AUROBINDO-AUR-APL-2023-039176,AUROBINDO,,75.0,YR,,F,Y,76.0,KG,20231118,,MD,FR,FR,2023,Q4,Elderly
229873692,22987369,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Asked But Unknown,,204629.0,10.0,MG,,,2023,Q4,Fournier's gangrene,,2023,Q4,2,F,20230801.0,20231003.0,20230926,20231005,EXP,,"ES-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-263287",BOEHRINGER INGELHEIM,,64.0,YR,A,M,Y,,,20231005,,MD,ES,ES,2023,Q4,Adult
229983792,22998379,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q4,Staphylococcal bacteraemia,,2023,Q4,2,F,,20230929.0,20230928,20231009,EXP,,CA-TEVA-2023-CA-2928659,TEVA,,50.0,YR,A,M,Y,,,20231009,,MD,CA,CA,2023,Q4,Adult
229983792,22998379,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q4,Haematological infection,,2023,Q4,2,F,,20230929.0,20230928,20231009,EXP,,CA-TEVA-2023-CA-2928659,TEVA,,50.0,YR,A,M,Y,,,20231009,,MD,CA,CA,2023,Q4,Adult
229983792,22998379,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q4,Thrombocytopenia,,2023,Q4,2,F,,20230929.0,20230928,20231009,EXP,,CA-TEVA-2023-CA-2928659,TEVA,,50.0,YR,A,M,Y,,,20231009,,MD,CA,CA,2023,Q4,Adult
229983792,22998379,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q4,Pneumonia bacterial,,2023,Q4,2,F,,20230929.0,20230928,20231009,EXP,,CA-TEVA-2023-CA-2928659,TEVA,,50.0,YR,A,M,Y,,,20231009,,MD,CA,CA,2023,Q4,Adult
229983792,22998379,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q4,Varicella zoster pneumonia,,2023,Q4,2,F,,20230929.0,20230928,20231009,EXP,,CA-TEVA-2023-CA-2928659,TEVA,,50.0,YR,A,M,Y,,,20231009,,MD,CA,CA,2023,Q4,Adult
229983792,22998379,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q4,Respiratory failure,,2023,Q4,2,F,,20230929.0,20230928,20231009,EXP,,CA-TEVA-2023-CA-2928659,TEVA,,50.0,YR,A,M,Y,,,20231009,,MD,CA,CA,2023,Q4,Adult
229983792,22998379,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q4,Drug reaction with eosinophilia and systemic symptoms,,2023,Q4,2,F,,20230929.0,20230928,20231009,EXP,,CA-TEVA-2023-CA-2928659,TEVA,,50.0,YR,A,M,Y,,,20231009,,MD,CA,CA,2023,Q4,Adult
229983792,22998379,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q4,Septic shock,,2023,Q4,2,F,,20230929.0,20230928,20231009,EXP,,CA-TEVA-2023-CA-2928659,TEVA,,50.0,YR,A,M,Y,,,20231009,,MD,CA,CA,2023,Q4,Adult
229983792,22998379,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q4,Pneumonia klebsiella,,2023,Q4,2,F,,20230929.0,20230928,20231009,EXP,,CA-TEVA-2023-CA-2928659,TEVA,,50.0,YR,A,M,Y,,,20231009,,MD,CA,CA,2023,Q4,Adult
229983792,22998379,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q4,Enterobacter infection,,2023,Q4,2,F,,20230929.0,20230928,20231009,EXP,,CA-TEVA-2023-CA-2928659,TEVA,,50.0,YR,A,M,Y,,,20231009,,MD,CA,CA,2023,Q4,Adult
230041062,23004106,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q4,Weight increased,,2023,Q4,2,F,20181001.0,20231218.0,20230928,20231221,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20231221,,MD,DE,DE,2023,Q4,Adult
230041062,23004106,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q4,Glycosylated haemoglobin increased,,2023,Q4,2,F,20181001.0,20231218.0,20230928,20231221,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20231221,,MD,DE,DE,2023,Q4,Adult
230041062,23004106,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q4,Vulvovaginal mycotic infection,,2023,Q4,2,F,20181001.0,20231218.0,20230928,20231221,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20231221,,MD,DE,DE,2023,Q4,Adult
230041062,23004106,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q4,Intervertebral disc protrusion,,2023,Q4,2,F,20181001.0,20231218.0,20230928,20231221,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20231221,,MD,DE,DE,2023,Q4,Adult
230041062,23004106,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q4,Blood glucose increased,,2023,Q4,2,F,20181001.0,20231218.0,20230928,20231221,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20231221,,MD,DE,DE,2023,Q4,Adult
230041062,23004106,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q4,Blood glucose abnormal,,2023,Q4,2,F,20181001.0,20231218.0,20230928,20231221,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20231221,,MD,DE,DE,2023,Q4,Adult
230041062,23004106,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q4,Coronary artery disease,,2023,Q4,2,F,20181001.0,20231218.0,20230928,20231221,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20231221,,MD,DE,DE,2023,Q4,Adult
230041062,23004106,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q4,Intervertebral disc disorder,,2023,Q4,2,F,20181001.0,20231218.0,20230928,20231221,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20231221,,MD,DE,DE,2023,Q4,Adult
230041062,23004106,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q4,Osteoarthritis,,2023,Q4,2,F,20181001.0,20231218.0,20230928,20231221,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20231221,,MD,DE,DE,2023,Q4,Adult
230044622,23004462,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,5 mg-1000 mg,,,U,,,,,,,,,2023,Q4,Nervous system disorder,,2023,Q4,2,F,,20230929.0,20230928,20231009,EXP,,ES-TEVA-2023-ES-2929889,TEVA,,7.0,DEC,E,M,Y,,,20231009,,HP,ES,ES,2023,Q4,Child
230044622,23004462,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,5 mg-1000 mg,,,U,,,,,,,,,2023,Q4,Thrombotic thrombocytopenic purpura,,2023,Q4,2,F,,20230929.0,20230928,20231009,EXP,,ES-TEVA-2023-ES-2929889,TEVA,,7.0,DEC,E,M,Y,,,20231009,,HP,ES,ES,2023,Q4,Child
230044622,23004462,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,5 mg-1000 mg,,,U,,,,,,,,,2023,Q4,Drug ineffective,,2023,Q4,2,F,,20230929.0,20230928,20231009,EXP,,ES-TEVA-2023-ES-2929889,TEVA,,7.0,DEC,E,M,Y,,,20231009,,HP,ES,ES,2023,Q4,Child
230144601,23014460,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,administration duration,,,N,,Unknown,,204629.0,10.0,MG,,,2023,Q4,Acute kidney injury,,2023,Q4,1,I,20230904.0,20230929.0,20231002,20231002,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-264132",BOEHRINGER INGELHEIM,,64.0,YR,A,F,Y,90.0,KG,20231002,,MD,DE,DE,2023,Q4,Adult
230144601,23014460,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,administration duration,,,N,,Unknown,,204629.0,10.0,MG,,,2023,Q4,Lactic acidosis,,2023,Q4,1,I,20230904.0,20230929.0,20231002,20231002,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-264132",BOEHRINGER INGELHEIM,,64.0,YR,A,F,Y,90.0,KG,20231002,,MD,DE,DE,2023,Q4,Adult
230144601,23014460,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,administration duration,,,N,,Unknown,,204629.0,10.0,MG,,,2023,Q4,Ketoacidosis,,2023,Q4,1,I,20230904.0,20230929.0,20231002,20231002,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-264132",BOEHRINGER INGELHEIM,,64.0,YR,A,F,Y,90.0,KG,20231002,,MD,DE,DE,2023,Q4,Adult
230149131,23014913,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,ASKU,,204629.0,,,,,2023,Q4,Peripheral ischaemia,,2023,Q4,1,I,20230808.0,20231001.0,20231002,20231002,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-264384",BOEHRINGER INGELHEIM,,64.0,YR,A,M,Y,,,20231002,,HP,GB,GB,2023,Q4,Adult
230158732,23015873,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,N,,ASKU,,204629.0,,,Tablet,,2023,Q4,Renal cell carcinoma,,2023,Q4,2,F,,20231008.0,20231002,20231010,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-264143",BOEHRINGER INGELHEIM,,71.0,YR,E,F,Y,,,20231010,,PH,GB,GB,2023,Q4,Elderly
230175305,23017530,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Aortic arteriosclerosis,,2023,Q4,5,F,20231001.0,20231211.0,20231003,20231213,EXP,,JP-ABBVIE-5431386,ABBVIE,,75.0,YR,,M,Y,84.0,KG,20231213,,MD,JP,JP,2023,Q4,Elderly
230175305,23017530,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Arteriosclerosis coronary artery,,2023,Q4,5,F,20231001.0,20231211.0,20231003,20231213,EXP,,JP-ABBVIE-5431386,ABBVIE,,75.0,YR,,M,Y,84.0,KG,20231213,,MD,JP,JP,2023,Q4,Elderly
230175305,23017530,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Cardiac failure,,2023,Q4,5,F,20231001.0,20231211.0,20231003,20231213,EXP,,JP-ABBVIE-5431386,ABBVIE,,75.0,YR,,M,Y,84.0,KG,20231213,,MD,JP,JP,2023,Q4,Elderly
230175305,23017530,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Drug ineffective,,2023,Q4,5,F,20231001.0,20231211.0,20231003,20231213,EXP,,JP-ABBVIE-5431386,ABBVIE,,75.0,YR,,M,Y,84.0,KG,20231213,,MD,JP,JP,2023,Q4,Elderly
230175305,23017530,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Cough,,2023,Q4,5,F,20231001.0,20231211.0,20231003,20231213,EXP,,JP-ABBVIE-5431386,ABBVIE,,75.0,YR,,M,Y,84.0,KG,20231213,,MD,JP,JP,2023,Q4,Elderly
230175305,23017530,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Pulmonary congestion,,2023,Q4,5,F,20231001.0,20231211.0,20231003,20231213,EXP,,JP-ABBVIE-5431386,ABBVIE,,75.0,YR,,M,Y,84.0,KG,20231213,,MD,JP,JP,2023,Q4,Elderly
230175305,23017530,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Congestive hepatopathy,,2023,Q4,5,F,20231001.0,20231211.0,20231003,20231213,EXP,,JP-ABBVIE-5431386,ABBVIE,,75.0,YR,,M,Y,84.0,KG,20231213,,MD,JP,JP,2023,Q4,Elderly
230175305,23017530,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Acute coronary syndrome,,2023,Q4,5,F,20231001.0,20231211.0,20231003,20231213,EXP,,JP-ABBVIE-5431386,ABBVIE,,75.0,YR,,M,Y,84.0,KG,20231213,,MD,JP,JP,2023,Q4,Elderly
230212072,23021207,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd (10mg daily)",,,N,,,,,10.0,MG,Tablet,QD,2023,Q4,Renal cell carcinoma,,2023,Q4,2,F,,20231008.0,20231003,20231013,EXP,,GB-MYLANLABS-2023M1103834,MYLAN,,71.0,YR,,F,Y,,,20231013,,PH,GB,GB,2023,Q4,Elderly
230212072,23021207,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd (10mg daily)",,,N,U,,,,10.0,MG,Powder for infusion,QD,2023,Q4,Renal cell carcinoma,,2023,Q4,2,F,,20231008.0,20231003,20231013,EXP,,GB-MYLANLABS-2023M1103834,MYLAN,,71.0,YR,,F,Y,,,20231013,,PH,GB,GB,2023,Q4,Elderly
230238231,23023823,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Pneumonia,,2023,Q4,1,I,20230726.0,20230923.0,20231003,20231003,EXP,,TH-TAKEDA-2023TUS083253,TAKEDA,,59.0,YR,,M,Y,,,20231003,,MD,TH,TH,2023,Q4,Adult
230238231,23023823,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Tracheobronchitis,,2023,Q4,1,I,20230726.0,20230923.0,20231003,20231003,EXP,,TH-TAKEDA-2023TUS083253,TAKEDA,,59.0,YR,,M,Y,,,20231003,,MD,TH,TH,2023,Q4,Adult
230240041,23024004,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q4,Cardiac arrest,,2023,Q4,1,I,,20230926.0,20231003,20231003,EXP,,CA-AUROBINDO-AUR-APL-2023-061175,AUROBINDO,,77.0,YR,,F,Y,79.0,KG,20231004,,PH,CA,CA,2023,Q4,Elderly
230240041,23024004,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q4,Clostridium test positive,,2023,Q4,1,I,,20230926.0,20231003,20231003,EXP,,CA-AUROBINDO-AUR-APL-2023-061175,AUROBINDO,,77.0,YR,,F,Y,79.0,KG,20231004,,PH,CA,CA,2023,Q4,Elderly
230240041,23024004,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q4,Eructation,,2023,Q4,1,I,,20230926.0,20231003,20231003,EXP,,CA-AUROBINDO-AUR-APL-2023-061175,AUROBINDO,,77.0,YR,,F,Y,79.0,KG,20231004,,PH,CA,CA,2023,Q4,Elderly
230240041,23024004,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q4,Epigastric discomfort,,2023,Q4,1,I,,20230926.0,20231003,20231003,EXP,,CA-AUROBINDO-AUR-APL-2023-061175,AUROBINDO,,77.0,YR,,F,Y,79.0,KG,20231004,,PH,CA,CA,2023,Q4,Elderly
230240041,23024004,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q4,Nausea,,2023,Q4,1,I,,20230926.0,20231003,20231003,EXP,,CA-AUROBINDO-AUR-APL-2023-061175,AUROBINDO,,77.0,YR,,F,Y,79.0,KG,20231004,,PH,CA,CA,2023,Q4,Elderly
230240041,23024004,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q4,Cardiogenic shock,,2023,Q4,1,I,,20230926.0,20231003,20231003,EXP,,CA-AUROBINDO-AUR-APL-2023-061175,AUROBINDO,,77.0,YR,,F,Y,79.0,KG,20231004,,PH,CA,CA,2023,Q4,Elderly
230240041,23024004,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q4,Diarrhoea,,2023,Q4,1,I,,20230926.0,20231003,20231003,EXP,,CA-AUROBINDO-AUR-APL-2023-061175,AUROBINDO,,77.0,YR,,F,Y,79.0,KG,20231004,,PH,CA,CA,2023,Q4,Elderly
230240041,23024004,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q4,Dyspnoea,,2023,Q4,1,I,,20230926.0,20231003,20231003,EXP,,CA-AUROBINDO-AUR-APL-2023-061175,AUROBINDO,,77.0,YR,,F,Y,79.0,KG,20231004,,PH,CA,CA,2023,Q4,Elderly
230240041,23024004,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q4,Hyperhidrosis,,2023,Q4,1,I,,20230926.0,20231003,20231003,EXP,,CA-AUROBINDO-AUR-APL-2023-061175,AUROBINDO,,77.0,YR,,F,Y,79.0,KG,20231004,,PH,CA,CA,2023,Q4,Elderly
230240041,23024004,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q4,Anuria,,2023,Q4,1,I,,20230926.0,20231003,20231003,EXP,,CA-AUROBINDO-AUR-APL-2023-061175,AUROBINDO,,77.0,YR,,F,Y,79.0,KG,20231004,,PH,CA,CA,2023,Q4,Elderly
230282791,23028279,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,,QD,2023,Q4,Suspected drug-induced liver injury,,2023,Q4,1,I,20230926.0,20230926.0,20231004,20231004,EXP,,MY-AstraZeneca-2023A219741,ASTRAZENECA,,54.0,YR,,M,Y,,,20231004,,MD,MY,,2023,Q4,Adult
230312111,23031211,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,N,U,ASKU,,,10.0,MG,,QD,2023,Q4,Renal cell carcinoma,,2023,Q4,1,I,,20230929.0,20231005,20231005,EXP,,GB-SA-2023SA298203,SANOFI AVENTIS,,71.0,YR,E,F,Y,,,20231005,,PH,GB,GB,2023,Q4,Elderly
230358001,23035800,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Einnahme seit Monaten.",,,N,,,,,10.0,MG,,,2023,Q4,Lactic acidosis,,2023,Q4,1,I,20230904.0,20230927.0,20231006,20231006,EXP,,DE-AUROBINDO-AUR-APL-2023-061494,AUROBINDO,,64.0,YR,,F,Y,90.0,KG,20231006,,MD,DE,DE,2023,Q4,Adult
230358001,23035800,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Einnahme seit Monaten.",,,N,,,,,10.0,MG,,,2023,Q4,Acute kidney injury,,2023,Q4,1,I,20230904.0,20230927.0,20231006,20231006,EXP,,DE-AUROBINDO-AUR-APL-2023-061494,AUROBINDO,,64.0,YR,,F,Y,90.0,KG,20231006,,MD,DE,DE,2023,Q4,Adult
230358001,23035800,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Einnahme seit Monaten.",,,N,,,,,10.0,MG,,,2023,Q4,Ketoacidosis,,2023,Q4,1,I,20230904.0,20230927.0,20231006,20231006,EXP,,DE-AUROBINDO-AUR-APL-2023-061494,AUROBINDO,,64.0,YR,,F,Y,90.0,KG,20231006,,MD,DE,DE,2023,Q4,Adult
230359081,23035908,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Einnahme seit Monaten.,,,N,,Unknown,,,10.0,MG,,,2023,Q4,Lactic acidosis,,2023,Q4,1,I,20230904.0,20231002.0,20231006,20231006,EXP,,DE-EMD Serono-2023478663,EMD SERONO INC,,64.0,YR,A,F,Y,90.0,KG,20231006,,MD,DE,DE,2023,Q4,Adult
230359081,23035908,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Einnahme seit Monaten.,,,N,,Unknown,,,10.0,MG,,,2023,Q4,Acute kidney injury,,2023,Q4,1,I,20230904.0,20231002.0,20231006,20231006,EXP,,DE-EMD Serono-2023478663,EMD SERONO INC,,64.0,YR,A,F,Y,90.0,KG,20231006,,MD,DE,DE,2023,Q4,Adult
230359081,23035908,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Einnahme seit Monaten.,,,N,,Unknown,,,10.0,MG,,,2023,Q4,Ketoacidosis,,2023,Q4,1,I,20230904.0,20231002.0,20231006,20231006,EXP,,DE-EMD Serono-2023478663,EMD SERONO INC,,64.0,YR,A,F,Y,90.0,KG,20231006,,MD,DE,DE,2023,Q4,Adult
230367091,23036709,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10mg daily,,,N,,Asked But Unknown,,,,,Powder for infusion,,2023,Q4,Renal cell carcinoma,,2023,Q4,1,I,,20230929.0,20231006,20231006,EXP,,GB-EMD Serono-2023478682,EMD SERONO INC,,71.0,YR,E,F,Y,,,20231006,,PH,GB,GB,2023,Q4,Elderly
230388331,23038833,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Neutropenia,,2023,Q4,1,I,20230827.0,20230927.0,20231006,20231006,EXP,,FR-AUROBINDO-AUR-APL-2023-061505,AUROBINDO,,74.0,YR,,F,Y,93.0,KG,20231006,,PH,FR,FR,2023,Q4,Elderly
230388331,23038833,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Septic shock,,2023,Q4,1,I,20230827.0,20230927.0,20231006,20231006,EXP,,FR-AUROBINDO-AUR-APL-2023-061505,AUROBINDO,,74.0,YR,,F,Y,93.0,KG,20231006,,PH,FR,FR,2023,Q4,Elderly
230396191,23039619,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,U,,,,,,,,,2023,Q4,Hypoglycaemia,,2023,Q4,1,I,,20230922.0,20231006,20231006,EXP,,ES-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-411389,RANBAXY,,62.0,YR,,F,Y,90.0,KG,20231006,,HP,ES,ES,2023,Q4,Adult
230396191,23039619,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,U,,,,,,,,,2023,Q4,Parkinsonism,,2023,Q4,1,I,,20230922.0,20231006,20231006,EXP,,ES-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-411389,RANBAXY,,62.0,YR,,F,Y,90.0,KG,20231006,,HP,ES,ES,2023,Q4,Adult
230396191,23039619,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,U,,,,,,,,,2023,Q4,Hypotension,,2023,Q4,1,I,,20230922.0,20231006,20231006,EXP,,ES-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-411389,RANBAXY,,62.0,YR,,F,Y,90.0,KG,20231006,,HP,ES,ES,2023,Q4,Adult
230396191,23039619,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,U,,,,,,,,,2023,Q4,Somnolence,,2023,Q4,1,I,,20230922.0,20231006,20231006,EXP,,ES-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-411389,RANBAXY,,62.0,YR,,F,Y,90.0,KG,20231006,,HP,ES,ES,2023,Q4,Adult
230396191,23039619,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,U,,,,,,,,,2023,Q4,Hallucination,,2023,Q4,1,I,,20230922.0,20231006,20231006,EXP,,ES-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-411389,RANBAXY,,62.0,YR,,F,Y,90.0,KG,20231006,,HP,ES,ES,2023,Q4,Adult
230396191,23039619,29,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,1000 mg/5 mg bid,,,Y,,,,,,,,,2023,Q4,Hypoglycaemia,,2023,Q4,1,I,,20230922.0,20231006,20231006,EXP,,ES-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-411389,RANBAXY,,62.0,YR,,F,Y,90.0,KG,20231006,,HP,ES,ES,2023,Q4,Adult
230396191,23039619,29,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,1000 mg/5 mg bid,,,Y,,,,,,,,,2023,Q4,Parkinsonism,,2023,Q4,1,I,,20230922.0,20231006,20231006,EXP,,ES-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-411389,RANBAXY,,62.0,YR,,F,Y,90.0,KG,20231006,,HP,ES,ES,2023,Q4,Adult
230396191,23039619,29,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,1000 mg/5 mg bid,,,Y,,,,,,,,,2023,Q4,Hypotension,,2023,Q4,1,I,,20230922.0,20231006,20231006,EXP,,ES-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-411389,RANBAXY,,62.0,YR,,F,Y,90.0,KG,20231006,,HP,ES,ES,2023,Q4,Adult
230396191,23039619,29,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,1000 mg/5 mg bid,,,Y,,,,,,,,,2023,Q4,Somnolence,,2023,Q4,1,I,,20230922.0,20231006,20231006,EXP,,ES-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-411389,RANBAXY,,62.0,YR,,F,Y,90.0,KG,20231006,,HP,ES,ES,2023,Q4,Adult
230396191,23039619,29,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,1000 mg/5 mg bid,,,Y,,,,,,,,,2023,Q4,Hallucination,,2023,Q4,1,I,,20230922.0,20231006,20231006,EXP,,ES-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-411389,RANBAXY,,62.0,YR,,F,Y,90.0,KG,20231006,,HP,ES,ES,2023,Q4,Adult
230402391,23040239,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q4,Septic shock,,2023,Q4,1,I,20230827.0,20230929.0,20231006,20231006,EXP,FR-AFSSAPS-AM2023000838,FR-BAXTER-2023BAX032225,BAXTER,,74.0,YR,,F,Y,93.0,KG,20231006,,PH,FR,FR,2023,Q4,Elderly
230402391,23040239,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q4,Neutropenia,,2023,Q4,1,I,20230827.0,20230929.0,20231006,20231006,EXP,FR-AFSSAPS-AM2023000838,FR-BAXTER-2023BAX032225,BAXTER,,74.0,YR,,F,Y,93.0,KG,20231006,,PH,FR,FR,2023,Q4,Elderly
230407291,23040729,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,,,2023,Q4,Septic shock,,2023,Q4,1,I,20230821.0,20230928.0,20231006,20231006,EXP,FR-AFSSAPS-AM2023000838,FR-PFIZER INC-202300312436,PFIZER,,74.0,YR,,F,Y,93.0,KG,20231006,,PH,FR,FR,2023,Q4,Elderly
230407291,23040729,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,,,2023,Q4,White blood cell count decreased,,2023,Q4,1,I,20230821.0,20230928.0,20231006,20231006,EXP,FR-AFSSAPS-AM2023000838,FR-PFIZER INC-202300312436,PFIZER,,74.0,YR,,F,Y,93.0,KG,20231006,,PH,FR,FR,2023,Q4,Elderly
230407291,23040729,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,,,2023,Q4,Off label use,,2023,Q4,1,I,20230821.0,20230928.0,20231006,20231006,EXP,FR-AFSSAPS-AM2023000838,FR-PFIZER INC-202300312436,PFIZER,,74.0,YR,,F,Y,93.0,KG,20231006,,PH,FR,FR,2023,Q4,Elderly
230407291,23040729,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,Unknown,,,,,,,2023,Q4,Neutropenia,,2023,Q4,1,I,20230821.0,20230928.0,20231006,20231006,EXP,FR-AFSSAPS-AM2023000838,FR-PFIZER INC-202300312436,PFIZER,,74.0,YR,,F,Y,93.0,KG,20231006,,PH,FR,FR,2023,Q4,Elderly
230412292,23041229,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Daily",,,N,U,,,,10.0,MG,Tablet,,2023,Q4,Renal cell carcinoma,,2023,Q4,2,F,,20231008.0,20231007,20231015,EXP,,GB-AUROBINDO-AUR-APL-2023-061480,AUROBINDO,,71.0,YR,,F,Y,,,20231015,,PH,GB,GB,2023,Q4,Elderly
230422626,23042262,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1 dosage form, Two Times a Day (12,5 + 100 mg bid)",,,U,,,,,,,,BID,2023,Q4,Intentional product misuse,,2023,Q4,6,F,20220101.0,20231219.0,20231008,20231230,EXP,,PT-AUROBINDO-AUR-APL-2023-062172,AUROBINDO,"Canha F, Pitta R, Conde M.E.N.G.. A import?ncia da continuidade de cuidados na patologia psiqui?trica: um relato de caso (The importance of continuity of care in psychiatric pathology: a case report). Rev Port Med Geral Fam. 2023;39(4):327-331",50.0,YR,,F,Y,,,20231230,,MD,PT,PT,2023,Q4,Adult
230422626,23042262,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1 dosage form, Two Times a Day (12,5 + 100 mg bid)",,,U,,,,,,,,BID,2023,Q4,Middle insomnia,,2023,Q4,6,F,20220101.0,20231219.0,20231008,20231230,EXP,,PT-AUROBINDO-AUR-APL-2023-062172,AUROBINDO,"Canha F, Pitta R, Conde M.E.N.G.. A import?ncia da continuidade de cuidados na patologia psiqui?trica: um relato de caso (The importance of continuity of care in psychiatric pathology: a case report). Rev Port Med Geral Fam. 2023;39(4):327-331",50.0,YR,,F,Y,,,20231230,,MD,PT,PT,2023,Q4,Adult
230422626,23042262,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1 dosage form, Two Times a Day (12,5 + 100 mg bid)",,,U,,,,,,,,BID,2023,Q4,Depressed mood,,2023,Q4,6,F,20220101.0,20231219.0,20231008,20231230,EXP,,PT-AUROBINDO-AUR-APL-2023-062172,AUROBINDO,"Canha F, Pitta R, Conde M.E.N.G.. A import?ncia da continuidade de cuidados na patologia psiqui?trica: um relato de caso (The importance of continuity of care in psychiatric pathology: a case report). Rev Port Med Geral Fam. 2023;39(4):327-331",50.0,YR,,F,Y,,,20231230,,MD,PT,PT,2023,Q4,Adult
230422626,23042262,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1 dosage form, Two Times a Day (12,5 + 100 mg bid)",,,U,,,,,,,,BID,2023,Q4,Affective disorder,,2023,Q4,6,F,20220101.0,20231219.0,20231008,20231230,EXP,,PT-AUROBINDO-AUR-APL-2023-062172,AUROBINDO,"Canha F, Pitta R, Conde M.E.N.G.. A import?ncia da continuidade de cuidados na patologia psiqui?trica: um relato de caso (The importance of continuity of care in psychiatric pathology: a case report). Rev Port Med Geral Fam. 2023;39(4):327-331",50.0,YR,,F,Y,,,20231230,,MD,PT,PT,2023,Q4,Adult
230422626,23042262,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1 dosage form, Two Times a Day (12,5 + 100 mg bid)",,,U,,,,,,,,BID,2023,Q4,Fatigue,,2023,Q4,6,F,20220101.0,20231219.0,20231008,20231230,EXP,,PT-AUROBINDO-AUR-APL-2023-062172,AUROBINDO,"Canha F, Pitta R, Conde M.E.N.G.. A import?ncia da continuidade de cuidados na patologia psiqui?trica: um relato de caso (The importance of continuity of care in psychiatric pathology: a case report). Rev Port Med Geral Fam. 2023;39(4):327-331",50.0,YR,,F,Y,,,20231230,,MD,PT,PT,2023,Q4,Adult
230422626,23042262,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1 dosage form, Two Times a Day (12,5 + 100 mg bid)",,,U,,,,,,,,BID,2023,Q4,Initial insomnia,,2023,Q4,6,F,20220101.0,20231219.0,20231008,20231230,EXP,,PT-AUROBINDO-AUR-APL-2023-062172,AUROBINDO,"Canha F, Pitta R, Conde M.E.N.G.. A import?ncia da continuidade de cuidados na patologia psiqui?trica: um relato de caso (The importance of continuity of care in psychiatric pathology: a case report). Rev Port Med Geral Fam. 2023;39(4):327-331",50.0,YR,,F,Y,,,20231230,,MD,PT,PT,2023,Q4,Adult
230422626,23042262,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1 dosage form, Two Times a Day (12,5 + 100 mg bid)",,,U,,,,,,,,BID,2023,Q4,"Hallucination, auditory",,2023,Q4,6,F,20220101.0,20231219.0,20231008,20231230,EXP,,PT-AUROBINDO-AUR-APL-2023-062172,AUROBINDO,"Canha F, Pitta R, Conde M.E.N.G.. A import?ncia da continuidade de cuidados na patologia psiqui?trica: um relato de caso (The importance of continuity of care in psychiatric pathology: a case report). Rev Port Med Geral Fam. 2023;39(4):327-331",50.0,YR,,F,Y,,,20231230,,MD,PT,PT,2023,Q4,Adult
230422626,23042262,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1 dosage form, Two Times a Day (12,5 + 100 mg bid)",,,U,,,,,,,,BID,2023,Q4,Irritability,,2023,Q4,6,F,20220101.0,20231219.0,20231008,20231230,EXP,,PT-AUROBINDO-AUR-APL-2023-062172,AUROBINDO,"Canha F, Pitta R, Conde M.E.N.G.. A import?ncia da continuidade de cuidados na patologia psiqui?trica: um relato de caso (The importance of continuity of care in psychiatric pathology: a case report). Rev Port Med Geral Fam. 2023;39(4):327-331",50.0,YR,,F,Y,,,20231230,,MD,PT,PT,2023,Q4,Adult
230422626,23042262,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1 dosage form, Two Times a Day (12,5 + 100 mg bid)",,,U,,,,,,,,BID,2023,Q4,Anhedonia,,2023,Q4,6,F,20220101.0,20231219.0,20231008,20231230,EXP,,PT-AUROBINDO-AUR-APL-2023-062172,AUROBINDO,"Canha F, Pitta R, Conde M.E.N.G.. A import?ncia da continuidade de cuidados na patologia psiqui?trica: um relato de caso (The importance of continuity of care in psychiatric pathology: a case report). Rev Port Med Geral Fam. 2023;39(4):327-331",50.0,YR,,F,Y,,,20231230,,MD,PT,PT,2023,Q4,Adult
230422626,23042262,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1 dosage form, Two Times a Day (12,5 + 100 mg bid)",,,U,,,,,,,,BID,2023,Q4,Panic attack,,2023,Q4,6,F,20220101.0,20231219.0,20231008,20231230,EXP,,PT-AUROBINDO-AUR-APL-2023-062172,AUROBINDO,"Canha F, Pitta R, Conde M.E.N.G.. A import?ncia da continuidade de cuidados na patologia psiqui?trica: um relato de caso (The importance of continuity of care in psychiatric pathology: a case report). Rev Port Med Geral Fam. 2023;39(4):327-331",50.0,YR,,F,Y,,,20231230,,MD,PT,PT,2023,Q4,Adult
230422626,23042262,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1 dosage form, Two Times a Day (12,5 + 100 mg bid)",,,U,,,,,,,,BID,2023,Q4,Accidental overdose,,2023,Q4,6,F,20220101.0,20231219.0,20231008,20231230,EXP,,PT-AUROBINDO-AUR-APL-2023-062172,AUROBINDO,"Canha F, Pitta R, Conde M.E.N.G.. A import?ncia da continuidade de cuidados na patologia psiqui?trica: um relato de caso (The importance of continuity of care in psychiatric pathology: a case report). Rev Port Med Geral Fam. 2023;39(4):327-331",50.0,YR,,F,Y,,,20231230,,MD,PT,PT,2023,Q4,Adult
230422626,23042262,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1 dosage form, Two Times a Day (12,5 + 100 mg bid)",,,U,,,,,,,,BID,2023,Q4,Insomnia,,2023,Q4,6,F,20220101.0,20231219.0,20231008,20231230,EXP,,PT-AUROBINDO-AUR-APL-2023-062172,AUROBINDO,"Canha F, Pitta R, Conde M.E.N.G.. A import?ncia da continuidade de cuidados na patologia psiqui?trica: um relato de caso (The importance of continuity of care in psychiatric pathology: a case report). Rev Port Med Geral Fam. 2023;39(4):327-331",50.0,YR,,F,Y,,,20231230,,MD,PT,PT,2023,Q4,Adult
230422626,23042262,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1 dosage form, Two Times a Day (12,5 + 100 mg bid)",,,U,,,,,,,,BID,2023,Q4,Wrong dose,,2023,Q4,6,F,20220101.0,20231219.0,20231008,20231230,EXP,,PT-AUROBINDO-AUR-APL-2023-062172,AUROBINDO,"Canha F, Pitta R, Conde M.E.N.G.. A import?ncia da continuidade de cuidados na patologia psiqui?trica: um relato de caso (The importance of continuity of care in psychiatric pathology: a case report). Rev Port Med Geral Fam. 2023;39(4):327-331",50.0,YR,,F,Y,,,20231230,,MD,PT,PT,2023,Q4,Adult
230422626,23042262,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1 dosage form, Two Times a Day (12,5 + 100 mg bid)",,,U,,,,,,,,BID,2023,Q4,Pseudohallucination,,2023,Q4,6,F,20220101.0,20231219.0,20231008,20231230,EXP,,PT-AUROBINDO-AUR-APL-2023-062172,AUROBINDO,"Canha F, Pitta R, Conde M.E.N.G.. A import?ncia da continuidade de cuidados na patologia psiqui?trica: um relato de caso (The importance of continuity of care in psychiatric pathology: a case report). Rev Port Med Geral Fam. 2023;39(4):327-331",50.0,YR,,F,Y,,,20231230,,MD,PT,PT,2023,Q4,Adult
230422626,23042262,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1 dosage form, Two Times a Day (12,5 + 100 mg bid)",,,U,,,,,,,,BID,2023,Q4,Treatment noncompliance,,2023,Q4,6,F,20220101.0,20231219.0,20231008,20231230,EXP,,PT-AUROBINDO-AUR-APL-2023-062172,AUROBINDO,"Canha F, Pitta R, Conde M.E.N.G.. A import?ncia da continuidade de cuidados na patologia psiqui?trica: um relato de caso (The importance of continuity of care in psychiatric pathology: a case report). Rev Port Med Geral Fam. 2023;39(4):327-331",50.0,YR,,F,Y,,,20231230,,MD,PT,PT,2023,Q4,Adult
230422626,23042262,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1 dosage form, Two Times a Day (12,5 + 100 mg bid)",,,U,,,,,,,,BID,2023,Q4,Self-injurious ideation,,2023,Q4,6,F,20220101.0,20231219.0,20231008,20231230,EXP,,PT-AUROBINDO-AUR-APL-2023-062172,AUROBINDO,"Canha F, Pitta R, Conde M.E.N.G.. A import?ncia da continuidade de cuidados na patologia psiqui?trica: um relato de caso (The importance of continuity of care in psychiatric pathology: a case report). Rev Port Med Geral Fam. 2023;39(4):327-331",50.0,YR,,F,Y,,,20231230,,MD,PT,PT,2023,Q4,Adult
230422626,23042262,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1 dosage form, Two Times a Day (12,5 + 100 mg bid)",,,U,,,,,,,,BID,2023,Q4,Nightmare,,2023,Q4,6,F,20220101.0,20231219.0,20231008,20231230,EXP,,PT-AUROBINDO-AUR-APL-2023-062172,AUROBINDO,"Canha F, Pitta R, Conde M.E.N.G.. A import?ncia da continuidade de cuidados na patologia psiqui?trica: um relato de caso (The importance of continuity of care in psychiatric pathology: a case report). Rev Port Med Geral Fam. 2023;39(4):327-331",50.0,YR,,F,Y,,,20231230,,MD,PT,PT,2023,Q4,Adult
230422626,23042262,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1 dosage form, Two Times a Day (12,5 + 100 mg bid)",,,U,,,,,,,,BID,2023,Q4,Incorrect dose administered,,2023,Q4,6,F,20220101.0,20231219.0,20231008,20231230,EXP,,PT-AUROBINDO-AUR-APL-2023-062172,AUROBINDO,"Canha F, Pitta R, Conde M.E.N.G.. A import?ncia da continuidade de cuidados na patologia psiqui?trica: um relato de caso (The importance of continuity of care in psychiatric pathology: a case report). Rev Port Med Geral Fam. 2023;39(4):327-331",50.0,YR,,F,Y,,,20231230,,MD,PT,PT,2023,Q4,Adult
230422626,23042262,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1 dosage form, Two Times a Day (12,5 + 100 mg bid)",,,U,,,,,,,,BID,2023,Q4,Weight decreased,,2023,Q4,6,F,20220101.0,20231219.0,20231008,20231230,EXP,,PT-AUROBINDO-AUR-APL-2023-062172,AUROBINDO,"Canha F, Pitta R, Conde M.E.N.G.. A import?ncia da continuidade de cuidados na patologia psiqui?trica: um relato de caso (The importance of continuity of care in psychiatric pathology: a case report). Rev Port Med Geral Fam. 2023;39(4):327-331",50.0,YR,,F,Y,,,20231230,,MD,PT,PT,2023,Q4,Adult
230422626,23042262,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1 dosage form, Two Times a Day (12,5 + 100 mg bid)",,,U,,,,,,,,BID,2023,Q4,Suicidal ideation,,2023,Q4,6,F,20220101.0,20231219.0,20231008,20231230,EXP,,PT-AUROBINDO-AUR-APL-2023-062172,AUROBINDO,"Canha F, Pitta R, Conde M.E.N.G.. A import?ncia da continuidade de cuidados na patologia psiqui?trica: um relato de caso (The importance of continuity of care in psychiatric pathology: a case report). Rev Port Med Geral Fam. 2023;39(4):327-331",50.0,YR,,F,Y,,,20231230,,MD,PT,PT,2023,Q4,Adult
230422626,23042262,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1 dosage form, Two Times a Day (12,5 + 100 mg bid)",,,U,,,,,,,,BID,2023,Q4,Agitation,,2023,Q4,6,F,20220101.0,20231219.0,20231008,20231230,EXP,,PT-AUROBINDO-AUR-APL-2023-062172,AUROBINDO,"Canha F, Pitta R, Conde M.E.N.G.. A import?ncia da continuidade de cuidados na patologia psiqui?trica: um relato de caso (The importance of continuity of care in psychiatric pathology: a case report). Rev Port Med Geral Fam. 2023;39(4):327-331",50.0,YR,,F,Y,,,20231230,,MD,PT,PT,2023,Q4,Adult
230422626,23042262,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1 dosage form, Two Times a Day (12,5 + 100 mg bid)",,,U,,,,,,,,BID,2023,Q4,Somnolence,,2023,Q4,6,F,20220101.0,20231219.0,20231008,20231230,EXP,,PT-AUROBINDO-AUR-APL-2023-062172,AUROBINDO,"Canha F, Pitta R, Conde M.E.N.G.. A import?ncia da continuidade de cuidados na patologia psiqui?trica: um relato de caso (The importance of continuity of care in psychiatric pathology: a case report). Rev Port Med Geral Fam. 2023;39(4):327-331",50.0,YR,,F,Y,,,20231230,,MD,PT,PT,2023,Q4,Adult
230422626,23042262,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1 dosage form, Two Times a Day (12,5 + 100 mg bid)",,,U,,,,,,,,BID,2023,Q4,Wrong product administered,,2023,Q4,6,F,20220101.0,20231219.0,20231008,20231230,EXP,,PT-AUROBINDO-AUR-APL-2023-062172,AUROBINDO,"Canha F, Pitta R, Conde M.E.N.G.. A import?ncia da continuidade de cuidados na patologia psiqui?trica: um relato de caso (The importance of continuity of care in psychiatric pathology: a case report). Rev Port Med Geral Fam. 2023;39(4):327-331",50.0,YR,,F,Y,,,20231230,,MD,PT,PT,2023,Q4,Adult
230422626,23042262,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1 dosage form, Two Times a Day (12,5 + 100 mg bid)",,,U,,,,,,,,BID,2023,Q4,Anxiety,,2023,Q4,6,F,20220101.0,20231219.0,20231008,20231230,EXP,,PT-AUROBINDO-AUR-APL-2023-062172,AUROBINDO,"Canha F, Pitta R, Conde M.E.N.G.. A import?ncia da continuidade de cuidados na patologia psiqui?trica: um relato de caso (The importance of continuity of care in psychiatric pathology: a case report). Rev Port Med Geral Fam. 2023;39(4):327-331",50.0,YR,,F,Y,,,20231230,,MD,PT,PT,2023,Q4,Adult
230422626,23042262,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1 dosage form, Two Times a Day (12,5 + 100 mg bid)",,,U,,,,,,,,BID,2023,Q4,Violence-related symptom,,2023,Q4,6,F,20220101.0,20231219.0,20231008,20231230,EXP,,PT-AUROBINDO-AUR-APL-2023-062172,AUROBINDO,"Canha F, Pitta R, Conde M.E.N.G.. A import?ncia da continuidade de cuidados na patologia psiqui?trica: um relato de caso (The importance of continuity of care in psychiatric pathology: a case report). Rev Port Med Geral Fam. 2023;39(4):327-331",50.0,YR,,F,Y,,,20231230,,MD,PT,PT,2023,Q4,Adult
230434471,23043447,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10mg daily,,,N,,ASKU,,,10.0,MG,,QD,2023,Q4,Renal cell carcinoma,,2023,Q4,1,I,,20230929.0,20231009,20231009,EXP,,GB-SANDOZ INC.-SDZ2023GB039099,SANDOZ,,71.0,YR,,F,Y,,,20231009,,PH,GB,GB,2023,Q4,Elderly
230436761,23043676,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q4,Clostridium test positive,,2023,Q4,1,I,,20230928.0,20231009,20231009,EXP,,CA-SANDOZ INC.-SDZ2023CA038947,SANDOZ,,60.0,YR,,M,Y,47.0,KG,20231009,,PH,CA,CA,2023,Q4,Adult
230436761,23043676,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q4,Clostridium test positive,,2023,Q4,1,I,,20230928.0,20231009,20231009,EXP,,CA-SANDOZ INC.-SDZ2023CA038947,SANDOZ,,60.0,YR,,M,Y,47.0,KG,20231009,,PH,CA,CA,2023,Q4,Adult
230452213,23045221,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,,,,,,,,Tablet,,2023,Q4,Dizziness,,2023,Q4,3,F,20230516.0,20231006.0,20231009,20231018,EXP,,HK-AstraZeneca-2023A214377,ASTRAZENECA,,65.0,YR,,M,Y,54.1,KG,20231018,,MD,HK,,2023,Q4,Elderly
230452213,23045221,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,,,,,,,,Tablet,,2023,Q4,Anaemia,,2023,Q4,3,F,20230516.0,20231006.0,20231009,20231018,EXP,,HK-AstraZeneca-2023A214377,ASTRAZENECA,,65.0,YR,,M,Y,54.1,KG,20231018,,MD,HK,,2023,Q4,Elderly
230452213,23045221,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,,,,,,,,Tablet,,2023,Q4,Cardiac failure congestive,,2023,Q4,3,F,20230516.0,20231006.0,20231009,20231018,EXP,,HK-AstraZeneca-2023A214377,ASTRAZENECA,,65.0,YR,,M,Y,54.1,KG,20231018,,MD,HK,,2023,Q4,Elderly
230457962,23045796,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 Milligram Daily; 10mg daily,,,N,U,ASKU,,,10.0,MG,Powder for infusion,QD,2023,Q4,Renal cell carcinoma,,2023,Q4,2,F,,20231008.0,20231009,20231018,EXP,,GB-TEVA-2023-GB-2932662,TEVA,,71.0,YR,E,F,Y,,,20231018,,PH,GB,GB,2023,Q4,Elderly
230460105,23046010,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Sepsis,,2023,Q4,5,F,20230729.0,20231020.0,20231009,20231025,EXP,,NVSC2023CA169372,NOVARTIS,,69.0,YR,,M,Y,,,20231025,,MD,CA,CA,2023,Q4,Elderly
230460105,23046010,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Pyrexia,,2023,Q4,5,F,20230729.0,20231020.0,20231009,20231025,EXP,,NVSC2023CA169372,NOVARTIS,,69.0,YR,,M,Y,,,20231025,,MD,CA,CA,2023,Q4,Elderly
230484861,23048486,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg 1X1,,,U,,,,,10.0,MG,,,2023,Q4,Hypertension,,2023,Q4,1,I,,20230928.0,20231010,20231010,EXP,DE-EMA-2023904-AUTODUP-1693861373310,DE-Accord-382946,ACCORD,,28.0,YR,,M,Y,,,20231010,,MD,DE,DE,2023,Q4,Young Adult
230484861,23048486,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg 1X1,,,U,,,,,10.0,MG,,,2023,Q4,Hyperkalaemia,,2023,Q4,1,I,,20230928.0,20231010,20231010,EXP,DE-EMA-2023904-AUTODUP-1693861373310,DE-Accord-382946,ACCORD,,28.0,YR,,M,Y,,,20231010,,MD,DE,DE,2023,Q4,Young Adult
230484861,23048486,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg 1X1,,,U,,,,,10.0,MG,,,2023,Q4,Renal impairment,,2023,Q4,1,I,,20230928.0,20231010,20231010,EXP,DE-EMA-2023904-AUTODUP-1693861373310,DE-Accord-382946,ACCORD,,28.0,YR,,M,Y,,,20231010,,MD,DE,DE,2023,Q4,Young Adult
230490991,23049099,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg  30 tablets,,,Y,,,,,5.0,MG,Film-coated tablet,,2023,Q4,Hepatitis cholestatic,,2023,Q4,1,I,20230711.0,20230928.0,20231010,20231010,EXP,ES-AEMPS-1420809,ES-Accord-383030,ACCORD,,80.0,YR,E,F,Y,,,20231010,,MD,ES,ES,2023,Q4,Elderly
230495851,23049585,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Neutropenia,,2023,Q4,1,I,,20230927.0,20231010,20231010,EXP,,FR-B.Braun Medical Inc.-2146895,B BRAUN,,74.0,YR,,F,Y,93.0,KG,20231010,,HP,FR,FR,2023,Q4,Elderly
230495851,23049585,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Septic shock,,2023,Q4,1,I,,20230927.0,20231010,20231010,EXP,,FR-B.Braun Medical Inc.-2146895,B BRAUN,,74.0,YR,,F,Y,93.0,KG,20231010,,HP,FR,FR,2023,Q4,Elderly
230530931,23053093,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q4,Acute generalised exanthematous pustulosis,,2023,Q4,1,I,20230909.0,20231010.0,20231011,20231011,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-266037",BOEHRINGER INGELHEIM,,60.0,YR,A,M,Y,,,20231011,,HP,SG,SG,2023,Q4,Adult
230536682,23053668,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10mg daily; ;,,,N,U,,,,10.0,MG,Powder for infusion,,2023,Q4,Renal cell carcinoma,,2023,Q4,2,F,,20231008.0,20231011,20231019,EXP,,GB-MICRO LABS LIMITED-ML2023-05663,MICRO LABS,,71.0,YR,E,F,Y,,,20231019,,PH,GB,,2023,Q4,Elderly
230539911,23053991,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,Film-coated tablet,,2023,Q4,Myalgia,,2023,Q4,1,I,20230101.0,20230929.0,20231011,20231011,EXP,SE-SEMPA-2023-014014,SE-Accord-383265,ACCORD,,84.0,YR,E,M,Y,,,20231011,,CN,SE,SE,2023,Q4,Elderly
230539911,23053991,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,Film-coated tablet,,2023,Q4,Feeling abnormal,,2023,Q4,1,I,20230101.0,20230929.0,20231011,20231011,EXP,SE-SEMPA-2023-014014,SE-Accord-383265,ACCORD,,84.0,YR,E,M,Y,,,20231011,,CN,SE,SE,2023,Q4,Elderly
230539911,23053991,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,Film-coated tablet,,2023,Q4,Pain,,2023,Q4,1,I,20230101.0,20230929.0,20231011,20231011,EXP,SE-SEMPA-2023-014014,SE-Accord-383265,ACCORD,,84.0,YR,E,M,Y,,,20231011,,CN,SE,SE,2023,Q4,Elderly
230539911,23053991,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,Film-coated tablet,,2023,Q4,Movement disorder,,2023,Q4,1,I,20230101.0,20230929.0,20231011,20231011,EXP,SE-SEMPA-2023-014014,SE-Accord-383265,ACCORD,,84.0,YR,E,M,Y,,,20231011,,CN,SE,SE,2023,Q4,Elderly
230539911,23053991,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,Film-coated tablet,,2023,Q4,Gait disturbance,,2023,Q4,1,I,20230101.0,20230929.0,20231011,20231011,EXP,SE-SEMPA-2023-014014,SE-Accord-383265,ACCORD,,84.0,YR,E,M,Y,,,20231011,,CN,SE,SE,2023,Q4,Elderly
230539911,23053991,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,Film-coated tablet,,2023,Q4,Hypoaesthesia,,2023,Q4,1,I,20230101.0,20230929.0,20231011,20231011,EXP,SE-SEMPA-2023-014014,SE-Accord-383265,ACCORD,,84.0,YR,E,M,Y,,,20231011,,CN,SE,SE,2023,Q4,Elderly
230539962,23053996,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10mg daily; ;,,,N,,,,,,,Powder for infusion,,2023,Q4,Renal cell carcinoma,,2023,Q4,2,F,,20231008.0,20231011,20231019,EXP,GB-MHRA-ADR 28217174,GB-Accord-383249,ACCORD,,71.0,YR,E,F,Y,,,20231019,,PH,GB,GB,2023,Q4,Elderly
230564761,23056476,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q4,Cholecystitis,,2023,Q4,1,I,,20231005.0,20231011,20231011,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-265206",BOEHRINGER INGELHEIM,"MAHMOUD A, KURT O, JAIN A, WASEEM S. A DIAGNOSTIC DILEMMA: UNRAVELING SEVERE ANION GAP METABOLIC ACIDOSIS IN SEPTIC SHOCK SECONDARY TO EUGLYCEMIC DIABETIC KETOACIDOSIS. Chest. 2023;164: doi:10.1016/j.chest.2023.07.1737.",67.0,YR,E,F,Y,,,20231012,,HP,US,US,2023,Q4,Elderly
230564761,23056476,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q4,Cardiac arrest,,2023,Q4,1,I,,20231005.0,20231011,20231011,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-265206",BOEHRINGER INGELHEIM,"MAHMOUD A, KURT O, JAIN A, WASEEM S. A DIAGNOSTIC DILEMMA: UNRAVELING SEVERE ANION GAP METABOLIC ACIDOSIS IN SEPTIC SHOCK SECONDARY TO EUGLYCEMIC DIABETIC KETOACIDOSIS. Chest. 2023;164: doi:10.1016/j.chest.2023.07.1737.",67.0,YR,E,F,Y,,,20231012,,HP,US,US,2023,Q4,Elderly
230564761,23056476,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q4,Septic shock,,2023,Q4,1,I,,20231005.0,20231011,20231011,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-265206",BOEHRINGER INGELHEIM,"MAHMOUD A, KURT O, JAIN A, WASEEM S. A DIAGNOSTIC DILEMMA: UNRAVELING SEVERE ANION GAP METABOLIC ACIDOSIS IN SEPTIC SHOCK SECONDARY TO EUGLYCEMIC DIABETIC KETOACIDOSIS. Chest. 2023;164: doi:10.1016/j.chest.2023.07.1737.",67.0,YR,E,F,Y,,,20231012,,HP,US,US,2023,Q4,Elderly
230564761,23056476,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q4,Euglycaemic diabetic ketoacidosis,,2023,Q4,1,I,,20231005.0,20231011,20231011,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-265206",BOEHRINGER INGELHEIM,"MAHMOUD A, KURT O, JAIN A, WASEEM S. A DIAGNOSTIC DILEMMA: UNRAVELING SEVERE ANION GAP METABOLIC ACIDOSIS IN SEPTIC SHOCK SECONDARY TO EUGLYCEMIC DIABETIC KETOACIDOSIS. Chest. 2023;164: doi:10.1016/j.chest.2023.07.1737.",67.0,YR,E,F,Y,,,20231012,,HP,US,US,2023,Q4,Elderly
230568631,23056863,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,204629.0,,,,,2023,Q4,Overdose,,2023,Q4,1,I,,20231005.0,20231012,20231012,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-265169",BOEHRINGER INGELHEIM,"DONG Q, Kyereme-Tuah EK, ZOU Y, JIN Z, WAZEEN FR. BRASH SYNDROME: AN UNDER-RECOGNIZED SYNDROME PRECIPITATED BY MEDICATION OVERDOSE. Chest. 2023;164: doi:10.1016/j.chest.2023.07.1472.",77.0,YR,E,M,Y,,,20231012,,HP,US,US,2023,Q4,Elderly
230568631,23056863,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,204629.0,,,,,2023,Q4,BRASH syndrome,,2023,Q4,1,I,,20231005.0,20231012,20231012,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-265169",BOEHRINGER INGELHEIM,"DONG Q, Kyereme-Tuah EK, ZOU Y, JIN Z, WAZEEN FR. BRASH SYNDROME: AN UNDER-RECOGNIZED SYNDROME PRECIPITATED BY MEDICATION OVERDOSE. Chest. 2023;164: doi:10.1016/j.chest.2023.07.1472.",77.0,YR,E,M,Y,,,20231012,,HP,US,US,2023,Q4,Elderly
230569611,23056961,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q4,Decreased appetite,,2023,Q4,1,I,,20231005.0,20231012,20231012,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-265203",BOEHRINGER INGELHEIM,"LEE J, NOOR F, BARUA A, AHMAD R. A RARE CASE OF EUGLYCEMIC DIABETIC KETOACIDOSIS IN SETTING OF SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS USE WITH UNDIAGNOSED METASTATIC PANCREATIC CANCER AND STARVATION. Chest. 2023;164: doi:10.1016/j.chest.2023.07.1645.",57.0,YR,A,M,Y,,,20231012,,HP,US,US,2023,Q4,Adult
230569611,23056961,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q4,Metastases to lung,,2023,Q4,1,I,,20231005.0,20231012,20231012,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-265203",BOEHRINGER INGELHEIM,"LEE J, NOOR F, BARUA A, AHMAD R. A RARE CASE OF EUGLYCEMIC DIABETIC KETOACIDOSIS IN SETTING OF SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS USE WITH UNDIAGNOSED METASTATIC PANCREATIC CANCER AND STARVATION. Chest. 2023;164: doi:10.1016/j.chest.2023.07.1645.",57.0,YR,A,M,Y,,,20231012,,HP,US,US,2023,Q4,Adult
230569611,23056961,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q4,Euglycaemic diabetic ketoacidosis,,2023,Q4,1,I,,20231005.0,20231012,20231012,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-265203",BOEHRINGER INGELHEIM,"LEE J, NOOR F, BARUA A, AHMAD R. A RARE CASE OF EUGLYCEMIC DIABETIC KETOACIDOSIS IN SETTING OF SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS USE WITH UNDIAGNOSED METASTATIC PANCREATIC CANCER AND STARVATION. Chest. 2023;164: doi:10.1016/j.chest.2023.07.1645.",57.0,YR,A,M,Y,,,20231012,,HP,US,US,2023,Q4,Adult
230569611,23056961,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q4,Adenocarcinoma pancreas,,2023,Q4,1,I,,20231005.0,20231012,20231012,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-265203",BOEHRINGER INGELHEIM,"LEE J, NOOR F, BARUA A, AHMAD R. A RARE CASE OF EUGLYCEMIC DIABETIC KETOACIDOSIS IN SETTING OF SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS USE WITH UNDIAGNOSED METASTATIC PANCREATIC CANCER AND STARVATION. Chest. 2023;164: doi:10.1016/j.chest.2023.07.1645.",57.0,YR,A,M,Y,,,20231012,,HP,US,US,2023,Q4,Adult
230569611,23056961,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q4,Abdominal pain upper,,2023,Q4,1,I,,20231005.0,20231012,20231012,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-265203",BOEHRINGER INGELHEIM,"LEE J, NOOR F, BARUA A, AHMAD R. A RARE CASE OF EUGLYCEMIC DIABETIC KETOACIDOSIS IN SETTING OF SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS USE WITH UNDIAGNOSED METASTATIC PANCREATIC CANCER AND STARVATION. Chest. 2023;164: doi:10.1016/j.chest.2023.07.1645.",57.0,YR,A,M,Y,,,20231012,,HP,US,US,2023,Q4,Adult
230570072,23057007,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 mg,,,,,,,,25.0,MG,Tablet,,2023,Q4,Diabetes mellitus inadequate control,,2023,Q4,2,F,,20231114.0,20231012,20231120,EXP,,NVSJ2023JP014732,NOVARTIS,,53.0,YR,,M,Y,132.3,KG,20231121,,MD,JP,JP,2023,Q4,Adult
230570072,23057007,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 mg,,,,,,,,25.0,MG,Tablet,,2023,Q4,Blood pressure inadequately controlled,,2023,Q4,2,F,,20231114.0,20231012,20231120,EXP,,NVSJ2023JP014732,NOVARTIS,,53.0,YR,,M,Y,132.3,KG,20231121,,MD,JP,JP,2023,Q4,Adult
230570582,23057058,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,,,Unknown,,206073.0,,,Tablet,,2023,Q4,Blood glucose increased,,2023,Q4,2,F,,20231017.0,20231012,20231019,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-266291",BOEHRINGER INGELHEIM,,9.0,DEC,E,M,Y,,,20231019,,PH,JP,JP,2023,Q4,Child
230570582,23057058,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,,,Unknown,,206073.0,,,Tablet,,2023,Q4,Glycosylated haemoglobin increased,,2023,Q4,2,F,,20231017.0,20231012,20231019,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-266291",BOEHRINGER INGELHEIM,,9.0,DEC,E,M,Y,,,20231019,,PH,JP,JP,2023,Q4,Child
230570582,23057058,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,,,Unknown,,206073.0,,,Tablet,,2023,Q4,Fracture,,2023,Q4,2,F,,20231017.0,20231012,20231019,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-266291",BOEHRINGER INGELHEIM,,9.0,DEC,E,M,Y,,,20231019,,PH,JP,JP,2023,Q4,Child
230579462,23057946,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10mg daily; ;,,,N,U,"ASKU,UNKNOWN",,,10.0,MG,Tablet,,2023,Q4,Renal cell carcinoma,,2023,Q4,2,F,,20231008.0,20231012,20231017,EXP,,GB-drreddys-SPO/UKI/23/0179126,DR REDDYS,,71.0,YR,E,F,Y,,,20231017,,PH,GB,GB,2023,Q4,Elderly
230587531,23058753,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,Unknown,,2023,Q4,Overdose,,2023,Q4,1,I,,20231004.0,20231012,20231012,EXP,,US-MYLANLABS-2023M1106356,MYLAN,"DONG Q, KYEREME-TUAH EK, ZOU Y, JIN Z, RAHIM WAZEEN FAZL. BRASH SYNDROME: AN UNDER-RECOGNIZED SYNDROME PRECIPITATED BY MEDICATION OVERDOSE. Chest 2023;164 (Suppl.)(4):A2167-A2168.",77.0,YR,,M,Y,,,20231012,,HP,US,US,2023,Q4,Elderly
230587531,23058753,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,Unknown,,2023,Q4,BRASH syndrome,,2023,Q4,1,I,,20231004.0,20231012,20231012,EXP,,US-MYLANLABS-2023M1106356,MYLAN,"DONG Q, KYEREME-TUAH EK, ZOU Y, JIN Z, RAHIM WAZEEN FAZL. BRASH SYNDROME: AN UNDER-RECOGNIZED SYNDROME PRECIPITATED BY MEDICATION OVERDOSE. Chest 2023;164 (Suppl.)(4):A2167-A2168.",77.0,YR,,M,Y,,,20231012,,HP,US,US,2023,Q4,Elderly
230597392,23059739,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"Unknown, Duration of administration } 6 months",,,N,,,,,10.0,MG,UNK,,2023,Q4,Lactic acidosis,,2023,Q4,2,F,20230904.0,20231013.0,20231012,20231023,EXP,DE-DCGMA-23201894,DE-TORRENT-00025485,TORRENT,,64.0,YR,A,F,Y,90.0,KG,20231023,,MD,DE,DE,2023,Q4,Adult
230597392,23059739,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"Unknown, Duration of administration } 6 months",,,N,,,,,10.0,MG,UNK,,2023,Q4,Ketoacidosis,,2023,Q4,2,F,20230904.0,20231013.0,20231012,20231023,EXP,DE-DCGMA-23201894,DE-TORRENT-00025485,TORRENT,,64.0,YR,A,F,Y,90.0,KG,20231023,,MD,DE,DE,2023,Q4,Adult
230597392,23059739,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"Unknown, Duration of administration } 6 months",,,N,,,,,10.0,MG,UNK,,2023,Q4,Acute kidney injury,,2023,Q4,2,F,20230904.0,20231013.0,20231012,20231023,EXP,DE-DCGMA-23201894,DE-TORRENT-00025485,TORRENT,,64.0,YR,A,F,Y,90.0,KG,20231023,,MD,DE,DE,2023,Q4,Adult
230600471,23060047,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q4,Septic shock,,2023,Q4,1,I,20230827.0,20231009.0,20231012,20231012,EXP,FR-AFSSAPS-AM2023000838,FR-FreseniusKabi-FK202316090,FRESENIUS KABI,,74.0,YR,A,F,Y,93.0,KG,20231012,,PH,FR,FR,2023,Q4,Elderly
230600471,23060047,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q4,Neutropenia,,2023,Q4,1,I,20230827.0,20231009.0,20231012,20231012,EXP,FR-AFSSAPS-AM2023000838,FR-FreseniusKabi-FK202316090,FRESENIUS KABI,,74.0,YR,A,F,Y,93.0,KG,20231012,,PH,FR,FR,2023,Q4,Elderly
230601571,23060157,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Confusional state,,2023,Q4,1,I,,20231004.0,20231012,20231012,EXP,,GB-AstraZeneca-2023A226109,ASTRAZENECA,,73.0,YR,,F,Y,112.0,KG,20231012,,MD,GB,,2023,Q4,Elderly
230601571,23060157,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Dyspnoea,,2023,Q4,1,I,,20231004.0,20231012,20231012,EXP,,GB-AstraZeneca-2023A226109,ASTRAZENECA,,73.0,YR,,F,Y,112.0,KG,20231012,,MD,GB,,2023,Q4,Elderly
230602542,23060254,18,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5mg/100mg bid,,,,,,,,,,,,2023,Q4,Accidental overdose,,2023,Q4,2,F,20220622.0,20231012.0,20231012,20231020,EXP,,PT-AstraZeneca-2023A225532,ASTRAZENECA,"Canha F, Pitta R, Esteves Nunes Gil Conde M.. The importance of continuity of care in psychiatric pathology: a case report.. Case reports.  Rev Port Med Geral Fam 2023;39:327-31..",50.0,YR,,F,Y,,,20231020,,MD,PT,,2023,Q4,Adult
230602542,23060254,18,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5mg/100mg bid,,,,,,,,,,,,2023,Q4,Initial insomnia,,2023,Q4,2,F,20220622.0,20231012.0,20231012,20231020,EXP,,PT-AstraZeneca-2023A225532,ASTRAZENECA,"Canha F, Pitta R, Esteves Nunes Gil Conde M.. The importance of continuity of care in psychiatric pathology: a case report.. Case reports.  Rev Port Med Geral Fam 2023;39:327-31..",50.0,YR,,F,Y,,,20231020,,MD,PT,,2023,Q4,Adult
230602542,23060254,18,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5mg/100mg bid,,,,,,,,,,,,2023,Q4,Suicidal ideation,,2023,Q4,2,F,20220622.0,20231012.0,20231012,20231020,EXP,,PT-AstraZeneca-2023A225532,ASTRAZENECA,"Canha F, Pitta R, Esteves Nunes Gil Conde M.. The importance of continuity of care in psychiatric pathology: a case report.. Case reports.  Rev Port Med Geral Fam 2023;39:327-31..",50.0,YR,,F,Y,,,20231020,,MD,PT,,2023,Q4,Adult
230602542,23060254,18,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5mg/100mg bid,,,,,,,,,,,,2023,Q4,Nightmare,,2023,Q4,2,F,20220622.0,20231012.0,20231012,20231020,EXP,,PT-AstraZeneca-2023A225532,ASTRAZENECA,"Canha F, Pitta R, Esteves Nunes Gil Conde M.. The importance of continuity of care in psychiatric pathology: a case report.. Case reports.  Rev Port Med Geral Fam 2023;39:327-31..",50.0,YR,,F,Y,,,20231020,,MD,PT,,2023,Q4,Adult
230602542,23060254,18,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5mg/100mg bid,,,,,,,,,,,,2023,Q4,Irritability,,2023,Q4,2,F,20220622.0,20231012.0,20231012,20231020,EXP,,PT-AstraZeneca-2023A225532,ASTRAZENECA,"Canha F, Pitta R, Esteves Nunes Gil Conde M.. The importance of continuity of care in psychiatric pathology: a case report.. Case reports.  Rev Port Med Geral Fam 2023;39:327-31..",50.0,YR,,F,Y,,,20231020,,MD,PT,,2023,Q4,Adult
230602542,23060254,18,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5mg/100mg bid,,,,,,,,,,,,2023,Q4,Affective disorder,,2023,Q4,2,F,20220622.0,20231012.0,20231012,20231020,EXP,,PT-AstraZeneca-2023A225532,ASTRAZENECA,"Canha F, Pitta R, Esteves Nunes Gil Conde M.. The importance of continuity of care in psychiatric pathology: a case report.. Case reports.  Rev Port Med Geral Fam 2023;39:327-31..",50.0,YR,,F,Y,,,20231020,,MD,PT,,2023,Q4,Adult
230602542,23060254,18,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5mg/100mg bid,,,,,,,,,,,,2023,Q4,Fatigue,,2023,Q4,2,F,20220622.0,20231012.0,20231012,20231020,EXP,,PT-AstraZeneca-2023A225532,ASTRAZENECA,"Canha F, Pitta R, Esteves Nunes Gil Conde M.. The importance of continuity of care in psychiatric pathology: a case report.. Case reports.  Rev Port Med Geral Fam 2023;39:327-31..",50.0,YR,,F,Y,,,20231020,,MD,PT,,2023,Q4,Adult
230602542,23060254,18,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5mg/100mg bid,,,,,,,,,,,,2023,Q4,Depressed mood,,2023,Q4,2,F,20220622.0,20231012.0,20231012,20231020,EXP,,PT-AstraZeneca-2023A225532,ASTRAZENECA,"Canha F, Pitta R, Esteves Nunes Gil Conde M.. The importance of continuity of care in psychiatric pathology: a case report.. Case reports.  Rev Port Med Geral Fam 2023;39:327-31..",50.0,YR,,F,Y,,,20231020,,MD,PT,,2023,Q4,Adult
230602542,23060254,18,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5mg/100mg bid,,,,,,,,,,,,2023,Q4,Pseudohallucination,,2023,Q4,2,F,20220622.0,20231012.0,20231012,20231020,EXP,,PT-AstraZeneca-2023A225532,ASTRAZENECA,"Canha F, Pitta R, Esteves Nunes Gil Conde M.. The importance of continuity of care in psychiatric pathology: a case report.. Case reports.  Rev Port Med Geral Fam 2023;39:327-31..",50.0,YR,,F,Y,,,20231020,,MD,PT,,2023,Q4,Adult
230602542,23060254,18,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5mg/100mg bid,,,,,,,,,,,,2023,Q4,Agitation,,2023,Q4,2,F,20220622.0,20231012.0,20231012,20231020,EXP,,PT-AstraZeneca-2023A225532,ASTRAZENECA,"Canha F, Pitta R, Esteves Nunes Gil Conde M.. The importance of continuity of care in psychiatric pathology: a case report.. Case reports.  Rev Port Med Geral Fam 2023;39:327-31..",50.0,YR,,F,Y,,,20231020,,MD,PT,,2023,Q4,Adult
230602542,23060254,18,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5mg/100mg bid,,,,,,,,,,,,2023,Q4,Somnolence,,2023,Q4,2,F,20220622.0,20231012.0,20231012,20231020,EXP,,PT-AstraZeneca-2023A225532,ASTRAZENECA,"Canha F, Pitta R, Esteves Nunes Gil Conde M.. The importance of continuity of care in psychiatric pathology: a case report.. Case reports.  Rev Port Med Geral Fam 2023;39:327-31..",50.0,YR,,F,Y,,,20231020,,MD,PT,,2023,Q4,Adult
230602542,23060254,18,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5mg/100mg bid,,,,,,,,,,,,2023,Q4,Anhedonia,,2023,Q4,2,F,20220622.0,20231012.0,20231012,20231020,EXP,,PT-AstraZeneca-2023A225532,ASTRAZENECA,"Canha F, Pitta R, Esteves Nunes Gil Conde M.. The importance of continuity of care in psychiatric pathology: a case report.. Case reports.  Rev Port Med Geral Fam 2023;39:327-31..",50.0,YR,,F,Y,,,20231020,,MD,PT,,2023,Q4,Adult
230602542,23060254,18,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5mg/100mg bid,,,,,,,,,,,,2023,Q4,Insomnia,,2023,Q4,2,F,20220622.0,20231012.0,20231012,20231020,EXP,,PT-AstraZeneca-2023A225532,ASTRAZENECA,"Canha F, Pitta R, Esteves Nunes Gil Conde M.. The importance of continuity of care in psychiatric pathology: a case report.. Case reports.  Rev Port Med Geral Fam 2023;39:327-31..",50.0,YR,,F,Y,,,20231020,,MD,PT,,2023,Q4,Adult
230602542,23060254,18,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5mg/100mg bid,,,,,,,,,,,,2023,Q4,Suicidal ideation,,2023,Q4,2,F,20220622.0,20231012.0,20231012,20231020,EXP,,PT-AstraZeneca-2023A225532,ASTRAZENECA,"Canha F, Pitta R, Esteves Nunes Gil Conde M.. The importance of continuity of care in psychiatric pathology: a case report.. Case reports.  Rev Port Med Geral Fam 2023;39:327-31..",50.0,YR,,F,Y,,,20231020,,MD,PT,,2023,Q4,Adult
230602542,23060254,18,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5mg/100mg bid,,,,,,,,,,,,2023,Q4,Wrong dose,,2023,Q4,2,F,20220622.0,20231012.0,20231012,20231020,EXP,,PT-AstraZeneca-2023A225532,ASTRAZENECA,"Canha F, Pitta R, Esteves Nunes Gil Conde M.. The importance of continuity of care in psychiatric pathology: a case report.. Case reports.  Rev Port Med Geral Fam 2023;39:327-31..",50.0,YR,,F,Y,,,20231020,,MD,PT,,2023,Q4,Adult
230602542,23060254,18,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5mg/100mg bid,,,,,,,,,,,,2023,Q4,Panic attack,,2023,Q4,2,F,20220622.0,20231012.0,20231012,20231020,EXP,,PT-AstraZeneca-2023A225532,ASTRAZENECA,"Canha F, Pitta R, Esteves Nunes Gil Conde M.. The importance of continuity of care in psychiatric pathology: a case report.. Case reports.  Rev Port Med Geral Fam 2023;39:327-31..",50.0,YR,,F,Y,,,20231020,,MD,PT,,2023,Q4,Adult
230602542,23060254,18,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5mg/100mg bid,,,,,,,,,,,,2023,Q4,Self-injurious ideation,,2023,Q4,2,F,20220622.0,20231012.0,20231012,20231020,EXP,,PT-AstraZeneca-2023A225532,ASTRAZENECA,"Canha F, Pitta R, Esteves Nunes Gil Conde M.. The importance of continuity of care in psychiatric pathology: a case report.. Case reports.  Rev Port Med Geral Fam 2023;39:327-31..",50.0,YR,,F,Y,,,20231020,,MD,PT,,2023,Q4,Adult
230602542,23060254,18,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5mg/100mg bid,,,,,,,,,,,,2023,Q4,Violence-related symptom,,2023,Q4,2,F,20220622.0,20231012.0,20231012,20231020,EXP,,PT-AstraZeneca-2023A225532,ASTRAZENECA,"Canha F, Pitta R, Esteves Nunes Gil Conde M.. The importance of continuity of care in psychiatric pathology: a case report.. Case reports.  Rev Port Med Geral Fam 2023;39:327-31..",50.0,YR,,F,Y,,,20231020,,MD,PT,,2023,Q4,Adult
230602542,23060254,18,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5mg/100mg bid,,,,,,,,,,,,2023,Q4,Middle insomnia,,2023,Q4,2,F,20220622.0,20231012.0,20231012,20231020,EXP,,PT-AstraZeneca-2023A225532,ASTRAZENECA,"Canha F, Pitta R, Esteves Nunes Gil Conde M.. The importance of continuity of care in psychiatric pathology: a case report.. Case reports.  Rev Port Med Geral Fam 2023;39:327-31..",50.0,YR,,F,Y,,,20231020,,MD,PT,,2023,Q4,Adult
230602542,23060254,18,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5mg/100mg bid,,,,,,,,,,,,2023,Q4,Anxiety,,2023,Q4,2,F,20220622.0,20231012.0,20231012,20231020,EXP,,PT-AstraZeneca-2023A225532,ASTRAZENECA,"Canha F, Pitta R, Esteves Nunes Gil Conde M.. The importance of continuity of care in psychiatric pathology: a case report.. Case reports.  Rev Port Med Geral Fam 2023;39:327-31..",50.0,YR,,F,Y,,,20231020,,MD,PT,,2023,Q4,Adult
230602542,23060254,18,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5mg/100mg bid,,,,,,,,,,,,2023,Q4,"Hallucination, auditory",,2023,Q4,2,F,20220622.0,20231012.0,20231012,20231020,EXP,,PT-AstraZeneca-2023A225532,ASTRAZENECA,"Canha F, Pitta R, Esteves Nunes Gil Conde M.. The importance of continuity of care in psychiatric pathology: a case report.. Case reports.  Rev Port Med Geral Fam 2023;39:327-31..",50.0,YR,,F,Y,,,20231020,,MD,PT,,2023,Q4,Adult
230602542,23060254,18,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5mg/100mg bid,,,,,,,,,,,,2023,Q4,Weight decreased,,2023,Q4,2,F,20220622.0,20231012.0,20231012,20231020,EXP,,PT-AstraZeneca-2023A225532,ASTRAZENECA,"Canha F, Pitta R, Esteves Nunes Gil Conde M.. The importance of continuity of care in psychiatric pathology: a case report.. Case reports.  Rev Port Med Geral Fam 2023;39:327-31..",50.0,YR,,F,Y,,,20231020,,MD,PT,,2023,Q4,Adult
230603627,23060362,31,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK UNK, bid (twice a day)",,,,,,,,,,Unknown,BID,2023,Q4,Irritability,,2023,Q4,7,F,20220622.0,20231218.0,20231012,20231221,EXP,,PT-MYLANLABS-2023M1106308,MYLAN,"Canha, F.; Pitta, R.; Conde, M.E.N.G.. The importance of continuity of care in psychiatric pathology: a case report. Portuguese Magazine of General and Familiar Medicine. 2023;39(4):327-331",50.0,YR,,F,Y,,,20231221,,MD,PT,PT,2023,Q4,Adult
230603627,23060362,31,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK UNK, bid (twice a day)",,,,,,,,,,Unknown,BID,2023,Q4,Panic attack,,2023,Q4,7,F,20220622.0,20231218.0,20231012,20231221,EXP,,PT-MYLANLABS-2023M1106308,MYLAN,"Canha, F.; Pitta, R.; Conde, M.E.N.G.. The importance of continuity of care in psychiatric pathology: a case report. Portuguese Magazine of General and Familiar Medicine. 2023;39(4):327-331",50.0,YR,,F,Y,,,20231221,,MD,PT,PT,2023,Q4,Adult
230603627,23060362,31,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK UNK, bid (twice a day)",,,,,,,,,,Unknown,BID,2023,Q4,Suicidal ideation,,2023,Q4,7,F,20220622.0,20231218.0,20231012,20231221,EXP,,PT-MYLANLABS-2023M1106308,MYLAN,"Canha, F.; Pitta, R.; Conde, M.E.N.G.. The importance of continuity of care in psychiatric pathology: a case report. Portuguese Magazine of General and Familiar Medicine. 2023;39(4):327-331",50.0,YR,,F,Y,,,20231221,,MD,PT,PT,2023,Q4,Adult
230603627,23060362,31,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK UNK, bid (twice a day)",,,,,,,,,,Unknown,BID,2023,Q4,Drug abuse,,2023,Q4,7,F,20220622.0,20231218.0,20231012,20231221,EXP,,PT-MYLANLABS-2023M1106308,MYLAN,"Canha, F.; Pitta, R.; Conde, M.E.N.G.. The importance of continuity of care in psychiatric pathology: a case report. Portuguese Magazine of General and Familiar Medicine. 2023;39(4):327-331",50.0,YR,,F,Y,,,20231221,,MD,PT,PT,2023,Q4,Adult
230603627,23060362,31,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK UNK, bid (twice a day)",,,,,,,,,,Unknown,BID,2023,Q4,Violence-related symptom,,2023,Q4,7,F,20220622.0,20231218.0,20231012,20231221,EXP,,PT-MYLANLABS-2023M1106308,MYLAN,"Canha, F.; Pitta, R.; Conde, M.E.N.G.. The importance of continuity of care in psychiatric pathology: a case report. Portuguese Magazine of General and Familiar Medicine. 2023;39(4):327-331",50.0,YR,,F,Y,,,20231221,,MD,PT,PT,2023,Q4,Adult
230603627,23060362,31,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK UNK, bid (twice a day)",,,,,,,,,,Unknown,BID,2023,Q4,Nightmare,,2023,Q4,7,F,20220622.0,20231218.0,20231012,20231221,EXP,,PT-MYLANLABS-2023M1106308,MYLAN,"Canha, F.; Pitta, R.; Conde, M.E.N.G.. The importance of continuity of care in psychiatric pathology: a case report. Portuguese Magazine of General and Familiar Medicine. 2023;39(4):327-331",50.0,YR,,F,Y,,,20231221,,MD,PT,PT,2023,Q4,Adult
230603627,23060362,31,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK UNK, bid (twice a day)",,,,,,,,,,Unknown,BID,2023,Q4,Agitation,,2023,Q4,7,F,20220622.0,20231218.0,20231012,20231221,EXP,,PT-MYLANLABS-2023M1106308,MYLAN,"Canha, F.; Pitta, R.; Conde, M.E.N.G.. The importance of continuity of care in psychiatric pathology: a case report. Portuguese Magazine of General and Familiar Medicine. 2023;39(4):327-331",50.0,YR,,F,Y,,,20231221,,MD,PT,PT,2023,Q4,Adult
230603627,23060362,31,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK UNK, bid (twice a day)",,,,,,,,,,Unknown,BID,2023,Q4,Accidental overdose,,2023,Q4,7,F,20220622.0,20231218.0,20231012,20231221,EXP,,PT-MYLANLABS-2023M1106308,MYLAN,"Canha, F.; Pitta, R.; Conde, M.E.N.G.. The importance of continuity of care in psychiatric pathology: a case report. Portuguese Magazine of General and Familiar Medicine. 2023;39(4):327-331",50.0,YR,,F,Y,,,20231221,,MD,PT,PT,2023,Q4,Adult
230603627,23060362,31,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK UNK, bid (twice a day)",,,,,,,,,,Unknown,BID,2023,Q4,Depressed mood,,2023,Q4,7,F,20220622.0,20231218.0,20231012,20231221,EXP,,PT-MYLANLABS-2023M1106308,MYLAN,"Canha, F.; Pitta, R.; Conde, M.E.N.G.. The importance of continuity of care in psychiatric pathology: a case report. Portuguese Magazine of General and Familiar Medicine. 2023;39(4):327-331",50.0,YR,,F,Y,,,20231221,,MD,PT,PT,2023,Q4,Adult
230603627,23060362,31,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK UNK, bid (twice a day)",,,,,,,,,,Unknown,BID,2023,Q4,Intentional product misuse,,2023,Q4,7,F,20220622.0,20231218.0,20231012,20231221,EXP,,PT-MYLANLABS-2023M1106308,MYLAN,"Canha, F.; Pitta, R.; Conde, M.E.N.G.. The importance of continuity of care in psychiatric pathology: a case report. Portuguese Magazine of General and Familiar Medicine. 2023;39(4):327-331",50.0,YR,,F,Y,,,20231221,,MD,PT,PT,2023,Q4,Adult
230603627,23060362,31,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK UNK, bid (twice a day)",,,,,,,,,,Unknown,BID,2023,Q4,Somnolence,,2023,Q4,7,F,20220622.0,20231218.0,20231012,20231221,EXP,,PT-MYLANLABS-2023M1106308,MYLAN,"Canha, F.; Pitta, R.; Conde, M.E.N.G.. The importance of continuity of care in psychiatric pathology: a case report. Portuguese Magazine of General and Familiar Medicine. 2023;39(4):327-331",50.0,YR,,F,Y,,,20231221,,MD,PT,PT,2023,Q4,Adult
230603627,23060362,31,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK UNK, bid (twice a day)",,,,,,,,,,Unknown,BID,2023,Q4,Middle insomnia,,2023,Q4,7,F,20220622.0,20231218.0,20231012,20231221,EXP,,PT-MYLANLABS-2023M1106308,MYLAN,"Canha, F.; Pitta, R.; Conde, M.E.N.G.. The importance of continuity of care in psychiatric pathology: a case report. Portuguese Magazine of General and Familiar Medicine. 2023;39(4):327-331",50.0,YR,,F,Y,,,20231221,,MD,PT,PT,2023,Q4,Adult
230603627,23060362,31,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK UNK, bid (twice a day)",,,,,,,,,,Unknown,BID,2023,Q4,Weight decreased,,2023,Q4,7,F,20220622.0,20231218.0,20231012,20231221,EXP,,PT-MYLANLABS-2023M1106308,MYLAN,"Canha, F.; Pitta, R.; Conde, M.E.N.G.. The importance of continuity of care in psychiatric pathology: a case report. Portuguese Magazine of General and Familiar Medicine. 2023;39(4):327-331",50.0,YR,,F,Y,,,20231221,,MD,PT,PT,2023,Q4,Adult
230603627,23060362,31,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK UNK, bid (twice a day)",,,,,,,,,,Unknown,BID,2023,Q4,Affective disorder,,2023,Q4,7,F,20220622.0,20231218.0,20231012,20231221,EXP,,PT-MYLANLABS-2023M1106308,MYLAN,"Canha, F.; Pitta, R.; Conde, M.E.N.G.. The importance of continuity of care in psychiatric pathology: a case report. Portuguese Magazine of General and Familiar Medicine. 2023;39(4):327-331",50.0,YR,,F,Y,,,20231221,,MD,PT,PT,2023,Q4,Adult
230603627,23060362,31,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK UNK, bid (twice a day)",,,,,,,,,,Unknown,BID,2023,Q4,"Hallucination, auditory",,2023,Q4,7,F,20220622.0,20231218.0,20231012,20231221,EXP,,PT-MYLANLABS-2023M1106308,MYLAN,"Canha, F.; Pitta, R.; Conde, M.E.N.G.. The importance of continuity of care in psychiatric pathology: a case report. Portuguese Magazine of General and Familiar Medicine. 2023;39(4):327-331",50.0,YR,,F,Y,,,20231221,,MD,PT,PT,2023,Q4,Adult
230603627,23060362,31,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK UNK, bid (twice a day)",,,,,,,,,,Unknown,BID,2023,Q4,Pseudohallucination,,2023,Q4,7,F,20220622.0,20231218.0,20231012,20231221,EXP,,PT-MYLANLABS-2023M1106308,MYLAN,"Canha, F.; Pitta, R.; Conde, M.E.N.G.. The importance of continuity of care in psychiatric pathology: a case report. Portuguese Magazine of General and Familiar Medicine. 2023;39(4):327-331",50.0,YR,,F,Y,,,20231221,,MD,PT,PT,2023,Q4,Adult
230603627,23060362,31,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK UNK, bid (twice a day)",,,,,,,,,,Unknown,BID,2023,Q4,Medication error,,2023,Q4,7,F,20220622.0,20231218.0,20231012,20231221,EXP,,PT-MYLANLABS-2023M1106308,MYLAN,"Canha, F.; Pitta, R.; Conde, M.E.N.G.. The importance of continuity of care in psychiatric pathology: a case report. Portuguese Magazine of General and Familiar Medicine. 2023;39(4):327-331",50.0,YR,,F,Y,,,20231221,,MD,PT,PT,2023,Q4,Adult
230603627,23060362,31,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK UNK, bid (twice a day)",,,,,,,,,,Unknown,BID,2023,Q4,Anxiety,,2023,Q4,7,F,20220622.0,20231218.0,20231012,20231221,EXP,,PT-MYLANLABS-2023M1106308,MYLAN,"Canha, F.; Pitta, R.; Conde, M.E.N.G.. The importance of continuity of care in psychiatric pathology: a case report. Portuguese Magazine of General and Familiar Medicine. 2023;39(4):327-331",50.0,YR,,F,Y,,,20231221,,MD,PT,PT,2023,Q4,Adult
230603627,23060362,31,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK UNK, bid (twice a day)",,,,,,,,,,Unknown,BID,2023,Q4,Insomnia,,2023,Q4,7,F,20220622.0,20231218.0,20231012,20231221,EXP,,PT-MYLANLABS-2023M1106308,MYLAN,"Canha, F.; Pitta, R.; Conde, M.E.N.G.. The importance of continuity of care in psychiatric pathology: a case report. Portuguese Magazine of General and Familiar Medicine. 2023;39(4):327-331",50.0,YR,,F,Y,,,20231221,,MD,PT,PT,2023,Q4,Adult
230603627,23060362,31,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK UNK, bid (twice a day)",,,,,,,,,,Unknown,BID,2023,Q4,Treatment noncompliance,,2023,Q4,7,F,20220622.0,20231218.0,20231012,20231221,EXP,,PT-MYLANLABS-2023M1106308,MYLAN,"Canha, F.; Pitta, R.; Conde, M.E.N.G.. The importance of continuity of care in psychiatric pathology: a case report. Portuguese Magazine of General and Familiar Medicine. 2023;39(4):327-331",50.0,YR,,F,Y,,,20231221,,MD,PT,PT,2023,Q4,Adult
230603627,23060362,31,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK UNK, bid (twice a day)",,,,,,,,,,Unknown,BID,2023,Q4,Self-injurious ideation,,2023,Q4,7,F,20220622.0,20231218.0,20231012,20231221,EXP,,PT-MYLANLABS-2023M1106308,MYLAN,"Canha, F.; Pitta, R.; Conde, M.E.N.G.. The importance of continuity of care in psychiatric pathology: a case report. Portuguese Magazine of General and Familiar Medicine. 2023;39(4):327-331",50.0,YR,,F,Y,,,20231221,,MD,PT,PT,2023,Q4,Adult
230603627,23060362,31,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK UNK, bid (twice a day)",,,,,,,,,,Unknown,BID,2023,Q4,Fatigue,,2023,Q4,7,F,20220622.0,20231218.0,20231012,20231221,EXP,,PT-MYLANLABS-2023M1106308,MYLAN,"Canha, F.; Pitta, R.; Conde, M.E.N.G.. The importance of continuity of care in psychiatric pathology: a case report. Portuguese Magazine of General and Familiar Medicine. 2023;39(4):327-331",50.0,YR,,F,Y,,,20231221,,MD,PT,PT,2023,Q4,Adult
230603627,23060362,31,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK UNK, bid (twice a day)",,,,,,,,,,Unknown,BID,2023,Q4,Anhedonia,,2023,Q4,7,F,20220622.0,20231218.0,20231012,20231221,EXP,,PT-MYLANLABS-2023M1106308,MYLAN,"Canha, F.; Pitta, R.; Conde, M.E.N.G.. The importance of continuity of care in psychiatric pathology: a case report. Portuguese Magazine of General and Familiar Medicine. 2023;39(4):327-331",50.0,YR,,F,Y,,,20231221,,MD,PT,PT,2023,Q4,Adult
230603627,23060362,31,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK UNK, bid (twice a day)",,,,,,,,,,Unknown,BID,2023,Q4,Initial insomnia,,2023,Q4,7,F,20220622.0,20231218.0,20231012,20231221,EXP,,PT-MYLANLABS-2023M1106308,MYLAN,"Canha, F.; Pitta, R.; Conde, M.E.N.G.. The importance of continuity of care in psychiatric pathology: a case report. Portuguese Magazine of General and Familiar Medicine. 2023;39(4):327-331",50.0,YR,,F,Y,,,20231221,,MD,PT,PT,2023,Q4,Adult
230616393,23061639,1,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"12.5 mg, qd",,,,,unknown,,,12.5,MG,Tablet,QD,2023,Q4,Diabetic metabolic decompensation,,2023,Q4,3,F,20140101.0,20231103.0,20231013,20231116,EXP,,CL-NOVOPROD-1124295,NOVO NORDISK,,51.0,YR,,M,Y,97.0,KG,20231117,,CN,CL,CL,2023,Q4,Adult
230616393,23061639,1,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"12.5 mg, qd",,,,,unknown,,,12.5,MG,Tablet,QD,2023,Q4,Eye haemorrhage,,2023,Q4,3,F,20140101.0,20231103.0,20231013,20231116,EXP,,CL-NOVOPROD-1124295,NOVO NORDISK,,51.0,YR,,M,Y,97.0,KG,20231117,,CN,CL,CL,2023,Q4,Adult
230616393,23061639,1,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"12.5 mg, qd",,,,,unknown,,,12.5,MG,Tablet,QD,2023,Q4,Myocardial infarction,,2023,Q4,3,F,20140101.0,20231103.0,20231013,20231116,EXP,,CL-NOVOPROD-1124295,NOVO NORDISK,,51.0,YR,,M,Y,97.0,KG,20231117,,CN,CL,CL,2023,Q4,Adult
230616393,23061639,1,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"12.5 mg, qd",,,,,unknown,,,12.5,MG,Tablet,QD,2023,Q4,Eye haemorrhage,,2023,Q4,3,F,20140101.0,20231103.0,20231013,20231116,EXP,,CL-NOVOPROD-1124295,NOVO NORDISK,,51.0,YR,,M,Y,97.0,KG,20231117,,CN,CL,CL,2023,Q4,Adult
230616393,23061639,1,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"12.5 mg, qd",,,,,unknown,,,12.5,MG,Tablet,QD,2023,Q4,Diabetic retinopathy,,2023,Q4,3,F,20140101.0,20231103.0,20231013,20231116,EXP,,CL-NOVOPROD-1124295,NOVO NORDISK,,51.0,YR,,M,Y,97.0,KG,20231117,,CN,CL,CL,2023,Q4,Adult
230617691,23061769,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q4,Pneumonia,,2023,Q4,1,I,20230812.0,20231011.0,20231013,20231013,EXP,,DE-ABBVIE-5445450,ABBVIE,,73.0,YR,,M,Y,73.0,KG,20231013,,HP,DE,DE,2023,Q4,Elderly
230628222,23062822,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,Powder for infusion,,2023,Q4,Renal cell carcinoma,,2023,Q4,2,F,,20231010.0,20231013,20231020,EXP,GB-MHRA-MED-202309281512401190-RLDSB,GB-STRIDES ARCOLAB LIMITED-2023SP015285,STRIDES,,71.0,YR,,F,Y,,,20231020,,PH,GB,GB,2023,Q4,Elderly
230635641,23063564,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,Unknown,,2023,Q4,Pneumonia,,2023,Q4,1,I,20230812.0,20231002.0,20231013,20231013,EXP,,DE-JNJFOC-20231013349,JOHNSON AND JOHNSON,,73.0,YR,E,M,Y,73.0,KG,20231013,,MD,DE,DE,2023,Q4,Elderly
230635641,23063564,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,Unknown,,2023,Q4,Off label use,,2023,Q4,1,I,20230812.0,20231002.0,20231013,20231013,EXP,,DE-JNJFOC-20231013349,JOHNSON AND JOHNSON,,73.0,YR,E,M,Y,73.0,KG,20231013,,MD,DE,DE,2023,Q4,Elderly
230635641,23063564,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,Unknown,,2023,Q4,Cardiac failure,,2023,Q4,1,I,20230812.0,20231002.0,20231013,20231013,EXP,,DE-JNJFOC-20231013349,JOHNSON AND JOHNSON,,73.0,YR,E,M,Y,73.0,KG,20231013,,MD,DE,DE,2023,Q4,Elderly
230637371,23063737,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2023,Q4,Hypophagia,,2023,Q4,1,I,20220819.0,,20231013,20231013,DIR,FDA-CDER-CTU-2023-75212,,FDA-CTU,,55.0,YR,,M,N,,,20221119,N,HP,US,,2023,Q4,Adult
230637371,23063737,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2023,Q4,Haemoglobin decreased,,2023,Q4,1,I,20220819.0,,20231013,20231013,DIR,FDA-CDER-CTU-2023-75212,,FDA-CTU,,55.0,YR,,M,N,,,20221119,N,HP,US,,2023,Q4,Adult
230637371,23063737,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2023,Q4,Atrial fibrillation,,2023,Q4,1,I,20220819.0,,20231013,20231013,DIR,FDA-CDER-CTU-2023-75212,,FDA-CTU,,55.0,YR,,M,N,,,20221119,N,HP,US,,2023,Q4,Adult
230637371,23063737,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2023,Q4,Abdominal pain,,2023,Q4,1,I,20220819.0,,20231013,20231013,DIR,FDA-CDER-CTU-2023-75212,,FDA-CTU,,55.0,YR,,M,N,,,20221119,N,HP,US,,2023,Q4,Adult
230637371,23063737,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2023,Q4,Diabetes mellitus inadequate control,,2023,Q4,1,I,20220819.0,,20231013,20231013,DIR,FDA-CDER-CTU-2023-75212,,FDA-CTU,,55.0,YR,,M,N,,,20221119,N,HP,US,,2023,Q4,Adult
230637371,23063737,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2023,Q4,Blood potassium increased,,2023,Q4,1,I,20220819.0,,20231013,20231013,DIR,FDA-CDER-CTU-2023-75212,,FDA-CTU,,55.0,YR,,M,N,,,20221119,N,HP,US,,2023,Q4,Adult
230637371,23063737,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2023,Q4,Vulvovaginal swelling,,2023,Q4,1,I,20220819.0,,20231013,20231013,DIR,FDA-CDER-CTU-2023-75212,,FDA-CTU,,55.0,YR,,M,N,,,20221119,N,HP,US,,2023,Q4,Adult
230637371,23063737,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2023,Q4,Lethargy,,2023,Q4,1,I,20220819.0,,20231013,20231013,DIR,FDA-CDER-CTU-2023-75212,,FDA-CTU,,55.0,YR,,M,N,,,20221119,N,HP,US,,2023,Q4,Adult
230637371,23063737,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2023,Q4,White blood cell count increased,,2023,Q4,1,I,20220819.0,,20231013,20231013,DIR,FDA-CDER-CTU-2023-75212,,FDA-CTU,,55.0,YR,,M,N,,,20221119,N,HP,US,,2023,Q4,Adult
230637371,23063737,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2023,Q4,Necrotising soft tissue infection,,2023,Q4,1,I,20220819.0,,20231013,20231013,DIR,FDA-CDER-CTU-2023-75212,,FDA-CTU,,55.0,YR,,M,N,,,20221119,N,HP,US,,2023,Q4,Adult
230637371,23063737,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2023,Q4,Chills,,2023,Q4,1,I,20220819.0,,20231013,20231013,DIR,FDA-CDER-CTU-2023-75212,,FDA-CTU,,55.0,YR,,M,N,,,20221119,N,HP,US,,2023,Q4,Adult
230637371,23063737,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2023,Q4,Skin ulcer,,2023,Q4,1,I,20220819.0,,20231013,20231013,DIR,FDA-CDER-CTU-2023-75212,,FDA-CTU,,55.0,YR,,M,N,,,20221119,N,HP,US,,2023,Q4,Adult
230637371,23063737,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2023,Q4,Sepsis,,2023,Q4,1,I,20220819.0,,20231013,20231013,DIR,FDA-CDER-CTU-2023-75212,,FDA-CTU,,55.0,YR,,M,N,,,20221119,N,HP,US,,2023,Q4,Adult
230637371,23063737,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2023,Q4,Blood urea increased,,2023,Q4,1,I,20220819.0,,20231013,20231013,DIR,FDA-CDER-CTU-2023-75212,,FDA-CTU,,55.0,YR,,M,N,,,20221119,N,HP,US,,2023,Q4,Adult
230637371,23063737,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2023,Q4,Blood creatinine increased,,2023,Q4,1,I,20220819.0,,20231013,20231013,DIR,FDA-CDER-CTU-2023-75212,,FDA-CTU,,55.0,YR,,M,N,,,20221119,N,HP,US,,2023,Q4,Adult
230637371,23063737,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2023,Q4,Computerised tomogram abnormal,,2023,Q4,1,I,20220819.0,,20231013,20231013,DIR,FDA-CDER-CTU-2023-75212,,FDA-CTU,,55.0,YR,,M,N,,,20221119,N,HP,US,,2023,Q4,Adult
230637371,23063737,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2023,Q4,Fall,,2023,Q4,1,I,20220819.0,,20231013,20231013,DIR,FDA-CDER-CTU-2023-75212,,FDA-CTU,,55.0,YR,,M,N,,,20221119,N,HP,US,,2023,Q4,Adult
230637371,23063737,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2023,Q4,Vulvovaginal pain,,2023,Q4,1,I,20220819.0,,20231013,20231013,DIR,FDA-CDER-CTU-2023-75212,,FDA-CTU,,55.0,YR,,M,N,,,20221119,N,HP,US,,2023,Q4,Adult
230638673,23063867,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,Tablet,,2023,Q4,Fistula,,2023,Q4,3,F,20221109.0,20231026.0,20231013,20231103,PER,,ES-Eisai-EC-2022-127999,EISAI,,62.0,YR,A,M,Y,68.6,KG,20231103,,MD,ES,ES,2023,Q4,Adult
230643831,23064383,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Urinary tract infection,,2023,Q4,1,I,20221030.0,,20231013,20231013,DIR,FDA-CDER-CTU-2023-75245,,FDA-CTU,,51.0,YR,,F,N,127.0,KG,20221215,N,PH,US,,2023,Q4,Adult
230644331,23064433,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2023,Q4,Hypoglycaemia,,2023,Q4,1,I,20220805.0,,20231013,20231013,DIR,FDA-CDER-CTU-2023-75216,,FDA-CTU,,78.0,YR,,M,N,154.0,KG,20221021,N,,US,,2023,Q4,Elderly
230644331,23064433,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2023,Q4,Diarrhoea,,2023,Q4,1,I,20220805.0,,20231013,20231013,DIR,FDA-CDER-CTU-2023-75216,,FDA-CTU,,78.0,YR,,M,N,154.0,KG,20221021,N,,US,,2023,Q4,Elderly
230644331,23064433,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2023,Q4,Diabetic ketoacidosis,,2023,Q4,1,I,20220805.0,,20231013,20231013,DIR,FDA-CDER-CTU-2023-75216,,FDA-CTU,,78.0,YR,,M,N,154.0,KG,20221021,N,,US,,2023,Q4,Elderly
230644331,23064433,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2023,Q4,Abdominal pain,,2023,Q4,1,I,20220805.0,,20231013,20231013,DIR,FDA-CDER-CTU-2023-75216,,FDA-CTU,,78.0,YR,,M,N,154.0,KG,20221021,N,,US,,2023,Q4,Elderly
230644331,23064433,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2023,Q4,Acute kidney injury,,2023,Q4,1,I,20220805.0,,20231013,20231013,DIR,FDA-CDER-CTU-2023-75216,,FDA-CTU,,78.0,YR,,M,N,154.0,KG,20221021,N,,US,,2023,Q4,Elderly
230644331,23064433,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2023,Q4,Treatment noncompliance,,2023,Q4,1,I,20220805.0,,20231013,20231013,DIR,FDA-CDER-CTU-2023-75216,,FDA-CTU,,78.0,YR,,M,N,154.0,KG,20221021,N,,US,,2023,Q4,Elderly
230644331,23064433,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2023,Q4,Nausea,,2023,Q4,1,I,20220805.0,,20231013,20231013,DIR,FDA-CDER-CTU-2023-75216,,FDA-CTU,,78.0,YR,,M,N,154.0,KG,20221021,N,,US,,2023,Q4,Elderly
230644331,23064433,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2023,Q4,Tachycardia,,2023,Q4,1,I,20220805.0,,20231013,20231013,DIR,FDA-CDER-CTU-2023-75216,,FDA-CTU,,78.0,YR,,M,N,154.0,KG,20221021,N,,US,,2023,Q4,Elderly
230644331,23064433,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2023,Q4,Hypotension,,2023,Q4,1,I,20220805.0,,20231013,20231013,DIR,FDA-CDER-CTU-2023-75216,,FDA-CTU,,78.0,YR,,M,N,154.0,KG,20221021,N,,US,,2023,Q4,Elderly
230646211,23064621,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Every day before noon;?,,,,,,,,12.5,MG,,QAM,2023,Q4,Diabetic ketoacidosis,,2023,Q4,1,I,20221113.0,,20231013,20231013,DIR,FDA-CDER-CTU-2023-75397,,FDA-CTU,,75.0,YR,,M,N,73.0,KG,20221117,N,PH,US,,2023,Q4,Elderly
230646211,23064621,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Every day before noon;?,,,,,,,,12.5,MG,,QAM,2023,Q4,Vomiting,,2023,Q4,1,I,20221113.0,,20231013,20231013,DIR,FDA-CDER-CTU-2023-75397,,FDA-CTU,,75.0,YR,,M,N,73.0,KG,20221117,N,PH,US,,2023,Q4,Elderly
230646211,23064621,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Every day before noon;?,,,,,,,,12.5,MG,,QAM,2023,Q4,Nausea,,2023,Q4,1,I,20221113.0,,20231013,20231013,DIR,FDA-CDER-CTU-2023-75397,,FDA-CTU,,75.0,YR,,M,N,73.0,KG,20221117,N,PH,US,,2023,Q4,Elderly
230646461,23064646,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10mg daily; ;,,,N,,ASKU,,,,,Tablet,,2023,Q4,Renal cell carcinoma,,2023,Q4,1,I,,20230930.0,20231013,20231013,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-412422,RANBAXY,,71.0,YR,,F,Y,,,20231013,,PH,GB,GB,2023,Q4,Elderly
230647331,23064733,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,12.5,MG,,QD,2023,Q4,Diabetic ketoacidosis,,2023,Q4,1,I,20221229.0,,20231013,20231013,DIR,FDA-CDER-CTU-2023-75401,,FDA-CTU,,68.0,YR,,M,N,47.0,KG,20221230,N,PH,US,,2023,Q4,Elderly
230649963,23064996,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,Tablet,,2023,Q4,Urinary tract infection,,2023,Q4,3,F,20231003.0,20231121.0,20231013,20231129,PER,,GB-Eisai-EC-2023-150421,EISAI,,55.0,YR,A,M,Y,83.5,KG,20231129,,MD,GB,GB,2023,Q4,Adult
230655271,23065527,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2023,Q4,Mental status changes,,2023,Q4,1,I,,20231004.0,20231013,20231013,EXP,,US-PRINSTON PHARMACEUTICAL INC.-2023PRN00514,PRINSTON PHARMACEUTICAL,"Dong Q, Kyereme-Tuah EK, Zou Y, et al.. Brash Syndrome: An Under-Recognized Syndrome Precipitated By Medication Overdose. Chest. 2023;164(4):A2167-A2168",77.0,YR,,M,Y,,,20231013,,HP,US,US,2023,Q4,Elderly
230655271,23065527,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2023,Q4,BRASH syndrome,,2023,Q4,1,I,,20231004.0,20231013,20231013,EXP,,US-PRINSTON PHARMACEUTICAL INC.-2023PRN00514,PRINSTON PHARMACEUTICAL,"Dong Q, Kyereme-Tuah EK, Zou Y, et al.. Brash Syndrome: An Under-Recognized Syndrome Precipitated By Medication Overdose. Chest. 2023;164(4):A2167-A2168",77.0,YR,,M,Y,,,20231013,,HP,US,US,2023,Q4,Elderly
230655271,23065527,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2023,Q4,Hypothermia,,2023,Q4,1,I,,20231004.0,20231013,20231013,EXP,,US-PRINSTON PHARMACEUTICAL INC.-2023PRN00514,PRINSTON PHARMACEUTICAL,"Dong Q, Kyereme-Tuah EK, Zou Y, et al.. Brash Syndrome: An Under-Recognized Syndrome Precipitated By Medication Overdose. Chest. 2023;164(4):A2167-A2168",77.0,YR,,M,Y,,,20231013,,HP,US,US,2023,Q4,Elderly
230658451,23065845,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q4,Umbilical hernia,,2023,Q4,1,I,,20231002.0,20231014,20231014,EXP,CA-MHPD-E2B_06473783,CA-Accord-382828,ACCORD,,57.0,YR,,F,Y,,,20231014,,HP,CA,CA,2023,Q4,Adult
230658451,23065845,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q4,Pulmonary toxicity,,2023,Q4,1,I,,20231002.0,20231014,20231014,EXP,CA-MHPD-E2B_06473783,CA-Accord-382828,ACCORD,,57.0,YR,,F,Y,,,20231014,,HP,CA,CA,2023,Q4,Adult
230658451,23065845,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q4,Hysterectomy,,2023,Q4,1,I,,20231002.0,20231014,20231014,EXP,CA-MHPD-E2B_06473783,CA-Accord-382828,ACCORD,,57.0,YR,,F,Y,,,20231014,,HP,CA,CA,2023,Q4,Adult
230658451,23065845,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q4,Hypertension,,2023,Q4,1,I,,20231002.0,20231014,20231014,EXP,CA-MHPD-E2B_06473783,CA-Accord-382828,ACCORD,,57.0,YR,,F,Y,,,20231014,,HP,CA,CA,2023,Q4,Adult
230658451,23065845,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q4,Rheumatoid arthritis,,2023,Q4,1,I,,20231002.0,20231014,20231014,EXP,CA-MHPD-E2B_06473783,CA-Accord-382828,ACCORD,,57.0,YR,,F,Y,,,20231014,,HP,CA,CA,2023,Q4,Adult
230658451,23065845,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q4,Drug ineffective,,2023,Q4,1,I,,20231002.0,20231014,20231014,EXP,CA-MHPD-E2B_06473783,CA-Accord-382828,ACCORD,,57.0,YR,,F,Y,,,20231014,,HP,CA,CA,2023,Q4,Adult
230658451,23065845,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q4,Prostatic specific antigen abnormal,,2023,Q4,1,I,,20231002.0,20231014,20231014,EXP,CA-MHPD-E2B_06473783,CA-Accord-382828,ACCORD,,57.0,YR,,F,Y,,,20231014,,HP,CA,CA,2023,Q4,Adult
230658451,23065845,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q4,Respiratory sinus arrhythmia magnitude,,2023,Q4,1,I,,20231002.0,20231014,20231014,EXP,CA-MHPD-E2B_06473783,CA-Accord-382828,ACCORD,,57.0,YR,,F,Y,,,20231014,,HP,CA,CA,2023,Q4,Adult
230658451,23065845,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q4,Gastrooesophageal reflux disease,,2023,Q4,1,I,,20231002.0,20231014,20231014,EXP,CA-MHPD-E2B_06473783,CA-Accord-382828,ACCORD,,57.0,YR,,F,Y,,,20231014,,HP,CA,CA,2023,Q4,Adult
230658451,23065845,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q4,Psoriatic arthropathy,,2023,Q4,1,I,,20231002.0,20231014,20231014,EXP,CA-MHPD-E2B_06473783,CA-Accord-382828,ACCORD,,57.0,YR,,F,Y,,,20231014,,HP,CA,CA,2023,Q4,Adult
230658451,23065845,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q4,Osteoarthritis,,2023,Q4,1,I,,20231002.0,20231014,20231014,EXP,CA-MHPD-E2B_06473783,CA-Accord-382828,ACCORD,,57.0,YR,,F,Y,,,20231014,,HP,CA,CA,2023,Q4,Adult
230658451,23065845,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q4,Trigger finger,,2023,Q4,1,I,,20231002.0,20231014,20231014,EXP,CA-MHPD-E2B_06473783,CA-Accord-382828,ACCORD,,57.0,YR,,F,Y,,,20231014,,HP,CA,CA,2023,Q4,Adult
230658451,23065845,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q4,Diabetes mellitus,,2023,Q4,1,I,,20231002.0,20231014,20231014,EXP,CA-MHPD-E2B_06473783,CA-Accord-382828,ACCORD,,57.0,YR,,F,Y,,,20231014,,HP,CA,CA,2023,Q4,Adult
230662991,23066299,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Taking it for months.,,,N,,UNKNOWN,,,10.0,MG,,,2023,Q4,Acute kidney injury,,2023,Q4,1,I,20230904.0,20231005.0,20231015,20231015,EXP,,DE-TEVA-2023-DE-2934353,TEVA,,64.0,YR,A,F,Y,90.0,KG,20231015,,MD,DE,DE,2023,Q4,Adult
230662991,23066299,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Taking it for months.,,,N,,UNKNOWN,,,10.0,MG,,,2023,Q4,Ketoacidosis,,2023,Q4,1,I,20230904.0,20231005.0,20231015,20231015,EXP,,DE-TEVA-2023-DE-2934353,TEVA,,64.0,YR,A,F,Y,90.0,KG,20231015,,MD,DE,DE,2023,Q4,Adult
230662991,23066299,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Taking it for months.,,,N,,UNKNOWN,,,10.0,MG,,,2023,Q4,Lactic acidosis,,2023,Q4,1,I,20230904.0,20231005.0,20231015,20231015,EXP,,DE-TEVA-2023-DE-2934353,TEVA,,64.0,YR,A,F,Y,90.0,KG,20231015,,MD,DE,DE,2023,Q4,Adult
230674671,23067467,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 tab qd,,,,,UNK,,,,,,,2023,Q4,Urticaria,,2023,Q4,1,I,,20231004.0,20231016,20231016,EXP,GB-MHRA-TPP36769562C3179297YC1695811870279,GB-NOVOPROD-1125282,NOVO NORDISK,,57.0,YR,,F,Y,87.0,KG,20231016,,HP,GB,GB,2023,Q4,Adult
230682611,23068261,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 Milligram Daily;,,,,,UNKNOWN,,,10.0,MG,Tablet,QD,2023,Q4,Cardiac failure chronic,,2023,Q4,1,I,,20231006.0,20231016,20231016,EXP,,HR-TEVA-2023-HR-2934118,TEVA,,68.0,YR,E,M,Y,,,20231016,,MD,HR,HR,2023,Q4,Elderly
230682611,23068261,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 Milligram Daily;,,,,,UNKNOWN,,,10.0,MG,Tablet,QD,2023,Q4,Oedema peripheral,,2023,Q4,1,I,,20231006.0,20231016,20231016,EXP,,HR-TEVA-2023-HR-2934118,TEVA,,68.0,YR,E,M,Y,,,20231016,,MD,HR,HR,2023,Q4,Elderly
230693011,23069301,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,Unknown,,,,,,,2023,Q4,Overdose,,2023,Q4,1,I,,20231004.0,20231016,20231016,EXP,,US-LUPIN PHARMACEUTICALS INC.-2023-08739,LUPIN,"Dong Q, Kyereme-Tuah EK, Zou Y, Jin Z, Wazeen RF. Brash Syndrome: An under-recognized syndrome precipitated by medication overdose. Chest. 2023;164(4):A2167-A2168",77.0,YR,,M,Y,,,20231016,,HP,US,US,2023,Q4,Elderly
230693011,23069301,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,Unknown,,,,,,,2023,Q4,BRASH syndrome,,2023,Q4,1,I,,20231004.0,20231016,20231016,EXP,,US-LUPIN PHARMACEUTICALS INC.-2023-08739,LUPIN,"Dong Q, Kyereme-Tuah EK, Zou Y, Jin Z, Wazeen RF. Brash Syndrome: An under-recognized syndrome precipitated by medication overdose. Chest. 2023;164(4):A2167-A2168",77.0,YR,,M,Y,,,20231016,,HP,US,US,2023,Q4,Elderly
230705261,23070526,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Blood test abnormal,,2023,Q4,1,I,,20231009.0,20231016,20231016,EXP,,DE-PFIZER INC-202300321954,PFIZER,,85.0,YR,,M,Y,,,20231016,,MD,DE,DE,2023,Q4,Elderly
230705261,23070526,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Cardiorenal syndrome,,2023,Q4,1,I,,20231009.0,20231016,20231016,EXP,,DE-PFIZER INC-202300321954,PFIZER,,85.0,YR,,M,Y,,,20231016,,MD,DE,DE,2023,Q4,Elderly
230724492,23072449,16,C,Empagliflozin/ Metformin,,2,,"12,5/100 mg, bid",,,,,,,,,,,,2023,Q4,Anxiety,,2023,Q4,2,F,20220101.0,20231012.0,20231017,20231019,EXP,,PT-CHEPLA-2023012868,CHEPLAPHARM,"Canha, F., Pitta, R., and Gil Conde, M. E. N. (2023). A import?ncia da continuidade de cuidados na patologia psiqui?trica: um relato de caso. Revista Portuguesa De Medicina Geral E Familiar, 39(4), 327?31.",50.0,YR,,F,Y,,,20231019,,MD,COUNTRY NOT SPECIFIED,PT,2023,Q4,Adult
230724492,23072449,16,C,Empagliflozin/ Metformin,,2,,"12,5/100 mg, bid",,,,,,,,,,,,2023,Q4,Nightmare,,2023,Q4,2,F,20220101.0,20231012.0,20231017,20231019,EXP,,PT-CHEPLA-2023012868,CHEPLAPHARM,"Canha, F., Pitta, R., and Gil Conde, M. E. N. (2023). A import?ncia da continuidade de cuidados na patologia psiqui?trica: um relato de caso. Revista Portuguesa De Medicina Geral E Familiar, 39(4), 327?31.",50.0,YR,,F,Y,,,20231019,,MD,COUNTRY NOT SPECIFIED,PT,2023,Q4,Adult
230724492,23072449,16,C,Empagliflozin/ Metformin,,2,,"12,5/100 mg, bid",,,,,,,,,,,,2023,Q4,Panic attack,,2023,Q4,2,F,20220101.0,20231012.0,20231017,20231019,EXP,,PT-CHEPLA-2023012868,CHEPLAPHARM,"Canha, F., Pitta, R., and Gil Conde, M. E. N. (2023). A import?ncia da continuidade de cuidados na patologia psiqui?trica: um relato de caso. Revista Portuguesa De Medicina Geral E Familiar, 39(4), 327?31.",50.0,YR,,F,Y,,,20231019,,MD,COUNTRY NOT SPECIFIED,PT,2023,Q4,Adult
230724492,23072449,16,C,Empagliflozin/ Metformin,,2,,"12,5/100 mg, bid",,,,,,,,,,,,2023,Q4,Insomnia,,2023,Q4,2,F,20220101.0,20231012.0,20231017,20231019,EXP,,PT-CHEPLA-2023012868,CHEPLAPHARM,"Canha, F., Pitta, R., and Gil Conde, M. E. N. (2023). A import?ncia da continuidade de cuidados na patologia psiqui?trica: um relato de caso. Revista Portuguesa De Medicina Geral E Familiar, 39(4), 327?31.",50.0,YR,,F,Y,,,20231019,,MD,COUNTRY NOT SPECIFIED,PT,2023,Q4,Adult
230724492,23072449,16,C,Empagliflozin/ Metformin,,2,,"12,5/100 mg, bid",,,,,,,,,,,,2023,Q4,Suicidal ideation,,2023,Q4,2,F,20220101.0,20231012.0,20231017,20231019,EXP,,PT-CHEPLA-2023012868,CHEPLAPHARM,"Canha, F., Pitta, R., and Gil Conde, M. E. N. (2023). A import?ncia da continuidade de cuidados na patologia psiqui?trica: um relato de caso. Revista Portuguesa De Medicina Geral E Familiar, 39(4), 327?31.",50.0,YR,,F,Y,,,20231019,,MD,COUNTRY NOT SPECIFIED,PT,2023,Q4,Adult
230724492,23072449,16,C,Empagliflozin/ Metformin,,2,,"12,5/100 mg, bid",,,,,,,,,,,,2023,Q4,Affective disorder,,2023,Q4,2,F,20220101.0,20231012.0,20231017,20231019,EXP,,PT-CHEPLA-2023012868,CHEPLAPHARM,"Canha, F., Pitta, R., and Gil Conde, M. E. N. (2023). A import?ncia da continuidade de cuidados na patologia psiqui?trica: um relato de caso. Revista Portuguesa De Medicina Geral E Familiar, 39(4), 327?31.",50.0,YR,,F,Y,,,20231019,,MD,COUNTRY NOT SPECIFIED,PT,2023,Q4,Adult
230724492,23072449,16,C,Empagliflozin/ Metformin,,2,,"12,5/100 mg, bid",,,,,,,,,,,,2023,Q4,Somnolence,,2023,Q4,2,F,20220101.0,20231012.0,20231017,20231019,EXP,,PT-CHEPLA-2023012868,CHEPLAPHARM,"Canha, F., Pitta, R., and Gil Conde, M. E. N. (2023). A import?ncia da continuidade de cuidados na patologia psiqui?trica: um relato de caso. Revista Portuguesa De Medicina Geral E Familiar, 39(4), 327?31.",50.0,YR,,F,Y,,,20231019,,MD,COUNTRY NOT SPECIFIED,PT,2023,Q4,Adult
230724492,23072449,16,C,Empagliflozin/ Metformin,,2,,"12,5/100 mg, bid",,,,,,,,,,,,2023,Q4,Depressed mood,,2023,Q4,2,F,20220101.0,20231012.0,20231017,20231019,EXP,,PT-CHEPLA-2023012868,CHEPLAPHARM,"Canha, F., Pitta, R., and Gil Conde, M. E. N. (2023). A import?ncia da continuidade de cuidados na patologia psiqui?trica: um relato de caso. Revista Portuguesa De Medicina Geral E Familiar, 39(4), 327?31.",50.0,YR,,F,Y,,,20231019,,MD,COUNTRY NOT SPECIFIED,PT,2023,Q4,Adult
230724492,23072449,16,C,Empagliflozin/ Metformin,,2,,"12,5/100 mg, bid",,,,,,,,,,,,2023,Q4,Anhedonia,,2023,Q4,2,F,20220101.0,20231012.0,20231017,20231019,EXP,,PT-CHEPLA-2023012868,CHEPLAPHARM,"Canha, F., Pitta, R., and Gil Conde, M. E. N. (2023). A import?ncia da continuidade de cuidados na patologia psiqui?trica: um relato de caso. Revista Portuguesa De Medicina Geral E Familiar, 39(4), 327?31.",50.0,YR,,F,Y,,,20231019,,MD,COUNTRY NOT SPECIFIED,PT,2023,Q4,Adult
230724492,23072449,16,C,Empagliflozin/ Metformin,,2,,"12,5/100 mg, bid",,,,,,,,,,,,2023,Q4,Intentional product misuse,,2023,Q4,2,F,20220101.0,20231012.0,20231017,20231019,EXP,,PT-CHEPLA-2023012868,CHEPLAPHARM,"Canha, F., Pitta, R., and Gil Conde, M. E. N. (2023). A import?ncia da continuidade de cuidados na patologia psiqui?trica: um relato de caso. Revista Portuguesa De Medicina Geral E Familiar, 39(4), 327?31.",50.0,YR,,F,Y,,,20231019,,MD,COUNTRY NOT SPECIFIED,PT,2023,Q4,Adult
230724492,23072449,16,C,Empagliflozin/ Metformin,,2,,"12,5/100 mg, bid",,,,,,,,,,,,2023,Q4,Violence-related symptom,,2023,Q4,2,F,20220101.0,20231012.0,20231017,20231019,EXP,,PT-CHEPLA-2023012868,CHEPLAPHARM,"Canha, F., Pitta, R., and Gil Conde, M. E. N. (2023). A import?ncia da continuidade de cuidados na patologia psiqui?trica: um relato de caso. Revista Portuguesa De Medicina Geral E Familiar, 39(4), 327?31.",50.0,YR,,F,Y,,,20231019,,MD,COUNTRY NOT SPECIFIED,PT,2023,Q4,Adult
230724492,23072449,16,C,Empagliflozin/ Metformin,,2,,"12,5/100 mg, bid",,,,,,,,,,,,2023,Q4,Irritability,,2023,Q4,2,F,20220101.0,20231012.0,20231017,20231019,EXP,,PT-CHEPLA-2023012868,CHEPLAPHARM,"Canha, F., Pitta, R., and Gil Conde, M. E. N. (2023). A import?ncia da continuidade de cuidados na patologia psiqui?trica: um relato de caso. Revista Portuguesa De Medicina Geral E Familiar, 39(4), 327?31.",50.0,YR,,F,Y,,,20231019,,MD,COUNTRY NOT SPECIFIED,PT,2023,Q4,Adult
230724492,23072449,16,C,Empagliflozin/ Metformin,,2,,"12,5/100 mg, bid",,,,,,,,,,,,2023,Q4,"Hallucination, auditory",,2023,Q4,2,F,20220101.0,20231012.0,20231017,20231019,EXP,,PT-CHEPLA-2023012868,CHEPLAPHARM,"Canha, F., Pitta, R., and Gil Conde, M. E. N. (2023). A import?ncia da continuidade de cuidados na patologia psiqui?trica: um relato de caso. Revista Portuguesa De Medicina Geral E Familiar, 39(4), 327?31.",50.0,YR,,F,Y,,,20231019,,MD,COUNTRY NOT SPECIFIED,PT,2023,Q4,Adult
230724492,23072449,16,C,Empagliflozin/ Metformin,,2,,"12,5/100 mg, bid",,,,,,,,,,,,2023,Q4,Treatment noncompliance,,2023,Q4,2,F,20220101.0,20231012.0,20231017,20231019,EXP,,PT-CHEPLA-2023012868,CHEPLAPHARM,"Canha, F., Pitta, R., and Gil Conde, M. E. N. (2023). A import?ncia da continuidade de cuidados na patologia psiqui?trica: um relato de caso. Revista Portuguesa De Medicina Geral E Familiar, 39(4), 327?31.",50.0,YR,,F,Y,,,20231019,,MD,COUNTRY NOT SPECIFIED,PT,2023,Q4,Adult
230724492,23072449,16,C,Empagliflozin/ Metformin,,2,,"12,5/100 mg, bid",,,,,,,,,,,,2023,Q4,Fatigue,,2023,Q4,2,F,20220101.0,20231012.0,20231017,20231019,EXP,,PT-CHEPLA-2023012868,CHEPLAPHARM,"Canha, F., Pitta, R., and Gil Conde, M. E. N. (2023). A import?ncia da continuidade de cuidados na patologia psiqui?trica: um relato de caso. Revista Portuguesa De Medicina Geral E Familiar, 39(4), 327?31.",50.0,YR,,F,Y,,,20231019,,MD,COUNTRY NOT SPECIFIED,PT,2023,Q4,Adult
230724492,23072449,16,C,Empagliflozin/ Metformin,,2,,"12,5/100 mg, bid",,,,,,,,,,,,2023,Q4,Weight decreased,,2023,Q4,2,F,20220101.0,20231012.0,20231017,20231019,EXP,,PT-CHEPLA-2023012868,CHEPLAPHARM,"Canha, F., Pitta, R., and Gil Conde, M. E. N. (2023). A import?ncia da continuidade de cuidados na patologia psiqui?trica: um relato de caso. Revista Portuguesa De Medicina Geral E Familiar, 39(4), 327?31.",50.0,YR,,F,Y,,,20231019,,MD,COUNTRY NOT SPECIFIED,PT,2023,Q4,Adult
230724492,23072449,16,C,Empagliflozin/ Metformin,,2,,"12,5/100 mg, bid",,,,,,,,,,,,2023,Q4,Agitation,,2023,Q4,2,F,20220101.0,20231012.0,20231017,20231019,EXP,,PT-CHEPLA-2023012868,CHEPLAPHARM,"Canha, F., Pitta, R., and Gil Conde, M. E. N. (2023). A import?ncia da continuidade de cuidados na patologia psiqui?trica: um relato de caso. Revista Portuguesa De Medicina Geral E Familiar, 39(4), 327?31.",50.0,YR,,F,Y,,,20231019,,MD,COUNTRY NOT SPECIFIED,PT,2023,Q4,Adult
230724492,23072449,16,C,Empagliflozin/ Metformin,,2,,"12,5/100 mg, bid",,,,,,,,,,,,2023,Q4,Self-injurious ideation,,2023,Q4,2,F,20220101.0,20231012.0,20231017,20231019,EXP,,PT-CHEPLA-2023012868,CHEPLAPHARM,"Canha, F., Pitta, R., and Gil Conde, M. E. N. (2023). A import?ncia da continuidade de cuidados na patologia psiqui?trica: um relato de caso. Revista Portuguesa De Medicina Geral E Familiar, 39(4), 327?31.",50.0,YR,,F,Y,,,20231019,,MD,COUNTRY NOT SPECIFIED,PT,2023,Q4,Adult
230732621,23073262,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,UNKNOWN,,,,,,,2023,Q4,Overdose,,2023,Q4,1,I,,20231004.0,20231017,20231017,EXP,,US-drreddys-LIT/USA/23/0179781,DR REDDYS,"Dong Q, Kyereme-Tuah E, Zou Y, Jin Z, Rahim W. BRASH SYNDROME: AN UNDER-RECOGNIZED SYNDROME PRECIPITATED BY MEDICATION OVERDOSE. Chest. 2022;164(4):A2167-8. doi:10.1016/j.chest.2023.07.1472",77.0,YR,E,M,Y,,,20231017,,MD,US,US,2023,Q4,Elderly
230732621,23073262,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,UNKNOWN,,,,,,,2023,Q4,BRASH syndrome,,2023,Q4,1,I,,20231004.0,20231017,20231017,EXP,,US-drreddys-LIT/USA/23/0179781,DR REDDYS,"Dong Q, Kyereme-Tuah E, Zou Y, Jin Z, Rahim W. BRASH SYNDROME: AN UNDER-RECOGNIZED SYNDROME PRECIPITATED BY MEDICATION OVERDOSE. Chest. 2022;164(4):A2167-8. doi:10.1016/j.chest.2023.07.1472",77.0,YR,E,M,Y,,,20231017,,MD,US,US,2023,Q4,Elderly
230736081,23073608,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Vomiting,,2023,Q4,1,I,,20231013.0,20231017,20231017,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-266950",BOEHRINGER INGELHEIM,,75.0,YR,E,F,Y,54.0,KG,20231017,,PH,CA,CA,2023,Q4,Elderly
230736081,23073608,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Pancreatitis acute,,2023,Q4,1,I,,20231013.0,20231017,20231017,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-266950",BOEHRINGER INGELHEIM,,75.0,YR,E,F,Y,54.0,KG,20231017,,PH,CA,CA,2023,Q4,Elderly
230736081,23073608,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Nausea,,2023,Q4,1,I,,20231013.0,20231017,20231017,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-266950",BOEHRINGER INGELHEIM,,75.0,YR,E,F,Y,54.0,KG,20231017,,PH,CA,CA,2023,Q4,Elderly
230736081,23073608,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Cholelithiasis,,2023,Q4,1,I,,20231013.0,20231017,20231017,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-266950",BOEHRINGER INGELHEIM,,75.0,YR,E,F,Y,54.0,KG,20231017,,PH,CA,CA,2023,Q4,Elderly
230736081,23073608,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Abdominal pain,,2023,Q4,1,I,,20231013.0,20231017,20231017,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-266950",BOEHRINGER INGELHEIM,,75.0,YR,E,F,Y,54.0,KG,20231017,,PH,CA,CA,2023,Q4,Elderly
230736081,23073608,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Abdominal discomfort,,2023,Q4,1,I,,20231013.0,20231017,20231017,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-266950",BOEHRINGER INGELHEIM,,75.0,YR,E,F,Y,54.0,KG,20231017,,PH,CA,CA,2023,Q4,Elderly
230751941,23075194,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,Unknown,,2023,Q4,Drug ineffective,,2023,Q4,1,I,20220101.0,20231011.0,20231017,20231017,EXP,,US-MYLANLABS-2023M1108597,MYLAN,"Ghotra M, Parsa K, Dolan B, Lim S, Kumar S, Berger N, et al. (NOT SO) DIABETIC KETOACIDOSIS. Chest 2023;164 (Suppl.)(4):A2892-A2893.",52.0,YR,,F,Y,,,20231017,,HP,US,US,2023,Q4,Adult
230751941,23075194,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,Unknown,,2023,Q4,Disease progression,,2023,Q4,1,I,20220101.0,20231011.0,20231017,20231017,EXP,,US-MYLANLABS-2023M1108597,MYLAN,"Ghotra M, Parsa K, Dolan B, Lim S, Kumar S, Berger N, et al. (NOT SO) DIABETIC KETOACIDOSIS. Chest 2023;164 (Suppl.)(4):A2892-A2893.",52.0,YR,,F,Y,,,20231017,,HP,US,US,2023,Q4,Adult
230757061,23075706,3,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,10.0,MG,Film-coated tablet,,2023,Q4,Acute kidney injury,,2023,Q4,1,I,20230414.0,20231005.0,20231017,20231017,EXP,ES-AEMPS-1425861,ES-Accord-384502,ACCORD,,68.0,YR,E,F,Y,,,20231017,,MD,ES,ES,2023,Q4,Elderly
230765751,23076575,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q4,Septic shock,,2023,Q4,1,I,,20231010.0,20231017,20231017,EXP,,US-SANDOZ INC.-SDZ2023US042417,SANDOZ,"MAHMOUD A., KURT O.N.U.R., JAIN A., WASEEM S.A.B.A. UNRAVELING SEVERE ANION GAP METABOLIC ACIDOSIS IN SEPTIC SHOCK SECONDARY TO EUGLYCEMIC DIABETIC KETOACIDOSIS. ches. 2023;164(4 Supplemen:A2614",67.0,YR,,M,Y,,,20231017,,HP,US,US,2023,Q4,Elderly
230765751,23076575,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q4,Vomiting,,2023,Q4,1,I,,20231010.0,20231017,20231017,EXP,,US-SANDOZ INC.-SDZ2023US042417,SANDOZ,"MAHMOUD A., KURT O.N.U.R., JAIN A., WASEEM S.A.B.A. UNRAVELING SEVERE ANION GAP METABOLIC ACIDOSIS IN SEPTIC SHOCK SECONDARY TO EUGLYCEMIC DIABETIC KETOACIDOSIS. ches. 2023;164(4 Supplemen:A2614",67.0,YR,,M,Y,,,20231017,,HP,US,US,2023,Q4,Elderly
230765751,23076575,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q4,Nausea,,2023,Q4,1,I,,20231010.0,20231017,20231017,EXP,,US-SANDOZ INC.-SDZ2023US042417,SANDOZ,"MAHMOUD A., KURT O.N.U.R., JAIN A., WASEEM S.A.B.A. UNRAVELING SEVERE ANION GAP METABOLIC ACIDOSIS IN SEPTIC SHOCK SECONDARY TO EUGLYCEMIC DIABETIC KETOACIDOSIS. ches. 2023;164(4 Supplemen:A2614",67.0,YR,,M,Y,,,20231017,,HP,US,US,2023,Q4,Elderly
230765751,23076575,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q4,Mental status changes,,2023,Q4,1,I,,20231010.0,20231017,20231017,EXP,,US-SANDOZ INC.-SDZ2023US042417,SANDOZ,"MAHMOUD A., KURT O.N.U.R., JAIN A., WASEEM S.A.B.A. UNRAVELING SEVERE ANION GAP METABOLIC ACIDOSIS IN SEPTIC SHOCK SECONDARY TO EUGLYCEMIC DIABETIC KETOACIDOSIS. ches. 2023;164(4 Supplemen:A2614",67.0,YR,,M,Y,,,20231017,,HP,US,US,2023,Q4,Elderly
230765751,23076575,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q4,Chronic kidney disease,,2023,Q4,1,I,,20231010.0,20231017,20231017,EXP,,US-SANDOZ INC.-SDZ2023US042417,SANDOZ,"MAHMOUD A., KURT O.N.U.R., JAIN A., WASEEM S.A.B.A. UNRAVELING SEVERE ANION GAP METABOLIC ACIDOSIS IN SEPTIC SHOCK SECONDARY TO EUGLYCEMIC DIABETIC KETOACIDOSIS. ches. 2023;164(4 Supplemen:A2614",67.0,YR,,M,Y,,,20231017,,HP,US,US,2023,Q4,Elderly
230765751,23076575,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q4,Septic shock,,2023,Q4,1,I,,20231010.0,20231017,20231017,EXP,,US-SANDOZ INC.-SDZ2023US042417,SANDOZ,"MAHMOUD A., KURT O.N.U.R., JAIN A., WASEEM S.A.B.A. UNRAVELING SEVERE ANION GAP METABOLIC ACIDOSIS IN SEPTIC SHOCK SECONDARY TO EUGLYCEMIC DIABETIC KETOACIDOSIS. ches. 2023;164(4 Supplemen:A2614",67.0,YR,,M,Y,,,20231017,,HP,US,US,2023,Q4,Elderly
230765751,23076575,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q4,Vomiting,,2023,Q4,1,I,,20231010.0,20231017,20231017,EXP,,US-SANDOZ INC.-SDZ2023US042417,SANDOZ,"MAHMOUD A., KURT O.N.U.R., JAIN A., WASEEM S.A.B.A. UNRAVELING SEVERE ANION GAP METABOLIC ACIDOSIS IN SEPTIC SHOCK SECONDARY TO EUGLYCEMIC DIABETIC KETOACIDOSIS. ches. 2023;164(4 Supplemen:A2614",67.0,YR,,M,Y,,,20231017,,HP,US,US,2023,Q4,Elderly
230765751,23076575,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q4,Nausea,,2023,Q4,1,I,,20231010.0,20231017,20231017,EXP,,US-SANDOZ INC.-SDZ2023US042417,SANDOZ,"MAHMOUD A., KURT O.N.U.R., JAIN A., WASEEM S.A.B.A. UNRAVELING SEVERE ANION GAP METABOLIC ACIDOSIS IN SEPTIC SHOCK SECONDARY TO EUGLYCEMIC DIABETIC KETOACIDOSIS. ches. 2023;164(4 Supplemen:A2614",67.0,YR,,M,Y,,,20231017,,HP,US,US,2023,Q4,Elderly
230765751,23076575,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q4,Mental status changes,,2023,Q4,1,I,,20231010.0,20231017,20231017,EXP,,US-SANDOZ INC.-SDZ2023US042417,SANDOZ,"MAHMOUD A., KURT O.N.U.R., JAIN A., WASEEM S.A.B.A. UNRAVELING SEVERE ANION GAP METABOLIC ACIDOSIS IN SEPTIC SHOCK SECONDARY TO EUGLYCEMIC DIABETIC KETOACIDOSIS. ches. 2023;164(4 Supplemen:A2614",67.0,YR,,M,Y,,,20231017,,HP,US,US,2023,Q4,Elderly
230765751,23076575,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q4,Chronic kidney disease,,2023,Q4,1,I,,20231010.0,20231017,20231017,EXP,,US-SANDOZ INC.-SDZ2023US042417,SANDOZ,"MAHMOUD A., KURT O.N.U.R., JAIN A., WASEEM S.A.B.A. UNRAVELING SEVERE ANION GAP METABOLIC ACIDOSIS IN SEPTIC SHOCK SECONDARY TO EUGLYCEMIC DIABETIC KETOACIDOSIS. ches. 2023;164(4 Supplemen:A2614",67.0,YR,,M,Y,,,20231017,,HP,US,US,2023,Q4,Elderly
230766651,23076665,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q4,Pneumonia,,2023,Q4,1,I,20230812.0,20231013.0,20231017,20231017,EXP,,DE-BAUSCHBL-2023BNL010040,BAUSCH AND LOMB,,73.0,YR,,M,Y,73.0,KG,20231018,,HP,DE,DE,2023,Q4,Elderly
230770741,23077074,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q4,BRASH syndrome,,2023,Q4,1,I,,20231010.0,20231018,20231018,EXP,,US-AUROBINDO-AUR-APL-2023-063440,AUROBINDO,"Dong Q, Kyereme-Tuah EK, Zou Y, Jin Z, Rahim Wazeen FAZL.. BRASH SYNDROME: AN UNDER-RECOGNIZED SYNDROME PRECIPITATED BY MEDICATION OVERDOSE.. Chest. 2023;164(4) Sup A2:167-8",77.0,YR,,M,Y,,,20231018,,MD,US,US,2023,Q4,Elderly
230770741,23077074,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q4,Overdose,,2023,Q4,1,I,,20231010.0,20231018,20231018,EXP,,US-AUROBINDO-AUR-APL-2023-063440,AUROBINDO,"Dong Q, Kyereme-Tuah EK, Zou Y, Jin Z, Rahim Wazeen FAZL.. BRASH SYNDROME: AN UNDER-RECOGNIZED SYNDROME PRECIPITATED BY MEDICATION OVERDOSE.. Chest. 2023;164(4) Sup A2:167-8",77.0,YR,,M,Y,,,20231018,,MD,US,US,2023,Q4,Elderly
230776652,23077665,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1-0-0,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q4,Diarrhoea,,2023,Q4,2,F,,20231019.0,20231018,20231020,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-266995",BOEHRINGER INGELHEIM,,79.0,YR,E,M,Y,,,20231020,,MD,DE,DE,2023,Q4,Elderly
230776652,23077665,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1-0-0,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q4,Prerenal failure,,2023,Q4,2,F,,20231019.0,20231018,20231020,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-266995",BOEHRINGER INGELHEIM,,79.0,YR,E,M,Y,,,20231020,,MD,DE,DE,2023,Q4,Elderly
230776652,23077665,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1-0-0,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q4,Bone contusion,,2023,Q4,2,F,,20231019.0,20231018,20231020,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-266995",BOEHRINGER INGELHEIM,,79.0,YR,E,M,Y,,,20231020,,MD,DE,DE,2023,Q4,Elderly
230776652,23077665,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1-0-0,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q4,Haemorrhage,,2023,Q4,2,F,,20231019.0,20231018,20231020,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-266995",BOEHRINGER INGELHEIM,,79.0,YR,E,M,Y,,,20231020,,MD,DE,DE,2023,Q4,Elderly
230776652,23077665,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1-0-0,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q4,Abdominal discomfort,,2023,Q4,2,F,,20231019.0,20231018,20231020,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-266995",BOEHRINGER INGELHEIM,,79.0,YR,E,M,Y,,,20231020,,MD,DE,DE,2023,Q4,Elderly
230776652,23077665,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1-0-0,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q4,Dizziness,,2023,Q4,2,F,,20231019.0,20231018,20231020,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-266995",BOEHRINGER INGELHEIM,,79.0,YR,E,M,Y,,,20231020,,MD,DE,DE,2023,Q4,Elderly
230776652,23077665,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1-0-0,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q4,Blood electrolytes abnormal,,2023,Q4,2,F,,20231019.0,20231018,20231020,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-266995",BOEHRINGER INGELHEIM,,79.0,YR,E,M,Y,,,20231020,,MD,DE,DE,2023,Q4,Elderly
230776652,23077665,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1-0-0,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q4,Vomiting,,2023,Q4,2,F,,20231019.0,20231018,20231020,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-266995",BOEHRINGER INGELHEIM,,79.0,YR,E,M,Y,,,20231020,,MD,DE,DE,2023,Q4,Elderly
230776652,23077665,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1-0-0,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q4,Dyspnoea,,2023,Q4,2,F,,20231019.0,20231018,20231020,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-266995",BOEHRINGER INGELHEIM,,79.0,YR,E,M,Y,,,20231020,,MD,DE,DE,2023,Q4,Elderly
230776652,23077665,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1-0-0,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q4,Gastrointestinal infection,,2023,Q4,2,F,,20231019.0,20231018,20231020,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-266995",BOEHRINGER INGELHEIM,,79.0,YR,E,M,Y,,,20231020,,MD,DE,DE,2023,Q4,Elderly
230776652,23077665,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1-0-0,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q4,Pain,,2023,Q4,2,F,,20231019.0,20231018,20231020,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-266995",BOEHRINGER INGELHEIM,,79.0,YR,E,M,Y,,,20231020,,MD,DE,DE,2023,Q4,Elderly
230790041,23079004,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Dyspnoea,,2023,Q4,1,I,20230921.0,20231006.0,20231018,20231018,EXP,,US-Accord-385459,ACCORD,,73.0,YR,E,M,Y,,,20231018,,CN,US,US,2023,Q4,Elderly
230790041,23079004,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Road traffic accident,,2023,Q4,1,I,20230921.0,20231006.0,20231018,20231018,EXP,,US-Accord-385459,ACCORD,,73.0,YR,E,M,Y,,,20231018,,CN,US,US,2023,Q4,Elderly
230790041,23079004,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Tremor,,2023,Q4,1,I,20230921.0,20231006.0,20231018,20231018,EXP,,US-Accord-385459,ACCORD,,73.0,YR,E,M,Y,,,20231018,,CN,US,US,2023,Q4,Elderly
230790041,23079004,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Dizziness,,2023,Q4,1,I,20230921.0,20231006.0,20231018,20231018,EXP,,US-Accord-385459,ACCORD,,73.0,YR,E,M,Y,,,20231018,,CN,US,US,2023,Q4,Elderly
230790041,23079004,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Insomnia,,2023,Q4,1,I,20230921.0,20231006.0,20231018,20231018,EXP,,US-Accord-385459,ACCORD,,73.0,YR,E,M,Y,,,20231018,,CN,US,US,2023,Q4,Elderly
230790041,23079004,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Fall,,2023,Q4,1,I,20230921.0,20231006.0,20231018,20231018,EXP,,US-Accord-385459,ACCORD,,73.0,YR,E,M,Y,,,20231018,,CN,US,US,2023,Q4,Elderly
230790041,23079004,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Injury,,2023,Q4,1,I,20230921.0,20231006.0,20231018,20231018,EXP,,US-Accord-385459,ACCORD,,73.0,YR,E,M,Y,,,20231018,,CN,US,US,2023,Q4,Elderly
230790511,23079051,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Diabetic ketoacidosis,,2023,Q4,1,I,20230109.0,,20231017,20231017,DIR,FDA-CDER-CTU-2023-76315,,FDA-CTU,,70.0,YR,,M,N,,,20230201,N,PH,US,,2023,Q4,Elderly
230790541,23079054,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Urinary tract infection,,2023,Q4,1,I,20230111.0,,20231017,20231017,DIR,FDA-CDER-CTU-2023-76314,,FDA-CTU,,76.0,YR,,M,N,,,20230201,N,PH,US,,2023,Q4,Elderly
230790911,23079091,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,OTHER FREQUENCY : AM;?,,,,,,,,12.5,MG,,999,2023,Q4,Acute kidney injury,,2023,Q4,1,I,20221214.0,,20231017,20231017,DIR,FDA-CDER-CTU-2023-76344,,FDA-CTU,,84.0,YR,,M,N,,,20230205,N,PH,US,,2023,Q4,Elderly
230807381,23080738,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,OCT-2022,,,12.5,MG,,QD,2023,Q4,Hypovolaemia,,2023,Q4,1,I,20221023.0,,20231018,20231018,DIR,FDA-CDER-CTU-2023-76438,,FDA-CTU,,74.0,YR,,M,N,89.0,KG,20230118,N,PH,US,,2023,Q4,Elderly
230807381,23080738,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,OCT-2022,,,12.5,MG,,QD,2023,Q4,Leukocytosis,,2023,Q4,1,I,20221023.0,,20231018,20231018,DIR,FDA-CDER-CTU-2023-76438,,FDA-CTU,,74.0,YR,,M,N,89.0,KG,20230118,N,PH,US,,2023,Q4,Elderly
230807381,23080738,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,OCT-2022,,,12.5,MG,,QD,2023,Q4,Acute kidney injury,,2023,Q4,1,I,20221023.0,,20231018,20231018,DIR,FDA-CDER-CTU-2023-76438,,FDA-CTU,,74.0,YR,,M,N,89.0,KG,20230118,N,PH,US,,2023,Q4,Elderly
230807381,23080738,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,OCT-2022,,,12.5,MG,,QD,2023,Q4,Muscular weakness,,2023,Q4,1,I,20221023.0,,20231018,20231018,DIR,FDA-CDER-CTU-2023-76438,,FDA-CTU,,74.0,YR,,M,N,89.0,KG,20230118,N,PH,US,,2023,Q4,Elderly
230807381,23080738,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,OCT-2022,,,12.5,MG,,QD,2023,Q4,Blood creatinine increased,,2023,Q4,1,I,20221023.0,,20231018,20231018,DIR,FDA-CDER-CTU-2023-76438,,FDA-CTU,,74.0,YR,,M,N,89.0,KG,20230118,N,PH,US,,2023,Q4,Elderly
230807381,23080738,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,OCT-2022,,,12.5,MG,,QD,2023,Q4,Dizziness,,2023,Q4,1,I,20221023.0,,20231018,20231018,DIR,FDA-CDER-CTU-2023-76438,,FDA-CTU,,74.0,YR,,M,N,89.0,KG,20230118,N,PH,US,,2023,Q4,Elderly
230807381,23080738,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,OCT-2022,,,12.5,MG,,QD,2023,Q4,Fall,,2023,Q4,1,I,20221023.0,,20231018,20231018,DIR,FDA-CDER-CTU-2023-76438,,FDA-CTU,,74.0,YR,,M,N,89.0,KG,20230118,N,PH,US,,2023,Q4,Elderly
230807381,23080738,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,OCT-2022,,,12.5,MG,,QD,2023,Q4,Dehydration,,2023,Q4,1,I,20221023.0,,20231018,20231018,DIR,FDA-CDER-CTU-2023-76438,,FDA-CTU,,74.0,YR,,M,N,89.0,KG,20230118,N,PH,US,,2023,Q4,Elderly
230807381,23080738,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,OCT-2022,,,12.5,MG,,QD,2023,Q4,Balance disorder,,2023,Q4,1,I,20221023.0,,20231018,20231018,DIR,FDA-CDER-CTU-2023-76438,,FDA-CTU,,74.0,YR,,M,N,89.0,KG,20230118,N,PH,US,,2023,Q4,Elderly
230807381,23080738,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,OCT-2022,,,12.5,MG,,QD,2023,Q4,Hypotension,,2023,Q4,1,I,20221023.0,,20231018,20231018,DIR,FDA-CDER-CTU-2023-76438,,FDA-CTU,,74.0,YR,,M,N,89.0,KG,20230118,N,PH,US,,2023,Q4,Elderly
230807381,23080738,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,OCT-2022,,,12.5,MG,,QD,2023,Q4,Hypophosphataemia,,2023,Q4,1,I,20221023.0,,20231018,20231018,DIR,FDA-CDER-CTU-2023-76438,,FDA-CTU,,74.0,YR,,M,N,89.0,KG,20230118,N,PH,US,,2023,Q4,Elderly
230807381,23080738,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,OCT-2022,,,12.5,MG,,QD,2023,Q4,Weight decreased,,2023,Q4,1,I,20221023.0,,20231018,20231018,DIR,FDA-CDER-CTU-2023-76438,,FDA-CTU,,74.0,YR,,M,N,89.0,KG,20230118,N,PH,US,,2023,Q4,Elderly
230807381,23080738,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,OCT-2022,,,12.5,MG,,QD,2023,Q4,Urinary tract infection,,2023,Q4,1,I,20221023.0,,20231018,20231018,DIR,FDA-CDER-CTU-2023-76438,,FDA-CTU,,74.0,YR,,M,N,89.0,KG,20230118,N,PH,US,,2023,Q4,Elderly
230807381,23080738,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,OCT-2022,,,12.5,MG,,QD,2023,Q4,Dizziness,,2023,Q4,1,I,20221023.0,,20231018,20231018,DIR,FDA-CDER-CTU-2023-76438,,FDA-CTU,,74.0,YR,,M,N,89.0,KG,20230118,N,PH,US,,2023,Q4,Elderly
230807391,23080739,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2023,Q4,Bacteraemia,,2023,Q4,1,I,20230208.0,,20231018,20231018,DIR,FDA-CDER-CTU-2023-76464,,FDA-CTU,,74.0,YR,,M,N,83.0,KG,20230217,N,PH,US,,2023,Q4,Elderly
230807391,23080739,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2023,Q4,Urinary tract infection,,2023,Q4,1,I,20230208.0,,20231018,20231018,DIR,FDA-CDER-CTU-2023-76464,,FDA-CTU,,74.0,YR,,M,N,83.0,KG,20230217,N,PH,US,,2023,Q4,Elderly
230807401,23080740,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,12.5,MG,,QD,2023,Q4,Euglycaemic diabetic ketoacidosis,,2023,Q4,1,I,20221121.0,,20231018,20231018,DIR,FDA-CDER-CTU-2023-76445,,FDA-CTU,,41.0,YR,,M,N,100.0,KG,20230118,N,PH,US,,2023,Q4,Adult
230807401,23080740,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,12.5,MG,,QD,2023,Q4,Upper respiratory tract infection,,2023,Q4,1,I,20221121.0,,20231018,20231018,DIR,FDA-CDER-CTU-2023-76445,,FDA-CTU,,41.0,YR,,M,N,100.0,KG,20230118,N,PH,US,,2023,Q4,Adult
230807401,23080740,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,12.5,MG,,QD,2023,Q4,Beta haemolytic streptococcal infection,,2023,Q4,1,I,20221121.0,,20231018,20231018,DIR,FDA-CDER-CTU-2023-76445,,FDA-CTU,,41.0,YR,,M,N,100.0,KG,20230118,N,PH,US,,2023,Q4,Adult
230807401,23080740,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,12.5,MG,,QD,2023,Q4,Sepsis,,2023,Q4,1,I,20221121.0,,20231018,20231018,DIR,FDA-CDER-CTU-2023-76445,,FDA-CTU,,41.0,YR,,M,N,100.0,KG,20230118,N,PH,US,,2023,Q4,Adult
230811563,23081156,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,Unknown,,204629.0,,,Tablet,,2023,Q4,Pneumothorax,,2023,Q4,3,F,20230404.0,20231024.0,20231018,20231031,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-265736",BOEHRINGER INGELHEIM,,67.0,YR,E,M,Y,81.6,KG,20231031,,MD,US,US,2023,Q4,Elderly
230830391,23083039,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,Unknown,,2023,Q4,Atrial fibrillation,,2023,Q4,1,I,,20231005.0,20231019,20231019,EXP,,PL-MYLANLABS-2023M1108701,MYLAN,"Zalewska?Adamiec M, Bach?rzewska?Gajewska H, Dobrzycki S. The use of sacubitril/ valsartan in Takotsubo syndrome with severe impairment of left ventricular systolic function.. POLISH ARCHIVES OF INTERNAL MEDICINE. 2023;133(9):1-2",71.0,YR,,F,Y,,,20231019,,MD,PL,PL,2023,Q4,Elderly
230830901,23083090,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,OTHER FREQUENCY   EVERY: AM;?,,,,,,,,25.0,MG,,999,2023,Q4,Cystitis,,2023,Q4,1,I,20221117.0,,20231017,20231017,DIR,FDA-CDER-CTU-2023-76632,,FDA-CTU,,68.0,YR,,M,N,,,20221215,N,PH,US,,2023,Q4,Elderly
230830901,23083090,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,OTHER FREQUENCY   EVERY: AM;?,,,,,,,,25.0,MG,,999,2023,Q4,Urinary tract infection,,2023,Q4,1,I,20221117.0,,20231017,20231017,DIR,FDA-CDER-CTU-2023-76632,,FDA-CTU,,68.0,YR,,M,N,,,20221215,N,PH,US,,2023,Q4,Elderly
230830911,23083091,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,12.5,MG,,QD,2023,Q4,Asthenia,,2023,Q4,1,I,20230221.0,,20231018,20231018,DIR,FDA-CDER-CTU-2023-76644,,FDA-CTU,,80.0,YR,,M,N,82.0,KG,20230224,N,PH,US,,2023,Q4,Elderly
230830911,23083091,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,12.5,MG,,QD,2023,Q4,Hypotension,,2023,Q4,1,I,20230221.0,,20231018,20231018,DIR,FDA-CDER-CTU-2023-76644,,FDA-CTU,,80.0,YR,,M,N,82.0,KG,20230224,N,PH,US,,2023,Q4,Elderly
230830921,23083092,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,OTHER QUANTITY : 12.5-25MG;?Frequency : Daily;?,,,,,,,,,,,QD,2023,Q4,Urinary tract infection,,2023,Q4,1,I,20230207.0,,20231017,20231017,DIR,FDA-CDER-CTU-2023-76617,,FDA-CTU,,42.0,YR,,F,N,,,20230208,N,PH,US,,2023,Q4,Adult
230830921,23083092,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,OTHER QUANTITY : 12.5-25MG;?Frequency : Daily;?,,,,,,,,,,,QD,2023,Q4,Glucose urine present,,2023,Q4,1,I,20230207.0,,20231017,20231017,DIR,FDA-CDER-CTU-2023-76617,,FDA-CTU,,42.0,YR,,F,N,,,20230208,N,PH,US,,2023,Q4,Adult
230830961,23083096,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,10.0,MG,,QD,2023,Q4,Acute kidney injury,,2023,Q4,1,I,20221010.0,,20231017,20231017,DIR,FDA-CDER-CTU-2023-76636,,FDA-CTU,,65.0,YR,,M,N,62.0,KG,20221215,N,PH,US,,2023,Q4,Elderly
230830961,23083096,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,10.0,MG,,QD,2023,Q4,Delirium,,2023,Q4,1,I,20221010.0,,20231017,20231017,DIR,FDA-CDER-CTU-2023-76636,,FDA-CTU,,65.0,YR,,M,N,62.0,KG,20221215,N,PH,US,,2023,Q4,Elderly
230830961,23083096,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,10.0,MG,,QD,2023,Q4,Alanine aminotransferase increased,,2023,Q4,1,I,20221010.0,,20231017,20231017,DIR,FDA-CDER-CTU-2023-76636,,FDA-CTU,,65.0,YR,,M,N,62.0,KG,20221215,N,PH,US,,2023,Q4,Elderly
230830961,23083096,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,10.0,MG,,QD,2023,Q4,Starvation ketoacidosis,,2023,Q4,1,I,20221010.0,,20231017,20231017,DIR,FDA-CDER-CTU-2023-76636,,FDA-CTU,,65.0,YR,,M,N,62.0,KG,20221215,N,PH,US,,2023,Q4,Elderly
230830961,23083096,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,10.0,MG,,QD,2023,Q4,Aspartate aminotransferase increased,,2023,Q4,1,I,20221010.0,,20231017,20231017,DIR,FDA-CDER-CTU-2023-76636,,FDA-CTU,,65.0,YR,,M,N,62.0,KG,20221215,N,PH,US,,2023,Q4,Elderly
230830961,23083096,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,10.0,MG,,QD,2023,Q4,Acute kidney injury,,2023,Q4,1,I,20221010.0,,20231017,20231017,DIR,FDA-CDER-CTU-2023-76636,,FDA-CTU,,65.0,YR,,M,N,62.0,KG,20221215,N,PH,US,,2023,Q4,Elderly
230830961,23083096,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,10.0,MG,,QD,2023,Q4,"Hallucination, visual",,2023,Q4,1,I,20221010.0,,20231017,20231017,DIR,FDA-CDER-CTU-2023-76636,,FDA-CTU,,65.0,YR,,M,N,62.0,KG,20221215,N,PH,US,,2023,Q4,Elderly
230831331,23083133,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,25.0,MG,,QD,2023,Q4,Constipation,,2023,Q4,1,I,20230206.0,,20231018,20231018,DIR,FDA-CDER-CTU-2023-76664,,FDA-CTU,,81.0,YR,,M,N,86.0,KG,20230228,N,PH,US,,2023,Q4,Elderly
230831331,23083133,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,25.0,MG,,QD,2023,Q4,Abdominal pain,,2023,Q4,1,I,20230206.0,,20231018,20231018,DIR,FDA-CDER-CTU-2023-76664,,FDA-CTU,,81.0,YR,,M,N,86.0,KG,20230228,N,PH,US,,2023,Q4,Elderly
230831331,23083133,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,25.0,MG,,QD,2023,Q4,Confusional state,,2023,Q4,1,I,20230206.0,,20231018,20231018,DIR,FDA-CDER-CTU-2023-76664,,FDA-CTU,,81.0,YR,,M,N,86.0,KG,20230228,N,PH,US,,2023,Q4,Elderly
230831331,23083133,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,25.0,MG,,QD,2023,Q4,Euglycaemic diabetic ketoacidosis,,2023,Q4,1,I,20230206.0,,20231018,20231018,DIR,FDA-CDER-CTU-2023-76664,,FDA-CTU,,81.0,YR,,M,N,86.0,KG,20230228,N,PH,US,,2023,Q4,Elderly
230835041,23083504,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Aggression,,2023,Q4,1,I,20210414.0,20231009.0,20231019,20231019,EXP,,ES-JNJFOC-20231033310,JOHNSON AND JOHNSON,,63.0,YR,A,M,Y,,,20231019,,MD,ES,ES,2023,Q4,Adult
230835041,23083504,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Confusional state,,2023,Q4,1,I,20210414.0,20231009.0,20231019,20231019,EXP,,ES-JNJFOC-20231033310,JOHNSON AND JOHNSON,,63.0,YR,A,M,Y,,,20231019,,MD,ES,ES,2023,Q4,Adult
230849061,23084906,4,C,EMPAGLIFLOZIN TABLET,,2,Oral,,,,,,,,,10.0,MG,Tablet,,2023,Q4,Cardiac failure,,2023,Q4,1,I,20230830.0,20231006.0,20231019,20231019,EXP,,HK-AstraZeneca-2023A228882,ASTRAZENECA,,65.0,YR,,M,Y,54.1,KG,20231019,,MD,HK,,2023,Q4,Elderly
230850101,23085010,3,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, daily",,,,,,,,10.0,MG,,QD,2023,Q4,Drug interaction,,2023,Q4,1,I,,20231009.0,20231019,20231019,EXP,,US-ELI_LILLY_AND_COMPANY-US202310008690,ELI LILLY AND CO,,69.0,YR,,M,Y,,,20231019,,CN,US,US,2023,Q4,Elderly
230850101,23085010,3,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, daily",,,,,,,,10.0,MG,,QD,2023,Q4,Incorrect dose administered,,2023,Q4,1,I,,20231009.0,20231019,20231019,EXP,,US-ELI_LILLY_AND_COMPANY-US202310008690,ELI LILLY AND CO,,69.0,YR,,M,Y,,,20231019,,CN,US,US,2023,Q4,Elderly
230850101,23085010,3,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, daily",,,,,,,,10.0,MG,,QD,2023,Q4,Hypotension,,2023,Q4,1,I,,20231009.0,20231019,20231019,EXP,,US-ELI_LILLY_AND_COMPANY-US202310008690,ELI LILLY AND CO,,69.0,YR,,M,Y,,,20231019,,CN,US,US,2023,Q4,Elderly
230850101,23085010,3,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, daily",,,,,,,,10.0,MG,,QD,2023,Q4,Dizziness,,2023,Q4,1,I,,20231009.0,20231019,20231019,EXP,,US-ELI_LILLY_AND_COMPANY-US202310008690,ELI LILLY AND CO,,69.0,YR,,M,Y,,,20231019,,CN,US,US,2023,Q4,Elderly
230850101,23085010,3,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, daily",,,,,,,,10.0,MG,,QD,2023,Q4,Blood creatinine increased,,2023,Q4,1,I,,20231009.0,20231019,20231019,EXP,,US-ELI_LILLY_AND_COMPANY-US202310008690,ELI LILLY AND CO,,69.0,YR,,M,Y,,,20231019,,CN,US,US,2023,Q4,Elderly
230850101,23085010,3,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, daily",,,,,,,,10.0,MG,,QD,2023,Q4,Off label use,,2023,Q4,1,I,,20231009.0,20231019,20231019,EXP,,US-ELI_LILLY_AND_COMPANY-US202310008690,ELI LILLY AND CO,,69.0,YR,,M,Y,,,20231019,,CN,US,US,2023,Q4,Elderly
230850101,23085010,3,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, daily",,,,,,,,10.0,MG,,QD,2023,Q4,Tachycardia,,2023,Q4,1,I,,20231009.0,20231019,20231019,EXP,,US-ELI_LILLY_AND_COMPANY-US202310008690,ELI LILLY AND CO,,69.0,YR,,M,Y,,,20231019,,CN,US,US,2023,Q4,Elderly
230850101,23085010,3,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, daily",,,,,,,,10.0,MG,,QD,2023,Q4,Hypovolaemia,,2023,Q4,1,I,,20231009.0,20231019,20231019,EXP,,US-ELI_LILLY_AND_COMPANY-US202310008690,ELI LILLY AND CO,,69.0,YR,,M,Y,,,20231019,,CN,US,US,2023,Q4,Elderly
230851291,23085129,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2023,Q4,Hyperglycaemia,,2023,Q4,1,I,20221215.0,,20231019,20231019,DIR,FDA-CDER-CTU-2023-76803,,FDA-CTU,,70.0,YR,,M,N,116.0,KG,20230217,N,PH,US,,2023,Q4,Elderly
230851291,23085129,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2023,Q4,Diabetic ketoacidosis,,2023,Q4,1,I,20221215.0,,20231019,20231019,DIR,FDA-CDER-CTU-2023-76803,,FDA-CTU,,70.0,YR,,M,N,116.0,KG,20230217,N,PH,US,,2023,Q4,Elderly
230851291,23085129,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2023,Q4,Abdominal pain,,2023,Q4,1,I,20221215.0,,20231019,20231019,DIR,FDA-CDER-CTU-2023-76803,,FDA-CTU,,70.0,YR,,M,N,116.0,KG,20230217,N,PH,US,,2023,Q4,Elderly
230851291,23085129,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2023,Q4,Vomiting,,2023,Q4,1,I,20221215.0,,20231019,20231019,DIR,FDA-CDER-CTU-2023-76803,,FDA-CTU,,70.0,YR,,M,N,116.0,KG,20230217,N,PH,US,,2023,Q4,Elderly
230851311,23085131,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,201055,,,0.5,MG,,QD,2023,Q4,Urinary tract infection,,2023,Q4,1,I,20221102.0,,20231019,20231019,DIR,FDA-CDER-CTU-2023-76795,,FDA-CTU,,82.0,YR,,M,N,108.0,KG,20230118,N,PH,US,,2023,Q4,Elderly
230851311,23085131,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,201055,,,0.5,MG,,QD,2023,Q4,Blood creatinine increased,,2023,Q4,1,I,20221102.0,,20231019,20231019,DIR,FDA-CDER-CTU-2023-76795,,FDA-CTU,,82.0,YR,,M,N,108.0,KG,20230118,N,PH,US,,2023,Q4,Elderly
230861061,23086106,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 tablet,,,,,,,,,,Tablet,,2023,Q4,Dyspnoea,,2023,Q4,1,I,20230301.0,20230914.0,20231019,20231019,PER,,US-JAZZ PHARMACEUTICALS-2023-US-006872,JAZZ,,70.0,YR,,M,Y,,,20231019,,HP,US,US,2023,Q4,Elderly
230861061,23086106,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 tablet,,,,,,,,,,Tablet,,2023,Q4,Rhinorrhoea,,2023,Q4,1,I,20230301.0,20230914.0,20231019,20231019,PER,,US-JAZZ PHARMACEUTICALS-2023-US-006872,JAZZ,,70.0,YR,,M,Y,,,20231019,,HP,US,US,2023,Q4,Elderly
230861061,23086106,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 tablet,,,,,,,,,,Tablet,,2023,Q4,Blood cholesterol increased,,2023,Q4,1,I,20230301.0,20230914.0,20231019,20231019,PER,,US-JAZZ PHARMACEUTICALS-2023-US-006872,JAZZ,,70.0,YR,,M,Y,,,20231019,,HP,US,US,2023,Q4,Elderly
230861061,23086106,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 tablet,,,,,,,,,,Tablet,,2023,Q4,Ear infection,,2023,Q4,1,I,20230301.0,20230914.0,20231019,20231019,PER,,US-JAZZ PHARMACEUTICALS-2023-US-006872,JAZZ,,70.0,YR,,M,Y,,,20231019,,HP,US,US,2023,Q4,Elderly
230861061,23086106,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 tablet,,,,,,,,,,Tablet,,2023,Q4,Glaucoma,,2023,Q4,1,I,20230301.0,20230914.0,20231019,20231019,PER,,US-JAZZ PHARMACEUTICALS-2023-US-006872,JAZZ,,70.0,YR,,M,Y,,,20231019,,HP,US,US,2023,Q4,Elderly
230861061,23086106,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q4,Dyspnoea,,2023,Q4,1,I,20230301.0,20230914.0,20231019,20231019,PER,,US-JAZZ PHARMACEUTICALS-2023-US-006872,JAZZ,,70.0,YR,,M,Y,,,20231019,,HP,US,US,2023,Q4,Elderly
230861061,23086106,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q4,Rhinorrhoea,,2023,Q4,1,I,20230301.0,20230914.0,20231019,20231019,PER,,US-JAZZ PHARMACEUTICALS-2023-US-006872,JAZZ,,70.0,YR,,M,Y,,,20231019,,HP,US,US,2023,Q4,Elderly
230861061,23086106,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q4,Blood cholesterol increased,,2023,Q4,1,I,20230301.0,20230914.0,20231019,20231019,PER,,US-JAZZ PHARMACEUTICALS-2023-US-006872,JAZZ,,70.0,YR,,M,Y,,,20231019,,HP,US,US,2023,Q4,Elderly
230861061,23086106,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q4,Ear infection,,2023,Q4,1,I,20230301.0,20230914.0,20231019,20231019,PER,,US-JAZZ PHARMACEUTICALS-2023-US-006872,JAZZ,,70.0,YR,,M,Y,,,20231019,,HP,US,US,2023,Q4,Elderly
230861061,23086106,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q4,Glaucoma,,2023,Q4,1,I,20230301.0,20230914.0,20231019,20231019,PER,,US-JAZZ PHARMACEUTICALS-2023-US-006872,JAZZ,,70.0,YR,,M,Y,,,20231019,,HP,US,US,2023,Q4,Elderly
230880831,23088083,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Off label use,,2023,Q4,1,I,20230812.0,20231016.0,20231020,20231020,EXP,,DE-BAUSCHBL-2023BNL010108,BAUSCH AND LOMB,,73.0,YR,,M,Y,73.0,KG,20231020,,MD,DE,DE,2023,Q4,Elderly
230880831,23088083,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Pneumonia,,2023,Q4,1,I,20230812.0,20231016.0,20231020,20231020,EXP,,DE-BAUSCHBL-2023BNL010108,BAUSCH AND LOMB,,73.0,YR,,M,Y,73.0,KG,20231020,,MD,DE,DE,2023,Q4,Elderly
230880831,23088083,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Cardiac failure,,2023,Q4,1,I,20230812.0,20231016.0,20231020,20231020,EXP,,DE-BAUSCHBL-2023BNL010108,BAUSCH AND LOMB,,73.0,YR,,M,Y,73.0,KG,20231020,,MD,DE,DE,2023,Q4,Elderly
230914991,23091499,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,Unknown,,204629.0,,,Tablet,,2023,Q4,Nephritis,,2023,Q4,1,I,20230830.0,20231014.0,20231020,20231020,EXP,,"FR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-261384",BOEHRINGER INGELHEIM,,76.0,YR,E,M,Y,70.0,KG,20231020,,MD,FR,FR,2023,Q4,Elderly
230914991,23091499,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,Unknown,,204629.0,,,Tablet,,2023,Q4,Anaemia,,2023,Q4,1,I,20230830.0,20231014.0,20231020,20231020,EXP,,"FR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-261384",BOEHRINGER INGELHEIM,,76.0,YR,E,M,Y,70.0,KG,20231020,,MD,FR,FR,2023,Q4,Elderly
230914991,23091499,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,Unknown,,204629.0,,,Tablet,,2023,Q4,Benign prostatic hyperplasia,,2023,Q4,1,I,20230830.0,20231014.0,20231020,20231020,EXP,,"FR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-261384",BOEHRINGER INGELHEIM,,76.0,YR,E,M,Y,70.0,KG,20231020,,MD,FR,FR,2023,Q4,Elderly
230914991,23091499,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,Unknown,,204629.0,,,Tablet,,2023,Q4,Urinary retention,,2023,Q4,1,I,20230830.0,20231014.0,20231020,20231020,EXP,,"FR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-261384",BOEHRINGER INGELHEIM,,76.0,YR,E,M,Y,70.0,KG,20231020,,MD,FR,FR,2023,Q4,Elderly
230926961,23092696,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,UNKNOWN,,,,,,,2023,Q4,Pneumonia,,2023,Q4,1,I,20230512.0,20231011.0,20231021,20231021,EXP,,FR-TEVA-2023-FR-2935996,TEVA,,75.0,YR,E,F,Y,76.0,KG,20231021,,MD,FR,FR,2023,Q4,Elderly
230926961,23092696,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,UNKNOWN,,,,,,,2023,Q4,COVID-19,,2023,Q4,1,I,20230512.0,20231011.0,20231021,20231021,EXP,,FR-TEVA-2023-FR-2935996,TEVA,,75.0,YR,E,F,Y,76.0,KG,20231021,,MD,FR,FR,2023,Q4,Elderly
230926961,23092696,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,UNKNOWN,,,,,,,2023,Q4,C-reactive protein increased,,2023,Q4,1,I,20230512.0,20231011.0,20231021,20231021,EXP,,FR-TEVA-2023-FR-2935996,TEVA,,75.0,YR,E,F,Y,76.0,KG,20231021,,MD,FR,FR,2023,Q4,Elderly
230926961,23092696,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,UNKNOWN,,,,,,,2023,Q4,Lower respiratory tract infection,,2023,Q4,1,I,20230512.0,20231011.0,20231021,20231021,EXP,,FR-TEVA-2023-FR-2935996,TEVA,,75.0,YR,E,F,Y,76.0,KG,20231021,,MD,FR,FR,2023,Q4,Elderly
230926961,23092696,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,UNKNOWN,,,,,,,2023,Q4,Chills,,2023,Q4,1,I,20230512.0,20231011.0,20231021,20231021,EXP,,FR-TEVA-2023-FR-2935996,TEVA,,75.0,YR,E,F,Y,76.0,KG,20231021,,MD,FR,FR,2023,Q4,Elderly
230926961,23092696,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,UNKNOWN,,,,,,,2023,Q4,Asthenia,,2023,Q4,1,I,20230512.0,20231011.0,20231021,20231021,EXP,,FR-TEVA-2023-FR-2935996,TEVA,,75.0,YR,E,F,Y,76.0,KG,20231021,,MD,FR,FR,2023,Q4,Elderly
230926961,23092696,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,UNKNOWN,,,,,,,2023,Q4,Anaemia,,2023,Q4,1,I,20230512.0,20231011.0,20231021,20231021,EXP,,FR-TEVA-2023-FR-2935996,TEVA,,75.0,YR,E,F,Y,76.0,KG,20231021,,MD,FR,FR,2023,Q4,Elderly
230926961,23092696,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,UNKNOWN,,,,,,,2023,Q4,Cough,,2023,Q4,1,I,20230512.0,20231011.0,20231021,20231021,EXP,,FR-TEVA-2023-FR-2935996,TEVA,,75.0,YR,E,F,Y,76.0,KG,20231021,,MD,FR,FR,2023,Q4,Elderly
230926961,23092696,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,UNKNOWN,,,,,,,2023,Q4,Abdominal pain upper,,2023,Q4,1,I,20230512.0,20231011.0,20231021,20231021,EXP,,FR-TEVA-2023-FR-2935996,TEVA,,75.0,YR,E,F,Y,76.0,KG,20231021,,MD,FR,FR,2023,Q4,Elderly
230926961,23092696,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,UNKNOWN,,,,,,,2023,Q4,Off label use,,2023,Q4,1,I,20230512.0,20231011.0,20231021,20231021,EXP,,FR-TEVA-2023-FR-2935996,TEVA,,75.0,YR,E,F,Y,76.0,KG,20231021,,MD,FR,FR,2023,Q4,Elderly
230926961,23092696,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,UNKNOWN,,,,,,,2023,Q4,Cardiac failure,,2023,Q4,1,I,20230512.0,20231011.0,20231021,20231021,EXP,,FR-TEVA-2023-FR-2935996,TEVA,,75.0,YR,E,F,Y,76.0,KG,20231021,,MD,FR,FR,2023,Q4,Elderly
230929701,23092970,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2023,Q4,BRASH syndrome,,2023,Q4,1,I,,20231010.0,20231021,20231021,EXP,,US-Accord-384816,ACCORD,"Dong Q, Kyereme-Tuah EK, Zou Y, Jin Z, Rahim Wazeen FAZL. Brash syndrome: an under-recognized syndrome precipitated by medication overdose. Chest. 2023;164(4) Supplement:A2167-8.",77.0,YR,E,M,Y,,,20231021,,MD,US,US,2023,Q4,Elderly
230929701,23092970,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2023,Q4,Overdose,,2023,Q4,1,I,,20231010.0,20231021,20231021,EXP,,US-Accord-384816,ACCORD,"Dong Q, Kyereme-Tuah EK, Zou Y, Jin Z, Rahim Wazeen FAZL. Brash syndrome: an under-recognized syndrome precipitated by medication overdose. Chest. 2023;164(4) Supplement:A2167-8.",77.0,YR,E,M,Y,,,20231021,,MD,US,US,2023,Q4,Elderly
230933148,23093314,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,,10.0,MG,Unknown,QD,2023,Q4,Febrile neutropenia,,2023,Q4,8,F,20231003.0,20231220.0,20231022,20231229,EXP,,AU-JNJFOC-20231046003,JOHNSON AND JOHNSON,,71.0,YR,E,M,Y,85.3,KG,20231229,,MD,AU,AU,2023,Q4,Elderly
230933148,23093314,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,,10.0,MG,Unknown,QD,2023,Q4,Diabetic ketoacidosis,,2023,Q4,8,F,20231003.0,20231220.0,20231022,20231229,EXP,,AU-JNJFOC-20231046003,JOHNSON AND JOHNSON,,71.0,YR,E,M,Y,85.3,KG,20231229,,MD,AU,AU,2023,Q4,Elderly
230948582,23094858,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,U,,,,,10.0,MG,,QD,2023,Q4,Constipation,,2023,Q4,2,F,,20231120.0,20231023,20231128,EXP,,CA-SANDOZ INC.-NVSC2022CA251360,SANDOZ,,67.0,YR,,F,Y,,,20231128,,CN,CA,CA,2023,Q4,Elderly
230948582,23094858,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,U,,,,,10.0,MG,,QD,2023,Q4,Fall,,2023,Q4,2,F,,20231120.0,20231023,20231128,EXP,,CA-SANDOZ INC.-NVSC2022CA251360,SANDOZ,,67.0,YR,,F,Y,,,20231128,,CN,CA,CA,2023,Q4,Elderly
230948582,23094858,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,U,,,,,10.0,MG,,QD,2023,Q4,Pain in extremity,,2023,Q4,2,F,,20231120.0,20231023,20231128,EXP,,CA-SANDOZ INC.-NVSC2022CA251360,SANDOZ,,67.0,YR,,F,Y,,,20231128,,CN,CA,CA,2023,Q4,Elderly
230948582,23094858,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,U,,,,,10.0,MG,,QD,2023,Q4,COVID-19,,2023,Q4,2,F,,20231120.0,20231023,20231128,EXP,,CA-SANDOZ INC.-NVSC2022CA251360,SANDOZ,,67.0,YR,,F,Y,,,20231128,,CN,CA,CA,2023,Q4,Elderly
230948582,23094858,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,U,,,,,10.0,MG,,QD,2023,Q4,Blood pressure increased,,2023,Q4,2,F,,20231120.0,20231023,20231128,EXP,,CA-SANDOZ INC.-NVSC2022CA251360,SANDOZ,,67.0,YR,,F,Y,,,20231128,,CN,CA,CA,2023,Q4,Elderly
230948582,23094858,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,U,,,,,10.0,MG,,QD,2023,Q4,Cardiac failure,,2023,Q4,2,F,,20231120.0,20231023,20231128,EXP,,CA-SANDOZ INC.-NVSC2022CA251360,SANDOZ,,67.0,YR,,F,Y,,,20231128,,CN,CA,CA,2023,Q4,Elderly
230948582,23094858,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,U,,,,,10.0,MG,,QD,2023,Q4,Chest pain,,2023,Q4,2,F,,20231120.0,20231023,20231128,EXP,,CA-SANDOZ INC.-NVSC2022CA251360,SANDOZ,,67.0,YR,,F,Y,,,20231128,,CN,CA,CA,2023,Q4,Elderly
230948582,23094858,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,U,,,,,10.0,MG,,QD,2023,Q4,Clostridium difficile colitis,,2023,Q4,2,F,,20231120.0,20231023,20231128,EXP,,CA-SANDOZ INC.-NVSC2022CA251360,SANDOZ,,67.0,YR,,F,Y,,,20231128,,CN,CA,CA,2023,Q4,Elderly
230948582,23094858,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,U,,,,,10.0,MG,,QD,2023,Q4,Haemorrhoidal haemorrhage,,2023,Q4,2,F,,20231120.0,20231023,20231128,EXP,,CA-SANDOZ INC.-NVSC2022CA251360,SANDOZ,,67.0,YR,,F,Y,,,20231128,,CN,CA,CA,2023,Q4,Elderly
230948582,23094858,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,U,,,,,10.0,MG,,QD,2023,Q4,Dyspnoea,,2023,Q4,2,F,,20231120.0,20231023,20231128,EXP,,CA-SANDOZ INC.-NVSC2022CA251360,SANDOZ,,67.0,YR,,F,Y,,,20231128,,CN,CA,CA,2023,Q4,Elderly
230948582,23094858,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,U,,,,,10.0,MG,,QD,2023,Q4,Neuropathy peripheral,,2023,Q4,2,F,,20231120.0,20231023,20231128,EXP,,CA-SANDOZ INC.-NVSC2022CA251360,SANDOZ,,67.0,YR,,F,Y,,,20231128,,CN,CA,CA,2023,Q4,Elderly
230948582,23094858,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,U,,,,,10.0,MG,,QD,2023,Q4,Neoplasm skin,,2023,Q4,2,F,,20231120.0,20231023,20231128,EXP,,CA-SANDOZ INC.-NVSC2022CA251360,SANDOZ,,67.0,YR,,F,Y,,,20231128,,CN,CA,CA,2023,Q4,Elderly
230948582,23094858,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,U,,,,,10.0,MG,,QD,2023,Q4,Chest discomfort,,2023,Q4,2,F,,20231120.0,20231023,20231128,EXP,,CA-SANDOZ INC.-NVSC2022CA251360,SANDOZ,,67.0,YR,,F,Y,,,20231128,,CN,CA,CA,2023,Q4,Elderly
230948582,23094858,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,U,,,,,10.0,MG,,QD,2023,Q4,Product use issue,,2023,Q4,2,F,,20231120.0,20231023,20231128,EXP,,CA-SANDOZ INC.-NVSC2022CA251360,SANDOZ,,67.0,YR,,F,Y,,,20231128,,CN,CA,CA,2023,Q4,Elderly
230948582,23094858,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,U,,,,,10.0,MG,,QD,2023,Q4,Pneumonia,,2023,Q4,2,F,,20231120.0,20231023,20231128,EXP,,CA-SANDOZ INC.-NVSC2022CA251360,SANDOZ,,67.0,YR,,F,Y,,,20231128,,CN,CA,CA,2023,Q4,Elderly
230948582,23094858,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,U,,,,,10.0,MG,,QD,2023,Q4,Transient ischaemic attack,,2023,Q4,2,F,,20231120.0,20231023,20231128,EXP,,CA-SANDOZ INC.-NVSC2022CA251360,SANDOZ,,67.0,YR,,F,Y,,,20231128,,CN,CA,CA,2023,Q4,Elderly
230948582,23094858,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,U,,,,,10.0,MG,,QD,2023,Q4,Cardiomegaly,,2023,Q4,2,F,,20231120.0,20231023,20231128,EXP,,CA-SANDOZ INC.-NVSC2022CA251360,SANDOZ,,67.0,YR,,F,Y,,,20231128,,CN,CA,CA,2023,Q4,Elderly
230948582,23094858,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,U,,,,,10.0,MG,,QD,2023,Q4,Haemorrhoids,,2023,Q4,2,F,,20231120.0,20231023,20231128,EXP,,CA-SANDOZ INC.-NVSC2022CA251360,SANDOZ,,67.0,YR,,F,Y,,,20231128,,CN,CA,CA,2023,Q4,Elderly
230948582,23094858,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,U,,,,,10.0,MG,,QD,2023,Q4,Drug ineffective,,2023,Q4,2,F,,20231120.0,20231023,20231128,EXP,,CA-SANDOZ INC.-NVSC2022CA251360,SANDOZ,,67.0,YR,,F,Y,,,20231128,,CN,CA,CA,2023,Q4,Elderly
230948582,23094858,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,U,,,,,10.0,MG,,QD,2023,Q4,Cataract,,2023,Q4,2,F,,20231120.0,20231023,20231128,EXP,,CA-SANDOZ INC.-NVSC2022CA251360,SANDOZ,,67.0,YR,,F,Y,,,20231128,,CN,CA,CA,2023,Q4,Elderly
230948582,23094858,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,U,,,,,10.0,MG,,QD,2023,Q4,Vulvovaginal mycotic infection,,2023,Q4,2,F,,20231120.0,20231023,20231128,EXP,,CA-SANDOZ INC.-NVSC2022CA251360,SANDOZ,,67.0,YR,,F,Y,,,20231128,,CN,CA,CA,2023,Q4,Elderly
230948582,23094858,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,U,,,,,10.0,MG,,QD,2023,Q4,Abdominal pain upper,,2023,Q4,2,F,,20231120.0,20231023,20231128,EXP,,CA-SANDOZ INC.-NVSC2022CA251360,SANDOZ,,67.0,YR,,F,Y,,,20231128,,CN,CA,CA,2023,Q4,Elderly
230948582,23094858,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,U,,,,,10.0,MG,,QD,2023,Q4,Hypoaesthesia,,2023,Q4,2,F,,20231120.0,20231023,20231128,EXP,,CA-SANDOZ INC.-NVSC2022CA251360,SANDOZ,,67.0,YR,,F,Y,,,20231128,,CN,CA,CA,2023,Q4,Elderly
230949651,23094965,16,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,"12,5/100 mg, bid",,,,,UNKNOWN,,,,,,BID,2023,Q4,Violence-related symptom,,2023,Q4,1,I,20220101.0,20231012.0,20231023,20231023,EXP,,PT-ROCHE-3440736,ROCHE,"Canha F, Pitta, R., and Gil Conde, M. E. N. The importance of the continuation of psychological pathology: a case report.. Revista Portuguesa De Medicina Geral E Familiar 2023;39(4):327-31.",50.0,YR,,F,Y,,,20231023,,MD,PT,PT,2023,Q4,Adult
230949651,23094965,16,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,"12,5/100 mg, bid",,,,,UNKNOWN,,,,,,BID,2023,Q4,Fatigue,,2023,Q4,1,I,20220101.0,20231012.0,20231023,20231023,EXP,,PT-ROCHE-3440736,ROCHE,"Canha F, Pitta, R., and Gil Conde, M. E. N. The importance of the continuation of psychological pathology: a case report.. Revista Portuguesa De Medicina Geral E Familiar 2023;39(4):327-31.",50.0,YR,,F,Y,,,20231023,,MD,PT,PT,2023,Q4,Adult
230949651,23094965,16,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,"12,5/100 mg, bid",,,,,UNKNOWN,,,,,,BID,2023,Q4,Self-injurious ideation,,2023,Q4,1,I,20220101.0,20231012.0,20231023,20231023,EXP,,PT-ROCHE-3440736,ROCHE,"Canha F, Pitta, R., and Gil Conde, M. E. N. The importance of the continuation of psychological pathology: a case report.. Revista Portuguesa De Medicina Geral E Familiar 2023;39(4):327-31.",50.0,YR,,F,Y,,,20231023,,MD,PT,PT,2023,Q4,Adult
230949651,23094965,16,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,"12,5/100 mg, bid",,,,,UNKNOWN,,,,,,BID,2023,Q4,Irritability,,2023,Q4,1,I,20220101.0,20231012.0,20231023,20231023,EXP,,PT-ROCHE-3440736,ROCHE,"Canha F, Pitta, R., and Gil Conde, M. E. N. The importance of the continuation of psychological pathology: a case report.. Revista Portuguesa De Medicina Geral E Familiar 2023;39(4):327-31.",50.0,YR,,F,Y,,,20231023,,MD,PT,PT,2023,Q4,Adult
230949651,23094965,16,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,"12,5/100 mg, bid",,,,,UNKNOWN,,,,,,BID,2023,Q4,Pseudohallucination,,2023,Q4,1,I,20220101.0,20231012.0,20231023,20231023,EXP,,PT-ROCHE-3440736,ROCHE,"Canha F, Pitta, R., and Gil Conde, M. E. N. The importance of the continuation of psychological pathology: a case report.. Revista Portuguesa De Medicina Geral E Familiar 2023;39(4):327-31.",50.0,YR,,F,Y,,,20231023,,MD,PT,PT,2023,Q4,Adult
230949651,23094965,16,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,"12,5/100 mg, bid",,,,,UNKNOWN,,,,,,BID,2023,Q4,Affective disorder,,2023,Q4,1,I,20220101.0,20231012.0,20231023,20231023,EXP,,PT-ROCHE-3440736,ROCHE,"Canha F, Pitta, R., and Gil Conde, M. E. N. The importance of the continuation of psychological pathology: a case report.. Revista Portuguesa De Medicina Geral E Familiar 2023;39(4):327-31.",50.0,YR,,F,Y,,,20231023,,MD,PT,PT,2023,Q4,Adult
230949651,23094965,16,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,"12,5/100 mg, bid",,,,,UNKNOWN,,,,,,BID,2023,Q4,Anxiety,,2023,Q4,1,I,20220101.0,20231012.0,20231023,20231023,EXP,,PT-ROCHE-3440736,ROCHE,"Canha F, Pitta, R., and Gil Conde, M. E. N. The importance of the continuation of psychological pathology: a case report.. Revista Portuguesa De Medicina Geral E Familiar 2023;39(4):327-31.",50.0,YR,,F,Y,,,20231023,,MD,PT,PT,2023,Q4,Adult
230949651,23094965,16,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,"12,5/100 mg, bid",,,,,UNKNOWN,,,,,,BID,2023,Q4,Nightmare,,2023,Q4,1,I,20220101.0,20231012.0,20231023,20231023,EXP,,PT-ROCHE-3440736,ROCHE,"Canha F, Pitta, R., and Gil Conde, M. E. N. The importance of the continuation of psychological pathology: a case report.. Revista Portuguesa De Medicina Geral E Familiar 2023;39(4):327-31.",50.0,YR,,F,Y,,,20231023,,MD,PT,PT,2023,Q4,Adult
230949651,23094965,16,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,"12,5/100 mg, bid",,,,,UNKNOWN,,,,,,BID,2023,Q4,Intentional product misuse,,2023,Q4,1,I,20220101.0,20231012.0,20231023,20231023,EXP,,PT-ROCHE-3440736,ROCHE,"Canha F, Pitta, R., and Gil Conde, M. E. N. The importance of the continuation of psychological pathology: a case report.. Revista Portuguesa De Medicina Geral E Familiar 2023;39(4):327-31.",50.0,YR,,F,Y,,,20231023,,MD,PT,PT,2023,Q4,Adult
230949651,23094965,16,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,"12,5/100 mg, bid",,,,,UNKNOWN,,,,,,BID,2023,Q4,Middle insomnia,,2023,Q4,1,I,20220101.0,20231012.0,20231023,20231023,EXP,,PT-ROCHE-3440736,ROCHE,"Canha F, Pitta, R., and Gil Conde, M. E. N. The importance of the continuation of psychological pathology: a case report.. Revista Portuguesa De Medicina Geral E Familiar 2023;39(4):327-31.",50.0,YR,,F,Y,,,20231023,,MD,PT,PT,2023,Q4,Adult
230949651,23094965,16,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,"12,5/100 mg, bid",,,,,UNKNOWN,,,,,,BID,2023,Q4,Insomnia,,2023,Q4,1,I,20220101.0,20231012.0,20231023,20231023,EXP,,PT-ROCHE-3440736,ROCHE,"Canha F, Pitta, R., and Gil Conde, M. E. N. The importance of the continuation of psychological pathology: a case report.. Revista Portuguesa De Medicina Geral E Familiar 2023;39(4):327-31.",50.0,YR,,F,Y,,,20231023,,MD,PT,PT,2023,Q4,Adult
230949651,23094965,16,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,"12,5/100 mg, bid",,,,,UNKNOWN,,,,,,BID,2023,Q4,Panic attack,,2023,Q4,1,I,20220101.0,20231012.0,20231023,20231023,EXP,,PT-ROCHE-3440736,ROCHE,"Canha F, Pitta, R., and Gil Conde, M. E. N. The importance of the continuation of psychological pathology: a case report.. Revista Portuguesa De Medicina Geral E Familiar 2023;39(4):327-31.",50.0,YR,,F,Y,,,20231023,,MD,PT,PT,2023,Q4,Adult
230949651,23094965,16,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,"12,5/100 mg, bid",,,,,UNKNOWN,,,,,,BID,2023,Q4,Initial insomnia,,2023,Q4,1,I,20220101.0,20231012.0,20231023,20231023,EXP,,PT-ROCHE-3440736,ROCHE,"Canha F, Pitta, R., and Gil Conde, M. E. N. The importance of the continuation of psychological pathology: a case report.. Revista Portuguesa De Medicina Geral E Familiar 2023;39(4):327-31.",50.0,YR,,F,Y,,,20231023,,MD,PT,PT,2023,Q4,Adult
230949651,23094965,16,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,"12,5/100 mg, bid",,,,,UNKNOWN,,,,,,BID,2023,Q4,Anhedonia,,2023,Q4,1,I,20220101.0,20231012.0,20231023,20231023,EXP,,PT-ROCHE-3440736,ROCHE,"Canha F, Pitta, R., and Gil Conde, M. E. N. The importance of the continuation of psychological pathology: a case report.. Revista Portuguesa De Medicina Geral E Familiar 2023;39(4):327-31.",50.0,YR,,F,Y,,,20231023,,MD,PT,PT,2023,Q4,Adult
230949651,23094965,16,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,"12,5/100 mg, bid",,,,,UNKNOWN,,,,,,BID,2023,Q4,Depressed mood,,2023,Q4,1,I,20220101.0,20231012.0,20231023,20231023,EXP,,PT-ROCHE-3440736,ROCHE,"Canha F, Pitta, R., and Gil Conde, M. E. N. The importance of the continuation of psychological pathology: a case report.. Revista Portuguesa De Medicina Geral E Familiar 2023;39(4):327-31.",50.0,YR,,F,Y,,,20231023,,MD,PT,PT,2023,Q4,Adult
230949651,23094965,16,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,"12,5/100 mg, bid",,,,,UNKNOWN,,,,,,BID,2023,Q4,Somnolence,,2023,Q4,1,I,20220101.0,20231012.0,20231023,20231023,EXP,,PT-ROCHE-3440736,ROCHE,"Canha F, Pitta, R., and Gil Conde, M. E. N. The importance of the continuation of psychological pathology: a case report.. Revista Portuguesa De Medicina Geral E Familiar 2023;39(4):327-31.",50.0,YR,,F,Y,,,20231023,,MD,PT,PT,2023,Q4,Adult
230949651,23094965,16,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,"12,5/100 mg, bid",,,,,UNKNOWN,,,,,,BID,2023,Q4,"Hallucination, auditory",,2023,Q4,1,I,20220101.0,20231012.0,20231023,20231023,EXP,,PT-ROCHE-3440736,ROCHE,"Canha F, Pitta, R., and Gil Conde, M. E. N. The importance of the continuation of psychological pathology: a case report.. Revista Portuguesa De Medicina Geral E Familiar 2023;39(4):327-31.",50.0,YR,,F,Y,,,20231023,,MD,PT,PT,2023,Q4,Adult
230949651,23094965,16,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,"12,5/100 mg, bid",,,,,UNKNOWN,,,,,,BID,2023,Q4,Accidental overdose,,2023,Q4,1,I,20220101.0,20231012.0,20231023,20231023,EXP,,PT-ROCHE-3440736,ROCHE,"Canha F, Pitta, R., and Gil Conde, M. E. N. The importance of the continuation of psychological pathology: a case report.. Revista Portuguesa De Medicina Geral E Familiar 2023;39(4):327-31.",50.0,YR,,F,Y,,,20231023,,MD,PT,PT,2023,Q4,Adult
230949651,23094965,16,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,"12,5/100 mg, bid",,,,,UNKNOWN,,,,,,BID,2023,Q4,Treatment noncompliance,,2023,Q4,1,I,20220101.0,20231012.0,20231023,20231023,EXP,,PT-ROCHE-3440736,ROCHE,"Canha F, Pitta, R., and Gil Conde, M. E. N. The importance of the continuation of psychological pathology: a case report.. Revista Portuguesa De Medicina Geral E Familiar 2023;39(4):327-31.",50.0,YR,,F,Y,,,20231023,,MD,PT,PT,2023,Q4,Adult
230949651,23094965,16,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,"12,5/100 mg, bid",,,,,UNKNOWN,,,,,,BID,2023,Q4,Agitation,,2023,Q4,1,I,20220101.0,20231012.0,20231023,20231023,EXP,,PT-ROCHE-3440736,ROCHE,"Canha F, Pitta, R., and Gil Conde, M. E. N. The importance of the continuation of psychological pathology: a case report.. Revista Portuguesa De Medicina Geral E Familiar 2023;39(4):327-31.",50.0,YR,,F,Y,,,20231023,,MD,PT,PT,2023,Q4,Adult
230949651,23094965,16,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,"12,5/100 mg, bid",,,,,UNKNOWN,,,,,,BID,2023,Q4,Weight decreased,,2023,Q4,1,I,20220101.0,20231012.0,20231023,20231023,EXP,,PT-ROCHE-3440736,ROCHE,"Canha F, Pitta, R., and Gil Conde, M. E. N. The importance of the continuation of psychological pathology: a case report.. Revista Portuguesa De Medicina Geral E Familiar 2023;39(4):327-31.",50.0,YR,,F,Y,,,20231023,,MD,PT,PT,2023,Q4,Adult
230949651,23094965,16,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,"12,5/100 mg, bid",,,,,UNKNOWN,,,,,,BID,2023,Q4,Somnolence,,2023,Q4,1,I,20220101.0,20231012.0,20231023,20231023,EXP,,PT-ROCHE-3440736,ROCHE,"Canha F, Pitta, R., and Gil Conde, M. E. N. The importance of the continuation of psychological pathology: a case report.. Revista Portuguesa De Medicina Geral E Familiar 2023;39(4):327-31.",50.0,YR,,F,Y,,,20231023,,MD,PT,PT,2023,Q4,Adult
230949651,23094965,16,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,"12,5/100 mg, bid",,,,,UNKNOWN,,,,,,BID,2023,Q4,Suicidal ideation,,2023,Q4,1,I,20220101.0,20231012.0,20231023,20231023,EXP,,PT-ROCHE-3440736,ROCHE,"Canha F, Pitta, R., and Gil Conde, M. E. N. The importance of the continuation of psychological pathology: a case report.. Revista Portuguesa De Medicina Geral E Familiar 2023;39(4):327-31.",50.0,YR,,F,Y,,,20231023,,MD,PT,PT,2023,Q4,Adult
230951961,23095196,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,25.0,MG,,QD,2023,Q4,Diabetic ketoacidosis,,2023,Q4,1,I,20220912.0,,20231019,20231019,DIR,FDA-CDER-CTU-2023-77194,,FDA-CTU,,41.0,YR,,M,N,233.0,KG,20221119,N,PH,US,,2023,Q4,Adult
230951961,23095196,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,25.0,MG,,QD,2023,Q4,Gastroenteritis viral,,2023,Q4,1,I,20220912.0,,20231019,20231019,DIR,FDA-CDER-CTU-2023-77194,,FDA-CTU,,41.0,YR,,M,N,233.0,KG,20221119,N,PH,US,,2023,Q4,Adult
230951961,23095196,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,25.0,MG,,QD,2023,Q4,Therapy cessation,,2023,Q4,1,I,20220912.0,,20231019,20231019,DIR,FDA-CDER-CTU-2023-77194,,FDA-CTU,,41.0,YR,,M,N,233.0,KG,20221119,N,PH,US,,2023,Q4,Adult
230951961,23095196,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,25.0,MG,,QD,2023,Q4,Diarrhoea,,2023,Q4,1,I,20220912.0,,20231019,20231019,DIR,FDA-CDER-CTU-2023-77194,,FDA-CTU,,41.0,YR,,M,N,233.0,KG,20221119,N,PH,US,,2023,Q4,Adult
230951961,23095196,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,25.0,MG,,QD,2023,Q4,Fatigue,,2023,Q4,1,I,20220912.0,,20231019,20231019,DIR,FDA-CDER-CTU-2023-77194,,FDA-CTU,,41.0,YR,,M,N,233.0,KG,20221119,N,PH,US,,2023,Q4,Adult
230951961,23095196,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,25.0,MG,,QD,2023,Q4,Blood potassium decreased,,2023,Q4,1,I,20220912.0,,20231019,20231019,DIR,FDA-CDER-CTU-2023-77194,,FDA-CTU,,41.0,YR,,M,N,233.0,KG,20221119,N,PH,US,,2023,Q4,Adult
230951961,23095196,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,25.0,MG,,QD,2023,Q4,Vomiting,,2023,Q4,1,I,20220912.0,,20231019,20231019,DIR,FDA-CDER-CTU-2023-77194,,FDA-CTU,,41.0,YR,,M,N,233.0,KG,20221119,N,PH,US,,2023,Q4,Adult
230956361,23095636,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2023,Q4,Coronary artery disease,,2023,Q4,1,I,20221121.0,,20231019,20231019,DIR,FDA-CDER-CTU-2023-77343,,FDA-CTU,,60.0,YR,,M,N,110.0,KG,20230217,N,PH,US,,2023,Q4,Adult
230956361,23095636,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2023,Q4,Hypertension,,2023,Q4,1,I,20221121.0,,20231019,20231019,DIR,FDA-CDER-CTU-2023-77343,,FDA-CTU,,60.0,YR,,M,N,110.0,KG,20230217,N,PH,US,,2023,Q4,Adult
230956361,23095636,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2023,Q4,Seizure,,2023,Q4,1,I,20221121.0,,20231019,20231019,DIR,FDA-CDER-CTU-2023-77343,,FDA-CTU,,60.0,YR,,M,N,110.0,KG,20230217,N,PH,US,,2023,Q4,Adult
230956361,23095636,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2023,Q4,Hyperlipidaemia,,2023,Q4,1,I,20221121.0,,20231019,20231019,DIR,FDA-CDER-CTU-2023-77343,,FDA-CTU,,60.0,YR,,M,N,110.0,KG,20230217,N,PH,US,,2023,Q4,Adult
230956361,23095636,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2023,Q4,Hypercalcaemia,,2023,Q4,1,I,20221121.0,,20231019,20231019,DIR,FDA-CDER-CTU-2023-77343,,FDA-CTU,,60.0,YR,,M,N,110.0,KG,20230217,N,PH,US,,2023,Q4,Adult
230956361,23095636,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2023,Q4,Bipolar disorder,,2023,Q4,1,I,20221121.0,,20231019,20231019,DIR,FDA-CDER-CTU-2023-77343,,FDA-CTU,,60.0,YR,,M,N,110.0,KG,20230217,N,PH,US,,2023,Q4,Adult
230956361,23095636,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2023,Q4,Diabetic ketoacidosis,,2023,Q4,1,I,20221121.0,,20231019,20231019,DIR,FDA-CDER-CTU-2023-77343,,FDA-CTU,,60.0,YR,,M,N,110.0,KG,20230217,N,PH,US,,2023,Q4,Adult
230956361,23095636,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2023,Q4,Acute kidney injury,,2023,Q4,1,I,20221121.0,,20231019,20231019,DIR,FDA-CDER-CTU-2023-77343,,FDA-CTU,,60.0,YR,,M,N,110.0,KG,20230217,N,PH,US,,2023,Q4,Adult
230956361,23095636,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2023,Q4,Flank pain,,2023,Q4,1,I,20221121.0,,20231019,20231019,DIR,FDA-CDER-CTU-2023-77343,,FDA-CTU,,60.0,YR,,M,N,110.0,KG,20230217,N,PH,US,,2023,Q4,Adult
230956361,23095636,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2023,Q4,Diabetes mellitus inadequate control,,2023,Q4,1,I,20221121.0,,20231019,20231019,DIR,FDA-CDER-CTU-2023-77343,,FDA-CTU,,60.0,YR,,M,N,110.0,KG,20230217,N,PH,US,,2023,Q4,Adult
230961461,23096146,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,10.0,MG,,QD,2023,Q4,Skin discolouration,,2023,Q4,1,I,20221121.0,,20231019,20231019,DIR,FDA-CDER-CTU-2023-77398,,FDA-CTU,,67.0,YR,,M,N,98.8,KG,20230320,N,PH,US,,2023,Q4,Elderly
230961461,23096146,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,10.0,MG,,QD,2023,Q4,Rash,,2023,Q4,1,I,20221121.0,,20231019,20231019,DIR,FDA-CDER-CTU-2023-77398,,FDA-CTU,,67.0,YR,,M,N,98.8,KG,20230320,N,PH,US,,2023,Q4,Elderly
230961461,23096146,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,10.0,MG,,QD,2023,Q4,Amputation,,2023,Q4,1,I,20221121.0,,20231019,20231019,DIR,FDA-CDER-CTU-2023-77398,,FDA-CTU,,67.0,YR,,M,N,98.8,KG,20230320,N,PH,US,,2023,Q4,Elderly
230961461,23096146,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,10.0,MG,,QD,2023,Q4,Necrotising fasciitis,,2023,Q4,1,I,20221121.0,,20231019,20231019,DIR,FDA-CDER-CTU-2023-77398,,FDA-CTU,,67.0,YR,,M,N,98.8,KG,20230320,N,PH,US,,2023,Q4,Elderly
230973101,23097310,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q4,Drug ineffective,,2023,Q4,1,I,,20231012.0,20231023,20231023,EXP,CA-MHPD-E2B_06480523,CA-Accord-385031,ACCORD,,57.0,YR,A,F,Y,,,20231023,,MD,CA,CA,2023,Q4,Adult
230973101,23097310,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q4,Pulmonary toxicity,,2023,Q4,1,I,,20231012.0,20231023,20231023,EXP,CA-MHPD-E2B_06480523,CA-Accord-385031,ACCORD,,57.0,YR,A,F,Y,,,20231023,,MD,CA,CA,2023,Q4,Adult
230992662,23099266,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Unknown,,204629.0,25.0,MG,,QD,2023,Q4,Hypotension,,2023,Q4,2,F,20231001.0,20231110.0,20231024,20231114,EXP,DE-CADRBFARM-2023323316,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-268639",BOEHRINGER INGELHEIM,,53.0,YR,A,M,Y,76.0,KG,20231114,,MD,DE,DE,2023,Q4,Adult
230992662,23099266,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Unknown,,204629.0,25.0,MG,,QD,2023,Q4,Metabolic acidosis,,2023,Q4,2,F,20231001.0,20231110.0,20231024,20231114,EXP,DE-CADRBFARM-2023323316,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-268639",BOEHRINGER INGELHEIM,,53.0,YR,A,M,Y,76.0,KG,20231114,,MD,DE,DE,2023,Q4,Adult
230992662,23099266,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Unknown,,204629.0,25.0,MG,,QD,2023,Q4,Tachypnoea,,2023,Q4,2,F,20231001.0,20231110.0,20231024,20231114,EXP,DE-CADRBFARM-2023323316,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-268639",BOEHRINGER INGELHEIM,,53.0,YR,A,M,Y,76.0,KG,20231114,,MD,DE,DE,2023,Q4,Adult
230992662,23099266,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Unknown,,204629.0,25.0,MG,,QD,2023,Q4,Tachycardia,,2023,Q4,2,F,20231001.0,20231110.0,20231024,20231114,EXP,DE-CADRBFARM-2023323316,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-268639",BOEHRINGER INGELHEIM,,53.0,YR,A,M,Y,76.0,KG,20231114,,MD,DE,DE,2023,Q4,Adult
230992662,23099266,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Unknown,,204629.0,25.0,MG,,QD,2023,Q4,Ketoacidosis,,2023,Q4,2,F,20231001.0,20231110.0,20231024,20231114,EXP,DE-CADRBFARM-2023323316,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-268639",BOEHRINGER INGELHEIM,,53.0,YR,A,M,Y,76.0,KG,20231114,,MD,DE,DE,2023,Q4,Adult
230992662,23099266,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Unknown,,204629.0,25.0,MG,,QD,2023,Q4,Nausea,,2023,Q4,2,F,20231001.0,20231110.0,20231024,20231114,EXP,DE-CADRBFARM-2023323316,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-268639",BOEHRINGER INGELHEIM,,53.0,YR,A,M,Y,76.0,KG,20231114,,MD,DE,DE,2023,Q4,Adult
230992662,23099266,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Unknown,,204629.0,25.0,MG,,QD,2023,Q4,Confusional state,,2023,Q4,2,F,20231001.0,20231110.0,20231024,20231114,EXP,DE-CADRBFARM-2023323316,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-268639",BOEHRINGER INGELHEIM,,53.0,YR,A,M,Y,76.0,KG,20231114,,MD,DE,DE,2023,Q4,Adult
230992662,23099266,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Unknown,,204629.0,25.0,MG,,QD,2023,Q4,Acute respiratory failure,,2023,Q4,2,F,20231001.0,20231110.0,20231024,20231114,EXP,DE-CADRBFARM-2023323316,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-268639",BOEHRINGER INGELHEIM,,53.0,YR,A,M,Y,76.0,KG,20231114,,MD,DE,DE,2023,Q4,Adult
230993871,23099387,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,,,2023,Q4,Urinary tract infection,,2023,Q4,1,I,,20231020.0,20231024,20231024,EXP,,"CO-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-268560",BOEHRINGER INGELHEIM,,66.0,YR,E,M,Y,,,20231024,,MD,CO,CO,2023,Q4,Elderly
230993871,23099387,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,,,2023,Q4,Prostatitis,,2023,Q4,1,I,,20231020.0,20231024,20231024,EXP,,"CO-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-268560",BOEHRINGER INGELHEIM,,66.0,YR,E,M,Y,,,20231024,,MD,CO,CO,2023,Q4,Elderly
230993871,23099387,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,204629.0,,,,,2023,Q4,Urinary tract infection,,2023,Q4,1,I,,20231020.0,20231024,20231024,EXP,,"CO-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-268560",BOEHRINGER INGELHEIM,,66.0,YR,E,M,Y,,,20231024,,MD,CO,CO,2023,Q4,Elderly
230993871,23099387,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,204629.0,,,,,2023,Q4,Prostatitis,,2023,Q4,1,I,,20231020.0,20231024,20231024,EXP,,"CO-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-268560",BOEHRINGER INGELHEIM,,66.0,YR,E,M,Y,,,20231024,,MD,CO,CO,2023,Q4,Elderly
230998271,23099827,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,12.5,MG,,QD,2023,Q4,Hypovolaemia,,2023,Q4,1,I,20230310.0,,20231020,20231020,DIR,FDA-CDER-CTU-2023-77743,,FDA-CTU,,87.0,YR,,M,N,,,20230322,N,PH,US,,2023,Q4,Elderly
230998271,23099827,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,12.5,MG,,QD,2023,Q4,Atrial fibrillation,,2023,Q4,1,I,20230310.0,,20231020,20231020,DIR,FDA-CDER-CTU-2023-77743,,FDA-CTU,,87.0,YR,,M,N,,,20230322,N,PH,US,,2023,Q4,Elderly
230998271,23099827,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,12.5,MG,,QD,2023,Q4,Kidney infection,,2023,Q4,1,I,20230310.0,,20231020,20231020,DIR,FDA-CDER-CTU-2023-77743,,FDA-CTU,,87.0,YR,,M,N,,,20230322,N,PH,US,,2023,Q4,Elderly
230998271,23099827,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,12.5,MG,,QD,2023,Q4,Therapy cessation,,2023,Q4,1,I,20230310.0,,20231020,20231020,DIR,FDA-CDER-CTU-2023-77743,,FDA-CTU,,87.0,YR,,M,N,,,20230322,N,PH,US,,2023,Q4,Elderly
230998301,23099830,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,12.5,MG,,QD,2023,Q4,Diabetic ketoacidosis,,2023,Q4,1,I,20221203.0,,20231020,20231020,DIR,FDA-CDER-CTU-2023-77654,,FDA-CTU,,58.0,YR,,M,N,114.0,KG,20230217,N,PH,US,,2023,Q4,Adult
230998981,23099898,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Euglycaemic diabetic ketoacidosis,,2023,Q4,1,I,20230228.0,,20231020,20231020,DIR,FDA-CDER-CTU-2023-77922,,FDA-CTU,,42.0,YR,,M,N,,,20230313,N,PH,US,,2023,Q4,Adult
230999001,23099900,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2023,Q4,Euglycaemic diabetic ketoacidosis,,2023,Q4,1,I,20230130.0,,20231020,20231020,DIR,FDA-CDER-CTU-2023-77669,,FDA-CTU,,73.0,YR,,,N,112.0,KG,20230310,N,PH,US,,2023,Q4,Elderly
230999021,23099902,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2023,Q4,Acidosis,,2023,Q4,1,I,20230220.0,,20231020,20231020,DIR,FDA-CDER-CTU-2023-77907,,FDA-CTU,,60.0,YR,,M,N,,,20230313,N,PH,US,,2023,Q4,Adult
230999051,23099905,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,OTHER FREQUENCY : AM;?,,,Y,,,,,10.0,MG,,999,2023,Q4,Pancreatitis,,2023,Q4,1,I,20230127.0,,20231020,20231020,DIR,FDA-CDER-CTU-2023-77719,,FDA-CTU,,74.0,YR,,M,N,,,20230320,N,PH,US,,2023,Q4,Elderly
231002491,23100249,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Insomnia,,2023,Q4,1,I,,20230930.0,20231024,20231024,PER,,US-BAYER-2023A138975,BAYER,,68.0,YR,E,F,Y,132.0,KG,20231024,,CN,US,US,2023,Q4,Elderly
231004151,23100415,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,OTHER FREQUENCY : AM;?,,,Y,,,,,25.0,MG,,999,2023,Q4,Diabetic ketoacidosis,,2023,Q4,1,I,20221010.0,,20231020,20231020,DIR,FDA-CDER-CTU-2023-77697,,FDA-CTU,,65.0,YR,,M,N,,,20230217,N,PH,US,,2023,Q4,Elderly
231008531,23100853,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Diabetic ketoacidosis,,2023,Q4,1,I,20230305.0,,20231021,20231021,DIR,FDA-CDER-CTU-2023-78008,,FDA-CTU,,71.0,YR,,M,N,,,20230330,N,PH,US,,2023,Q4,Elderly
231008541,23100854,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Pain,,2023,Q4,1,I,20221231.0,,20231021,20231021,DIR,FDA-CDER-CTU-2023-77985,,FDA-CTU,,54.0,YR,,M,N,,,20230215,N,PH,US,,2023,Q4,Adult
231008541,23100854,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Influenza,,2023,Q4,1,I,20221231.0,,20231021,20231021,DIR,FDA-CDER-CTU-2023-77985,,FDA-CTU,,54.0,YR,,M,N,,,20230215,N,PH,US,,2023,Q4,Adult
231008541,23100854,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Pancreatitis acute,,2023,Q4,1,I,20221231.0,,20231021,20231021,DIR,FDA-CDER-CTU-2023-77985,,FDA-CTU,,54.0,YR,,M,N,,,20230215,N,PH,US,,2023,Q4,Adult
231008541,23100854,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Euglycaemic diabetic ketoacidosis,,2023,Q4,1,I,20221231.0,,20231021,20231021,DIR,FDA-CDER-CTU-2023-77985,,FDA-CTU,,54.0,YR,,M,N,,,20230215,N,PH,US,,2023,Q4,Adult
231008551,23100855,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : AM?,,,Y,,,,,25.0,MG,,PC,2023,Q4,Euglycaemic diabetic ketoacidosis,,2023,Q4,1,I,20220823.0,,20231021,20231021,DIR,FDA-CDER-CTU-2023-78013,,FDA-CTU,,72.0,YR,,M,N,80.0,KG,20221021,N,PH,US,,2023,Q4,Elderly
231026401,23102640,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,UNKNOWN,,,,,,,2023,Q4,Neoplasm progression,,2023,Q4,1,I,,20231011.0,20231025,20231025,EXP,,US-drreddys-LIT/USA/23/0180398,DR REDDYS,"Ghotra M, Parsa K, Dolan B, Lim S, Kumar S, Berger N, Rapoport F. (Not so) diabetic ketoacidosis. Chest. 2023;164(4):A2892-3. doi:10.1016/j.chest.2023.07.1899",52.0,YR,A,F,Y,,,20231025,,HP,US,US,2023,Q4,Adult
231026401,23102640,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,UNKNOWN,,,,,,,2023,Q4,Drug ineffective for unapproved indication,,2023,Q4,1,I,,20231011.0,20231025,20231025,EXP,,US-drreddys-LIT/USA/23/0180398,DR REDDYS,"Ghotra M, Parsa K, Dolan B, Lim S, Kumar S, Berger N, Rapoport F. (Not so) diabetic ketoacidosis. Chest. 2023;164(4):A2892-3. doi:10.1016/j.chest.2023.07.1899",52.0,YR,A,F,Y,,,20231025,,HP,US,US,2023,Q4,Adult
231026401,23102640,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,UNKNOWN,,,,,,,2023,Q4,Metastases to lung,,2023,Q4,1,I,,20231011.0,20231025,20231025,EXP,,US-drreddys-LIT/USA/23/0180398,DR REDDYS,"Ghotra M, Parsa K, Dolan B, Lim S, Kumar S, Berger N, Rapoport F. (Not so) diabetic ketoacidosis. Chest. 2023;164(4):A2892-3. doi:10.1016/j.chest.2023.07.1899",52.0,YR,A,F,Y,,,20231025,,HP,US,US,2023,Q4,Adult
231032091,23103209,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,Frequency : Daily;?,,,,,,,,,,Tablet,QD,2023,Q4,Fatigue,,2023,Q4,1,I,20230424.0,,20231022,20231022,DIR,FDA-CDER-CTU-2023-78259,,FDA-CTU,,63.0,YR,,M,N,116.0,KG,20230425,N,PH,US,,2023,Q4,Adult
231032091,23103209,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,Frequency : Daily;?,,,,,,,,,,Tablet,QD,2023,Q4,Sedation,,2023,Q4,1,I,20230424.0,,20231022,20231022,DIR,FDA-CDER-CTU-2023-78259,,FDA-CTU,,63.0,YR,,M,N,116.0,KG,20230425,N,PH,US,,2023,Q4,Adult
231032101,23103210,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Chills,,2023,Q4,1,I,20230418.0,,20231022,20231022,DIR,FDA-CDER-CTU-2023-78251,,FDA-CTU,,68.0,YR,,M,N,,,20230419,N,PH,US,,2023,Q4,Elderly
231032101,23103210,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Flank pain,,2023,Q4,1,I,20230418.0,,20231022,20231022,DIR,FDA-CDER-CTU-2023-78251,,FDA-CTU,,68.0,YR,,M,N,,,20230419,N,PH,US,,2023,Q4,Elderly
231032101,23103210,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Pain,,2023,Q4,1,I,20230418.0,,20231022,20231022,DIR,FDA-CDER-CTU-2023-78251,,FDA-CTU,,68.0,YR,,M,N,,,20230419,N,PH,US,,2023,Q4,Elderly
231032101,23103210,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Urosepsis,,2023,Q4,1,I,20230418.0,,20231022,20231022,DIR,FDA-CDER-CTU-2023-78251,,FDA-CTU,,68.0,YR,,M,N,,,20230419,N,PH,US,,2023,Q4,Elderly
231032101,23103210,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Acute kidney injury,,2023,Q4,1,I,20230418.0,,20231022,20231022,DIR,FDA-CDER-CTU-2023-78251,,FDA-CTU,,68.0,YR,,M,N,,,20230419,N,PH,US,,2023,Q4,Elderly
231032101,23103210,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Asthenia,,2023,Q4,1,I,20230418.0,,20231022,20231022,DIR,FDA-CDER-CTU-2023-78251,,FDA-CTU,,68.0,YR,,M,N,,,20230419,N,PH,US,,2023,Q4,Elderly
231032101,23103210,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Multiple allergies,,2023,Q4,1,I,20230418.0,,20231022,20231022,DIR,FDA-CDER-CTU-2023-78251,,FDA-CTU,,68.0,YR,,M,N,,,20230419,N,PH,US,,2023,Q4,Elderly
231032101,23103210,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Condition aggravated,,2023,Q4,1,I,20230418.0,,20231022,20231022,DIR,FDA-CDER-CTU-2023-78251,,FDA-CTU,,68.0,YR,,M,N,,,20230419,N,PH,US,,2023,Q4,Elderly
231032101,23103210,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Cough,,2023,Q4,1,I,20230418.0,,20231022,20231022,DIR,FDA-CDER-CTU-2023-78251,,FDA-CTU,,68.0,YR,,M,N,,,20230419,N,PH,US,,2023,Q4,Elderly
231032111,23103211,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2023,Q4,Ketoacidosis,,2023,Q4,1,I,20230319.0,,20231022,20231022,DIR,FDA-CDER-CTU-2023-78261,,FDA-CTU,,75.0,YR,,M,N,,,20230425,N,PH,US,,2023,Q4,Elderly
231032731,23103273,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2023,Q4,Pyrexia,,2023,Q4,1,I,20220927.0,,20231022,20231022,DIR,FDA-CDER-CTU-2023-78137,,FDA-CTU,,71.0,YR,,M,N,62.0,KG,20221024,N,PH,US,,2023,Q4,Elderly
231032731,23103273,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2023,Q4,Fournier's gangrene,,2023,Q4,1,I,20220927.0,,20231022,20231022,DIR,FDA-CDER-CTU-2023-78137,,FDA-CTU,,71.0,YR,,M,N,62.0,KG,20221024,N,PH,US,,2023,Q4,Elderly
231032731,23103273,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2023,Q4,Blood creatinine increased,,2023,Q4,1,I,20220927.0,,20231022,20231022,DIR,FDA-CDER-CTU-2023-78137,,FDA-CTU,,71.0,YR,,M,N,62.0,KG,20221024,N,PH,US,,2023,Q4,Elderly
231032731,23103273,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2023,Q4,Tachycardia,,2023,Q4,1,I,20220927.0,,20231022,20231022,DIR,FDA-CDER-CTU-2023-78137,,FDA-CTU,,71.0,YR,,M,N,62.0,KG,20221024,N,PH,US,,2023,Q4,Elderly
231032731,23103273,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2023,Q4,Acute kidney injury,,2023,Q4,1,I,20220927.0,,20231022,20231022,DIR,FDA-CDER-CTU-2023-78137,,FDA-CTU,,71.0,YR,,M,N,62.0,KG,20221024,N,PH,US,,2023,Q4,Elderly
231032831,23103283,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Diabetic ketoacidosis,,2023,Q4,1,I,20230314.0,,20231022,20231022,DIR,FDA-CDER-CTU-2023-78211,,FDA-CTU,,63.0,YR,,M,N,87.0,KG,20230404,N,PH,US,,2023,Q4,Adult
231032831,23103283,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Hyperglycaemia,,2023,Q4,1,I,20230314.0,,20231022,20231022,DIR,FDA-CDER-CTU-2023-78211,,FDA-CTU,,63.0,YR,,M,N,87.0,KG,20230404,N,PH,US,,2023,Q4,Adult
231032831,23103283,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Therapy cessation,,2023,Q4,1,I,20230314.0,,20231022,20231022,DIR,FDA-CDER-CTU-2023-78211,,FDA-CTU,,63.0,YR,,M,N,87.0,KG,20230404,N,PH,US,,2023,Q4,Adult
231032831,23103283,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Vomiting,,2023,Q4,1,I,20230314.0,,20231022,20231022,DIR,FDA-CDER-CTU-2023-78211,,FDA-CTU,,63.0,YR,,M,N,87.0,KG,20230404,N,PH,US,,2023,Q4,Adult
231052461,23105246,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,12.5,MG,,QD,2023,Q4,Pancreatitis necrotising,,2023,Q4,1,I,20230205.0,,20231023,20231023,DIR,FDA-CDER-CTU-2023-78450,,FDA-CTU,,74.0,YR,,M,N,94.8,KG,20230505,N,PH,US,,2023,Q4,Elderly
231052461,23105246,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,12.5,MG,,QD,2023,Q4,Euglycaemic diabetic ketoacidosis,,2023,Q4,1,I,20230205.0,,20231023,20231023,DIR,FDA-CDER-CTU-2023-78450,,FDA-CTU,,74.0,YR,,M,N,94.8,KG,20230505,N,PH,US,,2023,Q4,Elderly
231052461,23105246,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,12.5,MG,,QD,2023,Q4,Bacteraemia,,2023,Q4,1,I,20230205.0,,20231023,20231023,DIR,FDA-CDER-CTU-2023-78450,,FDA-CTU,,74.0,YR,,M,N,94.8,KG,20230505,N,PH,US,,2023,Q4,Elderly
231055492,23105549,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,,,,,2023,Q4,Overdose,,2023,Q4,2,F,,20231029.0,20231025,20231108,EXP,,US-TEVA-2023-US-2937866,TEVA,,77.0,YR,E,M,Y,,,20231108,,HP,US,US,2023,Q4,Elderly
231055492,23105549,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,,,,,2023,Q4,BRASH syndrome,,2023,Q4,2,F,,20231029.0,20231025,20231108,EXP,,US-TEVA-2023-US-2937866,TEVA,,77.0,YR,E,M,Y,,,20231108,,HP,US,US,2023,Q4,Elderly
231057691,23105769,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,12.5,MG,,QD,2023,Q4,Haemorrhage,,2023,Q4,1,I,20230121.0,,20231024,20231024,DIR,FDA-CDER-CTU-2023-78553,,FDA-CTU,,59.0,YR,,M,N,155.0,KG,20230420,N,PH,US,,2023,Q4,Adult
231057691,23105769,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,12.5,MG,,QD,2023,Q4,Urinary tract infection,,2023,Q4,1,I,20230121.0,,20231024,20231024,DIR,FDA-CDER-CTU-2023-78553,,FDA-CTU,,59.0,YR,,M,N,155.0,KG,20230420,N,PH,US,,2023,Q4,Adult
231057691,23105769,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,12.5,MG,,QD,2023,Q4,Angina pectoris,,2023,Q4,1,I,20230121.0,,20231024,20231024,DIR,FDA-CDER-CTU-2023-78553,,FDA-CTU,,59.0,YR,,M,N,155.0,KG,20230420,N,PH,US,,2023,Q4,Adult
231057701,23105770,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,12.5,MG,,QD,2023,Q4,Pollakiuria,,2023,Q4,1,I,20220419.0,,20231024,20231024,DIR,FDA-CDER-CTU-2023-78575,,FDA-CTU,,69.0,YR,,M,N,,,20220719,N,PH,US,,2023,Q4,Elderly
231057921,23105792,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,12.5,MG,,QD,2023,Q4,Anal incontinence,,2023,Q4,1,I,20220515.0,,20231024,20231024,DIR,FDA-CDER-CTU-2023-78544,,FDA-CTU,,78.0,YR,,M,N,96.1,KG,20230118,N,PH,US,,2023,Q4,Elderly
231057921,23105792,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,12.5,MG,,QD,2023,Q4,Diarrhoea,,2023,Q4,1,I,20220515.0,,20231024,20231024,DIR,FDA-CDER-CTU-2023-78544,,FDA-CTU,,78.0,YR,,M,N,96.1,KG,20230118,N,PH,US,,2023,Q4,Elderly
231057921,23105792,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,12.5,MG,,QD,2023,Q4,Urinary incontinence,,2023,Q4,1,I,20220515.0,,20231024,20231024,DIR,FDA-CDER-CTU-2023-78544,,FDA-CTU,,78.0,YR,,M,N,96.1,KG,20230118,N,PH,US,,2023,Q4,Elderly
231057921,23105792,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,12.5,MG,,QD,2023,Q4,Therapy cessation,,2023,Q4,1,I,20220515.0,,20231024,20231024,DIR,FDA-CDER-CTU-2023-78544,,FDA-CTU,,78.0,YR,,M,N,96.1,KG,20230118,N,PH,US,,2023,Q4,Elderly
231063571,23106357,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q4,Pneumonia,,2023,Q4,1,I,20230812.0,20231016.0,20231025,20231025,EXP,,DE-SANDOZ INC.-SDZ2023DE046324,SANDOZ,,73.0,YR,,M,Y,73.0,KG,20231025,,MD,DE,DE,2023,Q4,Elderly
231063571,23106357,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q4,Off label use,,2023,Q4,1,I,20230812.0,20231016.0,20231025,20231025,EXP,,DE-SANDOZ INC.-SDZ2023DE046324,SANDOZ,,73.0,YR,,M,Y,73.0,KG,20231025,,MD,DE,DE,2023,Q4,Elderly
231063571,23106357,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q4,Cardiac failure,,2023,Q4,1,I,20230812.0,20231016.0,20231025,20231025,EXP,,DE-SANDOZ INC.-SDZ2023DE046324,SANDOZ,,73.0,YR,,M,Y,73.0,KG,20231025,,MD,DE,DE,2023,Q4,Elderly
231067212,23106721,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q4,Lower respiratory tract infection,,2023,Q4,2,F,20230512.0,20231202.0,20231026,20231218,EXP,FR-EMA-20231001-AUTODUP-1696187376665,FR-Accord-386006,ACCORD,,75.0,YR,E,F,Y,76.0,KG,20231214,,MD,FR,FR,2023,Q4,Elderly
231067212,23106721,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q4,Abdominal pain upper,,2023,Q4,2,F,20230512.0,20231202.0,20231026,20231218,EXP,FR-EMA-20231001-AUTODUP-1696187376665,FR-Accord-386006,ACCORD,,75.0,YR,E,F,Y,76.0,KG,20231214,,MD,FR,FR,2023,Q4,Elderly
231067212,23106721,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q4,Cough,,2023,Q4,2,F,20230512.0,20231202.0,20231026,20231218,EXP,FR-EMA-20231001-AUTODUP-1696187376665,FR-Accord-386006,ACCORD,,75.0,YR,E,F,Y,76.0,KG,20231214,,MD,FR,FR,2023,Q4,Elderly
231067212,23106721,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q4,COVID-19,,2023,Q4,2,F,20230512.0,20231202.0,20231026,20231218,EXP,FR-EMA-20231001-AUTODUP-1696187376665,FR-Accord-386006,ACCORD,,75.0,YR,E,F,Y,76.0,KG,20231214,,MD,FR,FR,2023,Q4,Elderly
231067212,23106721,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q4,Chills,,2023,Q4,2,F,20230512.0,20231202.0,20231026,20231218,EXP,FR-EMA-20231001-AUTODUP-1696187376665,FR-Accord-386006,ACCORD,,75.0,YR,E,F,Y,76.0,KG,20231214,,MD,FR,FR,2023,Q4,Elderly
231067212,23106721,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q4,Cardiac failure,,2023,Q4,2,F,20230512.0,20231202.0,20231026,20231218,EXP,FR-EMA-20231001-AUTODUP-1696187376665,FR-Accord-386006,ACCORD,,75.0,YR,E,F,Y,76.0,KG,20231214,,MD,FR,FR,2023,Q4,Elderly
231067212,23106721,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q4,C-reactive protein increased,,2023,Q4,2,F,20230512.0,20231202.0,20231026,20231218,EXP,FR-EMA-20231001-AUTODUP-1696187376665,FR-Accord-386006,ACCORD,,75.0,YR,E,F,Y,76.0,KG,20231214,,MD,FR,FR,2023,Q4,Elderly
231067212,23106721,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q4,Anaemia,,2023,Q4,2,F,20230512.0,20231202.0,20231026,20231218,EXP,FR-EMA-20231001-AUTODUP-1696187376665,FR-Accord-386006,ACCORD,,75.0,YR,E,F,Y,76.0,KG,20231214,,MD,FR,FR,2023,Q4,Elderly
231067212,23106721,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q4,Asthenia,,2023,Q4,2,F,20230512.0,20231202.0,20231026,20231218,EXP,FR-EMA-20231001-AUTODUP-1696187376665,FR-Accord-386006,ACCORD,,75.0,YR,E,F,Y,76.0,KG,20231214,,MD,FR,FR,2023,Q4,Elderly
231067212,23106721,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q4,Pneumonia,,2023,Q4,2,F,20230512.0,20231202.0,20231026,20231218,EXP,FR-EMA-20231001-AUTODUP-1696187376665,FR-Accord-386006,ACCORD,,75.0,YR,E,F,Y,76.0,KG,20231214,,MD,FR,FR,2023,Q4,Elderly
231087261,23108726,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Diabetic ketoacidosis,,2023,Q4,1,I,20230517.0,,20231024,20231024,DIR,FDA-CDER-CTU-2023-78728,,FDA-CTU,,63.0,YR,,F,N,46.0,KG,20230518,N,PH,US,,2023,Q4,Adult
231087501,23108750,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Sepsis,,2023,Q4,1,I,20230410.0,,20231024,20231024,DIR,FDA-CDER-CTU-2023-78697,,FDA-CTU,,83.0,YR,,M,N,,,20230510,N,PH,US,,2023,Q4,Elderly
231087501,23108750,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Urinary tract infection,,2023,Q4,1,I,20230410.0,,20231024,20231024,DIR,FDA-CDER-CTU-2023-78697,,FDA-CTU,,83.0,YR,,M,N,,,20230510,N,PH,US,,2023,Q4,Elderly
231087541,23108754,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,,,,QD,2023,Q4,Vomiting,,2023,Q4,1,I,20211028.0,,20231024,20231024,DIR,FDA-CDER-CTU-2023-78684,,FDA-CTU,,40.0,YR,,M,N,93.4,KG,20211220,N,PH,US,,2023,Q4,Adult
231087541,23108754,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,,,,QD,2023,Q4,Nausea,,2023,Q4,1,I,20211028.0,,20231024,20231024,DIR,FDA-CDER-CTU-2023-78684,,FDA-CTU,,40.0,YR,,M,N,93.4,KG,20211220,N,PH,US,,2023,Q4,Adult
231094421,23109442,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Euglycaemic diabetic ketoacidosis,,2023,Q4,1,I,20220709.0,,20231024,20231024,DIR,FDA-CDER-CTU-2023-78894,,FDA-CTU,,44.0,YR,,UNK,N,123.0,KG,20220918,N,HP,US,,2023,Q4,Adult
231094421,23109442,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Nausea,,2023,Q4,1,I,20220709.0,,20231024,20231024,DIR,FDA-CDER-CTU-2023-78894,,FDA-CTU,,44.0,YR,,UNK,N,123.0,KG,20220918,N,HP,US,,2023,Q4,Adult
231094421,23109442,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Diarrhoea,,2023,Q4,1,I,20220709.0,,20231024,20231024,DIR,FDA-CDER-CTU-2023-78894,,FDA-CTU,,44.0,YR,,UNK,N,123.0,KG,20220918,N,HP,US,,2023,Q4,Adult
231094421,23109442,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Wrong product administered,,2023,Q4,1,I,20220709.0,,20231024,20231024,DIR,FDA-CDER-CTU-2023-78894,,FDA-CTU,,44.0,YR,,UNK,N,123.0,KG,20220918,N,HP,US,,2023,Q4,Adult
231095901,23109590,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q4,Respiratory tract infection,,2023,Q4,1,I,,20231020.0,20231026,20231026,EXP,,"PT-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-268178",BOEHRINGER INGELHEIM,"PO 01 Cetoacidose diab?tica euglic?mica, a prop?sito de um caso cl?nico. 17? Reuni?o N?cleo de Estudos de Diabetes Mellitus. 2023 Oct;6-6.",74.0,YR,E,M,Y,,,20231026,,HP,PT,PT,2023,Q4,Elderly
231095901,23109590,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q4,Euglycaemic diabetic ketoacidosis,,2023,Q4,1,I,,20231020.0,20231026,20231026,EXP,,"PT-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-268178",BOEHRINGER INGELHEIM,"PO 01 Cetoacidose diab?tica euglic?mica, a prop?sito de um caso cl?nico. 17? Reuni?o N?cleo de Estudos de Diabetes Mellitus. 2023 Oct;6-6.",74.0,YR,E,M,Y,,,20231026,,HP,PT,PT,2023,Q4,Elderly
231103251,23110325,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Unknown,,2023,Q4,Cardiac failure,,2023,Q4,1,I,20230812.0,20231020.0,20231026,20231026,EXP,,DE-MYLANLABS-2023M1109952,MYLAN,,73.0,YR,,M,Y,73.0,KG,20231026,,HP,DE,DE,2023,Q4,Elderly
231103251,23110325,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Unknown,,2023,Q4,Pneumonia,,2023,Q4,1,I,20230812.0,20231020.0,20231026,20231026,EXP,,DE-MYLANLABS-2023M1109952,MYLAN,,73.0,YR,,M,Y,73.0,KG,20231026,,HP,DE,DE,2023,Q4,Elderly
231103251,23110325,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Unknown,,2023,Q4,Off label use,,2023,Q4,1,I,20230812.0,20231020.0,20231026,20231026,EXP,,DE-MYLANLABS-2023M1109952,MYLAN,,73.0,YR,,M,Y,73.0,KG,20231026,,HP,DE,DE,2023,Q4,Elderly
231106981,23110698,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once Daily (qd)",,,U,,,,,10.0,MG,,QD,2023,Q4,Vascular device infection,,2023,Q4,1,I,20220203.0,20230319.0,20231026,20231026,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-414198,RANBAXY,,62.0,YR,,M,Y,113.0,KG,20231026,,MD,GB,GB,2023,Q4,Adult
231110002,23111000,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Kounis syndrome,,2023,Q4,2,F,20231009.0,20231027.0,20231026,20231102,EXP,,US-BRACCO-2023US05342,BRACCO,,75.0,YR,,M,Y,,,20231102,,HP,US,US,2023,Q4,Elderly
231117331,23111733,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,took daily,,,,,,,,,,,,2023,Q4,Nausea,,2023,Q4,1,I,20230717.0,20230720.0,20231026,20231026,PER,,US-MEITHEAL-2023MPSPO00108,MEITHEAL PHARMACEUTICALS,,75.0,YR,E,F,Y,,,20231023,,HP,US,US,2023,Q4,Elderly
231133582,23113358,27,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q4,Chest pain,,2023,Q4,2,F,,20231018.0,20231027,20231109,EXP,,CA-SANDOZ INC.-NVSC2023CA005723,SANDOZ,,67.0,YR,,F,Y,,,20231109,,PH,CA,CA,2023,Q4,Elderly
231133582,23113358,27,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q4,Dyspnoea,,2023,Q4,2,F,,20231018.0,20231027,20231109,EXP,,CA-SANDOZ INC.-NVSC2023CA005723,SANDOZ,,67.0,YR,,F,Y,,,20231109,,PH,CA,CA,2023,Q4,Elderly
231133582,23113358,27,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q4,Neuropathy peripheral,,2023,Q4,2,F,,20231018.0,20231027,20231109,EXP,,CA-SANDOZ INC.-NVSC2023CA005723,SANDOZ,,67.0,YR,,F,Y,,,20231109,,PH,CA,CA,2023,Q4,Elderly
231133582,23113358,27,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q4,Haemorrhoidal haemorrhage,,2023,Q4,2,F,,20231018.0,20231027,20231109,EXP,,CA-SANDOZ INC.-NVSC2023CA005723,SANDOZ,,67.0,YR,,F,Y,,,20231109,,PH,CA,CA,2023,Q4,Elderly
231133582,23113358,27,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q4,Constipation,,2023,Q4,2,F,,20231018.0,20231027,20231109,EXP,,CA-SANDOZ INC.-NVSC2023CA005723,SANDOZ,,67.0,YR,,F,Y,,,20231109,,PH,CA,CA,2023,Q4,Elderly
231133582,23113358,27,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q4,Off label use,,2023,Q4,2,F,,20231018.0,20231027,20231109,EXP,,CA-SANDOZ INC.-NVSC2023CA005723,SANDOZ,,67.0,YR,,F,Y,,,20231109,,PH,CA,CA,2023,Q4,Elderly
231133582,23113358,27,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q4,COVID-19,,2023,Q4,2,F,,20231018.0,20231027,20231109,EXP,,CA-SANDOZ INC.-NVSC2023CA005723,SANDOZ,,67.0,YR,,F,Y,,,20231109,,PH,CA,CA,2023,Q4,Elderly
231133582,23113358,27,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q4,Neoplasm skin,,2023,Q4,2,F,,20231018.0,20231027,20231109,EXP,,CA-SANDOZ INC.-NVSC2023CA005723,SANDOZ,,67.0,YR,,F,Y,,,20231109,,PH,CA,CA,2023,Q4,Elderly
231133582,23113358,27,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q4,Abdominal pain upper,,2023,Q4,2,F,,20231018.0,20231027,20231109,EXP,,CA-SANDOZ INC.-NVSC2023CA005723,SANDOZ,,67.0,YR,,F,Y,,,20231109,,PH,CA,CA,2023,Q4,Elderly
231133582,23113358,27,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q4,Pain in extremity,,2023,Q4,2,F,,20231018.0,20231027,20231109,EXP,,CA-SANDOZ INC.-NVSC2023CA005723,SANDOZ,,67.0,YR,,F,Y,,,20231109,,PH,CA,CA,2023,Q4,Elderly
231133582,23113358,27,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q4,Clostridium difficile colitis,,2023,Q4,2,F,,20231018.0,20231027,20231109,EXP,,CA-SANDOZ INC.-NVSC2023CA005723,SANDOZ,,67.0,YR,,F,Y,,,20231109,,PH,CA,CA,2023,Q4,Elderly
231133582,23113358,27,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q4,Hypoaesthesia,,2023,Q4,2,F,,20231018.0,20231027,20231109,EXP,,CA-SANDOZ INC.-NVSC2023CA005723,SANDOZ,,67.0,YR,,F,Y,,,20231109,,PH,CA,CA,2023,Q4,Elderly
231133582,23113358,27,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q4,Vulvovaginal mycotic infection,,2023,Q4,2,F,,20231018.0,20231027,20231109,EXP,,CA-SANDOZ INC.-NVSC2023CA005723,SANDOZ,,67.0,YR,,F,Y,,,20231109,,PH,CA,CA,2023,Q4,Elderly
231133582,23113358,27,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q4,Cataract,,2023,Q4,2,F,,20231018.0,20231027,20231109,EXP,,CA-SANDOZ INC.-NVSC2023CA005723,SANDOZ,,67.0,YR,,F,Y,,,20231109,,PH,CA,CA,2023,Q4,Elderly
231133582,23113358,27,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q4,COVID-19 immunisation,,2023,Q4,2,F,,20231018.0,20231027,20231109,EXP,,CA-SANDOZ INC.-NVSC2023CA005723,SANDOZ,,67.0,YR,,F,Y,,,20231109,,PH,CA,CA,2023,Q4,Elderly
231133582,23113358,27,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q4,Cardiac failure,,2023,Q4,2,F,,20231018.0,20231027,20231109,EXP,,CA-SANDOZ INC.-NVSC2023CA005723,SANDOZ,,67.0,YR,,F,Y,,,20231109,,PH,CA,CA,2023,Q4,Elderly
231133582,23113358,27,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q4,Cardiomegaly,,2023,Q4,2,F,,20231018.0,20231027,20231109,EXP,,CA-SANDOZ INC.-NVSC2023CA005723,SANDOZ,,67.0,YR,,F,Y,,,20231109,,PH,CA,CA,2023,Q4,Elderly
231133582,23113358,27,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q4,Chest discomfort,,2023,Q4,2,F,,20231018.0,20231027,20231109,EXP,,CA-SANDOZ INC.-NVSC2023CA005723,SANDOZ,,67.0,YR,,F,Y,,,20231109,,PH,CA,CA,2023,Q4,Elderly
231133582,23113358,27,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q4,Fall,,2023,Q4,2,F,,20231018.0,20231027,20231109,EXP,,CA-SANDOZ INC.-NVSC2023CA005723,SANDOZ,,67.0,YR,,F,Y,,,20231109,,PH,CA,CA,2023,Q4,Elderly
231133582,23113358,27,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q4,Transient ischaemic attack,,2023,Q4,2,F,,20231018.0,20231027,20231109,EXP,,CA-SANDOZ INC.-NVSC2023CA005723,SANDOZ,,67.0,YR,,F,Y,,,20231109,,PH,CA,CA,2023,Q4,Elderly
231133582,23113358,27,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q4,Drug ineffective,,2023,Q4,2,F,,20231018.0,20231027,20231109,EXP,,CA-SANDOZ INC.-NVSC2023CA005723,SANDOZ,,67.0,YR,,F,Y,,,20231109,,PH,CA,CA,2023,Q4,Elderly
231133582,23113358,27,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q4,Product use issue,,2023,Q4,2,F,,20231018.0,20231027,20231109,EXP,,CA-SANDOZ INC.-NVSC2023CA005723,SANDOZ,,67.0,YR,,F,Y,,,20231109,,PH,CA,CA,2023,Q4,Elderly
231133582,23113358,27,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q4,Blood pressure increased,,2023,Q4,2,F,,20231018.0,20231027,20231109,EXP,,CA-SANDOZ INC.-NVSC2023CA005723,SANDOZ,,67.0,YR,,F,Y,,,20231109,,PH,CA,CA,2023,Q4,Elderly
231133582,23113358,27,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q4,Pneumonia,,2023,Q4,2,F,,20231018.0,20231027,20231109,EXP,,CA-SANDOZ INC.-NVSC2023CA005723,SANDOZ,,67.0,YR,,F,Y,,,20231109,,PH,CA,CA,2023,Q4,Elderly
231133582,23113358,27,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10.0 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q4,Haemorrhoids,,2023,Q4,2,F,,20231018.0,20231027,20231109,EXP,,CA-SANDOZ INC.-NVSC2023CA005723,SANDOZ,,67.0,YR,,F,Y,,,20231109,,PH,CA,CA,2023,Q4,Elderly
231137441,23113744,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,,,,,2023,Q4,Adverse drug reaction,,2023,Q4,1,I,20230916.0,20231026.0,20231027,20231027,EXP,GB-MHRA-TPP15825237C5363021YC1698255569568,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-269337",BOEHRINGER INGELHEIM,,73.0,YR,E,M,Y,108.0,KG,20231027,,MD,GB,GB,2023,Q4,Elderly
231148341,23114834,3,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,UNK,,,,,,,,,,Tablet,,2023,Q4,Faeces discoloured,,2023,Q4,1,I,20231024.0,20231025.0,20231027,20231027,EXP,,JP-009507513-2310JPN003596J,MERCK,,65.0,YR,,F,Y,,,20231027,,MD,JP,JP,2023,Q4,Elderly
231148341,23114834,3,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,UNK,,,,,,,,,,Tablet,,2023,Q4,Haematochezia,,2023,Q4,1,I,20231024.0,20231025.0,20231027,20231027,EXP,,JP-009507513-2310JPN003596J,MERCK,,65.0,YR,,F,Y,,,20231027,,MD,JP,JP,2023,Q4,Elderly
231148881,23114888,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,U,,,,,,Unknown,,2023,Q4,Drug ineffective,,2023,Q4,1,I,,20231018.0,20231027,20231027,EXP,,US-MYLANLABS-2023M1112413,MYLAN,"LEE J, NOOR F, BARUA AMIT, AHMAD R. A RARE CASE OF EUGLYCEMIC DIABETIC KETOACIDOSIS IN SETTING OF SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS USE WITH UNDIAGNOSED METASTATIC PANCREATIC CANCER AND STARVATION. Chest 2023;164 (Suppl.)(4):A2466-A2467.",57.0,YR,,M,Y,,,20231027,,HP,US,US,2023,Q4,Adult
231148881,23114888,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,U,,,,,,Unknown,,2023,Q4,Euglycaemic diabetic ketoacidosis,,2023,Q4,1,I,,20231018.0,20231027,20231027,EXP,,US-MYLANLABS-2023M1112413,MYLAN,"LEE J, NOOR F, BARUA AMIT, AHMAD R. A RARE CASE OF EUGLYCEMIC DIABETIC KETOACIDOSIS IN SETTING OF SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS USE WITH UNDIAGNOSED METASTATIC PANCREATIC CANCER AND STARVATION. Chest 2023;164 (Suppl.)(4):A2466-A2467.",57.0,YR,,M,Y,,,20231027,,HP,US,US,2023,Q4,Adult
231149441,23114944,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Prostate cancer,,2023,Q4,1,I,20230301.0,20231016.0,20231027,20231027,EXP,,SI-JNJFOC-20231041400,JOHNSON AND JOHNSON,,65.0,YR,E,M,Y,,,20231027,,MD,SI,SI,2023,Q4,Elderly
231149441,23114944,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Hypothyroidism,,2023,Q4,1,I,20230301.0,20231016.0,20231027,20231027,EXP,,SI-JNJFOC-20231041400,JOHNSON AND JOHNSON,,65.0,YR,E,M,Y,,,20231027,,MD,SI,SI,2023,Q4,Elderly
231149441,23114944,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Abdominal pain upper,,2023,Q4,1,I,20230301.0,20231016.0,20231027,20231027,EXP,,SI-JNJFOC-20231041400,JOHNSON AND JOHNSON,,65.0,YR,E,M,Y,,,20231027,,MD,SI,SI,2023,Q4,Elderly
231149441,23114944,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,General physical health deterioration,,2023,Q4,1,I,20230301.0,20231016.0,20231027,20231027,EXP,,SI-JNJFOC-20231041400,JOHNSON AND JOHNSON,,65.0,YR,E,M,Y,,,20231027,,MD,SI,SI,2023,Q4,Elderly
231164711,23116471,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q4,BRASH syndrome,,2023,Q4,1,I,,20231016.0,20231027,20231027,EXP,,US-SLATERUN-2023SRLIT00010,SLATE RUN,"DONG Q, et al..BRASH SYNDROME: AN UNDER-RECOGNIZED SYNDROME PRECIPITATED BY MEDICATION OVERDOSE.CHEST.09-OCT-2023;164 (4):A2167-A2168",77.0,YR,E,M,Y,,,20231027,,HP,US,US,2023,Q4,Elderly
231164711,23116471,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q4,Drug titration,,2023,Q4,1,I,,20231016.0,20231027,20231027,EXP,,US-SLATERUN-2023SRLIT00010,SLATE RUN,"DONG Q, et al..BRASH SYNDROME: AN UNDER-RECOGNIZED SYNDROME PRECIPITATED BY MEDICATION OVERDOSE.CHEST.09-OCT-2023;164 (4):A2167-A2168",77.0,YR,E,M,Y,,,20231027,,HP,US,US,2023,Q4,Elderly
231164711,23116471,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q4,Overdose,,2023,Q4,1,I,,20231016.0,20231027,20231027,EXP,,US-SLATERUN-2023SRLIT00010,SLATE RUN,"DONG Q, et al..BRASH SYNDROME: AN UNDER-RECOGNIZED SYNDROME PRECIPITATED BY MEDICATION OVERDOSE.CHEST.09-OCT-2023;164 (4):A2167-A2168",77.0,YR,E,M,Y,,,20231027,,HP,US,US,2023,Q4,Elderly
231176082,23117608,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q4,Lower respiratory tract infection,,2023,Q4,2,F,,20231031.0,20231027,20231108,EXP,IT-ROCHE-3375698,IT-SANDOZ INC.-SDZ2023IT047057,SANDOZ,,55.0,YR,,F,Y,,,20231108,,HP,IT,IT,2023,Q4,Adult
231176082,23117608,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q4,Cardiac failure congestive,,2023,Q4,2,F,,20231031.0,20231027,20231108,EXP,IT-ROCHE-3375698,IT-SANDOZ INC.-SDZ2023IT047057,SANDOZ,,55.0,YR,,F,Y,,,20231108,,HP,IT,IT,2023,Q4,Adult
231176082,23117608,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q4,Left ventricular dysfunction,,2023,Q4,2,F,,20231031.0,20231027,20231108,EXP,IT-ROCHE-3375698,IT-SANDOZ INC.-SDZ2023IT047057,SANDOZ,,55.0,YR,,F,Y,,,20231108,,HP,IT,IT,2023,Q4,Adult
231176082,23117608,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q4,Disease progression,,2023,Q4,2,F,,20231031.0,20231027,20231108,EXP,IT-ROCHE-3375698,IT-SANDOZ INC.-SDZ2023IT047057,SANDOZ,,55.0,YR,,F,Y,,,20231108,,HP,IT,IT,2023,Q4,Adult
231176082,23117608,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q4,Lower respiratory tract infection,,2023,Q4,2,F,,20231031.0,20231027,20231108,EXP,IT-ROCHE-3375698,IT-SANDOZ INC.-SDZ2023IT047057,SANDOZ,,55.0,YR,,F,Y,,,20231108,,HP,IT,IT,2023,Q4,Adult
231176082,23117608,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q4,Cardiac failure congestive,,2023,Q4,2,F,,20231031.0,20231027,20231108,EXP,IT-ROCHE-3375698,IT-SANDOZ INC.-SDZ2023IT047057,SANDOZ,,55.0,YR,,F,Y,,,20231108,,HP,IT,IT,2023,Q4,Adult
231176082,23117608,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q4,Left ventricular dysfunction,,2023,Q4,2,F,,20231031.0,20231027,20231108,EXP,IT-ROCHE-3375698,IT-SANDOZ INC.-SDZ2023IT047057,SANDOZ,,55.0,YR,,F,Y,,,20231108,,HP,IT,IT,2023,Q4,Adult
231176082,23117608,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q4,Disease progression,,2023,Q4,2,F,,20231031.0,20231027,20231108,EXP,IT-ROCHE-3375698,IT-SANDOZ INC.-SDZ2023IT047057,SANDOZ,,55.0,YR,,F,Y,,,20231108,,HP,IT,IT,2023,Q4,Adult
231180811,23118081,5,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1 DF, Once every 12hr (Strength: 1000/12.5 mg)",,,,,,,,,,,Q12H,2023,Q4,Anaemia,,2023,Q4,1,I,20230802.0,20231027.0,20231027,20231027,EXP,,ES-DSJP-DSE-2023-144257,DAIICHI,,78.0,YR,,M,Y,,,20231027,,MD,ES,ES,2023,Q4,Elderly
231180811,23118081,5,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1 DF, Once every 12hr (Strength: 1000/12.5 mg)",,,,,,,,,,,Q12H,2023,Q4,Angina pectoris,,2023,Q4,1,I,20230802.0,20231027.0,20231027,20231027,EXP,,ES-DSJP-DSE-2023-144257,DAIICHI,,78.0,YR,,M,Y,,,20231027,,MD,ES,ES,2023,Q4,Elderly
231191722,23119172,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Disease progression,,2023,Q4,2,F,,20231121.0,20231028,20231123,EXP,,IT-SANDOZ INC.-SDZ2023IT047314,SANDOZ,,55.0,YR,,F,Y,,,20231123,,HP,IT,IT,2023,Q4,Adult
231191722,23119172,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Cardiac failure congestive,,2023,Q4,2,F,,20231121.0,20231028,20231123,EXP,,IT-SANDOZ INC.-SDZ2023IT047314,SANDOZ,,55.0,YR,,F,Y,,,20231123,,HP,IT,IT,2023,Q4,Adult
231191722,23119172,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Breast cancer,,2023,Q4,2,F,,20231121.0,20231028,20231123,EXP,,IT-SANDOZ INC.-SDZ2023IT047314,SANDOZ,,55.0,YR,,F,Y,,,20231123,,HP,IT,IT,2023,Q4,Adult
231191722,23119172,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Lower respiratory tract infection,,2023,Q4,2,F,,20231121.0,20231028,20231123,EXP,,IT-SANDOZ INC.-SDZ2023IT047314,SANDOZ,,55.0,YR,,F,Y,,,20231123,,HP,IT,IT,2023,Q4,Adult
231191722,23119172,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Cardiac ventricular thrombosis,,2023,Q4,2,F,,20231121.0,20231028,20231123,EXP,,IT-SANDOZ INC.-SDZ2023IT047314,SANDOZ,,55.0,YR,,F,Y,,,20231123,,HP,IT,IT,2023,Q4,Adult
231191722,23119172,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Off label use,,2023,Q4,2,F,,20231121.0,20231028,20231123,EXP,,IT-SANDOZ INC.-SDZ2023IT047314,SANDOZ,,55.0,YR,,F,Y,,,20231123,,HP,IT,IT,2023,Q4,Adult
231191722,23119172,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Left ventricular dysfunction,,2023,Q4,2,F,,20231121.0,20231028,20231123,EXP,,IT-SANDOZ INC.-SDZ2023IT047314,SANDOZ,,55.0,YR,,F,Y,,,20231123,,HP,IT,IT,2023,Q4,Adult
231191722,23119172,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Type 2 diabetes mellitus,,2023,Q4,2,F,,20231121.0,20231028,20231123,EXP,,IT-SANDOZ INC.-SDZ2023IT047314,SANDOZ,,55.0,YR,,F,Y,,,20231123,,HP,IT,IT,2023,Q4,Adult
231233282,23123328,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Anaemia,,2023,Q4,2,F,20230717.0,20231117.0,20231030,20231129,EXP,,IT-Accord-379137,ACCORD,,73.0,YR,E,M,Y,59.0,KG,20231129,,HP,IT,IT,2023,Q4,Elderly
231233282,23123328,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Pneumonia legionella,,2023,Q4,2,F,20230717.0,20231117.0,20231030,20231129,EXP,,IT-Accord-379137,ACCORD,,73.0,YR,E,M,Y,59.0,KG,20231129,,HP,IT,IT,2023,Q4,Elderly
231233282,23123328,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Lymphopenia,,2023,Q4,2,F,20230717.0,20231117.0,20231030,20231129,EXP,,IT-Accord-379137,ACCORD,,73.0,YR,E,M,Y,59.0,KG,20231129,,HP,IT,IT,2023,Q4,Elderly
231268042,23126804,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,204629.0,,,Film-coated tablet,,2023,Q4,Fournier's gangrene,,2023,Q4,2,F,20230801.0,20231101.0,20231030,20231103,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-269818",BOEHRINGER INGELHEIM,,5.0,DEC,A,M,Y,,,20231103,,MD,DE,DE,2023,Q4,Child
231268173,23126817,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,Film-coated tablet,,2023,Q4,Pancreatitis necrotising,,2023,Q4,3,F,,20231207.0,20231030,20231211,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-269820",BOEHRINGER INGELHEIM,,4.0,DEC,A,F,Y,,,20231211,,MD,DE,DE,2023,Q4,Child
231271861,23127186,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Platelet count decreased,,2023,Q4,1,I,,20231023.0,20231030,20231030,EXP,,JP-ABBVIE-5463598,ABBVIE,,76.0,YR,,M,Y,,,20231030,,MD,JP,JP,2023,Q4,Elderly
231271861,23127186,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,White blood cell count decreased,,2023,Q4,1,I,,20231023.0,20231030,20231030,EXP,,JP-ABBVIE-5463598,ABBVIE,,76.0,YR,,M,Y,,,20231030,,MD,JP,JP,2023,Q4,Elderly
231271861,23127186,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Pulmonary oedema,,2023,Q4,1,I,,20231023.0,20231030,20231030,EXP,,JP-ABBVIE-5463598,ABBVIE,,76.0,YR,,M,Y,,,20231030,,MD,JP,JP,2023,Q4,Elderly
231271861,23127186,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Neutrophil count decreased,,2023,Q4,1,I,,20231023.0,20231030,20231030,EXP,,JP-ABBVIE-5463598,ABBVIE,,76.0,YR,,M,Y,,,20231030,,MD,JP,JP,2023,Q4,Elderly
231271861,23127186,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Pulmonary alveolar haemorrhage,,2023,Q4,1,I,,20231023.0,20231030,20231030,EXP,,JP-ABBVIE-5463598,ABBVIE,,76.0,YR,,M,Y,,,20231030,,MD,JP,JP,2023,Q4,Elderly
231305771,23130577,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, 1 Dose",,,U,,,,,,,,QD,2023,Q4,Restless legs syndrome,,2023,Q4,1,I,,20230329.0,20231031,20231031,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-415537,RANBAXY,,40.0,YR,,F,Y,100.0,KG,20231031,,MD,GB,GB,2023,Q4,Adult
231305771,23130577,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, 1 Dose",,,U,,,,,,,,QD,2023,Q4,Drug hypersensitivity,,2023,Q4,1,I,,20230329.0,20231031,20231031,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-415537,RANBAXY,,40.0,YR,,F,Y,100.0,KG,20231031,,MD,GB,GB,2023,Q4,Adult
231319721,23131972,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,Unknown,,208658.0,,,,,2023,Q4,Diarrhoea haemorrhagic,,2023,Q4,1,I,20231001.0,20231028.0,20231101,20231101,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-270020",BOEHRINGER INGELHEIM,,42.0,YR,A,M,Y,,,20231101,,CN,AU,AU,2023,Q4,Adult
231319721,23131972,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,Unknown,,208658.0,,,,,2023,Q4,Extra dose administered,,2023,Q4,1,I,20231001.0,20231028.0,20231101,20231101,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-270020",BOEHRINGER INGELHEIM,,42.0,YR,A,M,Y,,,20231101,,CN,AU,AU,2023,Q4,Adult
231319721,23131972,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,Unknown,,208658.0,,,,,2023,Q4,Hepatic steatosis,,2023,Q4,1,I,20231001.0,20231028.0,20231101,20231101,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-270020",BOEHRINGER INGELHEIM,,42.0,YR,A,M,Y,,,20231101,,CN,AU,AU,2023,Q4,Adult
231319721,23131972,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,Unknown,,208658.0,,,,,2023,Q4,Flatulence,,2023,Q4,1,I,20231001.0,20231028.0,20231101,20231101,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-270020",BOEHRINGER INGELHEIM,,42.0,YR,A,M,Y,,,20231101,,CN,AU,AU,2023,Q4,Adult
231319721,23131972,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,Unknown,,208658.0,,,,,2023,Q4,Abdominal pain,,2023,Q4,1,I,20231001.0,20231028.0,20231101,20231101,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-270020",BOEHRINGER INGELHEIM,,42.0,YR,A,M,Y,,,20231101,,CN,AU,AU,2023,Q4,Adult
231319721,23131972,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,Unknown,,208658.0,,,,,2023,Q4,Diarrhoea haemorrhagic,,2023,Q4,1,I,20231001.0,20231028.0,20231101,20231101,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-270020",BOEHRINGER INGELHEIM,,42.0,YR,A,M,Y,,,20231101,,CN,AU,AU,2023,Q4,Adult
231328261,23132826,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2023,Q4,Ejection fraction decreased,,2023,Q4,1,I,,20231018.0,20231101,20231101,EXP,,AU-ALKEM LABORATORIES LIMITED-AU-ALKEM-2023-12860,ALKEM,,74.0,YR,,M,Y,,,20231101,,HP,AU,AU,2023,Q4,Elderly
231328261,23132826,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2023,Q4,Dyspnoea,,2023,Q4,1,I,,20231018.0,20231101,20231101,EXP,,AU-ALKEM LABORATORIES LIMITED-AU-ALKEM-2023-12860,ALKEM,,74.0,YR,,M,Y,,,20231101,,HP,AU,AU,2023,Q4,Elderly
231328261,23132826,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2023,Q4,Weight increased,,2023,Q4,1,I,,20231018.0,20231101,20231101,EXP,,AU-ALKEM LABORATORIES LIMITED-AU-ALKEM-2023-12860,ALKEM,,74.0,YR,,M,Y,,,20231101,,HP,AU,AU,2023,Q4,Elderly
231328261,23132826,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2023,Q4,Waist circumference increased,,2023,Q4,1,I,,20231018.0,20231101,20231101,EXP,,AU-ALKEM LABORATORIES LIMITED-AU-ALKEM-2023-12860,ALKEM,,74.0,YR,,M,Y,,,20231101,,HP,AU,AU,2023,Q4,Elderly
231328261,23132826,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2023,Q4,Peripheral swelling,,2023,Q4,1,I,,20231018.0,20231101,20231101,EXP,,AU-ALKEM LABORATORIES LIMITED-AU-ALKEM-2023-12860,ALKEM,,74.0,YR,,M,Y,,,20231101,,HP,AU,AU,2023,Q4,Elderly
231328261,23132826,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2023,Q4,Left ventricular dysfunction,,2023,Q4,1,I,,20231018.0,20231101,20231101,EXP,,AU-ALKEM LABORATORIES LIMITED-AU-ALKEM-2023-12860,ALKEM,,74.0,YR,,M,Y,,,20231101,,HP,AU,AU,2023,Q4,Elderly
231328261,23132826,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2023,Q4,N-terminal prohormone brain natriuretic peptide abnormal,,2023,Q4,1,I,,20231018.0,20231101,20231101,EXP,,AU-ALKEM LABORATORIES LIMITED-AU-ALKEM-2023-12860,ALKEM,,74.0,YR,,M,Y,,,20231101,,HP,AU,AU,2023,Q4,Elderly
231328261,23132826,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2023,Q4,Decreased appetite,,2023,Q4,1,I,,20231018.0,20231101,20231101,EXP,,AU-ALKEM LABORATORIES LIMITED-AU-ALKEM-2023-12860,ALKEM,,74.0,YR,,M,Y,,,20231101,,HP,AU,AU,2023,Q4,Elderly
231328261,23132826,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2023,Q4,Incorrect dose administered,,2023,Q4,1,I,,20231018.0,20231101,20231101,EXP,,AU-ALKEM LABORATORIES LIMITED-AU-ALKEM-2023-12860,ALKEM,,74.0,YR,,M,Y,,,20231101,,HP,AU,AU,2023,Q4,Elderly
231328261,23132826,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2023,Q4,Bundle branch block left,,2023,Q4,1,I,,20231018.0,20231101,20231101,EXP,,AU-ALKEM LABORATORIES LIMITED-AU-ALKEM-2023-12860,ALKEM,,74.0,YR,,M,Y,,,20231101,,HP,AU,AU,2023,Q4,Elderly
231328261,23132826,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2023,Q4,Arteriosclerosis coronary artery,,2023,Q4,1,I,,20231018.0,20231101,20231101,EXP,,AU-ALKEM LABORATORIES LIMITED-AU-ALKEM-2023-12860,ALKEM,,74.0,YR,,M,Y,,,20231101,,HP,AU,AU,2023,Q4,Elderly
231328261,23132826,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2023,Q4,Atrial fibrillation,,2023,Q4,1,I,,20231018.0,20231101,20231101,EXP,,AU-ALKEM LABORATORIES LIMITED-AU-ALKEM-2023-12860,ALKEM,,74.0,YR,,M,Y,,,20231101,,HP,AU,AU,2023,Q4,Elderly
231329211,23132921,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,UNKNOWN,,,,,,,2023,Q4,Adenocarcinoma pancreas,,2023,Q4,1,I,,20231018.0,20231101,20231101,EXP,,US-drreddys-LIT/USA/23/0180914,DR REDDYS,"Lee J, Noor F, Barua A, Ahmad R. A RARE CASE OF EUGLYCEMIC DIABETIC KETOACIDOSIS IN SETTING OF SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS USE WITH UNDIAGNOSED METASTATIC PANCREATIC CANCER AND STARVATION. Chest. 2023;164(4):A2466-7. doi:10.1016/j.chest.2023.07.1645",57.0,YR,A,M,Y,,,20231101,,HP,US,US,2023,Q4,Adult
231329211,23132921,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,UNKNOWN,,,,,,,2023,Q4,Metastases to lung,,2023,Q4,1,I,,20231018.0,20231101,20231101,EXP,,US-drreddys-LIT/USA/23/0180914,DR REDDYS,"Lee J, Noor F, Barua A, Ahmad R. A RARE CASE OF EUGLYCEMIC DIABETIC KETOACIDOSIS IN SETTING OF SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS USE WITH UNDIAGNOSED METASTATIC PANCREATIC CANCER AND STARVATION. Chest. 2023;164(4):A2466-7. doi:10.1016/j.chest.2023.07.1645",57.0,YR,A,M,Y,,,20231101,,HP,US,US,2023,Q4,Adult
231329211,23132921,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,UNKNOWN,,,,,,,2023,Q4,Euglycaemic diabetic ketoacidosis,,2023,Q4,1,I,,20231018.0,20231101,20231101,EXP,,US-drreddys-LIT/USA/23/0180914,DR REDDYS,"Lee J, Noor F, Barua A, Ahmad R. A RARE CASE OF EUGLYCEMIC DIABETIC KETOACIDOSIS IN SETTING OF SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS USE WITH UNDIAGNOSED METASTATIC PANCREATIC CANCER AND STARVATION. Chest. 2023;164(4):A2466-7. doi:10.1016/j.chest.2023.07.1645",57.0,YR,A,M,Y,,,20231101,,HP,US,US,2023,Q4,Adult
231329211,23132921,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,UNKNOWN,,,,,,,2023,Q4,Drug ineffective,,2023,Q4,1,I,,20231018.0,20231101,20231101,EXP,,US-drreddys-LIT/USA/23/0180914,DR REDDYS,"Lee J, Noor F, Barua A, Ahmad R. A RARE CASE OF EUGLYCEMIC DIABETIC KETOACIDOSIS IN SETTING OF SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS USE WITH UNDIAGNOSED METASTATIC PANCREATIC CANCER AND STARVATION. Chest. 2023;164(4):A2466-7. doi:10.1016/j.chest.2023.07.1645",57.0,YR,A,M,Y,,,20231101,,HP,US,US,2023,Q4,Adult
231331841,23133184,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q4,Dizziness,,2023,Q4,1,I,20231004.0,20231031.0,20231101,20231101,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-270235",BOEHRINGER INGELHEIM,,76.0,YR,E,F,Y,,,20231101,,HP,SG,SG,2023,Q4,Elderly
231335371,23133537,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q4,Blood alkaline phosphatase increased,,2023,Q4,1,I,20231009.0,20231024.0,20231101,20231101,EXP,,CN-AstraZeneca-2023A246514,ASTRAZENECA,,50.0,YR,,M,Y,60.0,KG,20231101,,MD,CN,,2023,Q4,Adult
231335371,23133537,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q4,Hypoaesthesia,,2023,Q4,1,I,20231009.0,20231024.0,20231101,20231101,EXP,,CN-AstraZeneca-2023A246514,ASTRAZENECA,,50.0,YR,,M,Y,60.0,KG,20231101,,MD,CN,,2023,Q4,Adult
231335371,23133537,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q4,Pulse abnormal,,2023,Q4,1,I,20231009.0,20231024.0,20231101,20231101,EXP,,CN-AstraZeneca-2023A246514,ASTRAZENECA,,50.0,YR,,M,Y,60.0,KG,20231101,,MD,CN,,2023,Q4,Adult
231335371,23133537,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q4,Movement disorder,,2023,Q4,1,I,20231009.0,20231024.0,20231101,20231101,EXP,,CN-AstraZeneca-2023A246514,ASTRAZENECA,,50.0,YR,,M,Y,60.0,KG,20231101,,MD,CN,,2023,Q4,Adult
231335371,23133537,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q4,Muscle strength abnormal,,2023,Q4,1,I,20231009.0,20231024.0,20231101,20231101,EXP,,CN-AstraZeneca-2023A246514,ASTRAZENECA,,50.0,YR,,M,Y,60.0,KG,20231101,,MD,CN,,2023,Q4,Adult
231335371,23133537,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q4,Transaminases increased,,2023,Q4,1,I,20231009.0,20231024.0,20231101,20231101,EXP,,CN-AstraZeneca-2023A246514,ASTRAZENECA,,50.0,YR,,M,Y,60.0,KG,20231101,,MD,CN,,2023,Q4,Adult
231335371,23133537,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q4,Headache,,2023,Q4,1,I,20231009.0,20231024.0,20231101,20231101,EXP,,CN-AstraZeneca-2023A246514,ASTRAZENECA,,50.0,YR,,M,Y,60.0,KG,20231101,,MD,CN,,2023,Q4,Adult
231335371,23133537,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q4,Furuncle,,2023,Q4,1,I,20231009.0,20231024.0,20231101,20231101,EXP,,CN-AstraZeneca-2023A246514,ASTRAZENECA,,50.0,YR,,M,Y,60.0,KG,20231101,,MD,CN,,2023,Q4,Adult
231335371,23133537,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q4,Type 2 diabetes mellitus,,2023,Q4,1,I,20231009.0,20231024.0,20231101,20231101,EXP,,CN-AstraZeneca-2023A246514,ASTRAZENECA,,50.0,YR,,M,Y,60.0,KG,20231101,,MD,CN,,2023,Q4,Adult
231346542,23134654,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,D,,,,,,,,,2023,Q4,Product use issue,,2023,Q4,2,F,20231001.0,20231121.0,20231101,20231129,EXP,,"US-RIGEL PHARMACEUTICALS, INC.-2023FOS001133",RIGEL PHARMACEUTICALS,,75.0,YR,,F,Y,,,20231129,,HP,US,US,2023,Q4,Elderly
231346542,23134654,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,D,,,,,,,,,2023,Q4,Heart rate decreased,,2023,Q4,2,F,20231001.0,20231121.0,20231101,20231129,EXP,,"US-RIGEL PHARMACEUTICALS, INC.-2023FOS001133",RIGEL PHARMACEUTICALS,,75.0,YR,,F,Y,,,20231129,,HP,US,US,2023,Q4,Elderly
231346542,23134654,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,D,,,,,,,,,2023,Q4,Fatigue,,2023,Q4,2,F,20231001.0,20231121.0,20231101,20231129,EXP,,"US-RIGEL PHARMACEUTICALS, INC.-2023FOS001133",RIGEL PHARMACEUTICALS,,75.0,YR,,F,Y,,,20231129,,HP,US,US,2023,Q4,Elderly
231346542,23134654,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,D,,,,,,,,,2023,Q4,Product dose omission issue,,2023,Q4,2,F,20231001.0,20231121.0,20231101,20231129,EXP,,"US-RIGEL PHARMACEUTICALS, INC.-2023FOS001133",RIGEL PHARMACEUTICALS,,75.0,YR,,F,Y,,,20231129,,HP,US,US,2023,Q4,Elderly
231354372,23135437,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q4,Drug ineffective,,2023,Q4,2,F,20220101.0,20231103.0,20231101,20231113,EXP,,US-TEVA-2023-US-2940301,TEVA,,52.0,YR,A,F,Y,,,20231113,,HP,US,US,2023,Q4,Adult
231354372,23135437,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q4,Diabetic ketoacidosis,,2023,Q4,2,F,20220101.0,20231103.0,20231101,20231113,EXP,,US-TEVA-2023-US-2940301,TEVA,,52.0,YR,A,F,Y,,,20231113,,HP,US,US,2023,Q4,Adult
231355231,23135523,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,Unknown,,,,,,,2023,Q4,BRASH syndrome,,2023,Q4,1,I,,20231018.0,20231101,20231101,EXP,,US-GRANULES-US-2023GRALIT00299,GRANULES INDIA,QIMING DONG.Brash Syndrome: An Under-Recognized Syndrome Precipitated By Medication Overdose.Chest.02-OCT-2023;164:A2167-A2168,77.0,YR,E,M,Y,,,20231101,,HP,US,US,2023,Q4,Elderly
231355231,23135523,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,Unknown,,,,,,,2023,Q4,Overdose,,2023,Q4,1,I,,20231018.0,20231101,20231101,EXP,,US-GRANULES-US-2023GRALIT00299,GRANULES INDIA,QIMING DONG.Brash Syndrome: An Under-Recognized Syndrome Precipitated By Medication Overdose.Chest.02-OCT-2023;164:A2167-A2168,77.0,YR,E,M,Y,,,20231101,,HP,US,US,2023,Q4,Elderly
231375761,23137576,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,U,,,,,,,,2023,Q4,Overdose,,2023,Q4,1,I,,20231019.0,20231102,20231102,EXP,,US-Renata Limited-2147736,RENATA LIMITED,"Dong Q, Kyereme-tuah EK, Zou Y, Wazeen FR, Jin Z. BRASH SYNDROME: AN UNDER-RECOGNIZED SYNDROME PRECIPITATED BY MEDICATION OVERDOSE. Chest 164 (Suppl.): A2167-A2168, No. 4, 02 Oct 2023. http://doi.org/10.1016/j.chest.2023.07.1472",77.0,YR,,M,Y,,,20231102,,HP,US,US,2023,Q4,Elderly
231375761,23137576,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,U,,,,,,,,2023,Q4,BRASH syndrome,,2023,Q4,1,I,,20231019.0,20231102,20231102,EXP,,US-Renata Limited-2147736,RENATA LIMITED,"Dong Q, Kyereme-tuah EK, Zou Y, Wazeen FR, Jin Z. BRASH SYNDROME: AN UNDER-RECOGNIZED SYNDROME PRECIPITATED BY MEDICATION OVERDOSE. Chest 164 (Suppl.): A2167-A2168, No. 4, 02 Oct 2023. http://doi.org/10.1016/j.chest.2023.07.1472",77.0,YR,,M,Y,,,20231102,,HP,US,US,2023,Q4,Elderly
231375791,23137579,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,U,,,,,,,,2023,Q4,BRASH syndrome,,2023,Q4,1,I,,20231020.0,20231102,20231102,EXP,,"US-YoungTech Pharmaceuticals, Inc.-2147742","YOUNGTECH PHARMACEUTICALS, INC","Dong Q, Kyereme-tuah EK, Zou Y, Wazeen FR, Jin Z. BRASH SYNDROME: AN UNDER-RECOGNIZED SYNDROME PRECIPITATED BY MEDICATION OVERDOSE. Chest 164 (Suppl.): A2167-A2168, No. 4, 02 Oct 2023. http://doi.org/10.1016/j.chest.2023.07.1472",77.0,YR,,M,Y,,,20231102,,HP,US,US,2023,Q4,Elderly
231375791,23137579,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,U,,,,,,,,2023,Q4,Overdose,,2023,Q4,1,I,,20231020.0,20231102,20231102,EXP,,"US-YoungTech Pharmaceuticals, Inc.-2147742","YOUNGTECH PHARMACEUTICALS, INC","Dong Q, Kyereme-tuah EK, Zou Y, Wazeen FR, Jin Z. BRASH SYNDROME: AN UNDER-RECOGNIZED SYNDROME PRECIPITATED BY MEDICATION OVERDOSE. Chest 164 (Suppl.): A2167-A2168, No. 4, 02 Oct 2023. http://doi.org/10.1016/j.chest.2023.07.1472",77.0,YR,,M,Y,,,20231102,,HP,US,US,2023,Q4,Elderly
231378421,23137842,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,,Unknown,,,,,,,2023,Q4,Haemodynamic instability,,2023,Q4,1,I,,20231021.0,20231102,20231102,EXP,,CN-EPICPHARMA-CN-2023EPCLIT01612,EPIC PHARM,J Han.Sodium-glucose cotransporter-2 inhibitor-induced euglycemic diabetic ketoacidosis: A case report.Journal of Clinical Pharmacy and Therapeutics.SEP-2022;47(9):1482-1485,74.0,YR,E,M,Y,,,20231102,,HP,CN,CN,2023,Q4,Elderly
231380001,23138000,3,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,Tablet,,2023,Q4,Blood cholesterol increased,,2023,Q4,1,I,20230113.0,20231025.0,20231102,20231102,EXP,,JP-EMD Serono-2023484383,EMD SERONO INC,,90.0,YR,E,F,Y,,,20231102,,MD,JP,JP,2023,Q4,Elderly
231380001,23138000,3,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,Tablet,,2023,Q4,Fall,,2023,Q4,1,I,20230113.0,20231025.0,20231102,20231102,EXP,,JP-EMD Serono-2023484383,EMD SERONO INC,,90.0,YR,E,F,Y,,,20231102,,MD,JP,JP,2023,Q4,Elderly
231380001,23138000,3,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,Tablet,,2023,Q4,High density lipoprotein increased,,2023,Q4,1,I,20230113.0,20231025.0,20231102,20231102,EXP,,JP-EMD Serono-2023484383,EMD SERONO INC,,90.0,YR,E,F,Y,,,20231102,,MD,JP,JP,2023,Q4,Elderly
231380001,23138000,3,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,Tablet,,2023,Q4,Glycosylated haemoglobin increased,,2023,Q4,1,I,20230113.0,20231025.0,20231102,20231102,EXP,,JP-EMD Serono-2023484383,EMD SERONO INC,,90.0,YR,E,F,Y,,,20231102,,MD,JP,JP,2023,Q4,Elderly
231380001,23138000,3,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,Tablet,,2023,Q4,Low density lipoprotein increased,,2023,Q4,1,I,20230113.0,20231025.0,20231102,20231102,EXP,,JP-EMD Serono-2023484383,EMD SERONO INC,,90.0,YR,E,F,Y,,,20231102,,MD,JP,JP,2023,Q4,Elderly
231380001,23138000,3,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,Tablet,,2023,Q4,Dementia,,2023,Q4,1,I,20230113.0,20231025.0,20231102,20231102,EXP,,JP-EMD Serono-2023484383,EMD SERONO INC,,90.0,YR,E,F,Y,,,20231102,,MD,JP,JP,2023,Q4,Elderly
231393981,23139398,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Euglycaemic diabetic ketoacidosis,,2023,Q4,1,I,,20231018.0,20231102,20231102,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-415786,RANBAXY,"Lee J, Noor F, Barua A, Ahmad R. A rare case of euglycemic diabetic ketoacidosis in setting of sodium-glucose cotransporter 2 inhibitors use with undiagnosed metastatic pancreatic cancer and starvation. Chest. 2023;Oct; 164(S4):A2466-A2467",57.0,YR,,M,Y,,,20231102,,HP,US,US,2023,Q4,Adult
231393981,23139398,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Adenocarcinoma pancreas,,2023,Q4,1,I,,20231018.0,20231102,20231102,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-415786,RANBAXY,"Lee J, Noor F, Barua A, Ahmad R. A rare case of euglycemic diabetic ketoacidosis in setting of sodium-glucose cotransporter 2 inhibitors use with undiagnosed metastatic pancreatic cancer and starvation. Chest. 2023;Oct; 164(S4):A2466-A2467",57.0,YR,,M,Y,,,20231102,,HP,US,US,2023,Q4,Adult
231396022,23139602,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,Tablet,,2023,Q4,Abdominal discomfort,,2023,Q4,2,F,20230901.0,20231124.0,20231102,20231130,PER,,US-JAZZ-2023-US-001579,JAZZ,,57.0,YR,,M,Y,,,20231130,,MD,US,US,2023,Q4,Adult
231396022,23139602,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,Tablet,,2023,Q4,Trigger finger,,2023,Q4,2,F,20230901.0,20231124.0,20231102,20231130,PER,,US-JAZZ-2023-US-001579,JAZZ,,57.0,YR,,M,Y,,,20231130,,MD,US,US,2023,Q4,Adult
231396022,23139602,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,Tablet,,2023,Q4,Cough,,2023,Q4,2,F,20230901.0,20231124.0,20231102,20231130,PER,,US-JAZZ-2023-US-001579,JAZZ,,57.0,YR,,M,Y,,,20231130,,MD,US,US,2023,Q4,Adult
231396022,23139602,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,Tablet,,2023,Q4,Oedema,,2023,Q4,2,F,20230901.0,20231124.0,20231102,20231130,PER,,US-JAZZ-2023-US-001579,JAZZ,,57.0,YR,,M,Y,,,20231130,,MD,US,US,2023,Q4,Adult
231396022,23139602,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,Tablet,,2023,Q4,Abdominal discomfort,,2023,Q4,2,F,20230901.0,20231124.0,20231102,20231130,PER,,US-JAZZ-2023-US-001579,JAZZ,,57.0,YR,,M,Y,,,20231130,,MD,US,US,2023,Q4,Adult
231396022,23139602,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,Tablet,,2023,Q4,Trigger finger,,2023,Q4,2,F,20230901.0,20231124.0,20231102,20231130,PER,,US-JAZZ-2023-US-001579,JAZZ,,57.0,YR,,M,Y,,,20231130,,MD,US,US,2023,Q4,Adult
231396022,23139602,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,Tablet,,2023,Q4,Cough,,2023,Q4,2,F,20230901.0,20231124.0,20231102,20231130,PER,,US-JAZZ-2023-US-001579,JAZZ,,57.0,YR,,M,Y,,,20231130,,MD,US,US,2023,Q4,Adult
231396022,23139602,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,Tablet,,2023,Q4,Oedema,,2023,Q4,2,F,20230901.0,20231124.0,20231102,20231130,PER,,US-JAZZ-2023-US-001579,JAZZ,,57.0,YR,,M,Y,,,20231130,,MD,US,US,2023,Q4,Adult
231403982,23140398,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Lower respiratory tract infection,,2023,Q4,2,F,20230512.0,20231103.0,20231102,20231111,EXP,,FR-SANDOZ INC.-NVSC2023FR128112,SANDOZ,,75.0,YR,,F,Y,76.0,KG,20231111,,MD,FR,FR,2023,Q4,Elderly
231403982,23140398,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Abdominal pain upper,,2023,Q4,2,F,20230512.0,20231103.0,20231102,20231111,EXP,,FR-SANDOZ INC.-NVSC2023FR128112,SANDOZ,,75.0,YR,,F,Y,76.0,KG,20231111,,MD,FR,FR,2023,Q4,Elderly
231403982,23140398,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Asthenia,,2023,Q4,2,F,20230512.0,20231103.0,20231102,20231111,EXP,,FR-SANDOZ INC.-NVSC2023FR128112,SANDOZ,,75.0,YR,,F,Y,76.0,KG,20231111,,MD,FR,FR,2023,Q4,Elderly
231403982,23140398,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,COVID-19,,2023,Q4,2,F,20230512.0,20231103.0,20231102,20231111,EXP,,FR-SANDOZ INC.-NVSC2023FR128112,SANDOZ,,75.0,YR,,F,Y,76.0,KG,20231111,,MD,FR,FR,2023,Q4,Elderly
231403982,23140398,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Anaemia,,2023,Q4,2,F,20230512.0,20231103.0,20231102,20231111,EXP,,FR-SANDOZ INC.-NVSC2023FR128112,SANDOZ,,75.0,YR,,F,Y,76.0,KG,20231111,,MD,FR,FR,2023,Q4,Elderly
231403982,23140398,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Cardiac failure,,2023,Q4,2,F,20230512.0,20231103.0,20231102,20231111,EXP,,FR-SANDOZ INC.-NVSC2023FR128112,SANDOZ,,75.0,YR,,F,Y,76.0,KG,20231111,,MD,FR,FR,2023,Q4,Elderly
231403982,23140398,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Chills,,2023,Q4,2,F,20230512.0,20231103.0,20231102,20231111,EXP,,FR-SANDOZ INC.-NVSC2023FR128112,SANDOZ,,75.0,YR,,F,Y,76.0,KG,20231111,,MD,FR,FR,2023,Q4,Elderly
231410582,23141058,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,UNKNOWN,,,,,,,2023,Q4,Off label use,,2023,Q4,2,F,20230512.0,20231116.0,20231103,20231122,EXP,,FR-drreddys-CLI/FRA/23/0180812,DR REDDYS,,75.0,YR,E,F,Y,76.0,KG,20231122,,HP,FR,FR,2023,Q4,Elderly
231410582,23141058,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,UNKNOWN,,,,,,,2023,Q4,Asthenia,,2023,Q4,2,F,20230512.0,20231116.0,20231103,20231122,EXP,,FR-drreddys-CLI/FRA/23/0180812,DR REDDYS,,75.0,YR,E,F,Y,76.0,KG,20231122,,HP,FR,FR,2023,Q4,Elderly
231410582,23141058,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,UNKNOWN,,,,,,,2023,Q4,C-reactive protein increased,,2023,Q4,2,F,20230512.0,20231116.0,20231103,20231122,EXP,,FR-drreddys-CLI/FRA/23/0180812,DR REDDYS,,75.0,YR,E,F,Y,76.0,KG,20231122,,HP,FR,FR,2023,Q4,Elderly
231410582,23141058,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,UNKNOWN,,,,,,,2023,Q4,COVID-19,,2023,Q4,2,F,20230512.0,20231116.0,20231103,20231122,EXP,,FR-drreddys-CLI/FRA/23/0180812,DR REDDYS,,75.0,YR,E,F,Y,76.0,KG,20231122,,HP,FR,FR,2023,Q4,Elderly
231410582,23141058,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,UNKNOWN,,,,,,,2023,Q4,Pneumonia,,2023,Q4,2,F,20230512.0,20231116.0,20231103,20231122,EXP,,FR-drreddys-CLI/FRA/23/0180812,DR REDDYS,,75.0,YR,E,F,Y,76.0,KG,20231122,,HP,FR,FR,2023,Q4,Elderly
231410582,23141058,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,UNKNOWN,,,,,,,2023,Q4,Lower respiratory tract infection,,2023,Q4,2,F,20230512.0,20231116.0,20231103,20231122,EXP,,FR-drreddys-CLI/FRA/23/0180812,DR REDDYS,,75.0,YR,E,F,Y,76.0,KG,20231122,,HP,FR,FR,2023,Q4,Elderly
231410582,23141058,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,UNKNOWN,,,,,,,2023,Q4,Abdominal pain upper,,2023,Q4,2,F,20230512.0,20231116.0,20231103,20231122,EXP,,FR-drreddys-CLI/FRA/23/0180812,DR REDDYS,,75.0,YR,E,F,Y,76.0,KG,20231122,,HP,FR,FR,2023,Q4,Elderly
231410582,23141058,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,UNKNOWN,,,,,,,2023,Q4,Chills,,2023,Q4,2,F,20230512.0,20231116.0,20231103,20231122,EXP,,FR-drreddys-CLI/FRA/23/0180812,DR REDDYS,,75.0,YR,E,F,Y,76.0,KG,20231122,,HP,FR,FR,2023,Q4,Elderly
231410582,23141058,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,UNKNOWN,,,,,,,2023,Q4,Cardiac failure,,2023,Q4,2,F,20230512.0,20231116.0,20231103,20231122,EXP,,FR-drreddys-CLI/FRA/23/0180812,DR REDDYS,,75.0,YR,E,F,Y,76.0,KG,20231122,,HP,FR,FR,2023,Q4,Elderly
231410582,23141058,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,UNKNOWN,,,,,,,2023,Q4,Anaemia,,2023,Q4,2,F,20230512.0,20231116.0,20231103,20231122,EXP,,FR-drreddys-CLI/FRA/23/0180812,DR REDDYS,,75.0,YR,E,F,Y,76.0,KG,20231122,,HP,FR,FR,2023,Q4,Elderly
231410582,23141058,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,UNKNOWN,,,,,,,2023,Q4,Cough,,2023,Q4,2,F,20230512.0,20231116.0,20231103,20231122,EXP,,FR-drreddys-CLI/FRA/23/0180812,DR REDDYS,,75.0,YR,E,F,Y,76.0,KG,20231122,,HP,FR,FR,2023,Q4,Elderly
231437771,23143777,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2023,Q4,Therapy interrupted,,2023,Q4,1,I,20230701.0,20230717.0,20231103,20231103,PER,,US-MYOVANT SCIENCES GMBH-2023MYSCI0700352,MYOVANT SCIENCES,,85.0,YR,,M,Y,,,20231103,,CN,US,US,2023,Q4,Elderly
231446891,23144689,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q4,Pituitary-dependent Cushing's syndrome,,2023,Q4,1,I,,20231102.0,20231103,20231103,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-270821",BOEHRINGER INGELHEIM,"Zahid H, Whitelaw BC, Mustafa OG, Taylor DR, Iqbal M. Hidden life-threatening complication of Cushing?s syndrome identified by blood gas analysis. British Journal of Diabetes. 2023;23(1): 2. doi:10.15277/bjd. 2023.407.",55.0,YR,A,F,Y,,,20231103,,HP,GB,GB,2023,Q4,Adult
231446891,23144689,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q4,Euglycaemic diabetic ketoacidosis,,2023,Q4,1,I,,20231102.0,20231103,20231103,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-270821",BOEHRINGER INGELHEIM,"Zahid H, Whitelaw BC, Mustafa OG, Taylor DR, Iqbal M. Hidden life-threatening complication of Cushing?s syndrome identified by blood gas analysis. British Journal of Diabetes. 2023;23(1): 2. doi:10.15277/bjd. 2023.407.",55.0,YR,A,F,Y,,,20231103,,HP,GB,GB,2023,Q4,Adult
231446891,23144689,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q4,General physical health deterioration,,2023,Q4,1,I,,20231102.0,20231103,20231103,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-270821",BOEHRINGER INGELHEIM,"Zahid H, Whitelaw BC, Mustafa OG, Taylor DR, Iqbal M. Hidden life-threatening complication of Cushing?s syndrome identified by blood gas analysis. British Journal of Diabetes. 2023;23(1): 2. doi:10.15277/bjd. 2023.407.",55.0,YR,A,F,Y,,,20231103,,HP,GB,GB,2023,Q4,Adult
231455702,23145570,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,,10.0,MG,Tablet,QD,2023,Q4,Pain in extremity,,2023,Q4,2,F,20231026.0,20231116.0,20231103,20231120,EXP,,NL-JNJFOC-20231068382,JOHNSON AND JOHNSON,,65.0,YR,E,M,Y,137.0,KG,20231120,,MD,NL,NL,2023,Q4,Elderly
231487731,23148773,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, qd, Take 1 tablet in the morning",,,,,,,,,,Tablet,QD,2023,Q4,Renal impairment,,2023,Q4,1,I,,20231031.0,20231106,20231106,EXP,,BR-DSJP-DSE-2023-145181,DAIICHI,,75.0,YR,,M,Y,75.0,KG,20231106,,MD,BR,BR,2023,Q4,Elderly
231502321,23150232,5,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,,,,,,,,2023,Q4,Haematemesis,,2023,Q4,1,I,,20231031.0,20231106,20231106,EXP,,IL-BRISTOL-MYERS SQUIBB COMPANY-2023-158208,BRISTOL MYERS SQUIBB,,73.0,YR,E,F,Y,,,20231106,,PH,IL,IL,2023,Q4,Elderly
231502321,23150232,5,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,,,,,,,,2023,Q4,Faeces discoloured,,2023,Q4,1,I,,20231031.0,20231106,20231106,EXP,,IL-BRISTOL-MYERS SQUIBB COMPANY-2023-158208,BRISTOL MYERS SQUIBB,,73.0,YR,E,F,Y,,,20231106,,PH,IL,IL,2023,Q4,Elderly
231509702,23150970,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2023,Q4,Cardiac failure chronic,,2023,Q4,2,F,20230511.0,20231208.0,20231106,20231215,EXP,,NVSJ2023JP015817,NOVARTIS,,83.0,YR,,M,Y,,,20231214,,HP,JP,JP,2023,Q4,Elderly
231509702,23150970,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2023,Q4,Atrioventricular block,,2023,Q4,2,F,20230511.0,20231208.0,20231106,20231215,EXP,,NVSJ2023JP015817,NOVARTIS,,83.0,YR,,M,Y,,,20231214,,HP,JP,JP,2023,Q4,Elderly
231509702,23150970,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2023,Q4,Glomerular filtration rate abnormal,,2023,Q4,2,F,20230511.0,20231208.0,20231106,20231215,EXP,,NVSJ2023JP015817,NOVARTIS,,83.0,YR,,M,Y,,,20231214,,HP,JP,JP,2023,Q4,Elderly
231509702,23150970,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2023,Q4,Oedema peripheral,,2023,Q4,2,F,20230511.0,20231208.0,20231106,20231215,EXP,,NVSJ2023JP015817,NOVARTIS,,83.0,YR,,M,Y,,,20231214,,HP,JP,JP,2023,Q4,Elderly
231509702,23150970,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2023,Q4,Weight decreased,,2023,Q4,2,F,20230511.0,20231208.0,20231106,20231215,EXP,,NVSJ2023JP015817,NOVARTIS,,83.0,YR,,M,Y,,,20231214,,HP,JP,JP,2023,Q4,Elderly
231509702,23150970,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2023,Q4,Weight increased,,2023,Q4,2,F,20230511.0,20231208.0,20231106,20231215,EXP,,NVSJ2023JP015817,NOVARTIS,,83.0,YR,,M,Y,,,20231214,,HP,JP,JP,2023,Q4,Elderly
231509702,23150970,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2023,Q4,Pleural effusion,,2023,Q4,2,F,20230511.0,20231208.0,20231106,20231215,EXP,,NVSJ2023JP015817,NOVARTIS,,83.0,YR,,M,Y,,,20231214,,HP,JP,JP,2023,Q4,Elderly
231509702,23150970,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2023,Q4,Oxygen saturation decreased,,2023,Q4,2,F,20230511.0,20231208.0,20231106,20231215,EXP,,NVSJ2023JP015817,NOVARTIS,,83.0,YR,,M,Y,,,20231214,,HP,JP,JP,2023,Q4,Elderly
231509702,23150970,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2023,Q4,Hepatic vein dilatation,,2023,Q4,2,F,20230511.0,20231208.0,20231106,20231215,EXP,,NVSJ2023JP015817,NOVARTIS,,83.0,YR,,M,Y,,,20231214,,HP,JP,JP,2023,Q4,Elderly
231516311,23151631,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,204629.0,10.0,MG,,QD,2023,Q4,Coma,,2023,Q4,1,I,,20231031.0,20231107,20231107,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-270167",BOEHRINGER INGELHEIM,Nagamine T. Sepsis associated with sodium glucose cotransporter 2 inhibitor in an elderly patient with chronic kidney disease. Geriatrics and Gerontology International. 2023;23(10): 757-758. doi:10.1111/ ggi.14659.,72.0,YR,E,F,Y,52.0,KG,20231107,,HP,JP,JP,2023,Q4,Elderly
231516311,23151631,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,204629.0,10.0,MG,,QD,2023,Q4,Enterococcal infection,,2023,Q4,1,I,,20231031.0,20231107,20231107,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-270167",BOEHRINGER INGELHEIM,Nagamine T. Sepsis associated with sodium glucose cotransporter 2 inhibitor in an elderly patient with chronic kidney disease. Geriatrics and Gerontology International. 2023;23(10): 757-758. doi:10.1111/ ggi.14659.,72.0,YR,E,F,Y,52.0,KG,20231107,,HP,JP,JP,2023,Q4,Elderly
231516311,23151631,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,204629.0,10.0,MG,,QD,2023,Q4,Escherichia infection,,2023,Q4,1,I,,20231031.0,20231107,20231107,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-270167",BOEHRINGER INGELHEIM,Nagamine T. Sepsis associated with sodium glucose cotransporter 2 inhibitor in an elderly patient with chronic kidney disease. Geriatrics and Gerontology International. 2023;23(10): 757-758. doi:10.1111/ ggi.14659.,72.0,YR,E,F,Y,52.0,KG,20231107,,HP,JP,JP,2023,Q4,Elderly
231516311,23151631,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,204629.0,10.0,MG,,QD,2023,Q4,Sepsis,,2023,Q4,1,I,,20231031.0,20231107,20231107,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-270167",BOEHRINGER INGELHEIM,Nagamine T. Sepsis associated with sodium glucose cotransporter 2 inhibitor in an elderly patient with chronic kidney disease. Geriatrics and Gerontology International. 2023;23(10): 757-758. doi:10.1111/ ggi.14659.,72.0,YR,E,F,Y,52.0,KG,20231107,,HP,JP,JP,2023,Q4,Elderly
231520541,23152054,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,unk,,,,,,,2023,Q4,Hypokalaemia,,2023,Q4,1,I,,20231027.0,20231107,20231107,EXP,GB-MHRA-MED-202310262028591480-TBRFV,GB-NOVOPROD-1133815,NOVO NORDISK,,58.0,YR,,M,Y,88.0,KG,20231107,,MD,GB,GB,2023,Q4,Adult
231525731,23152573,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"0.1 milligram/kilogram, per day for the first 2days",,,,,,,,0.1,MG/KG,,QD,2023,Q4,Splenomegaly,,2023,Q4,1,I,,20231101.0,20231107,20231107,EXP,,IT-AMGEN-ITASP2023196066,AMGEN,Zuin G. Crohn-like disease long remission in a pediatric patient with glycogen storage disease type lb treated with empagliflozin: a case report. Therapeutic Advances in Gastroenterology. 2023;16:1-7,7.0,YR,C,M,Y,,,20231107,,HP,IT,IT,2023,Q4,Child
231525731,23152573,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"0.1 milligram/kilogram, per day for the first 2days",,,,,,,,0.1,MG/KG,,QD,2023,Q4,Infection,,2023,Q4,1,I,,20231101.0,20231107,20231107,EXP,,IT-AMGEN-ITASP2023196066,AMGEN,Zuin G. Crohn-like disease long remission in a pediatric patient with glycogen storage disease type lb treated with empagliflozin: a case report. Therapeutic Advances in Gastroenterology. 2023;16:1-7,7.0,YR,C,M,Y,,,20231107,,HP,IT,IT,2023,Q4,Child
231525731,23152573,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"0.1 milligram/kilogram, per day for the first 2days",,,,,,,,0.1,MG/KG,,QD,2023,Q4,Glycosuria,,2023,Q4,1,I,,20231101.0,20231107,20231107,EXP,,IT-AMGEN-ITASP2023196066,AMGEN,Zuin G. Crohn-like disease long remission in a pediatric patient with glycogen storage disease type lb treated with empagliflozin: a case report. Therapeutic Advances in Gastroenterology. 2023;16:1-7,7.0,YR,C,M,Y,,,20231107,,HP,IT,IT,2023,Q4,Child
231525731,23152573,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"0.1 milligram/kilogram, per day for the first 2days",,,,,,,,0.1,MG/KG,,QD,2023,Q4,Aphthous ulcer,,2023,Q4,1,I,,20231101.0,20231107,20231107,EXP,,IT-AMGEN-ITASP2023196066,AMGEN,Zuin G. Crohn-like disease long remission in a pediatric patient with glycogen storage disease type lb treated with empagliflozin: a case report. Therapeutic Advances in Gastroenterology. 2023;16:1-7,7.0,YR,C,M,Y,,,20231107,,HP,IT,IT,2023,Q4,Child
231525731,23152573,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"0.1 milligram/kilogram, per day for the first 2days",,,,,,,,0.1,MG/KG,,QD,2023,Q4,Inflammatory bowel disease,,2023,Q4,1,I,,20231101.0,20231107,20231107,EXP,,IT-AMGEN-ITASP2023196066,AMGEN,Zuin G. Crohn-like disease long remission in a pediatric patient with glycogen storage disease type lb treated with empagliflozin: a case report. Therapeutic Advances in Gastroenterology. 2023;16:1-7,7.0,YR,C,M,Y,,,20231107,,HP,IT,IT,2023,Q4,Child
231525731,23152573,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"0.1 milligram/kilogram, per day for the first 2days",,,,,,,,0.1,MG/KG,,QD,2023,Q4,Hypersplenism,,2023,Q4,1,I,,20231101.0,20231107,20231107,EXP,,IT-AMGEN-ITASP2023196066,AMGEN,Zuin G. Crohn-like disease long remission in a pediatric patient with glycogen storage disease type lb treated with empagliflozin: a case report. Therapeutic Advances in Gastroenterology. 2023;16:1-7,7.0,YR,C,M,Y,,,20231107,,HP,IT,IT,2023,Q4,Child
231525731,23152573,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"0.1 milligram/kilogram, per day for the first 2days",,,,,,,,0.1,MG/KG,,QD,2023,Q4,Hypoglycaemia,,2023,Q4,1,I,,20231101.0,20231107,20231107,EXP,,IT-AMGEN-ITASP2023196066,AMGEN,Zuin G. Crohn-like disease long remission in a pediatric patient with glycogen storage disease type lb treated with empagliflozin: a case report. Therapeutic Advances in Gastroenterology. 2023;16:1-7,7.0,YR,C,M,Y,,,20231107,,HP,IT,IT,2023,Q4,Child
231525731,23152573,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"0.1 milligram/kilogram, two doses from day+ 3 of treatment as planned",,,,,,,,0.2,MG/KG,,,2023,Q4,Splenomegaly,,2023,Q4,1,I,,20231101.0,20231107,20231107,EXP,,IT-AMGEN-ITASP2023196066,AMGEN,Zuin G. Crohn-like disease long remission in a pediatric patient with glycogen storage disease type lb treated with empagliflozin: a case report. Therapeutic Advances in Gastroenterology. 2023;16:1-7,7.0,YR,C,M,Y,,,20231107,,HP,IT,IT,2023,Q4,Child
231525731,23152573,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"0.1 milligram/kilogram, two doses from day+ 3 of treatment as planned",,,,,,,,0.2,MG/KG,,,2023,Q4,Infection,,2023,Q4,1,I,,20231101.0,20231107,20231107,EXP,,IT-AMGEN-ITASP2023196066,AMGEN,Zuin G. Crohn-like disease long remission in a pediatric patient with glycogen storage disease type lb treated with empagliflozin: a case report. Therapeutic Advances in Gastroenterology. 2023;16:1-7,7.0,YR,C,M,Y,,,20231107,,HP,IT,IT,2023,Q4,Child
231525731,23152573,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"0.1 milligram/kilogram, two doses from day+ 3 of treatment as planned",,,,,,,,0.2,MG/KG,,,2023,Q4,Glycosuria,,2023,Q4,1,I,,20231101.0,20231107,20231107,EXP,,IT-AMGEN-ITASP2023196066,AMGEN,Zuin G. Crohn-like disease long remission in a pediatric patient with glycogen storage disease type lb treated with empagliflozin: a case report. Therapeutic Advances in Gastroenterology. 2023;16:1-7,7.0,YR,C,M,Y,,,20231107,,HP,IT,IT,2023,Q4,Child
231525731,23152573,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"0.1 milligram/kilogram, two doses from day+ 3 of treatment as planned",,,,,,,,0.2,MG/KG,,,2023,Q4,Aphthous ulcer,,2023,Q4,1,I,,20231101.0,20231107,20231107,EXP,,IT-AMGEN-ITASP2023196066,AMGEN,Zuin G. Crohn-like disease long remission in a pediatric patient with glycogen storage disease type lb treated with empagliflozin: a case report. Therapeutic Advances in Gastroenterology. 2023;16:1-7,7.0,YR,C,M,Y,,,20231107,,HP,IT,IT,2023,Q4,Child
231525731,23152573,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"0.1 milligram/kilogram, two doses from day+ 3 of treatment as planned",,,,,,,,0.2,MG/KG,,,2023,Q4,Inflammatory bowel disease,,2023,Q4,1,I,,20231101.0,20231107,20231107,EXP,,IT-AMGEN-ITASP2023196066,AMGEN,Zuin G. Crohn-like disease long remission in a pediatric patient with glycogen storage disease type lb treated with empagliflozin: a case report. Therapeutic Advances in Gastroenterology. 2023;16:1-7,7.0,YR,C,M,Y,,,20231107,,HP,IT,IT,2023,Q4,Child
231525731,23152573,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"0.1 milligram/kilogram, two doses from day+ 3 of treatment as planned",,,,,,,,0.2,MG/KG,,,2023,Q4,Hypersplenism,,2023,Q4,1,I,,20231101.0,20231107,20231107,EXP,,IT-AMGEN-ITASP2023196066,AMGEN,Zuin G. Crohn-like disease long remission in a pediatric patient with glycogen storage disease type lb treated with empagliflozin: a case report. Therapeutic Advances in Gastroenterology. 2023;16:1-7,7.0,YR,C,M,Y,,,20231107,,HP,IT,IT,2023,Q4,Child
231525731,23152573,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"0.1 milligram/kilogram, two doses from day+ 3 of treatment as planned",,,,,,,,0.2,MG/KG,,,2023,Q4,Hypoglycaemia,,2023,Q4,1,I,,20231101.0,20231107,20231107,EXP,,IT-AMGEN-ITASP2023196066,AMGEN,Zuin G. Crohn-like disease long remission in a pediatric patient with glycogen storage disease type lb treated with empagliflozin: a case report. Therapeutic Advances in Gastroenterology. 2023;16:1-7,7.0,YR,C,M,Y,,,20231107,,HP,IT,IT,2023,Q4,Child
231529041,23152904,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Asked But Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q4,Syncope,,2023,Q4,1,I,20231006.0,20231107.0,20231107,20231107,EXP,NO-NOMAADVRE-RELISN-2023-Vrx9z7,"NO-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-271352",BOEHRINGER INGELHEIM,,55.0,YR,A,M,Y,,,20231107,,MD,NO,NO,2023,Q4,Adult
231529041,23152904,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Asked But Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q4,Drug interaction,,2023,Q4,1,I,20231006.0,20231107.0,20231107,20231107,EXP,NO-NOMAADVRE-RELISN-2023-Vrx9z7,"NO-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-271352",BOEHRINGER INGELHEIM,,55.0,YR,A,M,Y,,,20231107,,MD,NO,NO,2023,Q4,Adult
231529041,23152904,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Asked But Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q4,General physical health deterioration,,2023,Q4,1,I,20231006.0,20231107.0,20231107,20231107,EXP,NO-NOMAADVRE-RELISN-2023-Vrx9z7,"NO-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-271352",BOEHRINGER INGELHEIM,,55.0,YR,A,M,Y,,,20231107,,MD,NO,NO,2023,Q4,Adult
231529041,23152904,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Asked But Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q4,Increased appetite,,2023,Q4,1,I,20231006.0,20231107.0,20231107,20231107,EXP,NO-NOMAADVRE-RELISN-2023-Vrx9z7,"NO-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-271352",BOEHRINGER INGELHEIM,,55.0,YR,A,M,Y,,,20231107,,MD,NO,NO,2023,Q4,Adult
231529041,23152904,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Asked But Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q4,Hypotension,,2023,Q4,1,I,20231006.0,20231107.0,20231107,20231107,EXP,NO-NOMAADVRE-RELISN-2023-Vrx9z7,"NO-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-271352",BOEHRINGER INGELHEIM,,55.0,YR,A,M,Y,,,20231107,,MD,NO,NO,2023,Q4,Adult
231529041,23152904,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Asked But Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q4,Hyponatraemia,,2023,Q4,1,I,20231006.0,20231107.0,20231107,20231107,EXP,NO-NOMAADVRE-RELISN-2023-Vrx9z7,"NO-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-271352",BOEHRINGER INGELHEIM,,55.0,YR,A,M,Y,,,20231107,,MD,NO,NO,2023,Q4,Adult
231529041,23152904,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Asked But Unknown,,204629.0,,,,,2023,Q4,Syncope,,2023,Q4,1,I,20231006.0,20231107.0,20231107,20231107,EXP,NO-NOMAADVRE-RELISN-2023-Vrx9z7,"NO-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-271352",BOEHRINGER INGELHEIM,,55.0,YR,A,M,Y,,,20231107,,MD,NO,NO,2023,Q4,Adult
231529041,23152904,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Asked But Unknown,,204629.0,,,,,2023,Q4,Drug interaction,,2023,Q4,1,I,20231006.0,20231107.0,20231107,20231107,EXP,NO-NOMAADVRE-RELISN-2023-Vrx9z7,"NO-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-271352",BOEHRINGER INGELHEIM,,55.0,YR,A,M,Y,,,20231107,,MD,NO,NO,2023,Q4,Adult
231529041,23152904,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Asked But Unknown,,204629.0,,,,,2023,Q4,General physical health deterioration,,2023,Q4,1,I,20231006.0,20231107.0,20231107,20231107,EXP,NO-NOMAADVRE-RELISN-2023-Vrx9z7,"NO-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-271352",BOEHRINGER INGELHEIM,,55.0,YR,A,M,Y,,,20231107,,MD,NO,NO,2023,Q4,Adult
231529041,23152904,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Asked But Unknown,,204629.0,,,,,2023,Q4,Increased appetite,,2023,Q4,1,I,20231006.0,20231107.0,20231107,20231107,EXP,NO-NOMAADVRE-RELISN-2023-Vrx9z7,"NO-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-271352",BOEHRINGER INGELHEIM,,55.0,YR,A,M,Y,,,20231107,,MD,NO,NO,2023,Q4,Adult
231529041,23152904,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Asked But Unknown,,204629.0,,,,,2023,Q4,Hypotension,,2023,Q4,1,I,20231006.0,20231107.0,20231107,20231107,EXP,NO-NOMAADVRE-RELISN-2023-Vrx9z7,"NO-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-271352",BOEHRINGER INGELHEIM,,55.0,YR,A,M,Y,,,20231107,,MD,NO,NO,2023,Q4,Adult
231529041,23152904,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Asked But Unknown,,204629.0,,,,,2023,Q4,Hyponatraemia,,2023,Q4,1,I,20231006.0,20231107.0,20231107,20231107,EXP,NO-NOMAADVRE-RELISN-2023-Vrx9z7,"NO-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-271352",BOEHRINGER INGELHEIM,,55.0,YR,A,M,Y,,,20231107,,MD,NO,NO,2023,Q4,Adult
231540331,23154033,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q4,Staphylococcal infection,,2023,Q4,1,I,20230602.0,20231031.0,20231107,20231107,EXP,,ES-SA-2023SA177982,SANOFI AVENTIS,,64.0,YR,A,F,Y,80.0,KG,20231107,,HP,ES,ES,2023,Q4,Adult
231540331,23154033,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q4,Hip fracture,,2023,Q4,1,I,20230602.0,20231031.0,20231107,20231107,EXP,,ES-SA-2023SA177982,SANOFI AVENTIS,,64.0,YR,A,F,Y,80.0,KG,20231107,,HP,ES,ES,2023,Q4,Adult
231582491,23158249,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg film-coated tablets 30 tablets,,,,,,,,10.0,MG,,,2023,Q4,Abdominal pain,,2023,Q4,1,I,20230611.0,20231027.0,20231108,20231108,EXP,ES-AEMPS-1437452,ES-Accord-388319,ACCORD,,69.0,YR,E,M,Y,,,20231108,,MD,ES,ES,2023,Q4,Elderly
231582491,23158249,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg film-coated tablets 30 tablets,,,,,,,,10.0,MG,,,2023,Q4,Urticaria,,2023,Q4,1,I,20230611.0,20231027.0,20231108,20231108,EXP,ES-AEMPS-1437452,ES-Accord-388319,ACCORD,,69.0,YR,E,M,Y,,,20231108,,MD,ES,ES,2023,Q4,Elderly
231582491,23158249,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg film-coated tablets 30 tablets,,,,,,,,10.0,MG,,,2023,Q4,Nausea,,2023,Q4,1,I,20230611.0,20231027.0,20231108,20231108,EXP,ES-AEMPS-1437452,ES-Accord-388319,ACCORD,,69.0,YR,E,M,Y,,,20231108,,MD,ES,ES,2023,Q4,Elderly
231582491,23158249,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg film-coated tablets 30 tablets,,,,,,,,10.0,MG,,,2023,Q4,Diarrhoea,,2023,Q4,1,I,20230611.0,20231027.0,20231108,20231108,EXP,ES-AEMPS-1437452,ES-Accord-388319,ACCORD,,69.0,YR,E,M,Y,,,20231108,,MD,ES,ES,2023,Q4,Elderly
231597761,23159776,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q4,Drug ineffective,,2023,Q4,1,I,,20231030.0,20231108,20231108,EXP,,US-TEVA-2023-US-2942263,TEVA,,57.0,YR,A,M,Y,,,20231108,,HP,US,US,2023,Q4,Adult
231597761,23159776,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q4,Euglycaemic diabetic ketoacidosis,,2023,Q4,1,I,,20231030.0,20231108,20231108,EXP,,US-TEVA-2023-US-2942263,TEVA,,57.0,YR,A,M,Y,,,20231108,,HP,US,US,2023,Q4,Adult
231599312,23159931,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg/day,,,,,,,,,,,,2023,Q4,Oxygen saturation decreased,,2023,Q4,2,F,20230511.0,20231208.0,20231108,20231219,EXP,,JP-OTSUKA-2023_028778,OTSUKA,,83.0,YR,,M,Y,60.0,KG,20231219,,HP,JP,JP,2023,Q4,Elderly
231599312,23159931,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg/day,,,,,,,,,,,,2023,Q4,Oedema,,2023,Q4,2,F,20230511.0,20231208.0,20231108,20231219,EXP,,JP-OTSUKA-2023_028778,OTSUKA,,83.0,YR,,M,Y,60.0,KG,20231219,,HP,JP,JP,2023,Q4,Elderly
231599312,23159931,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg/day,,,,,,,,,,,,2023,Q4,Weight increased,,2023,Q4,2,F,20230511.0,20231208.0,20231108,20231219,EXP,,JP-OTSUKA-2023_028778,OTSUKA,,83.0,YR,,M,Y,60.0,KG,20231219,,HP,JP,JP,2023,Q4,Elderly
231599312,23159931,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg/day,,,,,,,,,,,,2023,Q4,Atrial fibrillation,,2023,Q4,2,F,20230511.0,20231208.0,20231108,20231219,EXP,,JP-OTSUKA-2023_028778,OTSUKA,,83.0,YR,,M,Y,60.0,KG,20231219,,HP,JP,JP,2023,Q4,Elderly
231599312,23159931,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg/day,,,,,,,,,,,,2023,Q4,Underdose,,2023,Q4,2,F,20230511.0,20231208.0,20231108,20231219,EXP,,JP-OTSUKA-2023_028778,OTSUKA,,83.0,YR,,M,Y,60.0,KG,20231219,,HP,JP,JP,2023,Q4,Elderly
231625752,23162575,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q4,Pancreatitis acute,,2023,Q4,2,F,,20231031.0,20231109,20231109,EXP,,JP-EMD Serono-2023486761,EMD SERONO INC,,58.0,YR,A,M,Y,68.0,KG,20231109,,HP,JP,JP,2023,Q4,Adult
231625752,23162575,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q4,Hypoglycaemia,,2023,Q4,2,F,,20231031.0,20231109,20231109,EXP,,JP-EMD Serono-2023486761,EMD SERONO INC,,58.0,YR,A,M,Y,68.0,KG,20231109,,HP,JP,JP,2023,Q4,Adult
231625752,23162575,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q4,Lactic acidosis,,2023,Q4,2,F,,20231031.0,20231109,20231109,EXP,,JP-EMD Serono-2023486761,EMD SERONO INC,,58.0,YR,A,M,Y,68.0,KG,20231109,,HP,JP,JP,2023,Q4,Adult
231625752,23162575,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q4,Hypokinesia,,2023,Q4,2,F,,20231031.0,20231109,20231109,EXP,,JP-EMD Serono-2023486761,EMD SERONO INC,,58.0,YR,A,M,Y,68.0,KG,20231109,,HP,JP,JP,2023,Q4,Adult
231625752,23162575,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q4,Nasopharyngitis,,2023,Q4,2,F,,20231031.0,20231109,20231109,EXP,,JP-EMD Serono-2023486761,EMD SERONO INC,,58.0,YR,A,M,Y,68.0,KG,20231109,,HP,JP,JP,2023,Q4,Adult
231625752,23162575,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q4,Acute kidney injury,,2023,Q4,2,F,,20231031.0,20231109,20231109,EXP,,JP-EMD Serono-2023486761,EMD SERONO INC,,58.0,YR,A,M,Y,68.0,KG,20231109,,HP,JP,JP,2023,Q4,Adult
231625752,23162575,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q4,Diabetic ketoacidosis,,2023,Q4,2,F,,20231031.0,20231109,20231109,EXP,,JP-EMD Serono-2023486761,EMD SERONO INC,,58.0,YR,A,M,Y,68.0,KG,20231109,,HP,JP,JP,2023,Q4,Adult
231625752,23162575,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q4,Blood pressure increased,,2023,Q4,2,F,,20231031.0,20231109,20231109,EXP,,JP-EMD Serono-2023486761,EMD SERONO INC,,58.0,YR,A,M,Y,68.0,KG,20231109,,HP,JP,JP,2023,Q4,Adult
231625752,23162575,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q4,Dehydration,,2023,Q4,2,F,,20231031.0,20231109,20231109,EXP,,JP-EMD Serono-2023486761,EMD SERONO INC,,58.0,YR,A,M,Y,68.0,KG,20231109,,HP,JP,JP,2023,Q4,Adult
231640961,23164096,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,Unknown,,2023,Q4,Drug ineffective,,2023,Q4,1,I,,20231030.0,20231109,20231109,EXP,,HK-MYLANLABS-2023M1117255,MYLAN,"Ching S, Yue CS. Acute perimyocarditis following heterologous vaccination of CoronaVac and BNT162b2 SARS-CoV-2 vaccine in an elderly woman. J-Geriatr-Cardiol 2022;19(10):785-787.",72.0,YR,,F,Y,,,20231109,,HP,HK,HK,2023,Q4,Elderly
231694852,23169485,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,,,,25.0,MG,Tablet,QD,2023,Q4,Nausea,,2023,Q4,2,F,20220101.0,20231115.0,20231110,20231124,EXP,,JP-NOVOPROD-963951,NOVO NORDISK,,72.0,YR,,F,Y,68.0,KG,20231124,,MD,JP,JP,2023,Q4,Elderly
231694852,23169485,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,,,,25.0,MG,Tablet,QD,2023,Q4,Faeces hard,,2023,Q4,2,F,20220101.0,20231115.0,20231110,20231124,EXP,,JP-NOVOPROD-963951,NOVO NORDISK,,72.0,YR,,F,Y,68.0,KG,20231124,,MD,JP,JP,2023,Q4,Elderly
231694852,23169485,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,,,,25.0,MG,Tablet,QD,2023,Q4,Vomiting,,2023,Q4,2,F,20220101.0,20231115.0,20231110,20231124,EXP,,JP-NOVOPROD-963951,NOVO NORDISK,,72.0,YR,,F,Y,68.0,KG,20231124,,MD,JP,JP,2023,Q4,Elderly
231694852,23169485,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,,,,25.0,MG,Tablet,QD,2023,Q4,Ketosis,,2023,Q4,2,F,20220101.0,20231115.0,20231110,20231124,EXP,,JP-NOVOPROD-963951,NOVO NORDISK,,72.0,YR,,F,Y,68.0,KG,20231124,,MD,JP,JP,2023,Q4,Elderly
231694852,23169485,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,,,,25.0,MG,Tablet,QD,2023,Q4,Dehydration,,2023,Q4,2,F,20220101.0,20231115.0,20231110,20231124,EXP,,JP-NOVOPROD-963951,NOVO NORDISK,,72.0,YR,,F,Y,68.0,KG,20231124,,MD,JP,JP,2023,Q4,Elderly
231694852,23169485,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,,,,25.0,MG,Tablet,QD,2023,Q4,Decreased appetite,,2023,Q4,2,F,20220101.0,20231115.0,20231110,20231124,EXP,,JP-NOVOPROD-963951,NOVO NORDISK,,72.0,YR,,F,Y,68.0,KG,20231124,,MD,JP,JP,2023,Q4,Elderly
231694852,23169485,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,,,,25.0,MG,Tablet,QD,2023,Q4,Diarrhoea,,2023,Q4,2,F,20220101.0,20231115.0,20231110,20231124,EXP,,JP-NOVOPROD-963951,NOVO NORDISK,,72.0,YR,,F,Y,68.0,KG,20231124,,MD,JP,JP,2023,Q4,Elderly
231703591,23170359,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q4,Fall,,2023,Q4,1,I,,20231104.0,20231110,20231110,EXP,CA-MHPD-001057519,CA-Accord-389416,ACCORD,,78.0,YR,E,F,Y,,,20231110,,HP,CA,CA,2023,Q4,Elderly
231703591,23170359,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q4,Muscular weakness,,2023,Q4,1,I,,20231104.0,20231110,20231110,EXP,CA-MHPD-001057519,CA-Accord-389416,ACCORD,,78.0,YR,E,F,Y,,,20231110,,HP,CA,CA,2023,Q4,Elderly
231703591,23170359,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q4,Liver function test abnormal,,2023,Q4,1,I,,20231104.0,20231110,20231110,EXP,CA-MHPD-001057519,CA-Accord-389416,ACCORD,,78.0,YR,E,F,Y,,,20231110,,HP,CA,CA,2023,Q4,Elderly
231703591,23170359,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q4,Myalgia,,2023,Q4,1,I,,20231104.0,20231110,20231110,EXP,CA-MHPD-001057519,CA-Accord-389416,ACCORD,,78.0,YR,E,F,Y,,,20231110,,HP,CA,CA,2023,Q4,Elderly
231703591,23170359,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q4,Acute kidney injury,,2023,Q4,1,I,,20231104.0,20231110,20231110,EXP,CA-MHPD-001057519,CA-Accord-389416,ACCORD,,78.0,YR,E,F,Y,,,20231110,,HP,CA,CA,2023,Q4,Elderly
231703591,23170359,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q4,Hypoglycaemia,,2023,Q4,1,I,,20231104.0,20231110,20231110,EXP,CA-MHPD-001057519,CA-Accord-389416,ACCORD,,78.0,YR,E,F,Y,,,20231110,,HP,CA,CA,2023,Q4,Elderly
231703591,23170359,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q4,Myositis,,2023,Q4,1,I,,20231104.0,20231110,20231110,EXP,CA-MHPD-001057519,CA-Accord-389416,ACCORD,,78.0,YR,E,F,Y,,,20231110,,HP,CA,CA,2023,Q4,Elderly
231703591,23170359,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q4,Blood creatine phosphokinase increased,,2023,Q4,1,I,,20231104.0,20231110,20231110,EXP,CA-MHPD-001057519,CA-Accord-389416,ACCORD,,78.0,YR,E,F,Y,,,20231110,,HP,CA,CA,2023,Q4,Elderly
231717162,23171716,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, qd (10 mg, 1-0-0)",,,,,,,,,,,QD,2023,Q4,Emotional distress,,2023,Q4,2,F,20231005.0,20231110.0,20231110,20231117,EXP,,DE-DSJP-DSE-2023-146152,DAIICHI,,68.0,YR,,M,Y,82.0,KG,20231117,,MD,DE,DE,2023,Q4,Elderly
231717162,23171716,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, qd (10 mg, 1-0-0)",,,,,,,,,,,QD,2023,Q4,Urethral haemorrhage,,2023,Q4,2,F,20231005.0,20231110.0,20231110,20231117,EXP,,DE-DSJP-DSE-2023-146152,DAIICHI,,68.0,YR,,M,Y,82.0,KG,20231117,,MD,DE,DE,2023,Q4,Elderly
231717162,23171716,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, qd (10 mg, 1-0-0)",,,,,,,,,,,QD,2023,Q4,Haemorrhage urinary tract,,2023,Q4,2,F,20231005.0,20231110.0,20231110,20231117,EXP,,DE-DSJP-DSE-2023-146152,DAIICHI,,68.0,YR,,M,Y,82.0,KG,20231117,,MD,DE,DE,2023,Q4,Elderly
231733811,23173381,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,U,,,,,10.0,MG,Tablet,QD,2023,Q4,Syncope,,2023,Q4,1,I,20231006.0,20231107.0,20231111,20231111,EXP,NO-NOMAADVRE-RELISN-2023-Vrx9z7,NVSC2023NO237903,NOVARTIS,,55.0,YR,,M,Y,,,20231111,,MD,NO,NO,2023,Q4,Adult
231733811,23173381,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,U,,,,,10.0,MG,Tablet,QD,2023,Q4,Hypotension,,2023,Q4,1,I,20231006.0,20231107.0,20231111,20231111,EXP,NO-NOMAADVRE-RELISN-2023-Vrx9z7,NVSC2023NO237903,NOVARTIS,,55.0,YR,,M,Y,,,20231111,,MD,NO,NO,2023,Q4,Adult
231733811,23173381,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,U,,,,,10.0,MG,Tablet,QD,2023,Q4,General physical health deterioration,,2023,Q4,1,I,20231006.0,20231107.0,20231111,20231111,EXP,NO-NOMAADVRE-RELISN-2023-Vrx9z7,NVSC2023NO237903,NOVARTIS,,55.0,YR,,M,Y,,,20231111,,MD,NO,NO,2023,Q4,Adult
231733811,23173381,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,U,,,,,10.0,MG,Tablet,QD,2023,Q4,Drug interaction,,2023,Q4,1,I,20231006.0,20231107.0,20231111,20231111,EXP,NO-NOMAADVRE-RELISN-2023-Vrx9z7,NVSC2023NO237903,NOVARTIS,,55.0,YR,,M,Y,,,20231111,,MD,NO,NO,2023,Q4,Adult
231733811,23173381,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,U,,,,,10.0,MG,Tablet,QD,2023,Q4,Hyponatraemia,,2023,Q4,1,I,20231006.0,20231107.0,20231111,20231111,EXP,NO-NOMAADVRE-RELISN-2023-Vrx9z7,NVSC2023NO237903,NOVARTIS,,55.0,YR,,M,Y,,,20231111,,MD,NO,NO,2023,Q4,Adult
231733811,23173381,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,U,,,,,10.0,MG,Tablet,QD,2023,Q4,Increased appetite,,2023,Q4,1,I,20231006.0,20231107.0,20231111,20231111,EXP,NO-NOMAADVRE-RELISN-2023-Vrx9z7,NVSC2023NO237903,NOVARTIS,,55.0,YR,,M,Y,,,20231111,,MD,NO,NO,2023,Q4,Adult
231749591,23174959,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2023,Q4,Cardiogenic shock,,2023,Q4,1,I,20230310.0,20231103.0,20231112,20231112,EXP,,AU-SANDOZ INC.-NVSC2023AU108375,SANDOZ,,74.0,YR,,M,Y,75.2,KG,20231112,,MD,AU,AU,2023,Q4,Elderly
231752211,23175221,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Drug ineffective,,2023,Q4,1,I,,20231102.0,20231113,20231113,EXP,,US-AUROBINDO-AUR-APL-2023-067763,AUROBINDO,"LEE J, NOOR F, BARUA AMIT, AHMAD R. A RARE CASE OF EUGLYCEMIC DIABETIC KETOACIDOSIS IN SETTING OF SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS USE WITH UNDIAGNOSED METASTATIC PANCREATIC CANCER AND STARVATION.. Chest. 2023;164 (Suppl.)(4):A2466-A2467",57.0,YR,,M,Y,,,20231113,,HP,US,US,2023,Q4,Adult
231752211,23175221,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Euglycaemic diabetic ketoacidosis,,2023,Q4,1,I,,20231102.0,20231113,20231113,EXP,,US-AUROBINDO-AUR-APL-2023-067763,AUROBINDO,"LEE J, NOOR F, BARUA AMIT, AHMAD R. A RARE CASE OF EUGLYCEMIC DIABETIC KETOACIDOSIS IN SETTING OF SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS USE WITH UNDIAGNOSED METASTATIC PANCREATIC CANCER AND STARVATION.. Chest. 2023;164 (Suppl.)(4):A2466-A2467",57.0,YR,,M,Y,,,20231113,,HP,US,US,2023,Q4,Adult
231779291,23177929,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2023,Q4,Injection site swelling,,2023,Q4,1,I,20210202.0,20231106.0,20231113,20231113,EXP,,CA-TAKEDA-2021TUS007766,TAKEDA,,72.0,YR,,M,Y,75.0,KG,20231113,,CN,CA,CA,2023,Q4,Elderly
231779291,23177929,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2023,Q4,Depression,,2023,Q4,1,I,20210202.0,20231106.0,20231113,20231113,EXP,,CA-TAKEDA-2021TUS007766,TAKEDA,,72.0,YR,,M,Y,75.0,KG,20231113,,CN,CA,CA,2023,Q4,Elderly
231779291,23177929,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2023,Q4,Pneumonia,,2023,Q4,1,I,20210202.0,20231106.0,20231113,20231113,EXP,,CA-TAKEDA-2021TUS007766,TAKEDA,,72.0,YR,,M,Y,75.0,KG,20231113,,CN,CA,CA,2023,Q4,Elderly
231779291,23177929,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2023,Q4,Off label use,,2023,Q4,1,I,20210202.0,20231106.0,20231113,20231113,EXP,,CA-TAKEDA-2021TUS007766,TAKEDA,,72.0,YR,,M,Y,75.0,KG,20231113,,CN,CA,CA,2023,Q4,Elderly
231780091,23178009,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Diabetes mellitus inadequate control,,2023,Q4,1,I,20230502.0,,20231113,20231113,DIR,680864,,FDA-CTU,,57.0,YR,,F,N,86.4,KG,20231113,N,PH,US,,2023,Q4,Adult
231780091,23178009,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Trigger finger,,2023,Q4,1,I,20230502.0,,20231113,20231113,DIR,680864,,FDA-CTU,,57.0,YR,,F,N,86.4,KG,20231113,N,PH,US,,2023,Q4,Adult
231780091,23178009,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Pain,,2023,Q4,1,I,20230502.0,,20231113,20231113,DIR,680864,,FDA-CTU,,57.0,YR,,F,N,86.4,KG,20231113,N,PH,US,,2023,Q4,Adult
231780091,23178009,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Joint stiffness,,2023,Q4,1,I,20230502.0,,20231113,20231113,DIR,680864,,FDA-CTU,,57.0,YR,,F,N,86.4,KG,20231113,N,PH,US,,2023,Q4,Adult
231780091,23178009,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Pain in extremity,,2023,Q4,1,I,20230502.0,,20231113,20231113,DIR,680864,,FDA-CTU,,57.0,YR,,F,N,86.4,KG,20231113,N,PH,US,,2023,Q4,Adult
231780091,23178009,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Arthralgia,,2023,Q4,1,I,20230502.0,,20231113,20231113,DIR,680864,,FDA-CTU,,57.0,YR,,F,N,86.4,KG,20231113,N,PH,US,,2023,Q4,Adult
231780091,23178009,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Low density lipoprotein increased,,2023,Q4,1,I,20230502.0,,20231113,20231113,DIR,680864,,FDA-CTU,,57.0,YR,,F,N,86.4,KG,20231113,N,PH,US,,2023,Q4,Adult
231780091,23178009,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Oedema peripheral,,2023,Q4,1,I,20230502.0,,20231113,20231113,DIR,680864,,FDA-CTU,,57.0,YR,,F,N,86.4,KG,20231113,N,PH,US,,2023,Q4,Adult
231789521,23178952,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,ASKU,,204629.0,10.0,MG,Tablet,QD,2023,Q4,Fournier's gangrene,,2023,Q4,1,I,20231108.0,20231113.0,20231113,20231113,EXP,GB-MHRA-MED-202311111459454770-BMHFL,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-272441",BOEHRINGER INGELHEIM,,52.0,YR,A,M,Y,120.0,KG,20231113,,PH,GB,GB,2023,Q4,Adult
231814951,23181495,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2023,Q4,Eye infection fungal,,2023,Q4,1,I,,20231114.0,20231114,20231114,EXP,GB-MHRA-ADR 28320515,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-272629",BOEHRINGER INGELHEIM,,67.0,YR,E,M,Y,,,20231114,,HP,GB,GB,2023,Q4,Elderly
231814951,23181495,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2023,Q4,Systemic mycosis,,2023,Q4,1,I,,20231114.0,20231114,20231114,EXP,GB-MHRA-ADR 28320515,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-272629",BOEHRINGER INGELHEIM,,67.0,YR,E,M,Y,,,20231114,,HP,GB,GB,2023,Q4,Elderly
231834961,23183496,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Blood glucose abnormal,,2023,Q4,1,I,20230901.0,20231102.0,20231114,20231114,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202311003118,ELI LILLY AND CO,,53.0,YR,,F,Y,80.0,KG,20231114,,CN,CN,CN,2023,Q4,Adult
231855991,23185599,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q4,Drug ineffective,,2023,Q4,1,I,,20231106.0,20231115,20231115,EXP,,HK-AUROBINDO-AUR-APL-2023-068498,AUROBINDO,"Ching S, Yue CS. Acute perimyocarditis following heterologous vaccination of CoronaVac and BNT162b2 SARS-CoV-2 vaccine in an elderly woman.. J-Geriatr-Cardiol. 2022;19(10):785-787",72.0,YR,,F,Y,,,20231115,,HP,HK,HK,2023,Q4,Elderly
231855991,23185599,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,,,,,,,,2023,Q4,Drug ineffective,,2023,Q4,1,I,,20231106.0,20231115,20231115,EXP,,HK-AUROBINDO-AUR-APL-2023-068498,AUROBINDO,"Ching S, Yue CS. Acute perimyocarditis following heterologous vaccination of CoronaVac and BNT162b2 SARS-CoV-2 vaccine in an elderly woman.. J-Geriatr-Cardiol. 2022;19(10):785-787",72.0,YR,,F,Y,,,20231115,,HP,HK,HK,2023,Q4,Elderly
231873182,23187318,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q4,Pulseless electrical activity,,2023,Q4,2,F,,20231221.0,20231115,20231222,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-272797",BOEHRINGER INGELHEIM,"Maknojia A, Ali R. A case of emphysematous pyelonephritis with use of empagliflozin in a patient with heart failure with reduced ejection fraction. Australian Heart Association.",50.0,YR,A,F,Y,,,20231222,,MD,US,US,2023,Q4,Adult
231873182,23187318,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q4,Pleural effusion,,2023,Q4,2,F,,20231221.0,20231115,20231222,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-272797",BOEHRINGER INGELHEIM,"Maknojia A, Ali R. A case of emphysematous pyelonephritis with use of empagliflozin in a patient with heart failure with reduced ejection fraction. Australian Heart Association.",50.0,YR,A,F,Y,,,20231222,,MD,US,US,2023,Q4,Adult
231873182,23187318,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q4,Generalised oedema,,2023,Q4,2,F,,20231221.0,20231115,20231222,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-272797",BOEHRINGER INGELHEIM,"Maknojia A, Ali R. A case of emphysematous pyelonephritis with use of empagliflozin in a patient with heart failure with reduced ejection fraction. Australian Heart Association.",50.0,YR,A,F,Y,,,20231222,,MD,US,US,2023,Q4,Adult
231873182,23187318,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q4,Septic shock,,2023,Q4,2,F,,20231221.0,20231115,20231222,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-272797",BOEHRINGER INGELHEIM,"Maknojia A, Ali R. A case of emphysematous pyelonephritis with use of empagliflozin in a patient with heart failure with reduced ejection fraction. Australian Heart Association.",50.0,YR,A,F,Y,,,20231222,,MD,US,US,2023,Q4,Adult
231873182,23187318,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q4,Emphysematous pyelonephritis,,2023,Q4,2,F,,20231221.0,20231115,20231222,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-272797",BOEHRINGER INGELHEIM,"Maknojia A, Ali R. A case of emphysematous pyelonephritis with use of empagliflozin in a patient with heart failure with reduced ejection fraction. Australian Heart Association.",50.0,YR,A,F,Y,,,20231222,,MD,US,US,2023,Q4,Adult
231873182,23187318,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q4,Cardiac failure,,2023,Q4,2,F,,20231221.0,20231115,20231222,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-272797",BOEHRINGER INGELHEIM,"Maknojia A, Ali R. A case of emphysematous pyelonephritis with use of empagliflozin in a patient with heart failure with reduced ejection fraction. Australian Heart Association.",50.0,YR,A,F,Y,,,20231222,,MD,US,US,2023,Q4,Adult
231873182,23187318,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q4,Cardiomyopathy,,2023,Q4,2,F,,20231221.0,20231115,20231222,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-272797",BOEHRINGER INGELHEIM,"Maknojia A, Ali R. A case of emphysematous pyelonephritis with use of empagliflozin in a patient with heart failure with reduced ejection fraction. Australian Heart Association.",50.0,YR,A,F,Y,,,20231222,,MD,US,US,2023,Q4,Adult
231873281,23187328,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,N,,Asked But Unknown,,204629.0,,,,,2023,Q4,Fournier's gangrene,,2023,Q4,1,I,20231113.0,20231115.0,20231115,20231115,EXP,GB-MHRA-MED-202311141252546370-JSKWH,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-272868",BOEHRINGER INGELHEIM,,52.0,YR,A,M,Y,,,20231115,,HP,GB,GB,2023,Q4,Adult
231883841,23188384,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q4,Genital abscess,,2023,Q4,1,I,,20231115.0,20231115,20231115,EXP,GB-MHRA-TPP12270079C2178545YC1699556759913,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-272873",BOEHRINGER INGELHEIM,,65.0,YR,E,F,Y,138.0,KG,20231115,,PH,GB,GB,2023,Q4,Elderly
231894951,23189495,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q4,Euglycaemic diabetic ketoacidosis,,2023,Q4,1,I,,20231109.0,20231116,20231116,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-271907",BOEHRINGER INGELHEIM,"Bakhtiari AT, Butina JP, Gillis Funderburk SA, Brundavanam HV. Euglycemic DKA Associated With SGLT2 Inhibitors. Journal of the Endocrine Society. 2021;5: A382. doi:10.1210/jends o/bvab048.778.",53.0,YR,A,M,Y,,,20231116,,MD,US,US,2023,Q4,Adult
231894951,23189495,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q4,Metabolic acidosis,,2023,Q4,1,I,,20231109.0,20231116,20231116,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-271907",BOEHRINGER INGELHEIM,"Bakhtiari AT, Butina JP, Gillis Funderburk SA, Brundavanam HV. Euglycemic DKA Associated With SGLT2 Inhibitors. Journal of the Endocrine Society. 2021;5: A382. doi:10.1210/jends o/bvab048.778.",53.0,YR,A,M,Y,,,20231116,,MD,US,US,2023,Q4,Adult
231894951,23189495,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q4,Acute kidney injury,,2023,Q4,1,I,,20231109.0,20231116,20231116,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-271907",BOEHRINGER INGELHEIM,"Bakhtiari AT, Butina JP, Gillis Funderburk SA, Brundavanam HV. Euglycemic DKA Associated With SGLT2 Inhibitors. Journal of the Endocrine Society. 2021;5: A382. doi:10.1210/jends o/bvab048.778.",53.0,YR,A,M,Y,,,20231116,,MD,US,US,2023,Q4,Adult
231894951,23189495,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q4,COVID-19,,2023,Q4,1,I,,20231109.0,20231116,20231116,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-271907",BOEHRINGER INGELHEIM,"Bakhtiari AT, Butina JP, Gillis Funderburk SA, Brundavanam HV. Euglycemic DKA Associated With SGLT2 Inhibitors. Journal of the Endocrine Society. 2021;5: A382. doi:10.1210/jends o/bvab048.778.",53.0,YR,A,M,Y,,,20231116,,MD,US,US,2023,Q4,Adult
231908391,23190839,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q4,Erythema,,2023,Q4,1,I,20231011.0,20231116.0,20231116,20231116,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273033",BOEHRINGER INGELHEIM,,45.0,YR,A,M,Y,,,20231116,,HP,SG,SG,2023,Q4,Adult
231908391,23190839,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q4,Pruritus,,2023,Q4,1,I,20231011.0,20231116.0,20231116,20231116,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273033",BOEHRINGER INGELHEIM,,45.0,YR,A,M,Y,,,20231116,,HP,SG,SG,2023,Q4,Adult
231917841,23191784,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Asked But Unknown,,204629.0,25.0,MG,Tablet,QD,2023,Q4,Weight decreased,,2023,Q4,1,I,20231115.0,20231116.0,20231116,20231116,EXP,GB-MHRA-MED-202311151601076060-YFVBT,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273086",BOEHRINGER INGELHEIM,,68.0,YR,E,M,Y,84.0,KG,20231116,,HP,GB,GB,2023,Q4,Elderly
231938251,23193825,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, unknown",,,,,,,,,,,,2023,Q4,Hypotension,,2023,Q4,1,I,,20231112.0,20231116,20231116,EXP,,US-ELI_LILLY_AND_COMPANY-US202311008524,ELI LILLY AND CO,"Bhat S.Z.,Goudarzi A..Necrotizing Pancreatitis Secondary to Dulaglutide Use..Journal of the Endocrine Society 2021;5 (supp. 1):A393.DOI:https://dx.doi.org/10.1210/jendso/bvab048.800",69.0,YR,,M,Y,,,20231116,,MD,US,US,2023,Q4,Elderly
231938251,23193825,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, unknown",,,,,,,,,,,,2023,Q4,Cholecystitis,,2023,Q4,1,I,,20231112.0,20231116,20231116,EXP,,US-ELI_LILLY_AND_COMPANY-US202311008524,ELI LILLY AND CO,"Bhat S.Z.,Goudarzi A..Necrotizing Pancreatitis Secondary to Dulaglutide Use..Journal of the Endocrine Society 2021;5 (supp. 1):A393.DOI:https://dx.doi.org/10.1210/jendso/bvab048.800",69.0,YR,,M,Y,,,20231116,,MD,US,US,2023,Q4,Elderly
231938251,23193825,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, unknown",,,,,,,,,,,,2023,Q4,Pancreatitis necrotising,,2023,Q4,1,I,,20231112.0,20231116,20231116,EXP,,US-ELI_LILLY_AND_COMPANY-US202311008524,ELI LILLY AND CO,"Bhat S.Z.,Goudarzi A..Necrotizing Pancreatitis Secondary to Dulaglutide Use..Journal of the Endocrine Society 2021;5 (supp. 1):A393.DOI:https://dx.doi.org/10.1210/jendso/bvab048.800",69.0,YR,,M,Y,,,20231116,,MD,US,US,2023,Q4,Elderly
231938251,23193825,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, unknown",,,,,,,,,,,,2023,Q4,Hypoxia,,2023,Q4,1,I,,20231112.0,20231116,20231116,EXP,,US-ELI_LILLY_AND_COMPANY-US202311008524,ELI LILLY AND CO,"Bhat S.Z.,Goudarzi A..Necrotizing Pancreatitis Secondary to Dulaglutide Use..Journal of the Endocrine Society 2021;5 (supp. 1):A393.DOI:https://dx.doi.org/10.1210/jendso/bvab048.800",69.0,YR,,M,Y,,,20231116,,MD,US,US,2023,Q4,Elderly
231954451,23195445,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q4,Acute kidney injury,,2023,Q4,1,I,,20231115.0,20231117,20231117,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273019",BOEHRINGER INGELHEIM,,53.0,YR,A,M,Y,,,20231117,,MD,US,US,2023,Q4,Adult
231954451,23195445,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q4,Gastroenteritis,,2023,Q4,1,I,,20231115.0,20231117,20231117,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273019",BOEHRINGER INGELHEIM,,53.0,YR,A,M,Y,,,20231117,,MD,US,US,2023,Q4,Adult
231954451,23195445,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q4,Euglycaemic diabetic ketoacidosis,,2023,Q4,1,I,,20231115.0,20231117,20231117,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273019",BOEHRINGER INGELHEIM,,53.0,YR,A,M,Y,,,20231117,,MD,US,US,2023,Q4,Adult
231954451,23195445,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q4,Lactic acidosis,,2023,Q4,1,I,,20231115.0,20231117,20231117,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273019",BOEHRINGER INGELHEIM,,53.0,YR,A,M,Y,,,20231117,,MD,US,US,2023,Q4,Adult
231978661,23197866,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Peripheral swelling,,2023,Q4,1,I,20190319.0,20231108.0,20231117,20231117,EXP,,NL-JNJFOC-A-CH2019-189421,JOHNSON AND JOHNSON,,56.0,YR,A,F,Y,66.0,KG,20231117,,MD,NL,NL,2023,Q4,Adult
231978661,23197866,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Liver function test increased,,2023,Q4,1,I,20190319.0,20231108.0,20231117,20231117,EXP,,NL-JNJFOC-A-CH2019-189421,JOHNSON AND JOHNSON,,56.0,YR,A,F,Y,66.0,KG,20231117,,MD,NL,NL,2023,Q4,Adult
231978661,23197866,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Oedema,,2023,Q4,1,I,20190319.0,20231108.0,20231117,20231117,EXP,,NL-JNJFOC-A-CH2019-189421,JOHNSON AND JOHNSON,,56.0,YR,A,F,Y,66.0,KG,20231117,,MD,NL,NL,2023,Q4,Adult
231978661,23197866,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Fatigue,,2023,Q4,1,I,20190319.0,20231108.0,20231117,20231117,EXP,,NL-JNJFOC-A-CH2019-189421,JOHNSON AND JOHNSON,,56.0,YR,A,F,Y,66.0,KG,20231117,,MD,NL,NL,2023,Q4,Adult
231978661,23197866,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Nausea,,2023,Q4,1,I,20190319.0,20231108.0,20231117,20231117,EXP,,NL-JNJFOC-A-CH2019-189421,JOHNSON AND JOHNSON,,56.0,YR,A,F,Y,66.0,KG,20231117,,MD,NL,NL,2023,Q4,Adult
231978661,23197866,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Depressed level of consciousness,,2023,Q4,1,I,20190319.0,20231108.0,20231117,20231117,EXP,,NL-JNJFOC-A-CH2019-189421,JOHNSON AND JOHNSON,,56.0,YR,A,F,Y,66.0,KG,20231117,,MD,NL,NL,2023,Q4,Adult
231978661,23197866,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Dizziness,,2023,Q4,1,I,20190319.0,20231108.0,20231117,20231117,EXP,,NL-JNJFOC-A-CH2019-189421,JOHNSON AND JOHNSON,,56.0,YR,A,F,Y,66.0,KG,20231117,,MD,NL,NL,2023,Q4,Adult
231991131,23199113,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,Unknown,,2023,Q4,Nausea,,2023,Q4,1,I,,20231002.0,20231117,20231117,PER,,"US-Stemline Therapeutics, Inc.-2023ST003572",STEMLINE THERAPEUTICS,,71.0,YR,E,F,Y,,,20231116,,CN,US,US,2023,Q4,Elderly
231991131,23199113,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,Unknown,,2023,Q4,Fatigue,,2023,Q4,1,I,,20231002.0,20231117,20231117,PER,,"US-Stemline Therapeutics, Inc.-2023ST003572",STEMLINE THERAPEUTICS,,71.0,YR,E,F,Y,,,20231116,,CN,US,US,2023,Q4,Elderly
232008791,23200879,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg per day,,,Y,,,,,10.0,MG,,QD,2023,Q4,Urinary tract infection,,2023,Q4,1,I,20231006.0,20231109.0,20231118,20231118,EXP,,FR-AUROBINDO-AUR-APL-2023-068431,AUROBINDO,,76.0,YR,,F,Y,,,20231118,,PH,FR,FR,2023,Q4,Elderly
232008791,23200879,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg per day,,,Y,,,,,10.0,MG,,QD,2023,Q4,Acute kidney injury,,2023,Q4,1,I,20231006.0,20231109.0,20231118,20231118,EXP,,FR-AUROBINDO-AUR-APL-2023-068431,AUROBINDO,,76.0,YR,,F,Y,,,20231118,,PH,FR,FR,2023,Q4,Elderly
232031451,23203145,2,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"UNK (2 tablets, qd)",,,,,Unknown,,,,,Tablet,,2023,Q4,Constipation,,2023,Q4,1,I,20230822.0,20231109.0,20231120,20231120,EXP,,CO-NOVOPROD-1117613,NOVO NORDISK,,37.0,YR,,M,Y,100.0,KG,20231120,,CN,CO,CO,2023,Q4,Adult
232031451,23203145,2,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"UNK (2 tablets, qd)",,,,,Unknown,,,,,Tablet,,2023,Q4,Product use in unapproved indication,,2023,Q4,1,I,20230822.0,20231109.0,20231120,20231120,EXP,,CO-NOVOPROD-1117613,NOVO NORDISK,,37.0,YR,,M,Y,100.0,KG,20231120,,CN,CO,CO,2023,Q4,Adult
232031451,23203145,2,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"UNK (2 tablets, qd)",,,,,Unknown,,,,,Tablet,,2023,Q4,Diabetic ketoacidosis,,2023,Q4,1,I,20230822.0,20231109.0,20231120,20231120,EXP,,CO-NOVOPROD-1117613,NOVO NORDISK,,37.0,YR,,M,Y,100.0,KG,20231120,,CN,CO,CO,2023,Q4,Adult
232031451,23203145,2,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"UNK (2 tablets, qd)",,,,,Unknown,,,,,Tablet,,2023,Q4,Discouragement,,2023,Q4,1,I,20230822.0,20231109.0,20231120,20231120,EXP,,CO-NOVOPROD-1117613,NOVO NORDISK,,37.0,YR,,M,Y,100.0,KG,20231120,,CN,CO,CO,2023,Q4,Adult
232031451,23203145,2,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"UNK (2 tablets, qd)",,,,,Unknown,,,,,Tablet,,2023,Q4,Decreased appetite,,2023,Q4,1,I,20230822.0,20231109.0,20231120,20231120,EXP,,CO-NOVOPROD-1117613,NOVO NORDISK,,37.0,YR,,M,Y,100.0,KG,20231120,,CN,CO,CO,2023,Q4,Adult
232038021,23203802,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1-0-0,,,Y,,Unknown,,204629.0,25.0,MG,,QD,2023,Q4,Sepsis,,2023,Q4,1,I,20221108.0,20231120.0,20231120,20231120,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273524",BOEHRINGER INGELHEIM,,55.0,YR,A,M,Y,83.0,KG,20231120,,PH,DE,DE,2023,Q4,Adult
232038021,23203802,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1-0-0,,,Y,,Unknown,,204629.0,25.0,MG,,QD,2023,Q4,Fall,,2023,Q4,1,I,20221108.0,20231120.0,20231120,20231120,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273524",BOEHRINGER INGELHEIM,,55.0,YR,A,M,Y,83.0,KG,20231120,,PH,DE,DE,2023,Q4,Adult
232038021,23203802,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1-0-0,,,Y,,Unknown,,204629.0,25.0,MG,,QD,2023,Q4,Disturbance in attention,,2023,Q4,1,I,20221108.0,20231120.0,20231120,20231120,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273524",BOEHRINGER INGELHEIM,,55.0,YR,A,M,Y,83.0,KG,20231120,,PH,DE,DE,2023,Q4,Adult
232038021,23203802,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1-0-0,,,Y,,Unknown,,204629.0,25.0,MG,,QD,2023,Q4,Ketoacidosis,,2023,Q4,1,I,20221108.0,20231120.0,20231120,20231120,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273524",BOEHRINGER INGELHEIM,,55.0,YR,A,M,Y,83.0,KG,20231120,,PH,DE,DE,2023,Q4,Adult
232038511,23203851,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg per day,,,Y,,Unknown,,,10.0,MG,,QD,2023,Q4,Acute kidney injury,,2023,Q4,1,I,20231006.0,20231114.0,20231120,20231120,EXP,,FR-EMD Serono-2023487867,EMD SERONO INC,,76.0,YR,E,F,Y,,,20231120,,PH,FR,FR,2023,Q4,Elderly
232038511,23203851,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg per day,,,Y,,Unknown,,,10.0,MG,,QD,2023,Q4,Urinary tract infection,,2023,Q4,1,I,20231006.0,20231114.0,20231120,20231120,EXP,,FR-EMD Serono-2023487867,EMD SERONO INC,,76.0,YR,E,F,Y,,,20231120,,PH,FR,FR,2023,Q4,Elderly
232053773,23205377,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,QD,2023,Q4,Hepatitis acute,,2023,Q4,3,F,20231114.0,20231122.0,20231120,20231124,EXP,,CO-ROCHE-3459143,ROCHE,,70.0,YR,,M,Y,,,20231124,,MD,CO,,2023,Q4,Elderly
232073461,23207346,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Anaphylactic reaction,,2023,Q4,1,I,20230313.0,20230314.0,20231120,20231120,5DAY,,US-BRACCO-2023US01171,BRACCO,,61.0,YR,,M,Y,,,20231121,,MD,US,US,2023,Q4,Adult
232073751,23207375,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,,,,,,10.0,MG,,,2023,Q4,Pruritus,,2023,Q4,1,I,20230606.0,20230627.0,20231120,20231120,5DAY,,US-BRACCO-2023US03220,BRACCO,,68.0,YR,,M,Y,,,20231121,,CN,US,US,2023,Q4,Elderly
232073751,23207375,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,,,,,,10.0,MG,,,2023,Q4,Dizziness,,2023,Q4,1,I,20230606.0,20230627.0,20231120,20231120,5DAY,,US-BRACCO-2023US03220,BRACCO,,68.0,YR,,M,Y,,,20231121,,CN,US,US,2023,Q4,Elderly
232073751,23207375,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,,,,,,10.0,MG,,,2023,Q4,Pulseless electrical activity,,2023,Q4,1,I,20230606.0,20230627.0,20231120,20231120,5DAY,,US-BRACCO-2023US03220,BRACCO,,68.0,YR,,M,Y,,,20231121,,CN,US,US,2023,Q4,Elderly
232073751,23207375,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,,,,,,10.0,MG,,,2023,Q4,Feeling abnormal,,2023,Q4,1,I,20230606.0,20230627.0,20231120,20231120,5DAY,,US-BRACCO-2023US03220,BRACCO,,68.0,YR,,M,Y,,,20231121,,CN,US,US,2023,Q4,Elderly
232073751,23207375,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,,,,,,10.0,MG,,,2023,Q4,Agonal respiration,,2023,Q4,1,I,20230606.0,20230627.0,20231120,20231120,5DAY,,US-BRACCO-2023US03220,BRACCO,,68.0,YR,,M,Y,,,20231121,,CN,US,US,2023,Q4,Elderly
232073751,23207375,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,,,,,,10.0,MG,,,2023,Q4,Unresponsive to stimuli,,2023,Q4,1,I,20230606.0,20230627.0,20231120,20231120,5DAY,,US-BRACCO-2023US03220,BRACCO,,68.0,YR,,M,Y,,,20231121,,CN,US,US,2023,Q4,Elderly
232073751,23207375,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,,,,,,10.0,MG,,,2023,Q4,Cardiac arrest,,2023,Q4,1,I,20230606.0,20230627.0,20231120,20231120,5DAY,,US-BRACCO-2023US03220,BRACCO,,68.0,YR,,M,Y,,,20231121,,CN,US,US,2023,Q4,Elderly
232081561,23208156,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q4,Pancreatitis acute,,2023,Q4,1,I,,20231117.0,20231121,20231121,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273420",BOEHRINGER INGELHEIM,"Arora G, Gerais Y. A rare, sordid tale of the two most dreaded adverse effects of SGLT-2 inhibitors occurring concurrently - acute pancreatitis and euglycemic diabetic ketoacidosis - within days of initiating empagliflozin therapy. Journal of the Endocrine Society. 2022;6 (1): 290.",49.0,YR,A,M,Y,,,20231121,,MD,US,US,2023,Q4,Adult
232081561,23208156,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q4,Euglycaemic diabetic ketoacidosis,,2023,Q4,1,I,,20231117.0,20231121,20231121,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273420",BOEHRINGER INGELHEIM,"Arora G, Gerais Y. A rare, sordid tale of the two most dreaded adverse effects of SGLT-2 inhibitors occurring concurrently - acute pancreatitis and euglycemic diabetic ketoacidosis - within days of initiating empagliflozin therapy. Journal of the Endocrine Society. 2022;6 (1): 290.",49.0,YR,A,M,Y,,,20231121,,MD,US,US,2023,Q4,Adult
232094601,23209460,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,,,,,,,,2023,Q4,Syncope,,2023,Q4,1,I,,20231113.0,20231121,20231121,EXP,,SI-JNJFOC-20231152715,JOHNSON AND JOHNSON,,85.0,YR,E,M,Y,,,20231121,,MD,SI,SI,2023,Q4,Elderly
232094601,23209460,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,,,,,,,,2023,Q4,Faeces discoloured,,2023,Q4,1,I,,20231113.0,20231121,20231121,EXP,,SI-JNJFOC-20231152715,JOHNSON AND JOHNSON,,85.0,YR,E,M,Y,,,20231121,,MD,SI,SI,2023,Q4,Elderly
232094601,23209460,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,,,,,,,,2023,Q4,Nausea,,2023,Q4,1,I,,20231113.0,20231121,20231121,EXP,,SI-JNJFOC-20231152715,JOHNSON AND JOHNSON,,85.0,YR,E,M,Y,,,20231121,,MD,SI,SI,2023,Q4,Elderly
232094601,23209460,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,,,,,,,,2023,Q4,Asthenia,,2023,Q4,1,I,,20231113.0,20231121,20231121,EXP,,SI-JNJFOC-20231152715,JOHNSON AND JOHNSON,,85.0,YR,E,M,Y,,,20231121,,MD,SI,SI,2023,Q4,Elderly
232094601,23209460,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,,,,,,,,2023,Q4,Transient ischaemic attack,,2023,Q4,1,I,,20231113.0,20231121,20231121,EXP,,SI-JNJFOC-20231152715,JOHNSON AND JOHNSON,,85.0,YR,E,M,Y,,,20231121,,MD,SI,SI,2023,Q4,Elderly
232094601,23209460,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,,,,,,,,2023,Q4,Dizziness,,2023,Q4,1,I,,20231113.0,20231121,20231121,EXP,,SI-JNJFOC-20231152715,JOHNSON AND JOHNSON,,85.0,YR,E,M,Y,,,20231121,,MD,SI,SI,2023,Q4,Elderly
232094601,23209460,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,,,,,,,,2023,Q4,Contusion,,2023,Q4,1,I,,20231113.0,20231121,20231121,EXP,,SI-JNJFOC-20231152715,JOHNSON AND JOHNSON,,85.0,YR,E,M,Y,,,20231121,,MD,SI,SI,2023,Q4,Elderly
232094601,23209460,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,,,,,,,,2023,Q4,Microcytic anaemia,,2023,Q4,1,I,,20231113.0,20231121,20231121,EXP,,SI-JNJFOC-20231152715,JOHNSON AND JOHNSON,,85.0,YR,E,M,Y,,,20231121,,MD,SI,SI,2023,Q4,Elderly
232094601,23209460,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,,,,,,,,2023,Q4,Confusional state,,2023,Q4,1,I,,20231113.0,20231121,20231121,EXP,,SI-JNJFOC-20231152715,JOHNSON AND JOHNSON,,85.0,YR,E,M,Y,,,20231121,,MD,SI,SI,2023,Q4,Elderly
232101441,23210144,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,10.0,MG,,,2023,Q4,Lipase increased,,2023,Q4,1,I,20230908.0,20231109.0,20231121,20231121,EXP,FR-AFSSAPS-AM2023000904,FR-Accord-390917,ACCORD,,59.0,YR,A,M,Y,129.0,KG,20231121,,PH,FR,FR,2023,Q4,Adult
232101441,23210144,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,10.0,MG,,,2023,Q4,Acute kidney injury,,2023,Q4,1,I,20230908.0,20231109.0,20231121,20231121,EXP,FR-AFSSAPS-AM2023000904,FR-Accord-390917,ACCORD,,59.0,YR,A,M,Y,129.0,KG,20231121,,PH,FR,FR,2023,Q4,Adult
232101441,23210144,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,10.0,MG,,,2023,Q4,Nausea,,2023,Q4,1,I,20230908.0,20231109.0,20231121,20231121,EXP,FR-AFSSAPS-AM2023000904,FR-Accord-390917,ACCORD,,59.0,YR,A,M,Y,129.0,KG,20231121,,PH,FR,FR,2023,Q4,Adult
232101441,23210144,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,10.0,MG,,,2023,Q4,Diarrhoea,,2023,Q4,1,I,20230908.0,20231109.0,20231121,20231121,EXP,FR-AFSSAPS-AM2023000904,FR-Accord-390917,ACCORD,,59.0,YR,A,M,Y,129.0,KG,20231121,,PH,FR,FR,2023,Q4,Adult
232155591,23215559,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q4,Urinary tract infection,,2023,Q4,1,I,20220101.0,20231121.0,20231122,20231122,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-274122",BOEHRINGER INGELHEIM,,62.0,YR,A,F,Y,,,20231122,,HP,SG,SG,2023,Q4,Adult
232155591,23215559,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q4,Vulval disorder,,2023,Q4,1,I,20220101.0,20231121.0,20231122,20231122,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-274122",BOEHRINGER INGELHEIM,,62.0,YR,A,F,Y,,,20231122,,HP,SG,SG,2023,Q4,Adult
232156271,23215627,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,,,,,,2023,Q4,Lactic acidosis,,2023,Q4,1,I,,20231114.0,20231122,20231122,EXP,,US-EMD Serono-2023488206,EMD SERONO INC,,53.0,YR,A,M,Y,,,20231122,,HP,US,US,2023,Q4,Adult
232156271,23215627,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,,,,,,2023,Q4,Euglycaemic diabetic ketoacidosis,,2023,Q4,1,I,,20231114.0,20231122,20231122,EXP,,US-EMD Serono-2023488206,EMD SERONO INC,,53.0,YR,A,M,Y,,,20231122,,HP,US,US,2023,Q4,Adult
232156271,23215627,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,,,,,,2023,Q4,Hyperkalaemia,,2023,Q4,1,I,,20231114.0,20231122,20231122,EXP,,US-EMD Serono-2023488206,EMD SERONO INC,,53.0,YR,A,M,Y,,,20231122,,HP,US,US,2023,Q4,Adult
232156271,23215627,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,,,,,,2023,Q4,Acute kidney injury,,2023,Q4,1,I,,20231114.0,20231122,20231122,EXP,,US-EMD Serono-2023488206,EMD SERONO INC,,53.0,YR,A,M,Y,,,20231122,,HP,US,US,2023,Q4,Adult
232156271,23215627,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,,,,,,2023,Q4,Dehydration,,2023,Q4,1,I,,20231114.0,20231122,20231122,EXP,,US-EMD Serono-2023488206,EMD SERONO INC,,53.0,YR,A,M,Y,,,20231122,,HP,US,US,2023,Q4,Adult
232168171,23216817,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Swelling face,,2023,Q4,1,I,,20231110.0,20231122,20231122,EXP,CA-MHPD-001053320,CA-Accord-391028,ACCORD,,74.0,YR,E,F,Y,72.0,KG,20231122,,PH,CA,CA,2023,Q4,Elderly
232168171,23216817,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Hypersensitivity,,2023,Q4,1,I,,20231110.0,20231122,20231122,EXP,CA-MHPD-001053320,CA-Accord-391028,ACCORD,,74.0,YR,E,F,Y,72.0,KG,20231122,,PH,CA,CA,2023,Q4,Elderly
232168171,23216817,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Cough,,2023,Q4,1,I,,20231110.0,20231122,20231122,EXP,CA-MHPD-001053320,CA-Accord-391028,ACCORD,,74.0,YR,E,F,Y,72.0,KG,20231122,,PH,CA,CA,2023,Q4,Elderly
232168171,23216817,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Chills,,2023,Q4,1,I,,20231110.0,20231122,20231122,EXP,CA-MHPD-001053320,CA-Accord-391028,ACCORD,,74.0,YR,E,F,Y,72.0,KG,20231122,,PH,CA,CA,2023,Q4,Elderly
232168171,23216817,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Chest discomfort,,2023,Q4,1,I,,20231110.0,20231122,20231122,EXP,CA-MHPD-001053320,CA-Accord-391028,ACCORD,,74.0,YR,E,F,Y,72.0,KG,20231122,,PH,CA,CA,2023,Q4,Elderly
232168171,23216817,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Flushing,,2023,Q4,1,I,,20231110.0,20231122,20231122,EXP,CA-MHPD-001053320,CA-Accord-391028,ACCORD,,74.0,YR,E,F,Y,72.0,KG,20231122,,PH,CA,CA,2023,Q4,Elderly
232168171,23216817,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Dyspnoea,,2023,Q4,1,I,,20231110.0,20231122,20231122,EXP,CA-MHPD-001053320,CA-Accord-391028,ACCORD,,74.0,YR,E,F,Y,72.0,KG,20231122,,PH,CA,CA,2023,Q4,Elderly
232168171,23216817,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Wheezing,,2023,Q4,1,I,,20231110.0,20231122,20231122,EXP,CA-MHPD-001053320,CA-Accord-391028,ACCORD,,74.0,YR,E,F,Y,72.0,KG,20231122,,PH,CA,CA,2023,Q4,Elderly
232171871,23217187,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"Daily Dose: 25 milligram(s), Form Strength: 25 Milligram",,,U,,Unknown,,204629.0,,,,,2023,Q4,Drug abuse,,2023,Q4,1,I,,20231120.0,20231122,20231122,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273855",BOEHRINGER INGELHEIM,"Squicimari-de Cardenas FA, Bosques-Lorenzo J, Alejandro L, Rodriguez C, Carlos C, Colon Castellano JM. Euglycemic diabetic ketoacidosis when combining empagliflozin with cocaine. Journal of the Endocrine Society. 2023;7(1): A570. doi:10.1210/jendso/bvad114.1069.",66.0,YR,E,M,Y,,,20231122,,MD,US,US,2023,Q4,Elderly
232171871,23217187,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"Daily Dose: 25 milligram(s), Form Strength: 25 Milligram",,,U,,Unknown,,204629.0,,,,,2023,Q4,Euglycaemic diabetic ketoacidosis,,2023,Q4,1,I,,20231120.0,20231122,20231122,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273855",BOEHRINGER INGELHEIM,"Squicimari-de Cardenas FA, Bosques-Lorenzo J, Alejandro L, Rodriguez C, Carlos C, Colon Castellano JM. Euglycemic diabetic ketoacidosis when combining empagliflozin with cocaine. Journal of the Endocrine Society. 2023;7(1): A570. doi:10.1210/jendso/bvad114.1069.",66.0,YR,E,M,Y,,,20231122,,MD,US,US,2023,Q4,Elderly
232175071,23217507,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q4,Heart rate irregular,,2023,Q4,1,I,20230508.0,20231109.0,20231122,20231122,EXP,GB-MHRA-MED-202311080934114390-VZNKS,GB-ELI_LILLY_AND_COMPANY-GB202311005979,ELI LILLY AND CO,,57.0,YR,,F,Y,89.0,KG,20231122,,CN,GB,GB,2023,Q4,Adult
232180561,23218056,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,Unknown,,2023,Q4,Acute kidney injury,,2023,Q4,1,I,,20231115.0,20231122,20231122,EXP,,US-MYLANLABS-2023M1124017,MYLAN,"Heckart JC, Shaw M. EDKA and MALA in the Setting of Severe Heart Failure and Acute Renal Failure, Due to SGLT2-i. J-Endocr-Soc 2020; 4 A853.",53.0,YR,,M,Y,,,20231122,,HP,US,US,2023,Q4,Adult
232180561,23218056,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,Unknown,,2023,Q4,Lactic acidosis,,2023,Q4,1,I,,20231115.0,20231122,20231122,EXP,,US-MYLANLABS-2023M1124017,MYLAN,"Heckart JC, Shaw M. EDKA and MALA in the Setting of Severe Heart Failure and Acute Renal Failure, Due to SGLT2-i. J-Endocr-Soc 2020; 4 A853.",53.0,YR,,M,Y,,,20231122,,HP,US,US,2023,Q4,Adult
232184161,23218416,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q4,Respiratory failure,,2023,Q4,1,I,,20231120.0,20231122,20231122,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273690",BOEHRINGER INGELHEIM,"Penna LE, Rivera MO, Burgos AR, Martin LM, Nieves YR, Cordero NH. SGLT2 Inhibitor-Induced Euglycemic DKA and its Challenges. Journal of Endocrine Society. 2022;doi:10.1210/jendso/bvac150.692.",61.0,YR,A,M,Y,,,20231122,,MD,US,US,2023,Q4,Adult
232184161,23218416,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q4,General physical health deterioration,,2023,Q4,1,I,,20231120.0,20231122,20231122,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273690",BOEHRINGER INGELHEIM,"Penna LE, Rivera MO, Burgos AR, Martin LM, Nieves YR, Cordero NH. SGLT2 Inhibitor-Induced Euglycemic DKA and its Challenges. Journal of Endocrine Society. 2022;doi:10.1210/jendso/bvac150.692.",61.0,YR,A,M,Y,,,20231122,,MD,US,US,2023,Q4,Adult
232184161,23218416,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q4,Sepsis,,2023,Q4,1,I,,20231120.0,20231122,20231122,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273690",BOEHRINGER INGELHEIM,"Penna LE, Rivera MO, Burgos AR, Martin LM, Nieves YR, Cordero NH. SGLT2 Inhibitor-Induced Euglycemic DKA and its Challenges. Journal of Endocrine Society. 2022;doi:10.1210/jendso/bvac150.692.",61.0,YR,A,M,Y,,,20231122,,MD,US,US,2023,Q4,Adult
232184161,23218416,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q4,Candida infection,,2023,Q4,1,I,,20231120.0,20231122,20231122,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273690",BOEHRINGER INGELHEIM,"Penna LE, Rivera MO, Burgos AR, Martin LM, Nieves YR, Cordero NH. SGLT2 Inhibitor-Induced Euglycemic DKA and its Challenges. Journal of Endocrine Society. 2022;doi:10.1210/jendso/bvac150.692.",61.0,YR,A,M,Y,,,20231122,,MD,US,US,2023,Q4,Adult
232184161,23218416,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q4,Penile abscess,,2023,Q4,1,I,,20231120.0,20231122,20231122,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273690",BOEHRINGER INGELHEIM,"Penna LE, Rivera MO, Burgos AR, Martin LM, Nieves YR, Cordero NH. SGLT2 Inhibitor-Induced Euglycemic DKA and its Challenges. Journal of Endocrine Society. 2022;doi:10.1210/jendso/bvac150.692.",61.0,YR,A,M,Y,,,20231122,,MD,US,US,2023,Q4,Adult
232184161,23218416,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q4,Euglycaemic diabetic ketoacidosis,,2023,Q4,1,I,,20231120.0,20231122,20231122,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273690",BOEHRINGER INGELHEIM,"Penna LE, Rivera MO, Burgos AR, Martin LM, Nieves YR, Cordero NH. SGLT2 Inhibitor-Induced Euglycemic DKA and its Challenges. Journal of Endocrine Society. 2022;doi:10.1210/jendso/bvac150.692.",61.0,YR,A,M,Y,,,20231122,,MD,US,US,2023,Q4,Adult
232192821,23219282,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,N,,Unknown,,204629.0,10.0,MG,,QD,2023,Q4,Acute kidney injury,,2023,Q4,1,I,20231108.0,20231121.0,20231122,20231122,EXP,IT-MINISAL02-955435,"IT-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273908",BOEHRINGER INGELHEIM,,86.0,YR,E,F,Y,70.0,KG,20231122,,MD,IT,IT,2023,Q4,Elderly
232192821,23219282,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,N,,Unknown,,204629.0,10.0,MG,,QD,2023,Q4,Metabolic acidosis,,2023,Q4,1,I,20231108.0,20231121.0,20231122,20231122,EXP,IT-MINISAL02-955435,"IT-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273908",BOEHRINGER INGELHEIM,,86.0,YR,E,F,Y,70.0,KG,20231122,,MD,IT,IT,2023,Q4,Elderly
232197971,23219797,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,Oral,in the morning,,,D,,Unknown,,212614.0,10.5,MG,Tablet,QD,2023,Q4,Blood glucose increased,,2023,Q4,1,I,20231101.0,20231122.0,20231122,20231122,PER,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-274391",BOEHRINGER INGELHEIM,,37.0,YR,A,F,Y,,,20231122,,CN,US,US,2023,Q4,Adult
232198901,23219890,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,,,,,,,,2023,Q4,Faeces discoloured,,2023,Q4,1,I,20230101.0,20231117.0,20231122,20231122,EXP,,HR-JNJFOC-20231163947,JOHNSON AND JOHNSON,,77.0,YR,E,M,Y,,,20231123,,CN,HR,HR,2023,Q4,Elderly
232198901,23219890,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,,,,,,,,2023,Q4,Cardiac failure congestive,,2023,Q4,1,I,20230101.0,20231117.0,20231122,20231122,EXP,,HR-JNJFOC-20231163947,JOHNSON AND JOHNSON,,77.0,YR,E,M,Y,,,20231123,,CN,HR,HR,2023,Q4,Elderly
232198901,23219890,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,,,,,,,,2023,Q4,Anaemia,,2023,Q4,1,I,20230101.0,20231117.0,20231122,20231122,EXP,,HR-JNJFOC-20231163947,JOHNSON AND JOHNSON,,77.0,YR,E,M,Y,,,20231123,,CN,HR,HR,2023,Q4,Elderly
232198901,23219890,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,,,,,,,,2023,Q4,Melaena,,2023,Q4,1,I,20230101.0,20231117.0,20231122,20231122,EXP,,HR-JNJFOC-20231163947,JOHNSON AND JOHNSON,,77.0,YR,E,M,Y,,,20231123,,CN,HR,HR,2023,Q4,Elderly
232198901,23219890,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,,,,,,,,2023,Q4,Fatigue,,2023,Q4,1,I,20230101.0,20231117.0,20231122,20231122,EXP,,HR-JNJFOC-20231163947,JOHNSON AND JOHNSON,,77.0,YR,E,M,Y,,,20231123,,CN,HR,HR,2023,Q4,Elderly
232198901,23219890,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,,,,,,,,2023,Q4,Aortic stenosis,,2023,Q4,1,I,20230101.0,20231117.0,20231122,20231122,EXP,,HR-JNJFOC-20231163947,JOHNSON AND JOHNSON,,77.0,YR,E,M,Y,,,20231123,,CN,HR,HR,2023,Q4,Elderly
232198901,23219890,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,,,,,,,,2023,Q4,Cardiac failure,,2023,Q4,1,I,20230101.0,20231117.0,20231122,20231122,EXP,,HR-JNJFOC-20231163947,JOHNSON AND JOHNSON,,77.0,YR,E,M,Y,,,20231123,,CN,HR,HR,2023,Q4,Elderly
232207891,23220789,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q4,Diabetic ketoacidosis,,2023,Q4,1,I,,20231115.0,20231123,20231123,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273053",BOEHRINGER INGELHEIM,"Abushamat LA, Bhalla R, Reusch JE. The Perfect Storm for Diabetic Ketoacidosis. Journal of the Endocrine Society. 2020;4: 883-884. doi:10.1210/jendso/bvaa046.1751.",63.0,YR,A,M,Y,,,20231123,,HP,US,US,2023,Q4,Adult
232207891,23220789,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q4,Hyperglycaemia,,2023,Q4,1,I,,20231115.0,20231123,20231123,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273053",BOEHRINGER INGELHEIM,"Abushamat LA, Bhalla R, Reusch JE. The Perfect Storm for Diabetic Ketoacidosis. Journal of the Endocrine Society. 2020;4: 883-884. doi:10.1210/jendso/bvaa046.1751.",63.0,YR,A,M,Y,,,20231123,,HP,US,US,2023,Q4,Adult
232207891,23220789,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q4,Insulin resistance,,2023,Q4,1,I,,20231115.0,20231123,20231123,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273053",BOEHRINGER INGELHEIM,"Abushamat LA, Bhalla R, Reusch JE. The Perfect Storm for Diabetic Ketoacidosis. Journal of the Endocrine Society. 2020;4: 883-884. doi:10.1210/jendso/bvaa046.1751.",63.0,YR,A,M,Y,,,20231123,,HP,US,US,2023,Q4,Adult
232207891,23220789,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q4,Lactic acidosis,,2023,Q4,1,I,,20231115.0,20231123,20231123,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273053",BOEHRINGER INGELHEIM,"Abushamat LA, Bhalla R, Reusch JE. The Perfect Storm for Diabetic Ketoacidosis. Journal of the Endocrine Society. 2020;4: 883-884. doi:10.1210/jendso/bvaa046.1751.",63.0,YR,A,M,Y,,,20231123,,HP,US,US,2023,Q4,Adult
232207891,23220789,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q4,Fat tissue decreased,,2023,Q4,1,I,,20231115.0,20231123,20231123,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273053",BOEHRINGER INGELHEIM,"Abushamat LA, Bhalla R, Reusch JE. The Perfect Storm for Diabetic Ketoacidosis. Journal of the Endocrine Society. 2020;4: 883-884. doi:10.1210/jendso/bvaa046.1751.",63.0,YR,A,M,Y,,,20231123,,HP,US,US,2023,Q4,Adult
232207891,23220789,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q4,Ketosis,,2023,Q4,1,I,,20231115.0,20231123,20231123,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273053",BOEHRINGER INGELHEIM,"Abushamat LA, Bhalla R, Reusch JE. The Perfect Storm for Diabetic Ketoacidosis. Journal of the Endocrine Society. 2020;4: 883-884. doi:10.1210/jendso/bvaa046.1751.",63.0,YR,A,M,Y,,,20231123,,HP,US,US,2023,Q4,Adult
232207891,23220789,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q4,Acute kidney injury,,2023,Q4,1,I,,20231115.0,20231123,20231123,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273053",BOEHRINGER INGELHEIM,"Abushamat LA, Bhalla R, Reusch JE. The Perfect Storm for Diabetic Ketoacidosis. Journal of the Endocrine Society. 2020;4: 883-884. doi:10.1210/jendso/bvaa046.1751.",63.0,YR,A,M,Y,,,20231123,,HP,US,US,2023,Q4,Adult
232207891,23220789,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q4,Starvation,,2023,Q4,1,I,,20231115.0,20231123,20231123,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273053",BOEHRINGER INGELHEIM,"Abushamat LA, Bhalla R, Reusch JE. The Perfect Storm for Diabetic Ketoacidosis. Journal of the Endocrine Society. 2020;4: 883-884. doi:10.1210/jendso/bvaa046.1751.",63.0,YR,A,M,Y,,,20231123,,HP,US,US,2023,Q4,Adult
232207891,23220789,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q4,Influenza like illness,,2023,Q4,1,I,,20231115.0,20231123,20231123,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273053",BOEHRINGER INGELHEIM,"Abushamat LA, Bhalla R, Reusch JE. The Perfect Storm for Diabetic Ketoacidosis. Journal of the Endocrine Society. 2020;4: 883-884. doi:10.1210/jendso/bvaa046.1751.",63.0,YR,A,M,Y,,,20231123,,HP,US,US,2023,Q4,Adult
232208761,23220876,2,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Drug interaction,,2023,Q4,1,I,,20231115.0,20231123,20231123,EXP,,US-APOTEX-2023AP016763,APOTEX,"Heckart JC, Shaw M.. EDKA and MALA in the Setting of Severe Heart Failure and Acute Renal Failure, Due to SGLT2-i.. Journal of the Endocrine Society. 2020;4 (Suppl.1):A853",53.0,YR,,M,Y,,,20231123,,HP,US,US,2023,Q4,Adult
232208761,23220876,2,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Euglycaemic diabetic ketoacidosis,,2023,Q4,1,I,,20231115.0,20231123,20231123,EXP,,US-APOTEX-2023AP016763,APOTEX,"Heckart JC, Shaw M.. EDKA and MALA in the Setting of Severe Heart Failure and Acute Renal Failure, Due to SGLT2-i.. Journal of the Endocrine Society. 2020;4 (Suppl.1):A853",53.0,YR,,M,Y,,,20231123,,HP,US,US,2023,Q4,Adult
232208761,23220876,2,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Lactic acidosis,,2023,Q4,1,I,,20231115.0,20231123,20231123,EXP,,US-APOTEX-2023AP016763,APOTEX,"Heckart JC, Shaw M.. EDKA and MALA in the Setting of Severe Heart Failure and Acute Renal Failure, Due to SGLT2-i.. Journal of the Endocrine Society. 2020;4 (Suppl.1):A853",53.0,YR,,M,Y,,,20231123,,HP,US,US,2023,Q4,Adult
232208761,23220876,2,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Acute kidney injury,,2023,Q4,1,I,,20231115.0,20231123,20231123,EXP,,US-APOTEX-2023AP016763,APOTEX,"Heckart JC, Shaw M.. EDKA and MALA in the Setting of Severe Heart Failure and Acute Renal Failure, Due to SGLT2-i.. Journal of the Endocrine Society. 2020;4 (Suppl.1):A853",53.0,YR,,M,Y,,,20231123,,HP,US,US,2023,Q4,Adult
232221351,23222135,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Daily Dose: 25 milligram(s),,,N,,Unknown,,204629.0,,,,,2023,Q4,Bladder transitional cell carcinoma,,2023,Q4,1,I,,20231117.0,20231123,20231123,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273350",BOEHRINGER INGELHEIM,"Alzenaidi A, Alkhalidi H. Empagliflozin Induced Bladder Cancer in an Adult Patient With Latent Autoimmune Diabetes. Journal of the endocrine society. 2022;6 (1): 392. doi:10.1210/jendso/bvac150.815.",51.0,YR,A,M,Y,,,20231123,,MD,US,US,2023,Q4,Adult
232221351,23222135,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Daily Dose: 25 milligram(s),,,N,,Unknown,,204629.0,,,,,2023,Q4,Latent autoimmune diabetes in adults,,2023,Q4,1,I,,20231117.0,20231123,20231123,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273350",BOEHRINGER INGELHEIM,"Alzenaidi A, Alkhalidi H. Empagliflozin Induced Bladder Cancer in an Adult Patient With Latent Autoimmune Diabetes. Journal of the endocrine society. 2022;6 (1): 392. doi:10.1210/jendso/bvac150.815.",51.0,YR,A,M,Y,,,20231123,,MD,US,US,2023,Q4,Adult
232221351,23222135,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Daily Dose: 25 milligram(s),,,N,,Unknown,,204629.0,,,,,2023,Q4,Hyperglycaemia,,2023,Q4,1,I,,20231117.0,20231123,20231123,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273350",BOEHRINGER INGELHEIM,"Alzenaidi A, Alkhalidi H. Empagliflozin Induced Bladder Cancer in an Adult Patient With Latent Autoimmune Diabetes. Journal of the endocrine society. 2022;6 (1): 392. doi:10.1210/jendso/bvac150.815.",51.0,YR,A,M,Y,,,20231123,,MD,US,US,2023,Q4,Adult
232224051,23222405,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q4,Pneumonia,,2023,Q4,1,I,20230512.0,20231115.0,20231123,20231123,EXP,,FR-ABBVIE-2316045US,ABBVIE,,75.0,YR,,F,Y,76.0,KG,20231123,,MD,FR,FR,2023,Q4,Elderly
232224051,23222405,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q4,Abdominal pain upper,,2023,Q4,1,I,20230512.0,20231115.0,20231123,20231123,EXP,,FR-ABBVIE-2316045US,ABBVIE,,75.0,YR,,F,Y,76.0,KG,20231123,,MD,FR,FR,2023,Q4,Elderly
232224051,23222405,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q4,Asthenia,,2023,Q4,1,I,20230512.0,20231115.0,20231123,20231123,EXP,,FR-ABBVIE-2316045US,ABBVIE,,75.0,YR,,F,Y,76.0,KG,20231123,,MD,FR,FR,2023,Q4,Elderly
232224051,23222405,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q4,Anaemia,,2023,Q4,1,I,20230512.0,20231115.0,20231123,20231123,EXP,,FR-ABBVIE-2316045US,ABBVIE,,75.0,YR,,F,Y,76.0,KG,20231123,,MD,FR,FR,2023,Q4,Elderly
232224051,23222405,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q4,Cough,,2023,Q4,1,I,20230512.0,20231115.0,20231123,20231123,EXP,,FR-ABBVIE-2316045US,ABBVIE,,75.0,YR,,F,Y,76.0,KG,20231123,,MD,FR,FR,2023,Q4,Elderly
232224051,23222405,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q4,Cardiac failure,,2023,Q4,1,I,20230512.0,20231115.0,20231123,20231123,EXP,,FR-ABBVIE-2316045US,ABBVIE,,75.0,YR,,F,Y,76.0,KG,20231123,,MD,FR,FR,2023,Q4,Elderly
232224051,23222405,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q4,C-reactive protein increased,,2023,Q4,1,I,20230512.0,20231115.0,20231123,20231123,EXP,,FR-ABBVIE-2316045US,ABBVIE,,75.0,YR,,F,Y,76.0,KG,20231123,,MD,FR,FR,2023,Q4,Elderly
232224051,23222405,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q4,Chills,,2023,Q4,1,I,20230512.0,20231115.0,20231123,20231123,EXP,,FR-ABBVIE-2316045US,ABBVIE,,75.0,YR,,F,Y,76.0,KG,20231123,,MD,FR,FR,2023,Q4,Elderly
232224051,23222405,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q4,Pneumonia,,2023,Q4,1,I,20230512.0,20231115.0,20231123,20231123,EXP,,FR-ABBVIE-2316045US,ABBVIE,,75.0,YR,,F,Y,76.0,KG,20231123,,MD,FR,FR,2023,Q4,Elderly
232224051,23222405,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q4,Product use in unapproved indication,,2023,Q4,1,I,20230512.0,20231115.0,20231123,20231123,EXP,,FR-ABBVIE-2316045US,ABBVIE,,75.0,YR,,F,Y,76.0,KG,20231123,,MD,FR,FR,2023,Q4,Elderly
232224051,23222405,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2023,Q4,COVID-19,,2023,Q4,1,I,20230512.0,20231115.0,20231123,20231123,EXP,,FR-ABBVIE-2316045US,ABBVIE,,75.0,YR,,F,Y,76.0,KG,20231123,,MD,FR,FR,2023,Q4,Elderly
232226041,23222604,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, Daily",,,U,,,,,25.0,MG,,,2023,Q4,Euglycaemic diabetic ketoacidosis,,2023,Q4,1,I,,20231108.0,20231123,20231123,EXP,,CA-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-419794,RANBAXY,"Chaudhry A, Roels C, Lee J. Sodium-Glucose Cotransporter-2 Inhibitor-associated Euglycemic Diabetic Ketoacidosis: Lessons From a Case Series of 4 Patients Undergoing Coronary Artery Bypass Grafting Surgery. Can J Diab. 2022;46(8):843-850",70.0,YR,,M,Y,,,20231123,,MD,CA,CA,2023,Q4,Elderly
232226061,23222606,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, Daily",,,U,,,,,25.0,MG,,,2023,Q4,Euglycaemic diabetic ketoacidosis,,2023,Q4,1,I,,20231108.0,20231123,20231123,EXP,,CA-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-419795,RANBAXY,"Chaudhry A, Roels C, Lee J. Sodium-Glucose Cotransporter-2 Inhibitor-associated Euglycemic Diabetic Ketoacidosis: Lessons From a Case Series of 4 Patients Undergoing Coronary Artery Bypass Grafting Surgery. Can J Diab. 2022;46(8):843-850",70.0,YR,,M,Y,,,20231123,,MD,CA,CA,2023,Q4,Elderly
232229441,23222944,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,25.0,MG,,QD,2023,Q4,Acidosis,,2023,Q4,1,I,,20231117.0,20231123,20231123,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273371",BOEHRINGER INGELHEIM,"Nievera KH, Uy MC. Empagliflozin associated euglycemic diabetic ketoacidosis and the terrible triad. Journal of the Endocrine Society. 2022;6 (1): 311. doi:10.1210/jendso/bvac150.644.",31.0,YR,A,M,Y,,,20231123,,MD,US,US,2023,Q4,Young Adult
232229441,23222944,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,25.0,MG,,QD,2023,Q4,Pancreatitis acute,,2023,Q4,1,I,,20231117.0,20231123,20231123,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273371",BOEHRINGER INGELHEIM,"Nievera KH, Uy MC. Empagliflozin associated euglycemic diabetic ketoacidosis and the terrible triad. Journal of the Endocrine Society. 2022;6 (1): 311. doi:10.1210/jendso/bvac150.644.",31.0,YR,A,M,Y,,,20231123,,MD,US,US,2023,Q4,Young Adult
232229441,23222944,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,25.0,MG,,QD,2023,Q4,Euglycaemic diabetic ketoacidosis,,2023,Q4,1,I,,20231117.0,20231123,20231123,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273371",BOEHRINGER INGELHEIM,"Nievera KH, Uy MC. Empagliflozin associated euglycemic diabetic ketoacidosis and the terrible triad. Journal of the Endocrine Society. 2022;6 (1): 311. doi:10.1210/jendso/bvac150.644.",31.0,YR,A,M,Y,,,20231123,,MD,US,US,2023,Q4,Young Adult
232229441,23222944,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,25.0,MG,,QD,2023,Q4,Hypertriglyceridaemia,,2023,Q4,1,I,,20231117.0,20231123,20231123,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273371",BOEHRINGER INGELHEIM,"Nievera KH, Uy MC. Empagliflozin associated euglycemic diabetic ketoacidosis and the terrible triad. Journal of the Endocrine Society. 2022;6 (1): 311. doi:10.1210/jendso/bvac150.644.",31.0,YR,A,M,Y,,,20231123,,MD,US,US,2023,Q4,Young Adult
232231151,23223115,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q4,Post procedural complication,,2023,Q4,1,I,,20231117.0,20231123,20231123,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273440",BOEHRINGER INGELHEIM,"Vaghasia N, Bononi P, Custodio P. Diabetes and Glucose Metabolism ODP195 Euglycemic diabetic ketoacidosis after bariatric surgery in association with use of SGLT2i.. Journal of the Endocrine Society. 2022;6 (1): 312. doi:10.1210/jendso/bvac150.647.",43.0,YR,A,M,Y,,,20231123,,MD,US,US,2023,Q4,Adult
232231151,23223115,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q4,Euglycaemic diabetic ketoacidosis,,2023,Q4,1,I,,20231117.0,20231123,20231123,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273440",BOEHRINGER INGELHEIM,"Vaghasia N, Bononi P, Custodio P. Diabetes and Glucose Metabolism ODP195 Euglycemic diabetic ketoacidosis after bariatric surgery in association with use of SGLT2i.. Journal of the Endocrine Society. 2022;6 (1): 312. doi:10.1210/jendso/bvac150.647.",43.0,YR,A,M,Y,,,20231123,,MD,US,US,2023,Q4,Adult
232239971,23223997,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, qd",,,Y,,,,,10.0,MG,,QD,2023,Q4,Treatment noncompliance,,2023,Q4,1,I,,20231110.0,20231124,20231124,EXP,,PL-NOVOPROD-1143291,NOVO NORDISK,Micha? Kania. COVID-19 in a patent with early onset type 2 diabetes mellitus. Diabetology. 2023;10,30.0,YR,,M,Y,,,20231124,,HP,PL,PL,2023,Q4,Young Adult
232239971,23223997,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, qd",,,Y,,,,,10.0,MG,,QD,2023,Q4,Diabetic ketoacidosis,,2023,Q4,1,I,,20231110.0,20231124,20231124,EXP,,PL-NOVOPROD-1143291,NOVO NORDISK,Micha? Kania. COVID-19 in a patent with early onset type 2 diabetes mellitus. Diabetology. 2023;10,30.0,YR,,M,Y,,,20231124,,HP,PL,PL,2023,Q4,Young Adult
232245221,23224522,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q4,Post procedural complication,,2023,Q4,1,I,,20231117.0,20231124,20231124,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273441",BOEHRINGER INGELHEIM,"Vaghasia N, Bononi P, Custodio P. EUGLYCEMIC DIABETIC KETOACIDOSIS AFTER BARIATRIC SURGERY IN ASSOCIATION WITH USE OF SGLT2I.. Journal of the Endocrine Society. 2022;6(1): 312. doi:10.1210/jendso/bvac150.647.",31.0,YR,A,F,Y,,,20231124,,MD,US,US,2023,Q4,Young Adult
232245221,23224522,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2023,Q4,Euglycaemic diabetic ketoacidosis,,2023,Q4,1,I,,20231117.0,20231124,20231124,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273441",BOEHRINGER INGELHEIM,"Vaghasia N, Bononi P, Custodio P. EUGLYCEMIC DIABETIC KETOACIDOSIS AFTER BARIATRIC SURGERY IN ASSOCIATION WITH USE OF SGLT2I.. Journal of the Endocrine Society. 2022;6(1): 312. doi:10.1210/jendso/bvac150.647.",31.0,YR,A,F,Y,,,20231124,,MD,US,US,2023,Q4,Young Adult
232245551,23224555,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,,,Unknown,,,25.0,MG,,QD,2023,Q4,Euglycaemic diabetic ketoacidosis,,2023,Q4,1,I,,20221103.0,20231124,20231124,EXP,,US-ALKEM LABORATORIES LIMITED-US-ALKEM-2022-12627,ALKEM,"Sardarli K, Leong R, Gill I, Zarouk SS et.al.. A patient with combined metformin-induced lactic acidosis and euglycemic diabetic ketoacidosis. J Am Soc Nephrol. Unk;Unk:Unk",66.0,YR,,F,Y,,,20231124,,HP,US,US,2023,Q4,Elderly
232245551,23224555,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,,,Unknown,,,25.0,MG,,QD,2023,Q4,Lactic acidosis,,2023,Q4,1,I,,20221103.0,20231124,20231124,EXP,,US-ALKEM LABORATORIES LIMITED-US-ALKEM-2022-12627,ALKEM,"Sardarli K, Leong R, Gill I, Zarouk SS et.al.. A patient with combined metformin-induced lactic acidosis and euglycemic diabetic ketoacidosis. J Am Soc Nephrol. Unk;Unk:Unk",66.0,YR,,F,Y,,,20231124,,HP,US,US,2023,Q4,Elderly
232250821,23225082,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2023,Q4,Vomiting,,2023,Q4,1,I,20221223.0,20231124.0,20231124,20231124,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-274586",BOEHRINGER INGELHEIM,,63.0,YR,A,F,Y,70.0,KG,20231124,,MD,DE,DE,2023,Q4,Adult
232250821,23225082,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2023,Q4,Metabolic acidosis,,2023,Q4,1,I,20221223.0,20231124.0,20231124,20231124,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-274586",BOEHRINGER INGELHEIM,,63.0,YR,A,F,Y,70.0,KG,20231124,,MD,DE,DE,2023,Q4,Adult
232250821,23225082,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2023,Q4,Nausea,,2023,Q4,1,I,20221223.0,20231124.0,20231124,20231124,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-274586",BOEHRINGER INGELHEIM,,63.0,YR,A,F,Y,70.0,KG,20231124,,MD,DE,DE,2023,Q4,Adult
232250821,23225082,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2023,Q4,Disturbance in attention,,2023,Q4,1,I,20221223.0,20231124.0,20231124,20231124,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-274586",BOEHRINGER INGELHEIM,,63.0,YR,A,F,Y,70.0,KG,20231124,,MD,DE,DE,2023,Q4,Adult
232250821,23225082,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2023,Q4,Nervous system disorder,,2023,Q4,1,I,20221223.0,20231124.0,20231124,20231124,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-274586",BOEHRINGER INGELHEIM,,63.0,YR,A,F,Y,70.0,KG,20231124,,MD,DE,DE,2023,Q4,Adult
232252141,23225214,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q4,Euglycaemic diabetic ketoacidosis,,2023,Q4,1,I,,20231117.0,20231124,20231124,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273353",BOEHRINGER INGELHEIM,"Arora G, Gerais Y. Ketonuria ? A Possible Early Indicator Of Impending Euglycemic DKA In Setting Of Recent SGLT-2 Inhibitor Use And Acute Stress. Journal of the Endocrine Society. 2022;6 (1): 289. doi:10.1210/jendso/bvac150.597.",67.0,YR,E,M,Y,,,20231124,,MD,US,US,2023,Q4,Elderly
232252141,23225214,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q4,Cerebellar infarction,,2023,Q4,1,I,,20231117.0,20231124,20231124,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273353",BOEHRINGER INGELHEIM,"Arora G, Gerais Y. Ketonuria ? A Possible Early Indicator Of Impending Euglycemic DKA In Setting Of Recent SGLT-2 Inhibitor Use And Acute Stress. Journal of the Endocrine Society. 2022;6 (1): 289. doi:10.1210/jendso/bvac150.597.",67.0,YR,E,M,Y,,,20231124,,MD,US,US,2023,Q4,Elderly
232252944,23225294,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,,10.0,MG,,QD,2023,Q4,Peripheral swelling,,2023,Q4,4,F,20230101.0,20231226.0,20231124,20231227,EXP,,HR-BRISTOL-MYERS SQUIBB COMPANY-2023-167318,BRISTOL MYERS SQUIBB,,85.0,YR,E,F,Y,,,20231227,,MD,HR,HR,2023,Q4,Elderly
232252944,23225294,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,,10.0,MG,,QD,2023,Q4,Cardiac amyloidosis,,2023,Q4,4,F,20230101.0,20231226.0,20231124,20231227,EXP,,HR-BRISTOL-MYERS SQUIBB COMPANY-2023-167318,BRISTOL MYERS SQUIBB,,85.0,YR,E,F,Y,,,20231227,,MD,HR,HR,2023,Q4,Elderly
232252944,23225294,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,,10.0,MG,,QD,2023,Q4,Renal impairment,,2023,Q4,4,F,20230101.0,20231226.0,20231124,20231227,EXP,,HR-BRISTOL-MYERS SQUIBB COMPANY-2023-167318,BRISTOL MYERS SQUIBB,,85.0,YR,E,F,Y,,,20231227,,MD,HR,HR,2023,Q4,Elderly
232252944,23225294,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,,10.0,MG,,QD,2023,Q4,Pseudomonas infection,,2023,Q4,4,F,20230101.0,20231226.0,20231124,20231227,EXP,,HR-BRISTOL-MYERS SQUIBB COMPANY-2023-167318,BRISTOL MYERS SQUIBB,,85.0,YR,E,F,Y,,,20231227,,MD,HR,HR,2023,Q4,Elderly
232252944,23225294,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,,10.0,MG,,QD,2023,Q4,Cardiopulmonary failure,,2023,Q4,4,F,20230101.0,20231226.0,20231124,20231227,EXP,,HR-BRISTOL-MYERS SQUIBB COMPANY-2023-167318,BRISTOL MYERS SQUIBB,,85.0,YR,E,F,Y,,,20231227,,MD,HR,HR,2023,Q4,Elderly
232252944,23225294,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,,10.0,MG,,QD,2023,Q4,Pleural effusion,,2023,Q4,4,F,20230101.0,20231226.0,20231124,20231227,EXP,,HR-BRISTOL-MYERS SQUIBB COMPANY-2023-167318,BRISTOL MYERS SQUIBB,,85.0,YR,E,F,Y,,,20231227,,MD,HR,HR,2023,Q4,Elderly
232252944,23225294,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,,10.0,MG,,QD,2023,Q4,Oedema peripheral,,2023,Q4,4,F,20230101.0,20231226.0,20231124,20231227,EXP,,HR-BRISTOL-MYERS SQUIBB COMPANY-2023-167318,BRISTOL MYERS SQUIBB,,85.0,YR,E,F,Y,,,20231227,,MD,HR,HR,2023,Q4,Elderly
232252944,23225294,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,,10.0,MG,,QD,2023,Q4,Anaemia,,2023,Q4,4,F,20230101.0,20231226.0,20231124,20231227,EXP,,HR-BRISTOL-MYERS SQUIBB COMPANY-2023-167318,BRISTOL MYERS SQUIBB,,85.0,YR,E,F,Y,,,20231227,,MD,HR,HR,2023,Q4,Elderly
232252944,23225294,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,,10.0,MG,,QD,2023,Q4,Generalised oedema,,2023,Q4,4,F,20230101.0,20231226.0,20231124,20231227,EXP,,HR-BRISTOL-MYERS SQUIBB COMPANY-2023-167318,BRISTOL MYERS SQUIBB,,85.0,YR,E,F,Y,,,20231227,,MD,HR,HR,2023,Q4,Elderly
232252944,23225294,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,,10.0,MG,,QD,2023,Q4,Dyspnoea,,2023,Q4,4,F,20230101.0,20231226.0,20231124,20231227,EXP,,HR-BRISTOL-MYERS SQUIBB COMPANY-2023-167318,BRISTOL MYERS SQUIBB,,85.0,YR,E,F,Y,,,20231227,,MD,HR,HR,2023,Q4,Elderly
232252944,23225294,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,,10.0,MG,,QD,2023,Q4,Morganella infection,,2023,Q4,4,F,20230101.0,20231226.0,20231124,20231227,EXP,,HR-BRISTOL-MYERS SQUIBB COMPANY-2023-167318,BRISTOL MYERS SQUIBB,,85.0,YR,E,F,Y,,,20231227,,MD,HR,HR,2023,Q4,Elderly
232290641,23229064,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,UNKNOWN,,,,,,,2023,Q4,Acute kidney injury,,2023,Q4,1,I,,20231122.0,20231127,20231127,EXP,,US-drreddys-SPO/USA/23/0187255,DR REDDYS,"Khawaja U, Shah N, Wang A. Zoledronate-Induced Acute Tubular Necrosis With Baseline Normal Renal Function: A Rare Phenomenon.. J Endocr Soc. 2022;6(1):A180-A180. doi:10.1210/jendso/bvac150.371",51.0,YR,A,F,Y,,,20231127,,MD,US,US,2023,Q4,Adult
232290641,23229064,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,UNKNOWN,,,,,,,2023,Q4,Renal tubular necrosis,,2023,Q4,1,I,,20231122.0,20231127,20231127,EXP,,US-drreddys-SPO/USA/23/0187255,DR REDDYS,"Khawaja U, Shah N, Wang A. Zoledronate-Induced Acute Tubular Necrosis With Baseline Normal Renal Function: A Rare Phenomenon.. J Endocr Soc. 2022;6(1):A180-A180. doi:10.1210/jendso/bvac150.371",51.0,YR,A,F,Y,,,20231127,,MD,US,US,2023,Q4,Adult
232290641,23229064,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,UNKNOWN,,,,,,,2023,Q4,Product use in unapproved indication,,2023,Q4,1,I,,20231122.0,20231127,20231127,EXP,,US-drreddys-SPO/USA/23/0187255,DR REDDYS,"Khawaja U, Shah N, Wang A. Zoledronate-Induced Acute Tubular Necrosis With Baseline Normal Renal Function: A Rare Phenomenon.. J Endocr Soc. 2022;6(1):A180-A180. doi:10.1210/jendso/bvac150.371",51.0,YR,A,F,Y,,,20231127,,MD,US,US,2023,Q4,Adult
232309672,23230967,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,U,,,,,25.0,MG,,,2023,Q4,Euglycaemic diabetic ketoacidosis,,2023,Q4,2,F,,20231115.0,20231127,20231129,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-420390,RANBAXY,"Tuna KM, Abdelmasih R, Abdelmaseih R, Alsamman M, Robbins J. A Case of Euglycemic DKA With SGLT 2 Inhibitor Use- A Diagnostic and Therapeutic Dilemma. J Endocrine Soc. 2021;5:A358",32.0,YR,,F,Y,,,20231129,,MD,US,US,2023,Q4,Young Adult
232310011,23231001,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q4,Diabetic ketoacidosis,,2023,Q4,1,I,,20231115.0,20231127,20231127,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-420370,RANBAXY,"Abushamat LA, Bhalla R, Reusch JE. The Perfect Storm for Diabetic Ketoacidosis. J Endocr Soc. 2020;4(S1):A883-A884",63.0,YR,,M,Y,,,20231127,,MD,US,US,2023,Q4,Adult
232310051,23231005,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, Daily",,,Y,,,,,25.0,MG,,,2023,Q4,Euglycaemic diabetic ketoacidosis,,2023,Q4,1,I,,20231115.0,20231127,20231127,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-420349,RANBAXY,"Popli R, Chao JH. Precipitation of Euglycemic DKA (euDKA) From the Initiation of SGLT2 Inhibitor (SGLT2i) and 0-Carb Diet Inpatient. J Endocr Soc. 2021;Apr-May;5 (S1):A395",54.0,YR,,M,Y,,,20231127,,MD,US,US,2023,Q4,Adult
232310521,23231052,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Euglycaemic diabetic ketoacidosis,,2023,Q4,1,I,,20231115.0,20231127,20231127,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-420562,RANBAXY,"Heckart JC, Shaw M. EDKA and MALA in the Setting of Severe Heart Failure and Acute Renal Failure, Due to SGLT2-i. JESOCI. 2020;4:A853",53.0,YR,,M,Y,,,20231127,,MD,US,US,2023,Q4,Adult
232310521,23231052,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Lactic acidosis,,2023,Q4,1,I,,20231115.0,20231127,20231127,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-420562,RANBAXY,"Heckart JC, Shaw M. EDKA and MALA in the Setting of Severe Heart Failure and Acute Renal Failure, Due to SGLT2-i. JESOCI. 2020;4:A853",53.0,YR,,M,Y,,,20231127,,MD,US,US,2023,Q4,Adult
232310521,23231052,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Acute kidney injury,,2023,Q4,1,I,,20231115.0,20231127,20231127,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-420562,RANBAXY,"Heckart JC, Shaw M. EDKA and MALA in the Setting of Severe Heart Failure and Acute Renal Failure, Due to SGLT2-i. JESOCI. 2020;4:A853",53.0,YR,,M,Y,,,20231127,,MD,US,US,2023,Q4,Adult
232312251,23231225,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,ASKU,,204629.0,10.0,MG,Tablet,,2023,Q4,Pneumonia aspiration,,2023,Q4,1,I,20231105.0,20231123.0,20231127,20231127,EXP,GB-MHRA-MED-202311161513166150-NRPWC,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-274609",BOEHRINGER INGELHEIM,,72.0,YR,E,M,Y,68.0,KG,20231127,,PH,GB,GB,2023,Q4,Elderly
232312251,23231225,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,ASKU,,204629.0,10.0,MG,Tablet,,2023,Q4,Euglycaemic diabetic ketoacidosis,,2023,Q4,1,I,20231105.0,20231123.0,20231127,20231127,EXP,GB-MHRA-MED-202311161513166150-NRPWC,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-274609",BOEHRINGER INGELHEIM,,72.0,YR,E,M,Y,68.0,KG,20231127,,PH,GB,GB,2023,Q4,Elderly
232312251,23231225,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,ASKU,,204629.0,10.0,MG,Tablet,,2023,Q4,Confusional state,,2023,Q4,1,I,20231105.0,20231123.0,20231127,20231127,EXP,GB-MHRA-MED-202311161513166150-NRPWC,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-274609",BOEHRINGER INGELHEIM,,72.0,YR,E,M,Y,68.0,KG,20231127,,PH,GB,GB,2023,Q4,Elderly
232321511,23232151,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,,,,,,2023,Q4,Lactic acidosis,,2023,Q4,1,I,,20231114.0,20231127,20231127,EXP,,US-EMD Serono-2023488157,EMD SERONO INC,"Abushamat LA, Bhalla R, Reusch JE. The Perfect Storm for Diabetic Ketoacidosis. Journal of the Endocrine Society. 2020 May 01;4(1): A883-A884. doi:10.1210/jendso/bvaa046.",63.0,YR,A,M,Y,,,20231127,,MD,US,US,2023,Q4,Adult
232321511,23232151,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,,,,,,2023,Q4,Dehydration,,2023,Q4,1,I,,20231114.0,20231127,20231127,EXP,,US-EMD Serono-2023488157,EMD SERONO INC,"Abushamat LA, Bhalla R, Reusch JE. The Perfect Storm for Diabetic Ketoacidosis. Journal of the Endocrine Society. 2020 May 01;4(1): A883-A884. doi:10.1210/jendso/bvaa046.",63.0,YR,A,M,Y,,,20231127,,MD,US,US,2023,Q4,Adult
232321511,23232151,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,,,,,,2023,Q4,Diabetic ketoacidosis,,2023,Q4,1,I,,20231114.0,20231127,20231127,EXP,,US-EMD Serono-2023488157,EMD SERONO INC,"Abushamat LA, Bhalla R, Reusch JE. The Perfect Storm for Diabetic Ketoacidosis. Journal of the Endocrine Society. 2020 May 01;4(1): A883-A884. doi:10.1210/jendso/bvaa046.",63.0,YR,A,M,Y,,,20231127,,MD,US,US,2023,Q4,Adult
232321511,23232151,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,,,,,,2023,Q4,Pyrexia,,2023,Q4,1,I,,20231114.0,20231127,20231127,EXP,,US-EMD Serono-2023488157,EMD SERONO INC,"Abushamat LA, Bhalla R, Reusch JE. The Perfect Storm for Diabetic Ketoacidosis. Journal of the Endocrine Society. 2020 May 01;4(1): A883-A884. doi:10.1210/jendso/bvaa046.",63.0,YR,A,M,Y,,,20231127,,MD,US,US,2023,Q4,Adult
232321511,23232151,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,,,,,,2023,Q4,Acute kidney injury,,2023,Q4,1,I,,20231114.0,20231127,20231127,EXP,,US-EMD Serono-2023488157,EMD SERONO INC,"Abushamat LA, Bhalla R, Reusch JE. The Perfect Storm for Diabetic Ketoacidosis. Journal of the Endocrine Society. 2020 May 01;4(1): A883-A884. doi:10.1210/jendso/bvaa046.",63.0,YR,A,M,Y,,,20231127,,MD,US,US,2023,Q4,Adult
232322271,23232227,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"date d?introduction exacte non connue, entre 10.2022 et 2023, en tout cas pr?sent depuis plusieur...",,,Y,,Unknown,,206111.0,,,,Q12H,2023,Q4,Nausea,,2023,Q4,1,I,20220101.0,20231121.0,20231127,20231127,EXP,CH-SM-2023-17269,"CH-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273921",BOEHRINGER INGELHEIM,,72.0,YR,E,F,Y,,,20231128,,PH,CH,CH,2023,Q4,Elderly
232322271,23232227,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"date d?introduction exacte non connue, entre 10.2022 et 2023, en tout cas pr?sent depuis plusieur...",,,Y,,Unknown,,206111.0,,,,Q12H,2023,Q4,General physical health deterioration,,2023,Q4,1,I,20220101.0,20231121.0,20231127,20231127,EXP,CH-SM-2023-17269,"CH-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273921",BOEHRINGER INGELHEIM,,72.0,YR,E,F,Y,,,20231128,,PH,CH,CH,2023,Q4,Elderly
232322271,23232227,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"date d?introduction exacte non connue, entre 10.2022 et 2023, en tout cas pr?sent depuis plusieur...",,,Y,,Unknown,,206111.0,,,,Q12H,2023,Q4,Abnormal loss of weight,,2023,Q4,1,I,20220101.0,20231121.0,20231127,20231127,EXP,CH-SM-2023-17269,"CH-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273921",BOEHRINGER INGELHEIM,,72.0,YR,E,F,Y,,,20231128,,PH,CH,CH,2023,Q4,Elderly
232322271,23232227,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"date d?introduction exacte non connue, entre 10.2022 et 2023, en tout cas pr?sent depuis plusieur...",,,Y,,Unknown,,206111.0,,,,Q12H,2023,Q4,Decreased appetite,,2023,Q4,1,I,20220101.0,20231121.0,20231127,20231127,EXP,CH-SM-2023-17269,"CH-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273921",BOEHRINGER INGELHEIM,,72.0,YR,E,F,Y,,,20231128,,PH,CH,CH,2023,Q4,Elderly
232322271,23232227,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"date d?introduction exacte non connue, entre 10.2022 et 2023, en tout cas pr?sent depuis plusieur...",,,Y,,Unknown,,206111.0,,,,Q12H,2023,Q4,Vomiting,,2023,Q4,1,I,20220101.0,20231121.0,20231127,20231127,EXP,CH-SM-2023-17269,"CH-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273921",BOEHRINGER INGELHEIM,,72.0,YR,E,F,Y,,,20231128,,PH,CH,CH,2023,Q4,Elderly
232322331,23232233,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q4,Genital lesion,,2023,Q4,1,I,,20231121.0,20231127,20231127,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273950",BOEHRINGER INGELHEIM,"Simhadri P, Vaitla P, Sriperumbuduri S, Murari U. Invasive fungal infection associated with SGLT2 inhibitor use. Journal of the American Society of Nephrology. 2023;34: 1174.",75.0,YR,E,M,Y,,,20231128,,HP,US,US,2023,Q4,Elderly
232322331,23232233,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q4,Renal abscess,,2023,Q4,1,I,,20231121.0,20231127,20231127,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273950",BOEHRINGER INGELHEIM,"Simhadri P, Vaitla P, Sriperumbuduri S, Murari U. Invasive fungal infection associated with SGLT2 inhibitor use. Journal of the American Society of Nephrology. 2023;34: 1174.",75.0,YR,E,M,Y,,,20231128,,HP,US,US,2023,Q4,Elderly
232322331,23232233,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q4,Systemic candida,,2023,Q4,1,I,,20231121.0,20231127,20231127,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273950",BOEHRINGER INGELHEIM,"Simhadri P, Vaitla P, Sriperumbuduri S, Murari U. Invasive fungal infection associated with SGLT2 inhibitor use. Journal of the American Society of Nephrology. 2023;34: 1174.",75.0,YR,E,M,Y,,,20231128,,HP,US,US,2023,Q4,Elderly
232322331,23232233,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q4,Urinary tract inflammation,,2023,Q4,1,I,,20231121.0,20231127,20231127,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273950",BOEHRINGER INGELHEIM,"Simhadri P, Vaitla P, Sriperumbuduri S, Murari U. Invasive fungal infection associated with SGLT2 inhibitor use. Journal of the American Society of Nephrology. 2023;34: 1174.",75.0,YR,E,M,Y,,,20231128,,HP,US,US,2023,Q4,Elderly
232341531,23234153,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,,2023,Q4,Atrioventricular block complete,,2023,Q4,1,I,20221128.0,20231123.0,20231128,20231128,EXP,DE-DCGMA-22200014,DE-BRACCO-2023DE06308,BRACCO,,51.0,YR,,M,Y,85.0,KG,20231127,,MD,DE,DE,2023,Q4,Adult
232341531,23234153,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,,2023,Q4,Resuscitation,,2023,Q4,1,I,20221128.0,20231123.0,20231128,20231128,EXP,DE-DCGMA-22200014,DE-BRACCO-2023DE06308,BRACCO,,51.0,YR,,M,Y,85.0,KG,20231127,,MD,DE,DE,2023,Q4,Adult
232362751,23236275,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Euglycaemic diabetic ketoacidosis,,2023,Q4,1,I,,20231115.0,20231128,20231128,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-420456,RANBAXY,"Hester CJ, Zimmerman S, Nimmo AT, Cunningham W, Liu, J, Sukpraprut-Braaten S. Euglycemic Diabetic Ketoacidosis Secondary to SGLT2-inhibitor Use in Combination With a Ketogenic Diet. J Endocr Soc. 2021;5(Suppl.):A381-A382",72.0,YR,,F,Y,,,20231128,,MD,US,US,2023,Q4,Elderly
232362781,23236278,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Daily",,,U,,,,,25.0,MG,,,2023,Q4,Euglycaemic diabetic ketoacidosis,,2023,Q4,1,I,,20231115.0,20231128,20231128,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-420446,RANBAXY,"Khalifa M, Aftab H, Kantorovich V. Euglycemic DKA in Patients on SGLT2 Inhibitor and Potentially Ketotic State. J Endocr Soc. 2021;5(Suppl.):A382",36.0,YR,,F,Y,,,20231128,,MD,US,US,2023,Q4,Adult
232363351,23236335,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2023,Q4,Balanoposthitis,,2023,Q4,1,I,20231123.0,20231124.0,20231128,20231128,EXP,GB-MHRA-TPP5419457C7426252YC1700761499094,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-274833",BOEHRINGER INGELHEIM,,79.0,YR,E,M,Y,105.0,KG,20231128,,HP,GB,GB,2023,Q4,Elderly
232363351,23236335,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2023,Q4,Pain in extremity,,2023,Q4,1,I,20231123.0,20231124.0,20231128,20231128,EXP,GB-MHRA-TPP5419457C7426252YC1700761499094,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-274833",BOEHRINGER INGELHEIM,,79.0,YR,E,M,Y,105.0,KG,20231128,,HP,GB,GB,2023,Q4,Elderly
232363351,23236335,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2023,Q4,Balanoposthitis,,2023,Q4,1,I,20231123.0,20231124.0,20231128,20231128,EXP,GB-MHRA-TPP5419457C7426252YC1700761499094,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-274833",BOEHRINGER INGELHEIM,,79.0,YR,E,M,Y,105.0,KG,20231128,,HP,GB,GB,2023,Q4,Elderly
232363351,23236335,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2023,Q4,Pain in extremity,,2023,Q4,1,I,20231123.0,20231124.0,20231128,20231128,EXP,GB-MHRA-TPP5419457C7426252YC1700761499094,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-274833",BOEHRINGER INGELHEIM,,79.0,YR,E,M,Y,105.0,KG,20231128,,HP,GB,GB,2023,Q4,Elderly
232375402,23237540,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,,,2023,Q4,Genital swelling,,2023,Q4,2,F,20230925.0,20231128.0,20231128,20231130,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-274912",BOEHRINGER INGELHEIM,,83.0,YR,E,F,Y,,,20231130,,MD,CA,CA,2023,Q4,Elderly
232375402,23237540,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,,,2023,Q4,Intentional product use issue,,2023,Q4,2,F,20230925.0,20231128.0,20231128,20231130,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-274912",BOEHRINGER INGELHEIM,,83.0,YR,E,F,Y,,,20231130,,MD,CA,CA,2023,Q4,Elderly
232375402,23237540,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,,,2023,Q4,Swelling face,,2023,Q4,2,F,20230925.0,20231128.0,20231128,20231130,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-274912",BOEHRINGER INGELHEIM,,83.0,YR,E,F,Y,,,20231130,,MD,CA,CA,2023,Q4,Elderly
232409091,23240909,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,Unknown,,212614.0,,,,,2023,Q4,Blood glucose increased,,2023,Q4,1,I,20231129.0,20231129.0,20231129,20231129,PER,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-275442",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,,,20231129,,CN,US,US,2023,Q4,Elderly
232410571,23241057,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,U,,,,,,Unknown,,2023,Q4,Drug ineffective,,2023,Q4,1,I,,20231115.0,20231129,20231129,EXP,,US-MYLANLABS-2023M1124174,MYLAN,"Abushamat LA, Bhalla R, Reusch JE. The Perfect Storm for Diabetic Ketoacidosis. J-Endocr-Soc 2020; 4 (Suppl.) A883-A884 abstr. SAT-670.",63.0,YR,,M,Y,,,20231127,,MD,US,US,2023,Q4,Adult
232411211,23241121,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q4,Tongue neoplasm malignant stage unspecified,,2023,Q4,1,I,,20231113.0,20231129,20231129,EXP,,CA-HLS-202302452,HLS THERAPEUTICS,,41.0,YR,A,M,Y,,,20231128,,PH,CA,CA,2023,Q4,Adult
232411211,23241121,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q4,Delirium,,2023,Q4,1,I,,20231113.0,20231129,20231129,EXP,,CA-HLS-202302452,HLS THERAPEUTICS,,41.0,YR,A,M,Y,,,20231128,,PH,CA,CA,2023,Q4,Adult
232411211,23241121,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q4,Nausea,,2023,Q4,1,I,,20231113.0,20231129,20231129,EXP,,CA-HLS-202302452,HLS THERAPEUTICS,,41.0,YR,A,M,Y,,,20231128,,PH,CA,CA,2023,Q4,Adult
232411211,23241121,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q4,Vomiting,,2023,Q4,1,I,,20231113.0,20231129,20231129,EXP,,CA-HLS-202302452,HLS THERAPEUTICS,,41.0,YR,A,M,Y,,,20231128,,PH,CA,CA,2023,Q4,Adult
232411211,23241121,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q4,Tremor,,2023,Q4,1,I,,20231113.0,20231129,20231129,EXP,,CA-HLS-202302452,HLS THERAPEUTICS,,41.0,YR,A,M,Y,,,20231128,,PH,CA,CA,2023,Q4,Adult
232411211,23241121,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q4,Insomnia,,2023,Q4,1,I,,20231113.0,20231129,20231129,EXP,,CA-HLS-202302452,HLS THERAPEUTICS,,41.0,YR,A,M,Y,,,20231128,,PH,CA,CA,2023,Q4,Adult
232420471,23242047,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd (10 mg per day)",,,Y,,,,,10.0,MG,Unknown,QD,2023,Q4,Acute kidney injury,,2023,Q4,1,I,20231006.0,20231117.0,20231129,20231129,EXP,FR-AFSSAPS-PC2023000927,FR-MYLANLABS-2023M1123669,MYLAN,,76.0,YR,,F,Y,,,20231129,,PH,FR,FR,2023,Q4,Elderly
232420471,23242047,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd (10 mg per day)",,,Y,,,,,10.0,MG,Unknown,QD,2023,Q4,Urinary tract infection,,2023,Q4,1,I,20231006.0,20231117.0,20231129,20231129,EXP,FR-AFSSAPS-PC2023000927,FR-MYLANLABS-2023M1123669,MYLAN,,76.0,YR,,F,Y,,,20231129,,PH,FR,FR,2023,Q4,Elderly
232420784,23242078,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,D,,,,,10.0,MG,Unknown,QD,2023,Q4,Renal impairment,,2023,Q4,4,F,20230101.0,20231218.0,20231129,20231222,EXP,,HR-MYLANLABS-2023M1124589,MYLAN,,85.0,YR,,F,Y,,,20231222,,MD,HR,HR,2023,Q4,Elderly
232420784,23242078,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,D,,,,,10.0,MG,Unknown,QD,2023,Q4,Dyspnoea,,2023,Q4,4,F,20230101.0,20231218.0,20231129,20231222,EXP,,HR-MYLANLABS-2023M1124589,MYLAN,,85.0,YR,,F,Y,,,20231222,,MD,HR,HR,2023,Q4,Elderly
232420784,23242078,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,D,,,,,10.0,MG,Unknown,QD,2023,Q4,Generalised oedema,,2023,Q4,4,F,20230101.0,20231218.0,20231129,20231222,EXP,,HR-MYLANLABS-2023M1124589,MYLAN,,85.0,YR,,F,Y,,,20231222,,MD,HR,HR,2023,Q4,Elderly
232420784,23242078,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,D,,,,,10.0,MG,Unknown,QD,2023,Q4,Cardiac failure,,2023,Q4,4,F,20230101.0,20231218.0,20231129,20231222,EXP,,HR-MYLANLABS-2023M1124589,MYLAN,,85.0,YR,,F,Y,,,20231222,,MD,HR,HR,2023,Q4,Elderly
232420784,23242078,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,D,,,,,10.0,MG,Unknown,QD,2023,Q4,Pleural effusion,,2023,Q4,4,F,20230101.0,20231218.0,20231129,20231222,EXP,,HR-MYLANLABS-2023M1124589,MYLAN,,85.0,YR,,F,Y,,,20231222,,MD,HR,HR,2023,Q4,Elderly
232420784,23242078,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,D,,,,,10.0,MG,Unknown,QD,2023,Q4,Oedema peripheral,,2023,Q4,4,F,20230101.0,20231218.0,20231129,20231222,EXP,,HR-MYLANLABS-2023M1124589,MYLAN,,85.0,YR,,F,Y,,,20231222,,MD,HR,HR,2023,Q4,Elderly
232420784,23242078,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,D,,,,,10.0,MG,Unknown,QD,2023,Q4,Morganella infection,,2023,Q4,4,F,20230101.0,20231218.0,20231129,20231222,EXP,,HR-MYLANLABS-2023M1124589,MYLAN,,85.0,YR,,F,Y,,,20231222,,MD,HR,HR,2023,Q4,Elderly
232420784,23242078,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,D,,,,,10.0,MG,Unknown,QD,2023,Q4,Anaemia,,2023,Q4,4,F,20230101.0,20231218.0,20231129,20231222,EXP,,HR-MYLANLABS-2023M1124589,MYLAN,,85.0,YR,,F,Y,,,20231222,,MD,HR,HR,2023,Q4,Elderly
232420784,23242078,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,D,,,,,10.0,MG,Unknown,QD,2023,Q4,Pseudomonas infection,,2023,Q4,4,F,20230101.0,20231218.0,20231129,20231222,EXP,,HR-MYLANLABS-2023M1124589,MYLAN,,85.0,YR,,F,Y,,,20231222,,MD,HR,HR,2023,Q4,Elderly
232420784,23242078,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,D,,,,,10.0,MG,Unknown,QD,2023,Q4,Peripheral swelling,,2023,Q4,4,F,20230101.0,20231218.0,20231129,20231222,EXP,,HR-MYLANLABS-2023M1124589,MYLAN,,85.0,YR,,F,Y,,,20231222,,MD,HR,HR,2023,Q4,Elderly
232420784,23242078,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,D,,,,,10.0,MG,Unknown,QD,2023,Q4,Cardiac amyloidosis,,2023,Q4,4,F,20230101.0,20231218.0,20231129,20231222,EXP,,HR-MYLANLABS-2023M1124589,MYLAN,,85.0,YR,,F,Y,,,20231222,,MD,HR,HR,2023,Q4,Elderly
232420931,23242093,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Renal tubular necrosis,,2023,Q4,1,I,,20231122.0,20231129,20231129,EXP,,US-FreseniusKabi-FK202319080,FRESENIUS KABI,"Khawaja US, Shah N, Wang A. Zoledronate-Induced Acute Tubular Necrosis With Baseline Normal Renal Function: A Rare Phenomenon.. Journal of the Endocrine Society. 2023;6: doi:https://dx.doi.org/10.1210/jendso/bvac150.371.",51.0,YR,A,F,Y,,,20231129,,MD,US,US,2023,Q4,Adult
232428031,23242803,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Form Strength: 10 Milligram,,,Y,U,Unknown,,204629.0,,,,,2023,Q4,Klebsiella infection,,2023,Q4,1,I,,20231124.0,20231129,20231129,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-274637",BOEHRINGER INGELHEIM,"Sheth M, Arnaud-Borboa I. Do we stop SGLT2 inhibitor after UTI with septic shock?. American Journal of Medicine. 2023;doi:10.1016/j.amjmed.2023.10.036.",90.0,YR,E,M,Y,,,20231130,,MD,US,US,2023,Q4,Elderly
232428031,23242803,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Form Strength: 10 Milligram,,,Y,U,Unknown,,204629.0,,,,,2023,Q4,Candida infection,,2023,Q4,1,I,,20231124.0,20231129,20231129,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-274637",BOEHRINGER INGELHEIM,"Sheth M, Arnaud-Borboa I. Do we stop SGLT2 inhibitor after UTI with septic shock?. American Journal of Medicine. 2023;doi:10.1016/j.amjmed.2023.10.036.",90.0,YR,E,M,Y,,,20231130,,MD,US,US,2023,Q4,Elderly
232428031,23242803,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Form Strength: 10 Milligram,,,Y,U,Unknown,,204629.0,,,,,2023,Q4,Septic shock,,2023,Q4,1,I,,20231124.0,20231129,20231129,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-274637",BOEHRINGER INGELHEIM,"Sheth M, Arnaud-Borboa I. Do we stop SGLT2 inhibitor after UTI with septic shock?. American Journal of Medicine. 2023;doi:10.1016/j.amjmed.2023.10.036.",90.0,YR,E,M,Y,,,20231130,,MD,US,US,2023,Q4,Elderly
232428031,23242803,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Form Strength: 10 Milligram,,,Y,U,Unknown,,204629.0,,,,,2023,Q4,Urinary tract infection,,2023,Q4,1,I,,20231124.0,20231129,20231129,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-274637",BOEHRINGER INGELHEIM,"Sheth M, Arnaud-Borboa I. Do we stop SGLT2 inhibitor after UTI with septic shock?. American Journal of Medicine. 2023;doi:10.1016/j.amjmed.2023.10.036.",90.0,YR,E,M,Y,,,20231130,,MD,US,US,2023,Q4,Elderly
232428031,23242803,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Form Strength: 10 Milligram,,,Y,U,Unknown,,204629.0,,,,,2023,Q4,Mental status changes,,2023,Q4,1,I,,20231124.0,20231129,20231129,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-274637",BOEHRINGER INGELHEIM,"Sheth M, Arnaud-Borboa I. Do we stop SGLT2 inhibitor after UTI with septic shock?. American Journal of Medicine. 2023;doi:10.1016/j.amjmed.2023.10.036.",90.0,YR,E,M,Y,,,20231130,,MD,US,US,2023,Q4,Elderly
232454211,23245421,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q4,Renal tubular necrosis,,2023,Q4,1,I,,20231122.0,20231130,20231130,EXP,,US-APOTEX-2023AP017248,APOTEX,"Khawaja US, Shah N, Wang A.. Zoledronate-Induced Acute Tubular Necrosis With Baseline Normal Renal Function: A Rare Phenomenon. Journal of the Endocrine Society. 2022;6(Suppl.1):A180",51.0,YR,,F,Y,,,20231130,,HP,US,US,2023,Q4,Adult
232469171,23246917,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,Unknown,,2023,Q4,Drug ineffective,,2023,Q4,1,I,,20231122.0,20231130,20231130,EXP,,US-MYLANLABS-2023M1126832,MYLAN,"El Musa Penna L, Rivera MO, Burgos AR, Marin LM, Nieves YR, Cordero NH, et al. SGLT2 Inhibitor-Induced Euglycemic DKA and its Challenges. J-Endocr-Soc 2022; 6 (Suppl. 1) A333-A334 abstr. ODP244.",61.0,YR,,M,Y,,,20231130,,MD,US,US,2023,Q4,Adult
232469181,23246918,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,,U,,,,25.0,MG,Unknown,QD,2023,Q4,Drug ineffective,,2023,Q4,1,I,,20231122.0,20231130,20231130,EXP,,US-MYLANLABS-2023M1127307,MYLAN,"Sekar V, Shaik S. A Case Of Alpelisib Induced Diabetic Ketoacidosis (Dka) In A Patient With Type 2 Diabetes Mellitus And Rechallenge With SGLT2 Inhibitor. J-Endocr-Soc 2023; 7 (Suppl. 1) A437-A438 abstr. THU380.",60.0,YR,,F,Y,,,20231130,,MD,US,US,2023,Q4,Adult
232480221,23248022,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,dose and frequency unknown,,,,,,,,,,,,2023,Q4,Hypertension,,2023,Q4,1,I,20220601.0,20231122.0,20231130,20231130,PER,,JP-Eisai-EC-2022-119234,EISAI,,70.0,YR,E,M,Y,,,20231130,,MD,JP,JP,2023,Q4,Elderly
232487631,23248763,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,Unknown,,,,,,,2023,Q4,Urinary tract infection,,2023,Q4,1,I,,20231108.0,20231201,20231201,EXP,,AE-ALKEM LABORATORIES LIMITED-AE-ALKEM-2023-13726,ALKEM,"Attallah N, Yassine L. Use of Empagliflozin in Recipients of Kidney Transplant: A Report of 8 Cases. Transplantation Proceedings. 2019;51(10):3275-3280",47.0,YR,,F,Y,,,20231201,,MD,AE,AE,2023,Q4,Adult
232487641,23248764,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,Unknown,,,,,,,2023,Q4,Urinary tract infection,,2023,Q4,1,I,,20231108.0,20231201,20231201,EXP,,AE-ALKEM LABORATORIES LIMITED-AE-ALKEM-2023-14189,ALKEM,"Attallah N, Yassine L. Use of Empagliflozin in Recipients of Kidney Transplant: A Report of 8 Cases. Transplantation Proceedings. 2019;51:3275-3280",52.0,YR,,F,Y,,,20231201,,MD,AE,AE,2023,Q4,Adult
232508501,23250850,3,C,EMPAGLIFLOZIN,,1,,,,,,,,,,,,,,2023,Q4,Retching,,2023,Q4,1,I,20231114.0,,20231130,20231130,DIR,682932,,FDA-CTU,,49.0,YR,,M,N,87.4,KG,20231130,N,PH,US,,2023,Q4,Adult
232508501,23250850,3,C,EMPAGLIFLOZIN,,1,,,,,,,,,,,,,,2023,Q4,Hyperhidrosis,,2023,Q4,1,I,20231114.0,,20231130,20231130,DIR,682932,,FDA-CTU,,49.0,YR,,M,N,87.4,KG,20231130,N,PH,US,,2023,Q4,Adult
232508501,23250850,3,C,EMPAGLIFLOZIN,,1,,,,,,,,,,,,,,2023,Q4,Vomiting,,2023,Q4,1,I,20231114.0,,20231130,20231130,DIR,682932,,FDA-CTU,,49.0,YR,,M,N,87.4,KG,20231130,N,PH,US,,2023,Q4,Adult
232508501,23250850,3,C,EMPAGLIFLOZIN,,1,,,,,,,,,,,,,,2023,Q4,Feeling hot,,2023,Q4,1,I,20231114.0,,20231130,20231130,DIR,682932,,FDA-CTU,,49.0,YR,,M,N,87.4,KG,20231130,N,PH,US,,2023,Q4,Adult
232508501,23250850,3,C,EMPAGLIFLOZIN,,1,,,,,,,,,,,,,,2023,Q4,Pulse absent,,2023,Q4,1,I,20231114.0,,20231130,20231130,DIR,682932,,FDA-CTU,,49.0,YR,,M,N,87.4,KG,20231130,N,PH,US,,2023,Q4,Adult
232508501,23250850,3,C,EMPAGLIFLOZIN,,1,,,,,,,,,,,,,,2023,Q4,Cardio-respiratory arrest,,2023,Q4,1,I,20231114.0,,20231130,20231130,DIR,682932,,FDA-CTU,,49.0,YR,,M,N,87.4,KG,20231130,N,PH,US,,2023,Q4,Adult
232508831,23250883,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, QD",,,Y,,,,,25.0,MG,,QD,2023,Q4,Euglycaemic diabetic ketoacidosis,,2023,Q4,1,I,,20231122.0,20231201,20231201,EXP,,NVSC2023US251594,NOVARTIS,"Sekar V, Shaik S. A Case of Alpelisib Induced Diabetic Ketoacidosis (Dka) In A Patient with Type 2. JOURNAL OF THE ENDOCRINE SOCIETY. 2023;7:A437-A438",60.0,YR,,F,Y,,,20231201,,HP,US,US,2023,Q4,Adult
232508831,23250883,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, QD",,,Y,,,,,25.0,MG,,QD,2023,Q4,Hyperglycaemia,,2023,Q4,1,I,,20231122.0,20231201,20231201,EXP,,NVSC2023US251594,NOVARTIS,"Sekar V, Shaik S. A Case of Alpelisib Induced Diabetic Ketoacidosis (Dka) In A Patient with Type 2. JOURNAL OF THE ENDOCRINE SOCIETY. 2023;7:A437-A438",60.0,YR,,F,Y,,,20231201,,HP,US,US,2023,Q4,Adult
232508831,23250883,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, QD",,,Y,,,,,25.0,MG,,QD,2023,Q4,Condition aggravated,,2023,Q4,1,I,,20231122.0,20231201,20231201,EXP,,NVSC2023US251594,NOVARTIS,"Sekar V, Shaik S. A Case of Alpelisib Induced Diabetic Ketoacidosis (Dka) In A Patient with Type 2. JOURNAL OF THE ENDOCRINE SOCIETY. 2023;7:A437-A438",60.0,YR,,F,Y,,,20231201,,HP,US,US,2023,Q4,Adult
232511181,23251118,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,dose and frequency unknown,,,,,,,,,,,,2023,Q4,Haematuria,,2023,Q4,1,I,20230208.0,20231122.0,20231201,20231201,PER,,JP-Eisai-EC-2023-137529,EISAI,,70.0,YR,E,M,Y,,,20231201,,MD,JP,JP,2023,Q4,Elderly
232516391,23251639,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,Unknown,,2023,Q4,Renal tubular necrosis,,2023,Q4,1,I,,20231122.0,20231201,20231201,EXP,,US-MYLANLABS-2023M1126594,MYLAN,"Khawaja US, Shah N, Wang A. Zoledronate-Induced Acute Tubular Necrosis With Baseline Normal Renal Function: A Rare Phenomenon. J-Endocr-Soc 2022; 6 (Suppl. 1) A180.",51.0,YR,,F,Y,,,20231201,,MD,US,US,2023,Q4,Adult
232516391,23251639,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,Unknown,,2023,Q4,Acute kidney injury,,2023,Q4,1,I,,20231122.0,20231201,20231201,EXP,,US-MYLANLABS-2023M1126594,MYLAN,"Khawaja US, Shah N, Wang A. Zoledronate-Induced Acute Tubular Necrosis With Baseline Normal Renal Function: A Rare Phenomenon. J-Endocr-Soc 2022; 6 (Suppl. 1) A180.",51.0,YR,,F,Y,,,20231201,,MD,US,US,2023,Q4,Adult
232519232,23251923,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q4,Heart rate decreased,,2023,Q4,2,F,20230101.0,20231206.0,20231201,20231207,EXP,,CO-SA-2023SA371420,SANOFI AVENTIS,,61.0,YR,A,F,Y,,,20231207,,MD,CO,CO,2023,Q4,Adult
232519232,23251923,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q4,Somnolence,,2023,Q4,2,F,20230101.0,20231206.0,20231201,20231207,EXP,,CO-SA-2023SA371420,SANOFI AVENTIS,,61.0,YR,A,F,Y,,,20231207,,MD,CO,CO,2023,Q4,Adult
232519232,23251923,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q4,Chest pain,,2023,Q4,2,F,20230101.0,20231206.0,20231201,20231207,EXP,,CO-SA-2023SA371420,SANOFI AVENTIS,,61.0,YR,A,F,Y,,,20231207,,MD,CO,CO,2023,Q4,Adult
232519232,23251923,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q4,Fatigue,,2023,Q4,2,F,20230101.0,20231206.0,20231201,20231207,EXP,,CO-SA-2023SA371420,SANOFI AVENTIS,,61.0,YR,A,F,Y,,,20231207,,MD,CO,CO,2023,Q4,Adult
232519232,23251923,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q4,Asthenia,,2023,Q4,2,F,20230101.0,20231206.0,20231201,20231207,EXP,,CO-SA-2023SA371420,SANOFI AVENTIS,,61.0,YR,A,F,Y,,,20231207,,MD,CO,CO,2023,Q4,Adult
232519232,23251923,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q4,Cardiac failure,,2023,Q4,2,F,20230101.0,20231206.0,20231201,20231207,EXP,,CO-SA-2023SA371420,SANOFI AVENTIS,,61.0,YR,A,F,Y,,,20231207,,MD,CO,CO,2023,Q4,Adult
232519232,23251923,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q4,Dizziness,,2023,Q4,2,F,20230101.0,20231206.0,20231201,20231207,EXP,,CO-SA-2023SA371420,SANOFI AVENTIS,,61.0,YR,A,F,Y,,,20231207,,MD,CO,CO,2023,Q4,Adult
232519232,23251923,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q4,Choking,,2023,Q4,2,F,20230101.0,20231206.0,20231201,20231207,EXP,,CO-SA-2023SA371420,SANOFI AVENTIS,,61.0,YR,A,F,Y,,,20231207,,MD,CO,CO,2023,Q4,Adult
232541131,23254113,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Renal tubular necrosis,,2023,Q4,1,I,,20231122.0,20231202,20231202,EXP,,US-AUROBINDO-AUR-APL-2023-074650,AUROBINDO,"Khawaja US, Shah N, Wang A.. Zoledronate-Induced Acute Tubular Necrosis With Baseline Normal Renal Function: A Rare Phenomenon.. Journal of the Endocrine Society. 2022;6(Supplement 1):A180",51.0,YR,,F,Y,,,20231202,,MD,US,US,2023,Q4,Adult
232541131,23254113,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Acute kidney injury,,2023,Q4,1,I,,20231122.0,20231202,20231202,EXP,,US-AUROBINDO-AUR-APL-2023-074650,AUROBINDO,"Khawaja US, Shah N, Wang A.. Zoledronate-Induced Acute Tubular Necrosis With Baseline Normal Renal Function: A Rare Phenomenon.. Journal of the Endocrine Society. 2022;6(Supplement 1):A180",51.0,YR,,F,Y,,,20231202,,MD,US,US,2023,Q4,Adult
232542261,23254226,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q4,Arthralgia,,2023,Q4,1,I,,20231120.0,20231202,20231202,EXP,CA-MHPD-E2B_06579479,CA-Accord-392468,ACCORD,,61.0,YR,A,F,Y,,,20231202,,HP,CA,CA,2023,Q4,Adult
232542261,23254226,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q4,Off label use,,2023,Q4,1,I,,20231120.0,20231202,20231202,EXP,CA-MHPD-E2B_06579479,CA-Accord-392468,ACCORD,,61.0,YR,A,F,Y,,,20231202,,HP,CA,CA,2023,Q4,Adult
232542261,23254226,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q4,Joint swelling,,2023,Q4,1,I,,20231120.0,20231202,20231202,EXP,CA-MHPD-E2B_06579479,CA-Accord-392468,ACCORD,,61.0,YR,A,F,Y,,,20231202,,HP,CA,CA,2023,Q4,Adult
232542261,23254226,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2023,Q4,Condition aggravated,,2023,Q4,1,I,,20231120.0,20231202,20231202,EXP,CA-MHPD-E2B_06579479,CA-Accord-392468,ACCORD,,61.0,YR,A,F,Y,,,20231202,,HP,CA,CA,2023,Q4,Adult
232568491,23256849,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Asked But Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q4,Fournier's gangrene,,2023,Q4,1,I,20231001.0,20231201.0,20231204,20231204,EXP,GB-MHRA-MED-202311301708511750-JCZYF,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-276170",BOEHRINGER INGELHEIM,,79.0,YR,E,F,Y,,,20231204,,MD,GB,GB,2023,Q4,Elderly
232572721,23257272,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,1,,,,,,,,,,,,2023,Q4,Vomiting,,2023,Q4,1,I,20231101.0,20231126.0,20231204,20231204,EXP,,GB-AstraZeneca-2023A268075,ASTRAZENECA,,84.0,YR,,M,Y,71.0,KG,20231204,,MD,GB,,2023,Q4,Elderly
232572721,23257272,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,1,,,,,,,,,,,,2023,Q4,Diarrhoea,,2023,Q4,1,I,20231101.0,20231126.0,20231204,20231204,EXP,,GB-AstraZeneca-2023A268075,ASTRAZENECA,,84.0,YR,,M,Y,71.0,KG,20231204,,MD,GB,,2023,Q4,Elderly
232572721,23257272,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,1,,,,,,,,,,,,2023,Q4,Dehydration,,2023,Q4,1,I,20231101.0,20231126.0,20231204,20231204,EXP,,GB-AstraZeneca-2023A268075,ASTRAZENECA,,84.0,YR,,M,Y,71.0,KG,20231204,,MD,GB,,2023,Q4,Elderly
232572721,23257272,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,1,,,,,,,,,,,,2023,Q4,Diabetic ketoacidosis,,2023,Q4,1,I,20231101.0,20231126.0,20231204,20231204,EXP,,GB-AstraZeneca-2023A268075,ASTRAZENECA,,84.0,YR,,M,Y,71.0,KG,20231204,,MD,GB,,2023,Q4,Elderly
232572721,23257272,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,1,,,,,,,,,,,,2023,Q4,Respiratory rate increased,,2023,Q4,1,I,20231101.0,20231126.0,20231204,20231204,EXP,,GB-AstraZeneca-2023A268075,ASTRAZENECA,,84.0,YR,,M,Y,71.0,KG,20231204,,MD,GB,,2023,Q4,Elderly
232572721,23257272,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,1,,,,,,,,,,,,2023,Q4,Blood glucose increased,,2023,Q4,1,I,20231101.0,20231126.0,20231204,20231204,EXP,,GB-AstraZeneca-2023A268075,ASTRAZENECA,,84.0,YR,,M,Y,71.0,KG,20231204,,MD,GB,,2023,Q4,Elderly
232573754,23257375,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,Unknown,,204629.0,10.0,MG,Unknown (other/unspecified),QD,2023,Q4,Anaemia,,2023,Q4,4,F,20230101.0,20231227.0,20231204,20231228,EXP,,"HR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-276165",BOEHRINGER INGELHEIM,,85.0,YR,E,F,Y,,,20231228,,MD,HR,HR,2023,Q4,Elderly
232573754,23257375,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,Unknown,,204629.0,10.0,MG,Unknown (other/unspecified),QD,2023,Q4,Pseudomonas infection,,2023,Q4,4,F,20230101.0,20231227.0,20231204,20231228,EXP,,"HR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-276165",BOEHRINGER INGELHEIM,,85.0,YR,E,F,Y,,,20231228,,MD,HR,HR,2023,Q4,Elderly
232573754,23257375,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,Unknown,,204629.0,10.0,MG,Unknown (other/unspecified),QD,2023,Q4,Cardiac failure,,2023,Q4,4,F,20230101.0,20231227.0,20231204,20231228,EXP,,"HR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-276165",BOEHRINGER INGELHEIM,,85.0,YR,E,F,Y,,,20231228,,MD,HR,HR,2023,Q4,Elderly
232573754,23257375,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,Unknown,,204629.0,10.0,MG,Unknown (other/unspecified),QD,2023,Q4,Peripheral swelling,,2023,Q4,4,F,20230101.0,20231227.0,20231204,20231228,EXP,,"HR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-276165",BOEHRINGER INGELHEIM,,85.0,YR,E,F,Y,,,20231228,,MD,HR,HR,2023,Q4,Elderly
232573754,23257375,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,Unknown,,204629.0,10.0,MG,Unknown (other/unspecified),QD,2023,Q4,Morganella infection,,2023,Q4,4,F,20230101.0,20231227.0,20231204,20231228,EXP,,"HR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-276165",BOEHRINGER INGELHEIM,,85.0,YR,E,F,Y,,,20231228,,MD,HR,HR,2023,Q4,Elderly
232573754,23257375,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,Unknown,,204629.0,10.0,MG,Unknown (other/unspecified),QD,2023,Q4,Dyspnoea,,2023,Q4,4,F,20230101.0,20231227.0,20231204,20231228,EXP,,"HR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-276165",BOEHRINGER INGELHEIM,,85.0,YR,E,F,Y,,,20231228,,MD,HR,HR,2023,Q4,Elderly
232573754,23257375,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,Unknown,,204629.0,10.0,MG,Unknown (other/unspecified),QD,2023,Q4,Generalised oedema,,2023,Q4,4,F,20230101.0,20231227.0,20231204,20231228,EXP,,"HR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-276165",BOEHRINGER INGELHEIM,,85.0,YR,E,F,Y,,,20231228,,MD,HR,HR,2023,Q4,Elderly
232573754,23257375,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,Unknown,,204629.0,10.0,MG,Unknown (other/unspecified),QD,2023,Q4,Pleural effusion,,2023,Q4,4,F,20230101.0,20231227.0,20231204,20231228,EXP,,"HR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-276165",BOEHRINGER INGELHEIM,,85.0,YR,E,F,Y,,,20231228,,MD,HR,HR,2023,Q4,Elderly
232573754,23257375,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,Unknown,,204629.0,10.0,MG,Unknown (other/unspecified),QD,2023,Q4,Oedema peripheral,,2023,Q4,4,F,20230101.0,20231227.0,20231204,20231228,EXP,,"HR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-276165",BOEHRINGER INGELHEIM,,85.0,YR,E,F,Y,,,20231228,,MD,HR,HR,2023,Q4,Elderly
232573754,23257375,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,Unknown,,204629.0,10.0,MG,Unknown (other/unspecified),QD,2023,Q4,Renal impairment,,2023,Q4,4,F,20230101.0,20231227.0,20231204,20231228,EXP,,"HR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-276165",BOEHRINGER INGELHEIM,,85.0,YR,E,F,Y,,,20231228,,MD,HR,HR,2023,Q4,Elderly
232573754,23257375,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,Unknown,,204629.0,10.0,MG,Unknown (other/unspecified),QD,2023,Q4,Cardiac amyloidosis,,2023,Q4,4,F,20230101.0,20231227.0,20231204,20231228,EXP,,"HR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-276165",BOEHRINGER INGELHEIM,,85.0,YR,E,F,Y,,,20231228,,MD,HR,HR,2023,Q4,Elderly
232577852,23257785,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,U,,,,,10.0,MG,Tablet,QD,2023,Q4,Decreased appetite,,2023,Q4,2,F,,20231207.0,20231204,20231212,EXP,,JP-009507513-2311JPN003655J,MERCK,,81.0,YR,,M,Y,69.3,KG,20231212,,MD,JP,JP,2023,Q4,Elderly
232577852,23257785,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,U,,,,,10.0,MG,Tablet,QD,2023,Q4,Altered state of consciousness,,2023,Q4,2,F,,20231207.0,20231204,20231212,EXP,,JP-009507513-2311JPN003655J,MERCK,,81.0,YR,,M,Y,69.3,KG,20231212,,MD,JP,JP,2023,Q4,Elderly
232577852,23257785,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,U,,,,,10.0,MG,Tablet,QD,2023,Q4,Gait disturbance,,2023,Q4,2,F,,20231207.0,20231204,20231212,EXP,,JP-009507513-2311JPN003655J,MERCK,,81.0,YR,,M,Y,69.3,KG,20231212,,MD,JP,JP,2023,Q4,Elderly
232577852,23257785,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,U,,,,,10.0,MG,Tablet,QD,2023,Q4,Malaise,,2023,Q4,2,F,,20231207.0,20231204,20231212,EXP,,JP-009507513-2311JPN003655J,MERCK,,81.0,YR,,M,Y,69.3,KG,20231212,,MD,JP,JP,2023,Q4,Elderly
232577852,23257785,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,U,,,,,10.0,MG,Tablet,QD,2023,Q4,Oedema peripheral,,2023,Q4,2,F,,20231207.0,20231204,20231212,EXP,,JP-009507513-2311JPN003655J,MERCK,,81.0,YR,,M,Y,69.3,KG,20231212,,MD,JP,JP,2023,Q4,Elderly
232577852,23257785,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,U,,,,,10.0,MG,Tablet,QD,2023,Q4,Gastric cancer,,2023,Q4,2,F,,20231207.0,20231204,20231212,EXP,,JP-009507513-2311JPN003655J,MERCK,,81.0,YR,,M,Y,69.3,KG,20231212,,MD,JP,JP,2023,Q4,Elderly
232577852,23257785,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"UNK UNK, qd",,,U,,,,,,,Tablet,,2023,Q4,Decreased appetite,,2023,Q4,2,F,,20231207.0,20231204,20231212,EXP,,JP-009507513-2311JPN003655J,MERCK,,81.0,YR,,M,Y,69.3,KG,20231212,,MD,JP,JP,2023,Q4,Elderly
232577852,23257785,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"UNK UNK, qd",,,U,,,,,,,Tablet,,2023,Q4,Altered state of consciousness,,2023,Q4,2,F,,20231207.0,20231204,20231212,EXP,,JP-009507513-2311JPN003655J,MERCK,,81.0,YR,,M,Y,69.3,KG,20231212,,MD,JP,JP,2023,Q4,Elderly
232577852,23257785,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"UNK UNK, qd",,,U,,,,,,,Tablet,,2023,Q4,Gait disturbance,,2023,Q4,2,F,,20231207.0,20231204,20231212,EXP,,JP-009507513-2311JPN003655J,MERCK,,81.0,YR,,M,Y,69.3,KG,20231212,,MD,JP,JP,2023,Q4,Elderly
232577852,23257785,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"UNK UNK, qd",,,U,,,,,,,Tablet,,2023,Q4,Malaise,,2023,Q4,2,F,,20231207.0,20231204,20231212,EXP,,JP-009507513-2311JPN003655J,MERCK,,81.0,YR,,M,Y,69.3,KG,20231212,,MD,JP,JP,2023,Q4,Elderly
232577852,23257785,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"UNK UNK, qd",,,U,,,,,,,Tablet,,2023,Q4,Oedema peripheral,,2023,Q4,2,F,,20231207.0,20231204,20231212,EXP,,JP-009507513-2311JPN003655J,MERCK,,81.0,YR,,M,Y,69.3,KG,20231212,,MD,JP,JP,2023,Q4,Elderly
232577852,23257785,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"UNK UNK, qd",,,U,,,,,,,Tablet,,2023,Q4,Gastric cancer,,2023,Q4,2,F,,20231207.0,20231204,20231212,EXP,,JP-009507513-2311JPN003655J,MERCK,,81.0,YR,,M,Y,69.3,KG,20231212,,MD,JP,JP,2023,Q4,Elderly
232594261,23259426,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,,,,QD,2023,Q4,Diabetic ketoacidosis,,2023,Q4,1,I,20231109.0,,20231204,20231204,DIR,FDA-CDER-CTU-2023-88599,,FDA-CTU,,67.0,YR,,M,N,86.0,KG,20231113,N,PH,US,,2023,Q4,Elderly
232618171,23261817,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,UNKNOWN,,,25.0,MG,,QD,2023,Q4,Drug ineffective,,2023,Q4,1,I,,20231122.0,20231205,20231205,EXP,,US-drreddys-LIT/USA/23/0187615,DR REDDYS,"Sekar V, Shaik S. A Case Of Alpelisib Induced Diabetic Ketoacidosis (Dka) In A Patient With Type 2 Diabetes Mellitus And Rechallenge With SGLT2 Inhibitor. Journal of the Endocrine Society. 2023;7(SUPPL.1):A437-38. doi:10.1210/jendso/bvad114.813",60.0,YR,A,F,Y,,,20231205,,HP,US,US,2023,Q4,Adult
232618171,23261817,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,UNKNOWN,,,25.0,MG,,QD,2023,Q4,Hyperglycaemia,,2023,Q4,1,I,,20231122.0,20231205,20231205,EXP,,US-drreddys-LIT/USA/23/0187615,DR REDDYS,"Sekar V, Shaik S. A Case Of Alpelisib Induced Diabetic Ketoacidosis (Dka) In A Patient With Type 2 Diabetes Mellitus And Rechallenge With SGLT2 Inhibitor. Journal of the Endocrine Society. 2023;7(SUPPL.1):A437-38. doi:10.1210/jendso/bvad114.813",60.0,YR,A,F,Y,,,20231205,,HP,US,US,2023,Q4,Adult
232633221,23263322,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,12.5,MG,,QD,2023,Q4,Metabolic acidosis,,2023,Q4,1,I,20231115.0,20231205.0,20231205,20231205,DIR,FDA-CDER-CTU-2023-88855,,FDA-CTU,,36.0,YR,,M,N,,,20231205,N,PH,US,,2023,Q4,Adult
232660721,23266072,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,10.0,MG,,QD,2023,Q4,Pneumonia,,2023,Q4,1,I,,20231130.0,20231206,20231206,EXP,,BA-BRISTOL-MYERS SQUIBB COMPANY-2023-174816,BRISTOL MYERS SQUIBB,,80.0,YR,E,,Y,,,20231206,,MD,BA,BA,2023,Q4,Elderly
232660721,23266072,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,10.0,MG,,QD,2023,Q4,Mitral valve incompetence,,2023,Q4,1,I,,20231130.0,20231206,20231206,EXP,,BA-BRISTOL-MYERS SQUIBB COMPANY-2023-174816,BRISTOL MYERS SQUIBB,,80.0,YR,E,,Y,,,20231206,,MD,BA,BA,2023,Q4,Elderly
232660721,23266072,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,10.0,MG,,QD,2023,Q4,Pulmonary oedema,,2023,Q4,1,I,,20231130.0,20231206,20231206,EXP,,BA-BRISTOL-MYERS SQUIBB COMPANY-2023-174816,BRISTOL MYERS SQUIBB,,80.0,YR,E,,Y,,,20231206,,MD,BA,BA,2023,Q4,Elderly
232660721,23266072,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,10.0,MG,,QD,2023,Q4,Metastases to bone,,2023,Q4,1,I,,20231130.0,20231206,20231206,EXP,,BA-BRISTOL-MYERS SQUIBB COMPANY-2023-174816,BRISTOL MYERS SQUIBB,,80.0,YR,E,,Y,,,20231206,,MD,BA,BA,2023,Q4,Elderly
232660721,23266072,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,10.0,MG,,QD,2023,Q4,Haemoglobin urine,,2023,Q4,1,I,,20231130.0,20231206,20231206,EXP,,BA-BRISTOL-MYERS SQUIBB COMPANY-2023-174816,BRISTOL MYERS SQUIBB,,80.0,YR,E,,Y,,,20231206,,MD,BA,BA,2023,Q4,Elderly
232660721,23266072,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,10.0,MG,,QD,2023,Q4,COVID-19,,2023,Q4,1,I,,20231130.0,20231206,20231206,EXP,,BA-BRISTOL-MYERS SQUIBB COMPANY-2023-174816,BRISTOL MYERS SQUIBB,,80.0,YR,E,,Y,,,20231206,,MD,BA,BA,2023,Q4,Elderly
232660721,23266072,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,10.0,MG,,QD,2023,Q4,Cardiac failure,,2023,Q4,1,I,,20231130.0,20231206,20231206,EXP,,BA-BRISTOL-MYERS SQUIBB COMPANY-2023-174816,BRISTOL MYERS SQUIBB,,80.0,YR,E,,Y,,,20231206,,MD,BA,BA,2023,Q4,Elderly
232660721,23266072,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,10.0,MG,,QD,2023,Q4,Protein urine present,,2023,Q4,1,I,,20231130.0,20231206,20231206,EXP,,BA-BRISTOL-MYERS SQUIBB COMPANY-2023-174816,BRISTOL MYERS SQUIBB,,80.0,YR,E,,Y,,,20231206,,MD,BA,BA,2023,Q4,Elderly
232660721,23266072,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,10.0,MG,,QD,2023,Q4,Hydronephrosis,,2023,Q4,1,I,,20231130.0,20231206,20231206,EXP,,BA-BRISTOL-MYERS SQUIBB COMPANY-2023-174816,BRISTOL MYERS SQUIBB,,80.0,YR,E,,Y,,,20231206,,MD,BA,BA,2023,Q4,Elderly
232660721,23266072,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,10.0,MG,,QD,2023,Q4,Tricuspid valve incompetence,,2023,Q4,1,I,,20231130.0,20231206,20231206,EXP,,BA-BRISTOL-MYERS SQUIBB COMPANY-2023-174816,BRISTOL MYERS SQUIBB,,80.0,YR,E,,Y,,,20231206,,MD,BA,BA,2023,Q4,Elderly
232660721,23266072,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,10.0,MG,,QD,2023,Q4,Testicular disorder,,2023,Q4,1,I,,20231130.0,20231206,20231206,EXP,,BA-BRISTOL-MYERS SQUIBB COMPANY-2023-174816,BRISTOL MYERS SQUIBB,,80.0,YR,E,,Y,,,20231206,,MD,BA,BA,2023,Q4,Elderly
232660721,23266072,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,10.0,MG,,QD,2023,Q4,Urinary tract infection,,2023,Q4,1,I,,20231130.0,20231206,20231206,EXP,,BA-BRISTOL-MYERS SQUIBB COMPANY-2023-174816,BRISTOL MYERS SQUIBB,,80.0,YR,E,,Y,,,20231206,,MD,BA,BA,2023,Q4,Elderly
232690091,23269009,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q4,Diarrhoea,,2023,Q4,1,I,20231128.0,20231130.0,20231206,20231206,EXP,GB-MHRA-TPP7778230C8813904YC1701181934691,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-275704",BOEHRINGER INGELHEIM,,83.0,YR,E,F,Y,68.0,KG,20231207,,MD,GB,GB,2023,Q4,Elderly
232690091,23269009,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q4,Nausea,,2023,Q4,1,I,20231128.0,20231130.0,20231206,20231206,EXP,GB-MHRA-TPP7778230C8813904YC1701181934691,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-275704",BOEHRINGER INGELHEIM,,83.0,YR,E,F,Y,68.0,KG,20231207,,MD,GB,GB,2023,Q4,Elderly
232690091,23269009,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q4,Urinary tract infection,,2023,Q4,1,I,20231128.0,20231130.0,20231206,20231206,EXP,GB-MHRA-TPP7778230C8813904YC1701181934691,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-275704",BOEHRINGER INGELHEIM,,83.0,YR,E,F,Y,68.0,KG,20231207,,MD,GB,GB,2023,Q4,Elderly
232704621,23270462,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q4,Renal tubular necrosis,,2023,Q4,1,I,,20231122.0,20231207,20231207,EXP,,US-Accord-392439,ACCORD,"Khawaja US, Shah N, Wang A. Zoledronate-Induced Acute Tubular Necrosis With Baseline Normal Renal Function: A Rare Phenomenon. Journal of the Endocrine Society. 2022;6(Supplement 1):A180",51.0,YR,A,F,Y,,,20231204,,MD,US,US,2023,Q4,Adult
232704621,23270462,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q4,Acute kidney injury,,2023,Q4,1,I,,20231122.0,20231207,20231207,EXP,,US-Accord-392439,ACCORD,"Khawaja US, Shah N, Wang A. Zoledronate-Induced Acute Tubular Necrosis With Baseline Normal Renal Function: A Rare Phenomenon. Journal of the Endocrine Society. 2022;6(Supplement 1):A180",51.0,YR,A,F,Y,,,20231204,,MD,US,US,2023,Q4,Adult
232704621,23270462,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q4,Off label use,,2023,Q4,1,I,,20231122.0,20231207,20231207,EXP,,US-Accord-392439,ACCORD,"Khawaja US, Shah N, Wang A. Zoledronate-Induced Acute Tubular Necrosis With Baseline Normal Renal Function: A Rare Phenomenon. Journal of the Endocrine Society. 2022;6(Supplement 1):A180",51.0,YR,A,F,Y,,,20231204,,MD,US,US,2023,Q4,Adult
232706271,23270627,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Unknown,,,,,Unknown,,,,,,,2023,Q4,Acute kidney injury,,2023,Q4,1,I,,20231122.0,20231207,20231207,EXP,,US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-23-67491,HIKMA,"Khawaja US, Shah N, Wang A.. Khawaja US, Shah N, Wang A. Zoledronate-Induced Acute Tubular Necrosis With Baseline Normal Renal Function: A Rare Phenomenon. Journal of the Endocrine Society. 2022;6 (1):A180",51.0,YR,,F,Y,,,20231207,,MD,US,US,2023,Q4,Adult
232706271,23270627,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Unknown,,,,,Unknown,,,,,,,2023,Q4,Renal tubular necrosis,,2023,Q4,1,I,,20231122.0,20231207,20231207,EXP,,US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-23-67491,HIKMA,"Khawaja US, Shah N, Wang A.. Khawaja US, Shah N, Wang A. Zoledronate-Induced Acute Tubular Necrosis With Baseline Normal Renal Function: A Rare Phenomenon. Journal of the Endocrine Society. 2022;6 (1):A180",51.0,YR,,F,Y,,,20231207,,MD,US,US,2023,Q4,Adult
232713871,23271387,4,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,Tablet,,2023,Q4,Urine albumin/creatinine ratio increased,,2023,Q4,1,I,20230303.0,20231129.0,20231207,20231207,EXP,,JP-EMD Serono-2023491703,EMD SERONO INC,,66.0,YR,E,F,Y,48.0,KG,20231207,,HP,JP,JP,2023,Q4,Elderly
232713871,23271387,4,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,Tablet,,2023,Q4,Blood pressure diastolic increased,,2023,Q4,1,I,20230303.0,20231129.0,20231207,20231207,EXP,,JP-EMD Serono-2023491703,EMD SERONO INC,,66.0,YR,E,F,Y,48.0,KG,20231207,,HP,JP,JP,2023,Q4,Elderly
232713871,23271387,4,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,Tablet,,2023,Q4,Abscess limb,,2023,Q4,1,I,20230303.0,20231129.0,20231207,20231207,EXP,,JP-EMD Serono-2023491703,EMD SERONO INC,,66.0,YR,E,F,Y,48.0,KG,20231207,,HP,JP,JP,2023,Q4,Elderly
232713871,23271387,4,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,Tablet,,2023,Q4,Blood pressure systolic increased,,2023,Q4,1,I,20230303.0,20231129.0,20231207,20231207,EXP,,JP-EMD Serono-2023491703,EMD SERONO INC,,66.0,YR,E,F,Y,48.0,KG,20231207,,HP,JP,JP,2023,Q4,Elderly
232716611,23271661,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q4,Death,,2023,Q4,1,I,20231118.0,20231205.0,20231207,20231207,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-2023-176872,BRISTOL MYERS SQUIBB,,89.0,YR,E,F,Y,,,20231207,,CN,US,US,2023,Q4,Elderly
232718241,23271824,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q4,Renal tubular necrosis,,2023,Q4,1,I,,20231122.0,20231207,20231207,EXP,,US-USV-002231,USV PRIVATE,"Khawaja US, Shah N, Wang A. Zoledronate-Induced Acute Tubular Necrosis With Baseline Normal Renal Function: A Rare Phenomenon. Journal of the Endocrine Society. 2022;6(Supplement 1):A180",51.0,YR,A,F,Y,,,20231206,,MD,US,US,2023,Q4,Adult
232718241,23271824,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q4,Acute kidney injury,,2023,Q4,1,I,,20231122.0,20231207,20231207,EXP,,US-USV-002231,USV PRIVATE,"Khawaja US, Shah N, Wang A. Zoledronate-Induced Acute Tubular Necrosis With Baseline Normal Renal Function: A Rare Phenomenon. Journal of the Endocrine Society. 2022;6(Supplement 1):A180",51.0,YR,A,F,Y,,,20231206,,MD,US,US,2023,Q4,Adult
232718241,23271824,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q4,Off label use,,2023,Q4,1,I,,20231122.0,20231207,20231207,EXP,,US-USV-002231,USV PRIVATE,"Khawaja US, Shah N, Wang A. Zoledronate-Induced Acute Tubular Necrosis With Baseline Normal Renal Function: A Rare Phenomenon. Journal of the Endocrine Society. 2022;6(Supplement 1):A180",51.0,YR,A,F,Y,,,20231206,,MD,US,US,2023,Q4,Adult
232719831,23271983,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Nephrotic syndrome,,2023,Q4,1,I,20230418.0,20231128.0,20231207,20231207,EXP,,TR-JNJFOC-20231182758,JOHNSON AND JOHNSON,,57.0,YR,A,F,Y,84.0,KG,20231207,,MD,TR,TR,2023,Q4,Adult
232720741,23272074,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2023,Q4,Dyspnoea,,2023,Q4,1,I,20230806.0,20231129.0,20231207,20231207,EXP,,NVSC2023HR256736,NOVARTIS,,68.0,YR,,M,Y,,,20231207,,MD,HR,HR,2023,Q4,Elderly
232723611,23272361,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Euglycaemic diabetic ketoacidosis,,2023,Q4,1,I,,20231122.0,20231207,20231207,EXP,,PH-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-421706,RANBAXY,"Nievera KH, Uy MC. Empagliflozin associated Euglycemic Diabetic Ketoacidosis and the Terrible Triad. J Endocrine Soc. 2022;6 (Suppl.):ODP192/A311",31.0,YR,,M,Y,,,20231207,,MD,PH,PH,2023,Q4,Young Adult
232723611,23272361,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Pancreatitis acute,,2023,Q4,1,I,,20231122.0,20231207,20231207,EXP,,PH-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-421706,RANBAXY,"Nievera KH, Uy MC. Empagliflozin associated Euglycemic Diabetic Ketoacidosis and the Terrible Triad. J Endocrine Soc. 2022;6 (Suppl.):ODP192/A311",31.0,YR,,M,Y,,,20231207,,MD,PH,PH,2023,Q4,Young Adult
232723611,23272361,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Hypertriglyceridaemia,,2023,Q4,1,I,,20231122.0,20231207,20231207,EXP,,PH-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-421706,RANBAXY,"Nievera KH, Uy MC. Empagliflozin associated Euglycemic Diabetic Ketoacidosis and the Terrible Triad. J Endocrine Soc. 2022;6 (Suppl.):ODP192/A311",31.0,YR,,M,Y,,,20231207,,MD,PH,PH,2023,Q4,Young Adult
232723681,23272368,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Euglycaemic diabetic ketoacidosis,,2023,Q4,1,I,,20231122.0,20231207,20231207,EXP,,PR-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-421708,RANBAXY,"El Musa Penna L, Rivera MO, Burgos AR, Marin LM, Nieves YR, Cordero NH, et al. SGLT2 Inhibitor-Induced Euglycemic DKA and its Challenges. J Endocrine Soc. 2022;6:A333-A334 (ODP244)",61.0,YR,,M,Y,,,20231207,,MD,PR,PR,2023,Q4,Adult
232723881,23272388,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Daily",,,,,,,,25.0,MG,,,2023,Q4,Bladder cancer,,2023,Q4,1,I,,20231122.0,20231207,20231207,EXP,,SA-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-422207,RANBAXY,"Alzenaidi A, Alkhalidi H. Empagli flozin Induced Bladder Cancer in an Adult Patient With Latent Autoimmune Diabetes. J Endocr Soc. 2022;6(Suppl.):A392",51.0,YR,,M,Y,,,20231207,,MD,SA,SA,2023,Q4,Adult
232724341,23272434,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Pancreatitis,,2023,Q4,1,I,,20231122.0,20231207,20231207,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-422365,RANBAXY,"Poloju A, Majety P, Groysman AY. Empagliflozin Associated Pancreatitis: A Case Report. J Endocr Soc. 2023;7:A433 (THU371)",57.0,YR,,F,Y,,,20231207,,MD,US,US,2023,Q4,Adult
232724481,23272448,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Fungal infection,,2023,Q4,1,I,,20231122.0,20231207,20231207,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-422321,RANBAXY,"Simhadri P, Vaitla P, Sriperumbuduri S, Murari U. Invasive Fungal Infection Associated with SGLT2 Inhibitor Use. J Am Soc Nephrol. 2023;34:1174/PUB438",75.0,YR,,M,Y,,,20231207,,HP,US,US,2023,Q4,Elderly
232724881,23272488,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Daily",,,U,,,,,10.0,MG,,,2023,Q4,Euglycaemic diabetic ketoacidosis,,2023,Q4,1,I,,20231122.0,20231207,20231207,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-422458,RANBAXY,"Katwal D, Pokharel Y, Ghawji M, Liu Z, Steinberg HO, Dagogo-Jack S. Euglycemic Diabetes Ketoacidosis Associated With Sodium-glucose Cotransporter Inhibitors: A Case Series To Raise Awareness. J Endocr Soc. 2023;Oct/Nov; 7(1):A522(SAT110)",54.0,YR,,M,Y,,,20231207,,MD,US,US,2023,Q4,Adult
232724891,23272489,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Daily",,,U,,,,,25.0,MG,,,2023,Q4,Euglycaemic diabetic ketoacidosis,,2023,Q4,1,I,,20231122.0,20231207,20231207,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-422463,RANBAXY,"Katwal D, Pokharel Y, Ghawji M, Liu Z, Steinberg HO, Dagogo-Jack S. Euglycemic Diabetes Ketoacidosis Associated With Sodium-glucose Cotransporter Inhibitors: A Case Series To Raise Awareness. J Endocr Soc. 2023;Oct-Nov; 7(1):A522(SAT110)",68.0,YR,,M,Y,,,20231207,,MD,US,US,2023,Q4,Elderly
232725051,23272505,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"12.5 milligram, Daily",,,,,,,,12.5,MG,,,2023,Q4,Haemochromatosis,,2023,Q4,1,I,,20231122.0,20231207,20231207,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-422354,RANBAXY,"Schumacher K, Gosmanova EO. SGLT2i-Induced Erythrocytosis Unveiling Heterozygous Hereditary Hemochromatosis (HH) Gene Mutation in an Individual with CKD. J am soc nephrol. 2023;34:356",72.0,YR,,M,Y,,,20231207,,HP,US,US,2023,Q4,Elderly
232725051,23272505,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"12.5 milligram, Daily",,,,,,,,12.5,MG,,,2023,Q4,Polycythaemia,,2023,Q4,1,I,,20231122.0,20231207,20231207,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-422354,RANBAXY,"Schumacher K, Gosmanova EO. SGLT2i-Induced Erythrocytosis Unveiling Heterozygous Hereditary Hemochromatosis (HH) Gene Mutation in an Individual with CKD. J am soc nephrol. 2023;34:356",72.0,YR,,M,Y,,,20231207,,HP,US,US,2023,Q4,Elderly
232725051,23272505,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"12.5 milligram, Daily",,,,,,,,12.5,MG,,,2023,Q4,Gene mutation,,2023,Q4,1,I,,20231122.0,20231207,20231207,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-422354,RANBAXY,"Schumacher K, Gosmanova EO. SGLT2i-Induced Erythrocytosis Unveiling Heterozygous Hereditary Hemochromatosis (HH) Gene Mutation in an Individual with CKD. J am soc nephrol. 2023;34:356",72.0,YR,,M,Y,,,20231207,,HP,US,US,2023,Q4,Elderly
232741301,23274130,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Lactic acidosis,,2023,Q4,1,I,,20231127.0,20231208,20231208,EXP,,US-AUROBINDO-AUR-APL-2023-076207,AUROBINDO,"Heckart JC, Shaw M. EDKA and MALA in the Setting of Severe Heart Failure and Acute Renal Failure, Due to SGLT2-i.. Journal of the Endocrine Society. 2020;4:853",53.0,YR,,M,Y,,,20231208,,MD,US,US,2023,Q4,Adult
232741301,23274130,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Acute kidney injury,,2023,Q4,1,I,,20231127.0,20231208,20231208,EXP,,US-AUROBINDO-AUR-APL-2023-076207,AUROBINDO,"Heckart JC, Shaw M. EDKA and MALA in the Setting of Severe Heart Failure and Acute Renal Failure, Due to SGLT2-i.. Journal of the Endocrine Society. 2020;4:853",53.0,YR,,M,Y,,,20231208,,MD,US,US,2023,Q4,Adult
232750672,23275067,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,UNK,,204629.0,10.0,MG,Tablet,QD,2023,Q4,Infection,,2023,Q4,2,F,20230901.0,20231219.0,20231208,20231221,EXP,,"CZ-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-276989",BOEHRINGER INGELHEIM,,59.0,YR,A,F,Y,70.0,KG,20231221,,MD,CZ,CZ,2023,Q4,Adult
232750672,23275067,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,UNK,,204629.0,10.0,MG,Tablet,QD,2023,Q4,Acute kidney injury,,2023,Q4,2,F,20230901.0,20231219.0,20231208,20231221,EXP,,"CZ-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-276989",BOEHRINGER INGELHEIM,,59.0,YR,A,F,Y,70.0,KG,20231221,,MD,CZ,CZ,2023,Q4,Adult
232750672,23275067,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,UNK,,204629.0,10.0,MG,Tablet,QD,2023,Q4,Renal tubular acidosis,,2023,Q4,2,F,20230901.0,20231219.0,20231208,20231221,EXP,,"CZ-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-276989",BOEHRINGER INGELHEIM,,59.0,YR,A,F,Y,70.0,KG,20231221,,MD,CZ,CZ,2023,Q4,Adult
232750672,23275067,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,UNK,,204629.0,10.0,MG,Tablet,QD,2023,Q4,Acute myocardial infarction,,2023,Q4,2,F,20230901.0,20231219.0,20231208,20231221,EXP,,"CZ-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-276989",BOEHRINGER INGELHEIM,,59.0,YR,A,F,Y,70.0,KG,20231221,,MD,CZ,CZ,2023,Q4,Adult
232750672,23275067,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,UNK,,204629.0,10.0,MG,Tablet,QD,2023,Q4,Acidosis hyperchloraemic,,2023,Q4,2,F,20230901.0,20231219.0,20231208,20231221,EXP,,"CZ-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-276989",BOEHRINGER INGELHEIM,,59.0,YR,A,F,Y,70.0,KG,20231221,,MD,CZ,CZ,2023,Q4,Adult
232750672,23275067,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,UNK,,204629.0,10.0,MG,Tablet,QD,2023,Q4,Cardiac arrest,,2023,Q4,2,F,20230901.0,20231219.0,20231208,20231221,EXP,,"CZ-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-276989",BOEHRINGER INGELHEIM,,59.0,YR,A,F,Y,70.0,KG,20231221,,MD,CZ,CZ,2023,Q4,Adult
232750672,23275067,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,UNK,,204629.0,10.0,MG,Tablet,QD,2023,Q4,Ketoacidosis,,2023,Q4,2,F,20230901.0,20231219.0,20231208,20231221,EXP,,"CZ-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-276989",BOEHRINGER INGELHEIM,,59.0,YR,A,F,Y,70.0,KG,20231221,,MD,CZ,CZ,2023,Q4,Adult
232756111,23275611,21,C,"EMPAGLIFLOZIN, METFORMIN",,2,,,,,,,,,,,,,,2023,Q4,Pyrexia,,2023,Q4,1,I,20230303.0,20231127.0,20231208,20231208,EXP,ES-EMA-20231108-AUTODUP-1699474519527,ES-Accord-393985,ACCORD,,53.0,YR,A,F,Y,71.0,KG,20231208,,HP,ES,ES,2023,Q4,Adult
232756111,23275611,21,C,"EMPAGLIFLOZIN, METFORMIN",,2,,,,,,,,,,,,,,2023,Q4,Off label use,,2023,Q4,1,I,20230303.0,20231127.0,20231208,20231208,EXP,ES-EMA-20231108-AUTODUP-1699474519527,ES-Accord-393985,ACCORD,,53.0,YR,A,F,Y,71.0,KG,20231208,,HP,ES,ES,2023,Q4,Adult
232756111,23275611,21,C,"EMPAGLIFLOZIN, METFORMIN",,2,,,,,,,,,,,,,,2023,Q4,Nausea,,2023,Q4,1,I,20230303.0,20231127.0,20231208,20231208,EXP,ES-EMA-20231108-AUTODUP-1699474519527,ES-Accord-393985,ACCORD,,53.0,YR,A,F,Y,71.0,KG,20231208,,HP,ES,ES,2023,Q4,Adult
232756111,23275611,21,C,"EMPAGLIFLOZIN, METFORMIN",,2,,,,,,,,,,,,,,2023,Q4,Infusion related reaction,,2023,Q4,1,I,20230303.0,20231127.0,20231208,20231208,EXP,ES-EMA-20231108-AUTODUP-1699474519527,ES-Accord-393985,ACCORD,,53.0,YR,A,F,Y,71.0,KG,20231208,,HP,ES,ES,2023,Q4,Adult
232756111,23275611,21,C,"EMPAGLIFLOZIN, METFORMIN",,2,,,,,,,,,,,,,,2023,Q4,Constipation,,2023,Q4,1,I,20230303.0,20231127.0,20231208,20231208,EXP,ES-EMA-20231108-AUTODUP-1699474519527,ES-Accord-393985,ACCORD,,53.0,YR,A,F,Y,71.0,KG,20231208,,HP,ES,ES,2023,Q4,Adult
232756111,23275611,21,C,"EMPAGLIFLOZIN, METFORMIN",,2,,,,,,,,,,,,,,2023,Q4,Abdominal discomfort,,2023,Q4,1,I,20230303.0,20231127.0,20231208,20231208,EXP,ES-EMA-20231108-AUTODUP-1699474519527,ES-Accord-393985,ACCORD,,53.0,YR,A,F,Y,71.0,KG,20231208,,HP,ES,ES,2023,Q4,Adult
232756111,23275611,21,C,"EMPAGLIFLOZIN, METFORMIN",,2,,,,,,,,,,,,,,2023,Q4,Chest pain,,2023,Q4,1,I,20230303.0,20231127.0,20231208,20231208,EXP,ES-EMA-20231108-AUTODUP-1699474519527,ES-Accord-393985,ACCORD,,53.0,YR,A,F,Y,71.0,KG,20231208,,HP,ES,ES,2023,Q4,Adult
232768691,23276869,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,,,Tablet,,2023,Q4,Urinary bladder haemorrhage,,2023,Q4,1,I,20230625.0,20231204.0,20231208,20231208,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-2023-176348,BRISTOL MYERS SQUIBB,,85.0,YR,E,M,Y,58.0,KG,20231208,,PH,JP,JP,2023,Q4,Elderly
232768691,23276869,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,,,Tablet,,2023,Q4,Haematuria,,2023,Q4,1,I,20230625.0,20231204.0,20231208,20231208,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-2023-176348,BRISTOL MYERS SQUIBB,,85.0,YR,E,M,Y,58.0,KG,20231208,,PH,JP,JP,2023,Q4,Elderly
232768691,23276869,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,,,Tablet,,2023,Q4,Chest pain,,2023,Q4,1,I,20230625.0,20231204.0,20231208,20231208,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-2023-176348,BRISTOL MYERS SQUIBB,,85.0,YR,E,M,Y,58.0,KG,20231208,,PH,JP,JP,2023,Q4,Elderly
232768691,23276869,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,,,Tablet,,2023,Q4,Cardiac failure,,2023,Q4,1,I,20230625.0,20231204.0,20231208,20231208,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-2023-176348,BRISTOL MYERS SQUIBB,,85.0,YR,E,M,Y,58.0,KG,20231208,,PH,JP,JP,2023,Q4,Elderly
232768691,23276869,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,,,Tablet,,2023,Q4,Bladder cancer,,2023,Q4,1,I,20230625.0,20231204.0,20231208,20231208,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-2023-176348,BRISTOL MYERS SQUIBB,,85.0,YR,E,M,Y,58.0,KG,20231208,,PH,JP,JP,2023,Q4,Elderly
232777411,23277741,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,U,,,,,,,,2023,Q4,Pancreatitis acute,,2023,Q4,1,I,,20231123.0,20231208,20231208,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-422017,RANBAXY,"Arora G, Gerais Y. A Rare, Sordid Tale Of The Two Most Dreaded Adverse Effects Of SGLT-2 Inhibitors Occurring Concurrently - Acute Pancreatitis And Euglycemic Diabetic Ketoacidosis - Within Days Of Initiating Empagliflozin Therapy. Journal of the Endocrine Society. 2022;6 (Suppl.):A290",49.0,YR,,M,Y,,,20231208,,MD,US,US,2023,Q4,Adult
232777411,23277741,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,U,,,,,,,,2023,Q4,Euglycaemic diabetic ketoacidosis,,2023,Q4,1,I,,20231123.0,20231208,20231208,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-422017,RANBAXY,"Arora G, Gerais Y. A Rare, Sordid Tale Of The Two Most Dreaded Adverse Effects Of SGLT-2 Inhibitors Occurring Concurrently - Acute Pancreatitis And Euglycemic Diabetic Ketoacidosis - Within Days Of Initiating Empagliflozin Therapy. Journal of the Endocrine Society. 2022;6 (Suppl.):A290",49.0,YR,,M,Y,,,20231208,,MD,US,US,2023,Q4,Adult
232797101,23279710,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Diabetic ketoacidosis,,2023,Q4,1,I,,20231127.0,20231210,20231210,EXP,,US-AUROBINDO-AUR-APL-2023-077493,AUROBINDO,"Abushamat LA, Bhalla R, Reusch JE.. The Perfect Storm for Diabetic Ketoacidosis. J-Endocr-Soc. 2020;4 (Suppl.):A883-A884",63.0,YR,,M,Y,,,20231210,,MD,US,US,2023,Q4,Adult
232797101,23279710,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Drug ineffective,,2023,Q4,1,I,,20231127.0,20231210,20231210,EXP,,US-AUROBINDO-AUR-APL-2023-077493,AUROBINDO,"Abushamat LA, Bhalla R, Reusch JE.. The Perfect Storm for Diabetic Ketoacidosis. J-Endocr-Soc. 2020;4 (Suppl.):A883-A884",63.0,YR,,M,Y,,,20231210,,MD,US,US,2023,Q4,Adult
232803891,23280389,7,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/850mg,,,D,,,,,,,,,2023,Q4,Fatigue,,2023,Q4,1,I,,20231203.0,20231211,20231211,EXP,,HR-JNJFOC-20231221717,JOHNSON AND JOHNSON,,68.0,YR,E,M,Y,,,20231211,,MD,HR,HR,2023,Q4,Elderly
232803891,23280389,7,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/850mg,,,D,,,,,,,,,2023,Q4,Peripheral swelling,,2023,Q4,1,I,,20231203.0,20231211,20231211,EXP,,HR-JNJFOC-20231221717,JOHNSON AND JOHNSON,,68.0,YR,E,M,Y,,,20231211,,MD,HR,HR,2023,Q4,Elderly
232804071,23280407,27,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 mg,,,D,,,,,25.0,MG,,,2023,Q4,Hypothyroidism,,2023,Q4,1,I,20210401.0,20231203.0,20231211,20231211,EXP,,HR-JNJFOC-20231220355,JOHNSON AND JOHNSON,,64.0,YR,A,M,Y,,,20231211,,MD,HR,HR,2023,Q4,Adult
232804071,23280407,27,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 mg,,,D,,,,,25.0,MG,,,2023,Q4,Hypotension,,2023,Q4,1,I,20210401.0,20231203.0,20231211,20231211,EXP,,HR-JNJFOC-20231220355,JOHNSON AND JOHNSON,,64.0,YR,A,M,Y,,,20231211,,MD,HR,HR,2023,Q4,Adult
232804071,23280407,27,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 mg,,,D,,,,,25.0,MG,,,2023,Q4,Chest discomfort,,2023,Q4,1,I,20210401.0,20231203.0,20231211,20231211,EXP,,HR-JNJFOC-20231220355,JOHNSON AND JOHNSON,,64.0,YR,A,M,Y,,,20231211,,MD,HR,HR,2023,Q4,Adult
232804071,23280407,27,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 mg,,,D,,,,,25.0,MG,,,2023,Q4,Cardiac failure,,2023,Q4,1,I,20210401.0,20231203.0,20231211,20231211,EXP,,HR-JNJFOC-20231220355,JOHNSON AND JOHNSON,,64.0,YR,A,M,Y,,,20231211,,MD,HR,HR,2023,Q4,Adult
232804071,23280407,27,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 mg,,,D,,,,,25.0,MG,,,2023,Q4,Blood pressure fluctuation,,2023,Q4,1,I,20210401.0,20231203.0,20231211,20231211,EXP,,HR-JNJFOC-20231220355,JOHNSON AND JOHNSON,,64.0,YR,A,M,Y,,,20231211,,MD,HR,HR,2023,Q4,Adult
232810222,23281022,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,U,,,,,10.0,MG,,,2023,Q4,Therapeutic response unexpected,,2023,Q4,2,F,,20231204.0,20231211,20231212,EXP,,HR-JNJFOC-20231217969,JOHNSON AND JOHNSON,,78.0,YR,E,F,Y,,,20231212,,MD,HR,HR,2023,Q4,Elderly
232810222,23281022,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,U,,,,,10.0,MG,,,2023,Q4,Glycosylated haemoglobin decreased,,2023,Q4,2,F,,20231204.0,20231211,20231212,EXP,,HR-JNJFOC-20231217969,JOHNSON AND JOHNSON,,78.0,YR,E,F,Y,,,20231212,,MD,HR,HR,2023,Q4,Elderly
232810222,23281022,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,U,,,,,10.0,MG,,,2023,Q4,Creatinine renal clearance decreased,,2023,Q4,2,F,,20231204.0,20231211,20231212,EXP,,HR-JNJFOC-20231217969,JOHNSON AND JOHNSON,,78.0,YR,E,F,Y,,,20231212,,MD,HR,HR,2023,Q4,Elderly
232826422,23282642,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q4,Hypotension,,2023,Q4,2,F,20211201.0,20231220.0,20231211,20231222,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-276532",BOEHRINGER INGELHEIM,,79.0,YR,E,M,Y,,,20231222,,MD,DE,DE,2023,Q4,Elderly
232826422,23282642,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q4,Cardiac failure,,2023,Q4,2,F,20211201.0,20231220.0,20231211,20231222,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-276532",BOEHRINGER INGELHEIM,,79.0,YR,E,M,Y,,,20231222,,MD,DE,DE,2023,Q4,Elderly
232826422,23282642,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2023,Q4,Hyperkalaemia,,2023,Q4,2,F,20211201.0,20231220.0,20231211,20231222,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-276532",BOEHRINGER INGELHEIM,,79.0,YR,E,M,Y,,,20231222,,MD,DE,DE,2023,Q4,Elderly
232840642,23284064,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q4,Lactic acidosis,,2023,Q4,2,F,,20231127.0,20231211,20231212,EXP,,US-TEVA-VS-3135023,TEVA,"Heckart JC, Shaw M. EDKA and MALA in the Setting of Severe Heart Failure and Acute Renal Failure, Due to SGLT2-i. J-Endocr-Soc 2020; 4 A853.",53.0,YR,,,Y,,,20231212,,HP,US,US,2023,Q4,Adult
232840642,23284064,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q4,Lactic acidosis,,2023,Q4,2,F,,20231127.0,20231211,20231212,EXP,,US-TEVA-VS-3135023,TEVA,"Heckart JC, Shaw M. EDKA and MALA in the Setting of Severe Heart Failure and Acute Renal Failure, Due to SGLT2-i. J-Endocr-Soc 2020; 4 A853.",53.0,YR,,,Y,,,20231212,,HP,US,US,2023,Q4,Adult
232840642,23284064,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q4,Acute kidney injury,,2023,Q4,2,F,,20231127.0,20231211,20231212,EXP,,US-TEVA-VS-3135023,TEVA,"Heckart JC, Shaw M. EDKA and MALA in the Setting of Severe Heart Failure and Acute Renal Failure, Due to SGLT2-i. J-Endocr-Soc 2020; 4 A853.",53.0,YR,,,Y,,,20231212,,HP,US,US,2023,Q4,Adult
232841781,23284178,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,morning,,,,,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q4,Necrosis,,2023,Q4,1,I,,20231208.0,20231211,20231211,EXP,GB-MHRA-ADR 28379568,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-277484",BOEHRINGER INGELHEIM,,84.0,YR,E,M,Y,79.55,KG,20231211,,PH,GB,GB,2023,Q4,Elderly
232841781,23284178,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,morning,,,,,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q4,Diabetic foot,,2023,Q4,1,I,,20231208.0,20231211,20231211,EXP,GB-MHRA-ADR 28379568,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-277484",BOEHRINGER INGELHEIM,,84.0,YR,E,M,Y,79.55,KG,20231211,,PH,GB,GB,2023,Q4,Elderly
232844741,23284474,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q4,Diabetic ketoacidosis,,2023,Q4,1,I,,20231204.0,20231211,20231211,EXP,,NVSC2021CA166776,NOVARTIS,"Leung M, Roitman D, Rodrigues P. PIK3CA inhibitor, alpelisib, and diabetic ketoacidosis: A case study on choosing wisely. JOURNAL OF ONCOLOGY PHARMACY PRACTICE. 2021;27(5):9",58.0,YR,,F,Y,,,20231211,,HP,CA,CA,2023,Q4,Adult
232844741,23284474,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q4,Rash,,2023,Q4,1,I,,20231204.0,20231211,20231211,EXP,,NVSC2021CA166776,NOVARTIS,"Leung M, Roitman D, Rodrigues P. PIK3CA inhibitor, alpelisib, and diabetic ketoacidosis: A case study on choosing wisely. JOURNAL OF ONCOLOGY PHARMACY PRACTICE. 2021;27(5):9",58.0,YR,,F,Y,,,20231211,,HP,CA,CA,2023,Q4,Adult
232844741,23284474,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q4,Pneumonia,,2023,Q4,1,I,,20231204.0,20231211,20231211,EXP,,NVSC2021CA166776,NOVARTIS,"Leung M, Roitman D, Rodrigues P. PIK3CA inhibitor, alpelisib, and diabetic ketoacidosis: A case study on choosing wisely. JOURNAL OF ONCOLOGY PHARMACY PRACTICE. 2021;27(5):9",58.0,YR,,F,Y,,,20231211,,HP,CA,CA,2023,Q4,Adult
232865241,23286524,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q4,Pruritus,,2023,Q4,1,I,20230526.0,20231211.0,20231212,20231212,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-277476",BOEHRINGER INGELHEIM,,40.0,YR,A,M,Y,,,20231212,,HP,SG,SG,2023,Q4,Adult
232865241,23286524,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q4,Dyspnoea,,2023,Q4,1,I,20230526.0,20231211.0,20231212,20231212,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-277476",BOEHRINGER INGELHEIM,,40.0,YR,A,M,Y,,,20231212,,HP,SG,SG,2023,Q4,Adult
232865501,23286550,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q4,Vulvovaginal pruritus,,2023,Q4,1,I,20230101.0,20231211.0,20231212,20231212,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-277453",BOEHRINGER INGELHEIM,,70.0,YR,E,F,Y,,,20231212,,HP,SG,SG,2023,Q4,Elderly
232885552,23288555,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Dose unknown,,,,,,,,,,,,2023,Q4,Off label use,,2023,Q4,2,F,20230111.0,20231211.0,20231212,20231219,EXP,,JP-AstraZeneca-2023A272858,ASTRAZENECA,,87.0,YR,,F,Y,,,20231219,,MD,JP,,2023,Q4,Elderly
232885552,23288555,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Dose unknown,,,,,,,,,,,,2023,Q4,Hypokalaemia,,2023,Q4,2,F,20230111.0,20231211.0,20231212,20231219,EXP,,JP-AstraZeneca-2023A272858,ASTRAZENECA,,87.0,YR,,F,Y,,,20231219,,MD,JP,,2023,Q4,Elderly
232885552,23288555,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Dose unknown,,,,,,,,,,,,2023,Q4,Cardiac failure chronic,,2023,Q4,2,F,20230111.0,20231211.0,20231212,20231219,EXP,,JP-AstraZeneca-2023A272858,ASTRAZENECA,,87.0,YR,,F,Y,,,20231219,,MD,JP,,2023,Q4,Elderly
232885801,23288580,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Asked But Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q4,Hypernatraemia,,2023,Q4,1,I,20230721.0,20231212.0,20231212,20231212,EXP,GB-MHRA-MED-202312112032335740-FLRVT,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-277785",BOEHRINGER INGELHEIM,,65.0,YR,E,M,Y,93.0,KG,20231212,,MD,GB,GB,2023,Q4,Elderly
232899041,23289904,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 mg, BID (1000 mg/5 mg (1-0-1-0), Two Times a Day)",,,,,,,,5.0,MG,,BID,2023,Q4,Hypoglycaemia,,2023,Q4,1,I,,20231206.0,20231212,20231212,EXP,,ES-SANDOZ INC.-NVSC2023ES111967,SANDOZ,,62.0,YR,,F,Y,90.0,KG,20231212,,MD,ES,ES,2023,Q4,Adult
232899041,23289904,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 mg, BID (1000 mg/5 mg (1-0-1-0), Two Times a Day)",,,,,,,,5.0,MG,,BID,2023,Q4,Parkinsonism,,2023,Q4,1,I,,20231206.0,20231212,20231212,EXP,,ES-SANDOZ INC.-NVSC2023ES111967,SANDOZ,,62.0,YR,,F,Y,90.0,KG,20231212,,MD,ES,ES,2023,Q4,Adult
232899041,23289904,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 mg, BID (1000 mg/5 mg (1-0-1-0), Two Times a Day)",,,,,,,,5.0,MG,,BID,2023,Q4,Hypotension,,2023,Q4,1,I,,20231206.0,20231212,20231212,EXP,,ES-SANDOZ INC.-NVSC2023ES111967,SANDOZ,,62.0,YR,,F,Y,90.0,KG,20231212,,MD,ES,ES,2023,Q4,Adult
232899041,23289904,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 mg, BID (1000 mg/5 mg (1-0-1-0), Two Times a Day)",,,,,,,,5.0,MG,,BID,2023,Q4,Hallucination,,2023,Q4,1,I,,20231206.0,20231212,20231212,EXP,,ES-SANDOZ INC.-NVSC2023ES111967,SANDOZ,,62.0,YR,,F,Y,90.0,KG,20231212,,MD,ES,ES,2023,Q4,Adult
232899041,23289904,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 mg, BID (1000 mg/5 mg (1-0-1-0), Two Times a Day)",,,,,,,,5.0,MG,,BID,2023,Q4,Somnolence,,2023,Q4,1,I,,20231206.0,20231212,20231212,EXP,,ES-SANDOZ INC.-NVSC2023ES111967,SANDOZ,,62.0,YR,,F,Y,90.0,KG,20231212,,MD,ES,ES,2023,Q4,Adult
232899041,23289904,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 mg, BID (1000 mg/5 mg (1-0-1-0), Two Times a Day)",,,,,,,,5.0,MG,,BID,2023,Q4,Tachycardia,,2023,Q4,1,I,,20231206.0,20231212,20231212,EXP,,ES-SANDOZ INC.-NVSC2023ES111967,SANDOZ,,62.0,YR,,F,Y,90.0,KG,20231212,,MD,ES,ES,2023,Q4,Adult
232899041,23289904,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 mg, BID (1000 mg/5 mg (1-0-1-0), Two Times a Day)",,,,,,,,5.0,MG,,BID,2023,Q4,Drug interaction,,2023,Q4,1,I,,20231206.0,20231212,20231212,EXP,,ES-SANDOZ INC.-NVSC2023ES111967,SANDOZ,,62.0,YR,,F,Y,90.0,KG,20231212,,MD,ES,ES,2023,Q4,Adult
232899041,23289904,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 mg, BID (1000 mg/5 mg (1-0-1-0), Two Times a Day)",,,,,,,,5.0,MG,,BID,2023,Q4,Hyperhidrosis,,2023,Q4,1,I,,20231206.0,20231212,20231212,EXP,,ES-SANDOZ INC.-NVSC2023ES111967,SANDOZ,,62.0,YR,,F,Y,90.0,KG,20231212,,MD,ES,ES,2023,Q4,Adult
232899041,23289904,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Hypoglycaemia,,2023,Q4,1,I,,20231206.0,20231212,20231212,EXP,,ES-SANDOZ INC.-NVSC2023ES111967,SANDOZ,,62.0,YR,,F,Y,90.0,KG,20231212,,MD,ES,ES,2023,Q4,Adult
232899041,23289904,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Parkinsonism,,2023,Q4,1,I,,20231206.0,20231212,20231212,EXP,,ES-SANDOZ INC.-NVSC2023ES111967,SANDOZ,,62.0,YR,,F,Y,90.0,KG,20231212,,MD,ES,ES,2023,Q4,Adult
232899041,23289904,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Hypotension,,2023,Q4,1,I,,20231206.0,20231212,20231212,EXP,,ES-SANDOZ INC.-NVSC2023ES111967,SANDOZ,,62.0,YR,,F,Y,90.0,KG,20231212,,MD,ES,ES,2023,Q4,Adult
232899041,23289904,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Hallucination,,2023,Q4,1,I,,20231206.0,20231212,20231212,EXP,,ES-SANDOZ INC.-NVSC2023ES111967,SANDOZ,,62.0,YR,,F,Y,90.0,KG,20231212,,MD,ES,ES,2023,Q4,Adult
232899041,23289904,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Somnolence,,2023,Q4,1,I,,20231206.0,20231212,20231212,EXP,,ES-SANDOZ INC.-NVSC2023ES111967,SANDOZ,,62.0,YR,,F,Y,90.0,KG,20231212,,MD,ES,ES,2023,Q4,Adult
232899041,23289904,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Tachycardia,,2023,Q4,1,I,,20231206.0,20231212,20231212,EXP,,ES-SANDOZ INC.-NVSC2023ES111967,SANDOZ,,62.0,YR,,F,Y,90.0,KG,20231212,,MD,ES,ES,2023,Q4,Adult
232899041,23289904,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Drug interaction,,2023,Q4,1,I,,20231206.0,20231212,20231212,EXP,,ES-SANDOZ INC.-NVSC2023ES111967,SANDOZ,,62.0,YR,,F,Y,90.0,KG,20231212,,MD,ES,ES,2023,Q4,Adult
232899041,23289904,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Hyperhidrosis,,2023,Q4,1,I,,20231206.0,20231212,20231212,EXP,,ES-SANDOZ INC.-NVSC2023ES111967,SANDOZ,,62.0,YR,,F,Y,90.0,KG,20231212,,MD,ES,ES,2023,Q4,Adult
232899041,23289904,12,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,Y,,,,,,,Unknown,,2023,Q4,Hypoglycaemia,,2023,Q4,1,I,,20231206.0,20231212,20231212,EXP,,ES-SANDOZ INC.-NVSC2023ES111967,SANDOZ,,62.0,YR,,F,Y,90.0,KG,20231212,,MD,ES,ES,2023,Q4,Adult
232899041,23289904,12,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,Y,,,,,,,Unknown,,2023,Q4,Parkinsonism,,2023,Q4,1,I,,20231206.0,20231212,20231212,EXP,,ES-SANDOZ INC.-NVSC2023ES111967,SANDOZ,,62.0,YR,,F,Y,90.0,KG,20231212,,MD,ES,ES,2023,Q4,Adult
232899041,23289904,12,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,Y,,,,,,,Unknown,,2023,Q4,Hypotension,,2023,Q4,1,I,,20231206.0,20231212,20231212,EXP,,ES-SANDOZ INC.-NVSC2023ES111967,SANDOZ,,62.0,YR,,F,Y,90.0,KG,20231212,,MD,ES,ES,2023,Q4,Adult
232899041,23289904,12,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,Y,,,,,,,Unknown,,2023,Q4,Hallucination,,2023,Q4,1,I,,20231206.0,20231212,20231212,EXP,,ES-SANDOZ INC.-NVSC2023ES111967,SANDOZ,,62.0,YR,,F,Y,90.0,KG,20231212,,MD,ES,ES,2023,Q4,Adult
232899041,23289904,12,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,Y,,,,,,,Unknown,,2023,Q4,Somnolence,,2023,Q4,1,I,,20231206.0,20231212,20231212,EXP,,ES-SANDOZ INC.-NVSC2023ES111967,SANDOZ,,62.0,YR,,F,Y,90.0,KG,20231212,,MD,ES,ES,2023,Q4,Adult
232899041,23289904,12,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,Y,,,,,,,Unknown,,2023,Q4,Tachycardia,,2023,Q4,1,I,,20231206.0,20231212,20231212,EXP,,ES-SANDOZ INC.-NVSC2023ES111967,SANDOZ,,62.0,YR,,F,Y,90.0,KG,20231212,,MD,ES,ES,2023,Q4,Adult
232899041,23289904,12,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,Y,,,,,,,Unknown,,2023,Q4,Drug interaction,,2023,Q4,1,I,,20231206.0,20231212,20231212,EXP,,ES-SANDOZ INC.-NVSC2023ES111967,SANDOZ,,62.0,YR,,F,Y,90.0,KG,20231212,,MD,ES,ES,2023,Q4,Adult
232899041,23289904,12,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1000 mg/5 mg (1-0-1-0), Two Times a Day",,,Y,,,,,,,Unknown,,2023,Q4,Hyperhidrosis,,2023,Q4,1,I,,20231206.0,20231212,20231212,EXP,,ES-SANDOZ INC.-NVSC2023ES111967,SANDOZ,,62.0,YR,,F,Y,90.0,KG,20231212,,MD,ES,ES,2023,Q4,Adult
232899041,23289904,13,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK UNK (1-0-1-0) (0.5/day),,,Y,,,,,,,Unknown,,2023,Q4,Hypoglycaemia,,2023,Q4,1,I,,20231206.0,20231212,20231212,EXP,,ES-SANDOZ INC.-NVSC2023ES111967,SANDOZ,,62.0,YR,,F,Y,90.0,KG,20231212,,MD,ES,ES,2023,Q4,Adult
232899041,23289904,13,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK UNK (1-0-1-0) (0.5/day),,,Y,,,,,,,Unknown,,2023,Q4,Parkinsonism,,2023,Q4,1,I,,20231206.0,20231212,20231212,EXP,,ES-SANDOZ INC.-NVSC2023ES111967,SANDOZ,,62.0,YR,,F,Y,90.0,KG,20231212,,MD,ES,ES,2023,Q4,Adult
232899041,23289904,13,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK UNK (1-0-1-0) (0.5/day),,,Y,,,,,,,Unknown,,2023,Q4,Hypotension,,2023,Q4,1,I,,20231206.0,20231212,20231212,EXP,,ES-SANDOZ INC.-NVSC2023ES111967,SANDOZ,,62.0,YR,,F,Y,90.0,KG,20231212,,MD,ES,ES,2023,Q4,Adult
232899041,23289904,13,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK UNK (1-0-1-0) (0.5/day),,,Y,,,,,,,Unknown,,2023,Q4,Hallucination,,2023,Q4,1,I,,20231206.0,20231212,20231212,EXP,,ES-SANDOZ INC.-NVSC2023ES111967,SANDOZ,,62.0,YR,,F,Y,90.0,KG,20231212,,MD,ES,ES,2023,Q4,Adult
232899041,23289904,13,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK UNK (1-0-1-0) (0.5/day),,,Y,,,,,,,Unknown,,2023,Q4,Somnolence,,2023,Q4,1,I,,20231206.0,20231212,20231212,EXP,,ES-SANDOZ INC.-NVSC2023ES111967,SANDOZ,,62.0,YR,,F,Y,90.0,KG,20231212,,MD,ES,ES,2023,Q4,Adult
232899041,23289904,13,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK UNK (1-0-1-0) (0.5/day),,,Y,,,,,,,Unknown,,2023,Q4,Tachycardia,,2023,Q4,1,I,,20231206.0,20231212,20231212,EXP,,ES-SANDOZ INC.-NVSC2023ES111967,SANDOZ,,62.0,YR,,F,Y,90.0,KG,20231212,,MD,ES,ES,2023,Q4,Adult
232899041,23289904,13,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK UNK (1-0-1-0) (0.5/day),,,Y,,,,,,,Unknown,,2023,Q4,Drug interaction,,2023,Q4,1,I,,20231206.0,20231212,20231212,EXP,,ES-SANDOZ INC.-NVSC2023ES111967,SANDOZ,,62.0,YR,,F,Y,90.0,KG,20231212,,MD,ES,ES,2023,Q4,Adult
232899041,23289904,13,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK UNK (1-0-1-0) (0.5/day),,,Y,,,,,,,Unknown,,2023,Q4,Hyperhidrosis,,2023,Q4,1,I,,20231206.0,20231212,20231212,EXP,,ES-SANDOZ INC.-NVSC2023ES111967,SANDOZ,,62.0,YR,,F,Y,90.0,KG,20231212,,MD,ES,ES,2023,Q4,Adult
232900041,23290004,8,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,D,,,,,,,,,2023,Q4,Blood creatinine increased,,2023,Q4,1,I,20230101.0,20231204.0,20231212,20231212,EXP,,HR-JNJFOC-20231225181,JOHNSON AND JOHNSON,,63.0,YR,A,M,Y,,,20231213,,MD,HR,HR,2023,Q4,Adult
232900041,23290004,8,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,D,,,,,,,,,2023,Q4,Post procedural haematoma,,2023,Q4,1,I,20230101.0,20231204.0,20231212,20231212,EXP,,HR-JNJFOC-20231225181,JOHNSON AND JOHNSON,,63.0,YR,A,M,Y,,,20231213,,MD,HR,HR,2023,Q4,Adult
232900041,23290004,8,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,D,,,,,,,,,2023,Q4,Aortic bypass,,2023,Q4,1,I,20230101.0,20231204.0,20231212,20231212,EXP,,HR-JNJFOC-20231225181,JOHNSON AND JOHNSON,,63.0,YR,A,M,Y,,,20231213,,MD,HR,HR,2023,Q4,Adult
232900041,23290004,8,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,D,,,,,,,,,2023,Q4,Wound infection,,2023,Q4,1,I,20230101.0,20231204.0,20231212,20231212,EXP,,HR-JNJFOC-20231225181,JOHNSON AND JOHNSON,,63.0,YR,A,M,Y,,,20231213,,MD,HR,HR,2023,Q4,Adult
232900041,23290004,8,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,D,,,,,,,,,2023,Q4,Acute kidney injury,,2023,Q4,1,I,20230101.0,20231204.0,20231212,20231212,EXP,,HR-JNJFOC-20231225181,JOHNSON AND JOHNSON,,63.0,YR,A,M,Y,,,20231213,,MD,HR,HR,2023,Q4,Adult
232912331,23291233,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Frequency text: Not Provided,,,,,,,,,,,,2023,Q4,Vomiting,,2023,Q4,1,I,20180530.0,20231207.0,20231213,20231213,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-CAN-20210203228,BRISTOL MYERS SQUIBB,,66.0,YR,E,M,Y,,,20231213,,HP,CA,CA,2023,Q4,Elderly
232912331,23291233,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Frequency text: Not Provided,,,,,,,,,,,,2023,Q4,Chills,,2023,Q4,1,I,20180530.0,20231207.0,20231213,20231213,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-CAN-20210203228,BRISTOL MYERS SQUIBB,,66.0,YR,E,M,Y,,,20231213,,HP,CA,CA,2023,Q4,Elderly
232912331,23291233,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Frequency text: Not Provided,,,,,,,,,,,,2023,Q4,Sepsis,,2023,Q4,1,I,20180530.0,20231207.0,20231213,20231213,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-CAN-20210203228,BRISTOL MYERS SQUIBB,,66.0,YR,E,M,Y,,,20231213,,HP,CA,CA,2023,Q4,Elderly
232912331,23291233,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Frequency text: Not Provided,,,,,,,,,,,,2023,Q4,Blood pressure decreased,,2023,Q4,1,I,20180530.0,20231207.0,20231213,20231213,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-CAN-20210203228,BRISTOL MYERS SQUIBB,,66.0,YR,E,M,Y,,,20231213,,HP,CA,CA,2023,Q4,Elderly
232915911,23291591,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram per day,,,U,,,,,10.0,MG,,,2023,Q4,Drug ineffective,,2023,Q4,1,I,,20231204.0,20231213,20231213,EXP,,JP-STRIDES ARCOLAB LIMITED-2023SP018559,STRIDES,"Sugihara R, Hashimura T, Sakata Y.. Goreisan as a successful adjuvant therapy of heart failure with preserved ejection fraction and advanced chronic kidney disease: a case report.. Oxf-Med-Case-Reports. 2023;2023",76.0,YR,,M,Y,,,20231213,,HP,JP,JP,2023,Q4,Elderly
232915911,23291591,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram per day,,,U,,,,,10.0,MG,,,2023,Q4,Chronic kidney disease,,2023,Q4,1,I,,20231204.0,20231213,20231213,EXP,,JP-STRIDES ARCOLAB LIMITED-2023SP018559,STRIDES,"Sugihara R, Hashimura T, Sakata Y.. Goreisan as a successful adjuvant therapy of heart failure with preserved ejection fraction and advanced chronic kidney disease: a case report.. Oxf-Med-Case-Reports. 2023;2023",76.0,YR,,M,Y,,,20231213,,HP,JP,JP,2023,Q4,Elderly
232982461,23298246,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Diabetic ketoacidosis,,2023,Q4,1,I,,20231214.0,20231214,20231214,DIR,684597,,FDA-CTU,,59.0,YR,,M,N,,,20231214,N,PH,US,,2023,Q4,Adult
232989521,23298952,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,D,,,,,10.0,MG,,,2023,Q4,COVID-19,,2023,Q4,1,I,,20231207.0,20231215,20231215,EXP,,HR-JNJFOC-20231235935,JOHNSON AND JOHNSON,,66.0,YR,E,F,Y,,,20231214,,MD,HR,HR,2023,Q4,Elderly
232999081,23299908,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q4,Fournier's gangrene,,2023,Q4,1,I,20231130.0,20231213.0,20231215,20231215,EXP,GB-MHRA-EMIS-2317-0df0fa4e-a594-4194-8d30-ec0e43ca6d55,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-278098",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,86.4,KG,20231215,,MD,GB,GB,2023,Q4,Elderly
233000491,23300049,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,D,,,,,,,,,2023,Q4,Liver injury,,2023,Q4,1,I,20230301.0,20231212.0,20231215,20231215,EXP,FR-AFSSAPS-TO2023002111,FR-ORGANON-O2312FRA001147,ORGANON,,96.0,YR,,F,Y,,,20231215,,PH,FR,FR,2023,Q4,Elderly
233003091,23300309,2,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,1-0-0,,,,,,,,,,Tablet,,2023,Q4,Carcinoembryonic antigen increased,,2023,Q4,1,I,,20231205.0,20231215,20231215,EXP,,JP-EMD Serono-2023494022,EMD SERONO INC,,75.0,YR,E,M,Y,76.0,KG,20231215,,HP,JP,JP,2023,Q4,Elderly
233003091,23300309,2,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,1-0-0,,,,,,,,,,Tablet,,2023,Q4,Diabetes mellitus inadequate control,,2023,Q4,1,I,,20231205.0,20231215,20231215,EXP,,JP-EMD Serono-2023494022,EMD SERONO INC,,75.0,YR,E,M,Y,76.0,KG,20231215,,HP,JP,JP,2023,Q4,Elderly
233010012,23301001,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,Tablet,QD,2023,Q4,Ileus paralytic,,2023,Q4,2,F,20220101.0,20231220.0,20231215,20231228,EXP,,JP-MYLANLABS-2023M1132051,MYLAN,"Tomida T, Itohara K, Yamamoto K, Kimura T, Fujita K, Uda A, et al. A model-based pharmacokinetic assessment of drug-drug interaction between tacrolimus and nirmatrelvir/ritonavir in a kidney transplant patient with COVID-19. Drug-Metab-Pharmacokinet 2023; 53.. 2023;53",56.0,YR,,M,Y,84.5,KG,20231228,,HP,JP,JP,2023,Q4,Adult
233010012,23301001,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,Tablet,QD,2023,Q4,Acute kidney injury,,2023,Q4,2,F,20220101.0,20231220.0,20231215,20231228,EXP,,JP-MYLANLABS-2023M1132051,MYLAN,"Tomida T, Itohara K, Yamamoto K, Kimura T, Fujita K, Uda A, et al. A model-based pharmacokinetic assessment of drug-drug interaction between tacrolimus and nirmatrelvir/ritonavir in a kidney transplant patient with COVID-19. Drug-Metab-Pharmacokinet 2023; 53.. 2023;53",56.0,YR,,M,Y,84.5,KG,20231228,,HP,JP,JP,2023,Q4,Adult
233010012,23301001,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,Tablet,QD,2023,Q4,Hyperkalaemia,,2023,Q4,2,F,20220101.0,20231220.0,20231215,20231228,EXP,,JP-MYLANLABS-2023M1132051,MYLAN,"Tomida T, Itohara K, Yamamoto K, Kimura T, Fujita K, Uda A, et al. A model-based pharmacokinetic assessment of drug-drug interaction between tacrolimus and nirmatrelvir/ritonavir in a kidney transplant patient with COVID-19. Drug-Metab-Pharmacokinet 2023; 53.. 2023;53",56.0,YR,,M,Y,84.5,KG,20231228,,HP,JP,JP,2023,Q4,Adult
233010012,23301001,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,Tablet,QD,2023,Q4,Drug interaction,,2023,Q4,2,F,20220101.0,20231220.0,20231215,20231228,EXP,,JP-MYLANLABS-2023M1132051,MYLAN,"Tomida T, Itohara K, Yamamoto K, Kimura T, Fujita K, Uda A, et al. A model-based pharmacokinetic assessment of drug-drug interaction between tacrolimus and nirmatrelvir/ritonavir in a kidney transplant patient with COVID-19. Drug-Metab-Pharmacokinet 2023; 53.. 2023;53",56.0,YR,,M,Y,84.5,KG,20231228,,HP,JP,JP,2023,Q4,Adult
233010012,23301001,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,Tablet,QD,2023,Q4,Drug level increased,,2023,Q4,2,F,20220101.0,20231220.0,20231215,20231228,EXP,,JP-MYLANLABS-2023M1132051,MYLAN,"Tomida T, Itohara K, Yamamoto K, Kimura T, Fujita K, Uda A, et al. A model-based pharmacokinetic assessment of drug-drug interaction between tacrolimus and nirmatrelvir/ritonavir in a kidney transplant patient with COVID-19. Drug-Metab-Pharmacokinet 2023; 53.. 2023;53",56.0,YR,,M,Y,84.5,KG,20231228,,HP,JP,JP,2023,Q4,Adult
233031571,23303157,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Nausea,,2023,Q4,1,I,,20231201.0,20231215,20231215,EXP,,CA-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-423981,RANBAXY,"Leung M, Rodrigues P, Roitman D. Ketoacidosis in a Patient with Type 2 Diabetes Requiring Alpelisib: Learnings and Observations Regarding Alpelisib Initiation and Rechallenge. OncoTargets Therap. 2022;15:1309-1315",58.0,YR,,F,Y,,,20231215,,HP,CA,CA,2023,Q4,Adult
233031571,23303157,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Dyspnoea,,2023,Q4,1,I,,20231201.0,20231215,20231215,EXP,,CA-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-423981,RANBAXY,"Leung M, Rodrigues P, Roitman D. Ketoacidosis in a Patient with Type 2 Diabetes Requiring Alpelisib: Learnings and Observations Regarding Alpelisib Initiation and Rechallenge. OncoTargets Therap. 2022;15:1309-1315",58.0,YR,,F,Y,,,20231215,,HP,CA,CA,2023,Q4,Adult
233031571,23303157,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Gene mutation,,2023,Q4,1,I,,20231201.0,20231215,20231215,EXP,,CA-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-423981,RANBAXY,"Leung M, Rodrigues P, Roitman D. Ketoacidosis in a Patient with Type 2 Diabetes Requiring Alpelisib: Learnings and Observations Regarding Alpelisib Initiation and Rechallenge. OncoTargets Therap. 2022;15:1309-1315",58.0,YR,,F,Y,,,20231215,,HP,CA,CA,2023,Q4,Adult
233031571,23303157,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Rash,,2023,Q4,1,I,,20231201.0,20231215,20231215,EXP,,CA-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-423981,RANBAXY,"Leung M, Rodrigues P, Roitman D. Ketoacidosis in a Patient with Type 2 Diabetes Requiring Alpelisib: Learnings and Observations Regarding Alpelisib Initiation and Rechallenge. OncoTargets Therap. 2022;15:1309-1315",58.0,YR,,F,Y,,,20231215,,HP,CA,CA,2023,Q4,Adult
233031571,23303157,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2023,Q4,Vomiting,,2023,Q4,1,I,,20231201.0,20231215,20231215,EXP,,CA-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-423981,RANBAXY,"Leung M, Rodrigues P, Roitman D. Ketoacidosis in a Patient with Type 2 Diabetes Requiring Alpelisib: Learnings and Observations Regarding Alpelisib Initiation and Rechallenge. OncoTargets Therap. 2022;15:1309-1315",58.0,YR,,F,Y,,,20231215,,HP,CA,CA,2023,Q4,Adult
233043441,23304344,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Daily",,,D,,,,,25.0,MG,,,2023,Q4,Drug ineffective,,2023,Q4,1,I,,20231204.0,20231218,20231218,EXP,,US-AUROBINDO-AUR-APL-2023-078314,AUROBINDO,"Sekar V, Shaik S. A Case Of Alpelisib Induced Diabetic Ketoacidosis (Dka) In A Patient With Type 2 Diabetes Mellitus And Rechallenge With SGLT2 Inhibitor. J-Endocr-Soc. 2023;7 (Suppl. 1):A437- A438",60.0,YR,,F,Y,,,20231216,,MD,US,US,2023,Q4,Adult
233069091,23306909,1,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"1.000tablet,bid",,,U,,230*323,,,,,,,2023,Q4,Diabetic ketoacidosis,,2023,Q4,1,I,20231129.0,20231207.0,20231218,20231218,EXP,CN-NMPA-3710811010689202300566,CN-NOVOPROD-1151081,NOVO NORDISK,,33.0,YR,,F,Y,61.0,KG,20231218,,HP,CN,CN,2023,Q4,Young Adult
233081341,23308134,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,Unknown,,,,,,,2023,Q4,Exposure to toxic agent,,2023,Q4,1,I,20220101.0,20231213.0,20231218,20231218,EXP,,US-PERRIGO-23US014502,PERRIGO,,29.0,YR,,F,Y,,,20231218,,MD,US,US,2023,Q4,Young Adult
233081341,23308134,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,Unknown,,,,,,,2023,Q4,Completed suicide,,2023,Q4,1,I,20220101.0,20231213.0,20231218,20231218,EXP,,US-PERRIGO-23US014502,PERRIGO,,29.0,YR,,F,Y,,,20231218,,MD,US,US,2023,Q4,Young Adult
233081921,23308192,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,10.0,MG,,,2023,Q4,Ulcerative duodenitis,,2023,Q4,1,I,20231120.0,20231210.0,20231218,20231218,EXP,,LT-BRISTOL-MYERS SQUIBB COMPANY-2023-180666,BRISTOL MYERS SQUIBB,,62.0,YR,A,M,Y,,,20231218,,MD,LT,LT,2023,Q4,Adult
233081921,23308192,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,10.0,MG,,,2023,Q4,Immune-mediated enterocolitis,,2023,Q4,1,I,20231120.0,20231210.0,20231218,20231218,EXP,,LT-BRISTOL-MYERS SQUIBB COMPANY-2023-180666,BRISTOL MYERS SQUIBB,,62.0,YR,A,M,Y,,,20231218,,MD,LT,LT,2023,Q4,Adult
233090021,23309002,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, tid",,,,,,,,25.0,MG,Unknown,TID,2023,Q4,Treatment failure,,2023,Q4,1,I,,20231214.0,20231218,20231218,EXP,,CA-MYLANLABS-2023M1134340,MYLAN,lentente de pratique avancee en partenariat avec les pharmaciens: un outil precieeux pour les GMF. Profession Sante. 2023;9:26,72.0,YR,,,Y,,,20231218,,HP,CA,CA,2023,Q4,Elderly
233090021,23309002,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, tid",,,,,,,,25.0,MG,Unknown,TID,2023,Q4,Diabetes mellitus inadequate control,,2023,Q4,1,I,,20231214.0,20231218,20231218,EXP,,CA-MYLANLABS-2023M1134340,MYLAN,lentente de pratique avancee en partenariat avec les pharmaciens: un outil precieeux pour les GMF. Profession Sante. 2023;9:26,72.0,YR,,,Y,,,20231218,,HP,CA,CA,2023,Q4,Elderly
233090021,23309002,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, tid",,,,,,,,25.0,MG,Unknown,TID,2023,Q4,Dizziness,,2023,Q4,1,I,,20231214.0,20231218,20231218,EXP,,CA-MYLANLABS-2023M1134340,MYLAN,lentente de pratique avancee en partenariat avec les pharmaciens: un outil precieeux pour les GMF. Profession Sante. 2023;9:26,72.0,YR,,,Y,,,20231218,,HP,CA,CA,2023,Q4,Elderly
233090981,23309098,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,ongoing since prescribed,,204629.0,25.0,MG,Tablet,QD,2023,Q4,Candida infection,,2023,Q4,1,I,20200802.0,20231218.0,20231218,20231218,EXP,GB-MHRA-MED-202312161440437050-RKZWP,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-278721",BOEHRINGER INGELHEIM,,61.0,YR,A,F,Y,74.0,KG,20231218,,CN,GB,GB,2023,Q4,Adult
233106371,23310637,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2023,Q4,Death,,2023,Q4,1,I,20231212.0,20231214.0,20231218,20231218,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-2023-183001,BRISTOL MYERS SQUIBB,,88.0,YR,E,F,Y,,,20231219,,CN,US,US,2023,Q4,Elderly
233124431,23312443,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q4,Acute kidney injury,,2023,Q4,1,I,,20231204.0,20231219,20231219,EXP,,US-TEVA-VS-3136503,TEVA,"Khawaja US, Shah N, Wang A. Zoledronate-Induced Acute Tubular Necrosis With Baseline Normal Renal Function: A Rare Phenomenon. J-Endocr-Soc 2022; 6 (Suppl. 1) A180.",51.0,YR,,,Y,,,20231219,,MD,US,US,2023,Q4,Adult
233124431,23312443,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q4,Renal tubular necrosis,,2023,Q4,1,I,,20231204.0,20231219,20231219,EXP,,US-TEVA-VS-3136503,TEVA,"Khawaja US, Shah N, Wang A. Zoledronate-Induced Acute Tubular Necrosis With Baseline Normal Renal Function: A Rare Phenomenon. J-Endocr-Soc 2022; 6 (Suppl. 1) A180.",51.0,YR,,,Y,,,20231219,,MD,US,US,2023,Q4,Adult
233126421,23312642,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2023,Q4,Renal tubular necrosis,,2023,Q4,1,I,,20231212.0,20231219,20231219,PER,,US-KOANAAP-SML-US-2023-01718,Unknown Manufacturer,"Khawaja US, Shah N, Wang A. Zoledronate-Induced Acute Tubular Necrosis With Baseline Normal Renal Function: A Rare Phenomenon. Journal of the Endocrine Society. 2022;6(Supplement 1):A180. DOI: 10.1210/jendso/bvac150.371.",51.0,YR,A,F,Y,,,20231219,,MD,US,US,2023,Q4,Adult
233126421,23312642,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2023,Q4,Acute kidney injury,,2023,Q4,1,I,,20231212.0,20231219,20231219,PER,,US-KOANAAP-SML-US-2023-01718,Unknown Manufacturer,"Khawaja US, Shah N, Wang A. Zoledronate-Induced Acute Tubular Necrosis With Baseline Normal Renal Function: A Rare Phenomenon. Journal of the Endocrine Society. 2022;6(Supplement 1):A180. DOI: 10.1210/jendso/bvac150.371.",51.0,YR,A,F,Y,,,20231219,,MD,US,US,2023,Q4,Adult
233127721,23312772,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,Poultice,,2023,Q4,Aortic aneurysm,,2023,Q4,1,I,,20231207.0,20231219,20231219,EXP,CA-MHPD-E2B_06621737,CA-Accord-395853,ACCORD,,85.0,YR,,M,Y,,,20231219,,MD,CA,CA,2023,Q4,Elderly
233127721,23312772,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,Poultice,,2023,Q4,Rheumatoid factor positive,,2023,Q4,1,I,,20231207.0,20231219,20231219,EXP,CA-MHPD-E2B_06621737,CA-Accord-395853,ACCORD,,85.0,YR,,M,Y,,,20231219,,MD,CA,CA,2023,Q4,Elderly
233127721,23312772,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,Poultice,,2023,Q4,Vitamin D decreased,,2023,Q4,1,I,,20231207.0,20231219,20231219,EXP,CA-MHPD-E2B_06621737,CA-Accord-395853,ACCORD,,85.0,YR,,M,Y,,,20231219,,MD,CA,CA,2023,Q4,Elderly
233127721,23312772,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,Poultice,,2023,Q4,Nodal osteoarthritis,,2023,Q4,1,I,,20231207.0,20231219,20231219,EXP,CA-MHPD-E2B_06621737,CA-Accord-395853,ACCORD,,85.0,YR,,M,Y,,,20231219,,MD,CA,CA,2023,Q4,Elderly
233127721,23312772,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,Poultice,,2023,Q4,Peripheral artery thrombosis,,2023,Q4,1,I,,20231207.0,20231219,20231219,EXP,CA-MHPD-E2B_06621737,CA-Accord-395853,ACCORD,,85.0,YR,,M,Y,,,20231219,,MD,CA,CA,2023,Q4,Elderly
233127721,23312772,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,Poultice,,2023,Q4,Pain in extremity,,2023,Q4,1,I,,20231207.0,20231219,20231219,EXP,CA-MHPD-E2B_06621737,CA-Accord-395853,ACCORD,,85.0,YR,,M,Y,,,20231219,,MD,CA,CA,2023,Q4,Elderly
233127721,23312772,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,Poultice,,2023,Q4,Blood pressure systolic increased,,2023,Q4,1,I,,20231207.0,20231219,20231219,EXP,CA-MHPD-E2B_06621737,CA-Accord-395853,ACCORD,,85.0,YR,,M,Y,,,20231219,,MD,CA,CA,2023,Q4,Elderly
233131072,23313107,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q4,Acute kidney injury,,2023,Q4,2,F,,20231207.0,20231219,20231219,EXP,,US-SCIEGENP-2023SCLIT00757,SCIEGEN,"Heckart JC, et al..EDKA and MALA in the Setting of Severe Heart Failure and Acute Renal Failure, Due to SGLT2-i.Journal of the Endocrine Society.MAY-2020;4 (1):A853",53.0,YR,A,M,Y,,,20231219,,HP,US,US,2023,Q4,Adult
233131072,23313107,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q4,Lactic acidosis,,2023,Q4,2,F,,20231207.0,20231219,20231219,EXP,,US-SCIEGENP-2023SCLIT00757,SCIEGEN,"Heckart JC, et al..EDKA and MALA in the Setting of Severe Heart Failure and Acute Renal Failure, Due to SGLT2-i.Journal of the Endocrine Society.MAY-2020;4 (1):A853",53.0,YR,A,M,Y,,,20231219,,HP,US,US,2023,Q4,Adult
233131072,23313107,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2023,Q4,Euglycaemic diabetic ketoacidosis,,2023,Q4,2,F,,20231207.0,20231219,20231219,EXP,,US-SCIEGENP-2023SCLIT00757,SCIEGEN,"Heckart JC, et al..EDKA and MALA in the Setting of Severe Heart Failure and Acute Renal Failure, Due to SGLT2-i.Journal of the Endocrine Society.MAY-2020;4 (1):A853",53.0,YR,A,M,Y,,,20231219,,HP,US,US,2023,Q4,Adult
233133801,23313380,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,Unknown,QD,2023,Q4,Drug effect less than expected,,2023,Q4,1,I,20140101.0,20221003.0,20231219,20231219,EXP,,HU-MYLANLABS-2023M1135057,MYLAN,,53.0,YR,,M,Y,118.0,KG,20231219,,MD,HU,HU,2023,Q4,Adult
233133801,23313380,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,Unknown,QD,2023,Q4,Extrasystoles,,2023,Q4,1,I,20140101.0,20221003.0,20231219,20231219,EXP,,HU-MYLANLABS-2023M1135057,MYLAN,,53.0,YR,,M,Y,118.0,KG,20231219,,MD,HU,HU,2023,Q4,Adult
233133801,23313380,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,Unknown,QD,2023,Q4,Heart rate irregular,,2023,Q4,1,I,20140101.0,20221003.0,20231219,20231219,EXP,,HU-MYLANLABS-2023M1135057,MYLAN,,53.0,YR,,M,Y,118.0,KG,20231219,,MD,HU,HU,2023,Q4,Adult
233133801,23313380,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,Unknown,QD,2023,Q4,Atrial fibrillation,,2023,Q4,1,I,20140101.0,20221003.0,20231219,20231219,EXP,,HU-MYLANLABS-2023M1135057,MYLAN,,53.0,YR,,M,Y,118.0,KG,20231219,,MD,HU,HU,2023,Q4,Adult
233133801,23313380,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,Unknown,QD,2023,Q4,Mean cell volume increased,,2023,Q4,1,I,20140101.0,20221003.0,20231219,20231219,EXP,,HU-MYLANLABS-2023M1135057,MYLAN,,53.0,YR,,M,Y,118.0,KG,20231219,,MD,HU,HU,2023,Q4,Adult
233133801,23313380,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,Unknown,QD,2023,Q4,Cholelithiasis,,2023,Q4,1,I,20140101.0,20221003.0,20231219,20231219,EXP,,HU-MYLANLABS-2023M1135057,MYLAN,,53.0,YR,,M,Y,118.0,KG,20231219,,MD,HU,HU,2023,Q4,Adult
233133801,23313380,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,Unknown,QD,2023,Q4,Sciatica,,2023,Q4,1,I,20140101.0,20221003.0,20231219,20231219,EXP,,HU-MYLANLABS-2023M1135057,MYLAN,,53.0,YR,,M,Y,118.0,KG,20231219,,MD,HU,HU,2023,Q4,Adult
233133801,23313380,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,Unknown,QD,2023,Q4,Dilated cardiomyopathy,,2023,Q4,1,I,20140101.0,20221003.0,20231219,20231219,EXP,,HU-MYLANLABS-2023M1135057,MYLAN,,53.0,YR,,M,Y,118.0,KG,20231219,,MD,HU,HU,2023,Q4,Adult
233133801,23313380,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,Unknown,QD,2023,Q4,Glomerular filtration rate increased,,2023,Q4,1,I,20140101.0,20221003.0,20231219,20231219,EXP,,HU-MYLANLABS-2023M1135057,MYLAN,,53.0,YR,,M,Y,118.0,KG,20231219,,MD,HU,HU,2023,Q4,Adult
233133801,23313380,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,Unknown,QD,2023,Q4,Sinus arrest,,2023,Q4,1,I,20140101.0,20221003.0,20231219,20231219,EXP,,HU-MYLANLABS-2023M1135057,MYLAN,,53.0,YR,,M,Y,118.0,KG,20231219,,MD,HU,HU,2023,Q4,Adult
233133801,23313380,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,Unknown,QD,2023,Q4,Dyspnoea,,2023,Q4,1,I,20140101.0,20221003.0,20231219,20231219,EXP,,HU-MYLANLABS-2023M1135057,MYLAN,,53.0,YR,,M,Y,118.0,KG,20231219,,MD,HU,HU,2023,Q4,Adult
233133801,23313380,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,Unknown,QD,2023,Q4,Electrocardiogram ST segment abnormal,,2023,Q4,1,I,20140101.0,20221003.0,20231219,20231219,EXP,,HU-MYLANLABS-2023M1135057,MYLAN,,53.0,YR,,M,Y,118.0,KG,20231219,,MD,HU,HU,2023,Q4,Adult
233133801,23313380,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,Unknown,QD,2023,Q4,Atrial enlargement,,2023,Q4,1,I,20140101.0,20221003.0,20231219,20231219,EXP,,HU-MYLANLABS-2023M1135057,MYLAN,,53.0,YR,,M,Y,118.0,KG,20231219,,MD,HU,HU,2023,Q4,Adult
233133801,23313380,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,Unknown,QD,2023,Q4,Hyperlipidaemia,,2023,Q4,1,I,20140101.0,20221003.0,20231219,20231219,EXP,,HU-MYLANLABS-2023M1135057,MYLAN,,53.0,YR,,M,Y,118.0,KG,20231219,,MD,HU,HU,2023,Q4,Adult
233133801,23313380,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,Unknown,QD,2023,Q4,Mean cell haemoglobin increased,,2023,Q4,1,I,20140101.0,20221003.0,20231219,20231219,EXP,,HU-MYLANLABS-2023M1135057,MYLAN,,53.0,YR,,M,Y,118.0,KG,20231219,,MD,HU,HU,2023,Q4,Adult
233133801,23313380,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,Unknown,QD,2023,Q4,Exercise tolerance decreased,,2023,Q4,1,I,20140101.0,20221003.0,20231219,20231219,EXP,,HU-MYLANLABS-2023M1135057,MYLAN,,53.0,YR,,M,Y,118.0,KG,20231219,,MD,HU,HU,2023,Q4,Adult
233133801,23313380,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,Unknown,QD,2023,Q4,International normalised ratio fluctuation,,2023,Q4,1,I,20140101.0,20221003.0,20231219,20231219,EXP,,HU-MYLANLABS-2023M1135057,MYLAN,,53.0,YR,,M,Y,118.0,KG,20231219,,MD,HU,HU,2023,Q4,Adult
233133801,23313380,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,Unknown,QD,2023,Q4,Chest pain,,2023,Q4,1,I,20140101.0,20221003.0,20231219,20231219,EXP,,HU-MYLANLABS-2023M1135057,MYLAN,,53.0,YR,,M,Y,118.0,KG,20231219,,MD,HU,HU,2023,Q4,Adult
233133801,23313380,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,Unknown,QD,2023,Q4,Haemoglobin decreased,,2023,Q4,1,I,20140101.0,20221003.0,20231219,20231219,EXP,,HU-MYLANLABS-2023M1135057,MYLAN,,53.0,YR,,M,Y,118.0,KG,20231219,,MD,HU,HU,2023,Q4,Adult
233133801,23313380,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,Unknown,QD,2023,Q4,Supraventricular extrasystoles,,2023,Q4,1,I,20140101.0,20221003.0,20231219,20231219,EXP,,HU-MYLANLABS-2023M1135057,MYLAN,,53.0,YR,,M,Y,118.0,KG,20231219,,MD,HU,HU,2023,Q4,Adult
233133801,23313380,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,Unknown,QD,2023,Q4,Electrocardiogram abnormal,,2023,Q4,1,I,20140101.0,20221003.0,20231219,20231219,EXP,,HU-MYLANLABS-2023M1135057,MYLAN,,53.0,YR,,M,Y,118.0,KG,20231219,,MD,HU,HU,2023,Q4,Adult
233133801,23313380,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,Unknown,QD,2023,Q4,Ventricular extrasystoles,,2023,Q4,1,I,20140101.0,20221003.0,20231219,20231219,EXP,,HU-MYLANLABS-2023M1135057,MYLAN,,53.0,YR,,M,Y,118.0,KG,20231219,,MD,HU,HU,2023,Q4,Adult
233133801,23313380,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,Unknown,QD,2023,Q4,Hydrocholecystis,,2023,Q4,1,I,20140101.0,20221003.0,20231219,20231219,EXP,,HU-MYLANLABS-2023M1135057,MYLAN,,53.0,YR,,M,Y,118.0,KG,20231219,,MD,HU,HU,2023,Q4,Adult
233133801,23313380,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,Unknown,QD,2023,Q4,Platelet count decreased,,2023,Q4,1,I,20140101.0,20221003.0,20231219,20231219,EXP,,HU-MYLANLABS-2023M1135057,MYLAN,,53.0,YR,,M,Y,118.0,KG,20231219,,MD,HU,HU,2023,Q4,Adult
233133801,23313380,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,Unknown,QD,2023,Q4,Ejection fraction decreased,,2023,Q4,1,I,20140101.0,20221003.0,20231219,20231219,EXP,,HU-MYLANLABS-2023M1135057,MYLAN,,53.0,YR,,M,Y,118.0,KG,20231219,,MD,HU,HU,2023,Q4,Adult
233133801,23313380,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,Unknown,QD,2023,Q4,Bundle branch block left,,2023,Q4,1,I,20140101.0,20221003.0,20231219,20231219,EXP,,HU-MYLANLABS-2023M1135057,MYLAN,,53.0,YR,,M,Y,118.0,KG,20231219,,MD,HU,HU,2023,Q4,Adult
233133801,23313380,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,Unknown,QD,2023,Q4,Fatigue,,2023,Q4,1,I,20140101.0,20221003.0,20231219,20231219,EXP,,HU-MYLANLABS-2023M1135057,MYLAN,,53.0,YR,,M,Y,118.0,KG,20231219,,MD,HU,HU,2023,Q4,Adult
233133801,23313380,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,Unknown,QD,2023,Q4,Pancreatitis,,2023,Q4,1,I,20140101.0,20221003.0,20231219,20231219,EXP,,HU-MYLANLABS-2023M1135057,MYLAN,,53.0,YR,,M,Y,118.0,KG,20231219,,MD,HU,HU,2023,Q4,Adult
233133801,23313380,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,Unknown,QD,2023,Q4,Atrial flutter,,2023,Q4,1,I,20140101.0,20221003.0,20231219,20231219,EXP,,HU-MYLANLABS-2023M1135057,MYLAN,,53.0,YR,,M,Y,118.0,KG,20231219,,MD,HU,HU,2023,Q4,Adult
233133801,23313380,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,Unknown,QD,2023,Q4,Electrocardiogram T wave amplitude decreased,,2023,Q4,1,I,20140101.0,20221003.0,20231219,20231219,EXP,,HU-MYLANLABS-2023M1135057,MYLAN,,53.0,YR,,M,Y,118.0,KG,20231219,,MD,HU,HU,2023,Q4,Adult
233133801,23313380,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,Unknown,QD,2023,Q4,Ventricular fibrillation,,2023,Q4,1,I,20140101.0,20221003.0,20231219,20231219,EXP,,HU-MYLANLABS-2023M1135057,MYLAN,,53.0,YR,,M,Y,118.0,KG,20231219,,MD,HU,HU,2023,Q4,Adult
233133801,23313380,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,Unknown,QD,2023,Q4,Red cell distribution width increased,,2023,Q4,1,I,20140101.0,20221003.0,20231219,20231219,EXP,,HU-MYLANLABS-2023M1135057,MYLAN,,53.0,YR,,M,Y,118.0,KG,20231219,,MD,HU,HU,2023,Q4,Adult
233133801,23313380,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,Unknown,QD,2023,Q4,Inflammatory marker increased,,2023,Q4,1,I,20140101.0,20221003.0,20231219,20231219,EXP,,HU-MYLANLABS-2023M1135057,MYLAN,,53.0,YR,,M,Y,118.0,KG,20231219,,MD,HU,HU,2023,Q4,Adult
233133801,23313380,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,Unknown,QD,2023,Q4,Troponin T increased,,2023,Q4,1,I,20140101.0,20221003.0,20231219,20231219,EXP,,HU-MYLANLABS-2023M1135057,MYLAN,,53.0,YR,,M,Y,118.0,KG,20231219,,MD,HU,HU,2023,Q4,Adult
233133801,23313380,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,Unknown,QD,2023,Q4,Ventricular tachycardia,,2023,Q4,1,I,20140101.0,20221003.0,20231219,20231219,EXP,,HU-MYLANLABS-2023M1135057,MYLAN,,53.0,YR,,M,Y,118.0,KG,20231219,,MD,HU,HU,2023,Q4,Adult
233133801,23313380,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,Unknown,QD,2023,Q4,Heart rate increased,,2023,Q4,1,I,20140101.0,20221003.0,20231219,20231219,EXP,,HU-MYLANLABS-2023M1135057,MYLAN,,53.0,YR,,M,Y,118.0,KG,20231219,,MD,HU,HU,2023,Q4,Adult
233133801,23313380,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,Unknown,QD,2023,Q4,Asthenia,,2023,Q4,1,I,20140101.0,20221003.0,20231219,20231219,EXP,,HU-MYLANLABS-2023M1135057,MYLAN,,53.0,YR,,M,Y,118.0,KG,20231219,,MD,HU,HU,2023,Q4,Adult
233133801,23313380,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,Unknown,QD,2023,Q4,Blood thyroid stimulating hormone increased,,2023,Q4,1,I,20140101.0,20221003.0,20231219,20231219,EXP,,HU-MYLANLABS-2023M1135057,MYLAN,,53.0,YR,,M,Y,118.0,KG,20231219,,MD,HU,HU,2023,Q4,Adult
233133801,23313380,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,Unknown,QD,2023,Q4,Cardiac failure congestive,,2023,Q4,1,I,20140101.0,20221003.0,20231219,20231219,EXP,,HU-MYLANLABS-2023M1135057,MYLAN,,53.0,YR,,M,Y,118.0,KG,20231219,,MD,HU,HU,2023,Q4,Adult
233133801,23313380,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,Unknown,QD,2023,Q4,Condition aggravated,,2023,Q4,1,I,20140101.0,20221003.0,20231219,20231219,EXP,,HU-MYLANLABS-2023M1135057,MYLAN,,53.0,YR,,M,Y,118.0,KG,20231219,,MD,HU,HU,2023,Q4,Adult
233133801,23313380,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,Unknown,QD,2023,Q4,Arrhythmia supraventricular,,2023,Q4,1,I,20140101.0,20221003.0,20231219,20231219,EXP,,HU-MYLANLABS-2023M1135057,MYLAN,,53.0,YR,,M,Y,118.0,KG,20231219,,MD,HU,HU,2023,Q4,Adult
233133801,23313380,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,Unknown,QD,2023,Q4,Transferrin saturation decreased,,2023,Q4,1,I,20140101.0,20221003.0,20231219,20231219,EXP,,HU-MYLANLABS-2023M1135057,MYLAN,,53.0,YR,,M,Y,118.0,KG,20231219,,MD,HU,HU,2023,Q4,Adult
233133801,23313380,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,Unknown,QD,2023,Q4,Vitamin B12 deficiency,,2023,Q4,1,I,20140101.0,20221003.0,20231219,20231219,EXP,,HU-MYLANLABS-2023M1135057,MYLAN,,53.0,YR,,M,Y,118.0,KG,20231219,,MD,HU,HU,2023,Q4,Adult
233133801,23313380,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,Unknown,QD,2023,Q4,Anaemia,,2023,Q4,1,I,20140101.0,20221003.0,20231219,20231219,EXP,,HU-MYLANLABS-2023M1135057,MYLAN,,53.0,YR,,M,Y,118.0,KG,20231219,,MD,HU,HU,2023,Q4,Adult
233133801,23313380,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,Unknown,QD,2023,Q4,Glycosylated haemoglobin increased,,2023,Q4,1,I,20140101.0,20221003.0,20231219,20231219,EXP,,HU-MYLANLABS-2023M1135057,MYLAN,,53.0,YR,,M,Y,118.0,KG,20231219,,MD,HU,HU,2023,Q4,Adult
233133801,23313380,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,Unknown,QD,2023,Q4,Arrhythmia,,2023,Q4,1,I,20140101.0,20221003.0,20231219,20231219,EXP,,HU-MYLANLABS-2023M1135057,MYLAN,,53.0,YR,,M,Y,118.0,KG,20231219,,MD,HU,HU,2023,Q4,Adult
233133801,23313380,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,Unknown,QD,2023,Q4,Weight increased,,2023,Q4,1,I,20140101.0,20221003.0,20231219,20231219,EXP,,HU-MYLANLABS-2023M1135057,MYLAN,,53.0,YR,,M,Y,118.0,KG,20231219,,MD,HU,HU,2023,Q4,Adult
233137751,23313775,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2023,Q4,Pancreatic carcinoma,,2023,Q4,1,I,20231201.0,20231219.0,20231219,20231219,DIR,684991,,FDA-CTU,,77.0,YR,,M,N,94.3,KG,20231219,N,PH,US,,2023,Q4,Elderly
233146261,23314626,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Daily",,,U,,,,,10.0,MG,,,2023,Q4,Drug ineffective,,2023,Q4,1,I,,20231204.0,20231219,20231219,EXP,,JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-423044,RANBAXY,"Sugihara R, Hashimura T, Sakata Y.. Goreisan as a successful adjuvant therapy of heart failure with preserved ejection fraction and advanced chronic kidney disease: a case report. Oxf Med Case Reports. 2023;10:392-396",84.0,YR,,M,Y,,,20231219,,HP,JP,JP,2023,Q4,Elderly
233146261,23314626,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Daily",,,U,,,,,10.0,MG,,,2023,Q4,Disease progression,,2023,Q4,1,I,,20231204.0,20231219,20231219,EXP,,JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-423044,RANBAXY,"Sugihara R, Hashimura T, Sakata Y.. Goreisan as a successful adjuvant therapy of heart failure with preserved ejection fraction and advanced chronic kidney disease: a case report. Oxf Med Case Reports. 2023;10:392-396",84.0,YR,,M,Y,,,20231219,,HP,JP,JP,2023,Q4,Elderly
233146261,23314626,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Daily",,,U,,,,,10.0,MG,,,2023,Q4,Gynaecomastia,,2023,Q4,1,I,,20231204.0,20231219,20231219,EXP,,JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-423044,RANBAXY,"Sugihara R, Hashimura T, Sakata Y.. Goreisan as a successful adjuvant therapy of heart failure with preserved ejection fraction and advanced chronic kidney disease: a case report. Oxf Med Case Reports. 2023;10:392-396",84.0,YR,,M,Y,,,20231219,,HP,JP,JP,2023,Q4,Elderly
233146261,23314626,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Daily",,,U,,,,,10.0,MG,,,2023,Q4,Oedema,,2023,Q4,1,I,,20231204.0,20231219,20231219,EXP,,JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-423044,RANBAXY,"Sugihara R, Hashimura T, Sakata Y.. Goreisan as a successful adjuvant therapy of heart failure with preserved ejection fraction and advanced chronic kidney disease: a case report. Oxf Med Case Reports. 2023;10:392-396",84.0,YR,,M,Y,,,20231219,,HP,JP,JP,2023,Q4,Elderly
233146261,23314626,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Daily",,,U,,,,,10.0,MG,,,2023,Q4,Hyperkalaemia,,2023,Q4,1,I,,20231204.0,20231219,20231219,EXP,,JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-423044,RANBAXY,"Sugihara R, Hashimura T, Sakata Y.. Goreisan as a successful adjuvant therapy of heart failure with preserved ejection fraction and advanced chronic kidney disease: a case report. Oxf Med Case Reports. 2023;10:392-396",84.0,YR,,M,Y,,,20231219,,HP,JP,JP,2023,Q4,Elderly
233194311,23319431,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q4,Urinary retention,,2023,Q4,1,I,20231120.0,20231219.0,20231220,20231220,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-279140",BOEHRINGER INGELHEIM,,79.0,YR,E,F,Y,,,20231220,,HP,SG,SG,2023,Q4,Elderly
233194321,23319432,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q4,Salmonellosis,,2023,Q4,1,I,20230425.0,20231219.0,20231220,20231220,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-279141",BOEHRINGER INGELHEIM,,66.0,YR,E,M,Y,,,20231220,,HP,SG,SG,2023,Q4,Elderly
233194321,23319432,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2023,Q4,Urinary tract infection,,2023,Q4,1,I,20230425.0,20231219.0,20231220,20231220,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-279141",BOEHRINGER INGELHEIM,,66.0,YR,E,M,Y,,,20231220,,HP,SG,SG,2023,Q4,Elderly
233206221,23320622,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, Daily",,,,,,,,10.0,MG,,QD,2023,Q4,Death,,2023,Q4,1,I,20231113.0,20231206.0,20231220,20231220,EXP,,US-SCPHARMACEUTICALS-2023-SCPH-US000260,SCPHARMACEUTICALS,,61.0,YR,,M,Y,67.8,KG,20231220,,MD,US,US,2023,Q4,Adult
233238421,23323842,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q4,Acidosis hyperchloraemic,,2023,Q4,1,I,,20231211.0,20231220,20231220,EXP,,CZ-AUROBINDO-AUR-APL-2023-078653,AUROBINDO,,61.0,YR,,M,Y,,,20231221,,MD,CZ,CZ,2023,Q4,Adult
233275191,23327519,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, 1X1",,,U,,,,,10.0,MG,,,2023,Q4,Hyperkalaemia,,2023,Q4,1,I,,20231206.0,20231221,20231221,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-423677,RANBAXY,,28.0,YR,,M,Y,,,20231221,,MD,DE,DE,2023,Q4,Young Adult
233275191,23327519,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, 1X1",,,U,,,,,10.0,MG,,,2023,Q4,Hypertension,,2023,Q4,1,I,,20231206.0,20231221,20231221,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-423677,RANBAXY,,28.0,YR,,M,Y,,,20231221,,MD,DE,DE,2023,Q4,Young Adult
233275191,23327519,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, 1X1",,,U,,,,,10.0,MG,,,2023,Q4,Renal impairment,,2023,Q4,1,I,,20231206.0,20231221,20231221,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-423677,RANBAXY,,28.0,YR,,M,Y,,,20231221,,MD,DE,DE,2023,Q4,Young Adult
233289391,23328939,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q4,Liver function test abnormal,,2023,Q4,1,I,,20231219.0,20231222,20231222,EXP,GB-MHRA-TPP15032904C4753071YC1702381207037,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-279038",BOEHRINGER INGELHEIM,,69.0,YR,E,M,Y,71.0,KG,20231222,,MD,GB,GB,2023,Q4,Elderly
233289391,23328939,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q4,Abnormal loss of weight,,2023,Q4,1,I,,20231219.0,20231222,20231222,EXP,GB-MHRA-TPP15032904C4753071YC1702381207037,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-279038",BOEHRINGER INGELHEIM,,69.0,YR,E,M,Y,71.0,KG,20231222,,MD,GB,GB,2023,Q4,Elderly
233289391,23328939,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2023,Q4,Decreased appetite,,2023,Q4,1,I,,20231219.0,20231222,20231222,EXP,GB-MHRA-TPP15032904C4753071YC1702381207037,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-279038",BOEHRINGER INGELHEIM,,69.0,YR,E,M,Y,71.0,KG,20231222,,MD,GB,GB,2023,Q4,Elderly
233338361,23333836,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,25.0,MG,Tablet,,2023,Q4,Mitral valve repair,,2023,Q4,1,I,20230518.0,20231218.0,20231223,20231223,EXP,,US-JNJFOC-20231248924,JOHNSON AND JOHNSON,,80.0,YR,E,M,Y,,,20231223,,CN,US,US,2023,Q4,Elderly
233345821,23334582,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2023,Q4,Liver injury,,2023,Q4,1,I,20230301.0,20231212.0,20231224,20231224,EXP,,FR-AUROBINDO-AUR-APL-2023-078832,AUROBINDO,,96.0,YR,,F,Y,,,20231224,,PH,FR,FR,2023,Q4,Elderly
233360841,23336084,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,UNK,,,,,,,2023,Q4,Condition aggravated,,2023,Q4,1,I,,20231212.0,20231225,20231225,EXP,,US-ALVOGEN-2023092714,ALVOGEN,"Mohamed AN, Michel MA, McFarlane SI. Gabapentin-Induced Myoclonus in a Patient With Chronic Kidney Disease. Cureus. 2023 Oct 19;15(10):e47351. doi:https://dx.doi.org/10.7759/cureus.47351",83.0,YR,,M,Y,70.62,KG,20231225,,HP,US,US,2023,Q4,Elderly
233360841,23336084,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,UNK,,,,,,,2023,Q4,Off label use,,2023,Q4,1,I,,20231212.0,20231225,20231225,EXP,,US-ALVOGEN-2023092714,ALVOGEN,"Mohamed AN, Michel MA, McFarlane SI. Gabapentin-Induced Myoclonus in a Patient With Chronic Kidney Disease. Cureus. 2023 Oct 19;15(10):e47351. doi:https://dx.doi.org/10.7759/cureus.47351",83.0,YR,,M,Y,70.62,KG,20231225,,HP,US,US,2023,Q4,Elderly
233360841,23336084,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,UNK,,,,,,,2023,Q4,Renal impairment,,2023,Q4,1,I,,20231212.0,20231225,20231225,EXP,,US-ALVOGEN-2023092714,ALVOGEN,"Mohamed AN, Michel MA, McFarlane SI. Gabapentin-Induced Myoclonus in a Patient With Chronic Kidney Disease. Cureus. 2023 Oct 19;15(10):e47351. doi:https://dx.doi.org/10.7759/cureus.47351",83.0,YR,,M,Y,70.62,KG,20231225,,HP,US,US,2023,Q4,Elderly
233360841,23336084,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,UNK,,,,,,,2023,Q4,Myoclonus,,2023,Q4,1,I,,20231212.0,20231225,20231225,EXP,,US-ALVOGEN-2023092714,ALVOGEN,"Mohamed AN, Michel MA, McFarlane SI. Gabapentin-Induced Myoclonus in a Patient With Chronic Kidney Disease. Cureus. 2023 Oct 19;15(10):e47351. doi:https://dx.doi.org/10.7759/cureus.47351",83.0,YR,,M,Y,70.62,KG,20231225,,HP,US,US,2023,Q4,Elderly
233376211,23337621,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, film-coated tablet",,,,,,,,,,,,2023,Q4,Acute kidney injury,,2023,Q4,1,I,20231109.0,20231215.0,20231226,20231226,EXP,FR-AFSSAPS-AN2023001525,FR-Accord-397331,ACCORD,,81.0,YR,E,M,Y,105.0,KG,20231226,,MD,FR,FR,2023,Q4,Elderly
233376211,23337621,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, film-coated tablet",,,,,,,,,,,,2023,Q4,Drug interaction,,2023,Q4,1,I,20231109.0,20231215.0,20231226,20231226,EXP,FR-AFSSAPS-AN2023001525,FR-Accord-397331,ACCORD,,81.0,YR,E,M,Y,105.0,KG,20231226,,MD,FR,FR,2023,Q4,Elderly
233392991,23339299,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,UNKNOWN,,,10.0,MG,,QD,2023,Q4,Hyperkalaemia,,2023,Q4,1,I,,20231211.0,20231226,20231226,EXP,,JP-TEVA-VS-3138020,TEVA,"Sugihara R, Hashimura T, Sakata Y. Goreisan as a successful adjuvant therapy of heart failure with preserved ejection fraction and advanced chronic kidney disease: a case report. Oxf-Med-Case-Reports 2023; 2023.",76.0,YR,,,Y,,,20231226,,HP,JP,JP,2023,Q4,Elderly
233392991,23339299,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,UNKNOWN,,,10.0,MG,,QD,2023,Q4,Angioedema,,2023,Q4,1,I,,20231211.0,20231226,20231226,EXP,,JP-TEVA-VS-3138020,TEVA,"Sugihara R, Hashimura T, Sakata Y. Goreisan as a successful adjuvant therapy of heart failure with preserved ejection fraction and advanced chronic kidney disease: a case report. Oxf-Med-Case-Reports 2023; 2023.",76.0,YR,,,Y,,,20231226,,HP,JP,JP,2023,Q4,Elderly
233392991,23339299,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,UNKNOWN,,,10.0,MG,,QD,2023,Q4,Chronic kidney disease,,2023,Q4,1,I,,20231211.0,20231226,20231226,EXP,,JP-TEVA-VS-3138020,TEVA,"Sugihara R, Hashimura T, Sakata Y. Goreisan as a successful adjuvant therapy of heart failure with preserved ejection fraction and advanced chronic kidney disease: a case report. Oxf-Med-Case-Reports 2023; 2023.",76.0,YR,,,Y,,,20231226,,HP,JP,JP,2023,Q4,Elderly
233392991,23339299,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,UNKNOWN,,,10.0,MG,,QD,2023,Q4,Drug ineffective,,2023,Q4,1,I,,20231211.0,20231226,20231226,EXP,,JP-TEVA-VS-3138020,TEVA,"Sugihara R, Hashimura T, Sakata Y. Goreisan as a successful adjuvant therapy of heart failure with preserved ejection fraction and advanced chronic kidney disease: a case report. Oxf-Med-Case-Reports 2023; 2023.",76.0,YR,,,Y,,,20231226,,HP,JP,JP,2023,Q4,Elderly
233392991,23339299,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,UNKNOWN,,,10.0,MG,,QD,2023,Q4,Gynaecomastia,,2023,Q4,1,I,,20231211.0,20231226,20231226,EXP,,JP-TEVA-VS-3138020,TEVA,"Sugihara R, Hashimura T, Sakata Y. Goreisan as a successful adjuvant therapy of heart failure with preserved ejection fraction and advanced chronic kidney disease: a case report. Oxf-Med-Case-Reports 2023; 2023.",76.0,YR,,,Y,,,20231226,,HP,JP,JP,2023,Q4,Elderly
233407501,23340750,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Unknown,,204629.0,10.0,MG,,QD,2023,Q4,Eosinophilia,,2023,Q4,1,I,20230407.0,20231227.0,20231227,20231227,EXP,FR-AFSSAPS-TS2023001669,"FR-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-280061",BOEHRINGER INGELHEIM,,78.0,YR,E,F,Y,,,20231227,,MD,FR,FR,2023,Q4,Elderly
233416651,23341665,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,,,2023,Q4,Diabetic ketoacidosis,,2023,Q4,1,I,20231205.0,20231219.0,20231226,20231226,DIR,FDA-CDER-CTU-2023-94574,,FDA-CTU,,67.0,YR,,M,N,,,20231219,N,PH,US,,2023,Q4,Elderly
233420971,23342097,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg per day,,,Y,U,,,,10.0,MG,,QD,2023,Q4,Acute kidney injury,,2023,Q4,1,I,20231006.0,20231122.0,20231227,20231227,EXP,FR-AFSSAPS-PC2023000927,FR-TEVA-VS-3134666,TEVA,,76.0,YR,,,Y,,,20231227,,PH,FR,FR,2023,Q4,Elderly
233420971,23342097,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg per day,,,Y,U,,,,10.0,MG,,QD,2023,Q4,Urinary tract infection,,2023,Q4,1,I,20231006.0,20231122.0,20231227,20231227,EXP,FR-AFSSAPS-PC2023000927,FR-TEVA-VS-3134666,TEVA,,76.0,YR,,,Y,,,20231227,,PH,FR,FR,2023,Q4,Elderly
233421201,23342120,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg 1X1,,,U,,,,,10.0,MG,Unknown,,2023,Q4,Renal impairment,,2023,Q4,1,I,,20231226.0,20231227,20231227,EXP,,DE-SANDOZ INC.-SDZ2023DE017381,SANDOZ,,28.0,YR,,M,Y,,,20231227,,MD,DE,DE,2023,Q4,Young Adult
233421201,23342120,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg 1X1,,,U,,,,,10.0,MG,Unknown,,2023,Q4,Hypertension,,2023,Q4,1,I,,20231226.0,20231227,20231227,EXP,,DE-SANDOZ INC.-SDZ2023DE017381,SANDOZ,,28.0,YR,,M,Y,,,20231227,,MD,DE,DE,2023,Q4,Young Adult
233421201,23342120,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg 1X1,,,U,,,,,10.0,MG,Unknown,,2023,Q4,Renal impairment,,2023,Q4,1,I,,20231226.0,20231227,20231227,EXP,,DE-SANDOZ INC.-SDZ2023DE017381,SANDOZ,,28.0,YR,,M,Y,,,20231227,,MD,DE,DE,2023,Q4,Young Adult
233421201,23342120,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg 1X1,,,U,,,,,10.0,MG,Unknown,,2023,Q4,Hyperkalaemia,,2023,Q4,1,I,,20231226.0,20231227,20231227,EXP,,DE-SANDOZ INC.-SDZ2023DE017381,SANDOZ,,28.0,YR,,M,Y,,,20231227,,MD,DE,DE,2023,Q4,Young Adult
233449761,23344976,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg (1x1),,,U,,,,,10.0,MG,,QD,2023,Q4,Hyperkalaemia,,2023,Q4,1,I,,20231226.0,20231228,20231228,EXP,,DE-SANDOZ INC.-SDZ2023DE072846,SANDOZ,,28.0,YR,,M,Y,,,20231228,,MD,DE,DE,2023,Q4,Young Adult
233449761,23344976,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg (1x1),,,U,,,,,10.0,MG,,QD,2023,Q4,Renal impairment,,2023,Q4,1,I,,20231226.0,20231228,20231228,EXP,,DE-SANDOZ INC.-SDZ2023DE072846,SANDOZ,,28.0,YR,,M,Y,,,20231228,,MD,DE,DE,2023,Q4,Young Adult
233449761,23344976,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg (1x1),,,U,,,,,10.0,MG,,QD,2023,Q4,Hypertension,,2023,Q4,1,I,,20231226.0,20231228,20231228,EXP,,DE-SANDOZ INC.-SDZ2023DE072846,SANDOZ,,28.0,YR,,M,Y,,,20231228,,MD,DE,DE,2023,Q4,Young Adult
233450211,23345021,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,D,,,,,10.0,MG,,,2023,Q4,Gastrointestinal disorder,,2023,Q4,1,I,,20230808.0,20231228,20231228,PER,,US-APOTEX-2023AP012171,APOTEX,"Goldman JD, Sangave N.. Misdiagnosis of Type 1 Diabetes Identified at a Primary Care Pharmacist Visit. DIABETESJOURNALS. 2023;41(2):322-326",68.0,YR,,F,Y,77.098,KG,20231228,,PH,US,US,2023,Q4,Elderly
233450211,23345021,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,D,,,,,25.0,MG,,,2023,Q4,Gastrointestinal disorder,,2023,Q4,1,I,,20230808.0,20231228,20231228,PER,,US-APOTEX-2023AP012171,APOTEX,"Goldman JD, Sangave N.. Misdiagnosis of Type 1 Diabetes Identified at a Primary Care Pharmacist Visit. DIABETESJOURNALS. 2023;41(2):322-326",68.0,YR,,F,Y,77.098,KG,20231228,,PH,US,US,2023,Q4,Elderly
233464411,23346441,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q4,Euglycaemic diabetic ketoacidosis,,2023,Q4,1,I,,20231213.0,20231228,20231228,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-425560,RANBAXY,"Thomas M, Tran L, White C, Deppe J, Davidson J. Empagliflozin Causing Euglycemic Diabetic Ketoacidosis. J Endocr Soc. 2019;Apr-May13;3(S1):SUN-LB030",60.0,YR,,F,Y,,,20231228,,HP,US,US,2023,Q4,Adult
233479931,23347993,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Unknown,,2023,Q4,Acidosis hyperchloraemic,,2023,Q4,1,I,,20231221.0,20231228,20231228,EXP,,CZ-MYLANLABS-2023M1136393,MYLAN,,61.0,YR,,M,Y,,,20231228,,MD,CZ,CZ,2023,Q4,Adult
233480001,23348000,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Unknown,,2023,Q4,Acidosis hyperchloraemic,,2023,Q4,1,I,,20231221.0,20231228,20231228,EXP,,CZ-MYLANLABS-2023M1136380,MYLAN,,59.0,YR,,F,Y,,,20231228,,MD,CZ,CZ,2023,Q4,Adult
233480961,23348096,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Unknown,,2023,Q4,Liver injury,,2023,Q4,1,I,20230301.0,20231222.0,20231228,20231228,EXP,FR-AFSSAPS-TO2023002111,FR-MYLANLABS-2023M1137041,MYLAN,,96.0,YR,,F,Y,,,20231228,,PH,FR,FR,2023,Q4,Elderly
233487701,23348770,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,,,Unknown,,206073.0,,,Tablet,,2023,Q4,Disseminated intravascular coagulation,,2023,Q4,1,I,20231215.0,20231227.0,20231229,20231229,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-279891",BOEHRINGER INGELHEIM,,59.0,YR,A,M,Y,,,20231229,,MD,JP,JP,2023,Q4,Adult
233487701,23348770,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,,,Unknown,,206073.0,,,Tablet,,2023,Q4,Chest pain,,2023,Q4,1,I,20231215.0,20231227.0,20231229,20231229,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-279891",BOEHRINGER INGELHEIM,,59.0,YR,A,M,Y,,,20231229,,MD,JP,JP,2023,Q4,Adult
233487701,23348770,2,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,,,Unknown,,206073.0,,,Tablet,,2023,Q4,Disseminated intravascular coagulation,,2023,Q4,1,I,20231215.0,20231227.0,20231229,20231229,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-279891",BOEHRINGER INGELHEIM,,59.0,YR,A,M,Y,,,20231229,,MD,JP,JP,2023,Q4,Adult
233487701,23348770,2,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,,,Unknown,,206073.0,,,Tablet,,2023,Q4,Chest pain,,2023,Q4,1,I,20231215.0,20231227.0,20231229,20231229,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-279891",BOEHRINGER INGELHEIM,,59.0,YR,A,M,Y,,,20231229,,MD,JP,JP,2023,Q4,Adult
233530881,23353088,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q4,Electrocardiogram QT prolonged,,2023,Q4,1,I,,20231127.0,20231230,20231230,EXP,,CH-TEVA-VS-3135352,TEVA,"Lazic M, Brack T, Henzi A. What is your diagnosis? Tremor in the polimedic patient Internet-Doc 2023;104(24):56-58.",72.0,YR,,,Y,,,20231230,,HP,CH,CH,2023,Q4,Elderly
233530881,23353088,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q4,Calcium deficiency,,2023,Q4,1,I,,20231127.0,20231230,20231230,EXP,,CH-TEVA-VS-3135352,TEVA,"Lazic M, Brack T, Henzi A. What is your diagnosis? Tremor in the polimedic patient Internet-Doc 2023;104(24):56-58.",72.0,YR,,,Y,,,20231230,,HP,CH,CH,2023,Q4,Elderly
233530881,23353088,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q4,Hypokalaemia,,2023,Q4,1,I,,20231127.0,20231230,20231230,EXP,,CH-TEVA-VS-3135352,TEVA,"Lazic M, Brack T, Henzi A. What is your diagnosis? Tremor in the polimedic patient Internet-Doc 2023;104(24):56-58.",72.0,YR,,,Y,,,20231230,,HP,CH,CH,2023,Q4,Elderly
233530881,23353088,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2023,Q4,Hypomagnesaemia,,2023,Q4,1,I,,20231127.0,20231230,20231230,EXP,,CH-TEVA-VS-3135352,TEVA,"Lazic M, Brack T, Henzi A. What is your diagnosis? Tremor in the polimedic patient Internet-Doc 2023;104(24):56-58.",72.0,YR,,,Y,,,20231230,,HP,CH,CH,2023,Q4,Elderly
902813624,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Joint injury,,2023,Q4,24,F,20121025.0,20231129.0,20130123,20231208,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20231208,,MD,CA,CA,2023,Q4,Elderly
902813624,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Fatigue,,2023,Q4,24,F,20121025.0,20231129.0,20130123,20231208,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20231208,,MD,CA,CA,2023,Q4,Elderly
902813624,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Palpitations,,2023,Q4,24,F,20121025.0,20231129.0,20130123,20231208,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20231208,,MD,CA,CA,2023,Q4,Elderly
902813624,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Dizziness,,2023,Q4,24,F,20121025.0,20231129.0,20130123,20231208,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20231208,,MD,CA,CA,2023,Q4,Elderly
902813624,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Pneumonia,,2023,Q4,24,F,20121025.0,20231129.0,20130123,20231208,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20231208,,MD,CA,CA,2023,Q4,Elderly
902813624,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Pericardial effusion,,2023,Q4,24,F,20121025.0,20231129.0,20130123,20231208,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20231208,,MD,CA,CA,2023,Q4,Elderly
902813624,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Cardiac failure congestive,,2023,Q4,24,F,20121025.0,20231129.0,20130123,20231208,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20231208,,MD,CA,CA,2023,Q4,Elderly
902813624,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Cough,,2023,Q4,24,F,20121025.0,20231129.0,20130123,20231208,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20231208,,MD,CA,CA,2023,Q4,Elderly
902813624,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Orthopnoea,,2023,Q4,24,F,20121025.0,20231129.0,20130123,20231208,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20231208,,MD,CA,CA,2023,Q4,Elderly
902813624,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Atrial fibrillation,,2023,Q4,24,F,20121025.0,20231129.0,20130123,20231208,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20231208,,MD,CA,CA,2023,Q4,Elderly
902813624,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Fall,,2023,Q4,24,F,20121025.0,20231129.0,20130123,20231208,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20231208,,MD,CA,CA,2023,Q4,Elderly
902813624,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Pulmonary oedema,,2023,Q4,24,F,20121025.0,20231129.0,20130123,20231208,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20231208,,MD,CA,CA,2023,Q4,Elderly
902813624,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Blood pressure fluctuation,,2023,Q4,24,F,20121025.0,20231129.0,20130123,20231208,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20231208,,MD,CA,CA,2023,Q4,Elderly
902813624,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Small intestinal obstruction,,2023,Q4,24,F,20121025.0,20231129.0,20130123,20231208,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20231208,,MD,CA,CA,2023,Q4,Elderly
902813624,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Pneumonia,,2023,Q4,24,F,20121025.0,20231129.0,20130123,20231208,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20231208,,MD,CA,CA,2023,Q4,Elderly
902813624,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Oedema peripheral,,2023,Q4,24,F,20121025.0,20231129.0,20130123,20231208,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20231208,,MD,CA,CA,2023,Q4,Elderly
902813624,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Limb injury,,2023,Q4,24,F,20121025.0,20231129.0,20130123,20231208,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20231208,,MD,CA,CA,2023,Q4,Elderly
902813624,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Bronchitis,,2023,Q4,24,F,20121025.0,20231129.0,20130123,20231208,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20231208,,MD,CA,CA,2023,Q4,Elderly
902813624,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Heart rate decreased,,2023,Q4,24,F,20121025.0,20231129.0,20130123,20231208,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20231208,,MD,CA,CA,2023,Q4,Elderly
902813624,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Blood pressure systolic increased,,2023,Q4,24,F,20121025.0,20231129.0,20130123,20231208,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20231208,,MD,CA,CA,2023,Q4,Elderly
902813624,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Blood pressure diastolic increased,,2023,Q4,24,F,20121025.0,20231129.0,20130123,20231208,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20231208,,MD,CA,CA,2023,Q4,Elderly
902813624,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Blood pressure decreased,,2023,Q4,24,F,20121025.0,20231129.0,20130123,20231208,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20231208,,MD,CA,CA,2023,Q4,Elderly
902813624,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Vital functions abnormal,,2023,Q4,24,F,20121025.0,20231129.0,20130123,20231208,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20231208,,MD,CA,CA,2023,Q4,Elderly
902813624,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Rales,,2023,Q4,24,F,20121025.0,20231129.0,20130123,20231208,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20231208,,MD,CA,CA,2023,Q4,Elderly
902813624,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Malaise,,2023,Q4,24,F,20121025.0,20231129.0,20130123,20231208,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20231208,,MD,CA,CA,2023,Q4,Elderly
902813624,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Influenza,,2023,Q4,24,F,20121025.0,20231129.0,20130123,20231208,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20231208,,MD,CA,CA,2023,Q4,Elderly
902813624,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Blood pressure increased,,2023,Q4,24,F,20121025.0,20231129.0,20130123,20231208,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20231208,,MD,CA,CA,2023,Q4,Elderly
902813624,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Heart rate increased,,2023,Q4,24,F,20121025.0,20231129.0,20130123,20231208,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20231208,,MD,CA,CA,2023,Q4,Elderly
902813624,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Dyspnoea,,2023,Q4,24,F,20121025.0,20231129.0,20130123,20231208,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20231208,,MD,CA,CA,2023,Q4,Elderly
902813624,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Dyspnoea,,2023,Q4,24,F,20121025.0,20231129.0,20130123,20231208,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20231208,,MD,CA,CA,2023,Q4,Elderly
902813624,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Inappropriate schedule of product administration,,2023,Q4,24,F,20121025.0,20231129.0,20130123,20231208,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20231208,,MD,CA,CA,2023,Q4,Elderly
